BC8_BioRED_Task1_Doc0	51	55	MMP1	Gene	4312	Association between promoter -1607 polymorphism of MMP1 and lumbar disc disease in Southern Chinese.
BC8_BioRED_Task1_Doc0	60	79	lumbar disc disease	Disease	C535531	Association between promoter -1607 polymorphism of MMP1 and lumbar disc disease in Southern Chinese.
BC8_BioRED_Task1_Doc0	113	138	Matrix metalloproteinases	Gene	4312	BACKGROUND: Matrix metalloproteinases (MMPs) are involved in the degradation of the extracellular matrix of the intervertebral disc.
BC8_BioRED_Task1_Doc0	140	144	MMPs	Gene	4312	BACKGROUND: Matrix metalloproteinases (MMPs) are involved in the degradation of the extracellular matrix of the intervertebral disc.
BC8_BioRED_Task1_Doc0	244	309	guanine insertion/deletion (G/D), the -1607 promoter polymorphism	SequenceVariant	c|DEL|-1607|G	A SNP for guanine insertion/deletion (G/D), the -1607 promoter polymorphism, of the MMP1 gene was found significantly affecting promoter activity and corresponding transcription level.
BC8_BioRED_Task1_Doc0	318	322	MMP1	Gene	4312	A SNP for guanine insertion/deletion (G/D), the -1607 promoter polymorphism, of the MMP1 gene was found significantly affecting promoter activity and corresponding transcription level.
BC8_BioRED_Task1_Doc0	471	474	DDD	Disease	D055959	Hence it is a good candidate for genetic studies in DDD.
BC8_BioRED_Task1_Doc0	573	576	DDD	Disease	D055959	DDD in the lumbar spine was defined by MRI using Schneiderman's classification.
BC8_BioRED_Task1_Doc0	969	973	MMP1	Gene	4312	RESULTS: Our results showed substantial evidence of association between -1607 promoter polymorphism of MMP1 and DDD in the Southern Chinese subjects.
BC8_BioRED_Task1_Doc0	978	981	DDD	Disease	D055959	RESULTS: Our results showed substantial evidence of association between -1607 promoter polymorphism of MMP1 and DDD in the Southern Chinese subjects.
BC8_BioRED_Task1_Doc0	1060	1063	DDD	Disease	D055959	D allelic was significantly associated with DDD (p value = 0.027, odds ratio = 1.41 with 95% CI = 1.04-1.90) while Genotypic association on the presence of D allele was also significantly associated with DDD (p value = 0.046, odds ratio = 1.50 with 95% CI = 1.01-2.24).
BC8_BioRED_Task1_Doc0	1220	1223	DDD	Disease	D055959	D allelic was significantly associated with DDD (p value = 0.027, odds ratio = 1.41 with 95% CI = 1.04-1.90) while Genotypic association on the presence of D allele was also significantly associated with DDD (p value = 0.046, odds ratio = 1.50 with 95% CI = 1.01-2.24).
BC8_BioRED_Task1_Doc0	1706	1728	D allele for the -1607	SequenceVariant	c|Allele|D|-1607	CONCLUSION: We demonstrated that individuals with the presence of D allele for the -1607 promoter polymorphism of MMP1 are about 1.5 times more susceptible to develop DDD when compared with those having G allele only.
BC8_BioRED_Task1_Doc0	1754	1758	MMP1	Gene	4312	CONCLUSION: We demonstrated that individuals with the presence of D allele for the -1607 promoter polymorphism of MMP1 are about 1.5 times more susceptible to develop DDD when compared with those having G allele only.
BC8_BioRED_Task1_Doc0	1807	1810	DDD	Disease	D055959	CONCLUSION: We demonstrated that individuals with the presence of D allele for the -1607 promoter polymorphism of MMP1 are about 1.5 times more susceptible to develop DDD when compared with those having G allele only.
BC8_BioRED_Task1_Doc1	0	15	Ginsenoside Rg1	Chemical	C035054	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
BC8_BioRED_Task1_Doc1	29	51	impairment of learning	Disease	D007859	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
BC8_BioRED_Task1_Doc1	71	79	morphine	Chemical	D009020	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
BC8_BioRED_Task1_Doc1	98	102	rats	OrganismTaxon	10116	Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
BC8_BioRED_Task1_Doc1	104	107	Rg1	Chemical	C035054	Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.
BC8_BioRED_Task1_Doc1	114	125	ginsenoside	Chemical	D036145	Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.
BC8_BioRED_Task1_Doc1	141	154	Panax ginseng	OrganismTaxon	4054	Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.
BC8_BioRED_Task1_Doc1	181	200	learning impairment	Disease	D007859	Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.
BC8_BioRED_Task1_Doc1	242	245	Rg1	Chemical	C035054	Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.
BC8_BioRED_Task1_Doc1	329	337	morphine	Chemical	D009020	Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.
BC8_BioRED_Task1_Doc1	394	397	Rg1	Chemical	C035054	The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.
BC8_BioRED_Task1_Doc1	401	420	learning impairment	Disease	D007859	The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.
BC8_BioRED_Task1_Doc1	432	440	morphine	Chemical	D009020	The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.
BC8_BioRED_Task1_Doc1	508	512	rats	OrganismTaxon	10116	Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.
BC8_BioRED_Task1_Doc1	547	555	morphine	Chemical	D009020	Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.
BC8_BioRED_Task1_Doc1	617	620	Rg1	Chemical	C035054	Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.
BC8_BioRED_Task1_Doc1	701	709	morphine	Chemical	D009020	Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.
BC8_BioRED_Task1_Doc1	823	827	rats	OrganismTaxon	10116	The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.
BC8_BioRED_Task1_Doc1	841	849	Morphine	Chemical	D009020	The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.
BC8_BioRED_Task1_Doc1	850	853	Rg1	Chemical	C035054	The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.
BC8_BioRED_Task1_Doc1	1051	1054	Rg1	Chemical	C035054	By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.
BC8_BioRED_Task1_Doc1	1109	1117	morphine	Chemical	D009020	By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.
BC8_BioRED_Task1_Doc1	1158	1162	rats	OrganismTaxon	10116	By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.
BC8_BioRED_Task1_Doc1	1220	1223	Rg1	Chemical	C035054	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1260	1264	rats	OrganismTaxon	10116	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1278	1286	morphine	Chemical	D009020	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1345	1353	morphine	Chemical	D009020	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1354	1357	Rg1	Chemical	C035054	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1366	1370	rats	OrganismTaxon	10116	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1411	1447	N-methyl-D-aspartate (NMDA) receptor	Gene	24408	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1459	1464	MK801	Chemical	D016291	The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.
BC8_BioRED_Task1_Doc1	1483	1486	Rg1	Chemical	C035054	We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.
BC8_BioRED_Task1_Doc1	1562	1570	morphine	Chemical	D009020	We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.
BC8_BioRED_Task1_Doc1	1602	1610	morphine	Chemical	D009020	We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.
BC8_BioRED_Task1_Doc1	1641	1654	NMDA receptor	Gene	24408	This effect is NMDA receptor dependent.
BC8_BioRED_Task1_Doc2	28	34	ADRA2B	Gene	151	Lack of association between ADRA2B-4825 gene insertion/deletion polymorphism and migraine in Chinese Han population.
BC8_BioRED_Task1_Doc2	34	63	-4825 gene insertion/deletion	SequenceVariant	c|INDEL|-4825||	Lack of association between ADRA2B-4825 gene insertion/deletion polymorphism and migraine in Chinese Han population.
BC8_BioRED_Task1_Doc2	81	89	migraine	Disease	D008881	Lack of association between ADRA2B-4825 gene insertion/deletion polymorphism and migraine in Chinese Han population.
BC8_BioRED_Task1_Doc2	206	214	migraine	Disease	D008881	OBJECTIVE: The present study aimed to estimate the association between susceptibility to migraine and the 12-nucleotide insertion/deletion (indel) polymorphism in promoter region of alpha(2B)-adrenergic receptor gene (ADRA2B).
BC8_BioRED_Task1_Doc2	223	263	12-nucleotide insertion/deletion (indel)	SequenceVariant	c|INDEL||12	OBJECTIVE: The present study aimed to estimate the association between susceptibility to migraine and the 12-nucleotide insertion/deletion (indel) polymorphism in promoter region of alpha(2B)-adrenergic receptor gene (ADRA2B).
BC8_BioRED_Task1_Doc2	299	328	alpha(2B)-adrenergic receptor	Gene	151	OBJECTIVE: The present study aimed to estimate the association between susceptibility to migraine and the 12-nucleotide insertion/deletion (indel) polymorphism in promoter region of alpha(2B)-adrenergic receptor gene (ADRA2B).
BC8_BioRED_Task1_Doc2	335	341	ADRA2B	Gene	151	OBJECTIVE: The present study aimed to estimate the association between susceptibility to migraine and the 12-nucleotide insertion/deletion (indel) polymorphism in promoter region of alpha(2B)-adrenergic receptor gene (ADRA2B).
BC8_BioRED_Task1_Doc2	440	448	migraine	Disease	D008881	METHODS: A case-control study was carried out in Chinese Han population, including 368 cases of migraine and 517 controls.
BC8_BioRED_Task1_Doc2	623	631	migraine	Disease	D008881	Data were adjusted for sex, age, migraine history and family history, and analyzed using a logistic regression model.
BC8_BioRED_Task1_Doc2	773	781	migraine	Disease	D008881	RESULTS: There was no association between indel polymorphism and migraine, at either the allele or the genotype level.
BC8_BioRED_Task1_Doc2	898	904	ADRA2B	Gene	151	CONCLUSION: These findings do not support a functional significance of ADRA2B indel polymorphism at position -4825 relative to the start codon in the far upstream region of the promoter in the present migraine subjects.
BC8_BioRED_Task1_Doc2	905	941	indel polymorphism at position -4825	SequenceVariant	c|INDEL|-4825||	CONCLUSION: These findings do not support a functional significance of ADRA2B indel polymorphism at position -4825 relative to the start codon in the far upstream region of the promoter in the present migraine subjects.
BC8_BioRED_Task1_Doc2	1028	1036	migraine	Disease	D008881	CONCLUSION: These findings do not support a functional significance of ADRA2B indel polymorphism at position -4825 relative to the start codon in the far upstream region of the promoter in the present migraine subjects.
BC8_BioRED_Task1_Doc3	29	35	TSPYL1	Gene	7259	Genetic investigation of the TSPYL1 gene in sudden infant death syndrome.
BC8_BioRED_Task1_Doc3	44	72	sudden infant death syndrome	Disease	D013398	Genetic investigation of the TSPYL1 gene in sudden infant death syndrome.
BC8_BioRED_Task1_Doc3	86	114	Sudden infant death syndrome	Disease	D013398	BACKGROUND: Sudden infant death syndrome (SIDS) constitutes the most frequent cause of death in the postperinatal period in Germany.
BC8_BioRED_Task1_Doc3	116	120	SIDS	Disease	D013398	BACKGROUND: Sudden infant death syndrome (SIDS) constitutes the most frequent cause of death in the postperinatal period in Germany.
BC8_BioRED_Task1_Doc3	161	166	death	Disease	D003643	BACKGROUND: Sudden infant death syndrome (SIDS) constitutes the most frequent cause of death in the postperinatal period in Germany.
BC8_BioRED_Task1_Doc3	253	311	sudden infant death with dysgenesis of the testes syndrome	Disease	C563856	Recently, a lethal phenotype characterized by sudden infant death with dysgenesis of the testes syndrome (SIDDT) was identified to be caused by loss of function mutations in the TSPYL1 gene.
BC8_BioRED_Task1_Doc3	313	318	SIDDT	Disease	C563856	Recently, a lethal phenotype characterized by sudden infant death with dysgenesis of the testes syndrome (SIDDT) was identified to be caused by loss of function mutations in the TSPYL1 gene.
BC8_BioRED_Task1_Doc3	385	391	TSPYL1	Gene	7259	Recently, a lethal phenotype characterized by sudden infant death with dysgenesis of the testes syndrome (SIDDT) was identified to be caused by loss of function mutations in the TSPYL1 gene.
BC8_BioRED_Task1_Doc3	460	466	TSPYL1	Gene	7259	PURPOSE: The study's purpose was to reveal a possible role of TSPYL1 in SIDS.
BC8_BioRED_Task1_Doc3	470	474	SIDS	Disease	D013398	PURPOSE: The study's purpose was to reveal a possible role of TSPYL1 in SIDS.
BC8_BioRED_Task1_Doc3	504	508	SIDS	Disease	D013398	METHODS: DNA samples of 126 SIDS cases and 261 controls were investigated.
BC8_BioRED_Task1_Doc3	737	745	patients	OrganismTaxon	9606	No Hardy Weinberg disequilibrium and no significant difference in allele frequencies between patients and controls were observed for any variation.
BC8_BioRED_Task1_Doc3	806	813	patient	OrganismTaxon	9606	In one female patient a p.F366L amino acid polymorphism was found heterozygous, which could not be displayed in controls.
BC8_BioRED_Task1_Doc3	816	823	p.F366L	SequenceVariant	rs140756663	In one female patient a p.F366L amino acid polymorphism was found heterozygous, which could not be displayed in controls.
BC8_BioRED_Task1_Doc3	1045	1050	SIDDT	Disease	C563856	Because SIDDT is the result of homozygous TSPYL1 mutations, this heterozygous exchange cannot solely explain the sudden death in this child.
BC8_BioRED_Task1_Doc3	1079	1085	TSPYL1	Gene	7259	Because SIDDT is the result of homozygous TSPYL1 mutations, this heterozygous exchange cannot solely explain the sudden death in this child.
BC8_BioRED_Task1_Doc3	1150	1162	sudden death	Disease	D003645	Because SIDDT is the result of homozygous TSPYL1 mutations, this heterozygous exchange cannot solely explain the sudden death in this child.
BC8_BioRED_Task1_Doc3	1216	1221	SIDDT	Disease	C563856	The reported mutation associated with SIDDT (457_458insG) was not detectable in our cohort.
BC8_BioRED_Task1_Doc3	1223	1234	457_458insG	SequenceVariant	c|INS|457_458|G	The reported mutation associated with SIDDT (457_458insG) was not detectable in our cohort.
BC8_BioRED_Task1_Doc3	1327	1333	TSPYL1	Gene	7259	CONCLUSION: No association of sequence variations in the TSPYL1 gene and SIDS has been found in a German cohort.
BC8_BioRED_Task1_Doc3	1343	1347	SIDS	Disease	D013398	CONCLUSION: No association of sequence variations in the TSPYL1 gene and SIDS has been found in a German cohort.
BC8_BioRED_Task1_Doc3	1403	1409	TSPYL1	Gene	7259	Genetic analysis of TSPYL1 seems to be of limited significance in the differential diagnosis of SIDS without dysgenesis of the testes.
BC8_BioRED_Task1_Doc3	1479	1483	SIDS	Disease	D013398	Genetic analysis of TSPYL1 seems to be of limited significance in the differential diagnosis of SIDS without dysgenesis of the testes.
BC8_BioRED_Task1_Doc3	1492	1516	dysgenesis of the testes	Disease	D013733	Genetic analysis of TSPYL1 seems to be of limited significance in the differential diagnosis of SIDS without dysgenesis of the testes.
BC8_BioRED_Task1_Doc4	0	8	Gartanin	Chemical	C000605798	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	84	88	PI3K	Gene	5291	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	89	92	Akt	Gene	207	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	93	97	mTOR	Gene	2475	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	102	106	MAPK	Gene	5594	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	129	134	human	OrganismTaxon	9606	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	135	141	glioma	Disease	D005910	Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.
BC8_BioRED_Task1_Doc4	176	182	glioma	Disease	D005910	In central nervous system, glioma is the most common primary brain tumour.
BC8_BioRED_Task1_Doc4	202	222	primary brain tumour	Disease	D001932	In central nervous system, glioma is the most common primary brain tumour.
BC8_BioRED_Task1_Doc4	315	323	Gartanin	Chemical	C000605798	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	335	343	xanthone	Chemical	C009689	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	347	357	mangosteen	OrganismTaxon	58228	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	465	469	T98G	CellLine	CVCL_0556	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	470	476	glioma	Disease	D005910	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	494	499	mouse	OrganismTaxon	10090	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	516	520	HT22	CellLine	CVCL_0321	Gartanin, a natural xanthone of mangosteen, suppressed proliferation, migration and colony formation in a time- and concentration-dependent manner in T98G glioma cells but not in mouse normal neuronal HT22 cells.
BC8_BioRED_Task1_Doc4	528	536	Gartanin	Chemical	C000605798	Gartanin, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.
BC8_BioRED_Task1_Doc4	672	681	cyclin D1	Gene	595	Gartanin, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.
BC8_BioRED_Task1_Doc4	719	742	cyclin-dependent kinase	Gene	983	Gartanin, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.
BC8_BioRED_Task1_Doc4	753	760	p27Kip1	Gene	1027	Gartanin, at low micromole, led to cell cycle arrest in G1 phase accompanied by inhibited expression level of G1 cell cycle regulatory proteins cyclin D1, while increased expression level of cyclin-dependent kinase inhibitor p27Kip1.
BC8_BioRED_Task1_Doc4	805	834	matrix metalloproteinases 2/9	Gene	4313,4318	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	836	844	MMP-2/-9	Gene	4313,4318	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	879	883	T98G	CellLine	CVCL_0556	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	903	911	gartanin	Chemical	C000605798	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	949	982	mitogen-activated protein kinases	Gene	5594	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	984	988	MAPK	Gene	5594	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	1012	1016	T98G	CellLine	CVCL_0556	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	1017	1023	glioma	Disease	D005910	In addition, the secretion and activity of matrix metalloproteinases 2/9 (MMP-2/-9) were significantly suppressed in T98G cells treated with gartanin, and it might result from modulating mitogen-activated protein kinases (MAPK) signalling pathway in T98G glioma cells.
BC8_BioRED_Task1_Doc4	1041	1049	gartanin	Chemical	C000605798	Moreover, gartanin significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.
BC8_BioRED_Task1_Doc4	1085	1089	T98G	CellLine	CVCL_0556	Moreover, gartanin significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.
BC8_BioRED_Task1_Doc4	1114	1117	LC3	Gene	84557	Moreover, gartanin significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.
BC8_BioRED_Task1_Doc4	1189	1197	Beclin 1	Gene	8678	Moreover, gartanin significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.
BC8_BioRED_Task1_Doc4	1202	1205	LC3	Gene	84557	Moreover, gartanin significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.
BC8_BioRED_Task1_Doc4	1247	1250	p62	Gene	8878	Moreover, gartanin significantly induced autophagy in T98G cells and increased GFP-LC3 punctate fluorescence accompanied by the increased expression level of Beclin 1 and LC3-II, while suppressed expression level of p62.
BC8_BioRED_Task1_Doc4	1252	1260	Gartanin	Chemical	C000605798	Gartanin treatment resulted in obvious inhibition of PI3K/Akt/mTOR signalling pathway, which is important in modulating autophagy.
BC8_BioRED_Task1_Doc4	1305	1309	PI3K	Gene	5291	Gartanin treatment resulted in obvious inhibition of PI3K/Akt/mTOR signalling pathway, which is important in modulating autophagy.
BC8_BioRED_Task1_Doc4	1310	1313	Akt	Gene	207	Gartanin treatment resulted in obvious inhibition of PI3K/Akt/mTOR signalling pathway, which is important in modulating autophagy.
BC8_BioRED_Task1_Doc4	1314	1318	mTOR	Gene	2475	Gartanin treatment resulted in obvious inhibition of PI3K/Akt/mTOR signalling pathway, which is important in modulating autophagy.
BC8_BioRED_Task1_Doc4	1392	1400	gartanin	Chemical	C000605798	Notably, gartanin-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and chloroquine (CQ).
BC8_BioRED_Task1_Doc4	1487	1502	3-methyladenine	Chemical	C025946	Notably, gartanin-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and chloroquine (CQ).
BC8_BioRED_Task1_Doc4	1504	1508	3-MA	Chemical	C025946	Notably, gartanin-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and chloroquine (CQ).
BC8_BioRED_Task1_Doc4	1514	1525	chloroquine	Chemical	D002738	Notably, gartanin-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and chloroquine (CQ).
BC8_BioRED_Task1_Doc4	1527	1529	CQ	Chemical	D002738	Notably, gartanin-mediated anti-viability was significantly abrogated by autophagy inhibitors including 3-methyladenine (3-MA) and chloroquine (CQ).
BC8_BioRED_Task1_Doc4	1589	1597	gartanin	Chemical	C000605798	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc4	1601	1605	T98G	CellLine	CVCL_0556	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc4	1695	1699	PI3K	Gene	5291	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc4	1700	1703	Akt	Gene	207	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc4	1704	1708	mTOR	Gene	2475	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc4	1791	1799	MMP-2/-9	Gene	4313,4318	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc4	1830	1834	MAPK	Gene	5594	These results indicate that anti-proliferation effect of gartanin in T98G cells is most likely via cell cycle arrest modulated by autophagy, which is regulated by PI3K/Akt/mTOR signalling pathway, while anti-migration effect is most likely via suppression of MMP-2/-9 activity which is involved in MAPK signalling pathway.
BC8_BioRED_Task1_Doc5	21	31	nelarabine	Chemical	C104457	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
BC8_BioRED_Task1_Doc5	33	42	etoposide	Chemical	D005047	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
BC8_BioRED_Task1_Doc5	48	64	cyclophosphamide	Chemical	D003520	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
BC8_BioRED_Task1_Doc5	99	142	T-cell lymphoblastic leukaemia and lymphoma	Disease	D015458|D016399	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
BC8_BioRED_Task1_Doc5	168	178	nelarabine	Chemical	C104457	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	180	184	AraG	Chemical	C104457	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	198	207	etoposide	Chemical	D005047	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	209	211	VP	Chemical	D005047	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	217	233	cyclophosphamide	Chemical	D003520	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	235	238	CPM	Chemical	D003520	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	356	384	T-cell leukaemia or lymphoma	Disease	D015458|D016399	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
BC8_BioRED_Task1_Doc5	435	439	AraG	Chemical	C104457	The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.
BC8_BioRED_Task1_Doc5	481	491	neuropathy	Disease	D009422	The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.
BC8_BioRED_Task1_Doc5	496	516	musculoskeletal pain	Disease	D059352	The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.
BC8_BioRED_Task1_Doc5	518	541	Haematological toxicity	Disease	D006402	Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.
BC8_BioRED_Task1_Doc5	579	583	AraG	Chemical	C104457	Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.
BC8_BioRED_Task1_Doc5	697	705	patients	OrganismTaxon	9606	All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM.
BC8_BioRED_Task1_Doc5	827	831	AraG	Chemical	C104457	All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM.
BC8_BioRED_Task1_Doc5	832	834	VP	Chemical	D005047	All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM.
BC8_BioRED_Task1_Doc5	835	838	CPM	Chemical	D003520	All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM.
BC8_BioRED_Task1_Doc5	885	889	AraG	Chemical	C104457	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.
BC8_BioRED_Task1_Doc5	927	936	etoposide	Chemical	D005047	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.
BC8_BioRED_Task1_Doc5	941	957	cyclophosphamide	Chemical	D003520	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.
BC8_BioRED_Task1_Doc5	968	989	neurological toxicity	Disease	D009422	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.
BC8_BioRED_Task1_Doc6	0	4	Ca2+	Chemical	D002118	Ca2+ dependence of the Ca2+-selective TRPV6 channel.
BC8_BioRED_Task1_Doc6	23	27	Ca2+	Chemical	D002118	Ca2+ dependence of the Ca2+-selective TRPV6 channel.
BC8_BioRED_Task1_Doc6	38	43	TRPV6	Gene	55503	Ca2+ dependence of the Ca2+-selective TRPV6 channel.
BC8_BioRED_Task1_Doc6	116	121	TRPV6	Gene	55503	Microfluorimetry and patch-clamp experiments were performed on TRPV6-expressing HEK cells to determine whether this Ca(2+)-sensing Ca(2+) channel is constitutively active.
BC8_BioRED_Task1_Doc6	133	136	HEK	CellLine	CVCL_M624	Microfluorimetry and patch-clamp experiments were performed on TRPV6-expressing HEK cells to determine whether this Ca(2+)-sensing Ca(2+) channel is constitutively active.
BC8_BioRED_Task1_Doc6	169	175	Ca(2+)	Chemical	D002118	Microfluorimetry and patch-clamp experiments were performed on TRPV6-expressing HEK cells to determine whether this Ca(2+)-sensing Ca(2+) channel is constitutively active.
BC8_BioRED_Task1_Doc6	184	190	Ca(2+)	Chemical	D002118	Microfluorimetry and patch-clamp experiments were performed on TRPV6-expressing HEK cells to determine whether this Ca(2+)-sensing Ca(2+) channel is constitutively active.
BC8_BioRED_Task1_Doc6	250	256	fura-2	Chemical	D016257	Intact cells loaded with fura-2 had an elevated intracellular free Ca(2+) concentration ((i)), which decreased to the same level such as in non-transfected cells if external Ca(2+) was chelated by EGTA.
BC8_BioRED_Task1_Doc6	292	298	Ca(2+)	Chemical	D002118	Intact cells loaded with fura-2 had an elevated intracellular free Ca(2+) concentration ((i)), which decreased to the same level such as in non-transfected cells if external Ca(2+) was chelated by EGTA.
BC8_BioRED_Task1_Doc6	399	405	Ca(2+)	Chemical	D002118	Intact cells loaded with fura-2 had an elevated intracellular free Ca(2+) concentration ((i)), which decreased to the same level such as in non-transfected cells if external Ca(2+) was chelated by EGTA.
BC8_BioRED_Task1_Doc6	422	426	EGTA	Chemical	D004533	Intact cells loaded with fura-2 had an elevated intracellular free Ca(2+) concentration ((i)), which decreased to the same level such as in non-transfected cells if external Ca(2+) was chelated by EGTA.
BC8_BioRED_Task1_Doc6	471	474	HEK	CellLine	CVCL_M624	Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm EGTA and 100 nm (i) or if the cytosolic Ca(2+) buffering remained undisturbed in perforated patch-clamp experiments.
BC8_BioRED_Task1_Doc6	502	507	human	OrganismTaxon	9606	Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm EGTA and 100 nm (i) or if the cytosolic Ca(2+) buffering remained undisturbed in perforated patch-clamp experiments.
BC8_BioRED_Task1_Doc6	508	513	TRPV6	Gene	55503	Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm EGTA and 100 nm (i) or if the cytosolic Ca(2+) buffering remained undisturbed in perforated patch-clamp experiments.
BC8_BioRED_Task1_Doc6	629	633	EGTA	Chemical	D004533	Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm EGTA and 100 nm (i) or if the cytosolic Ca(2+) buffering remained undisturbed in perforated patch-clamp experiments.
BC8_BioRED_Task1_Doc6	669	675	Ca(2+)	Chemical	D002118	Whole cell recordings from non-transfected HEK cells and cells expressing human TRPV6 revealed the presence of a basal inward current in both types of cells when the internal solution contained 0.1 mm EGTA and 100 nm (i) or if the cytosolic Ca(2+) buffering remained undisturbed in perforated patch-clamp experiments.
BC8_BioRED_Task1_Doc6	773	778	TRPV6	Gene	55503	If recombinantly expressed TRPV6 forms open channels, one would expect Ca(2+)-induced current inhibition, because TRPV6 is negatively regulated by internal Ca(2+).
BC8_BioRED_Task1_Doc6	817	823	Ca(2+)	Chemical	D002118	If recombinantly expressed TRPV6 forms open channels, one would expect Ca(2+)-induced current inhibition, because TRPV6 is negatively regulated by internal Ca(2+).
BC8_BioRED_Task1_Doc6	860	865	TRPV6	Gene	55503	If recombinantly expressed TRPV6 forms open channels, one would expect Ca(2+)-induced current inhibition, because TRPV6 is negatively regulated by internal Ca(2+).
BC8_BioRED_Task1_Doc6	902	908	Ca(2+)	Chemical	D002118	If recombinantly expressed TRPV6 forms open channels, one would expect Ca(2+)-induced current inhibition, because TRPV6 is negatively regulated by internal Ca(2+).
BC8_BioRED_Task1_Doc6	972	977	TRPV6	Gene	55503	However, dialyzing solutions with high  such as 1 microm into TRPV6-expressing cells did not block the basal inward current, which was not different from the recordings from non-transfected cells.
BC8_BioRED_Task1_Doc6	1137	1141	EGTA	Chemical	D004533	In contrast, dialyzing 0.5 mm EGTA into TRPV6-expressing cells readily activated Ca(2+) inward currents, which were undetectable in non-transfected cells.
BC8_BioRED_Task1_Doc6	1147	1152	TRPV6	Gene	55503	In contrast, dialyzing 0.5 mm EGTA into TRPV6-expressing cells readily activated Ca(2+) inward currents, which were undetectable in non-transfected cells.
BC8_BioRED_Task1_Doc6	1188	1194	Ca(2+)	Chemical	D002118	In contrast, dialyzing 0.5 mm EGTA into TRPV6-expressing cells readily activated Ca(2+) inward currents, which were undetectable in non-transfected cells.
BC8_BioRED_Task1_Doc6	1310	1315	TRPV6	Gene	55503	Interestingly, monovalent cations permeated the TRPV6 channels under conditions where no Ca(2+) permeation was detectable, indicating that divalent cations block TRPV6 channels from the extracellular side.
BC8_BioRED_Task1_Doc6	1351	1357	Ca(2+)	Chemical	D002118	Interestingly, monovalent cations permeated the TRPV6 channels under conditions where no Ca(2+) permeation was detectable, indicating that divalent cations block TRPV6 channels from the extracellular side.
BC8_BioRED_Task1_Doc6	1424	1429	TRPV6	Gene	55503	Interestingly, monovalent cations permeated the TRPV6 channels under conditions where no Ca(2+) permeation was detectable, indicating that divalent cations block TRPV6 channels from the extracellular side.
BC8_BioRED_Task1_Doc6	1473	1478	human	OrganismTaxon	9606	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1479	1484	TRPV6	Gene	55503	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1500	1505	human	OrganismTaxon	9606	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1506	1511	TRPV6	Gene	55503	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1512	1524	Delta695-725	SequenceVariant	p|DEL|695-725|	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1574	1580	Ca(2+)	Chemical	D002118	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1657	1662	human	OrganismTaxon	9606	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1663	1668	TRPV6	Gene	55503	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1669	1674	D542A	SequenceVariant	p|SUB|D|542|A	Like human TRPV6, the truncated human TRPV6(Delta695-725), which lacks the C-terminal domain required for Ca(2+)-calmodulin binding, does not form constitutive active channels, whereas the human TRPV6(D542A), carrying a point mutation in the presumed pore region, does not function as a channel.
BC8_BioRED_Task1_Doc6	1797	1802	TRPV6	Gene	55503	In summary, no constitutive open TRPV6 channels were detected in patch-clamp experiments from transfected HEK cells.
BC8_BioRED_Task1_Doc6	1870	1873	HEK	CellLine	CVCL_M624	In summary, no constitutive open TRPV6 channels were detected in patch-clamp experiments from transfected HEK cells.
BC8_BioRED_Task1_Doc7	44	48	MLH1	Gene	4292	Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC).
BC8_BioRED_Task1_Doc7	53	57	MSH2	Gene	4436	Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC).
BC8_BioRED_Task1_Doc7	128	142	Lynch syndrome	Disease	D003123	Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC).
BC8_BioRED_Task1_Doc7	144	149	HNPCC	Disease	D003123	Distinct patterns of germ-line deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC).
BC8_BioRED_Task1_Doc7	219	223	MLH1	Gene	4292	A relatively high frequency of germ-line genomic rearrangements in MLH1 and MSH2 has been reported among Lynch Syndrome (HNPCC) patients from different ethnic populations.
BC8_BioRED_Task1_Doc7	228	232	MSH2	Gene	4436	A relatively high frequency of germ-line genomic rearrangements in MLH1 and MSH2 has been reported among Lynch Syndrome (HNPCC) patients from different ethnic populations.
BC8_BioRED_Task1_Doc7	257	271	Lynch Syndrome	Disease	D003123	A relatively high frequency of germ-line genomic rearrangements in MLH1 and MSH2 has been reported among Lynch Syndrome (HNPCC) patients from different ethnic populations.
BC8_BioRED_Task1_Doc7	273	278	HNPCC	Disease	D003123	A relatively high frequency of germ-line genomic rearrangements in MLH1 and MSH2 has been reported among Lynch Syndrome (HNPCC) patients from different ethnic populations.
BC8_BioRED_Task1_Doc7	280	288	patients	OrganismTaxon	9606	A relatively high frequency of germ-line genomic rearrangements in MLH1 and MSH2 has been reported among Lynch Syndrome (HNPCC) patients from different ethnic populations.
BC8_BioRED_Task1_Doc7	448	452	MLH1	Gene	4292	To investigate the underlying molecular mechanisms, we characterized the DNA breakpoints of 11 germ-line deletions, six for MLH1 and five for MSH2.
BC8_BioRED_Task1_Doc7	466	470	MSH2	Gene	4436	To investigate the underlying molecular mechanisms, we characterized the DNA breakpoints of 11 germ-line deletions, six for MLH1 and five for MSH2.
BC8_BioRED_Task1_Doc7	547	551	MSH2	Gene	4436	The five cases of MSH2 deletions result exclusively from intragenic unequal recombination mediated by repetitive Alu sequences.
BC8_BioRED_Task1_Doc7	690	694	MLH1	Gene	4292	In contrast, five out of the six MLH1 deletions are due to recombinations involving sequences of no significant homology (P=0.015).
BC8_BioRED_Task1_Doc7	990	994	MSH2	Gene	4436	A detailed analysis of the DNA breakpoints in the two genes, previously characterized by other groups, validated the observation that Alu-mediated unequal recombination is the main type of deletion in MSH2 (n=34), but not in MLH1 (n=21) (P<0.0001).
BC8_BioRED_Task1_Doc7	1014	1018	MLH1	Gene	4292	A detailed analysis of the DNA breakpoints in the two genes, previously characterized by other groups, validated the observation that Alu-mediated unequal recombination is the main type of deletion in MSH2 (n=34), but not in MLH1 (n=21) (P<0.0001).
BC8_BioRED_Task1_Doc7	1303	1307	MLH1	Gene	4292	Our study suggests that Alu is a promoting factor for the genomic recombinations in both MLH1 and MSH2, and the local Alu density may be involved in shaping the deletion pattern.
BC8_BioRED_Task1_Doc7	1312	1316	MSH2	Gene	4436	Our study suggests that Alu is a promoting factor for the genomic recombinations in both MLH1 and MSH2, and the local Alu density may be involved in shaping the deletion pattern.
BC8_BioRED_Task1_Doc8	2	15	Cys 23-Ser 23	SequenceVariant	rs6318	A Cys 23-Ser 23 substitution in the 5-HT(2C) receptor gene influences body weight regulation in females with seasonal affective disorder: an Austrian-Canadian collaborative study.
BC8_BioRED_Task1_Doc8	36	53	5-HT(2C) receptor	Gene	3358	A Cys 23-Ser 23 substitution in the 5-HT(2C) receptor gene influences body weight regulation in females with seasonal affective disorder: an Austrian-Canadian collaborative study.
BC8_BioRED_Task1_Doc8	109	136	seasonal affective disorder	Disease	D016574	A Cys 23-Ser 23 substitution in the 5-HT(2C) receptor gene influences body weight regulation in females with seasonal affective disorder: an Austrian-Canadian collaborative study.
BC8_BioRED_Task1_Doc8	198	225	seasonal affective disorder	Disease	D016574	Most females with seasonal affective disorder (SAD) exhibit atypical vegetative symptoms such as overeating, and weight gain when depressed.
BC8_BioRED_Task1_Doc8	227	230	SAD	Disease	D016574	Most females with seasonal affective disorder (SAD) exhibit atypical vegetative symptoms such as overeating, and weight gain when depressed.
BC8_BioRED_Task1_Doc8	293	319	weight gain when depressed	Disease	D015430	Most females with seasonal affective disorder (SAD) exhibit atypical vegetative symptoms such as overeating, and weight gain when depressed.
BC8_BioRED_Task1_Doc8	325	346	serotonin 2C receptor	Gene	3358	The serotonin 2C receptor (5-HT(2C)) plays a key role in control of appetite and satiety.
BC8_BioRED_Task1_Doc8	348	356	5-HT(2C)	Gene	3358	The serotonin 2C receptor (5-HT(2C)) plays a key role in control of appetite and satiety.
BC8_BioRED_Task1_Doc8	413	421	5-HT(2C)	Gene	3358	A 5-HT(2C) Cys 23 Ser substitution, coded for by a single nucleotide polymorphism (Cys 23 Ser) within the 5-HT(2C) gene, has been shown to influence 5-HT(2C) function.
BC8_BioRED_Task1_Doc8	422	432	Cys 23 Ser	SequenceVariant	rs6318	A 5-HT(2C) Cys 23 Ser substitution, coded for by a single nucleotide polymorphism (Cys 23 Ser) within the 5-HT(2C) gene, has been shown to influence 5-HT(2C) function.
BC8_BioRED_Task1_Doc8	494	504	Cys 23 Ser	SequenceVariant	rs6318	A 5-HT(2C) Cys 23 Ser substitution, coded for by a single nucleotide polymorphism (Cys 23 Ser) within the 5-HT(2C) gene, has been shown to influence 5-HT(2C) function.
BC8_BioRED_Task1_Doc8	517	525	5-HT(2C)	Gene	3358	A 5-HT(2C) Cys 23 Ser substitution, coded for by a single nucleotide polymorphism (Cys 23 Ser) within the 5-HT(2C) gene, has been shown to influence 5-HT(2C) function.
BC8_BioRED_Task1_Doc8	560	568	5-HT(2C)	Gene	3358	A 5-HT(2C) Cys 23 Ser substitution, coded for by a single nucleotide polymorphism (Cys 23 Ser) within the 5-HT(2C) gene, has been shown to influence 5-HT(2C) function.
BC8_BioRED_Task1_Doc8	600	610	Cys 23 Ser	SequenceVariant	rs6318	We hypothesized that Cys 23 Ser influences weight regulation in females with SAD.
BC8_BioRED_Task1_Doc8	656	659	SAD	Disease	D016574	We hypothesized that Cys 23 Ser influences weight regulation in females with SAD.
BC8_BioRED_Task1_Doc8	716	719	SAD	Disease	D016574	Two independent samples from Austria (162 females with SAD, 119 controls), and Canada (90 females with SAD, 42 controls) were genotyped for Cys 23 Ser.
BC8_BioRED_Task1_Doc8	764	767	SAD	Disease	D016574	Two independent samples from Austria (162 females with SAD, 119 controls), and Canada (90 females with SAD, 42 controls) were genotyped for Cys 23 Ser.
BC8_BioRED_Task1_Doc8	801	811	Cys 23 Ser	SequenceVariant	rs6318	Two independent samples from Austria (162 females with SAD, 119 controls), and Canada (90 females with SAD, 42 controls) were genotyped for Cys 23 Ser.
BC8_BioRED_Task1_Doc8	864	872	patients	OrganismTaxon	9606	Influence on weight regulation was analyzed within patients with atypical features.
BC8_BioRED_Task1_Doc8	950	958	patients	OrganismTaxon	9606	In Austrians, genotype distribution differed between patients and controls (p=0.044) and Cys 23 Ser was associated with weight (p=0.039), body mass index (BMI; p=0.038), and seasonal appetite change (p=0.031).
BC8_BioRED_Task1_Doc8	986	996	Cys 23 Ser	SequenceVariant	rs6318	In Austrians, genotype distribution differed between patients and controls (p=0.044) and Cys 23 Ser was associated with weight (p=0.039), body mass index (BMI; p=0.038), and seasonal appetite change (p=0.031).
BC8_BioRED_Task1_Doc8	1212	1220	patients	OrganismTaxon	9606	In Canadian patients, Cys 23 Ser was associated with minimum lifetime BMI (p=0.046), with lowest values in Ser/Ser carriers.
BC8_BioRED_Task1_Doc8	1222	1232	Cys 23 Ser	SequenceVariant	rs6318	In Canadian patients, Cys 23 Ser was associated with minimum lifetime BMI (p=0.046), with lowest values in Ser/Ser carriers.
BC8_BioRED_Task1_Doc8	1356	1366	Cys 23 Ser	SequenceVariant	rs6318	Our data provide evidence that Cys 23 Ser mediates severity of weight regulation disturbances in females with SAD, and the gene-dose effect-like differences suggest a direct functional role of Cys 23 Ser in the behavioral regulation of body weight.
BC8_BioRED_Task1_Doc8	1435	1438	SAD	Disease	D016574	Our data provide evidence that Cys 23 Ser mediates severity of weight regulation disturbances in females with SAD, and the gene-dose effect-like differences suggest a direct functional role of Cys 23 Ser in the behavioral regulation of body weight.
BC8_BioRED_Task1_Doc8	1518	1528	Cys 23 Ser	SequenceVariant	rs6318	Our data provide evidence that Cys 23 Ser mediates severity of weight regulation disturbances in females with SAD, and the gene-dose effect-like differences suggest a direct functional role of Cys 23 Ser in the behavioral regulation of body weight.
BC8_BioRED_Task1_Doc9	18	38	maltolyl p-coumarate	Chemical	C524754	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
BC8_BioRED_Task1_Doc9	51	69	cognitive deficits	Disease	D003072	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
BC8_BioRED_Task1_Doc9	125	133	dementia	Disease	D003704	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
BC8_BioRED_Task1_Doc9	260	280	maltolyl p-coumarate	Chemical	C524754	To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.
BC8_BioRED_Task1_Doc9	306	312	maltol	Chemical	C008316	To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.
BC8_BioRED_Task1_Doc9	317	332	p-coumaric acid	Chemical	C495469	To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.
BC8_BioRED_Task1_Doc9	380	400	maltolyl p-coumarate	Chemical	C524754	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	415	432	cognitive decline	Disease	D003072	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	436	447	scopolamine	Chemical	D012601	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	457	461	rats	OrganismTaxon	10116	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	469	495	amyloid beta peptide(1-42)	Chemical	C544092	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	504	508	rats	OrganismTaxon	10116	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	510	530	Maltolyl p-coumarate	Chemical	C524754	Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	554	572	cognitive deficits	Disease	D003072	Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	581	584	rat	OrganismTaxon	10116	Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	691	717	amyloid beta peptide(1-42)	Chemical	C544092	Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	726	730	rats	OrganismTaxon	10116	Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
BC8_BioRED_Task1_Doc9	780	800	maltolyl p-coumarate	Chemical	C524754	We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.
BC8_BioRED_Task1_Doc9	816	823	SH-SY5Y	CellLine	CVCL_0019	We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.
BC8_BioRED_Task1_Doc9	858	878	maltolyl p-coumarate	Chemical	C524754	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.
BC8_BioRED_Task1_Doc9	898	924	amyloid beta peptide(1-42)	Chemical	C544092	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.
BC8_BioRED_Task1_Doc9	926	935	glutamate	Chemical	D018698	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.
BC8_BioRED_Task1_Doc9	939	943	H2O2	Chemical	D006861	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.
BC8_BioRED_Task1_Doc9	959	979	maltolyl p-coumarate	Chemical	C524754	We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.
BC8_BioRED_Task1_Doc9	1037	1060	reactive oxygen species	Chemical	D017382	We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.
BC8_BioRED_Task1_Doc9	1062	1074	cytochrome c	Chemical	D045304	We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.
BC8_BioRED_Task1_Doc9	1088	1097	caspase 3	Gene	25402	We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.
BC8_BioRED_Task1_Doc9	1186	1206	maltolyl p-coumarate	Chemical	C524754	Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
BC8_BioRED_Task1_Doc9	1252	1271	Alzheimer's disease	Disease	D000544	Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
BC8_BioRED_Task1_Doc9	1309	1323	neuronal death	Disease	D009410	Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
BC8_BioRED_Task1_Doc9	1340	1369	decline of cognitive function	Disease	D003072	Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.
BC8_BioRED_Task1_Doc10	0	39	Ubiquitin carboxyl-terminal esterase L1	Gene	7345	Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma.
BC8_BioRED_Task1_Doc10	41	46	UCHL1	Gene	7345	Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma.
BC8_BioRED_Task1_Doc10	77	83	cancer	Disease	D009369	Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma.
BC8_BioRED_Task1_Doc10	123	129	glioma	Disease	D005910	Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma.
BC8_BioRED_Task1_Doc10	152	159	gliomas	Disease	D005910	Pediatric high-grade gliomas represent 8-12% of all primary tumors of the nervous system in children.
BC8_BioRED_Task1_Doc10	191	197	tumors	Disease	D009369	Pediatric high-grade gliomas represent 8-12% of all primary tumors of the nervous system in children.
BC8_BioRED_Task1_Doc10	283	289	tumors	Disease	D009369	Five-year survival for these pediatric aggressive tumors is poor (15-35%) indicating the need to develop better treatments for pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	381	388	gliomas	Disease	D005910	Five-year survival for these pediatric aggressive tumors is poor (15-35%) indicating the need to develop better treatments for pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	411	416	SF188	CellLine	CVCL_6948	In this work we used SF188 and SJ-GBM2 cell lines to study the function of the ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	421	428	SJ-GBM2	CellLine	CVCL_M141	In this work we used SF188 and SJ-GBM2 cell lines to study the function of the ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	469	508	ubiquitin carboxyl-terminal esterase L1	Gene	7345	In this work we used SF188 and SJ-GBM2 cell lines to study the function of the ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	510	515	UCHL1	Gene	7345	In this work we used SF188 and SJ-GBM2 cell lines to study the function of the ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	559	566	cancers	Disease	D009369	In this work we used SF188 and SJ-GBM2 cell lines to study the function of the ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	592	599	gliomas	Disease	D005910	In this work we used SF188 and SJ-GBM2 cell lines to study the function of the ubiquitin carboxyl-terminal esterase L1 (UCHL1), a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas.
BC8_BioRED_Task1_Doc10	601	606	UCHL1	Gene	7345	UCHL1 depletion in SF188 and SJ-GBM2 glioma cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres (i.e.
BC8_BioRED_Task1_Doc10	620	625	SF188	CellLine	CVCL_6948	UCHL1 depletion in SF188 and SJ-GBM2 glioma cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres (i.e.
BC8_BioRED_Task1_Doc10	630	637	SJ-GBM2	CellLine	CVCL_M141	UCHL1 depletion in SF188 and SJ-GBM2 glioma cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres (i.e.
BC8_BioRED_Task1_Doc10	638	644	glioma	Disease	D005910	UCHL1 depletion in SF188 and SJ-GBM2 glioma cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres (i.e.
BC8_BioRED_Task1_Doc10	759	763	agar	Chemical	D000362	UCHL1 depletion in SF188 and SJ-GBM2 glioma cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres (i.e.
BC8_BioRED_Task1_Doc10	832	835	Wnt	Gene	7474	A 70% reduction in Wnt signaling was also observed in the SF188 and SJ-GBM2 UCHL1 knockdowns (KDs) using a TCF-dependent TOPflash reporter assay.
BC8_BioRED_Task1_Doc10	871	876	SF188	CellLine	CVCL_6948	A 70% reduction in Wnt signaling was also observed in the SF188 and SJ-GBM2 UCHL1 knockdowns (KDs) using a TCF-dependent TOPflash reporter assay.
BC8_BioRED_Task1_Doc10	881	888	SJ-GBM2	CellLine	CVCL_M141	A 70% reduction in Wnt signaling was also observed in the SF188 and SJ-GBM2 UCHL1 knockdowns (KDs) using a TCF-dependent TOPflash reporter assay.
BC8_BioRED_Task1_Doc10	889	894	UCHL1	Gene	7345	A 70% reduction in Wnt signaling was also observed in the SF188 and SJ-GBM2 UCHL1 knockdowns (KDs) using a TCF-dependent TOPflash reporter assay.
BC8_BioRED_Task1_Doc10	920	923	TCF	Gene	6934	A 70% reduction in Wnt signaling was also observed in the SF188 and SJ-GBM2 UCHL1 knockdowns (KDs) using a TCF-dependent TOPflash reporter assay.
BC8_BioRED_Task1_Doc10	988	993	UCHL1	Gene	7345	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1158	1164	cancer	Disease	D009369	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1170	1175	ACTA2	Gene	59	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1177	1182	POSTN	Gene	10631	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1184	1187	LIF	Gene	3976	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1189	1194	FBXL7	Gene	23194	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1196	1202	FBXW11	Gene	23291	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1204	1209	GDF15	Gene	9518	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1211	1215	HEY2	Gene	23493	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1256	1261	IGLL5	Gene	100423062	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1263	1268	ABCA4	Gene	24	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1270	1274	AQP3	Gene	360	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1276	1280	AQP4	Gene	361	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1282	1287	CALB1	Gene	793	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1293	1296	ALK	Gene	238	Transcriptome comparisons of UCHL1 KDs versus vector control identified a list of 306 differentially expressed genes (at least 2-fold change; p    <0.05) which included genes known to be involved in cancer like ACTA2, POSTN, LIF, FBXL7, FBXW11, GDF15, HEY2, but also potential novel genes such us IGLL5, ABCA4, AQP3, AQP4, CALB1, and ALK.
BC8_BioRED_Task1_Doc10	1725	1733	Clathrin	Gene	1213	Top canonical pathways identified by Ingenuity Pathway Analysis (IPA) included "Clathrin-mediated Endocytosis Signaling" (p = 5.14x10-4), "Virus Entry via Endocytic Pathways" (p = 6.15x 10-4), and "High Mobility Group-Box 1 (HMGB1) Signaling" (p = 6.15x10-4).
BC8_BioRED_Task1_Doc10	1843	1868	High Mobility Group-Box 1	Gene	3146	Top canonical pathways identified by Ingenuity Pathway Analysis (IPA) included "Clathrin-mediated Endocytosis Signaling" (p = 5.14x10-4), "Virus Entry via Endocytic Pathways" (p = 6.15x 10-4), and "High Mobility Group-Box 1 (HMGB1) Signaling" (p = 6.15x10-4).
BC8_BioRED_Task1_Doc10	1870	1875	HMGB1	Gene	3146	Top canonical pathways identified by Ingenuity Pathway Analysis (IPA) included "Clathrin-mediated Endocytosis Signaling" (p = 5.14x10-4), "Virus Entry via Endocytic Pathways" (p = 6.15x 10-4), and "High Mobility Group-Box 1 (HMGB1) Signaling" (p = 6.15x10-4).
BC8_BioRED_Task1_Doc10	1911	1915	FGF2	Gene	2247	While FGF2, IL1B, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the UCHL1 KD-associated transcriptome.
BC8_BioRED_Task1_Doc10	1917	1921	IL1B	Gene	3553	While FGF2, IL1B, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the UCHL1 KD-associated transcriptome.
BC8_BioRED_Task1_Doc10	1923	1926	TNF	Gene	7124	While FGF2, IL1B, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the UCHL1 KD-associated transcriptome.
BC8_BioRED_Task1_Doc10	1931	1936	PDGFB	Gene	5155	While FGF2, IL1B, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the UCHL1 KD-associated transcriptome.
BC8_BioRED_Task1_Doc10	2003	2008	UCHL1	Gene	7345	While FGF2, IL1B, TNF and PDGFB were predicted as top upstream regulators (p    < 2x10-16) of the UCHL1 KD-associated transcriptome.
BC8_BioRED_Task1_Doc10	2061	2066	UCHL1	Gene	7345	Aberrant expression of UCHL1 in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/Beta catenin activity.
BC8_BioRED_Task1_Doc10	2091	2098	gliomas	Disease	D005910	Aberrant expression of UCHL1 in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/Beta catenin activity.
BC8_BioRED_Task1_Doc10	2203	2206	Wnt	Gene	7474	Aberrant expression of UCHL1 in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/Beta catenin activity.
BC8_BioRED_Task1_Doc10	2207	2219	Beta catenin	Gene	1499	Aberrant expression of UCHL1 in pediatric high-grade gliomas may promote cell invasion, transformation, and self-renewal properties, at least in part, by modulating Wnt/Beta catenin activity.
BC8_BioRED_Task1_Doc10	2230	2235	UCHL1	Gene	7345	UCHL1 might act as an oncogene in glioma within the gene network that imparts stem-like characteristics to these cancer cells.
BC8_BioRED_Task1_Doc10	2264	2270	glioma	Disease	D005910	UCHL1 might act as an oncogene in glioma within the gene network that imparts stem-like characteristics to these cancer cells.
BC8_BioRED_Task1_Doc10	2343	2349	cancer	Disease	D009369	UCHL1 might act as an oncogene in glioma within the gene network that imparts stem-like characteristics to these cancer cells.
BC8_BioRED_Task1_Doc11	11	16	human	OrganismTaxon	9606	Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients.
BC8_BioRED_Task1_Doc11	17	62	very-long-chain acyl-coenzyme A dehydrogenase	Gene	37	Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients.
BC8_BioRED_Task1_Doc11	119	127	patients	OrganismTaxon	9606	Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients.
BC8_BioRED_Task1_Doc11	220	225	human	OrganismTaxon	9606	Two overlapping cDNA clones (1, 991 bp and 736 bp, respectively) encoding the precursor of human mitochondrial very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) were cloned and sequenced.
BC8_BioRED_Task1_Doc11	240	285	very-long-chain acyl-coenzyme A dehydrogenase	Gene	37	Two overlapping cDNA clones (1, 991 bp and 736 bp, respectively) encoding the precursor of human mitochondrial very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) were cloned and sequenced.
BC8_BioRED_Task1_Doc11	287	292	VLCAD	Gene	37	Two overlapping cDNA clones (1, 991 bp and 736 bp, respectively) encoding the precursor of human mitochondrial very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) were cloned and sequenced.
BC8_BioRED_Task1_Doc11	543	548	VLCAD	Gene	37	PCR-amplified VLCAD cDNAs were sequenced in cultured fibroblasts from two VLCAD-deficient patients.
BC8_BioRED_Task1_Doc11	603	618	VLCAD-deficient	Disease	C536353	PCR-amplified VLCAD cDNAs were sequenced in cultured fibroblasts from two VLCAD-deficient patients.
BC8_BioRED_Task1_Doc11	619	627	patients	OrganismTaxon	9606	PCR-amplified VLCAD cDNAs were sequenced in cultured fibroblasts from two VLCAD-deficient patients.
BC8_BioRED_Task1_Doc11	637	645	patients	OrganismTaxon	9606	In both patients, a 105-bp deletion encompassing bases 1078-1182 in VLCAD cDNA was identified.
BC8_BioRED_Task1_Doc11	649	693	105-bp deletion encompassing bases 1078-1182	SequenceVariant	c|DEL|1078-1182|	In both patients, a 105-bp deletion encompassing bases 1078-1182 in VLCAD cDNA was identified.
BC8_BioRED_Task1_Doc11	697	702	VLCAD	Gene	37	In both patients, a 105-bp deletion encompassing bases 1078-1182 in VLCAD cDNA was identified.
BC8_BioRED_Task1_Doc11	794	799	VLCAD	Gene	37	The deletion seems to occur due to exon skipping during processing of VLCAD pre-mRNA.
BC8_BioRED_Task1_Doc11	864	880	VLCAD deficiency	Disease	C536353	This is the first demonstration of a mutation causing VLCAD deficiency.
BC8_BioRED_Task1_Doc11	921	926	human	OrganismTaxon	9606	Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the deficiency of the normal VLCAD protein causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.
BC8_BioRED_Task1_Doc11	927	932	VLCAD	Gene	37	Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the deficiency of the normal VLCAD protein causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.
BC8_BioRED_Task1_Doc11	954	962	patients	OrganismTaxon	9606	Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the deficiency of the normal VLCAD protein causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.
BC8_BioRED_Task1_Doc11	1033	1071	deficiency of the normal VLCAD protein	Disease	C536353	Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the deficiency of the normal VLCAD protein causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.
BC8_BioRED_Task1_Doc11	1088	1109	long-chain fatty acid	Chemical	D005227	Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the deficiency of the normal VLCAD protein causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.
BC8_BioRED_Task1_Doc11	1141	1149	patients	OrganismTaxon	9606	Quantitative cDNA expression of normal human VLCAD was performed in the patients fibroblasts, using vaccinia viral system, which demonstrated that the deficiency of the normal VLCAD protein causes impaired long-chain fatty acid beta-oxidation activity in the patients fibroblasts.
BC8_BioRED_Task1_Doc11	1166	1173	patient	OrganismTaxon	9606	In patient fibroblasts, raising VLCAD activity to approximately 20% of normal control fibroblast activity raised palmitic acid beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for VLCAD deficiency..
BC8_BioRED_Task1_Doc11	1195	1200	VLCAD	Gene	37	In patient fibroblasts, raising VLCAD activity to approximately 20% of normal control fibroblast activity raised palmitic acid beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for VLCAD deficiency..
BC8_BioRED_Task1_Doc11	1276	1289	palmitic acid	Chemical	D019308	In patient fibroblasts, raising VLCAD activity to approximately 20% of normal control fibroblast activity raised palmitic acid beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for VLCAD deficiency..
BC8_BioRED_Task1_Doc11	1450	1466	VLCAD deficiency	Disease	C536353	In patient fibroblasts, raising VLCAD activity to approximately 20% of normal control fibroblast activity raised palmitic acid beta-oxidation flux to the level found in control fibroblasts, which may offer important information for the rational design of future somatic gene therapy for VLCAD deficiency..
BC8_BioRED_Task1_Doc12	10	17	alcohol	Chemical	D000431	Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures.
BC8_BioRED_Task1_Doc12	197	204	alcohol	Chemical	D000431	BACKGROUND: More than 3 decades after Jones and Smith (1973) reported on the devastation caused by alcohol exposure on fetal development, the rates of heavy drinking during pregnancy remain relatively unchanged.
BC8_BioRED_Task1_Doc12	340	347	alcohol	Chemical	D000431	Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes.
BC8_BioRED_Task1_Doc12	470	477	alcohol	Chemical	D000431	This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.
BC8_BioRED_Task1_Doc12	492	509	growth impairment	Disease	D006130	This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.
BC8_BioRED_Task1_Doc12	660	667	alcohol	Chemical	D000431	METHODS: We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study.
BC8_BioRED_Task1_Doc12	711	716	women	OrganismTaxon	9606	The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies.
BC8_BioRED_Task1_Doc12	794	799	women	OrganismTaxon	9606	The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies.
BC8_BioRED_Task1_Doc12	893	900	alcohol	Chemical	D000431	Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.
BC8_BioRED_Task1_Doc12	1045	1052	alcohol	Chemical	D000431	Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.
BC8_BioRED_Task1_Doc12	1395	1405	drug abuse	Disease	D019966	Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.
BC8_BioRED_Task1_Doc12	1505	1510	women	OrganismTaxon	9606	When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns.
BC8_BioRED_Task1_Doc12	1630	1637	alcohol	Chemical	D000431	When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns.
BC8_BioRED_Task1_Doc12	1696	1703	alcohol	Chemical	D000431	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.
BC8_BioRED_Task1_Doc12	1779	1804	reduced cerebellar growth	Disease	D006130	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.
BC8_BioRED_Task1_Doc12	1816	1848	decreased cranial to body growth	Disease	D006130	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.
BC8_BioRED_Task1_Doc12	1868	1873	women	OrganismTaxon	9606	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.
BC8_BioRED_Task1_Doc12	1924	1935	Amphetamine	Chemical	D000661	Amphetamine abuse was predictive of larger cranial to body growth ratios.
BC8_BioRED_Task1_Doc12	2378	2385	alcohol	Chemical	D000431	Although the reliance on self-reported drinking is a limitation in this study, these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects.
BC8_BioRED_Task1_Doc13	25	30	OCT4A	Gene	5460	Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide.
BC8_BioRED_Task1_Doc13	61	80	embryonal carcinoma	Disease	D018236	Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide.
BC8_BioRED_Task1_Doc13	100	109	etoposide	Chemical	D005047	Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide.
BC8_BioRED_Task1_Doc13	326	332	tumors	Disease	D009369	This observation is critical as it directly impinges upon the response of tumors to current chemo-radio-therapy treatment regimens.
BC8_BioRED_Task1_Doc13	421	430	etoposide	Chemical	D005047	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	432	435	ETO	Chemical	D005047	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	447	466	embryonal carcinoma	Disease	D018236	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	467	471	PA-1	CellLine	CVCL_0479	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	488	491	p53	Gene	7157	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	518	523	OCT4A	Gene	5460	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	528	535	p21Cip1	Gene	1026	Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively).
BC8_BioRED_Task1_Doc13	733	737	PA-1	CellLine	CVCL_0479	PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe.
BC8_BioRED_Task1_Doc13	757	760	ETO	Chemical	D005047	PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe.
BC8_BioRED_Task1_Doc13	803	808	OCT4A	Gene	5460	PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe.
BC8_BioRED_Task1_Doc13	813	820	p21Cip1	Gene	1026	PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe.
BC8_BioRED_Task1_Doc13	873	878	OCT4A	Gene	5460	Silencing OCT4A suppresses p21Cip1, changes cell cycle regulation and subsequently suppresses terminal senescence; p21Cip1-silencing did not affect OCT4A expression or cellular phenotype.
BC8_BioRED_Task1_Doc13	890	897	p21Cip1	Gene	1026	Silencing OCT4A suppresses p21Cip1, changes cell cycle regulation and subsequently suppresses terminal senescence; p21Cip1-silencing did not affect OCT4A expression or cellular phenotype.
BC8_BioRED_Task1_Doc13	978	985	p21Cip1	Gene	1026	Silencing OCT4A suppresses p21Cip1, changes cell cycle regulation and subsequently suppresses terminal senescence; p21Cip1-silencing did not affect OCT4A expression or cellular phenotype.
BC8_BioRED_Task1_Doc13	1011	1016	OCT4A	Gene	5460	Silencing OCT4A suppresses p21Cip1, changes cell cycle regulation and subsequently suppresses terminal senescence; p21Cip1-silencing did not affect OCT4A expression or cellular phenotype.
BC8_BioRED_Task1_Doc13	1051	1055	SOX2	Gene	6657	SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of OCT4A from its pluripotency function.
BC8_BioRED_Task1_Doc13	1060	1065	NANOG	Gene	79923	SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of OCT4A from its pluripotency function.
BC8_BioRED_Task1_Doc13	1102	1105	ETO	Chemical	D005047	SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of OCT4A from its pluripotency function.
BC8_BioRED_Task1_Doc13	1145	1150	OCT4A	Gene	5460	SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of OCT4A from its pluripotency function.
BC8_BioRED_Task1_Doc13	1192	1195	ETO	Chemical	D005047	Instead, ETO-induced OCT4A was concomitant with activation of AMPK, a key component of metabolic stress and autophagy regulation.
BC8_BioRED_Task1_Doc13	1204	1209	OCT4A	Gene	5460	Instead, ETO-induced OCT4A was concomitant with activation of AMPK, a key component of metabolic stress and autophagy regulation.
BC8_BioRED_Task1_Doc13	1245	1249	AMPK	Gene	5562	Instead, ETO-induced OCT4A was concomitant with activation of AMPK, a key component of metabolic stress and autophagy regulation.
BC8_BioRED_Task1_Doc13	1313	1321	p16ink4a	Gene	1029	p16ink4a, the inducer of terminal senescence, underwent autophagic sequestration in the cytoplasm of ETO-treated cells, allowing alternative cell fates.
BC8_BioRED_Task1_Doc13	1414	1417	ETO	Chemical	D005047	p16ink4a, the inducer of terminal senescence, underwent autophagic sequestration in the cytoplasm of ETO-treated cells, allowing alternative cell fates.
BC8_BioRED_Task1_Doc13	1538	1546	p16ink4a	Gene	1029	Accordingly, failure of autophagy was accompanied by an accumulation of p16ink4a, nuclear disintegration, and loss of cell recovery.
BC8_BioRED_Task1_Doc13	1635	1640	OCT4A	Gene	5460	Together, these findings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of p21Cip1, which alongside AMPK helps to then regulate autophagy.
BC8_BioRED_Task1_Doc13	1675	1679	PA-1	CellLine	CVCL_0479	Together, these findings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of p21Cip1, which alongside AMPK helps to then regulate autophagy.
BC8_BioRED_Task1_Doc13	1778	1785	p21Cip1	Gene	1026	Together, these findings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of p21Cip1, which alongside AMPK helps to then regulate autophagy.
BC8_BioRED_Task1_Doc13	1803	1807	AMPK	Gene	5562	Together, these findings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of p21Cip1, which alongside AMPK helps to then regulate autophagy.
BC8_BioRED_Task1_Doc14	13	17	POLG	Gene	5428	Mono-allelic POLG expression resulting from nonsense-mediated decay and alternative splicing in a patient with Alpers syndrome.
BC8_BioRED_Task1_Doc14	98	105	patient	OrganismTaxon	9606	Mono-allelic POLG expression resulting from nonsense-mediated decay and alternative splicing in a patient with Alpers syndrome.
BC8_BioRED_Task1_Doc14	111	126	Alpers syndrome	Disease	D002549	Mono-allelic POLG expression resulting from nonsense-mediated decay and alternative splicing in a patient with Alpers syndrome.
BC8_BioRED_Task1_Doc14	128	143	Alpers syndrome	Disease	D002549	Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults.
BC8_BioRED_Task1_Doc14	170	197	mitochondrial DNA depletion	Disease	D028361	Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults.
BC8_BioRED_Task1_Doc14	301	314	liver disease	Disease	D008107	It is characterized by a progressive, fatal brain and liver disease.
BC8_BioRED_Task1_Doc14	368	372	POLG	Gene	5428	This syndrome has been associated with mutations in POLG, the gene encoding the mitochondrial DNA polymerase (pol gamma).
BC8_BioRED_Task1_Doc14	426	435	pol gamma	Gene	5428	This syndrome has been associated with mutations in POLG, the gene encoding the mitochondrial DNA polymerase (pol gamma).
BC8_BioRED_Task1_Doc14	443	451	patients	OrganismTaxon	9606	Most patients with Alpers syndrome have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the POLG locus.
BC8_BioRED_Task1_Doc14	457	472	Alpers syndrome	Disease	D002549	Most patients with Alpers syndrome have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the POLG locus.
BC8_BioRED_Task1_Doc14	569	573	POLG	Gene	5428	Most patients with Alpers syndrome have been found to be compound heterozygotes, carrying two pathogenic mutations in trans at the POLG locus.
BC8_BioRED_Task1_Doc14	581	585	POLG	Gene	5428	POLG is a nuclear-encoded gene whose protein product is imported into mitochondria, where it is essential for mtDNA replication and repair.
BC8_BioRED_Task1_Doc14	758	765	patient	OrganismTaxon	9606	We studied the skin fibroblasts of a patient with Alpers syndrome having the genotype E873stop/A467T.
BC8_BioRED_Task1_Doc14	771	786	Alpers syndrome	Disease	D002549	We studied the skin fibroblasts of a patient with Alpers syndrome having the genotype E873stop/A467T.
BC8_BioRED_Task1_Doc14	807	815	E873stop	SequenceVariant	rs121918047	We studied the skin fibroblasts of a patient with Alpers syndrome having the genotype E873stop/A467T.
BC8_BioRED_Task1_Doc14	816	821	A467T	SequenceVariant	rs113994095	We studied the skin fibroblasts of a patient with Alpers syndrome having the genotype E873stop/A467T.
BC8_BioRED_Task1_Doc14	827	835	E873stop	SequenceVariant	rs121918047	The E873stop mutation produces a premature termination codon (TAG) in exon 17.
BC8_BioRED_Task1_Doc14	906	911	A467T	SequenceVariant	rs113994095	The A467T mutation produces a threonine to alanine substitution at a highly conserved site in exon 7.
BC8_BioRED_Task1_Doc14	932	952	threonine to alanine	SequenceVariant	rs113994095	The A467T mutation produces a threonine to alanine substitution at a highly conserved site in exon 7.
BC8_BioRED_Task1_Doc14	1039	1047	E873-TAG	SequenceVariant	rs121918047	The allele bearing the stop codon (E873-TAG) is predicted to produce a truncated, catalytically inactive polymerase.
BC8_BioRED_Task1_Doc14	1147	1156	pol gamma	Gene	5428	However, only full-length pol gamma protein was detected by Western blot analysis.
BC8_BioRED_Task1_Doc14	1372	1376	POLG	Gene	5428	More than 95% of the functional POLG mRNA was derived from the allele bearing the A467T mutation and less than 5% contained the E873stop mutation.
BC8_BioRED_Task1_Doc14	1422	1427	A467T	SequenceVariant	rs113994095	More than 95% of the functional POLG mRNA was derived from the allele bearing the A467T mutation and less than 5% contained the E873stop mutation.
BC8_BioRED_Task1_Doc14	1468	1476	E873stop	SequenceVariant	rs121918047	More than 95% of the functional POLG mRNA was derived from the allele bearing the A467T mutation and less than 5% contained the E873stop mutation.
BC8_BioRED_Task1_Doc14	1527	1531	POLG	Gene	5428	These events ensured that virtually all POLG protein in the cell was expressed from the A467T allele.
BC8_BioRED_Task1_Doc14	1575	1580	A467T	SequenceVariant	rs113994095	These events ensured that virtually all POLG protein in the cell was expressed from the A467T allele.
BC8_BioRED_Task1_Doc14	1629	1636	patient	OrganismTaxon	9606	Therefore, the Alpers phenotype in this patient was a consequence of a single-copy gene dose of the A467T allele, and selective elimination of transcripts bearing the E873stop mutation.
BC8_BioRED_Task1_Doc14	1689	1694	A467T	SequenceVariant	rs113994095	Therefore, the Alpers phenotype in this patient was a consequence of a single-copy gene dose of the A467T allele, and selective elimination of transcripts bearing the E873stop mutation.
BC8_BioRED_Task1_Doc14	1756	1764	E873stop	SequenceVariant	rs121918047	Therefore, the Alpers phenotype in this patient was a consequence of a single-copy gene dose of the A467T allele, and selective elimination of transcripts bearing the E873stop mutation.
BC8_BioRED_Task1_Doc15	43	78	multiple endocrine neoplasia type 1	Disease	D018761	Mutation analysis in a Chinese family with multiple endocrine neoplasia type 1.
BC8_BioRED_Task1_Doc15	92	127	Multiple endocrine neoplasia type 1	Disease	D018761	BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer syndrome which is caused by germline mutations of the tumor suppressor gene MEN1.
BC8_BioRED_Task1_Doc15	129	133	MEN1	Disease	D018761	BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer syndrome which is caused by germline mutations of the tumor suppressor gene MEN1.
BC8_BioRED_Task1_Doc15	141	175	autosomal dominant cancer syndrome	Disease	D009386	BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer syndrome which is caused by germline mutations of the tumor suppressor gene MEN1.
BC8_BioRED_Task1_Doc15	221	226	tumor	Disease	D009369	BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer syndrome which is caused by germline mutations of the tumor suppressor gene MEN1.
BC8_BioRED_Task1_Doc15	243	247	MEN1	Gene	4221	BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer syndrome which is caused by germline mutations of the tumor suppressor gene MEN1.
BC8_BioRED_Task1_Doc15	315	319	MEN1	Disease	D018761	This study aimed to identify mutations in a Chinese pedigree with MEN1.
BC8_BioRED_Task1_Doc15	358	362	MEN1	Disease	D018761	METHODS: A large Chinese family with MEN1 was collected.
BC8_BioRED_Task1_Doc15	439	443	MEN1	Gene	4221	All of the coded regions and their adjacent sequences of the MEN1 gene were amplified and sequenced.
BC8_BioRED_Task1_Doc15	519	537	cytosine insertion	SequenceVariant	c|INS||C	RESULTS: In this family, a heterozygous cytosine insertion in exon 10 (c.1546_1547insC) inducing a frame shift mutation of MEN1 was found in the proband and the other two suffering members of his family.
BC8_BioRED_Task1_Doc15	550	565	c.1546_1547insC	SequenceVariant	c|INS|1546_1547|C	RESULTS: In this family, a heterozygous cytosine insertion in exon 10 (c.1546_1547insC) inducing a frame shift mutation of MEN1 was found in the proband and the other two suffering members of his family.
BC8_BioRED_Task1_Doc15	602	606	MEN1	Gene	4221	RESULTS: In this family, a heterozygous cytosine insertion in exon 10 (c.1546_1547insC) inducing a frame shift mutation of MEN1 was found in the proband and the other two suffering members of his family.
BC8_BioRED_Task1_Doc15	769	783	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T	This mutation was linked to a novel single nucleotide polymorphism (SNP) in intron 3 (IVS3 + 18C > T).
BC8_BioRED_Task1_Doc15	826	830	MEN1	Gene	4221	CONCLUSIONS: The mutation in exon 10 of MEN1 gene might induce development of parathyroid hyperplasia and pituitary adenoma and cosegregate with MEN1 syndrome.
BC8_BioRED_Task1_Doc15	864	887	parathyroid hyperplasia	Disease	D006965	CONCLUSIONS: The mutation in exon 10 of MEN1 gene might induce development of parathyroid hyperplasia and pituitary adenoma and cosegregate with MEN1 syndrome.
BC8_BioRED_Task1_Doc15	892	909	pituitary adenoma	Disease	D010911	CONCLUSIONS: The mutation in exon 10 of MEN1 gene might induce development of parathyroid hyperplasia and pituitary adenoma and cosegregate with MEN1 syndrome.
BC8_BioRED_Task1_Doc15	931	944	MEN1 syndrome	Disease	D018761	CONCLUSIONS: The mutation in exon 10 of MEN1 gene might induce development of parathyroid hyperplasia and pituitary adenoma and cosegregate with MEN1 syndrome.
BC8_BioRED_Task1_Doc15	980	994	IVS3 + 18C > T	SequenceVariant	c|SUB|C|IVS3+18|T	The significance of the new found IVS3 + 18C > T of MEN1 needs a further investigation.
BC8_BioRED_Task1_Doc15	998	1002	MEN1	Gene	4221	The significance of the new found IVS3 + 18C > T of MEN1 needs a further investigation.
BC8_BioRED_Task1_Doc16	3	12	Ag-globin	Gene	3047	An Ag-globin G->A gene polymorphism associated with b(0)39 thalassemia globin gene and high fetal hemoglobin production.
BC8_BioRED_Task1_Doc16	13	17	G->A	SequenceVariant	rs368698783	An Ag-globin G->A gene polymorphism associated with b(0)39 thalassemia globin gene and high fetal hemoglobin production.
BC8_BioRED_Task1_Doc16	52	77	b(0)39 thalassemia globin	Gene	3043	An Ag-globin G->A gene polymorphism associated with b(0)39 thalassemia globin gene and high fetal hemoglobin production.
BC8_BioRED_Task1_Doc16	92	108	fetal hemoglobin	Gene	3040,3048	An Ag-globin G->A gene polymorphism associated with b(0)39 thalassemia globin gene and high fetal hemoglobin production.
BC8_BioRED_Task1_Doc16	163	171	g-globin	Gene	3047,3048	BACKGROUND: Increase of the expression of g-globin gene and high production of fetal hemoglobin (HbF) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.
BC8_BioRED_Task1_Doc16	200	216	fetal hemoglobin	Gene	3040,3048	BACKGROUND: Increase of the expression of g-globin gene and high production of fetal hemoglobin (HbF) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.
BC8_BioRED_Task1_Doc16	218	221	HbF	Gene	3040,3048	BACKGROUND: Increase of the expression of g-globin gene and high production of fetal hemoglobin (HbF) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.
BC8_BioRED_Task1_Doc16	226	239	b-thalassemia	Disease	D017086	BACKGROUND: Increase of the expression of g-globin gene and high production of fetal hemoglobin (HbF) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.
BC8_BioRED_Task1_Doc16	240	248	patients	OrganismTaxon	9606	BACKGROUND: Increase of the expression of g-globin gene and high production of fetal hemoglobin (HbF) in b-thalassemia patients is widely accepted as associated with a milder or even asymptomatic disease.
BC8_BioRED_Task1_Doc16	341	344	HbF	Gene	3040,3048	The search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
BC8_BioRED_Task1_Doc16	389	395	BCL11A	Gene	53335	The search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
BC8_BioRED_Task1_Doc16	400	403	MYB	Gene	4602	The search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
BC8_BioRED_Task1_Doc16	477	490	b-thalassemia	Disease	D017086	The search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
BC8_BioRED_Task1_Doc16	491	499	patients	OrganismTaxon	9606	The search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
BC8_BioRED_Task1_Doc16	598	601	HbF	Gene	3040,3048	The search for HbF-associated polymorphisms (such as the XmnI, BCL11A and MYB polymorphisms) has recently gained great attention, in order to stratify b-thalassemia patients with respect to expectancy of the first transfusion, need for annual intake of blood, response to HbF inducers (the most studied of which is hydroxyurea).
BC8_BioRED_Task1_Doc16	664	673	Ag-globin	Gene	3047	METHODS: Ag-globin gene sequencing was performed on genomic DNA isolated from a total of 75 b-thalassemia patients, including 31 b(0)39/b(0)39, 33 b(0)39/b(+)IVSI-110, 9 b(+)IVSI-110/b(+)IVSI-110, one b(0)IVSI-1/b(+)IVSI-6 and one b(0)39/b(+)IVSI-6.
BC8_BioRED_Task1_Doc16	747	760	b-thalassemia	Disease	D017086	METHODS: Ag-globin gene sequencing was performed on genomic DNA isolated from a total of 75 b-thalassemia patients, including 31 b(0)39/b(0)39, 33 b(0)39/b(+)IVSI-110, 9 b(+)IVSI-110/b(+)IVSI-110, one b(0)IVSI-1/b(+)IVSI-6 and one b(0)39/b(+)IVSI-6.
BC8_BioRED_Task1_Doc16	761	769	patients	OrganismTaxon	9606	METHODS: Ag-globin gene sequencing was performed on genomic DNA isolated from a total of 75 b-thalassemia patients, including 31 b(0)39/b(0)39, 33 b(0)39/b(+)IVSI-110, 9 b(+)IVSI-110/b(+)IVSI-110, one b(0)IVSI-1/b(+)IVSI-6 and one b(0)39/b(+)IVSI-6.
BC8_BioRED_Task1_Doc16	940	951	rs368698783	SequenceVariant	rs368698783	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	979	992	b-thalassemia	Disease	D017086	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	993	1001	patients	OrganismTaxon	9606	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	1037	1046	Ag-globin	Gene	3047	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	1073	1077	LYAR	Gene	55646	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	1079	1084	human	OrganismTaxon	9606	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	1098	1103	mouse	OrganismTaxon	10090	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	1104	1132	Ly-1 antibody reactive clone	Gene	17089	RESULTS: The results show that the rs368698783 polymorphism is present in b-thalassemia patients in the 5'UTR sequence (+25) of the Ag-globin gene, known to affect the LYAR (human homologue of mouse Ly-1 antibody reactive clone) binding site 5'-GGTTAT-3'.
BC8_BioRED_Task1_Doc16	1166	1168	Ag	Gene	3047	This Ag(+25 G->A) polymorphism is associated with the Gg-globin-XmnI polymorphism and both are linked with the b(0)39-globin gene, but not with the b(+)IVSI-110-globin gene.
BC8_BioRED_Task1_Doc16	1169	1177	+25 G->A	SequenceVariant	rs368698783	This Ag(+25 G->A) polymorphism is associated with the Gg-globin-XmnI polymorphism and both are linked with the b(0)39-globin gene, but not with the b(+)IVSI-110-globin gene.
BC8_BioRED_Task1_Doc16	1215	1224	Gg-globin	Gene	3048	This Ag(+25 G->A) polymorphism is associated with the Gg-globin-XmnI polymorphism and both are linked with the b(0)39-globin gene, but not with the b(+)IVSI-110-globin gene.
BC8_BioRED_Task1_Doc16	1272	1285	b(0)39-globin	Gene	3043	This Ag(+25 G->A) polymorphism is associated with the Gg-globin-XmnI polymorphism and both are linked with the b(0)39-globin gene, but not with the b(+)IVSI-110-globin gene.
BC8_BioRED_Task1_Doc16	1309	1328	b(+)IVSI-110-globin	Gene	3043	This Ag(+25 G->A) polymorphism is associated with the Gg-globin-XmnI polymorphism and both are linked with the b(0)39-globin gene, but not with the b(+)IVSI-110-globin gene.
BC8_BioRED_Task1_Doc16	1399	1403	LYAR	Gene	55646	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1440	1442	Ag	Gene	3047	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1443	1451	+25 G->A	SequenceVariant	rs368698783	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1457	1466	Gg-globin	Gene	3048	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1511	1514	HbF	Gene	3040,3048	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1558	1583	b(0)39/b(0)39 thalassemia	Disease	D017086	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1584	1592	patients	OrganismTaxon	9606	In agreement with the expectation that this mutation alters the LYAR binding activity, we found that the Ag(+25 G->A) and Gg-globin-XmnI polymorphisms are associated with high HbF in erythroid precursor cells isolated from b(0)39/b(0)39 thalassemia patients.
BC8_BioRED_Task1_Doc16	1674	1687	b-thalassemia	Disease	D017086	CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e.
BC8_BioRED_Task1_Doc16	1692	1701	Gg-globin	Gene	3048	CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e.
BC8_BioRED_Task1_Doc16	1707	1716	Ag-globin	Gene	3047	CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e.
BC8_BioRED_Task1_Doc16	1718	1722	G->A	SequenceVariant	rs368698783	CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e.
BC8_BioRED_Task1_Doc16	1774	1790	b(0)-thalassemia	Disease	D017086	CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e.
BC8_BioRED_Task1_Doc16	1819	1835	b(+)-thalassemia	Disease	D017086	CONCLUSIONS: As a potential explanation of our findings, we hypothesize that in b-thalassemia the Gg-globin-XmnI/Ag-globin-(G->A) genotype is frequently under genetic linkage with b(0)-thalassemia mutations, but not with the b(+)-thalassemia mutation here studied (i.e.
BC8_BioRED_Task1_Doc16	1955	1971	b(0)-thalassemia	Disease	D017086	b(+)IVSI-110) and that this genetic combination has been selected within the population of b(0)-thalassemia patients, due to functional association with high HbF.
BC8_BioRED_Task1_Doc16	1972	1980	patients	OrganismTaxon	9606	b(+)IVSI-110) and that this genetic combination has been selected within the population of b(0)-thalassemia patients, due to functional association with high HbF.
BC8_BioRED_Task1_Doc16	2022	2025	HbF	Gene	3040,3048	b(+)IVSI-110) and that this genetic combination has been selected within the population of b(0)-thalassemia patients, due to functional association with high HbF.
BC8_BioRED_Task1_Doc16	2072	2083	rs368698783	SequenceVariant	rs368698783	Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in b(0)39 thalassemia patients with high HbF in erythroid precursor cells.
BC8_BioRED_Task1_Doc16	2085	2093	+25 G->A	SequenceVariant	rs368698783	Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in b(0)39 thalassemia patients with high HbF in erythroid precursor cells.
BC8_BioRED_Task1_Doc16	2115	2124	Ag-globin	Gene	3047	Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in b(0)39 thalassemia patients with high HbF in erythroid precursor cells.
BC8_BioRED_Task1_Doc16	2144	2162	b(0)39 thalassemia	Disease	D017086	Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in b(0)39 thalassemia patients with high HbF in erythroid precursor cells.
BC8_BioRED_Task1_Doc16	2163	2171	patients	OrganismTaxon	9606	Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in b(0)39 thalassemia patients with high HbF in erythroid precursor cells.
BC8_BioRED_Task1_Doc16	2182	2185	HbF	Gene	3040,3048	Here we describe the characterization of the rs368698783 (+25 G->A) polymorphism of the Ag-globin gene associated in b(0)39 thalassemia patients with high HbF in erythroid precursor cells.
BC8_BioRED_Task1_Doc17	0	21	Cauda equina syndrome	Disease	D011128	Cauda equina syndrome after epidural steroid injection: a case report.
BC8_BioRED_Task1_Doc17	37	44	steroid	Chemical	D013256	Cauda equina syndrome after epidural steroid injection: a case report.
BC8_BioRED_Task1_Doc17	128	141	radiculopathy	Disease	D011843	OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.
BC8_BioRED_Task1_Doc17	173	180	steroid	Chemical	D013256	OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.
BC8_BioRED_Task1_Doc17	244	265	Cauda equina syndrome	Disease	D011128	Cauda equina syndrome is a rare complication of epidural anesthesia.
BC8_BioRED_Task1_Doc17	347	368	cauda equina syndrome	Disease	D011128	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.
BC8_BioRED_Task1_Doc17	410	423	triamcinolone	Chemical	D014221	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.
BC8_BioRED_Task1_Doc17	428	439	bupivacaine	Chemical	D002045	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.
BC8_BioRED_Task1_Doc17	474	479	woman	OrganismTaxon	9606	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.
BC8_BioRED_Task1_Doc17	485	512	low back and right leg pain	Disease	D010146,D017116	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.
BC8_BioRED_Task1_Doc17	540	547	steroid	Chemical	D013256	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.
BC8_BioRED_Task1_Doc17	808	819	bupivacaine	Chemical	D002045	After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.
BC8_BioRED_Task1_Doc17	824	847	triamcinolone diacetate	Chemical	C030262	After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.
BC8_BioRED_Task1_Doc17	975	983	numbness	Disease	D006987	Three hours later, she complained of perineal numbness and lower extremity weakness.
BC8_BioRED_Task1_Doc17	988	1012	lower extremity weakness	Disease	D020335	Three hours later, she complained of perineal numbness and lower extremity weakness.
BC8_BioRED_Task1_Doc17	1049	1066	loss of sensation	Disease	D006987	The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.
BC8_BioRED_Task1_Doc17	1275	1282	patient	OrganismTaxon	9606	The patient's symptoms improved slightly over the next few hours.
BC8_BioRED_Task1_Doc17	1538	1545	steroid	Chemical	D013256	CONCLUSION: Complications associated with epidural steroid injections are rare.
BC8_BioRED_Task1_Doc17	1616	1640	neurologic deterioration	Disease	D009422	Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.
BC8_BioRED_Task1_Doc17	1656	1663	steroid	Chemical	D013256	Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.
BC8_BioRED_Task1_Doc18	28	37	TGF-beta1	Gene	4052	Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.
BC8_BioRED_Task1_Doc18	51	67	oligonucleotides	Chemical	D009841	Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.
BC8_BioRED_Task1_Doc18	89	135	TGF-beta-isoforms and their receptors I and II	Gene	7046,7048	Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.
BC8_BioRED_Task1_Doc18	165	177	keloid scars	Disease	D007627	Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.
BC8_BioRED_Task1_Doc18	343	349	keloid	Disease	D007627	In susceptible genetically predisposed individuals, keloid formation can be observed.
BC8_BioRED_Task1_Doc18	377	391	Keloid disease	Disease	D007627	Keloid disease represents a benign dermal fibroproliferative tumor that is unique to humans.
BC8_BioRED_Task1_Doc18	438	443	tumor	Disease	D009369	Keloid disease represents a benign dermal fibroproliferative tumor that is unique to humans.
BC8_BioRED_Task1_Doc18	462	468	humans	OrganismTaxon	9606	Keloid disease represents a benign dermal fibroproliferative tumor that is unique to humans.
BC8_BioRED_Task1_Doc18	470	478	TGF-beta	Gene	7040,7042,7043	TGF-beta is known to play a key role in the pathogenesis of this disease which is still not fully understood.
BC8_BioRED_Task1_Doc18	593	602	TGF-beta1	Gene	4052	The isoforms TGF-beta1 and TGF-beta2 have profibrotic properties, whereas TGF-beta3 may have antifibrotic functions.
BC8_BioRED_Task1_Doc18	607	616	TGF-beta2	Gene	7042	The isoforms TGF-beta1 and TGF-beta2 have profibrotic properties, whereas TGF-beta3 may have antifibrotic functions.
BC8_BioRED_Task1_Doc18	654	663	TGF-beta3	Gene	7043	The isoforms TGF-beta1 and TGF-beta2 have profibrotic properties, whereas TGF-beta3 may have antifibrotic functions.
BC8_BioRED_Task1_Doc18	697	705	TGF-beta	Gene	7040,7042,7043	TGF-beta exerts its influence by binding to type I and type II TGF-beta receptors, thereby forming a complex and activating specific downstream effector molecules.
BC8_BioRED_Task1_Doc18	741	778	type I and type II TGF-beta receptors	Gene	7046,7048	TGF-beta exerts its influence by binding to type I and type II TGF-beta receptors, thereby forming a complex and activating specific downstream effector molecules.
BC8_BioRED_Task1_Doc18	916	925	TGF-beta1	Gene	4052	The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts.
BC8_BioRED_Task1_Doc18	949	965	oligonucleotides	Chemical	D009841	The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts.
BC8_BioRED_Task1_Doc18	1013	1021	TGF-beta	Gene	7040,7042,7043	The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts.
BC8_BioRED_Task1_Doc18	1054	1060	keloid	Disease	D007627	The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts.
BC8_BioRED_Task1_Doc18	1172	1192	TGF-beta1 and -beta2	Gene	4052,7042	In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to keloid fibroblasts (KFs), while expression of TGF-beta3 and of TGF-betaRII was significantly higher in NFs.
BC8_BioRED_Task1_Doc18	1224	1230	keloid	Disease	D007627	In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to keloid fibroblasts (KFs), while expression of TGF-beta3 and of TGF-betaRII was significantly higher in NFs.
BC8_BioRED_Task1_Doc18	1270	1279	TGF-beta3	Gene	7043	In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to keloid fibroblasts (KFs), while expression of TGF-beta3 and of TGF-betaRII was significantly higher in NFs.
BC8_BioRED_Task1_Doc18	1287	1298	TGF-betaRII	Gene	7048	In tissue samples with normal fibroblasts (NFs) serving as control samples, expression of TGF-beta1 and -beta2 was decreased when compared to keloid fibroblasts (KFs), while expression of TGF-beta3 and of TGF-betaRII was significantly higher in NFs.
BC8_BioRED_Task1_Doc18	1366	1375	TGF-beta1	Gene	4052	In the ELISA assay, abrogation of TGF-beta1 led to a significant decrease in TGF-beta1 and -beta2 (p<0.05).
BC8_BioRED_Task1_Doc18	1409	1429	TGF-beta1 and -beta2	Gene	4052,7042	In the ELISA assay, abrogation of TGF-beta1 led to a significant decrease in TGF-beta1 and -beta2 (p<0.05).
BC8_BioRED_Task1_Doc18	1454	1463	TGF-beta2	Gene	7042	Expression of TGF-beta2 mRNA was reduced.
BC8_BioRED_Task1_Doc18	1496	1505	TGF-beta3	Gene	7043	Expression of TGF-beta3 mRNA revealed contrary patterns in KFs from different patients while expression of TGF-betaRI was found to be equal during the measurement period.
BC8_BioRED_Task1_Doc18	1560	1568	patients	OrganismTaxon	9606	Expression of TGF-beta3 mRNA revealed contrary patterns in KFs from different patients while expression of TGF-betaRI was found to be equal during the measurement period.
BC8_BioRED_Task1_Doc18	1589	1599	TGF-betaRI	Gene	7046	Expression of TGF-beta3 mRNA revealed contrary patterns in KFs from different patients while expression of TGF-betaRI was found to be equal during the measurement period.
BC8_BioRED_Task1_Doc18	1653	1664	TGF-betaRII	Gene	7048	TGF-betaRII mRNA expression was increased after 48 and 72 h respectively.
BC8_BioRED_Task1_Doc18	1788	1797	TGF-beta1	Gene	4052	There is growing evidence for a regulatory mechanism between TGF-beta1 and its receptors.
BC8_BioRED_Task1_Doc18	1901	1909	TGF-beta	Gene	7040,7042,7043	Our findings support this theory by suggesting interrelations between the different TGF-beta isoforms and their receptors.
BC8_BioRED_Task1_Doc18	2135	2143	TGF-beta	Gene	7040,7042,7043	Improving the understanding of TGF-beta in keloid disease could lead to the development of clinically useful therapeutic modalities for treatment of keloid disease or even allow identification of preventive strategies.
BC8_BioRED_Task1_Doc18	2147	2161	keloid disease	Disease	D007627	Improving the understanding of TGF-beta in keloid disease could lead to the development of clinically useful therapeutic modalities for treatment of keloid disease or even allow identification of preventive strategies.
BC8_BioRED_Task1_Doc18	2253	2267	keloid disease	Disease	D007627	Improving the understanding of TGF-beta in keloid disease could lead to the development of clinically useful therapeutic modalities for treatment of keloid disease or even allow identification of preventive strategies.
BC8_BioRED_Task1_Doc19	47	52	G145R	SequenceVariant	p|SUB|G|145|R	Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
BC8_BioRED_Task1_Doc19	57	62	P120T	SequenceVariant	c|SUB|P|120|T	Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
BC8_BioRED_Task1_Doc19	85	95	lamivudine	Chemical	D019259	Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
BC8_BioRED_Task1_Doc19	106	133	hepatitis B virus e antigen	Chemical	D006513	Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
BC8_BioRED_Task1_Doc19	196	213	hepatitis B virus	OrganismTaxon	10407	Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.
BC8_BioRED_Task1_Doc19	215	218	HBV	OrganismTaxon	10407	Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.
BC8_BioRED_Task1_Doc19	314	317	HBV	OrganismTaxon	10407	Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests.
BC8_BioRED_Task1_Doc19	622	627	G145R	SequenceVariant	p|SUB|G|145|R	We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.
BC8_BioRED_Task1_Doc19	633	638	P120T	SequenceVariant	c|SUB|P|120|T	We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.
BC8_BioRED_Task1_Doc19	774	784	lamivudine	Chemical	D019259	We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.
BC8_BioRED_Task1_Doc19	786	789	LAM	Chemical	D019259	We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.
BC8_BioRED_Task1_Doc19	798	803	HBeAg	Chemical	D006513	We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.
BC8_BioRED_Task1_Doc19	838	841	HBV	OrganismTaxon	10407	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	856	861	G145R	SequenceVariant	p|SUB|G|145|R	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	866	871	P120T	SequenceVariant	c|SUB|P|120|T	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	876	879	LAM	Chemical	D019259	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	894	899	M204I	SequenceVariant	p|SUB|M|204|I	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	905	910	L180M	SequenceVariant	p|SUB|L|180|M	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	913	918	M204V	SequenceVariant	p|SUB|M|204|V	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	941	946	HBeAg	Chemical	D006513	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	963	968	HBeAg	Chemical	D006513	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	994	1001	precore	Gene	944568	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	1003	1005	PC	Gene	944568	Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
BC8_BioRED_Task1_Doc19	1051	1056	G145R	SequenceVariant	p|SUB|G|145|R	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.
BC8_BioRED_Task1_Doc19	1083	1088	HBsAg	Chemical	D006514	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.
BC8_BioRED_Task1_Doc19	1154	1157	LAM	Chemical	D019259	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.
BC8_BioRED_Task1_Doc19	1168	1171	HBV	OrganismTaxon	10407	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.
BC8_BioRED_Task1_Doc19	1207	1210	HBV	OrganismTaxon	10407	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.
BC8_BioRED_Task1_Doc19	1216	1218	PC	Gene	944568	The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.
BC8_BioRED_Task1_Doc19	1286	1291	P120T	SequenceVariant	c|SUB|P|120|T	Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.
BC8_BioRED_Task1_Doc19	1319	1324	HBsAg	Chemical	D006514	Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.
BC8_BioRED_Task1_Doc19	1374	1377	LAM	Chemical	D019259	Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.
BC8_BioRED_Task1_Doc19	1435	1440	HBeAg	Chemical	D006513	However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.
BC8_BioRED_Task1_Doc19	1453	1455	PC	Gene	944568	However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.
BC8_BioRED_Task1_Doc19	1463	1468	P120T	SequenceVariant	c|SUB|P|120|T	However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.
BC8_BioRED_Task1_Doc19	1474	1477	LAM	Chemical	D019259	However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.
BC8_BioRED_Task1_Doc19	1555	1558	HBV	OrganismTaxon	10407	However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.
BC8_BioRED_Task1_Doc19	1606	1609	LAM	Chemical	D019259	In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.
BC8_BioRED_Task1_Doc19	1657	1665	adefovir	Chemical	C053001	In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.
BC8_BioRED_Task1_Doc19	1670	1679	tenofovir	Chemical	D000068698	In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.
BC8_BioRED_Task1_Doc19	1868	1871	HBV	OrganismTaxon	10407	These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.
BC8_BioRED_Task1_Doc20	22	26	BRAF	Gene	673	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
BC8_BioRED_Task1_Doc20	27	32	V600E	SequenceVariant	rs113488022	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
BC8_BioRED_Task1_Doc20	45	89	gastroenteropancreatic neuroendocrine tumors	Disease	C535650	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
BC8_BioRED_Task1_Doc20	111	155	gastroenteropancreatic neuroendocrine tumors	Disease	C535650	Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still insufficiently understood, and the genetic alterations associated with drug responses have not been studied.
BC8_BioRED_Task1_Doc20	157	165	GEP-NETs	Disease	C535650	Genomic profiles of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are still insufficiently understood, and the genetic alterations associated with drug responses have not been studied.
BC8_BioRED_Task1_Doc20	334	342	GEP-NETs	Disease	C535650	Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for pazopanib, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).
BC8_BioRED_Task1_Doc20	348	356	patients	OrganismTaxon	9606	Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for pazopanib, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).
BC8_BioRED_Task1_Doc20	433	442	pazopanib	Chemical	C516667	Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for pazopanib, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).
BC8_BioRED_Task1_Doc20	536	550	intestine NETs	Disease	D007414	Here, we performed whole exome sequencing of 12 GEP-NETs from patients enrolled in a nonrandomized, open-labeled, single-center phase II study for pazopanib, and integrated our results with previously published results on pancreas (n = 12) and small intestine NETs (n = 50).
BC8_BioRED_Task1_Doc20	652	660	GEP-NETs	Disease	C535650	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	702	708	cancer	Disease	D009369	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	733	737	TP53	Gene	7157	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	739	744	CNBD1	Gene	168975	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	746	749	RB1	Gene	5925	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	751	754	APC	Gene	324	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	756	760	BCOR	Gene	54880	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	762	766	BRAF	Gene	673	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	768	774	CTNNB1	Gene	1499	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	776	780	EGFR	Gene	1956	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	782	787	EP300	Gene	2033	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	789	794	ERBB3	Gene	2065	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	796	801	KDM6A	Gene	7403	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	803	807	KRAS	Gene	3845	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	809	812	MGA	Gene	23269	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	814	818	MLL3	Gene	58508	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	820	824	PTEN	Gene	5728	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	826	831	RASA1	Gene	5921	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	833	840	SMARCB1	Gene	6598	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	842	846	SPEN	Gene	23013	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	848	855	TBC1D12	Gene	23232	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	861	864	VHL	Gene	7428	Among 12 GEP-NETs, eight showed mutations of more than one cancer-related gene, including TP53, CNBD1, RB1, APC, BCOR, BRAF, CTNNB1, EGFR, EP300, ERBB3, KDM6A, KRAS, MGA, MLL3, PTEN, RASA1, SMARCB1, SPEN, TBC1D12, and VHL.
BC8_BioRED_Task1_Doc20	866	870	TP53	Gene	7157	TP53 was recurrently mutated in three cases, whereas CNBD1 and RB1 mutations were identified in two cases.
BC8_BioRED_Task1_Doc20	919	924	CNBD1	Gene	168975	TP53 was recurrently mutated in three cases, whereas CNBD1 and RB1 mutations were identified in two cases.
BC8_BioRED_Task1_Doc20	929	932	RB1	Gene	5925	TP53 was recurrently mutated in three cases, whereas CNBD1 and RB1 mutations were identified in two cases.
BC8_BioRED_Task1_Doc20	979	986	GEP-NET	Disease	C535650	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	987	995	patients	OrganismTaxon	9606	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1001	1005	TP53	Gene	7157	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1062	1088	intestinal grade (G) 1 NET	Disease	D007414	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1089	1096	patient	OrganismTaxon	9606	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1102	1106	BRAF	Gene	673	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1107	1112	V600E	SequenceVariant	rs113488022	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1147	1156	pazopanib	Chemical	C516667	Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment.
BC8_BioRED_Task1_Doc20	1177	1181	BRAF	Gene	673	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1182	1187	V600E	SequenceVariant	rs113488022	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1192	1195	NET	Disease	D018358	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1219	1223	NETs	Disease	D018358	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1240	1244	BRAF	Gene	673	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1245	1250	G593S	SequenceVariant	p.G593S	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1255	1258	NET	Disease	D018358	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1331	1339	GEP-NETs	Disease	C535650	We found BRAF V600E (G1 NET from rectum and two G3 NETs from colon) and BRAF G593S (G2 NET from pancreas) missense mutations (9.1%) in an independent cohort of 44 GEP-NETs from the rectum (n = 26), colon (n = 7), pancreas (n = 4), small intestine (n = 3), stomach (n = 3) and appendix (n = 1) by Sanger sequencing.
BC8_BioRED_Task1_Doc20	1487	1492	tumor	Disease	D009369	All tumor specimens were obtained before chemotherapy.
BC8_BioRED_Task1_Doc20	1553	1557	BRAF	Gene	673	In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
BC8_BioRED_Task1_Doc20	1558	1563	V600E	SequenceVariant	rs113488022	In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
BC8_BioRED_Task1_Doc20	1610	1619	pazopanib	Chemical	C516667	In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
BC8_BioRED_Task1_Doc20	1681	1689	GEP-NETs	Disease	C535650	In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
BC8_BioRED_Task1_Doc20	1690	1698	patients	OrganismTaxon	9606	In conclusion, BRAF V600E mutation is likely to result in resistance to pazopanib but may be a potentianally actionable mutation in metastatic GEP-NETs patients.
BC8_BioRED_Task1_Doc21	29	34	human	OrganismTaxon	9606	Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneity.
BC8_BioRED_Task1_Doc21	35	44	uroplakin	Gene	11045,7380	Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneity.
BC8_BioRED_Task1_Doc21	54	75	vesicoureteral reflux	Disease	C564042	Lack of major involvement of human uroplakin genes in vesicoureteral reflux: implications for disease heterogeneity.
BC8_BioRED_Task1_Doc21	137	158	vesicoureteral reflux	Disease	C564042	BACKGROUND: Primary vesicoureteral reflux (VUR) is a hereditary disorder characterized by the retrograde flow of urine into the ureters and kidneys.
BC8_BioRED_Task1_Doc21	160	163	VUR	Disease	C564042	BACKGROUND: Primary vesicoureteral reflux (VUR) is a hereditary disorder characterized by the retrograde flow of urine into the ureters and kidneys.
BC8_BioRED_Task1_Doc21	170	189	hereditary disorder	Disease	D030342	BACKGROUND: Primary vesicoureteral reflux (VUR) is a hereditary disorder characterized by the retrograde flow of urine into the ureters and kidneys.
BC8_BioRED_Task1_Doc21	343	362	hereditary diseases	Disease	D030342	It affects about 1% of the young children and is thus one of the most common hereditary diseases.
BC8_BioRED_Task1_Doc21	379	390	nephropathy	Disease	D007674	Its associated nephropathy is an important cause of end-stage renal failure in children and adults.
BC8_BioRED_Task1_Doc21	416	439	end-stage renal failure	Disease	D007676	Its associated nephropathy is an important cause of end-stage renal failure in children and adults.
BC8_BioRED_Task1_Doc21	513	518	mouse	OrganismTaxon	10090	Recent studies indicate that genetic ablation of mouse uroplakin (UP) III gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes VUR and hydronephrosis.
BC8_BioRED_Task1_Doc21	519	537	uroplakin (UP) III	Gene	22270	Recent studies indicate that genetic ablation of mouse uroplakin (UP) III gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes VUR and hydronephrosis.
BC8_BioRED_Task1_Doc21	647	650	VUR	Disease	C564042	Recent studies indicate that genetic ablation of mouse uroplakin (UP) III gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes VUR and hydronephrosis.
BC8_BioRED_Task1_Doc21	655	669	hydronephrosis	Disease	D006869	Recent studies indicate that genetic ablation of mouse uroplakin (UP) III gene, which encodes a 47 kD urothelial-specific integral membrane protein forming urothelial plaques, causes VUR and hydronephrosis.
BC8_BioRED_Task1_Doc21	723	725	UP	Gene	11045,7380	METHODS: To begin to determine whether mutations in UP genes might play a role in human VUR, we genotyped all four UP genes in 76 patients with radiologically proven primary VUR by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.
BC8_BioRED_Task1_Doc21	753	758	human	OrganismTaxon	9606	METHODS: To begin to determine whether mutations in UP genes might play a role in human VUR, we genotyped all four UP genes in 76 patients with radiologically proven primary VUR by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.
BC8_BioRED_Task1_Doc21	759	762	VUR	Disease	C564042	METHODS: To begin to determine whether mutations in UP genes might play a role in human VUR, we genotyped all four UP genes in 76 patients with radiologically proven primary VUR by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.
BC8_BioRED_Task1_Doc21	786	788	UP	Gene	11045,7380	METHODS: To begin to determine whether mutations in UP genes might play a role in human VUR, we genotyped all four UP genes in 76 patients with radiologically proven primary VUR by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.
BC8_BioRED_Task1_Doc21	801	809	patients	OrganismTaxon	9606	METHODS: To begin to determine whether mutations in UP genes might play a role in human VUR, we genotyped all four UP genes in 76 patients with radiologically proven primary VUR by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.
BC8_BioRED_Task1_Doc21	845	848	VUR	Disease	C564042	METHODS: To begin to determine whether mutations in UP genes might play a role in human VUR, we genotyped all four UP genes in 76 patients with radiologically proven primary VUR by polymerase chain reaction (PCR) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences.
BC8_BioRED_Task1_Doc21	1162	1165	VUR	Disease	C564042	Since healthy relatives of the VUR probands are not reliable negative controls for VUR, we used a population of 90 race-matched, healthy individuals, unrelated to the VUR patients, as controls to perform an association study.
BC8_BioRED_Task1_Doc21	1214	1217	VUR	Disease	C564042	Since healthy relatives of the VUR probands are not reliable negative controls for VUR, we used a population of 90 race-matched, healthy individuals, unrelated to the VUR patients, as controls to perform an association study.
BC8_BioRED_Task1_Doc21	1298	1301	VUR	Disease	C564042	Since healthy relatives of the VUR probands are not reliable negative controls for VUR, we used a population of 90 race-matched, healthy individuals, unrelated to the VUR patients, as controls to perform an association study.
BC8_BioRED_Task1_Doc21	1302	1310	patients	OrganismTaxon	9606	Since healthy relatives of the VUR probands are not reliable negative controls for VUR, we used a population of 90 race-matched, healthy individuals, unrelated to the VUR patients, as controls to perform an association study.
BC8_BioRED_Task1_Doc21	1425	1428	VUR	Disease	C564042	Most of the SNPs were not found to be significantly associated with VUR.
BC8_BioRED_Task1_Doc21	1447	1452	UP Ia	Gene	11045	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1470	1476	C to T	SequenceVariant	rs373513519	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1495	1502	Ala7Val	SequenceVariant	rs373513519	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1523	1529	UP III	Gene	7380	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1542	1548	C to G	SequenceVariant	c|SUB|C||G	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1566	1575	Pro154Ala	SequenceVariant	p|SUB|P|154|A	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1616	1619	VUR	Disease	C564042	However, SNP1 of UP Ia gene affecting a C to T conversion and an Ala7Val change, and SNP7 of UP III affecting a C to G conversion and a Pro154Ala change, were marginally associated with VUR (both P= 0.08).
BC8_BioRED_Task1_Doc21	1766	1772	UP III	Gene	7380	Studies of additional cases yielded a second set of data that, in combination with the first set, confirmed a weak association of UP III SNP7 in VUR (P= 0.036 adjusted for both subsets of cases vs. controls).
BC8_BioRED_Task1_Doc21	1781	1784	VUR	Disease	C564042	Studies of additional cases yielded a second set of data that, in combination with the first set, confirmed a weak association of UP III SNP7 in VUR (P= 0.036 adjusted for both subsets of cases vs. controls).
BC8_BioRED_Task1_Doc21	1982	1991	uroplakin	Gene	11045,7380	CONCLUSION: Such a weak association and the lack of families with simple dominant Mendelian inheritance suggest that missense changes of uroplakin genes cannot play a dominant role in causing VUR in humans, although they may be weak risk factors contributing to a complex polygenic disease.
BC8_BioRED_Task1_Doc21	2037	2040	VUR	Disease	C564042	CONCLUSION: Such a weak association and the lack of families with simple dominant Mendelian inheritance suggest that missense changes of uroplakin genes cannot play a dominant role in causing VUR in humans, although they may be weak risk factors contributing to a complex polygenic disease.
BC8_BioRED_Task1_Doc21	2044	2050	humans	OrganismTaxon	9606	CONCLUSION: Such a weak association and the lack of families with simple dominant Mendelian inheritance suggest that missense changes of uroplakin genes cannot play a dominant role in causing VUR in humans, although they may be weak risk factors contributing to a complex polygenic disease.
BC8_BioRED_Task1_Doc21	2219	2222	VUR	Disease	C564042	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2223	2231	patients	OrganismTaxon	9606	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2293	2299	UP III	Gene	22270	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2309	2313	mice	OrganismTaxon	10090	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2347	2350	VUR	Disease	C564042	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2368	2382	hydronephrosis	Disease	D006869	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2387	2401	neonatal death	Disease	D066087	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2437	2446	uroplakin	Gene	11045,7380	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc21	2505	2511	humans	OrganismTaxon	9606	The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
BC8_BioRED_Task1_Doc22	19	38	histone deacetylase	Gene	3065	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	49	61	depsipeptide	Chemical	D047630	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	66	80	5-fluorouracil	Chemical	D005472	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	93	134	major histocompatibility complex class II	Gene	3119	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	139	142	p21	Gene	1026	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	163	174	caspase-3/7	Gene	836,840	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	178	183	human	OrganismTaxon	9606	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	184	196	colon cancer	Disease	D003110	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	197	204	HCT-116	CellLine	CVCL_0291	Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
BC8_BioRED_Task1_Doc22	248	267	histone deacetylase	Gene	3065	Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects.
BC8_BioRED_Task1_Doc22	269	273	HDAC	Gene	3065	Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects.
BC8_BioRED_Task1_Doc22	437	449	depsipeptide	Chemical	D047630	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	454	458	HDAC	Gene	3065	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	508	522	5-fluorouracil	Chemical	D005472	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	524	528	5-FU	Chemical	D005472	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	535	540	human	OrganismTaxon	9606	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	541	553	colon cancer	Disease	D003110	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	571	578	HCT-116	CellLine	CVCL_0291	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	580	584	HT29	CellLine	CVCL_0320	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	590	594	SW48	CellLine	CVCL_1724	In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability.
BC8_BioRED_Task1_Doc22	700	704	5-FU	Chemical	D005472	Exposure to a combination of 5-FU (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.
BC8_BioRED_Task1_Doc22	724	736	depsipeptide	Chemical	D047630	Exposure to a combination of 5-FU (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.
BC8_BioRED_Task1_Doc22	802	813	caspase-3/7	Gene	836,840	Exposure to a combination of 5-FU (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.
BC8_BioRED_Task1_Doc22	821	825	5-FU	Chemical	D005472	Exposure to a combination of 5-FU (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.
BC8_BioRED_Task1_Doc22	851	862	caspase-3/7	Gene	836,840	Exposure to a combination of 5-FU (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7.
BC8_BioRED_Task1_Doc22	939	943	5-FU	Chemical	D005472	Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation.
BC8_BioRED_Task1_Doc22	947	959	depsipeptide	Chemical	D047630	Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation.
BC8_BioRED_Task1_Doc22	996	1000	5-FU	Chemical	D005472	Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation.
BC8_BioRED_Task1_Doc22	1005	1017	depsipeptide	Chemical	D047630	Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation.
BC8_BioRED_Task1_Doc22	1139	1150	caspase-3/7	Gene	836,840	Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation.
BC8_BioRED_Task1_Doc22	1261	1275	polysaccharide	Chemical	D011134	These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611).
BC8_BioRED_Task1_Doc22	1288	1332	major histocompatibility complex (MHC) class	Gene	3123	These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611).
BC8_BioRED_Task1_Doc22	1350	1369	MHC protein complex	Gene	3123	These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611).
BC8_BioRED_Task1_Doc22	1458	1462	5-FU	Chemical	D005472	Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes.
BC8_BioRED_Task1_Doc22	1467	1479	depsipeptide	Chemical	D047630	Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes.
BC8_BioRED_Task1_Doc22	1538	1556	MHC class II genes	Gene	3119	Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes.
BC8_BioRED_Task1_Doc22	1569	1586	MHC class I genes	Gene	3106	Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes.
BC8_BioRED_Task1_Doc22	1708	1726	MHC class II genes	Gene	3119	Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide.
BC8_BioRED_Task1_Doc22	1764	1768	PCAF	Gene	8850	Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide.
BC8_BioRED_Task1_Doc22	1773	1778	CIITA	Gene	4261	Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide.
BC8_BioRED_Task1_Doc22	1804	1808	5-FU	Chemical	D005472	Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide.
BC8_BioRED_Task1_Doc22	1813	1825	depsipeptide	Chemical	D047630	Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide.
BC8_BioRED_Task1_Doc22	1897	1909	MHC class II	Gene	3119	These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU.
BC8_BioRED_Task1_Doc22	1974	1986	depsipeptide	Chemical	D047630	These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU.
BC8_BioRED_Task1_Doc22	1991	1995	5-FU	Chemical	D005472	These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU.
BC8_BioRED_Task1_Doc22	2085	2089	5-FU	Chemical	D005472	To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
BC8_BioRED_Task1_Doc22	2094	2106	depsipeptide	Chemical	D047630	To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
BC8_BioRED_Task1_Doc22	2115	2120	human	OrganismTaxon	9606	To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
BC8_BioRED_Task1_Doc22	2121	2133	colon cancer	Disease	D003110	To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
BC8_BioRED_Task1_Doc22	2193	2205	MHC class II	Gene	3119	To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
BC8_BioRED_Task1_Doc23	0	4	Mice	OrganismTaxon	10090	Mice lacking mPGES-1 are resistant to lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	13	20	mPGES-1	Gene	64292	Mice lacking mPGES-1 are resistant to lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	38	45	lithium	Chemical	D008094	Mice lacking mPGES-1 are resistant to lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	54	62	polyuria	Disease	D011141	Mice lacking mPGES-1 are resistant to lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	64	80	Cyclooxygenase-2	Gene	19225	Cyclooxygenase-2 activity is required for the development of lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	125	132	lithium	Chemical	D008094	Cyclooxygenase-2 activity is required for the development of lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	141	149	polyuria	Disease	D011141	Cyclooxygenase-2 activity is required for the development of lithium-induced polyuria.
BC8_BioRED_Task1_Doc23	200	213	prostaglandin	Chemical	D011453	However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.
BC8_BioRED_Task1_Doc23	215	217	PG	Chemical	D011453	However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.
BC8_BioRED_Task1_Doc23	296	303	lithium	Chemical	D008094	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
BC8_BioRED_Task1_Doc23	312	320	polyuria	Disease	D011141	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
BC8_BioRED_Task1_Doc23	324	328	mice	OrganismTaxon	10090	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
BC8_BioRED_Task1_Doc23	342	379	microsomal prostaglandin E synthase-1	Gene	64292	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
BC8_BioRED_Task1_Doc23	381	388	mPGES-1	Gene	64292	The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
BC8_BioRED_Task1_Doc23	416	420	LiCl	Chemical	D018021	A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
BC8_BioRED_Task1_Doc23	451	458	mPGES-1	Gene	64292	A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
BC8_BioRED_Task1_Doc23	463	467	mice	OrganismTaxon	10090	A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
BC8_BioRED_Task1_Doc23	484	492	polyuria	Disease	D011141	A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
BC8_BioRED_Task1_Doc23	556	563	mPGES-1	Gene	64292	This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
BC8_BioRED_Task1_Doc23	603	609	PGE(2)	Chemical	D015232	This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
BC8_BioRED_Task1_Doc23	634	641	mPGES-1	Gene	64292	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
BC8_BioRED_Task1_Doc23	646	650	mice	OrganismTaxon	10090	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
BC8_BioRED_Task1_Doc23	677	684	lithium	Chemical	D008094	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
BC8_BioRED_Task1_Doc23	693	701	polyuria	Disease	D011141	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
BC8_BioRED_Task1_Doc23	790	796	PGE(2)	Chemical	D015232	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
BC8_BioRED_Task1_Doc23	801	805	cAMP	Chemical	D000242	In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
BC8_BioRED_Task1_Doc23	928	939	aquaporin-2	Gene	11827	Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.
BC8_BioRED_Task1_Doc23	941	945	AQP2	Gene	11827	Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.
BC8_BioRED_Task1_Doc23	1006	1013	lithium	Chemical	D008094	Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.
BC8_BioRED_Task1_Doc23	1026	1030	mice	OrganismTaxon	10090	Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.
BC8_BioRED_Task1_Doc23	1086	1090	mice	OrganismTaxon	10090	This decrease was significantly attenuated in the -/- mice.
BC8_BioRED_Task1_Doc23	1140	1144	AQP2	Gene	11827	qRT-PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex.
BC8_BioRED_Task1_Doc23	1234	1256	Na-K-2Cl cotransporter	Gene	20495	Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.
BC8_BioRED_Task1_Doc23	1258	1263	NKCC2	Gene	20495	Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.
BC8_BioRED_Task1_Doc23	1313	1317	mice	OrganismTaxon	10090	Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.
BC8_BioRED_Task1_Doc23	1347	1354	lithium	Chemical	D008094	Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.
BC8_BioRED_Task1_Doc23	1416	1421	NKCC2	Gene	20495	In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
BC8_BioRED_Task1_Doc23	1473	1477	mice	OrganismTaxon	10090	In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
BC8_BioRED_Task1_Doc23	1496	1503	mPGES-1	Gene	64292	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
BC8_BioRED_Task1_Doc23	1512	1518	PGE(2)	Chemical	D015232	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
BC8_BioRED_Task1_Doc23	1528	1535	lithium	Chemical	D008094	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
BC8_BioRED_Task1_Doc23	1544	1552	polyuria	Disease	D011141	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
BC8_BioRED_Task1_Doc23	1578	1582	AQP2	Gene	11827	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
BC8_BioRED_Task1_Doc23	1587	1592	NKCC2	Gene	20495	We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.
BC8_BioRED_Task1_Doc24	51	64	ENaC subunits	Gene	24767,24768,25122	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.
BC8_BioRED_Task1_Doc24	68	93	puromycin aminonucleoside	Chemical	D011692	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.
BC8_BioRED_Task1_Doc24	102	120	nephrotic syndrome	Disease	D009404	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.
BC8_BioRED_Task1_Doc24	124	128	rats	OrganismTaxon	10116	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.
BC8_BioRED_Task1_Doc24	130	148	Nephrotic syndrome	Disease	D009404	Nephrotic syndrome is often accompanied by sodium retention and generalized edema.
BC8_BioRED_Task1_Doc24	173	179	sodium	Chemical	D012964	Nephrotic syndrome is often accompanied by sodium retention and generalized edema.
BC8_BioRED_Task1_Doc24	206	211	edema	Disease	D004487	Nephrotic syndrome is often accompanied by sodium retention and generalized edema.
BC8_BioRED_Task1_Doc24	266	272	sodium	Chemical	D012964	However, the molecular basis for the decreased renal sodium excretion remains undefined.
BC8_BioRED_Task1_Doc24	323	359	epithelial Na channel (ENaC) subunit	Gene	24767,24768,25122	We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.
BC8_BioRED_Task1_Doc24	411	417	sodium	Chemical	D012964	We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.
BC8_BioRED_Task1_Doc24	454	458	rats	OrganismTaxon	10116	An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.
BC8_BioRED_Task1_Doc24	476	501	puromycin aminonucleoside	Chemical	D011692	An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.
BC8_BioRED_Task1_Doc24	503	506	PAN	Chemical	D011692	An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.
BC8_BioRED_Task1_Doc24	586	589	PAN	Chemical	D011692	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
BC8_BioRED_Task1_Doc24	620	631	proteinuria	Disease	D011507	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
BC8_BioRED_Task1_Doc24	633	648	hypoalbuminemia	Disease	D034141	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
BC8_BioRED_Task1_Doc24	668	674	sodium	Chemical	D012964	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
BC8_BioRED_Task1_Doc24	700	707	ascites	Disease	D001201	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
BC8_BioRED_Task1_Doc24	734	744	alpha-ENaC	Gene	25122	The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
BC8_BioRED_Task1_Doc24	749	758	beta-ENaC	Gene	24767	The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
BC8_BioRED_Task1_Doc24	886	896	gamma-ENaC	Gene	24768	gamma-ENaC abundance was increased in the cortex, ISOM, and IM.
BC8_BioRED_Task1_Doc24	1068	1078	alpha-ENaC	Gene	25122	Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.
BC8_BioRED_Task1_Doc24	1080	1089	beta-ENaC	Gene	24767	Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.
BC8_BioRED_Task1_Doc24	1095	1105	gamma-ENaC	Gene	24768	Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.
BC8_BioRED_Task1_Doc24	1325	1335	alpha-ENaC	Gene	25122	Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.
BC8_BioRED_Task1_Doc24	1413	1416	PAN	Chemical	D011692	Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.
BC8_BioRED_Task1_Doc24	1425	1429	rats	OrganismTaxon	10116	Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.
BC8_BioRED_Task1_Doc24	1471	1481	alpha-ENaC	Gene	25122	Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.
BC8_BioRED_Task1_Doc24	1531	1558	Na(+)/H(+) exchanger type 3	Gene	24784	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.
BC8_BioRED_Task1_Doc24	1560	1564	NHE3	Gene	24784	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.
BC8_BioRED_Task1_Doc24	1567	1598	Na(+)-K(+)-2Cl(-) cotransporter	Gene	25065	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.
BC8_BioRED_Task1_Doc24	1600	1605	BSC-1	Gene	25065	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.
BC8_BioRED_Task1_Doc24	1612	1656	thiazide-sensitive Na(+)-Cl(-) cotransporter	Gene	54300	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.
BC8_BioRED_Task1_Doc24	1658	1661	TSC	Gene	54300	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.
BC8_BioRED_Task1_Doc24	1710	1745	alpha(1)-subunit of the Na-K-ATPase	Gene	24211	Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
BC8_BioRED_Task1_Doc24	1877	1890	ENaC subunits	Gene	24767,24768,25122	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc24	2017	2023	sodium	Chemical	D012964	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc24	2050	2053	PAN	Chemical	D011692	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc24	2062	2080	nephrotic syndrome	Disease	D009404	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc24	2109	2113	NHE3	Gene	24784	The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.
BC8_BioRED_Task1_Doc24	2115	2120	BSC-1	Gene	25065	The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.
BC8_BioRED_Task1_Doc24	2122	2125	TSC	Gene	54300	The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.
BC8_BioRED_Task1_Doc24	2131	2142	Na-K-ATPase	Gene	24211	The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.
BC8_BioRED_Task1_Doc24	2183	2189	sodium	Chemical	D012964	The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.
BC8_BioRED_Task1_Doc25	0	11	Dexrazoxane	Chemical	D064730	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
BC8_BioRED_Task1_Doc25	29	45	myelosuppression	Disease	D001855	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
BC8_BioRED_Task1_Doc25	84	93	etoposide	Chemical	D005047	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
BC8_BioRED_Task1_Doc25	98	110	daunorubicin	Chemical	D003630	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
BC8_BioRED_Task1_Doc25	119	130	doxorubicin	Chemical	D004317	Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
BC8_BioRED_Task1_Doc25	145	159	anthracyclines	Chemical	D018943	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	160	172	daunorubicin	Chemical	D003630	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	177	188	doxorubicin	Chemical	D004317	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	197	215	epipodophyllotoxin	Chemical	D011034	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	216	225	etoposide	Chemical	D005047	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	318	334	myelosuppression	Disease	D001855	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	339	355	cardiac toxicity	Disease	D066126	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
BC8_BioRED_Task1_Doc25	373	384	Dexrazoxane	Chemical	D064730	Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
BC8_BioRED_Task1_Doc25	386	394	ICRF-187	Chemical	D064730	Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
BC8_BioRED_Task1_Doc25	434	447	anthracycline	Chemical	D018943	Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
BC8_BioRED_Task1_Doc25	456	470	cardiotoxicity	Disease	D066126	Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
BC8_BioRED_Task1_Doc25	530	550	hematologic toxicity	Disease	D006402	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	581	592	dexrazoxane	Chemical	D064730	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	688	693	human	OrganismTaxon	9606	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	698	704	murine	OrganismTaxon	10090	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	731	740	etoposide	Chemical	D005047	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	742	754	daunorubicin	Chemical	D003630	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	760	771	doxorubicin	Chemical	D004317	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	776	787	dexrazoxane	Chemical	D064730	EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
BC8_BioRED_Task1_Doc25	878	882	mice	OrganismTaxon	10090	Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.
BC8_BioRED_Task1_Doc25	901	910	etoposide	Chemical	D005047	Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.
BC8_BioRED_Task1_Doc25	912	924	daunorubicin	Chemical	D003630	Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.
BC8_BioRED_Task1_Doc25	930	941	doxorubicin	Chemical	D004317	Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.
BC8_BioRED_Task1_Doc25	959	970	dexrazoxane	Chemical	D064730	Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.
BC8_BioRED_Task1_Doc25	1081	1092	dexrazoxane	Chemical	D064730	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1101	1117	myelosuppression	Disease	D001855	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1122	1133	weight loss	Disease	D015431	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1139	1151	daunorubicin	Chemical	D003630	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1156	1165	etoposide	Chemical	D005047	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1169	1173	mice	OrganismTaxon	10090	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1252	1263	dexrazoxane	Chemical	D064730	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1280	1296	myelosuppression	Disease	D001855	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1298	1309	weight loss	Disease	D015431	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1328	1340	cytotoxicity	Disease	D064420	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1346	1357	doxorubicin	Chemical	D004317	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
BC8_BioRED_Task1_Doc25	1422	1433	dexrazoxane	Chemical	D064730	CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
BC8_BioRED_Task1_Doc25	1499	1510	doxorubicin	Chemical	D004317	CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
BC8_BioRED_Task1_Doc25	1548	1560	daunorubicin	Chemical	D003630	CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
BC8_BioRED_Task1_Doc25	1718	1727	etoposide	Chemical	D005047	Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
BC8_BioRED_Task1_Doc25	1778	1789	dexrazoxane	Chemical	D064730	Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
BC8_BioRED_Task1_Doc25	1810	1818	patients	OrganismTaxon	9606	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
BC8_BioRED_Task1_Doc25	1830	1840	metastases	Disease	D009362	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
BC8_BioRED_Task1_Doc25	1851	1862	dexrazoxane	Chemical	D064730	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
BC8_BioRED_Task1_Doc25	1881	1890	etoposide	Chemical	D005047	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
BC8_BioRED_Task1_Doc25	1957	1977	hematologic toxicity	Disease	D006402	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.
BC8_BioRED_Task1_Doc25	2082	2091	cytotoxic	Disease	D064420	If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy.
BC8_BioRED_Task1_Doc26	0	31	Pleomorphic adenoma gene like-2	Gene	5326	Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human colorectal adenocarcinoma.
BC8_BioRED_Task1_Doc26	78	81	Wnt	Gene	7474	Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human colorectal adenocarcinoma.
BC8_BioRED_Task1_Doc26	82	91	b-catenin	Gene	1499	Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human colorectal adenocarcinoma.
BC8_BioRED_Task1_Doc26	113	118	human	OrganismTaxon	9606	Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human colorectal adenocarcinoma.
BC8_BioRED_Task1_Doc26	119	144	colorectal adenocarcinoma	Disease	D015179	Pleomorphic adenoma gene like-2 induces epithelial-mesenchymal transition via Wnt/b-catenin signaling pathway in human colorectal adenocarcinoma.
BC8_BioRED_Task1_Doc26	261	266	tumor	Disease	D009369	Epithelial-mesenchymal transition (EMT) is a critical step in the acquisition of metastatic and invasive power for tumor cells.
BC8_BioRED_Task1_Doc26	274	299	Colorectal adenocarcinoma	Disease	D015179	Colorectal adenocarcinoma (CRC) is a common cancer where metastasis is directly linked to patient survival.
BC8_BioRED_Task1_Doc26	301	304	CRC	Disease	D015179	Colorectal adenocarcinoma (CRC) is a common cancer where metastasis is directly linked to patient survival.
BC8_BioRED_Task1_Doc26	318	324	cancer	Disease	D009369	Colorectal adenocarcinoma (CRC) is a common cancer where metastasis is directly linked to patient survival.
BC8_BioRED_Task1_Doc26	331	341	metastasis	Disease	D009362	Colorectal adenocarcinoma (CRC) is a common cancer where metastasis is directly linked to patient survival.
BC8_BioRED_Task1_Doc26	364	371	patient	OrganismTaxon	9606	Colorectal adenocarcinoma (CRC) is a common cancer where metastasis is directly linked to patient survival.
BC8_BioRED_Task1_Doc26	407	438	pleomorphic adenoma gene like-2	Gene	5326	Recent studies show that pleomorphic adenoma gene like-2 (PLAGL2) could induce tumor EMT and is an independent predictive factor associated with poor prognosis in cancer.
BC8_BioRED_Task1_Doc26	440	446	PLAGL2	Gene	5326	Recent studies show that pleomorphic adenoma gene like-2 (PLAGL2) could induce tumor EMT and is an independent predictive factor associated with poor prognosis in cancer.
BC8_BioRED_Task1_Doc26	461	466	tumor	Disease	D009369	Recent studies show that pleomorphic adenoma gene like-2 (PLAGL2) could induce tumor EMT and is an independent predictive factor associated with poor prognosis in cancer.
BC8_BioRED_Task1_Doc26	545	551	cancer	Disease	D009369	Recent studies show that pleomorphic adenoma gene like-2 (PLAGL2) could induce tumor EMT and is an independent predictive factor associated with poor prognosis in cancer.
BC8_BioRED_Task1_Doc26	600	606	PLAGL2	Gene	5326	In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.
BC8_BioRED_Task1_Doc26	627	630	CRC	Disease	D015179	In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.
BC8_BioRED_Task1_Doc26	631	639	patients	OrganismTaxon	9606	In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.
BC8_BioRED_Task1_Doc26	674	680	PLAGL2	Gene	5326	In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.
BC8_BioRED_Task1_Doc26	697	700	CRC	Disease	D015179	In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.
BC8_BioRED_Task1_Doc26	711	716	SW480	CellLine	CVCL_0546	In the present study, we confirmed the role of PLAGL2 in the prognosis of CRC patients and provide molecular evidence of PLAGL2 promoted EMT in CRC cell line SW480.
BC8_BioRED_Task1_Doc26	732	738	PLAGL2	Gene	5326	We found that PLAGL2 expression was upregulated in the paraffin-embedded CRC tissues compared to borderline or benign tissues.
BC8_BioRED_Task1_Doc26	773	781	paraffin	Chemical	D010232	We found that PLAGL2 expression was upregulated in the paraffin-embedded CRC tissues compared to borderline or benign tissues.
BC8_BioRED_Task1_Doc26	791	794	CRC	Disease	D015179	We found that PLAGL2 expression was upregulated in the paraffin-embedded CRC tissues compared to borderline or benign tissues.
BC8_BioRED_Task1_Doc26	873	879	PLAGL2	Gene	5326	Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of E-cadherin.
BC8_BioRED_Task1_Doc26	908	914	PLAGL2	Gene	5326	Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of E-cadherin.
BC8_BioRED_Task1_Doc26	1064	1074	N-cadherin	Gene	1000	Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of E-cadherin.
BC8_BioRED_Task1_Doc26	1079	1087	vimentin	Gene	7431	Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of E-cadherin.
BC8_BioRED_Task1_Doc26	1140	1150	E-cadherin	Gene	999	Experimental EMT induced by PLAGL2 plasmid transfection proved PLAGL2 protein overexpression could enhance the cell scratch wound-healing and transwell ability and significantly upregulated mesenchymal marker proteins, N-cadherin and vimentin and concurrently downregulated epithelial marker of E-cadherin.
BC8_BioRED_Task1_Doc26	1208	1214	PLAGL2	Gene	5326	Subsequently, through western blot assay, we found that PLAGL2 could activate the wnt-signaling component b-catenin in the nuclei.
BC8_BioRED_Task1_Doc26	1234	1237	wnt	Gene	7474	Subsequently, through western blot assay, we found that PLAGL2 could activate the wnt-signaling component b-catenin in the nuclei.
BC8_BioRED_Task1_Doc26	1258	1267	b-catenin	Gene	1499	Subsequently, through western blot assay, we found that PLAGL2 could activate the wnt-signaling component b-catenin in the nuclei.
BC8_BioRED_Task1_Doc26	1288	1291	CRC	Disease	D015179	More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group.
BC8_BioRED_Task1_Doc26	1297	1307	metastasis	Disease	D009362	More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group.
BC8_BioRED_Task1_Doc26	1343	1349	PLAGL2	Gene	5326	More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group.
BC8_BioRED_Task1_Doc26	1365	1370	SW480	CellLine	CVCL_0546	More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group.
BC8_BioRED_Task1_Doc26	1413	1417	rats	OrganismTaxon	10116	More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group.
BC8_BioRED_Task1_Doc26	1454	1460	PLAGL2	Gene	5326	More CRC cell metastasis to the lungs was observed when the PLAGL2 overexpressing SW480 cells were injected into the tail vein of rats, compared with the cell control and PLAGL2 silence group.
BC8_BioRED_Task1_Doc26	1504	1510	PLAGL2	Gene	5326	Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in Wnt/b-catenin signaling pathway.
BC8_BioRED_Task1_Doc26	1576	1579	Wnt	Gene	7474	Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in Wnt/b-catenin signaling pathway.
BC8_BioRED_Task1_Doc26	1580	1589	b-catenin	Gene	1499	Our findings indicated that PLAGL2 might be a very upstream key molecule regulating EMT involved in Wnt/b-catenin signaling pathway.
BC8_BioRED_Task1_Doc27	42	47	human	OrganismTaxon	9606	A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain.
BC8_BioRED_Task1_Doc27	48	71	glucocorticoid receptor	Gene	2908	A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain.
BC8_BioRED_Task1_Doc27	91	116	glucocorticoid resistance	Disease	C564221	A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain.
BC8_BioRED_Task1_Doc27	196	221	glucocorticoid resistance	Disease	C564221	CONTEXT: Generalized glucocorticoid resistance syndrome is a rare familial or sporadic condition characterized by partial insensitivity to glucocorticoids, caused by mutations in the glucocorticoid receptor (GR) gene.
BC8_BioRED_Task1_Doc27	314	329	glucocorticoids	Chemical	D005938	CONTEXT: Generalized glucocorticoid resistance syndrome is a rare familial or sporadic condition characterized by partial insensitivity to glucocorticoids, caused by mutations in the glucocorticoid receptor (GR) gene.
BC8_BioRED_Task1_Doc27	358	381	glucocorticoid receptor	Gene	2908	CONTEXT: Generalized glucocorticoid resistance syndrome is a rare familial or sporadic condition characterized by partial insensitivity to glucocorticoids, caused by mutations in the glucocorticoid receptor (GR) gene.
BC8_BioRED_Task1_Doc27	383	385	GR	Gene	2908	CONTEXT: Generalized glucocorticoid resistance syndrome is a rare familial or sporadic condition characterized by partial insensitivity to glucocorticoids, caused by mutations in the glucocorticoid receptor (GR) gene.
BC8_BioRED_Task1_Doc27	471	488	mineralocorticoid	Chemical	D008901	Most of the reported cases are adults, demonstrating symptoms associated with mineralocorticoid and/or adrenal androgen excess caused by compensatively increased secretion of the adrenocorticotropic hormone.
BC8_BioRED_Task1_Doc27	504	512	androgen	Chemical	D000728	Most of the reported cases are adults, demonstrating symptoms associated with mineralocorticoid and/or adrenal androgen excess caused by compensatively increased secretion of the adrenocorticotropic hormone.
BC8_BioRED_Task1_Doc27	601	608	PATIENT	OrganismTaxon	9606	PATIENT: We identified a new 2-yr-old female case of generalized glucocorticoid resistance syndrome.
BC8_BioRED_Task1_Doc27	666	691	glucocorticoid resistance	Disease	C564221	PATIENT: We identified a new 2-yr-old female case of generalized glucocorticoid resistance syndrome.
BC8_BioRED_Task1_Doc27	706	713	patient	OrganismTaxon	9606	The patient (TJ) presented with a generalized seizure associated with hypoglycemia and hypokalemia.
BC8_BioRED_Task1_Doc27	748	755	seizure	Disease	D012640	The patient (TJ) presented with a generalized seizure associated with hypoglycemia and hypokalemia.
BC8_BioRED_Task1_Doc27	772	784	hypoglycemia	Disease	D007003	The patient (TJ) presented with a generalized seizure associated with hypoglycemia and hypokalemia.
BC8_BioRED_Task1_Doc27	789	800	hypokalemia	Disease	D007008	The patient (TJ) presented with a generalized seizure associated with hypoglycemia and hypokalemia.
BC8_BioRED_Task1_Doc27	815	827	hypertension	Disease	D006973	She also had hypertension and premature pubarche, whereas dexamethasone effectively suppressed these clinical manifestations.
BC8_BioRED_Task1_Doc27	832	850	premature pubarche	Disease	C567552	She also had hypertension and premature pubarche, whereas dexamethasone effectively suppressed these clinical manifestations.
BC8_BioRED_Task1_Doc27	860	873	dexamethasone	Chemical	D003907	She also had hypertension and premature pubarche, whereas dexamethasone effectively suppressed these clinical manifestations.
BC8_BioRED_Task1_Doc27	941	948	patient	OrganismTaxon	9606	RESULTS: The patient's GR gene had a heterozygotic mutation (G-->A) at nucleotide position 2141 (exon 8), which resulted in substitution of arginine by glutamine at amino acid position 714 in the ligand-binding domain (LBD) of the GR alpha.
BC8_BioRED_Task1_Doc27	951	953	GR	Gene	2908	RESULTS: The patient's GR gene had a heterozygotic mutation (G-->A) at nucleotide position 2141 (exon 8), which resulted in substitution of arginine by glutamine at amino acid position 714 in the ligand-binding domain (LBD) of the GR alpha.
BC8_BioRED_Task1_Doc27	988	1023	(G-->A) at nucleotide position 2141	SequenceVariant	c|SUB|G|2141|A	RESULTS: The patient's GR gene had a heterozygotic mutation (G-->A) at nucleotide position 2141 (exon 8), which resulted in substitution of arginine by glutamine at amino acid position 714 in the ligand-binding domain (LBD) of the GR alpha.
BC8_BioRED_Task1_Doc27	1068	1116	arginine by glutamine at amino acid position 714	SequenceVariant	c|SUB|R|714|Q	RESULTS: The patient's GR gene had a heterozygotic mutation (G-->A) at nucleotide position 2141 (exon 8), which resulted in substitution of arginine by glutamine at amino acid position 714 in the ligand-binding domain (LBD) of the GR alpha.
BC8_BioRED_Task1_Doc27	1159	1167	GR alpha	Gene	2908	RESULTS: The patient's GR gene had a heterozygotic mutation (G-->A) at nucleotide position 2141 (exon 8), which resulted in substitution of arginine by glutamine at amino acid position 714 in the ligand-binding domain (LBD) of the GR alpha.
BC8_BioRED_Task1_Doc27	1417	1450	p160 nuclear receptor coactivator	Gene	8648	It showed attenuated transactivation of the activation function (AF)-2 and reduced binding to a p160 nuclear receptor coactivator.
BC8_BioRED_Task1_Doc27	1516	1553	arginine by glutamine at position 714	SequenceVariant	c|SUB|R|714|Q	Computer-based structural analysis revealed that replacement of arginine by glutamine at position 714 transmitted a conformational change to the LBD and the AF-2 transactivation surface, resulting in a decreased binding affinity to ligand and to the LXXLL coactivator motif.
BC8_BioRED_Task1_Doc27	1740	1753	Dexamethasone	Chemical	D003907	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc27	1796	1814	premature pubarche	Disease	C567552	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc27	1816	1828	hypoglycemia	Disease	D007003	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc27	1830	1842	hypertension	Disease	D006973	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc27	1848	1859	hypokalemia	Disease	D007008	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc27	1888	1900	arginine 714	SequenceVariant	c|Allele|R|714	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc27	1999	2007	GR alpha	Gene	2908	CONCLUSIONS: Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD.
BC8_BioRED_Task1_Doc28	19	45	norepinephrine transporter	Gene	20538	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.
BC8_BioRED_Task1_Doc28	92	103	desipramine	Chemical	D003891	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.
BC8_BioRED_Task1_Doc28	154	165	anesthetics	Chemical	D000777	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.
BC8_BioRED_Task1_Doc28	174	185	convulsions	Disease	D012640	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.
BC8_BioRED_Task1_Doc28	240	251	anesthetics	Chemical	D000777	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.
BC8_BioRED_Task1_Doc28	268	294	norepinephrine transporter	Gene	20538	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	296	299	NET	Gene	20538	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	335	338	NET	Gene	20538	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	371	379	seizures	Disease	D012640	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	390	397	cocaine	Chemical	D003042	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	408	419	anesthetics	Chemical	D000777	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	436	440	mice	OrganismTaxon	10090	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
BC8_BioRED_Task1_Doc28	466	477	desipramine	Chemical	D003891	Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.
BC8_BioRED_Task1_Doc28	499	502	NET	Gene	20538	Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.
BC8_BioRED_Task1_Doc28	525	545	[(3)H]norepinephrine	Chemical	D009638	Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.
BC8_BioRED_Task1_Doc28	648	657	lidocaine	Chemical	D008012	Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.
BC8_BioRED_Task1_Doc28	659	670	bupivacaine	Chemical	D002045	Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.
BC8_BioRED_Task1_Doc28	674	682	tricaine	Chemical	C003636	Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.
BC8_BioRED_Task1_Doc28	688	699	desipramine	Chemical	D003891	Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.
BC8_BioRED_Task1_Doc28	741	748	cocaine	Chemical	D003042	Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
BC8_BioRED_Task1_Doc28	759	779	[(3)H]norepinephrine	Chemical	D009638	Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
BC8_BioRED_Task1_Doc28	833	844	desipramine	Chemical	D003891	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
BC8_BioRED_Task1_Doc28	886	895	lidocaine	Chemical	D008012	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
BC8_BioRED_Task1_Doc28	904	915	convulsions	Disease	D012640	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
BC8_BioRED_Task1_Doc28	938	945	cocaine	Chemical	D003042	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
BC8_BioRED_Task1_Doc28	954	965	convulsions	Disease	D012640	Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
BC8_BioRED_Task1_Doc28	988	997	lidocaine	Chemical	D008012	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
BC8_BioRED_Task1_Doc28	1003	1014	desipramine	Chemical	D003891	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
BC8_BioRED_Task1_Doc28	1039	1049	convulsive	Disease	D012640	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
BC8_BioRED_Task1_Doc28	1062	1071	lidocaine	Chemical	D008012	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
BC8_BioRED_Task1_Doc28	1076	1083	cocaine	Chemical	D003042	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
BC8_BioRED_Task1_Doc28	1122	1133	desipramine	Chemical	D003891	Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
BC8_BioRED_Task1_Doc28	1193	1196	NET	Gene	20538	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
BC8_BioRED_Task1_Doc28	1234	1245	desipramine	Chemical	D003891	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
BC8_BioRED_Task1_Doc28	1265	1276	desipramine	Chemical	D003891	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
BC8_BioRED_Task1_Doc28	1302	1311	lidocaine	Chemical	D008012	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
BC8_BioRED_Task1_Doc28	1312	1323	convulsions	Disease	D012640	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.
BC8_BioRED_Task1_Doc28	1339	1344	Na(+)	Chemical	D012964	Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.
BC8_BioRED_Task1_Doc28	1363	1374	anesthetics	Chemical	D000777	Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.
BC8_BioRED_Task1_Doc28	1388	1399	desipramine	Chemical	D003891	Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.
BC8_BioRED_Task1_Doc28	1427	1430	NET	Gene	20538	Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.
BC8_BioRED_Task1_Doc28	1468	1475	cocaine	Chemical	D003042	Repeated administration of cocaine induces up-regulation of hippocampal NET function.
BC8_BioRED_Task1_Doc28	1513	1516	NET	Gene	20538	Repeated administration of cocaine induces up-regulation of hippocampal NET function.
BC8_BioRED_Task1_Doc28	1527	1538	Desipramine	Chemical	D003891	Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.
BC8_BioRED_Task1_Doc28	1564	1573	lidocaine	Chemical	D008012	Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.
BC8_BioRED_Task1_Doc28	1574	1582	seizures	Disease	D012640	Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.
BC8_BioRED_Task1_Doc28	1669	1676	cocaine	Chemical	D003042	Desipramine-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine.
BC8_BioRED_Task1_Doc29	0	5	TBX21	Gene	30009	TBX21 and HLX1 polymorphisms influence cytokine secretion at birth.
BC8_BioRED_Task1_Doc29	10	14	HLX1	Gene	3142	TBX21 and HLX1 polymorphisms influence cytokine secretion at birth.
BC8_BioRED_Task1_Doc29	80	85	TBX21	Gene	30009	BACKGROUND: TBX21 (T cell specific T-box transcription factor) and HLX1 (H.20-like homeobox 1) are crucial transcription factors of T(H)1-cells, inducing their differentiation and suppressing T(H)2 commitment, particularly important for early life immune development.
BC8_BioRED_Task1_Doc29	87	129	T cell specific T-box transcription factor	Gene	30009	BACKGROUND: TBX21 (T cell specific T-box transcription factor) and HLX1 (H.20-like homeobox 1) are crucial transcription factors of T(H)1-cells, inducing their differentiation and suppressing T(H)2 commitment, particularly important for early life immune development.
BC8_BioRED_Task1_Doc29	135	139	HLX1	Gene	3142	BACKGROUND: TBX21 (T cell specific T-box transcription factor) and HLX1 (H.20-like homeobox 1) are crucial transcription factors of T(H)1-cells, inducing their differentiation and suppressing T(H)2 commitment, particularly important for early life immune development.
BC8_BioRED_Task1_Doc29	141	161	H.20-like homeobox 1	Gene	3142	BACKGROUND: TBX21 (T cell specific T-box transcription factor) and HLX1 (H.20-like homeobox 1) are crucial transcription factors of T(H)1-cells, inducing their differentiation and suppressing T(H)2 commitment, particularly important for early life immune development.
BC8_BioRED_Task1_Doc29	377	382	TBX21	Gene	30009	This study investigated the influence of TBX21 and HLX1 single nucleotide polymorphisms (SNPs), which have previously been shown to be associated with asthma, on T(H)1/T(H)2 lineage cytokines at birth.
BC8_BioRED_Task1_Doc29	387	391	HLX1	Gene	3142	This study investigated the influence of TBX21 and HLX1 single nucleotide polymorphisms (SNPs), which have previously been shown to be associated with asthma, on T(H)1/T(H)2 lineage cytokines at birth.
BC8_BioRED_Task1_Doc29	487	493	asthma	Disease	D001249	This study investigated the influence of TBX21 and HLX1 single nucleotide polymorphisms (SNPs), which have previously been shown to be associated with asthma, on T(H)1/T(H)2 lineage cytokines at birth.
BC8_BioRED_Task1_Doc29	636	641	TBX21	Gene	30009	METHODS AND FINDINGS: Cord blood mononuclear cells (CBMCs) of 200 neonates were genotyped for two TBX21 and three HLX1 SNPs.
BC8_BioRED_Task1_Doc29	652	656	HLX1	Gene	3142	METHODS AND FINDINGS: Cord blood mononuclear cells (CBMCs) of 200 neonates were genotyped for two TBX21 and three HLX1 SNPs.
BC8_BioRED_Task1_Doc29	698	705	Lipid A	Chemical	D008050	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	707	710	LpA	Chemical	D008050	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	712	725	Peptidoglycan	Chemical	D010457	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	727	730	Ppg	Chemical	D010457	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	767	799	Dermatophagoides pteronyssinus 1	Gene	113791973	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	801	806	Derp1	Gene	113791973	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	820	838	phytohemagglutinin	Chemical	D010835	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	840	843	PHA	Chemical	D010835	CBMCs were stimulated with innate (Lipid A, LpA; Peptidoglycan, Ppg), adaptive stimuli (house dust mite Dermatophagoides pteronyssinus 1, Derp1) or mitogen (phytohemagglutinin, PHA).
BC8_BioRED_Task1_Doc29	1046	1051	TBX21	Gene	30009	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1065	1075	rs17250932	SequenceVariant	rs17250932	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1080	1084	HLX1	Gene	3142	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1098	1107	rs2738751	SequenceVariant	rs2738751	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1153	1157	IL-5	Gene	3567	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1159	1164	IL-13	Gene	3596	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1169	1174	TNF-a	Gene	7124	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1191	1194	LpA	Chemical	D008050	Carriers of TBX21 promoter SNP rs17250932 and HLX1 promoter SNP rs2738751 showed reduced or trendwise reduced (p<0.07) IL-5, IL-13 and TNF-a secretion after LpA-stimulation.
BC8_BioRED_Task1_Doc29	1220	1224	HLX1	Gene	3142	Carriers of HLX1 SNP rs2738751 had lower IL-13 levels following Ppg-stimulation (p = 0.08).
BC8_BioRED_Task1_Doc29	1229	1238	rs2738751	SequenceVariant	rs2738751	Carriers of HLX1 SNP rs2738751 had lower IL-13 levels following Ppg-stimulation (p = 0.08).
BC8_BioRED_Task1_Doc29	1249	1254	IL-13	Gene	3596	Carriers of HLX1 SNP rs2738751 had lower IL-13 levels following Ppg-stimulation (p = 0.08).
BC8_BioRED_Task1_Doc29	1272	1275	Ppg	Chemical	D010457	Carriers of HLX1 SNP rs2738751 had lower IL-13 levels following Ppg-stimulation (p = 0.08).
BC8_BioRED_Task1_Doc29	1312	1316	HLX1	Gene	3142	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1328	1338	rs12141189	SequenceVariant	rs12141189	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1356	1360	IL-5	Gene	3567	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1362	1365	LpA	Chemical	D008050	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1378	1381	Ppg	Chemical	D010457	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1414	1419	IL-13	Gene	3596	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1421	1424	LpA	Chemical	D008050	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1434	1440	GM-CSF	Gene	1437	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1442	1445	LpA	Chemical	D008050	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1446	1449	Ppg	Chemical	D010457	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1483	1488	IFN-g	Gene	3458	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1500	1505	Derp1	Gene	113791973	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1506	1509	LpA	Chemical	D008050	Carriers of HLX1 exon 1 SNP rs12141189 showed increased IL-5 (LpA, p = 0.007; Ppg, p = 0.10), trendwise increased IL-13 (LpA), higher GM-CSF (LpA/Ppg, p<0.05) and trendwise decreased IFN-g secretion (Derp1+LpA-stimulation, p = 0.1).
BC8_BioRED_Task1_Doc29	1556	1560	HLX1	Gene	3142	Homozygous carriers of HLX1 promoter SNP rs3806325 showed increased IL-13 and IL-6 (unstimulated, p<0.03).
BC8_BioRED_Task1_Doc29	1574	1583	rs3806325	SequenceVariant	rs3806325	Homozygous carriers of HLX1 promoter SNP rs3806325 showed increased IL-13 and IL-6 (unstimulated, p<0.03).
BC8_BioRED_Task1_Doc29	1601	1606	IL-13	Gene	3596	Homozygous carriers of HLX1 promoter SNP rs3806325 showed increased IL-13 and IL-6 (unstimulated, p<0.03).
BC8_BioRED_Task1_Doc29	1611	1615	IL-6	Gene	3569	Homozygous carriers of HLX1 promoter SNP rs3806325 showed increased IL-13 and IL-6 (unstimulated, p<0.03).
BC8_BioRED_Task1_Doc29	1655	1660	TBX21	Gene	30009	In carriers of TBX21 intron 3 SNP rs11079788 no differences in cytokine secretion were observed.
BC8_BioRED_Task1_Doc29	1674	1684	rs11079788	SequenceVariant	rs11079788	In carriers of TBX21 intron 3 SNP rs11079788 no differences in cytokine secretion were observed.
BC8_BioRED_Task1_Doc29	1833	1838	TBX21	Gene	30009	TBX21 SNP rs11079788 carriers developed less symptoms of atopic dermatitis at 3 years of age (p = 0.03).
BC8_BioRED_Task1_Doc29	1843	1853	rs11079788	SequenceVariant	rs11079788	TBX21 SNP rs11079788 carriers developed less symptoms of atopic dermatitis at 3 years of age (p = 0.03).
BC8_BioRED_Task1_Doc29	1890	1907	atopic dermatitis	Disease	D003876	TBX21 SNP rs11079788 carriers developed less symptoms of atopic dermatitis at 3 years of age (p = 0.03).
BC8_BioRED_Task1_Doc29	1968	1973	TBX21	Gene	30009	CONCLUSIONS: Polymorphisms in TBX21 and HLX1 influenced primarily IL-5 and IL-13 secretion after LpA-stimulation in cord blood suggesting that genetic variations in the transcription factors essential for the T(H)1-pathway may contribute to modified T(H)2-immune responses already early in life.
BC8_BioRED_Task1_Doc29	1978	1982	HLX1	Gene	3142	CONCLUSIONS: Polymorphisms in TBX21 and HLX1 influenced primarily IL-5 and IL-13 secretion after LpA-stimulation in cord blood suggesting that genetic variations in the transcription factors essential for the T(H)1-pathway may contribute to modified T(H)2-immune responses already early in life.
BC8_BioRED_Task1_Doc29	2004	2008	IL-5	Gene	3567	CONCLUSIONS: Polymorphisms in TBX21 and HLX1 influenced primarily IL-5 and IL-13 secretion after LpA-stimulation in cord blood suggesting that genetic variations in the transcription factors essential for the T(H)1-pathway may contribute to modified T(H)2-immune responses already early in life.
BC8_BioRED_Task1_Doc29	2013	2018	IL-13	Gene	3596	CONCLUSIONS: Polymorphisms in TBX21 and HLX1 influenced primarily IL-5 and IL-13 secretion after LpA-stimulation in cord blood suggesting that genetic variations in the transcription factors essential for the T(H)1-pathway may contribute to modified T(H)2-immune responses already early in life.
BC8_BioRED_Task1_Doc29	2035	2038	LpA	Chemical	D008050	CONCLUSIONS: Polymorphisms in TBX21 and HLX1 influenced primarily IL-5 and IL-13 secretion after LpA-stimulation in cord blood suggesting that genetic variations in the transcription factors essential for the T(H)1-pathway may contribute to modified T(H)2-immune responses already early in life.
BC8_BioRED_Task1_Doc29	2320	2344	immune-mediated diseases	Disease	D007154	Further follow-up of the cohort is required to study the polymorphisms' relevance for immune-mediated diseases such as childhood asthma.
BC8_BioRED_Task1_Doc29	2363	2369	asthma	Disease	D001249	Further follow-up of the cohort is required to study the polymorphisms' relevance for immune-mediated diseases such as childhood asthma.
BC8_BioRED_Task1_Doc30	19	23	BMP4	Gene	652	Over-expression of BMP4 and BMP5 in a child with axial skeletal malformations and heterotopic ossification: a new syndrome.
BC8_BioRED_Task1_Doc30	28	32	BMP5	Gene	653	Over-expression of BMP4 and BMP5 in a child with axial skeletal malformations and heterotopic ossification: a new syndrome.
BC8_BioRED_Task1_Doc30	49	77	axial skeletal malformations	Disease	D001848	Over-expression of BMP4 and BMP5 in a child with axial skeletal malformations and heterotopic ossification: a new syndrome.
BC8_BioRED_Task1_Doc30	82	106	heterotopic ossification	Disease	D009999	Over-expression of BMP4 and BMP5 in a child with axial skeletal malformations and heterotopic ossification: a new syndrome.
BC8_BioRED_Task1_Doc30	124	151	Bone morphogenetic proteins	Gene	649,650,652,653	Bone morphogenetic proteins (BMPs) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo.
BC8_BioRED_Task1_Doc30	153	157	BMPs	Gene	649,650,652,653	Bone morphogenetic proteins (BMPs) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo.
BC8_BioRED_Task1_Doc30	223	259	ectopic cartilage and bone formation	Disease	D001847,D002357	Bone morphogenetic proteins (BMPs) are a highly conserved class of signaling molecules that induce ectopic cartilage and bone formation in vivo.
BC8_BioRED_Task1_Doc30	296	324	bone morphogenetic protein 4	Gene	652	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	326	330	BMP4	Gene	652	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	357	365	patients	OrganismTaxon	9606	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	375	412	fibrodysplasia ossificans progressiva	Disease	D009221	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	414	417	FOP	Disease	D009221	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	442	486	axial and appendicular skeletal malformation	Disease	D001848	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	503	527	heterotopic ossification	Disease	D009999	Dysregulated expression of bone morphogenetic protein 4 (BMP4) is found in the cells of patients who have fibrodysplasia ossificans progressiva (FOP), a genetic disorder of axial and appendicular skeletal malformation and progressive heterotopic ossification.
BC8_BioRED_Task1_Doc30	563	591	bone morphogenetic protein 5	Gene	653	Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of axial skeletal malformations.
BC8_BioRED_Task1_Doc30	593	597	bmp5	Gene	653	Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of axial skeletal malformations.
BC8_BioRED_Task1_Doc30	635	639	BMP5	Gene	653	Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of axial skeletal malformations.
BC8_BioRED_Task1_Doc30	650	656	murine	OrganismTaxon	10090	Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of axial skeletal malformations.
BC8_BioRED_Task1_Doc30	657	675	short ear syndrome	Disease	D004427	Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of axial skeletal malformations.
BC8_BioRED_Task1_Doc30	736	764	axial skeletal malformations	Disease	D001848	Loss of function mutations in the bone morphogenetic protein 5 (bmp5) gene leading to under-expression of BMP5 cause the murine short ear syndrome, characterized by small malformed ears and a broad range of axial skeletal malformations.
BC8_BioRED_Task1_Doc30	818	823	mouse	OrganismTaxon	10090	We found features reminiscent of both the short ear mouse and FOP in a child with malformed external ears, multiple malformations of the axial skeleton, and progressive heterotopic ossification in the neck and back.
BC8_BioRED_Task1_Doc30	828	831	FOP	Disease	D009221	We found features reminiscent of both the short ear mouse and FOP in a child with malformed external ears, multiple malformations of the axial skeleton, and progressive heterotopic ossification in the neck and back.
BC8_BioRED_Task1_Doc30	848	871	malformed external ears	Disease	D004426	We found features reminiscent of both the short ear mouse and FOP in a child with malformed external ears, multiple malformations of the axial skeleton, and progressive heterotopic ossification in the neck and back.
BC8_BioRED_Task1_Doc30	873	917	multiple malformations of the axial skeleton	Disease	D001848	We found features reminiscent of both the short ear mouse and FOP in a child with malformed external ears, multiple malformations of the axial skeleton, and progressive heterotopic ossification in the neck and back.
BC8_BioRED_Task1_Doc30	935	959	heterotopic ossification	Disease	D009999	We found features reminiscent of both the short ear mouse and FOP in a child with malformed external ears, multiple malformations of the axial skeleton, and progressive heterotopic ossification in the neck and back.
BC8_BioRED_Task1_Doc30	994	997	BMP	Gene	649,650,652,653	We examined BMP mRNA expression in transformed lymphocytes by semi-quantitative RT-PCR and protein expression by ELISA assays and immunohistochemistry.
BC8_BioRED_Task1_Doc30	1153	1157	BMP4	Gene	652	Elevated levels of BMP4 and BMP5 mRNA and protein were detected in the patient's cells while levels of BMP2 mRNA were unchanged.
BC8_BioRED_Task1_Doc30	1162	1166	BMP5	Gene	653	Elevated levels of BMP4 and BMP5 mRNA and protein were detected in the patient's cells while levels of BMP2 mRNA were unchanged.
BC8_BioRED_Task1_Doc30	1205	1212	patient	OrganismTaxon	9606	Elevated levels of BMP4 and BMP5 mRNA and protein were detected in the patient's cells while levels of BMP2 mRNA were unchanged.
BC8_BioRED_Task1_Doc30	1237	1241	BMP2	Gene	650	Elevated levels of BMP4 and BMP5 mRNA and protein were detected in the patient's cells while levels of BMP2 mRNA were unchanged.
BC8_BioRED_Task1_Doc30	1312	1316	BMP4	Gene	652	Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP.
BC8_BioRED_Task1_Doc30	1321	1325	BMP5	Gene	653	Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP.
BC8_BioRED_Task1_Doc30	1363	1368	human	OrganismTaxon	9606	Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP.
BC8_BioRED_Task1_Doc30	1369	1397	axial skeletal abnormalities	Disease	D001848	Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP.
BC8_BioRED_Task1_Doc30	1423	1428	mouse	OrganismTaxon	10090	Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP.
BC8_BioRED_Task1_Doc30	1433	1436	FOP	Disease	D009221	Our data suggest that dysregulated expression of BMP4 and BMP5 genes is associated with an array of human axial skeletal abnormalities similar to the short ear mouse and FOP.
BC8_BioRED_Task1_Doc31	31	61	non-autoimmune hyperthyroidism	Disease	C563786	Expanding clinical spectrum of non-autoimmune hyperthyroidism due to an activating germline mutation, p.M453T, in the thyrotropin receptor gene.
BC8_BioRED_Task1_Doc31	102	109	p.M453T	SequenceVariant	rs121908864	Expanding clinical spectrum of non-autoimmune hyperthyroidism due to an activating germline mutation, p.M453T, in the thyrotropin receptor gene.
BC8_BioRED_Task1_Doc31	118	138	thyrotropin receptor	Gene	7253	Expanding clinical spectrum of non-autoimmune hyperthyroidism due to an activating germline mutation, p.M453T, in the thyrotropin receptor gene.
BC8_BioRED_Task1_Doc31	220	250	non-autoimmune hyperthyroidism	Disease	C563786	OBJECTIVE: To describe clinical and genetic features of a Thai family with non-autoimmune hyperthyroidism (NAH) caused by an activating germline mutation in the thyrotropin receptor (TSHR) gene.
BC8_BioRED_Task1_Doc31	252	255	NAH	Disease	C563786	OBJECTIVE: To describe clinical and genetic features of a Thai family with non-autoimmune hyperthyroidism (NAH) caused by an activating germline mutation in the thyrotropin receptor (TSHR) gene.
BC8_BioRED_Task1_Doc31	306	326	thyrotropin receptor	Gene	7253	OBJECTIVE: To describe clinical and genetic features of a Thai family with non-autoimmune hyperthyroidism (NAH) caused by an activating germline mutation in the thyrotropin receptor (TSHR) gene.
BC8_BioRED_Task1_Doc31	328	332	TSHR	Gene	7253	OBJECTIVE: To describe clinical and genetic features of a Thai family with non-autoimmune hyperthyroidism (NAH) caused by an activating germline mutation in the thyrotropin receptor (TSHR) gene.
BC8_BioRED_Task1_Doc31	340	348	PATIENTS	OrganismTaxon	9606	PATIENTS: Three affected individuals from the same family (a father and his two children) were studied.
BC8_BioRED_Task1_Doc31	638	642	TSHR	Gene	7253	GENETIC ANALYSIS: Genomic DNA was extracted from peripheral blood leukocytes and mutation analysis of the entire coding sequence of the TSHR gene was performed in both children and their parents by direct DNA sequencing.
BC8_BioRED_Task1_Doc31	756	762	T to C	SequenceVariant	rs121908864	RESULTS: A heterozygous germline T to C transition in exon 10 of the TSHR gene (c.1358T-->C) resulting in the substitution of methionine (ATG) by threonine (ACG) at codon 453 (p.M453T) was identified in the father and his two children.
BC8_BioRED_Task1_Doc31	792	796	TSHR	Gene	7253	RESULTS: A heterozygous germline T to C transition in exon 10 of the TSHR gene (c.1358T-->C) resulting in the substitution of methionine (ATG) by threonine (ACG) at codon 453 (p.M453T) was identified in the father and his two children.
BC8_BioRED_Task1_Doc31	803	814	c.1358T-->C	SequenceVariant	rs121908864	RESULTS: A heterozygous germline T to C transition in exon 10 of the TSHR gene (c.1358T-->C) resulting in the substitution of methionine (ATG) by threonine (ACG) at codon 453 (p.M453T) was identified in the father and his two children.
BC8_BioRED_Task1_Doc31	849	897	methionine (ATG) by threonine (ACG) at codon 453	SequenceVariant	rs121908864	RESULTS: A heterozygous germline T to C transition in exon 10 of the TSHR gene (c.1358T-->C) resulting in the substitution of methionine (ATG) by threonine (ACG) at codon 453 (p.M453T) was identified in the father and his two children.
BC8_BioRED_Task1_Doc31	899	906	p.M453T	SequenceVariant	rs121908864	RESULTS: A heterozygous germline T to C transition in exon 10 of the TSHR gene (c.1358T-->C) resulting in the substitution of methionine (ATG) by threonine (ACG) at codon 453 (p.M453T) was identified in the father and his two children.
BC8_BioRED_Task1_Doc31	1049	1064	hyperthyroidism	Disease	D006980	In addition to hyperthyroidism, ventriculomegaly and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers were consistently found in all affected individuals.
BC8_BioRED_Task1_Doc31	1066	1082	ventriculomegaly	Disease	D006849	In addition to hyperthyroidism, ventriculomegaly and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers were consistently found in all affected individuals.
BC8_BioRED_Task1_Doc31	1250	1266	Ventriculomegaly	Disease	D006849	CONCLUSIONS: Ventriculomegaly and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers might be characteristic features of NAH because of an activating TSHR germline mutation.
BC8_BioRED_Task1_Doc31	1404	1407	NAH	Disease	C563786	CONCLUSIONS: Ventriculomegaly and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers might be characteristic features of NAH because of an activating TSHR germline mutation.
BC8_BioRED_Task1_Doc31	1433	1437	TSHR	Gene	7253	CONCLUSIONS: Ventriculomegaly and bilateral shortening of the fifth metacarpal bones and the middle phalanges of the fifth fingers might be characteristic features of NAH because of an activating TSHR germline mutation.
BC8_BioRED_Task1_Doc32	9	19	caveolin-1	Gene	857	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
BC8_BioRED_Task1_Doc32	29	33	Smad	Gene	4086,4090,4093	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
BC8_BioRED_Task1_Doc32	88	108	adenine 474 deletion	SequenceVariant	rs587777017	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
BC8_BioRED_Task1_Doc32	119	128	c.474delA	SequenceVariant	rs587777017	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
BC8_BioRED_Task1_Doc32	133	140	patient	OrganismTaxon	9606	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
BC8_BioRED_Task1_Doc32	192	214	pulmonary hypertension	Disease	D006976	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.
BC8_BioRED_Task1_Doc32	231	241	caveolin-1	Gene	857	A heterozygous caveolin-1 c.474delA mutation has been identified in a family with heritable pulmonary arterial hypertension (PAH).
BC8_BioRED_Task1_Doc32	242	251	c.474delA	SequenceVariant	rs587777017	A heterozygous caveolin-1 c.474delA mutation has been identified in a family with heritable pulmonary arterial hypertension (PAH).
BC8_BioRED_Task1_Doc32	308	339	pulmonary arterial hypertension	Disease	D000081029	A heterozygous caveolin-1 c.474delA mutation has been identified in a family with heritable pulmonary arterial hypertension (PAH).
BC8_BioRED_Task1_Doc32	341	344	PAH	Disease	D000081029	A heterozygous caveolin-1 c.474delA mutation has been identified in a family with heritable pulmonary arterial hypertension (PAH).
BC8_BioRED_Task1_Doc32	383	393	caveolin-1	Gene	857	This frameshift mutation leads to a caveolin-1 protein that contains all known functional domains but has a change in only the final 20 amino acids of the C-terminus.
BC8_BioRED_Task1_Doc32	555	565	caveolin-1	Gene	857	Here we studied how this mutation alters caveolin-1 function, using patient-derived fibroblasts.
BC8_BioRED_Task1_Doc32	582	589	patient	OrganismTaxon	9606	Here we studied how this mutation alters caveolin-1 function, using patient-derived fibroblasts.
BC8_BioRED_Task1_Doc32	681	690	c.474delA	SequenceVariant	rs587777017	Transmission electron microscopy showed that fibroblasts carrying the c.474delA mutation form typical caveolae.
BC8_BioRED_Task1_Doc32	745	755	caveolin-1	Gene	857	Expression of mutated caveolin-1 in caveolin-1-null mouse fibroblasts failed to induce formation of caveolae due to retention of the mutated protein in the endoplasmic reticulum.
BC8_BioRED_Task1_Doc32	759	769	caveolin-1	Gene	12389	Expression of mutated caveolin-1 in caveolin-1-null mouse fibroblasts failed to induce formation of caveolae due to retention of the mutated protein in the endoplasmic reticulum.
BC8_BioRED_Task1_Doc32	775	780	mouse	OrganismTaxon	10090	Expression of mutated caveolin-1 in caveolin-1-null mouse fibroblasts failed to induce formation of caveolae due to retention of the mutated protein in the endoplasmic reticulum.
BC8_BioRED_Task1_Doc32	937	947	caveolin-1	Gene	857	However, coexpression of wild-type caveolin-1 with mutated caveolin-1 restored the ability to form caveolae.
BC8_BioRED_Task1_Doc32	961	971	caveolin-1	Gene	857	However, coexpression of wild-type caveolin-1 with mutated caveolin-1 restored the ability to form caveolae.
BC8_BioRED_Task1_Doc32	1144	1153	Smad1/5/8	Gene	4086,4090,4093	Importantly, fibroblasts carrying the mutation showed twofold increase in proliferation rate associated with hyperphosphorylation of Smad1/5/8.
BC8_BioRED_Task1_Doc32	1212	1222	caveolin-1	Gene	857	This mutation impaired the antiproliferative function of caveolin-1.
BC8_BioRED_Task1_Doc32	1238	1259	type I TGFb receptors	Gene	657,658,90,94	Inhibition of type I TGFb receptors ALK1/2/3/6 responsible for phosphorylation of Smad1/5/8 reduced the hyperproliferation seen in c.474delA fibroblasts.
BC8_BioRED_Task1_Doc32	1260	1270	ALK1/2/3/6	Gene	657,658,90,94	Inhibition of type I TGFb receptors ALK1/2/3/6 responsible for phosphorylation of Smad1/5/8 reduced the hyperproliferation seen in c.474delA fibroblasts.
BC8_BioRED_Task1_Doc32	1306	1315	Smad1/5/8	Gene	4086,4090,4093	Inhibition of type I TGFb receptors ALK1/2/3/6 responsible for phosphorylation of Smad1/5/8 reduced the hyperproliferation seen in c.474delA fibroblasts.
BC8_BioRED_Task1_Doc32	1355	1364	c.474delA	SequenceVariant	rs587777017	Inhibition of type I TGFb receptors ALK1/2/3/6 responsible for phosphorylation of Smad1/5/8 reduced the hyperproliferation seen in c.474delA fibroblasts.
BC8_BioRED_Task1_Doc32	1453	1463	caveolin-1	Gene	857	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc32	1516	1520	Smad	Gene	4086,4090,4093	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc32	1558	1562	Smad	Gene	4086,4090,4093	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc32	1655	1658	PAH	Disease	D000081029	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc32	1662	1670	patients	OrganismTaxon	9606	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc32	1676	1686	caveolin-1	Gene	857	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc32	1687	1696	c.474delA	SequenceVariant	rs587777017	These results demonstrate the critical role of the final 20 amino acids of caveolin-1 in modulating fibroblast proliferation by dampening Smad signaling and suggest that augmented Smad signaling and fibroblast hyperproliferation are contributing factors in the pathogenesis of PAH in patients with caveolin-1 c.474delA mutation.
BC8_BioRED_Task1_Doc33	21	40	complement factor H	Gene	3075	Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population.
BC8_BioRED_Task1_Doc33	42	44	C2	Gene	717	Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population.
BC8_BioRED_Task1_Doc33	46	49	CFB	Gene	629	Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population.
BC8_BioRED_Task1_Doc33	55	57	C3	Gene	718	Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population.
BC8_BioRED_Task1_Doc33	62	94	age-related macular degeneration	Disease	D008268	Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population.
BC8_BioRED_Task1_Doc33	176	195	complement factor H	Gene	3075	PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD).
BC8_BioRED_Task1_Doc33	197	200	CFH	Gene	3075	PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD).
BC8_BioRED_Task1_Doc33	203	208	C2/BF	Gene	629,717	PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD).
BC8_BioRED_Task1_Doc33	214	216	C3	Gene	718	PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD).
BC8_BioRED_Task1_Doc33	259	291	age-related macular degeneration	Disease	D008268	PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD).
BC8_BioRED_Task1_Doc33	293	296	AMD	Disease	D008268	PURPOSE: Genes in the complement pathway, including complement factor H (CFH), C2/BF, and C3, have been reported to be associated with age-related macular degeneration (AMD).
BC8_BioRED_Task1_Doc33	500	508	patients	OrganismTaxon	9606	METHODS: One hundred and fifty-eight patients with wet AMD, 80 patients with soft drusen, and 220 matched control subjects were recruited among Han Chinese in mainland China.
BC8_BioRED_Task1_Doc33	518	521	AMD	Disease	D008268	METHODS: One hundred and fifty-eight patients with wet AMD, 80 patients with soft drusen, and 220 matched control subjects were recruited among Han Chinese in mainland China.
BC8_BioRED_Task1_Doc33	526	534	patients	OrganismTaxon	9606	METHODS: One hundred and fifty-eight patients with wet AMD, 80 patients with soft drusen, and 220 matched control subjects were recruited among Han Chinese in mainland China.
BC8_BioRED_Task1_Doc33	545	551	drusen	Disease	D005128	METHODS: One hundred and fifty-eight patients with wet AMD, 80 patients with soft drusen, and 220 matched control subjects were recruited among Han Chinese in mainland China.
BC8_BioRED_Task1_Doc33	652	655	CFH	Gene	3075	Seven SNPs in CFH and two SNPs in C2, CFB', and C3 were genotyped using the ABI SNaPshot method.
BC8_BioRED_Task1_Doc33	672	674	C2	Gene	717	Seven SNPs in CFH and two SNPs in C2, CFB', and C3 were genotyped using the ABI SNaPshot method.
BC8_BioRED_Task1_Doc33	676	679	CFB	Gene	629	Seven SNPs in CFH and two SNPs in C2, CFB', and C3 were genotyped using the ABI SNaPshot method.
BC8_BioRED_Task1_Doc33	686	688	C3	Gene	718	Seven SNPs in CFH and two SNPs in C2, CFB', and C3 were genotyped using the ABI SNaPshot method.
BC8_BioRED_Task1_Doc33	780	785	CFHR1	Gene	3078	A deletion of 84,682 base pairs covering the CFHR1 and CFHR3 genes was detected by direct polymerase chain reaction and gel electrophoresis.
BC8_BioRED_Task1_Doc33	790	795	CFHR3	Gene	10878	A deletion of 84,682 base pairs covering the CFHR1 and CFHR3 genes was detected by direct polymerase chain reaction and gel electrophoresis.
BC8_BioRED_Task1_Doc33	906	915	rs3753394	SequenceVariant	rs3753394	RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study.
BC8_BioRED_Task1_Doc33	930	938	rs800292	SequenceVariant	rs800292	RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study.
BC8_BioRED_Task1_Doc33	953	962	rs1061170	SequenceVariant	rs1061170	RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study.
BC8_BioRED_Task1_Doc33	982	991	rs1329428	SequenceVariant	rs1329428	RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study.
BC8_BioRED_Task1_Doc33	1009	1012	CFH	Gene	3075	RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study.
BC8_BioRED_Task1_Doc33	1055	1058	AMD	Disease	D008268	RESULTS: Four SNPs, including rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), in CFH showed a significant association with wet AMD in the cohort of this study.
BC8_BioRED_Task1_Doc33	1176	1179	AMD	Disease	D008268	A haplotype containing these four SNPs (CATA) significantly increased protection of wet AMD with a P value of 0.0005 and an odds ratio of 0.29 (95% confidence interval: 0.15-0.60).
BC8_BioRED_Task1_Doc33	1298	1307	rs2274700	SequenceVariant	rs2274700	Unlike in other populations, rs2274700 and rs1410996 did not show a significant association with AMD in the Chinese population of this study.
BC8_BioRED_Task1_Doc33	1312	1321	rs1410996	SequenceVariant	rs1410996	Unlike in other populations, rs2274700 and rs1410996 did not show a significant association with AMD in the Chinese population of this study.
BC8_BioRED_Task1_Doc33	1366	1369	AMD	Disease	D008268	Unlike in other populations, rs2274700 and rs1410996 did not show a significant association with AMD in the Chinese population of this study.
BC8_BioRED_Task1_Doc33	1431	1434	CFH	Gene	3075	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1473	1479	drusen	Disease	D005128	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1505	1508	CFH	Gene	3075	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1510	1512	C2	Gene	717	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1514	1517	CFB	Gene	629	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1523	1525	C3	Gene	718	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1575	1578	AMD	Disease	D008268	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1582	1588	drusen	Disease	D005128	None of the SNPs in CFH showed a significant association with drusen, and none of the SNPs in CFH, C2, CFB, and C3 showed a significant association with either wet AMD or drusen in the cohort of this study.
BC8_BioRED_Task1_Doc33	1622	1627	CFHR1	Gene	3078	The CFHR1 and CFHR3 deletion was not polymorphic in the Chinese population and was not associated with wet AMD or drusen.
BC8_BioRED_Task1_Doc33	1632	1637	CFHR3	Gene	10878	The CFHR1 and CFHR3 deletion was not polymorphic in the Chinese population and was not associated with wet AMD or drusen.
BC8_BioRED_Task1_Doc33	1725	1728	AMD	Disease	D008268	The CFHR1 and CFHR3 deletion was not polymorphic in the Chinese population and was not associated with wet AMD or drusen.
BC8_BioRED_Task1_Doc33	1732	1738	drusen	Disease	D005128	The CFHR1 and CFHR3 deletion was not polymorphic in the Chinese population and was not associated with wet AMD or drusen.
BC8_BioRED_Task1_Doc33	1780	1789	rs3753394	SequenceVariant	rs3753394	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1804	1812	rs800292	SequenceVariant	rs800292	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1827	1836	rs1061170	SequenceVariant	rs1061170	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1856	1865	rs1329428	SequenceVariant	rs1329428	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1888	1897	rs7535263	SequenceVariant	rs7535263	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1899	1908	rs1410996	SequenceVariant	rs1410996	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1913	1922	rs2274700	SequenceVariant	rs2274700	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1927	1930	CFH	Gene	3075	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	1970	1973	AMD	Disease	D008268	CONCLUSION: This study showed that SNPs rs3753394 (P = 0.0276), rs800292 (P = 0.0266), rs1061170 (P = 0.00514), and rs1329428 (P = 0.0089), but not rs7535263, rs1410996, or rs2274700, in CFH were significantly associated with wet AMD in a mainland Han Chinese population.
BC8_BioRED_Task1_Doc33	2035	2038	CFH	Gene	3075	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2061	2064	AMD	Disease	D008268	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2127	2132	CFHR1	Gene	3078	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2137	2142	CFHR3	Gene	10878	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2262	2265	AMD	Disease	D008268	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2291	2293	C2	Gene	717	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2295	2298	CFB	Gene	629	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2304	2306	C3	Gene	718	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc33	2351	2354	AMD	Disease	D008268	This study showed that CFH was more likely to be AMD susceptibility gene at Chr.1q31 based on the finding that the CFHR1 and CFHR3 deletion was not polymorphic in the cohort of this study, and none of the SNPs that were significantly associated with AMD in a white population in C2, CFB, and C3 genes showed a significant association with AMD.
BC8_BioRED_Task1_Doc34	47	52	women	OrganismTaxon	9606	Genetic investigation of four meiotic genes in women with premature ovarian failure.
BC8_BioRED_Task1_Doc34	58	83	premature ovarian failure	Disease	D016649	Genetic investigation of four meiotic genes in women with premature ovarian failure.
BC8_BioRED_Task1_Doc34	204	208	DMC1	Gene	11144	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	211	215	MutS	Gene	850545	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	225	229	MSH4	Gene	4438	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	232	236	MSH5	Gene	4439	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	242	255	S. cerevisiae	OrganismTaxon	4932	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	265	270	SPO11	Gene	856364	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	294	319	premature ovarian failure	Disease	D016649	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	321	324	POF	Disease	D016649	OBJECTIVE: The goal of this study was to determine whether mutations of meiotic genes, such as disrupted meiotic cDNA (DMC1), MutS homolog (MSH4), MSH5, and S. cerevisiae homolog (SPO11), were associated with premature ovarian failure (POF).
BC8_BioRED_Task1_Doc34	464	472	patients	OrganismTaxon	9606	METHODS: Blood sampling, karyotype, hormonal dosage, ultrasound, and ovarian biopsy were carried out on most patients.
BC8_BioRED_Task1_Doc34	578	583	women	OrganismTaxon	9606	However, the main outcome measure was the sequencing of genomic DNA from peripheral blood samples of 41 women with POF and 36 fertile women (controls).
BC8_BioRED_Task1_Doc34	589	592	POF	Disease	D016649	However, the main outcome measure was the sequencing of genomic DNA from peripheral blood samples of 41 women with POF and 36 fertile women (controls).
BC8_BioRED_Task1_Doc34	608	613	women	OrganismTaxon	9606	However, the main outcome measure was the sequencing of genomic DNA from peripheral blood samples of 41 women with POF and 36 fertile women (controls).
BC8_BioRED_Task1_Doc34	694	725	cytosine residue with thymidine	SequenceVariant	rs2075789	RESULTS: A single heterozygous missense mutation, substitution of a cytosine residue with thymidine in exon 2 of MSH5, was found in two Caucasian women in whom POF developed at 18 and 36 years of age.
BC8_BioRED_Task1_Doc34	739	743	MSH5	Gene	4439	RESULTS: A single heterozygous missense mutation, substitution of a cytosine residue with thymidine in exon 2 of MSH5, was found in two Caucasian women in whom POF developed at 18 and 36 years of age.
BC8_BioRED_Task1_Doc34	772	777	women	OrganismTaxon	9606	RESULTS: A single heterozygous missense mutation, substitution of a cytosine residue with thymidine in exon 2 of MSH5, was found in two Caucasian women in whom POF developed at 18 and 36 years of age.
BC8_BioRED_Task1_Doc34	786	789	POF	Disease	D016649	RESULTS: A single heterozygous missense mutation, substitution of a cytosine residue with thymidine in exon 2 of MSH5, was found in two Caucasian women in whom POF developed at 18 and 36 years of age.
BC8_BioRED_Task1_Doc34	891	948	(proline) with a polar amino acid (serine) at position 29	SequenceVariant	rs2075789	This mutation resulted in replacement of a non-polar amino acid (proline) with a polar amino acid (serine) at position 29 (P29S).
BC8_BioRED_Task1_Doc34	950	954	P29S	SequenceVariant	rs2075789	This mutation resulted in replacement of a non-polar amino acid (proline) with a polar amino acid (serine) at position 29 (P29S).
BC8_BioRED_Task1_Doc34	976	981	women	OrganismTaxon	9606	Neither 36 control women nor 39 other patients with POF possessed this genetic perturbation.
BC8_BioRED_Task1_Doc34	995	1003	patients	OrganismTaxon	9606	Neither 36 control women nor 39 other patients with POF possessed this genetic perturbation.
BC8_BioRED_Task1_Doc34	1009	1012	POF	Disease	D016649	Neither 36 control women nor 39 other patients with POF possessed this genetic perturbation.
BC8_BioRED_Task1_Doc34	1058	1061	POF	Disease	D016649	Another POF patient of African origin showed a homozygous nucleotide change in the tenth of DMC1 gene that led to an alteration of the amino acid composition of the protein (M200V).
BC8_BioRED_Task1_Doc34	1062	1069	patient	OrganismTaxon	9606	Another POF patient of African origin showed a homozygous nucleotide change in the tenth of DMC1 gene that led to an alteration of the amino acid composition of the protein (M200V).
BC8_BioRED_Task1_Doc34	1142	1146	DMC1	Gene	11144	Another POF patient of African origin showed a homozygous nucleotide change in the tenth of DMC1 gene that led to an alteration of the amino acid composition of the protein (M200V).
BC8_BioRED_Task1_Doc34	1224	1229	M200V	SequenceVariant	rs2227914	Another POF patient of African origin showed a homozygous nucleotide change in the tenth of DMC1 gene that led to an alteration of the amino acid composition of the protein (M200V).
BC8_BioRED_Task1_Doc34	1261	1272	infertility	Disease	D007247	CONCLUSIONS: The symptoms of infertility observed in the DMC1 homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the MSH5 gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function.
BC8_BioRED_Task1_Doc34	1289	1293	DMC1	Gene	11144	CONCLUSIONS: The symptoms of infertility observed in the DMC1 homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the MSH5 gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function.
BC8_BioRED_Task1_Doc34	1334	1342	patients	OrganismTaxon	9606	CONCLUSIONS: The symptoms of infertility observed in the DMC1 homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the MSH5 gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function.
BC8_BioRED_Task1_Doc34	1393	1397	MSH5	Gene	4439	CONCLUSIONS: The symptoms of infertility observed in the DMC1 homozygote mutation carrier and in both patients with a heterozygous substitution in exon 2 of the MSH5 gene provide indirect evidence of the role of genes involved in meiotic recombination in the regulation of ovarian function.
BC8_BioRED_Task1_Doc34	1523	1527	MSH5	Gene	4439	MSH5 and DMC1 mutations may be one explanation for POF, albeit uncommon.
BC8_BioRED_Task1_Doc34	1532	1536	DMC1	Gene	11144	MSH5 and DMC1 mutations may be one explanation for POF, albeit uncommon.
BC8_BioRED_Task1_Doc34	1574	1577	POF	Disease	D016649	MSH5 and DMC1 mutations may be one explanation for POF, albeit uncommon.
BC8_BioRED_Task1_Doc35	20	24	PEMT	Gene	10400	Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD).
BC8_BioRED_Task1_Doc35	52	84	nonalcoholic fatty liver disease	Disease	D065626	Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD).
BC8_BioRED_Task1_Doc35	86	91	NAFLD	Disease	D065626	Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD).
BC8_BioRED_Task1_Doc35	94	138	Phosphatidylethanolamine N-methyltransferase	Gene	10400	Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes phosphatidylcholine synthesis.
BC8_BioRED_Task1_Doc35	140	144	PEMT	Gene	10400	Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes phosphatidylcholine synthesis.
BC8_BioRED_Task1_Doc35	156	175	phosphatidylcholine	Chemical	D010713	Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes phosphatidylcholine synthesis.
BC8_BioRED_Task1_Doc35	187	191	PEMT	Gene	18618	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	201	205	mice	OrganismTaxon	10090	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	211	223	fatty livers	Disease	D005234	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	253	259	humans	OrganismTaxon	9606	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	261	293	nonalcoholic fatty liver disease	Disease	D065626	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	295	300	NAFLD	Disease	D065626	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	327	331	PEMT	Gene	10400	PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms.
BC8_BioRED_Task1_Doc35	372	378	humans	OrganismTaxon	9606	DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution.
BC8_BioRED_Task1_Doc35	387	398	fatty liver	Disease	D005234	DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution.
BC8_BioRED_Task1_Doc35	411	417	humans	OrganismTaxon	9606	DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution.
BC8_BioRED_Task1_Doc35	423	428	NAFLD	Disease	D065626	DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution.
BC8_BioRED_Task1_Doc35	494	498	PEMT	Gene	10400	DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution.
BC8_BioRED_Task1_Doc35	517	522	V175M	SequenceVariant	rs7946	DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution.
BC8_BioRED_Task1_Doc35	537	542	V175M	SequenceVariant	rs7946	V175M is a loss of function mutation, as determined by transiently transfecting McArdle-RH7777 cells with constructs of wild-type PEMT open reading frame or the V175M mutant.
BC8_BioRED_Task1_Doc35	617	631	McArdle-RH7777	CellLine	CVCL_0444	V175M is a loss of function mutation, as determined by transiently transfecting McArdle-RH7777 cells with constructs of wild-type PEMT open reading frame or the V175M mutant.
BC8_BioRED_Task1_Doc35	667	671	PEMT	Gene	25511	V175M is a loss of function mutation, as determined by transiently transfecting McArdle-RH7777 cells with constructs of wild-type PEMT open reading frame or the V175M mutant.
BC8_BioRED_Task1_Doc35	698	703	V175M	SequenceVariant	rs7946	V175M is a loss of function mutation, as determined by transiently transfecting McArdle-RH7777 cells with constructs of wild-type PEMT open reading frame or the V175M mutant.
BC8_BioRED_Task1_Doc35	712	734	Met/Met at residue 175	SequenceVariant	rs7946	Met/Met at residue 175 (loss of function SNP) occurred in 67.9% of the NAFLD subjects and in only 40.7% of control subjects (P<0.03).
BC8_BioRED_Task1_Doc35	783	788	NAFLD	Disease	D065626	Met/Met at residue 175 (loss of function SNP) occurred in 67.9% of the NAFLD subjects and in only 40.7% of control subjects (P<0.03).
BC8_BioRED_Task1_Doc35	902	907	human	OrganismTaxon	9606	For the first time we report that a polymorphism of the human PEMT gene (V175M) is associated with diminished activity and may confer susceptibility to NAFLD.
BC8_BioRED_Task1_Doc35	908	912	PEMT	Gene	10400	For the first time we report that a polymorphism of the human PEMT gene (V175M) is associated with diminished activity and may confer susceptibility to NAFLD.
BC8_BioRED_Task1_Doc35	919	924	V175M	SequenceVariant	rs7946	For the first time we report that a polymorphism of the human PEMT gene (V175M) is associated with diminished activity and may confer susceptibility to NAFLD.
BC8_BioRED_Task1_Doc35	998	1003	NAFLD	Disease	D065626	For the first time we report that a polymorphism of the human PEMT gene (V175M) is associated with diminished activity and may confer susceptibility to NAFLD.
BC8_BioRED_Task1_Doc36	25	50	cyclooxygenase inhibitors	Chemical	D016861	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
BC8_BioRED_Task1_Doc36	190	211	myocardial infarction	Disease	D009203	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
BC8_BioRED_Task1_Doc36	213	219	stroke	Disease	D020521	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
BC8_BioRED_Task1_Doc36	221	233	hypertension	Disease	D006973	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
BC8_BioRED_Task1_Doc36	238	251	heart failure	Disease	D006333	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
BC8_BioRED_Task1_Doc36	274	299	cyclooxygenase inhibitors	Chemical	D016861	Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
BC8_BioRED_Task1_Doc36	373	381	patients	OrganismTaxon	9606	Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
BC8_BioRED_Task1_Doc36	413	438	Cyclooxygenase inhibitors	Chemical	D016861	Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.
BC8_BioRED_Task1_Doc36	492	502	prostanoid	Chemical	D011453	Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.
BC8_BioRED_Task1_Doc36	589	618	cardiovascular adverse events	Disease	D002318	The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time.
BC8_BioRED_Task1_Doc36	735	760	cyclooxygenase inhibitors	Chemical	D016861	A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.
BC8_BioRED_Task1_Doc36	912	925	prostaglandin	Chemical	D011453	A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.
BC8_BioRED_Task1_Doc36	974	1014	N-terminal pro brain natriuretic peptide	Chemical	C109794	Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.
BC8_BioRED_Task1_Doc36	1016	1025	NT-proBNP	Chemical	C109794	Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.
BC8_BioRED_Task1_Doc36	1045	1063	C-reactive protein	Gene	1401	Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.
BC8_BioRED_Task1_Doc36	1106	1114	patients	OrganismTaxon	9606	Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.
BC8_BioRED_Task1_Doc36	1164	1187	cardiovascular toxicity	Disease	D002318	Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.
BC8_BioRED_Task1_Doc37	86	105	dengue virus type 2	OrganismTaxon	11060	Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
BC8_BioRED_Task1_Doc37	121	140	dengue virus type 2	OrganismTaxon	11060	BACKGROUND: A dengue virus type 2 (DEN-2 Tonga/74) isolated from a 1974 epidemic was characterized by mild illness and belongs to the American genotype of DEN-2 viruses.
BC8_BioRED_Task1_Doc37	142	147	DEN-2	OrganismTaxon	11060	BACKGROUND: A dengue virus type 2 (DEN-2 Tonga/74) isolated from a 1974 epidemic was characterized by mild illness and belongs to the American genotype of DEN-2 viruses.
BC8_BioRED_Task1_Doc37	262	267	DEN-2	OrganismTaxon	11060	BACKGROUND: A dengue virus type 2 (DEN-2 Tonga/74) isolated from a 1974 epidemic was characterized by mild illness and belongs to the American genotype of DEN-2 viruses.
BC8_BioRED_Task1_Doc37	332	354	30 nucleotide deletion	SequenceVariant	c|DEL||30	To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate.
BC8_BioRED_Task1_Doc37	356	363	Delta30	SequenceVariant	c|DEL||30	To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate.
BC8_BioRED_Task1_Doc37	398	403	DEN-4	OrganismTaxon	11070	To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate.
BC8_BioRED_Task1_Doc37	433	438	DEN-2	OrganismTaxon	11060	To prepare a vaccine candidate, a previously described 30 nucleotide deletion (Delta30) in the 3' untranslated region of DEN-4 has been engineered into the DEN-2 isolate.
BC8_BioRED_Task1_Doc37	505	510	DEN-2	OrganismTaxon	11060	METHODS: A full-length cDNA clone was generated from the DEN-2 virus and used to produce recombinant DEN-2 (rDEN-2) and rDEN2Delta30.
BC8_BioRED_Task1_Doc37	549	554	DEN-2	OrganismTaxon	11060	METHODS: A full-length cDNA clone was generated from the DEN-2 virus and used to produce recombinant DEN-2 (rDEN-2) and rDEN2Delta30.
BC8_BioRED_Task1_Doc37	556	562	rDEN-2	OrganismTaxon	11060	METHODS: A full-length cDNA clone was generated from the DEN-2 virus and used to produce recombinant DEN-2 (rDEN-2) and rDEN2Delta30.
BC8_BioRED_Task1_Doc37	568	573	rDEN2	OrganismTaxon	11060	METHODS: A full-length cDNA clone was generated from the DEN-2 virus and used to produce recombinant DEN-2 (rDEN-2) and rDEN2Delta30.
BC8_BioRED_Task1_Doc37	573	580	Delta30	SequenceVariant	c|DEL||30	METHODS: A full-length cDNA clone was generated from the DEN-2 virus and used to produce recombinant DEN-2 (rDEN-2) and rDEN2Delta30.
BC8_BioRED_Task1_Doc37	629	633	mice	OrganismTaxon	10090	Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys.
BC8_BioRED_Task1_Doc37	652	657	human	OrganismTaxon	9606	Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys.
BC8_BioRED_Task1_Doc37	658	666	hepatoma	Disease	D006528	Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys.
BC8_BioRED_Task1_Doc37	674	684	SCID-HuH-7	CellLine	CVCL_0336	Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys.
BC8_BioRED_Task1_Doc37	685	689	mice	OrganismTaxon	10090	Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys.
BC8_BioRED_Task1_Doc37	714	728	rhesus monkeys	OrganismTaxon	9544	Viruses were evaluated for replication in SCID mice transplanted with human hepatoma cells (SCID-HuH-7 mice), in mosquitoes, and in rhesus monkeys.
BC8_BioRED_Task1_Doc37	808	822	rhesus monkeys	OrganismTaxon	9544	Neutralizing antibody induction and protective efficacy were also assessed in rhesus monkeys.
BC8_BioRED_Task1_Doc37	837	842	rDEN2	OrganismTaxon	11060	RESULTS: The rDEN2Delta30 virus was ten-fold reduced in replication in SCID-HuH-7 mice when compared to the parent virus.
BC8_BioRED_Task1_Doc37	842	849	Delta30	SequenceVariant	c|DEL||30	RESULTS: The rDEN2Delta30 virus was ten-fold reduced in replication in SCID-HuH-7 mice when compared to the parent virus.
BC8_BioRED_Task1_Doc37	895	905	SCID-HuH-7	CellLine	CVCL_0336	RESULTS: The rDEN2Delta30 virus was ten-fold reduced in replication in SCID-HuH-7 mice when compared to the parent virus.
BC8_BioRED_Task1_Doc37	906	910	mice	OrganismTaxon	10090	RESULTS: The rDEN2Delta30 virus was ten-fold reduced in replication in SCID-HuH-7 mice when compared to the parent virus.
BC8_BioRED_Task1_Doc37	950	956	rDEN-2	OrganismTaxon	11060	The rDEN-2 viruses were not infectious for Aedes mosquitoes, but both readily infected Toxorynchites mosquitoes.
BC8_BioRED_Task1_Doc37	989	1005	Aedes mosquitoes	OrganismTaxon	1245352	The rDEN-2 viruses were not infectious for Aedes mosquitoes, but both readily infected Toxorynchites mosquitoes.
BC8_BioRED_Task1_Doc37	1033	1057	Toxorynchites mosquitoes	OrganismTaxon	2498889	The rDEN-2 viruses were not infectious for Aedes mosquitoes, but both readily infected Toxorynchites mosquitoes.
BC8_BioRED_Task1_Doc37	1062	1076	rhesus monkeys	OrganismTaxon	9544	In rhesus monkeys, rDEN2Delta30 appeared to be slightly attenuated when compared to the parent virus as measured by duration and peak of viremia and neutralizing antibody induction.
BC8_BioRED_Task1_Doc37	1078	1083	rDEN2	OrganismTaxon	11060	In rhesus monkeys, rDEN2Delta30 appeared to be slightly attenuated when compared to the parent virus as measured by duration and peak of viremia and neutralizing antibody induction.
BC8_BioRED_Task1_Doc37	1083	1090	Delta30	SequenceVariant	c|DEL||30	In rhesus monkeys, rDEN2Delta30 appeared to be slightly attenuated when compared to the parent virus as measured by duration and peak of viremia and neutralizing antibody induction.
BC8_BioRED_Task1_Doc37	1196	1203	viremia	Disease	D014766	In rhesus monkeys, rDEN2Delta30 appeared to be slightly attenuated when compared to the parent virus as measured by duration and peak of viremia and neutralizing antibody induction.
BC8_BioRED_Task1_Doc37	1257	1262	rDEN2	OrganismTaxon	11060	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1262	1269	Delta30	SequenceVariant	c|DEL||30	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1282	1287	rDEN2	OrganismTaxon	11060	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1287	1299	Delta30-4995	SequenceVariant	c|DEL|4995|30	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1381	1384	NS3	Gene	5130010	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1393	1398	DEN-4	OrganismTaxon	11070	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1440	1445	rDEN2	OrganismTaxon	11060	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1445	1452	Delta30	SequenceVariant	c|DEL||30	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1456	1466	SCID-HuH-7	CellLine	CVCL_0336	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1467	1471	mice	OrganismTaxon	10090	A derivative of rDEN2Delta30, designated rDEN2Delta30-4995, was generated by incorporation of a point mutation previously identified in the NS3 gene of DEN-4 and was found to be more attenuated than rDEN2Delta30 in SCID-HuH-7 mice.
BC8_BioRED_Task1_Doc37	1490	1495	rDEN2	OrganismTaxon	11060	CONCLUSIONS: The rDEN2Delta30 and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.
BC8_BioRED_Task1_Doc37	1495	1502	Delta30	SequenceVariant	c|DEL||30	CONCLUSIONS: The rDEN2Delta30 and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.
BC8_BioRED_Task1_Doc37	1507	1512	rDEN2	OrganismTaxon	11060	CONCLUSIONS: The rDEN2Delta30 and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.
BC8_BioRED_Task1_Doc37	1512	1524	Delta30-4995	SequenceVariant	c|DEL|4995|30	CONCLUSIONS: The rDEN2Delta30 and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.
BC8_BioRED_Task1_Doc37	1569	1575	humans	OrganismTaxon	9606	CONCLUSIONS: The rDEN2Delta30 and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.
BC8_BioRED_Task1_Doc37	1611	1617	dengue	Disease	D003715	CONCLUSIONS: The rDEN2Delta30 and rDEN2Delta30-4995 viruses can be considered for evaluation in humans and for inclusion in a tetravalent dengue vaccine.
BC8_BioRED_Task1_Doc38	36	66	type 2B von Willebrand disease	Disease	D056728	A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
BC8_BioRED_Task1_Doc38	72	78	R1306W	SequenceVariant	rs61749384	A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
BC8_BioRED_Task1_Doc38	114	128	genetic defect	Disease	D030342	Clinical, laboratory and genetic defect of a Taiwanese family with type 2B von Willebrand disease (VWD) were studied.
BC8_BioRED_Task1_Doc38	156	186	type 2B von Willebrand disease	Disease	D056728	Clinical, laboratory and genetic defect of a Taiwanese family with type 2B von Willebrand disease (VWD) were studied.
BC8_BioRED_Task1_Doc38	188	191	VWD	Disease	D014842	Clinical, laboratory and genetic defect of a Taiwanese family with type 2B von Willebrand disease (VWD) were studied.
BC8_BioRED_Task1_Doc38	237	242	woman	OrganismTaxon	9606	The proband was a 55-year-old woman who gave birth to two daughters and one son aged 30, 29 and 27, respectively.
BC8_BioRED_Task1_Doc38	352	361	bleedings	Disease	D006470	All had abnormal mucocutaneous bleedings since their childhood.
BC8_BioRED_Task1_Doc38	446	454	bleeding	Disease	D006470	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	472	476	VIII	Gene	2157	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	488	509	von Willebrand factor	Gene	7450	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	519	522	VWF	Gene	7450	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	536	556	von Willerand factor	Gene	7450	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	557	567	ristocetin	Chemical	D012310	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	578	581	VWF	Gene	7450	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	593	632	ristocetin-induced platelet aggregation	Disease	D001791	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	634	638	RIPA	Disease	D001791	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	664	674	ristocetin	Chemical	D012310	In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively.
BC8_BioRED_Task1_Doc38	731	741	ristocetin	Chemical	D012310	The enhanced response to ristocetin was identified to be in plasma, not in platelet itself, by mixing studies.
BC8_BioRED_Task1_Doc38	829	850	von Willebrand factor	Gene	7450	Analysis of von Willebrand factor (VWF) multimer of plasma but not of platelets showed absence of high-molecular weight (HMW) multimer.
BC8_BioRED_Task1_Doc38	852	855	VWF	Gene	7450	Analysis of von Willebrand factor (VWF) multimer of plasma but not of platelets showed absence of high-molecular weight (HMW) multimer.
BC8_BioRED_Task1_Doc38	1016	1019	VWF	Gene	7450	Exon 28 of VWF gene was amplified using polymerase chain reaction (PCR) and sequenced.
BC8_BioRED_Task1_Doc38	1161	1197	C to T transition at nucleotide 3916	SequenceVariant	rs61749384	The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution.
BC8_BioRED_Task1_Doc38	1211	1223	Arg 1306 Trp	SequenceVariant	rs61749384	The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution.
BC8_BioRED_Task1_Doc38	1225	1231	R1306W	SequenceVariant	rs61749384	The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution.
BC8_BioRED_Task1_Doc38	1268	1283	glycoprotein Ib	Gene	2811	This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia.
BC8_BioRED_Task1_Doc38	1285	1289	GPIb	Gene	2811	This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia.
BC8_BioRED_Task1_Doc38	1354	1357	VWF	Gene	7450	This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia.
BC8_BioRED_Task1_Doc38	1420	1436	thrombocytopenia	Disease	D013921	This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia.
BC8_BioRED_Task1_Doc38	1471	1482	type 2B VWD	Disease	D056728	In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.
BC8_BioRED_Task1_Doc38	1522	1528	R1306W	SequenceVariant	rs61749384	In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.
BC8_BioRED_Task1_Doc38	1541	1544	VWF	Gene	7450	In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.
BC8_BioRED_Task1_Doc39	27	36	melatonin	Chemical	D008550	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
BC8_BioRED_Task1_Doc39	81	84	rat	OrganismTaxon	10116	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
BC8_BioRED_Task1_Doc39	94	98	BCNU	Chemical	D002330	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
BC8_BioRED_Task1_Doc39	107	125	cortical dysplasia	Disease	D054220	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.
BC8_BioRED_Task1_Doc39	127	145	Cortical dysplasia	Disease	D054220	Cortical dysplasia is a malformation characterized by defects in proliferation, migration and maturation.
BC8_BioRED_Task1_Doc39	298	301	rat	OrganismTaxon	10116	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	345	355	carmustine	Chemical	D002330	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	357	393	1,3-bis (2-chloroethyl)-1-nitrosoure	Chemical	D002330	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	396	400	BCNU	Chemical	D002330	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	446	455	melatonin	Chemical	D008550	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	472	476	BCNU	Chemical	D002330	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	485	503	cortical dysplasia	Disease	D054220	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.
BC8_BioRED_Task1_Doc39	566	570	rats	OrganismTaxon	10116	Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin.
BC8_BioRED_Task1_Doc39	633	642	melatonin	Chemical	D008550	Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin.
BC8_BioRED_Task1_Doc39	652	656	BCNU	Chemical	D002330	Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin.
BC8_BioRED_Task1_Doc39	669	673	BCNU	Chemical	D002330	Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin.
BC8_BioRED_Task1_Doc39	687	696	melatonin	Chemical	D008550	Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin.
BC8_BioRED_Task1_Doc39	698	702	Rats	OrganismTaxon	10116	Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery.
BC8_BioRED_Task1_Doc39	719	723	BCNU	Chemical	D002330	Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery.
BC8_BioRED_Task1_Doc39	748	757	melatonin	Chemical	D008550	Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery.
BC8_BioRED_Task1_Doc39	890	905	malondialdehyde	Chemical	D008315	Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined.
BC8_BioRED_Task1_Doc39	910	920	superoxide	Chemical	D013481	Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined.
BC8_BioRED_Task1_Doc39	1117	1121	BCNU	Chemical	D002330	Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.
BC8_BioRED_Task1_Doc39	1130	1148	cortical dysplasia	Disease	D054220	Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.
BC8_BioRED_Task1_Doc39	1251	1255	BCNU	Chemical	D002330	There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes.
BC8_BioRED_Task1_Doc39	1307	1338	glial fibrillary acidic protein	Gene	24387	There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes.
BC8_BioRED_Task1_Doc39	1340	1353	synaptophysin	Gene	24804	There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes.
BC8_BioRED_Task1_Doc39	1358	1390	transforming growth factor beta1	Gene	59086	There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes.
BC8_BioRED_Task1_Doc39	1442	1451	melatonin	Chemical	D008550	There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes.
BC8_BioRED_Task1_Doc39	1490	1505	Malondialdehyde	Chemical	D008315	Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups.
BC8_BioRED_Task1_Doc39	1515	1519	BCNU	Chemical	D002330	Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups.
BC8_BioRED_Task1_Doc39	1578	1587	melatonin	Chemical	D008550	Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups.
BC8_BioRED_Task1_Doc39	1598	1613	malondialdehyde	Chemical	D008315	Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups.
BC8_BioRED_Task1_Doc39	1624	1628	BCNU	Chemical	D002330	Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups.
BC8_BioRED_Task1_Doc39	1696	1716	superoxide dismutase	Gene	24786	Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups.
BC8_BioRED_Task1_Doc39	1793	1797	BCNU	Chemical	D002330	These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU.
BC8_BioRED_Task1_Doc39	1871	1880	melatonin	Chemical	D008550	These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU.
BC8_BioRED_Task1_Doc39	1928	1932	BCNU	Chemical	D002330	These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU.
BC8_BioRED_Task1_Doc40	0	4	CD25	Gene	3559	CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil.
BC8_BioRED_Task1_Doc40	8	12	Bcl6	Gene	604	CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil.
BC8_BioRED_Task1_Doc40	100	105	human	OrganismTaxon	9606	CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil.
BC8_BioRED_Task1_Doc40	130	135	CXCR5	Gene	643	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	139	142	PD1	Gene	5133	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	146	149	CD4	Gene	920	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	199	203	CD25	Gene	3559	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	207	211	Bcl6	Gene	604	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	260	264	CD25	Gene	3559	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	268	272	Bcl6	Gene	604	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	297	302	FoxP3	Gene	50943	The majority of CXCR5(+) PD1(+) CD4(+) T follicular helper (Tfh) cells (   >90%) are CD25(-) Bcl6(hi) , while a small subpopulation (   <10%) are CD25(+) Bcl6(low) but do not express FoxP3 and are not T regulatory cells.
BC8_BioRED_Task1_Doc40	417	421	CD25	Gene	3559	We purified T:B-cell conjugates from tonsils and found they were enriched for the CD25(+) Bcl6(low) Tfh-cell subpopulation.
BC8_BioRED_Task1_Doc40	425	429	Bcl6	Gene	604	We purified T:B-cell conjugates from tonsils and found they were enriched for the CD25(+) Bcl6(low) Tfh-cell subpopulation.
BC8_BioRED_Task1_Doc40	474	478	IL-2	Gene	3558	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	486	490	CD25	Gene	3559	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	552	556	ICOS	Gene	29851	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	560	564	OX40	Gene	7293	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	599	603	cMaf	Gene	4094	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	624	629	IL-21	Gene	59067	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	631	636	IL-17	Gene	3605	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	642	647	IL-10	Gene	3586	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	696	700	Bcl2	Gene	596	In response to IL-2, these CD25(+) Tfh cells increased expression of costimulatory molecules ICOS or OX40, upregulated transcription factor cMaf, produced cytokines IL-21, IL-17, and IL-10, and raised the levels of antiapoptotic protein Bcl2.
BC8_BioRED_Task1_Doc40	725	729	CD25	Gene	3559	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	733	737	BCl6	Gene	604	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	798	835	activation-induced cytidine deaminase	Gene	57379	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	837	840	AID	Gene	57379	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	857	863	CD45RO	Gene	5788	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	873	876	IgG	Gene	3500	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	880	883	IgA	Gene	3493	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	889	901	MHC class II	Gene	3108	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	942	946	CD25	Gene	3559	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	950	954	Bcl6	Gene	604	Conjugates formed with CD25(+) BCl6(low) Tfh cells included B cells expressing higher levels of activation-induced cytidine deaminase (AID), memory marker CD45RO, surface IgG or IgA, and MHC class II compared to B-cell conjugates including CD25(-) Bcl6(hi) Tfh cells.
BC8_BioRED_Task1_Doc40	976	980	IL-2	Gene	3558	While IL-2 suppresses early Tfh-cell differentiation, Tfh-cell recognition of antigen-presenting B cells and signaling through the T-cell receptor likely triggers expression of the high-affinity IL-2 receptor and responses to IL-2 including downregulation of Bcl6.
BC8_BioRED_Task1_Doc40	1101	1116	T-cell receptor	Gene	6955	While IL-2 suppresses early Tfh-cell differentiation, Tfh-cell recognition of antigen-presenting B cells and signaling through the T-cell receptor likely triggers expression of the high-affinity IL-2 receptor and responses to IL-2 including downregulation of Bcl6.
BC8_BioRED_Task1_Doc40	1165	1178	IL-2 receptor	Gene	3559,3560	While IL-2 suppresses early Tfh-cell differentiation, Tfh-cell recognition of antigen-presenting B cells and signaling through the T-cell receptor likely triggers expression of the high-affinity IL-2 receptor and responses to IL-2 including downregulation of Bcl6.
BC8_BioRED_Task1_Doc40	1196	1200	IL-2	Gene	3558	While IL-2 suppresses early Tfh-cell differentiation, Tfh-cell recognition of antigen-presenting B cells and signaling through the T-cell receptor likely triggers expression of the high-affinity IL-2 receptor and responses to IL-2 including downregulation of Bcl6.
BC8_BioRED_Task1_Doc40	1229	1233	Bcl6	Gene	604	While IL-2 suppresses early Tfh-cell differentiation, Tfh-cell recognition of antigen-presenting B cells and signaling through the T-cell receptor likely triggers expression of the high-affinity IL-2 receptor and responses to IL-2 including downregulation of Bcl6.
BC8_BioRED_Task1_Doc40	1235	1239	CD25	Gene	3559	CD25 expression on Tfh cells and local production of IL-2 in tonsil or lymph node may support B helper T-cell function during later stages of B-cell maturation and the development of immune memory.
BC8_BioRED_Task1_Doc40	1288	1292	IL-2	Gene	3558	CD25 expression on Tfh cells and local production of IL-2 in tonsil or lymph node may support B helper T-cell function during later stages of B-cell maturation and the development of immune memory.
BC8_BioRED_Task1_Doc41	16	20	IRS2	Gene	8660	Resequencing of IRS2 reveals rare variants for obesity but not fasting glucose homeostasis in Hispanic children.
BC8_BioRED_Task1_Doc41	47	54	obesity	Disease	D009765	Resequencing of IRS2 reveals rare variants for obesity but not fasting glucose homeostasis in Hispanic children.
BC8_BioRED_Task1_Doc41	71	78	glucose	Chemical	D005947	Resequencing of IRS2 reveals rare variants for obesity but not fasting glucose homeostasis in Hispanic children.
BC8_BioRED_Task1_Doc41	145	173	insulin receptor substrate 2	Gene	8660	Our objective was to resequence insulin receptor substrate 2 (IRS2) to identify variants associated with obesity- and diabetes-related traits in Hispanic children.
BC8_BioRED_Task1_Doc41	175	179	IRS2	Gene	8660	Our objective was to resequence insulin receptor substrate 2 (IRS2) to identify variants associated with obesity- and diabetes-related traits in Hispanic children.
BC8_BioRED_Task1_Doc41	218	225	obesity	Disease	D009765	Our objective was to resequence insulin receptor substrate 2 (IRS2) to identify variants associated with obesity- and diabetes-related traits in Hispanic children.
BC8_BioRED_Task1_Doc41	231	239	diabetes	Disease	D003920	Our objective was to resequence insulin receptor substrate 2 (IRS2) to identify variants associated with obesity- and diabetes-related traits in Hispanic children.
BC8_BioRED_Task1_Doc41	337	341	IRS2	Gene	8660	Exonic and intronic segments, 5' and 3' flanking regions of IRS2 ( 14.5 kb), were bidirectionally sequenced for single nucleotide polymorphism (SNP) discovery in 934 Hispanic children using 3730XL DNA Sequencers.
BC8_BioRED_Task1_Doc41	639	646	obesity	Disease	D009765	Measured genotype analysis tested associations between SNPs and obesity and diabetes-related traits.
BC8_BioRED_Task1_Doc41	651	659	diabetes	Disease	D003920	Measured genotype analysis tested associations between SNPs and obesity and diabetes-related traits.
BC8_BioRED_Task1_Doc41	1223	1230	obesity	Disease	D009765	Ten independent rare SNPs (MAF = 0.001-0.009) were associated with obesity-related traits (P = 0.01-0.00002).
BC8_BioRED_Task1_Doc41	1266	1282	SNP 10510452_139	SequenceVariant	10510452_139	SNP 10510452_139 in the promoter region was shown to have a high posterior probability (P = 0.77-0.86) of influencing BMI, fat mass, and waist circumference in Hispanic children.
BC8_BioRED_Task1_Doc41	1445	1461	SNP 10510452_139	SequenceVariant	10510452_139	SNP 10510452_139 contributed between 2 and 4% of the population variance in body weight and composition.
BC8_BioRED_Task1_Doc41	1598	1606	diabetes	Disease	D003920	None of the SNPs or indels were associated with diabetes-related traits or accounted for a previously identified quantitative trait locus on chromosome 13 for fasting serum glucose.
BC8_BioRED_Task1_Doc41	1723	1730	glucose	Chemical	D005947	None of the SNPs or indels were associated with diabetes-related traits or accounted for a previously identified quantitative trait locus on chromosome 13 for fasting serum glucose.
BC8_BioRED_Task1_Doc41	1752	1756	IRS2	Gene	8660	Rare but not common IRS2 variants may play a role in the regulation of body weight but not an essential role in fasting glucose homeostasis in Hispanic children.
BC8_BioRED_Task1_Doc41	1852	1859	glucose	Chemical	D005947	Rare but not common IRS2 variants may play a role in the regulation of body weight but not an essential role in fasting glucose homeostasis in Hispanic children.
BC8_BioRED_Task1_Doc42	14	64	signal transducer and activator of transcription 3	Gene	25125	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
BC8_BioRED_Task1_Doc42	91	98	betaine	Chemical	D001622	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
BC8_BioRED_Task1_Doc42	110	123	isoproterenol	Chemical	D007545	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
BC8_BioRED_Task1_Doc42	138	155	myocardial injury	Disease	D009202	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
BC8_BioRED_Task1_Doc42	159	163	rats	OrganismTaxon	10116	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.
BC8_BioRED_Task1_Doc42	243	250	betaine	Chemical	D001622	The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
BC8_BioRED_Task1_Doc42	260	279	myocardial ischemia	Disease	D017202	The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
BC8_BioRED_Task1_Doc42	306	310	rats	OrganismTaxon	10116	The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
BC8_BioRED_Task1_Doc42	337	387	signal transducer and activator of transcription 3	Gene	25125	The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
BC8_BioRED_Task1_Doc42	389	394	STAT3	Gene	25125	The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
BC8_BioRED_Task1_Doc42	494	498	rats	OrganismTaxon	10116	Male Sprague Dawley rats were treated with betaine (100, 200, and 400 mg/kg) orally for 40 days.
BC8_BioRED_Task1_Doc42	517	524	betaine	Chemical	D001622	Male Sprague Dawley rats were treated with betaine (100, 200, and 400 mg/kg) orally for 40 days.
BC8_BioRED_Task1_Doc42	577	603	myocardial ischemic injury	Disease	D017202	Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.
BC8_BioRED_Task1_Doc42	619	623	rats	OrganismTaxon	10116	Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.
BC8_BioRED_Task1_Doc42	653	666	isoproterenol	Chemical	D007545	Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.
BC8_BioRED_Task1_Doc42	833	840	betaine	Chemical	D001622	Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling.
BC8_BioRED_Task1_Doc42	950	972	ventricular remodeling	Disease	D020257	Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling.
BC8_BioRED_Task1_Doc42	1008	1021	isoproterenol	Chemical	D007545	Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium.
BC8_BioRED_Task1_Doc42	1049	1054	STAT3	Gene	25125	Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium.
BC8_BioRED_Task1_Doc42	1093	1100	betaine	Chemical	D001622	Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium.
BC8_BioRED_Task1_Doc42	1139	1146	betaine	Chemical	D001622	Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.
BC8_BioRED_Task1_Doc42	1217	1222	Bcl-2	Gene	24224	Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.
BC8_BioRED_Task1_Doc42	1248	1251	Bax	Gene	24887	Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.
BC8_BioRED_Task1_Doc42	1310	1315	Bcl-2	Gene	24224	Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.
BC8_BioRED_Task1_Doc42	1316	1319	Bax	Gene	24887	Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax.
BC8_BioRED_Task1_Doc42	1344	1351	betaine	Chemical	D001622	The protective role of betaine on myocardial damage was further confirmed by histopathological examination.
BC8_BioRED_Task1_Doc42	1355	1372	myocardial damage	Disease	D009202	The protective role of betaine on myocardial damage was further confirmed by histopathological examination.
BC8_BioRED_Task1_Doc42	1465	1472	betaine	Chemical	D001622	In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
BC8_BioRED_Task1_Doc42	1497	1510	isoproterenol	Chemical	D007545	In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
BC8_BioRED_Task1_Doc42	1525	1544	myocardial ischemia	Disease	D017202	In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
BC8_BioRED_Task1_Doc42	1567	1572	STAT3	Gene	25125	In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.
BC8_BioRED_Task1_Doc43	0	5	GATA4	Gene	2626	GATA4 mutations in 486 Chinese patients with congenital heart disease.
BC8_BioRED_Task1_Doc43	31	39	patients	OrganismTaxon	9606	GATA4 mutations in 486 Chinese patients with congenital heart disease.
BC8_BioRED_Task1_Doc43	45	69	congenital heart disease	Disease	D006331	GATA4 mutations in 486 Chinese patients with congenital heart disease.
BC8_BioRED_Task1_Doc43	122	127	GATA4	Gene	2626	Recent studies have reported germline mutations in GATA4 gene in some types of congenital heart disease (CHD).
BC8_BioRED_Task1_Doc43	150	174	congenital heart disease	Disease	D006331	Recent studies have reported germline mutations in GATA4 gene in some types of congenital heart disease (CHD).
BC8_BioRED_Task1_Doc43	176	179	CHD	Disease	D006331	Recent studies have reported germline mutations in GATA4 gene in some types of congenital heart disease (CHD).
BC8_BioRED_Task1_Doc43	209	214	GATA4	Gene	2626	However, the prevalence of GATA4 mutations in CHD and the correlation between the GATA4 genotype and CHD phenotype have not been extensively studied.
BC8_BioRED_Task1_Doc43	228	231	CHD	Disease	D006331	However, the prevalence of GATA4 mutations in CHD and the correlation between the GATA4 genotype and CHD phenotype have not been extensively studied.
BC8_BioRED_Task1_Doc43	264	269	GATA4	Gene	2626	However, the prevalence of GATA4 mutations in CHD and the correlation between the GATA4 genotype and CHD phenotype have not been extensively studied.
BC8_BioRED_Task1_Doc43	283	286	CHD	Disease	D006331	However, the prevalence of GATA4 mutations in CHD and the correlation between the GATA4 genotype and CHD phenotype have not been extensively studied.
BC8_BioRED_Task1_Doc43	424	429	GATA4	Gene	2626	We screened germline mutations in the coding exons and the flanking intron sequences of the GATA4 gene in 486 CHD patients by denaturing high-performance liquid chromatography (DHPLC), and confirmed the mutations by sequencing.
BC8_BioRED_Task1_Doc43	442	445	CHD	Disease	D006331	We screened germline mutations in the coding exons and the flanking intron sequences of the GATA4 gene in 486 CHD patients by denaturing high-performance liquid chromatography (DHPLC), and confirmed the mutations by sequencing.
BC8_BioRED_Task1_Doc43	446	454	patients	OrganismTaxon	9606	We screened germline mutations in the coding exons and the flanking intron sequences of the GATA4 gene in 486 CHD patients by denaturing high-performance liquid chromatography (DHPLC), and confirmed the mutations by sequencing.
BC8_BioRED_Task1_Doc43	623	629	46delS	SequenceVariant	|DEL|46|S	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	663	674	118-119insA	SequenceVariant	|INS|118_119|A	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	679	691	125-126insAA	SequenceVariant	|INS|125_126|AA	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	728	731	A6V	SequenceVariant	rs199922907	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	733	738	P163S	SequenceVariant	rs387906769	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	740	745	E359K	SequenceVariant	rs368489876	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	747	752	P407Q	SequenceVariant	rs115099192	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	754	759	S429T	SequenceVariant	p|SUB|S|429|T	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	764	769	A442V	SequenceVariant	rs146017816	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	804	812	patients	OrganismTaxon	9606	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	824	849	ventricular septal defect	Disease	D006345	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	860	879	Tetralogy of Fallot	Disease	D013771	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	894	920	endocardial cushion defect	Disease	D004694	Nine distinct mutations including one small deletion mutation (46delS), two small insertion mutations (118-119insA and 125-126insAA), and six non-synonymous mutations (A6V, P163S, E359K, P407Q, S429T and A442V) were identified in 12 of the 486 patients (nine with ventricular septal defect, two with Tetralogy of Fallot, and one with endocardial cushion defect).
BC8_BioRED_Task1_Doc43	936	944	patients	OrganismTaxon	9606	Of them, two patients carrying E359K mutation were from two generations in one family with ventricular septal defect (VSD).
BC8_BioRED_Task1_Doc43	954	959	E359K	SequenceVariant	rs368489876	Of them, two patients carrying E359K mutation were from two generations in one family with ventricular septal defect (VSD).
BC8_BioRED_Task1_Doc43	1014	1039	ventricular septal defect	Disease	D006345	Of them, two patients carrying E359K mutation were from two generations in one family with ventricular septal defect (VSD).
BC8_BioRED_Task1_Doc43	1041	1044	VSD	Disease	D006345	Of them, two patients carrying E359K mutation were from two generations in one family with ventricular septal defect (VSD).
BC8_BioRED_Task1_Doc43	1088	1101	c.1146+25insA	SequenceVariant	c|INS|1146+25|A	Interestingly, a nucleotide insertion of c.1146+25insA in exon 6 was detected in five VSD patients, but not in 486 normal healthy controls.
BC8_BioRED_Task1_Doc43	1133	1136	VSD	Disease	D006345	Interestingly, a nucleotide insertion of c.1146+25insA in exon 6 was detected in five VSD patients, but not in 486 normal healthy controls.
BC8_BioRED_Task1_Doc43	1137	1145	patients	OrganismTaxon	9606	Interestingly, a nucleotide insertion of c.1146+25insA in exon 6 was detected in five VSD patients, but not in 486 normal healthy controls.
BC8_BioRED_Task1_Doc43	1246	1251	GATA4	Gene	2626	Our findings are useful in understanding the prevalence of GATA4 mutations and the correlation between the GATA4 genotype and the CHD phenotype in Chinese patients.
BC8_BioRED_Task1_Doc43	1294	1299	GATA4	Gene	2626	Our findings are useful in understanding the prevalence of GATA4 mutations and the correlation between the GATA4 genotype and the CHD phenotype in Chinese patients.
BC8_BioRED_Task1_Doc43	1317	1320	CHD	Disease	D006331	Our findings are useful in understanding the prevalence of GATA4 mutations and the correlation between the GATA4 genotype and the CHD phenotype in Chinese patients.
BC8_BioRED_Task1_Doc43	1342	1350	patients	OrganismTaxon	9606	Our findings are useful in understanding the prevalence of GATA4 mutations and the correlation between the GATA4 genotype and the CHD phenotype in Chinese patients.
BC8_BioRED_Task1_Doc44	0	15	Neurofibromin 1	Gene	4763	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
BC8_BioRED_Task1_Doc44	17	20	NF1	Gene	4763	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
BC8_BioRED_Task1_Doc44	44	49	human	OrganismTaxon	9606	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
BC8_BioRED_Task1_Doc44	50	75	ovarian serous carcinomas	Disease	D010051	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
BC8_BioRED_Task1_Doc44	94	98	TP53	Gene	7157	Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
BC8_BioRED_Task1_Doc44	110	134	Ovarian serous carcinoma	Disease	D010051	Ovarian serous carcinoma (OSC) is the most common and lethal histologic type of ovarian epithelial malignancy.
BC8_BioRED_Task1_Doc44	136	139	OSC	Disease	D010051	Ovarian serous carcinoma (OSC) is the most common and lethal histologic type of ovarian epithelial malignancy.
BC8_BioRED_Task1_Doc44	190	219	ovarian epithelial malignancy	Disease	D002277	Ovarian serous carcinoma (OSC) is the most common and lethal histologic type of ovarian epithelial malignancy.
BC8_BioRED_Task1_Doc44	234	238	TP53	Gene	7157	Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.
BC8_BioRED_Task1_Doc44	262	267	Brca1	Gene	672	Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.
BC8_BioRED_Task1_Doc44	275	280	Brca2	Gene	675	Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.
BC8_BioRED_Task1_Doc44	281	286	tumor	Disease	D009369	Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.
BC8_BioRED_Task1_Doc44	381	385	OSCs	Disease	D010051	Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.
BC8_BioRED_Task1_Doc44	444	449	tumor	Disease	D009369	Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified.
BC8_BioRED_Task1_Doc44	565	569	OSCs	Disease	D010051	Using a genome-wide screen of DNA copy number alterations in 36 primary OSCs, we identified two tumors with apparent homozygous deletions of the NF1 gene.
BC8_BioRED_Task1_Doc44	589	595	tumors	Disease	D009369	Using a genome-wide screen of DNA copy number alterations in 36 primary OSCs, we identified two tumors with apparent homozygous deletions of the NF1 gene.
BC8_BioRED_Task1_Doc44	638	641	NF1	Gene	4763	Using a genome-wide screen of DNA copy number alterations in 36 primary OSCs, we identified two tumors with apparent homozygous deletions of the NF1 gene.
BC8_BioRED_Task1_Doc44	665	682	ovarian carcinoma	Disease	D010051	Subsequently, 18 ovarian carcinoma-derived cell lines and 41 primary OSCs were evaluated for NF1 alterations.
BC8_BioRED_Task1_Doc44	717	721	OSCs	Disease	D010051	Subsequently, 18 ovarian carcinoma-derived cell lines and 41 primary OSCs were evaluated for NF1 alterations.
BC8_BioRED_Task1_Doc44	741	744	NF1	Gene	4763	Subsequently, 18 ovarian carcinoma-derived cell lines and 41 primary OSCs were evaluated for NF1 alterations.
BC8_BioRED_Task1_Doc44	799	802	Nf1	Gene	4763	Markedly reduced or absent expression of Nf1 protein was observed in 6 of the 18 cell lines, and using the protein truncation test and sequencing of cDNA and genomic DNA, NF1 mutations resulting in deletion of exons and/or aberrant splicing of NF1 transcripts were detected in 5 of the 6 cell lines with loss of NF1 expression.
BC8_BioRED_Task1_Doc44	929	932	NF1	Gene	4763	Markedly reduced or absent expression of Nf1 protein was observed in 6 of the 18 cell lines, and using the protein truncation test and sequencing of cDNA and genomic DNA, NF1 mutations resulting in deletion of exons and/or aberrant splicing of NF1 transcripts were detected in 5 of the 6 cell lines with loss of NF1 expression.
BC8_BioRED_Task1_Doc44	1002	1005	NF1	Gene	4763	Markedly reduced or absent expression of Nf1 protein was observed in 6 of the 18 cell lines, and using the protein truncation test and sequencing of cDNA and genomic DNA, NF1 mutations resulting in deletion of exons and/or aberrant splicing of NF1 transcripts were detected in 5 of the 6 cell lines with loss of NF1 expression.
BC8_BioRED_Task1_Doc44	1070	1073	NF1	Gene	4763	Markedly reduced or absent expression of Nf1 protein was observed in 6 of the 18 cell lines, and using the protein truncation test and sequencing of cDNA and genomic DNA, NF1 mutations resulting in deletion of exons and/or aberrant splicing of NF1 transcripts were detected in 5 of the 6 cell lines with loss of NF1 expression.
BC8_BioRED_Task1_Doc44	1097	1100	NF1	Gene	4763	Similarly, NF1 alterations including homozygous deletions and splicing mutations were identified in 9 (22%) of 41 primary OSCs.
BC8_BioRED_Task1_Doc44	1208	1212	OSCs	Disease	D010051	Similarly, NF1 alterations including homozygous deletions and splicing mutations were identified in 9 (22%) of 41 primary OSCs.
BC8_BioRED_Task1_Doc44	1227	1233	tumors	Disease	D009369	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1254	1257	NF1	Gene	4763	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1286	1290	KRAS	Gene	3845	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1294	1298	BRAF	Gene	673	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1310	1313	Ras	Gene	3845	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1390	1394	MAPK	Gene	5594	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1404	1410	tumors	Disease	D009369	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1435	1438	GTP	Chemical	D006160	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1445	1448	Ras	Gene	3845	As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines).
BC8_BioRED_Task1_Doc44	1467	1471	TP53	Gene	7157	The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
BC8_BioRED_Task1_Doc44	1472	1477	tumor	Disease	D009369	The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
BC8_BioRED_Task1_Doc44	1513	1517	OSCs	Disease	D010051	The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
BC8_BioRED_Task1_Doc44	1534	1537	NF1	Gene	4763	The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
BC8_BioRED_Task1_Doc44	1600	1605	tumor	Disease	D009369	The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
BC8_BioRED_Task1_Doc44	1664	1682	ovarian carcinomas	Disease	D010051	The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1 mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the development of ovarian carcinomas with serous differentiation.
BC8_BioRED_Task1_Doc45	17	23	FGFR-4	Gene	2264	Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress.
BC8_BioRED_Task1_Doc45	47	73	bronchopulmonary dysplasia	Disease	D001997	Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress.
BC8_BioRED_Task1_Doc45	78	107	neonatal respiratory distress	Disease	D012127	Association of a FGFR-4 gene polymorphism with bronchopulmonary dysplasia and neonatal respiratory distress.
BC8_BioRED_Task1_Doc45	121	147	Bronchopulmonary dysplasia	Disease	D001997	BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation.
BC8_BioRED_Task1_Doc45	149	152	BPD	Disease	D001997	BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation.
BC8_BioRED_Task1_Doc45	181	193	lung disease	Disease	D008171	BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation.
BC8_BioRED_Task1_Doc45	197	212	premature birth	Disease	D047928	BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation.
BC8_BioRED_Task1_Doc45	231	260	impaired alveolar development	Disease	D008171	BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation.
BC8_BioRED_Task1_Doc45	265	277	inflammation	Disease	D007249	BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation.
BC8_BioRED_Task1_Doc45	311	314	BPD	Disease	D001997	Pathomechanisms contributing to BPD are poorly understood.
BC8_BioRED_Task1_Doc45	396	399	BPD	Disease	D001997	However, it is assumed that genetic factors predispose to BPD and other pulmonary diseases of preterm neonates, such as neonatal respiratory distress syndrome (RDS).
BC8_BioRED_Task1_Doc45	410	428	pulmonary diseases	Disease	D008171	However, it is assumed that genetic factors predispose to BPD and other pulmonary diseases of preterm neonates, such as neonatal respiratory distress syndrome (RDS).
BC8_BioRED_Task1_Doc45	458	496	neonatal respiratory distress syndrome	Disease	D012127	However, it is assumed that genetic factors predispose to BPD and other pulmonary diseases of preterm neonates, such as neonatal respiratory distress syndrome (RDS).
BC8_BioRED_Task1_Doc45	498	501	RDS	Disease	D012127	However, it is assumed that genetic factors predispose to BPD and other pulmonary diseases of preterm neonates, such as neonatal respiratory distress syndrome (RDS).
BC8_BioRED_Task1_Doc45	626	651	matrix metalloproteinases	Gene	4312,4313,4318,4321,4325	For association studies, genes upregulated during alveolarization are major candidates for genetic analysis, for example, matrix metalloproteinases (MMPs) and fibroblast growth factors (FGFs) and their receptors (FGFR).
BC8_BioRED_Task1_Doc45	653	657	MMPs	Gene	4312,4313,4318,4321,4325	For association studies, genes upregulated during alveolarization are major candidates for genetic analysis, for example, matrix metalloproteinases (MMPs) and fibroblast growth factors (FGFs) and their receptors (FGFR).
BC8_BioRED_Task1_Doc45	663	688	fibroblast growth factors	Gene	2247,2248,2249,2252,8817	For association studies, genes upregulated during alveolarization are major candidates for genetic analysis, for example, matrix metalloproteinases (MMPs) and fibroblast growth factors (FGFs) and their receptors (FGFR).
BC8_BioRED_Task1_Doc45	690	694	FGFs	Gene	2247,2248,2249,2252,8817	For association studies, genes upregulated during alveolarization are major candidates for genetic analysis, for example, matrix metalloproteinases (MMPs) and fibroblast growth factors (FGFs) and their receptors (FGFR).
BC8_BioRED_Task1_Doc45	717	721	FGFR	Gene	2263,2264	For association studies, genes upregulated during alveolarization are major candidates for genetic analysis, for example, matrix metalloproteinases (MMPs) and fibroblast growth factors (FGFs) and their receptors (FGFR).
BC8_BioRED_Task1_Doc45	822	825	BPD	Disease	D001997	OBJECTIVE: Determining genetic risk variants in a Caucasian population of premature neonates with BPD and RDS.
BC8_BioRED_Task1_Doc45	830	833	RDS	Disease	D012127	OBJECTIVE: Determining genetic risk variants in a Caucasian population of premature neonates with BPD and RDS.
BC8_BioRED_Task1_Doc45	953	980	MMP-1, -2, -9, and -12, -16	Gene	4312,4313,4318,4321,4325	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	982	1003	FGF receptors 2 and 4	Gene	2263,2264	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	1005	1031	FGF-2, -3, -4, -7, and -18	Gene	2247,2248,2249,2252,8817	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	1033	1060	Signal-Regulatory Protein a	Gene	140885	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	1062	1067	SIRPA	Gene	140885	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	1073	1103	Thyroid Transcription Factor-1	Gene	7080	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	1105	1110	TTF-1	Gene	7080	We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein a (SIRPA) and Thyroid Transcription Factor-1 (TTF-1).
BC8_BioRED_Task1_Doc45	1169	1174	MMP-9	Gene	4318	RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.
BC8_BioRED_Task1_Doc45	1176	1182	MMP-12	Gene	4321	RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.
BC8_BioRED_Task1_Doc45	1184	1190	FGFR-4	Gene	2264	RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.
BC8_BioRED_Task1_Doc45	1192	1197	FGF-3	Gene	2248	RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.
BC8_BioRED_Task1_Doc45	1203	1208	FGF-7	Gene	2252	RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.
BC8_BioRED_Task1_Doc45	1240	1243	RDS	Disease	D012127	RESULTS: Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated (P < 0.05) with RDS, defined as surfactant application within the first 24 hours after birth.
BC8_BioRED_Task1_Doc45	1334	1340	FGFR-4	Gene	2264	One of them, in FGFR-4 (rs1966265), is associated with both RDS (P = 0.003) and BPD (P = 0.023).
BC8_BioRED_Task1_Doc45	1342	1351	rs1966265	SequenceVariant	rs1966265	One of them, in FGFR-4 (rs1966265), is associated with both RDS (P = 0.003) and BPD (P = 0.023).
BC8_BioRED_Task1_Doc45	1378	1381	RDS	Disease	D012127	One of them, in FGFR-4 (rs1966265), is associated with both RDS (P = 0.003) and BPD (P = 0.023).
BC8_BioRED_Task1_Doc45	1398	1401	BPD	Disease	D001997	One of them, in FGFR-4 (rs1966265), is associated with both RDS (P = 0.003) and BPD (P = 0.023).
BC8_BioRED_Task1_Doc45	1427	1436	rs1966265	SequenceVariant	rs1966265	CONCLUSION: rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns.
BC8_BioRED_Task1_Doc45	1440	1454	FGF receptor 4	Gene	2264	CONCLUSION: rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns.
BC8_BioRED_Task1_Doc45	1492	1509	alveolar diseases	Disease	D002282	CONCLUSION: rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns.
BC8_BioRED_Task1_Doc46	26	30	WFS1	Gene	7466	Identification of a novel WFS1 mutation (AFF344-345ins) in Japanese patients with Wolfram syndrome.
BC8_BioRED_Task1_Doc46	41	54	AFF344-345ins	SequenceVariant	p|INS|344_345|AFF	Identification of a novel WFS1 mutation (AFF344-345ins) in Japanese patients with Wolfram syndrome.
BC8_BioRED_Task1_Doc46	68	76	patients	OrganismTaxon	9606	Identification of a novel WFS1 mutation (AFF344-345ins) in Japanese patients with Wolfram syndrome.
BC8_BioRED_Task1_Doc46	82	98	Wolfram syndrome	Disease	D014929	Identification of a novel WFS1 mutation (AFF344-345ins) in Japanese patients with Wolfram syndrome.
BC8_BioRED_Task1_Doc46	100	116	Wolfram syndrome	Disease	D014929	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	118	121	WFS	Disease	D014929	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	129	157	autosomal recessive disorder	Disease	D030342	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	187	204	diabetes mellitus	Disease	D003920	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	218	231	optic atrophy	Disease	D009896	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	233	255	sensorineural deafness	Disease	D006319	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	260	278	diabetes insipidus	Disease	D003919	Wolfram syndrome (WFS) is an autosomal recessive disorder characterized by early onset diabetes mellitus, progressive optic atrophy, sensorineural deafness and diabetes insipidus.
BC8_BioRED_Task1_Doc46	315	340	renal tract abnormalities	Disease	D007674	Affected individuals may also have renal tract abnormalities as well as neurogical and psychiatric syndromes.
BC8_BioRED_Task1_Doc46	367	388	psychiatric syndromes	Disease	D001523	Affected individuals may also have renal tract abnormalities as well as neurogical and psychiatric syndromes.
BC8_BioRED_Task1_Doc46	390	394	WFS1	Gene	7466	WFS1 encoding a transmembrane protein was identified as the gene responsible for WFS.
BC8_BioRED_Task1_Doc46	471	474	WFS	Disease	D014929	WFS1 encoding a transmembrane protein was identified as the gene responsible for WFS.
BC8_BioRED_Task1_Doc46	559	563	WFS1	Gene	7466	In the WFS1 gene of these patients, we identified a novel mutation, a nine nucleotide insertion (AFF344-345ins).
BC8_BioRED_Task1_Doc46	578	586	patients	OrganismTaxon	9606	In the WFS1 gene of these patients, we identified a novel mutation, a nine nucleotide insertion (AFF344-345ins).
BC8_BioRED_Task1_Doc46	622	647	nine nucleotide insertion	SequenceVariant	c|INS||9	In the WFS1 gene of these patients, we identified a novel mutation, a nine nucleotide insertion (AFF344-345ins).
BC8_BioRED_Task1_Doc46	649	662	AFF344-345ins	SequenceVariant	p|INS|344_345|AFF	In the WFS1 gene of these patients, we identified a novel mutation, a nine nucleotide insertion (AFF344-345ins).
BC8_BioRED_Task1_Doc46	691	699	patients	OrganismTaxon	9606	In addition, one of these patients had preclinical hypopituitarism, which is an unusual feature of WFS.
BC8_BioRED_Task1_Doc46	716	731	hypopituitarism	Disease	D007018	In addition, one of these patients had preclinical hypopituitarism, which is an unusual feature of WFS.
BC8_BioRED_Task1_Doc46	764	767	WFS	Disease	D014929	In addition, one of these patients had preclinical hypopituitarism, which is an unusual feature of WFS.
BC8_BioRED_Task1_Doc46	835	838	WFS	Disease	D014929	As only the two family members homozygous for the mutation showed WFS, these data support the notion that this mutation is the cause of WFS.
BC8_BioRED_Task1_Doc46	905	908	WFS	Disease	D014929	As only the two family members homozygous for the mutation showed WFS, these data support the notion that this mutation is the cause of WFS.
BC8_BioRED_Task1_Doc47	0	4	TAK1	Gene	26409	TAK1 is an essential regulator of BMP signalling in cartilage.
BC8_BioRED_Task1_Doc47	34	37	BMP	Gene	12159	TAK1 is an essential regulator of BMP signalling in cartilage.
BC8_BioRED_Task1_Doc47	63	89	TGFbeta activated kinase 1	Gene	26409	TGFbeta activated kinase 1 (TAK1), a member of the MAPKKK family, controls diverse functions ranging from innate and adaptive immune system activation to vascular development and apoptosis.
BC8_BioRED_Task1_Doc47	91	95	TAK1	Gene	26409	TGFbeta activated kinase 1 (TAK1), a member of the MAPKKK family, controls diverse functions ranging from innate and adaptive immune system activation to vascular development and apoptosis.
BC8_BioRED_Task1_Doc47	114	120	MAPKKK	Gene	26409	TGFbeta activated kinase 1 (TAK1), a member of the MAPKKK family, controls diverse functions ranging from innate and adaptive immune system activation to vascular development and apoptosis.
BC8_BioRED_Task1_Doc47	288	292	TAK1	Gene	26409	To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter.
BC8_BioRED_Task1_Doc47	320	324	mice	OrganismTaxon	10090	To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter.
BC8_BioRED_Task1_Doc47	356	360	Tak1	Gene	26409	To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter.
BC8_BioRED_Task1_Doc47	375	385	collagen 2	Gene	12824	To analyse the in vivo function of TAK1 in cartilage, we generated mice with a conditional deletion of Tak1 driven by the collagen 2 promoter.
BC8_BioRED_Task1_Doc47	396	400	Tak1	Gene	26409	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	401	405	col2	Gene	12824	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	407	411	mice	OrganismTaxon	10090	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	429	445	chondrodysplasia	Disease	D010009	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	521	540	joint abnormalities	Disease	D007592	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	551	568	elbow dislocation	Disease	D004204	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	573	586	tarsal fusion	Disease	D000070604	Tak1(col2) mice displayed severe chondrodysplasia with runting, impaired formation of secondary centres of ossification, and joint abnormalities including elbow dislocation and tarsal fusion.
BC8_BioRED_Task1_Doc47	621	664	bone morphogenetic protein receptor (BMPR)1	Gene	12166	This phenotype resembled that of bone morphogenetic protein receptor (BMPR)1 and Gdf5-deficient mice.
BC8_BioRED_Task1_Doc47	669	673	Gdf5	Gene	14563	This phenotype resembled that of bone morphogenetic protein receptor (BMPR)1 and Gdf5-deficient mice.
BC8_BioRED_Task1_Doc47	684	688	mice	OrganismTaxon	10090	This phenotype resembled that of bone morphogenetic protein receptor (BMPR)1 and Gdf5-deficient mice.
BC8_BioRED_Task1_Doc47	690	694	BMPR	Gene	12166	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	731	735	TAK1	Gene	26409	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	803	806	BMP	Gene	12159	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	858	867	Smad1/5/8	Gene	17125,17129,55994	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	872	875	p38	Gene	26416	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	876	879	Jnk	Gene	26419	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	880	883	Erk	Gene	26413	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	884	895	MAP kinases	Gene	26413,26416,26419	BMPR signalling was markedly impaired in TAK1-deficient chondrocytes as evidenced by reduced expression of known BMP target genes as well as reduced phosphorylation of Smad1/5/8 and p38/Jnk/Erk MAP kinases.
BC8_BioRED_Task1_Doc47	897	901	TAK1	Gene	26409	TAK1 mediates Smad1 phosphorylation at C-terminal serine residues.
BC8_BioRED_Task1_Doc47	911	916	Smad1	Gene	17125	TAK1 mediates Smad1 phosphorylation at C-terminal serine residues.
BC8_BioRED_Task1_Doc47	1041	1045	TAK1	Gene	26409	These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways.
BC8_BioRED_Task1_Doc47	1062	1065	BMP	Gene	12159	These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways.
BC8_BioRED_Task1_Doc47	1128	1137	Smad1/5/8	Gene	17125,17129,55994	These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways.
BC8_BioRED_Task1_Doc47	1182	1192	MAP kinase	Gene	26413,26416,26419	These findings provide the first in vivo evidence in a mammalian system that TAK1 is required for BMP signalling and functions as an upstream activating kinase for Smad1/5/8 in addition to its known role in regulating MAP kinase pathways.
BC8_BioRED_Task1_Doc47	1248	1252	TAK1	Gene	26409	Our experiments reveal an essential role for TAK1 in the morphogenesis, growth, and maintenance of cartilage.
BC8_BioRED_Task1_Doc48	0	8	Caffeine	Chemical	D002110	Caffeine challenge test in panic disorder and depression with panic attacks.
BC8_BioRED_Task1_Doc48	27	41	panic disorder	Disease	D016584	Caffeine challenge test in panic disorder and depression with panic attacks.
BC8_BioRED_Task1_Doc48	46	56	depression	Disease	D003866	Caffeine challenge test in panic disorder and depression with panic attacks.
BC8_BioRED_Task1_Doc48	62	75	panic attacks	Disease	D016584	Caffeine challenge test in panic disorder and depression with panic attacks.
BC8_BioRED_Task1_Doc48	103	111	patients	OrganismTaxon	9606	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	117	131	panic disorder	Disease	D016584	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	133	135	PD	Disease	D016584	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	141	149	patients	OrganismTaxon	9606	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	155	171	major depression	Disease	D003865	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	177	190	panic attacks	Disease	D016584	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	192	195	MDP	Disease	D003865,D016584	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	235	251	Mental Disorders	Disease	D001523	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	323	336	panic attacks	Disease	D016584	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	348	356	caffeine	Chemical	D002110	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	397	405	patients	OrganismTaxon	9606	We randomly selected 29 patients with PD, 27 with MDP, 25 with major depression without panic attacks (MD), and 28 healthy volunteers.
BC8_BioRED_Task1_Doc48	411	413	PD	Disease	D016584	We randomly selected 29 patients with PD, 27 with MDP, 25 with major depression without panic attacks (MD), and 28 healthy volunteers.
BC8_BioRED_Task1_Doc48	423	426	MDP	Disease	D003865,D016584	We randomly selected 29 patients with PD, 27 with MDP, 25 with major depression without panic attacks (MD), and 28 healthy volunteers.
BC8_BioRED_Task1_Doc48	436	452	major depression	Disease	D003865	We randomly selected 29 patients with PD, 27 with MDP, 25 with major depression without panic attacks (MD), and 28 healthy volunteers.
BC8_BioRED_Task1_Doc48	461	474	panic attacks	Disease	D016584	We randomly selected 29 patients with PD, 27 with MDP, 25 with major depression without panic attacks (MD), and 28 healthy volunteers.
BC8_BioRED_Task1_Doc48	476	478	MD	Disease	D003865	We randomly selected 29 patients with PD, 27 with MDP, 25 with major depression without panic attacks (MD), and 28 healthy volunteers.
BC8_BioRED_Task1_Doc48	512	520	patients	OrganismTaxon	9606	The patients had no psychotropic drug for at least a 4-week period.
BC8_BioRED_Task1_Doc48	662	670	caffeine	Chemical	D002110	In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.
BC8_BioRED_Task1_Doc48	677	685	caffeine	Chemical	D002110	In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.
BC8_BioRED_Task1_Doc48	749	756	anxiety	Disease	D001008	In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.
BC8_BioRED_Task1_Doc48	834	842	patients	OrganismTaxon	9606	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	848	850	PD	Disease	D016584	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	870	878	patients	OrganismTaxon	9606	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	884	887	MDP	Disease	D003865,D016584	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	906	914	patients	OrganismTaxon	9606	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	920	922	MD	Disease	D003865	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	966	978	panic attack	Disease	D016584	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	996	1004	caffeine	Chemical	D002110	A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).
BC8_BioRED_Task1_Doc48	1055	1063	patients	OrganismTaxon	9606	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
BC8_BioRED_Task1_Doc48	1069	1071	PD	Disease	D016584	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
BC8_BioRED_Task1_Doc48	1076	1079	MDP	Disease	D003865,D016584	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
BC8_BioRED_Task1_Doc48	1103	1111	caffeine	Chemical	D002110	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
BC8_BioRED_Task1_Doc48	1122	1130	patients	OrganismTaxon	9606	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
BC8_BioRED_Task1_Doc48	1136	1138	MD	Disease	D003865	The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
BC8_BioRED_Task1_Doc48	1166	1178	panic attack	Disease	D016584	No panic attack was observed after the caffeine-free solution intake.
BC8_BioRED_Task1_Doc48	1202	1210	caffeine	Chemical	D002110	No panic attack was observed after the caffeine-free solution intake.
BC8_BioRED_Task1_Doc48	1237	1245	patients	OrganismTaxon	9606	The patients with MD had a lower heart rate response to the test than all the other groups (2-way analysis of variance, group by time interaction with Greenhouse-Geisser correction: F(3,762) = 2.85, P = .026).
BC8_BioRED_Task1_Doc48	1251	1253	MD	Disease	D003865	The patients with MD had a lower heart rate response to the test than all the other groups (2-way analysis of variance, group by time interaction with Greenhouse-Geisser correction: F(3,762) = 2.85, P = .026).
BC8_BioRED_Task1_Doc48	1497	1510	panic attacks	Disease	D016584	Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	1541	1543	PD	Disease	D016584	Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	1547	1550	MDP	Disease	D003865,D016584	Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.
BC8_BioRED_Task1_Doc48	1583	1591	caffeine	Chemical	D002110	Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.
BC8_BioRED_Task1_Doc49	20	50	Becker muscular dystrophy gene	Gene	1756	Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences.
BC8_BioRED_Task1_Doc49	146	171	Becker muscular dystrophy	Disease	D020388	A linkage study in 30 Becker muscular dystrophy (BMD) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms (RFLPs), suggests that the BMD gene is located on the short arm of the X chromosome, in the p21 region.
BC8_BioRED_Task1_Doc49	173	176	BMD	Disease	D020388	A linkage study in 30 Becker muscular dystrophy (BMD) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms (RFLPs), suggests that the BMD gene is located on the short arm of the X chromosome, in the p21 region.
BC8_BioRED_Task1_Doc49	329	332	BMD	Gene	1756	A linkage study in 30 Becker muscular dystrophy (BMD) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms (RFLPs), suggests that the BMD gene is located on the short arm of the X chromosome, in the p21 region.
BC8_BioRED_Task1_Doc49	420	451	Becker and Duchenne dystrophies	Disease	D020388	The genes for Becker and Duchenne dystrophies must therefore be closely linked, if not allelic, and any future DNA probes found to be of practical use in one disorder should be equally applicable to the other.
BC8_BioRED_Task1_Doc50	26	36	raloxifene	Chemical	D020849	The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
BC8_BioRED_Task1_Doc50	70	74	TAFI	Gene	1361	The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
BC8_BioRED_Task1_Doc50	76	79	tPA	Gene	5327	The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
BC8_BioRED_Task1_Doc50	85	90	PAI-1	Gene	5054	The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
BC8_BioRED_Task1_Doc50	129	172	thrombin-activatable fibrinolysis inhibitor	Gene	1361	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	174	178	TAFI	Gene	1361	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	181	214	tissue-type plasminogen activator	Gene	5327	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	216	219	tPA	Gene	5327	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	226	259	plasminogen activator inhibitor-1	Gene	5054	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	261	266	PAI-1	Gene	5054	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	332	342	raloxifene	Chemical	D020849	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	376	381	women	OrganismTaxon	9606	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.
BC8_BioRED_Task1_Doc50	419	424	women	OrganismTaxon	9606	METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.
BC8_BioRED_Task1_Doc50	430	440	osteopenia	Disease	D001851	METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.
BC8_BioRED_Task1_Doc50	444	456	osteoporosis	Disease	D010024	METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.
BC8_BioRED_Task1_Doc50	531	536	women	OrganismTaxon	9606	Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).
BC8_BioRED_Task1_Doc50	548	572	raloxifene hydrochloride	Chemical	D020849	Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).
BC8_BioRED_Task1_Doc50	590	597	calcium	Chemical	D002118	Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).
BC8_BioRED_Task1_Doc50	658	665	calcium	Chemical	D002118	Age-matched controls (n = 14) were given only calcium.
BC8_BioRED_Task1_Doc50	674	678	TAFI	Gene	1361	Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits.
BC8_BioRED_Task1_Doc50	680	683	tPA	Gene	5327	Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits.
BC8_BioRED_Task1_Doc50	689	694	PAI-1	Gene	5054	Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits.
BC8_BioRED_Task1_Doc50	977	987	raloxifene	Chemical	D020849	RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).
BC8_BioRED_Task1_Doc50	1055	1059	TAFI	Gene	1361	RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).
BC8_BioRED_Task1_Doc50	1137	1140	tPA	Gene	5327	RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).
BC8_BioRED_Task1_Doc50	1241	1245	TAFI	Gene	1361	A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).
BC8_BioRED_Task1_Doc50	1372	1394	venous thromboembolism	Disease	D054556	CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.
BC8_BioRED_Task1_Doc50	1402	1412	raloxifene	Chemical	D020849	CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.
BC8_BioRED_Task1_Doc50	1451	1454	tPA	Gene	5327	CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.
BC8_BioRED_Task1_Doc50	1471	1475	TAFI	Gene	1361	CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.
BC8_BioRED_Task1_Doc51	24	30	DFNA36	Gene	117531	A novel mutation at the DFNA36 hearing loss locus reveals a critical function and potential genotype-phenotype correlation for amino acid-572 of TMC1.
BC8_BioRED_Task1_Doc51	31	43	hearing loss	Disease	D034381	A novel mutation at the DFNA36 hearing loss locus reveals a critical function and potential genotype-phenotype correlation for amino acid-572 of TMC1.
BC8_BioRED_Task1_Doc51	145	149	TMC1	Gene	117531	A novel mutation at the DFNA36 hearing loss locus reveals a critical function and potential genotype-phenotype correlation for amino acid-572 of TMC1.
BC8_BioRED_Task1_Doc51	282	308	sensorineural hearing loss	Disease	D006319	We ascertained a North American Caucasian family (LMG248) segregating autosomal dominant, non-syndromic, post-lingual, progressive sensorineural hearing loss.
BC8_BioRED_Task1_Doc51	314	326	hearing loss	Disease	D034381	The hearing loss begins in the second decade of life and initially affects high frequencies.
BC8_BioRED_Task1_Doc51	429	437	deafness	Disease	D003638	It progresses to profound deafness at all frequencies by the fourth or fifth decade.
BC8_BioRED_Task1_Doc51	562	566	TMC1	Gene	117531	The phenotype co-segregates with short-tandem repeat markers flanking the TMC1 gene at the DFNA36 locus on chromosome 9q31-q21.
BC8_BioRED_Task1_Doc51	579	585	DFNA36	Gene	117531	The phenotype co-segregates with short-tandem repeat markers flanking the TMC1 gene at the DFNA36 locus on chromosome 9q31-q21.
BC8_BioRED_Task1_Doc51	678	685	p.D572H	SequenceVariant	rs121908072	The affected individuals carry a novel missense substitution, p.D572H (c.G1714C), of the TMC1 gene.
BC8_BioRED_Task1_Doc51	687	695	c.G1714C	SequenceVariant	rs121908072	The affected individuals carry a novel missense substitution, p.D572H (c.G1714C), of the TMC1 gene.
BC8_BioRED_Task1_Doc51	705	709	TMC1	Gene	117531	The affected individuals carry a novel missense substitution, p.D572H (c.G1714C), of the TMC1 gene.
BC8_BioRED_Task1_Doc51	807	813	DFNA36	Gene	117531	This mutation is at the same nucleotide and amino acid position as the only other reported DFNA36 mutation, p.D572N (c.G1714A).
BC8_BioRED_Task1_Doc51	824	831	p.D572N	SequenceVariant	rs121908072	This mutation is at the same nucleotide and amino acid position as the only other reported DFNA36 mutation, p.D572N (c.G1714A).
BC8_BioRED_Task1_Doc51	833	841	c.G1714A	SequenceVariant	rs121908072	This mutation is at the same nucleotide and amino acid position as the only other reported DFNA36 mutation, p.D572N (c.G1714A).
BC8_BioRED_Task1_Doc51	924	928	TMC1	Gene	117531	Our observations implicate a critical function for amino acid-572 for wild-type TMC1 function or the pathogenesis of DFNA36 hearing loss.
BC8_BioRED_Task1_Doc51	961	967	DFNA36	Gene	117531	Our observations implicate a critical function for amino acid-572 for wild-type TMC1 function or the pathogenesis of DFNA36 hearing loss.
BC8_BioRED_Task1_Doc51	968	980	hearing loss	Disease	D034381	Our observations implicate a critical function for amino acid-572 for wild-type TMC1 function or the pathogenesis of DFNA36 hearing loss.
BC8_BioRED_Task1_Doc51	1008	1020	hearing loss	Disease	D034381	The slower progression of hearing loss associated with p.D572H, in comparison with that caused by p.D572N, may reflect a correlation of DFNA36 phenotype with TMC1 genotype.
BC8_BioRED_Task1_Doc51	1037	1044	p.D572H	SequenceVariant	rs121908072	The slower progression of hearing loss associated with p.D572H, in comparison with that caused by p.D572N, may reflect a correlation of DFNA36 phenotype with TMC1 genotype.
BC8_BioRED_Task1_Doc51	1080	1087	p.D572N	SequenceVariant	rs121908072	The slower progression of hearing loss associated with p.D572H, in comparison with that caused by p.D572N, may reflect a correlation of DFNA36 phenotype with TMC1 genotype.
BC8_BioRED_Task1_Doc51	1118	1124	DFNA36	Gene	117531	The slower progression of hearing loss associated with p.D572H, in comparison with that caused by p.D572N, may reflect a correlation of DFNA36 phenotype with TMC1 genotype.
BC8_BioRED_Task1_Doc51	1140	1144	TMC1	Gene	117531	The slower progression of hearing loss associated with p.D572H, in comparison with that caused by p.D572N, may reflect a correlation of DFNA36 phenotype with TMC1 genotype.
BC8_BioRED_Task1_Doc52	6	19	low back pain	Disease	D017116	Acute low back pain during intravenous administration of amiodarone: a report of two cases.
BC8_BioRED_Task1_Doc52	57	67	amiodarone	Chemical	D000638	Acute low back pain during intravenous administration of amiodarone: a report of two cases.
BC8_BioRED_Task1_Doc52	92	102	Amiodarone	Chemical	D000638	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.
BC8_BioRED_Task1_Doc52	127	146	antiarrhythmic drug	Chemical	D000889	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.
BC8_BioRED_Task1_Doc52	181	200	atrial fibrillation	Disease	D001281	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.
BC8_BioRED_Task1_Doc52	202	204	AF	Disease	D001281	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.
BC8_BioRED_Task1_Doc52	263	271	patients	OrganismTaxon	9606	We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.
BC8_BioRED_Task1_Doc52	300	319	atrial fibrillation	Disease	D001281	We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.
BC8_BioRED_Task1_Doc52	358	371	low back pain	Disease	D017116	We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.
BC8_BioRED_Task1_Doc52	418	428	amiodarone	Chemical	D000638	We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.
BC8_BioRED_Task1_Doc53	9	24	Prostate Cancer	Disease	D011471	Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
BC8_BioRED_Task1_Doc53	40	57	Androgen Receptor	Gene	367	Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
BC8_BioRED_Task1_Doc53	78	90	Melanophilin	Gene	79083	Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
BC8_BioRED_Task1_Doc53	135	152	Androgen Receptor	Gene	367	Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
BC8_BioRED_Task1_Doc53	288	303	prostate cancer	Disease	D011471	Genome-wide association studies have identified genomic loci, whose single-nucleotide polymorphisms (SNPs) predispose to prostate cancer (PCa).
BC8_BioRED_Task1_Doc53	305	308	PCa	Disease	D011471	Genome-wide association studies have identified genomic loci, whose single-nucleotide polymorphisms (SNPs) predispose to prostate cancer (PCa).
BC8_BioRED_Task1_Doc53	484	491	TMPRSS2	Gene	7113	We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
BC8_BioRED_Task1_Doc53	492	495	ERG	Gene	2078	We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
BC8_BioRED_Task1_Doc53	524	529	DUCaP	CellLine	CVCL_2025	We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
BC8_BioRED_Task1_Doc53	550	553	PCa	Disease	D011471	We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
BC8_BioRED_Task1_Doc53	640	657	androgen receptor	Gene	367	We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
BC8_BioRED_Task1_Doc53	673	675	AR	Gene	367	We integrated chromatin-immunoprecipitation-coupled sequencing and microarray expression profiling in TMPRSS2-ERG gene rearrangement positive DUCaP cells with the GWAS PCa risk SNPs catalog to identify disease susceptibility SNPs localized within functional androgen receptor-binding sites (ARBSs).
BC8_BioRED_Task1_Doc53	763	765	AR	Gene	367	Among the 48 GWAS index risk SNPs and 3,917 linked SNPs, 80 were found located in ARBSs.
BC8_BioRED_Task1_Doc53	780	790	rs11891426	SequenceVariant	rs11891426	Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.
BC8_BioRED_Task1_Doc53	791	794	T>G	SequenceVariant	rs11891426	Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.
BC8_BioRED_Task1_Doc53	815	827	melanophilin	Gene	79083	Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.
BC8_BioRED_Task1_Doc53	834	838	MLPH	Gene	79083	Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.
BC8_BioRED_Task1_Doc53	878	880	AR	Gene	367	Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.
BC8_BioRED_Task1_Doc53	947	955	androgen	Chemical	D000728	Of these, rs11891426:T>G in an intron of the melanophilin gene (MLPH) was within a novel putative auxiliary AR-binding motif, which is enriched in the neighborhood of canonical androgen-responsive elements.
BC8_BioRED_Task1_Doc53	977	980	T>G	SequenceVariant	rs11891426	T>G exchange attenuated the transcriptional activity of the ARBS in an AR reporter gene assay.
BC8_BioRED_Task1_Doc53	1037	1039	AR	Gene	367	T>G exchange attenuated the transcriptional activity of the ARBS in an AR reporter gene assay.
BC8_BioRED_Task1_Doc53	1048	1050	AR	Gene	367	T>G exchange attenuated the transcriptional activity of the ARBS in an AR reporter gene assay.
BC8_BioRED_Task1_Doc53	1090	1094	MLPH	Gene	79083	The expression of MLPH in primary prostate tumors was significantly lower in those with the G compared with the T allele and correlated significantly with AR protein.
BC8_BioRED_Task1_Doc53	1106	1121	prostate tumors	Disease	D011471	The expression of MLPH in primary prostate tumors was significantly lower in those with the G compared with the T allele and correlated significantly with AR protein.
BC8_BioRED_Task1_Doc53	1227	1229	AR	Gene	367	The expression of MLPH in primary prostate tumors was significantly lower in those with the G compared with the T allele and correlated significantly with AR protein.
BC8_BioRED_Task1_Doc53	1246	1258	melanophilin	Gene	79083	Higher melanophilin level in prostate tissue of patients with a favorable PCa risk profile points out a tumor-suppressive effect.
BC8_BioRED_Task1_Doc53	1287	1295	patients	OrganismTaxon	9606	Higher melanophilin level in prostate tissue of patients with a favorable PCa risk profile points out a tumor-suppressive effect.
BC8_BioRED_Task1_Doc53	1313	1316	PCa	Disease	D011471	Higher melanophilin level in prostate tissue of patients with a favorable PCa risk profile points out a tumor-suppressive effect.
BC8_BioRED_Task1_Doc53	1343	1348	tumor	Disease	D009369	Higher melanophilin level in prostate tissue of patients with a favorable PCa risk profile points out a tumor-suppressive effect.
BC8_BioRED_Task1_Doc53	1413	1415	AR	Gene	367	These results unravel a hidden link between AR and a functional putative PCa risk SNP, whose allele alteration affects androgen regulation of its host gene MLPH.
BC8_BioRED_Task1_Doc53	1442	1445	PCa	Disease	D011471	These results unravel a hidden link between AR and a functional putative PCa risk SNP, whose allele alteration affects androgen regulation of its host gene MLPH.
BC8_BioRED_Task1_Doc53	1488	1496	androgen	Chemical	D000728	These results unravel a hidden link between AR and a functional putative PCa risk SNP, whose allele alteration affects androgen regulation of its host gene MLPH.
BC8_BioRED_Task1_Doc53	1525	1529	MLPH	Gene	79083	These results unravel a hidden link between AR and a functional putative PCa risk SNP, whose allele alteration affects androgen regulation of its host gene MLPH.
BC8_BioRED_Task1_Doc54	20	24	GJA8	Gene	2703	A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree.
BC8_BioRED_Task1_Doc54	44	73	cataract-microcornea syndrome	Disease	C538287	A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree.
BC8_BioRED_Task1_Doc54	133	147	genetic defect	Disease	D030342	PURPOSE: To identify the underlying genetic defect in a four-generation family of Chinese origin with autosomal dominant congenital cataract-microcornea syndrome (CCMC).
BC8_BioRED_Task1_Doc54	229	258	cataract-microcornea syndrome	Disease	C538287	PURPOSE: To identify the underlying genetic defect in a four-generation family of Chinese origin with autosomal dominant congenital cataract-microcornea syndrome (CCMC).
BC8_BioRED_Task1_Doc54	260	264	CCMC	Disease	C538287	PURPOSE: To identify the underlying genetic defect in a four-generation family of Chinese origin with autosomal dominant congenital cataract-microcornea syndrome (CCMC).
BC8_BioRED_Task1_Doc54	647	657	c.592C-->T	SequenceVariant	c|SUB|C|592|T	RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene.
BC8_BioRED_Task1_Doc54	675	704	gap junction protein, alpha 8	Gene	2703	RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene.
BC8_BioRED_Task1_Doc54	706	710	GJA8	Gene	2703	RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene.
BC8_BioRED_Task1_Doc54	821	856	arginine to tryptophan at codon 198	SequenceVariant	p|SUB|R|198|W	This mutation was responsible for the familial disorder through the substitution of a highly conserved arginine to tryptophan at codon 198 (p.R198W).
BC8_BioRED_Task1_Doc54	858	865	p.R198W	SequenceVariant	p|SUB|R|198|W	This mutation was responsible for the familial disorder through the substitution of a highly conserved arginine to tryptophan at codon 198 (p.R198W).
BC8_BioRED_Task1_Doc54	1071	1078	p.R198W	SequenceVariant	p|SUB|R|198|W	CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC.
BC8_BioRED_Task1_Doc54	1091	1095	GJA8	Gene	2703	CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC.
BC8_BioRED_Task1_Doc54	1101	1105	CCMC	Disease	C538287	CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC.
BC8_BioRED_Task1_Doc54	1151	1155	GJA8	Gene	2703	The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.
BC8_BioRED_Task1_Doc54	1186	1194	cataract	Disease	D002386	The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.
BC8_BioRED_Task1_Doc54	1199	1210	microcornea	Disease	D005124	The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.
BC8_BioRED_Task1_Doc55	94	97	ACE	Gene	1636	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	99	104	TPA25	Gene	-	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	106	110	PV92	Gene	-	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	112	115	APO	Gene	84909	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	117	123	FXIIIB	Gene	2165	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	125	127	D1	Gene	-	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	129	132	A25	Gene	28936	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc55	137	140	B65	Gene	-	Eight Alu sequences (ACE, TPA25, PV92, APO, FXIIIB, D1, A25 and B65) were analyzed in two samples from Navarre and Guipuzcoa provinces (Basque Country, Spain).
BC8_BioRED_Task1_Doc56	4	48	phosphatidylethanolamine N-methyltransferase	Gene	10400	The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population.
BC8_BioRED_Task1_Doc56	54	59	V175M	SequenceVariant	rs7946	The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population.
BC8_BioRED_Task1_Doc56	121	125	NASH	Disease	D065626	The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population.
BC8_BioRED_Task1_Doc56	216	244	nonalcoholic steatohepatitis	Disease	D065626	BACKGROUND/AIMS: The genetic predisposition on the development of nonalcoholic steatohepatitis (NASH) has been poorly understood.
BC8_BioRED_Task1_Doc56	246	250	NASH	Disease	D065626	BACKGROUND/AIMS: The genetic predisposition on the development of nonalcoholic steatohepatitis (NASH) has been poorly understood.
BC8_BioRED_Task1_Doc56	306	315	Val175Met	SequenceVariant	rs7946	A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine.
BC8_BioRED_Task1_Doc56	332	376	phosphatidylethanolamine N-methyltransferase	Gene	10400	A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine.
BC8_BioRED_Task1_Doc56	378	382	PEMT	Gene	10400	A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine.
BC8_BioRED_Task1_Doc56	417	441	phosphatidylethanolamine	Chemical	D010714	A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine.
BC8_BioRED_Task1_Doc56	445	464	phosphatidylcholine	Chemical	D010713	A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine.
BC8_BioRED_Task1_Doc56	531	540	Val175Met	SequenceVariant	rs7946	The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH.
BC8_BioRED_Task1_Doc56	561	565	PEMT	Gene	10400	The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH.
BC8_BioRED_Task1_Doc56	599	603	NASH	Disease	D065626	The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH.
BC8_BioRED_Task1_Doc56	635	643	patients	OrganismTaxon	9606	METHODS: Blood samples of 107 patients with biopsy-proven NASH and of 150 healthy volunteers were analyzed by the polymerase chain reaction (PCR) and restriction fragment length polymorphism.
BC8_BioRED_Task1_Doc56	663	667	NASH	Disease	D065626	METHODS: Blood samples of 107 patients with biopsy-proven NASH and of 150 healthy volunteers were analyzed by the polymerase chain reaction (PCR) and restriction fragment length polymorphism.
BC8_BioRED_Task1_Doc56	806	815	Val175Met	SequenceVariant	rs7946	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	838	842	PEMT	Gene	10400	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	883	887	NASH	Disease	D065626	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	888	896	patients	OrganismTaxon	9606	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	951	960	Val175Met	SequenceVariant	rs7946	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	1005	1009	NASH	Disease	D065626	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	1010	1018	patients	OrganismTaxon	9606	RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01).
BC8_BioRED_Task1_Doc56	1062	1066	NASH	Disease	D065626	Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT.
BC8_BioRED_Task1_Doc56	1067	1075	patients	OrganismTaxon	9606	Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT.
BC8_BioRED_Task1_Doc56	1135	1140	obese	Disease	D009765	Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT.
BC8_BioRED_Task1_Doc56	1141	1149	patients	OrganismTaxon	9606	Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT.
BC8_BioRED_Task1_Doc56	1208	1217	Val175Met	SequenceVariant	rs7946	Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT.
BC8_BioRED_Task1_Doc56	1259	1263	PEMT	Gene	10400	Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT.
BC8_BioRED_Task1_Doc56	1278	1287	Val175Met	SequenceVariant	rs7946	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1299	1303	PEMT	Gene	10400	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1372	1376	NASH	Disease	D065626	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1420	1424	NASH	Disease	D065626	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1425	1433	patients	OrganismTaxon	9606	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1442	1447	obese	Disease	D009765	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1461	1470	Val175Met	SequenceVariant	rs7946	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1482	1486	PEMT	Gene	10400	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc56	1514	1518	NASH	Disease	D065626	CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.
BC8_BioRED_Task1_Doc57	0	8	Seizures	Disease	D012640	Seizures associated with levofloxacin: case presentation and literature review.
BC8_BioRED_Task1_Doc57	25	37	levofloxacin	Chemical	D064704	Seizures associated with levofloxacin: case presentation and literature review.
BC8_BioRED_Task1_Doc57	112	119	patient	OrganismTaxon	9606	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
BC8_BioRED_Task1_Doc57	134	142	seizures	Disease	D012640	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
BC8_BioRED_Task1_Doc57	183	195	levofloxacin	Chemical	D064704	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
BC8_BioRED_Task1_Doc57	277	302	cytochrome P450 (CYP) 1A2	Gene	1544	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
BC8_BioRED_Task1_Doc57	347	359	levofloxacin	Chemical	D064704	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
BC8_BioRED_Task1_Doc57	368	376	seizures	Disease	D012640	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.
BC8_BioRED_Task1_Doc57	520	532	levofloxacin	Chemical	D064704	The main search terms utilized were case report and levofloxacin.
BC8_BioRED_Task1_Doc57	612	624	levofloxacin	Chemical	D064704	RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.
BC8_BioRED_Task1_Doc57	633	641	seizures	Disease	D012640	RESULTS: Six cases of levofloxacin-induced seizures have been reported in the literature.
BC8_BioRED_Task1_Doc57	732	738	CYP1A2	Gene	1544	Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.
BC8_BioRED_Task1_Doc57	742	754	levofloxacin	Chemical	D064704	Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.
BC8_BioRED_Task1_Doc57	891	903	levofloxacin	Chemical	D064704	CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.
BC8_BioRED_Task1_Doc57	915	923	patients	OrganismTaxon	9606	CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.
BC8_BioRED_Task1_Doc57	982	988	CYP1A2	Gene	1544	CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.
BC8_BioRED_Task1_Doc58	4	11	-930A>G	SequenceVariant	rs9932581	The -930A>G polymorphism of the CYBA gene is associated with premature coronary artery disease.
BC8_BioRED_Task1_Doc58	32	36	CYBA	Gene	1535	The -930A>G polymorphism of the CYBA gene is associated with premature coronary artery disease.
BC8_BioRED_Task1_Doc58	71	94	coronary artery disease	Disease	D003324	The -930A>G polymorphism of the CYBA gene is associated with premature coronary artery disease.
BC8_BioRED_Task1_Doc58	153	176	Reactive oxygen species	Chemical	D017382	Reactive oxygen species (ROS) are involved in the pathogenesis of atherosclerosis and coronary artery disease (CAD).
BC8_BioRED_Task1_Doc58	178	181	ROS	Chemical	D017382	Reactive oxygen species (ROS) are involved in the pathogenesis of atherosclerosis and coronary artery disease (CAD).
BC8_BioRED_Task1_Doc58	219	234	atherosclerosis	Disease	D050197	Reactive oxygen species (ROS) are involved in the pathogenesis of atherosclerosis and coronary artery disease (CAD).
BC8_BioRED_Task1_Doc58	239	262	coronary artery disease	Disease	D003324	Reactive oxygen species (ROS) are involved in the pathogenesis of atherosclerosis and coronary artery disease (CAD).
BC8_BioRED_Task1_Doc58	264	267	CAD	Disease	D003324	Reactive oxygen species (ROS) are involved in the pathogenesis of atherosclerosis and coronary artery disease (CAD).
BC8_BioRED_Task1_Doc58	270	284	NADPH oxidases	Gene	1666	NADPH oxidases are the main source of ROS in the vasculature.
BC8_BioRED_Task1_Doc58	308	311	ROS	Chemical	D017382	NADPH oxidases are the main source of ROS in the vasculature.
BC8_BioRED_Task1_Doc58	332	339	p22phox	Gene	1535	p22phox is a critical component of vascular NADPH oxidases and is encoded by the CYBA (cytochrome b245 alpha) gene.
BC8_BioRED_Task1_Doc58	376	390	NADPH oxidases	Gene	1666	p22phox is a critical component of vascular NADPH oxidases and is encoded by the CYBA (cytochrome b245 alpha) gene.
BC8_BioRED_Task1_Doc58	413	417	CYBA	Gene	1535	p22phox is a critical component of vascular NADPH oxidases and is encoded by the CYBA (cytochrome b245 alpha) gene.
BC8_BioRED_Task1_Doc58	419	440	cytochrome b245 alpha	Gene	1535	p22phox is a critical component of vascular NADPH oxidases and is encoded by the CYBA (cytochrome b245 alpha) gene.
BC8_BioRED_Task1_Doc58	452	459	-930A>G	SequenceVariant	rs9932581	The -930A>G CYBA polymorphism (rs9932581:A>G) modulates the activity of the CYBA promoter, and influences CYBA transcriptional activity.
BC8_BioRED_Task1_Doc58	460	464	CYBA	Gene	1535	The -930A>G CYBA polymorphism (rs9932581:A>G) modulates the activity of the CYBA promoter, and influences CYBA transcriptional activity.
BC8_BioRED_Task1_Doc58	479	488	rs9932581	SequenceVariant	rs9932581	The -930A>G CYBA polymorphism (rs9932581:A>G) modulates the activity of the CYBA promoter, and influences CYBA transcriptional activity.
BC8_BioRED_Task1_Doc58	489	492	A>G	SequenceVariant	rs9932581	The -930A>G CYBA polymorphism (rs9932581:A>G) modulates the activity of the CYBA promoter, and influences CYBA transcriptional activity.
BC8_BioRED_Task1_Doc58	524	528	CYBA	Gene	1535	The -930A>G CYBA polymorphism (rs9932581:A>G) modulates the activity of the CYBA promoter, and influences CYBA transcriptional activity.
BC8_BioRED_Task1_Doc58	554	558	CYBA	Gene	1535	The -930A>G CYBA polymorphism (rs9932581:A>G) modulates the activity of the CYBA promoter, and influences CYBA transcriptional activity.
BC8_BioRED_Task1_Doc58	664	671	-930A>G	SequenceVariant	rs9932581	The aim of the present study was to analyze a possible association between the -930A>G polymorphism and CAD and to search for gene-traditional risk factors interactions.
BC8_BioRED_Task1_Doc58	689	692	CAD	Disease	D003324	The aim of the present study was to analyze a possible association between the -930A>G polymorphism and CAD and to search for gene-traditional risk factors interactions.
BC8_BioRED_Task1_Doc58	786	794	patients	OrganismTaxon	9606	480 subjects were studied: 240 patients with premature CAD, 240 age and sex matched blood donors.
BC8_BioRED_Task1_Doc58	810	813	CAD	Disease	D003324	480 subjects were studied: 240 patients with premature CAD, 240 age and sex matched blood donors.
BC8_BioRED_Task1_Doc58	857	864	-930A>G	SequenceVariant	rs9932581	The -930A>G polymorphism was genotyped using the TaqMan - Pre-designed SNP Genotyping Assay (Applied Biosystems).
BC8_BioRED_Task1_Doc58	971	976	-930G	SequenceVariant	rs9932581	The -930G allele carrier state was a risk factor for CAD (OR 2.03, 95% CI 1.21-3.44, P=0.007).
BC8_BioRED_Task1_Doc58	1020	1023	CAD	Disease	D003324	The -930G allele carrier state was a risk factor for CAD (OR 2.03, 95% CI 1.21-3.44, P=0.007).
BC8_BioRED_Task1_Doc58	1090	1095	-930G	SequenceVariant	rs9932581	A synergistic effect of the -930G allele with overweight/obesity (BMI --25) and cigarette smoking was found.
BC8_BioRED_Task1_Doc58	1108	1118	overweight	Disease	D050177	A synergistic effect of the -930G allele with overweight/obesity (BMI --25) and cigarette smoking was found.
BC8_BioRED_Task1_Doc58	1119	1126	obesity	Disease	D009765	A synergistic effect of the -930G allele with overweight/obesity (BMI --25) and cigarette smoking was found.
BC8_BioRED_Task1_Doc58	1185	1188	CAD	Disease	D003324	The estimated CAD risk for BMI --25 and the -930G allele interaction was about 160% greater than that predicted by assuming additivity of the effects, and about 40% greater for interaction of cigarette smoking and the -930G allele.
BC8_BioRED_Task1_Doc58	1215	1220	-930G	SequenceVariant	rs9932581	The estimated CAD risk for BMI --25 and the -930G allele interaction was about 160% greater than that predicted by assuming additivity of the effects, and about 40% greater for interaction of cigarette smoking and the -930G allele.
BC8_BioRED_Task1_Doc58	1389	1394	-930G	SequenceVariant	rs9932581	The estimated CAD risk for BMI --25 and the -930G allele interaction was about 160% greater than that predicted by assuming additivity of the effects, and about 40% greater for interaction of cigarette smoking and the -930G allele.
BC8_BioRED_Task1_Doc58	1403	1413	Overweight	Disease	D050177	Overweight/obesity was a risk factor for CAD only in the -930G allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).
BC8_BioRED_Task1_Doc58	1414	1421	obesity	Disease	D009765	Overweight/obesity was a risk factor for CAD only in the -930G allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).
BC8_BioRED_Task1_Doc58	1444	1447	CAD	Disease	D003324	Overweight/obesity was a risk factor for CAD only in the -930G allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).
BC8_BioRED_Task1_Doc58	1460	1465	-930G	SequenceVariant	rs9932581	Overweight/obesity was a risk factor for CAD only in the -930G allele carriers (P<10(-10)) but not in the AA homozygotes (P=1.00).
BC8_BioRED_Task1_Doc58	1552	1559	-930A>G	SequenceVariant	rs9932581	In conclusion the -930A>G CYBA polymorphism is associated with CAD in the Polish population.
BC8_BioRED_Task1_Doc58	1560	1564	CYBA	Gene	1535	In conclusion the -930A>G CYBA polymorphism is associated with CAD in the Polish population.
BC8_BioRED_Task1_Doc58	1597	1600	CAD	Disease	D003324	In conclusion the -930A>G CYBA polymorphism is associated with CAD in the Polish population.
BC8_BioRED_Task1_Doc58	1631	1636	-930G	SequenceVariant	rs9932581	The -930G allele carriers are particularly at risk of consequences of obesity and tobacco smoke exposure.
BC8_BioRED_Task1_Doc58	1697	1704	obesity	Disease	D009765	The -930G allele carriers are particularly at risk of consequences of obesity and tobacco smoke exposure.
BC8_BioRED_Task1_Doc58	1709	1716	tobacco	OrganismTaxon	4097	The -930G allele carriers are particularly at risk of consequences of obesity and tobacco smoke exposure.
BC8_BioRED_Task1_Doc59	70	90	thymidylate synthase	Gene	7298	Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
BC8_BioRED_Task1_Doc59	118	132	5 fluorouracil	Chemical	D005472	Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
BC8_BioRED_Task1_Doc59	141	158	colorectal cancer	Disease	D015179	Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
BC8_BioRED_Task1_Doc59	159	167	patients	OrganismTaxon	9606	Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
BC8_BioRED_Task1_Doc59	243	245	TS	Gene	7298	In the present study we explored the effect of three polymorphisms of the TS gene on overall and progression- free survival of colorectal cancer (CRC) patients subjected to 5FU chemotherapy.
BC8_BioRED_Task1_Doc59	296	313	colorectal cancer	Disease	D015179	In the present study we explored the effect of three polymorphisms of the TS gene on overall and progression- free survival of colorectal cancer (CRC) patients subjected to 5FU chemotherapy.
BC8_BioRED_Task1_Doc59	315	318	CRC	Disease	D015179	In the present study we explored the effect of three polymorphisms of the TS gene on overall and progression- free survival of colorectal cancer (CRC) patients subjected to 5FU chemotherapy.
BC8_BioRED_Task1_Doc59	320	328	patients	OrganismTaxon	9606	In the present study we explored the effect of three polymorphisms of the TS gene on overall and progression- free survival of colorectal cancer (CRC) patients subjected to 5FU chemotherapy.
BC8_BioRED_Task1_Doc59	342	345	5FU	Chemical	D005472	In the present study we explored the effect of three polymorphisms of the TS gene on overall and progression- free survival of colorectal cancer (CRC) patients subjected to 5FU chemotherapy.
BC8_BioRED_Task1_Doc59	362	401	28 bp variable number of tandem repeats	SequenceVariant	c|DUP||28	A 28 bp variable number of tandem repeats (VNTR), a G/C single nucleotide polymorphism (SNP), and a deletion of 6 bp at position 1494 were studied.
BC8_BioRED_Task1_Doc59	412	415	G/C	SequenceVariant	c|SUB|G||C	A 28 bp variable number of tandem repeats (VNTR), a G/C single nucleotide polymorphism (SNP), and a deletion of 6 bp at position 1494 were studied.
BC8_BioRED_Task1_Doc59	460	493	deletion of 6 bp at position 1494	SequenceVariant	c|DEL|194|6	A 28 bp variable number of tandem repeats (VNTR), a G/C single nucleotide polymorphism (SNP), and a deletion of 6 bp at position 1494 were studied.
BC8_BioRED_Task1_Doc59	591	599	patients	OrganismTaxon	9606	The possible combined effect of these DNA polymorphisms on the clinical outcome of patients was also evaluated.
BC8_BioRED_Task1_Doc59	661	669	paraffin	Chemical	D010232	A retrospective study was carried out on paraffin-embedded sections from 113 patients diagnosed of advanced CRC.
BC8_BioRED_Task1_Doc59	697	705	patients	OrganismTaxon	9606	A retrospective study was carried out on paraffin-embedded sections from 113 patients diagnosed of advanced CRC.
BC8_BioRED_Task1_Doc59	728	731	CRC	Disease	D015179	A retrospective study was carried out on paraffin-embedded sections from 113 patients diagnosed of advanced CRC.
BC8_BioRED_Task1_Doc59	733	735	TS	Gene	7298	TS genotyping methods were polymerase chain reaction (PCR) for VNTR and PCR, followed by restriction length fragment polymorphism (PCR-RFLP) for SNP and ins/del 6 bp.
BC8_BioRED_Task1_Doc59	886	898	ins/del 6 bp	SequenceVariant	c|INDEL||6	TS genotyping methods were polymerase chain reaction (PCR) for VNTR and PCR, followed by restriction length fragment polymorphism (PCR-RFLP) for SNP and ins/del 6 bp.
BC8_BioRED_Task1_Doc59	932	934	TS	Gene	7298	To study the combined effect of TS polymorphisms, four categories were defined accordingly to the level of expression attributed to SNP and ins/del 6 bp genotypes: C_allele 6-, C_6+/6+, G_allele6- and G_6+/6+.
BC8_BioRED_Task1_Doc59	1040	1052	ins/del 6 bp	SequenceVariant	c|INDEL||6	To study the combined effect of TS polymorphisms, four categories were defined accordingly to the level of expression attributed to SNP and ins/del 6 bp genotypes: C_allele 6-, C_6+/6+, G_allele6- and G_6+/6+.
BC8_BioRED_Task1_Doc59	1119	1131	ins/del 6 bp	SequenceVariant	c|INDEL||6	VNTR and ins/del 6 bp genotypes varied with tumour anatomical site: 2R/2R genotype was rare in left-sided tumours (7.0% vs. 26.3% of right-sided and 24.1% of rectal cancers; P<0.01), where the variant allele 6- was very frequent (69.0%).
BC8_BioRED_Task1_Doc59	1154	1160	tumour	Disease	D009369	VNTR and ins/del 6 bp genotypes varied with tumour anatomical site: 2R/2R genotype was rare in left-sided tumours (7.0% vs. 26.3% of right-sided and 24.1% of rectal cancers; P<0.01), where the variant allele 6- was very frequent (69.0%).
BC8_BioRED_Task1_Doc59	1216	1223	tumours	Disease	D009369	VNTR and ins/del 6 bp genotypes varied with tumour anatomical site: 2R/2R genotype was rare in left-sided tumours (7.0% vs. 26.3% of right-sided and 24.1% of rectal cancers; P<0.01), where the variant allele 6- was very frequent (69.0%).
BC8_BioRED_Task1_Doc59	1268	1282	rectal cancers	Disease	D012004	VNTR and ins/del 6 bp genotypes varied with tumour anatomical site: 2R/2R genotype was rare in left-sided tumours (7.0% vs. 26.3% of right-sided and 24.1% of rectal cancers; P<0.01), where the variant allele 6- was very frequent (69.0%).
BC8_BioRED_Task1_Doc59	1362	1370	patients	OrganismTaxon	9606	Instead, most patients with right-sided tumours were wild-type homozygous 6+/6+ (63.9%) (P<0.01).
BC8_BioRED_Task1_Doc59	1388	1395	tumours	Disease	D009369	Instead, most patients with right-sided tumours were wild-type homozygous 6+/6+ (63.9%) (P<0.01).
BC8_BioRED_Task1_Doc59	1498	1505	tumours	Disease	D009369	Heterozygous 6+/6- genotype was more frequent among tumours classified as C (50.0%) and D (76.5%) Dukes stages (P=0.05).
BC8_BioRED_Task1_Doc59	1964	1971	tumours	Disease	D009369	The rate of Dukes B stage tumours was unexpectedly high (59.1%) among patients with the unfavourable G_6+/6+ combination.
BC8_BioRED_Task1_Doc59	2008	2016	patients	OrganismTaxon	9606	The rate of Dukes B stage tumours was unexpectedly high (59.1%) among patients with the unfavourable G_6+/6+ combination.
BC8_BioRED_Task1_Doc59	2097	2099	TS	Gene	7298	In our study the combination of high TS expression genotypes G_6+/6+ identifies a group of high risk within CRC patients treated with 5FU.
BC8_BioRED_Task1_Doc59	2168	2171	CRC	Disease	D015179	In our study the combination of high TS expression genotypes G_6+/6+ identifies a group of high risk within CRC patients treated with 5FU.
BC8_BioRED_Task1_Doc59	2172	2180	patients	OrganismTaxon	9606	In our study the combination of high TS expression genotypes G_6+/6+ identifies a group of high risk within CRC patients treated with 5FU.
BC8_BioRED_Task1_Doc59	2194	2197	5FU	Chemical	D005472	In our study the combination of high TS expression genotypes G_6+/6+ identifies a group of high risk within CRC patients treated with 5FU.
BC8_BioRED_Task1_Doc60	52	69	collagen receptor	Gene	4921,780	Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
BC8_BioRED_Task1_Doc60	70	74	DDR1	Gene	780	Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
BC8_BioRED_Task1_Doc60	138	164	discoidin domain receptors	Gene	4921,780	The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen.
BC8_BioRED_Task1_Doc60	166	170	DDRs	Gene	4921,780	The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen.
BC8_BioRED_Task1_Doc60	173	177	DDR1	Gene	780	The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen.
BC8_BioRED_Task1_Doc60	182	186	DDR2	Gene	4921	The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen.
BC8_BioRED_Task1_Doc60	215	240	receptor tyrosine kinases	Gene	4921,780	The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen.
BC8_BioRED_Task1_Doc60	293	301	collagen	Gene	1277	The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen.
BC8_BioRED_Task1_Doc60	326	330	DDR1	Gene	780	Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
BC8_BioRED_Task1_Doc60	335	339	DDR2	Gene	4921	Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
BC8_BioRED_Task1_Doc60	386	391	human	OrganismTaxon	9606	Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
BC8_BioRED_Task1_Doc60	412	420	fibrosis	Disease	D005355	Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
BC8_BioRED_Task1_Doc60	422	437	atherosclerosis	Disease	D050197	Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
BC8_BioRED_Task1_Doc60	442	448	cancer	Disease	D009369	Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer.
BC8_BioRED_Task1_Doc60	492	517	receptor tyrosine kinases	Gene	4921,780	We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1.
BC8_BioRED_Task1_Doc60	540	546	cancer	Disease	D009369	We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1.
BC8_BioRED_Task1_Doc60	553	561	imatinib	Chemical	D000068877	We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1.
BC8_BioRED_Task1_Doc60	566	575	ponatinib	Chemical	C545373	We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1.
BC8_BioRED_Task1_Doc60	620	629	DDR1-IN-1	Chemical	-	We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1.
BC8_BioRED_Task1_Doc60	631	640	Ponatinib	Chemical	C545373	Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM.
BC8_BioRED_Task1_Doc60	699	703	DDR1	Gene	780	Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM.
BC8_BioRED_Task1_Doc60	708	712	DDR2	Gene	4921	Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM.
BC8_BioRED_Task1_Doc60	759	764	human	OrganismTaxon	9606	Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix.
BC8_BioRED_Task1_Doc60	765	769	DDR1	Gene	780	Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix.
BC8_BioRED_Task1_Doc60	779	782	DFG	Chemical	C553185	Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix.
BC8_BioRED_Task1_Doc60	801	804	DFG	Chemical	C553185	Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix.
BC8_BioRED_Task1_Doc60	806	817	Asp-Phe-Gly	Chemical	C553185	Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix.
BC8_BioRED_Task1_Doc60	942	956	Abelson kinase	Gene	25	Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL.
BC8_BioRED_Task1_Doc60	958	961	ABL	Gene	25	Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL.
BC8_BioRED_Task1_Doc60	983	987	DDR1	Gene	780	Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL.
BC8_BioRED_Task1_Doc60	1050	1053	ABL	Gene	25	Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL.
BC8_BioRED_Task1_Doc60	1074	1078	DDR1	Gene	780	P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket.
BC8_BioRED_Task1_Doc60	1110	1113	ABL	Gene	25	P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket.
BC8_BioRED_Task1_Doc60	1153	1156	ATP	Chemical	D000255	P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket.
BC8_BioRED_Task1_Doc60	1173	1181	imatinib	Chemical	D000068877	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1186	1195	ponatinib	Chemical	C545373	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1222	1225	DDR	Gene	4921,780	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1230	1233	ABL	Gene	25	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1279	1282	ABL	Gene	25	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1317	1326	DDR1-IN-1	Chemical	-	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1365	1369	DDR1	Gene	780	Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity.
BC8_BioRED_Task1_Doc60	1448	1452	DDR1	Gene	780	Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.
BC8_BioRED_Task1_Doc60	1457	1461	DDR2	Gene	4921	Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.
BC8_BioRED_Task1_Doc60	1500	1511	lung cancer	Disease	D008175	Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.
BC8_BioRED_Task1_Doc61	35	71	adenosine A2A/A1 receptor antagonist	Chemical	D058915	In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
BC8_BioRED_Task1_Doc61	92	111	Parkinson's disease	Disease	D010300	In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
BC8_BioRED_Task1_Doc61	152	192	adenosine A(2A)/A(1) receptor antagonist	Chemical	D058915	The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.
BC8_BioRED_Task1_Doc61	221	240	Parkinson's disease	Disease	D010300	The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.
BC8_BioRED_Task1_Doc61	441	471	A(2A)/A(1) receptor antagonist	Chemical	D058915	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	616	635	Parkinson's disease	Disease	D010300	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	646	651	mouse	OrganismTaxon	10090	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	656	659	rat	OrganismTaxon	10116	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	670	681	haloperidol	Chemical	D006220	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	690	699	catalepsy	Disease	D002375	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	701	706	mouse	OrganismTaxon	10090	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	716	725	reserpine	Chemical	D012110	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	734	742	akinesia	Disease	D004409	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	744	747	rat	OrganismTaxon	10116	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	748	765	6-hydroxydopamine	Chemical	D016627	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	767	773	6-OHDA	Chemical	D016627	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	818	822	MPTP	Chemical	D015632	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc61	835	840	human	OrganismTaxon	9606	Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.
BC8_BioRED_Task1_Doc62	4	21	androgen receptor	Gene	11835	The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
BC8_BioRED_Task1_Doc62	62	77	atherosclerosis	Disease	D050197	The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
BC8_BioRED_Task1_Doc62	79	86	obesity	Disease	D009765	The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
BC8_BioRED_Task1_Doc62	92	104	dyslipidemia	Disease	D050171	The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
BC8_BioRED_Task1_Doc62	115	119	mice	OrganismTaxon	10090	The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
BC8_BioRED_Task1_Doc62	121	130	Androgens	Chemical	D000728	Androgens have important cardiometabolic actions in males, but their metabolic role in females is unclear.
BC8_BioRED_Task1_Doc62	257	274	androgen receptor	Gene	11835	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	276	278	AR	Gene	11835	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	301	310	androgens	Chemical	D000728	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	314	327	atherogenesis	Disease	D050197	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	338	342	mice	OrganismTaxon	10090	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	364	366	AR	Gene	11835	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	377	379	AR	Gene	11835	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	383	387	mice	OrganismTaxon	10090	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	394	409	atherosclerosis	Disease	D050197	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	416	432	apolipoprotein E	Gene	11816	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	434	438	apoE	Gene	11816	To determine the physiologic androgen receptor (AR)-dependent actions of androgens on atherogenesis in female mice, we generated female AR-knockout (ARKO) mice on an atherosclerosis-prone apolipoprotein E (apoE)-deficient background.
BC8_BioRED_Task1_Doc62	527	542	atherosclerosis	Disease	D050197	After 8 weeks on a high-fat diet, but not on a normal chow diet, atherosclerosis in aorta was increased in ARKO females (+59% vs. control apoE-deficient mice with intact AR gene).
BC8_BioRED_Task1_Doc62	569	571	AR	Gene	11835	After 8 weeks on a high-fat diet, but not on a normal chow diet, atherosclerosis in aorta was increased in ARKO females (+59% vs. control apoE-deficient mice with intact AR gene).
BC8_BioRED_Task1_Doc62	600	604	apoE	Gene	11816	After 8 weeks on a high-fat diet, but not on a normal chow diet, atherosclerosis in aorta was increased in ARKO females (+59% vs. control apoE-deficient mice with intact AR gene).
BC8_BioRED_Task1_Doc62	615	619	mice	OrganismTaxon	10090	After 8 weeks on a high-fat diet, but not on a normal chow diet, atherosclerosis in aorta was increased in ARKO females (+59% vs. control apoE-deficient mice with intact AR gene).
BC8_BioRED_Task1_Doc62	632	634	AR	Gene	11835	After 8 weeks on a high-fat diet, but not on a normal chow diet, atherosclerosis in aorta was increased in ARKO females (+59% vs. control apoE-deficient mice with intact AR gene).
BC8_BioRED_Task1_Doc62	732	744	triglyceride	Gene	100035834	They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic dyslipidemia (serum cholesterol, +52%).
BC8_BioRED_Task1_Doc62	761	768	insulin	Gene	16334	They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic dyslipidemia (serum cholesterol, +52%).
BC8_BioRED_Task1_Doc62	795	806	atherogenic	Disease	D050197	They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic dyslipidemia (serum cholesterol, +52%).
BC8_BioRED_Task1_Doc62	807	819	dyslipidemia	Disease	D050171	They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic dyslipidemia (serum cholesterol, +52%).
BC8_BioRED_Task1_Doc62	827	838	cholesterol	Chemical	D002784	They also displayed increased body weight (+18%), body fat percentage (+62%), and hepatic triglyceride levels, reduced insulin sensitivity, and a marked atherogenic dyslipidemia (serum cholesterol, +52%).
BC8_BioRED_Task1_Doc62	862	877	atherosclerosis	Disease	D050197	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	896	901	lipid	Chemical	D008055	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	917	919	AR	Gene	11835	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	934	938	mice	OrganismTaxon	10090	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	957	961	mice	OrganismTaxon	10090	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	1050	1059	androgens	Chemical	D000728	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	1077	1079	AR	Gene	11835	Differences in atherosclerosis, body weight, and lipid levels between ARKO and control mice were abolished in mice that were ovariectomized before puberty, consistent with a protective action of ovarian androgens mediated via the AR.
BC8_BioRED_Task1_Doc62	1098	1100	AR	Gene	11835	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1109	1128	dihydrotestosterone	Chemical	D013196	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1137	1152	atherosclerosis	Disease	D050197	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1211	1222	cholesterol	Chemical	D002784	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1255	1259	mice	OrganismTaxon	10090	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1280	1285	lipid	Chemical	D008055	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1302	1310	hepatoma	Disease	D006528	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1386	1391	lipid	Chemical	D008055	Furthermore, the AR agonist dihydrotestosterone reduced atherosclerosis (-41%; thoracic aorta), subcutaneous fat mass (-44%), and cholesterol levels (-35%) in ovariectomized mice, reduced hepatocyte lipid accumulation in hepatoma cells in vitro, and regulated mRNA expression of hepatic genes pivotal for lipid homeostasis.
BC8_BioRED_Task1_Doc62	1444	1446	AR	Gene	11835	In conclusion, we demonstrate that the AR protects against diet-induced atherosclerosis in female mice and propose that this is mediated by modulation of body composition and lipid metabolism.
BC8_BioRED_Task1_Doc62	1477	1492	atherosclerosis	Disease	D050197	In conclusion, we demonstrate that the AR protects against diet-induced atherosclerosis in female mice and propose that this is mediated by modulation of body composition and lipid metabolism.
BC8_BioRED_Task1_Doc62	1503	1507	mice	OrganismTaxon	10090	In conclusion, we demonstrate that the AR protects against diet-induced atherosclerosis in female mice and propose that this is mediated by modulation of body composition and lipid metabolism.
BC8_BioRED_Task1_Doc62	1580	1585	lipid	Chemical	D008055	In conclusion, we demonstrate that the AR protects against diet-induced atherosclerosis in female mice and propose that this is mediated by modulation of body composition and lipid metabolism.
BC8_BioRED_Task1_Doc63	34	49	sodium chloride	Chemical	D012965	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
BC8_BioRED_Task1_Doc63	55	64	diltiazem	Chemical	D004110	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
BC8_BioRED_Task1_Doc63	82	90	contrast	Chemical	D003287	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
BC8_BioRED_Task1_Doc63	99	110	nephropathy	Disease	D007674	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.
BC8_BioRED_Task1_Doc63	140	148	Contrast	Chemical	D003287	INTRODUCTION AND OBJECTIVE: Contrast-induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
BC8_BioRED_Task1_Doc63	157	168	nephropathy	Disease	D007674	INTRODUCTION AND OBJECTIVE: Contrast-induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
BC8_BioRED_Task1_Doc63	170	173	CIN	Disease	D007674	INTRODUCTION AND OBJECTIVE: Contrast-induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
BC8_BioRED_Task1_Doc63	230	238	patients	OrganismTaxon	9606	INTRODUCTION AND OBJECTIVE: Contrast-induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
BC8_BioRED_Task1_Doc63	327	342	sodium chloride	Chemical	D012965	The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.
BC8_BioRED_Task1_Doc63	348	366	sodium bicarbonate	Chemical	D017693	The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.
BC8_BioRED_Task1_Doc63	389	404	sodium chloride	Chemical	D012965	The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.
BC8_BioRED_Task1_Doc63	419	428	diltiazem	Chemical	D004110	The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.
BC8_BioRED_Task1_Doc63	432	439	calcium	Chemical	D002118	The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.
BC8_BioRED_Task1_Doc63	471	474	CIN	Disease	D007674	The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.
BC8_BioRED_Task1_Doc63	518	526	patients	OrganismTaxon	9606	MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with creatinine values between 1.1 and 3.1 mg/dL.
BC8_BioRED_Task1_Doc63	571	579	contrast	Chemical	D003287	MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with creatinine values between 1.1 and 3.1 mg/dL.
BC8_BioRED_Task1_Doc63	641	651	creatinine	Chemical	D003404	MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with creatinine values between 1.1 and 3.1 mg/dL.
BC8_BioRED_Task1_Doc63	686	694	Patients	OrganismTaxon	9606	Patients were divided into three groups and each group had 20 patients.
BC8_BioRED_Task1_Doc63	748	756	patients	OrganismTaxon	9606	Patients were divided into three groups and each group had 20 patients.
BC8_BioRED_Task1_Doc63	777	785	patients	OrganismTaxon	9606	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% dextrose and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection.
BC8_BioRED_Task1_Doc63	812	827	sodium chloride	Chemical	D012965	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% dextrose and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection.
BC8_BioRED_Task1_Doc63	885	893	dextrose	Chemical	D005947	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% dextrose and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection.
BC8_BioRED_Task1_Doc63	898	916	sodium bicarbonate	Chemical	D017693	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% dextrose and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection.
BC8_BioRED_Task1_Doc63	966	981	sodium chloride	Chemical	D012965	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% dextrose and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection.
BC8_BioRED_Task1_Doc63	1003	1011	contrast	Chemical	D003287	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% dextrose and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection.
BC8_BioRED_Task1_Doc63	1075	1084	diltiazem	Chemical	D004110	The third group received an additional injection of diltiazem the day before and first 2 days after the contrast injection.
BC8_BioRED_Task1_Doc63	1127	1135	contrast	Chemical	D003287	The third group received an additional injection of diltiazem the day before and first 2 days after the contrast injection.
BC8_BioRED_Task1_Doc63	1158	1166	patients	OrganismTaxon	9606	All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material.
BC8_BioRED_Task1_Doc63	1175	1194	blood urea nitrogen	Chemical	D001806	All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material.
BC8_BioRED_Task1_Doc63	1196	1199	BUN	Chemical	D001806	All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material.
BC8_BioRED_Task1_Doc63	1205	1215	creatinine	Chemical	D003404	All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material.
BC8_BioRED_Task1_Doc63	1307	1315	contrast	Chemical	D003287	All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material.
BC8_BioRED_Task1_Doc63	1345	1355	creatinine	Chemical	D003404	RESULTS: The basal creatinine levels were similar for all three groups (p > 0.05).
BC8_BioRED_Task1_Doc63	1429	1437	patients	OrganismTaxon	9606	Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
BC8_BioRED_Task1_Doc63	1464	1472	patients	OrganismTaxon	9606	Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
BC8_BioRED_Task1_Doc63	1483	1502	acute renal failure	Disease	D058186	Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
BC8_BioRED_Task1_Doc63	1504	1507	ARF	Disease	D058186	Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
BC8_BioRED_Task1_Doc63	1533	1541	contrast	Chemical	D003287	Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
BC8_BioRED_Task1_Doc63	1587	1595	patients	OrganismTaxon	9606	The number of patients who developed ARF on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05).
BC8_BioRED_Task1_Doc63	1610	1613	ARF	Disease	D058186	The number of patients who developed ARF on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05).
BC8_BioRED_Task1_Doc63	1833	1848	sodium chloride	Chemical	D012965	CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.
BC8_BioRED_Task1_Doc63	1850	1868	sodium bicarbonate	Chemical	D017693	CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.
BC8_BioRED_Task1_Doc63	1882	1897	sodium chloride	Chemical	D012965	CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.
BC8_BioRED_Task1_Doc63	1903	1912	diltiazem	Chemical	D004110	CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.
BC8_BioRED_Task1_Doc63	1942	1945	CIN	Disease	D007674	CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.
BC8_BioRED_Task1_Doc64	11	33	drop in blood pressure	Disease	D007022	A dramatic drop in blood pressure following prehospital GTN administration.
BC8_BioRED_Task1_Doc64	56	59	GTN	Chemical	D005996	A dramatic drop in blood pressure following prehospital GTN administration.
BC8_BioRED_Task1_Doc64	125	135	chest pain	Disease	D002637	A male in his sixties with no history of cardiac chest pain awoke with chest pain following an afternoon sleep.
BC8_BioRED_Task1_Doc64	147	157	chest pain	Disease	D002637	A male in his sixties with no history of cardiac chest pain awoke with chest pain following an afternoon sleep.
BC8_BioRED_Task1_Doc64	192	199	patient	OrganismTaxon	9606	The patient did not self medicate.
BC8_BioRED_Task1_Doc64	227	234	patient	OrganismTaxon	9606	The patient's observations were within normal limits, he was administered oxygen via a face mask and glyceryl trinitrate (GTN).
BC8_BioRED_Task1_Doc64	297	303	oxygen	Chemical	D010100	The patient's observations were within normal limits, he was administered oxygen via a face mask and glyceryl trinitrate (GTN).
BC8_BioRED_Task1_Doc64	324	343	glyceryl trinitrate	Chemical	D005996	The patient's observations were within normal limits, he was administered oxygen via a face mask and glyceryl trinitrate (GTN).
BC8_BioRED_Task1_Doc64	345	348	GTN	Chemical	D005996	The patient's observations were within normal limits, he was administered oxygen via a face mask and glyceryl trinitrate (GTN).
BC8_BioRED_Task1_Doc64	377	380	GTN	Chemical	D005996	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
BC8_BioRED_Task1_Doc64	385	392	patient	OrganismTaxon	9606	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
BC8_BioRED_Task1_Doc64	414	436	drop in blood pressure	Disease	D007022	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
BC8_BioRED_Task1_Doc64	475	492	atropine sulphate	Chemical	D001285	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
BC8_BioRED_Task1_Doc64	558	565	patient	OrganismTaxon	9606	There was no further deterioration in the patient's condition during transport to hospital.
BC8_BioRED_Task1_Doc64	901	908	patient	OrganismTaxon	9606	Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly.
BC8_BioRED_Task1_Doc64	916	932	syncopal episode	Disease	D013575	Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly.
BC8_BioRED_Task1_Doc64	1056	1063	patient	OrganismTaxon	9606	Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly.
BC8_BioRED_Task1_Doc65	24	34	argatroban	Chemical	C031942	Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency.
BC8_BioRED_Task1_Doc65	59	74	vein thrombosis	Disease	D020246	Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency.
BC8_BioRED_Task1_Doc65	80	87	patient	OrganismTaxon	9606	Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency.
BC8_BioRED_Task1_Doc65	93	127	congenital antithrombin deficiency	Disease	D020152	Successful therapy with argatroban for superior mesenteric vein thrombosis in a patient with congenital antithrombin deficiency.
BC8_BioRED_Task1_Doc65	143	148	woman	OrganismTaxon	9606	A 38-year-old woman was admitted with superior mesenteric vein (SMV) thrombosis, which was refractory to anticoagulation therapy.
BC8_BioRED_Task1_Doc65	167	208	superior mesenteric vein (SMV) thrombosis	Disease	D020246	A 38-year-old woman was admitted with superior mesenteric vein (SMV) thrombosis, which was refractory to anticoagulation therapy.
BC8_BioRED_Task1_Doc65	270	282	antithrombin	Gene	462	The plasma antithrombin activity was decreased and hardly compensated by concentrated antithrombin preparation due to high consumption rate.
BC8_BioRED_Task1_Doc65	345	357	antithrombin	Gene	462	The plasma antithrombin activity was decreased and hardly compensated by concentrated antithrombin preparation due to high consumption rate.
BC8_BioRED_Task1_Doc65	477	485	thrombin	Gene	2147	However, successful anticoagulation was achieved by administration of direct thrombin inhibitor, argatroban.
BC8_BioRED_Task1_Doc65	497	507	argatroban	Chemical	C031942	However, successful anticoagulation was achieved by administration of direct thrombin inhibitor, argatroban.
BC8_BioRED_Task1_Doc65	527	539	antithrombin	Gene	462	Family studies of antithrombin activity revealed that she had type I congenital antithrombin deficiency.
BC8_BioRED_Task1_Doc65	571	612	type I congenital antithrombin deficiency	Disease	D025861	Family studies of antithrombin activity revealed that she had type I congenital antithrombin deficiency.
BC8_BioRED_Task1_Doc65	660	672	antithrombin	Gene	462	A novel heterozygous mutation in the gene for antithrombin (single nucleotide T insertion at 7916 and 7917, Glu 272 to stop in exon 4) was identified.
BC8_BioRED_Task1_Doc65	681	720	nucleotide T insertion at 7916 and 7917	SequenceVariant	c|INS|7916_7917|T	A novel heterozygous mutation in the gene for antithrombin (single nucleotide T insertion at 7916 and 7917, Glu 272 to stop in exon 4) was identified.
BC8_BioRED_Task1_Doc65	722	737	Glu 272 to stop	SequenceVariant	p|SUB|E|272|X	A novel heterozygous mutation in the gene for antithrombin (single nucleotide T insertion at 7916 and 7917, Glu 272 to stop in exon 4) was identified.
BC8_BioRED_Task1_Doc65	765	775	Argatroban	Chemical	C031942	Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis.
BC8_BioRED_Task1_Doc65	830	864	congenital antithrombin deficiency	Disease	D020152	Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis.
BC8_BioRED_Task1_Doc65	870	884	SMV thrombosis	Disease	D020246	Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis.
BC8_BioRED_Task1_Doc66	0	30	Manganese superoxide dismutase	Gene	6648	Manganese superoxide dismutase (Mn-SOD) gene polymorphisms in urolithiasis.
BC8_BioRED_Task1_Doc66	32	38	Mn-SOD	Gene	6648	Manganese superoxide dismutase (Mn-SOD) gene polymorphisms in urolithiasis.
BC8_BioRED_Task1_Doc66	62	74	urolithiasis	Disease	D052878	Manganese superoxide dismutase (Mn-SOD) gene polymorphisms in urolithiasis.
BC8_BioRED_Task1_Doc66	92	122	manganese superoxide dismutase	Gene	6648	Polymorphism in manganese superoxide dismutase gene (Mn-SOD) is a new approach to identify its probable association with urolithiasis.
BC8_BioRED_Task1_Doc66	129	135	Mn-SOD	Gene	6648	Polymorphism in manganese superoxide dismutase gene (Mn-SOD) is a new approach to identify its probable association with urolithiasis.
BC8_BioRED_Task1_Doc66	197	209	urolithiasis	Disease	D052878	Polymorphism in manganese superoxide dismutase gene (Mn-SOD) is a new approach to identify its probable association with urolithiasis.
BC8_BioRED_Task1_Doc66	266	281	stone formation	Disease	D002137	Oxidative stress may be involved in the development of stone formation in the renal system.
BC8_BioRED_Task1_Doc66	303	308	MnSOD	Gene	6648	MnSOD is one of the primary enzymes that directly scavenges potential harmful oxidizing species.
BC8_BioRED_Task1_Doc66	402	461	valine (Val) to alanine (Ala) substitution at amino acid 16	SequenceVariant	p|SUB|V|16|A	A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in urolithiasis risk.
BC8_BioRED_Task1_Doc66	520	525	MnSOD	Gene	6648	A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in urolithiasis risk.
BC8_BioRED_Task1_Doc66	572	584	urolithiasis	Disease	D052878	A valine (Val) to alanine (Ala) substitution at amino acid 16, occurring in the mitochondrial targeting sequence of the MnSOD gene, has been associated with an increase in urolithiasis risk.
BC8_BioRED_Task1_Doc66	650	655	MnSOD	Gene	6648	This study was conducted to investigate the association of MnSOD gene polymorphism with the risk of urolithiasis.
BC8_BioRED_Task1_Doc66	691	703	urolithiasis	Disease	D052878	This study was conducted to investigate the association of MnSOD gene polymorphism with the risk of urolithiasis.
BC8_BioRED_Task1_Doc66	725	730	MnSOD	Gene	6648	We investigated the MnSOD in 66 stone-forming adults and 72 healthy volunteers.
BC8_BioRED_Task1_Doc66	737	750	stone-forming	Disease	D002137	We investigated the MnSOD in 66 stone-forming adults and 72 healthy volunteers.
BC8_BioRED_Task1_Doc66	938	945	agarose	Chemical	D012685	Products were run on 3% agarose gel, 246 bp regions were 1-Ala-9, 164 and 82 bp products were determined as 2 Val-9.
BC8_BioRED_Task1_Doc66	1079	1087	patients	OrganismTaxon	9606	Chi-square test was used for comparison between patients and controls.
BC8_BioRED_Task1_Doc66	1186	1193	patient	OrganismTaxon	9606	In the control group the homozygote Ala allele was significantly higher than in the patient group (P < 0.01).
BC8_BioRED_Task1_Doc66	1274	1281	patient	OrganismTaxon	9606	The distribution of Ala/Val and homozygote Val alleles in the patient group was significantly higher than in the control group (P < 0.05).
BC8_BioRED_Task1_Doc66	1351	1356	MnSOD	Gene	6648	MnSOD genotype determination may provide a tool to identify individuals who are at risk of urolithiasis.
BC8_BioRED_Task1_Doc66	1442	1454	urolithiasis	Disease	D052878	MnSOD genotype determination may provide a tool to identify individuals who are at risk of urolithiasis.
BC8_BioRED_Task1_Doc66	1520	1535	stone formation	Disease	D002137	This experiment also provides data about antioxidant status and stone formation.
BC8_BioRED_Task1_Doc67	0	3	MHC	Gene	3123,720	MHC region and risk of systemic lupus erythematosus in African American women.
BC8_BioRED_Task1_Doc67	23	51	systemic lupus erythematosus	Disease	D008180	MHC region and risk of systemic lupus erythematosus in African American women.
BC8_BioRED_Task1_Doc67	72	77	women	OrganismTaxon	9606	MHC region and risk of systemic lupus erythematosus in African American women.
BC8_BioRED_Task1_Doc67	83	115	major histocompatibility complex	Gene	3123,720	The major histocompatibility complex (MHC) on chromosome 6p21 is a key contributor to the genetic basis of systemic lupus erythematosus (SLE).
BC8_BioRED_Task1_Doc67	117	120	MHC	Gene	3123,720	The major histocompatibility complex (MHC) on chromosome 6p21 is a key contributor to the genetic basis of systemic lupus erythematosus (SLE).
BC8_BioRED_Task1_Doc67	186	214	systemic lupus erythematosus	Disease	D008180	The major histocompatibility complex (MHC) on chromosome 6p21 is a key contributor to the genetic basis of systemic lupus erythematosus (SLE).
BC8_BioRED_Task1_Doc67	216	219	SLE	Disease	D008180	The major histocompatibility complex (MHC) on chromosome 6p21 is a key contributor to the genetic basis of systemic lupus erythematosus (SLE).
BC8_BioRED_Task1_Doc67	231	234	SLE	Disease	D008180	Although SLE affects African Americans disproportionately compared to European Americans, there has been no comprehensive analysis of the MHC region in relationship to SLE in African Americans.
BC8_BioRED_Task1_Doc67	360	363	MHC	Gene	3123,720	Although SLE affects African Americans disproportionately compared to European Americans, there has been no comprehensive analysis of the MHC region in relationship to SLE in African Americans.
BC8_BioRED_Task1_Doc67	390	393	SLE	Disease	D008180	Although SLE affects African Americans disproportionately compared to European Americans, there has been no comprehensive analysis of the MHC region in relationship to SLE in African Americans.
BC8_BioRED_Task1_Doc67	448	451	MHC	Gene	3123,720	We conducted a screening of the MHC region for 1,536 single nucleotide polymorphisms (SNPs) and the deletion of the C4A gene in a SLE case-control study (380 cases, 765 age-matched controls) nested within the prospective Black Women's Health Study.
BC8_BioRED_Task1_Doc67	532	535	C4A	Gene	720	We conducted a screening of the MHC region for 1,536 single nucleotide polymorphisms (SNPs) and the deletion of the C4A gene in a SLE case-control study (380 cases, 765 age-matched controls) nested within the prospective Black Women's Health Study.
BC8_BioRED_Task1_Doc67	546	549	SLE	Disease	D008180	We conducted a screening of the MHC region for 1,536 single nucleotide polymorphisms (SNPs) and the deletion of the C4A gene in a SLE case-control study (380 cases, 765 age-matched controls) nested within the prospective Black Women's Health Study.
BC8_BioRED_Task1_Doc67	643	648	Women	OrganismTaxon	9606	We conducted a screening of the MHC region for 1,536 single nucleotide polymorphisms (SNPs) and the deletion of the C4A gene in a SLE case-control study (380 cases, 765 age-matched controls) nested within the prospective Black Women's Health Study.
BC8_BioRED_Task1_Doc67	879	882	SLE	Disease	D008180	The most strongly associated SNP with SLE was the rs9271366 (odds ratio, OR = 1.70, p = 5.6 10(-5)) near the HLA-DRB1 gene.
BC8_BioRED_Task1_Doc67	891	900	rs9271366	SequenceVariant	rs9271366	The most strongly associated SNP with SLE was the rs9271366 (odds ratio, OR = 1.70, p = 5.6 10(-5)) near the HLA-DRB1 gene.
BC8_BioRED_Task1_Doc67	950	958	HLA-DRB1	Gene	3123	The most strongly associated SNP with SLE was the rs9271366 (odds ratio, OR = 1.70, p = 5.6 10(-5)) near the HLA-DRB1 gene.
BC8_BioRED_Task1_Doc67	1023	1031	rs204890	SequenceVariant	rs204890	Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with SLE independent of the rs9271366 SNP.
BC8_BioRED_Task1_Doc67	1061	1070	rs2071349	SequenceVariant	rs2071349	Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with SLE independent of the rs9271366 SNP.
BC8_BioRED_Task1_Doc67	1104	1113	rs2844580	SequenceVariant	rs2844580	Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with SLE independent of the rs9271366 SNP.
BC8_BioRED_Task1_Doc67	1165	1168	SLE	Disease	D008180	Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with SLE independent of the rs9271366 SNP.
BC8_BioRED_Task1_Doc67	1188	1197	rs9271366	SequenceVariant	rs9271366	Conditional haplotype analysis revealed three other SNPs, rs204890 (OR = 1.86, p = 1.2 10(-4)), rs2071349 (OR = 1.53, p = 1.0 10(-3)), and rs2844580 (OR = 1.43, p = 1.3 10(-3)), to be associated with SLE independent of the rs9271366 SNP.
BC8_BioRED_Task1_Doc67	1242	1245	C4A	Gene	720	In univariate analysis, the OR for the C4A deletion was 1.38, p = 0.075, but after simultaneous adjustment for the other four SNPs the odds ratio was 1.01, p = 0.98.
BC8_BioRED_Task1_Doc67	1568	1577	rs9271366	SequenceVariant	rs9271366	Our strongest signal, the rs9271366 SNP, was also associated with higher risk of SLE in a previous Chinese genome-wide association study (GWAS).
BC8_BioRED_Task1_Doc67	1623	1626	SLE	Disease	D008180	Our strongest signal, the rs9271366 SNP, was also associated with higher risk of SLE in a previous Chinese genome-wide association study (GWAS).
BC8_BioRED_Task1_Doc67	1746	1751	women	OrganismTaxon	9606	In addition, two SNPs found in a GWAS of European ancestry women were confirmed in our study, indicating that African Americans share some genetic risk factors for SLE with European and Chinese subjects.
BC8_BioRED_Task1_Doc67	1851	1854	SLE	Disease	D008180	In addition, two SNPs found in a GWAS of European ancestry women were confirmed in our study, indicating that African Americans share some genetic risk factors for SLE with European and Chinese subjects.
BC8_BioRED_Task1_Doc67	1944	1947	MHC	Gene	3123,720	In summary, we found four independent signals in the MHC region associated with risk of SLE in African American women.
BC8_BioRED_Task1_Doc67	1979	1982	SLE	Disease	D008180	In summary, we found four independent signals in the MHC region associated with risk of SLE in African American women.
BC8_BioRED_Task1_Doc67	2003	2008	women	OrganismTaxon	9606	In summary, we found four independent signals in the MHC region associated with risk of SLE in African American women.
BC8_BioRED_Task1_Doc68	31	39	levodopa	Chemical	D007980	Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
BC8_BioRED_Task1_Doc68	48	58	dyskinesia	Disease	D004409	Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
BC8_BioRED_Task1_Doc68	93	112	Parkinson's disease	Disease	D010300	Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
BC8_BioRED_Task1_Doc68	132	140	levodopa	Chemical	D007980	Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
BC8_BioRED_Task1_Doc68	153	172	Parkinson's disease	Disease	D010300	Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
BC8_BioRED_Task1_Doc68	174	176	PD	Disease	D010300	Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
BC8_BioRED_Task1_Doc68	229	239	dyskinesia	Disease	D004409	Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
BC8_BioRED_Task1_Doc68	285	293	levodopa	Chemical	D007980	We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
BC8_BioRED_Task1_Doc68	302	312	dyskinesia	Disease	D004409	We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
BC8_BioRED_Task1_Doc68	341	349	patients	OrganismTaxon	9606	We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
BC8_BioRED_Task1_Doc68	355	357	PD	Disease	D010300	We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.
BC8_BioRED_Task1_Doc68	413	421	patients	OrganismTaxon	9606	METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.
BC8_BioRED_Task1_Doc68	427	429	PD	Disease	D010300	METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.
BC8_BioRED_Task1_Doc68	447	455	levodopa	Chemical	D007980	METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.
BC8_BioRED_Task1_Doc68	555	565	dyskinesia	Disease	D004409	The predictors of dyskinesia were determined using multivariate logistic regression analysis.
BC8_BioRED_Task1_Doc68	761	771	Dyskinesia	Disease	D004409	Dyskinesia was present in 44% (n = 42) with median levodopa therapy of 3 years.
BC8_BioRED_Task1_Doc68	812	820	levodopa	Chemical	D007980	Dyskinesia was present in 44% (n = 42) with median levodopa therapy of 3 years.
BC8_BioRED_Task1_Doc68	943	951	patients	OrganismTaxon	9606	Eighty-one percent of patients with dyskinesia had clinical fluctuations.
BC8_BioRED_Task1_Doc68	957	967	dyskinesia	Disease	D004409	Eighty-one percent of patients with dyskinesia had clinical fluctuations.
BC8_BioRED_Task1_Doc68	995	1003	Patients	OrganismTaxon	9606	Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
BC8_BioRED_Task1_Doc68	1009	1019	dyskinesia	Disease	D004409	Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
BC8_BioRED_Task1_Doc68	1073	1081	levodopa	Chemical	D007980	Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
BC8_BioRED_Task1_Doc68	1161	1169	levodopa	Chemical	D007980	Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
BC8_BioRED_Task1_Doc68	1237	1245	patients	OrganismTaxon	9606	Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
BC8_BioRED_Task1_Doc68	1254	1264	dyskinesia	Disease	D004409	Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
BC8_BioRED_Task1_Doc68	1302	1312	dyskinesia	Disease	D004409	The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.
BC8_BioRED_Task1_Doc68	1330	1338	levodopa	Chemical	D007980	The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.
BC8_BioRED_Task1_Doc68	1375	1383	levodopa	Chemical	D007980	The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.
BC8_BioRED_Task1_Doc68	1421	1429	levodopa	Chemical	D007980	CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.
BC8_BioRED_Task1_Doc68	1438	1448	dyskinesia	Disease	D004409	CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.
BC8_BioRED_Task1_Doc68	1456	1464	patients	OrganismTaxon	9606	CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.
BC8_BioRED_Task1_Doc68	1523	1531	levodopa	Chemical	D007980	The most significant predictors were duration of levodopa therapy, total daily levodopa dose, and onset age.
BC8_BioRED_Task1_Doc68	1553	1561	levodopa	Chemical	D007980	The most significant predictors were duration of levodopa therapy, total daily levodopa dose, and onset age.
BC8_BioRED_Task1_Doc69	0	10	Bortezomib	Chemical	D000069286	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
BC8_BioRED_Task1_Doc69	15	28	dexamethasone	Chemical	D003907	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
BC8_BioRED_Task1_Doc69	51	59	patients	OrganismTaxon	9606	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
BC8_BioRED_Task1_Doc69	85	101	multiple myeloma	Disease	D009101	Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
BC8_BioRED_Task1_Doc69	144	154	Bortezomib	Chemical	D000069286	Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
BC8_BioRED_Task1_Doc69	156	160	bort	Chemical	D000069286	Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
BC8_BioRED_Task1_Doc69	162	175	dexamethasone	Chemical	D003907	Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
BC8_BioRED_Task1_Doc69	177	180	dex	Chemical	D003907	Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
BC8_BioRED_Task1_Doc69	236	252	multiple myeloma	Disease	D009101	Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
BC8_BioRED_Task1_Doc69	254	256	MM	Disease	D009101	Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
BC8_BioRED_Task1_Doc69	316	320	bort	Chemical	D000069286	This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
BC8_BioRED_Task1_Doc69	377	380	dex	Chemical	D003907	This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
BC8_BioRED_Task1_Doc69	420	424	bort	Chemical	D000069286	This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
BC8_BioRED_Task1_Doc69	453	461	patients	OrganismTaxon	9606	This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
BC8_BioRED_Task1_Doc69	471	473	MM	Disease	D009101	This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
BC8_BioRED_Task1_Doc69	632	640	patients	OrganismTaxon	9606	Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort-dex.
BC8_BioRED_Task1_Doc69	717	721	bort	Chemical	D000069286	Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort-dex.
BC8_BioRED_Task1_Doc69	722	725	dex	Chemical	D003907	Eighty-seven percent of the patients had received immunomodulatory drugs included in some line of therapy before bort-dex.
BC8_BioRED_Task1_Doc69	748	752	bort	Chemical	D000069286	The median number of bort-dex cycles was 6, up to a maximum of 12 cycles.
BC8_BioRED_Task1_Doc69	753	756	dex	Chemical	D003907	The median number of bort-dex cycles was 6, up to a maximum of 12 cycles.
BC8_BioRED_Task1_Doc69	845	853	patients	OrganismTaxon	9606	On an intention-to-treat basis, 55 % of the patients achieved at least partial response, including 19 % CR and 35 % achieved at least very good partial response.
BC8_BioRED_Task1_Doc69	1122	1143	peripheral neuropathy	Disease	D010523	The most relevant adverse event was peripheral neuropathy, which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %.
BC8_BioRED_Task1_Doc69	1175	1183	patients	OrganismTaxon	9606	The most relevant adverse event was peripheral neuropathy, which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %.
BC8_BioRED_Task1_Doc69	1469	1477	patients	OrganismTaxon	9606	Prolonged PFS and OS were observed in patients achieving CR and receiving bort-dex a single line of prior therapy.
BC8_BioRED_Task1_Doc69	1505	1509	bort	Chemical	D000069286	Prolonged PFS and OS were observed in patients achieving CR and receiving bort-dex a single line of prior therapy.
BC8_BioRED_Task1_Doc69	1510	1513	dex	Chemical	D003907	Prolonged PFS and OS were observed in patients achieving CR and receiving bort-dex a single line of prior therapy.
BC8_BioRED_Task1_Doc69	1546	1550	Bort	Chemical	D000069286	Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
BC8_BioRED_Task1_Doc69	1551	1554	dex	Chemical	D003907	Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
BC8_BioRED_Task1_Doc69	1594	1596	MM	Disease	D009101	Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
BC8_BioRED_Task1_Doc69	1597	1605	patients	OrganismTaxon	9606	Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.
BC8_BioRED_Task1_Doc70	0	14	5-Fluorouracil	Chemical	D005472	5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
BC8_BioRED_Task1_Doc70	15	29	cardiotoxicity	Disease	D066126	5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
BC8_BioRED_Task1_Doc70	41	66	alpha-fluoro-beta-alanine	Chemical	C032348	5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
BC8_BioRED_Task1_Doc70	68	82	Cardiotoxicity	Disease	D066126	Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
BC8_BioRED_Task1_Doc70	123	137	5-fluorouracil	Chemical	D005472	Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
BC8_BioRED_Task1_Doc70	139	143	5-FU	Chemical	D005472	Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
BC8_BioRED_Task1_Doc70	159	171	malignancies	Disease	D009369	Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
BC8_BioRED_Task1_Doc70	216	219	man	OrganismTaxon	9606	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
BC8_BioRED_Task1_Doc70	225	229	5-FU	Chemical	D005472	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
BC8_BioRED_Task1_Doc70	238	252	cardiotoxicity	Disease	D066126	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
BC8_BioRED_Task1_Doc70	284	309	alpha-fluoro-beta-alanine	Chemical	C032348	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
BC8_BioRED_Task1_Doc70	311	315	FBAL	Chemical	C032348	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
BC8_BioRED_Task1_Doc70	335	342	patient	OrganismTaxon	9606	The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history.
BC8_BioRED_Task1_Doc70	365	377	colon cancer	Disease	D003110	The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history.
BC8_BioRED_Task1_Doc70	378	388	metastases	Disease	D009362	The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history.
BC8_BioRED_Task1_Doc70	525	532	patient	OrganismTaxon	9606	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
BC8_BioRED_Task1_Doc70	579	583	5-FU	Chemical	D005472	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
BC8_BioRED_Task1_Doc70	612	627	precordial pain	Disease	D002637	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
BC8_BioRED_Task1_Doc70	633	658	right bundle branch block	Disease	D002037	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
BC8_BioRED_Task1_Doc70	700	704	FBAL	Chemical	C032348	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
BC8_BioRED_Task1_Doc70	743	758	precordial pain	Disease	D002637	Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.
BC8_BioRED_Task1_Doc70	851	855	5-FU	Chemical	D005472	Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.
BC8_BioRED_Task1_Doc70	864	879	precordial pain	Disease	D002637	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
BC8_BioRED_Task1_Doc70	888	895	patient	OrganismTaxon	9606	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
BC8_BioRED_Task1_Doc70	931	935	5-FU	Chemical	D005472	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
BC8_BioRED_Task1_Doc70	944	958	cardiotoxicity	Disease	D066126	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
BC8_BioRED_Task1_Doc70	982	986	5-FU	Chemical	D005472	As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.
BC8_BioRED_Task1_Doc70	1034	1037	S-1	Chemical	C079198	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL.
BC8_BioRED_Task1_Doc70	1055	1059	5-FU	Chemical	D005472	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL.
BC8_BioRED_Task1_Doc70	1114	1117	S-1	Chemical	C079198	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL.
BC8_BioRED_Task1_Doc70	1152	1169	dihydropyrimidine	Chemical	-	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL.
BC8_BioRED_Task1_Doc70	1220	1224	5-FU	Chemical	D005472	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL.
BC8_BioRED_Task1_Doc70	1230	1234	FBAL	Chemical	C032348	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL.
BC8_BioRED_Task1_Doc70	1246	1250	FBAL	Chemical	C032348	The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration.
BC8_BioRED_Task1_Doc70	1353	1356	S-1	Chemical	C079198	The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration.
BC8_BioRED_Task1_Doc70	1388	1404	cardiac symptoms	Disease	D006331	Thereafter, no cardiac symptoms were observed.
BC8_BioRED_Task1_Doc70	1424	1431	patient	OrganismTaxon	9606	The patient achieved a partial response 6 months after the initiation of the S-1 treatment.
BC8_BioRED_Task1_Doc70	1497	1500	S-1	Chemical	C079198	The patient achieved a partial response 6 months after the initiation of the S-1 treatment.
BC8_BioRED_Task1_Doc70	1597	1601	FBAL	Chemical	C032348	The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc70	1616	1620	5-FU	Chemical	D005472	The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc70	1629	1643	cardiotoxicity	Disease	D066126	The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc70	1645	1648	S-1	Chemical	C079198	S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc70	1679	1687	patients	OrganismTaxon	9606	S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc70	1693	1697	5-FU	Chemical	D005472	S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc70	1706	1720	cardiotoxicity	Disease	D066126	S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
BC8_BioRED_Task1_Doc71	12	31	Fatty Acid Synthase	Gene	2194	Circulating Fatty Acid Synthase in pregnant women: Relationship to blood pressure, maternal metabolism and newborn parameters.
BC8_BioRED_Task1_Doc71	44	49	women	OrganismTaxon	9606	Circulating Fatty Acid Synthase in pregnant women: Relationship to blood pressure, maternal metabolism and newborn parameters.
BC8_BioRED_Task1_Doc71	138	142	FASN	Gene	2194	The enzyme FASN (fatty acid synthase) is potentially related with hypertension and metabolic dysfunction.
BC8_BioRED_Task1_Doc71	144	163	fatty acid synthase	Gene	2194	The enzyme FASN (fatty acid synthase) is potentially related with hypertension and metabolic dysfunction.
BC8_BioRED_Task1_Doc71	193	205	hypertension	Disease	D006973	The enzyme FASN (fatty acid synthase) is potentially related with hypertension and metabolic dysfunction.
BC8_BioRED_Task1_Doc71	210	231	metabolic dysfunction	Disease	D008659	The enzyme FASN (fatty acid synthase) is potentially related with hypertension and metabolic dysfunction.
BC8_BioRED_Task1_Doc71	233	237	FASN	Gene	2194	FASN is highly expressed in the human placenta.
BC8_BioRED_Task1_Doc71	265	270	human	OrganismTaxon	9606	FASN is highly expressed in the human placenta.
BC8_BioRED_Task1_Doc71	334	338	FASN	Gene	2194	We aimed to investigate the relationship circulating FASN has with blood pressure, maternal metabolism and newborn parameters in healthy pregnant women.
BC8_BioRED_Task1_Doc71	427	432	women	OrganismTaxon	9606	We aimed to investigate the relationship circulating FASN has with blood pressure, maternal metabolism and newborn parameters in healthy pregnant women.
BC8_BioRED_Task1_Doc71	446	450	FASN	Gene	2194	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	493	498	women	OrganismTaxon	9606	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	547	556	C-peptide	Chemical	D002096	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	566	573	glucose	Chemical	D005947	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	578	585	insulin	Gene	3630	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	597	604	glucose	Chemical	D005947	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	605	611	lipids	Chemical	D008055	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	613	616	HMW	Gene	57587	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	617	628	adiponectin	Gene	9370	Circulating FASN was assessed in 115 asymptomatic pregnant women in the second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation).
BC8_BioRED_Task1_Doc71	753	757	FASN	Gene	2194	FASN expression was also able to be assessed in 80 placentas.
BC8_BioRED_Task1_Doc71	834	838	FASN	Gene	2194	Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).
BC8_BioRED_Task1_Doc71	954	961	glucose	Chemical	D005947	Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).
BC8_BioRED_Task1_Doc71	966	973	insulin	Gene	3630	Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).
BC8_BioRED_Task1_Doc71	985	992	glucose	Chemical	D005947	Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).
BC8_BioRED_Task1_Doc71	994	999	HbAc1	Gene	3043	Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).
BC8_BioRED_Task1_Doc71	1013	1022	C-peptide	Chemical	D002096	Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001).
BC8_BioRED_Task1_Doc71	1106	1110	FASN	Gene	2194	Placental FASN expression related positively to circulating FASN (p < 0.005) and negatively to placental weight (p < 0.05).
BC8_BioRED_Task1_Doc71	1156	1160	FASN	Gene	2194	Placental FASN expression related positively to circulating FASN (p < 0.005) and negatively to placental weight (p < 0.05).
BC8_BioRED_Task1_Doc71	1279	1283	FASN	Gene	2194	Our observations suggest a physiological role of placental FASN in human pregnancy.
BC8_BioRED_Task1_Doc71	1287	1292	human	OrganismTaxon	9606	Our observations suggest a physiological role of placental FASN in human pregnancy.
BC8_BioRED_Task1_Doc71	1352	1356	FASN	Gene	2194	Future studies will clarify whether circulating FASN of placental origin does actually regulate placental and fetal growth, and (thereby) has a favourable influence on the pregnant mother's insulin sensitivity and blood pressure.
BC8_BioRED_Task1_Doc71	1494	1501	insulin	Gene	3630	Future studies will clarify whether circulating FASN of placental origin does actually regulate placental and fetal growth, and (thereby) has a favourable influence on the pregnant mother's insulin sensitivity and blood pressure.
BC8_BioRED_Task1_Doc72	107	126	Parkinson's disease	Disease	D010300	A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.
BC8_BioRED_Task1_Doc72	128	130	PD	Disease	D010300	A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.
BC8_BioRED_Task1_Doc72	271	273	PD	Disease	D010300	Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.
BC8_BioRED_Task1_Doc72	666	668	PD	Disease	D010300	According to the literature pallidotomy improves the "on" symptoms of PD, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.
BC8_BioRED_Task1_Doc72	678	689	dyskinesias	Disease	D004409	According to the literature pallidotomy improves the "on" symptoms of PD, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.
BC8_BioRED_Task1_Doc72	730	738	rigidity	Disease	D009127	According to the literature pallidotomy improves the "on" symptoms of PD, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.
BC8_BioRED_Task1_Doc72	740	752	bradykinesia	Disease	D018476	According to the literature pallidotomy improves the "on" symptoms of PD, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.
BC8_BioRED_Task1_Doc72	809	821	bradykinesia	Disease	D018476	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc72	826	834	rigidity	Disease	D009127	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc72	901	909	levodopa	Chemical	D007980	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc72	918	929	dyskinesias	Disease	D004409	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc72	980	1000	hyper- or dyskinetic	Disease	D004409,D006948	Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the "freezing" phenomenon in the lower limbs at the same time.
BC8_BioRED_Task1_Doc72	1129	1136	patient	OrganismTaxon	9606	Considering the small increase in the patient's independence, the high costs of bilateral implants, and the difficulty most patients experience in handling the devices, the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy.
BC8_BioRED_Task1_Doc72	1215	1223	patients	OrganismTaxon	9606	Considering the small increase in the patient's independence, the high costs of bilateral implants, and the difficulty most patients experience in handling the devices, the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy.
BC8_BioRED_Task1_Doc73	0	13	Isoproterenol	Chemical	D007545	Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.
BC8_BioRED_Task1_Doc73	38	48	dystrophin	Gene	24907	Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.
BC8_BioRED_Task1_Doc73	52	55	rat	OrganismTaxon	10116	Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.
BC8_BioRED_Task1_Doc73	81	98	myocardial injury	Disease	D009202	Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.
BC8_BioRED_Task1_Doc73	117	130	isoproterenol	Chemical	D007545	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
BC8_BioRED_Task1_Doc73	139	156	myocardial damage	Disease	D009202	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
BC8_BioRED_Task1_Doc73	187	193	oxygen	Chemical	D010100	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
BC8_BioRED_Task1_Doc73	231	242	hypotension	Disease	D007022	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
BC8_BioRED_Task1_Doc73	247	271	myocardial hyperactivity	Disease	D009202	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
BC8_BioRED_Task1_Doc73	470	483	isoproterenol	Chemical	D007545	Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
BC8_BioRED_Task1_Doc73	557	567	dystrophin	Gene	24907	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.
BC8_BioRED_Task1_Doc73	568	580	glycoprotein	Gene	11820	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.
BC8_BioRED_Task1_Doc73	609	614	actin	Gene	60	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.
BC8_BioRED_Task1_Doc73	619	626	laminin	Gene	309368	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.
BC8_BioRED_Task1_Doc73	732	745	isoproterenol	Chemical	D007545	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.
BC8_BioRED_Task1_Doc73	876	889	isoproterenol	Chemical	D007545	We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.
BC8_BioRED_Task1_Doc73	960	970	dystrophin	Gene	24907	Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix.
BC8_BioRED_Task1_Doc73	1029	1034	actin	Gene	60	Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix.
BC8_BioRED_Task1_Doc73	1114	1119	actin	Gene	60	The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin.
BC8_BioRED_Task1_Doc73	1172	1182	dystrophin	Gene	24907	The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin.
BC8_BioRED_Task1_Doc73	1227	1244	gamma-sarcoglycan	Gene	305941	Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.
BC8_BioRED_Task1_Doc73	1246	1263	beta-dystroglycan	Gene	114489	Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.
BC8_BioRED_Task1_Doc73	1265	1279	beta1-integrin	Gene	24511	Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.
BC8_BioRED_Task1_Doc73	1285	1300	laminin alpha-2	Gene	309368	Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.
BC8_BioRED_Task1_Doc73	1433	1446	isoproterenol	Chemical	D007545	In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.
BC8_BioRED_Task1_Doc73	1450	1454	rats	OrganismTaxon	10116	In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.
BC8_BioRED_Task1_Doc73	1482	1492	dystrophin	Gene	24907	In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.
BC8_BioRED_Task1_Doc73	1665	1681	ischaemic injury	Disease	D007511	These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.
BC8_BioRED_Task1_Doc73	1830	1843	isoproterenol	Chemical	D007545	These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.
BC8_BioRED_Task1_Doc74	25	40	cytomegalovirus	OrganismTaxon	10358	Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
BC8_BioRED_Task1_Doc74	55	62	patient	OrganismTaxon	9606	Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
BC8_BioRED_Task1_Doc74	68	76	lymphoma	Disease	D008223	Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
BC8_BioRED_Task1_Doc74	120	150	Long-term anti-cytomegalovirus	Disease	D003586	BACKGROUND: Long-term anti-cytomegalovirus (CMV) treatments in immunocompromised patients are hampered by resistance to antiviral drugs.
BC8_BioRED_Task1_Doc74	152	155	CMV	Disease	D003586	BACKGROUND: Long-term anti-cytomegalovirus (CMV) treatments in immunocompromised patients are hampered by resistance to antiviral drugs.
BC8_BioRED_Task1_Doc74	189	197	patients	OrganismTaxon	9606	BACKGROUND: Long-term anti-cytomegalovirus (CMV) treatments in immunocompromised patients are hampered by resistance to antiviral drugs.
BC8_BioRED_Task1_Doc74	359	362	CMV	Disease	D003586	Longitudinal changes in the resistance genotype may depend on changes in selective pressure and the complexity of CMV isolates.
BC8_BioRED_Task1_Doc74	424	427	CMV	Disease	D003586	OBJECTIVE: To evaluate longitudinal changes in the CMV resistance genotype and phenotype along with strain-specific variability in a patient with non-Hodgkin's lymphoma in whom successive anti-CMV treatments failed.
BC8_BioRED_Task1_Doc74	506	513	patient	OrganismTaxon	9606	OBJECTIVE: To evaluate longitudinal changes in the CMV resistance genotype and phenotype along with strain-specific variability in a patient with non-Hodgkin's lymphoma in whom successive anti-CMV treatments failed.
BC8_BioRED_Task1_Doc74	519	541	non-Hodgkin's lymphoma	Disease	D008228	OBJECTIVE: To evaluate longitudinal changes in the CMV resistance genotype and phenotype along with strain-specific variability in a patient with non-Hodgkin's lymphoma in whom successive anti-CMV treatments failed.
BC8_BioRED_Task1_Doc74	566	569	CMV	Disease	D003586	OBJECTIVE: To evaluate longitudinal changes in the CMV resistance genotype and phenotype along with strain-specific variability in a patient with non-Hodgkin's lymphoma in whom successive anti-CMV treatments failed.
BC8_BioRED_Task1_Doc74	650	653	CMV	Disease	D003586	STUDY DESIGN: The resistance phenotype and genotype of seven CMV isolates collected from one patient during a 2-year follow-up period were retrospectively analysed.
BC8_BioRED_Task1_Doc74	682	689	patient	OrganismTaxon	9606	STUDY DESIGN: The resistance phenotype and genotype of seven CMV isolates collected from one patient during a 2-year follow-up period were retrospectively analysed.
BC8_BioRED_Task1_Doc74	775	789	glycoprotein B	Gene	2813	In parallel, we used glycoprotein B (gB) genotyping, and a- and UL10-13-sequence analysis to study CMV interstrain variability.
BC8_BioRED_Task1_Doc74	791	793	gB	Gene	2813	In parallel, we used glycoprotein B (gB) genotyping, and a- and UL10-13-sequence analysis to study CMV interstrain variability.
BC8_BioRED_Task1_Doc74	853	856	CMV	Disease	D003586	In parallel, we used glycoprotein B (gB) genotyping, and a- and UL10-13-sequence analysis to study CMV interstrain variability.
BC8_BioRED_Task1_Doc74	895	902	patient	OrganismTaxon	9606	RESULTS: The patient was infected by at least three CMV strains plus variants of the parental strains.
BC8_BioRED_Task1_Doc74	934	937	CMV	Disease	D003586	RESULTS: The patient was infected by at least three CMV strains plus variants of the parental strains.
BC8_BioRED_Task1_Doc74	999	1010	ganciclovir	Chemical	D015774	Resistance to ganciclovir, cidofovir and foscarnet was successively detected during the follow-up period.
BC8_BioRED_Task1_Doc74	1012	1021	cidofovir	Chemical	D000077404	Resistance to ganciclovir, cidofovir and foscarnet was successively detected during the follow-up period.
BC8_BioRED_Task1_Doc74	1026	1035	foscarnet	Chemical	D017245	Resistance to ganciclovir, cidofovir and foscarnet was successively detected during the follow-up period.
BC8_BioRED_Task1_Doc74	1091	1110	UL97 protein kinase	Gene	3077517	UL97 protein kinase changes responsible for resistance to ganciclovir were initially detected at residues 591 and 592, and then at position 594.
BC8_BioRED_Task1_Doc74	1149	1160	ganciclovir	Chemical	D015774	UL97 protein kinase changes responsible for resistance to ganciclovir were initially detected at residues 591 and 592, and then at position 594.
BC8_BioRED_Task1_Doc74	1261	1270	foscarnet	Chemical	D017245	Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.
BC8_BioRED_Task1_Doc74	1328	1333	N495K	SequenceVariant	p|SUB|N|495|K	Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.
BC8_BioRED_Task1_Doc74	1381	1392	ganciclovir	Chemical	D015774	Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.
BC8_BioRED_Task1_Doc74	1397	1406	cidofovir	Chemical	D000077404	Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.
BC8_BioRED_Task1_Doc74	1422	1427	L501I	SequenceVariant	p|SUB|L|501|I	Decreased sensitivity to foscarnet coincided with the appearance of amino acid substitution N495K in DNA polymerase, whereas cross-resistance to ganciclovir and cidofovir was due to the L501I substitution.
BC8_BioRED_Task1_Doc74	1459	1462	CMV	Disease	D003586	CONCLUSIONS: The CMV isolates obtained from our patient were complex mixtures of strains.
BC8_BioRED_Task1_Doc74	1490	1497	patient	OrganismTaxon	9606	CONCLUSIONS: The CMV isolates obtained from our patient were complex mixtures of strains.
BC8_BioRED_Task1_Doc75	0	10	Sildenafil	Chemical	D000068677	Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells.
BC8_BioRED_Task1_Doc75	22	51	hypoxic pulmonary remodelling	Disease	D066253	Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells.
BC8_BioRED_Task1_Doc75	183	204	pulmonary remodelling	Disease	D066253	The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary remodelling and the pathogenesis of pulmonary hypertension (PH).
BC8_BioRED_Task1_Doc75	229	251	pulmonary hypertension	Disease	D006976	The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary remodelling and the pathogenesis of pulmonary hypertension (PH).
BC8_BioRED_Task1_Doc75	253	255	PH	Disease	D006976	The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary remodelling and the pathogenesis of pulmonary hypertension (PH).
BC8_BioRED_Task1_Doc75	267	277	sildenafil	Chemical	D000068677	Although sildenafil is a known target in PH treatment, the underlying molecular mechanism is still elusive.
BC8_BioRED_Task1_Doc75	299	301	PH	Disease	D006976	Although sildenafil is a known target in PH treatment, the underlying molecular mechanism is still elusive.
BC8_BioRED_Task1_Doc75	420	430	sildenafil	Chemical	D000068677	To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.
BC8_BioRED_Task1_Doc75	511	532	pulmonary remodelling	Disease	D066253	To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.
BC8_BioRED_Task1_Doc75	536	540	rats	OrganismTaxon	10116	To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.
BC8_BioRED_Task1_Doc75	573	580	hypoxia	Disease	D000860	To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.
BC8_BioRED_Task1_Doc75	582	584	CH	Disease	D000860	To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.
BC8_BioRED_Task1_Doc75	590	596	oxygen	Chemical	D010100	To test the hypothesis that the therapeutic effect of sildenafil is linked to the reduced recruitment of BM-derived progenitor cells, we induced pulmonary remodelling in rats by two-week exposure to chronic hypoxia (CH, 10% oxygen), a trigger of BM-derived progenitor cells.
BC8_BioRED_Task1_Doc75	641	645	Rats	OrganismTaxon	10116	Rats were treated with either placebo (saline) or sildenafil (1.4 mg/kg/day ip) during CH.
BC8_BioRED_Task1_Doc75	691	701	sildenafil	Chemical	D000068677	Rats were treated with either placebo (saline) or sildenafil (1.4 mg/kg/day ip) during CH.
BC8_BioRED_Task1_Doc75	728	730	CH	Disease	D000860	Rats were treated with either placebo (saline) or sildenafil (1.4 mg/kg/day ip) during CH.
BC8_BioRED_Task1_Doc75	740	744	rats	OrganismTaxon	10116	Control rats were kept in room air (21% oxygen) with no treatment.
BC8_BioRED_Task1_Doc75	772	778	oxygen	Chemical	D010100	Control rats were kept in room air (21% oxygen) with no treatment.
BC8_BioRED_Task1_Doc75	812	822	sildenafil	Chemical	D000068677	As expected, sildenafil attenuated the CH-induced increase in right ventricular systolic pressure and right ventricular hypertrophy.
BC8_BioRED_Task1_Doc75	838	840	CH	Disease	D000860	As expected, sildenafil attenuated the CH-induced increase in right ventricular systolic pressure and right ventricular hypertrophy.
BC8_BioRED_Task1_Doc75	901	930	right ventricular hypertrophy	Disease	D017380	As expected, sildenafil attenuated the CH-induced increase in right ventricular systolic pressure and right ventricular hypertrophy.
BC8_BioRED_Task1_Doc75	941	951	sildenafil	Chemical	D000068677	However, sildenafil suppressed the CH-induced increase in c-kit(+) cells in the adventitia of pulmonary arteries.
BC8_BioRED_Task1_Doc75	967	969	CH	Disease	D000860	However, sildenafil suppressed the CH-induced increase in c-kit(+) cells in the adventitia of pulmonary arteries.
BC8_BioRED_Task1_Doc75	990	995	c-kit	Gene	64030	However, sildenafil suppressed the CH-induced increase in c-kit(+) cells in the adventitia of pulmonary arteries.
BC8_BioRED_Task1_Doc75	1056	1066	sildenafil	Chemical	D000068677	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1089	1094	c-kit	Gene	64030	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1125	1151	tyrosine kinase receptor 2	Gene	25589	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1153	1160	VEGF-R2	Gene	25589	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1166	1170	CD68	Gene	287435	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1242	1249	hypoxia	Disease	D000860	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1295	1307	inflammation	Disease	D007249	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1350	1383	hypoxia-inducible factor (HIF)-1a	Gene	29560	Moreover, sildenafil reduced the number of c-kit(+) cells that colocalize with tyrosine kinase receptor 2 (VEGF-R2) and CD68 (a marker for macrophages), indicating a positive effect on moderating hypoxia-induced smooth muscle cell proliferation and inflammation without affecting the pulmonary levels of hypoxia-inducible factor (HIF)-1a.
BC8_BioRED_Task1_Doc75	1398	1408	sildenafil	Chemical	D000068677	Furthermore, sildenafil depressed the number of CXCR4(+) cells.
BC8_BioRED_Task1_Doc75	1433	1438	CXCR4	Gene	60628	Furthermore, sildenafil depressed the number of CXCR4(+) cells.
BC8_BioRED_Task1_Doc75	1537	1547	sildenafil	Chemical	D000068677	Collectively, these findings indicate that the improvement in pulmonary haemodynamic by sildenafil is linked to decreased recruitment of BM-derived c-kit(+) cells in the pulmonary tissue.
BC8_BioRED_Task1_Doc75	1597	1602	c-kit	Gene	64030	Collectively, these findings indicate that the improvement in pulmonary haemodynamic by sildenafil is linked to decreased recruitment of BM-derived c-kit(+) cells in the pulmonary tissue.
BC8_BioRED_Task1_Doc75	1686	1691	c-kit	Gene	64030	The attenuation of the recruitment of BM-derived c-kit(+) cells by sildenafil may provide novel therapeutic insights into the control of pulmonary remodelling.
BC8_BioRED_Task1_Doc75	1704	1714	sildenafil	Chemical	D000068677	The attenuation of the recruitment of BM-derived c-kit(+) cells by sildenafil may provide novel therapeutic insights into the control of pulmonary remodelling.
BC8_BioRED_Task1_Doc75	1774	1795	pulmonary remodelling	Disease	D066253	The attenuation of the recruitment of BM-derived c-kit(+) cells by sildenafil may provide novel therapeutic insights into the control of pulmonary remodelling.
BC8_BioRED_Task1_Doc76	16	26	chemokines	Gene	3576,6347,6348,6351,6352,6374	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.
BC8_BioRED_Task1_Doc76	27	31	CCL4	Gene	6351	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.
BC8_BioRED_Task1_Doc76	36	40	CCL5	Gene	6352	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.
BC8_BioRED_Task1_Doc76	44	53	cirrhotic	Disease	D008103	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.
BC8_BioRED_Task1_Doc76	54	62	patients	OrganismTaxon	9606	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.
BC8_BioRED_Task1_Doc76	88	112	hepatocellular carcinoma	Disease	D006528	Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.
BC8_BioRED_Task1_Doc76	131	156	hepatocellular carcinomas	Disease	D006528	BACKGROUND: Most hepatocellular carcinomas (HCCs) are diagnosed at an advanced stage.
BC8_BioRED_Task1_Doc76	158	162	HCCs	Disease	D006528	BACKGROUND: Most hepatocellular carcinomas (HCCs) are diagnosed at an advanced stage.
BC8_BioRED_Task1_Doc76	230	236	tumour	Disease	D009369	The prognostic value of serum tumour markers alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) is limited.
BC8_BioRED_Task1_Doc76	245	262	alpha-fetoprotein	Gene	174	The prognostic value of serum tumour markers alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) is limited.
BC8_BioRED_Task1_Doc76	264	267	AFP	Gene	174	The prognostic value of serum tumour markers alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) is limited.
BC8_BioRED_Task1_Doc76	273	302	des-gamma-carboxy prothrombin	Gene	2147	The prognostic value of serum tumour markers alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) is limited.
BC8_BioRED_Task1_Doc76	304	307	DCP	Gene	2147	The prognostic value of serum tumour markers alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) is limited.
BC8_BioRED_Task1_Doc76	417	429	inflammatory	Disease	D007249	The aim of our study is to evaluate the diagnostic value of serum growth factors, apoptotic and inflammatory mediators of cirrhotic patients with and without HCC.
BC8_BioRED_Task1_Doc76	443	452	cirrhotic	Disease	D008103	The aim of our study is to evaluate the diagnostic value of serum growth factors, apoptotic and inflammatory mediators of cirrhotic patients with and without HCC.
BC8_BioRED_Task1_Doc76	453	461	patients	OrganismTaxon	9606	The aim of our study is to evaluate the diagnostic value of serum growth factors, apoptotic and inflammatory mediators of cirrhotic patients with and without HCC.
BC8_BioRED_Task1_Doc76	479	482	HCC	Disease	D006528	The aim of our study is to evaluate the diagnostic value of serum growth factors, apoptotic and inflammatory mediators of cirrhotic patients with and without HCC.
BC8_BioRED_Task1_Doc76	527	536	cirrhotic	Disease	D008103	METHODS: Serum samples were collected from cirrhotic potential liver transplant patients (LTx) with (n=61) and without HCC (n=78) as well as from healthy controls (HCs; n=39).
BC8_BioRED_Task1_Doc76	564	572	patients	OrganismTaxon	9606	METHODS: Serum samples were collected from cirrhotic potential liver transplant patients (LTx) with (n=61) and without HCC (n=78) as well as from healthy controls (HCs; n=39).
BC8_BioRED_Task1_Doc76	603	606	HCC	Disease	D006528	METHODS: Serum samples were collected from cirrhotic potential liver transplant patients (LTx) with (n=61) and without HCC (n=78) as well as from healthy controls (HCs; n=39).
BC8_BioRED_Task1_Doc76	684	687	CRP	Gene	1401	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	689	698	neopterin	Chemical	D019798	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	703	707	IL-6	Gene	3569	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	722	734	inflammation	Disease	D007249	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	739	753	thrombopoietin	Gene	7066	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	755	758	TPO	Gene	7066	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	761	765	GCSF	Gene	1440	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	767	776	FGF basic	Gene	2247	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	781	785	VEGF	Gene	7422	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	787	792	HMGB1	Gene	3146	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	794	799	CK-18	Gene	3875	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	810	814	CK18	Gene	3875	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	845	871	proinflammatory chemokines	Gene	3576,6347,6348,6351,6352,6374	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	873	877	CCL2	Gene	6347	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	879	883	CCL3	Gene	6348	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	885	889	CCL4	Gene	6351	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	891	895	CCL5	Gene	6352	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	897	902	CXCL5	Gene	6374	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	907	911	IL-8	Gene	3576	Serum concentrations of CRP, neopterin and IL-6 as markers of inflammation and thrombopoietin (TPO), GCSF, FGF basic and VEGF, HMGB1, CK-18 (M65) and CK18 fragment (M30) and a panel of proinflammatory chemokines (CCL2, CCL3, CCL4, CCL5, CXCL5 and IL-8) were measured.
BC8_BioRED_Task1_Doc76	1068	1076	Patients	OrganismTaxon	9606	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1082	1085	HCC	Disease	D006528	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1103	1106	TPO	Gene	7066	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1111	1121	chemokines	Gene	3576,6347,6348,6351,6352,6374	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1138	1141	TPO	Gene	7066	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1143	1147	CCL4	Gene	6351	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1149	1153	CCL5	Gene	6352	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1158	1163	CXCL5	Gene	6374	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1175	1179	CCL2	Gene	6347	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1202	1211	cirrhotic	Disease	D008103	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1212	1220	patients	OrganismTaxon	9606	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1229	1232	HCC	Disease	D006528	RESULTS: Patients with HCC had higher serum TPO and chemokines (P   <0.001 for TPO, CCL4, CCL5 and CXCL5) and lower CCL2 (P=0.008) levels than cirrhotic patients without HCC.
BC8_BioRED_Task1_Doc76	1352	1356	CCL4	Gene	6351	Multivariate forward stepwise regression analysis for significant parameters showed that among the studied parameters CCL4 and CCL5 (P=0.001) are diagnostic markers of HCC.
BC8_BioRED_Task1_Doc76	1361	1365	CCL5	Gene	6352	Multivariate forward stepwise regression analysis for significant parameters showed that among the studied parameters CCL4 and CCL5 (P=0.001) are diagnostic markers of HCC.
BC8_BioRED_Task1_Doc76	1402	1405	HCC	Disease	D006528	Multivariate forward stepwise regression analysis for significant parameters showed that among the studied parameters CCL4 and CCL5 (P=0.001) are diagnostic markers of HCC.
BC8_BioRED_Task1_Doc76	1423	1426	TPO	Gene	7066	Serum levels of TPO and chemokines were lower, whereas M30 was significantly higher in cirrhotic patients than in HCs.
BC8_BioRED_Task1_Doc76	1431	1441	chemokines	Gene	3576,6347,6348,6351,6352,6374	Serum levels of TPO and chemokines were lower, whereas M30 was significantly higher in cirrhotic patients than in HCs.
BC8_BioRED_Task1_Doc76	1494	1503	cirrhotic	Disease	D008103	Serum levels of TPO and chemokines were lower, whereas M30 was significantly higher in cirrhotic patients than in HCs.
BC8_BioRED_Task1_Doc76	1504	1512	patients	OrganismTaxon	9606	Serum levels of TPO and chemokines were lower, whereas M30 was significantly higher in cirrhotic patients than in HCs.
BC8_BioRED_Task1_Doc76	1560	1572	inflammatory	Disease	D007249	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc76	1573	1583	chemokines	Gene	3576,6347,6348,6351,6352,6374	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc76	1592	1596	CCL4	Gene	6351	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc76	1601	1605	CCL5	Gene	6352	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc76	1622	1631	cirrhotic	Disease	D008103	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc76	1632	1640	patients	OrganismTaxon	9606	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc76	1666	1669	HCC	Disease	D006528	CONCLUSIONS: High serum levels of inflammatory chemokines such as CCL4 and CCL5 in the serum of cirrhotic patients indicate the presence of HCC.
BC8_BioRED_Task1_Doc77	2	6	TSPO	Gene	12257	A TSPO ligand attenuates brain injury after intracerebral hemorrhage.	A TSPO ligand attenuates brain injury after intracerebral hemorrhage.
BC8_BioRED_Task1_Doc77	25	37	brain injury	Disease	D001927	A TSPO ligand attenuates brain injury after intracerebral hemorrhage.	A TSPO ligand attenuates brain injury after intracerebral hemorrhage.
BC8_BioRED_Task1_Doc77	44	68	intracerebral hemorrhage	Disease	D002543	A TSPO ligand attenuates brain injury after intracerebral hemorrhage.	A TSPO ligand attenuates brain injury after intracerebral hemorrhage.
BC8_BioRED_Task1_Doc77	70	94	Intracerebral hemorrhage	Disease	D002543	Intracerebral hemorrhage (ICH) is a devastating disease without effective treatment.
BC8_BioRED_Task1_Doc77	96	99	ICH	Disease	D002543	Intracerebral hemorrhage (ICH) is a devastating disease without effective treatment.
BC8_BioRED_Task1_Doc77	161	164	ICH	Disease	D002543	After ICH, the immediate infiltration of leukocytes and activation of microglia are accompanied by a rapid up-regulation of the 18-kDa translocator protein (TSPO).
BC8_BioRED_Task1_Doc77	290	310	translocator protein	Gene	12257	After ICH, the immediate infiltration of leukocytes and activation of microglia are accompanied by a rapid up-regulation of the 18-kDa translocator protein (TSPO).
BC8_BioRED_Task1_Doc77	312	316	TSPO	Gene	12257	After ICH, the immediate infiltration of leukocytes and activation of microglia are accompanied by a rapid up-regulation of the 18-kDa translocator protein (TSPO).
BC8_BioRED_Task1_Doc77	319	323	TSPO	Gene	12257	TSPO ligands have shown anti-inflammatory and neuroprotective properties in models of CNS injury.
BC8_BioRED_Task1_Doc77	348	360	inflammatory	Disease	D007249	TSPO ligands have shown anti-inflammatory and neuroprotective properties in models of CNS injury.
BC8_BioRED_Task1_Doc77	405	415	CNS injury	Disease	D002493	TSPO ligands have shown anti-inflammatory and neuroprotective properties in models of CNS injury.
BC8_BioRED_Task1_Doc77	462	466	TSPO	Gene	12257	In this study, we determined the impact of a TSPO ligand, etifoxine, on brain injury and inflammation in 2 mouse models of ICH.
BC8_BioRED_Task1_Doc77	475	484	etifoxine	Chemical	C002125	In this study, we determined the impact of a TSPO ligand, etifoxine, on brain injury and inflammation in 2 mouse models of ICH.
BC8_BioRED_Task1_Doc77	489	501	brain injury	Disease	D001927	In this study, we determined the impact of a TSPO ligand, etifoxine, on brain injury and inflammation in 2 mouse models of ICH.
BC8_BioRED_Task1_Doc77	506	518	inflammation	Disease	D007249	In this study, we determined the impact of a TSPO ligand, etifoxine, on brain injury and inflammation in 2 mouse models of ICH.
BC8_BioRED_Task1_Doc77	524	529	mouse	OrganismTaxon	10090	In this study, we determined the impact of a TSPO ligand, etifoxine, on brain injury and inflammation in 2 mouse models of ICH.
BC8_BioRED_Task1_Doc77	540	543	ICH	Disease	D002543	In this study, we determined the impact of a TSPO ligand, etifoxine, on brain injury and inflammation in 2 mouse models of ICH.
BC8_BioRED_Task1_Doc77	545	549	TSPO	Gene	706	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	570	574	Iba1	Gene	199	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	599	607	patients	OrganismTaxon	9606	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	613	616	ICH	Disease	D002543	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	624	629	CD11b	Gene	16409	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	632	636	CD45	Gene	19264	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	653	657	mice	OrganismTaxon	10090	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	671	682	collagenase	Chemical	D017364	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	691	694	ICH	Disease	D002543	TSPO was up-regulated in Iba1(+) cells from brains of patients with ICH and in CD11b(+)CD45(int) cells from mice subjected to collagenase-induced ICH.
BC8_BioRED_Task1_Doc77	696	705	Etifoxine	Chemical	C002125	Etifoxine significantly reduced neurodeficits and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase.
BC8_BioRED_Task1_Doc77	728	741	neurodeficits	Disease	D001927	Etifoxine significantly reduced neurodeficits and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase.
BC8_BioRED_Task1_Doc77	760	771	brain edema	Disease	D001929	Etifoxine significantly reduced neurodeficits and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase.
BC8_BioRED_Task1_Doc77	778	781	ICH	Disease	D002543	Etifoxine significantly reduced neurodeficits and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase.
BC8_BioRED_Task1_Doc77	835	846	collagenase	Chemical	D017364	Etifoxine significantly reduced neurodeficits and perihematomal brain edema after ICH induction by injection of either autologous blood or collagenase.
BC8_BioRED_Task1_Doc77	851	862	collagenase	Chemical	D017364	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.
BC8_BioRED_Task1_Doc77	871	874	ICH	Disease	D002543	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.
BC8_BioRED_Task1_Doc77	875	879	mice	OrganismTaxon	10090	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.
BC8_BioRED_Task1_Doc77	899	908	etifoxine	Chemical	C002125	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.
BC8_BioRED_Task1_Doc77	1004	1008	IL-6	Gene	16193	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.
BC8_BioRED_Task1_Doc77	1013	1018	TNF-a	Gene	21926	In collagenase-induced ICH mice, the protection of etifoxine was associated with reduced leukocyte infiltration into the brain and microglial production of IL-6 and TNF-a.
BC8_BioRED_Task1_Doc77	1020	1029	Etifoxine	Chemical	C002125	Etifoxine improved blood-brain barrier integrity and diminished cell death.
BC8_BioRED_Task1_Doc77	1130	1139	etifoxine	Chemical	C002125	Notably, the protective effect of etifoxine was abolished in mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.
BC8_BioRED_Task1_Doc77	1157	1161	mice	OrganismTaxon	10090	Notably, the protective effect of etifoxine was abolished in mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.
BC8_BioRED_Task1_Doc77	1195	1231	colony-stimulating factor 1 receptor	Gene	12978	Notably, the protective effect of etifoxine was abolished in mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.
BC8_BioRED_Task1_Doc77	1275	1279	TSPO	Gene	12257	These results indicate that the TSPO ligand etifoxine attenuates brain injury and inflammation after ICH.
BC8_BioRED_Task1_Doc77	1287	1296	etifoxine	Chemical	C002125	These results indicate that the TSPO ligand etifoxine attenuates brain injury and inflammation after ICH.
BC8_BioRED_Task1_Doc77	1308	1320	brain injury	Disease	D001927	These results indicate that the TSPO ligand etifoxine attenuates brain injury and inflammation after ICH.
BC8_BioRED_Task1_Doc77	1325	1337	inflammation	Disease	D007249	These results indicate that the TSPO ligand etifoxine attenuates brain injury and inflammation after ICH.
BC8_BioRED_Task1_Doc77	1344	1347	ICH	Disease	D002543	These results indicate that the TSPO ligand etifoxine attenuates brain injury and inflammation after ICH.
BC8_BioRED_Task1_Doc77	1349	1353	TSPO	Gene	12257	TSPO may be a viable therapeutic target that requires further investigations in ICH.-Li, M., Ren, H., Sheth, K. N., Shi, F.-D., Liu, Q.
BC8_BioRED_Task1_Doc77	1429	1432	ICH	Disease	D002543	TSPO may be a viable therapeutic target that requires further investigations in ICH.-Li, M., Ren, H., Sheth, K. N., Shi, F.-D., Liu, Q.
BC8_BioRED_Task1_Doc77	1487	1491	TSPO	Gene	12257
BC8_BioRED_Task1_Doc77	1510	1522	brain injury	Disease	D001927
BC8_BioRED_Task1_Doc77	1529	1553	intracerebral hemorrhage	Disease	D002543
BC8_BioRED_Task1_Doc78	28	46	X linked nystagmus	Disease	C580539	Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene.
BC8_BioRED_Task1_Doc78	77	84	p.R229G	SequenceVariant	rs137852212	Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene.
BC8_BioRED_Task1_Doc78	111	116	FRMD7	Gene	90167	Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene.
BC8_BioRED_Task1_Doc78	173	187	genetic defect	Disease	D030342	AIMS: This study aimed to identify the underlying genetic defect of a large Turkish X linked nystagmus (NYS) family.
BC8_BioRED_Task1_Doc78	207	225	X linked nystagmus	Disease	C580539	AIMS: This study aimed to identify the underlying genetic defect of a large Turkish X linked nystagmus (NYS) family.
BC8_BioRED_Task1_Doc78	227	230	NYS	Disease	C580539	AIMS: This study aimed to identify the underlying genetic defect of a large Turkish X linked nystagmus (NYS) family.
BC8_BioRED_Task1_Doc78	352	357	FRMD7	Gene	90167	The 12 exons and intron-exon junctions of the FRMD7 gene were screened by direct sequencing.
BC8_BioRED_Task1_Doc78	553	563	CAG repeat	SequenceVariant	c|DUP||CAG|	X chromosome inactivation analysis was performed by enzymatic predigestion of DNA with a methylation-sensitive enzyme, followed by PCR of the polymorphic CAG repeat of the androgen receptor gene.
BC8_BioRED_Task1_Doc78	571	588	androgen receptor	Gene	367	X chromosome inactivation analysis was performed by enzymatic predigestion of DNA with a methylation-sensitive enzyme, followed by PCR of the polymorphic CAG repeat of the androgen receptor gene.
BC8_BioRED_Task1_Doc78	660	663	NYS	Disease	C580539	RESULTS: The family contained 162 individuals, among whom 28 had NYS.
BC8_BioRED_Task1_Doc78	725	733	c.686C>G	SequenceVariant	rs137852212	A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed.
BC8_BioRED_Task1_Doc78	789	835	arginine at amino acid position 229 by glycine	SequenceVariant	rs137852212	A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed.
BC8_BioRED_Task1_Doc78	837	844	p.R229G	SequenceVariant	rs137852212	A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed.
BC8_BioRED_Task1_Doc78	863	868	FRMD7	Gene	90167	A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed.
BC8_BioRED_Task1_Doc78	1179	1186	p.R229G	SequenceVariant	rs137852212	CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.
BC8_BioRED_Task1_Doc78	1203	1208	FRMD7	Gene	90167	CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.
BC8_BioRED_Task1_Doc78	1225	1228	NYS	Disease	C580539	CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.
BC8_BioRED_Task1_Doc78	1313	1325	X linked NYS	Disease	C580539	CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.
BC8_BioRED_Task1_Doc79	105	110	renin	Gene	5972	Hemodynamic parameters and heart rate variability during a tilt test in relation to gene polymorphism of renin-angiotensin and serotonin system.
BC8_BioRED_Task1_Doc79	111	122	angiotensin	Gene	183	Hemodynamic parameters and heart rate variability during a tilt test in relation to gene polymorphism of renin-angiotensin and serotonin system.
BC8_BioRED_Task1_Doc79	127	136	serotonin	Chemical	D012701	Hemodynamic parameters and heart rate variability during a tilt test in relation to gene polymorphism of renin-angiotensin and serotonin system.
BC8_BioRED_Task1_Doc79	195	200	renin	Gene	5972	PURPOSE: The aim of the study was to evaluate the renin-angiotensin system and serotonin transporter gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head-up tilt test (HUT) in patients with vasovagal syncope.
BC8_BioRED_Task1_Doc79	201	212	angiotensin	Gene	183	PURPOSE: The aim of the study was to evaluate the renin-angiotensin system and serotonin transporter gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head-up tilt test (HUT) in patients with vasovagal syncope.
BC8_BioRED_Task1_Doc79	224	245	serotonin transporter	Gene	6532	PURPOSE: The aim of the study was to evaluate the renin-angiotensin system and serotonin transporter gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head-up tilt test (HUT) in patients with vasovagal syncope.
BC8_BioRED_Task1_Doc79	366	374	patients	OrganismTaxon	9606	PURPOSE: The aim of the study was to evaluate the renin-angiotensin system and serotonin transporter gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head-up tilt test (HUT) in patients with vasovagal syncope.
BC8_BioRED_Task1_Doc79	380	397	vasovagal syncope	Disease	D019462	PURPOSE: The aim of the study was to evaluate the renin-angiotensin system and serotonin transporter gene polymorphisms in relation to hemodynamic parameters and heart rate variability during a head-up tilt test (HUT) in patients with vasovagal syncope.
BC8_BioRED_Task1_Doc79	435	443	patients	OrganismTaxon	9606	METHODS: DNA was collected from 191 patients (mean age 44+/-18 years, 61 men, 130 women).
BC8_BioRED_Task1_Doc79	472	475	men	OrganismTaxon	9606	METHODS: DNA was collected from 191 patients (mean age 44+/-18 years, 61 men, 130 women).
BC8_BioRED_Task1_Doc79	481	486	women	OrganismTaxon	9606	METHODS: DNA was collected from 191 patients (mean age 44+/-18 years, 61 men, 130 women).
BC8_BioRED_Task1_Doc79	554	583	angiotensin-converting enzyme	Gene	1636	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	621	624	ACE	Gene	1636	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	627	642	angiotensinogen	Gene	183	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	662	667	M 235	SequenceVariant	p|Allele|M|235	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	670	700	angiotensin II receptor type 1	Gene	185	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	702	706	ATR1	Gene	185	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	722	730	A 11666C	SequenceVariant	rs5186	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	753	774	serotonin transporter	Gene	6532	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	781	788	5HTTLPR	Gene	6532	The following gene polymorphisms were determined in genomic DNA: angiotensin-converting enzyme insertion/deletion polymorphism (I/D ACE), angiotensinogen gene polymorphism (M 235), angiotensin II receptor type 1 (ATR1) polymorphism (A 11666C), and polymorphism of serotonin transporter gene (5HTTLPR).Heart rate variability during HUT was assessed in 5-minute intervals by low frequency, high frequency, standard deviation of the normal-to-normal (SDNN), and root mean square successive difference parameters.
BC8_BioRED_Task1_Doc79	1023	1030	A 1166C	SequenceVariant	rs5186	RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the ATR1 gene may be associated with hypotension and decline in sympathetic tone during HUT.
BC8_BioRED_Task1_Doc79	1531	1538	syncope	Disease	D013575	RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the ATR1 gene may be associated with hypotension and decline in sympathetic tone during HUT.
BC8_BioRED_Task1_Doc79	1636	1643	A 1166C	SequenceVariant	rs5186	RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the ATR1 gene may be associated with hypotension and decline in sympathetic tone during HUT.
BC8_BioRED_Task1_Doc79	1664	1668	ATR1	Gene	185	RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the ATR1 gene may be associated with hypotension and decline in sympathetic tone during HUT.
BC8_BioRED_Task1_Doc79	1697	1708	hypotension	Disease	D007022	RESULTS: AA genotype of A 1166C polymorphism was associated with lower minimal systolic blood pressure (SBP) and diastolic blood pressure (DBP) during HUT compared with other genotypes (minimal SBP: AA 59.6+/-21,8, AC 79.9+/-22.7, CC 65.4+/-22.7 mmHg, P=0.007), (minimal DBP: AA 36.4+/-22.7, AC 52.3+/-22.9, CC 45.4+/-19.5 mmHg, P=0.007).AA genotype was also associated with higher SDNN compared to other genotypes in the early phase of HUT (SDNN in 5 minutes of tilt: AA 59.7+/-24.6, AC 50.6+/-20.6, CC 46.0+/-13.2, P=0.01) and at syncope occurrence (SDNN: AA 71.0+/-20.9, AC 58.2+/-17.9, CC 58+/-10, P=0.04) CONCLUSION: AA genotype of A 1166C polymorphism in the ATR1 gene may be associated with hypotension and decline in sympathetic tone during HUT.
BC8_BioRED_Task1_Doc79	1791	1808	vasovagal syncope	Disease	D019462	Its role in genetic predisposition to vasovagal syncope cannot be excluded.
BC8_BioRED_Task1_Doc80	59	70	pilocarpine	Chemical	D010862	The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models.
BC8_BioRED_Task1_Doc80	140	151	pilocarpine	Chemical	D010862	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
BC8_BioRED_Task1_Doc80	207	216	aconitine	Chemical	D000157	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
BC8_BioRED_Task1_Doc80	225	228	rat	OrganismTaxon	10116	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
BC8_BioRED_Task1_Doc80	233	240	ouabain	Chemical	D010042	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
BC8_BioRED_Task1_Doc80	249	259	guinea pig	OrganismTaxon	10141	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
BC8_BioRED_Task1_Doc80	260	270	arrhythmia	Disease	D001145	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig arrhythmia models.
BC8_BioRED_Task1_Doc80	338	345	calcium	Chemical	D002118	Confocal microscopy was used to measure intracellular free-calcium concentrations ([Ca(2+)](i)) in isolated myocytes.
BC8_BioRED_Task1_Doc80	363	369	Ca(2+)	Chemical	D002118	Confocal microscopy was used to measure intracellular free-calcium concentrations ([Ca(2+)](i)) in isolated myocytes.
BC8_BioRED_Task1_Doc80	426	437	pilocarpine	Chemical	D010862	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	469	480	arrhythmias	Disease	D001145	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	511	551	ventricular tachycardia and fibrillation	Disease	D017180|D014693	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	561	571	arrhythmia	Disease	D001145	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	614	624	arrhythmic	Disease	D001145	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	625	629	rats	OrganismTaxon	10116	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	634	645	guinea pigs	OrganismTaxon	10141	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.
BC8_BioRED_Task1_Doc80	648	654	Ca(2+)	Chemical	D002118	[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
BC8_BioRED_Task1_Doc80	679	688	aconitine	Chemical	D000157	[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
BC8_BioRED_Task1_Doc80	692	699	ouabain	Chemical	D010042	[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
BC8_BioRED_Task1_Doc80	749	760	pilocarpine	Chemical	D010862	[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
BC8_BioRED_Task1_Doc80	772	810	M(3)-muscarinic acetylcholine receptor	Gene	100379235,24260	Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.
BC8_BioRED_Task1_Doc80	812	817	mAChR	Gene	100379235,24260	Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.
BC8_BioRED_Task1_Doc80	830	836	4-DAMP	Chemical	C042375	Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.
BC8_BioRED_Task1_Doc80	838	885	4-diphenylacetoxy-N-methylpiperidine-methiodide	Chemical	C042375	Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.
BC8_BioRED_Task1_Doc80	933	944	pilocarpine	Chemical	D010862	Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.
BC8_BioRED_Task1_Doc80	970	981	pilocarpine	Chemical	D010862	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1017	1027	arrhythmic	Disease	D001145	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1028	1031	rat	OrganismTaxon	10116	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1036	1046	guinea pig	OrganismTaxon	10141	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1065	1074	aconitine	Chemical	D000157	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1078	1085	ouabain	Chemical	D010042	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1114	1124	M(3)-mAChR	Gene	100379235,24260	These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
BC8_BioRED_Task1_Doc80	1177	1183	Ca(2+)	Chemical	D002118	The mechanism may be related to the improvement of Ca(2+) handling.
BC8_BioRED_Task1_Doc81	77	107	idiopathic Parkinson's disease	Disease	D010300	Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.
BC8_BioRED_Task1_Doc81	254	284	idiopathic Parkinson's disease	Disease	D010300	A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.
BC8_BioRED_Task1_Doc81	286	288	PD	Disease	D010300	A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.
BC8_BioRED_Task1_Doc81	352	360	patients	OrganismTaxon	9606	Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.
BC8_BioRED_Task1_Doc81	394	397	men	OrganismTaxon	9606	Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.
BC8_BioRED_Task1_Doc81	401	406	women	OrganismTaxon	9606	Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.
BC8_BioRED_Task1_Doc81	581	589	levodopa	Chemical	D007980	Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.
BC8_BioRED_Task1_Doc81	598	609	dyskinesias	Disease	D004409	Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.
BC8_BioRED_Task1_Doc81	629	637	patients	OrganismTaxon	9606	All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.
BC8_BioRED_Task1_Doc81	671	679	levodopa	Chemical	D007980	All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.
BC8_BioRED_Task1_Doc81	717	725	patients	OrganismTaxon	9606	Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).
BC8_BioRED_Task1_Doc81	875	894	Parkinson's Disease	Disease	D010300	Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.
BC8_BioRED_Task1_Doc81	1145	1157	parkinsonian	Disease	D010300	There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.
BC8_BioRED_Task1_Doc81	1177	1185	patients	OrganismTaxon	9606	There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.
BC8_BioRED_Task1_Doc81	1209	1217	Levodopa	Chemical	D007980	Levodopa equivalent daily intake was significantly reduced in the STN group.
BC8_BioRED_Task1_Doc81	1462	1470	patients	OrganismTaxon	9606	Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.
BC8_BioRED_Task1_Doc81	1487	1509	homonymous hemianopsia	Disease	D006423	Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.
BC8_BioRED_Task1_Doc81	1653	1662	Valproate	Chemical	D014635	Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.
BC8_BioRED_Task1_Doc81	1790	1798	patients	OrganismTaxon	9606	The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.
BC8_BioRED_Task1_Doc81	1813	1815	PD	Disease	D010300	The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.
BC8_BioRED_Task1_Doc82	0	26	Thyroid hormone receptor a	Gene	21833	Thyroid hormone receptor a mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.
BC8_BioRED_Task1_Doc82	56	65	thyroxine	Chemical	D013974	Thyroid hormone receptor a mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.
BC8_BioRED_Task1_Doc82	76	94	skeletal dysplasia	Disease	D001848	Thyroid hormone receptor a mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.
BC8_BioRED_Task1_Doc82	105	109	mice	OrganismTaxon	10090	Thyroid hormone receptor a mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice.
BC8_BioRED_Task1_Doc82	184	188	THRA	Gene	7067	A new genetic disorder has been identified that results from mutation of THRA, encoding thyroid hormone receptor a1 (TRa1).
BC8_BioRED_Task1_Doc82	199	226	thyroid hormone receptor a1	Gene	7067	A new genetic disorder has been identified that results from mutation of THRA, encoding thyroid hormone receptor a1 (TRa1).
BC8_BioRED_Task1_Doc82	228	232	TRa1	Gene	7067	A new genetic disorder has been identified that results from mutation of THRA, encoding thyroid hormone receptor a1 (TRa1).
BC8_BioRED_Task1_Doc82	271	273	T3	Chemical	D014284	Affected children have a high serum T3:T4 ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe skeletal dysplasia.
BC8_BioRED_Task1_Doc82	274	276	T4	Chemical	D013974	Affected children have a high serum T3:T4 ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe skeletal dysplasia.
BC8_BioRED_Task1_Doc82	307	327	intellectual deficit	Disease	D008607	Affected children have a high serum T3:T4 ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe skeletal dysplasia.
BC8_BioRED_Task1_Doc82	332	344	constipation	Disease	D003248	Affected children have a high serum T3:T4 ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe skeletal dysplasia.
BC8_BioRED_Task1_Doc82	379	397	skeletal dysplasia	Disease	D001848	Affected children have a high serum T3:T4 ratio and variable degrees of intellectual deficit and constipation but exhibit a consistently severe skeletal dysplasia.
BC8_BioRED_Task1_Doc82	424	443	developmental delay	Disease	D002658	In an attempt to improve developmental delay and alleviate symptoms of hypothyroidism, patients are receiving varying doses and durations of T4 treatment, but responses have been inconsistent so far.
BC8_BioRED_Task1_Doc82	470	484	hypothyroidism	Disease	D007037	In an attempt to improve developmental delay and alleviate symptoms of hypothyroidism, patients are receiving varying doses and durations of T4 treatment, but responses have been inconsistent so far.
BC8_BioRED_Task1_Doc82	486	494	patients	OrganismTaxon	9606	In an attempt to improve developmental delay and alleviate symptoms of hypothyroidism, patients are receiving varying doses and durations of T4 treatment, but responses have been inconsistent so far.
BC8_BioRED_Task1_Doc82	540	542	T4	Chemical	D013974	In an attempt to improve developmental delay and alleviate symptoms of hypothyroidism, patients are receiving varying doses and durations of T4 treatment, but responses have been inconsistent so far.
BC8_BioRED_Task1_Doc82	599	604	Thra1	Gene	21833	Thra1(PV/+) mice express a similar potent dominant-negative mutant TRa1 to affected individuals, and thus represent an excellent disease model.
BC8_BioRED_Task1_Doc82	611	615	mice	OrganismTaxon	10090	Thra1(PV/+) mice express a similar potent dominant-negative mutant TRa1 to affected individuals, and thus represent an excellent disease model.
BC8_BioRED_Task1_Doc82	666	670	TRa1	Gene	21833	Thra1(PV/+) mice express a similar potent dominant-negative mutant TRa1 to affected individuals, and thus represent an excellent disease model.
BC8_BioRED_Task1_Doc82	764	769	Thra1	Gene	21833	We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities.
BC8_BioRED_Task1_Doc82	776	780	mice	OrganismTaxon	10090	We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities.
BC8_BioRED_Task1_Doc82	830	835	human	OrganismTaxon	9606	We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities.
BC8_BioRED_Task1_Doc82	836	840	THRA	Gene	7067	We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities.
BC8_BioRED_Task1_Doc82	927	929	T4	Chemical	D013974	We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities.
BC8_BioRED_Task1_Doc82	946	968	skeletal abnormalities	Disease	D001847	We hypothesized that Thra1(PV/+) mice could be used to predict the skeletal outcome of human THRA mutations and determine whether prolonged treatment with a supraphysiological dose of T4 ameliorates the skeletal abnormalities.
BC8_BioRED_Task1_Doc82	983	988	Thra1	Gene	21833	Adult female Thra1(PV/+) mice had short stature, grossly abnormal bone morphology but normal bone strength despite high bone mass.
BC8_BioRED_Task1_Doc82	995	999	mice	OrganismTaxon	10090	Adult female Thra1(PV/+) mice had short stature, grossly abnormal bone morphology but normal bone strength despite high bone mass.
BC8_BioRED_Task1_Doc82	1004	1017	short stature	Disease	D006130	Adult female Thra1(PV/+) mice had short stature, grossly abnormal bone morphology but normal bone strength despite high bone mass.
BC8_BioRED_Task1_Doc82	1110	1112	T4	Chemical	D013974	Although T4 treatment suppressed TSH secretion, it had no effect on skeletal maturation, linear growth, or bone mineralization, thus demonstrating profound tissue resistance to thyroid hormone.
BC8_BioRED_Task1_Doc82	1134	1137	TSH	Gene	12640,22094	Although T4 treatment suppressed TSH secretion, it had no effect on skeletal maturation, linear growth, or bone mineralization, thus demonstrating profound tissue resistance to thyroid hormone.
BC8_BioRED_Task1_Doc82	1264	1293	resistance to thyroid hormone	Disease	D018382	Although T4 treatment suppressed TSH secretion, it had no effect on skeletal maturation, linear growth, or bone mineralization, thus demonstrating profound tissue resistance to thyroid hormone.
BC8_BioRED_Task1_Doc82	1319	1321	T4	Chemical	D013974	Despite this, prolonged T4 treatment abnormally increased bone stiffness and strength, suggesting the potential for detrimental consequences in the long term.
BC8_BioRED_Task1_Doc82	1481	1485	TRa1	Gene	7067	Our studies establish that TRa1 has an essential role in the developing and adult skeleton and predict that patients with different THRA mutations will display variable responses to T4 treatment, which depend on the severity of the causative mutation.
BC8_BioRED_Task1_Doc82	1562	1570	patients	OrganismTaxon	9606	Our studies establish that TRa1 has an essential role in the developing and adult skeleton and predict that patients with different THRA mutations will display variable responses to T4 treatment, which depend on the severity of the causative mutation.
BC8_BioRED_Task1_Doc82	1586	1590	THRA	Gene	7067	Our studies establish that TRa1 has an essential role in the developing and adult skeleton and predict that patients with different THRA mutations will display variable responses to T4 treatment, which depend on the severity of the causative mutation.
BC8_BioRED_Task1_Doc82	1636	1638	T4	Chemical	D013974	Our studies establish that TRa1 has an essential role in the developing and adult skeleton and predict that patients with different THRA mutations will display variable responses to T4 treatment, which depend on the severity of the causative mutation.
BC8_BioRED_Task1_Doc83	0	24	Calcium sensing receptor	Gene	24247	Calcium sensing receptor protects high glucose-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.
BC8_BioRED_Task1_Doc83	39	46	glucose	Chemical	D005947	Calcium sensing receptor protects high glucose-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.
BC8_BioRED_Task1_Doc83	62	81	metabolism disorder	Disease	D008659	Calcium sensing receptor protects high glucose-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.
BC8_BioRED_Task1_Doc83	95	99	gp78	Gene	361367	Calcium sensing receptor protects high glucose-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway.
BC8_BioRED_Task1_Doc83	130	153	Diabetic cardiomyopathy	Disease	D058065	Diabetic cardiomyopathy (DCM) is a major complication and fatal cause of the patients with diabetes.
BC8_BioRED_Task1_Doc83	155	158	DCM	Disease	D002311	Diabetic cardiomyopathy (DCM) is a major complication and fatal cause of the patients with diabetes.
BC8_BioRED_Task1_Doc83	207	215	patients	OrganismTaxon	9606	Diabetic cardiomyopathy (DCM) is a major complication and fatal cause of the patients with diabetes.
BC8_BioRED_Task1_Doc83	221	229	diabetes	Disease	D003920	Diabetic cardiomyopathy (DCM) is a major complication and fatal cause of the patients with diabetes.
BC8_BioRED_Task1_Doc83	235	259	calcium sensing receptor	Gene	24247	The calcium sensing receptor (CaSR) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.
BC8_BioRED_Task1_Doc83	261	265	CaSR	Gene	24247	The calcium sensing receptor (CaSR) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.
BC8_BioRED_Task1_Doc83	272	298	G protein-coupled receptor	Gene	24247	The calcium sensing receptor (CaSR) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.
BC8_BioRED_Task1_Doc83	333	340	calcium	Chemical	D002118	The calcium sensing receptor (CaSR) is a G protein-coupled receptor, which is involved in maintaining calcium homeostasis, regulating cell proliferation and apoptosis, and so on.
BC8_BioRED_Task1_Doc83	447	451	CaSR	Gene	24247	In our previous study, we found that CaSR expression, intracellular calcium levels and cardiac function were all significantly decreased in DCM rats; however, the exact mechanism are not clear yet.
BC8_BioRED_Task1_Doc83	478	485	calcium	Chemical	D002118	In our previous study, we found that CaSR expression, intracellular calcium levels and cardiac function were all significantly decreased in DCM rats; however, the exact mechanism are not clear yet.
BC8_BioRED_Task1_Doc83	550	553	DCM	Disease	D002311	In our previous study, we found that CaSR expression, intracellular calcium levels and cardiac function were all significantly decreased in DCM rats; however, the exact mechanism are not clear yet.
BC8_BioRED_Task1_Doc83	554	558	rats	OrganismTaxon	10116	In our previous study, we found that CaSR expression, intracellular calcium levels and cardiac function were all significantly decreased in DCM rats; however, the exact mechanism are not clear yet.
BC8_BioRED_Task1_Doc83	658	662	CaSR	Gene	24247	The present study revealed the protective role of CaSR in myocardial energy metabolism disorder induced by high glucose (HG) as well as the underlying mechanism.
BC8_BioRED_Task1_Doc83	666	703	myocardial energy metabolism disorder	Disease	D009202	The present study revealed the protective role of CaSR in myocardial energy metabolism disorder induced by high glucose (HG) as well as the underlying mechanism.
BC8_BioRED_Task1_Doc83	720	727	glucose	Chemical	D005947	The present study revealed the protective role of CaSR in myocardial energy metabolism disorder induced by high glucose (HG) as well as the underlying mechanism.
BC8_BioRED_Task1_Doc83	828	832	CaSR	Gene	24247	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	865	869	Mfn1	Gene	192647	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	871	875	Mfn2	Gene	64476	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	914	918	Cx43	Gene	24392	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	920	932	beta-catenin	Gene	84353	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	934	944	N-cadherin	Gene	83501	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	965	968	ATP	Chemical	D000255	Here, we demonstrated that HG decreased the expression of CaSR, mitochondrial fusion proteins (Mfn1, Mfn2), cell gap junction related proteins (Cx43, beta-catenin, N-cadherin), and intracellular ATP concentration.
BC8_BioRED_Task1_Doc83	1024	1027	ATP	Chemical	D000255	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1061	1065	gp78	Gene	361367	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1099	1103	Fis1	Gene	288584	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1105	1109	Drp1	Gene	114114	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1145	1149	Mfn1	Gene	192647	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1151	1155	Mfn2	Gene	64476	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1160	1164	Cx43	Gene	24392	In contrast, HG increased extracellular ATP concentration, the expression of gp78, mitochondrial fission proteins (Fis1, Drp1), and the ubiquitination levels of Mfn1, Mfn2 and Cx43.
BC8_BioRED_Task1_Doc83	1176	1180	CaSR	Gene	24247	Moreover, CaSR agonist and gp78-siRNA significantly reduced the above changes.
BC8_BioRED_Task1_Doc83	1193	1197	gp78	Gene	361367	Moreover, CaSR agonist and gp78-siRNA significantly reduced the above changes.
BC8_BioRED_Task1_Doc83	1299	1336	myocardial energy metabolism disorder	Disease	D009202	Taken together, these results suggest that HG induces myocardial energy metabolism disorder via decrease of CaSR expression, and activation of gp78-ubiquitin proteasome system.
BC8_BioRED_Task1_Doc83	1353	1357	CaSR	Gene	24247	Taken together, these results suggest that HG induces myocardial energy metabolism disorder via decrease of CaSR expression, and activation of gp78-ubiquitin proteasome system.
BC8_BioRED_Task1_Doc83	1388	1392	gp78	Gene	361367	Taken together, these results suggest that HG induces myocardial energy metabolism disorder via decrease of CaSR expression, and activation of gp78-ubiquitin proteasome system.
BC8_BioRED_Task1_Doc83	1549	1552	ATP	Chemical	D000255	In turn, these effects disrupt the structure and function of the mitochondria and the cell gap junction, result in the reduced ATP synthesis and the increased ATP leakage.
BC8_BioRED_Task1_Doc83	1581	1584	ATP	Chemical	D000255	In turn, these effects disrupt the structure and function of the mitochondria and the cell gap junction, result in the reduced ATP synthesis and the increased ATP leakage.
BC8_BioRED_Task1_Doc83	1609	1613	CaSR	Gene	24247	Stimulation of CaSR significantly attenuates HG-induced abnormal myocardial energy metabolism, suggesting CaSR would be a promising potential therapeutic target for DCM.
BC8_BioRED_Task1_Doc83	1650	1687	abnormal myocardial energy metabolism	Disease	D009202	Stimulation of CaSR significantly attenuates HG-induced abnormal myocardial energy metabolism, suggesting CaSR would be a promising potential therapeutic target for DCM.
BC8_BioRED_Task1_Doc83	1700	1704	CaSR	Gene	24247	Stimulation of CaSR significantly attenuates HG-induced abnormal myocardial energy metabolism, suggesting CaSR would be a promising potential therapeutic target for DCM.
BC8_BioRED_Task1_Doc83	1759	1762	DCM	Disease	D002311	Stimulation of CaSR significantly attenuates HG-induced abnormal myocardial energy metabolism, suggesting CaSR would be a promising potential therapeutic target for DCM.
BC8_BioRED_Task1_Doc84	20	35	desipramine HCl	Chemical	D003891	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.
BC8_BioRED_Task1_Doc84	59	73	cinacalcet HCl	Chemical	C476217	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.
BC8_BioRED_Task1_Doc84	122	132	cinacalcet	Chemical	C476217	OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.
BC8_BioRED_Task1_Doc84	158	193	cytochrome P450 isoenzyme (CYP) 2D6	Gene	1565	OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.
BC8_BioRED_Task1_Doc84	251	261	cinacalcet	Chemical	C476217	The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.
BC8_BioRED_Task1_Doc84	265	271	CYP2D6	Gene	1565	The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.
BC8_BioRED_Task1_Doc84	288	299	desipramine	Chemical	D003891	The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.
BC8_BioRED_Task1_Doc84	393	399	CYP2D6	Gene	1565	METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).
BC8_BioRED_Task1_Doc84	518	529	desipramine	Chemical	D003891	METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).
BC8_BioRED_Task1_Doc84	609	619	cinacalcet	Chemical	C476217	METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).
BC8_BioRED_Task1_Doc84	771	782	desipramine	Chemical	D003891	Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.
BC8_BioRED_Task1_Doc84	813	824	desipramine	Chemical	D003891	Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.
BC8_BioRED_Task1_Doc84	878	888	cinacalcet	Chemical	C476217	Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.
BC8_BioRED_Task1_Doc84	907	918	desipramine	Chemical	D003891	The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).
BC8_BioRED_Task1_Doc84	935	946	desipramine	Chemical	D003891	The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).
BC8_BioRED_Task1_Doc84	971	981	cinacalcet	Chemical	C476217	The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).
BC8_BioRED_Task1_Doc84	1115	1126	desipramine	Chemical	D003891	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1153	1164	desipramine	Chemical	D003891	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1170	1180	cinacalcet	Chemical	C476217	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1226	1232	nausea	Disease	D009325	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1237	1245	headache	Disease	D006261	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1270	1278	patients	OrganismTaxon	9606	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1299	1310	desipramine	Chemical	D003891	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1314	1324	cinacalcet	Chemical	C476217	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
BC8_BioRED_Task1_Doc84	1367	1377	cinacalcet	Chemical	C476217	CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.
BC8_BioRED_Task1_Doc84	1403	1409	CYP2D6	Gene	1565	CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.
BC8_BioRED_Task1_Doc84	1469	1479	cinacalcet	Chemical	C476217	These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.
BC8_BioRED_Task1_Doc84	1591	1597	CYP2D6	Gene	1565	These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.
BC8_BioRED_Task1_Doc85	4	9	human	OrganismTaxon	9606	The human AHR: identification of single nucleotide polymorphisms from six ethnic populations.
BC8_BioRED_Task1_Doc85	10	13	AHR	Gene	196	The human AHR: identification of single nucleotide polymorphisms from six ethnic populations.
BC8_BioRED_Task1_Doc85	121	156	2,3,7,8-tetrachlorodibenzo-p-dioxin	Chemical	D000072317	BACKGROUND: The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related dioxin-like chemicals are mediated through binding-dependent activation of the cytosolic aryl hydrocarbon receptor (AHR).
BC8_BioRED_Task1_Doc85	169	175	dioxin	Chemical	D004147	BACKGROUND: The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related dioxin-like chemicals are mediated through binding-dependent activation of the cytosolic aryl hydrocarbon receptor (AHR).
BC8_BioRED_Task1_Doc85	258	283	aryl hydrocarbon receptor	Gene	196	BACKGROUND: The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related dioxin-like chemicals are mediated through binding-dependent activation of the cytosolic aryl hydrocarbon receptor (AHR).
BC8_BioRED_Task1_Doc85	285	288	AHR	Gene	196	BACKGROUND: The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related dioxin-like chemicals are mediated through binding-dependent activation of the cytosolic aryl hydrocarbon receptor (AHR).
BC8_BioRED_Task1_Doc85	295	300	human	OrganismTaxon	9606	The human AHR is a low-affinity receptor relative to most rodents, but some reports suggest that there may be individuals with polymorphic high-affinity receptors, thereby possibly increasing the sensitivity to dioxins in such people.
BC8_BioRED_Task1_Doc85	301	304	AHR	Gene	196	The human AHR is a low-affinity receptor relative to most rodents, but some reports suggest that there may be individuals with polymorphic high-affinity receptors, thereby possibly increasing the sensitivity to dioxins in such people.
BC8_BioRED_Task1_Doc85	502	509	dioxins	Chemical	D004147	The human AHR is a low-affinity receptor relative to most rodents, but some reports suggest that there may be individuals with polymorphic high-affinity receptors, thereby possibly increasing the sensitivity to dioxins in such people.
BC8_BioRED_Task1_Doc85	616	619	AHR	Gene	196	METHODS: Although no polymorphisms have been reported in the ligand binding region of the AHR in the over 100 reported sequences, we sequenced 108 additional human AHR genes in an effort to further identify single single nucleotide polymorphisms (SNPs) within the open reading frames of the AHR locus.
BC8_BioRED_Task1_Doc85	684	689	human	OrganismTaxon	9606	METHODS: Although no polymorphisms have been reported in the ligand binding region of the AHR in the over 100 reported sequences, we sequenced 108 additional human AHR genes in an effort to further identify single single nucleotide polymorphisms (SNPs) within the open reading frames of the AHR locus.
BC8_BioRED_Task1_Doc85	690	693	AHR	Gene	196	METHODS: Although no polymorphisms have been reported in the ligand binding region of the AHR in the over 100 reported sequences, we sequenced 108 additional human AHR genes in an effort to further identify single single nucleotide polymorphisms (SNPs) within the open reading frames of the AHR locus.
BC8_BioRED_Task1_Doc85	817	820	AHR	Gene	196	METHODS: Although no polymorphisms have been reported in the ligand binding region of the AHR in the over 100 reported sequences, we sequenced 108 additional human AHR genes in an effort to further identify single single nucleotide polymorphisms (SNPs) within the open reading frames of the AHR locus.
BC8_BioRED_Task1_Doc85	1158	1161	AHR	Gene	196	Four of the SNPs identified lead to amino acid changes in the AHR protein and two of the SNPs lead to synonymous substitutions.
BC8_BioRED_Task1_Doc85	1367	1372	human	OrganismTaxon	9606	With these new sequences, more than 200 human AHR gene sequences have been analyzed for SNPs.
BC8_BioRED_Task1_Doc85	1373	1376	AHR	Gene	196	With these new sequences, more than 200 human AHR gene sequences have been analyzed for SNPs.
BC8_BioRED_Task1_Doc85	1536	1541	human	OrganismTaxon	9606	CONCLUSION: The results indicate a very limited presence of polymorphisms in the core ligand binding region of the human AHR.
BC8_BioRED_Task1_Doc85	1542	1545	AHR	Gene	196	CONCLUSION: The results indicate a very limited presence of polymorphisms in the core ligand binding region of the human AHR.
BC8_BioRED_Task1_Doc85	1642	1647	human	OrganismTaxon	9606	Other regions, such as the transactivation domain, seem to be slightly more polymorphic in the human population and the impact on functionality should be further examined.
BC8_BioRED_Task1_Doc86	30	37	657del5	SequenceVariant	c|DEL|657|5	Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies.
BC8_BioRED_Task1_Doc86	45	49	NBS1	Gene	4683	Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies.
BC8_BioRED_Task1_Doc86	91	99	patients	OrganismTaxon	9606	Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies.
BC8_BioRED_Task1_Doc86	105	135	sporadic lymphoid malignancies	Disease	D008223	Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies.
BC8_BioRED_Task1_Doc86	137	163	Nijmegen breakage syndrome	Disease	D049932	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	165	168	NBS	Disease	D049932	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	175	180	human	OrganismTaxon	9606	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	181	208	autosomal recessive disease	Disease	D030342	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	259	265	cancer	Disease	D009369	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	299	307	lymphoma	Disease	D008223	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	312	320	leukemia	Disease	D007938	Nijmegen breakage syndrome (NBS) is a human autosomal recessive disease characterized by genomic instability and enhanced cancer predisposition, in particular to lymphoma and leukemia.
BC8_BioRED_Task1_Doc86	412	416	NBS1	Gene	4683	Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin lymphoma (NHL).
BC8_BioRED_Task1_Doc86	427	434	657del5	SequenceVariant	c|DEL|657|5	Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin lymphoma (NHL).
BC8_BioRED_Task1_Doc86	472	502	sporadic lymphoid malignancies	Disease	D008223	Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin lymphoma (NHL).
BC8_BioRED_Task1_Doc86	530	550	non-Hodgkin lymphoma	Disease	D008228	Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin lymphoma (NHL).
BC8_BioRED_Task1_Doc86	552	555	NHL	Disease	D008228	Recently, significantly higher frequencies of heterozygous carriers of the Slavic founder NBS1 mutation, 657del5, were found in Russian children with sporadic lymphoid malignancies, and in Polish adults with non-Hodgkin lymphoma (NHL).
BC8_BioRED_Task1_Doc86	588	594	643C>T	SequenceVariant	c|SUB|C|643|T	In addition, the substitution 643C>T (R215W) has also been found in excess among children with acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc86	596	601	R215W	SequenceVariant	p|SUB|R|215|W	In addition, the substitution 643C>T (R215W) has also been found in excess among children with acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc86	653	681	acute lymphoblastic leukemia	Disease	D054198	In addition, the substitution 643C>T (R215W) has also been found in excess among children with acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc86	683	686	ALL	Disease	D054198	In addition, the substitution 643C>T (R215W) has also been found in excess among children with acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc86	769	799	sporadic lymphoid malignancies	Disease	D008223	In an attempt to asses the contribution of both mutations to the development of sporadic lymphoid malignancies, we analyzed DNA samples from a large group of Polish pediatric patients.
BC8_BioRED_Task1_Doc86	864	872	patients	OrganismTaxon	9606	In an attempt to asses the contribution of both mutations to the development of sporadic lymphoid malignancies, we analyzed DNA samples from a large group of Polish pediatric patients.
BC8_BioRED_Task1_Doc86	878	882	NBS1	Gene	4683	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	892	899	657del5	SequenceVariant	c|DEL|657|5	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	936	944	patients	OrganismTaxon	9606	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	950	953	ALL	Disease	D054198	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	997	1000	NHL	Disease	D008228	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	1032	1040	patients	OrganismTaxon	9606	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	1046	1062	Hodgkin lymphoma	Disease	D006689	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	1064	1066	HL	Disease	D006689	The NBS1 mutation 657del5 on one allele was found in 3 of 270 patients with ALL and 2 of 212 children and adolescents with NHL; no carrier was found among 63 patients with Hodgkin lymphoma (HL).
BC8_BioRED_Task1_Doc86	1096	1101	R215W	SequenceVariant	p|SUB|R|215|W	No carriers of the variant R215W were detected in any studied group.
BC8_BioRED_Task1_Doc86	1168	1175	657del5	SequenceVariant	c|DEL|657|5	The relative frequency of the 657del5 mutation was calculated from a total of 6,984 controls matched by place of patient residence, of whom 42 were found to be carriers (frequency = 0.006).
BC8_BioRED_Task1_Doc86	1251	1258	patient	OrganismTaxon	9606	The relative frequency of the 657del5 mutation was calculated from a total of 6,984 controls matched by place of patient residence, of whom 42 were found to be carriers (frequency = 0.006).
BC8_BioRED_Task1_Doc86	1360	1372	malignancies	Disease	D009369	In the analyzed population with malignancies, an increased odds ratio for the occurrence of mutation 657del5 was found in comparison with the control Polish population (OR range 1.48-1.85, 95% confidence interval 1.18-2.65).
BC8_BioRED_Task1_Doc86	1429	1436	657del5	SequenceVariant	c|DEL|657|5	In the analyzed population with malignancies, an increased odds ratio for the occurrence of mutation 657del5 was found in comparison with the control Polish population (OR range 1.48-1.85, 95% confidence interval 1.18-2.65).
BC8_BioRED_Task1_Doc86	1644	1652	patients	OrganismTaxon	9606	This finding indicates that the frequency of the mutation carriers was indeed increased in patients with ALL and NHL (p < 0.05).
BC8_BioRED_Task1_Doc86	1658	1661	ALL	Disease	D054198	This finding indicates that the frequency of the mutation carriers was indeed increased in patients with ALL and NHL (p < 0.05).
BC8_BioRED_Task1_Doc86	1666	1669	NHL	Disease	D008228	This finding indicates that the frequency of the mutation carriers was indeed increased in patients with ALL and NHL (p < 0.05).
BC8_BioRED_Task1_Doc86	1695	1699	NBS1	Gene	4683	Nonetheless, NBS1 gene heterozygosity is not a major risk factor for lymphoid malignancies in childhood and adolescence.
BC8_BioRED_Task1_Doc86	1751	1772	lymphoid malignancies	Disease	D008223	Nonetheless, NBS1 gene heterozygosity is not a major risk factor for lymphoid malignancies in childhood and adolescence.
BC8_BioRED_Task1_Doc87	28	32	BCHE	Gene	590	Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
BC8_BioRED_Task1_Doc87	66	77	p.Val204Asp	SequenceVariant	p|SUB|V|204|D	Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
BC8_BioRED_Task1_Doc87	117	122	apnea	Disease	D001049	Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
BC8_BioRED_Task1_Doc87	128	141	suxamethonium	Chemical	D013390	Characterization of a novel BCHE "silent" allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
BC8_BioRED_Task1_Doc87	143	175	Butyrylcholinesterase deficiency	Disease	C537417	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	206	211	apnea	Disease	D001049	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	229	245	muscle relaxants	Chemical	-	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	247	260	suxamethonium	Chemical	D013390	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	264	274	mivacurium	Chemical	D000077590	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	279	287	patients	OrganismTaxon	9606	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	314	318	BCHE	Gene	590	Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
BC8_BioRED_Task1_Doc87	361	380	neuromuscular block	Disease	D055191	Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp).
BC8_BioRED_Task1_Doc87	405	418	suxamethonium	Chemical	D013390	Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp).
BC8_BioRED_Task1_Doc87	455	459	BCHE	Gene	590	Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp).
BC8_BioRED_Task1_Doc87	469	477	c.695T>A	SequenceVariant	c|SUB|T|695|A	Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp).
BC8_BioRED_Task1_Doc87	479	490	p.Val204Asp	SequenceVariant	p|SUB|V|204|D	Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp).
BC8_BioRED_Task1_Doc87	683	690	patient	OrganismTaxon	9606	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	698	719	butyrylcholinesterase	Gene	590	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	725	743	butyrylthiocholine	Chemical	D002092	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	745	748	BTC	Chemical	D002092	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	754	768	benzoylcholine	Chemical	D001588	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	784	793	dibucaine	Chemical	D003992	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	798	806	fluoride	Chemical	D005459	Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype.
BC8_BioRED_Task1_Doc87	898	902	BChE	Gene	590	Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing.
BC8_BioRED_Task1_Doc87	945	952	patient	OrganismTaxon	9606	Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing.
BC8_BioRED_Task1_Doc87	1032	1036	BChE	Gene	590	Electrophoretic analysis of plasma BChE of the proband and his mother showed that patient has a reduced amount of tetrameric enzyme in plasma and that minor fast-moving BChE components: monomer, dimer, and monomer-albumin conjugate are missing.
BC8_BioRED_Task1_Doc87	1141	1152	p.Val204Asp	SequenceVariant	p|SUB|V|204|D	Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate.
BC8_BioRED_Task1_Doc87	1153	1163	p.Asp70Gly	SequenceVariant	rs1799807	Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate.
BC8_BioRED_Task1_Doc87	1164	1175	p.Ala539Thr	SequenceVariant	rs1803274	Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate.
BC8_BioRED_Task1_Doc87	1176	1180	BChE	Gene	590	Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate.
BC8_BioRED_Task1_Doc87	1222	1225	BTC	Chemical	D002092	Kinetic analysis showed that the p.Val204Asp/p.Asp70Gly-p.Ala539Thr BChE displays a pure Michaelian behavior with BTC as the substrate.
BC8_BioRED_Task1_Doc87	1286	1289	BTC	Chemical	D002092	Both catalytic parameters Km = 265 uM for BTC, two times higher than that of the atypical enzyme, and a low Vmax are consistent with the absence of activity against suxamethonium.
BC8_BioRED_Task1_Doc87	1409	1422	suxamethonium	Chemical	D013390	Both catalytic parameters Km = 265 uM for BTC, two times higher than that of the atypical enzyme, and a low Vmax are consistent with the absence of activity against suxamethonium.
BC8_BioRED_Task1_Doc87	1506	1517	p.Val204Asp	SequenceVariant	p|SUB|V|204|D	Molecular dynamic (MD) simulations showed that the overall effect of the mutation p.Val204Asp is disruption of hydrogen bonding between Gln223 and Glu441, leading Ser198 and His438 to move away from each other with subsequent disruption of the catalytic triad functionality regardless of the type of substrate.
BC8_BioRED_Task1_Doc87	1868	1879	p.Ala204Asp	SequenceVariant	p|SUB|A|204|D	This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.
BC8_BioRED_Task1_Doc87	1880	1890	p.Asp70Gly	SequenceVariant	rs1799807	This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.
BC8_BioRED_Task1_Doc87	1891	1902	p.Ala539Thr	SequenceVariant	rs1803274	This fits with the reduced concentration of p.Ala204Asp/p.Asp70Gly-p.Ala539Thr tetrameric enzyme in the plasma and non-detectable fast moving-bands on electrophoresis gels.
BC8_BioRED_Task1_Doc88	95	108	breast cancer	Disease	D001943	Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer.
BC8_BioRED_Task1_Doc88	136	149	breast cancer	Disease	D001943	PURPOSE: The prognosis of breast cancer varies considerably among individuals, and inherited genetic factors may help explain this variability.
BC8_BioRED_Task1_Doc88	315	338	reactive oxygen species	Chemical	D017382	Of particular interest are genes involved in defense against reactive oxygen species (ROS) because ROS are thought to cause DNA damage and contribute to the pathogenesis of cancer.
BC8_BioRED_Task1_Doc88	340	343	ROS	Chemical	D017382	Of particular interest are genes involved in defense against reactive oxygen species (ROS) because ROS are thought to cause DNA damage and contribute to the pathogenesis of cancer.
BC8_BioRED_Task1_Doc88	353	356	ROS	Chemical	D017382	Of particular interest are genes involved in defense against reactive oxygen species (ROS) because ROS are thought to cause DNA damage and contribute to the pathogenesis of cancer.
BC8_BioRED_Task1_Doc88	427	433	cancer	Disease	D009369	Of particular interest are genes involved in defense against reactive oxygen species (ROS) because ROS are thought to cause DNA damage and contribute to the pathogenesis of cancer.
BC8_BioRED_Task1_Doc88	435	443	PATIENTS	OrganismTaxon	9606	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	623	626	CAT	Gene	847	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	628	632	SOD1	Gene	6647	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	634	638	SOD2	Gene	6648	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	640	644	GPX1	Gene	2876	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	646	650	GPX4	Gene	2879	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	652	655	GSR	Gene	2936	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	657	660	TXN	Gene	7295	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	662	666	TXN2	Gene	25828	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	668	674	TXNRD1	Gene	7296	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	680	686	TXNRD2	Gene	10587	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	710	715	women	OrganismTaxon	9606	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	721	734	breast cancer	Disease	D001943	PATIENTS AND METHODS: We examined associations between 54 polymorphisms that tag the known common variants (minor allele frequency > 0.05) in 10 genes involved in oxidative damage repair (CAT, SOD1, SOD2, GPX1, GPX4, GSR, TXN, TXN2, TXNRD1, and TXNRD2) and survival in 4,470 women with breast cancer.
BC8_BioRED_Task1_Doc88	791	795	GPX4	Gene	2879	RESULTS: Two single nucleotide polymorphisms (SNPs) in GPX4 (rs713041 and rs757229) were associated with all-cause mortality even after adjusting for multiple hypothesis testing (adjusted P = .0041 and P = .0035).
BC8_BioRED_Task1_Doc88	797	805	rs713041	SequenceVariant	rs713041	RESULTS: Two single nucleotide polymorphisms (SNPs) in GPX4 (rs713041 and rs757229) were associated with all-cause mortality even after adjusting for multiple hypothesis testing (adjusted P = .0041 and P = .0035).
BC8_BioRED_Task1_Doc88	810	818	rs757229	SequenceVariant	rs757229	RESULTS: Two single nucleotide polymorphisms (SNPs) in GPX4 (rs713041 and rs757229) were associated with all-cause mortality even after adjusting for multiple hypothesis testing (adjusted P = .0041 and P = .0035).
BC8_BioRED_Task1_Doc88	1005	1009	GPX4	Gene	2879	GPX4 rs713041 is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of death, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).
BC8_BioRED_Task1_Doc88	1010	1018	rs713041	SequenceVariant	rs713041	GPX4 rs713041 is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of death, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).
BC8_BioRED_Task1_Doc88	1039	1053	selenocysteine	Chemical	D017279	GPX4 rs713041 is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of death, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).
BC8_BioRED_Task1_Doc88	1088	1092	GPX4	Gene	2879	GPX4 rs713041 is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of death, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).
BC8_BioRED_Task1_Doc88	1189	1194	death	Disease	D003643	GPX4 rs713041 is located near the selenocysteine insertion sequence element in the GPX4 3' untranslated region, and the rare allele of this SNP is associated with an increased risk of death, with a hazard ratio of 1.27 per rare allele carried (95% CI, 1.13 to 11.43).
BC8_BioRED_Task1_Doc88	1324	1329	tumor	Disease	D009369	This effect was not attenuated after adjusting for tumor stage, grade, or estrogen receptor status.
BC8_BioRED_Task1_Doc88	1347	1364	estrogen receptor	Gene	2099	This effect was not attenuated after adjusting for tumor stage, grade, or estrogen receptor status.
BC8_BioRED_Task1_Doc88	1475	1488	breast tumors	Disease	D001943	We found that the common allele is preferentially expressed in normal lymphocytes, normal breast, and breast tumors compared with the rare allele, but there were no differences in total levels of GPX4 mRNA across genotypes.
BC8_BioRED_Task1_Doc88	1569	1573	GPX4	Gene	2879	We found that the common allele is preferentially expressed in normal lymphocytes, normal breast, and breast tumors compared with the rare allele, but there were no differences in total levels of GPX4 mRNA across genotypes.
BC8_BioRED_Task1_Doc88	1687	1691	GPX4	Gene	2879	CONCLUSION: These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.
BC8_BioRED_Task1_Doc88	1742	1755	breast cancer	Disease	D001943	CONCLUSION: These data provide strong support for the hypothesis that common variation in GPX4 is associated with prognosis after a diagnosis of breast cancer.
BC8_BioRED_Task1_Doc89	38	48	penicillin	Chemical	D010406	Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.
BC8_BioRED_Task1_Doc89	57	78	epileptiform activity	Disease	D004827	Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.
BC8_BioRED_Task1_Doc89	95	99	rats	OrganismTaxon	10116	Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.
BC8_BioRED_Task1_Doc89	101	111	Penicillin	Chemical	D010406	Penicillin model is a widely used experimental model for epilepsy research.
BC8_BioRED_Task1_Doc89	158	166	epilepsy	Disease	D004827	Penicillin model is a widely used experimental model for epilepsy research.
BC8_BioRED_Task1_Doc89	250	260	penicillin	Chemical	D010406	In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.
BC8_BioRED_Task1_Doc89	269	290	epileptiform activity	Disease	D004827	In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.
BC8_BioRED_Task1_Doc89	354	358	rats	OrganismTaxon	10116	In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.
BC8_BioRED_Task1_Doc89	372	376	rats	OrganismTaxon	10116	Male Wistar rats were anesthetized with i.p.
BC8_BioRED_Task1_Doc89	405	413	urethane	Chemical	D014520	urethane and connected to an electrocorticogram setup.
BC8_BioRED_Task1_Doc89	510	519	epileptic	Disease	D004827	After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.
BC8_BioRED_Task1_Doc89	566	588	penicillin-G potassium	Chemical	D010400	After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.
BC8_BioRED_Task1_Doc89	714	724	penicillin	Chemical	D010406	Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.
BC8_BioRED_Task1_Doc89	733	754	epileptiform activity	Disease	D004827	Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.
BC8_BioRED_Task1_Doc89	1138	1159	epileptiform activity	Disease	D004827	Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).
BC8_BioRED_Task1_Doc89	1296	1317	epileptiform activity	Disease	D004827	Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).
BC8_BioRED_Task1_Doc89	1566	1576	epilepsies	Disease	D004827	Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.
BC8_BioRED_Task1_Doc90	16	29	synaptotagmin	Gene	255928	Disruption of a synaptotagmin (SYT14) associated with neurodevelopmental abnormalities.
BC8_BioRED_Task1_Doc90	31	36	SYT14	Gene	255928	Disruption of a synaptotagmin (SYT14) associated with neurodevelopmental abnormalities.
BC8_BioRED_Task1_Doc90	54	86	neurodevelopmental abnormalities	Disease	D009421	Disruption of a synaptotagmin (SYT14) associated with neurodevelopmental abnormalities.
BC8_BioRED_Task1_Doc90	247	263	cerebral atrophy	Disease	D001927	We report cytogenetic and molecular studies of a de novo, apparently balanced t(1;3)(q32.1;q25.1) identified in a 12-year-old female (designated DGAP128) with cerebral atrophy, macrocephaly seizures, and developmental delay.
BC8_BioRED_Task1_Doc90	265	277	macrocephaly	Disease	D058627	We report cytogenetic and molecular studies of a de novo, apparently balanced t(1;3)(q32.1;q25.1) identified in a 12-year-old female (designated DGAP128) with cerebral atrophy, macrocephaly seizures, and developmental delay.
BC8_BioRED_Task1_Doc90	278	286	seizures	Disease	D012640	We report cytogenetic and molecular studies of a de novo, apparently balanced t(1;3)(q32.1;q25.1) identified in a 12-year-old female (designated DGAP128) with cerebral atrophy, macrocephaly seizures, and developmental delay.
BC8_BioRED_Task1_Doc90	292	311	developmental delay	Disease	D002658	We report cytogenetic and molecular studies of a de novo, apparently balanced t(1;3)(q32.1;q25.1) identified in a 12-year-old female (designated DGAP128) with cerebral atrophy, macrocephaly seizures, and developmental delay.
BC8_BioRED_Task1_Doc90	428	441	synaptotagmin	Gene	255928	A combination of fluorescence in situ hybridization (FISH) and Southern blot analysis demonstrated disruption of a synaptotagmin gene (SYT14) at the 1q32 breakpoint.
BC8_BioRED_Task1_Doc90	448	453	SYT14	Gene	255928	A combination of fluorescence in situ hybridization (FISH) and Southern blot analysis demonstrated disruption of a synaptotagmin gene (SYT14) at the 1q32 breakpoint.
BC8_BioRED_Task1_Doc90	493	498	SYT14	Gene	255928	Expression of SYT14 in human brain was confirmed using Northern analysis.
BC8_BioRED_Task1_Doc90	502	507	human	OrganismTaxon	9606	Expression of SYT14 in human brain was confirmed using Northern analysis.
BC8_BioRED_Task1_Doc90	576	589	synaptotagmin	Gene	255928	Because members of the synaptotagmin family of proteins function as sensors that link changes in calcium levels with a variety of biological processes, including neurotransmission and hormone-responsiveness, SYT14 is an intriguing candidate gene for the abnormal development in this child.
BC8_BioRED_Task1_Doc90	650	657	calcium	Chemical	D002118	Because members of the synaptotagmin family of proteins function as sensors that link changes in calcium levels with a variety of biological processes, including neurotransmission and hormone-responsiveness, SYT14 is an intriguing candidate gene for the abnormal development in this child.
BC8_BioRED_Task1_Doc90	761	766	SYT14	Gene	255928	Because members of the synaptotagmin family of proteins function as sensors that link changes in calcium levels with a variety of biological processes, including neurotransmission and hormone-responsiveness, SYT14 is an intriguing candidate gene for the abnormal development in this child.
BC8_BioRED_Task1_Doc90	899	904	SYT14	Gene	255928	This is the first known constitutional rearrangement of SYT14, and further systematic genetic analysis and clinical studies of DGAP128 may offer unique insights into the role of SYT14 in neurodevelopment.
BC8_BioRED_Task1_Doc90	1021	1026	SYT14	Gene	255928	This is the first known constitutional rearrangement of SYT14, and further systematic genetic analysis and clinical studies of DGAP128 may offer unique insights into the role of SYT14 in neurodevelopment.
BC8_BioRED_Task1_Doc91	32	58	Mycobacterium tuberculosis	OrganismTaxon	1773	Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe.
BC8_BioRED_Task1_Doc91	100	132	multidrug-resistant tuberculosis	Disease	D018088	Molecular surveillance of multidrug-resistant tuberculosis (MDR TB) was implemented in Europe as case reporting in 2005.
BC8_BioRED_Task1_Doc91	134	140	MDR TB	Disease	D018088	Molecular surveillance of multidrug-resistant tuberculosis (MDR TB) was implemented in Europe as case reporting in 2005.
BC8_BioRED_Task1_Doc91	207	213	MDR TB	Disease	D018088	For all new MDR TB cases detected from January 2003 through June 2007, countries reported case-based epidemiologic data and DNA fingerprint patterns of MDR TB strains when available.
BC8_BioRED_Task1_Doc91	347	353	MDR TB	Disease	D018088	For all new MDR TB cases detected from January 2003 through June 2007, countries reported case-based epidemiologic data and DNA fingerprint patterns of MDR TB strains when available.
BC8_BioRED_Task1_Doc91	482	488	MDR TB	Disease	D018088	From 2003 through mid-2007 in Europe, 2,494 cases of MDR TB were reported from 24 European countries.
BC8_BioRED_Task1_Doc92	46	57	risperidone	Chemical	D018967	A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.
BC8_BioRED_Task1_Doc92	62	101	selective serotonin reuptake inhibitors	Chemical	D017367	A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.
BC8_BioRED_Task1_Doc92	208	219	risperidone	Chemical	D018967	OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.
BC8_BioRED_Task1_Doc92	228	246	hyperprolactinemia	Disease	D006966	OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.
BC8_BioRED_Task1_Doc92	420	431	risperidone	Chemical	D018967	METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.
BC8_BioRED_Task1_Doc92	503	513	outpatient	OrganismTaxon	9606	METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.
BC8_BioRED_Task1_Doc92	957	975	Hyperprolactinemia	Disease	D006966	RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.
BC8_BioRED_Task1_Doc92	1028	1039	risperidone	Chemical	D018967	RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.
BC8_BioRED_Task1_Doc92	1071	1083	testosterone	Chemical	D013739	Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1153	1171	hyperprolactinemia	Disease	D006966	Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1334	1343	prolactin	Gene	5617	After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).
BC8_BioRED_Task1_Doc92	1504	1543	selective serotonin reuptake inhibitors	Chemical	D017367	Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).
BC8_BioRED_Task1_Doc92	1545	1550	SSRIs	Chemical	D017367	Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).
BC8_BioRED_Task1_Doc92	1755	1763	patients	OrganismTaxon	9606	These findings became more marked when the analysis was restricted to non-Hispanic white patients.
BC8_BioRED_Task1_Doc92	1782	1791	fractures	Disease	D050723	Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1810	1821	risperidone	Chemical	D018967	Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1826	1831	SSRIs	Chemical	D017367	Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1867	1875	patients	OrganismTaxon	9606	Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1881	1899	hyperprolactinemia	Disease	D006966	Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
BC8_BioRED_Task1_Doc92	1946	1957	risperidone	Chemical	D018967	CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.
BC8_BioRED_Task1_Doc92	1966	1984	hyperprolactinemia	Disease	D006966	CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.
BC8_BioRED_Task1_Doc92	1989	1993	SSRI	Chemical	D017367	CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.
BC8_BioRED_Task1_Doc92	2181	2189	fracture	Disease	D050723	Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.
BC8_BioRED_Task1_Doc93	31	44	glioblastomas	Disease	D005909	Genetic alterations in primary glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	99	112	glioblastomas	Disease	D005909	Current knowledge of genetic alterations in glioblastomas is based largely on genetic analyses of tumors from mainly caucasian patients in the United States and Europe.
BC8_BioRED_Task1_Doc93	153	159	tumors	Disease	D009369	Current knowledge of genetic alterations in glioblastomas is based largely on genetic analyses of tumors from mainly caucasian patients in the United States and Europe.
BC8_BioRED_Task1_Doc93	182	190	patients	OrganismTaxon	9606	Current knowledge of genetic alterations in glioblastomas is based largely on genetic analyses of tumors from mainly caucasian patients in the United States and Europe.
BC8_BioRED_Task1_Doc93	330	343	glioblastomas	Disease	D005909	In the present study, screening for several key genetic alterations was performed on 77 primary (de novo) glioblastomas in Japanese patients.
BC8_BioRED_Task1_Doc93	356	364	patients	OrganismTaxon	9606	In the present study, screening for several key genetic alterations was performed on 77 primary (de novo) glioblastomas in Japanese patients.
BC8_BioRED_Task1_Doc93	407	411	TP53	Gene	7157	SSCP followed by DNA sequencing revealed TP53 mutations in 16 of 73 (22%) glioblastomas and PTEN mutations in 13 of 63 (21%) cases analyzed.
BC8_BioRED_Task1_Doc93	440	453	glioblastomas	Disease	D005909	SSCP followed by DNA sequencing revealed TP53 mutations in 16 of 73 (22%) glioblastomas and PTEN mutations in 13 of 63 (21%) cases analyzed.
BC8_BioRED_Task1_Doc93	458	462	PTEN	Gene	5728	SSCP followed by DNA sequencing revealed TP53 mutations in 16 of 73 (22%) glioblastomas and PTEN mutations in 13 of 63 (21%) cases analyzed.
BC8_BioRED_Task1_Doc93	546	550	EGFR	Gene	1956	Polymerase chain reaction (PCR) showed EGFR amplification in 25 of 77 (32%) cases and p16 homozygous deletion in 32 of 77 (42%) cases.
BC8_BioRED_Task1_Doc93	593	596	p16	Gene	1029	Polymerase chain reaction (PCR) showed EGFR amplification in 25 of 77 (32%) cases and p16 homozygous deletion in 32 of 77 (42%) cases.
BC8_BioRED_Task1_Doc93	714	727	glioblastomas	Disease	D005909	Quantitative microsatellite analysis revealed LOH 10q in 41 of 59 (69%) glioblastomas.
BC8_BioRED_Task1_Doc93	817	830	glioblastomas	Disease	D005909	The frequencies of these genetic alterations were similar to those reported for primary glioblastomas at the population level in Switzerland.
BC8_BioRED_Task1_Doc93	898	911	glioblastomas	Disease	D005909	As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	964	968	EGFR	Gene	1956	As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	987	990	p16	Gene	1029	As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	1060	1064	TP53	Gene	7157	As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	1079	1082	p16	Gene	1029	As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	1105	1118	glioblastomas	Disease	D005909	As previously observed for glioblastomas in Europe, there was a positive association between EGFR amplification and p16 deletion (p=0.009), whereas there was an inverse association between TP53 mutations and p16 deletion (p=0.049) in glioblastomas in Japan.
BC8_BioRED_Task1_Doc93	1228	1240	glioblastoma	Disease	D005909	Multivariate analyses showed that radiotherapy was significantly predictive for longer survival of glioblastoma patients (p=0.002).
BC8_BioRED_Task1_Doc93	1241	1249	patients	OrganismTaxon	9606	Multivariate analyses showed that radiotherapy was significantly predictive for longer survival of glioblastoma patients (p=0.002).
BC8_BioRED_Task1_Doc93	1335	1339	EGFR	Gene	1956	SSCP followed by DNA sequencing of the kinase domain (exons 18-21) of the EGFR gene revealed mutations in 2 ou of 69 (3%) glioblastomas in Japan and in 4 of 81 (5%) glioblastomas in Switzerland.
BC8_BioRED_Task1_Doc93	1383	1396	glioblastomas	Disease	D005909	SSCP followed by DNA sequencing of the kinase domain (exons 18-21) of the EGFR gene revealed mutations in 2 ou of 69 (3%) glioblastomas in Japan and in 4 of 81 (5%) glioblastomas in Switzerland.
BC8_BioRED_Task1_Doc93	1426	1439	glioblastomas	Disease	D005909	SSCP followed by DNA sequencing of the kinase domain (exons 18-21) of the EGFR gene revealed mutations in 2 ou of 69 (3%) glioblastomas in Japan and in 4 of 81 (5%) glioblastomas in Switzerland.
BC8_BioRED_Task1_Doc93	1499	1516	codon 787 CAG/CAA	SequenceVariant	p|SUB|Q|787|Q	The allele frequencies of polymorphisms at codon 787 CAG/CAA (Gln/Gln) in glioblastomas in Japan were G/G (82.4%), G/A (10.8%), A/A (6.8%), corresponding to G 0.878 versus A 0.122, significantly different from those in glioblastomas in Switzerland: G/G (27.2%), G/A (28.4%), A/A (44.4%), corresponding to G 0.414 versus A 0.586 (p < 0.0001).
BC8_BioRED_Task1_Doc93	1518	1525	Gln/Gln	SequenceVariant	p|SUB|Q||Q	The allele frequencies of polymorphisms at codon 787 CAG/CAA (Gln/Gln) in glioblastomas in Japan were G/G (82.4%), G/A (10.8%), A/A (6.8%), corresponding to G 0.878 versus A 0.122, significantly different from those in glioblastomas in Switzerland: G/G (27.2%), G/A (28.4%), A/A (44.4%), corresponding to G 0.414 versus A 0.586 (p < 0.0001).
BC8_BioRED_Task1_Doc93	1530	1543	glioblastomas	Disease	D005909	The allele frequencies of polymorphisms at codon 787 CAG/CAA (Gln/Gln) in glioblastomas in Japan were G/G (82.4%), G/A (10.8%), A/A (6.8%), corresponding to G 0.878 versus A 0.122, significantly different from those in glioblastomas in Switzerland: G/G (27.2%), G/A (28.4%), A/A (44.4%), corresponding to G 0.414 versus A 0.586 (p < 0.0001).
BC8_BioRED_Task1_Doc93	1675	1688	glioblastomas	Disease	D005909	The allele frequencies of polymorphisms at codon 787 CAG/CAA (Gln/Gln) in glioblastomas in Japan were G/G (82.4%), G/A (10.8%), A/A (6.8%), corresponding to G 0.878 versus A 0.122, significantly different from those in glioblastomas in Switzerland: G/G (27.2%), G/A (28.4%), A/A (44.4%), corresponding to G 0.414 versus A 0.586 (p < 0.0001).
BC8_BioRED_Task1_Doc93	1833	1846	glioblastomas	Disease	D005909	These results suggest that primary glioblastomas in Japan show genetic alterations similar to those in Switzerland, suggesting a similar molecular basis in caucasians and Asians, despite different genetic backgrounds, including different status of a polymorphism in the EGFR gene.
BC8_BioRED_Task1_Doc93	2068	2072	EGFR	Gene	1956	These results suggest that primary glioblastomas in Japan show genetic alterations similar to those in Switzerland, suggesting a similar molecular basis in caucasians and Asians, despite different genetic backgrounds, including different status of a polymorphism in the EGFR gene.
BC8_BioRED_Task1_Doc94	27	36	filamin B	Gene	2317	Differential expression of filamin B splice variants in giant cell tumor cells.
BC8_BioRED_Task1_Doc94	56	72	giant cell tumor	Disease	D005870	Differential expression of filamin B splice variants in giant cell tumor cells.
BC8_BioRED_Task1_Doc94	80	104	Giant cell tumor of bone	Disease	D018212	Giant cell tumor of bone (GCT) is the most commonly reported non-malignant bone tumor in Hong Kong.
BC8_BioRED_Task1_Doc94	106	109	GCT	Disease	D005870	Giant cell tumor of bone (GCT) is the most commonly reported non-malignant bone tumor in Hong Kong.
BC8_BioRED_Task1_Doc94	155	165	bone tumor	Disease	D001859	Giant cell tumor of bone (GCT) is the most commonly reported non-malignant bone tumor in Hong Kong.
BC8_BioRED_Task1_Doc94	193	198	tumor	Disease	D009369	This kind of tumor usually affects people aged 20-40 years.
BC8_BioRED_Task1_Doc94	307	312	tumor	Disease	D009369	Also, it is well known for recurrence locally, especially when the tumor cannot be removed completely.
BC8_BioRED_Task1_Doc94	343	351	Filamins	Gene	2316,2317,2318	Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types.
BC8_BioRED_Task1_Doc94	356	378	actin-binding proteins	Gene	2316,2317,2318	Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types.
BC8_BioRED_Task1_Doc94	415	433	filamin A, B and C	Gene	2316,2317,2318	Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types.
BC8_BioRED_Task1_Doc94	483	487	FLNA	Gene	2316	Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types.
BC8_BioRED_Task1_Doc94	489	493	FLNB	Gene	2317	Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types.
BC8_BioRED_Task1_Doc94	498	502	FLNC	Gene	2318	Filamins are actin-binding proteins which contain three family members, filamin A, B and C. They are the products of three different genes, FLNA, FLNB and FLNC, which can generate various transcript variants in different cell types.
BC8_BioRED_Task1_Doc94	620	626	FLNBv2	Gene	2317	In this study, we focused on the effects of FLNBv2 and FLNBv4 toward GCT cells.
BC8_BioRED_Task1_Doc94	631	637	FLNBv4	Gene	2317	In this study, we focused on the effects of FLNBv2 and FLNBv4 toward GCT cells.
BC8_BioRED_Task1_Doc94	645	648	GCT	Disease	D005870	In this study, we focused on the effects of FLNBv2 and FLNBv4 toward GCT cells.
BC8_BioRED_Task1_Doc94	684	690	FLNBv2	Gene	2317	The only difference between FLNBv2 and FLNBv4 is that FLNBv4 does not contain hinge 1 region.
BC8_BioRED_Task1_Doc94	695	701	FLNBv4	Gene	2317	The only difference between FLNBv2 and FLNBv4 is that FLNBv4 does not contain hinge 1 region.
BC8_BioRED_Task1_Doc94	710	716	FLNBv4	Gene	2317	The only difference between FLNBv2 and FLNBv4 is that FLNBv4 does not contain hinge 1 region.
BC8_BioRED_Task1_Doc94	790	796	FLNBv4	Gene	2317	We found that the relative abundance of FLNBv4 varies among different GCT cell lines while the expression level of FLNBv4 in normal osteoblasts was only marginally detectable.
BC8_BioRED_Task1_Doc94	820	823	GCT	Disease	D005870	We found that the relative abundance of FLNBv4 varies among different GCT cell lines while the expression level of FLNBv4 in normal osteoblasts was only marginally detectable.
BC8_BioRED_Task1_Doc94	865	871	FLNBv4	Gene	2317	We found that the relative abundance of FLNBv4 varies among different GCT cell lines while the expression level of FLNBv4 in normal osteoblasts was only marginally detectable.
BC8_BioRED_Task1_Doc94	970	976	FLNBv4	Gene	2317	In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation.
BC8_BioRED_Task1_Doc94	1000	1005	RANKL	Gene	8600	In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation.
BC8_BioRED_Task1_Doc94	1007	1010	OCN	Gene	632	In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation.
BC8_BioRED_Task1_Doc94	1012	1015	OPG	Gene	4982	In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation.
BC8_BioRED_Task1_Doc94	1020	1025	RUNX2	Gene	860	In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation.
BC8_BioRED_Task1_Doc94	1056	1059	GCT	Disease	D005870	In the functional aspect, overexpression of FLNBv4 led to upregulation of RANKL, OCN, OPG and RUNX2, which are closely related to GCT cell survival and differentiation.
BC8_BioRED_Task1_Doc94	1105	1111	FLNBv4	Gene	2317	Moreover, FLNBv4 can have a negative effect on cell viability of GCT cells when compare with FLNBv2.
BC8_BioRED_Task1_Doc94	1160	1163	GCT	Disease	D005870	Moreover, FLNBv4 can have a negative effect on cell viability of GCT cells when compare with FLNBv2.
BC8_BioRED_Task1_Doc94	1188	1194	FLNBv2	Gene	2317	Moreover, FLNBv4 can have a negative effect on cell viability of GCT cells when compare with FLNBv2.
BC8_BioRED_Task1_Doc94	1232	1236	FLNB	Gene	2317	In conclusion, splicing variants of FLNB are differentially expressed in GCT cells and may play a role in the proliferation and differentiation of tumor cells.
BC8_BioRED_Task1_Doc94	1269	1272	GCT	Disease	D005870	In conclusion, splicing variants of FLNB are differentially expressed in GCT cells and may play a role in the proliferation and differentiation of tumor cells.
BC8_BioRED_Task1_Doc94	1343	1348	tumor	Disease	D009369	In conclusion, splicing variants of FLNB are differentially expressed in GCT cells and may play a role in the proliferation and differentiation of tumor cells.
BC8_BioRED_Task1_Doc95	0	10	Nimodipine	Chemical	D009553	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
BC8_BioRED_Task1_Doc95	20	37	memory impairment	Disease	D008569	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
BC8_BioRED_Task1_Doc95	48	61	nitroglycerin	Chemical	D005996	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
BC8_BioRED_Task1_Doc95	70	81	hypotension	Disease	D007022	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
BC8_BioRED_Task1_Doc95	91	95	mice	OrganismTaxon	10090	Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.
BC8_BioRED_Task1_Doc95	109	120	Hypotension	Disease	D007022	BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.
BC8_BioRED_Task1_Doc95	212	233	cognitive dysfunction	Disease	D003072	BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.
BC8_BioRED_Task1_Doc95	265	275	nimodipine	Chemical	D009553	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
BC8_BioRED_Task1_Doc95	277	281	NIMO	Chemical	D009553	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
BC8_BioRED_Task1_Doc95	312	325	nitroglycerin	Chemical	D005996	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
BC8_BioRED_Task1_Doc95	327	330	NTG	Chemical	D005996	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
BC8_BioRED_Task1_Doc95	340	351	hypotension	Disease	D007022	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
BC8_BioRED_Task1_Doc95	712	716	mice	OrganismTaxon	10090	Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.
BC8_BioRED_Task1_Doc95	790	793	NTG	Chemical	D005996	Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.
BC8_BioRED_Task1_Doc95	825	828	NTG	Chemical	D005996	Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.
BC8_BioRED_Task1_Doc95	852	855	NTG	Chemical	D005996	Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.
BC8_BioRED_Task1_Doc95	860	864	NIMO	Chemical	D009553	Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.
BC8_BioRED_Task1_Doc95	885	889	NIMO	Chemical	D009553	Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.
BC8_BioRED_Task1_Doc95	911	922	hypotension	Disease	D007022	The extent of hypotension and changes in brain tissue oxygenation (PbtO(2)) and in cerebral blood flow were studied in a separate group of animals.
BC8_BioRED_Task1_Doc95	1120	1124	Mice	OrganismTaxon	10090	Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).
BC8_BioRED_Task1_Doc95	1138	1149	hypotensive	Disease	D007022	Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).
BC8_BioRED_Task1_Doc95	1263	1266	NTG	Chemical	D005996	Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).
BC8_BioRED_Task1_Doc95	1269	1273	NIMO	Chemical	D009553	Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).
BC8_BioRED_Task1_Doc95	1286	1289	NTG	Chemical	D005996	Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).
BC8_BioRED_Task1_Doc95	1508	1512	mice	OrganismTaxon	10090	In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.
BC8_BioRED_Task1_Doc95	1567	1570	NTG	Chemical	D005996	In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.
BC8_BioRED_Task1_Doc95	1583	1586	NTG	Chemical	D005996	In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.
BC8_BioRED_Task1_Doc95	1589	1593	NIMO	Chemical	D009553	In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.
BC8_BioRED_Task1_Doc95	1809	1813	mice	OrganismTaxon	10090	Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.
BC8_BioRED_Task1_Doc95	1827	1831	NIMO	Chemical	D009553	Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.
BC8_BioRED_Task1_Doc95	2042	2045	NTG	Chemical	D005996	PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.
BC8_BioRED_Task1_Doc95	2117	2120	NTG	Chemical	D005996	PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.
BC8_BioRED_Task1_Doc95	2123	2127	NIMO	Chemical	D009553	PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.
BC8_BioRED_Task1_Doc95	2259	2262	NTG	Chemical	D005996	CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.
BC8_BioRED_Task1_Doc95	2359	2363	mice	OrganismTaxon	10090	CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.
BC8_BioRED_Task1_Doc95	2389	2400	hypotension	Disease	D007022	CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.
BC8_BioRED_Task1_Doc95	2416	2420	NIMO	Chemical	D009553	NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.
BC8_BioRED_Task1_Doc95	2494	2497	NTG	Chemical	D005996	NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.
BC8_BioRED_Task1_Doc95	2544	2555	hypotension	Disease	D007022	NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.
BC8_BioRED_Task1_Doc95	2580	2584	NIMO	Chemical	D009553	The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.
BC8_BioRED_Task1_Doc95	2635	2642	calcium	Chemical	D002118	The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.
BC8_BioRED_Task1_Doc95	2662	2673	hypotension	Disease	D007022	The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.
BC8_BioRED_Task1_Doc96	14	35	lymph node metastases	Disease	D009362	The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.
BC8_BioRED_Task1_Doc96	39	53	gastric cancer	Disease	D013274	The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.
BC8_BioRED_Task1_Doc96	74	105	angiotensin I-converting enzyme	Gene	1636	The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism.
BC8_BioRED_Task1_Doc96	229	260	angiotensin I-converting enzyme	Gene	1636	PURPOSE: In the present study, we aimed to substantiate the putative significance of angiotensin I-converting enzyme (ACE) on gastric cancer biology by investigating the influence of its gene polymorphism on gastric cancer progression.
BC8_BioRED_Task1_Doc96	262	265	ACE	Gene	1636	PURPOSE: In the present study, we aimed to substantiate the putative significance of angiotensin I-converting enzyme (ACE) on gastric cancer biology by investigating the influence of its gene polymorphism on gastric cancer progression.
BC8_BioRED_Task1_Doc96	270	284	gastric cancer	Disease	D013274	PURPOSE: In the present study, we aimed to substantiate the putative significance of angiotensin I-converting enzyme (ACE) on gastric cancer biology by investigating the influence of its gene polymorphism on gastric cancer progression.
BC8_BioRED_Task1_Doc96	352	366	gastric cancer	Disease	D013274	PURPOSE: In the present study, we aimed to substantiate the putative significance of angiotensin I-converting enzyme (ACE) on gastric cancer biology by investigating the influence of its gene polymorphism on gastric cancer progression.
BC8_BioRED_Task1_Doc96	497	500	ACE	Gene	1636	Amplified ACE gene fragments were separated on agarose gels.
BC8_BioRED_Task1_Doc96	534	541	agarose	Chemical	D012685	Amplified ACE gene fragments were separated on agarose gels.
BC8_BioRED_Task1_Doc96	658	661	ACE	Gene	1636	Local expression of ACE was investigated by immunohistochemistry.
BC8_BioRED_Task1_Doc96	738	752	gastric cancer	Disease	D013274	RESULTS: Twenty-four of 113 (21%) gastric cancer patients had the II, 57 (51%) the ID, and 32 (28%) the DD genotype.
BC8_BioRED_Task1_Doc96	753	761	patients	OrganismTaxon	9606	RESULTS: Twenty-four of 113 (21%) gastric cancer patients had the II, 57 (51%) the ID, and 32 (28%) the DD genotype.
BC8_BioRED_Task1_Doc96	845	848	ACE	Gene	1636	The distribution of the ACE genotypes did not differ significantly from the control group of 189 patients without gastric cancer.
BC8_BioRED_Task1_Doc96	918	926	patients	OrganismTaxon	9606	The distribution of the ACE genotypes did not differ significantly from the control group of 189 patients without gastric cancer.
BC8_BioRED_Task1_Doc96	935	949	gastric cancer	Disease	D013274	The distribution of the ACE genotypes did not differ significantly from the control group of 189 patients without gastric cancer.
BC8_BioRED_Task1_Doc96	964	967	ACE	Gene	1636	However, the ACE genotypes correlated with the number of lymph node metastases and the Unio Internationale Contra Cancrum (UICC) tumor stage.
BC8_BioRED_Task1_Doc96	1008	1029	lymph node metastases	Disease	D009362	However, the ACE genotypes correlated with the number of lymph node metastases and the Unio Internationale Contra Cancrum (UICC) tumor stage.
BC8_BioRED_Task1_Doc96	1080	1085	tumor	Disease	D009369	However, the ACE genotypes correlated with the number of lymph node metastases and the Unio Internationale Contra Cancrum (UICC) tumor stage.
BC8_BioRED_Task1_Doc96	1093	1101	Patients	OrganismTaxon	9606	Patients with the II genotype had a highly significantly smaller number of lymph node metastases (P < 0.001) and a significantly lower UICC tumor stage (P = 0.01) than patients with the DD genotype.
BC8_BioRED_Task1_Doc96	1168	1189	lymph node metastases	Disease	D009362	Patients with the II genotype had a highly significantly smaller number of lymph node metastases (P < 0.001) and a significantly lower UICC tumor stage (P = 0.01) than patients with the DD genotype.
BC8_BioRED_Task1_Doc96	1233	1238	tumor	Disease	D009369	Patients with the II genotype had a highly significantly smaller number of lymph node metastases (P < 0.001) and a significantly lower UICC tumor stage (P = 0.01) than patients with the DD genotype.
BC8_BioRED_Task1_Doc96	1261	1269	patients	OrganismTaxon	9606	Patients with the II genotype had a highly significantly smaller number of lymph node metastases (P < 0.001) and a significantly lower UICC tumor stage (P = 0.01) than patients with the DD genotype.
BC8_BioRED_Task1_Doc96	1325	1330	tumor	Disease	D009369	No correlation was found between tumor type, tumor location, local tumor growth, distant metastases, and the ACE genotype.
BC8_BioRED_Task1_Doc96	1337	1342	tumor	Disease	D009369	No correlation was found between tumor type, tumor location, local tumor growth, distant metastases, and the ACE genotype.
BC8_BioRED_Task1_Doc96	1359	1364	tumor	Disease	D009369	No correlation was found between tumor type, tumor location, local tumor growth, distant metastases, and the ACE genotype.
BC8_BioRED_Task1_Doc96	1381	1391	metastases	Disease	D009362	No correlation was found between tumor type, tumor location, local tumor growth, distant metastases, and the ACE genotype.
BC8_BioRED_Task1_Doc96	1401	1404	ACE	Gene	1636	No correlation was found between tumor type, tumor location, local tumor growth, distant metastases, and the ACE genotype.
BC8_BioRED_Task1_Doc96	1433	1436	ACE	Gene	1636	The expression of ACE in gastric cancer was investigated by immunohistochemistry in 100 of 113 patients.
BC8_BioRED_Task1_Doc96	1440	1454	gastric cancer	Disease	D013274	The expression of ACE in gastric cancer was investigated by immunohistochemistry in 100 of 113 patients.
BC8_BioRED_Task1_Doc96	1510	1518	patients	OrganismTaxon	9606	The expression of ACE in gastric cancer was investigated by immunohistochemistry in 100 of 113 patients.
BC8_BioRED_Task1_Doc96	1520	1523	ACE	Gene	1636	ACE was expressed by endothelial cells in all (100%) specimens and by tumor cells in 56 (56%) specimens.
BC8_BioRED_Task1_Doc96	1590	1595	tumor	Disease	D009369	ACE was expressed by endothelial cells in all (100%) specimens and by tumor cells in 56 (56%) specimens.
BC8_BioRED_Task1_Doc96	1659	1662	ACE	Gene	1636	CONCLUSIONS: Our study shows that ACE is expressed locally in gastric cancer and that the gene polymorphism influences metastatic behavior.
BC8_BioRED_Task1_Doc96	1687	1701	gastric cancer	Disease	D013274	CONCLUSIONS: Our study shows that ACE is expressed locally in gastric cancer and that the gene polymorphism influences metastatic behavior.
BC8_BioRED_Task1_Doc97	14	23	etomidate	Chemical	D005045	Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?
BC8_BioRED_Task1_Doc97	32	41	myoclonus	Disease	D009207	Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?
BC8_BioRED_Task1_Doc97	62	70	Fentanyl	Chemical	D005283	Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?
BC8_BioRED_Task1_Doc97	72	81	midazolam	Chemical	D008874	Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?
BC8_BioRED_Task1_Doc97	230	238	fentanyl	Chemical	D005283	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	240	249	midazolam	Chemical	D008874	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	272	280	fentanyl	Chemical	D005283	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	285	294	midazolam	Chemical	D008874	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	306	315	etomidate	Chemical	D005045	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	324	333	myoclonus	Disease	D009207	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	494	503	etomidate	Chemical	D005045	Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM).
BC8_BioRED_Task1_Doc97	509	517	patients	OrganismTaxon	9606	Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM).
BC8_BioRED_Task1_Doc97	576	584	fentanyl	Chemical	D005283	Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM).
BC8_BioRED_Task1_Doc97	606	615	midazolam	Chemical	D008874	Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM).
BC8_BioRED_Task1_Doc97	644	653	midazolam	Chemical	D008874	Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM).
BC8_BioRED_Task1_Doc97	670	678	fentanyl	Chemical	D005283	Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM).
BC8_BioRED_Task1_Doc97	703	711	Patients	OrganismTaxon	9606	Patients who received the same anesthetic procedure were selected: 2 minutes after intravenous injections of the pretreatment drugs, anesthesia is induced with 0.3 mg.kg-1 etomidate injected intravenously over a period of 20-30 seconds.
BC8_BioRED_Task1_Doc97	875	884	etomidate	Chemical	D005045	Patients who received the same anesthetic procedure were selected: 2 minutes after intravenous injections of the pretreatment drugs, anesthesia is induced with 0.3 mg.kg-1 etomidate injected intravenously over a period of 20-30 seconds.
BC8_BioRED_Task1_Doc97	940	959	Myoclonic movements	Disease	D009069	Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.
BC8_BioRED_Task1_Doc97	1064	1073	etomidate	Chemical	D005045	Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.
BC8_BioRED_Task1_Doc97	1101	1105	pain	Disease	D010146	The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.
BC8_BioRED_Task1_Doc97	1113	1122	etomidate	Chemical	D005045	The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.
BC8_BioRED_Task1_Doc97	1246	1255	myoclonus	Disease	D009207	RESULTS: Study results showed that myoclonus incidence was 85%, 40%, 70%, and 25% in Group NP, Group F, Group M, and Group FM, respectively, and were significantly lower in Group F and Group FM.
BC8_BioRED_Task1_Doc97	1454	1462	fentanyl	Chemical	D005283	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	1481	1489	fentanyl	Chemical	D005283	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	1494	1503	midazolam	Chemical	D008874	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	1532	1541	etomidate	Chemical	D005045	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc97	1550	1559	myoclonus	Disease	D009207	CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.
BC8_BioRED_Task1_Doc98	63	67	SOX2	Gene	6657	Identification of novel mutations and sequence variants in the SOX2 and CHX10 genes in patients with anophthalmia/microphthalmia.
BC8_BioRED_Task1_Doc98	72	77	CHX10	Gene	338917	Identification of novel mutations and sequence variants in the SOX2 and CHX10 genes in patients with anophthalmia/microphthalmia.
BC8_BioRED_Task1_Doc98	87	95	patients	OrganismTaxon	9606	Identification of novel mutations and sequence variants in the SOX2 and CHX10 genes in patients with anophthalmia/microphthalmia.
BC8_BioRED_Task1_Doc98	101	113	anophthalmia	Disease	D000853	Identification of novel mutations and sequence variants in the SOX2 and CHX10 genes in patients with anophthalmia/microphthalmia.
BC8_BioRED_Task1_Doc98	114	128	microphthalmia	Disease	D008850	Identification of novel mutations and sequence variants in the SOX2 and CHX10 genes in patients with anophthalmia/microphthalmia.
BC8_BioRED_Task1_Doc98	156	160	SOX2	Gene	6657	PURPOSE: Mutations in the SOX2 and CHX10 genes have been reported in patients with anophthalmia and/or microphthalmia.
BC8_BioRED_Task1_Doc98	165	170	CHX10	Gene	338917	PURPOSE: Mutations in the SOX2 and CHX10 genes have been reported in patients with anophthalmia and/or microphthalmia.
BC8_BioRED_Task1_Doc98	199	207	patients	OrganismTaxon	9606	PURPOSE: Mutations in the SOX2 and CHX10 genes have been reported in patients with anophthalmia and/or microphthalmia.
BC8_BioRED_Task1_Doc98	213	225	anophthalmia	Disease	D000853	PURPOSE: Mutations in the SOX2 and CHX10 genes have been reported in patients with anophthalmia and/or microphthalmia.
BC8_BioRED_Task1_Doc98	233	247	microphthalmia	Disease	D008850	PURPOSE: Mutations in the SOX2 and CHX10 genes have been reported in patients with anophthalmia and/or microphthalmia.
BC8_BioRED_Task1_Doc98	280	292	anophthalmic	Disease	D000853	In this study, we evaluated 34 anophthalmic/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and CHX10.
BC8_BioRED_Task1_Doc98	293	307	microphthalmic	Disease	D008850	In this study, we evaluated 34 anophthalmic/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and CHX10.
BC8_BioRED_Task1_Doc98	308	315	patient	OrganismTaxon	9606	In this study, we evaluated 34 anophthalmic/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and CHX10.
BC8_BioRED_Task1_Doc98	399	403	SOX2	Gene	6657	In this study, we evaluated 34 anophthalmic/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and CHX10.
BC8_BioRED_Task1_Doc98	408	413	CHX10	Gene	338917	In this study, we evaluated 34 anophthalmic/microphthalmic patient DNA samples (two sets of siblings included) for mutations and sequence variants in SOX2 and CHX10.
BC8_BioRED_Task1_Doc98	501	505	SOX2	Gene	6657	METHODS: Conformational sensitive gel electrophoresis (CSGE) was used for the initial SOX2 and CHX10 screening of 34 affected individuals (two sets of siblings), five unaffected family members, and 80 healthy controls.
BC8_BioRED_Task1_Doc98	510	515	CHX10	Gene	338917	METHODS: Conformational sensitive gel electrophoresis (CSGE) was used for the initial SOX2 and CHX10 screening of 34 affected individuals (two sets of siblings), five unaffected family members, and 80 healthy controls.
BC8_BioRED_Task1_Doc98	634	641	Patient	OrganismTaxon	9606	Patient samples containing heteroduplexes were selected for sequence analysis.
BC8_BioRED_Task1_Doc98	734	738	SOX2	Gene	6657	Base pair changes in SOX2 and CHX10 were confirmed by sequencing bidirectionally in patient samples.
BC8_BioRED_Task1_Doc98	743	748	CHX10	Gene	338917	Base pair changes in SOX2 and CHX10 were confirmed by sequencing bidirectionally in patient samples.
BC8_BioRED_Task1_Doc98	797	804	patient	OrganismTaxon	9606	Base pair changes in SOX2 and CHX10 were confirmed by sequencing bidirectionally in patient samples.
BC8_BioRED_Task1_Doc98	897	901	SOX2	Gene	6657	RESULTS: Two novel heterozygous mutations and two sequence variants (one known) in SOX2 were identified in this cohort.
BC8_BioRED_Task1_Doc98	943	952	c.310 G>T	SequenceVariant	c|SUB|G|310|T	Mutation c.310 G>T (p. Glu104X), found in one patient, was in the region encoding the high mobility group (HMG) DNA-binding domain and resulted in a change from glutamic acid to a stop codon.
BC8_BioRED_Task1_Doc98	954	964	p. Glu104X	SequenceVariant	p|SUB|E|104|X	Mutation c.310 G>T (p. Glu104X), found in one patient, was in the region encoding the high mobility group (HMG) DNA-binding domain and resulted in a change from glutamic acid to a stop codon.
BC8_BioRED_Task1_Doc98	980	987	patient	OrganismTaxon	9606	Mutation c.310 G>T (p. Glu104X), found in one patient, was in the region encoding the high mobility group (HMG) DNA-binding domain and resulted in a change from glutamic acid to a stop codon.
BC8_BioRED_Task1_Doc98	1095	1124	glutamic acid to a stop codon	SequenceVariant	p|SUB|E||X	Mutation c.310 G>T (p. Glu104X), found in one patient, was in the region encoding the high mobility group (HMG) DNA-binding domain and resulted in a change from glutamic acid to a stop codon.
BC8_BioRED_Task1_Doc98	1212	1221	c.549delC	SequenceVariant	rs587776776	The second mutation, noted in two affected siblings, was a single nucleotide deletion c.549delC (p. Pro184ArgfsX19) in the region encoding the activation domain, resulting in a frameshift and premature termination of the coding sequence.
BC8_BioRED_Task1_Doc98	1223	1240	p. Pro184ArgfsX19	SequenceVariant	rs587776776	The second mutation, noted in two affected siblings, was a single nucleotide deletion c.549delC (p. Pro184ArgfsX19) in the region encoding the activation domain, resulting in a frameshift and premature termination of the coding sequence.
BC8_BioRED_Task1_Doc98	1476	1485	c.*557G>A	SequenceVariant	rs77677339	In addition, a novel nucleotide substitution c.*557G>A was identified in the 3'-untranslated region in one patient.
BC8_BioRED_Task1_Doc98	1538	1545	patient	OrganismTaxon	9606	In addition, a novel nucleotide substitution c.*557G>A was identified in the 3'-untranslated region in one patient.
BC8_BioRED_Task1_Doc98	1677	1688	c. *469 C>A	SequenceVariant	rs11915160	A known single nucleotide polymorphism (c. *469 C>A, SNP rs11915160) was also detected in 2 of the 34 patients.
BC8_BioRED_Task1_Doc98	1694	1704	rs11915160	SequenceVariant	rs11915160	A known single nucleotide polymorphism (c. *469 C>A, SNP rs11915160) was also detected in 2 of the 34 patients.
BC8_BioRED_Task1_Doc98	1739	1747	patients	OrganismTaxon	9606	A known single nucleotide polymorphism (c. *469 C>A, SNP rs11915160) was also detected in 2 of the 34 patients.
BC8_BioRED_Task1_Doc98	1762	1767	CHX10	Gene	338917	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1813	1822	c.471 C>T	SequenceVariant	rs35435463	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1824	1835	p.Ser157Ser	SequenceVariant	rs35435463	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1837	1847	rs35435463	SequenceVariant	rs35435463	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1853	1862	c.579 G>A	SequenceVariant	rs182972044	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1864	1876	p. Gln193Gln	SequenceVariant	rs182972044	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1931	1940	c.871 G>A	SequenceVariant	rs75395981	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	1942	1954	p. Asp291Asn	SequenceVariant	rs75395981	Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463) and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel SNP).
BC8_BioRED_Task1_Doc98	2111	2115	SOX2	Gene	6657	CONCLUSIONS: These results support the role of SOX2 in ocular development.
BC8_BioRED_Task1_Doc98	2147	2151	SOX2	Gene	6657	Loss of SOX2 function results in severe eye malformation.
BC8_BioRED_Task1_Doc98	2179	2195	eye malformation	Disease	D005124	Loss of SOX2 function results in severe eye malformation.
BC8_BioRED_Task1_Doc98	2197	2202	CHX10	Gene	338917	CHX10 was not implicated with microphthalmia/anophthalmia in our patient cohort.
BC8_BioRED_Task1_Doc98	2227	2241	microphthalmia	Disease	D008850	CHX10 was not implicated with microphthalmia/anophthalmia in our patient cohort.
BC8_BioRED_Task1_Doc98	2242	2254	anophthalmia	Disease	D000853	CHX10 was not implicated with microphthalmia/anophthalmia in our patient cohort.
BC8_BioRED_Task1_Doc98	2262	2269	patient	OrganismTaxon	9606	CHX10 was not implicated with microphthalmia/anophthalmia in our patient cohort.
BC8_BioRED_Task1_Doc99	66	74	patients	OrganismTaxon	9606	Coincidence of mutations in different connexin genes in Hungarian patients.
BC8_BioRED_Task1_Doc99	93	97	GJB2	Gene	2706	Mutations in the GJB2 gene are the most common cause of hereditary prelingual sensorineural hearing impairment in Europe.
BC8_BioRED_Task1_Doc99	154	186	sensorineural hearing impairment	Disease	D034381	Mutations in the GJB2 gene are the most common cause of hereditary prelingual sensorineural hearing impairment in Europe.
BC8_BioRED_Task1_Doc99	405	423	hearing impairment	Disease	D034381	Mutations in different connexin genes may accumulate and, consequently lead to hearing impairment.
BC8_BioRED_Task1_Doc99	461	465	GJB2	Gene	2706	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	516	520	GJB2	Gene	2706	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	527	535	patients	OrganismTaxon	9606	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	541	559	hearing impairment	Disease	D034381	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	607	611	GJB6	Gene	10804	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	616	620	GJB3	Gene	2707	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	657	661	GJB2	Gene	2706	Therefore, we screened 47 Hungarian GJB2- heterozygous (one mutation in coding exon of the GJB2 gene) patients with hearing impairment for DNA changes in two further connexin genes (GJB6 and GJB3) and in the 5' non-coding region of GJB2 including the splice sites.
BC8_BioRED_Task1_Doc99	707	711	GJB2	Gene	2706	Eleven out of 47 GJB2-heterozygous patients analyzed carried the splice site mutation -3170G>A in the 5'UTR region of GJB2.
BC8_BioRED_Task1_Doc99	725	733	patients	OrganismTaxon	9606	Eleven out of 47 GJB2-heterozygous patients analyzed carried the splice site mutation -3170G>A in the 5'UTR region of GJB2.
BC8_BioRED_Task1_Doc99	776	784	-3170G>A	SequenceVariant	c|SUB|G|-3170|A	Eleven out of 47 GJB2-heterozygous patients analyzed carried the splice site mutation -3170G>A in the 5'UTR region of GJB2.
BC8_BioRED_Task1_Doc99	808	812	GJB2	Gene	2706	Eleven out of 47 GJB2-heterozygous patients analyzed carried the splice site mutation -3170G>A in the 5'UTR region of GJB2.
BC8_BioRED_Task1_Doc99	834	842	patients	OrganismTaxon	9606	One out of these 11 patients showed homozygous -3170G>A genotype in combination with p.R127H.
BC8_BioRED_Task1_Doc99	861	869	-3170G>A	SequenceVariant	c|SUB|G|-3170|A	One out of these 11 patients showed homozygous -3170G>A genotype in combination with p.R127H.
BC8_BioRED_Task1_Doc99	899	906	p.R127H	SequenceVariant	rs111033196	One out of these 11 patients showed homozygous -3170G>A genotype in combination with p.R127H.
BC8_BioRED_Task1_Doc99	920	924	GJB2	Gene	2706	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	967	971	GJB6	Gene	10804	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	979	983	GJB6	Gene	10804	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	1047	1051	GJB3	Gene	2707	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	1053	1061	c.357C>T	SequenceVariant	rs41310442	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	1063	1071	c.798C>T	SequenceVariant	rs35983826	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	1076	1083	c.94C>T	SequenceVariant	rs1805063	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	1085	1091	p.R32W	SequenceVariant	rs1805063	Next to the GJB2 mutations we noted 2 cases of deletion in GJB6 [Delta(GJB6-D13S1830)] and 3 (2 new and 1 described) base substitutions in GJB3 [c.357C>T, c.798C>T and c.94C>T (p.R32W)] which are unlikely disease-causing.
BC8_BioRED_Task1_Doc99	1210	1218	-3170G>A	SequenceVariant	c|SUB|G|-3170|A	Our results suggest the importance of routine screening for the rather frequent -3170G>A mutation (in addition to c.35delG) in patients with hearing impairment.
BC8_BioRED_Task1_Doc99	1244	1252	c.35delG	SequenceVariant	rs80338939	Our results suggest the importance of routine screening for the rather frequent -3170G>A mutation (in addition to c.35delG) in patients with hearing impairment.
BC8_BioRED_Task1_Doc99	1257	1265	patients	OrganismTaxon	9606	Our results suggest the importance of routine screening for the rather frequent -3170G>A mutation (in addition to c.35delG) in patients with hearing impairment.
BC8_BioRED_Task1_Doc99	1271	1289	hearing impairment	Disease	D034381	Our results suggest the importance of routine screening for the rather frequent -3170G>A mutation (in addition to c.35delG) in patients with hearing impairment.
BC8_BioRED_Task1_Doc100	14	23	valsartan	Chemical	C081489	Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
BC8_BioRED_Task1_Doc100	24	43	hydrochlorothiazide	Chemical	D006852	Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
BC8_BioRED_Task1_Doc100	195	207	hypertensive	Disease	D006973	Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
BC8_BioRED_Task1_Doc100	241	249	patients	OrganismTaxon	9606	BACKGROUND: One third of patients treated for hypertension attain adequate blood pressure (BP) control, and multidrug regimens are often required.
BC8_BioRED_Task1_Doc100	262	274	hypertension	Disease	D006973	BACKGROUND: One third of patients treated for hypertension attain adequate blood pressure (BP) control, and multidrug regimens are often required.
BC8_BioRED_Task1_Doc100	392	404	hypertension	Disease	D006973	Given the lifelong nature of hypertension, there is a need to evaluate the long-term efficacy and tolerability of higher doses of combination anti-hypertensive therapies.
BC8_BioRED_Task1_Doc100	510	522	hypertensive	Disease	D006973	Given the lifelong nature of hypertension, there is a need to evaluate the long-term efficacy and tolerability of higher doses of combination anti-hypertensive therapies.
BC8_BioRED_Task1_Doc100	602	611	valsartan	Chemical	C081489	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
BC8_BioRED_Task1_Doc100	613	616	VAL	Chemical	C081489	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
BC8_BioRED_Task1_Doc100	621	640	hydrochlorothiazide	Chemical	D006852	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
BC8_BioRED_Task1_Doc100	642	646	HCTZ	Chemical	D006852	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
BC8_BioRED_Task1_Doc100	692	700	patients	OrganismTaxon	9606	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
BC8_BioRED_Task1_Doc100	706	728	essential hypertension	Disease	D000075222	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
BC8_BioRED_Task1_Doc100	864	872	Patients	OrganismTaxon	9606	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
BC8_BioRED_Task1_Doc100	878	900	essential hypertension	Disease	D000075222	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
BC8_BioRED_Task1_Doc100	1012	1015	VAL	Chemical	C081489	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
BC8_BioRED_Task1_Doc100	1031	1035	HCTZ	Chemical	D006852	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
BC8_BioRED_Task1_Doc100	1051	1054	VAL	Chemical	C081489	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
BC8_BioRED_Task1_Doc100	1055	1059	HCTZ	Chemical	D006852	Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
BC8_BioRED_Task1_Doc100	1215	1218	VAL	Chemical	C081489	VAL/HCTZ 320/12.5 and 320/25 mg were further investigated in a 54-week, open-label extension.
BC8_BioRED_Task1_Doc100	1219	1223	HCTZ	Chemical	D006852	VAL/HCTZ 320/12.5 and 320/25 mg were further investigated in a 54-week, open-label extension.
BC8_BioRED_Task1_Doc100	1650	1658	patients	OrganismTaxon	9606	RESULTS: A total of 1346 patients were randomized into the 8-week core study (734 men, 612 women; 924 white, 291 black, 23 Asian, 108 other; mean age, 52.7 years; mean weight, 92.6 kg).
BC8_BioRED_Task1_Doc100	1707	1710	men	OrganismTaxon	9606	RESULTS: A total of 1346 patients were randomized into the 8-week core study (734 men, 612 women; 924 white, 291 black, 23 Asian, 108 other; mean age, 52.7 years; mean weight, 92.6 kg).
BC8_BioRED_Task1_Doc100	1716	1721	women	OrganismTaxon	9606	RESULTS: A total of 1346 patients were randomized into the 8-week core study (734 men, 612 women; 924 white, 291 black, 23 Asian, 108 other; mean age, 52.7 years; mean weight, 92.6 kg).
BC8_BioRED_Task1_Doc100	2017	2020	VAL	Chemical	C081489	All active treatments were associated with significantly reduced MSSBP and MSDBP during the core 8-week study, with each monotherapy significantly contributing to the overall effect of combination therapy (VAL and HCTZ, P < 0.001).
BC8_BioRED_Task1_Doc100	2025	2029	HCTZ	Chemical	D006852	All active treatments were associated with significantly reduced MSSBP and MSDBP during the core 8-week study, with each monotherapy significantly contributing to the overall effect of combination therapy (VAL and HCTZ, P < 0.001).
BC8_BioRED_Task1_Doc100	2233	2236	VAL	Chemical	C081489	The mean reduction in MSSBP/MSDBP with VAL/HCTZ 320/25 mg was 24.7/16.6 mm Hg, compared with 5.9/7.0 mm Hg with placebo.
BC8_BioRED_Task1_Doc100	2237	2241	HCTZ	Chemical	D006852	The mean reduction in MSSBP/MSDBP with VAL/HCTZ 320/25 mg was 24.7/16.6 mm Hg, compared with 5.9/7.0 mm Hg with placebo.
BC8_BioRED_Task1_Doc100	2369	2372	VAL	Chemical	C081489	The reduction in MSSBP was significantly greater with VAL/HCTZ 320/25 mg compared with VAL/HCTZ 160/12.5 mg (P < 0.002).
BC8_BioRED_Task1_Doc100	2373	2377	HCTZ	Chemical	D006852	The reduction in MSSBP was significantly greater with VAL/HCTZ 320/25 mg compared with VAL/HCTZ 160/12.5 mg (P < 0.002).
BC8_BioRED_Task1_Doc100	2402	2405	VAL	Chemical	C081489	The reduction in MSSBP was significantly greater with VAL/HCTZ 320/25 mg compared with VAL/HCTZ 160/12.5 mg (P < 0.002).
BC8_BioRED_Task1_Doc100	2406	2410	HCTZ	Chemical	D006852	The reduction in MSSBP was significantly greater with VAL/HCTZ 320/25 mg compared with VAL/HCTZ 160/12.5 mg (P < 0.002).
BC8_BioRED_Task1_Doc100	2609	2620	hypokalemia	Disease	D007008	The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
BC8_BioRED_Task1_Doc100	2636	2639	VAL	Chemical	C081489	The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
BC8_BioRED_Task1_Doc100	2640	2644	HCTZ	Chemical	D006852	The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
BC8_BioRED_Task1_Doc100	2680	2684	HCTZ	Chemical	D006852	The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
BC8_BioRED_Task1_Doc100	2830	2833	VAL	Chemical	C081489	The efficacy and tolerability of VAL/HCTZ combinations were maintained during the extension (797 patients).
BC8_BioRED_Task1_Doc100	2834	2838	HCTZ	Chemical	D006852	The efficacy and tolerability of VAL/HCTZ combinations were maintained during the extension (797 patients).
BC8_BioRED_Task1_Doc100	2894	2902	patients	OrganismTaxon	9606	The efficacy and tolerability of VAL/HCTZ combinations were maintained during the extension (797 patients).
BC8_BioRED_Task1_Doc100	2971	2974	VAL	Chemical	C081489	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.
BC8_BioRED_Task1_Doc100	2975	2979	HCTZ	Chemical	D006852	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.
BC8_BioRED_Task1_Doc100	3122	3133	hypokalemia	Disease	D007008	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.
BC8_BioRED_Task1_Doc100	3139	3143	HCTZ	Chemical	D006852	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.
BC8_BioRED_Task1_Doc101	0	4	MDMA	Chemical	D018817	MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
BC8_BioRED_Task1_Doc101	85	134	impaired social and emotional judgement processes	Disease	D003072	MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
BC8_BioRED_Task1_Doc101	160	175	memory deficits	Disease	D008569	In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).
BC8_BioRED_Task1_Doc101	207	211	MDMA	Chemical	D018817	In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).
BC8_BioRED_Task1_Doc101	213	246	3,4-methylenedioxymethamphetamine	Chemical	D018817	In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).
BC8_BioRED_Task1_Doc101	248	255	ecstasy	Chemical	D018817	In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).
BC8_BioRED_Task1_Doc101	306	310	MDMA	Chemical	D018817	The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on "prefrontal" mediated social and emotional judgement processes.
BC8_BioRED_Task1_Doc101	501	508	ecstasy	Chemical	D018817	Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).
BC8_BioRED_Task1_Doc101	535	542	ecstasy	Chemical	D018817	Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).
BC8_BioRED_Task1_Doc101	865	869	MDMA	Chemical	D018817	Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.
BC8_BioRED_Task1_Doc101	894	898	MDMA	Chemical	D018817	Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.
BC8_BioRED_Task1_Doc101	1246	1253	ecstasy	Chemical	D018817	These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use.
BC8_BioRED_Task1_Doc102	0	29	X-linked adrenoleukodystrophy	Disease	D000326	X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes.
BC8_BioRED_Task1_Doc102	31	34	ALD	Disease	D000326	X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes.
BC8_BioRED_Task1_Doc102	61	64	ALD	Gene	215	X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes.
BC8_BioRED_Task1_Doc102	152	172	adrenoleukodystrophy	Disease	D000326	Fragments of the adrenoleukodystrophy (ALD) cDNA from a patient with adolescent ALD were amplified by polymerase chain reaction and subcloned.
BC8_BioRED_Task1_Doc102	174	177	ALD	Disease	D000326	Fragments of the adrenoleukodystrophy (ALD) cDNA from a patient with adolescent ALD were amplified by polymerase chain reaction and subcloned.
BC8_BioRED_Task1_Doc102	191	198	patient	OrganismTaxon	9606	Fragments of the adrenoleukodystrophy (ALD) cDNA from a patient with adolescent ALD were amplified by polymerase chain reaction and subcloned.
BC8_BioRED_Task1_Doc102	215	218	ALD	Disease	D000326	Fragments of the adrenoleukodystrophy (ALD) cDNA from a patient with adolescent ALD were amplified by polymerase chain reaction and subcloned.
BC8_BioRED_Task1_Doc102	324	327	ALD	Gene	215	Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine.
BC8_BioRED_Task1_Doc102	345	396	cytosine to guanine transversion at nucleotide 1451	SequenceVariant	rs128624214	Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine.
BC8_BioRED_Task1_Doc102	440	463	proline 484 by arginine	SequenceVariant	rs128624214	Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine.
BC8_BioRED_Task1_Doc102	494	501	patient	OrganismTaxon	9606	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc102	527	530	ALD	Disease	D000326	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc102	536	557	adrenomyeloneuropathy	Disease	D000326	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc102	563	570	Addison	Disease	D000224	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc102	633	655	long chain fatty acids	Chemical	D005227	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc102	745	748	ALD	Disease	D000326	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc102	749	757	patients	OrganismTaxon	9606	Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls.
BC8_BioRED_Task1_Doc103	50	55	human	OrganismTaxon	9606	A novel missense mutation in the paired domain of human PAX9 causes oligodontia.
BC8_BioRED_Task1_Doc103	56	60	PAX9	Gene	5083	A novel missense mutation in the paired domain of human PAX9 causes oligodontia.
BC8_BioRED_Task1_Doc103	68	79	oligodontia	Disease	C538049	A novel missense mutation in the paired domain of human PAX9 causes oligodontia.
BC8_BioRED_Task1_Doc103	81	85	PAX9	Gene	5083	PAX9 and MSX1 are transcription factors that play essential roles in craniofacial and limb development.
BC8_BioRED_Task1_Doc103	90	94	MSX1	Gene	4487	PAX9 and MSX1 are transcription factors that play essential roles in craniofacial and limb development.
BC8_BioRED_Task1_Doc103	188	194	humans	OrganismTaxon	9606	In humans, mutations in both genes are associated with nonsyndromic and syndromic oligodontia, respectively.
BC8_BioRED_Task1_Doc103	240	278	nonsyndromic and syndromic oligodontia	Disease	C538049	In humans, mutations in both genes are associated with nonsyndromic and syndromic oligodontia, respectively.
BC8_BioRED_Task1_Doc103	322	346	nonsyndromic oligodontia	Disease	C538049	We screened one family with nonsyndromic oligodontia for mutations in PAX9 and MSX1.
BC8_BioRED_Task1_Doc103	364	368	PAX9	Gene	5083	We screened one family with nonsyndromic oligodontia for mutations in PAX9 and MSX1.
BC8_BioRED_Task1_Doc103	373	377	MSX1	Gene	4487	We screened one family with nonsyndromic oligodontia for mutations in PAX9 and MSX1.
BC8_BioRED_Task1_Doc103	484	489	C139T	SequenceVariant	rs121917720	Single stranded conformational polymorphism (SSCP) analysis and sequencing revealed a novel heterozygous C139T transition in PAX9 in the affected members of the family.
BC8_BioRED_Task1_Doc103	504	508	PAX9	Gene	5083	Single stranded conformational polymorphism (SSCP) analysis and sequencing revealed a novel heterozygous C139T transition in PAX9 in the affected members of the family.
BC8_BioRED_Task1_Doc103	614	618	MSX1	Gene	4487	There were no mutations detected in the entire coding sequence of MSX1.
BC8_BioRED_Task1_Doc103	624	629	C139T	SequenceVariant	rs121917720	The C139T mutation, predicted to result in the substitution of an arginine by a tryptophan (R47W) in the N-terminal subdomain, affected conserved residues in the PAX9 paired domain.
BC8_BioRED_Task1_Doc103	686	710	arginine by a tryptophan	SequenceVariant	rs121917720	The C139T mutation, predicted to result in the substitution of an arginine by a tryptophan (R47W) in the N-terminal subdomain, affected conserved residues in the PAX9 paired domain.
BC8_BioRED_Task1_Doc103	712	716	R47W	SequenceVariant	rs121917720	The C139T mutation, predicted to result in the substitution of an arginine by a tryptophan (R47W) in the N-terminal subdomain, affected conserved residues in the PAX9 paired domain.
BC8_BioRED_Task1_Doc103	782	786	PAX9	Gene	5083	The C139T mutation, predicted to result in the substitution of an arginine by a tryptophan (R47W) in the N-terminal subdomain, affected conserved residues in the PAX9 paired domain.
BC8_BioRED_Task1_Doc103	850	871	oligodontia phenotype	Disease	C538049	To elucidate the pathogenic mechanism producing oligodontia phenotype caused by this mutation, we analyzed the binding of wild-type and mutant PAX9 paired domain protein to double-stranded DNA targets.
BC8_BioRED_Task1_Doc103	945	949	PAX9	Gene	5083	To elucidate the pathogenic mechanism producing oligodontia phenotype caused by this mutation, we analyzed the binding of wild-type and mutant PAX9 paired domain protein to double-stranded DNA targets.
BC8_BioRED_Task1_Doc103	1008	1012	R47W	SequenceVariant	rs121917720	The R47W mutation dramatically reduced DNA binding suggesting that the mutant protein with consequent haploinsufficiency results in a clinical phenotype.
BC8_BioRED_Task1_Doc104	0	13	Antipsychotic	Chemical	D014150	Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
BC8_BioRED_Task1_Doc104	30	42	thioperamide	Chemical	C052075	Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
BC8_BioRED_Task1_Doc104	56	67	H3-receptor	Gene	99296	Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
BC8_BioRED_Task1_Doc104	82	86	mice	OrganismTaxon	10090	Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
BC8_BioRED_Task1_Doc104	195	208	schizophrenia	Disease	D012559	Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia.
BC8_BioRED_Task1_Doc104	264	287	histamine H(3)-receptor	Gene	99296	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
BC8_BioRED_Task1_Doc104	299	310	neuroleptic	Chemical	D014150	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
BC8_BioRED_Task1_Doc104	319	328	catalepsy	Disease	D002375	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
BC8_BioRED_Task1_Doc104	330	341	apomorphine	Chemical	D001058	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
BC8_BioRED_Task1_Doc104	372	383	amphetamine	Chemical	D000661	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
BC8_BioRED_Task1_Doc104	416	420	mice	OrganismTaxon	10090	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.
BC8_BioRED_Task1_Doc104	422	431	Catalepsy	Disease	D002375	Catalepsy was induced by haloperidol (2 mg/kg p.o.
BC8_BioRED_Task1_Doc104	447	458	haloperidol	Chemical	D006220	Catalepsy was induced by haloperidol (2 mg/kg p.o.
BC8_BioRED_Task1_Doc104	481	492	apomorphine	Chemical	D001058	), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.
BC8_BioRED_Task1_Doc104	514	525	amphetamine	Chemical	D000661	), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.
BC8_BioRED_Task1_Doc104	622	647	(R)-alpha-methylhistamine	Chemical	C069357	(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.)
BC8_BioRED_Task1_Doc104	649	653	RAMH	Chemical	C069357	(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.)
BC8_BioRED_Task1_Doc104	677	689	thioperamide	Chemical	C052075	and thioperamide (THP) (15 mg/kg i.p.
BC8_BioRED_Task1_Doc104	691	694	THP	Chemical	C052075	and thioperamide (THP) (15 mg/kg i.p.
BC8_BioRED_Task1_Doc104	734	743	catalepsy	Disease	D002375	), per se did not cause catalepsy.
BC8_BioRED_Task1_Doc104	763	766	THP	Chemical	C052075	Administration of THP (3.75, 7.5 and 15 mg/kg i.p.)
BC8_BioRED_Task1_Doc104	810	821	haloperidol	Chemical	D006220	1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).
BC8_BioRED_Task1_Doc104	867	876	catalepsy	Disease	D002375	1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).
BC8_BioRED_Task1_Doc104	922	926	RAMH	Chemical	C069357	However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).
BC8_BioRED_Task1_Doc104	968	971	THP	Chemical	C052075	However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).
BC8_BioRED_Task1_Doc104	989	993	RAMH	Chemical	C069357	RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.)
BC8_BioRED_Task1_Doc104	1089	1092	THP	Chemical	C052075	RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.)
BC8_BioRED_Task1_Doc104	1154	1165	amphetamine	Chemical	D000661	On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.)
BC8_BioRED_Task1_Doc104	1174	1187	hyperactivity	Disease	D006948	On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.)
BC8_BioRED_Task1_Doc104	1189	1192	THP	Chemical	C052075	On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.)
BC8_BioRED_Task1_Doc104	1309	1313	RAMH	Chemical	C069357	Pretreatment with RAMH (5 microg i.c.v.)
BC8_BioRED_Task1_Doc104	1372	1375	THP	Chemical	C052075	could partially reverse such effects of THP (3.75 mg/kg i.p.).
BC8_BioRED_Task1_Doc104	1424	1435	apomorphine	Chemical	D001058	Climbing behavior induced by apomorphine was reduced in animals treated with THP.
BC8_BioRED_Task1_Doc104	1472	1475	THP	Chemical	C052075	Climbing behavior induced by apomorphine was reduced in animals treated with THP.
BC8_BioRED_Task1_Doc104	1530	1534	RAMH	Chemical	C069357	Such an effect was, however, reversed in presence of RAMH.
BC8_BioRED_Task1_Doc104	1536	1539	THP	Chemical	C052075	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1553	1566	antipsychotic	Chemical	D014150	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1596	1607	haloperidol	Chemical	D006220	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1616	1625	catalepsy	Disease	D002375	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1636	1647	amphetamine	Chemical	D000661	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1656	1669	hyperactivity	Disease	D006948	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1683	1694	apomorphine	Chemical	D001058	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1715	1719	mice	OrganismTaxon	10090	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.
BC8_BioRED_Task1_Doc104	1737	1740	THP	Chemical	C052075	Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.
BC8_BioRED_Task1_Doc104	1758	1762	RAMH	Chemical	C069357	Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.
BC8_BioRED_Task1_Doc104	1793	1817	histamine H(3)-receptors	Gene	99296	Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.
BC8_BioRED_Task1_Doc104	1852	1877	H(3)-receptor antagonists	Chemical	D054828	Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia.
BC8_BioRED_Task1_Doc104	1915	1928	schizophrenia	Disease	D012559	Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia.
BC8_BioRED_Task1_Doc105	0	27	Metalloprotease-disintegrin	Gene	8038	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
BC8_BioRED_Task1_Doc105	28	34	ADAM12	Gene	8038	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
BC8_BioRED_Task1_Doc105	85	92	claudin	Gene	9076	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
BC8_BioRED_Task1_Doc105	97	110	breast cancer	Disease	D001943	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
BC8_BioRED_Task1_Doc105	124	130	ADAM12	Gene	8038	BACKGROUND: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors.
BC8_BioRED_Task1_Doc105	149	154	human	OrganismTaxon	9606	BACKGROUND: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors.
BC8_BioRED_Task1_Doc105	155	169	breast cancers	Disease	D001943	BACKGROUND: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors.
BC8_BioRED_Task1_Doc105	211	228	estrogen receptor	Gene	2099	BACKGROUND: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors.
BC8_BioRED_Task1_Doc105	238	244	tumors	Disease	D009369	BACKGROUND: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors.
BC8_BioRED_Task1_Doc105	246	252	ADAM12	Gene	8038	ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers.
BC8_BioRED_Task1_Doc105	335	342	claudin	Gene	9076	ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers.
BC8_BioRED_Task1_Doc105	347	360	breast tumors	Disease	D001943	ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers.
BC8_BioRED_Task1_Doc105	384	390	cancer	Disease	D009369	ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers.
BC8_BioRED_Task1_Doc105	448	454	ADAM12	Gene	8038	It is currently unknown whether ADAM12 plays an active role in promoting the CSC phenotype in breast cancer cells.
BC8_BioRED_Task1_Doc105	510	523	breast cancer	Disease	D001943	It is currently unknown whether ADAM12 plays an active role in promoting the CSC phenotype in breast cancer cells.
BC8_BioRED_Task1_Doc105	540	546	ADAM12	Gene	8038	METHODS: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.
BC8_BioRED_Task1_Doc105	594	601	claudin	Gene	9076	METHODS: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.
BC8_BioRED_Task1_Doc105	606	619	breast cancer	Disease	D001943	METHODS: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.
BC8_BioRED_Task1_Doc105	632	640	SUM159PT	CellLine	CVCL_5423	METHODS: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.
BC8_BioRED_Task1_Doc105	645	651	Hs578T	CellLine	CVCL_0332	METHODS: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT and Hs578T, using siRNA transfection or inducible shRNA expression.
BC8_BioRED_Task1_Doc105	852	856	ALDH	Gene	217	Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated.
BC8_BioRED_Task1_Doc105	889	893	CD44	Gene	960	Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated.
BC8_BioRED_Task1_Doc105	898	902	CD24	Gene	100133941	Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated.
BC8_BioRED_Task1_Doc105	938	943	tumor	Disease	D009369	Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated.
BC8_BioRED_Task1_Doc105	957	961	mice	OrganismTaxon	10090	Cell characteristics commonly associated with the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution transplantation assays) were evaluated.
BC8_BioRED_Task1_Doc105	1104	1110	ADAM12	Gene	8038	RNA sequencing was performed to identify global gene expression changes after ADAM12 knockdown.
BC8_BioRED_Task1_Doc105	1152	1160	SUM159PT	CellLine	CVCL_5423	RESULTS: We found that sorted SUM159PT cell populations with high ADAM12 levels had elevated expression of CSC markers and an increased ability to form mammospheres.
BC8_BioRED_Task1_Doc105	1188	1194	ADAM12	Gene	8038	RESULTS: We found that sorted SUM159PT cell populations with high ADAM12 levels had elevated expression of CSC markers and an increased ability to form mammospheres.
BC8_BioRED_Task1_Doc105	1288	1294	ADAM12	Gene	8038	ADAM12 knockdown reduced cell migration and invasion, decreased anoikis resistance, and compromised mammosphere formation.
BC8_BioRED_Task1_Doc105	1411	1417	ADAM12	Gene	8038	ADAM12 knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo.
BC8_BioRED_Task1_Doc105	1461	1465	CD44	Gene	960	ADAM12 knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo.
BC8_BioRED_Task1_Doc105	1470	1474	CD24	Gene	100133941	ADAM12 knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo.
BC8_BioRED_Task1_Doc105	1527	1540	tumorigenesis	Disease	D009369	ADAM12 knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo.
BC8_BioRED_Task1_Doc105	1544	1548	mice	OrganismTaxon	10090	ADAM12 knockdown also diminished ALDEFLUOR(+) and CD44(hi)/CD24(-/lo) CSC-enriched populations in vitro and reduced tumorigenesis in mice in vivo.
BC8_BioRED_Task1_Doc105	1614	1620	ADAM12	Gene	8038	RNA sequencing identified a significant overlap between ADAM12- and Epidermal Growth Factor Receptor (EGFR)-regulated genes.
BC8_BioRED_Task1_Doc105	1626	1658	Epidermal Growth Factor Receptor	Gene	1956	RNA sequencing identified a significant overlap between ADAM12- and Epidermal Growth Factor Receptor (EGFR)-regulated genes.
BC8_BioRED_Task1_Doc105	1660	1664	EGFR	Gene	1956	RNA sequencing identified a significant overlap between ADAM12- and Epidermal Growth Factor Receptor (EGFR)-regulated genes.
BC8_BioRED_Task1_Doc105	1697	1703	ADAM12	Gene	8038	Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this effect was abolished by batimastat, a metalloproteinase inhibitor.
BC8_BioRED_Task1_Doc105	1752	1756	EGFR	Gene	1956	Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this effect was abolished by batimastat, a metalloproteinase inhibitor.
BC8_BioRED_Task1_Doc105	1791	1801	batimastat	Chemical	C080985	Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this effect was abolished by batimastat, a metalloproteinase inhibitor.
BC8_BioRED_Task1_Doc105	1805	1822	metalloproteinase	Gene	8038	Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this effect was abolished by batimastat, a metalloproteinase inhibitor.
BC8_BioRED_Task1_Doc105	1890	1893	EGF	Gene	1950	Furthermore, incubation of cells with exogenously added EGF prevented the downregulation of CD44(hi)/CD24(-/lo) cell population by ADAM12 knockdown.
BC8_BioRED_Task1_Doc105	1926	1930	CD44	Gene	960	Furthermore, incubation of cells with exogenously added EGF prevented the downregulation of CD44(hi)/CD24(-/lo) cell population by ADAM12 knockdown.
BC8_BioRED_Task1_Doc105	1935	1939	CD24	Gene	100133941	Furthermore, incubation of cells with exogenously added EGF prevented the downregulation of CD44(hi)/CD24(-/lo) cell population by ADAM12 knockdown.
BC8_BioRED_Task1_Doc105	1965	1971	ADAM12	Gene	8038	Furthermore, incubation of cells with exogenously added EGF prevented the downregulation of CD44(hi)/CD24(-/lo) cell population by ADAM12 knockdown.
BC8_BioRED_Task1_Doc105	2024	2030	ADAM12	Gene	8038	CONCLUSIONS: These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the EGFR pathway.
BC8_BioRED_Task1_Doc105	2070	2077	claudin	Gene	9076	CONCLUSIONS: These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the EGFR pathway.
BC8_BioRED_Task1_Doc105	2082	2095	breast cancer	Disease	D001943	CONCLUSIONS: These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the EGFR pathway.
BC8_BioRED_Task1_Doc105	2124	2128	EGFR	Gene	1956	CONCLUSIONS: These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast cancer cells via modulation of the EGFR pathway.
BC8_BioRED_Task1_Doc106	26	33	calcium	Chemical	D002118	Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy.
BC8_BioRED_Task1_Doc106	50	58	CACNA2D4	Gene	93589	Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy.
BC8_BioRED_Task1_Doc106	86	100	cone dystrophy	Disease	D000077765	Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy.
BC8_BioRED_Task1_Doc106	183	190	calcium	Chemical	D002118	Retinal signal transmission depends on the activity of high voltage-gated l-type calcium channels in photoreceptor ribbon synapses.
BC8_BioRED_Task1_Doc106	297	305	Cacna2d4	Gene	319734	We recently identified a truncating frameshift mutation in the Cacna2d4 gene in a spontaneous mouse mutant with profound loss of retinal signaling and an abnormal morphology of ribbon synapses in rods and cones.
BC8_BioRED_Task1_Doc106	328	333	mouse	OrganismTaxon	10090	We recently identified a truncating frameshift mutation in the Cacna2d4 gene in a spontaneous mouse mutant with profound loss of retinal signaling and an abnormal morphology of ribbon synapses in rods and cones.
BC8_BioRED_Task1_Doc106	450	458	Cacna2d4	Gene	319734	The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type.
BC8_BioRED_Task1_Doc106	475	543	l-type calcium-channel auxiliary subunit of the alpha (2) delta type	Gene	781	The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type.
BC8_BioRED_Task1_Doc106	562	567	human	OrganismTaxon	9606	Mutations in its human orthologue, CACNA2D4, were not yet known to be associated with a disease.
BC8_BioRED_Task1_Doc106	580	588	CACNA2D4	Gene	93589	Mutations in its human orthologue, CACNA2D4, were not yet known to be associated with a disease.
BC8_BioRED_Task1_Doc106	679	687	patients	OrganismTaxon	9606	We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4.
BC8_BioRED_Task1_Doc106	725	740	night blindness	Disease	D009755	We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4.
BC8_BioRED_Task1_Doc106	823	834	c.2406C-->A	SequenceVariant	rs71454844	We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4.
BC8_BioRED_Task1_Doc106	839	847	CACNA2D4	Gene	93589	We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4.
BC8_BioRED_Task1_Doc106	967	975	patients	OrganismTaxon	9606	Both patients share symptoms of slowly progressing cone dystrophy.
BC8_BioRED_Task1_Doc106	1013	1027	cone dystrophy	Disease	D000077765	Both patients share symptoms of slowly progressing cone dystrophy.
BC8_BioRED_Task1_Doc106	1092	1097	human	OrganismTaxon	9606	These findings represent the first report of a mutation in the human CACNA2D4 gene and define a novel gene defect that causes autosomal recessive cone dystrophy.
BC8_BioRED_Task1_Doc106	1098	1106	CACNA2D4	Gene	93589	These findings represent the first report of a mutation in the human CACNA2D4 gene and define a novel gene defect that causes autosomal recessive cone dystrophy.
BC8_BioRED_Task1_Doc106	1175	1189	cone dystrophy	Disease	D000077765	These findings represent the first report of a mutation in the human CACNA2D4 gene and define a novel gene defect that causes autosomal recessive cone dystrophy.
BC8_BioRED_Task1_Doc107	40	44	IRF5	Gene	3663	A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population.
BC8_BioRED_Task1_Doc107	98	118	rheumatoid arthritis	Disease	D001172	A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population.
BC8_BioRED_Task1_Doc107	159	189	Interferon regulatory factor 5	Gene	3663	OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines.
BC8_BioRED_Task1_Doc107	191	195	IRF5	Gene	3663	OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines.
BC8_BioRED_Task1_Doc107	216	219	IRF	Gene	3663	OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines.
BC8_BioRED_Task1_Doc107	286	311	proinflammatory cytokines	Gene	3553	OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines.
BC8_BioRED_Task1_Doc107	334	338	IRF5	Gene	3663	Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain.
BC8_BioRED_Task1_Doc107	388	417	systemic lupus erythaematosus	Disease	D008180	Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain.
BC8_BioRED_Task1_Doc107	419	422	SLE	Disease	D008180	Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain.
BC8_BioRED_Task1_Doc107	491	510	autoimmune diseases	Disease	D001327	Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain.
BC8_BioRED_Task1_Doc107	569	573	IRF5	Gene	3663	Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects.
BC8_BioRED_Task1_Doc107	595	615	rheumatoid arthritis	Disease	D001172	Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects.
BC8_BioRED_Task1_Doc107	617	619	RA	Disease	D001172	Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects.
BC8_BioRED_Task1_Doc107	757	761	IRF5	Gene	3663	METHODS: We selected 13 single nucleotide polymorphisms (SNPs) and a CGGGG insertion-deletion polymorphism in the IRF5 gene.
BC8_BioRED_Task1_Doc107	856	864	patients	OrganismTaxon	9606	We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status.
BC8_BioRED_Task1_Doc107	870	872	RA	Disease	D001172	We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status.
BC8_BioRED_Task1_Doc107	908	916	patients	OrganismTaxon	9606	We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status.
BC8_BioRED_Task1_Doc107	922	924	RA	Disease	D001172	We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status.
BC8_BioRED_Task1_Doc107	991	996	human	OrganismTaxon	9606	We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status.
BC8_BioRED_Task1_Doc107	997	1025	leukocyte antigen (HLA)-DRB1	Gene	3123	We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status.
BC8_BioRED_Task1_Doc107	1139	1147	rs729302	SequenceVariant	rs729302	RESULTS: A significant association of the rs729302 A allele with RA susceptibility was found in both sets (odds ratio (OR) 1.22, 95% CI 1.09 to 1.35, p<0.001 in the combined analysis).
BC8_BioRED_Task1_Doc107	1162	1164	RA	Disease	D001172	RESULTS: A significant association of the rs729302 A allele with RA susceptibility was found in both sets (odds ratio (OR) 1.22, 95% CI 1.09 to 1.35, p<0.001 in the combined analysis).
BC8_BioRED_Task1_Doc107	1291	1299	patients	OrganismTaxon	9606	When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24).
BC8_BioRED_Task1_Doc107	1331	1339	rs729302	SequenceVariant	rs729302	When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24).
BC8_BioRED_Task1_Doc107	1387	1389	RA	Disease	D001172	When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24).
BC8_BioRED_Task1_Doc107	1393	1401	patients	OrganismTaxon	9606	When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24).
BC8_BioRED_Task1_Doc107	1483	1491	patients	OrganismTaxon	9606	When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24).
BC8_BioRED_Task1_Doc107	1626	1628	RA	Disease	D001172	In both sets, no genotyped polymorphisms were significantly associated with RA susceptibility, but rs729302 was significantly associated.
BC8_BioRED_Task1_Doc107	1649	1657	rs729302	SequenceVariant	rs729302	In both sets, no genotyped polymorphisms were significantly associated with RA susceptibility, but rs729302 was significantly associated.
BC8_BioRED_Task1_Doc107	1759	1763	IRF5	Gene	3663	CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.
BC8_BioRED_Task1_Doc107	1813	1815	RA	Disease	D001172	CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.
BC8_BioRED_Task1_Doc107	1881	1889	patients	OrganismTaxon	9606	CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.
BC8_BioRED_Task1_Doc108	0	9	Zebrafish	OrganismTaxon	7955	Zebrafish chordin-like and chordin are functionally redundant in regulating patterning of the dorsoventral axis.
BC8_BioRED_Task1_Doc108	10	22	chordin-like	Gene	563085	Zebrafish chordin-like and chordin are functionally redundant in regulating patterning of the dorsoventral axis.
BC8_BioRED_Task1_Doc108	27	34	chordin	Gene	30161	Zebrafish chordin-like and chordin are functionally redundant in regulating patterning of the dorsoventral axis.
BC8_BioRED_Task1_Doc108	113	120	Chordin	Gene	30161	Chordin is the prototype of a group of cysteine-rich domain-containing proteins that bind and modulate signaling of various TGFbeta-like ligands.
BC8_BioRED_Task1_Doc108	152	192	cysteine-rich domain-containing proteins	Gene	25884,30161,373985,419054,563085,69121,83453,91851	Chordin is the prototype of a group of cysteine-rich domain-containing proteins that bind and modulate signaling of various TGFbeta-like ligands.
BC8_BioRED_Task1_Doc108	237	244	TGFbeta	Gene	359834	Chordin is the prototype of a group of cysteine-rich domain-containing proteins that bind and modulate signaling of various TGFbeta-like ligands.
BC8_BioRED_Task1_Doc108	259	279	Chordin-like 1 and 2	Gene	373985,83453,91851,25884,419054,69121	Chordin-like 1 and 2 (CHL1 and 2) are two members of this group that have been described in human, mouse, and chick.
BC8_BioRED_Task1_Doc108	281	291	CHL1 and 2	Gene	373985,83453,91851,25884,419054,69121	Chordin-like 1 and 2 (CHL1 and 2) are two members of this group that have been described in human, mouse, and chick.
BC8_BioRED_Task1_Doc108	351	356	human	OrganismTaxon	9606	Chordin-like 1 and 2 (CHL1 and 2) are two members of this group that have been described in human, mouse, and chick.
BC8_BioRED_Task1_Doc108	358	363	mouse	OrganismTaxon	10090	Chordin-like 1 and 2 (CHL1 and 2) are two members of this group that have been described in human, mouse, and chick.
BC8_BioRED_Task1_Doc108	369	374	chick	OrganismTaxon	9031	Chordin-like 1 and 2 (CHL1 and 2) are two members of this group that have been described in human, mouse, and chick.
BC8_BioRED_Task1_Doc108	403	413	CHL1 and 2	Gene	373985,83453,91851,25884,419054,69121	However, in vivo roles for CHL1 and 2 in early development are unknown due to lack of loss-of-function analysis.
BC8_BioRED_Task1_Doc108	523	532	zebrafish	OrganismTaxon	7955	Here we identify and characterize zebrafish, Danio rerio, CHL (Chl).
BC8_BioRED_Task1_Doc108	534	545	Danio rerio	OrganismTaxon	7955	Here we identify and characterize zebrafish, Danio rerio, CHL (Chl).
BC8_BioRED_Task1_Doc108	547	550	CHL	Gene	563085	Here we identify and characterize zebrafish, Danio rerio, CHL (Chl).
BC8_BioRED_Task1_Doc108	552	555	Chl	Gene	563085	Here we identify and characterize zebrafish, Danio rerio, CHL (Chl).
BC8_BioRED_Task1_Doc108	562	565	chl	Gene	563085	The chl gene is on a region of chromosome 21 syntenic with the area of murine chromosome 7 bearing the CHL2 gene.
BC8_BioRED_Task1_Doc108	629	635	murine	OrganismTaxon	10090	The chl gene is on a region of chromosome 21 syntenic with the area of murine chromosome 7 bearing the CHL2 gene.
BC8_BioRED_Task1_Doc108	661	665	CHL2	Gene	69121	The chl gene is on a region of chromosome 21 syntenic with the area of murine chromosome 7 bearing the CHL2 gene.
BC8_BioRED_Task1_Doc108	705	714	zebrafish	OrganismTaxon	7955	Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that Chl may serve roles in zebrafish distributed between CHL1 and CHL2 in other species.
BC8_BioRED_Task1_Doc108	751	755	CHL1	Gene	91851	Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that Chl may serve roles in zebrafish distributed between CHL1 and CHL2 in other species.
BC8_BioRED_Task1_Doc108	775	778	Chl	Gene	563085	Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that Chl may serve roles in zebrafish distributed between CHL1 and CHL2 in other species.
BC8_BioRED_Task1_Doc108	798	807	zebrafish	OrganismTaxon	7955	Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that Chl may serve roles in zebrafish distributed between CHL1 and CHL2 in other species.
BC8_BioRED_Task1_Doc108	828	832	CHL1	Gene	91851	Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that Chl may serve roles in zebrafish distributed between CHL1 and CHL2 in other species.
BC8_BioRED_Task1_Doc108	837	841	CHL2	Gene	25884	Inability to identify a separate zebrafish gene corresponding to the mammalian CHL1 gene suggests that Chl may serve roles in zebrafish distributed between CHL1 and CHL2 in other species.
BC8_BioRED_Task1_Doc108	860	863	Chl	Gene	563085	Chl is a maternal factor that is also zygotically expressed later in development and has spatiotemporal expression patterns that differ from but overlap those of zebrafish chordin (Chd), suggesting differences but also possible overlap in developmental roles of the two proteins.
BC8_BioRED_Task1_Doc108	1022	1031	zebrafish	OrganismTaxon	7955	Chl is a maternal factor that is also zygotically expressed later in development and has spatiotemporal expression patterns that differ from but overlap those of zebrafish chordin (Chd), suggesting differences but also possible overlap in developmental roles of the two proteins.
BC8_BioRED_Task1_Doc108	1032	1039	chordin	Gene	30161	Chl is a maternal factor that is also zygotically expressed later in development and has spatiotemporal expression patterns that differ from but overlap those of zebrafish chordin (Chd), suggesting differences but also possible overlap in developmental roles of the two proteins.
BC8_BioRED_Task1_Doc108	1041	1044	Chd	Gene	30161	Chl is a maternal factor that is also zygotically expressed later in development and has spatiotemporal expression patterns that differ from but overlap those of zebrafish chordin (Chd), suggesting differences but also possible overlap in developmental roles of the two proteins.
BC8_BioRED_Task1_Doc108	1140	1143	Chl	Gene	563085	Chl, like Chd, dorsalizes embryos upon overexpression and is cleaved by BMP1, which antagonizes this activity.
BC8_BioRED_Task1_Doc108	1150	1153	Chd	Gene	30161	Chl, like Chd, dorsalizes embryos upon overexpression and is cleaved by BMP1, which antagonizes this activity.
BC8_BioRED_Task1_Doc108	1212	1216	BMP1	Gene	30204	Chl, like Chd, dorsalizes embryos upon overexpression and is cleaved by BMP1, which antagonizes this activity.
BC8_BioRED_Task1_Doc108	1297	1300	Chl	Gene	563085	Loss-of-function experiments demonstrate that Chl serves as a BMP antagonist with functions that overlap and are redundant with those of Chd in forming the dorsoventral axis.
BC8_BioRED_Task1_Doc108	1313	1316	BMP	Gene	30204	Loss-of-function experiments demonstrate that Chl serves as a BMP antagonist with functions that overlap and are redundant with those of Chd in forming the dorsoventral axis.
BC8_BioRED_Task1_Doc108	1388	1391	Chd	Gene	30161	Loss-of-function experiments demonstrate that Chl serves as a BMP antagonist with functions that overlap and are redundant with those of Chd in forming the dorsoventral axis.
BC8_BioRED_Task1_Doc109	0	7	Hypoxia	Disease	D000860	Hypoxia in renal disease with proteinuria and/or glomerular hypertension.
BC8_BioRED_Task1_Doc109	11	24	renal disease	Disease	D007674	Hypoxia in renal disease with proteinuria and/or glomerular hypertension.
BC8_BioRED_Task1_Doc109	30	41	proteinuria	Disease	D011507	Hypoxia in renal disease with proteinuria and/or glomerular hypertension.
BC8_BioRED_Task1_Doc109	60	72	hypertension	Disease	D006973	Hypoxia in renal disease with proteinuria and/or glomerular hypertension.
BC8_BioRED_Task1_Doc109	247	254	hypoxia	Disease	D000860	In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.
BC8_BioRED_Task1_Doc109	290	297	hypoxia	Disease	D000860	In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.
BC8_BioRED_Task1_Doc109	327	361	vascular endothelial growth factor	Gene	83785	In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.
BC8_BioRED_Task1_Doc109	404	411	hypoxia	Disease	D000860	In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.
BC8_BioRED_Task1_Doc109	431	434	rat	OrganismTaxon	10116	In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.
BC8_BioRED_Task1_Doc109	509	516	hypoxia	Disease	D000860	We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.
BC8_BioRED_Task1_Doc109	524	539	diseased kidney	Disease	D007674	We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.
BC8_BioRED_Task1_Doc109	600	607	hypoxia	Disease	D000860	With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
BC8_BioRED_Task1_Doc109	615	640	puromycin aminonucleoside	Chemical	D011692	With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
BC8_BioRED_Task1_Doc109	649	667	nephrotic syndrome	Disease	D009404	With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
BC8_BioRED_Task1_Doc109	692	699	hypoxia	Disease	D000860	With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
BC8_BioRED_Task1_Doc109	747	754	hypoxia	Disease	D000860	Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
BC8_BioRED_Task1_Doc109	857	882	puromycin aminonucleoside	Chemical	D011692	Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
BC8_BioRED_Task1_Doc109	958	992	vascular endothelial growth factor	Gene	83785	Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
BC8_BioRED_Task1_Doc109	1079	1086	hypoxia	Disease	D000860	The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.
BC8_BioRED_Task1_Doc109	1134	1159	tubulointerstitial injury	Disease	D007674	The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.
BC8_BioRED_Task1_Doc109	1264	1268	ED-1	Gene	302424	Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.
BC8_BioRED_Task1_Doc109	1292	1296	dUTP	Chemical	C027078	Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.
BC8_BioRED_Task1_Doc109	1336	1343	hypoxic	Disease	D000860	Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.
BC8_BioRED_Task1_Doc109	1466	1473	hypoxia	Disease	D000860	We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.
BC8_BioRED_Task1_Doc109	1490	1509	glomerular diseases	Disease	D007674	We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.
BC8_BioRED_Task1_Doc110	0	25	Macular corneal dystrophy	Disease	D003317	Macular corneal dystrophy in a Chinese family related with novel mutations of CHST6.
BC8_BioRED_Task1_Doc110	78	83	CHST6	Gene	4166	Macular corneal dystrophy in a Chinese family related with novel mutations of CHST6.
BC8_BioRED_Task1_Doc110	123	157	carbohydrate sulfotransferase gene	Gene	4166	PURPOSE: To identify mutations in the carbohydrate sulfotransferase gene (CHST6) for a Chinese family with macular corneal dystrophy (MCD) and to investigate the histopathological changes in the affected cornea.
BC8_BioRED_Task1_Doc110	159	164	CHST6	Gene	4166	PURPOSE: To identify mutations in the carbohydrate sulfotransferase gene (CHST6) for a Chinese family with macular corneal dystrophy (MCD) and to investigate the histopathological changes in the affected cornea.
BC8_BioRED_Task1_Doc110	192	217	macular corneal dystrophy	Disease	D003317	PURPOSE: To identify mutations in the carbohydrate sulfotransferase gene (CHST6) for a Chinese family with macular corneal dystrophy (MCD) and to investigate the histopathological changes in the affected cornea.
BC8_BioRED_Task1_Doc110	219	222	MCD	Disease	D003317	PURPOSE: To identify mutations in the carbohydrate sulfotransferase gene (CHST6) for a Chinese family with macular corneal dystrophy (MCD) and to investigate the histopathological changes in the affected cornea.
BC8_BioRED_Task1_Doc110	649	654	CHST6	Gene	4166	Genomic DNA was extracted from peripheral blood of 11 family members, and the coding region of CHST6 was amplified by the polymerase chain reaction (PCR) method.
BC8_BioRED_Task1_Doc110	846	850	iron	Chemical	D007501	RESULTS: The positive reaction to colloidal iron stain (extracellular blue accumulations in the stroma) was detected under light microscopy.
BC8_BioRED_Task1_Doc110	1117	1125	c.892C>T	SequenceVariant	c|SUB|C|892|T	The compound heterozygous mutations, c.892C>T and c.1072T>C, were identified in exon 3 of CHST6 in three patients.
BC8_BioRED_Task1_Doc110	1130	1139	c.1072T>C	SequenceVariant	c|SUB|T|1072|C	The compound heterozygous mutations, c.892C>T and c.1072T>C, were identified in exon 3 of CHST6 in three patients.
BC8_BioRED_Task1_Doc110	1170	1175	CHST6	Gene	4166	The compound heterozygous mutations, c.892C>T and c.1072T>C, were identified in exon 3 of CHST6 in three patients.
BC8_BioRED_Task1_Doc110	1185	1193	patients	OrganismTaxon	9606	The compound heterozygous mutations, c.892C>T and c.1072T>C, were identified in exon 3 of CHST6 in three patients.
BC8_BioRED_Task1_Doc110	1251	1288	stop codon for glutamine at codon 298	SequenceVariant	p|SUB|Q|298|X	The two transversions resulted in the substitution of a stop codon for glutamine at codon 298 (p.Q298X) and a missense mutation at codon 358, tyrosine to histidine (p.Y358H).
BC8_BioRED_Task1_Doc110	1290	1297	p.Q298X	SequenceVariant	p|SUB|Q|298|X	The two transversions resulted in the substitution of a stop codon for glutamine at codon 298 (p.Q298X) and a missense mutation at codon 358, tyrosine to histidine (p.Y358H).
BC8_BioRED_Task1_Doc110	1326	1358	codon 358, tyrosine to histidine	SequenceVariant	p|SUB|Y|358|H	The two transversions resulted in the substitution of a stop codon for glutamine at codon 298 (p.Q298X) and a missense mutation at codon 358, tyrosine to histidine (p.Y358H).
BC8_BioRED_Task1_Doc110	1360	1367	p.Y358H	SequenceVariant	p|SUB|Y|358|H	The two transversions resulted in the substitution of a stop codon for glutamine at codon 298 (p.Q298X) and a missense mutation at codon 358, tyrosine to histidine (p.Y358H).
BC8_BioRED_Task1_Doc110	1625	1630	CHST6	Gene	4166	CONCLUSIONS: Those novel compound heterozygous mutations were thought to contribute to the loss of CHST6 function, which induced the abnormal metabolism of keratan sulfate (KS) that deposited in the corneal stroma.
BC8_BioRED_Task1_Doc110	1682	1697	keratan sulfate	Chemical	D007632	CONCLUSIONS: Those novel compound heterozygous mutations were thought to contribute to the loss of CHST6 function, which induced the abnormal metabolism of keratan sulfate (KS) that deposited in the corneal stroma.
BC8_BioRED_Task1_Doc110	1699	1701	KS	Chemical	D007632	CONCLUSIONS: Those novel compound heterozygous mutations were thought to contribute to the loss of CHST6 function, which induced the abnormal metabolism of keratan sulfate (KS) that deposited in the corneal stroma.
BC8_BioRED_Task1_Doc110	1825	1833	collagen	Gene	1277	It could be proved by the observation of a positive stain reaction and the enlarged collagen fibers as well as hyperplastic fibroblasts under microscopes.
BC8_BioRED_Task1_Doc111	0	29	Phosphatidylinositol 3-kinase	Gene	5295	Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
BC8_BioRED_Task1_Doc111	30	38	p85alpha	Gene	5295	Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
BC8_BioRED_Task1_Doc111	63	72	Met326Ile	SequenceVariant	rs3730089	Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
BC8_BioRED_Task1_Doc111	89	94	women	OrganismTaxon	9606	Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
BC8_BioRED_Task1_Doc111	100	125	polycystic ovary syndrome	Disease	D011085	Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome.
BC8_BioRED_Task1_Doc111	139	157	Insulin resistance	Disease	D007333	BACKGROUND: Insulin resistance is a core feature of polycystic ovary syndrome (PCOS).
BC8_BioRED_Task1_Doc111	179	204	polycystic ovary syndrome	Disease	D011085	BACKGROUND: Insulin resistance is a core feature of polycystic ovary syndrome (PCOS).
BC8_BioRED_Task1_Doc111	206	210	PCOS	Disease	D011085	BACKGROUND: Insulin resistance is a core feature of polycystic ovary syndrome (PCOS).
BC8_BioRED_Task1_Doc111	213	247	Phosphatidylinositol (PI) 3-kinase	Gene	5295	Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport.
BC8_BioRED_Task1_Doc111	284	291	insulin	Gene	3630	Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport.
BC8_BioRED_Task1_Doc111	334	341	insulin	Gene	3630	Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport.
BC8_BioRED_Task1_Doc111	351	358	glucose	Chemical	D005947	Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport.
BC8_BioRED_Task1_Doc111	397	405	p85alpha	Gene	5295	In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase.
BC8_BioRED_Task1_Doc111	454	463	Met326Ile	SequenceVariant	rs3730089	In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase.
BC8_BioRED_Task1_Doc111	538	546	p85alpha	Gene	5295	In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase.
BC8_BioRED_Task1_Doc111	570	580	PI3-kinase	Gene	5295	In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase.
BC8_BioRED_Task1_Doc111	607	616	Met326Ile	SequenceVariant	rs3730089	METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls.
BC8_BioRED_Task1_Doc111	670	674	PCOS	Disease	D011085	METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls.
BC8_BioRED_Task1_Doc111	675	683	patients	OrganismTaxon	9606	METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls.
BC8_BioRED_Task1_Doc111	814	823	Met326Ile	SequenceVariant	rs3730089	RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72).
BC8_BioRED_Task1_Doc111	844	848	PCOS	Disease	D011085	RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72).
BC8_BioRED_Task1_Doc111	900	909	Met326Met	SequenceVariant	rs3730089	RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72).
BC8_BioRED_Task1_Doc111	910	919	Met326Ile	SequenceVariant	rs3730089	RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72).
BC8_BioRED_Task1_Doc111	920	929	Ile326Ile	SequenceVariant	rs3730089	RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72).
BC8_BioRED_Task1_Doc111	987	991	PCOS	Disease	D011085	RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72).
BC8_BioRED_Task1_Doc111	1041	1045	PCOS	Disease	D011085	The PCOS group was divided into two subgroups according to the presence of the variant 326Ile allele.
BC8_BioRED_Task1_Doc111	1124	1130	326Ile	SequenceVariant	rs3730089	The PCOS group was divided into two subgroups according to the presence of the variant 326Ile allele.
BC8_BioRED_Task1_Doc111	1189	1195	326Ile	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1222	1231	Met326Met	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1258	1280	17-hydroxyprogesterone	Chemical	D019326	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1282	1288	17-OHP	Chemical	D019326	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1358	1367	Met326Met	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1425	1434	Ile326Ile	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1439	1448	Met326Ile	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1481	1493	testosterone	Chemical	D013739	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1533	1542	Met326Met	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1590	1599	Ile326Ile	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1604	1613	Met326Ile	SequenceVariant	rs3730089	Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038].
BC8_BioRED_Task1_Doc111	1679	1689	PI3-kinase	Gene	5295	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc111	1695	1704	Met326Ile	SequenceVariant	rs3730089	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc111	1772	1776	PCOS	Disease	D011085	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc111	1826	1832	17-OHP	Chemical	D019326	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc111	1841	1853	testosterone	Chemical	D013739	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc111	1857	1861	PCOS	Disease	D011085	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc111	1862	1870	patients	OrganismTaxon	9606	CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.
BC8_BioRED_Task1_Doc112	0	4	D90A	SequenceVariant	rs80265967	D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.
BC8_BioRED_Task1_Doc112	5	9	SOD1	Gene	6647	D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.
BC8_BioRED_Task1_Doc112	19	48	amyotrophic lateral sclerosis	Disease	D000690	D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype.
BC8_BioRED_Task1_Doc112	207	239	copper/zinc superoxide dismutase	Gene	6647	More than 100 different heterozygous mutations in copper/zinc superoxide dismutase (SOD1) have been found in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
BC8_BioRED_Task1_Doc112	241	245	SOD1	Gene	6647	More than 100 different heterozygous mutations in copper/zinc superoxide dismutase (SOD1) have been found in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
BC8_BioRED_Task1_Doc112	266	274	patients	OrganismTaxon	9606	More than 100 different heterozygous mutations in copper/zinc superoxide dismutase (SOD1) have been found in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
BC8_BioRED_Task1_Doc112	280	309	amyotrophic lateral sclerosis	Disease	D000690	More than 100 different heterozygous mutations in copper/zinc superoxide dismutase (SOD1) have been found in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
BC8_BioRED_Task1_Doc112	311	314	ALS	Disease	D000690	More than 100 different heterozygous mutations in copper/zinc superoxide dismutase (SOD1) have been found in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
BC8_BioRED_Task1_Doc112	325	350	neurodegenerative disease	Disease	D019636	More than 100 different heterozygous mutations in copper/zinc superoxide dismutase (SOD1) have been found in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
BC8_BioRED_Task1_Doc112	362	366	D90A	SequenceVariant	rs80265967	Uniquely, D90A-SOD1 has been identified in recessive, dominant and apparently sporadic pedigrees.
BC8_BioRED_Task1_Doc112	367	371	SOD1	Gene	6647	Uniquely, D90A-SOD1 has been identified in recessive, dominant and apparently sporadic pedigrees.
BC8_BioRED_Task1_Doc112	585	589	D90A	SequenceVariant	rs80265967	The frequency of D90A-SOD1 is 50 times higher in Scandinavia (2.5%) than elsewhere, though ALS prevalence is not raised there.
BC8_BioRED_Task1_Doc112	590	594	SOD1	Gene	6647	The frequency of D90A-SOD1 is 50 times higher in Scandinavia (2.5%) than elsewhere, though ALS prevalence is not raised there.
BC8_BioRED_Task1_Doc112	659	662	ALS	Disease	D000690	The frequency of D90A-SOD1 is 50 times higher in Scandinavia (2.5%) than elsewhere, though ALS prevalence is not raised there.
BC8_BioRED_Task1_Doc112	777	780	ALS	Disease	D000690	Our earlier study indicated separate founders for recessive and dominant/sporadic ALS and we proposed a disease-modifying factor linked to the recessive mutation.
BC8_BioRED_Task1_Doc112	1041	1045	D90A	SequenceVariant	rs80265967	Linkage disequilibrium analysis indicates that D90A homozygotes and heterozygotes share a rare haplotype and are all descended from a single ancient founder (alpha 0.974) c.895 generations ago.
BC8_BioRED_Task1_Doc112	1346	1350	SOD1	Gene	6647	Recombination has reduced the region shared by recessive kindreds to 97-265 kb around SOD1, excluding all neighbouring genes.
BC8_BioRED_Task1_Doc112	1459	1463	D90A	SequenceVariant	rs80265967	We propose that a cis-acting regulatory polymorphism has arisen close to D90A-SOD1 in the recessive founder, which decreases ALS susceptibility in heterozygotes and slows disease progression.
BC8_BioRED_Task1_Doc112	1464	1468	SOD1	Gene	6647	We propose that a cis-acting regulatory polymorphism has arisen close to D90A-SOD1 in the recessive founder, which decreases ALS susceptibility in heterozygotes and slows disease progression.
BC8_BioRED_Task1_Doc112	1511	1514	ALS	Disease	D000690	We propose that a cis-acting regulatory polymorphism has arisen close to D90A-SOD1 in the recessive founder, which decreases ALS susceptibility in heterozygotes and slows disease progression.
BC8_BioRED_Task1_Doc113	0	18	Takotsubo syndrome	Disease	D054549	Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.
BC8_BioRED_Task1_Doc113	23	49	apical ballooning syndrome	Disease	D054549	Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.
BC8_BioRED_Task1_Doc113	64	76	Zolmitriptan	Chemical	C089750	Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.
BC8_BioRED_Task1_Doc113	78	96	Takotsubo syndrome	Disease	D054549	Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves).
BC8_BioRED_Task1_Doc113	98	100	TS	Disease	D054549	Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves).
BC8_BioRED_Task1_Doc113	117	138	broken heart syndrome	Disease	D054549	Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves).
BC8_BioRED_Task1_Doc113	276	299	acute coronary syndrome	Disease	D054058	Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves).
BC8_BioRED_Task1_Doc113	403	408	woman	OrganismTaxon	9606	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS.
BC8_BioRED_Task1_Doc113	433	454	mitral valve prolapse	Disease	D008945	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS.
BC8_BioRED_Task1_Doc113	459	468	migraines	Disease	D008881	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS.
BC8_BioRED_Task1_Doc113	518	528	chest pain	Disease	D002637	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS.
BC8_BioRED_Task1_Doc113	782	802	motion abnormalities	Disease	D009041	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS.
BC8_BioRED_Task1_Doc113	819	821	TS	Disease	D054549	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS.
BC8_BioRED_Task1_Doc113	883	890	patient	OrganismTaxon	9606	Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.
BC8_BioRED_Task1_Doc113	896	908	zolmitriptan	Chemical	C089750	Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.
BC8_BioRED_Task1_Doc113	937	946	migraines	Disease	D008881	Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.
BC8_BioRED_Task1_Doc113	986	998	zolmitriptan	Chemical	C089750	But before this event, she was taking zolmitriptan 2-3 times daily for several days because of a persistent migraine headache.
BC8_BioRED_Task1_Doc113	1056	1073	migraine headache	Disease	D008881	But before this event, she was taking zolmitriptan 2-3 times daily for several days because of a persistent migraine headache.
BC8_BioRED_Task1_Doc113	1130	1136	horses	OrganismTaxon	9796	She otherwise reported that she is quite active, rides horses, and does show jumping without any limitations in her physical activity.
BC8_BioRED_Task1_Doc113	1256	1274	status migrainosus	Disease	D008881	There was no evidence of any recent stress or status migrainosus.
BC8_BioRED_Task1_Doc113	1331	1356	coronary artery vasospasm	Disease	D003329	Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.
BC8_BioRED_Task1_Doc113	1370	1382	zolmitriptan	Chemical	C089750	Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.
BC8_BioRED_Task1_Doc113	1427	1429	TS	Disease	D054549	Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.
BC8_BioRED_Task1_Doc114	16	31	T-cell factor-4	Gene	6934	Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc114	67	91	hepatocellular carcinoma	Disease	D006528	Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc114	109	112	Wnt	Gene	7474	BACKGROUND: The Wnt/beta-catenin signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by T-cell factor (TCF)-4 transcription factor proteins.
BC8_BioRED_Task1_Doc114	113	125	beta-catenin	Gene	1499	BACKGROUND: The Wnt/beta-catenin signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by T-cell factor (TCF)-4 transcription factor proteins.
BC8_BioRED_Task1_Doc114	248	290	T-cell factor (TCF)-4 transcription factor	Gene	6934	BACKGROUND: The Wnt/beta-catenin signalling pathway regulates genes involved in cell proliferation, survival, migration and invasion through regulation by T-cell factor (TCF)-4 transcription factor proteins.
BC8_BioRED_Task1_Doc114	322	327	TCF-4	Gene	6934	However, the role of TCF-4 isoforms generated by alternative splicing events in hepatocellular carcinoma (HCC) is unknown.
BC8_BioRED_Task1_Doc114	381	405	hepatocellular carcinoma	Disease	D006528	However, the role of TCF-4 isoforms generated by alternative splicing events in hepatocellular carcinoma (HCC) is unknown.
BC8_BioRED_Task1_Doc114	407	410	HCC	Disease	D006528	However, the role of TCF-4 isoforms generated by alternative splicing events in hepatocellular carcinoma (HCC) is unknown.
BC8_BioRED_Task1_Doc114	451	456	TCF-4	Gene	6934	AIM: Here, we investigated TCF-4 isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and tumour development.
BC8_BioRED_Task1_Doc114	467	479	TCF-4J and K	Gene	6934	AIM: Here, we investigated TCF-4 isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and tumour development.
BC8_BioRED_Task1_Doc114	527	546	hepatic oncogenesis	Disease	D006528	AIM: Here, we investigated TCF-4 isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and tumour development.
BC8_BioRED_Task1_Doc114	551	557	tumour	Disease	D009369	AIM: Here, we investigated TCF-4 isoforms (TCF-4J and K)-responsive target genes that are important in hepatic oncogenesis and tumour development.
BC8_BioRED_Task1_Doc114	624	627	HCC	Disease	D006528	METHODS: Gene expression microarray was performed on HCC cells overexpressing TCF-4J and K isoforms.
BC8_BioRED_Task1_Doc114	649	661	TCF-4J and K	Gene	6934	METHODS: Gene expression microarray was performed on HCC cells overexpressing TCF-4J and K isoforms.
BC8_BioRED_Task1_Doc114	798	803	TCF-4	Gene	6934	Expression level of selected target genes was evaluated and correlations were made between their expression level and that of TCF-4 isoform in 47 pairs of human HCC tumours.
BC8_BioRED_Task1_Doc114	827	832	human	OrganismTaxon	9606	Expression level of selected target genes was evaluated and correlations were made between their expression level and that of TCF-4 isoform in 47 pairs of human HCC tumours.
BC8_BioRED_Task1_Doc114	833	844	HCC tumours	Disease	D006528	Expression level of selected target genes was evaluated and correlations were made between their expression level and that of TCF-4 isoform in 47 pairs of human HCC tumours.
BC8_BioRED_Task1_Doc114	981	987	TCF-4J	Gene	6934	RESULTS: Comparison by gene expression microarray revealed that 447 genes were upregulated and 343 downregulated more than 2.0-fold in TCF-4J compared with TCF-4K expressing cells.
BC8_BioRED_Task1_Doc114	1002	1008	TCF-4K	Gene	6934	RESULTS: Comparison by gene expression microarray revealed that 447 genes were upregulated and 343 downregulated more than 2.0-fold in TCF-4J compared with TCF-4K expressing cells.
BC8_BioRED_Task1_Doc114	1091	1094	Wnt	Gene	7474	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1095	1107	beta-catenin	Gene	1499	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1109	1116	insulin	Gene	3630	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1117	1122	IGF-1	Gene	3479	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1123	1127	IRS1	Gene	3667	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1132	1137	Notch	Gene	4851	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1173	1178	human	OrganismTaxon	9606	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1179	1183	HCCs	Disease	D006528	We validated expression of 18 selected target genes involved in Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signalling pathways in 47 pairs of human HCCs and adjacent uninvolved liver tissues.
BC8_BioRED_Task1_Doc114	1254	1259	CLDN2	Gene	9075	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1261	1267	STK17B	Gene	9262	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1269	1273	SPP1	Gene	6696	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1275	1280	AXIN2	Gene	8313	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1282	1287	WISP2	Gene	8839	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1289	1293	MMP7	Gene	4316	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1295	1299	IRS1	Gene	3667	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1301	1306	ANXA1	Gene	301	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1308	1315	CAMK2N1	Gene	55450	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1317	1321	ASPH	Gene	444	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1323	1328	GPR56	Gene	9289	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1330	1334	CD24	Gene	100133941	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1339	1343	JAG1	Gene	182	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1358	1364	TCF-4J	Gene	6934	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1376	1379	HCC	Disease	D006528	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1412	1423	HCC tumours	Disease	D006528	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1538	1544	TCF-4J	Gene	6934	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1565	1571	tumour	Disease	D009369	It was observed that 13 genes (CLDN2, STK17B, SPP1, AXIN2, WISP2, MMP7, IRS1, ANXA1, CAMK2N1, ASPH, GPR56, CD24 and JAG1) activated by TCF-4J isoform in HCC cells, were also upregulated in HCC tumours compared with adjacent peritumour tissue; more importantly, 10 genes exhibited a significant correlation with the TCF-4J expression level in tumour.
BC8_BioRED_Task1_Doc114	1585	1590	TCF-4	Gene	6934	CONCLUSION: TCF-4 isoforms (TCF-4J and K) activated different downstream target genes in HCC.
BC8_BioRED_Task1_Doc114	1601	1613	TCF-4J and K	Gene	6934	CONCLUSION: TCF-4 isoforms (TCF-4J and K) activated different downstream target genes in HCC.
BC8_BioRED_Task1_Doc114	1662	1665	HCC	Disease	D006528	CONCLUSION: TCF-4 isoforms (TCF-4J and K) activated different downstream target genes in HCC.
BC8_BioRED_Task1_Doc114	1697	1703	TCF-4J	Gene	6934	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1776	1779	Wnt	Gene	7474	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1780	1792	beta-catenin	Gene	1499	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1794	1801	insulin	Gene	3630	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1802	1807	IGF-1	Gene	3479	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1808	1812	IRS1	Gene	3667	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1817	1822	Notch	Gene	4851	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc114	1903	1906	HCC	Disease	D006528	The biological consequence of TCF-4J isoform expression was upregulation of genes associated with tripartite Wnt/beta-catenin, insulin/IGF-1/IRS1 and Notch signal transduction pathway activation, which contribute to the pathogenesis of HCC.
BC8_BioRED_Task1_Doc115	23	32	metformin	Chemical	D008687	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
BC8_BioRED_Task1_Doc115	44	64	toll-like receptor 4	Gene	29260	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
BC8_BioRED_Task1_Doc115	90	118	left ventricular dysfunction	Disease	D018487	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
BC8_BioRED_Task1_Doc115	129	150	myocardial infarction	Disease	D009203	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
BC8_BioRED_Task1_Doc115	173	182	metformin	Chemical	D008687	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
BC8_BioRED_Task1_Doc115	210	231	myocardial infarction	Disease	D009203	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
BC8_BioRED_Task1_Doc115	250	262	inflammatory	Disease	D007249	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
BC8_BioRED_Task1_Doc115	294	322	AMP-activated protein kinase	Gene	65248	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
BC8_BioRED_Task1_Doc115	324	328	AMPK	Gene	65248	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
BC8_BioRED_Task1_Doc115	394	403	metformin	Chemical	D008687	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
BC8_BioRED_Task1_Doc115	407	426	cardiac dysfunction	Disease	D006331	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
BC8_BioRED_Task1_Doc115	431	451	toll-like receptor 4	Gene	29260	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
BC8_BioRED_Task1_Doc115	453	457	TLR4	Gene	29260	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
BC8_BioRED_Task1_Doc115	480	501	myocardial infarction	Disease	D009203	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
BC8_BioRED_Task1_Doc115	526	530	AMPK	Gene	65248	In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
BC8_BioRED_Task1_Doc115	558	562	rats	OrganismTaxon	10116	Male Wistar rats were randomly assigned to one of 5 groups (n=6): normal control and groups were injected isoproterenol after chronic pre-treatment with 0, 25, 50, or 100mg/kg of metformin twice daily for 14 days.
BC8_BioRED_Task1_Doc115	652	665	isoproterenol	Chemical	D007545	Male Wistar rats were randomly assigned to one of 5 groups (n=6): normal control and groups were injected isoproterenol after chronic pre-treatment with 0, 25, 50, or 100mg/kg of metformin twice daily for 14 days.
BC8_BioRED_Task1_Doc115	725	734	metformin	Chemical	D008687	Male Wistar rats were randomly assigned to one of 5 groups (n=6): normal control and groups were injected isoproterenol after chronic pre-treatment with 0, 25, 50, or 100mg/kg of metformin twice daily for 14 days.
BC8_BioRED_Task1_Doc115	760	773	Isoproterenol	Chemical	D007545	Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.
BC8_BioRED_Task1_Doc115	849	876	acute myocardial infarction	Disease	D009203	Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.
BC8_BioRED_Task1_Doc115	878	891	Isoproterenol	Chemical	D007545	Isoproterenol alone decreased left ventricular systolic pressure and myocardial contractility indexed as LVdp/dtmax and LVdp/dtmin.
BC8_BioRED_Task1_Doc115	1014	1042	left ventricular dysfunction	Disease	D018487	The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of metformin.
BC8_BioRED_Task1_Doc115	1112	1121	metformin	Chemical	D008687	The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of metformin.
BC8_BioRED_Task1_Doc115	1123	1132	Metfromin	Chemical	D008687	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1150	1163	isoproterenol	Chemical	D007545	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1199	1203	TLR4	Gene	29260	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1210	1244	myeloid differentiation protein 88	Gene	301059	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1246	1251	MyD88	Gene	301059	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1254	1281	tumor necrosis factor-alpha	Gene	24835	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1283	1288	TNF-a	Gene	24835	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1295	1308	interleukin 6	Gene	24498	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1310	1314	IL-6	Gene	24498	Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
BC8_BioRED_Task1_Doc115	1392	1397	TNF-a	Gene	24835	Similar changes were also seen in the serum levels of TNF-a and IL-6.
BC8_BioRED_Task1_Doc115	1402	1406	IL-6	Gene	24498	Similar changes were also seen in the serum levels of TNF-a and IL-6.
BC8_BioRED_Task1_Doc115	1501	1506	AMPKa	Gene	65248	Phosphorylated AMPKa (p-AMPK) in the myocardium was significantly elevated by 25mg/kg of metformin, slightly by 50mg/kg, but not by 100mg/kg.
BC8_BioRED_Task1_Doc115	1510	1514	AMPK	Gene	65248	Phosphorylated AMPKa (p-AMPK) in the myocardium was significantly elevated by 25mg/kg of metformin, slightly by 50mg/kg, but not by 100mg/kg.
BC8_BioRED_Task1_Doc115	1575	1584	metformin	Chemical	D008687	Phosphorylated AMPKa (p-AMPK) in the myocardium was significantly elevated by 25mg/kg of metformin, slightly by 50mg/kg, but not by 100mg/kg.
BC8_BioRED_Task1_Doc115	1655	1664	metformin	Chemical	D008687	Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
BC8_BioRED_Task1_Doc115	1678	1699	myocardial infarction	Disease	D009203	Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
BC8_BioRED_Task1_Doc115	1700	1719	cardiac dysfunction	Disease	D006331	Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
BC8_BioRED_Task1_Doc115	1735	1747	inflammatory	Disease	D007249	Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
BC8_BioRED_Task1_Doc115	1790	1794	TLR4	Gene	29260	Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.
BC8_BioRED_Task1_Doc115	1863	1883	infarcted myocardium	Disease	D009203	This mechanism can be considered as a target to protect infarcted myocardium.
BC8_BioRED_Task1_Doc116	0	14	Rhabdomyolysis	Disease	D012206	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
BC8_BioRED_Task1_Doc116	20	46	hepatitis C virus infected	Disease	D006526	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
BC8_BioRED_Task1_Doc116	47	54	patient	OrganismTaxon	9606	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
BC8_BioRED_Task1_Doc116	68	78	telaprevir	Chemical	C486464	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
BC8_BioRED_Task1_Doc116	83	94	simvastatin	Chemical	D019821	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
BC8_BioRED_Task1_Doc116	110	113	man	OrganismTaxon	9606	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
BC8_BioRED_Task1_Doc116	129	156	hepatitis C virus infection	Disease	D006526	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
BC8_BioRED_Task1_Doc116	186	195	ribavirin	Chemical	D012254	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
BC8_BioRED_Task1_Doc116	197	217	pegylated interferon	Chemical	C417083	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
BC8_BioRED_Task1_Doc116	222	232	telaprevir	Chemical	C486464	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
BC8_BioRED_Task1_Doc116	238	245	patient	OrganismTaxon	9606	The patient also received simvastatin.
BC8_BioRED_Task1_Doc116	260	271	simvastatin	Chemical	D019821	The patient also received simvastatin.
BC8_BioRED_Task1_Doc116	325	332	patient	OrganismTaxon	9606	One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis.
BC8_BioRED_Task1_Doc116	383	397	rhabdomyolysis	Disease	D012206	One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis.
BC8_BioRED_Task1_Doc116	412	423	simvastatin	Chemical	D019821	At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.
BC8_BioRED_Task1_Doc116	432	447	antiviral drugs	Chemical	D000998	At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.
BC8_BioRED_Task1_Doc116	474	482	toxicity	Disease	D064420	At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.
BC8_BioRED_Task1_Doc116	533	548	creatine kinase	Chemical	D003402	The creatine kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline.
BC8_BioRED_Task1_Doc116	579	586	patient	OrganismTaxon	9606	The creatine kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline.
BC8_BioRED_Task1_Doc116	635	642	patient	OrganismTaxon	9606	The patient's renal function remained unaffected.
BC8_BioRED_Task1_Doc116	718	733	creatine kinase	Chemical	D003402	Fourteen days after hospitalization, creatine kinase level had returned to 230 IU/L and the patient was discharged.
BC8_BioRED_Task1_Doc116	773	780	patient	OrganismTaxon	9606	Fourteen days after hospitalization, creatine kinase level had returned to 230 IU/L and the patient was discharged.
BC8_BioRED_Task1_Doc116	797	807	Telaprevir	Chemical	C486464	Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale.
BC8_BioRED_Task1_Doc116	875	886	simvastatin	Chemical	D019821	Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale.
BC8_BioRED_Task1_Doc116	980	986	CYP3A4	Gene	1576	The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance.
BC8_BioRED_Task1_Doc116	996	1007	simvastatin	Chemical	D019821	The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance.
BC8_BioRED_Task1_Doc116	1019	1030	Simvastatin	Chemical	D019821	Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
BC8_BioRED_Task1_Doc116	1079	1086	patient	OrganismTaxon	9606	Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
BC8_BioRED_Task1_Doc116	1091	1097	statin	Chemical	D019821	Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
BC8_BioRED_Task1_Doc116	1106	1121	muscle toxicity	Disease	D009135	Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
BC8_BioRED_Task1_Doc116	1161	1167	statin	Chemical	D019821	Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
BC8_BioRED_Task1_Doc116	1227	1237	telaprevir	Chemical	C486464	In conclusion, with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug-drug interactions.
BC8_BioRED_Task1_Doc116	1249	1256	statins	Chemical	D019821	In conclusion, with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug-drug interactions.
BC8_BioRED_Task1_Doc117	91	99	Toxicity	Disease	D064420	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
BC8_BioRED_Task1_Doc117	103	116	Rectal Cancer	Disease	D012004	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
BC8_BioRED_Task1_Doc117	117	125	Patients	OrganismTaxon	9606	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
BC8_BioRED_Task1_Doc117	139	143	5-FU	Chemical	D005472	Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
BC8_BioRED_Task1_Doc117	216	221	GSTP1	Gene	2950	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	223	227	COX2	Gene	4513	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	229	233	IL10	Gene	3586	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	235	239	EGFR	Gene	1956	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	241	244	EGF	Gene	1950	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	246	251	FGFR4	Gene	2264	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	253	258	CCDN1	Gene	595	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	260	266	VEGFR2	Gene	3791	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	268	272	VEGF	Gene	7422	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	274	279	CXCR2	Gene	3579	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	281	284	IL8	Gene	3576	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	286	290	MMP3	Gene	4314	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	292	297	ICAM1	Gene	3383	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	299	304	ERCC1	Gene	2067	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	306	311	RAD51	Gene	5888	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	317	322	XRCC3	Gene	7517	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	394	402	toxicity	Disease	D064420	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	495	509	5-fluorouracil	Chemical	D005472	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	511	515	5-FU	Chemical	D005472	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	564	578	rectal cancers	Disease	D012004	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	605	609	5-FU	Chemical	D005472	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	622	626	5-FU	Chemical	D005472	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	719	723	5-FU	Chemical	D005472	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	788	792	5-FU	Chemical	D005472	PURPOSE: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
BC8_BioRED_Task1_Doc117	866	874	patients	OrganismTaxon	9606	EXPERIMENTAL DESIGN: DNA from 746 stage II/III rectal patients enrolled in the Southwest Oncology Group (SWOG) S9304 phase III trial was analyzed.
BC8_BioRED_Task1_Doc117	990	998	formalin	Chemical	D005557	Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
BC8_BioRED_Task1_Doc117	1006	1014	paraffin	Chemical	D010232	Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
BC8_BioRED_Task1_Doc117	1031	1036	tumor	Disease	D009369	Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
BC8_BioRED_Task1_Doc117	1196	1201	GSTP1	Gene	2950	RESULTS: GSTP1-Ile105Val (rs1695) was significantly associated with DFS and OS and its effect did not vary by treatment arm.
BC8_BioRED_Task1_Doc117	1202	1211	Ile105Val	SequenceVariant	rs1695	RESULTS: GSTP1-Ile105Val (rs1695) was significantly associated with DFS and OS and its effect did not vary by treatment arm.
BC8_BioRED_Task1_Doc117	1213	1219	rs1695	SequenceVariant	rs1695	RESULTS: GSTP1-Ile105Val (rs1695) was significantly associated with DFS and OS and its effect did not vary by treatment arm.
BC8_BioRED_Task1_Doc117	1423	1431	patients	OrganismTaxon	9606	The five-year DFS and OS were 53% and 58%, respectively, for G/G, 66% and 72% for G/A, and 57% and 66% for A/A patients.
BC8_BioRED_Task1_Doc117	1443	1446	IL8	Gene	3576	In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04).
BC8_BioRED_Task1_Doc117	1446	1453	-251A/A	SequenceVariant	rs4073	In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04).
BC8_BioRED_Task1_Doc117	1464	1470	rs4073	SequenceVariant	rs4073	In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04).
BC8_BioRED_Task1_Doc117	1508	1518	toxicities	Disease	D064420	In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04).
BC8_BioRED_Task1_Doc117	1535	1541	VEGFR2	Gene	3791	The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2.
BC8_BioRED_Task1_Doc117	1542	1547	H472Q	SequenceVariant	rs1870377	The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2.
BC8_BioRED_Task1_Doc117	1562	1571	rs1870377	SequenceVariant	rs1870377	The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2.
BC8_BioRED_Task1_Doc117	1666	1675	mucositis	Disease	D052016	The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2.
BC8_BioRED_Task1_Doc117	1772	1781	mucositis	Disease	D052016	However, in arm 1, this genotype was associated with a lower risk of PUGIT mucositis (P = 0.004).
BC8_BioRED_Task1_Doc117	1807	1813	rs1695	SequenceVariant	rs1695	CONCLUSION: rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT.
BC8_BioRED_Task1_Doc117	1835	1843	patients	OrganismTaxon	9606	CONCLUSION: rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT.
BC8_BioRED_Task1_Doc117	1849	1862	rectal cancer	Disease	D012004	CONCLUSION: rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT.
BC8_BioRED_Task1_Doc117	1890	1896	rs4073	SequenceVariant	rs4073	rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule.
BC8_BioRED_Task1_Doc117	1901	1910	rs1870377	SequenceVariant	rs1870377	rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule.
BC8_BioRED_Task1_Doc117	1951	1959	toxicity	Disease	D064420	rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule.
BC8_BioRED_Task1_Doc117	1978	1982	5-FU	Chemical	D005472	rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule.
BC8_BioRED_Task1_Doc118	22	34	inflammation	Disease	D007249	Regulatory network of inflammation downstream of proteinase-activated receptors.
BC8_BioRED_Task1_Doc118	49	79	proteinase-activated receptors	Gene	14062,14063	Regulatory network of inflammation downstream of proteinase-activated receptors.
BC8_BioRED_Task1_Doc118	93	121	Protease-activated receptors	Gene	14062,14063	BACKGROUND: Protease-activated receptors (PAR) are present in the urinary bladder, and their expression is altered in response to inflammation.
BC8_BioRED_Task1_Doc118	123	126	PAR	Gene	14062,14063	BACKGROUND: Protease-activated receptors (PAR) are present in the urinary bladder, and their expression is altered in response to inflammation.
BC8_BioRED_Task1_Doc118	211	223	inflammation	Disease	D007249	BACKGROUND: Protease-activated receptors (PAR) are present in the urinary bladder, and their expression is altered in response to inflammation.
BC8_BioRED_Task1_Doc118	225	229	PARs	Gene	14062,14063	PARs are a unique class of G protein-coupled that carry their own ligands, which remain cryptic until unmasked by proteolytic cleavage.
BC8_BioRED_Task1_Doc118	426	429	PAR	Gene	14062,14063	Although the canonical signal transduction pathway downstream of PAR activation and coupling with various G proteins is known and leads to the rapid transcription of genes involved in inflammation, the effect of PAR activation on the downstream transcriptome is unknown.
BC8_BioRED_Task1_Doc118	545	557	inflammation	Disease	D007249	Although the canonical signal transduction pathway downstream of PAR activation and coupling with various G proteins is known and leads to the rapid transcription of genes involved in inflammation, the effect of PAR activation on the downstream transcriptome is unknown.
BC8_BioRED_Task1_Doc118	573	576	PAR	Gene	14062,14063	Although the canonical signal transduction pathway downstream of PAR activation and coupling with various G proteins is known and leads to the rapid transcription of genes involved in inflammation, the effect of PAR activation on the downstream transcriptome is unknown.
BC8_BioRED_Task1_Doc118	682	685	PAR	Gene	14062,14063	We have shown that intravesical administration of PAR-activating peptides leads to an inflammatory reaction characterized by edema and granulocyte infiltration.
BC8_BioRED_Task1_Doc118	718	730	inflammatory	Disease	D007249	We have shown that intravesical administration of PAR-activating peptides leads to an inflammatory reaction characterized by edema and granulocyte infiltration.
BC8_BioRED_Task1_Doc118	757	762	edema	Disease	D004487	We have shown that intravesical administration of PAR-activating peptides leads to an inflammatory reaction characterized by edema and granulocyte infiltration.
BC8_BioRED_Task1_Doc118	807	819	inflammatory	Disease	D007249	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	871	883	inflammatory	Disease	D007249	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	900	907	E. coli	OrganismTaxon	562	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	908	926	lipopolysaccharide	Chemical	D008070	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	928	931	LPS	Chemical	D008070	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	934	945	substance P	Chemical	D013373	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	947	949	SP	Chemical	D013373	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	991	995	PAR1	Gene	14062	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	1023	1027	PAR2	Gene	14063	Moreover, the inflammatory response to intravesical instillation of known pro-inflammatory stimuli such as E. coli lipopolysaccharide (LPS), substance P (SP), and antigen was strongly attenuated by PAR1- and to a lesser extent by PAR2-deficiency.
BC8_BioRED_Task1_Doc118	1089	1101	inflammatory	Disease	D007249	RESULTS: Here, cDNA array experiments determined inflammatory genes whose expression is dependent on PAR1 activation.
BC8_BioRED_Task1_Doc118	1141	1145	PAR1	Gene	14062	RESULTS: Here, cDNA array experiments determined inflammatory genes whose expression is dependent on PAR1 activation.
BC8_BioRED_Task1_Doc118	1239	1243	PAR1	Gene	14062	For this purpose, we compared the alteration in gene expression in wild type and PAR1-/- mice induced by classical pro-inflammatory stimuli (LPS, SP, and antigen).
BC8_BioRED_Task1_Doc118	1247	1251	mice	OrganismTaxon	10090	For this purpose, we compared the alteration in gene expression in wild type and PAR1-/- mice induced by classical pro-inflammatory stimuli (LPS, SP, and antigen).
BC8_BioRED_Task1_Doc118	1277	1289	inflammatory	Disease	D007249	For this purpose, we compared the alteration in gene expression in wild type and PAR1-/- mice induced by classical pro-inflammatory stimuli (LPS, SP, and antigen).
BC8_BioRED_Task1_Doc118	1299	1302	LPS	Chemical	D008070	For this purpose, we compared the alteration in gene expression in wild type and PAR1-/- mice induced by classical pro-inflammatory stimuli (LPS, SP, and antigen).
BC8_BioRED_Task1_Doc118	1304	1306	SP	Chemical	D013373	For this purpose, we compared the alteration in gene expression in wild type and PAR1-/- mice induced by classical pro-inflammatory stimuli (LPS, SP, and antigen).
BC8_BioRED_Task1_Doc118	1372	1377	PAR-1	Gene	14062	75 transcripts were considered to be dependent on PAR-1 activation and further annotated in silico by Ingenuity Pathways Analysis (IPA) and gene ontology (GO).
BC8_BioRED_Task1_Doc118	1560	1564	PAR1	Gene	14062	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1630	1642	inflammatory	Disease	D007249	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1652	1655	b2m	Gene	12010	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1657	1661	ccl7	Gene	20306	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1663	1668	cd200	Gene	17470	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1670	1674	cd63	Gene	12512	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1676	1681	cdbpd	Gene	-	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1683	1687	cfl1	Gene	12631	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1689	1694	dusp1	Gene	19252	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1696	1702	fkbp1a	Gene	14225	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1704	1708	fth1	Gene	14319	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1710	1715	hspb1	Gene	15507	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1717	1725	marcksl1	Gene	17357	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1727	1731	mmp2	Gene	17390	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1733	1738	myo5a	Gene	17918	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1740	1746	nfkbia	Gene	18035	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1748	1752	pax1	Gene	18503	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1754	1759	plaur	Gene	18793	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1761	1765	ppia	Gene	268373	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1767	1772	ptpn1	Gene	19246	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1774	1781	ptprcap	Gene	19265	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1783	1790	s100a10	Gene	20194	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1792	1796	sim2	Gene	20465	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1802	1809	tnfaip2	Gene	21928	Among PAR1-dependent transcripts, the following have been implicated in the inflammatory process: b2m, ccl7, cd200, cd63, cdbpd, cfl1, dusp1, fkbp1a, fth1, hspb1, marcksl1, mmp2, myo5a, nfkbia, pax1, plaur, ppia, ptpn1, ptprcap, s100a10, sim2, and tnfaip2.
BC8_BioRED_Task1_Doc118	1984	1996	inflammation	Disease	D007249	However, a balanced response to signals of injury requires a transient cellular activation of a panel of genes together with inhibitory systems that temper the overwhelming inflammation.
BC8_BioRED_Task1_Doc118	2047	2052	dusp1	Gene	19252	In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production.
BC8_BioRED_Task1_Doc118	2057	2063	nfkbia	Gene	18035	In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production.
BC8_BioRED_Task1_Doc118	2093	2105	inflammatory	Disease	D007249	In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production.
BC8_BioRED_Task1_Doc118	2118	2121	PAR	Gene	14062,14063	In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production.
BC8_BioRED_Task1_Doc118	2169	2177	p38 MAPK	Gene	26416	In this context, the activation of genes such as dusp1 and nfkbia seems to counter-balance the inflammatory response to PAR activation by limiting prolonged activation of p38 MAPK and increased cytokine production.
BC8_BioRED_Task1_Doc118	2246	2250	arf6	Gene	11845	In contrast, transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the inflammatory reaction in response to common pro-inflammatory stimuli.
BC8_BioRED_Task1_Doc118	2255	2260	dcnt1	Gene	13426	In contrast, transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the inflammatory reaction in response to common pro-inflammatory stimuli.
BC8_BioRED_Task1_Doc118	2299	2302	PAR	Gene	14062,14063	In contrast, transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the inflammatory reaction in response to common pro-inflammatory stimuli.
BC8_BioRED_Task1_Doc118	2349	2361	inflammatory	Disease	D007249	In contrast, transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the inflammatory reaction in response to common pro-inflammatory stimuli.
BC8_BioRED_Task1_Doc118	2397	2409	inflammatory	Disease	D007249	In contrast, transcripts such as arf6 and dcnt1 that are involved in the mechanism of PAR re-sensitization would tend to perpetuate the inflammatory reaction in response to common pro-inflammatory stimuli.
BC8_BioRED_Task1_Doc118	2529	2533	PAR1	Gene	14062	CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of PAR1 in bladder inflammation, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.
BC8_BioRED_Task1_Doc118	2537	2557	bladder inflammation	Disease	D003556	CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of PAR1 in bladder inflammation, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.
BC8_BioRED_Task1_Doc118	2702	2706	PAR1	Gene	14062	CONCLUSION: The combination of cDNA array results and genomic networks reveals an overriding participation of PAR1 in bladder inflammation, provides a working model for the involvement of downstream signaling, and evokes testable hypotheses regarding the transcriptome downstream of PAR1 activation.
BC8_BioRED_Task1_Doc118	2783	2787	PAR1	Gene	14062	It remains to be determined whether or not mechanisms targeting PAR1 gene silencing or PAR1 blockade will ameliorate the clinical manifestation of cystitis.
BC8_BioRED_Task1_Doc118	2806	2810	PAR1	Gene	14062	It remains to be determined whether or not mechanisms targeting PAR1 gene silencing or PAR1 blockade will ameliorate the clinical manifestation of cystitis.
BC8_BioRED_Task1_Doc118	2866	2874	cystitis	Disease	D003556	It remains to be determined whether or not mechanisms targeting PAR1 gene silencing or PAR1 blockade will ameliorate the clinical manifestation of cystitis.
BC8_BioRED_Task1_Doc119	0	8	Gankyrin	Gene	53380	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc119	17	22	STAT3	Gene	20848	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc119	37	42	tumor	Disease	D009369	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc119	64	73	sorafenib	Chemical	D000077157	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc119	88	112	hepatocellular carcinoma	Disease	D006528	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
BC8_BioRED_Task1_Doc119	119	144	hepatocellular carcinomas	Disease	D006528	Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation.
BC8_BioRED_Task1_Doc119	146	149	HCC	Disease	D006528	Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation.
BC8_BioRED_Task1_Doc119	174	200	chronic liver inflammation	Disease	D007249	Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation.
BC8_BioRED_Task1_Doc119	225	236	oncoprotein	Gene	53380	We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon.
BC8_BioRED_Task1_Doc119	237	245	gankyrin	Gene	53380	We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon.
BC8_BioRED_Task1_Doc119	262	274	inflammation	Disease	D007249	We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon.
BC8_BioRED_Task1_Doc119	283	296	tumorigenesis	Disease	D009369	We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon.
BC8_BioRED_Task1_Doc119	345	353	gankyrin	Gene	5716	Although the in vitro function of gankyrin is well known, its role in vivo remains to be elucidated.
BC8_BioRED_Task1_Doc119	442	450	gankyrin	Gene	53380	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	458	463	tumor	Disease	D009369	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	484	488	mice	OrganismTaxon	10090	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	526	534	gankyrin	Gene	53380	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	545	548	Alb	Gene	11657	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	553	561	gankyrin	Gene	53380	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	573	581	gankyrin	Gene	53380	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	644	647	Mx1	Gene	17857	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	652	660	gankyrin	Gene	53380	We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f) ) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f) ).
BC8_BioRED_Task1_Doc119	669	677	Gankyrin	Gene	5716	Gankyrin upregulates vascular endothelial growth factor expression in tumor cells.
BC8_BioRED_Task1_Doc119	690	724	vascular endothelial growth factor	Gene	22339	Gankyrin upregulates vascular endothelial growth factor expression in tumor cells.
BC8_BioRED_Task1_Doc119	739	744	tumor	Disease	D009369	Gankyrin upregulates vascular endothelial growth factor expression in tumor cells.
BC8_BioRED_Task1_Doc119	752	760	Gankyrin	Gene	53380	Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3).
BC8_BioRED_Task1_Doc119	770	833	Src homology 2 domain-containing protein tyrosine phosphatase-1	Gene	15170	Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3).
BC8_BioRED_Task1_Doc119	835	840	SHP-1	Gene	15170	Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3).
BC8_BioRED_Task1_Doc119	939	989	signal transducer and activator of transcription 3	Gene	20848	Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3).
BC8_BioRED_Task1_Doc119	991	996	STAT3	Gene	20848	Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3).
BC8_BioRED_Task1_Doc119	999	1007	Gankyrin	Gene	53380	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1083	1088	STAT3	Gene	20848	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1099	1117	interleukin (IL)-6	Gene	16193	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1134	1140	cancer	Disease	D009369	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1159	1163	Bmi1	Gene	12151	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1168	1201	epithelial cell adhesion molecule	Gene	17075	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1203	1208	EpCAM	Gene	17075	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1245	1256	tumorigenic	Disease	D009369	Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential.
BC8_BioRED_Task1_Doc119	1268	1288	Chronic inflammation	Disease	D007249	Chronic inflammation enhances gankyrin expression in the human liver.
BC8_BioRED_Task1_Doc119	1298	1306	gankyrin	Gene	5716	Chronic inflammation enhances gankyrin expression in the human liver.
BC8_BioRED_Task1_Doc119	1325	1330	human	OrganismTaxon	9606	Chronic inflammation enhances gankyrin expression in the human liver.
BC8_BioRED_Task1_Doc119	1338	1346	Gankyrin	Gene	5716	Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC.
BC8_BioRED_Task1_Doc119	1365	1370	tumor	Disease	D009369	Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC.
BC8_BioRED_Task1_Doc119	1447	1455	patients	OrganismTaxon	9606	Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC.
BC8_BioRED_Task1_Doc119	1467	1476	sorafenib	Chemical	D000077157	Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC.
BC8_BioRED_Task1_Doc119	1491	1494	HCC	Disease	D006528	Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC.
BC8_BioRED_Task1_Doc119	1502	1510	gankyrin	Gene	53380	Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
BC8_BioRED_Task1_Doc119	1560	1565	tumor	Disease	D009369	Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
BC8_BioRED_Task1_Doc119	1674	1677	HCC	Disease	D006528	Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
BC8_BioRED_Task1_Doc120	0	7	Alcohol	Chemical	D000438	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study.
BC8_BioRED_Task1_Doc120	24	39	prostate cancer	Disease	D011471	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study.
BC8_BioRED_Task1_Doc120	100	115	Prostate cancer	Disease	D011471	Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies.
BC8_BioRED_Task1_Doc120	135	141	cancer	Disease	D009369	Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies.
BC8_BioRED_Task1_Doc120	145	148	men	OrganismTaxon	9606	Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies.
BC8_BioRED_Task1_Doc120	235	242	alcohol	Chemical	D000438	The effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially due to methodological limitations of observational studies.
BC8_BioRED_Task1_Doc120	258	273	prostate cancer	Disease	D011471	The effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially due to methodological limitations of observational studies.
BC8_BioRED_Task1_Doc120	456	463	alcohol	Chemical	D000438	In this study, we investigated the associations of genetic variants in alcohol-metabolising genes with prostate cancer incidence and survival.
BC8_BioRED_Task1_Doc120	488	503	prostate cancer	Disease	D011471	In this study, we investigated the associations of genetic variants in alcohol-metabolising genes with prostate cancer incidence and survival.
BC8_BioRED_Task1_Doc120	557	560	men	OrganismTaxon	9606	We analysed data from 23,868 men with prostate cancer and 23,051 controls from 25 studies within the international PRACTICAL Consortium.
BC8_BioRED_Task1_Doc120	566	581	prostate cancer	Disease	D011471	We analysed data from 23,868 men with prostate cancer and 23,051 controls from 25 studies within the international PRACTICAL Consortium.
BC8_BioRED_Task1_Doc120	743	750	alcohol	Chemical	D000438	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	771	793	Alcohol Dehydrogenases	Gene	125	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	795	799	ADHs	Gene	125	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	805	828	Aldehyde Dehydrogenases	Gene	8854	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	830	835	ALDHs	Gene	8854	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	843	858	prostate cancer	Disease	D011471	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	873	888	prostate cancer	Disease	D011471	Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively.
BC8_BioRED_Task1_Doc120	1127	1134	alcohol	Chemical	D000438	We found little evidence that variants in alcohol metabolising genes were associated with prostate cancer diagnosis.
BC8_BioRED_Task1_Doc120	1175	1190	prostate cancer	Disease	D011471	We found little evidence that variants in alcohol metabolising genes were associated with prostate cancer diagnosis.
BC8_BioRED_Task1_Doc120	1291	1306	prostate cancer	Disease	D011471	Four variants in two genes exceeded the multiple testing threshold for associations with prostate cancer mortality in fixed-effect meta-analyses.
BC8_BioRED_Task1_Doc120	1360	1367	ALDH1A2	Gene	8854	SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).
BC8_BioRED_Task1_Doc120	1384	1399	prostate cancer	Disease	D011471	SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).
BC8_BioRED_Task1_Doc120	1415	1424	rs1441817	SequenceVariant	rs1441817	SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).
BC8_BioRED_Task1_Doc120	1533	1543	rs12910509	SequenceVariant	rs12910509	SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).
BC8_BioRED_Task1_Doc120	1602	1611	rs8041922	SequenceVariant	rs8041922	SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio, HRfixed  = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed  = 0.76; 95%CI:0.64,0.91; p values = 0.002).
BC8_BioRED_Task1_Doc120	1728	1735	ALDH1B1	Gene	219	In ALDH1B1, rs10973794 (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with prostate cancer mortality in men with low-grade prostate cancer.
BC8_BioRED_Task1_Doc120	1737	1747	rs10973794	SequenceVariant	rs10973794	In ALDH1B1, rs10973794 (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with prostate cancer mortality in men with low-grade prostate cancer.
BC8_BioRED_Task1_Doc120	1821	1836	prostate cancer	Disease	D011471	In ALDH1B1, rs10973794 (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with prostate cancer mortality in men with low-grade prostate cancer.
BC8_BioRED_Task1_Doc120	1850	1853	men	OrganismTaxon	9606	In ALDH1B1, rs10973794 (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with prostate cancer mortality in men with low-grade prostate cancer.
BC8_BioRED_Task1_Doc120	1869	1884	prostate cancer	Disease	D011471	In ALDH1B1, rs10973794 (HRfixed  = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with prostate cancer mortality in men with low-grade prostate cancer.
BC8_BioRED_Task1_Doc120	1913	1920	alcohol	Chemical	D000438	These results suggest that alcohol consumption is unlikely to affect prostate cancer incidence, but it may influence disease progression.
BC8_BioRED_Task1_Doc120	1955	1970	prostate cancer	Disease	D011471	These results suggest that alcohol consumption is unlikely to affect prostate cancer incidence, but it may influence disease progression.
BC8_BioRED_Task1_Doc121	9	26	otilonium bromide	Chemical	C013934	Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
BC8_BioRED_Task1_Doc121	51	67	neurotransmitter	Chemical	D018377	Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
BC8_BioRED_Task1_Doc121	88	92	rats	OrganismTaxon	10116	Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
BC8_BioRED_Task1_Doc121	129	146	Otilonium bromide	Chemical	C013934	Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
BC8_BioRED_Task1_Doc121	148	150	OB	Chemical	C013934	Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
BC8_BioRED_Task1_Doc121	213	237	irritable bowel syndrome	Disease	D043183	Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
BC8_BioRED_Task1_Doc121	239	242	IBS	Disease	D043183	Otilonium bromide (OB) is a spasmolytic drug successfully used for the treatment of irritable bowel syndrome (IBS).
BC8_BioRED_Task1_Doc121	294	323	L- and T-type Ca(2+) channels	Gene	24239,83810	Its efficacy has been attributed to the block of L- and T-type Ca(2+) channels and muscarinic and tachykinin receptors in the smooth muscle.
BC8_BioRED_Task1_Doc121	328	363	muscarinic and tachykinin receptors	Gene	1128,6869	Its efficacy has been attributed to the block of L- and T-type Ca(2+) channels and muscarinic and tachykinin receptors in the smooth muscle.
BC8_BioRED_Task1_Doc121	410	414	rats	OrganismTaxon	10116	Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action.
BC8_BioRED_Task1_Doc121	425	427	OB	Chemical	C013934	Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action.
BC8_BioRED_Task1_Doc121	452	468	neurotransmitter	Chemical	D018377	Furthermore, in healthy rats, repeated OB administration modified neurotransmitter expression and function suggesting other mechanisms of action.
BC8_BioRED_Task1_Doc121	580	582	OB	Chemical	C013934	On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms.
BC8_BioRED_Task1_Doc121	669	673	rats	OrganismTaxon	10116	On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms.
BC8_BioRED_Task1_Doc121	780	783	IBS	Disease	D043183	On this basis, we investigated whether repeated OB treatment prevented the functional and neurochemical changes observed in the colon of rats underwent to wrap restrain stress (WRS) a psychosocial stressor considered suitable to reproduce the main IBS signs and symptoms.
BC8_BioRED_Task1_Doc121	824	826	OB	Chemical	C013934	In control, WRS and OB/WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon.
BC8_BioRED_Task1_Doc121	831	835	rats	OrganismTaxon	10116	In control, WRS and OB/WRS rats functional parameters were measured in vivo and morphological investigations were done ex vivo in the colon.
BC8_BioRED_Task1_Doc121	969	971	OB	Chemical	C013934	The results showed that OB counteracts most of the neurotransmitters changes caused by WRS.
BC8_BioRED_Task1_Doc121	996	1013	neurotransmitters	Chemical	D018377	The results showed that OB counteracts most of the neurotransmitters changes caused by WRS.
BC8_BioRED_Task1_Doc121	1086	1088	SP	Gene	24806	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1091	1095	NK1r	Gene	24807	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1098	1102	nNOS	Gene	24598	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1105	1108	VIP	Gene	117064	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1115	1120	S100b	Gene	25742	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1163	1167	CGRP	Gene	24241	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1174	1179	CRF1r	Gene	58959	In particular, the drug prevents the decrease in SP-, NK1r-, nNOS-, VIP-, and S100b-immunoreactivity (IR) and the increase in CGRP-, and CRF1r-IR.
BC8_BioRED_Task1_Doc121	1201	1203	OB	Chemical	C013934	On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
BC8_BioRED_Task1_Doc121	1236	1241	CRF2r	Gene	64680	On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
BC8_BioRED_Task1_Doc121	1269	1273	rats	OrganismTaxon	10116	On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
BC8_BioRED_Task1_Doc121	1311	1331	mucosal inflammation	Disease	D052016	On the contrary, OB does not affect the increase in CRF2r-IR neurons observed in WRS rats and does not interfere with the mild mucosal inflammation due to WRS.
BC8_BioRED_Task1_Doc121	1353	1355	OB	Chemical	C013934	Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.
BC8_BioRED_Task1_Doc121	1377	1380	Mr2	Gene	81645	Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.
BC8_BioRED_Task1_Doc121	1453	1457	ChAT	Gene	290567	Finally, OB per se increases the Mr2 expression in the muscle wall and decreases the number of the myenteric ChAT-IR neurons.
BC8_BioRED_Task1_Doc121	1575	1577	OB	Chemical	C013934	Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats.
BC8_BioRED_Task1_Doc121	1586	1590	rats	OrganismTaxon	10116	Functional findings show a significantly reduction in the number of spontaneous abdominal contraction in OB treated rats.
BC8_BioRED_Task1_Doc121	1607	1609	OB	Chemical	C013934	The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.
BC8_BioRED_Task1_Doc121	1619	1641	L-type Ca(2+) channels	Gene	24239	The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.
BC8_BioRED_Task1_Doc121	1729	1731	OB	Chemical	C013934	The ability of OB to block L-type Ca(2+) channels, also expressed by enteric neurons, might represent a possible mechanism through which OB exerts its actions.
BC8_BioRED_Task1_Doc122	13	38	phospholipase C epsilon 1	Gene	51196	Mutations in phospholipase C epsilon 1 are not sufficient to cause diffuse mesangial sclerosis.
BC8_BioRED_Task1_Doc122	67	94	diffuse mesangial sclerosis	Disease	C537346	Mutations in phospholipase C epsilon 1 are not sufficient to cause diffuse mesangial sclerosis.
BC8_BioRED_Task1_Doc122	96	123	Diffuse mesangial sclerosis	Disease	C537346	Diffuse mesangial sclerosis occurs as an isolated abnormality or as a part of a syndrome.
BC8_BioRED_Task1_Doc122	209	234	phospholipase C epsilon 1	Gene	51196	Recently, mutations in phospholipase C epsilon 1 (PLCE1) were found to cause a nonsyndromic, autosomal recessive form of this disease.
BC8_BioRED_Task1_Doc122	236	241	PLCE1	Gene	51196	Recently, mutations in phospholipase C epsilon 1 (PLCE1) were found to cause a nonsyndromic, autosomal recessive form of this disease.
BC8_BioRED_Task1_Doc122	410	437	diffuse mesangial sclerosis	Disease	C537346	Here we describe three children from one consanguineous kindred of Pakistani origin with diffuse mesangial sclerosis who presented with congenital or infantile nephrotic syndrome.
BC8_BioRED_Task1_Doc122	457	499	congenital or infantile nephrotic syndrome	Disease	C535761	Here we describe three children from one consanguineous kindred of Pakistani origin with diffuse mesangial sclerosis who presented with congenital or infantile nephrotic syndrome.
BC8_BioRED_Task1_Doc122	525	530	PLCE1	Gene	51196	Homozygous mutations in PLCE1 (also known as KIAA1516, PLCE, or NPHS3) were identified following genome-wide mapping of single-nucleotide polymorphisms.
BC8_BioRED_Task1_Doc122	546	554	KIAA1516	Gene	51196	Homozygous mutations in PLCE1 (also known as KIAA1516, PLCE, or NPHS3) were identified following genome-wide mapping of single-nucleotide polymorphisms.
BC8_BioRED_Task1_Doc122	556	560	PLCE	Gene	51196	Homozygous mutations in PLCE1 (also known as KIAA1516, PLCE, or NPHS3) were identified following genome-wide mapping of single-nucleotide polymorphisms.
BC8_BioRED_Task1_Doc122	565	570	NPHS3	Gene	51196	Homozygous mutations in PLCE1 (also known as KIAA1516, PLCE, or NPHS3) were identified following genome-wide mapping of single-nucleotide polymorphisms.
BC8_BioRED_Task1_Doc122	698	720	four-basepair deletion	SequenceVariant	c|DEL||4	All affected children were homozygous for a four-basepair deletion in exon 3, which created a premature translational stop codon.
BC8_BioRED_Task1_Doc122	1014	1019	PLCE1	Gene	51196	We conclude this nonpenetrance may be due to compensatory mutations at a second locus and that mutation within PLCE1 is not always sufficient to cause diffuse mesangial sclerosis.
BC8_BioRED_Task1_Doc122	1054	1081	diffuse mesangial sclerosis	Disease	C537346	We conclude this nonpenetrance may be due to compensatory mutations at a second locus and that mutation within PLCE1 is not always sufficient to cause diffuse mesangial sclerosis.
BC8_BioRED_Task1_Doc123	21	36	alpha-synuclein	Gene	6622	Novel suppressors of alpha-synuclein toxicity identified using yeast.
BC8_BioRED_Task1_Doc123	37	45	toxicity	Disease	D064420	Novel suppressors of alpha-synuclein toxicity identified using yeast.
BC8_BioRED_Task1_Doc123	63	68	yeast	OrganismTaxon	4932	Novel suppressors of alpha-synuclein toxicity identified using yeast.
BC8_BioRED_Task1_Doc123	97	116	Parkinson's disease	Disease	D010300	The mechanism by which the Parkinson's disease-related protein alpha-synuclein (alpha-syn) causes neurodegeneration has not been elucidated.
BC8_BioRED_Task1_Doc123	133	148	alpha-synuclein	Gene	6622	The mechanism by which the Parkinson's disease-related protein alpha-synuclein (alpha-syn) causes neurodegeneration has not been elucidated.
BC8_BioRED_Task1_Doc123	150	159	alpha-syn	Gene	6622	The mechanism by which the Parkinson's disease-related protein alpha-synuclein (alpha-syn) causes neurodegeneration has not been elucidated.
BC8_BioRED_Task1_Doc123	168	185	neurodegeneration	Disease	D019636	The mechanism by which the Parkinson's disease-related protein alpha-synuclein (alpha-syn) causes neurodegeneration has not been elucidated.
BC8_BioRED_Task1_Doc123	258	267	alpha-syn	Gene	6622	To determine the genes that protect cells from alpha-syn, we used a genetic screen to identify suppressors of the super sensitivity of the yeast Saccharomyces cerevisiae expressing alpha-syn to killing by hydrogen peroxide.
BC8_BioRED_Task1_Doc123	350	355	yeast	OrganismTaxon	4932	To determine the genes that protect cells from alpha-syn, we used a genetic screen to identify suppressors of the super sensitivity of the yeast Saccharomyces cerevisiae expressing alpha-syn to killing by hydrogen peroxide.
BC8_BioRED_Task1_Doc123	356	380	Saccharomyces cerevisiae	OrganismTaxon	4932	To determine the genes that protect cells from alpha-syn, we used a genetic screen to identify suppressors of the super sensitivity of the yeast Saccharomyces cerevisiae expressing alpha-syn to killing by hydrogen peroxide.
BC8_BioRED_Task1_Doc123	392	401	alpha-syn	Gene	6622	To determine the genes that protect cells from alpha-syn, we used a genetic screen to identify suppressors of the super sensitivity of the yeast Saccharomyces cerevisiae expressing alpha-syn to killing by hydrogen peroxide.
BC8_BioRED_Task1_Doc123	416	433	hydrogen peroxide	Chemical	D006861	To determine the genes that protect cells from alpha-syn, we used a genetic screen to identify suppressors of the super sensitivity of the yeast Saccharomyces cerevisiae expressing alpha-syn to killing by hydrogen peroxide.
BC8_BioRED_Task1_Doc123	450	459	ubiquitin	Gene	850620	Forty genes in ubiquitin-dependent protein catabolism, protein biosynthesis, vesicle trafficking and the response to stress were identified.
BC8_BioRED_Task1_Doc123	601	605	ENT3	Gene	853589	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	607	611	IDP3	Gene	855723	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	613	617	JEM1	Gene	853372	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	619	623	ARG2	Gene	853374	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	628	633	HSP82	Gene	855836	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	676	685	alpha-syn	Gene	6622	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	694	717	reactive oxygen species	Chemical	D017382	Five of the forty genes--ENT3, IDP3, JEM1, ARG2 and HSP82--ranked highest in their ability to block alpha-syn-induced reactive oxygen species accumulation, and these five genes were characterized in more detail.
BC8_BioRED_Task1_Doc123	841	849	toxicity	Disease	D064420	The deletion of any of these five genes enhanced the toxicity of alpha-syn as judged by growth defects compared with wild-type cells expressing alpha-syn, which indicates that these genes protect cells from alpha-syn.
BC8_BioRED_Task1_Doc123	853	862	alpha-syn	Gene	6622	The deletion of any of these five genes enhanced the toxicity of alpha-syn as judged by growth defects compared with wild-type cells expressing alpha-syn, which indicates that these genes protect cells from alpha-syn.
BC8_BioRED_Task1_Doc123	932	941	alpha-syn	Gene	6622	The deletion of any of these five genes enhanced the toxicity of alpha-syn as judged by growth defects compared with wild-type cells expressing alpha-syn, which indicates that these genes protect cells from alpha-syn.
BC8_BioRED_Task1_Doc123	995	1004	alpha-syn	Gene	6622	The deletion of any of these five genes enhanced the toxicity of alpha-syn as judged by growth defects compared with wild-type cells expressing alpha-syn, which indicates that these genes protect cells from alpha-syn.
BC8_BioRED_Task1_Doc123	1058	1067	alpha-syn	Gene	6622	Strikingly, four of the five genes are specific for alpha-syn in that they fail to protect cells from the toxicity of the two inherited mutants A30P or A53T.
BC8_BioRED_Task1_Doc123	1112	1120	toxicity	Disease	D064420	Strikingly, four of the five genes are specific for alpha-syn in that they fail to protect cells from the toxicity of the two inherited mutants A30P or A53T.
BC8_BioRED_Task1_Doc123	1150	1154	A30P	SequenceVariant	p|SUB|A|30|P	Strikingly, four of the five genes are specific for alpha-syn in that they fail to protect cells from the toxicity of the two inherited mutants A30P or A53T.
BC8_BioRED_Task1_Doc123	1158	1162	A53T	SequenceVariant	p|SUB|A|53|T	Strikingly, four of the five genes are specific for alpha-syn in that they fail to protect cells from the toxicity of the two inherited mutants A30P or A53T.
BC8_BioRED_Task1_Doc123	1191	1200	alpha-syn	Gene	6622	This finding suggests that alpha-syn causes toxicity to cells through a different pathway than these two inherited mutants.
BC8_BioRED_Task1_Doc123	1208	1216	toxicity	Disease	D064420	This finding suggests that alpha-syn causes toxicity to cells through a different pathway than these two inherited mutants.
BC8_BioRED_Task1_Doc123	1314	1319	Ent3p	Gene	853589	Lastly, overexpression of Ent3p, which is a clathrin adapter protein involved in protein transport between the Golgi and the vacuole, causes alpha-syn to redistribute from the plasma membrane into cytoplasmic vesicular structures.
BC8_BioRED_Task1_Doc123	1332	1340	clathrin	Chemical	D002966	Lastly, overexpression of Ent3p, which is a clathrin adapter protein involved in protein transport between the Golgi and the vacuole, causes alpha-syn to redistribute from the plasma membrane into cytoplasmic vesicular structures.
BC8_BioRED_Task1_Doc123	1429	1438	alpha-syn	Gene	6622	Lastly, overexpression of Ent3p, which is a clathrin adapter protein involved in protein transport between the Golgi and the vacuole, causes alpha-syn to redistribute from the plasma membrane into cytoplasmic vesicular structures.
BC8_BioRED_Task1_Doc123	1546	1551	Ent3p	Gene	853589	Our interpretation is that Ent3p mediates the transport of alpha-syn to the vacuole for proteolytic degradation.
BC8_BioRED_Task1_Doc123	1578	1587	alpha-syn	Gene	6622	Our interpretation is that Ent3p mediates the transport of alpha-syn to the vacuole for proteolytic degradation.
BC8_BioRED_Task1_Doc123	1642	1650	clathrin	Chemical	D002966	A similar clathrin adaptor protein, epsinR, exists in humans.
BC8_BioRED_Task1_Doc123	1668	1674	epsinR	Gene	9685	A similar clathrin adaptor protein, epsinR, exists in humans.
BC8_BioRED_Task1_Doc123	1686	1692	humans	OrganismTaxon	9606	A similar clathrin adaptor protein, epsinR, exists in humans.
BC8_BioRED_Task1_Doc124	0	5	P2RX7	Gene	5027	P2RX7: A bipolar and unipolar disorder candidate susceptibility gene?
BC8_BioRED_Task1_Doc124	9	38	bipolar and unipolar disorder	Disease	D001714,D003866	P2RX7: A bipolar and unipolar disorder candidate susceptibility gene?
BC8_BioRED_Task1_Doc124	157	173	bipolar disorder	Disease	D001714	The chromosomal region 12q24 has been previously implicated by linkage studies of both bipolar disorder and unipolar mood disorder and we have reported two pedigrees segregating both bipolar disorder and Darier's disease that show linkage across this region.
BC8_BioRED_Task1_Doc124	178	200	unipolar mood disorder	Disease	D003866,D019964	The chromosomal region 12q24 has been previously implicated by linkage studies of both bipolar disorder and unipolar mood disorder and we have reported two pedigrees segregating both bipolar disorder and Darier's disease that show linkage across this region.
BC8_BioRED_Task1_Doc124	253	269	bipolar disorder	Disease	D001714	The chromosomal region 12q24 has been previously implicated by linkage studies of both bipolar disorder and unipolar mood disorder and we have reported two pedigrees segregating both bipolar disorder and Darier's disease that show linkage across this region.
BC8_BioRED_Task1_Doc124	274	290	Darier's disease	Disease	D007644	The chromosomal region 12q24 has been previously implicated by linkage studies of both bipolar disorder and unipolar mood disorder and we have reported two pedigrees segregating both bipolar disorder and Darier's disease that show linkage across this region.
BC8_BioRED_Task1_Doc124	338	343	P2RX7	Gene	5027	The gene P2RX7 is located in this chromosomal region and has been recently reported as a susceptibility gene for bipolar disorder and unipolar depression.
BC8_BioRED_Task1_Doc124	442	458	bipolar disorder	Disease	D001714	The gene P2RX7 is located in this chromosomal region and has been recently reported as a susceptibility gene for bipolar disorder and unipolar depression.
BC8_BioRED_Task1_Doc124	463	482	unipolar depression	Disease	D003866	The gene P2RX7 is located in this chromosomal region and has been recently reported as a susceptibility gene for bipolar disorder and unipolar depression.
BC8_BioRED_Task1_Doc124	507	516	rs2230912	SequenceVariant	rs2230912	The non-synonymous SNP rs2230912 (resulting in amino-acid polymorphism Q460R) showed the strongest association and has been postulated to be pathogenically relevant.
BC8_BioRED_Task1_Doc124	555	560	Q460R	SequenceVariant	rs2230912	The non-synonymous SNP rs2230912 (resulting in amino-acid polymorphism Q460R) showed the strongest association and has been postulated to be pathogenically relevant.
BC8_BioRED_Task1_Doc124	716	734	bipolar I disorder	Disease	D001714	We have investigated this gene in a large UK case-control sample (bipolar I disorder N = 687, unipolar recurrent major depression N = 1,036, controls N = 1,204).
BC8_BioRED_Task1_Doc124	744	779	unipolar recurrent major depression	Disease	D003865	We have investigated this gene in a large UK case-control sample (bipolar I disorder N = 687, unipolar recurrent major depression N = 1,036, controls N = 1,204).
BC8_BioRED_Task1_Doc124	820	829	rs2230912	SequenceVariant	rs2230912	Neither rs2230912 nor any of 8 other SNPs genotyped across P2RX7 was found to be associated with mood disorder in general, nor specifically with bipolar or unipolar disorder.
BC8_BioRED_Task1_Doc124	871	876	P2RX7	Gene	5027	Neither rs2230912 nor any of 8 other SNPs genotyped across P2RX7 was found to be associated with mood disorder in general, nor specifically with bipolar or unipolar disorder.
BC8_BioRED_Task1_Doc124	909	922	mood disorder	Disease	D019964	Neither rs2230912 nor any of 8 other SNPs genotyped across P2RX7 was found to be associated with mood disorder in general, nor specifically with bipolar or unipolar disorder.
BC8_BioRED_Task1_Doc124	957	985	bipolar or unipolar disorder	Disease	D001714,D003866	Neither rs2230912 nor any of 8 other SNPs genotyped across P2RX7 was found to be associated with mood disorder in general, nor specifically with bipolar or unipolar disorder.
BC8_BioRED_Task1_Doc124	1102	1107	P2RX7	Gene	5027	Further, sequencing of our two chromosome 12-linked bipolar-Darier families showed no evidence of rare variants at P2RX7 that could explain the linkage.
BC8_BioRED_Task1_Doc124	1176	1185	rs2230912	SequenceVariant	rs2230912	Our data do not provide support for rs2230912 or the other polymorphisms studied within the P2RX7 locus, being involved in susceptibility to mood disorders.
BC8_BioRED_Task1_Doc124	1232	1237	P2RX7	Gene	5027	Our data do not provide support for rs2230912 or the other polymorphisms studied within the P2RX7 locus, being involved in susceptibility to mood disorders.
BC8_BioRED_Task1_Doc124	1281	1295	mood disorders	Disease	D019964	Our data do not provide support for rs2230912 or the other polymorphisms studied within the P2RX7 locus, being involved in susceptibility to mood disorders.
BC8_BioRED_Task1_Doc125	0	5	GLUT4	Gene	20528	GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle.
BC8_BioRED_Task1_Doc125	44	51	Glucose	Chemical	D005947	GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle.
BC8_BioRED_Task1_Doc125	85	90	Mouse	OrganismTaxon	10090	GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle.
BC8_BioRED_Task1_Doc125	108	113	GLUT4	Gene	20528	GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown.
BC8_BioRED_Task1_Doc125	137	144	insulin	Gene	3630	GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown.
BC8_BioRED_Task1_Doc125	186	193	glucose	Chemical	D005947	GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown.
BC8_BioRED_Task1_Doc125	260	267	glucose	Chemical	D005947	GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown.
BC8_BioRED_Task1_Doc125	321	326	GLUT4	Gene	20528	Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	360	367	glucose	Chemical	D005947	Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	400	405	mouse	OrganismTaxon	10090	Overload was induced in mouse plantaris muscle by unilateral synergist ablation.
BC8_BioRED_Task1_Doc125	498	522	[(3)H]-2-deoxy-d-glucose	Chemical	D003847	After 5 days, muscle weights and ex vivo [(3)H]-2-deoxy-d-glucose uptake were assessed.
BC8_BioRED_Task1_Doc125	569	576	glucose	Chemical	D005947	Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes.
BC8_BioRED_Task1_Doc125	645	650	GLUT4	Gene	20528	Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes.
BC8_BioRED_Task1_Doc125	660	664	mice	OrganismTaxon	10090	Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes.
BC8_BioRED_Task1_Doc125	685	690	GLUT4	Gene	20528	Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes.
BC8_BioRED_Task1_Doc125	783	790	glucose	Chemical	D005947	To assess which transporters mediate overload-induced glucose uptake, chemical inhibitors were used.
BC8_BioRED_Task1_Doc125	847	851	GLUT	Gene	170441,20525,20526,20527,20528,227659,353169,56017,56485	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.
BC8_BioRED_Task1_Doc125	862	876	cytochalasin B	Chemical	D003571	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.
BC8_BioRED_Task1_Doc125	890	896	sodium	Chemical	D012964	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.
BC8_BioRED_Task1_Doc125	907	914	glucose	Chemical	D005947	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.
BC8_BioRED_Task1_Doc125	937	947	phloridzin	Chemical	D010695	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.
BC8_BioRED_Task1_Doc125	1002	1007	GLUTs	Gene	170441,20525,20526,20527,20528,227659,353169,56017,56485	The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect.
BC8_BioRED_Task1_Doc125	1045	1049	GLUT	Gene	170441,20525,20526,20527,20528,227659,353169,56017,56485	To assess which GLUT, hexose competition experiments were performed.
BC8_BioRED_Task1_Doc125	1051	1057	hexose	Chemical	D006601	To assess which GLUT, hexose competition experiments were performed.
BC8_BioRED_Task1_Doc125	1115	1139	[(3)H]-2-deoxy-d-glucose	Chemical	D003847	Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect.
BC8_BioRED_Task1_Doc125	1168	1178	d-fructose	Chemical	D005632	Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect.
BC8_BioRED_Task1_Doc125	1225	1230	GLUT2	Gene	20526	Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect.
BC8_BioRED_Task1_Doc125	1232	1237	GLUT5	Gene	56485	Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect.
BC8_BioRED_Task1_Doc125	1239	1244	GLUT8	Gene	56017	Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect.
BC8_BioRED_Task1_Doc125	1250	1256	GLUT12	Gene	353169	Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect.
BC8_BioRED_Task1_Doc125	1306	1311	GLUTs	Gene	170441,20525,20526,20527,20528,227659,353169,56017,56485	To assess additional GLUTs, immunoblots were performed.
BC8_BioRED_Task1_Doc125	1360	1365	GLUT1	Gene	20525	Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold.
BC8_BioRED_Task1_Doc125	1367	1372	GLUT3	Gene	20527	Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold.
BC8_BioRED_Task1_Doc125	1374	1379	GLUT6	Gene	227659	Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold.
BC8_BioRED_Task1_Doc125	1385	1391	GLUT10	Gene	170441	Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold.
BC8_BioRED_Task1_Doc125	1473	1478	GLUT4	Gene	20528	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	1524	1531	glucose	Chemical	D005947	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	1579	1584	GLUT1	Gene	20525	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	1586	1591	GLUT3	Gene	20527	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	1593	1598	GLUT6	Gene	227659	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	1607	1613	GLUT10	Gene	170441	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc125	1639	1646	glucose	Chemical	D005947	Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.
BC8_BioRED_Task1_Doc126	109	134	puromycin aminonucleoside	Chemical	D011692	Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.
BC8_BioRED_Task1_Doc126	135	144	nephrosis	Disease	D009401	Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.
BC8_BioRED_Task1_Doc126	219	230	proteinuria	Disease	D011507	BACKGROUND/AIMS: It is still unclear what happens in the glomerulus when proteinuria starts.
BC8_BioRED_Task1_Doc126	245	270	puromycin aminonucleoside	Chemical	D011692	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	271	280	nephrosis	Disease	D009401	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	282	285	PAN	Disease	D009401	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	287	291	rats	OrganismTaxon	10116	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	418	425	nephrin	Gene	64563	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	427	436	a-actinin	Gene	81634	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	438	445	dendrin	Gene	25113	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	451	458	plekhh2	Gene	313866	Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
BC8_BioRED_Task1_Doc126	725	728	ACE	Gene	24310	Possible effects of ACE inhibition were tested.
BC8_BioRED_Task1_Doc126	816	827	proteinuria	Disease	D011507	RESULTS: By day 2, some patchy foot process effacement, but no proteinuria, appeared.
BC8_BioRED_Task1_Doc126	853	860	nephrin	Gene	64563	The amount of nephrin was reduced in both diseased and normal areas.
BC8_BioRED_Task1_Doc126	1036	1047	proteinuria	Disease	D011507	By day 4, foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage.
BC8_BioRED_Task1_Doc126	1104	1111	Nephrin	Gene	64563	Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.
BC8_BioRED_Task1_Doc126	1137	1144	dendrin	Gene	25113	Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.
BC8_BioRED_Task1_Doc126	1149	1156	plekhh2	Gene	313866	Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.
BC8_BioRED_Task1_Doc126	1176	1185	a-actinin	Gene	81634	Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.
BC8_BioRED_Task1_Doc126	1206	1209	ACE	Gene	24310	ACE inhibition had no significant protective effect.
BC8_BioRED_Task1_Doc126	1272	1275	PAN	Disease	D009401	CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.
BC8_BioRED_Task1_Doc126	1357	1368	proteinuria	Disease	D011507	CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.
BC8_BioRED_Task1_Doc126	1399	1406	nephrin	Gene	64563	This was preceded by altered nephrin expression, supporting its pivotal role in podocyte morphology.
BC8_BioRED_Task1_Doc126	1490	1497	dendrin	Gene	25113	The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.
BC8_BioRED_Task1_Doc126	1502	1509	plekhh2	Gene	313866	The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.
BC8_BioRED_Task1_Doc126	1549	1552	PAN	Disease	D009401	The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.
BC8_BioRED_Task1_Doc126	1562	1571	a-actinin	Gene	81634	The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.
BC8_BioRED_Task1_Doc127	0	6	Sepsis	Disease	D018805	Sepsis-induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle.
BC8_BioRED_Task1_Doc127	26	49	amino acid transporters	Gene	246235,25648,29642,84551	Sepsis-induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle.
BC8_BioRED_Task1_Doc127	54	61	leucine	Chemical	D007930	Sepsis-induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle.
BC8_BioRED_Task1_Doc127	76	80	mTOR	Gene	56718	Sepsis-induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle.
BC8_BioRED_Task1_Doc127	146	152	sepsis	Disease	D018805	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	161	168	leucine	Chemical	D007930	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	170	173	Leu	Chemical	D007930	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	245	268	amino acid transporters	Gene	246235,25648,29642,84551	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	293	296	Leu	Chemical	D007930	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	343	346	Leu	Chemical	D007930	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	357	361	mTOR	Gene	56718	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	362	379	Ragulator complex	Gene	295234,308869	The present study tested the hypothesis that sepsis-induced leucine (Leu) resistance in skeletal muscle is associated with a down-regulation of amino acid transporters important in regulating Leu flux or an impairment in the formation of the Leu-sensitive mTOR-Ragulator complex.
BC8_BioRED_Task1_Doc127	381	387	Sepsis	Disease	D018805	Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in mTOR activation as indicated by decreased 4E-BP1 and S6K1 phosphorylation.
BC8_BioRED_Task1_Doc127	402	406	rats	OrganismTaxon	10116	Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in mTOR activation as indicated by decreased 4E-BP1 and S6K1 phosphorylation.
BC8_BioRED_Task1_Doc127	490	494	mTOR	Gene	56718	Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in mTOR activation as indicated by decreased 4E-BP1 and S6K1 phosphorylation.
BC8_BioRED_Task1_Doc127	532	538	4E-BP1	Gene	116636	Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in mTOR activation as indicated by decreased 4E-BP1 and S6K1 phosphorylation.
BC8_BioRED_Task1_Doc127	543	547	S6K1	Gene	83840	Sepsis in adult male rats decreased basal protein synthesis in gastrocnemius, associated with a reduction in mTOR activation as indicated by decreased 4E-BP1 and S6K1 phosphorylation.
BC8_BioRED_Task1_Doc127	585	588	Leu	Chemical	D007930	The ability of oral Leu to increase protein synthesis and mTOR kinase after 1 h was largely prevented in sepsis.
BC8_BioRED_Task1_Doc127	623	627	mTOR	Gene	56718	The ability of oral Leu to increase protein synthesis and mTOR kinase after 1 h was largely prevented in sepsis.
BC8_BioRED_Task1_Doc127	670	676	sepsis	Disease	D018805	The ability of oral Leu to increase protein synthesis and mTOR kinase after 1 h was largely prevented in sepsis.
BC8_BioRED_Task1_Doc127	678	684	Sepsis	Disease	D018805	Sepsis increased CAT1, LAT2 and SNAT2 mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.
BC8_BioRED_Task1_Doc127	695	699	CAT1	Gene	25648	Sepsis increased CAT1, LAT2 and SNAT2 mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.
BC8_BioRED_Task1_Doc127	701	705	LAT2	Gene	84551	Sepsis increased CAT1, LAT2 and SNAT2 mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.
BC8_BioRED_Task1_Doc127	710	715	SNAT2	Gene	29642	Sepsis increased CAT1, LAT2 and SNAT2 mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.
BC8_BioRED_Task1_Doc127	780	784	CAT1	Gene	25648	Sepsis increased CAT1, LAT2 and SNAT2 mRNA content two- to fourfold, but only the protein content for CAT1 (20 % decrease) differed significantly.
BC8_BioRED_Task1_Doc127	837	843	sepsis	Disease	D018805	Conversely, sepsis decreased the proton-assisted amino acid transporter (PAT)-2 mRNA by 60 %, but without a coordinate change in PAT2 protein.
BC8_BioRED_Task1_Doc127	858	904	proton-assisted amino acid transporter (PAT)-2	Gene	246235	Conversely, sepsis decreased the proton-assisted amino acid transporter (PAT)-2 mRNA by 60 %, but without a coordinate change in PAT2 protein.
BC8_BioRED_Task1_Doc127	954	958	PAT2	Gene	246235	Conversely, sepsis decreased the proton-assisted amino acid transporter (PAT)-2 mRNA by 60 %, but without a coordinate change in PAT2 protein.
BC8_BioRED_Task1_Doc127	981	987	sepsis	Disease	D018805	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	991	994	Leu	Chemical	D007930	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	1029	1035	RagA-D	Gene	117043,117044,297960,298514	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	1037	1052	LAMTOR-1 and -2	Gene	295234,308869	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	1054	1060	raptor	Gene	287871	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	1062	1066	Rheb	Gene	26954	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	1070	1074	mTOR	Gene	56718	There was no sepsis or Leu effect on the protein content for RagA-D, LAMTOR-1 and -2, raptor, Rheb or mTOR in muscle.
BC8_BioRED_Task1_Doc127	1101	1105	mTOR	Gene	56718	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1107	1113	PRAS40	Gene	292887	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1118	1122	RagC	Gene	298514	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1126	1132	raptor	Gene	287871	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1215	1218	Leu	Chemical	D007930	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1239	1245	PRAS40	Gene	292887	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1246	1252	raptor	Gene	287871	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1269	1273	RagC	Gene	298514	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1274	1280	raptor	Gene	287871	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1318	1324	sepsis	Disease	D018805	The binding of mTOR, PRAS40 and RagC to raptor did not differ for control and septic muscle in the basal condition; however, the Leu-induced decrease in PRAS40 raptor and increase in RagC raptor seen in control muscle was absent in sepsis.
BC8_BioRED_Task1_Doc127	1344	1347	Leu	Chemical	D007930	The intracellular Leu concentration was increased in septic muscle, compared to basal control conditions, and oral Leu further increased the intracellular Leu concentration similarly in both control and septic rats.
BC8_BioRED_Task1_Doc127	1441	1444	Leu	Chemical	D007930	The intracellular Leu concentration was increased in septic muscle, compared to basal control conditions, and oral Leu further increased the intracellular Leu concentration similarly in both control and septic rats.
BC8_BioRED_Task1_Doc127	1481	1484	Leu	Chemical	D007930	The intracellular Leu concentration was increased in septic muscle, compared to basal control conditions, and oral Leu further increased the intracellular Leu concentration similarly in both control and septic rats.
BC8_BioRED_Task1_Doc127	1536	1540	rats	OrganismTaxon	10116	The intracellular Leu concentration was increased in septic muscle, compared to basal control conditions, and oral Leu further increased the intracellular Leu concentration similarly in both control and septic rats.
BC8_BioRED_Task1_Doc127	1577	1600	amino acid transporters	Gene	246235,25648,29642,84551	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1640	1646	sepsis	Disease	D018805	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1655	1658	Leu	Chemical	D007930	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1675	1678	Leu	Chemical	D007930	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1701	1707	raptor	Gene	287871	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1713	1717	RagC	Gene	298514	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1741	1745	mTOR	Gene	56718	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1746	1752	raptor	Gene	287871	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1830	1833	Leu	Chemical	D007930	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc127	1852	1856	mTOR	Gene	56718	Hence, while alterations in select amino acid transporters are not associated with development of sepsis-induced Leu resistance, the Leu-stimulated binding of raptor with RagC and the recruitment of mTOR/raptor to the endosome-lysosomal compartment may partially explain the inability of Leu to fully activate mTOR and muscle protein synthesis.
BC8_BioRED_Task1_Doc128	71	78	miR-501	Gene	751560	MicroRNA deep sequencing in two adult stem cell populations identifies miR-501 as a novel regulator of myosin heavy chain during muscle regeneration.
BC8_BioRED_Task1_Doc128	103	121	myosin heavy chain	Gene	17883	MicroRNA deep sequencing in two adult stem cell populations identifies miR-501 as a novel regulator of myosin heavy chain during muscle regeneration.
BC8_BioRED_Task1_Doc128	435	446	cardiotoxin	Chemical	D054715	Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced muscle injury uncovered miR-501 as a novel muscle-specific miRNA.
BC8_BioRED_Task1_Doc128	448	451	CTX	Chemical	D054715	Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced muscle injury uncovered miR-501 as a novel muscle-specific miRNA.
BC8_BioRED_Task1_Doc128	461	474	muscle injury	Disease	D009135	Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced muscle injury uncovered miR-501 as a novel muscle-specific miRNA.
BC8_BioRED_Task1_Doc128	485	492	miR-501	Gene	751560	Here, comparative miRNA sequencing analysis of myogenic progenitor cells (MPs) and non-myogenic fibroblast-adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced muscle injury uncovered miR-501 as a novel muscle-specific miRNA.
BC8_BioRED_Task1_Doc128	527	534	miR-501	Gene	751560	miR-501 is an intronic miRNA and its expression levels in MPs correlated with its host gene, chloride channel, voltage-sensitive 5 (Clcn5).
BC8_BioRED_Task1_Doc128	620	657	chloride channel, voltage-sensitive 5	Gene	12728	miR-501 is an intronic miRNA and its expression levels in MPs correlated with its host gene, chloride channel, voltage-sensitive 5 (Clcn5).
BC8_BioRED_Task1_Doc128	659	664	Clcn5	Gene	12728	miR-501 is an intronic miRNA and its expression levels in MPs correlated with its host gene, chloride channel, voltage-sensitive 5 (Clcn5).
BC8_BioRED_Task1_Doc128	697	704	miR-501	Gene	751560	Pharmacological inhibition of miR-501 dramatically blunted the induction of embryonic myosin heavy chain (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.
BC8_BioRED_Task1_Doc128	753	771	myosin heavy chain	Gene	17883	Pharmacological inhibition of miR-501 dramatically blunted the induction of embryonic myosin heavy chain (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.
BC8_BioRED_Task1_Doc128	773	777	MYH3	Gene	17883	Pharmacological inhibition of miR-501 dramatically blunted the induction of embryonic myosin heavy chain (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.
BC8_BioRED_Task1_Doc128	804	825	adult myosin isoforms	Gene	17879	Pharmacological inhibition of miR-501 dramatically blunted the induction of embryonic myosin heavy chain (MYH3) and, to a lesser extent, adult myosin isoforms during muscle regeneration, and promoted small-diameter neofibers.
BC8_BioRED_Task1_Doc128	967	976	gigaxonin	Gene	209239	An unbiased target identification approach in primary myoblasts validated gigaxonin as a target of miR-501 that mimicked the effect of miR-501 inhibition on MYH3 expression.
BC8_BioRED_Task1_Doc128	992	999	miR-501	Gene	751560	An unbiased target identification approach in primary myoblasts validated gigaxonin as a target of miR-501 that mimicked the effect of miR-501 inhibition on MYH3 expression.
BC8_BioRED_Task1_Doc128	1028	1035	miR-501	Gene	751560	An unbiased target identification approach in primary myoblasts validated gigaxonin as a target of miR-501 that mimicked the effect of miR-501 inhibition on MYH3 expression.
BC8_BioRED_Task1_Doc128	1050	1054	MYH3	Gene	17883	An unbiased target identification approach in primary myoblasts validated gigaxonin as a target of miR-501 that mimicked the effect of miR-501 inhibition on MYH3 expression.
BC8_BioRED_Task1_Doc128	1078	1083	mouse	OrganismTaxon	10090	In the mdx mouse model, which models a pathological disease state, not only was miR-501 induced in regenerating skeletal muscle, but also its serum levels were increased, which correlated with the disease state of the animals.
BC8_BioRED_Task1_Doc128	1147	1154	miR-501	Gene	751560	In the mdx mouse model, which models a pathological disease state, not only was miR-501 induced in regenerating skeletal muscle, but also its serum levels were increased, which correlated with the disease state of the animals.
BC8_BioRED_Task1_Doc128	1319	1326	miR-501	Gene	751560	Our results suggest that miR-501 plays a key role in adult muscle regeneration and might serve as a novel serum biomarker for the activation of adult muscle stem cells.
BC8_BioRED_Task1_Doc129	59	64	human	OrganismTaxon	9606	A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression.
BC8_BioRED_Task1_Doc129	65	88	glucocorticoid receptor	Gene	2908	A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression.
BC8_BioRED_Task1_Doc129	90	93	hGR	Gene	2908	A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression.
BC8_BioRED_Task1_Doc129	110	113	hGR	Gene	2908	A novel point mutation in the amino terminal domain of the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression.
BC8_BioRED_Task1_Doc129	179	193	glucocorticoid	Chemical	D005938	CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the human glucocorticoid receptor (hGR) gene.
BC8_BioRED_Task1_Doc129	250	258	cortisol	Chemical	D006854	CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the human glucocorticoid receptor (hGR) gene.
BC8_BioRED_Task1_Doc129	332	337	human	OrganismTaxon	9606	CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the human glucocorticoid receptor (hGR) gene.
BC8_BioRED_Task1_Doc129	338	361	glucocorticoid receptor	Gene	2908	CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the human glucocorticoid receptor (hGR) gene.
BC8_BioRED_Task1_Doc129	363	366	hGR	Gene	2908	CONTEXT: Interindividual variations in glucocorticoid sensitivity have been associated with manifestations of cortisol excess or deficiency and may be partly explained by polymorphisms in the human glucocorticoid receptor (hGR) gene.
BC8_BioRED_Task1_Doc129	472	486	glucocorticoid	Chemical	D005938	We studied a 43-yr-old female, who presented with manifestations consistent with tissue-selective glucocorticoid hypersensitivity.
BC8_BioRED_Task1_Doc129	487	503	hypersensitivity	Disease	D004342	We studied a 43-yr-old female, who presented with manifestations consistent with tissue-selective glucocorticoid hypersensitivity.
BC8_BioRED_Task1_Doc129	558	597	(G --> C) substitution at position 1201	SequenceVariant	c|SUB|G|1201|C	We detected a novel, single, heterozygous nucleotide (G --> C) substitution at position 1201 (exon 2) of the hGR gene, which resulted in aspartic acid to histidine substitution at amino acid position 401 in the amino-terminal domain of the hGRalpha.
BC8_BioRED_Task1_Doc129	614	617	hGR	Gene	2908	We detected a novel, single, heterozygous nucleotide (G --> C) substitution at position 1201 (exon 2) of the hGR gene, which resulted in aspartic acid to histidine substitution at amino acid position 401 in the amino-terminal domain of the hGRalpha.
BC8_BioRED_Task1_Doc129	642	708	aspartic acid to histidine substitution at amino acid position 401	SequenceVariant	p|SUB|D|401|H	We detected a novel, single, heterozygous nucleotide (G --> C) substitution at position 1201 (exon 2) of the hGR gene, which resulted in aspartic acid to histidine substitution at amino acid position 401 in the amino-terminal domain of the hGRalpha.
BC8_BioRED_Task1_Doc129	745	753	hGRalpha	Gene	2908	We detected a novel, single, heterozygous nucleotide (G --> C) substitution at position 1201 (exon 2) of the hGR gene, which resulted in aspartic acid to histidine substitution at amino acid position 401 in the amino-terminal domain of the hGRalpha.
BC8_BioRED_Task1_Doc129	837	845	hGRalpha	Gene	2908	We investigated the molecular mechanisms of action of the natural mutant receptor hGRalphaD401H.
BC8_BioRED_Task1_Doc129	845	850	D401H	SequenceVariant	p|SUB|D|401|H	We investigated the molecular mechanisms of action of the natural mutant receptor hGRalphaD401H.
BC8_BioRED_Task1_Doc129	897	905	hGRalpha	Gene	2908	METHODS-RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min).
BC8_BioRED_Task1_Doc129	927	935	hGRalpha	Gene	2908	METHODS-RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min).
BC8_BioRED_Task1_Doc129	935	940	D401H	SequenceVariant	p|SUB|D|401|H	METHODS-RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min).
BC8_BioRED_Task1_Doc129	1010	1024	glucocorticoid	Chemical	D005938	METHODS-RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min).
BC8_BioRED_Task1_Doc129	1035	1060	mouse mammary tumor virus	OrganismTaxon	11757	METHODS-RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min).
BC8_BioRED_Task1_Doc129	1085	1098	dexamethasone	Chemical	D003907	METHODS-RESULTS: Compared with the wild-type hGRalpha, the mutant receptor hGRalphaD401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-inducible mouse mammary tumor virus promoter in response to dexamethasone but had similar affinity for the ligand (dissociation constant = 6.2 +/- 0.6 vs. 6.1 +/- 0.6 nm) and time to nuclear translocation (14.75 +/- 0.25 vs. 14.25 +/- 1.13 min).
BC8_BioRED_Task1_Doc129	1291	1299	hGRalpha	Gene	2908	The mutant receptor hGRalphaD401H did not exert a dominant positive or negative effect upon the wild-type receptor, it preserved its ability to bind to glucocorticoid response elements, and displayed a normal interaction with the glucocorticoid receptor-interacting protein 1 coactivator.
BC8_BioRED_Task1_Doc129	1299	1304	D401H	SequenceVariant	p|SUB|D|401|H	The mutant receptor hGRalphaD401H did not exert a dominant positive or negative effect upon the wild-type receptor, it preserved its ability to bind to glucocorticoid response elements, and displayed a normal interaction with the glucocorticoid receptor-interacting protein 1 coactivator.
BC8_BioRED_Task1_Doc129	1423	1437	glucocorticoid	Chemical	D005938	The mutant receptor hGRalphaD401H did not exert a dominant positive or negative effect upon the wild-type receptor, it preserved its ability to bind to glucocorticoid response elements, and displayed a normal interaction with the glucocorticoid receptor-interacting protein 1 coactivator.
BC8_BioRED_Task1_Doc129	1501	1546	glucocorticoid receptor-interacting protein 1	Gene	23426	The mutant receptor hGRalphaD401H did not exert a dominant positive or negative effect upon the wild-type receptor, it preserved its ability to bind to glucocorticoid response elements, and displayed a normal interaction with the glucocorticoid receptor-interacting protein 1 coactivator.
BC8_BioRED_Task1_Doc129	1593	1601	hGRalpha	Gene	2908	CONCLUSIONS: The mutant receptor hGRalphaD401H enhances the transcriptional activity of glucocorticoid-responsive genes.
BC8_BioRED_Task1_Doc129	1601	1606	D401H	SequenceVariant	p|SUB|D|401|H	CONCLUSIONS: The mutant receptor hGRalphaD401H enhances the transcriptional activity of glucocorticoid-responsive genes.
BC8_BioRED_Task1_Doc129	1648	1679	glucocorticoid-responsive genes	Gene	2908	CONCLUSIONS: The mutant receptor hGRalphaD401H enhances the transcriptional activity of glucocorticoid-responsive genes.
BC8_BioRED_Task1_Doc129	1701	1706	D401H	SequenceVariant	p|SUB|D|401|H	The presence of the D401H mutation may predispose subjects to obesity, hypertension, and other manifestations of the metabolic syndrome.
BC8_BioRED_Task1_Doc129	1743	1750	obesity	Disease	D009765	The presence of the D401H mutation may predispose subjects to obesity, hypertension, and other manifestations of the metabolic syndrome.
BC8_BioRED_Task1_Doc129	1752	1764	hypertension	Disease	D006973	The presence of the D401H mutation may predispose subjects to obesity, hypertension, and other manifestations of the metabolic syndrome.
BC8_BioRED_Task1_Doc129	1798	1816	metabolic syndrome	Disease	D008659	The presence of the D401H mutation may predispose subjects to obesity, hypertension, and other manifestations of the metabolic syndrome.
BC8_BioRED_Task1_Doc130	0	10	Arginase 1	Gene	11846	Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice.
BC8_BioRED_Task1_Doc130	49	61	inflammatory	Disease	D007249	Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice.
BC8_BioRED_Task1_Doc130	83	89	asthma	Disease	D001249	Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice.
BC8_BioRED_Task1_Doc130	125	129	mice	OrganismTaxon	10090	Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice.
BC8_BioRED_Task1_Doc130	164	172	arginase	Gene	11846	BACKGROUND: (Over-)expression of arginase may limit local availability of arginine for nitric oxide synthesis.
BC8_BioRED_Task1_Doc130	218	230	nitric oxide	Chemical	D009569	BACKGROUND: (Over-)expression of arginase may limit local availability of arginine for nitric oxide synthesis.
BC8_BioRED_Task1_Doc130	278	287	arginase1	Gene	11846	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	289	293	ARG1	Gene	11846	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	355	372	lung inflammation	Disease	D011014	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	383	387	mice	OrganismTaxon	10090	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	393	402	ovalbumin	Gene	66222	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	404	407	OVA	Gene	66222	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	426	432	asthma	Disease	D001249	We investigated the significance of arginase1 (ARG1) for the development of airway hyperresponsiveness (AHR) and lung inflammation in female mice with ovalbumin (OVA)-induced allergic asthma.
BC8_BioRED_Task1_Doc130	443	447	Arg1	Gene	11846	METHODS: Arg1 was ablated in the lung by crossing Arg1 fl/fl and Tie2Cre tg/- mice.
BC8_BioRED_Task1_Doc130	484	488	Arg1	Gene	11846	METHODS: Arg1 was ablated in the lung by crossing Arg1 fl/fl and Tie2Cre tg/- mice.
BC8_BioRED_Task1_Doc130	512	516	mice	OrganismTaxon	10090	METHODS: Arg1 was ablated in the lung by crossing Arg1 fl/fl and Tie2Cre tg/- mice.
BC8_BioRED_Task1_Doc130	518	521	OVA	Gene	66222	OVA sensitization and challenge were conducted, and AHR to methacholine was determined using the Flexivent system.
BC8_BioRED_Task1_Doc130	577	589	methacholine	Chemical	D016210	OVA sensitization and challenge were conducted, and AHR to methacholine was determined using the Flexivent system.
BC8_BioRED_Task1_Doc130	702	705	IgE	Gene	629822	Changes in gene expression, chemokine and cytokine secretion, plasma IgE, and lung histology were quantified using RT-qPCR, ELISA, and immunohistochemistry, respectively.
BC8_BioRED_Task1_Doc130	813	817	Arg1	Gene	11846	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	866	869	OVA	Gene	66222	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	898	901	OVA	Gene	66222	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	937	941	Arg2	Gene	11847	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	946	950	Nos2	Gene	18126	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	952	958	Slc7a1	Gene	11987	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	960	966	Slc7a2	Gene	11988	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	972	978	Slc7a7	Gene	20540	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	980	1001	arginine transporters	Gene	11987,11988,20540	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1004	1007	Il4	Gene	16189	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1009	1012	Il5	Gene	16191	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1017	1021	Il13	Gene	16163	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1023	1041	TH2-type cytokines	Gene	16163,16189,16191	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1044	1048	Ccl2	Gene	20296	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1053	1058	Ccl11	Gene	20292	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1060	1070	chemokines	Gene	20292,20296	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1073	1077	Ifng	Gene	15978	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1079	1096	TH1-type cytokine	Gene	15978	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1099	1104	Clca3	Gene	23844	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1109	1115	Muc5ac	Gene	17833	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1143	1146	OVA	Gene	66222	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1156	1159	IgE	Gene	629822	RESULTS: Arg1 ablation had no influence on the development of OVA-induced AHR, but attenuated OVA-induced increases in expression of Arg2 and Nos2, Slc7a1, Slc7a2, and Slc7a7 (arginine transporters), Il4, Il5 and Il13 (TH2-type cytokines), Ccl2 and Ccl11 (chemokines), Ifng (TH1-type cytokine), Clca3 and Muc5ac (goblet cell markers), and OVA-specific IgE.
BC8_BioRED_Task1_Doc130	1171	1176	IL-10	Gene	16153	Pulmonary IL-10 protein content increased, but IL-4, IL-5, IL-13, TNFalpha and IFNgamma content, and lung histopathology, were not affected.
BC8_BioRED_Task1_Doc130	1208	1212	IL-4	Gene	16189	Pulmonary IL-10 protein content increased, but IL-4, IL-5, IL-13, TNFalpha and IFNgamma content, and lung histopathology, were not affected.
BC8_BioRED_Task1_Doc130	1214	1218	IL-5	Gene	16191	Pulmonary IL-10 protein content increased, but IL-4, IL-5, IL-13, TNFalpha and IFNgamma content, and lung histopathology, were not affected.
BC8_BioRED_Task1_Doc130	1220	1225	IL-13	Gene	16163	Pulmonary IL-10 protein content increased, but IL-4, IL-5, IL-13, TNFalpha and IFNgamma content, and lung histopathology, were not affected.
BC8_BioRED_Task1_Doc130	1227	1235	TNFalpha	Gene	21926	Pulmonary IL-10 protein content increased, but IL-4, IL-5, IL-13, TNFalpha and IFNgamma content, and lung histopathology, were not affected.
BC8_BioRED_Task1_Doc130	1240	1248	IFNgamma	Gene	15978	Pulmonary IL-10 protein content increased, but IL-4, IL-5, IL-13, TNFalpha and IFNgamma content, and lung histopathology, were not affected.
BC8_BioRED_Task1_Doc130	1302	1306	Arg1	Gene	11846	Arg1 elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in OVA/OVA-treated female mice.
BC8_BioRED_Task1_Doc130	1417	1429	inflammatory	Disease	D007249	Arg1 elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in OVA/OVA-treated female mice.
BC8_BioRED_Task1_Doc130	1444	1447	OVA	Gene	66222	Arg1 elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in OVA/OVA-treated female mice.
BC8_BioRED_Task1_Doc130	1448	1451	OVA	Gene	66222	Arg1 elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in OVA/OVA-treated female mice.
BC8_BioRED_Task1_Doc130	1467	1471	mice	OrganismTaxon	10090	Arg1 elimination also decreased number and tightness of correlations between adaptive changes in lung function and inflammatory parameters in OVA/OVA-treated female mice.
BC8_BioRED_Task1_Doc130	1473	1476	OVA	Gene	66222	OVA/OVA-treated female mice mounted a higher OVA-IgE response than males, but the correlation between lung function and inflammation was lower.
BC8_BioRED_Task1_Doc130	1477	1480	OVA	Gene	66222	OVA/OVA-treated female mice mounted a higher OVA-IgE response than males, but the correlation between lung function and inflammation was lower.
BC8_BioRED_Task1_Doc130	1496	1500	mice	OrganismTaxon	10090	OVA/OVA-treated female mice mounted a higher OVA-IgE response than males, but the correlation between lung function and inflammation was lower.
BC8_BioRED_Task1_Doc130	1518	1521	OVA	Gene	66222	OVA/OVA-treated female mice mounted a higher OVA-IgE response than males, but the correlation between lung function and inflammation was lower.
BC8_BioRED_Task1_Doc130	1522	1525	IgE	Gene	629822	OVA/OVA-treated female mice mounted a higher OVA-IgE response than males, but the correlation between lung function and inflammation was lower.
BC8_BioRED_Task1_Doc130	1593	1605	inflammation	Disease	D007249	OVA/OVA-treated female mice mounted a higher OVA-IgE response than males, but the correlation between lung function and inflammation was lower.
BC8_BioRED_Task1_Doc130	1617	1621	Arg1	Gene	11846	Arg1-deficient OVA/OVA-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller OVA-specific IgE response, and no improvement of peripheral lung function.
BC8_BioRED_Task1_Doc130	1632	1635	OVA	Gene	66222	Arg1-deficient OVA/OVA-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller OVA-specific IgE response, and no improvement of peripheral lung function.
BC8_BioRED_Task1_Doc130	1636	1639	OVA	Gene	66222	Arg1-deficient OVA/OVA-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller OVA-specific IgE response, and no improvement of peripheral lung function.
BC8_BioRED_Task1_Doc130	1796	1799	OVA	Gene	66222	Arg1-deficient OVA/OVA-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller OVA-specific IgE response, and no improvement of peripheral lung function.
BC8_BioRED_Task1_Doc130	1809	1812	IgE	Gene	629822	Arg1-deficient OVA/OVA-treated females differed from males in a more pronounced decline of arginine-metabolizing and -transporting genes, higher plasma arginine levels, a smaller OVA-specific IgE response, and no improvement of peripheral lung function.
BC8_BioRED_Task1_Doc130	1904	1908	Arg1	Gene	11846	CONCLUSION: Complete ablation of Arg1 in the lung affects mRNA abundance of arginine-transporting and -metabolizing genes, and pro-inflammatory genes, but not methacholine responsiveness or accumulation of inflammatory cells.
BC8_BioRED_Task1_Doc130	2002	2014	inflammatory	Disease	D007249	CONCLUSION: Complete ablation of Arg1 in the lung affects mRNA abundance of arginine-transporting and -metabolizing genes, and pro-inflammatory genes, but not methacholine responsiveness or accumulation of inflammatory cells.
BC8_BioRED_Task1_Doc130	2030	2042	methacholine	Chemical	D016210	CONCLUSION: Complete ablation of Arg1 in the lung affects mRNA abundance of arginine-transporting and -metabolizing genes, and pro-inflammatory genes, but not methacholine responsiveness or accumulation of inflammatory cells.
BC8_BioRED_Task1_Doc130	2077	2089	inflammatory	Disease	D007249	CONCLUSION: Complete ablation of Arg1 in the lung affects mRNA abundance of arginine-transporting and -metabolizing genes, and pro-inflammatory genes, but not methacholine responsiveness or accumulation of inflammatory cells.
BC8_BioRED_Task1_Doc131	14	18	LDHA	Gene	3939	Inhibition of LDHA suppresses tumor progression in prostate cancer.
BC8_BioRED_Task1_Doc131	30	35	tumor	Disease	D009369	Inhibition of LDHA suppresses tumor progression in prostate cancer.
BC8_BioRED_Task1_Doc131	51	66	prostate cancer	Disease	D011471	Inhibition of LDHA suppresses tumor progression in prostate cancer.
BC8_BioRED_Task1_Doc131	86	92	cancer	Disease	D009369	A key hallmark of cancer cells is their altered metabolism, known as Warburg effect.
BC8_BioRED_Task1_Doc131	153	176	Lactate dehydrogenase A	Gene	3939	Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression.
BC8_BioRED_Task1_Doc131	178	182	LDHA	Gene	3939	Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression.
BC8_BioRED_Task1_Doc131	274	279	tumor	Disease	D009369	Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression.
BC8_BioRED_Task1_Doc131	318	322	LDHA	Gene	3939	However, the function of LDHA in prostate cancer has not been studied.
BC8_BioRED_Task1_Doc131	326	341	prostate cancer	Disease	D011471	However, the function of LDHA in prostate cancer has not been studied.
BC8_BioRED_Task1_Doc131	412	416	LDHA	Gene	3939	In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR.
BC8_BioRED_Task1_Doc131	433	448	prostate cancer	Disease	D011471	In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR.
BC8_BioRED_Task1_Doc131	471	498	benign prostate hyperplasia	Disease	D011470	In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR.
BC8_BioRED_Task1_Doc131	592	596	LDHA	Gene	3939	Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	623	627	LDHA	Gene	3939	Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	642	646	FX11	Chemical	C547455	Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	729	733	PC-3	CellLine	CVCL_0035	Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	738	743	DU145	CellLine	CVCL_0105	Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	820	827	glucose	Chemical	D005947	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	844	851	lactate	Chemical	D019344	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	888	893	MMP-9	Gene	4318	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	895	899	PLAU	Gene	5328	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	905	916	cathepsin B	Gene	1508	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	934	938	LDHA	Gene	3939	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	952	956	FX11	Chemical	C547455	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	970	974	PC-3	CellLine	CVCL_0035	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	979	984	DU145	CellLine	CVCL_0105	Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells.
BC8_BioRED_Task1_Doc131	1049	1053	LDHA	Gene	3939	Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.
BC8_BioRED_Task1_Doc131	1057	1072	prostate cancer	Disease	D011471	Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.
BC8_BioRED_Task1_Doc131	1092	1096	LDHA	Gene	3939	Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.
BC8_BioRED_Task1_Doc132	36	40	AT2R	Gene	24182	Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.
BC8_BioRED_Task1_Doc132	78	96	glomerulosclerosis	Disease	D005921	Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.
BC8_BioRED_Task1_Doc132	136	144	caffeine	Chemical	D002110	Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.
BC8_BioRED_Task1_Doc132	214	222	caffeine	Chemical	D002110	UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.
BC8_BioRED_Task1_Doc132	251	282	intrauterine growth retardation	Disease	D005317	UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.
BC8_BioRED_Task1_Doc132	284	288	IUGR	Disease	D005317	UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.
BC8_BioRED_Task1_Doc132	335	339	IUGR	Disease	D005317	Recent research suggested that IUGR is a risk factor for glomerulosclerosis.
BC8_BioRED_Task1_Doc132	361	379	glomerulosclerosis	Disease	D005921	Recent research suggested that IUGR is a risk factor for glomerulosclerosis.
BC8_BioRED_Task1_Doc132	415	433	glomerulosclerosis	Disease	D005921	However, whether PCE could induce glomerulosclerosis and its underlying mechanisms remain unknown.
BC8_BioRED_Task1_Doc132	529	547	glomerulosclerosis	Disease	D005921	This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by PCE and its intrauterine programming mechanisms.
BC8_BioRED_Task1_Doc132	621	624	rat	OrganismTaxon	10116	A rat model of IUGR was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized.
BC8_BioRED_Task1_Doc132	634	638	IUGR	Disease	D005317	A rat model of IUGR was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized.
BC8_BioRED_Task1_Doc132	826	844	glomerulosclerosis	Disease	D005921	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
BC8_BioRED_Task1_Doc132	856	877	interstitial fibrosis	Disease	D005355	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
BC8_BioRED_Task1_Doc132	919	929	creatinine	Chemical	D003404	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
BC8_BioRED_Task1_Doc132	955	985	angiotensin II receptor type 2	Gene	24182	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased.
BC8_BioRED_Task1_Doc132	987	991	AT2R	Gene	24182	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased.
BC8_BioRED_Task1_Doc132	1066	1097	angiotensin II receptor type 1a	Gene	24180	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased.
BC8_BioRED_Task1_Doc132	1099	1104	AT1aR	Gene	24180	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased.
BC8_BioRED_Task1_Doc132	1106	1110	AT2R	Gene	24182	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased.
BC8_BioRED_Task1_Doc132	1479	1486	nephrin	Gene	64563	Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR.
BC8_BioRED_Task1_Doc132	1491	1498	podocin	Gene	170672	Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR.
BC8_BioRED_Task1_Doc132	1538	1542	AT2R	Gene	24182	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway.
BC8_BioRED_Task1_Doc132	1669	1712	glial-cell-line-derived neurotrophic factor	Gene	25453	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway.
BC8_BioRED_Task1_Doc132	1714	1718	GDNF	Gene	25453	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway.
BC8_BioRED_Task1_Doc132	1720	1744	tyrosine kinase receptor	Gene	24716	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway.
BC8_BioRED_Task1_Doc132	1746	1751	c-Ret	Gene	24716	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway.
BC8_BioRED_Task1_Doc132	1821	1847	dysplasia of fetal kidneys	Disease	D007674	These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.
BC8_BioRED_Task1_Doc132	1859	1877	glomerulosclerosis	Disease	D005921	These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.
BC8_BioRED_Task1_Doc132	1942	1946	AT2R	Gene	24182	These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.
BC8_BioRED_Task1_Doc132	1995	2013	glomerulosclerosis	Disease	D005921	These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.
BC8_BioRED_Task1_Doc133	26	32	CYP2F1	Gene	1572	Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant.
BC8_BioRED_Task1_Doc133	104	110	CYP2F1	Gene	1572	The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects.
BC8_BioRED_Task1_Doc133	116	121	human	OrganismTaxon	9606	The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects.
BC8_BioRED_Task1_Doc133	122	137	cytochrome P450	Gene	1572	The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects.
BC8_BioRED_Task1_Doc133	256	268	carcinogenic	Disease	D009369	The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects.
BC8_BioRED_Task1_Doc133	433	439	CYP2F1	Gene	1572	We analyzed the nucleotidic sequence of the CYP2F1 gene in DNA samples from 90 French Caucasians consisting in 44 patients with lung cancer and 46 control individuals, using single-strand conformation polymorphism analysis of PCR products (PCR-SSCP).
BC8_BioRED_Task1_Doc133	503	511	patients	OrganismTaxon	9606	We analyzed the nucleotidic sequence of the CYP2F1 gene in DNA samples from 90 French Caucasians consisting in 44 patients with lung cancer and 46 control individuals, using single-strand conformation polymorphism analysis of PCR products (PCR-SSCP).
BC8_BioRED_Task1_Doc133	517	528	lung cancer	Disease	D008175	We analyzed the nucleotidic sequence of the CYP2F1 gene in DNA samples from 90 French Caucasians consisting in 44 patients with lung cancer and 46 control individuals, using single-strand conformation polymorphism analysis of PCR products (PCR-SSCP).
BC8_BioRED_Task1_Doc133	822	828	CYP2F1	Gene	1572	In addition to the wild-type CYP2F1*1 allele, seven allelic variant, CYP2F1*2A, *2B, *3, *4, *5A, *5B and *6, were characterized.
BC8_BioRED_Task1_Doc133	862	868	CYP2F1	Gene	1572	In addition to the wild-type CYP2F1*1 allele, seven allelic variant, CYP2F1*2A, *2B, *3, *4, *5A, *5B and *6, were characterized.
BC8_BioRED_Task1_Doc133	958	964	CYP2F1	Gene	1572	The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity.
BC8_BioRED_Task1_Doc133	1047	1056	Asp218Asn	SequenceVariant	rs305974	The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity.
BC8_BioRED_Task1_Doc133	1061	1070	Gln266His	SequenceVariant	rs75405062	The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity.
BC8_BioRED_Task1_Doc133	1078	1092	1-bp insertion	SequenceVariant	rs11399890	The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity.
BC8_BioRED_Task1_Doc133	1094	1105	c.14_15insC	SequenceVariant	rs11399890	The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity.
BC8_BioRED_Task1_Doc133	1413	1419	CYP2F1	Gene	1572	The identification of around 7% of homozygotes for the frameshift mutation in our Caucasian population suggests the existence of an interindividual variation of the CYP2F1 activity and, consequently, the possibility of interindividual differences in the toxic response to some pneumotoxicants and in the susceptibility to certain chemically induced diseases.
BC8_BioRED_Task1_Doc133	1675	1681	CYP2F1	Gene	1572	However, our preliminary results did not show any evidence that the CYP2F1 genetic polymorphism has implications in the pathogenesis of lung cancer.
BC8_BioRED_Task1_Doc133	1743	1754	lung cancer	Disease	D008175	However, our preliminary results did not show any evidence that the CYP2F1 genetic polymorphism has implications in the pathogenesis of lung cancer.
BC8_BioRED_Task1_Doc134	0	24	TNFR-associated factor 2	Gene	22030	TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.
BC8_BioRED_Task1_Doc134	68	96	chronic lymphocytic leukemia	Disease	D015451	TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.
BC8_BioRED_Task1_Doc134	97	123	small lymphocytic lymphoma	Disease	D015451	TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.
BC8_BioRED_Task1_Doc134	127	131	mice	OrganismTaxon	10090	TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.
BC8_BioRED_Task1_Doc134	179	183	mice	OrganismTaxon	10090	We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.
BC8_BioRED_Task1_Doc134	217	222	BCL-2	Gene	596	We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.
BC8_BioRED_Task1_Doc134	229	253	TNFR-associated factor 2	Gene	22030	We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.
BC8_BioRED_Task1_Doc134	255	260	TRAF2	Gene	22030	We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.
BC8_BioRED_Task1_Doc134	351	377	small lymphocytic lymphoma	Disease	D015451	We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.
BC8_BioRED_Task1_Doc134	382	410	chronic lymphocytic leukemia	Disease	D015451	We have previously shown that transgenic (tg) mice expressing in B lymphocytes both BCL-2 and a TNFR-associated factor 2 (TRAF2) mutant lacking the really interesting new gene and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leukemia with high incidence (Zapata et al.
BC8_BioRED_Task1_Doc134	535	540	TRAF2	Gene	22030	Further analysis of the expression of TRAF2 and TRAF2DN in purified B cells demonstrated that expression of both endogenous TRAF2 and tg TRAF2DN was negligible in Traf2DN-tg B cells compared with wild-type mice.
BC8_BioRED_Task1_Doc134	621	626	TRAF2	Gene	22030	Further analysis of the expression of TRAF2 and TRAF2DN in purified B cells demonstrated that expression of both endogenous TRAF2 and tg TRAF2DN was negligible in Traf2DN-tg B cells compared with wild-type mice.
BC8_BioRED_Task1_Doc134	660	672	Traf2DN-tg B	CellLine	CVCL_TT54	Further analysis of the expression of TRAF2 and TRAF2DN in purified B cells demonstrated that expression of both endogenous TRAF2 and tg TRAF2DN was negligible in Traf2DN-tg B cells compared with wild-type mice.
BC8_BioRED_Task1_Doc134	703	707	mice	OrganismTaxon	10090	Further analysis of the expression of TRAF2 and TRAF2DN in purified B cells demonstrated that expression of both endogenous TRAF2 and tg TRAF2DN was negligible in Traf2DN-tg B cells compared with wild-type mice.
BC8_BioRED_Task1_Doc134	732	742	proteasome	Gene	16912	This was the result of proteasome-dependent degradation, and rendered TRAF2DN B cells as bona fide TRAF2-deficient B cells.
BC8_BioRED_Task1_Doc134	808	813	TRAF2	Gene	22030	This was the result of proteasome-dependent degradation, and rendered TRAF2DN B cells as bona fide TRAF2-deficient B cells.
BC8_BioRED_Task1_Doc134	866	871	Traf2	Gene	22030	Similar to B cells with targeted Traf2 deletion, Traf2DN-tg mice show expanded marginal zone B cell population and have constitutive p100 NF-kappaB2 processing.
BC8_BioRED_Task1_Doc134	882	892	Traf2DN-tg	CellLine	CVCL_TT54	Similar to B cells with targeted Traf2 deletion, Traf2DN-tg mice show expanded marginal zone B cell population and have constitutive p100 NF-kappaB2 processing.
BC8_BioRED_Task1_Doc134	893	897	mice	OrganismTaxon	10090	Similar to B cells with targeted Traf2 deletion, Traf2DN-tg mice show expanded marginal zone B cell population and have constitutive p100 NF-kappaB2 processing.
BC8_BioRED_Task1_Doc134	966	981	p100 NF-kappaB2	Gene	18034	Similar to B cells with targeted Traf2 deletion, Traf2DN-tg mice show expanded marginal zone B cell population and have constitutive p100 NF-kappaB2 processing.
BC8_BioRED_Task1_Doc134	1000	1005	TRAF3	Gene	22031	Also, TRAF3, X-linked inhibitor of apoptosis, and Bcl-X(L) expression levels were increased, whereas cellular inhibitors of apoptosis 1 and 2 levels were drastically reduced compared with those found in wild-type B cells.
BC8_BioRED_Task1_Doc134	1007	1038	X-linked inhibitor of apoptosis	Gene	11798	Also, TRAF3, X-linked inhibitor of apoptosis, and Bcl-X(L) expression levels were increased, whereas cellular inhibitors of apoptosis 1 and 2 levels were drastically reduced compared with those found in wild-type B cells.
BC8_BioRED_Task1_Doc134	1044	1052	Bcl-X(L)	Gene	12048	Also, TRAF3, X-linked inhibitor of apoptosis, and Bcl-X(L) expression levels were increased, whereas cellular inhibitors of apoptosis 1 and 2 levels were drastically reduced compared with those found in wild-type B cells.
BC8_BioRED_Task1_Doc134	1095	1135	cellular inhibitors of apoptosis 1 and 2	Gene	11796,11797	Also, TRAF3, X-linked inhibitor of apoptosis, and Bcl-X(L) expression levels were increased, whereas cellular inhibitors of apoptosis 1 and 2 levels were drastically reduced compared with those found in wild-type B cells.
BC8_BioRED_Task1_Doc134	1278	1283	TRAF2	Gene	22030	Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and ERK activation in response to CD40 engagement.
BC8_BioRED_Task1_Doc134	1311	1314	JNK	Gene	26419	Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and ERK activation in response to CD40 engagement.
BC8_BioRED_Task1_Doc134	1319	1322	ERK	Gene	26413	Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and ERK activation in response to CD40 engagement.
BC8_BioRED_Task1_Doc134	1349	1353	CD40	Gene	21939	Moreover, consistent with previous results, we also show that TRAF2 was required for efficient JNK and ERK activation in response to CD40 engagement.
BC8_BioRED_Task1_Doc134	1375	1380	TRAF2	Gene	22030	However, TRAF2 was deleterious for BCR-mediated activation of these kinases.
BC8_BioRED_Task1_Doc134	1401	1404	BCR	Gene	12518	However, TRAF2 was deleterious for BCR-mediated activation of these kinases.
BC8_BioRED_Task1_Doc134	1456	1461	TRAF2	Gene	22030	In contrast, TRAF2 deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation.
BC8_BioRED_Task1_Doc134	1490	1494	CD40	Gene	21939	In contrast, TRAF2 deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation.
BC8_BioRED_Task1_Doc134	1504	1512	p38 MAPK	Gene	26416	In contrast, TRAF2 deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation.
BC8_BioRED_Task1_Doc134	1550	1553	BCR	Gene	12518	In contrast, TRAF2 deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation.
BC8_BioRED_Task1_Doc134	1563	1566	p38	Gene	26416	In contrast, TRAF2 deficiency had no effect on CD40-mediated p38 MAPK activation but significantly reduced BCR-mediated p38 activation.
BC8_BioRED_Task1_Doc134	1612	1617	TRAF2	Gene	22030	Finally, we further confirm that TRAF2 was required for CD40-mediated proliferation, but its absence relieved B cells of the need for B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1635	1639	CD40	Gene	21939	Finally, we further confirm that TRAF2 was required for CD40-mediated proliferation, but its absence relieved B cells of the need for B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1713	1737	B cell activating factor	Gene	24099	Finally, we further confirm that TRAF2 was required for CD40-mediated proliferation, but its absence relieved B cells of the need for B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1789	1794	TRAF2	Gene	22030	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1822	1827	BCL-2	Gene	596	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1841	1869	chronic lymphocytic leukemia	Disease	D015451	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1870	1896	small lymphocytic lymphoma	Disease	D015451	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1900	1904	mice	OrganismTaxon	10090	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	1987	2018	X-linked inhibitor of apoptosis	Gene	11798	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc134	2068	2092	B cell activating factor	Gene	24099	Altogether, our results suggest that TRAF2 deficiency cooperates with BCL-2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specifically enforcing marginal zone B cell accumulation, increasing X-linked inhibitor of apoptosis expression, and rendering B cells independent of B cell activating factor for survival.
BC8_BioRED_Task1_Doc135	0	5	TIEG1	Gene	21847	TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway.
BC8_BioRED_Task1_Doc135	63	78	infarcted heart	Disease	D009203	TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway.
BC8_BioRED_Task1_Doc135	96	100	Pten	Gene	19211	TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway.
BC8_BioRED_Task1_Doc135	101	104	Akt	Gene	11651	TIEG1 deficiency confers enhanced myocardial protection in the infarcted heart by mediating the Pten/Akt signalling pathway.
BC8_BioRED_Task1_Doc135	129	186	transforming growth factor (TGF)-b-inducible early gene-1	Gene	21847	The transforming growth factor (TGF)-b-inducible early gene-1 (TIEG1) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, leukaemia and osteoporosis.
BC8_BioRED_Task1_Doc135	188	193	TIEG1	Gene	21847	The transforming growth factor (TGF)-b-inducible early gene-1 (TIEG1) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, leukaemia and osteoporosis.
BC8_BioRED_Task1_Doc135	298	315	pancreatic cancer	Disease	D010190	The transforming growth factor (TGF)-b-inducible early gene-1 (TIEG1) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, leukaemia and osteoporosis.
BC8_BioRED_Task1_Doc135	317	326	leukaemia	Disease	D007938	The transforming growth factor (TGF)-b-inducible early gene-1 (TIEG1) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, leukaemia and osteoporosis.
BC8_BioRED_Task1_Doc135	331	343	osteoporosis	Disease	D010024	The transforming growth factor (TGF)-b-inducible early gene-1 (TIEG1) plays a crucial role in modulating cell apoptosis and proliferation in a number of diseases, including pancreatic cancer, leukaemia and osteoporosis.
BC8_BioRED_Task1_Doc135	377	382	TIEG1	Gene	21847	However, the functional role of TIEG1 in the heart has not been fully defined.
BC8_BioRED_Task1_Doc135	473	478	TIEG1	Gene	21847	In this study, we first investigated the role of TIEG1 in ischaemic heart disease.
BC8_BioRED_Task1_Doc135	482	505	ischaemic heart disease	Disease	D017202	In this study, we first investigated the role of TIEG1 in ischaemic heart disease.
BC8_BioRED_Task1_Doc135	572	577	TIEG1	Gene	21847	For in vitro experiments, cardiomyocytes were isolated from both TIEG1 knockout (KO) and wile-type (WT) mice, and the apoptotic ratios were evaluated after a 48-h ischaemic insult.
BC8_BioRED_Task1_Doc135	611	615	mice	OrganismTaxon	10090	For in vitro experiments, cardiomyocytes were isolated from both TIEG1 knockout (KO) and wile-type (WT) mice, and the apoptotic ratios were evaluated after a 48-h ischaemic insult.
BC8_BioRED_Task1_Doc135	917	938	myocardial infarction	Disease	D009203	For in vivo experiments, a model of myocardial infarction (MI) was established using both TIEG1 KO and WT mice.
BC8_BioRED_Task1_Doc135	940	942	MI	Disease	D009203	For in vivo experiments, a model of myocardial infarction (MI) was established using both TIEG1 KO and WT mice.
BC8_BioRED_Task1_Doc135	971	976	TIEG1	Gene	21847	For in vivo experiments, a model of myocardial infarction (MI) was established using both TIEG1 KO and WT mice.
BC8_BioRED_Task1_Doc135	987	991	mice	OrganismTaxon	10090	For in vivo experiments, a model of myocardial infarction (MI) was established using both TIEG1 KO and WT mice.
BC8_BioRED_Task1_Doc135	1046	1048	MI	Disease	D009203	Echocardiography was performed at 3 and 28 days post-MI, whereas the haemodynamics test was performed 28 days post-MI.
BC8_BioRED_Task1_Doc135	1108	1110	MI	Disease	D009203	Echocardiography was performed at 3 and 28 days post-MI, whereas the haemodynamics test was performed 28 days post-MI.
BC8_BioRED_Task1_Doc135	1180	1187	infarct	Disease	D007238	Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.
BC8_BioRED_Task1_Doc135	1226	1262	terminal deoxynucleotidyltransferase	Gene	1791	Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.
BC8_BioRED_Task1_Doc135	1272	1276	dUTP	Chemical	C027078	Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.
BC8_BioRED_Task1_Doc135	1335	1356	a-smooth muscle actin	Gene	11475	Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.
BC8_BioRED_Task1_Doc135	1358	1363	a-SMA	Gene	11475	Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.
BC8_BioRED_Task1_Doc135	1365	1369	CD31	Gene	18613	Histological analyses of apoptosis, proliferation, angiogenesis and infarct zone assessments were performed using terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL) staining, BrdU immunostaining, a-smooth muscle actin (a-SMA)/CD31 immunostaining and Masson's trichrome staining, respectively.
BC8_BioRED_Task1_Doc135	1488	1493	TIEG1	Gene	21847	Changes in the expression of related proteins caused by TIEG1 deficiency were confirmed using both reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis.
BC8_BioRED_Task1_Doc135	1674	1679	TIEG1	Gene	21847	Our results demonstrated that the absence of TIEG1 prevented cardiomyocytes from undergoing apoptosis and promoted higher proliferation; it stimulated the proliferation of endothelial cells in vitro and in vivo.
BC8_BioRED_Task1_Doc135	1908	1913	TIEG1	Gene	21847	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	1917	1921	mice	OrganismTaxon	10090	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	1970	2000	phosphatase and tensin homolog	Gene	19211	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2002	2006	Pten	Gene	19211	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2009	2012	Akt	Gene	11651	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2017	2022	Bcl-2	Gene	12043	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2023	2026	Bax	Gene	12028	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2039	2073	vascular endothelial growth factor	Gene	22339	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2075	2079	VEGF	Gene	22339	Improved cardiac function and less scar formation were observed in TIEG1 KO mice, and we also observed the altered expression of phosphatase and tensin homolog (Pten), Akt and Bcl-2/Bax, as well as vascular endothelial growth factor (VEGF).
BC8_BioRED_Task1_Doc135	2138	2143	TIEG1	Gene	21847	On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in ischaemic heart disease by promoting changes in Pten/Akt signalling.
BC8_BioRED_Task1_Doc135	2177	2200	ischaemic heart disease	Disease	D017202	On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in ischaemic heart disease by promoting changes in Pten/Akt signalling.
BC8_BioRED_Task1_Doc135	2225	2229	Pten	Gene	19211	On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in ischaemic heart disease by promoting changes in Pten/Akt signalling.
BC8_BioRED_Task1_Doc135	2230	2233	Akt	Gene	11651	On the whole, our findings indicate that the absence of TIEG1 plays a cardioprotective role in ischaemic heart disease by promoting changes in Pten/Akt signalling.
BC8_BioRED_Task1_Doc136	43	50	monoHER	Chemical	C522803	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
BC8_BioRED_Task1_Doc136	55	66	doxorubicin	Chemical	D004317	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
BC8_BioRED_Task1_Doc136	108	119	doxorubicin	Chemical	D004317	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
BC8_BioRED_Task1_Doc136	128	142	cardiotoxicity	Disease	D066126	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
BC8_BioRED_Task1_Doc136	146	150	mice	OrganismTaxon	10090	The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
BC8_BioRED_Task1_Doc136	184	198	cardiotoxicity	Disease	D066126	PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.
BC8_BioRED_Task1_Doc136	204	216	anthracyclin	Chemical	D018943	PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.
BC8_BioRED_Task1_Doc136	217	228	doxorubicin	Chemical	D004317	PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.
BC8_BioRED_Task1_Doc136	230	233	DOX	Chemical	D004317	PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.
BC8_BioRED_Task1_Doc136	304	307	DOX	Chemical	D004317	DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.
BC8_BioRED_Task1_Doc136	316	330	cardiac damage	Disease	D006331	DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.
BC8_BioRED_Task1_Doc136	389	392	DOX	Chemical	D004317	DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.
BC8_BioRED_Task1_Doc136	403	409	oxygen	Chemical	D010100	Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system.
BC8_BioRED_Task1_Doc136	556	565	flavonoid	Chemical	D005419	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
BC8_BioRED_Task1_Doc136	566	590	monohydroxyethylrutoside	Chemical	C522803	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
BC8_BioRED_Task1_Doc136	592	599	monoHER	Chemical	C522803	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
BC8_BioRED_Task1_Doc136	633	636	DOX	Chemical	D004317	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
BC8_BioRED_Task1_Doc136	645	659	cardiotoxicity	Disease	D066126	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
BC8_BioRED_Task1_Doc136	695	699	iron	Chemical	D007501	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.
BC8_BioRED_Task1_Doc136	773	780	monoHER	Chemical	C522803	Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER.
BC8_BioRED_Task1_Doc136	843	850	monoHER	Chemical	C522803	Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER.
BC8_BioRED_Task1_Doc136	855	858	DOX	Chemical	D004317	Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER.
BC8_BioRED_Task1_Doc136	915	922	monoHER	Chemical	C522803	Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER.
BC8_BioRED_Task1_Doc136	1037	1041	mice	OrganismTaxon	10090	METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.)
BC8_BioRED_Task1_Doc136	1068	1071	DOX	Chemical	D004317	METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.)
BC8_BioRED_Task1_Doc136	1081	1084	DOX	Chemical	D004317	METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.)
BC8_BioRED_Task1_Doc136	1112	1119	monoHER	Chemical	C522803	preceded by monoHER (500 mg/kg i.p.)
BC8_BioRED_Task1_Doc136	1256	1260	mice	OrganismTaxon	10090	After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed.
BC8_BioRED_Task1_Doc136	1349	1369	cardiomyocyte damage	Disease	D009202	Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978).
BC8_BioRED_Task1_Doc136	1503	1506	DOX	Chemical	D004317	Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group (P<0.001).
BC8_BioRED_Task1_Doc136	1533	1547	cardiac damage	Disease	D006331	Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group (P<0.001).
BC8_BioRED_Task1_Doc136	1688	1692	mice	OrganismTaxon	10090	RESULTS: The number of damaged cardiomyocytes was 9.6-fold (95% CI 4.4-21.0) higher in mice treated with DOX alone than that in animals of the control group.
BC8_BioRED_Task1_Doc136	1706	1709	DOX	Chemical	D004317	RESULTS: The number of damaged cardiomyocytes was 9.6-fold (95% CI 4.4-21.0) higher in mice treated with DOX alone than that in animals of the control group.
BC8_BioRED_Task1_Doc136	1799	1803	mice	OrganismTaxon	10090	The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1.6 to 2.8 (mean 2.2, 95% CI 1.2-4.1, P=0.019).
BC8_BioRED_Task1_Doc136	1817	1820	DOX	Chemical	D004317	The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1.6 to 2.8 (mean 2.2, 95% CI 1.2-4.1, P=0.019).
BC8_BioRED_Task1_Doc136	1833	1840	monoHER	Chemical	C522803	The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1.6 to 2.8 (mean 2.2, 95% CI 1.2-4.1, P=0.019).
BC8_BioRED_Task1_Doc136	1854	1858	mice	OrganismTaxon	10090	The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1.6 to 2.8 (mean 2.2, 95% CI 1.2-4.1, P=0.019).
BC8_BioRED_Task1_Doc136	1976	1983	monoHER	Chemical	C522803	The mean protective effect by adding monoHER before DOX led to a significant 4.4-fold reduction (P<0.001, 95% CI 2.3-8.2) of abnormal cardiomyocytes.
BC8_BioRED_Task1_Doc136	1991	1994	DOX	Chemical	D004317	The mean protective effect by adding monoHER before DOX led to a significant 4.4-fold reduction (P<0.001, 95% CI 2.3-8.2) of abnormal cardiomyocytes.
BC8_BioRED_Task1_Doc136	2156	2163	monoHER	Chemical	C522803	This protective effect did not depend on the time interval between monoHER and DOX administration (P=0.345).
BC8_BioRED_Task1_Doc136	2168	2171	DOX	Chemical	D004317	This protective effect did not depend on the time interval between monoHER and DOX administration (P=0.345).
BC8_BioRED_Task1_Doc136	2242	2252	outpatient	OrganismTaxon	9606	CONCLUSION: The results indicate that in an outpatient clinical setting monoHER may be administered shortly before DOX.
BC8_BioRED_Task1_Doc136	2270	2277	monoHER	Chemical	C522803	CONCLUSION: The results indicate that in an outpatient clinical setting monoHER may be administered shortly before DOX.
BC8_BioRED_Task1_Doc136	2313	2316	DOX	Chemical	D004317	CONCLUSION: The results indicate that in an outpatient clinical setting monoHER may be administered shortly before DOX.
BC8_BioRED_Task1_Doc137	17	22	PCSK9	Gene	255738	Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
BC8_BioRED_Task1_Doc137	55	94	autosomal dominant hypercholesterolemia	Disease	D006938	Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
BC8_BioRED_Task1_Doc137	96	141	Proprotein convertase subtilisin/kexin type 9	Gene	255738	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis.
BC8_BioRED_Task1_Doc137	143	148	PCSK9	Gene	255738	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis.
BC8_BioRED_Task1_Doc137	168	207	autosomal dominant hypercholesterolemia	Disease	D006938	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis.
BC8_BioRED_Task1_Doc137	243	248	PCSK9	Gene	255738	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis.
BC8_BioRED_Task1_Doc137	269	280	cholesterol	Chemical	D002784	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis.
BC8_BioRED_Task1_Doc137	367	387	hypercholesterolemia	Disease	D006937	Mutations within this gene have previously been found to segregate with hypercholesterolemia.
BC8_BioRED_Task1_Doc137	442	447	PCSK9	Gene	255738	In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded.
BC8_BioRED_Task1_Doc137	526	555	familial hypercholesterolemia	Disease	D006937	In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded.
BC8_BioRED_Task1_Doc137	579	611	low-density lipoprotein receptor	Gene	3949	In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded.
BC8_BioRED_Task1_Doc137	630	636	R3500Q	SequenceVariant	rs5742904	In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded.
BC8_BioRED_Task1_Doc137	644	664	apolipoprotein B-100	Gene	338	In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded.
BC8_BioRED_Task1_Doc137	766	771	PCSK9	Gene	255738	Two novel missense mutations were detected in the catalytic subdomain of the PCSK9 gene.
BC8_BioRED_Task1_Doc137	782	790	patients	OrganismTaxon	9606	Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K.
BC8_BioRED_Task1_Doc137	814	819	D374Y	SequenceVariant	rs137852912	Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K.
BC8_BioRED_Task1_Doc137	829	836	patient	OrganismTaxon	9606	Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K.
BC8_BioRED_Task1_Doc137	867	872	D374Y	SequenceVariant	rs137852912	Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K.
BC8_BioRED_Task1_Doc137	877	882	N157K	SequenceVariant	rs143117125	Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K.
BC8_BioRED_Task1_Doc137	884	889	D374Y	SequenceVariant	rs137852912	D374Y segregated with hypercholesterolemia in the two former families where family members were available for study.
BC8_BioRED_Task1_Doc137	906	926	hypercholesterolemia	Disease	D006937	D374Y segregated with hypercholesterolemia in the two former families where family members were available for study.
BC8_BioRED_Task1_Doc137	1055	1060	PCSK9	Gene	255738	Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.
BC8_BioRED_Task1_Doc137	1072	1111	autosomal dominant hypercholesterolemia	Disease	D006938	Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.
BC8_BioRED_Task1_Doc138	0	23	End-stage renal disease	Disease	D007676	End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
BC8_BioRED_Task1_Doc138	25	29	ESRD	Disease	D007676	End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
BC8_BioRED_Task1_Doc138	83	94	calcineurin	Gene	5530	End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
BC8_BioRED_Task1_Doc138	167	178	calcineurin	Gene	5530	BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
BC8_BioRED_Task1_Doc138	190	202	cyclosporine	Chemical	D016572	BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
BC8_BioRED_Task1_Doc138	207	217	tacrolimus	Chemical	D016559	BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
BC8_BioRED_Task1_Doc138	239	250	nephrotoxic	Disease	D007674	BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
BC8_BioRED_Task1_Doc138	392	400	patients	OrganismTaxon	9606	Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).
BC8_BioRED_Task1_Doc138	436	459	end-stage renal disease	Disease	D007676	Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).
BC8_BioRED_Task1_Doc138	461	465	ESRD	Disease	D007676	Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).
BC8_BioRED_Task1_Doc138	533	537	ESRD	Disease	D007676	This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.
BC8_BioRED_Task1_Doc138	542	563	chronic renal failure	Disease	D007676	This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.
BC8_BioRED_Task1_Doc138	565	568	CRF	Disease	D007676	This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.
BC8_BioRED_Task1_Doc138	578	586	patients	OrganismTaxon	9606	This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.
BC8_BioRED_Task1_Doc138	597	605	Patients	OrganismTaxon	9606	METHODS: Patients receiving an OLTX only from June 1985 through December of 1994 who survived 6 months postoperatively were studied (n=834).
BC8_BioRED_Task1_Doc138	797	805	Patients	OrganismTaxon	9606	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
BC8_BioRED_Task1_Doc138	851	854	CRF	Disease	D007676	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
BC8_BioRED_Task1_Doc138	858	862	ESRD	Disease	D007676	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
BC8_BioRED_Task1_Doc138	871	874	CRF	Disease	D007676	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
BC8_BioRED_Task1_Doc138	892	902	creatinine	Chemical	D003404	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
BC8_BioRED_Task1_Doc138	925	929	ESRD	Disease	D007676	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
BC8_BioRED_Task1_Doc138	1051	1055	ESRD	Disease	D007676	Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.
BC8_BioRED_Task1_Doc138	1092	1096	ESRD	Disease	D007676	Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.
BC8_BioRED_Task1_Doc138	1155	1172	renal dysfunction	Disease	D007674	RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).
BC8_BioRED_Task1_Doc138	1184	1187	CRF	Disease	D007676	RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).
BC8_BioRED_Task1_Doc138	1197	1201	ESRD	Disease	D007676	RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).
BC8_BioRED_Task1_Doc138	1231	1239	patients	OrganismTaxon	9606	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1241	1244	CRF	Disease	D007676	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1249	1253	ESRD	Disease	D007676	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1254	1262	patients	OrganismTaxon	9606	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1293	1303	creatinine	Chemical	D003404	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1336	1344	patients	OrganismTaxon	9606	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1350	1370	hepatorenal syndrome	Disease	D006530	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1480	1490	creatinine	Chemical	D003404	Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
BC8_BioRED_Task1_Doc138	1627	1637	creatinine	Chemical	D003404	Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.
BC8_BioRED_Task1_Doc138	1762	1765	CRF	Disease	D007676	Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.
BC8_BioRED_Task1_Doc138	1769	1773	ESRD	Disease	D007676	Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.
BC8_BioRED_Task1_Doc138	1948	1956	patients	OrganismTaxon	9606	Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.
BC8_BioRED_Task1_Doc138	1965	1969	ESRD	Disease	D007676	Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.
BC8_BioRED_Task1_Doc138	2027	2035	Patients	OrganismTaxon	9606	Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.
BC8_BioRED_Task1_Doc138	2047	2051	ESRD	Disease	D007676	Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.
BC8_BioRED_Task1_Doc138	2089	2093	ESRD	Disease	D007676	Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.
BC8_BioRED_Task1_Doc138	2109	2117	patients	OrganismTaxon	9606	Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.
BC8_BioRED_Task1_Doc138	2162	2170	patients	OrganismTaxon	9606	Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.
BC8_BioRED_Task1_Doc138	2182	2186	ESRD	Disease	D007676	Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.
BC8_BioRED_Task1_Doc138	2246	2254	Patients	OrganismTaxon	9606	CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.
BC8_BioRED_Task1_Doc138	2297	2300	CRF	Disease	D007676	CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.
BC8_BioRED_Task1_Doc138	2305	2309	ESRD	Disease	D007676	CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.
BC8_BioRED_Task1_Doc138	2345	2349	ESRD	Disease	D007676	The development of ESRD decreases survival, particularly in those patients treated with dialysis only.
BC8_BioRED_Task1_Doc138	2392	2400	patients	OrganismTaxon	9606	The development of ESRD decreases survival, particularly in those patients treated with dialysis only.
BC8_BioRED_Task1_Doc138	2429	2437	Patients	OrganismTaxon	9606	Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
BC8_BioRED_Task1_Doc138	2450	2454	ESRD	Disease	D007676	Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
BC8_BioRED_Task1_Doc138	2499	2509	creatinine	Chemical	D003404	Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
BC8_BioRED_Task1_Doc138	2538	2558	hepatorenal syndrome	Disease	D006530	Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
BC8_BioRED_Task1_Doc138	2590	2600	creatinine	Chemical	D003404	However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.
BC8_BioRED_Task1_Doc138	2675	2678	CRF	Disease	D007676	However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.
BC8_BioRED_Task1_Doc138	2682	2686	ESRD	Disease	D007676	However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.
BC8_BioRED_Task1_Doc139	16	25	a-tubulin	Gene	22142	Mutation of the a-tubulin Tuba1a leads to straighter microtubules and perturbs neuronal migration.
BC8_BioRED_Task1_Doc139	26	32	Tuba1a	Gene	22142	Mutation of the a-tubulin Tuba1a leads to straighter microtubules and perturbs neuronal migration.
BC8_BioRED_Task1_Doc139	253	264	a/b-tubulin	Gene	22142,22152,53857	Microtubules (MTs) are key cellular effectors of neuronal displacement that are assembled from a/b-tubulin heterodimers.
BC8_BioRED_Task1_Doc139	295	304	a-tubulin	Gene	22142	Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans.
BC8_BioRED_Task1_Doc139	313	319	TUBA1A	Gene	7846	Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans.
BC8_BioRED_Task1_Doc139	339	361	cortical malformations	Disease	D054220	Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans.
BC8_BioRED_Task1_Doc139	365	371	humans	OrganismTaxon	9606	Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans.
BC8_BioRED_Task1_Doc139	441	447	Tuba1a	Gene	22142	In this study, we provide detailed in vivo and in vitro analyses of Tuba1a mutants.
BC8_BioRED_Task1_Doc139	460	464	mice	OrganismTaxon	10090	In mice carrying a Tuba1a missense mutation (S140G), neurons accumulate, and glial cells are dispersed along the rostral migratory stream in postnatal and adult brains.
BC8_BioRED_Task1_Doc139	476	482	Tuba1a	Gene	22142	In mice carrying a Tuba1a missense mutation (S140G), neurons accumulate, and glial cells are dispersed along the rostral migratory stream in postnatal and adult brains.
BC8_BioRED_Task1_Doc139	502	507	S140G	SequenceVariant	p|SUB|S|140|G	In mice carrying a Tuba1a missense mutation (S140G), neurons accumulate, and glial cells are dispersed along the rostral migratory stream in postnatal and adult brains.
BC8_BioRED_Task1_Doc139	642	648	Tuba1a	Gene	22142	Live imaging of Tuba1a-mutant neurons revealed slowed migration and increased neuronal branching, which correlated with directionality alterations and perturbed nucleus-centrosome (N-C) coupling.
BC8_BioRED_Task1_Doc139	822	828	Tuba1a	Gene	22142	Tuba1a mutation led to increased straightness of newly polymerized MTs, and structural modeling data suggest a conformational change in the a/b-tubulin heterodimer.
BC8_BioRED_Task1_Doc139	962	973	a/b-tubulin	Gene	22142,22152,53857	Tuba1a mutation led to increased straightness of newly polymerized MTs, and structural modeling data suggest a conformational change in the a/b-tubulin heterodimer.
BC8_BioRED_Task1_Doc139	1000	1005	Tuba8	Gene	53857	We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a.
BC8_BioRED_Task1_Doc139	1015	1024	a-tubulin	Gene	22142	We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a.
BC8_BioRED_Task1_Doc139	1060	1082	cortical malformations	Disease	D054220	We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a.
BC8_BioRED_Task1_Doc139	1119	1125	Tuba1a	Gene	22142	We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a.
BC8_BioRED_Task1_Doc139	1147	1153	Tuba1a	Gene	22142	Our work shows that Tuba1a plays an essential, noncompensated role in neuronal saltatory migration in vivo and highlights the importance of MT flexibility in N-C coupling and neuronal-branching regulation during neuronal migration.
BC8_BioRED_Task1_Doc140	5	16	domperidone	Chemical	D004294	Does domperidone potentiate mirtazapine-associated restless legs syndrome?
BC8_BioRED_Task1_Doc140	28	39	mirtazapine	Chemical	D000078785	Does domperidone potentiate mirtazapine-associated restless legs syndrome?
BC8_BioRED_Task1_Doc140	51	73	restless legs syndrome	Disease	D012148	Does domperidone potentiate mirtazapine-associated restless legs syndrome?
BC8_BioRED_Task1_Doc140	154	176	restless legs syndrome	Disease	D012148	There is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome (RLS).
BC8_BioRED_Task1_Doc140	178	181	RLS	Disease	D012148	There is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome (RLS).
BC8_BioRED_Task1_Doc140	213	216	RLS	Disease	D012148	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
BC8_BioRED_Task1_Doc140	249	257	levodopa	Chemical	D007980	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
BC8_BioRED_Task1_Doc140	262	270	dopamine	Chemical	D004298	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
BC8_BioRED_Task1_Doc140	297	329	dopamine D2 receptor antagonists	Chemical	D065127	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
BC8_BioRED_Task1_Doc140	354	357	RLS	Disease	D012148	For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
BC8_BioRED_Task1_Doc140	432	443	domperidone	Chemical	D004294	To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.
BC8_BioRED_Task1_Doc140	458	478	dopamine D2 receptor	Gene	1813	To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.
BC8_BioRED_Task1_Doc140	532	535	RLS	Disease	D012148	To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.
BC8_BioRED_Task1_Doc140	537	548	Mirtazapine	Chemical	D000078785	Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.
BC8_BioRED_Task1_Doc140	560	614	noradrenergic and specific serotonergic antidepressant	Chemical	D000928	Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.
BC8_BioRED_Task1_Doc140	616	621	NaSSA	Chemical	D000928	Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.
BC8_BioRED_Task1_Doc140	649	652	RLS	Disease	D012148	Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.
BC8_BioRED_Task1_Doc140	711	720	depressed	Disease	D003866	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
BC8_BioRED_Task1_Doc140	721	728	patient	OrganismTaxon	9606	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
BC8_BioRED_Task1_Doc140	743	765	postprandial dyspepsia	Disease	D004415	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
BC8_BioRED_Task1_Doc140	780	783	RLS	Disease	D012148	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
BC8_BioRED_Task1_Doc140	790	801	mirtazapine	Chemical	D000078785	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
BC8_BioRED_Task1_Doc140	824	835	domperidone	Chemical	D004294	The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
BC8_BioRED_Task1_Doc140	849	856	patient	OrganismTaxon	9606	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
BC8_BioRED_Task1_Doc140	885	888	RLS	Disease	D012148	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
BC8_BioRED_Task1_Doc140	925	936	mirtazapine	Chemical	D000078785	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
BC8_BioRED_Task1_Doc140	946	949	RLS	Disease	D012148	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
BC8_BioRED_Task1_Doc140	1007	1018	mirtazapine	Chemical	D000078785	Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
BC8_BioRED_Task1_Doc140	1068	1079	mirtazapine	Chemical	D000078785	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
BC8_BioRED_Task1_Doc140	1100	1103	RLS	Disease	D012148	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
BC8_BioRED_Task1_Doc140	1111	1118	patient	OrganismTaxon	9606	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
BC8_BioRED_Task1_Doc140	1160	1170	domperione	Chemical	D004294	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
BC8_BioRED_Task1_Doc140	1174	1185	mirtazapine	Chemical	D000078785	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
BC8_BioRED_Task1_Doc140	1197	1200	RLS	Disease	D012148	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
BC8_BioRED_Task1_Doc140	1262	1273	mirtazapine	Chemical	D000078785	However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.
BC8_BioRED_Task1_Doc140	1297	1300	RLS	Disease	D012148	However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.
BC8_BioRED_Task1_Doc140	1361	1393	dopamine D2 receptor antagonists	Chemical	D065127	However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.
BC8_BioRED_Task1_Doc141	5	8	fat	Chemical	D004041	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	18	23	obese	Disease	D009765	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	24	28	rats	OrganismTaxon	10116	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	53	64	doxorubicin	Chemical	D004317	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	73	87	cardiotoxicity	Disease	D066126	High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	112	123	doxorubicin	Chemical	D004317	Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.
BC8_BioRED_Task1_Doc141	125	135	Adriamycin	Chemical	D004317	Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.
BC8_BioRED_Task1_Doc141	172	186	cardiotoxicity	Disease	D066126	Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.
BC8_BioRED_Task1_Doc141	190	198	patients	OrganismTaxon	9606	Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.
BC8_BioRED_Task1_Doc141	306	317	doxorubicin	Chemical	D004317	Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	326	340	cardiotoxicity	Disease	D066126	Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	421	434	triglycerides	Chemical	D014280	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	457	467	fatty-acid	Chemical	D005227	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	479	482	ATP	Chemical	D000255	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	510	513	JAK	Gene	84598	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	514	519	STAT3	Gene	25125	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	624	627	fat	Chemical	D004041	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	654	661	obesity	Disease	D009765	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	685	689	rats	OrganismTaxon	10116	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	717	728	doxorubicin	Chemical	D004317	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	737	751	cardiotoxicity	Disease	D066126	In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
BC8_BioRED_Task1_Doc141	773	784	doxorubicin	Chemical	D004317	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	857	871	cardiotoxicity	Disease	D066126	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	873	892	cardiac dysfunction	Disease	D006331	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	894	899	lipid	Chemical	D008055	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	939	944	obese	Disease	D009765	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	946	948	OB	Disease	D009765	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	950	954	rats	OrganismTaxon	10116	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	989	1014	renal or hepatic toxicity	Disease	D007674,D056486	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
BC8_BioRED_Task1_Doc141	1016	1027	Doxorubicin	Chemical	D004317	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
BC8_BioRED_Task1_Doc141	1089	1100	doxorubicin	Chemical	D004317	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
BC8_BioRED_Task1_Doc141	1105	1118	doxorubicinol	Chemical	C010013	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
BC8_BioRED_Task1_Doc141	1170	1172	OB	Disease	D009765	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
BC8_BioRED_Task1_Doc141	1215	1217	OB	Disease	D009765	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1218	1222	rats	OrganismTaxon	10116	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1302	1329	uncoupling proteins 2 and 3	Gene	25708,54315	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1361	1410	peroxisome proliferators activated receptor-alpha	Gene	25747	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1433	1444	adiponectin	Gene	246253	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1475	1485	fatty-acid	Chemical	D005227	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1573	1575	OB	Disease	D009765	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1606	1631	AMP-alpha2 protein kinase	Gene	65248	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1661	1664	ATP	Chemical	D000255	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1697	1700	ATP	Chemical	D000255	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1701	1704	ADP	Chemical	D000244	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1717	1728	doxorubicin	Chemical	D004317	Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
BC8_BioRED_Task1_Doc141	1763	1777	erythropoietin	Gene	24335	Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1792	1797	SOCS3	Gene	89829	Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1841	1844	JAK	Gene	84598	Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1845	1850	STAT3	Gene	25125	Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1887	1892	obese	Disease	D009765	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1893	1897	rats	OrganismTaxon	10116	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1923	1934	doxorubicin	Chemical	D004317	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	1943	1957	cardiotoxicity	Disease	D066126	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	2012	2015	ATP	Chemical	D000255	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	2079	2082	JAK	Gene	84598	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc141	2083	2088	STAT3	Gene	25125	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.
BC8_BioRED_Task1_Doc142	36	39	ASP	Gene	718	Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects.
BC8_BioRED_Task1_Doc142	129	134	obese	Disease	D009765	Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects.
BC8_BioRED_Task1_Doc142	171	178	obesity	Disease	D009765	BACKGROUND: Prevalence of obesity is increasing to pandemic proportions.
BC8_BioRED_Task1_Doc142	227	232	obese	Disease	D009765	However, obese subjects differ in insulin resistance, adipokine production and co-morbidities.
BC8_BioRED_Task1_Doc142	252	270	insulin resistance	Disease	D007333	However, obese subjects differ in insulin resistance, adipokine production and co-morbidities.
BC8_BioRED_Task1_Doc142	272	281	adipokine	Gene	9370	However, obese subjects differ in insulin resistance, adipokine production and co-morbidities.
BC8_BioRED_Task1_Doc142	347	352	obese	Disease	D009765	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	382	411	Acylation Stimulating protein	Gene	718	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	413	416	ASP	Gene	718	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	422	434	Triglyceride	Chemical	D014280	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	436	438	TG	Chemical	D014280	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	454	457	ASP	Gene	718	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	462	464	TG	Chemical	D014280	Based on fasting plasma analysis, obese subjects were grouped as Low Acylation Stimulating protein (ASP) and Triglyceride (TG) (LAT) vs High ASP and TG (HAT).
BC8_BioRED_Task1_Doc142	586	591	lipid	Chemical	D008055	Subcutaneous (SC) and omental (OM) adipose tissues (n = 21) were analysed by microarray, and biologic pathways in lipid metabolism and inflammation were specifically examined.
BC8_BioRED_Task1_Doc142	607	619	inflammation	Disease	D007249	Subcutaneous (SC) and omental (OM) adipose tissues (n = 21) were analysed by microarray, and biologic pathways in lipid metabolism and inflammation were specifically examined.
BC8_BioRED_Task1_Doc142	697	704	obesity	Disease	D009765	METHODS: LAT and HAT groups were matched in age, obesity, insulin, and glucose, and had similar expression of insulin-related genes (InsR, IRS-1).
BC8_BioRED_Task1_Doc142	706	713	insulin	Gene	3630	METHODS: LAT and HAT groups were matched in age, obesity, insulin, and glucose, and had similar expression of insulin-related genes (InsR, IRS-1).
BC8_BioRED_Task1_Doc142	719	726	glucose	Chemical	D005947	METHODS: LAT and HAT groups were matched in age, obesity, insulin, and glucose, and had similar expression of insulin-related genes (InsR, IRS-1).
BC8_BioRED_Task1_Doc142	758	765	insulin	Gene	3630	METHODS: LAT and HAT groups were matched in age, obesity, insulin, and glucose, and had similar expression of insulin-related genes (InsR, IRS-1).
BC8_BioRED_Task1_Doc142	781	785	InsR	Gene	3643	METHODS: LAT and HAT groups were matched in age, obesity, insulin, and glucose, and had similar expression of insulin-related genes (InsR, IRS-1).
BC8_BioRED_Task1_Doc142	787	792	IRS-1	Gene	3667	METHODS: LAT and HAT groups were matched in age, obesity, insulin, and glucose, and had similar expression of insulin-related genes (InsR, IRS-1).
BC8_BioRED_Task1_Doc142	795	798	ASP	Gene	718	ASP related genes tended to be increased in the HAT group and were correlated (factor B, adipsin, complement C3, p < 0.01 each).
BC8_BioRED_Task1_Doc142	874	882	factor B	Gene	629	ASP related genes tended to be increased in the HAT group and were correlated (factor B, adipsin, complement C3, p < 0.01 each).
BC8_BioRED_Task1_Doc142	884	891	adipsin	Gene	1675	ASP related genes tended to be increased in the HAT group and were correlated (factor B, adipsin, complement C3, p < 0.01 each).
BC8_BioRED_Task1_Doc142	893	906	complement C3	Gene	718	ASP related genes tended to be increased in the HAT group and were correlated (factor B, adipsin, complement C3, p < 0.01 each).
BC8_BioRED_Task1_Doc142	1047	1051	C5L2	Gene	27202	Increased C5L2 (p < 0.01), an ASP receptor, in HAT suggests a compensatory ASP pathway, associated with increased TG storage.
BC8_BioRED_Task1_Doc142	1067	1079	ASP receptor	Gene	27202	Increased C5L2 (p < 0.01), an ASP receptor, in HAT suggests a compensatory ASP pathway, associated with increased TG storage.
BC8_BioRED_Task1_Doc142	1112	1115	ASP	Gene	718	Increased C5L2 (p < 0.01), an ASP receptor, in HAT suggests a compensatory ASP pathway, associated with increased TG storage.
BC8_BioRED_Task1_Doc142	1151	1153	TG	Chemical	D014280	Increased C5L2 (p < 0.01), an ASP receptor, in HAT suggests a compensatory ASP pathway, associated with increased TG storage.
BC8_BioRED_Task1_Doc142	1214	1219	lipid	Chemical	D008055	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1247	1251	CD36	Gene	948	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1253	1258	DGAT1	Gene	8694	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1260	1265	DGAT2	Gene	84649	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1267	1271	SCD1	Gene	6319	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1273	1277	FASN	Gene	2194	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1283	1286	LPL	Gene	4023	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1300	1303	HSL	Gene	3991	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1305	1309	CES1	Gene	1066	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1311	1320	perilipin	Gene	5346	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1323	1350	fatty acid binding proteins	Gene	2168,2170	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1352	1357	FABP1	Gene	2168	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1359	1364	FABP3	Gene	2170	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1405	1414	CEBPalpha	Gene	1050	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1416	1424	CEBPbeta	Gene	1051	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1426	1435	PPARgamma	Gene	5468	RESULTS: HAT adipose tissue demonstrated increased lipid related genes for storage (CD36, DGAT1, DGAT2, SCD1, FASN, and LPL), lipolysis (HSL, CES1, perilipin), fatty acid binding proteins (FABP1, FABP3) and adipocyte differentiation markers (CEBPalpha, CEBPbeta, PPARgamma).
BC8_BioRED_Task1_Doc142	1491	1495	AMPK	Gene	5562	By contrast, oxidation related genes were decreased (AMPK, UCP1, CPT1, FABP7).
BC8_BioRED_Task1_Doc142	1497	1501	UCP1	Gene	7350	By contrast, oxidation related genes were decreased (AMPK, UCP1, CPT1, FABP7).
BC8_BioRED_Task1_Doc142	1503	1507	CPT1	Gene	1374	By contrast, oxidation related genes were decreased (AMPK, UCP1, CPT1, FABP7).
BC8_BioRED_Task1_Doc142	1509	1514	FABP7	Gene	2173	By contrast, oxidation related genes were decreased (AMPK, UCP1, CPT1, FABP7).
BC8_BioRED_Task1_Doc142	1549	1561	inflammatory	Disease	D007249	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1568	1573	TGFB1	Gene	7040	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1575	1580	TIMP1	Gene	7076	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1582	1587	TIMP3	Gene	7078	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1593	1598	TIMP4	Gene	7079	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1605	1620	proinflammatory	Disease	D007249	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1621	1625	PIG7	Gene	9516	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1630	1634	MMP2	Gene	4313	HAT subjects had increased anti-inflammatory genes TGFB1, TIMP1, TIMP3, and TIMP4 while proinflammatory PIG7 and MMP2 were also significantly increased; all genes, p < 0.025.
BC8_BioRED_Task1_Doc142	1735	1739	C5L2	Gene	27202	CONCLUSION: Taken together, the profile of C5L2 receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma ASP and TG.
BC8_BioRED_Task1_Doc142	1750	1753	ASP	Gene	718	CONCLUSION: Taken together, the profile of C5L2 receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma ASP and TG.
BC8_BioRED_Task1_Doc142	1824	1829	obese	Disease	D009765	CONCLUSION: Taken together, the profile of C5L2 receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma ASP and TG.
BC8_BioRED_Task1_Doc142	1913	1916	ASP	Gene	718	CONCLUSION: Taken together, the profile of C5L2 receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma ASP and TG.
BC8_BioRED_Task1_Doc142	1921	1923	TG	Chemical	D014280	CONCLUSION: Taken together, the profile of C5L2 receptor, ASP gene expression and metabolic factors in adipose tissue from morbidly obese HAT subjects suggests a compensatory response associated with the increased plasma ASP and TG.
BC8_BioRED_Task1_Doc143	0	19	Thiamine deficiency	Disease	D013832	Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes.
BC8_BioRED_Task1_Doc143	30	57	hypoxia inducible factor-1a	Gene	15251	Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes.
BC8_BioRED_Task1_Doc143	99	104	mouse	OrganismTaxon	10090	Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes.
BC8_BioRED_Task1_Doc143	125	133	Thiamine	Chemical	D013831	Thiamine is an essential enzyme cofactor required for proper metabolic function and maintenance of metabolism and energy production in the brain.
BC8_BioRED_Task1_Doc143	295	314	thiamine deficiency	Disease	D013832	In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity.
BC8_BioRED_Task1_Doc143	316	318	TD	Disease	D013832	In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity.
BC8_BioRED_Task1_Doc143	363	370	alcohol	Chemical	D000438	In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity.
BC8_BioRED_Task1_Doc143	394	425	impaired mitochondrial function	Disease	D028361	In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity.
BC8_BioRED_Task1_Doc143	445	457	inflammation	Disease	D007249	In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity.
BC8_BioRED_Task1_Doc143	462	476	excitotoxicity	Disease	D064420	In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity.
BC8_BioRED_Task1_Doc143	603	611	patients	OrganismTaxon	9606	Comparable histological injuries in patients with hypoxia/ischemia and TD have been described in the thalamus and mammillary bodies, suggesting a congruency between the cellular responses to these stresses.
BC8_BioRED_Task1_Doc143	617	624	hypoxia	Disease	D000860	Comparable histological injuries in patients with hypoxia/ischemia and TD have been described in the thalamus and mammillary bodies, suggesting a congruency between the cellular responses to these stresses.
BC8_BioRED_Task1_Doc143	625	633	ischemia	Disease	D007511	Comparable histological injuries in patients with hypoxia/ischemia and TD have been described in the thalamus and mammillary bodies, suggesting a congruency between the cellular responses to these stresses.
BC8_BioRED_Task1_Doc143	638	640	TD	Disease	D013832	Comparable histological injuries in patients with hypoxia/ischemia and TD have been described in the thalamus and mammillary bodies, suggesting a congruency between the cellular responses to these stresses.
BC8_BioRED_Task1_Doc143	790	797	hypoxia	Disease	D000860	Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels.
BC8_BioRED_Task1_Doc143	798	806	ischemia	Disease	D007511	Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels.
BC8_BioRED_Task1_Doc143	808	810	TD	Disease	D013832	Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels.
BC8_BioRED_Task1_Doc143	836	863	Hypoxia Inducible Factor-1a	Gene	15251	Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels.
BC8_BioRED_Task1_Doc143	865	871	HIF-1a	Gene	15251	Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels.
BC8_BioRED_Task1_Doc143	893	899	oxygen	Chemical	D010100	Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels.
BC8_BioRED_Task1_Doc143	929	931	TD	Disease	D013832	However, the role of TD-induced HIF-1a in neurological injury is currently unknown.
BC8_BioRED_Task1_Doc143	940	946	HIF-1a	Gene	15251	However, the role of TD-induced HIF-1a in neurological injury is currently unknown.
BC8_BioRED_Task1_Doc143	950	969	neurological injury	Disease	D009422	However, the role of TD-induced HIF-1a in neurological injury is currently unknown.
BC8_BioRED_Task1_Doc143	1058	1060	TD	Disease	D013832	Using Western blot analysis and RT-PCR, we have demonstrated that TD induces HIF-1a expression and activity in primary mouse astrocytes.
BC8_BioRED_Task1_Doc143	1069	1075	HIF-1a	Gene	15251	Using Western blot analysis and RT-PCR, we have demonstrated that TD induces HIF-1a expression and activity in primary mouse astrocytes.
BC8_BioRED_Task1_Doc143	1111	1116	mouse	OrganismTaxon	10090	Using Western blot analysis and RT-PCR, we have demonstrated that TD induces HIF-1a expression and activity in primary mouse astrocytes.
BC8_BioRED_Task1_Doc143	1227	1239	inflammatory	Disease	D007249	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1240	1246	HIF-1a	Gene	15251	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1260	1264	MCP1	Gene	20296	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1266	1271	BNIP3	Gene	12176	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1273	1276	Nix	Gene	12177	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1281	1285	Noxa	Gene	58801	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1293	1295	TD	Disease	D013832	We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD.
BC8_BioRED_Task1_Doc143	1338	1340	TD	Disease	D013832	We also observed apoptotic cell death in TD as demonstrated by PI/Annexin V staining, TUNEL assay, and Cell Death ELISA.
BC8_BioRED_Task1_Doc143	1363	1372	Annexin V	Gene	11747	We also observed apoptotic cell death in TD as demonstrated by PI/Annexin V staining, TUNEL assay, and Cell Death ELISA.
BC8_BioRED_Task1_Doc143	1448	1454	HIF-1a	Gene	15251	Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD.
BC8_BioRED_Task1_Doc143	1470	1473	YC1	Gene	56878	Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD.
BC8_BioRED_Task1_Doc143	1478	1486	thiamine	Chemical	D013831	Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD.
BC8_BioRED_Task1_Doc143	1538	1544	HIF-1a	Gene	15251	Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD.
BC8_BioRED_Task1_Doc143	1586	1588	TD	Disease	D013832	Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD.
BC8_BioRED_Task1_Doc143	1634	1640	HIF-1a	Gene	15251	These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.
BC8_BioRED_Task1_Doc143	1697	1709	inflammatory	Disease	D007249	These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.
BC8_BioRED_Task1_Doc143	1763	1782	thiamine deficiency	Disease	D013832	These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.
BC8_BioRED_Task1_Doc144	0	9	Hsp90beta	Gene	301252	Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins.
BC8_BioRED_Task1_Doc144	49	53	salt	Chemical	D012492	Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins.
BC8_BioRED_Task1_Doc144	67	78	nephropathy	Disease	D007674	Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins.
BC8_BioRED_Task1_Doc144	136	140	salt	Chemical	D012492	A high-salt diet often leads to a local intrarenal increase in renal hypoxia and oxidative stress, which are responsible for an excess production of pathogenic substances.
BC8_BioRED_Task1_Doc144	192	205	renal hypoxia	Disease	D007674	A high-salt diet often leads to a local intrarenal increase in renal hypoxia and oxidative stress, which are responsible for an excess production of pathogenic substances.
BC8_BioRED_Task1_Doc144	332	344	hypertensive	Disease	D006973	Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis.
BC8_BioRED_Task1_Doc144	355	359	rats	OrganismTaxon	10116	Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis.
BC8_BioRED_Task1_Doc144	371	375	salt	Chemical	D012492	Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis.
BC8_BioRED_Task1_Doc144	398	409	proteinuria	Disease	D011507	Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis.
BC8_BioRED_Task1_Doc144	437	455	renal inflammation	Disease	D007674	Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis.
BC8_BioRED_Task1_Doc144	457	465	fibrosis	Disease	D005355	Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis.
BC8_BioRED_Task1_Doc144	557	566	Hsp90beta	Gene	301252	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	568	577	TGF-beta,	Gene	59086	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	578	588	HIF-1alpha	Gene	29560	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	590	599	TNF-alpha	Gene	24835	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	601	605	IL-6	Gene	24498	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	610	615	MCP-1	Gene	24770	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	665	669	salt	Chemical	D012492	Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading.
BC8_BioRED_Task1_Doc144	699	708	Hsp90beta	Gene	301252	Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation.
BC8_BioRED_Task1_Doc144	768	772	salt	Chemical	D012492	Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation.
BC8_BioRED_Task1_Doc144	843	852	NF-kappaB	Gene	81736	Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation.
BC8_BioRED_Task1_Doc144	854	857	p38	Gene	81649	Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation.
BC8_BioRED_Task1_Doc144	873	878	Bcl-2	Gene	24224	Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation.
BC8_BioRED_Task1_Doc144	893	902	Hsp90beta	Gene	301252	Hsp90beta was previously proven to regulate the upstream mediators in multiple cellular signalling cascades through stabilizing and maintaining their activities.
BC8_BioRED_Task1_Doc144	1069	1120	17-dimethylaminoethylamino-17-demethoxygeldanamycin	Chemical	C448659	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1122	1129	17-DMAG	Chemical	C448659	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1134	1143	Hsp90beta	Gene	301252	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1187	1191	salt	Chemical	D012492	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1205	1216	proteinuria	Disease	D011507	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1221	1233	renal damage	Disease	D007674	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1313	1322	NF-kappaB	Gene	81736	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1324	1328	mTOR	Gene	56718	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1333	1336	p38	Gene	81649	In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades.
BC8_BioRED_Task1_Doc144	1401	1410	Hsp90beta	Gene	301252	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1445	1449	TAK1	Gene	313121	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1451	1460	AMPKalpha	Gene	65248	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1462	1475	IKKalpha/beta	Gene	309361,84351	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1477	1487	HIF-1alpha	Gene	29560	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1492	1498	Raptor	Gene	287871	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1508	1517	Hsp90beta	Gene	301252	Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process.
BC8_BioRED_Task1_Doc144	1566	1575	Hsp90beta	Gene	301252	In addition, Hsp90beta inhibition-mediated renal improvements also accompanied the reduction of renal oxidative stress.
BC8_BioRED_Task1_Doc144	1688	1692	salt	Chemical	D012492	In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats.
BC8_BioRED_Task1_Doc144	1750	1761	proteinuria	Disease	D011507	In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats.
BC8_BioRED_Task1_Doc144	1766	1783	renal dysfunction	Disease	D051437	In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats.
BC8_BioRED_Task1_Doc144	1795	1799	rats	OrganismTaxon	10116	In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats.
BC8_BioRED_Task1_Doc144	1801	1810	Hsp90beta	Gene	301252	Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress.
BC8_BioRED_Task1_Doc144	1950	1961	nephropathy	Disease	D007674	Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress.
BC8_BioRED_Task1_Doc144	1971	1984	renal hypoxia	Disease	D007674	Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress.
BC8_BioRED_Task1_Doc145	11	14	CD4	Gene	12504	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	15	20	IFN-g	Gene	15978	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	54	57	CD4	Gene	12504	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	58	63	IFN-g	Gene	15978	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	64	69	IL-10	Gene	16153	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	94	99	IL-10	Gene	16153	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	168	185	Malaria Infection	Disease	D008288	Long-Lived CD4+IFN-g+ T Cells rather than Short-Lived CD4+IFN-g+IL-10+ T Cells Initiate Rapid IL-10 Production To Suppress Anamnestic T Cell Responses during Secondary Malaria Infection.
BC8_BioRED_Task1_Doc145	187	190	CD4	Gene	12504	CD4(+) T cells that produce IFN-g are the source of host-protective IL-10 during primary infection with a number of different pathogens, including Plasmodium spp.
BC8_BioRED_Task1_Doc145	215	220	IFN-g	Gene	15978	CD4(+) T cells that produce IFN-g are the source of host-protective IL-10 during primary infection with a number of different pathogens, including Plasmodium spp.
BC8_BioRED_Task1_Doc145	255	260	IL-10	Gene	16153	CD4(+) T cells that produce IFN-g are the source of host-protective IL-10 during primary infection with a number of different pathogens, including Plasmodium spp.
BC8_BioRED_Task1_Doc145	276	285	infection	Disease	D007239	CD4(+) T cells that produce IFN-g are the source of host-protective IL-10 during primary infection with a number of different pathogens, including Plasmodium spp.
BC8_BioRED_Task1_Doc145	368	371	CD4	Gene	12504	The fate of these CD4(+)IFN-g(+)IL-10(+) T cells following clearance of primary infection and their subsequent influence on the course of repeated infections is, however, presently unknown.
BC8_BioRED_Task1_Doc145	374	379	IFN-g	Gene	15978	The fate of these CD4(+)IFN-g(+)IL-10(+) T cells following clearance of primary infection and their subsequent influence on the course of repeated infections is, however, presently unknown.
BC8_BioRED_Task1_Doc145	382	387	IL-10	Gene	16153	The fate of these CD4(+)IFN-g(+)IL-10(+) T cells following clearance of primary infection and their subsequent influence on the course of repeated infections is, however, presently unknown.
BC8_BioRED_Task1_Doc145	430	439	infection	Disease	D007239	The fate of these CD4(+)IFN-g(+)IL-10(+) T cells following clearance of primary infection and their subsequent influence on the course of repeated infections is, however, presently unknown.
BC8_BioRED_Task1_Doc145	565	570	IFN-g	Gene	15978	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	608	613	IL-10	Gene	16153	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	632	636	mice	OrganismTaxon	10090	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	659	676	malaria infection	Disease	D008288	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	685	688	CD4	Gene	12504	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	765	770	IL-10	Gene	16153	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	828	831	CD4	Gene	12504	In this study, utilizing IFN-g-yellow fluorescent protein (YFP) and IL-10-GFP dual reporter mice, we show that primary malaria infection-induced CD4(+)YFP(+)GFP(+) T cells have limited memory potential, do not stably express IL-10, and are disproportionately lost from the Ag-experienced CD4(+) T cell memory population during the maintenance phase postinfection.
BC8_BioRED_Task1_Doc145	904	907	CD4	Gene	12504	CD4(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of PD-1, Lag-3, and TIGIT, indicative of cellular exhaustion.
BC8_BioRED_Task1_Doc145	1062	1066	PD-1	Gene	18566	CD4(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of PD-1, Lag-3, and TIGIT, indicative of cellular exhaustion.
BC8_BioRED_Task1_Doc145	1068	1073	Lag-3	Gene	16768	CD4(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of PD-1, Lag-3, and TIGIT, indicative of cellular exhaustion.
BC8_BioRED_Task1_Doc145	1079	1084	TIGIT	Gene	100043314	CD4(+)YFP(+)GFP(+) T cells generally exhibited a short-lived effector rather than effector memory T cell phenotype postinfection and expressed high levels of PD-1, Lag-3, and TIGIT, indicative of cellular exhaustion.
BC8_BioRED_Task1_Doc145	1149	1152	CD4	Gene	12504	Consistently, the surviving CD4(+)YFP(+)GFP(+) T cell-derived cells were unresponsive and failed to proliferate during the early phase of secondary infection.
BC8_BioRED_Task1_Doc145	1269	1278	infection	Disease	D007239	Consistently, the surviving CD4(+)YFP(+)GFP(+) T cell-derived cells were unresponsive and failed to proliferate during the early phase of secondary infection.
BC8_BioRED_Task1_Doc145	1293	1296	CD4	Gene	12504	In contrast, CD4(+)YFP(+)GFP(-) T cell-derived cells expanded rapidly and upregulated IL-10 expression during secondary infection.
BC8_BioRED_Task1_Doc145	1366	1371	IL-10	Gene	16153	In contrast, CD4(+)YFP(+)GFP(-) T cell-derived cells expanded rapidly and upregulated IL-10 expression during secondary infection.
BC8_BioRED_Task1_Doc145	1400	1409	infection	Disease	D007239	In contrast, CD4(+)YFP(+)GFP(-) T cell-derived cells expanded rapidly and upregulated IL-10 expression during secondary infection.
BC8_BioRED_Task1_Doc145	1428	1431	CD4	Gene	12504	Correspondingly, CD4(+) T cells were the major producers within an accelerated and amplified IL-10 response during the early stage of secondary malaria infection.
BC8_BioRED_Task1_Doc145	1504	1509	IL-10	Gene	16153	Correspondingly, CD4(+) T cells were the major producers within an accelerated and amplified IL-10 response during the early stage of secondary malaria infection.
BC8_BioRED_Task1_Doc145	1555	1572	malaria infection	Disease	D008288	Correspondingly, CD4(+) T cells were the major producers within an accelerated and amplified IL-10 response during the early stage of secondary malaria infection.
BC8_BioRED_Task1_Doc145	1583	1588	IL-10	Gene	16153	Notably, IL-10 exerted quantitatively stronger regulatory effects on innate and CD4(+) T cell responses during primary and secondary infections, respectively.
BC8_BioRED_Task1_Doc145	1654	1657	CD4	Gene	12504	Notably, IL-10 exerted quantitatively stronger regulatory effects on innate and CD4(+) T cell responses during primary and secondary infections, respectively.
BC8_BioRED_Task1_Doc145	1820	1825	IL-10	Gene	16153	The results in this study significantly improve our understanding of the durability of IL-10-producing CD4(+) T cells postinfection and provide information on how IL-10 may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated malaria infections.
BC8_BioRED_Task1_Doc145	1836	1839	CD4	Gene	12504	The results in this study significantly improve our understanding of the durability of IL-10-producing CD4(+) T cells postinfection and provide information on how IL-10 may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated malaria infections.
BC8_BioRED_Task1_Doc145	1896	1901	IL-10	Gene	16153	The results in this study significantly improve our understanding of the durability of IL-10-producing CD4(+) T cells postinfection and provide information on how IL-10 may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated malaria infections.
BC8_BioRED_Task1_Doc145	2007	2025	malaria infections	Disease	D008288	The results in this study significantly improve our understanding of the durability of IL-10-producing CD4(+) T cells postinfection and provide information on how IL-10 may contribute to optimized parasite control and prevention of immune-mediated pathology during repeated malaria infections.
BC8_BioRED_Task1_Doc146	13	29	long QT syndrome	Disease	D008133	Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
BC8_BioRED_Task1_Doc146	64	73	methadone	Chemical	D008691	Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
BC8_BioRED_Task1_Doc146	106	114	patients	OrganismTaxon	9606	Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
BC8_BioRED_Task1_Doc146	158	174	long QT syndrome	Disease	D008133	BACKGROUND: Drug-induced long QT syndrome is a serious adverse drug reaction.
BC8_BioRED_Task1_Doc146	211	220	Methadone	Chemical	D008691	Methadone prolongs the QT interval in vitro in a dose-dependent manner.
BC8_BioRED_Task1_Doc146	290	299	inpatient	OrganismTaxon	9606	In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.
BC8_BioRED_Task1_Doc146	326	350	QT interval prolongation	Disease	D008133	In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.
BC8_BioRED_Task1_Doc146	356	365	methadone	Chemical	D008691	In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.
BC8_BioRED_Task1_Doc146	593	602	methadone	Chemical	D008691	METHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital.
BC8_BioRED_Task1_Doc146	627	636	methadone	Chemical	D008691	METHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital.
BC8_BioRED_Task1_Doc146	647	655	patients	OrganismTaxon	9606	METHODS: We performed a systematic, retrospective study comparing active or former intravenous drug users receiving methadone and those not receiving methadone among all patients hospitalized over a 5-year period in a tertiary care hospital.
BC8_BioRED_Task1_Doc146	734	742	patients	OrganismTaxon	9606	A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone.
BC8_BioRED_Task1_Doc146	753	762	methadone	Chemical	D008691	A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone.
BC8_BioRED_Task1_Doc146	876	885	methadone	Chemical	D008691	A total of 167 patients receiving methadone fulfilled the inclusion criteria and were compared with a control group of 80 injection drug users not receiving methadone.
BC8_BioRED_Task1_Doc146	902	911	methadone	Chemical	D008691	In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.
BC8_BioRED_Task1_Doc146	1022	1037	QT prolongation	Disease	D008133	In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.
BC8_BioRED_Task1_Doc146	1058	1067	methadone	Chemical	D008691	RESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects.
BC8_BioRED_Task1_Doc146	1080	1088	patients	OrganismTaxon	9606	RESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects.
BC8_BioRED_Task1_Doc146	1108	1124	QTc prolongation	Disease	D008133	RESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects.
BC8_BioRED_Task1_Doc146	1212	1220	patients	OrganismTaxon	9606	Six patients (3.6%) in the methadone group presented torsades de pointes.
BC8_BioRED_Task1_Doc146	1235	1244	methadone	Chemical	D008691	Six patients (3.6%) in the methadone group presented torsades de pointes.
BC8_BioRED_Task1_Doc146	1261	1280	torsades de pointes	Disease	D016171	Six patients (3.6%) in the methadone group presented torsades de pointes.
BC8_BioRED_Task1_Doc146	1338	1347	methadone	Chemical	D008691	QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P<.01).
BC8_BioRED_Task1_Doc146	1497	1506	methadone	Chemical	D008691	Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.
BC8_BioRED_Task1_Doc146	1513	1533	cytochrome P-450 3A4	Gene	1576	Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.
BC8_BioRED_Task1_Doc146	1558	1569	hypokalemia	Disease	D007008	Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.
BC8_BioRED_Task1_Doc146	1612	1636	QT interval prolongation	Disease	D008133	CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.
BC8_BioRED_Task1_Doc146	1640	1649	methadone	Chemical	D008691	CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.
BC8_BioRED_Task1_Doc146	1662	1670	patients	OrganismTaxon	9606	CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.
BC8_BioRED_Task1_Doc146	1733	1742	Methadone	Chemical	D008691	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
BC8_BioRED_Task1_Doc146	1761	1792	cytochrome P-450 3A4 inhibitors	Chemical	D065692	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
BC8_BioRED_Task1_Doc146	1794	1803	potassium	Chemical	D011188	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
BC8_BioRED_Task1_Doc146	1844	1859	QT prolongation	Disease	D008133	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
BC8_BioRED_Task1_Doc146	1861	1877	Long QT syndrome	Disease	D008133	Long QT syndrome can occur with low doses of methadone.
BC8_BioRED_Task1_Doc146	1906	1915	methadone	Chemical	D008691	Long QT syndrome can occur with low doses of methadone.
BC8_BioRED_Task1_Doc147	20	28	warfarin	Chemical	D014859	Interaction between warfarin and levofloxacin: case series.
BC8_BioRED_Task1_Doc147	33	45	levofloxacin	Chemical	D064704	Interaction between warfarin and levofloxacin: case series.
BC8_BioRED_Task1_Doc147	60	68	Warfarin	Chemical	D014859	Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions.
BC8_BioRED_Task1_Doc147	159	171	Levofloxacin	Chemical	D064704	Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.
BC8_BioRED_Task1_Doc147	175	190	fluoroquinolone	Chemical	D024841	Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.
BC8_BioRED_Task1_Doc147	332	340	bacteria	OrganismTaxon	2	Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.
BC8_BioRED_Task1_Doc147	438	446	warfarin	Chemical	D014859	While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.
BC8_BioRED_Task1_Doc147	451	463	levofloxacin	Chemical	D064704	While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.
BC8_BioRED_Task1_Doc147	506	518	levofloxacin	Chemical	D064704	While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.
BC8_BioRED_Task1_Doc147	578	586	warfarin	Chemical	D014859	While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.
BC8_BioRED_Task1_Doc147	617	625	bleeding	Disease	D006470	We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.
BC8_BioRED_Task1_Doc147	696	704	warfarin	Chemical	D014859	We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.
BC8_BioRED_Task1_Doc147	709	721	levofloxacin	Chemical	D064704	We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.
BC8_BioRED_Task1_Doc147	813	825	levofloxacin	Chemical	D064704	Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.
BC8_BioRED_Task1_Doc147	829	837	patients	OrganismTaxon	9606	Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.
BC8_BioRED_Task1_Doc147	845	853	warfarin	Chemical	D014859	Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.
BC8_BioRED_Task1_Doc148	21	26	L490R	SequenceVariant	rs80338886	Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.
BC8_BioRED_Task1_Doc148	31	36	V561X	SequenceVariant	rs80338887	Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.
BC8_BioRED_Task1_Doc148	45	67	transferrin receptor 2	Gene	7036	Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.
BC8_BioRED_Task1_Doc148	85	93	patients	OrganismTaxon	9606	Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.
BC8_BioRED_Task1_Doc148	99	114	hemochromatosis	Disease	D006432	Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis.
BC8_BioRED_Task1_Doc148	169	174	C282Y	SequenceVariant	rs1800562	BACKGROUND AND OBJECTIVES: The low prevalence of the C282Y mutation of the HFE gene in Japan means that the genetic background of hemochromatosis in Japanese patients remains unclear.
BC8_BioRED_Task1_Doc148	191	194	HFE	Gene	3077	BACKGROUND AND OBJECTIVES: The low prevalence of the C282Y mutation of the HFE gene in Japan means that the genetic background of hemochromatosis in Japanese patients remains unclear.
BC8_BioRED_Task1_Doc148	246	261	hemochromatosis	Disease	D006432	BACKGROUND AND OBJECTIVES: The low prevalence of the C282Y mutation of the HFE gene in Japan means that the genetic background of hemochromatosis in Japanese patients remains unclear.
BC8_BioRED_Task1_Doc148	274	282	patients	OrganismTaxon	9606	BACKGROUND AND OBJECTIVES: The low prevalence of the C282Y mutation of the HFE gene in Japan means that the genetic background of hemochromatosis in Japanese patients remains unclear.
BC8_BioRED_Task1_Doc148	339	347	patients	OrganismTaxon	9606	In a previous report, we showed that 3 patients from one family had an AVAQ 594-597 deletion of the transferrin receptor (TfR2) gene.
BC8_BioRED_Task1_Doc148	371	392	AVAQ 594-597 deletion	SequenceVariant	p|DEL|594_597|AVAQ	In a previous report, we showed that 3 patients from one family had an AVAQ 594-597 deletion of the transferrin receptor (TfR2) gene.
BC8_BioRED_Task1_Doc148	400	420	transferrin receptor	Gene	7036	In a previous report, we showed that 3 patients from one family had an AVAQ 594-597 deletion of the transferrin receptor (TfR2) gene.
BC8_BioRED_Task1_Doc148	422	426	TfR2	Gene	7036	In a previous report, we showed that 3 patients from one family had an AVAQ 594-597 deletion of the transferrin receptor (TfR2) gene.
BC8_BioRED_Task1_Doc148	457	461	TfR2	Gene	7036	This suggests that the TfR2 gene is involved in hemochromatosis in Japanese patients.
BC8_BioRED_Task1_Doc148	482	497	hemochromatosis	Disease	D006432	This suggests that the TfR2 gene is involved in hemochromatosis in Japanese patients.
BC8_BioRED_Task1_Doc148	510	518	patients	OrganismTaxon	9606	This suggests that the TfR2 gene is involved in hemochromatosis in Japanese patients.
BC8_BioRED_Task1_Doc148	545	553	patients	OrganismTaxon	9606	DESIGN AND METHODS: Nine patients clinically diagnosed with hemochromatosis were included in the study.
BC8_BioRED_Task1_Doc148	580	595	hemochromatosis	Disease	D006432	DESIGN AND METHODS: Nine patients clinically diagnosed with hemochromatosis were included in the study.
BC8_BioRED_Task1_Doc148	704	707	HFE	Gene	3077	The HFE and TfR2 genes were analyzed by sequencing the coding region and splicing sites.
BC8_BioRED_Task1_Doc148	712	716	TfR2	Gene	7036	The HFE and TfR2 genes were analyzed by sequencing the coding region and splicing sites.
BC8_BioRED_Task1_Doc148	829	832	HFE	Gene	3077	RESULTS: There were no mutations in the HFE gene.
BC8_BioRED_Task1_Doc148	846	850	TfR2	Gene	7036	In the TfR2 gene, 2 novel mutations, 1469T->G (L490R) and 1665delC (V561X), were found in 2 patients.
BC8_BioRED_Task1_Doc148	876	884	1469T->G	SequenceVariant	rs80338886	In the TfR2 gene, 2 novel mutations, 1469T->G (L490R) and 1665delC (V561X), were found in 2 patients.
BC8_BioRED_Task1_Doc148	886	891	L490R	SequenceVariant	rs80338886	In the TfR2 gene, 2 novel mutations, 1469T->G (L490R) and 1665delC (V561X), were found in 2 patients.
BC8_BioRED_Task1_Doc148	897	905	1665delC	SequenceVariant	rs80338887	In the TfR2 gene, 2 novel mutations, 1469T->G (L490R) and 1665delC (V561X), were found in 2 patients.
BC8_BioRED_Task1_Doc148	907	912	V561X	SequenceVariant	rs80338887	In the TfR2 gene, 2 novel mutations, 1469T->G (L490R) and 1665delC (V561X), were found in 2 patients.
BC8_BioRED_Task1_Doc148	931	939	patients	OrganismTaxon	9606	In the TfR2 gene, 2 novel mutations, 1469T->G (L490R) and 1665delC (V561X), were found in 2 patients.
BC8_BioRED_Task1_Doc148	960	964	714C	SequenceVariant	rs34242818	A known variation, 714C-> (I238M), was also found in the patient with L490R.
BC8_BioRED_Task1_Doc148	968	973	I238M	SequenceVariant	rs34242818	A known variation, 714C-> (I238M), was also found in the patient with L490R.
BC8_BioRED_Task1_Doc148	998	1005	patient	OrganismTaxon	9606	A known variation, 714C-> (I238M), was also found in the patient with L490R.
BC8_BioRED_Task1_Doc148	1011	1016	L490R	SequenceVariant	rs80338886	A known variation, 714C-> (I238M), was also found in the patient with L490R.
BC8_BioRED_Task1_Doc148	1022	1029	patient	OrganismTaxon	9606	The patient homozygous for both L490R and I238M presented with a mild manifestation of hemochromatosis at the age of 41 years.
BC8_BioRED_Task1_Doc148	1050	1055	L490R	SequenceVariant	rs80338886	The patient homozygous for both L490R and I238M presented with a mild manifestation of hemochromatosis at the age of 41 years.
BC8_BioRED_Task1_Doc148	1060	1065	I238M	SequenceVariant	rs34242818	The patient homozygous for both L490R and I238M presented with a mild manifestation of hemochromatosis at the age of 41 years.
BC8_BioRED_Task1_Doc148	1105	1120	hemochromatosis	Disease	D006432	The patient homozygous for both L490R and I238M presented with a mild manifestation of hemochromatosis at the age of 41 years.
BC8_BioRED_Task1_Doc148	1159	1168	cirrhotic	Disease	D008103	His liver was cirrhotic with parenchymal iron deposits and the result of a glucose tolerance test was compatible with diabetes mellitus.
BC8_BioRED_Task1_Doc148	1186	1190	iron	Chemical	D007501	His liver was cirrhotic with parenchymal iron deposits and the result of a glucose tolerance test was compatible with diabetes mellitus.
BC8_BioRED_Task1_Doc148	1220	1227	glucose	Chemical	D005947	His liver was cirrhotic with parenchymal iron deposits and the result of a glucose tolerance test was compatible with diabetes mellitus.
BC8_BioRED_Task1_Doc148	1263	1280	diabetes mellitus	Disease	D003920	His liver was cirrhotic with parenchymal iron deposits and the result of a glucose tolerance test was compatible with diabetes mellitus.
BC8_BioRED_Task1_Doc148	1286	1293	patient	OrganismTaxon	9606	The patient homozygous for V561X had severe iron overload with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.
BC8_BioRED_Task1_Doc148	1309	1314	V561X	SequenceVariant	rs80338887	The patient homozygous for V561X had severe iron overload with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.
BC8_BioRED_Task1_Doc148	1326	1339	iron overload	Disease	D019190	The patient homozygous for V561X had severe iron overload with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.
BC8_BioRED_Task1_Doc148	1358	1367	cirrhosis	Disease	D008103	The patient homozygous for V561X had severe iron overload with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.
BC8_BioRED_Task1_Doc148	1369	1386	diabetes mellitus	Disease	D003920	The patient homozygous for V561X had severe iron overload with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.
BC8_BioRED_Task1_Doc148	1391	1408	skin pigmentation	Disease	D010859	The patient homozygous for V561X had severe iron overload with the triad of cirrhosis, diabetes mellitus and skin pigmentation at the age of 58 years.
BC8_BioRED_Task1_Doc148	1518	1526	patients	OrganismTaxon	9606	INTERPRETATION AND CONCLUSIONS: Taken together with the previous report, 5 of our 12 patients with hemochromatosis manifesting in middle age had mutations in the TfR2 gene.
BC8_BioRED_Task1_Doc148	1532	1547	hemochromatosis	Disease	D006432	INTERPRETATION AND CONCLUSIONS: Taken together with the previous report, 5 of our 12 patients with hemochromatosis manifesting in middle age had mutations in the TfR2 gene.
BC8_BioRED_Task1_Doc148	1595	1599	TfR2	Gene	7036	INTERPRETATION AND CONCLUSIONS: Taken together with the previous report, 5 of our 12 patients with hemochromatosis manifesting in middle age had mutations in the TfR2 gene.
BC8_BioRED_Task1_Doc148	1612	1616	TfR2	Gene	7036	Thus, TfR2 plays a role in the pathogenesis of hemochromatosis in Japan.
BC8_BioRED_Task1_Doc148	1653	1668	hemochromatosis	Disease	D006432	Thus, TfR2 plays a role in the pathogenesis of hemochromatosis in Japan.
BC8_BioRED_Task1_Doc149	0	11	Tenomodulin	Gene	64102	Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study.
BC8_BioRED_Task1_Doc149	31	38	obesity	Disease	D009765	Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study.
BC8_BioRED_Task1_Doc149	43	51	diabetes	Disease	D003920	Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study.
BC8_BioRED_Task1_Doc149	70	78	diabetes	Disease	D003920	Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study.
BC8_BioRED_Task1_Doc149	205	215	overweight	Disease	D050177	We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT).
BC8_BioRED_Task1_Doc149	233	259	impaired glucose tolerance	Disease	D018149	We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT).
BC8_BioRED_Task1_Doc149	261	264	IGT	Disease	D018149	We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT).
BC8_BioRED_Task1_Doc149	313	324	tenomodulin	Gene	64102	One of the responding genes was X-chromosomal tenomodulin (TNMD), a putative angiogenesis inhibitor.
BC8_BioRED_Task1_Doc149	326	330	TNMD	Gene	64102	One of the responding genes was X-chromosomal tenomodulin (TNMD), a putative angiogenesis inhibitor.
BC8_BioRED_Task1_Doc149	472	481	adiposity	Disease	D009765	Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D).
BC8_BioRED_Task1_Doc149	483	490	glucose	Chemical	D005947	Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D).
BC8_BioRED_Task1_Doc149	519	534	type 2 diabetes	Disease	D003924	Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D).
BC8_BioRED_Task1_Doc149	536	539	T2D	Disease	D003924	Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D).
BC8_BioRED_Task1_Doc149	663	671	Diabetes	Disease	D003920	Seven single nucleotide polymorphisms from two different haploblocks were genotyped from 507 participants of the Finnish Diabetes Prevention Study (DPS).
BC8_BioRED_Task1_Doc149	804	813	adiposity	Disease	D009765	Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018).
BC8_BioRED_Task1_Doc149	817	822	women	OrganismTaxon	9606	Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018).
BC8_BioRED_Task1_Doc149	824	833	rs5966709	SequenceVariant	rs5966709	Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018).
BC8_BioRED_Task1_Doc149	835	844	rs4828037	SequenceVariant	rs4828037	Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018).
BC8_BioRED_Task1_Doc149	850	853	men	OrganismTaxon	9606	Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018).
BC8_BioRED_Task1_Doc149	855	865	rs11798018	SequenceVariant	rs11798018	Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018).
BC8_BioRED_Task1_Doc149	876	885	rs2073163	SequenceVariant	rs2073163	Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up.
BC8_BioRED_Task1_Doc149	890	899	rs1155794	SequenceVariant	rs1155794	Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up.
BC8_BioRED_Task1_Doc149	953	960	glucose	Chemical	D005947	Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up.
BC8_BioRED_Task1_Doc149	971	974	men	OrganismTaxon	9606	Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up.
BC8_BioRED_Task1_Doc149	1039	1048	rs2073162	SequenceVariant	rs2073162	The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1083	1086	IGT	Disease	D018149	The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1090	1093	T2D	Disease	D003924	The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1097	1100	men	OrganismTaxon	9606	The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1125	1128	T2D	Disease	D003924	The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T.
BC8_BioRED_Task1_Doc149	1221	1228	glucose	Chemical	D005947	The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T.
BC8_BioRED_Task1_Doc149	1282	1291	rs2073162	SequenceVariant	rs2073162	The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T.
BC8_BioRED_Task1_Doc149	1317	1326	rs2073163	SequenceVariant	rs2073163	The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T.
BC8_BioRED_Task1_Doc149	1356	1365	rs1155974	SequenceVariant	rs1155974	The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T.
BC8_BioRED_Task1_Doc149	1396	1400	TNMD	Gene	64102	These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1435	1444	adiposity	Disease	D009765	These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1459	1466	glucose	Chemical	D005947	These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1498	1501	IGT	Disease	D018149	These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1505	1508	T2D	Disease	D003924	These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.
BC8_BioRED_Task1_Doc149	1512	1515	men	OrganismTaxon	9606	These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.
BC8_BioRED_Task1_Doc150	15	24	galactose	Chemical	D005690	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
BC8_BioRED_Task1_Doc150	44	62	cognitive deficits	Disease	D003072	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
BC8_BioRED_Task1_Doc150	78	82	rats	OrganismTaxon	10116	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
BC8_BioRED_Task1_Doc150	122	136	streptozotocin	Chemical	D013311	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
BC8_BioRED_Task1_Doc150	188	196	dementia	Disease	D003704	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	209	228	Alzheimer's disease	Disease	D000544	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	230	233	sAD	Disease	D000544	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	278	294	insulin-receptor	Gene	24954	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	296	298	IR	Gene	24954	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	329	336	glucose	Chemical	D005947	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	351	358	glucose	Chemical	D005947	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	371	376	GLUT4	Gene	25139	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	391	398	glucose	Chemical	D005947	Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
BC8_BioRED_Task1_Doc150	461	472	d-galactose	Chemical	D005690	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway.
BC8_BioRED_Task1_Doc150	492	501	d-glucose	Chemical	D005947	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway.
BC8_BioRED_Task1_Doc150	542	549	insulin	Gene	24505	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway.
BC8_BioRED_Task1_Doc150	562	567	GLUT3	Gene	25551	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway.
BC8_BioRED_Task1_Doc150	613	620	glucose	Chemical	D005947	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway.
BC8_BioRED_Task1_Doc150	688	697	galactose	Chemical	D005690	Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested.
BC8_BioRED_Task1_Doc150	705	725	memory deterioration	Disease	D008569	Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested.
BC8_BioRED_Task1_Doc150	806	815	galactose	Chemical	D005690	Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested.
BC8_BioRED_Task1_Doc150	931	940	galactose	Chemical	D005690	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
BC8_BioRED_Task1_Doc150	970	988	cognitive deficits	Disease	D003072	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
BC8_BioRED_Task1_Doc150	992	1006	streptozotocin	Chemical	D013311	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
BC8_BioRED_Task1_Doc150	1016	1019	STZ	Chemical	D013311	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
BC8_BioRED_Task1_Doc150	1025	1028	rat	OrganismTaxon	10116	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
BC8_BioRED_Task1_Doc150	1038	1041	sAD	Disease	D000544	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
BC8_BioRED_Task1_Doc150	1131	1140	galactose	Chemical	D005690	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.
BC8_BioRED_Task1_Doc150	1183	1186	STZ	Chemical	D013311	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.
BC8_BioRED_Task1_Doc150	1249	1252	STZ	Chemical	D013311	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.
BC8_BioRED_Task1_Doc150	1265	1283	cognitive deficits	Disease	D003072	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.
BC8_BioRED_Task1_Doc150	1311	1320	galactose	Chemical	D005690	Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg/kg/day.
BC8_BioRED_Task1_Doc150	1344	1347	rat	OrganismTaxon	10116	Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg/kg/day.
BC8_BioRED_Task1_Doc150	1363	1372	galactose	Chemical	D005690	Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg/kg/day.
BC8_BioRED_Task1_Doc150	1432	1441	galactose	Chemical	D005690	Additionally, oral galactose administration led to the appearance of galactose in the blood.
BC8_BioRED_Task1_Doc150	1482	1491	galactose	Chemical	D005690	Additionally, oral galactose administration led to the appearance of galactose in the blood.
BC8_BioRED_Task1_Doc150	1522	1531	galactose	Chemical	D005690	The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose.
BC8_BioRED_Task1_Doc150	1657	1666	galactose	Chemical	D005690	The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose.
BC8_BioRED_Task1_Doc150	1678	1687	galactose	Chemical	D005690	Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
BC8_BioRED_Task1_Doc150	1810	1828	cognitive deficits	Disease	D003072	Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
BC8_BioRED_Task1_Doc150	1845	1867	glucose hypometabolism	Disease	D018149	Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
BC8_BioRED_Task1_Doc150	1871	1873	AD	Disease	D000544	Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.
BC8_BioRED_Task1_Doc151	44	49	HIV-1	OrganismTaxon	11676	Is the European spatial distribution of the HIV-1-resistant CCR5-Delta32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion?
BC8_BioRED_Task1_Doc151	60	64	CCR5	Gene	1234	Is the European spatial distribution of the HIV-1-resistant CCR5-Delta32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion?
BC8_BioRED_Task1_Doc151	65	72	Delta32	SequenceVariant	c|DEL||32	Is the European spatial distribution of the HIV-1-resistant CCR5-Delta32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion?
BC8_BioRED_Task1_Doc151	357	375	chemokine receptor	Gene	1234	We studied the possible effects of the expansion of ancient Mediterranean civilizations during the five centuries before and after Christ on the European distribution of the mutant allele for the chemokine receptor gene CCR5 which has a 32-bp deletion (CCR5-Delta32).
BC8_BioRED_Task1_Doc151	381	385	CCR5	Gene	1234	We studied the possible effects of the expansion of ancient Mediterranean civilizations during the five centuries before and after Christ on the European distribution of the mutant allele for the chemokine receptor gene CCR5 which has a 32-bp deletion (CCR5-Delta32).
BC8_BioRED_Task1_Doc151	398	412	32-bp deletion	SequenceVariant	c|DEL||32	We studied the possible effects of the expansion of ancient Mediterranean civilizations during the five centuries before and after Christ on the European distribution of the mutant allele for the chemokine receptor gene CCR5 which has a 32-bp deletion (CCR5-Delta32).
BC8_BioRED_Task1_Doc151	414	418	CCR5	Gene	1234	We studied the possible effects of the expansion of ancient Mediterranean civilizations during the five centuries before and after Christ on the European distribution of the mutant allele for the chemokine receptor gene CCR5 which has a 32-bp deletion (CCR5-Delta32).
BC8_BioRED_Task1_Doc151	419	426	Delta32	SequenceVariant	c|DEL||32	We studied the possible effects of the expansion of ancient Mediterranean civilizations during the five centuries before and after Christ on the European distribution of the mutant allele for the chemokine receptor gene CCR5 which has a 32-bp deletion (CCR5-Delta32).
BC8_BioRED_Task1_Doc151	486	490	CCR5	Gene	1234	There is a strong evidence for the unitary origin of the CCR5-Delta32 mutation, this it is found principally in Europe and Western Asia, with generally a north-south downhill cline frequency.
BC8_BioRED_Task1_Doc151	491	498	Delta32	SequenceVariant	c|DEL||32	There is a strong evidence for the unitary origin of the CCR5-Delta32 mutation, this it is found principally in Europe and Western Asia, with generally a north-south downhill cline frequency.
BC8_BioRED_Task1_Doc151	679	694	HIV-1 infection	Disease	D015658	Homozygous carriers of this mutation show a resistance to HIV-1 infection and a slower progression towards AIDS.
BC8_BioRED_Task1_Doc151	728	732	AIDS	Disease	D000163	Homozygous carriers of this mutation show a resistance to HIV-1 infection and a slower progression towards AIDS.
BC8_BioRED_Task1_Doc151	743	746	HIV	OrganismTaxon	11676	However, HIV has clearly emerged too recently to have been the selective force on CCR5.
BC8_BioRED_Task1_Doc151	816	820	CCR5	Gene	1234	However, HIV has clearly emerged too recently to have been the selective force on CCR5.
BC8_BioRED_Task1_Doc151	1511	1526	West Nile virus	OrganismTaxon	11082	In addition, in West Nile virus pathogenesis, CCR5 plays an antimicrobial role showing that host genetic factors are highly pathogen-specific.
BC8_BioRED_Task1_Doc151	1541	1545	CCR5	Gene	1234	In addition, in West Nile virus pathogenesis, CCR5 plays an antimicrobial role showing that host genetic factors are highly pathogen-specific.
BC8_BioRED_Task1_Doc151	2047	2057	infections	Disease	D007239	Indeed, as gene flows from colonizers to European native populations were extremely low, the mutational changes might be associated with vulnerability to imported infections.
BC8_BioRED_Task1_Doc152	0	32	Bradykinin receptors antagonists	Chemical	D065168	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	37	69	nitric oxide synthase inhibitors	Chemical	C080122,C090663,D019335	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	73	84	vincristine	Chemical	D014750	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	89	103	streptozotocin	Chemical	D013311	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	112	124	hyperalgesia	Disease	D006930	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	145	164	diabetic neuropathy	Disease	D003929	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	165	168	rat	OrganismTaxon	10116	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
BC8_BioRED_Task1_Doc152	231	255	constitutive NO synthase	Gene	24600	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	257	264	L-NOArg	Chemical	D019335	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	317	338	inducible NO synthase	Gene	24599	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	340	345	L-NIL	Chemical	C090663	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	400	420	neuronal NO synthase	Gene	24598	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	422	426	7-NI	Chemical	C080122	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	498	517	B2 and B1 receptors	Gene	25245,81509	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	519	559	D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin	Chemical	C065679	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	561	568	HOE 140	Chemical	C065679	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	588	605	des Arg10 HOE 140	Chemical	C078665	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	648	724	diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy	Disease	D003929,D010523	PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.
BC8_BioRED_Task1_Doc152	767	771	pain	Disease	D010146	METHODS: The changes in pain thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto.
BC8_BioRED_Task1_Doc152	969	989	bradykinin receptors	Gene	25245,81509	RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.
BC8_BioRED_Task1_Doc152	994	1015	inducible NO synthase	Gene	24599	RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.
BC8_BioRED_Task1_Doc152	1024	1044	neuronal NO synthase	Gene	24598	RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.
BC8_BioRED_Task1_Doc152	1062	1083	diabetic hyperalgesia	Disease	D003920,D006930	RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.
BC8_BioRED_Task1_Doc152	1103	1110	L-NOArg	Chemical	D019335	Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.
BC8_BioRED_Task1_Doc152	1115	1120	L-NIL	Chemical	C090663	Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.
BC8_BioRED_Task1_Doc152	1129	1133	7-NI	Chemical	C080122	Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.
BC8_BioRED_Task1_Doc152	1190	1197	HOE 140	Chemical	C065679	Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.
BC8_BioRED_Task1_Doc152	1202	1219	des Arg10 HOE 140	Chemical	C078665	Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.
BC8_BioRED_Task1_Doc152	1261	1282	inducible NO synthase	Gene	24599	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
BC8_BioRED_Task1_Doc152	1287	1307	neuronal NO synthase	Gene	24598	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
BC8_BioRED_Task1_Doc152	1330	1340	bradykinin	Gene	3827	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
BC8_BioRED_Task1_Doc152	1357	1369	hyperalgesia	Disease	D006930	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
BC8_BioRED_Task1_Doc152	1382	1393	vincristine	Chemical	D014750	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
BC8_BioRED_Task1_Doc152	1405	1412	L-NOArg	Chemical	D019335	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
BC8_BioRED_Task1_Doc152	1417	1421	7-NI	Chemical	C080122	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
BC8_BioRED_Task1_Doc152	1430	1435	L-NIL	Chemical	C090663	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
BC8_BioRED_Task1_Doc152	1475	1482	HOE 140	Chemical	C065679	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
BC8_BioRED_Task1_Doc152	1486	1502	des-Arg10HOE 140	Chemical	C078665	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
BC8_BioRED_Task1_Doc152	1506	1522	toxic neuropathy	Disease	D010523	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
BC8_BioRED_Task1_Doc152	1575	1594	B1 and B2 receptors	Gene	25245,81509	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.
BC8_BioRED_Task1_Doc152	1654	1683	diabetic and toxic neuropathy	Disease	D003929,D010523	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.
BC8_BioRED_Task1_Doc152	1688	1702	streptozotocin	Chemical	D013311	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1711	1723	hyperalgesia	Disease	D006930	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1725	1746	inducible NO synthase	Gene	24599	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1790	1800	bradykinin	Gene	3827	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1813	1824	vincristine	Chemical	D014750	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1833	1845	hyperalgesia	Disease	D006930	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1846	1856	bradykinin	Gene	3827	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1876	1896	neuronal NO synthase	Gene	24598	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
BC8_BioRED_Task1_Doc152	1962	1993	bradykinin receptor antagonists	Chemical	D065168	Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.
BC8_BioRED_Task1_Doc152	1998	2020	NO synthase inhibitors	Chemical	C080122,C090663,D019335	Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.
BC8_BioRED_Task1_Doc152	2056	2072	neuropathic pain	Disease	D009437	Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.
BC8_BioRED_Task1_Doc153	21	34	carbamazepine	Chemical	D002220	Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.
BC8_BioRED_Task1_Doc153	39	49	vigabatrin	Chemical	D020888	Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.
BC8_BioRED_Task1_Doc153	61	77	absence seizures	Disease	D004832	Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.
BC8_BioRED_Task1_Doc153	79	92	Carbamazepine	Chemical	D002220	Carbamazepine and vigabatrin are contraindicated in typical absence seizures.
BC8_BioRED_Task1_Doc153	97	107	vigabatrin	Chemical	D020888	Carbamazepine and vigabatrin are contraindicated in typical absence seizures.
BC8_BioRED_Task1_Doc153	139	155	absence seizures	Disease	D004832	Carbamazepine and vigabatrin are contraindicated in typical absence seizures.
BC8_BioRED_Task1_Doc153	271	284	carbamazepine	Chemical	D002220	Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.
BC8_BioRED_Task1_Doc153	324	334	Vigabatrin	Chemical	D020888	Vigabatrin was also used in the treatment of two children.
BC8_BioRED_Task1_Doc153	445	458	carbamazepine	Chemical	D002220	Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.
BC8_BioRED_Task1_Doc153	486	501	myoclonic jerks	Disease	D009207	Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.
BC8_BioRED_Task1_Doc153	535	548	carbamazepine	Chemical	D002220	Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.
BC8_BioRED_Task1_Doc153	595	605	vigabatrin	Chemical	D020888	Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment.
BC8_BioRED_Task1_Doc153	694	710	sodium valproate	Chemical	D014635	Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.
BC8_BioRED_Task1_Doc153	712	723	lamotrigine	Chemical	D000077213	Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.
BC8_BioRED_Task1_Doc153	728	740	ethosuximide	Chemical	D005013	Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.
BC8_BioRED_Task1_Doc154	0	12	Azathioprine	Chemical	D001379	Azathioprine-induced suicidal erythrocyte death.
BC8_BioRED_Task1_Doc154	61	73	Azathioprine	Chemical	D001379	BACKGROUND: Azathioprine is widely used as an immunosuppressive drug.
BC8_BioRED_Task1_Doc154	139	151	azathioprine	Chemical	D001379	The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.
BC8_BioRED_Task1_Doc154	160	166	anemia	Disease	D000740	The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.
BC8_BioRED_Task1_Doc154	197	220	bone marrow suppression	Disease	D001855	The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.
BC8_BioRED_Task1_Doc154	237	243	anemia	Disease	D000740	Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.
BC8_BioRED_Task1_Doc154	353	371	phosphatidylserine	Chemical	D010718	Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.
BC8_BioRED_Task1_Doc154	373	375	PS	Chemical	D010718	Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.
BC8_BioRED_Task1_Doc154	477	489	azathioprine	Chemical	D001379	METHODS: The present experiments explored whether azathioprine influences eryptosis.
BC8_BioRED_Task1_Doc154	525	534	annexin V	Gene	308	According to annexin V binding, erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine.
BC8_BioRED_Task1_Doc154	562	570	patients	OrganismTaxon	9606	According to annexin V binding, erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine.
BC8_BioRED_Task1_Doc154	611	613	PS	Chemical	D010718	According to annexin V binding, erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine.
BC8_BioRED_Task1_Doc154	655	667	azathioprine	Chemical	D001379	According to annexin V binding, erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine.
BC8_BioRED_Task1_Doc154	699	703	Ca2+	Chemical	D002118	In a second series, cytosolic Ca2+ activity (Fluo3 fluorescence), cell volume (forward scatter), and PS-exposure (annexin V binding) were determined by FACS analysis in erythrocytes from healthy volunteers.
BC8_BioRED_Task1_Doc154	714	719	Fluo3	Chemical	C059715	In a second series, cytosolic Ca2+ activity (Fluo3 fluorescence), cell volume (forward scatter), and PS-exposure (annexin V binding) were determined by FACS analysis in erythrocytes from healthy volunteers.
BC8_BioRED_Task1_Doc154	770	772	PS	Chemical	D010718	In a second series, cytosolic Ca2+ activity (Fluo3 fluorescence), cell volume (forward scatter), and PS-exposure (annexin V binding) were determined by FACS analysis in erythrocytes from healthy volunteers.
BC8_BioRED_Task1_Doc154	783	792	annexin V	Gene	308	In a second series, cytosolic Ca2+ activity (Fluo3 fluorescence), cell volume (forward scatter), and PS-exposure (annexin V binding) were determined by FACS analysis in erythrocytes from healthy volunteers.
BC8_BioRED_Task1_Doc154	897	909	azathioprine	Chemical	D001379	RESULTS: Exposure to azathioprine (> or =2 microg/mL) for 48 hours increased cytosolic Ca2+ activity and annexin V binding and decreased forward scatter.
BC8_BioRED_Task1_Doc154	963	967	Ca2+	Chemical	D002118	RESULTS: Exposure to azathioprine (> or =2 microg/mL) for 48 hours increased cytosolic Ca2+ activity and annexin V binding and decreased forward scatter.
BC8_BioRED_Task1_Doc154	981	990	annexin V	Gene	308	RESULTS: Exposure to azathioprine (> or =2 microg/mL) for 48 hours increased cytosolic Ca2+ activity and annexin V binding and decreased forward scatter.
BC8_BioRED_Task1_Doc154	1044	1056	azathioprine	Chemical	D001379	The effect of azathioprine on both annexin V binding and forward scatter was significantly blunted in the nominal absence of extracellular Ca2+.
BC8_BioRED_Task1_Doc154	1065	1074	annexin V	Gene	308	The effect of azathioprine on both annexin V binding and forward scatter was significantly blunted in the nominal absence of extracellular Ca2+.
BC8_BioRED_Task1_Doc154	1169	1173	Ca2+	Chemical	D002118	The effect of azathioprine on both annexin V binding and forward scatter was significantly blunted in the nominal absence of extracellular Ca2+.
BC8_BioRED_Task1_Doc154	1188	1200	Azathioprine	Chemical	D001379	CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.
BC8_BioRED_Task1_Doc154	1275	1287	azathioprine	Chemical	D001379	CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.
BC8_BioRED_Task1_Doc154	1296	1302	anemia	Disease	D000740	CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.
BC8_BioRED_Task1_Doc155	0	9	Spirulina	OrganismTaxon	551299	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	10	29	lipopolysaccharides	Chemical	D008070	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	38	43	tumor	Disease	D009369	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	56	76	Toll-like receptor 4	Gene	21898	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	131	145	interleukin-17	Gene	16171	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	146	160	interleukin-23	Gene	83430	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	164	176	interferon-g	Gene	15978	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	220	239	interleukin (IL)-17	Gene	16171,3605	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	267	272	tumor	Disease	D009369	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	288	294	humans	OrganismTaxon	9606	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	302	306	mice	OrganismTaxon	10090	Spirulina lipopolysaccharides inhibit tumor growth in a Toll-like receptor 4-dependent manner by altering the cytokine milieu from interleukin-17/interleukin-23 to interferon-g. Th17 cells and the cytokine they produce, interleukin (IL)-17, play an important role in tumor progression in humans and in mice.
BC8_BioRED_Task1_Doc155	308	312	IL-6	Gene	16193	IL-6 and IL-23 are critical cytokines for the differentiation and propagation of Th17 cells, respectively.
BC8_BioRED_Task1_Doc155	317	322	IL-23	Gene	83430	IL-6 and IL-23 are critical cytokines for the differentiation and propagation of Th17 cells, respectively.
BC8_BioRED_Task1_Doc155	425	444	lipopolysaccharides	Chemical	D008070	Bacterial lipopolysaccharides (LPS) are known to stimulate immune cells to produce such inflammatory cytokines.
BC8_BioRED_Task1_Doc155	446	449	LPS	Chemical	D008070	Bacterial lipopolysaccharides (LPS) are known to stimulate immune cells to produce such inflammatory cytokines.
BC8_BioRED_Task1_Doc155	503	525	inflammatory cytokines	Gene	-	Bacterial lipopolysaccharides (LPS) are known to stimulate immune cells to produce such inflammatory cytokines.
BC8_BioRED_Task1_Doc155	539	555	Escherichia coli	OrganismTaxon	562	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	557	564	E. coli	OrganismTaxon	562	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	566	569	LPS	Chemical	D008070	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	571	574	LPS	Chemical	D008070	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	580	589	Spirulina	OrganismTaxon	551299	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	598	606	toxicity	Disease	D064420	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	648	652	IL-6	Gene	16193	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	657	662	IL-23	Gene	83430	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	666	670	mice	OrganismTaxon	10090	Contrary to Escherichia coli (E. coli) LPS, LPS from Spirulina has low toxicity and barely induces in vivo production of IL-6 and IL-23 in mice.
BC8_BioRED_Task1_Doc155	709	718	Spirulina	OrganismTaxon	551299	We examined the antitumor effects of Spirulina LPS compared to E. coli LPS in an MH134 hepatoma model.
BC8_BioRED_Task1_Doc155	719	722	LPS	Chemical	D008070	We examined the antitumor effects of Spirulina LPS compared to E. coli LPS in an MH134 hepatoma model.
BC8_BioRED_Task1_Doc155	735	742	E. coli	OrganismTaxon	562	We examined the antitumor effects of Spirulina LPS compared to E. coli LPS in an MH134 hepatoma model.
BC8_BioRED_Task1_Doc155	743	746	LPS	Chemical	D008070	We examined the antitumor effects of Spirulina LPS compared to E. coli LPS in an MH134 hepatoma model.
BC8_BioRED_Task1_Doc155	753	758	MH134	CellLine	CVCL_8111	We examined the antitumor effects of Spirulina LPS compared to E. coli LPS in an MH134 hepatoma model.
BC8_BioRED_Task1_Doc155	759	767	hepatoma	Disease	D006528	We examined the antitumor effects of Spirulina LPS compared to E. coli LPS in an MH134 hepatoma model.
BC8_BioRED_Task1_Doc155	793	802	Spirulina	OrganismTaxon	551299	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	803	806	LPS	Chemical	D008070	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	818	823	tumor	Disease	D009369	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	842	846	mice	OrganismTaxon	10090	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	859	879	Toll-like receptor 4	Gene	21898	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	881	885	TLR4	Gene	21898	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	902	906	mice	OrganismTaxon	10090	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	936	941	IL-17	Gene	16171	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	946	951	IL-23	Gene	83430	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	970	988	interferon (IFN)-g	Gene	15978	Administration of Spirulina LPS suppressed tumor growth in C3H/HeN mice, but not in Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice, by reducing serum levels of IL-17 and IL-23, while increasing interferon (IFN)-g levels.
BC8_BioRED_Task1_Doc155	1024	1029	IFN-g	Gene	15978	The antitumor activity and IFN-g production were mediated by T cells.
BC8_BioRED_Task1_Doc155	1110	1119	Spirulina	OrganismTaxon	551299	Moreover, in vitro experiments showed that Spirulina LPS impaired the antigen-presenting function that supports the generation of IL-17-producing cells in a toll-like receptor (TLR)4-dependent manner.
BC8_BioRED_Task1_Doc155	1120	1123	LPS	Chemical	D008070	Moreover, in vitro experiments showed that Spirulina LPS impaired the antigen-presenting function that supports the generation of IL-17-producing cells in a toll-like receptor (TLR)4-dependent manner.
BC8_BioRED_Task1_Doc155	1197	1202	IL-17	Gene	16171	Moreover, in vitro experiments showed that Spirulina LPS impaired the antigen-presenting function that supports the generation of IL-17-producing cells in a toll-like receptor (TLR)4-dependent manner.
BC8_BioRED_Task1_Doc155	1224	1249	toll-like receptor (TLR)4	Gene	21898	Moreover, in vitro experiments showed that Spirulina LPS impaired the antigen-presenting function that supports the generation of IL-17-producing cells in a toll-like receptor (TLR)4-dependent manner.
BC8_BioRED_Task1_Doc155	1295	1300	IL-17	Gene	16171	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1313	1318	tumor	Disease	D009369	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1335	1339	mice	OrganismTaxon	10090	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1358	1367	Spirulina	OrganismTaxon	551299	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1368	1371	LPS	Chemical	D008070	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1392	1397	tumor	Disease	D009369	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1419	1424	IFN-g	Gene	15978	Of note, injection of anti-IL-17 antibody in tumor-bearing C3H/HeN mice in the absence of Spirulina LPS markedly suppressed tumor growth and augmented IFN-g responses.
BC8_BioRED_Task1_Doc155	1478	1483	IFN-g	Gene	15978	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1488	1493	IL-17	Gene	16171	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1494	1499	IL-23	Gene	83430	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1544	1549	tumor	Disease	D009369	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1569	1578	Spirulina	OrganismTaxon	551299	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1579	1582	LPS	Chemical	D008070	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1612	1617	IFN-g	Gene	15978	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1618	1623	IL-17	Gene	16171	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1624	1629	IL-23	Gene	83430	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1643	1648	IFN-g	Gene	15978	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1676	1681	tumor	Disease	D009369	Thus, our results support the notion that IFN-g and IL-17/IL-23 mutually regulate Th17 and Th1 responses in tumor-bearing hosts, and Spirulina LPS modulates the balance of the IFN-g-IL-17/IL-23 axis towards IFN-g production, which leads to tumor inhibition.
BC8_BioRED_Task1_Doc155	1707	1716	Spirulina	OrganismTaxon	551299	Furthermore, Spirulina LPS effectively inhibited the spontaneous development of mammary tumors.
BC8_BioRED_Task1_Doc155	1717	1720	LPS	Chemical	D008070	Furthermore, Spirulina LPS effectively inhibited the spontaneous development of mammary tumors.
BC8_BioRED_Task1_Doc155	1774	1788	mammary tumors	Disease	D001943	Furthermore, Spirulina LPS effectively inhibited the spontaneous development of mammary tumors.
BC8_BioRED_Task1_Doc155	1852	1855	TLR	Gene	21898	This study has important implications for the exploitation of TLR-based immunomodulators for cancer immunotherapy.
BC8_BioRED_Task1_Doc155	1883	1889	cancer	Disease	D009369	This study has important implications for the exploitation of TLR-based immunomodulators for cancer immunotherapy.
BC8_BioRED_Task1_Doc156	0	8	Nicotine	Chemical	D009538	Nicotine antagonizes caffeine- but not pentylenetetrazole-induced anxiogenic effect in mice.
BC8_BioRED_Task1_Doc156	21	29	caffeine	Chemical	D002110	Nicotine antagonizes caffeine- but not pentylenetetrazole-induced anxiogenic effect in mice.
BC8_BioRED_Task1_Doc156	39	57	pentylenetetrazole	Chemical	D010433	Nicotine antagonizes caffeine- but not pentylenetetrazole-induced anxiogenic effect in mice.
BC8_BioRED_Task1_Doc156	66	83	anxiogenic effect	Disease	D001008	Nicotine antagonizes caffeine- but not pentylenetetrazole-induced anxiogenic effect in mice.
BC8_BioRED_Task1_Doc156	87	91	mice	OrganismTaxon	10090	Nicotine antagonizes caffeine- but not pentylenetetrazole-induced anxiogenic effect in mice.
BC8_BioRED_Task1_Doc156	104	112	Nicotine	Chemical	D009538	RATIONALE: Nicotine and caffeine are widely consumed licit psychoactive drugs worldwide.
BC8_BioRED_Task1_Doc156	117	125	caffeine	Chemical	D002110	RATIONALE: Nicotine and caffeine are widely consumed licit psychoactive drugs worldwide.
BC8_BioRED_Task1_Doc156	152	170	psychoactive drugs	Chemical	D011619	RATIONALE: Nicotine and caffeine are widely consumed licit psychoactive drugs worldwide.
BC8_BioRED_Task1_Doc156	409	416	anxiety	Disease	D001008	Although some studies in experimental animals indicate clear pharmacological interactions between them, no studies have shown a specific interaction on anxiety responses.
BC8_BioRED_Task1_Doc156	486	494	nicotine	Chemical	D009538	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
BC8_BioRED_Task1_Doc156	498	505	anxiety	Disease	D001008	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
BC8_BioRED_Task1_Doc156	517	525	caffeine	Chemical	D002110	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
BC8_BioRED_Task1_Doc156	538	553	anxiogenic drug	Chemical	D014151	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
BC8_BioRED_Task1_Doc156	555	573	pentylenetetrazole	Chemical	D010433	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
BC8_BioRED_Task1_Doc156	578	582	mice	OrganismTaxon	10090	OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
BC8_BioRED_Task1_Doc156	663	670	anxiety	Disease	D001008	The elevated plus-maze (EPM) test was used to evaluate the effects of drugs on anxiety.
BC8_BioRED_Task1_Doc156	706	710	mice	OrganismTaxon	10090	METHODS: Adult male Swiss Webster mice (25-32 g) were given nicotine (0.05-0.25 mg/kg s.c.) or saline 10 min before caffeine (70 mg/kg i.p.)
BC8_BioRED_Task1_Doc156	732	740	nicotine	Chemical	D009538	METHODS: Adult male Swiss Webster mice (25-32 g) were given nicotine (0.05-0.25 mg/kg s.c.) or saline 10 min before caffeine (70 mg/kg i.p.)
BC8_BioRED_Task1_Doc156	788	796	caffeine	Chemical	D002110	METHODS: Adult male Swiss Webster mice (25-32 g) were given nicotine (0.05-0.25 mg/kg s.c.) or saline 10 min before caffeine (70 mg/kg i.p.)
BC8_BioRED_Task1_Doc156	816	834	pentylenetetrazole	Chemical	D010433	or pentylenetetrazole (15 and 30 mg/kg i.p.)
BC8_BioRED_Task1_Doc156	884	888	mice	OrganismTaxon	10090	After 15 min, mice were evaluated for their open- and closed-arm time and entries on the EPM for a 10-min session.
BC8_BioRED_Task1_Doc156	1104	1112	Nicotine	Chemical	D009538	RESULTS: Nicotine (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas caffeine (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an anxiogenic effect, apparent with decreases in open-arm time and entry.
BC8_BioRED_Task1_Doc156	1202	1210	caffeine	Chemical	D002110	RESULTS: Nicotine (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas caffeine (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an anxiogenic effect, apparent with decreases in open-arm time and entry.
BC8_BioRED_Task1_Doc156	1226	1244	pentylenetetrazole	Chemical	D010433	RESULTS: Nicotine (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas caffeine (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an anxiogenic effect, apparent with decreases in open-arm time and entry.
BC8_BioRED_Task1_Doc156	1268	1285	anxiogenic effect	Disease	D001008	RESULTS: Nicotine (0.05-0.25 mg/kg) itself did not produce any significant effect in the EPM test, whereas caffeine (70 mg/kg) and pentylenetetrazole (30 mg/kg) produced an anxiogenic effect, apparent with decreases in open-arm time and entry.
BC8_BioRED_Task1_Doc156	1339	1347	Nicotine	Chemical	D009538	Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
BC8_BioRED_Task1_Doc156	1386	1394	caffeine	Chemical	D002110	Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
BC8_BioRED_Task1_Doc156	1404	1422	pentylenetetrazole	Chemical	D010433	Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
BC8_BioRED_Task1_Doc156	1431	1438	anxiety	Disease	D001008	Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.
BC8_BioRED_Task1_Doc156	1606	1614	nicotine	Chemical	D009538	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
BC8_BioRED_Task1_Doc156	1618	1626	caffeine	Chemical	D002110	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
BC8_BioRED_Task1_Doc156	1635	1642	anxiety	Disease	D001008	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
BC8_BioRED_Task1_Doc156	1658	1666	caffeine	Chemical	D002110	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
BC8_BioRED_Task1_Doc156	1781	1789	nicotine	Chemical	D009538	Thus, it may extend the current findings on the interaction between nicotine and caffeine.
BC8_BioRED_Task1_Doc156	1794	1802	caffeine	Chemical	D002110	Thus, it may extend the current findings on the interaction between nicotine and caffeine.
BC8_BioRED_Task1_Doc157	0	30	Interferon regulatory factor 6	Gene	3664	Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.
BC8_BioRED_Task1_Doc157	32	36	IRF6	Gene	3664	Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.
BC8_BioRED_Task1_Doc157	42	77	fibroblast growth factor receptor 1	Gene	2260	Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.
BC8_BioRED_Task1_Doc157	79	84	FGFR1	Gene	2260	Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.
BC8_BioRED_Task1_Doc157	100	105	human	OrganismTaxon	9606	Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.
BC8_BioRED_Task1_Doc157	106	120	tooth agenesis	Disease	D000848	Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis.
BC8_BioRED_Task1_Doc157	301	323	craniofacial syndromes	Disease	D019465	We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis.
BC8_BioRED_Task1_Doc157	325	330	FGFR1	Gene	2260	We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis.
BC8_BioRED_Task1_Doc157	335	339	IRF6	Gene	3664	We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis.
BC8_BioRED_Task1_Doc157	383	397	tooth agenesis	Disease	D000848	We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis.
BC8_BioRED_Task1_Doc157	856	860	IRF6	Gene	3664	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	900	916	orofacial clefts	Disease	C566121	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	942	947	human	OrganismTaxon	9606	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	948	962	tooth agenesis	Disease	D000848	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	964	972	rs861019	SequenceVariant	rs861019	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	985	995	rs17015215	SequenceVariant	rs17015215	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	996	1001	V274I	SequenceVariant	rs2235371	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	1015	1021	rs7802	SequenceVariant	rs7802	The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004).
BC8_BioRED_Task1_Doc157	1048	1052	IRF6	Gene	3664	Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes.
BC8_BioRED_Task1_Doc157	1059	1106	Van der Woude and popliteal pterygium syndromes	Disease	C536528,C562509	Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes.
BC8_BioRED_Task1_Doc157	1179	1190	oral clefts	Disease	D002972	The craniofacial phenotypic characteristics of these syndromes include oral clefts and preferential tooth agenesis of incisors and premolars, besides pits on the lower lips.
BC8_BioRED_Task1_Doc157	1208	1222	tooth agenesis	Disease	D000848	The craniofacial phenotypic characteristics of these syndromes include oral clefts and preferential tooth agenesis of incisors and premolars, besides pits on the lower lips.
BC8_BioRED_Task1_Doc157	1258	1280	pits on the lower lips	Disease	C536528,C562509	The craniofacial phenotypic characteristics of these syndromes include oral clefts and preferential tooth agenesis of incisors and premolars, besides pits on the lower lips.
BC8_BioRED_Task1_Doc157	1353	1358	FGFR1	Gene	2260	Also it appears that preferential premolar agenesis is associated with FGFR1 (P = 0.014) and IRF6 (P = 0.002) markers.
BC8_BioRED_Task1_Doc157	1375	1379	IRF6	Gene	3664	Also it appears that preferential premolar agenesis is associated with FGFR1 (P = 0.014) and IRF6 (P = 0.002) markers.
BC8_BioRED_Task1_Doc157	1459	1463	IRF6	Gene	3664	There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).
BC8_BioRED_Task1_Doc157	1488	1492	MSX1	Gene	4487	There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).
BC8_BioRED_Task1_Doc157	1520	1524	TGFA	Gene	7039	There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).
BC8_BioRED_Task1_Doc158	0	7	Glucose	Chemical	D005947	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
BC8_BioRED_Task1_Doc158	22	30	patients	OrganismTaxon	9606	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
BC8_BioRED_Task1_Doc158	36	49	schizophrenia	Disease	D012559	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
BC8_BioRED_Task1_Doc158	72	92	antipsychotic agents	Chemical	D014150	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
BC8_BioRED_Task1_Doc158	127	134	glucose	Chemical	D005947	Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
BC8_BioRED_Task1_Doc158	223	240	diabetes mellitus	Disease	D003920	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
BC8_BioRED_Task1_Doc158	262	270	patients	OrganismTaxon	9606	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
BC8_BioRED_Task1_Doc158	276	289	schizophrenia	Disease	D012559	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
BC8_BioRED_Task1_Doc158	320	340	antipsychotic agents	Chemical	D014150	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
BC8_BioRED_Task1_Doc158	408	415	glucose	Chemical	D005947	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
BC8_BioRED_Task1_Doc158	471	479	diabetes	Disease	D003920	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
BC8_BioRED_Task1_Doc158	538	547	clozapine	Chemical	D003024	OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.
BC8_BioRED_Task1_Doc158	552	562	olanzapine	Chemical	C076029	OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.
BC8_BioRED_Task1_Doc158	568	579	risperidone	Chemical	D018967	OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.
BC8_BioRED_Task1_Doc158	619	626	glucose	Chemical	D005947	OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.
BC8_BioRED_Task1_Doc158	695	703	patients	OrganismTaxon	9606	DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
BC8_BioRED_Task1_Doc158	709	722	schizophrenia	Disease	D012559	DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
BC8_BioRED_Task1_Doc158	772	779	glucose	Chemical	D005947	DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
BC8_BioRED_Task1_Doc158	969	977	Patients	OrganismTaxon	9606	Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test.
BC8_BioRED_Task1_Doc158	1069	1076	glucose	Chemical	D005947	Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test.
BC8_BioRED_Task1_Doc158	1127	1140	schizophrenia	Disease	D012559	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
BC8_BioRED_Task1_Doc158	1144	1168	schizoaffective disorder	Disease	D011618	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
BC8_BioRED_Task1_Doc158	1221	1230	clozapine	Chemical	D003024	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
BC8_BioRED_Task1_Doc158	1232	1242	olanzapine	Chemical	C076029	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
BC8_BioRED_Task1_Doc158	1247	1258	risperidone	Chemical	D018967	Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
BC8_BioRED_Task1_Doc158	1329	1336	glucose	Chemical	D005947	MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
BC8_BioRED_Task1_Doc158	1355	1362	insulin	Chemical	D007328	MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
BC8_BioRED_Task1_Doc158	1430	1448	insulin resistance	Disease	D007333	MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
BC8_BioRED_Task1_Doc158	1454	1461	glucose	Chemical	D005947	MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
BC8_BioRED_Task1_Doc158	1553	1572	antipsychotic agent	Chemical	D014150	RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (risperidone).
BC8_BioRED_Task1_Doc158	1599	1608	clozapine	Chemical	D003024	RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (risperidone).
BC8_BioRED_Task1_Doc158	1633	1643	olanzapine	Chemical	C076029	RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (risperidone).
BC8_BioRED_Task1_Doc158	1665	1676	risperidone	Chemical	D018967	RESULTS: The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (risperidone).
BC8_BioRED_Task1_Doc158	1693	1700	insulin	Chemical	D007328	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1764	1773	clozapine	Chemical	D003024	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1774	1784	olanzapine	Chemical	C076029	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1785	1796	risperidone	Chemical	D018967	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1835	1844	clozapine	Chemical	D003024	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1849	1860	risperidone	Chemical	D018967	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1889	1899	olanzapine	Chemical	C076029	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	1904	1915	risperidone	Chemical	D018967	Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
BC8_BioRED_Task1_Doc158	2043	2052	clozapine	Chemical	D003024	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2053	2063	olanzapine	Chemical	C076029	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2064	2075	risperidone	Chemical	D018967	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2105	2114	clozapine	Chemical	D003024	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2119	2129	olanzapine	Chemical	C076029	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2153	2171	insulin resistance	Disease	D007333	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2217	2228	risperidone	Chemical	D018967	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2230	2239	clozapine	Chemical	D003024	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2243	2254	risperidone	Chemical	D018967	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2279	2289	olanzapine	Chemical	C076029	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2293	2304	risperidone	Chemical	D018967	There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
BC8_BioRED_Task1_Doc158	2377	2395	insulin resistance	Disease	D007333	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2462	2471	clozapine	Chemical	D003024	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2472	2482	olanzapine	Chemical	C076029	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2483	2494	risperidone	Chemical	D018967	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2497	2506	clozapine	Chemical	D003024	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2510	2521	risperidone	Chemical	D018967	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2547	2557	olanzapine	Chemical	C076029	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2561	2572	risperidone	Chemical	D018967	The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
BC8_BioRED_Task1_Doc158	2649	2656	glucose	Chemical	D005947	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2696	2705	clozapine	Chemical	D003024	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2706	2716	olanzapine	Chemical	C076029	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2717	2728	risperidone	Chemical	D018967	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2767	2776	clozapine	Chemical	D003024	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2781	2792	risperidone	Chemical	D018967	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2822	2832	olanzapine	Chemical	C076029	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2837	2848	risperidone	Chemical	D018967	There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
BC8_BioRED_Task1_Doc158	2902	2911	clozapine	Chemical	D003024	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
BC8_BioRED_Task1_Doc158	2917	2927	olanzapine	Chemical	C076029	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
BC8_BioRED_Task1_Doc158	2965	2983	insulin resistance	Disease	D007333	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
BC8_BioRED_Task1_Doc158	3002	3009	glucose	Chemical	D005947	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
BC8_BioRED_Task1_Doc158	3038	3049	risperidone	Chemical	D018967	CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
BC8_BioRED_Task1_Doc158	3068	3076	Patients	OrganismTaxon	9606	Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
BC8_BioRED_Task1_Doc158	3084	3093	clozapine	Chemical	D003024	Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
BC8_BioRED_Task1_Doc158	3098	3108	olanzapine	Chemical	C076029	Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
BC8_BioRED_Task1_Doc158	3130	3148	insulin resistance	Disease	D007333	Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.
BC8_BioRED_Task1_Doc159	0	7	Quinine	Chemical	D011803	Quinine-induced arrhythmia in a patient with severe malaria.
BC8_BioRED_Task1_Doc159	16	26	arrhythmia	Disease	D001145	Quinine-induced arrhythmia in a patient with severe malaria.
BC8_BioRED_Task1_Doc159	32	39	patient	OrganismTaxon	9606	Quinine-induced arrhythmia in a patient with severe malaria.
BC8_BioRED_Task1_Doc159	45	59	severe malaria	Disease	D016778	Quinine-induced arrhythmia in a patient with severe malaria.
BC8_BioRED_Task1_Doc159	102	116	severe malaria	Disease	D016778	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
BC8_BioRED_Task1_Doc159	117	124	patient	OrganismTaxon	9606	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
BC8_BioRED_Task1_Doc159	130	138	jaundice	Disease	D007565	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
BC8_BioRED_Task1_Doc159	158	168	arrhythmia	Disease	D001145	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
BC8_BioRED_Task1_Doc159	170	203	premature ventricular contraction	Disease	D018879	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
BC8_BioRED_Task1_Doc159	219	226	quinine	Chemical	D011803	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
BC8_BioRED_Task1_Doc159	252	255	man	OrganismTaxon	9606	A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice.
BC8_BioRED_Task1_Doc159	306	311	fever	Disease	D005334	A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice.
BC8_BioRED_Task1_Doc159	313	318	chill	Disease	D023341	A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice.
BC8_BioRED_Task1_Doc159	320	328	vomiting	Disease	D014839	A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice.
BC8_BioRED_Task1_Doc159	330	338	jaundice	Disease	D007565	A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice.
BC8_BioRED_Task1_Doc159	344	351	patient	OrganismTaxon	9606	The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular.
BC8_BioRED_Task1_Doc159	479	500	Plasmodium falciparum	OrganismTaxon	5833	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	515	524	bilirubin	Chemical	D001663	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	548	557	bilirubin	Chemical	D001663	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	583	592	bilirubin	Chemical	D001663	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	605	614	potassium	Chemical	D011188	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	626	633	Patient	OrganismTaxon	9606	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	651	665	severe malaria	Disease	D016778	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	671	679	jaundice	Disease	D007565	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	688	695	quinine	Chemical	D011803	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	708	716	dextrose	Chemical	D005947	On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
BC8_BioRED_Task1_Doc159	757	764	patient	OrganismTaxon	9606	On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing.
BC8_BioRED_Task1_Doc159	769	776	vomitus	Disease	D014839	On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing.
BC8_BioRED_Task1_Doc159	778	786	diarrhea	Disease	D003967	On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing.
BC8_BioRED_Task1_Doc159	788	796	tinnitus	Disease	D014012	On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing.
BC8_BioRED_Task1_Doc159	798	813	loss of hearing	Disease	D034381	On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing.
BC8_BioRED_Task1_Doc159	833	840	quinine	Chemical	D011803	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
BC8_BioRED_Task1_Doc159	854	861	patient	OrganismTaxon	9606	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
BC8_BioRED_Task1_Doc159	867	878	palpitation	Disease	D006331	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
BC8_BioRED_Task1_Doc159	926	959	premature ventricular contraction	Disease	D018879	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
BC8_BioRED_Task1_Doc159	961	964	PVC	Disease	D018879	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
BC8_BioRED_Task1_Doc159	1006	1022	sinoatrial block	Disease	D012848	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
BC8_BioRED_Task1_Doc159	1061	1070	lidocaine	Chemical	D008012	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet.
BC8_BioRED_Task1_Doc159	1123	1131	dextrose	Chemical	D005947	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet.
BC8_BioRED_Task1_Doc159	1147	1166	potassium aspartate	Chemical	D001224	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet.
BC8_BioRED_Task1_Doc159	1175	1182	Quinine	Chemical	D011803	Quinine infusion was discontinued and changed with sulfate quinine tablets.
BC8_BioRED_Task1_Doc159	1234	1241	quinine	Chemical	D011803	Quinine infusion was discontinued and changed with sulfate quinine tablets.
BC8_BioRED_Task1_Doc159	1273	1280	patient	OrganismTaxon	9606	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L.
BC8_BioRED_Task1_Doc159	1311	1314	PVC	Disease	D018879	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L.
BC8_BioRED_Task1_Doc159	1378	1387	potassium	Chemical	D011188	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L.
BC8_BioRED_Task1_Doc159	1458	1465	Quinine	Chemical	D011803	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1472	1481	quinidine	Chemical	D011802	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1488	1505	chincona alkaloid	Chemical	-	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1520	1530	arrhythmic	Disease	D001145	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1562	1572	arrhythmic	Disease	D001145	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1596	1607	arrhythmias	Disease	D001145	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1626	1636	arrhythmia	Disease	D001145	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1654	1657	PVC	Disease	D018879	Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
BC8_BioRED_Task1_Doc159	1688	1695	quinine	Chemical	D011803	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1764	1774	arrhythmic	Disease	D001145	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1803	1811	patients	OrganismTaxon	9606	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1821	1835	heart diseases	Disease	D006331	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1839	1847	patients	OrganismTaxon	9606	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1853	1873	electrolyte disorder	Disease	D014883	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1875	1886	hypokalemia	Disease	D007008	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1919	1927	vomiting	Disease	D014839	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1935	1943	diarrhea	Disease	D003967	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc159	1947	1954	malaria	Disease	D008288	Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.
BC8_BioRED_Task1_Doc160	39	50	oral clefts	Disease	D002972	Regional analysis on the occurrence of oral clefts in South America.
BC8_BioRED_Task1_Doc160	149	158	cleft lip	Disease	D002971	The aim of this work was to search for unequal birth prevalence rates (BPRs) of cleft lip +/- cleft palate (CL/P), and cleft palate only (CPO), among different geographic areas in South America, and to analyze phenotypic characteristics and associated risk factors in each identified cluster.
BC8_BioRED_Task1_Doc160	163	175	cleft palate	Disease	D002972	The aim of this work was to search for unequal birth prevalence rates (BPRs) of cleft lip +/- cleft palate (CL/P), and cleft palate only (CPO), among different geographic areas in South America, and to analyze phenotypic characteristics and associated risk factors in each identified cluster.
BC8_BioRED_Task1_Doc160	177	181	CL/P	Disease	D002971,D002972	The aim of this work was to search for unequal birth prevalence rates (BPRs) of cleft lip +/- cleft palate (CL/P), and cleft palate only (CPO), among different geographic areas in South America, and to analyze phenotypic characteristics and associated risk factors in each identified cluster.
BC8_BioRED_Task1_Doc160	188	200	cleft palate	Disease	D002972	The aim of this work was to search for unequal birth prevalence rates (BPRs) of cleft lip +/- cleft palate (CL/P), and cleft palate only (CPO), among different geographic areas in South America, and to analyze phenotypic characteristics and associated risk factors in each identified cluster.
BC8_BioRED_Task1_Doc160	207	210	CPO	Disease	D002972	The aim of this work was to search for unequal birth prevalence rates (BPRs) of cleft lip +/- cleft palate (CL/P), and cleft palate only (CPO), among different geographic areas in South America, and to analyze phenotypic characteristics and associated risk factors in each identified cluster.
BC8_BioRED_Task1_Doc160	382	386	CL/P	Disease	D002971,D002972	Included were 5,128 CL/P cases, 1,745 CPO cases, and 3,712 controls (like-sexed, non-malformed liveborn infant, born immediately after a malformed one, in the same hospital), over 4,199,630 consecutive births.
BC8_BioRED_Task1_Doc160	400	403	CPO	Disease	D002972	Included were 5,128 CL/P cases, 1,745 CPO cases, and 3,712 controls (like-sexed, non-malformed liveborn infant, born immediately after a malformed one, in the same hospital), over 4,199,630 consecutive births.
BC8_BioRED_Task1_Doc160	1114	1120	clefts	Disease	D002971,D002972	Syndromic and non-syndromic clefts were considered for cluster analysis, and phenotypic characterization, while only non-syndromic for risk factor analysis.
BC8_BioRED_Task1_Doc160	1262	1266	CL/P	Disease	D002971,D002972	Seven clusters for CL/P, and four for CPO, with unusual BPRs were identified.
BC8_BioRED_Task1_Doc160	1281	1284	CPO	Disease	D002972	Seven clusters for CL/P, and four for CPO, with unusual BPRs were identified.
BC8_BioRED_Task1_Doc160	1321	1325	CL/P	Disease	D002971,D002972	CL/P cases in high BPR areas were more severe than elsewhere in the sample, similar to a previous ECLAMC report on microtia.
BC8_BioRED_Task1_Doc160	1436	1444	microtia	Disease	D065817	CL/P cases in high BPR areas were more severe than elsewhere in the sample, similar to a previous ECLAMC report on microtia.
BC8_BioRED_Task1_Doc160	1450	1454	CL/P	Disease	D002971,D002972	For CL/P, high BPR clusters were associated with high altitude above sea level, Amerindian ancestry, and low socioeconomic strata; low BPR clusters showed association with African Black ancestry.
BC8_BioRED_Task1_Doc160	1694	1697	CPO	Disease	D002972	Advanced maternal age, a recognized risk factor for CPO, was also associated with the only identified geographic cluster for CPO.
BC8_BioRED_Task1_Doc160	1767	1770	CPO	Disease	D002972	Advanced maternal age, a recognized risk factor for CPO, was also associated with the only identified geographic cluster for CPO.
BC8_BioRED_Task1_Doc161	0	3	HEB	Gene	21406	HEB is required for the specification of fetal IL-17-producing gd T cells.
BC8_BioRED_Task1_Doc161	47	52	IL-17	Gene	16171	HEB is required for the specification of fetal IL-17-producing gd T cells.
BC8_BioRED_Task1_Doc161	75	80	IL-17	Gene	16171	IL-17-producing gd T (gdT17) cells are critical components of the innate immune system.
BC8_BioRED_Task1_Doc161	252	255	HEB	Gene	21406	Here we show that HEB (HeLa E-box binding protein, encoded by Tcf12) is required for the generation of a newly defined subset of fetal-derived CD73- gdT17 cells.
BC8_BioRED_Task1_Doc161	257	283	HeLa E-box binding protein	Gene	21406	Here we show that HEB (HeLa E-box binding protein, encoded by Tcf12) is required for the generation of a newly defined subset of fetal-derived CD73- gdT17 cells.
BC8_BioRED_Task1_Doc161	296	301	Tcf12	Gene	21406	Here we show that HEB (HeLa E-box binding protein, encoded by Tcf12) is required for the generation of a newly defined subset of fetal-derived CD73- gdT17 cells.
BC8_BioRED_Task1_Doc161	377	381	CD73	Gene	23959	Here we show that HEB (HeLa E-box binding protein, encoded by Tcf12) is required for the generation of a newly defined subset of fetal-derived CD73- gdT17 cells.
BC8_BioRED_Task1_Doc161	396	399	HEB	Gene	21406	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	424	428	CD24	Gene	12484	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	429	433	CD73	Gene	23959	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	468	472	Sox4	Gene	20677	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	474	479	Sox13	Gene	20668	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	485	489	Rorc	Gene	19885	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	548	551	HEB	Gene	21406	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	563	566	Id3	Gene	15903	HEB is required in immature CD24+CD73- gd T cells for the expression of Sox4, Sox13, and Rorc, and these genes are repressed by acute expression of the HEB antagonist Id3.
BC8_BioRED_Task1_Doc161	568	571	HEB	Gene	21406	HEB-deficiency also affects mature CD73+ gd T cells, which are defective in RORgt expression and IL-17 production.
BC8_BioRED_Task1_Doc161	603	607	CD73	Gene	23959	HEB-deficiency also affects mature CD73+ gd T cells, which are defective in RORgt expression and IL-17 production.
BC8_BioRED_Task1_Doc161	644	649	RORgt	Gene	19885	HEB-deficiency also affects mature CD73+ gd T cells, which are defective in RORgt expression and IL-17 production.
BC8_BioRED_Task1_Doc161	665	670	IL-17	Gene	16171	HEB-deficiency also affects mature CD73+ gd T cells, which are defective in RORgt expression and IL-17 production.
BC8_BioRED_Task1_Doc161	707	711	TCRg	Gene	110067	Additionally, the fetal TCRg chain repertoire is altered, and peripheral Vg4 gd T cells are mostly restricted to the IFNg-producing phenotype in HEB-deficient mice.
BC8_BioRED_Task1_Doc161	756	759	Vg4	Gene	21638	Additionally, the fetal TCRg chain repertoire is altered, and peripheral Vg4 gd T cells are mostly restricted to the IFNg-producing phenotype in HEB-deficient mice.
BC8_BioRED_Task1_Doc161	800	804	IFNg	Gene	15978	Additionally, the fetal TCRg chain repertoire is altered, and peripheral Vg4 gd T cells are mostly restricted to the IFNg-producing phenotype in HEB-deficient mice.
BC8_BioRED_Task1_Doc161	828	831	HEB	Gene	21406	Additionally, the fetal TCRg chain repertoire is altered, and peripheral Vg4 gd T cells are mostly restricted to the IFNg-producing phenotype in HEB-deficient mice.
BC8_BioRED_Task1_Doc161	842	846	mice	OrganismTaxon	10090	Additionally, the fetal TCRg chain repertoire is altered, and peripheral Vg4 gd T cells are mostly restricted to the IFNg-producing phenotype in HEB-deficient mice.
BC8_BioRED_Task1_Doc161	879	882	HEB	Gene	21406	Therefore, our work identifies HEB-dependent pathways for the development of CD73+ and CD73- gdT17 cells, and provides mechanistic evidence for control of the gdT17 gene network by HEB.
BC8_BioRED_Task1_Doc161	925	929	CD73	Gene	23959	Therefore, our work identifies HEB-dependent pathways for the development of CD73+ and CD73- gdT17 cells, and provides mechanistic evidence for control of the gdT17 gene network by HEB.
BC8_BioRED_Task1_Doc161	935	939	CD73	Gene	23959	Therefore, our work identifies HEB-dependent pathways for the development of CD73+ and CD73- gdT17 cells, and provides mechanistic evidence for control of the gdT17 gene network by HEB.
BC8_BioRED_Task1_Doc161	1029	1032	HEB	Gene	21406	Therefore, our work identifies HEB-dependent pathways for the development of CD73+ and CD73- gdT17 cells, and provides mechanistic evidence for control of the gdT17 gene network by HEB.
BC8_BioRED_Task1_Doc162	0	15	Interleukin-17F	Gene	112744	Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia.
BC8_BioRED_Task1_Doc162	37	45	patients	OrganismTaxon	9606	Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia.
BC8_BioRED_Task1_Doc162	51	82	chronic immune thrombocytopenia	Disease	D016553	Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia.
BC8_BioRED_Task1_Doc162	98	104	IL-17F	Gene	112744	INTRODUCTION: IL-17F is a novel inflammatory cytokine and plays an important role in some autoimmune diseases.
BC8_BioRED_Task1_Doc162	116	137	inflammatory cytokine	Gene	112744	INTRODUCTION: IL-17F is a novel inflammatory cytokine and plays an important role in some autoimmune diseases.
BC8_BioRED_Task1_Doc162	174	193	autoimmune diseases	Disease	D001327	INTRODUCTION: IL-17F is a novel inflammatory cytokine and plays an important role in some autoimmune diseases.
BC8_BioRED_Task1_Doc162	235	246	chronic ITP	Disease	D016553	We investigated the association between chronic ITP and the frequency of the single-nucleotide polymorphism rs763780 (7488T/C), which causes a His-to-Arg substitution at amino acid 161.
BC8_BioRED_Task1_Doc162	303	311	rs763780	SequenceVariant	rs763780	We investigated the association between chronic ITP and the frequency of the single-nucleotide polymorphism rs763780 (7488T/C), which causes a His-to-Arg substitution at amino acid 161.
BC8_BioRED_Task1_Doc162	313	320	7488T/C	SequenceVariant	rs763780	We investigated the association between chronic ITP and the frequency of the single-nucleotide polymorphism rs763780 (7488T/C), which causes a His-to-Arg substitution at amino acid 161.
BC8_BioRED_Task1_Doc162	338	379	His-to-Arg substitution at amino acid 161	SequenceVariant	rs763780	We investigated the association between chronic ITP and the frequency of the single-nucleotide polymorphism rs763780 (7488T/C), which causes a His-to-Arg substitution at amino acid 161.
BC8_BioRED_Task1_Doc162	381	389	PATIENTS	OrganismTaxon	9606	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	419	427	patients	OrganismTaxon	9606	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	429	432	men	OrganismTaxon	9606	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	433	438	women	OrganismTaxon	9606	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	478	489	chronic ITP	Disease	D016553	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	516	519	men	OrganismTaxon	9606	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	520	525	women	OrganismTaxon	9606	PATIENTS AND METHODS: We examined 102 patients (men/women, 40/62; median age, 42) diagnosed with chronic ITP and 188 healthy controls (men/women, 78/110; median age, 38).
BC8_BioRED_Task1_Doc162	716	724	patients	OrganismTaxon	9606	RESULTS: Compared with the control group, patients with chronic ITP had a significantly lower frequency of the IL-17F 7488CC genotype (0% vs. 4.8%, P<0.05).
BC8_BioRED_Task1_Doc162	730	741	chronic ITP	Disease	D016553	RESULTS: Compared with the control group, patients with chronic ITP had a significantly lower frequency of the IL-17F 7488CC genotype (0% vs. 4.8%, P<0.05).
BC8_BioRED_Task1_Doc162	785	791	IL-17F	Gene	112744	RESULTS: Compared with the control group, patients with chronic ITP had a significantly lower frequency of the IL-17F 7488CC genotype (0% vs. 4.8%, P<0.05).
BC8_BioRED_Task1_Doc162	792	798	7488CC	SequenceVariant	rs763780	RESULTS: Compared with the control group, patients with chronic ITP had a significantly lower frequency of the IL-17F 7488CC genotype (0% vs. 4.8%, P<0.05).
BC8_BioRED_Task1_Doc162	845	851	IL-17F	Gene	112744	The number of IL-17F 7488C alleles among the patients with chronic ITP was also significantly lower than in the control group (8.7% vs. 15.2% OR=0.48, 95%CI=0.27-0.84, P=0.016).
BC8_BioRED_Task1_Doc162	852	857	7488C	SequenceVariant	rs763780	The number of IL-17F 7488C alleles among the patients with chronic ITP was also significantly lower than in the control group (8.7% vs. 15.2% OR=0.48, 95%CI=0.27-0.84, P=0.016).
BC8_BioRED_Task1_Doc162	876	884	patients	OrganismTaxon	9606	The number of IL-17F 7488C alleles among the patients with chronic ITP was also significantly lower than in the control group (8.7% vs. 15.2% OR=0.48, 95%CI=0.27-0.84, P=0.016).
BC8_BioRED_Task1_Doc162	890	901	chronic ITP	Disease	D016553	The number of IL-17F 7488C alleles among the patients with chronic ITP was also significantly lower than in the control group (8.7% vs. 15.2% OR=0.48, 95%CI=0.27-0.84, P=0.016).
BC8_BioRED_Task1_Doc162	1022	1030	patients	OrganismTaxon	9606	Furthermore, patients with the IL-17F 7488TT genotype showed a severe thrombocytopenic state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F 7488TC genotype (20.9% vs. 0%, P=0.04).
BC8_BioRED_Task1_Doc162	1040	1046	IL-17F	Gene	112744	Furthermore, patients with the IL-17F 7488TT genotype showed a severe thrombocytopenic state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F 7488TC genotype (20.9% vs. 0%, P=0.04).
BC8_BioRED_Task1_Doc162	1047	1053	7488TT	SequenceVariant	rs763780	Furthermore, patients with the IL-17F 7488TT genotype showed a severe thrombocytopenic state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F 7488TC genotype (20.9% vs. 0%, P=0.04).
BC8_BioRED_Task1_Doc162	1079	1095	thrombocytopenic	Disease	D011696	Furthermore, patients with the IL-17F 7488TT genotype showed a severe thrombocytopenic state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F 7488TC genotype (20.9% vs. 0%, P=0.04).
BC8_BioRED_Task1_Doc162	1164	1170	IL-17F	Gene	112744	Furthermore, patients with the IL-17F 7488TT genotype showed a severe thrombocytopenic state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F 7488TC genotype (20.9% vs. 0%, P=0.04).
BC8_BioRED_Task1_Doc162	1171	1177	7488TC	SequenceVariant	rs763780	Furthermore, patients with the IL-17F 7488TT genotype showed a severe thrombocytopenic state (platelet count<10 10(9) /L) at diagnosis than those with the IL-17F 7488TC genotype (20.9% vs. 0%, P=0.04).
BC8_BioRED_Task1_Doc162	1255	1261	IL-17F	Gene	112744	CONCLUSION: These findings suggest that the IL-17F 7488 T allele is significantly associated with the development of chronic ITP, suggesting a role for IL-17F in the pathogenesis of chronic ITP.
BC8_BioRED_Task1_Doc162	1262	1268	7488 T	SequenceVariant	rs763780	CONCLUSION: These findings suggest that the IL-17F 7488 T allele is significantly associated with the development of chronic ITP, suggesting a role for IL-17F in the pathogenesis of chronic ITP.
BC8_BioRED_Task1_Doc162	1328	1339	chronic ITP	Disease	D016553	CONCLUSION: These findings suggest that the IL-17F 7488 T allele is significantly associated with the development of chronic ITP, suggesting a role for IL-17F in the pathogenesis of chronic ITP.
BC8_BioRED_Task1_Doc162	1363	1369	IL-17F	Gene	112744	CONCLUSION: These findings suggest that the IL-17F 7488 T allele is significantly associated with the development of chronic ITP, suggesting a role for IL-17F in the pathogenesis of chronic ITP.
BC8_BioRED_Task1_Doc162	1393	1404	chronic ITP	Disease	D016553	CONCLUSION: These findings suggest that the IL-17F 7488 T allele is significantly associated with the development of chronic ITP, suggesting a role for IL-17F in the pathogenesis of chronic ITP.
BC8_BioRED_Task1_Doc163	27	35	patients	OrganismTaxon	9606	Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations.
BC8_BioRED_Task1_Doc163	41	71	17alpha-hydroxylase deficiency	Disease	C538237	Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations.
BC8_BioRED_Task1_Doc163	180	185	CYP17	Gene	1586	Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations.
BC8_BioRED_Task1_Doc163	206	236	17alpha-Hydroxylase deficiency	Disease	C538237	CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations.
BC8_BioRED_Task1_Doc163	255	285	congenital adrenal hyperplasia	Disease	D000312	CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations.
BC8_BioRED_Task1_Doc163	296	301	CYP17	Gene	1586	CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations.
BC8_BioRED_Task1_Doc163	342	350	patients	OrganismTaxon	9606	OBJECTIVE: Five Chinese patients with 17alpha-hydroxylase deficiency were genotyped.
BC8_BioRED_Task1_Doc163	356	386	17alpha-hydroxylase deficiency	Disease	C538237	OBJECTIVE: Five Chinese patients with 17alpha-hydroxylase deficiency were genotyped.
BC8_BioRED_Task1_Doc163	403	411	PATIENTS	OrganismTaxon	9606	PATIENTS: The five patients derived from four families living in Shandong Province, China.
BC8_BioRED_Task1_Doc163	422	430	patients	OrganismTaxon	9606	PATIENTS: The five patients derived from four families living in Shandong Province, China.
BC8_BioRED_Task1_Doc163	511	541	17alpha-hydroxylase deficiency	Disease	C538237	The diagnosis of 17alpha-hydroxylase deficiency was initially established through HPLC serum adrenal profiles in Qilu Hospital, China, from 1983-1993.
BC8_BioRED_Task1_Doc163	660	665	CYP17	Gene	1586	RESULTS: Three CYP17 gene mutations were identified from these patients.
BC8_BioRED_Task1_Doc163	708	716	patients	OrganismTaxon	9606	RESULTS: Three CYP17 gene mutations were identified from these patients.
BC8_BioRED_Task1_Doc163	730	736	V311fs	SequenceVariant	p|FS|V|311||	Among them, V311fs and Y329fs are two novel frame-shifting mutations.
BC8_BioRED_Task1_Doc163	741	747	Y329fs	SequenceVariant	p|FS|Y|329||	Among them, V311fs and Y329fs are two novel frame-shifting mutations.
BC8_BioRED_Task1_Doc163	788	794	V311fs	SequenceVariant	p|FS|V|311||	V311fs is an 8-bp nucleotide (TTAAATGG) deletion in exon 5.
BC8_BioRED_Task1_Doc163	801	836	8-bp nucleotide (TTAAATGG) deletion	SequenceVariant	c|DEL||TTAAATGG	V311fs is an 8-bp nucleotide (TTAAATGG) deletion in exon 5.
BC8_BioRED_Task1_Doc163	848	854	Y329fs	SequenceVariant	p|FS|Y|329||	Y329fs is a deletion-insertion combined mutation (TAC-->AA) at codon 329 in exon 6.
BC8_BioRED_Task1_Doc163	897	920	(TAC-->AA) at codon 329	SequenceVariant	c|SUB|TAC|CODON329|AA	Y329fs is a deletion-insertion combined mutation (TAC-->AA) at codon 329 in exon 6.
BC8_BioRED_Task1_Doc163	952	958	Y329fs	SequenceVariant	p|FS|Y|329||	Two homozygotes for Y329fs and one compound heterozygote for Y329fs and V311fs were identified from three different families.
BC8_BioRED_Task1_Doc163	993	999	Y329fs	SequenceVariant	p|FS|Y|329||	Two homozygotes for Y329fs and one compound heterozygote for Y329fs and V311fs were identified from three different families.
BC8_BioRED_Task1_Doc163	1004	1010	V311fs	SequenceVariant	p|FS|V|311||	Two homozygotes for Y329fs and one compound heterozygote for Y329fs and V311fs were identified from three different families.
BC8_BioRED_Task1_Doc163	1089	1112	D487_S488_F489 deletion	SequenceVariant	p|DEL|487_489|DSF	Two homozygous sisters for the D487_S488_F489 deletion were identified.
BC8_BioRED_Task1_Doc163	1223	1253	17alpha-hydroxylase deficiency	Disease	C538237	CONCLUSION: The results confirmed the diagnostic value of the HPLC serum adrenal profile for 17alpha-hydroxylase deficiency.
BC8_BioRED_Task1_Doc163	1259	1282	D487_S488_F489 deletion	SequenceVariant	p|DEL|487_489|DSF	The D487_S488_F489 deletion had been identified in two previously genotyped Chinese families.
BC8_BioRED_Task1_Doc163	1474	1479	CYP17	Gene	1586	In our present study, a third Chinese family with this mutation was identified, suggesting that this mutation is a prevalent CYP17 mutation in the Chinese population.
BC8_BioRED_Task1_Doc163	1538	1544	Y329fs	SequenceVariant	p|FS|Y|329||	The identification of Y329fs mutation in addition to three previously identified mutations at codon 329 suggests that codon 329 is an unstable point of the CYP17 gene.
BC8_BioRED_Task1_Doc163	1672	1677	CYP17	Gene	1586	The identification of Y329fs mutation in addition to three previously identified mutations at codon 329 suggests that codon 329 is an unstable point of the CYP17 gene.
BC8_BioRED_Task1_Doc163	1723	1731	patients	OrganismTaxon	9606	The mutations identified from our five patients appear to be random, but the recurrence of the Y329fs mutation may be attributed to a founder effect.
BC8_BioRED_Task1_Doc163	1779	1785	Y329fs	SequenceVariant	p|FS|Y|329||	The mutations identified from our five patients appear to be random, but the recurrence of the Y329fs mutation may be attributed to a founder effect.
BC8_BioRED_Task1_Doc163	1859	1889	17alpha-hydroxylase deficiency	Disease	C538237	Our studies suggest that 17alpha-hydroxylase deficiency may not be rare in the Chinese population.
BC8_BioRED_Task1_Doc164	49	57	levodopa	Chemical	D007980	Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
BC8_BioRED_Task1_Doc164	66	77	dyskinesias	Disease	D004409	Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
BC8_BioRED_Task1_Doc164	81	100	Parkinson's disease	Disease	D010300	Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
BC8_BioRED_Task1_Doc164	287	298	dyskinesias	Disease	D004409	In a placebo-controlled, single-blinded, crossover study, we assessed the effect of "real" repetitive transcranial magnetic stimulation (rTMS) versus "sham" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).
BC8_BioRED_Task1_Doc164	302	310	patients	OrganismTaxon	9606	In a placebo-controlled, single-blinded, crossover study, we assessed the effect of "real" repetitive transcranial magnetic stimulation (rTMS) versus "sham" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).
BC8_BioRED_Task1_Doc164	316	335	Parkinson's disease	Disease	D010300	In a placebo-controlled, single-blinded, crossover study, we assessed the effect of "real" repetitive transcranial magnetic stimulation (rTMS) versus "sham" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).
BC8_BioRED_Task1_Doc164	337	339	PD	Disease	D010300	In a placebo-controlled, single-blinded, crossover study, we assessed the effect of "real" repetitive transcranial magnetic stimulation (rTMS) versus "sham" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).
BC8_BioRED_Task1_Doc164	346	354	patients	OrganismTaxon	9606	Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.
BC8_BioRED_Task1_Doc164	360	362	PD	Disease	D010300	Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.
BC8_BioRED_Task1_Doc164	377	388	dyskinesias	Disease	D004409	Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.
BC8_BioRED_Task1_Doc164	744	754	dyskinesia	Disease	D004409	Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.
BC8_BioRED_Task1_Doc164	845	855	dyskinesia	Disease	D004409	However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo.
BC8_BioRED_Task1_Doc164	926	934	dystonia	Disease	D004421	The major effect was on dystonia subscore.
BC8_BioRED_Task1_Doc164	959	966	patient	OrganismTaxon	9606	Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only.
BC8_BioRED_Task1_Doc164	1032	1042	dyskinesia	Disease	D004409	Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only.
BC8_BioRED_Task1_Doc164	1243	1245	PD	Disease	D010300	Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.
BC8_BioRED_Task1_Doc164	1405	1416	dyskinesias	Disease	D004409	The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.
BC8_BioRED_Task1_Doc164	1420	1422	PD	Disease	D010300	The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.
BC8_BioRED_Task1_Doc165	35	39	IRF5	Gene	3663	Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells.
BC8_BioRED_Task1_Doc165	89	117	systemic lupus erythematosus	Disease	D008180	Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells.
BC8_BioRED_Task1_Doc165	321	325	IRF5	Gene	3663	OBJECTIVE: We examined the genetic association of the promoter insertion/deletion (indel) in IRF5 gene with systemic lupus erythematosus (SLE) in distinct populations and assessed its role in gene expression.
BC8_BioRED_Task1_Doc165	336	364	systemic lupus erythematosus	Disease	D008180	OBJECTIVE: We examined the genetic association of the promoter insertion/deletion (indel) in IRF5 gene with systemic lupus erythematosus (SLE) in distinct populations and assessed its role in gene expression.
BC8_BioRED_Task1_Doc165	366	369	SLE	Disease	D008180	OBJECTIVE: We examined the genetic association of the promoter insertion/deletion (indel) in IRF5 gene with systemic lupus erythematosus (SLE) in distinct populations and assessed its role in gene expression.
BC8_BioRED_Task1_Doc165	451	455	IRF5	Gene	3663	METHODS: Four IRF5 polymorphisms were genotyped in 1488 SLE patients and 1466 controls.
BC8_BioRED_Task1_Doc165	493	496	SLE	Disease	D008180	METHODS: Four IRF5 polymorphisms were genotyped in 1488 SLE patients and 1466 controls.
BC8_BioRED_Task1_Doc165	497	505	patients	OrganismTaxon	9606	METHODS: Four IRF5 polymorphisms were genotyped in 1488 SLE patients and 1466 controls.
BC8_BioRED_Task1_Doc165	674	683	rs2070197	SequenceVariant	rs2070197	RESULTS: The promoter indel and rs2070197 had independent genetic effects, which accounted for the association of rs2004640 and rs10954213.
BC8_BioRED_Task1_Doc165	756	765	rs2004640	SequenceVariant	rs2004640	RESULTS: The promoter indel and rs2070197 had independent genetic effects, which accounted for the association of rs2004640 and rs10954213.
BC8_BioRED_Task1_Doc165	770	780	rs10954213	SequenceVariant	rs10954213	RESULTS: The promoter indel and rs2070197 had independent genetic effects, which accounted for the association of rs2004640 and rs10954213.
BC8_BioRED_Task1_Doc165	821	831	rs10954213	SequenceVariant	rs10954213	Gene expression analysis revealed that rs10954213 exerted the greatest influence on IRF5 transcript levels.
BC8_BioRED_Task1_Doc165	866	870	IRF5	Gene	3663	Gene expression analysis revealed that rs10954213 exerted the greatest influence on IRF5 transcript levels.
BC8_BioRED_Task1_Doc165	961	964	SLE	Disease	D008180	CONCLUSION: We corroborated the association of the promoter indel with SLE in 5 different populations and revealed that rs10954213 is the main single-nucleotide polymorphism responsible for altered IRF5 expression in PBMC.
BC8_BioRED_Task1_Doc165	1010	1020	rs10954213	SequenceVariant	rs10954213	CONCLUSION: We corroborated the association of the promoter indel with SLE in 5 different populations and revealed that rs10954213 is the main single-nucleotide polymorphism responsible for altered IRF5 expression in PBMC.
BC8_BioRED_Task1_Doc165	1088	1092	IRF5	Gene	3663	CONCLUSION: We corroborated the association of the promoter indel with SLE in 5 different populations and revealed that rs10954213 is the main single-nucleotide polymorphism responsible for altered IRF5 expression in PBMC.
BC8_BioRED_Task1_Doc166	8	19	nephropathy	Disease	D007674	Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.
BC8_BioRED_Task1_Doc166	50	64	contrast media	Chemical	D003287	Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.
BC8_BioRED_Task1_Doc166	169	183	contrast media	Chemical	D003287	Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
BC8_BioRED_Task1_Doc166	192	203	nephropathy	Disease	D007674	Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
BC8_BioRED_Task1_Doc166	205	208	CIN	Disease	D007674	Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
BC8_BioRED_Task1_Doc166	232	240	patients	OrganismTaxon	9606	Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
BC8_BioRED_Task1_Doc166	389	397	patients	OrganismTaxon	9606	Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
BC8_BioRED_Task1_Doc166	481	484	CIN	Disease	D007674	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	502	516	contrast media	Chemical	D003287	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	518	520	CM	Chemical	D003287	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	523	532	iopromide	Chemical	C038192	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	537	544	iohexol	Chemical	D007472	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	555	563	patients	OrganismTaxon	9606	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	669	671	CM	Chemical	D003287	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	692	700	cyanosis	Disease	D003490	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
BC8_BioRED_Task1_Doc166	709	717	patients	OrganismTaxon	9606	The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).
BC8_BioRED_Task1_Doc166	761	770	iopromide	Chemical	C038192	The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).
BC8_BioRED_Task1_Doc166	792	799	iohexol	Chemical	D007472	The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).
BC8_BioRED_Task1_Doc166	825	831	sodium	Chemical	D012964	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	833	835	Na	Chemical	D012964	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	838	847	potassium	Chemical	D011188	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	849	850	K	Chemical	D011188	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	857	867	creatinine	Chemical	D003404	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	869	871	Cr	Chemical	D003404	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	989	991	CM	Chemical	D003287	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
BC8_BioRED_Task1_Doc166	1015	1017	Na	Chemical	D012964	Urine samples for Na and Cr also were checked at the same intervals.
BC8_BioRED_Task1_Doc166	1022	1024	Cr	Chemical	D003404	Urine samples for Na and Cr also were checked at the same intervals.
BC8_BioRED_Task1_Doc166	1074	1087	renal failure	Disease	D051437	Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
BC8_BioRED_Task1_Doc166	1089	1109	Injury to the kidney	Disease	D058186	Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
BC8_BioRED_Task1_Doc166	1111	1137	Failure of kidney function	Disease	D051437	Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
BC8_BioRED_Task1_Doc166	1139	1162	Loss of kidney function	Disease	D051437	Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
BC8_BioRED_Task1_Doc166	1178	1190	renal damage	Disease	D007674	Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
BC8_BioRED_Task1_Doc166	1228	1231	CIN	Disease	D007674	Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
BC8_BioRED_Task1_Doc166	1301	1304	CIN	Disease	D007674	Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
BC8_BioRED_Task1_Doc166	1305	1313	patients	OrganismTaxon	9606	Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
BC8_BioRED_Task1_Doc166	1336	1344	patients	OrganismTaxon	9606	Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
BC8_BioRED_Task1_Doc166	1389	1401	renal injury	Disease	D058186	Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
BC8_BioRED_Task1_Doc166	1457	1469	renal injury	Disease	D058186	Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
BC8_BioRED_Task1_Doc166	1492	1500	patients	OrganismTaxon	9606	Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
BC8_BioRED_Task1_Doc166	1506	1509	CIN	Disease	D007674	Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
BC8_BioRED_Task1_Doc166	1561	1563	CM	Chemical	D003287	Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
BC8_BioRED_Task1_Doc166	1688	1691	CIN	Disease	D007674	Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
BC8_BioRED_Task1_Doc166	1728	1730	CM	Chemical	D003287	Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
BC8_BioRED_Task1_Doc166	1757	1765	patients	OrganismTaxon	9606	Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).
BC8_BioRED_Task1_Doc166	1771	1774	CIN	Disease	D007674	Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).
BC8_BioRED_Task1_Doc166	1791	1816	congenital heart diseases	Disease	D006331	Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).
BC8_BioRED_Task1_Doc166	1895	1903	patients	OrganismTaxon	9606	Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).
BC8_BioRED_Task1_Doc166	1945	1948	CIN	Disease	D007674	Although clinically silent, CIN is not rare in pediatrics.
BC8_BioRED_Task1_Doc166	2049	2051	CM	Chemical	D003287	The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.
BC8_BioRED_Task1_Doc166	2076	2084	cyanosis	Disease	D003490	The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.
BC8_BioRED_Task1_Doc166	2099	2102	CIN	Disease	D007674	The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.
BC8_BioRED_Task1_Doc167	27	31	PAX6	Gene	5080	Two novel mutations of the PAX6 gene causing different phenotype in a cohort of Chinese patients.
BC8_BioRED_Task1_Doc167	88	96	patients	OrganismTaxon	9606	Two novel mutations of the PAX6 gene causing different phenotype in a cohort of Chinese patients.
BC8_BioRED_Task1_Doc167	107	115	Aniridia	Disease	D015783	PURPOSE: Aniridia (AN) is a rare congenital panocular disorder caused by the mutations of the paired box homeotic gene 6(PAX6) gene.
BC8_BioRED_Task1_Doc167	117	119	AN	Disease	D015783	PURPOSE: Aniridia (AN) is a rare congenital panocular disorder caused by the mutations of the paired box homeotic gene 6(PAX6) gene.
BC8_BioRED_Task1_Doc167	131	160	congenital panocular disorder	Disease	D000013	PURPOSE: Aniridia (AN) is a rare congenital panocular disorder caused by the mutations of the paired box homeotic gene 6(PAX6) gene.
BC8_BioRED_Task1_Doc167	192	218	paired box homeotic gene 6	Gene	5080	PURPOSE: Aniridia (AN) is a rare congenital panocular disorder caused by the mutations of the paired box homeotic gene 6(PAX6) gene.
BC8_BioRED_Task1_Doc167	219	223	PAX6	Gene	5080	PURPOSE: Aniridia (AN) is a rare congenital panocular disorder caused by the mutations of the paired box homeotic gene 6(PAX6) gene.
BC8_BioRED_Task1_Doc167	235	239	PAX6	Gene	5080	The PAX6 gene is also involved in other anterior segment malformations including Peters anomaly.
BC8_BioRED_Task1_Doc167	271	301	anterior segment malformations	Disease	C537775	The PAX6 gene is also involved in other anterior segment malformations including Peters anomaly.
BC8_BioRED_Task1_Doc167	312	326	Peters anomaly	Disease	C537884	The PAX6 gene is also involved in other anterior segment malformations including Peters anomaly.
BC8_BioRED_Task1_Doc167	343	347	PAX6	Gene	5080	We studied the PAX6 gene mutations in a cohort of affected individuals with different clinical phenotype including AN, coloboma of iris and choroid, or anterior segment malformations.
BC8_BioRED_Task1_Doc167	443	445	AN	Disease	D015783	We studied the PAX6 gene mutations in a cohort of affected individuals with different clinical phenotype including AN, coloboma of iris and choroid, or anterior segment malformations.
BC8_BioRED_Task1_Doc167	447	475	coloboma of iris and choroid	Disease	D003103	We studied the PAX6 gene mutations in a cohort of affected individuals with different clinical phenotype including AN, coloboma of iris and choroid, or anterior segment malformations.
BC8_BioRED_Task1_Doc167	480	510	anterior segment malformations	Disease	C537775	We studied the PAX6 gene mutations in a cohort of affected individuals with different clinical phenotype including AN, coloboma of iris and choroid, or anterior segment malformations.
BC8_BioRED_Task1_Doc167	512	520	PATIENTS	OrganismTaxon	9606	PATIENTS AND METHODS: Six unrelated families and 10 sporadic patients were examined clinically.
BC8_BioRED_Task1_Doc167	573	581	patients	OrganismTaxon	9606	PATIENTS AND METHODS: Six unrelated families and 10 sporadic patients were examined clinically.
BC8_BioRED_Task1_Doc167	753	757	PAX6	Gene	5080	Mutation screening of all exons of the PAX6 gene was performed by direct sequencing of PCR-amplified DNA fragments.
BC8_BioRED_Task1_Doc167	965	973	patients	OrganismTaxon	9606	RESULTS: By clinical examination, the patients and the pedigrees were divided into the following three groups: AN, coloboma of iris and choroids, and the anterior segment malformations including peters anomaly.
BC8_BioRED_Task1_Doc167	1038	1040	AN	Disease	D015783	RESULTS: By clinical examination, the patients and the pedigrees were divided into the following three groups: AN, coloboma of iris and choroids, and the anterior segment malformations including peters anomaly.
BC8_BioRED_Task1_Doc167	1042	1071	coloboma of iris and choroids	Disease	D003103	RESULTS: By clinical examination, the patients and the pedigrees were divided into the following three groups: AN, coloboma of iris and choroids, and the anterior segment malformations including peters anomaly.
BC8_BioRED_Task1_Doc167	1081	1111	anterior segment malformations	Disease	C537775	RESULTS: By clinical examination, the patients and the pedigrees were divided into the following three groups: AN, coloboma of iris and choroids, and the anterior segment malformations including peters anomaly.
BC8_BioRED_Task1_Doc167	1122	1136	peters anomaly	Disease	C537884	RESULTS: By clinical examination, the patients and the pedigrees were divided into the following three groups: AN, coloboma of iris and choroids, and the anterior segment malformations including peters anomaly.
BC8_BioRED_Task1_Doc167	1156	1160	PAX6	Gene	5080	Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the AN group.
BC8_BioRED_Task1_Doc167	1249	1259	c.357-3C>G	SequenceVariant	c|SUB|C|357-3|G	Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the AN group.
BC8_BioRED_Task1_Doc167	1261	1272	p.Ser119fsX	SequenceVariant	p|FS|S|119||	Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the AN group.
BC8_BioRED_Task1_Doc167	1297	1305	patients	OrganismTaxon	9606	Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the AN group.
BC8_BioRED_Task1_Doc167	1313	1315	AN	Disease	D015783	Sequencing of the PAX6 gene, three intragenic mutations including a novel heterozygous splicing-site mutations c.357-3C>G (p.Ser119fsX) were identified in the patients of the AN group.
BC8_BioRED_Task1_Doc167	1349	1357	c.643T>C	SequenceVariant	c|SUB|T|643|C	A novel missense mutation c.643T>C (p.S216P) was detected in the anterior segment malformation group.
BC8_BioRED_Task1_Doc167	1359	1366	p.S216P	SequenceVariant	p|SUB|S|216|P	A novel missense mutation c.643T>C (p.S216P) was detected in the anterior segment malformation group.
BC8_BioRED_Task1_Doc167	1388	1417	anterior segment malformation	Disease	C537775	A novel missense mutation c.643T>C (p.S216P) was detected in the anterior segment malformation group.
BC8_BioRED_Task1_Doc167	1438	1445	p.S216P	SequenceVariant	p|SUB|S|216|P	The mutation p.S216P located in the homeodomain region of the PAX6 caused the phenotype of Peters anomaly in family A6 with different expressing.
BC8_BioRED_Task1_Doc167	1487	1491	PAX6	Gene	5080	The mutation p.S216P located in the homeodomain region of the PAX6 caused the phenotype of Peters anomaly in family A6 with different expressing.
BC8_BioRED_Task1_Doc167	1516	1530	Peters anomaly	Disease	C537884	The mutation p.S216P located in the homeodomain region of the PAX6 caused the phenotype of Peters anomaly in family A6 with different expressing.
BC8_BioRED_Task1_Doc167	1631	1635	PAX6	Gene	5080	Through MLPA analysis, a large deletion including the whole PAX6 gene and DKFZ p686k1684 gene was detected in one sporadic patient from the AN group.
BC8_BioRED_Task1_Doc167	1645	1659	DKFZ p686k1684	Gene	-	Through MLPA analysis, a large deletion including the whole PAX6 gene and DKFZ p686k1684 gene was detected in one sporadic patient from the AN group.
BC8_BioRED_Task1_Doc167	1694	1701	patient	OrganismTaxon	9606	Through MLPA analysis, a large deletion including the whole PAX6 gene and DKFZ p686k1684 gene was detected in one sporadic patient from the AN group.
BC8_BioRED_Task1_Doc167	1711	1713	AN	Disease	D015783	Through MLPA analysis, a large deletion including the whole PAX6 gene and DKFZ p686k1684 gene was detected in one sporadic patient from the AN group.
BC8_BioRED_Task1_Doc167	1801	1829	coloboma of iris and choroid	Disease	D003103	Neither intragenic mutation nor large deletion was identified in the group with coloboma of iris and choroid.
BC8_BioRED_Task1_Doc167	2043	2047	PAX6	Gene	5080	CONCLUSION: Our findings further confirmed that different kind of mutations might cause different ocular phenotype, and clearly clinical phenotype classification might increase the mutation detection rate of the PAX6 gene.
BC8_BioRED_Task1_Doc168	0	33	Voltage-Dependent Anion Channel 1	Gene	7416,83529	Voltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy.
BC8_BioRED_Task1_Doc168	34	39	VDAC1	Gene	7416,83529	Voltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy.
BC8_BioRED_Task1_Doc168	75	100	Mitochondrial Dysfunction	Disease	D028361	Voltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy.
BC8_BioRED_Task1_Doc168	104	116	Desminopathy	Disease	C563319	Voltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy.
BC8_BioRED_Task1_Doc168	118	132	Desminopathies	Disease	C563319	Desminopathies caused by the mutation in the gene coding for desmin are genetically protein aggregation myopathies.
BC8_BioRED_Task1_Doc168	179	185	desmin	Gene	1674	Desminopathies caused by the mutation in the gene coding for desmin are genetically protein aggregation myopathies.
BC8_BioRED_Task1_Doc168	222	232	myopathies	Disease	D009135	Desminopathies caused by the mutation in the gene coding for desmin are genetically protein aggregation myopathies.
BC8_BioRED_Task1_Doc168	234	259	Mitochondrial dysfunction	Disease	D028361	Mitochondrial dysfunction is one of pathological changes in the desminopathies at the earliest stage.
BC8_BioRED_Task1_Doc168	298	312	desminopathies	Disease	C563319	Mitochondrial dysfunction is one of pathological changes in the desminopathies at the earliest stage.
BC8_BioRED_Task1_Doc168	364	388	mitochondria dysfunction	Disease	D028361	The molecular mechanisms of mitochondria dysfunction in desminopathies remain exclusive.
BC8_BioRED_Task1_Doc168	392	406	desminopathies	Disease	C563319	The molecular mechanisms of mitochondria dysfunction in desminopathies remain exclusive.
BC8_BioRED_Task1_Doc168	425	430	VDAC1	Gene	7416	VDAC1 regulates mitochondrial uptake across the outer membrane and mitochondrial outer membrane permeabilization (MOMP).
BC8_BioRED_Task1_Doc168	568	582	desminopathies	Disease	C563319	Relationships between desminopathies and Voltage-dependent anion channel 1 (VDAC1) remain unclear.
BC8_BioRED_Task1_Doc168	587	620	Voltage-dependent anion channel 1	Gene	7416	Relationships between desminopathies and Voltage-dependent anion channel 1 (VDAC1) remain unclear.
BC8_BioRED_Task1_Doc168	622	627	VDAC1	Gene	7416	Relationships between desminopathies and Voltage-dependent anion channel 1 (VDAC1) remain unclear.
BC8_BioRED_Task1_Doc168	682	694	desminopathy	Disease	C563319	Here we successfully constructed the desminopathy rat model, evaluated with conventional stains, containing hematoxylin and eosin (HE), Gomori Trichrome (MGT), (PAS), red oil (ORO), NADH-TR, SDH staining and immunohistochemistry.
BC8_BioRED_Task1_Doc168	695	698	rat	OrganismTaxon	10116	Here we successfully constructed the desminopathy rat model, evaluated with conventional stains, containing hematoxylin and eosin (HE), Gomori Trichrome (MGT), (PAS), red oil (ORO), NADH-TR, SDH staining and immunohistochemistry.
BC8_BioRED_Task1_Doc168	914	919	VDAC1	Gene	7416,83529	Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.
BC8_BioRED_Task1_Doc168	943	949	desmin	Gene	1674,64362	Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.
BC8_BioRED_Task1_Doc168	990	1002	desminopathy	Disease	C563319	Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.
BC8_BioRED_Task1_Doc168	1003	1011	patients	OrganismTaxon	9606	Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.
BC8_BioRED_Task1_Doc168	1015	1027	desminopathy	Disease	C563319	Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.
BC8_BioRED_Task1_Doc168	1028	1031	rat	OrganismTaxon	10116	Immunofluorescence results showed that VDAC1 was accumulated in the desmin highly stained area of muscle fibers of desminopathy patients or desminopathy rat model compared to the normal ones.
BC8_BioRED_Task1_Doc168	1104	1107	bax	Gene	24887,581	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1112	1116	ATF2	Gene	1386,81647	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1134	1146	desminopathy	Disease	C563319	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1147	1155	patients	OrganismTaxon	9606	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1160	1172	desminopathy	Disease	C563319	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1173	1176	rat	OrganismTaxon	10116	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1192	1197	bcl-2	Gene	24224,596	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1199	1205	bcl-xl	Gene	24888,598	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1209	1212	HK2	Gene	25059,3099	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1213	1218	VDAC1	Gene	7416,83529	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1223	1229	desmin	Gene	1674,64362	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1290	1298	patients	OrganismTaxon	9606	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1303	1307	rats	OrganismTaxon	10116	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1313	1325	desminopathy	Disease	C563319	Meanwhile apoptosis related proteins bax and ATF2 were involved in desminopathy patients and desminopathy rat model, but not bcl-2, bcl-xl or HK2.VDAC1 and desmin are closely relevant in the tissue splices of deminopathies patients and rats with desminopathy at protein lever.
BC8_BioRED_Task1_Doc168	1398	1412	desminopathies	Disease	C563319	Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2.
BC8_BioRED_Task1_Doc168	1419	1422	bax	Gene	24887,581	Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2.
BC8_BioRED_Task1_Doc168	1424	1428	ATF2	Gene	1386,81647	Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2.
BC8_BioRED_Task1_Doc168	1438	1443	bcl-2	Gene	24224,596	Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2.
BC8_BioRED_Task1_Doc168	1445	1451	bcl-xl	Gene	24888,598	Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2.
BC8_BioRED_Task1_Doc168	1455	1458	HK2	Gene	25059,3099	Moreover, apoptotic proteins are also involved in the desminopathies, like bax, ATF2, but not bcl-2, bcl-xl or HK2.
BC8_BioRED_Task1_Doc168	1520	1525	VDAC1	Gene	7416,83529	This pathological analysis presents the correlation between VDAC1 and desmin, and apoptosis related proteins are correlated in the desminopathy.
BC8_BioRED_Task1_Doc168	1530	1536	desmin	Gene	1674,64362	This pathological analysis presents the correlation between VDAC1 and desmin, and apoptosis related proteins are correlated in the desminopathy.
BC8_BioRED_Task1_Doc168	1591	1603	desminopathy	Disease	C563319	This pathological analysis presents the correlation between VDAC1 and desmin, and apoptosis related proteins are correlated in the desminopathy.
BC8_BioRED_Task1_Doc168	1631	1634	rat	OrganismTaxon	10116	Furthermore, we provide a rat model of desminopathy for the investigation of desmin related myopathy.
BC8_BioRED_Task1_Doc168	1644	1656	desminopathy	Disease	C563319	Furthermore, we provide a rat model of desminopathy for the investigation of desmin related myopathy.
BC8_BioRED_Task1_Doc168	1682	1688	desmin	Gene	64362	Furthermore, we provide a rat model of desminopathy for the investigation of desmin related myopathy.
BC8_BioRED_Task1_Doc168	1697	1705	myopathy	Disease	D009135	Furthermore, we provide a rat model of desminopathy for the investigation of desmin related myopathy.
BC8_BioRED_Task1_Doc169	0	22	Protein kinase C alpha	Gene	5578	Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.
BC8_BioRED_Task1_Doc169	52	70	endometrial cancer	Disease	D016889	Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.
BC8_BioRED_Task1_Doc169	87	100	tumorigenesis	Disease	D009369	Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis.
BC8_BioRED_Task1_Doc169	102	120	Endometrial cancer	Disease	D016889	Endometrial cancer is the most common invasive gynecologic malignancy, yet molecular mechanisms and signaling pathways underlying its etiology and pathophysiology remain poorly characterized.
BC8_BioRED_Task1_Doc169	149	171	gynecologic malignancy	Disease	D005833	Endometrial cancer is the most common invasive gynecologic malignancy, yet molecular mechanisms and signaling pathways underlying its etiology and pathophysiology remain poorly characterized.
BC8_BioRED_Task1_Doc169	340	356	protein kinase C	Gene	5578	We sought to define a functional role for the protein kinase C (PKC) isoform, PKCalpha, in an established cell model of endometrial adenocarcinoma.
BC8_BioRED_Task1_Doc169	358	361	PKC	Gene	5578	We sought to define a functional role for the protein kinase C (PKC) isoform, PKCalpha, in an established cell model of endometrial adenocarcinoma.
BC8_BioRED_Task1_Doc169	372	380	PKCalpha	Gene	5578	We sought to define a functional role for the protein kinase C (PKC) isoform, PKCalpha, in an established cell model of endometrial adenocarcinoma.
BC8_BioRED_Task1_Doc169	414	440	endometrial adenocarcinoma	Disease	D016889	We sought to define a functional role for the protein kinase C (PKC) isoform, PKCalpha, in an established cell model of endometrial adenocarcinoma.
BC8_BioRED_Task1_Doc169	442	450	Ishikawa	CellLine	CVCL_2529	Ishikawa cells depleted of PKCalpha protein grew slower, formed fewer colonies in anchorage-independent growth assays and exhibited impaired xenograft tumor formation in nude mice.
BC8_BioRED_Task1_Doc169	469	477	PKCalpha	Gene	5578	Ishikawa cells depleted of PKCalpha protein grew slower, formed fewer colonies in anchorage-independent growth assays and exhibited impaired xenograft tumor formation in nude mice.
BC8_BioRED_Task1_Doc169	593	598	tumor	Disease	D009369	Ishikawa cells depleted of PKCalpha protein grew slower, formed fewer colonies in anchorage-independent growth assays and exhibited impaired xenograft tumor formation in nude mice.
BC8_BioRED_Task1_Doc169	617	621	mice	OrganismTaxon	10090	Ishikawa cells depleted of PKCalpha protein grew slower, formed fewer colonies in anchorage-independent growth assays and exhibited impaired xenograft tumor formation in nude mice.
BC8_BioRED_Task1_Doc169	656	664	PKCalpha	Gene	5578	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	699	722	cyclin-dependent kinase	Gene	983	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	724	727	CDK	Gene	983	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	740	743	p21	Gene	1026	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	744	748	Cip1	Gene	1026	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	749	753	WAF1	Gene	1026	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	756	759	p21	Gene	1026	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	765	768	p27	Gene	1027	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	769	773	Kip1	Gene	1027	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	776	779	p27	Gene	1027	Consistent with impaired growth, PKCalpha knockdown increased levels of the cyclin-dependent kinase (CDK) inhibitors p21(Cip1/WAF1) (p21) and p27(Kip1) (p27).
BC8_BioRED_Task1_Doc169	816	846	phosphatase and tensin homolog	Gene	5728	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	848	852	PTEN	Gene	5728	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	865	873	Ishikawa	CellLine	CVCL_2529	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	881	889	PKCalpha	Gene	5578	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	908	911	Akt	Gene	207	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	993	996	Akt	Gene	207	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	1005	1035	glycogen synthase kinase-3beta	Gene	2932	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	1037	1046	GSK-3beta	Gene	2932	Despite the absence of functional phosphatase and tensin homolog (PTEN) protein in Ishikawa cells, PKCalpha knockdown reduced Akt phosphorylation at serine 473 and concomitantly inhibited phosphorylation of the Akt target, glycogen synthase kinase-3beta (GSK-3beta).
BC8_BioRED_Task1_Doc169	1049	1057	PKCalpha	Gene	5578	PKCalpha knockdown also resulted in decreased basal ERK phosphorylation and attenuated ERK activation following EGF stimulation.
BC8_BioRED_Task1_Doc169	1101	1104	ERK	Gene	5594	PKCalpha knockdown also resulted in decreased basal ERK phosphorylation and attenuated ERK activation following EGF stimulation.
BC8_BioRED_Task1_Doc169	1136	1139	ERK	Gene	5594	PKCalpha knockdown also resulted in decreased basal ERK phosphorylation and attenuated ERK activation following EGF stimulation.
BC8_BioRED_Task1_Doc169	1161	1164	EGF	Gene	1950	PKCalpha knockdown also resulted in decreased basal ERK phosphorylation and attenuated ERK activation following EGF stimulation.
BC8_BioRED_Task1_Doc169	1178	1181	p21	Gene	1026	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1186	1189	p27	Gene	1027	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1235	1243	Ishikawa	CellLine	CVCL_2529	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1255	1258	ERK	Gene	5594	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1263	1266	Akt	Gene	207	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1295	1303	PKCalpha	Gene	5578	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1314	1317	CDK	Gene	983	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1346	1349	Akt	Gene	207	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1354	1357	ERK	Gene	5594	p21 and p27 expression was not increased by treatment of Ishikawa cells with ERK and Akt inhibitors, suggesting that PKCalpha regulates CDK expression independently of Akt and ERK.
BC8_BioRED_Task1_Doc169	1399	1426	endometrioid adenocarcinoma	Disease	D016889	Immunohistochemical analysis of Grade 1 endometrioid adenocarcinoma revealed aberrant PKCalpha expression, with foci of elevated PKCalpha staining, not observed in normal endometrium.
BC8_BioRED_Task1_Doc169	1445	1453	PKCalpha	Gene	5578	Immunohistochemical analysis of Grade 1 endometrioid adenocarcinoma revealed aberrant PKCalpha expression, with foci of elevated PKCalpha staining, not observed in normal endometrium.
BC8_BioRED_Task1_Doc169	1488	1496	PKCalpha	Gene	5578	Immunohistochemical analysis of Grade 1 endometrioid adenocarcinoma revealed aberrant PKCalpha expression, with foci of elevated PKCalpha staining, not observed in normal endometrium.
BC8_BioRED_Task1_Doc169	1589	1597	PKCalpha	Gene	5578	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1623	1636	tumorigenesis	Disease	D009369	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1665	1668	CDK	Gene	983	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1680	1683	p21	Gene	1026	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1688	1691	p27	Gene	1027	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1710	1713	Akt	Gene	207	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1718	1721	ERK	Gene	5594	These studies demonstrate a critical role for PKCalpha signaling in endometrial tumorigenesis by regulating expression of CDK inhibitors p21 and p27 and activation of Akt and ERK-dependent proliferative pathways.
BC8_BioRED_Task1_Doc169	1772	1780	PKCalpha	Gene	5578	Thus, targeting PKCalpha may provide novel therapeutic options in endometrial tumors.
BC8_BioRED_Task1_Doc169	1822	1840	endometrial tumors	Disease	D016889	Thus, targeting PKCalpha may provide novel therapeutic options in endometrial tumors.
BC8_BioRED_Task1_Doc170	0	25	Gastrointestinal hormones	Chemical	D005768	Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms.
BC8_BioRED_Task1_Doc170	26	43	neurotransmitters	Chemical	D018377	Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms.
BC8_BioRED_Task1_Doc170	76	98	P21 activated kinase 2	Gene	29432	Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms.
BC8_BioRED_Task1_Doc170	147	169	P-21-activated kinases	Gene	292756,29431,29432,29433,296078,311450	P-21-activated kinases (PAKs) are serine/threonine kinases comprising six isoforms divided in two groups, group-I (PAK1-3)/group-II (PAK4-6) which play important roles in cell cytoskeletal dynamics, survival, secretion and proliferation and are activated by diverse stimuli.
BC8_BioRED_Task1_Doc170	171	175	PAKs	Gene	292756,29431,29432,29433,296078,311450	P-21-activated kinases (PAKs) are serine/threonine kinases comprising six isoforms divided in two groups, group-I (PAK1-3)/group-II (PAK4-6) which play important roles in cell cytoskeletal dynamics, survival, secretion and proliferation and are activated by diverse stimuli.
BC8_BioRED_Task1_Doc170	181	205	serine/threonine kinases	Gene	292756,29431,29432,29433,296078,311450	P-21-activated kinases (PAKs) are serine/threonine kinases comprising six isoforms divided in two groups, group-I (PAK1-3)/group-II (PAK4-6) which play important roles in cell cytoskeletal dynamics, survival, secretion and proliferation and are activated by diverse stimuli.
BC8_BioRED_Task1_Doc170	262	268	PAK1-3	Gene	29431,29432,29433	P-21-activated kinases (PAKs) are serine/threonine kinases comprising six isoforms divided in two groups, group-I (PAK1-3)/group-II (PAK4-6) which play important roles in cell cytoskeletal dynamics, survival, secretion and proliferation and are activated by diverse stimuli.
BC8_BioRED_Task1_Doc170	280	286	PAK4-6	Gene	292756,296078,311450	P-21-activated kinases (PAKs) are serine/threonine kinases comprising six isoforms divided in two groups, group-I (PAK1-3)/group-II (PAK4-6) which play important roles in cell cytoskeletal dynamics, survival, secretion and proliferation and are activated by diverse stimuli.
BC8_BioRED_Task1_Doc170	453	457	PAKs	Gene	292756,29431,29432,29433,296078,311450	However, little is known about PAKs ability to be activated by gastrointestinal (GI) hormones/neurotransmitters/growth-factors.
BC8_BioRED_Task1_Doc170	485	515	gastrointestinal (GI) hormones	Chemical	D005768	However, little is known about PAKs ability to be activated by gastrointestinal (GI) hormones/neurotransmitters/growth-factors.
BC8_BioRED_Task1_Doc170	516	533	neurotransmitters	Chemical	D018377	However, little is known about PAKs ability to be activated by gastrointestinal (GI) hormones/neurotransmitters/growth-factors.
BC8_BioRED_Task1_Doc170	558	561	rat	OrganismTaxon	10116	We used rat pancreatic acini to explore the ability of GI-hormones/neurotransmitters/growth-factors to activate Group-I-PAKs and the signaling cascades involved.
BC8_BioRED_Task1_Doc170	605	616	GI-hormones	Chemical	D005768	We used rat pancreatic acini to explore the ability of GI-hormones/neurotransmitters/growth-factors to activate Group-I-PAKs and the signaling cascades involved.
BC8_BioRED_Task1_Doc170	617	634	neurotransmitters	Chemical	D018377	We used rat pancreatic acini to explore the ability of GI-hormones/neurotransmitters/growth-factors to activate Group-I-PAKs and the signaling cascades involved.
BC8_BioRED_Task1_Doc170	662	674	Group-I-PAKs	Gene	29431,29432,29433	We used rat pancreatic acini to explore the ability of GI-hormones/neurotransmitters/growth-factors to activate Group-I-PAKs and the signaling cascades involved.
BC8_BioRED_Task1_Doc170	717	721	PAK2	Gene	29432	Only PAK2 was present in acini.
BC8_BioRED_Task1_Doc170	744	748	PAK2	Gene	29432	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	771	796	pancreatic growth-factors	Gene	25266,25313,54250	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	798	801	EGF	Gene	25313	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	803	807	PDGF	Gene	25266	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	809	813	bFGF	Gene	54250	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	844	859	phospholipase-C	Gene	24655	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	861	864	PLC	Gene	24655	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	867	870	CCK	Gene	25298	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	872	881	carbachol	Chemical	D002217	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	883	891	bombesin	Chemical	D001839	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	936	939	PKC	Gene	24681	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	941	944	TPA	Chemical	D013755	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	987	994	calcium	Chemical	D002118	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	1009	1019	cyclic AMP	Chemical	D000242	PAK2 was activated by some pancreatic growth-factors [EGF, PDGF, bFGF], by secretagogues activating phospholipase-C (PLC) [CCK, carbachol, bombesin] and by post-receptor stimulants activating PKC [TPA], but not agents only mobilizing cellular calcium or increasing cyclic AMP.
BC8_BioRED_Task1_Doc170	1021	1024	CCK	Gene	25298	CCK-activation of PAK2 required both high- and low-affinity-CCK1-receptor-state activation.
BC8_BioRED_Task1_Doc170	1039	1043	PAK2	Gene	29432	CCK-activation of PAK2 required both high- and low-affinity-CCK1-receptor-state activation.
BC8_BioRED_Task1_Doc170	1081	1094	CCK1-receptor	Gene	24889	CCK-activation of PAK2 required both high- and low-affinity-CCK1-receptor-state activation.
BC8_BioRED_Task1_Doc170	1141	1144	PKC	Gene	24681	It was partially reduced by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin.
BC8_BioRED_Task1_Doc170	1149	1152	Src	Gene	83805	It was partially reduced by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin.
BC8_BioRED_Task1_Doc170	1178	1182	PI3K	Gene	298947	It was partially reduced by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin.
BC8_BioRED_Task1_Doc170	1195	1205	wortmannin	Chemical	D000077191	It was partially reduced by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin.
BC8_BioRED_Task1_Doc170	1207	1215	LY294002	Chemical	C085911	It was partially reduced by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin.
BC8_BioRED_Task1_Doc170	1220	1232	thapsigargin	Chemical	D019284	It was partially reduced by PKC- or Src-inhibition, but not with PI3K-inhibitors (wortmannin, LY294002) or thapsigargin.
BC8_BioRED_Task1_Doc170	1234	1239	IPA-3	Chemical	C541795	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1256	1260	PAK2	Gene	29432	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1272	1285	small-GTPases	Gene	363875,64465	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1306	1310	PAK2	Gene	29432	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1342	1345	CCK	Gene	25298	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1354	1360	ERK1/2	Gene	116590,50689	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1376	1383	amylase	Gene	24203	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1403	1406	CCK	Gene	25298	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1410	1418	bombesin	Chemical	D001839	IPA-3, which prevents PAK2 binding to small-GTPases partially inhibited PAK2-activation, as well as reduced CCK-induced ERK1/2 activation and amylase release induced by CCK or bombesin.
BC8_BioRED_Task1_Doc170	1479	1490	Group-I-PAK	Gene	29431,29432,29433	This study demonstrates pancreatic acini, possess only one Group-I-PAK, PAK2.
BC8_BioRED_Task1_Doc170	1492	1496	PAK2	Gene	29432	This study demonstrates pancreatic acini, possess only one Group-I-PAK, PAK2.
BC8_BioRED_Task1_Doc170	1498	1501	CCK	Gene	25298	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1512	1523	GI-hormones	Chemical	D005768	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1524	1541	neurotransmitters	Chemical	D018377	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1566	1570	PAK2	Gene	29432	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1575	1588	small GTPases	Gene	363875,64465	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1590	1595	CDC42	Gene	64465	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1596	1600	Rac1	Gene	363875	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1603	1606	PKC	Gene	24681	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1611	1614	SFK	Gene	83805	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1633	1640	calcium	Chemical	D002118	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1644	1648	PI3K	Gene	298947	CCK and other GI-hormones/neurotransmitters/growth-factors activate PAK2 via small GTPases (CDC42/Rac1), PKC and SFK but not cytosolic calcium or PI3K.
BC8_BioRED_Task1_Doc170	1650	1653	CCK	Gene	25298	CCK-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and small-GTPase-dependent/independent components.
BC8_BioRED_Task1_Doc170	1668	1672	PAK2	Gene	29432	CCK-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and small-GTPase-dependent/independent components.
BC8_BioRED_Task1_Doc170	1762	1765	PLC	Gene	24655	CCK-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and small-GTPase-dependent/independent components.
BC8_BioRED_Task1_Doc170	1771	1774	PKC	Gene	24681	CCK-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and small-GTPase-dependent/independent components.
BC8_BioRED_Task1_Doc170	1812	1824	small-GTPase	Gene	363875,64465	CCK-activation of PAK2 showed several novel features being dependent on both receptor-activation states, having PLC- and PKC-dependent/independent components and small-GTPase-dependent/independent components.
BC8_BioRED_Task1_Doc170	1883	1887	PAK2	Gene	29432	These results show that PAK2 is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological/pathophysiological responses and thus could be a promising target for the development of therapies in some pancreatic disorders such as pancreatitis.
BC8_BioRED_Task1_Doc170	2113	2133	pancreatic disorders	Disease	D010182	These results show that PAK2 is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological/pathophysiological responses and thus could be a promising target for the development of therapies in some pancreatic disorders such as pancreatitis.
BC8_BioRED_Task1_Doc170	2142	2154	pancreatitis	Disease	D010195	These results show that PAK2 is important in signaling cascades activated by numerous pancreatic stimuli which mediate their various physiological/pathophysiological responses and thus could be a promising target for the development of therapies in some pancreatic disorders such as pancreatitis.
BC8_BioRED_Task1_Doc171	0	11	Pilocarpine	Chemical	D010862	Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.
BC8_BioRED_Task1_Doc171	12	20	seizures	Disease	D012640	Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.
BC8_BioRED_Task1_Doc171	41	87	impairment in auditory location discrimination	Disease	D001308	Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.
BC8_BioRED_Task1_Doc171	107	125	status epilepticus	Disease	D013226	Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.
BC8_BioRED_Task1_Doc171	163	171	seizures	Disease	D012640	Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.
BC8_BioRED_Task1_Doc171	276	294	status epilepticus	Disease	D013226	The extent to which status epilepticus causes deficits in auditory discrimination is unknown.
BC8_BioRED_Task1_Doc171	302	337	deficits in auditory discrimination	Disease	D001308	The extent to which status epilepticus causes deficits in auditory discrimination is unknown.
BC8_BioRED_Task1_Doc171	465	483	status epilepticus	Disease	D013226	A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.
BC8_BioRED_Task1_Doc171	505	509	rats	OrganismTaxon	10116	Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.
BC8_BioRED_Task1_Doc171	585	596	pilocarpine	Chemical	D010862	Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.
BC8_BioRED_Task1_Doc171	612	623	Pilocarpine	Chemical	D010862	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	646	664	status epilepticus	Disease	D013226	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	666	684	status epilepticus	Disease	D013226	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	704	707	CA3	CellLine	CVCL_JW73	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	734	742	seizures	Disease	D012640	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	756	760	rats	OrganismTaxon	10116	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	793	801	seizures	Disease	D012640	Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
BC8_BioRED_Task1_Doc171	810	814	rats	OrganismTaxon	10116	Mature rats were trained with sound-source location and sound-silence discriminations.
BC8_BioRED_Task1_Doc171	911	915	rats	OrganismTaxon	10116	Control (saline P20) rats acquired both discriminations immediately.
BC8_BioRED_Task1_Doc171	962	980	status epilepticus	Disease	D013226	In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.
BC8_BioRED_Task1_Doc171	987	991	rats	OrganismTaxon	10116	In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.
BC8_BioRED_Task1_Doc171	1074	1092	Status epilepticus	Disease	D013226	Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.
BC8_BioRED_Task1_Doc171	1099	1103	rats	OrganismTaxon	10116	Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.
BC8_BioRED_Task1_Doc171	1185	1203	Status epilepticus	Disease	D013226	Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.
BC8_BioRED_Task1_Doc171	1207	1210	rat	OrganismTaxon	10116	Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.
BC8_BioRED_Task1_Doc171	1246	1283	impairment in auditory discrimination	Disease	D001308	Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.
BC8_BioRED_Task1_Doc171	1326	1367	impaired auditory location discrimination	Disease	D001308	This impairment may explain one cause of impaired auditory location discrimination in humans.
BC8_BioRED_Task1_Doc171	1371	1377	humans	OrganismTaxon	9606	This impairment may explain one cause of impaired auditory location discrimination in humans.
BC8_BioRED_Task1_Doc172	0	33	Myotonic dystrophy protein kinase	Gene	13400	Myotonic dystrophy protein kinase is involved in the modulation of the Ca2+ homeostasis in skeletal muscle cells.
BC8_BioRED_Task1_Doc172	71	75	Ca2+	Chemical	D002118	Myotonic dystrophy protein kinase is involved in the modulation of the Ca2+ homeostasis in skeletal muscle cells.
BC8_BioRED_Task1_Doc172	114	132	Myotonic dystrophy	Disease	D009223	Myotonic dystrophy (DM), the most prevalent muscular disorder in adults, is caused by (CTG) n-repeat expansion in a gene encoding a protein kinase (DM protein kinase; DMPK) and involves changes in cytoarchitecture and ion homeostasis.
BC8_BioRED_Task1_Doc172	134	136	DM	Disease	D009223	Myotonic dystrophy (DM), the most prevalent muscular disorder in adults, is caused by (CTG) n-repeat expansion in a gene encoding a protein kinase (DM protein kinase; DMPK) and involves changes in cytoarchitecture and ion homeostasis.
BC8_BioRED_Task1_Doc172	158	175	muscular disorder	Disease	D009135	Myotonic dystrophy (DM), the most prevalent muscular disorder in adults, is caused by (CTG) n-repeat expansion in a gene encoding a protein kinase (DM protein kinase; DMPK) and involves changes in cytoarchitecture and ion homeostasis.
BC8_BioRED_Task1_Doc172	262	279	DM protein kinase	Gene	13400	Myotonic dystrophy (DM), the most prevalent muscular disorder in adults, is caused by (CTG) n-repeat expansion in a gene encoding a protein kinase (DM protein kinase; DMPK) and involves changes in cytoarchitecture and ion homeostasis.
BC8_BioRED_Task1_Doc172	281	285	DMPK	Gene	13400	Myotonic dystrophy (DM), the most prevalent muscular disorder in adults, is caused by (CTG) n-repeat expansion in a gene encoding a protein kinase (DM protein kinase; DMPK) and involves changes in cytoarchitecture and ion homeostasis.
BC8_BioRED_Task1_Doc172	398	402	DMPK	Gene	13400	To obtain clues to the normal biological role of DMPK in cellular ion homeostasis, we have compared the resting [Ca2 +] i, the amplitude and shape of depolarization-induced Ca2 + transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and DMPK [-/-] knockout mice.
BC8_BioRED_Task1_Doc172	462	467	Ca2 +	Chemical	D002118	To obtain clues to the normal biological role of DMPK in cellular ion homeostasis, we have compared the resting [Ca2 +] i, the amplitude and shape of depolarization-induced Ca2 + transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and DMPK [-/-] knockout mice.
BC8_BioRED_Task1_Doc172	522	527	Ca2 +	Chemical	D002118	To obtain clues to the normal biological role of DMPK in cellular ion homeostasis, we have compared the resting [Ca2 +] i, the amplitude and shape of depolarization-induced Ca2 + transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and DMPK [-/-] knockout mice.
BC8_BioRED_Task1_Doc172	559	562	ATP	Chemical	D000255	To obtain clues to the normal biological role of DMPK in cellular ion homeostasis, we have compared the resting [Ca2 +] i, the amplitude and shape of depolarization-induced Ca2 + transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and DMPK [-/-] knockout mice.
BC8_BioRED_Task1_Doc172	631	635	DMPK	Gene	13400	To obtain clues to the normal biological role of DMPK in cellular ion homeostasis, we have compared the resting [Ca2 +] i, the amplitude and shape of depolarization-induced Ca2 + transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and DMPK [-/-] knockout mice.
BC8_BioRED_Task1_Doc172	651	655	mice	OrganismTaxon	10090	To obtain clues to the normal biological role of DMPK in cellular ion homeostasis, we have compared the resting [Ca2 +] i, the amplitude and shape of depolarization-induced Ca2 + transients, and the content of ATP-driven ion pumps in cultured skeletal muscle cells of wild-type and DMPK [-/-] knockout mice.
BC8_BioRED_Task1_Doc172	681	685	DMPK	Gene	13400	In vitro-differentiated DMPK [-/-] myotubes exhibit a higher resting [Ca2 +] i than do wild-type myotubes because of an altered open probability of voltage-dependent l-type Ca2 + and Na + channels.
BC8_BioRED_Task1_Doc172	727	732	Ca2 +	Chemical	D002118	In vitro-differentiated DMPK [-/-] myotubes exhibit a higher resting [Ca2 +] i than do wild-type myotubes because of an altered open probability of voltage-dependent l-type Ca2 + and Na + channels.
BC8_BioRED_Task1_Doc172	830	835	Ca2 +	Chemical	D002118	In vitro-differentiated DMPK [-/-] myotubes exhibit a higher resting [Ca2 +] i than do wild-type myotubes because of an altered open probability of voltage-dependent l-type Ca2 + and Na + channels.
BC8_BioRED_Task1_Doc172	840	844	Na +	Chemical	D012964	In vitro-differentiated DMPK [-/-] myotubes exhibit a higher resting [Ca2 +] i than do wild-type myotubes because of an altered open probability of voltage-dependent l-type Ca2 + and Na + channels.
BC8_BioRED_Task1_Doc172	902	907	Ca2 +	Chemical	D002118	The mutant myotubes exhibit smaller and slower Ca2 + responses upon triggering by acetylcholine or high external K +.
BC8_BioRED_Task1_Doc172	937	950	acetylcholine	Chemical	D000109	The mutant myotubes exhibit smaller and slower Ca2 + responses upon triggering by acetylcholine or high external K +.
BC8_BioRED_Task1_Doc172	968	971	K +	Chemical	D011188	The mutant myotubes exhibit smaller and slower Ca2 + responses upon triggering by acetylcholine or high external K +.
BC8_BioRED_Task1_Doc172	1009	1014	Ca2 +	Chemical	D002118	In addition, we observed that these Ca2 + transients partially result from an influx of extracellular Ca2 + through the l-type Ca2 + channel.
BC8_BioRED_Task1_Doc172	1075	1080	Ca2 +	Chemical	D002118	In addition, we observed that these Ca2 + transients partially result from an influx of extracellular Ca2 + through the l-type Ca2 + channel.
BC8_BioRED_Task1_Doc172	1100	1105	Ca2 +	Chemical	D002118	In addition, we observed that these Ca2 + transients partially result from an influx of extracellular Ca2 + through the l-type Ca2 + channel.
BC8_BioRED_Task1_Doc172	1155	1170	Na +/K + ATPase	Chemical	-	Neither the content nor the activity of Na +/K + ATPase and sarcoplasmic reticulum Ca2 + -ATPase are affected by DMPK absence.
BC8_BioRED_Task1_Doc172	1175	1211	sarcoplasmic reticulum Ca2 + -ATPase	Chemical	D053498	Neither the content nor the activity of Na +/K + ATPase and sarcoplasmic reticulum Ca2 + -ATPase are affected by DMPK absence.
BC8_BioRED_Task1_Doc172	1228	1232	DMPK	Gene	13400	Neither the content nor the activity of Na +/K + ATPase and sarcoplasmic reticulum Ca2 + -ATPase are affected by DMPK absence.
BC8_BioRED_Task1_Doc172	1279	1283	DMPK	Gene	13400	In conclusion, our data suggest that DMPK is involved in modulating the initial events of excitation-contraction coupling in skeletal muscle..
BC8_BioRED_Task1_Doc173	0	19	Antithrombotic drug	Chemical	D005343	Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies.
BC8_BioRED_Task1_Doc173	25	45	cerebral microbleeds	Disease	D002543	Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies.
BC8_BioRED_Task1_Doc173	51	75	intracerebral hemorrhage	Disease	D002543	Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies.
BC8_BioRED_Task1_Doc173	159	179	Cerebral microbleeds	Disease	D002543	BACKGROUND AND PURPOSE: Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs.
BC8_BioRED_Task1_Doc173	181	183	MB	Disease	D002543	BACKGROUND AND PURPOSE: Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs.
BC8_BioRED_Task1_Doc173	216	240	intracerebral hemorrhage	Disease	D002543	BACKGROUND AND PURPOSE: Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs.
BC8_BioRED_Task1_Doc173	242	245	ICH	Disease	D002543	BACKGROUND AND PURPOSE: Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs.
BC8_BioRED_Task1_Doc173	306	326	antithrombotic drugs	Chemical	D005343	BACKGROUND AND PURPOSE: Cerebral microbleeds (MB) are potential risk factors for intracerebral hemorrhage (ICH), but it is unclear if they are a contraindication to using antithrombotic drugs.
BC8_BioRED_Task1_Doc173	372	374	MB	Disease	D002543	Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
BC8_BioRED_Task1_Doc173	434	437	ICH	Disease	D002543	Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
BC8_BioRED_Task1_Doc173	442	457	ischemic stroke	Disease	D002544	Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
BC8_BioRED_Task1_Doc173	459	461	IS	Disease	D002544	Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
BC8_BioRED_Task1_Doc173	463	488	transient ischemic attack	Disease	D002546	Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
BC8_BioRED_Task1_Doc173	490	493	TIA	Disease	D002546	Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke (IS)/transient ischemic attack (TIA).
BC8_BioRED_Task1_Doc173	590	596	stroke	Disease	D020521	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	600	603	TIA	Disease	D002546	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	631	633	MB	Disease	D002543	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	695	698	ICH	Disease	D002543	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	742	744	IS	Disease	D002544	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	745	748	TIA	Disease	D002546	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	758	761	ICH	Disease	D002543	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	765	773	ischemic	Disease	D007511	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use.
BC8_BioRED_Task1_Doc173	898	901	ICH	Disease	D002543	We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB.
BC8_BioRED_Task1_Doc173	931	933	MB	Disease	D002543	We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB.
BC8_BioRED_Task1_Doc173	973	976	ICH	Disease	D002543	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	986	988	IS	Disease	D002544	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	989	992	TIA	Disease	D002546	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	994	996	MB	Disease	D002543	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	1019	1022	ICH	Disease	D002543	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	1026	1028	IS	Disease	D002544	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	1029	1032	TIA	Disease	D002546	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	1223	1231	warfarin	Chemical	D014859	RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
BC8_BioRED_Task1_Doc173	1287	1289	MB	Disease	D002543	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
BC8_BioRED_Task1_Doc173	1293	1301	warfarin	Chemical	D014859	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
BC8_BioRED_Task1_Doc173	1325	1328	ICH	Disease	D002543	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
BC8_BioRED_Task1_Doc173	1377	1385	warfarin	Chemical	D014859	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
BC8_BioRED_Task1_Doc173	1397	1399	IS	Disease	D002544	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
BC8_BioRED_Task1_Doc173	1400	1403	TIA	Disease	D002546	There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
BC8_BioRED_Task1_Doc173	1489	1491	MB	Disease	D002543	There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P<0.001; P difference=0.25).
BC8_BioRED_Task1_Doc173	1531	1534	ICH	Disease	D002543	There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P<0.001; P difference=0.25).
BC8_BioRED_Task1_Doc173	1626	1628	IS	Disease	D002544	There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P<0.001; P difference=0.25).
BC8_BioRED_Task1_Doc173	1629	1632	TIA	Disease	D002546	There was a smaller excess of MB in antiplatelet users vs nonusers with ICH (OR, 1.7; 95% CI, 1.3-2.3; P<0.001), but findings were similar for antiplatelet users with IS/TIA (OR, 1.4; 95% CI, 1.2-1.7; P<0.001; P difference=0.25).
BC8_BioRED_Task1_Doc173	1756	1758	MB	Disease	D002543	In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4-42.5; P<0.001).
BC8_BioRED_Task1_Doc173	1836	1839	ICH	Disease	D002543	In pooled follow-up data for 768 antithrombotic users, presence of MB at baseline was associated with a substantially increased risk of subsequent ICH (OR, 12.1; 95% CI, 3.4-42.5; P<0.001).
BC8_BioRED_Task1_Doc173	1906	1908	MB	Disease	D002543	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
BC8_BioRED_Task1_Doc173	1912	1920	warfarin	Chemical	D014859	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
BC8_BioRED_Task1_Doc173	1932	1935	ICH	Disease	D002543	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
BC8_BioRED_Task1_Doc173	1975	1977	MB	Disease	D002543	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
BC8_BioRED_Task1_Doc173	1999	2007	warfarin	Chemical	D014859	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
BC8_BioRED_Task1_Doc173	2019	2022	ICH	Disease	D002543	CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.
BC8_BioRED_Task1_Doc174	7	30	dihydrofolate reductase	Gene	1719	Common dihydrofolate reductase 19-base pair deletion allele: a novel risk factor for preterm delivery.
BC8_BioRED_Task1_Doc174	31	52	19-base pair deletion	SequenceVariant	c|DEL||19	Common dihydrofolate reductase 19-base pair deletion allele: a novel risk factor for preterm delivery.
BC8_BioRED_Task1_Doc174	85	101	preterm delivery	Disease	D047928	Common dihydrofolate reductase 19-base pair deletion allele: a novel risk factor for preterm delivery.
BC8_BioRED_Task1_Doc174	115	121	Folate	Chemical	D005492	BACKGROUND: Folate is critical for cell division, a major feature of in utero development.
BC8_BioRED_Task1_Doc174	194	217	Dihydrofolate reductase	Gene	1719	Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.
BC8_BioRED_Task1_Doc174	219	223	DHFR	Gene	1719	Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.
BC8_BioRED_Task1_Doc174	252	262	folic acid	Chemical	D005492	Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.
BC8_BioRED_Task1_Doc174	318	331	dihydrofolate	Chemical	C010920	Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.
BC8_BioRED_Task1_Doc174	344	364	thymidylate synthase	Gene	7298	Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.
BC8_BioRED_Task1_Doc174	401	407	folate	Chemical	D005492	Dihydrofolate reductase (DHFR) is required to convert the folic acid used in supplements and for food fortification and the dihydrofolate produced by thymidylate synthase during DNA synthesis to the reduced folate forms used by the cell.
BC8_BioRED_Task1_Doc174	532	536	DHFR	Gene	1719	OBJECTIVE: We aimed to determine whether a common, recently discovered deletion polymorphism in the DHFR gene is a risk factor for preterm delivery or low birth weight.
BC8_BioRED_Task1_Doc174	563	579	preterm delivery	Disease	D047928	OBJECTIVE: We aimed to determine whether a common, recently discovered deletion polymorphism in the DHFR gene is a risk factor for preterm delivery or low birth weight.
BC8_BioRED_Task1_Doc174	633	638	women	OrganismTaxon	9606	DESIGN: We studied 324 pregnant women from Camden, NJ.
BC8_BioRED_Task1_Doc174	656	662	Folate	Chemical	D005492	Folate intake was computed from folate supplement intake plus the mean of two 24-h recalls completed during the course of pregnancy.
BC8_BioRED_Task1_Doc174	688	694	folate	Chemical	D005492	Folate intake was computed from folate supplement intake plus the mean of two 24-h recalls completed during the course of pregnancy.
BC8_BioRED_Task1_Doc174	824	829	women	OrganismTaxon	9606	Genomic DNA was extracted from the women's leukocytes and genotyped.
BC8_BioRED_Task1_Doc174	867	872	Women	OrganismTaxon	9606	RESULTS: Women with a deletion allele had a significantly greater risk of preterm delivery [adjusted odds ratio (AOR): 3.0; 95% CI: 1.0, 8.8; P < 0.05] than did those without a deletion allele.
BC8_BioRED_Task1_Doc174	932	948	preterm delivery	Disease	D047928	RESULTS: Women with a deletion allele had a significantly greater risk of preterm delivery [adjusted odds ratio (AOR): 3.0; 95% CI: 1.0, 8.8; P < 0.05] than did those without a deletion allele.
BC8_BioRED_Task1_Doc174	1052	1057	Women	OrganismTaxon	9606	Women with both a DHFR deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.
BC8_BioRED_Task1_Doc174	1070	1074	DHFR	Gene	1719	Women with both a DHFR deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.
BC8_BioRED_Task1_Doc174	1099	1105	folate	Chemical	D005492	Women with both a DHFR deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.
BC8_BioRED_Task1_Doc174	1192	1208	preterm delivery	Disease	D047928	Women with both a DHFR deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.
BC8_BioRED_Task1_Doc174	1375	1380	women	OrganismTaxon	9606	Women with both a DHFR deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.
BC8_BioRED_Task1_Doc174	1418	1424	folate	Chemical	D005492	Women with both a DHFR deletion allele and low folate intake (<400 microg/d from diet plus supplements) had a significantly greater risk of preterm delivery (AOR: 5.5; 95% CI: 1.5, 20.4; P = 0.01) and a significantly greater risk of having an infant with a low birth weight (AOR: 8.3; 95% CI: 1.8, 38.6; P = 0.01) than did women without a deletion allele and with a folate intake >/=400 microg/d.
BC8_BioRED_Task1_Doc174	1466	1470	DHFR	Gene	1719	CONCLUSIONS: The DHFR 19-base pair deletion allele may be a risk factor for preterm delivery.
BC8_BioRED_Task1_Doc174	1471	1492	19-base pair deletion	SequenceVariant	c|DEL||19	CONCLUSIONS: The DHFR 19-base pair deletion allele may be a risk factor for preterm delivery.
BC8_BioRED_Task1_Doc174	1525	1541	preterm delivery	Disease	D047928	CONCLUSIONS: The DHFR 19-base pair deletion allele may be a risk factor for preterm delivery.
BC8_BioRED_Task1_Doc174	1574	1580	folate	Chemical	D005492	In the presence of low dietary folate, the allele may also be a risk factor for low birth weight.
BC8_BioRED_Task1_Doc175	0	12	Atorvastatin	Chemical	D000069059	Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	30	58	contrast-induced nephropathy	Disease	D007674	Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	101	106	Hsp27	Gene	24471	Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	129	157	Contrast-induced nephropathy	Disease	D007674	Contrast-induced nephropathy (CIN) is an iatrogenic acute renal failure occurring following the intravascular injection of iodinated radiographic contrast medium.
BC8_BioRED_Task1_Doc175	159	162	CIN	Disease	D007674	Contrast-induced nephropathy (CIN) is an iatrogenic acute renal failure occurring following the intravascular injection of iodinated radiographic contrast medium.
BC8_BioRED_Task1_Doc175	181	200	acute renal failure	Disease	D058186	Contrast-induced nephropathy (CIN) is an iatrogenic acute renal failure occurring following the intravascular injection of iodinated radiographic contrast medium.
BC8_BioRED_Task1_Doc175	331	334	CIN	Disease	D007674	However, the regulatory mechanisms for CIN remain to be fully elucidated.
BC8_BioRED_Task1_Doc175	413	425	atorvastatin	Chemical	D000069059	The present study aimed to investigate whether atorvastatin protects against CIN via anti-apoptotic effects by the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	443	446	CIN	Disease	D007674	The present study aimed to investigate whether atorvastatin protects against CIN via anti-apoptotic effects by the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	497	502	Hsp27	Gene	24471	The present study aimed to investigate whether atorvastatin protects against CIN via anti-apoptotic effects by the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	546	558	atorvastatin	Chemical	D000069059	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	570	573	CIN	Disease	D007674	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	579	591	inflammatory	Disease	D007249	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	639	642	rat	OrganismTaxon	10116	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	652	661	iopamidol	Chemical	D007479	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	670	673	CIN	Disease	D007674	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	688	693	human	OrganismTaxon	9606	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	721	724	HK2	CellLine	CVCL_0302	To determine whether atorvastatin attenuated CIN, the inflammatory response and apoptosis in vivo and in vitro, a rat model of iopamidol-induced CIN was used, and human embryonic proximal tubule (HK2) cell damage was assessed.
BC8_BioRED_Task1_Doc175	756	760	rats	OrganismTaxon	10116	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	830	834	rats	OrganismTaxon	10116	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	836	840	rats	OrganismTaxon	10116	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	841	853	atorvastatin	Chemical	D000069059	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	855	859	rats	OrganismTaxon	10116	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	862	871	iopamidol	Chemical	D007479	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	873	877	rats	OrganismTaxon	10116	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	878	887	iopamidol	Chemical	D007479	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	888	900	atorvastatin	Chemical	D000069059	The rats were assigned into four groups (n=10 per group), as follows: Control rats; rats+atorvastatin; rats + iopamidol; rats+iopamidol+atorvastatin.
BC8_BioRED_Task1_Doc175	916	919	HK2	CellLine	CVCL_0302	In vitro, the HK2 cells were treated with iopamidol in the presence or absence of atorvastatin, heat shock protein (Hsp)27 small interfering (si)RNA or pcDNA3.1-Hsp27.
BC8_BioRED_Task1_Doc175	944	953	iopamidol	Chemical	D007479	In vitro, the HK2 cells were treated with iopamidol in the presence or absence of atorvastatin, heat shock protein (Hsp)27 small interfering (si)RNA or pcDNA3.1-Hsp27.
BC8_BioRED_Task1_Doc175	984	996	atorvastatin	Chemical	D000069059	In vitro, the HK2 cells were treated with iopamidol in the presence or absence of atorvastatin, heat shock protein (Hsp)27 small interfering (si)RNA or pcDNA3.1-Hsp27.
BC8_BioRED_Task1_Doc175	998	1024	heat shock protein (Hsp)27	Gene	3315	In vitro, the HK2 cells were treated with iopamidol in the presence or absence of atorvastatin, heat shock protein (Hsp)27 small interfering (si)RNA or pcDNA3.1-Hsp27.
BC8_BioRED_Task1_Doc175	1063	1068	Hsp27	Gene	3315	In vitro, the HK2 cells were treated with iopamidol in the presence or absence of atorvastatin, heat shock protein (Hsp)27 small interfering (si)RNA or pcDNA3.1-Hsp27.
BC8_BioRED_Task1_Doc175	1187	1199	atorvastatin	Chemical	D000069059	The results showed that atorvastatin ameliorated the apoptosis and deterioration of renal function (P<0.05).
BC8_BioRED_Task1_Doc175	1216	1261	apoptosis and deterioration of renal function	Disease	D007674	The results showed that atorvastatin ameliorated the apoptosis and deterioration of renal function (P<0.05).
BC8_BioRED_Task1_Doc175	1285	1297	atorvastatin	Chemical	D000069059	Furthermore, atorvastatin reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1310	1319	iopamidol	Chemical	D007479	Furthermore, atorvastatin reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1340	1386	B cell lymphoma-2 (Bcl-2)-associated X protein	Gene	24887	Furthermore, atorvastatin reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1388	1391	Bax	Gene	24887	Furthermore, atorvastatin reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1393	1402	caspase-3	Gene	25402	Furthermore, atorvastatin reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1435	1440	Bcl-2	Gene	24224	Furthermore, atorvastatin reduced the iopamidol-induced activity of B cell lymphoma-2 (Bcl-2)-associated X protein (Bax)/caspase-3 and increased the expression of Bcl-2 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1497	1502	Hsp27	Gene	3315	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1521	1526	Hsp27	Gene	3315	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1546	1555	iopamidol	Chemical	D007479	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1597	1600	Bax	Gene	581	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1601	1610	caspase-3	Gene	836	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1633	1638	Bcl-2	Gene	596	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1646	1649	HK2	CellLine	CVCL_0302	Notably, following treatment with Hsp27 siRNA or pcDNA3.1-Hsp27, it was found that iopamidol enhanced or weakened the upregulation of Bax/caspase-3 and downregulation of Bcl-2 in the HK2 cells, respectively.
BC8_BioRED_Task1_Doc175	1719	1731	atorvastatin	Chemical	D000069059	The results of the present study suggested that atorvastatin protected against contrast-induced renal tubular cell apoptosis through the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1750	1795	contrast-induced renal tubular cell apoptosis	Disease	D007674	The results of the present study suggested that atorvastatin protected against contrast-induced renal tubular cell apoptosis through the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc175	1824	1829	Hsp27	Gene	24471	The results of the present study suggested that atorvastatin protected against contrast-induced renal tubular cell apoptosis through the upregulation of Hsp27 in vivo and in vitro.
BC8_BioRED_Task1_Doc176	58	66	patients	OrganismTaxon	9606	New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2.
BC8_BioRED_Task1_Doc176	72	114	steroid 5alpha-reductase deficiency type 2	Disease	C535830	New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2.
BC8_BioRED_Task1_Doc176	133	164	steroid 5alpha-reductase type 2	Gene	6716	Mutations of the steroid 5alpha-reductase type 2 (SRD5A2) gene in 46,XY subjects cause masculinization defects of varying degrees, due to reduced or impaired enzymatic activity.
BC8_BioRED_Task1_Doc176	166	172	SRD5A2	Gene	6716	Mutations of the steroid 5alpha-reductase type 2 (SRD5A2) gene in 46,XY subjects cause masculinization defects of varying degrees, due to reduced or impaired enzymatic activity.
BC8_BioRED_Task1_Doc176	339	345	SRD5A2	Gene	6716	In this study, sequence abnormalities of the SRD5A2 gene were assessed by polymerase chain reaction with specific primers and automated sequencing analysis in DNA samples from 20 patients with suspected steroid 5alpha-reductase type 2 deficiency from 18 Brazilian families.
BC8_BioRED_Task1_Doc176	473	481	patients	OrganismTaxon	9606	In this study, sequence abnormalities of the SRD5A2 gene were assessed by polymerase chain reaction with specific primers and automated sequencing analysis in DNA samples from 20 patients with suspected steroid 5alpha-reductase type 2 deficiency from 18 Brazilian families.
BC8_BioRED_Task1_Doc176	497	539	steroid 5alpha-reductase type 2 deficiency	Disease	C535830	In this study, sequence abnormalities of the SRD5A2 gene were assessed by polymerase chain reaction with specific primers and automated sequencing analysis in DNA samples from 20 patients with suspected steroid 5alpha-reductase type 2 deficiency from 18 Brazilian families.
BC8_BioRED_Task1_Doc176	594	600	SRD5A2	Gene	6716	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	672	680	patients	OrganismTaxon	9606	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	686	691	G183S	SequenceVariant	rs121434247	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	702	707	R246W	SequenceVariant	rs121434244	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	718	725	del642T	SequenceVariant	c|DEL|642|T	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	736	741	G196S	SequenceVariant	rs121434250	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	756	767	217_218insC	SequenceVariant	c|INS|217_218|C	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	777	781	A49T	SequenceVariant	rs9282858	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	860	865	Q126R	SequenceVariant	rs368386747	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	866	875	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	886	891	Q126R	SequenceVariant	rs368386747	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	892	899	del418T	SequenceVariant	c|DEL|418|T	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	923	928	Q126R	SequenceVariant	rs368386747	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	929	934	G158R	SequenceVariant	p|SUB|G|158|R	Eleven subjects presented SRD5A2 homozygous single-base mutations (two first cousins and four unrelated patients with G183S, two with R246W, one with del642T, one with G196S, and one with 217_218insC plus the A49T variant in heterozygosis), whereas four were compound heterozygotes (one with Q126R/IVS3+1G>A, one with Q126R/del418T, and two brothers with Q126R/G158R).
BC8_BioRED_Task1_Doc176	943	951	patients	OrganismTaxon	9606	Three patients were heterozygous for A207D, G196S, and R266W substitutions.
BC8_BioRED_Task1_Doc176	974	979	A207D	SequenceVariant	rs767564684	Three patients were heterozygous for A207D, G196S, and R266W substitutions.
BC8_BioRED_Task1_Doc176	981	986	G196S	SequenceVariant	rs121434250	Three patients were heterozygous for A207D, G196S, and R266W substitutions.
BC8_BioRED_Task1_Doc176	992	997	R266W	SequenceVariant	p|SUB|R|266|W	Three patients were heterozygous for A207D, G196S, and R266W substitutions.
BC8_BioRED_Task1_Doc176	1017	1021	V89L	SequenceVariant	rs523349	The V89L polymorphism was found in heterozygosis in one of them (with A207D) and in one case with an otherwise normal gene sequence.
BC8_BioRED_Task1_Doc176	1083	1088	A207D	SequenceVariant	rs767564684	The V89L polymorphism was found in heterozygosis in one of them (with A207D) and in one case with an otherwise normal gene sequence.
BC8_BioRED_Task1_Doc176	1150	1154	A49T	SequenceVariant	rs9282858	The A49T variant was also detected in heterozygosis in the second case without other sequencing abnormalities.
BC8_BioRED_Task1_Doc176	1262	1270	patients	OrganismTaxon	9606	Four patients harbor yet non-described SRD5A2 gene mutations: a single nucleotide deletion (del642T), a G158R amino acid substitution, a splice junction mutation (IVS3+1G>A), and the insertion of a cytosine (217_218insC) occurring at a CCCC motif.
BC8_BioRED_Task1_Doc176	1296	1302	SRD5A2	Gene	6716	Four patients harbor yet non-described SRD5A2 gene mutations: a single nucleotide deletion (del642T), a G158R amino acid substitution, a splice junction mutation (IVS3+1G>A), and the insertion of a cytosine (217_218insC) occurring at a CCCC motif.
BC8_BioRED_Task1_Doc176	1349	1356	del642T	SequenceVariant	c|DEL|642|T	Four patients harbor yet non-described SRD5A2 gene mutations: a single nucleotide deletion (del642T), a G158R amino acid substitution, a splice junction mutation (IVS3+1G>A), and the insertion of a cytosine (217_218insC) occurring at a CCCC motif.
BC8_BioRED_Task1_Doc176	1361	1366	G158R	SequenceVariant	p|SUB|G|158|R	Four patients harbor yet non-described SRD5A2 gene mutations: a single nucleotide deletion (del642T), a G158R amino acid substitution, a splice junction mutation (IVS3+1G>A), and the insertion of a cytosine (217_218insC) occurring at a CCCC motif.
BC8_BioRED_Task1_Doc176	1420	1429	IVS3+1G>A	SequenceVariant	c|SUB|G|IVS3+1|A	Four patients harbor yet non-described SRD5A2 gene mutations: a single nucleotide deletion (del642T), a G158R amino acid substitution, a splice junction mutation (IVS3+1G>A), and the insertion of a cytosine (217_218insC) occurring at a CCCC motif.
BC8_BioRED_Task1_Doc176	1465	1476	217_218insC	SequenceVariant	c|INS|217_218|C	Four patients harbor yet non-described SRD5A2 gene mutations: a single nucleotide deletion (del642T), a G158R amino acid substitution, a splice junction mutation (IVS3+1G>A), and the insertion of a cytosine (217_218insC) occurring at a CCCC motif.
BC8_BioRED_Task1_Doc176	1593	1599	SRD5A2	Gene	6716	This is the first report of a single-nucleotide insertion in the coding sequence of the SRD5A2 gene.
BC8_BioRED_Task1_Doc176	1687	1692	G183S	SequenceVariant	rs121434247	In addition to these new mutations, this investigation reveals the prevalence of G183S substitution among a subset of African-Brazilian patients and presents evidences of the recurrence of already known mutations.
BC8_BioRED_Task1_Doc176	1742	1750	patients	OrganismTaxon	9606	In addition to these new mutations, this investigation reveals the prevalence of G183S substitution among a subset of African-Brazilian patients and presents evidences of the recurrence of already known mutations.
BC8_BioRED_Task1_Doc177	8	24	xanthine oxidase	Chemical	D014969	Role of xanthine oxidase in dexamethasone-induced hypertension in rats.
BC8_BioRED_Task1_Doc177	28	41	dexamethasone	Chemical	D003907	Role of xanthine oxidase in dexamethasone-induced hypertension in rats.
BC8_BioRED_Task1_Doc177	50	62	hypertension	Disease	D006973	Role of xanthine oxidase in dexamethasone-induced hypertension in rats.
BC8_BioRED_Task1_Doc177	66	70	rats	OrganismTaxon	10116	Role of xanthine oxidase in dexamethasone-induced hypertension in rats.
BC8_BioRED_Task1_Doc177	75	89	Glucocorticoid	Chemical	D005938	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.
BC8_BioRED_Task1_Doc177	98	110	hypertension	Disease	D006973	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.
BC8_BioRED_Task1_Doc177	112	114	GC	Chemical	D005938	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.
BC8_BioRED_Task1_Doc177	115	117	HT	Disease	D006973	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.
BC8_BioRED_Task1_Doc177	126	129	rat	OrganismTaxon	10116	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.
BC8_BioRED_Task1_Doc177	149	161	nitric oxide	Chemical	D009569	Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.
BC8_BioRED_Task1_Doc177	205	221	xanthine oxidase	Chemical	D014969	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	223	225	XO	Chemical	D014969	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	269	292	reactive oxygen species	Chemical	D017382	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	297	310	dexamethasone	Chemical	D003907	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	319	331	hypertension	Disease	D006973	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	333	336	dex	Chemical	D003907	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	337	339	HT	Disease	D006973	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).
BC8_BioRED_Task1_Doc177	372	376	rats	OrganismTaxon	10116	Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.
BC8_BioRED_Task1_Doc177	435	448	dexamethasone	Chemical	D003907	Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.
BC8_BioRED_Task1_Doc177	450	453	dex	Chemical	D003907	Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.
BC8_BioRED_Task1_Doc177	456	467	allopurinol	Chemical	D000493	Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.
BC8_BioRED_Task1_Doc177	485	496	allopurinol	Chemical	D000493	Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.
BC8_BioRED_Task1_Doc177	502	505	dex	Chemical	D003907	Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.
BC8_BioRED_Task1_Doc177	629	643	glucocorticoid	Chemical	D005938	Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.
BC8_BioRED_Task1_Doc177	664	669	urate	Chemical	D014527	Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.
BC8_BioRED_Task1_Doc177	680	682	XO	Chemical	D014969	Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.
BC8_BioRED_Task1_Doc177	698	701	Dex	Chemical	D003907	Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P" < 0.01).
BC8_BioRED_Task1_Doc177	816	827	Allopurinol	Chemical	D000493	Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.
BC8_BioRED_Task1_Doc177	844	849	urate	Chemical	D014527	Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.
BC8_BioRED_Task1_Doc177	954	957	dex	Chemical	D003907	Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.
BC8_BioRED_Task1_Doc177	988	999	Allopurinol	Chemical	D000493	Allopurinol did not prevent dex-HT.
BC8_BioRED_Task1_Doc177	1016	1019	dex	Chemical	D003907	Allopurinol did not prevent dex-HT.
BC8_BioRED_Task1_Doc177	1020	1022	HT	Disease	D006973	Allopurinol did not prevent dex-HT.
BC8_BioRED_Task1_Doc177	1071	1082	allopurinol	Chemical	D000493	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc177	1101	1129	adrenocorticotrophic hormone	Gene	5443	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc177	1138	1150	hypertension	Disease	D006973	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc177	1166	1168	XO	Chemical	D014969	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc177	1208	1210	GC	Chemical	D005938	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc177	1211	1213	HT	Disease	D006973	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc177	1221	1224	rat	OrganismTaxon	10116	This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.
BC8_BioRED_Task1_Doc178	29	41	VII collagen	Gene	1294	Identification of novel type VII collagen gene mutations resulting in severe recessive dystrophic epidermolysis bullosa.
BC8_BioRED_Task1_Doc178	77	119	recessive dystrophic epidermolysis bullosa	Disease	D016108	Identification of novel type VII collagen gene mutations resulting in severe recessive dystrophic epidermolysis bullosa.
BC8_BioRED_Task1_Doc178	267	279	VII collagen	Gene	1294	In this work, we studied the proband in a small nuclear family of Chinese and Dutch/German descent and identified two novel mutations in the type VII collagen gene leading to recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens variant (HS-RDEB).
BC8_BioRED_Task1_Doc178	296	338	recessive dystrophic epidermolysis bullosa	Disease	D016108	In this work, we studied the proband in a small nuclear family of Chinese and Dutch/German descent and identified two novel mutations in the type VII collagen gene leading to recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens variant (HS-RDEB).
BC8_BioRED_Task1_Doc178	340	357	Hallopeau-Siemens	Disease	D016108	In this work, we studied the proband in a small nuclear family of Chinese and Dutch/German descent and identified two novel mutations in the type VII collagen gene leading to recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens variant (HS-RDEB).
BC8_BioRED_Task1_Doc178	367	374	HS-RDEB	Disease	D016108	In this work, we studied the proband in a small nuclear family of Chinese and Dutch/German descent and identified two novel mutations in the type VII collagen gene leading to recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens variant (HS-RDEB).
BC8_BioRED_Task1_Doc178	404	454	single base pair deletion of a cytosine nucleotide	SequenceVariant	c|DEL||C	The maternal mutation is a single base pair deletion of a cytosine nucleotide in exon 26, designated 3472delC, resulting in a frameshift and a premature termination codon (PTC) within the same exon, 7 bp downstream of the site of the mutation.
BC8_BioRED_Task1_Doc178	478	486	3472delC	SequenceVariant	c|DEL|3472|C	The maternal mutation is a single base pair deletion of a cytosine nucleotide in exon 26, designated 3472delC, resulting in a frameshift and a premature termination codon (PTC) within the same exon, 7 bp downstream of the site of the mutation.
BC8_BioRED_Task1_Doc178	648	653	G-->A	SequenceVariant	c|SUB|G||A	The paternal mutation is a G-->A transition located at the 5' donor splice site within intron 51, designated IVS51 + 1G-->A.
BC8_BioRED_Task1_Doc178	730	744	IVS51 + 1G-->A	SequenceVariant	c|SUB|G|IVS51+1|A	The paternal mutation is a G-->A transition located at the 5' donor splice site within intron 51, designated IVS51 + 1G-->A.
BC8_BioRED_Task1_Doc178	1129	1136	HS-RDEB	Disease	D016108	These findings extend the body of evidence for compound heterozygous mutations leading to HS-RDEB and provide the basis for prenatal diagnosis in this family.
BC8_BioRED_Task1_Doc179	22	34	urotensin-II	Gene	24111	Behavioral effects of urotensin-II centrally administered in mice.
BC8_BioRED_Task1_Doc179	61	65	mice	OrganismTaxon	10090	Behavioral effects of urotensin-II centrally administered in mice.
BC8_BioRED_Task1_Doc179	67	79	Urotensin-II	Gene	24111	Urotensin-II (U-II) receptors are widely distributed in the central nervous system.
BC8_BioRED_Task1_Doc179	81	85	U-II	Gene	24111	Urotensin-II (U-II) receptors are widely distributed in the central nervous system.
BC8_BioRED_Task1_Doc179	197	201	U-II	Gene	24111	injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
BC8_BioRED_Task1_Doc179	209	221	hypertension	Disease	D006973	injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
BC8_BioRED_Task1_Doc179	226	237	bradycardia	Disease	D001919	injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
BC8_BioRED_Task1_Doc179	253	262	prolactin	Gene	19109	injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
BC8_BioRED_Task1_Doc179	267	278	thyrotropin	Gene	12640	injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
BC8_BioRED_Task1_Doc179	348	352	U-II	Gene	24111	However, the behavioral effects of centrally administered U-II have received little attention.
BC8_BioRED_Task1_Doc179	453	457	U-II	Gene	24111	injections of U-II on behavioral, metabolic, and endocrine responses in mice.
BC8_BioRED_Task1_Doc179	511	515	mice	OrganismTaxon	10090	injections of U-II on behavioral, metabolic, and endocrine responses in mice.
BC8_BioRED_Task1_Doc179	551	555	U-II	Gene	24111	Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.
BC8_BioRED_Task1_Doc179	569	574	mouse	OrganismTaxon	10090	Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.
BC8_BioRED_Task1_Doc179	1031	1035	U-II	Gene	24111	Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.
BC8_BioRED_Task1_Doc179	1105	1110	mouse	OrganismTaxon	10090	Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.
BC8_BioRED_Task1_Doc179	1151	1156	mouse	OrganismTaxon	10090	Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.
BC8_BioRED_Task1_Doc179	1216	1221	mouse	OrganismTaxon	10090	Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.
BC8_BioRED_Task1_Doc179	1276	1280	U-II	Gene	24111	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.
BC8_BioRED_Task1_Doc179	1329	1340	apomorphine	Chemical	D001058	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.
BC8_BioRED_Task1_Doc179	1414	1428	corticosterone	Chemical	D003345	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.
BC8_BioRED_Task1_Doc179	1513	1517	U-II	Gene	24111	Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.
BC8_BioRED_Task1_Doc179	1542	1547	mouse	OrganismTaxon	10090	Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.
BC8_BioRED_Task1_Doc179	1556	1566	anxiogenic	Disease	D001008	Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.
BC8_BioRED_Task1_Doc179	1572	1582	depressant	Disease	D003866	Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.
BC8_BioRED_Task1_Doc179	1599	1604	mouse	OrganismTaxon	10090	Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.
BC8_BioRED_Task1_Doc179	1630	1634	U-II	Gene	24111	These data suggest that U-II may be involved in some aspects of psychiatric disorders.
BC8_BioRED_Task1_Doc179	1670	1691	psychiatric disorders	Disease	D001523	These data suggest that U-II may be involved in some aspects of psychiatric disorders.
BC8_BioRED_Task1_Doc180	0	23	Melanocortin-4 receptor	Gene	17202,25635,4160	Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling.
BC8_BioRED_Task1_Doc180	44	67	c-Jun N-terminal kinase	Gene	116554,26419,5599	Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling.
BC8_BioRED_Task1_Doc180	90	97	insulin	Gene	16333,24505,3630	Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling.
BC8_BioRED_Task1_Doc180	113	125	melanocortin	Gene	5443	The melanocortin system is crucial to regulation of energy homeostasis.
BC8_BioRED_Task1_Doc180	185	213	melanocortin receptor type 4	Gene	4160	The melanocortin receptor type 4 (MC4R) modulates insulin signaling via effects on c-Jun N-terminal kinase (JNK).
BC8_BioRED_Task1_Doc180	215	219	MC4R	Gene	4160	The melanocortin receptor type 4 (MC4R) modulates insulin signaling via effects on c-Jun N-terminal kinase (JNK).
BC8_BioRED_Task1_Doc180	231	238	insulin	Gene	3630	The melanocortin receptor type 4 (MC4R) modulates insulin signaling via effects on c-Jun N-terminal kinase (JNK).
BC8_BioRED_Task1_Doc180	264	287	c-Jun N-terminal kinase	Gene	5599	The melanocortin receptor type 4 (MC4R) modulates insulin signaling via effects on c-Jun N-terminal kinase (JNK).
BC8_BioRED_Task1_Doc180	289	292	JNK	Gene	5599	The melanocortin receptor type 4 (MC4R) modulates insulin signaling via effects on c-Jun N-terminal kinase (JNK).
BC8_BioRED_Task1_Doc180	299	311	melanocortin	Gene	5443	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	320	327	NDP-MSH	Chemical	C027756	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	355	358	JNK	Gene	5599	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	371	377	HEK293	CellLine	CVCL_0045	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	406	411	human	OrganismTaxon	9606	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	412	416	MC4R	Gene	4160	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	443	464	melanocortin receptor	Gene	4160	The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	477	484	NDP-MSH	Chemical	C027756	NDP-MSH time- and dose-dependently inhibited IRS-1(ser307) phosphorylation, effects also reversed by a specific melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	522	527	IRS-1	Gene	3667	NDP-MSH time- and dose-dependently inhibited IRS-1(ser307) phosphorylation, effects also reversed by a specific melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	589	610	melanocortin receptor	Gene	4160	NDP-MSH time- and dose-dependently inhibited IRS-1(ser307) phosphorylation, effects also reversed by a specific melanocortin receptor antagonist.
BC8_BioRED_Task1_Doc180	623	630	NDP-MSH	Chemical	C027756	NDP-MSH augmented insulin-stimulated AKT phosphorylation in vitro.
BC8_BioRED_Task1_Doc180	641	648	insulin	Gene	3630	NDP-MSH augmented insulin-stimulated AKT phosphorylation in vitro.
BC8_BioRED_Task1_Doc180	660	663	AKT	Gene	207	NDP-MSH augmented insulin-stimulated AKT phosphorylation in vitro.
BC8_BioRED_Task1_Doc180	694	706	melanocortin	Gene	5443	The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo.
BC8_BioRED_Task1_Doc180	715	727	melanotan II	Chemical	C079282	The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo.
BC8_BioRED_Task1_Doc180	738	745	insulin	Gene	24505	The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo.
BC8_BioRED_Task1_Doc180	757	760	AKT	Gene	24185	The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo.
BC8_BioRED_Task1_Doc180	784	787	rat	OrganismTaxon	10116	The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo.
BC8_BioRED_Task1_Doc180	810	817	NDP-MSH	Chemical	C027756	NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.
BC8_BioRED_Task1_Doc180	828	835	insulin	Gene	16333	NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.
BC8_BioRED_Task1_Doc180	847	854	glucose	Chemical	D005947	NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.
BC8_BioRED_Task1_Doc180	878	883	GT1-1	CellLine	CVCL_6236	NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells.
BC8_BioRED_Task1_Doc180	964	971	insulin	Gene	16333,24505,3630	The current study shows that the melanocortinergic system interacts with insulin signaling via novel effects on JNK activity.
BC8_BioRED_Task1_Doc180	1003	1006	JNK	Gene	116554,26419,5599	The current study shows that the melanocortinergic system interacts with insulin signaling via novel effects on JNK activity.
BC8_BioRED_Task1_Doc181	14	23	sirolimus	Chemical	D020123	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
BC8_BioRED_Task1_Doc181	36	48	cyclosporine	Chemical	D016572	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
BC8_BioRED_Task1_Doc181	57	68	nephropathy	Disease	D007674	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
BC8_BioRED_Task1_Doc181	76	79	rat	OrganismTaxon	10116	Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
BC8_BioRED_Task1_Doc181	180	193	cyclosporin A	Chemical	D016572	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
BC8_BioRED_Task1_Doc181	195	198	CsA	Chemical	D016572	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
BC8_BioRED_Task1_Doc181	203	212	sirolimus	Chemical	D020123	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
BC8_BioRED_Task1_Doc181	214	217	SRL	Chemical	D020123	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
BC8_BioRED_Task1_Doc181	291	294	CsA	Chemical	D016572	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
BC8_BioRED_Task1_Doc181	303	314	nephropathy	Disease	D007674	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
BC8_BioRED_Task1_Doc181	467	470	CsA	Chemical	D016572	This study aimed to identify the molecular pathways and putative biomarkers of CsA-to-SRL conversion in a rat model.
BC8_BioRED_Task1_Doc181	474	477	SRL	Chemical	D020123	This study aimed to identify the molecular pathways and putative biomarkers of CsA-to-SRL conversion in a rat model.
BC8_BioRED_Task1_Doc181	494	497	rat	OrganismTaxon	10116	This study aimed to identify the molecular pathways and putative biomarkers of CsA-to-SRL conversion in a rat model.
BC8_BioRED_Task1_Doc181	569	572	CsA	Chemical	D016572	Four animal groups (n = 6) were tested during 9 weeks: control, CsA, SRL, and conversion (CsA for 3 weeks followed by SRL for 6 weeks).
BC8_BioRED_Task1_Doc181	574	577	SRL	Chemical	D020123	Four animal groups (n = 6) were tested during 9 weeks: control, CsA, SRL, and conversion (CsA for 3 weeks followed by SRL for 6 weeks).
BC8_BioRED_Task1_Doc181	595	598	CsA	Chemical	D016572	Four animal groups (n = 6) were tested during 9 weeks: control, CsA, SRL, and conversion (CsA for 3 weeks followed by SRL for 6 weeks).
BC8_BioRED_Task1_Doc181	623	626	SRL	Chemical	D020123	Four animal groups (n = 6) were tested during 9 weeks: control, CsA, SRL, and conversion (CsA for 3 weeks followed by SRL for 6 weeks).
BC8_BioRED_Task1_Doc181	751	764	Renal lesions	Disease	D007674	Renal lesions were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.
BC8_BioRED_Task1_Doc181	858	861	SRL	Chemical	D020123	SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
BC8_BioRED_Task1_Doc181	870	874	rats	OrganismTaxon	10116	SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
BC8_BioRED_Task1_Doc181	885	896	proteinuria	Disease	D011507	SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
BC8_BioRED_Task1_Doc181	901	905	NGAL	Gene	170496	SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
BC8_BioRED_Task1_Doc181	949	965	renal impairment	Disease	D007674	SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
BC8_BioRED_Task1_Doc181	973	976	CsA	Chemical	D016572	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1019	1033	kidney lesions	Disease	D007674	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1038	1043	TGF-b	Gene	59086	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1045	1051	NF- kb	Gene	81736	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1053	1057	mTOR	Gene	56718	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1059	1063	PCNA	Gene	25737	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1065	1069	TP53	Gene	24842	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1071	1076	KIM-1	Gene	286934	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1082	1086	CTGF	Gene	64032	Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
BC8_BioRED_Task1_Doc181	1135	1138	CsA	Chemical	D016572	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1159	1171	renal damage	Disease	D007674	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1250	1256	TGF- b	Gene	59086	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1261	1265	IL-7	Gene	25647	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1267	1272	TBARs	Chemical	D017392	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1295	1300	TGF-b	Gene	59086	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1305	1309	mTOR	Gene	56718	Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
BC8_BioRED_Task1_Doc181	1325	1328	SRL	Chemical	D020123	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
BC8_BioRED_Task1_Doc181	1339	1342	CsA	Chemical	D016572	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
BC8_BioRED_Task1_Doc181	1351	1363	renal damage	Disease	D007674	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
BC8_BioRED_Task1_Doc181	1409	1413	NGAL	Gene	170496	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
BC8_BioRED_Task1_Doc181	1471	1474	CsA	Chemical	D016572	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
BC8_BioRED_Task1_Doc181	1490	1493	SRL	Chemical	D020123	Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.
BC8_BioRED_Task1_Doc182	34	38	HIRA	Gene	7290	Altered replication timing of the HIRA/Tuple1 locus in the DiGeorge and Velocardiofacial syndromes.
BC8_BioRED_Task1_Doc182	39	45	Tuple1	Gene	7290	Altered replication timing of the HIRA/Tuple1 locus in the DiGeorge and Velocardiofacial syndromes.
BC8_BioRED_Task1_Doc182	59	98	DiGeorge and Velocardiofacial syndromes	Disease	D004062	Altered replication timing of the HIRA/Tuple1 locus in the DiGeorge and Velocardiofacial syndromes.
BC8_BioRED_Task1_Doc182	100	139	DiGeorge and Velocardiofacial syndromes	Disease	D004062	DiGeorge and Velocardiofacial syndromes (DGS/VCFS) are endowed by a similar complex phenotype including cardiovascular, craniofacial, and thymic malformations, and are associated with heterozygous deletions of 22q11 chromosomal band.
BC8_BioRED_Task1_Doc182	141	144	DGS	Disease	D004062	DiGeorge and Velocardiofacial syndromes (DGS/VCFS) are endowed by a similar complex phenotype including cardiovascular, craniofacial, and thymic malformations, and are associated with heterozygous deletions of 22q11 chromosomal band.
BC8_BioRED_Task1_Doc182	145	149	VCFS	Disease	D004062	DiGeorge and Velocardiofacial syndromes (DGS/VCFS) are endowed by a similar complex phenotype including cardiovascular, craniofacial, and thymic malformations, and are associated with heterozygous deletions of 22q11 chromosomal band.
BC8_BioRED_Task1_Doc182	204	258	cardiovascular, craniofacial, and thymic malformations	Disease	D018376,D019465	DiGeorge and Velocardiofacial syndromes (DGS/VCFS) are endowed by a similar complex phenotype including cardiovascular, craniofacial, and thymic malformations, and are associated with heterozygous deletions of 22q11 chromosomal band.
BC8_BioRED_Task1_Doc182	608	611	DGS	Disease	D004062	However, to date there is no evidence for a mechanism of haploinsufficiency that can fully explain the DGS/VCFS phenotype.
BC8_BioRED_Task1_Doc182	612	616	VCFS	Disease	D004062	However, to date there is no evidence for a mechanism of haploinsufficiency that can fully explain the DGS/VCFS phenotype.
BC8_BioRED_Task1_Doc182	675	679	HIRA	Gene	7290	In this study, we show that the candidate gene HIRA/Tuple1 mapping on the non-deleted TDR22, in DGS/VCFS subjects presents a delayed replication timing.
BC8_BioRED_Task1_Doc182	680	686	Tuple1	Gene	7290	In this study, we show that the candidate gene HIRA/Tuple1 mapping on the non-deleted TDR22, in DGS/VCFS subjects presents a delayed replication timing.
BC8_BioRED_Task1_Doc182	724	727	DGS	Disease	D004062	In this study, we show that the candidate gene HIRA/Tuple1 mapping on the non-deleted TDR22, in DGS/VCFS subjects presents a delayed replication timing.
BC8_BioRED_Task1_Doc182	728	732	VCFS	Disease	D004062	In this study, we show that the candidate gene HIRA/Tuple1 mapping on the non-deleted TDR22, in DGS/VCFS subjects presents a delayed replication timing.
BC8_BioRED_Task1_Doc182	845	849	HIRA	Gene	7290	Moreover, we observed an increase in the cell ratio showing the HIRA/Tuple1 locus localised toward the nuclear periphery.
BC8_BioRED_Task1_Doc182	850	856	Tuple1	Gene	7290	Moreover, we observed an increase in the cell ratio showing the HIRA/Tuple1 locus localised toward the nuclear periphery.
BC8_BioRED_Task1_Doc182	1214	1217	DGS	Disease	D004062	We propose that the alteration in the replication/nuclear location pattern of the non-deleted TDR22 indicates an altered gene regulation hence an altered transcritpion in DGS/VCFS.
BC8_BioRED_Task1_Doc182	1218	1222	VCFS	Disease	D004062	We propose that the alteration in the replication/nuclear location pattern of the non-deleted TDR22 indicates an altered gene regulation hence an altered transcritpion in DGS/VCFS.
BC8_BioRED_Task1_Doc183	0	6	PTPN22	Gene	19260	PTPN22 Is a Critical Regulator of Fcg Receptor-Mediated Neutrophil Activation.
BC8_BioRED_Task1_Doc183	34	46	Fcg Receptor	Gene	14130	PTPN22 Is a Critical Regulator of Fcg Receptor-Mediated Neutrophil Activation.
BC8_BioRED_Task1_Doc183	144	161	fungal infections	Disease	D009181	Neutrophils act as a first line of defense against bacterial and fungal infections, but they are also important effectors of acute and chronic inflammation.
BC8_BioRED_Task1_Doc183	204	234	acute and chronic inflammation	Disease	D007249	Neutrophils act as a first line of defense against bacterial and fungal infections, but they are also important effectors of acute and chronic inflammation.
BC8_BioRED_Task1_Doc183	312	355	protein tyrosine phosphatase nonreceptor 22	Gene	19260	Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (PTPN22) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid arthritis.
BC8_BioRED_Task1_Doc183	357	363	PTPN22	Gene	19260	Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (PTPN22) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid arthritis.
BC8_BioRED_Task1_Doc183	418	436	autoimmune disease	Disease	D001327	Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (PTPN22) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid arthritis.
BC8_BioRED_Task1_Doc183	446	466	rheumatoid arthritis	Disease	D001172	Genome-wide association studies have established that the gene encoding the protein tyrosine phosphatase nonreceptor 22 (PTPN22) makes an important contribution to susceptibility to autoimmune disease, notably rheumatoid arthritis.
BC8_BioRED_Task1_Doc183	477	483	PTPN22	Gene	19260	Although PTPN22 is most highly expressed in neutrophils, its function in these cells remains poorly characterized.
BC8_BioRED_Task1_Doc183	677	700	reactive oxygen species	Chemical	D017382	We show in this article that neutrophil effector functions, including adhesion, production of reactive oxygen species, and degranulation induced by immobilized immune complexes, were reduced in Ptpn22(-/-) neutrophils.
BC8_BioRED_Task1_Doc183	777	783	Ptpn22	Gene	19260	We show in this article that neutrophil effector functions, including adhesion, production of reactive oxygen species, and degranulation induced by immobilized immune complexes, were reduced in Ptpn22(-/-) neutrophils.
BC8_BioRED_Task1_Doc183	830	833	Lyn	Gene	17096	Tyrosine phosphorylation of Lyn and Syk was altered in Ptpn22(-/-) neutrophils.
BC8_BioRED_Task1_Doc183	838	841	Syk	Gene	20963	Tyrosine phosphorylation of Lyn and Syk was altered in Ptpn22(-/-) neutrophils.
BC8_BioRED_Task1_Doc183	857	863	Ptpn22	Gene	19260	Tyrosine phosphorylation of Lyn and Syk was altered in Ptpn22(-/-) neutrophils.
BC8_BioRED_Task1_Doc183	932	938	Ptpn22	Gene	19260	On stimulation with immobilized immune complexes, Ptpn22(-/-) neutrophils manifested reduced activation of key signaling intermediates.
BC8_BioRED_Task1_Doc183	1018	1024	Ptpn22	Gene	19260	Ptpn22(-/-) mice were protected from immune complex-mediated arthritis, induced by the transfer of arthritogenic serum.
BC8_BioRED_Task1_Doc183	1030	1034	mice	OrganismTaxon	10090	Ptpn22(-/-) mice were protected from immune complex-mediated arthritis, induced by the transfer of arthritogenic serum.
BC8_BioRED_Task1_Doc183	1079	1088	arthritis	Disease	D001168	Ptpn22(-/-) mice were protected from immune complex-mediated arthritis, induced by the transfer of arthritogenic serum.
BC8_BioRED_Task1_Doc183	1192	1206	thioglycollate	Chemical	D013864	In contrast, in vivo neutrophil recruitment following thioglycollate-induced peritonitis and in vitro chemotaxis were not affected by lack of PTPN22.
BC8_BioRED_Task1_Doc183	1215	1226	peritonitis	Disease	D010538	In contrast, in vivo neutrophil recruitment following thioglycollate-induced peritonitis and in vitro chemotaxis were not affected by lack of PTPN22.
BC8_BioRED_Task1_Doc183	1280	1286	PTPN22	Gene	19260	In contrast, in vivo neutrophil recruitment following thioglycollate-induced peritonitis and in vitro chemotaxis were not affected by lack of PTPN22.
BC8_BioRED_Task1_Doc183	1327	1333	PTPN22	Gene	19260	Our data suggest an important role for PTPN22-dependent dephosphorylation events, which are required to enable full FcgR-induced activation, pointing to an important role for this molecule in neutrophil function.
BC8_BioRED_Task1_Doc183	1404	1408	FcgR	Gene	14130	Our data suggest an important role for PTPN22-dependent dephosphorylation events, which are required to enable full FcgR-induced activation, pointing to an important role for this molecule in neutrophil function.
BC8_BioRED_Task1_Doc184	0	5	U87MG	CellLine	CVCL_0022	U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.
BC8_BioRED_Task1_Doc184	66	71	human	OrganismTaxon	9606	U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.
BC8_BioRED_Task1_Doc184	72	78	cancer	Disease	D009369	U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.
BC8_BioRED_Task1_Doc184	90	95	U87MG	CellLine	CVCL_0022	U87MG is a commonly studied grade IV glioma cell line that has been analyzed in at least 1,700 publications over four decades.
BC8_BioRED_Task1_Doc184	118	133	grade IV glioma	Disease	D005909	U87MG is a commonly studied grade IV glioma cell line that has been analyzed in at least 1,700 publications over four decades.
BC8_BioRED_Task1_Doc184	320	326	cancer	Disease	D009369	In order to comprehensively characterize the genome of this cell line and to serve as a model of broad cancer genome sequencing, we have generated greater than 30x genomic sequence coverage using a novel 50-base mate paired strategy with a 1.4kb mean insert library.
BC8_BioRED_Task1_Doc184	1068	1072	PTEN	Gene	5728	Among these observations, the known homozygous mutation in PTEN was robustly identified, and genes involved in cell adhesion were overrepresented in the mutated gene list.
BC8_BioRED_Task1_Doc184	1498	1504	cancer	Disease	D009369	Protein coding sequences were disrupted predominantly in this cancer cell line due to small indels, large deletions, and translocations.
BC8_BioRED_Task1_Doc184	1941	1947	cancer	Disease	D009369	These data demonstrate that routine generation of broad cancer genome sequence is possible outside of genome centers.
BC8_BioRED_Task1_Doc184	2028	2033	U87MG	CellLine	CVCL_0022	The sequence analysis of U87MG provides an unparalleled level of mutational resolution compared to any cell line to date.
BC8_BioRED_Task1_Doc185	6	12	CRELD1	Gene	78987	Novel CRELD1 gene mutations in patients with atrioventricular septal defect.
BC8_BioRED_Task1_Doc185	31	39	patients	OrganismTaxon	9606	Novel CRELD1 gene mutations in patients with atrioventricular septal defect.
BC8_BioRED_Task1_Doc185	45	75	atrioventricular septal defect	Disease	C562831	Novel CRELD1 gene mutations in patients with atrioventricular septal defect.
BC8_BioRED_Task1_Doc185	89	120	Atrioventricular septal defects	Disease	C562831	BACKGROUND: Atrioventricular septal defects (AVSDs) occur as clinical defects of several different syndromes, as autosomal dominant defects, and as sporadically occurring malformations.
BC8_BioRED_Task1_Doc185	122	127	AVSDs	Disease	C562831	BACKGROUND: Atrioventricular septal defects (AVSDs) occur as clinical defects of several different syndromes, as autosomal dominant defects, and as sporadically occurring malformations.
BC8_BioRED_Task1_Doc185	190	216	autosomal dominant defects	Disease	D030342	BACKGROUND: Atrioventricular septal defects (AVSDs) occur as clinical defects of several different syndromes, as autosomal dominant defects, and as sporadically occurring malformations.
BC8_BioRED_Task1_Doc185	248	261	malformations	Disease	D000013	BACKGROUND: Atrioventricular septal defects (AVSDs) occur as clinical defects of several different syndromes, as autosomal dominant defects, and as sporadically occurring malformations.
BC8_BioRED_Task1_Doc185	394	398	AVSD	Disease	C562831	Consequently, there is genetic heterogeneity, but until recently, little is known about the genes involving in the pathogenesis of AVSD.
BC8_BioRED_Task1_Doc185	400	406	CRELD1	Gene	78987	CRELD1 gene, a novel cell adhesion molecule, is a candidate gene for AVSD.
BC8_BioRED_Task1_Doc185	469	473	AVSD	Disease	C562831	CRELD1 gene, a novel cell adhesion molecule, is a candidate gene for AVSD.
BC8_BioRED_Task1_Doc185	508	516	patients	OrganismTaxon	9606	METHODS: This study included 133 patients with AVSD and 200 healthy controls.
BC8_BioRED_Task1_Doc185	522	526	AVSD	Disease	C562831	METHODS: This study included 133 patients with AVSD and 200 healthy controls.
BC8_BioRED_Task1_Doc185	644	650	CRELD1	Gene	78987	CRELD1 was amplified by polymerase chain reaction (PCR) with specific primers.
BC8_BioRED_Task1_Doc185	779	787	patients	OrganismTaxon	9606	The sequences of PCR products were compared between the patients and controls.
BC8_BioRED_Task1_Doc185	816	823	patient	OrganismTaxon	9606	RESULTS: In a patient, a C-to-G transition was identified at nucleotide 857 in exon 8 that resulted in a substitution of alanine for proline at amino acid 286 in the first calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	827	877	C-to-G transition was identified at nucleotide 857	SequenceVariant	c|SUB|C|857|G	RESULTS: In a patient, a C-to-G transition was identified at nucleotide 857 in exon 8 that resulted in a substitution of alanine for proline at amino acid 286 in the first calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	923	960	alanine for proline at amino acid 286	SequenceVariant	p|SUB|A|286|P	RESULTS: In a patient, a C-to-G transition was identified at nucleotide 857 in exon 8 that resulted in a substitution of alanine for proline at amino acid 286 in the first calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	974	981	calcium	Chemical	D002118	RESULTS: In a patient, a C-to-G transition was identified at nucleotide 857 in exon 8 that resulted in a substitution of alanine for proline at amino acid 286 in the first calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	990	993	EGF	Gene	1950	RESULTS: In a patient, a C-to-G transition was identified at nucleotide 857 in exon 8 that resulted in a substitution of alanine for proline at amino acid 286 in the first calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	1007	1014	patient	OrganismTaxon	9606	This patient had an isolated partial AVSD and the mutation was inherited from her mother.
BC8_BioRED_Task1_Doc185	1039	1043	AVSD	Disease	C562831	This patient had an isolated partial AVSD and the mutation was inherited from her mother.
BC8_BioRED_Task1_Doc185	1127	1134	patient	OrganismTaxon	9606	Another mutation was detected in a patient with a partial AVSD and evidence of Down syndrome.
BC8_BioRED_Task1_Doc185	1150	1154	AVSD	Disease	C562831	Another mutation was detected in a patient with a partial AVSD and evidence of Down syndrome.
BC8_BioRED_Task1_Doc185	1171	1184	Down syndrome	Disease	D004314	Another mutation was detected in a patient with a partial AVSD and evidence of Down syndrome.
BC8_BioRED_Task1_Doc185	1203	1211	c.973G>A	SequenceVariant	rs755981922	The heterozygous c.973G>A transition in exon 9 resulted in a substitution of lysine for glutamic acid at amino acid 325 (E325K) in the second calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	1263	1305	lysine for glutamic acid at amino acid 325	SequenceVariant	rs755981922	The heterozygous c.973G>A transition in exon 9 resulted in a substitution of lysine for glutamic acid at amino acid 325 (E325K) in the second calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	1307	1312	E325K	SequenceVariant	rs755981922	The heterozygous c.973G>A transition in exon 9 resulted in a substitution of lysine for glutamic acid at amino acid 325 (E325K) in the second calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	1328	1335	calcium	Chemical	D002118	The heterozygous c.973G>A transition in exon 9 resulted in a substitution of lysine for glutamic acid at amino acid 325 (E325K) in the second calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	1344	1347	EGF	Gene	1950	The heterozygous c.973G>A transition in exon 9 resulted in a substitution of lysine for glutamic acid at amino acid 325 (E325K) in the second calcium-binding EGF domain.
BC8_BioRED_Task1_Doc185	1379	1385	CRELD1	Gene	78987	CONCLUSIONS: Two novel CRELD1 mutations were identified in the calcium-binding EGF domain in patients with AVSD.
BC8_BioRED_Task1_Doc185	1419	1426	calcium	Chemical	D002118	CONCLUSIONS: Two novel CRELD1 mutations were identified in the calcium-binding EGF domain in patients with AVSD.
BC8_BioRED_Task1_Doc185	1435	1438	EGF	Gene	1950	CONCLUSIONS: Two novel CRELD1 mutations were identified in the calcium-binding EGF domain in patients with AVSD.
BC8_BioRED_Task1_Doc185	1449	1457	patients	OrganismTaxon	9606	CONCLUSIONS: Two novel CRELD1 mutations were identified in the calcium-binding EGF domain in patients with AVSD.
BC8_BioRED_Task1_Doc185	1463	1467	AVSD	Disease	C562831	CONCLUSIONS: Two novel CRELD1 mutations were identified in the calcium-binding EGF domain in patients with AVSD.
BC8_BioRED_Task1_Doc185	1469	1475	CRELD1	Gene	78987	CRELD1 is likely to be an AVSD-susceptibility gene and CRELD1 mutations may increase the risk of developing a heart defect rather than being a direct causative mutation.
BC8_BioRED_Task1_Doc185	1495	1499	AVSD	Disease	C562831	CRELD1 is likely to be an AVSD-susceptibility gene and CRELD1 mutations may increase the risk of developing a heart defect rather than being a direct causative mutation.
BC8_BioRED_Task1_Doc185	1524	1530	CRELD1	Gene	78987	CRELD1 is likely to be an AVSD-susceptibility gene and CRELD1 mutations may increase the risk of developing a heart defect rather than being a direct causative mutation.
BC8_BioRED_Task1_Doc185	1579	1591	heart defect	Disease	D006331	CRELD1 is likely to be an AVSD-susceptibility gene and CRELD1 mutations may increase the risk of developing a heart defect rather than being a direct causative mutation.
BC8_BioRED_Task1_Doc186	25	48	eslicarbazepine acetate	Chemical	C416835	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
BC8_BioRED_Task1_Doc186	50	59	BIA 2-093	Chemical	C416835	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
BC8_BioRED_Task1_Doc186	64	72	seizures	Disease	D012640	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
BC8_BioRED_Task1_Doc186	102	112	picrotoxin	Chemical	D010852	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
BC8_BioRED_Task1_Doc186	149	153	rats	OrganismTaxon	10116	Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
BC8_BioRED_Task1_Doc186	155	178	Eslicarbazepine acetate	Chemical	C416835	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	180	189	BIA 2-093	Chemical	C416835	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	191	258	S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide	Chemical	C416835	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	271	289	antiepileptic drug	Chemical	D000927	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	430	443	carbamazepine	Chemical	D002220	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	445	448	CBZ	Chemical	D002220	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	454	467	oxcarbazepine	Chemical	C036006	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	469	472	OXC	Chemical	C036006	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine (OXC).
BC8_BioRED_Task1_Doc186	526	549	eslicarbazepine acetate	Chemical	C416835	We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.
BC8_BioRED_Task1_Doc186	591	599	seizures	Disease	D012640	We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.
BC8_BioRED_Task1_Doc186	677	684	seizure	Disease	D012640	We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.
BC8_BioRED_Task1_Doc186	742	752	picrotoxin	Chemical	D010852	In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.
BC8_BioRED_Task1_Doc186	776	784	seizures	Disease	D012640	In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.
BC8_BioRED_Task1_Doc186	812	819	seizure	Disease	D012640	In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.
BC8_BioRED_Task1_Doc186	894	904	picrotoxin	Chemical	D010852	Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.
BC8_BioRED_Task1_Doc186	930	938	seizures	Disease	D012640	Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.
BC8_BioRED_Task1_Doc186	957	961	rats	OrganismTaxon	10116	Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.
BC8_BioRED_Task1_Doc186	1008	1016	seizures	Disease	D012640	Lower doses (3 and 10mg/kg) did not suppress seizures, however, after administration of 10mg/kg, significant reductions in seizures duration (24.3+/-6.8s) and seizure number (1.6+/-0.34) were found.
BC8_BioRED_Task1_Doc186	1086	1094	seizures	Disease	D012640	Lower doses (3 and 10mg/kg) did not suppress seizures, however, after administration of 10mg/kg, significant reductions in seizures duration (24.3+/-6.8s) and seizure number (1.6+/-0.34) were found.
BC8_BioRED_Task1_Doc186	1122	1129	seizure	Disease	D012640	Lower doses (3 and 10mg/kg) did not suppress seizures, however, after administration of 10mg/kg, significant reductions in seizures duration (24.3+/-6.8s) and seizure number (1.6+/-0.34) were found.
BC8_BioRED_Task1_Doc186	1184	1207	eslicarbazepine acetate	Chemical	C416835	No adverse effects of eslicarbazepine acetate were observed in the behavioral/EEG patterns studied, including sleep/wakefulness cycle, at the doses studied.
BC8_BioRED_Task1_Doc187	18	51	constituents of Crocus sativus L.	Chemical	D010936	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
BC8_BioRED_Task1_Doc187	53	59	crocin	Chemical	C029036	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
BC8_BioRED_Task1_Doc187	63	75	streptozocin	Chemical	D013311	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
BC8_BioRED_Task1_Doc187	102	121	Alzheimer's disease	Disease	D000544	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
BC8_BioRED_Task1_Doc187	130	134	rats	OrganismTaxon	10116	Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.
BC8_BioRED_Task1_Doc187	181	192	carotenoids	Chemical	D002338	BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.
BC8_BioRED_Task1_Doc187	194	201	crocins	Chemical	C029036	BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.
BC8_BioRED_Task1_Doc187	240	265	Crocus sativus L. extract	Chemical	D010936	BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.
BC8_BioRED_Task1_Doc187	354	361	crocins	Chemical	C029036	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
BC8_BioRED_Task1_Doc187	374	393	Alzheimer's disease	Disease	D000544	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
BC8_BioRED_Task1_Doc187	435	447	streptozocin	Chemical	D013311	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
BC8_BioRED_Task1_Doc187	449	452	STZ	Chemical	D013311	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
BC8_BioRED_Task1_Doc187	462	466	rats	OrganismTaxon	10116	In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
BC8_BioRED_Task1_Doc187	512	516	rats	OrganismTaxon	10116	METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.
BC8_BioRED_Task1_Doc187	579	586	crocins	Chemical	C029036	METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.
BC8_BioRED_Task1_Doc187	609	612	STZ	Chemical	D013311	METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.
BC8_BioRED_Task1_Doc187	623	626	STZ	Chemical	D013311	METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.
BC8_BioRED_Task1_Doc187	629	636	crocins	Chemical	C029036	METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.
BC8_BioRED_Task1_Doc187	666	685	Alzheimer's disease	Disease	D000544	In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.
BC8_BioRED_Task1_Doc187	694	698	rats	OrganismTaxon	10116	In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.
BC8_BioRED_Task1_Doc187	718	721	STZ	Chemical	D013311	In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.
BC8_BioRED_Task1_Doc187	789	792	STZ	Chemical	D013311	In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.
BC8_BioRED_Task1_Doc187	826	829	STZ	Chemical	D013311	In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.
BC8_BioRED_Task1_Doc187	832	838	crocin	Chemical	C029036	In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.
BC8_BioRED_Task1_Doc187	854	860	crocin	Chemical	C029036	In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.
BC8_BioRED_Task1_Doc187	975	981	crocin	Chemical	C029036	Prescription of crocin in each dose was repeated once for two days.
BC8_BioRED_Task1_Doc187	1210	1216	crocin	Chemical	C029036	RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.
BC8_BioRED_Task1_Doc187	1236	1239	STZ	Chemical	D013311	RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.
BC8_BioRED_Task1_Doc187	1249	1253	rats	OrganismTaxon	10116	RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.
BC8_BioRED_Task1_Doc187	1330	1333	STZ	Chemical	D013311	RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.
BC8_BioRED_Task1_Doc187	1343	1347	rats	OrganismTaxon	10116	RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.
BC8_BioRED_Task1_Doc187	1362	1368	crocin	Chemical	C029036	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
BC8_BioRED_Task1_Doc187	1422	1452	learning and memory impairment	Disease	D007859,D008569	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
BC8_BioRED_Task1_Doc187	1464	1467	STZ	Chemical	D013311	In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
BC8_BioRED_Task1_Doc187	1580	1586	crocin	Chemical	C029036	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
BC8_BioRED_Task1_Doc187	1618	1636	cognitive deficits	Disease	D003072	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
BC8_BioRED_Task1_Doc187	1647	1650	STZ	Chemical	D013311	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
BC8_BioRED_Task1_Doc187	1658	1662	rats	OrganismTaxon	10116	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
BC8_BioRED_Task1_Doc187	1701	1727	neurodegenerative diseases	Disease	D019636	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
BC8_BioRED_Task1_Doc187	1736	1755	Alzheimer's disease	Disease	D000544	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.
BC8_BioRED_Task1_Doc188	0	6	Crocin	Chemical	C029036	Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver.
BC8_BioRED_Task1_Doc188	16	21	lipid	Chemical	D008055	Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver.
BC8_BioRED_Task1_Doc188	48	56	diazinon	Chemical	D003976	Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver.
BC8_BioRED_Task1_Doc188	74	80	ERK1/2	Gene	116590,50689	Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver.
BC8_BioRED_Task1_Doc188	92	95	rat	OrganismTaxon	10116	Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver.
BC8_BioRED_Task1_Doc188	117	125	Diazinon	Chemical	D003976	INTRODUCTION: Diazinon Yis one of the most broadly used organophosphorus insecticides in agriculture.
BC8_BioRED_Task1_Doc188	159	175	organophosphorus	Chemical	D010755	INTRODUCTION: Diazinon Yis one of the most broadly used organophosphorus insecticides in agriculture.
BC8_BioRED_Task1_Doc188	240	248	diazinon	Chemical	D003976	It has been shown that exposure to diazinon may interfere with lipid metabolism.
BC8_BioRED_Task1_Doc188	268	273	lipid	Chemical	D008055	It has been shown that exposure to diazinon may interfere with lipid metabolism.
BC8_BioRED_Task1_Doc188	324	330	crocin	Chemical	C029036	Moreover, the hypolipidemic effect of crocin has been established.
BC8_BioRED_Task1_Doc188	396	433	Extracellular signal-regulated kinase	Gene	116590,50689	Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression.
BC8_BioRED_Task1_Doc188	435	438	ERK	Gene	116590,50689	Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression.
BC8_BioRED_Task1_Doc188	452	484	low-density lipoprotein receptor	Gene	300438	Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression.
BC8_BioRED_Task1_Doc188	486	490	LDLr	Gene	300438	Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression.
BC8_BioRED_Task1_Doc188	571	576	lipid	Chemical	D008055	The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon.
BC8_BioRED_Task1_Doc188	589	592	ERK	Gene	116590,50689	The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon.
BC8_BioRED_Task1_Doc188	597	601	LDLr	Gene	300438	The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon.
BC8_BioRED_Task1_Doc188	629	633	rats	OrganismTaxon	10116	The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon.
BC8_BioRED_Task1_Doc188	654	662	diazinon	Chemical	D003976	The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon.
BC8_BioRED_Task1_Doc188	699	705	crocin	Chemical	C029036	Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied.
BC8_BioRED_Task1_Doc188	709	717	diazinon	Chemical	D003976	Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied.
BC8_BioRED_Task1_Doc188	736	747	cholesterol	Chemical	D002784	Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied.
BC8_BioRED_Task1_Doc188	785	789	Rats	OrganismTaxon	10116	METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg).
BC8_BioRED_Task1_Doc188	864	872	Corn oil	Chemical	D003314	METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg).
BC8_BioRED_Task1_Doc188	884	892	diazinon	Chemical	D003976	METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg).
BC8_BioRED_Task1_Doc188	923	929	crocin	Chemical	C029036	METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg).
BC8_BioRED_Task1_Doc188	996	1004	diazinon	Chemical	D003976	METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg).
BC8_BioRED_Task1_Doc188	1031	1042	cholesterol	Chemical	D002784	The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed.
BC8_BioRED_Task1_Doc188	1044	1056	triglyceride	Chemical	D014280	The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed.
BC8_BioRED_Task1_Doc188	1061	1064	LDL	Chemical	D008077	The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed.
BC8_BioRED_Task1_Doc188	1077	1081	rats	OrganismTaxon	10116	The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed.
BC8_BioRED_Task1_Doc188	1121	1125	LDLr	Gene	300438	Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc188	1130	1136	ERK1/2	Gene	116590,50689	Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc188	1195	1201	ERK1/2	Gene	116590,50689	Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc188	1205	1208	rat	OrganismTaxon	10116	Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc188	1364	1372	diazinon	Chemical	D003976	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL.
BC8_BioRED_Task1_Doc188	1415	1426	cholesterol	Chemical	D002784	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL.
BC8_BioRED_Task1_Doc188	1428	1440	triglyceride	Chemical	D014280	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL.
BC8_BioRED_Task1_Doc188	1445	1448	LDL	Chemical	D008077	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL.
BC8_BioRED_Task1_Doc188	1459	1467	diazinon	Chemical	D003976	Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript.
BC8_BioRED_Task1_Doc188	1478	1484	ERK1/2	Gene	116590,50689	Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript.
BC8_BioRED_Task1_Doc188	1513	1517	LDLr	Gene	300438	Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript.
BC8_BioRED_Task1_Doc188	1530	1536	Crocin	Chemical	C029036	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
BC8_BioRED_Task1_Doc188	1559	1562	ERK	Gene	116590,50689	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
BC8_BioRED_Task1_Doc188	1578	1586	diazinon	Chemical	D003976	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
BC8_BioRED_Task1_Doc188	1595	1607	hyperlipemia	Disease	D006949	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
BC8_BioRED_Task1_Doc188	1632	1636	LDLr	Gene	300438	Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.
BC8_BioRED_Task1_Doc188	1662	1668	Crocin	Chemical	C029036	CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
BC8_BioRED_Task1_Doc188	1718	1726	diazinon	Chemical	D003976	CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
BC8_BioRED_Task1_Doc188	1735	1747	hyperlipemia	Disease	D006949	CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
BC8_BioRED_Task1_Doc188	1770	1773	ERK	Gene	116590,50689	CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
BC8_BioRED_Task1_Doc188	1798	1802	LDLr	Gene	300438	CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.
BC8_BioRED_Task1_Doc189	28	37	ESCRT-III	Gene	128866,27243,51652	Dynamic subunit turnover in ESCRT-III assemblies is regulated by Vps4 to mediate membrane remodelling during cytokinesis.
BC8_BioRED_Task1_Doc189	65	69	Vps4	Gene	27183,9525	Dynamic subunit turnover in ESCRT-III assemblies is regulated by Vps4 to mediate membrane remodelling during cytokinesis.
BC8_BioRED_Task1_Doc189	126	186	endosomal sorting complex required for transport (ESCRT)-III	Gene	128866,27243,51652	The endosomal sorting complex required for transport (ESCRT)-III mediates membrane fission in fundamental cellular processes, including cytokinesis.
BC8_BioRED_Task1_Doc189	271	280	ESCRT-III	Gene	128866,27243,51652	ESCRT-III is thought to form persistent filaments that over time increase their curvature to constrict membranes.
BC8_BioRED_Task1_Doc189	413	422	ESCRT-III	Gene	128866,27243,51652	Unexpectedly, we found that ESCRT-III at the midbody of human cells rapidly turns over subunits with cytoplasmic pools while gradually forming larger assemblies.
BC8_BioRED_Task1_Doc189	441	446	human	OrganismTaxon	9606	Unexpectedly, we found that ESCRT-III at the midbody of human cells rapidly turns over subunits with cytoplasmic pools while gradually forming larger assemblies.
BC8_BioRED_Task1_Doc189	547	556	ESCRT-III	Gene	128866,27243,51652	ESCRT-III turnover depended on the ATPase VPS4, which accumulated at the midbody simultaneously with ESCRT-III subunits, and was required for assembly of functional ESCRT-III structures.
BC8_BioRED_Task1_Doc189	582	588	ATPase	Gene	27183,9525	ESCRT-III turnover depended on the ATPase VPS4, which accumulated at the midbody simultaneously with ESCRT-III subunits, and was required for assembly of functional ESCRT-III structures.
BC8_BioRED_Task1_Doc189	589	593	VPS4	Gene	27183,9525	ESCRT-III turnover depended on the ATPase VPS4, which accumulated at the midbody simultaneously with ESCRT-III subunits, and was required for assembly of functional ESCRT-III structures.
BC8_BioRED_Task1_Doc189	648	657	ESCRT-III	Gene	128866,27243,51652	ESCRT-III turnover depended on the ATPase VPS4, which accumulated at the midbody simultaneously with ESCRT-III subunits, and was required for assembly of functional ESCRT-III structures.
BC8_BioRED_Task1_Doc189	712	721	ESCRT-III	Gene	128866,27243,51652	ESCRT-III turnover depended on the ATPase VPS4, which accumulated at the midbody simultaneously with ESCRT-III subunits, and was required for assembly of functional ESCRT-III structures.
BC8_BioRED_Task1_Doc189	748	752	Vps2	Gene	27243	In vitro, the Vps2/Vps24 subunits of ESCRT-III formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.
BC8_BioRED_Task1_Doc189	753	758	Vps24	Gene	51652	In vitro, the Vps2/Vps24 subunits of ESCRT-III formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.
BC8_BioRED_Task1_Doc189	771	780	ESCRT-III	Gene	128866,27243,51652	In vitro, the Vps2/Vps24 subunits of ESCRT-III formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.
BC8_BioRED_Task1_Doc189	816	820	Snf7	Gene	128866,29082	In vitro, the Vps2/Vps24 subunits of ESCRT-III formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.
BC8_BioRED_Task1_Doc189	919	923	Vps4	Gene	27183,9525	In vitro, the Vps2/Vps24 subunits of ESCRT-III formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.
BC8_BioRED_Task1_Doc189	928	931	ATP	Chemical	D000255	In vitro, the Vps2/Vps24 subunits of ESCRT-III formed side-by-side filaments with Snf7 and inhibited further polymerization, but the growth inhibition was alleviated by the addition of Vps4 and ATP.
BC8_BioRED_Task1_Doc189	1032	1041	ESCRT-III	Gene	128866,27243,51652	High-speed atomic force microscopy further revealed highly dynamic arrays of growing and shrinking ESCRT-III spirals in the presence of Vps4.
BC8_BioRED_Task1_Doc189	1069	1073	Vps4	Gene	27183,9525	High-speed atomic force microscopy further revealed highly dynamic arrays of growing and shrinking ESCRT-III spirals in the presence of Vps4.
BC8_BioRED_Task1_Doc189	1086	1095	ESCRT-III	Gene	128866,27243,51652	Continuous ESCRT-III remodelling by subunit turnover might facilitate shape adaptions to variable membrane geometries, with broad implications for diverse cellular processes.
BC8_BioRED_Task1_Doc190	9	34	GH insensitivity syndrome	Disease	D046150	Atypical GH insensitivity syndrome and severe insulin-like growth factor-I deficiency resulting from compound heterozygous mutations of the GH receptor, including a novel frameshift mutation affecting the intracellular domain.
BC8_BioRED_Task1_Doc190	46	85	insulin-like growth factor-I deficiency	Disease	C563867	Atypical GH insensitivity syndrome and severe insulin-like growth factor-I deficiency resulting from compound heterozygous mutations of the GH receptor, including a novel frameshift mutation affecting the intracellular domain.
BC8_BioRED_Task1_Doc190	140	151	GH receptor	Gene	2690	Atypical GH insensitivity syndrome and severe insulin-like growth factor-I deficiency resulting from compound heterozygous mutations of the GH receptor, including a novel frameshift mutation affecting the intracellular domain.
BC8_BioRED_Task1_Doc190	244	260	GH insensitivity	Disease	D046150	BACKGROUND/AIMS: GH insensitivity and IGF deficiency may result from aberrations of the GH receptor (GHR).
BC8_BioRED_Task1_Doc190	265	279	IGF deficiency	Disease	C563867	BACKGROUND/AIMS: GH insensitivity and IGF deficiency may result from aberrations of the GH receptor (GHR).
BC8_BioRED_Task1_Doc190	315	326	GH receptor	Gene	2690	BACKGROUND/AIMS: GH insensitivity and IGF deficiency may result from aberrations of the GH receptor (GHR).
BC8_BioRED_Task1_Doc190	328	331	GHR	Gene	2690	BACKGROUND/AIMS: GH insensitivity and IGF deficiency may result from aberrations of the GH receptor (GHR).
BC8_BioRED_Task1_Doc190	377	391	growth failure	Disease	D006130	We describe a 4-year-old child with modest growth failure and normal serum concentrations of GH-binding protein (GHBP), but clinical evidence of GH insensitivity.
BC8_BioRED_Task1_Doc190	427	445	GH-binding protein	Gene	2690	We describe a 4-year-old child with modest growth failure and normal serum concentrations of GH-binding protein (GHBP), but clinical evidence of GH insensitivity.
BC8_BioRED_Task1_Doc190	447	451	GHBP	Gene	2690	We describe a 4-year-old child with modest growth failure and normal serum concentrations of GH-binding protein (GHBP), but clinical evidence of GH insensitivity.
BC8_BioRED_Task1_Doc190	479	495	GH insensitivity	Disease	D046150	We describe a 4-year-old child with modest growth failure and normal serum concentrations of GH-binding protein (GHBP), but clinical evidence of GH insensitivity.
BC8_BioRED_Task1_Doc190	632	634	GH	Gene	2688	RESULTS: The child had a height of -4 SD, elevated serum GH concentrations, abnormally low serum IGF-I and IGFBP-3 concentrations and normal GHBP concentrations.
BC8_BioRED_Task1_Doc190	672	677	IGF-I	Gene	3479	RESULTS: The child had a height of -4 SD, elevated serum GH concentrations, abnormally low serum IGF-I and IGFBP-3 concentrations and normal GHBP concentrations.
BC8_BioRED_Task1_Doc190	682	689	IGFBP-3	Gene	3486	RESULTS: The child had a height of -4 SD, elevated serum GH concentrations, abnormally low serum IGF-I and IGFBP-3 concentrations and normal GHBP concentrations.
BC8_BioRED_Task1_Doc190	716	720	GHBP	Gene	2690	RESULTS: The child had a height of -4 SD, elevated serum GH concentrations, abnormally low serum IGF-I and IGFBP-3 concentrations and normal GHBP concentrations.
BC8_BioRED_Task1_Doc190	800	803	GHR	Gene	2690	DNA analysis revealed compound heterozygosity for mutations of GHR, including a previously reported R211H mutation and a novel duplication of a nucleotide in exon 9 (899dupC), the latter resulting in a frameshift and a premature stop codon.
BC8_BioRED_Task1_Doc190	837	842	R211H	SequenceVariant	p|SUB|R|211|H	DNA analysis revealed compound heterozygosity for mutations of GHR, including a previously reported R211H mutation and a novel duplication of a nucleotide in exon 9 (899dupC), the latter resulting in a frameshift and a premature stop codon.
BC8_BioRED_Task1_Doc190	903	910	899dupC	SequenceVariant	c|DUP|899|C|	DNA analysis revealed compound heterozygosity for mutations of GHR, including a previously reported R211H mutation and a novel duplication of a nucleotide in exon 9 (899dupC), the latter resulting in a frameshift and a premature stop codon.
BC8_BioRED_Task1_Doc190	1017	1022	IGF-I	Gene	3479	Treatment with recombinant DNA-derived IGF-I resulted in growth acceleration.
BC8_BioRED_Task1_Doc190	1120	1123	GHR	Gene	2690	CONCLUSION: Mutations affecting the intracellular domain of the GHR can result in GH insensitivity and IGF deficiency, despite normal serum concentrations of GHBP.
BC8_BioRED_Task1_Doc190	1138	1154	GH insensitivity	Disease	D046150	CONCLUSION: Mutations affecting the intracellular domain of the GHR can result in GH insensitivity and IGF deficiency, despite normal serum concentrations of GHBP.
BC8_BioRED_Task1_Doc190	1159	1173	IGF deficiency	Disease	C563867	CONCLUSION: Mutations affecting the intracellular domain of the GHR can result in GH insensitivity and IGF deficiency, despite normal serum concentrations of GHBP.
BC8_BioRED_Task1_Doc190	1214	1218	GHBP	Gene	2690	CONCLUSION: Mutations affecting the intracellular domain of the GHR can result in GH insensitivity and IGF deficiency, despite normal serum concentrations of GHBP.
BC8_BioRED_Task1_Doc190	1273	1275	GH	Gene	2688	The presence of clinical and biochemical evidence of GH resistance is sufficient to consider the possibility of aberrations of the GHR, even in the presence of normal serum GHBP concentrations.
BC8_BioRED_Task1_Doc190	1351	1354	GHR	Gene	2690	The presence of clinical and biochemical evidence of GH resistance is sufficient to consider the possibility of aberrations of the GHR, even in the presence of normal serum GHBP concentrations.
BC8_BioRED_Task1_Doc190	1393	1397	GHBP	Gene	2690	The presence of clinical and biochemical evidence of GH resistance is sufficient to consider the possibility of aberrations of the GHR, even in the presence of normal serum GHBP concentrations.
BC8_BioRED_Task1_Doc191	32	37	human	OrganismTaxon	9606	Disease-associated mutations in human BICD2 hyperactivate motility of dynein-dynactin.
BC8_BioRED_Task1_Doc191	38	43	BICD2	Gene	23299	Disease-associated mutations in human BICD2 hyperactivate motility of dynein-dynactin.
BC8_BioRED_Task1_Doc191	70	76	dynein	Gene	1778	Disease-associated mutations in human BICD2 hyperactivate motility of dynein-dynactin.
BC8_BioRED_Task1_Doc191	77	85	dynactin	Gene	1639	Disease-associated mutations in human BICD2 hyperactivate motility of dynein-dynactin.
BC8_BioRED_Task1_Doc191	87	98	Bicaudal D2	Gene	23299	Bicaudal D2 (BICD2) joins dynein with dynactin into a ternary complex (termed DDB) capable of processive movement.
BC8_BioRED_Task1_Doc191	100	105	BICD2	Gene	23299	Bicaudal D2 (BICD2) joins dynein with dynactin into a ternary complex (termed DDB) capable of processive movement.
BC8_BioRED_Task1_Doc191	113	119	dynein	Gene	1778	Bicaudal D2 (BICD2) joins dynein with dynactin into a ternary complex (termed DDB) capable of processive movement.
BC8_BioRED_Task1_Doc191	125	133	dynactin	Gene	1639	Bicaudal D2 (BICD2) joins dynein with dynactin into a ternary complex (termed DDB) capable of processive movement.
BC8_BioRED_Task1_Doc191	165	168	DDB	Gene	1639,1778,23299	Bicaudal D2 (BICD2) joins dynein with dynactin into a ternary complex (termed DDB) capable of processive movement.
BC8_BioRED_Task1_Doc191	225	230	BICD2	Gene	23299	Point mutations in the BICD2 gene have been identified in patients with a dominant form of spinal muscular atrophy, but how these mutations cause disease is unknown.
BC8_BioRED_Task1_Doc191	260	268	patients	OrganismTaxon	9606	Point mutations in the BICD2 gene have been identified in patients with a dominant form of spinal muscular atrophy, but how these mutations cause disease is unknown.
BC8_BioRED_Task1_Doc191	293	316	spinal muscular atrophy	Disease	D009134	Point mutations in the BICD2 gene have been identified in patients with a dominant form of spinal muscular atrophy, but how these mutations cause disease is unknown.
BC8_BioRED_Task1_Doc191	455	458	DDB	Gene	1639,1778,76895	To investigate this question, we have developed in vitro motility assays with purified DDB and BICD2's membrane vesicle partner, the GTPase Rab6a.
BC8_BioRED_Task1_Doc191	463	468	BICD2	Gene	76895	To investigate this question, we have developed in vitro motility assays with purified DDB and BICD2's membrane vesicle partner, the GTPase Rab6a.
BC8_BioRED_Task1_Doc191	501	513	GTPase Rab6a	Gene	5870	To investigate this question, we have developed in vitro motility assays with purified DDB and BICD2's membrane vesicle partner, the GTPase Rab6a.
BC8_BioRED_Task1_Doc191	515	524	Rab6a-GTP	Gene	5870	Rab6a-GTP, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust dynein-dynactin transport.
BC8_BioRED_Task1_Doc191	588	593	BICD2	Gene	76895	Rab6a-GTP, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust dynein-dynactin transport.
BC8_BioRED_Task1_Doc191	642	648	dynein	Gene	1778	Rab6a-GTP, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust dynein-dynactin transport.
BC8_BioRED_Task1_Doc191	649	657	dynactin	Gene	1639	Rab6a-GTP, either in solution or bound to artificial liposomes, released BICD2 from an autoinhibited state and promoted robust dynein-dynactin transport.
BC8_BioRED_Task1_Doc191	686	691	BICD2	Gene	76895	In these assays, BICD2 mutants showed an enhanced ability to form motile DDB complexes.
BC8_BioRED_Task1_Doc191	742	745	DDB	Gene	1639,1778,23299	In these assays, BICD2 mutants showed an enhanced ability to form motile DDB complexes.
BC8_BioRED_Task1_Doc191	791	796	BICD2	Gene	76895	Increased retrograde transport by BICD2 mutants also was observed in cells using an inducible organelle transport assay.
BC8_BioRED_Task1_Doc191	900	903	rat	OrganismTaxon	10116	When overexpressed in rat hippocampal neurons, the hyperactive BICD2 mutants decreased neurite growth.
BC8_BioRED_Task1_Doc191	941	946	BICD2	Gene	76895	When overexpressed in rat hippocampal neurons, the hyperactive BICD2 mutants decreased neurite growth.
BC8_BioRED_Task1_Doc191	1027	1032	BICD2	Gene	76895	Our results reveal that dominant mutations in BICD2 hyperactivate DDB motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie spinal muscular atrophy.
BC8_BioRED_Task1_Doc191	1047	1050	DDB	Gene	1639,1778,23299	Our results reveal that dominant mutations in BICD2 hyperactivate DDB motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie spinal muscular atrophy.
BC8_BioRED_Task1_Doc191	1169	1192	spinal muscular atrophy	Disease	D009134	Our results reveal that dominant mutations in BICD2 hyperactivate DDB motility and suggest that an imbalance of minus versus plus end-directed microtubule motility in neurons may underlie spinal muscular atrophy.
BC8_BioRED_Task1_Doc192	0	15	McArdle disease	Disease	D006012	McArdle disease: the mutation spectrum of PYGM in a large Italian cohort.
BC8_BioRED_Task1_Doc192	42	46	PYGM	Gene	5837	McArdle disease: the mutation spectrum of PYGM in a large Italian cohort.
BC8_BioRED_Task1_Doc192	74	132	Deficiency of the muscle isozyme of glycogen phosphorylase	Disease	D006012	Deficiency of the muscle isozyme of glycogen phosphorylase is causative of McArdle disease or Glycogen storage disease type V (GSD-V), the most common autosomal recessive disorder of glycogen metabolism.
BC8_BioRED_Task1_Doc192	149	164	McArdle disease	Disease	D006012	Deficiency of the muscle isozyme of glycogen phosphorylase is causative of McArdle disease or Glycogen storage disease type V (GSD-V), the most common autosomal recessive disorder of glycogen metabolism.
BC8_BioRED_Task1_Doc192	168	199	Glycogen storage disease type V	Disease	D006012	Deficiency of the muscle isozyme of glycogen phosphorylase is causative of McArdle disease or Glycogen storage disease type V (GSD-V), the most common autosomal recessive disorder of glycogen metabolism.
BC8_BioRED_Task1_Doc192	201	206	GSD-V	Disease	D006012	Deficiency of the muscle isozyme of glycogen phosphorylase is causative of McArdle disease or Glycogen storage disease type V (GSD-V), the most common autosomal recessive disorder of glycogen metabolism.
BC8_BioRED_Task1_Doc192	225	253	autosomal recessive disorder	Disease	D030342	Deficiency of the muscle isozyme of glycogen phosphorylase is causative of McArdle disease or Glycogen storage disease type V (GSD-V), the most common autosomal recessive disorder of glycogen metabolism.
BC8_BioRED_Task1_Doc192	257	265	glycogen	Chemical	D006003	Deficiency of the muscle isozyme of glycogen phosphorylase is causative of McArdle disease or Glycogen storage disease type V (GSD-V), the most common autosomal recessive disorder of glycogen metabolism.
BC8_BioRED_Task1_Doc192	358	364	cramps	Disease	D009120	The typical clinical presentation is characterized by exercise intolerance with cramps, and recurrent myoglobinuria.
BC8_BioRED_Task1_Doc192	380	393	myoglobinuria	Disease	D009212	The typical clinical presentation is characterized by exercise intolerance with cramps, and recurrent myoglobinuria.
BC8_BioRED_Task1_Doc192	424	428	PYGM	Gene	5837	To date, 46 mutations in the PYGM gene have been detected in GSD-V patients.
BC8_BioRED_Task1_Doc192	456	461	GSD-V	Disease	D006012	To date, 46 mutations in the PYGM gene have been detected in GSD-V patients.
BC8_BioRED_Task1_Doc192	462	470	patients	OrganismTaxon	9606	To date, 46 mutations in the PYGM gene have been detected in GSD-V patients.
BC8_BioRED_Task1_Doc192	520	528	patients	OrganismTaxon	9606	We report the mutational spectrum in 68 Italian patients.
BC8_BioRED_Task1_Doc192	574	578	PYGM	Gene	5837	We identified 30 different mutations in the PYGM gene, including 19 mutations that have not been reported previously.
BC8_BioRED_Task1_Doc192	703	711	c.475G>A	SequenceVariant	rs760654579	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	713	720	p.G159R	SequenceVariant	rs760654579	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	722	730	c.689C>G	SequenceVariant	c|SUB|C|689|G	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	732	739	p.P230R	SequenceVariant	p|SUB|P|230|R	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	741	750	c.1094C>T	SequenceVariant	c|SUB|C|1094|T	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	752	759	p.A365E	SequenceVariant	p|SUB|A|365|E	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	761	770	c.1151C>A	SequenceVariant	c|SUB|C|1151|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	772	779	p.A384D	SequenceVariant	p|SUB|A|384|D	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	781	791	c.1182C>T,	SequenceVariant	rs750700202	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	792	799	p.R428C	SequenceVariant	rs750700202	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	801	810	c.1471C>T	SequenceVariant	rs759977194	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	812	819	p.R491C	SequenceVariant	rs759977194	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	821	830	c.2444A>C	SequenceVariant	c|SUB|A|2444|C	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	832	839	p.D815A	SequenceVariant	p|SUB|D|815|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	841	850	c.2477G>C	SequenceVariant	c|SUB|G|2477|C	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	852	859	p.W826S	SequenceVariant	p|SUB|W|826|S	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	886	895	c.1475G>A	SequenceVariant	c|SUB|G|1475|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	897	904	p.W492X	SequenceVariant	p|SUB|W|492|X	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	906	915	c.1627A>T	SequenceVariant	c|SUB|A|1627|T	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	917	924	p.K543X	SequenceVariant	p|SUB|K|543|X	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	955	966	c.855 +1G>C	SequenceVariant	c|SUB|C|855+1|C	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	968	980	c.1092 +1G>A	SequenceVariant	c|SUB|G|1092+1|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	982	994	c. 1093-1G>T	SequenceVariant	c|SUB|G|1093-1|T	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	996	1008	c.1239 +1G>A	SequenceVariant	c|SUB|G|1239+1|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1010	1022	c.2380 +1G>A	SequenceVariant	c|SUB|G|2380+1|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1045	1060	c.715_717delGTC	SequenceVariant	c|DEL|715_717|GTC	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1062	1071	p.V239del	SequenceVariant	p|DEL|239|V	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1073	1082	c.304delA	SequenceVariant	c|DEL|304|A	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1084	1095	p.N102DfsX4	SequenceVariant	p|FS|N|102|D|4	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1097	1111	c.1970_2177del	SequenceVariant	c|DEL|1970_2177|	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1113	1124	p.V657_G726	SequenceVariant	p|DEL|657_726|	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1126	1142	c.2113_2114delGG	SequenceVariant	c|DEL|2113_2114|GG	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1144	1156	p.G705RfsX16	SequenceVariant	p|FS|G|705|R|16	The novel mutations include: eight missense mutations (c.475G>A, p.G159R; c.689C>G, p.P230R; c.1094C>T, p.A365E; c.1151C>A, p.A384D; c.1182C>T, p.R428C; c.1471C>T, p.R491C; c.2444A>C, p.D815A; c.2477G>C, p.W826S), two nonsense mutations (c.1475G>A, p.W492X; c.1627A>T, p.K543X), five splice site mutations (c.855 +1G>C; c.1092 +1G>A; c. 1093-1G>T; c.1239 +1G>A; c.2380 +1G>A), and four deletions (c.715_717delGTC, p.V239del; c.304delA, p.N102DfsX4; c.1970_2177del, p.V657_G726; c.2113_2114delGG, p.G705RfsX16).
BC8_BioRED_Task1_Doc192	1308	1314	p.R50X	SequenceVariant	rs116987552	Whereas we confirmed lack of direct correlation between the clinical phenotype and the genotype, we also found that the so-called 'common mutation' (p.R50X) accounted for about 43% of alleles in our cohort and that no population-related mutations are clearly identified in Italian patients.
BC8_BioRED_Task1_Doc192	1440	1448	patients	OrganismTaxon	9606	Whereas we confirmed lack of direct correlation between the clinical phenotype and the genotype, we also found that the so-called 'common mutation' (p.R50X) accounted for about 43% of alleles in our cohort and that no population-related mutations are clearly identified in Italian patients.
BC8_BioRED_Task1_Doc193	34	55	congenital microcoria	Disease	C537550	Genetic homogeneity for inherited congenital microcoria loci in an Asian Indian pedigree.
BC8_BioRED_Task1_Doc193	99	120	Congenital microcoria	Disease	C537550	PURPOSE: Congenital microcoria is a rare autosomal dominant developmental disorder of the iris associated with myopia and juvenile open angle glaucoma.
BC8_BioRED_Task1_Doc193	131	184	autosomal dominant developmental disorder of the iris	Disease	D007499	PURPOSE: Congenital microcoria is a rare autosomal dominant developmental disorder of the iris associated with myopia and juvenile open angle glaucoma.
BC8_BioRED_Task1_Doc193	201	207	myopia	Disease	D009216	PURPOSE: Congenital microcoria is a rare autosomal dominant developmental disorder of the iris associated with myopia and juvenile open angle glaucoma.
BC8_BioRED_Task1_Doc193	212	240	juvenile open angle glaucoma	Disease	D005902	PURPOSE: Congenital microcoria is a rare autosomal dominant developmental disorder of the iris associated with myopia and juvenile open angle glaucoma.
BC8_BioRED_Task1_Doc193	409	430	congenital microcoria	Disease	C537550	In the current study, a three generation Asian Indian family with 15 congenital microcoria (pupils with a diameter <2 mm) affected members was studied for linkage to candidate microsatellite markers at the 13q31-q32 locus.
BC8_BioRED_Task1_Doc193	1014	1017	DCT	Gene	1638	RESULTS: Peak two point LOD scores of 3.5, 4.7, and 5.3 were found co-incident with consecutive markers D13S154, DCT, and D13S1280.
BC8_BioRED_Task1_Doc193	1182	1203	congenital microcoria	Disease	C537550	Multipoint analysis revealed a 4 cM region encompassing D13S1300 to D13S1280 where the LOD remains just over 6.0 Thus we confirm localization of the congenital microcoria locus to chromosomal locus 13q31-q32.
BC8_BioRED_Task1_Doc193	1286	1296	microcoria	Disease	C537550	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1301	1309	glaucoma	Disease	D005901	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1328	1336	glaucoma	Disease	D005901	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1344	1352	myocilin	Gene	4653	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1354	1358	MYOC	Gene	4653	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1361	1371	optineurin	Gene	10133	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1373	1377	OPTN	Gene	10133	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1383	1389	CYP1B1	Gene	1545	In addition, eight individuals who had both microcoria and glaucoma were screened for glaucoma genes: myocilin (MYOC), optineurin (OPTN) and CYP1B1.
BC8_BioRED_Task1_Doc193	1433	1440	144 G>A	SequenceVariant	rs74315339	Using direct sequencing a point mutation (144 G>A) resulting in a Q48H substitution in exon 1 of the MYOC gene was observed in five of the eight glaucoma patients, but not in unaffected family members and 100 unrelated controls.
BC8_BioRED_Task1_Doc193	1457	1461	Q48H	SequenceVariant	rs74315339	Using direct sequencing a point mutation (144 G>A) resulting in a Q48H substitution in exon 1 of the MYOC gene was observed in five of the eight glaucoma patients, but not in unaffected family members and 100 unrelated controls.
BC8_BioRED_Task1_Doc193	1492	1496	MYOC	Gene	4653	Using direct sequencing a point mutation (144 G>A) resulting in a Q48H substitution in exon 1 of the MYOC gene was observed in five of the eight glaucoma patients, but not in unaffected family members and 100 unrelated controls.
BC8_BioRED_Task1_Doc193	1536	1544	glaucoma	Disease	D005901	Using direct sequencing a point mutation (144 G>A) resulting in a Q48H substitution in exon 1 of the MYOC gene was observed in five of the eight glaucoma patients, but not in unaffected family members and 100 unrelated controls.
BC8_BioRED_Task1_Doc193	1545	1553	patients	OrganismTaxon	9606	Using direct sequencing a point mutation (144 G>A) resulting in a Q48H substitution in exon 1 of the MYOC gene was observed in five of the eight glaucoma patients, but not in unaffected family members and 100 unrelated controls.
BC8_BioRED_Task1_Doc193	1675	1696	congenital microcoria	Disease	C537550	CONCLUSIONS: We have confirmed the localization of the congenital microcoria locus (MCOR) to 13q31-q32 in a large Asian Indian family and conclude that current information suggests this is a single locus disorder and genetically homogeneous.
BC8_BioRED_Task1_Doc193	1704	1708	MCOR	Gene	8104	CONCLUSIONS: We have confirmed the localization of the congenital microcoria locus (MCOR) to 13q31-q32 in a large Asian Indian family and conclude that current information suggests this is a single locus disorder and genetically homogeneous.
BC8_BioRED_Task1_Doc193	1946	1950	MCOR	Gene	8104	When combined with the initial linkage paper our haplotype and linkage data map the MCOR locus to a 6-7 cM region between D13S265 and D13S1280.
BC8_BioRED_Task1_Doc193	2010	2013	DCT	Gene	1638	The DCT locus, a member of the tyrosinase family involved in pigmentation, maps within this region.
BC8_BioRED_Task1_Doc193	2037	2047	tyrosinase	Gene	7299	The DCT locus, a member of the tyrosinase family involved in pigmentation, maps within this region.
BC8_BioRED_Task1_Doc193	2067	2079	pigmentation	Disease	D010859	The DCT locus, a member of the tyrosinase family involved in pigmentation, maps within this region.
BC8_BioRED_Task1_Doc193	2155	2176	congenital microcoria	Disease	C537550	Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of MYOC Q48H (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.
BC8_BioRED_Task1_Doc193	2208	2216	glaucoma	Disease	D005901	Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of MYOC Q48H (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.
BC8_BioRED_Task1_Doc193	2289	2293	MYOC	Gene	4653	Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of MYOC Q48H (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.
BC8_BioRED_Task1_Doc193	2294	2298	Q48H	SequenceVariant	rs74315339	Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of MYOC Q48H (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.
BC8_BioRED_Task1_Doc193	2354	2362	glaucoma	Disease	D005901	Data presented here supports the hypothesis that congenital microcoria is a potential risk factor for glaucoma, although this observation is complicated by the partial segregation of MYOC Q48H (1q24.3-q25.2), a mutation known to be associated with glaucoma in India.
BC8_BioRED_Task1_Doc193	2462	2471	micocoria	Gene	8104	Fine mapping and candidate gene analysis continues with the hope that characterizing the micocoria gene will lead to a better understanding of microcoria and glaucoma causation.
BC8_BioRED_Task1_Doc193	2516	2526	microcoria	Disease	C537550	Fine mapping and candidate gene analysis continues with the hope that characterizing the micocoria gene will lead to a better understanding of microcoria and glaucoma causation.
BC8_BioRED_Task1_Doc193	2531	2539	glaucoma	Disease	D005901	Fine mapping and candidate gene analysis continues with the hope that characterizing the micocoria gene will lead to a better understanding of microcoria and glaucoma causation.
BC8_BioRED_Task1_Doc193	2576	2586	microcoria	Disease	C537550	The relationship between microcoria, glaucoma, and the MYOC Q48H mutation in this family is discussed.
BC8_BioRED_Task1_Doc193	2588	2596	glaucoma	Disease	D005901	The relationship between microcoria, glaucoma, and the MYOC Q48H mutation in this family is discussed.
BC8_BioRED_Task1_Doc193	2606	2610	MYOC	Gene	4653	The relationship between microcoria, glaucoma, and the MYOC Q48H mutation in this family is discussed.
BC8_BioRED_Task1_Doc193	2611	2615	Q48H	SequenceVariant	rs74315339	The relationship between microcoria, glaucoma, and the MYOC Q48H mutation in this family is discussed.
BC8_BioRED_Task1_Doc194	52	63	propranolol	Chemical	D011433	The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.
BC8_BioRED_Task1_Doc194	85	104	cardiac arrhythmias	Disease	D001145	The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.
BC8_BioRED_Task1_Doc194	132	143	propranolol	Chemical	D011433	The optical isomers of propranolol have been compared for their beta-blocking and antiarrhythmic activities.2.
BC8_BioRED_Task1_Doc194	285	297	isoprenaline	Chemical	D007545	In blocking the positive inotropic and chronotropic responses to isoprenaline, (+)-propranolol had less than one hundredth the potency of (-)-propranolol.
BC8_BioRED_Task1_Doc194	303	314	propranolol	Chemical	D011433	In blocking the positive inotropic and chronotropic responses to isoprenaline, (+)-propranolol had less than one hundredth the potency of (-)-propranolol.
BC8_BioRED_Task1_Doc194	362	373	propranolol	Chemical	D011433	In blocking the positive inotropic and chronotropic responses to isoprenaline, (+)-propranolol had less than one hundredth the potency of (-)-propranolol.
BC8_BioRED_Task1_Doc194	397	408	propranolol	Chemical	D011433	At dose levels of (+)-propranolol which attenuated the responses to isoprenaline, there was a significant prolongation of the PR interval of the electrocardiogram.3.
BC8_BioRED_Task1_Doc194	443	455	isoprenaline	Chemical	D007545	At dose levels of (+)-propranolol which attenuated the responses to isoprenaline, there was a significant prolongation of the PR interval of the electrocardiogram.3.
BC8_BioRED_Task1_Doc194	568	580	isoprenaline	Chemical	D007545	The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol.
BC8_BioRED_Task1_Doc194	584	588	dogs	OrganismTaxon	9615	The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol.
BC8_BioRED_Task1_Doc194	617	624	glucose	Chemical	D005947	The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol.
BC8_BioRED_Task1_Doc194	626	633	lactate	Chemical	D019344	The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol.
BC8_BioRED_Task1_Doc194	643	654	fatty acids	Chemical	D005227	The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol.
BC8_BioRED_Task1_Doc194	680	691	propranolol	Chemical	D011433	The metabolic responses to isoprenaline in dogs (an increase in circulating glucose, lactate and free fatty acids) were all blocked by (-)-propranolol.
BC8_BioRED_Task1_Doc194	697	708	Propranolol	Chemical	D011433	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose.4.
BC8_BioRED_Task1_Doc194	726	736	fatty acid	Chemical	D005227	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose.4.
BC8_BioRED_Task1_Doc194	799	806	lactate	Chemical	D019344	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose.4.
BC8_BioRED_Task1_Doc194	811	818	glucose	Chemical	D005947	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose.4.
BC8_BioRED_Task1_Doc194	838	849	propranolol	Chemical	D011433	Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5.
BC8_BioRED_Task1_Doc194	924	935	guinea-pigs	OrganismTaxon	10141	Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5.
BC8_BioRED_Task1_Doc194	954	965	propranolol	Chemical	D011433	The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine.
BC8_BioRED_Task1_Doc194	1095	1103	procaine	Chemical	D011343	The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine.
BC8_BioRED_Task1_Doc194	1194	1205	propranolol	Chemical	D011433	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1233	1243	adrenaline	Chemical	D004837	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1252	1271	cardiac arrhythmias	Disease	D001145	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1275	1279	cats	OrganismTaxon	9685	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1299	1308	halothane	Chemical	D006221	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1335	1346	propranolol	Chemical	D011433	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1389	1400	propranolol	Chemical	D011433	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
BC8_BioRED_Task1_Doc194	1457	1468	propranolol	Chemical	D011433	At the effective dose level of (+)-propranolol there was a significant prolongation of the PR interval of the electrocardiogram.
BC8_BioRED_Task1_Doc194	1563	1574	arrhythmias	Disease	D001145	Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7.
BC8_BioRED_Task1_Doc194	1636	1646	adrenaline	Chemical	D004837	Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7.
BC8_BioRED_Task1_Doc194	1666	1677	propranolol	Chemical	D011433	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
BC8_BioRED_Task1_Doc194	1709	1732	ventricular tachycardia	Disease	D017180	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
BC8_BioRED_Task1_Doc194	1743	1750	ouabain	Chemical	D010042	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
BC8_BioRED_Task1_Doc194	1768	1772	cats	OrganismTaxon	9685	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
BC8_BioRED_Task1_Doc194	1777	1781	dogs	OrganismTaxon	9615	Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
BC8_BioRED_Task1_Doc194	1799	1810	propranolol	Chemical	D011433	The dose of (-)-propranolol was significantly smaller than that of (+)-propranolol in both species but much higher than that required to produce evidence of beta-blockade.8.
BC8_BioRED_Task1_Doc194	1854	1865	propranolol	Chemical	D011433	The dose of (-)-propranolol was significantly smaller than that of (+)-propranolol in both species but much higher than that required to produce evidence of beta-blockade.8.
BC8_BioRED_Task1_Doc195	185	190	human	OrganismTaxon	9606	Exposure to solar radiation, particularly its ultraviolet (UV) B component, has a variety of harmful effects on human health.
BC8_BioRED_Task1_Doc195	253	284	basal and squamous cell cancers	Disease	D002294,D018295	Some of these effects include sunburn cell formation, basal and squamous cell cancers, melanoma, cataracts, photoaging of the skin, and immune suppression.
BC8_BioRED_Task1_Doc195	286	294	melanoma	Disease	D008545	Some of these effects include sunburn cell formation, basal and squamous cell cancers, melanoma, cataracts, photoaging of the skin, and immune suppression.
BC8_BioRED_Task1_Doc195	296	305	cataracts	Disease	D002386	Some of these effects include sunburn cell formation, basal and squamous cell cancers, melanoma, cataracts, photoaging of the skin, and immune suppression.
BC8_BioRED_Task1_Doc195	410	421	skin cancer	Disease	D012878	Amongst these various adverse effects of UV radiation, skin cancer is of the greatest concern.
BC8_BioRED_Task1_Doc195	633	644	skin cancer	Disease	D012878	Over the years, changes in lifestyle has led to a significant increase in the amount of UV radiation that people receive, and this consequently has led to a surge in the incidence of skin cancer.
BC8_BioRED_Task1_Doc195	665	676	skin cancer	Disease	D012878	The development of skin cancer is a complex multistage phenomenon involving three distinct stages exemplified by initiation, promotion and progression stages.
BC8_BioRED_Task1_Doc195	945	959	carcinogenesis	Disease	D009369	Initiation, the first step in the carcinogenesis process is essentially an irreversible step in which genetic alterations occur in genes that ultimately leads to DNA modification and fixation of mutation.
BC8_BioRED_Task1_Doc195	1116	1121	Tumor	Disease	D009369	Tumor promotion is the essential process in cancer development involving clonal expansion of initiated cells giving rise to pre-malignant and then to malignant lesions, essentially by alterations in signal transduction pathways.
BC8_BioRED_Task1_Doc195	1160	1166	cancer	Disease	D009369	Tumor promotion is the essential process in cancer development involving clonal expansion of initiated cells giving rise to pre-malignant and then to malignant lesions, essentially by alterations in signal transduction pathways.
BC8_BioRED_Task1_Doc195	1345	1350	Tumor	Disease	D009369	Tumor progression involves the conversion of pre-malignant and malignant lesions into an invasive and potentially metastatic malignant tumor.
BC8_BioRED_Task1_Doc195	1480	1485	tumor	Disease	D009369	Tumor progression involves the conversion of pre-malignant and malignant lesions into an invasive and potentially metastatic malignant tumor.
BC8_BioRED_Task1_Doc195	1511	1522	skin cancer	Disease	D012878	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1603	1615	inflammation	Disease	D007249	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1636	1657	epidermal hyperplasia	Disease	D006965	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1698	1709	antioxidant	Chemical	D000975	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1777	1791	cyclooxygenase	Gene	5742	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1805	1818	prostaglandin	Chemical	D011453	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1847	1870	ornithine decarboxylase	Gene	4953	All these processes for skin cancer development involve stimulation of DNA synthesis, DNA damage and proliferation, inflammation, immunosuppression, epidermal hyperplasia, cell cycle dysregulation, depletion of antioxidant defenses, impairment of signal transduction pathways, induction of cyclooxygenase, increase in prostaglandin synthesis, and induction of ornithine decarboxylase.
BC8_BioRED_Task1_Doc195	1963	1974	skin cancer	Disease	D012878	Photochemoprevention has been appreciated as a viable approach to reduce the occurrence of skin cancer and in recent years, the use of agents, especially botanical antioxidants, present in the common diet and beverages consumed by human population have gained considerable attention as photochemopreventive agents for human use.
BC8_BioRED_Task1_Doc195	2036	2048	antioxidants	Chemical	D000975	Photochemoprevention has been appreciated as a viable approach to reduce the occurrence of skin cancer and in recent years, the use of agents, especially botanical antioxidants, present in the common diet and beverages consumed by human population have gained considerable attention as photochemopreventive agents for human use.
BC8_BioRED_Task1_Doc195	2103	2108	human	OrganismTaxon	9606	Photochemoprevention has been appreciated as a viable approach to reduce the occurrence of skin cancer and in recent years, the use of agents, especially botanical antioxidants, present in the common diet and beverages consumed by human population have gained considerable attention as photochemopreventive agents for human use.
BC8_BioRED_Task1_Doc195	2190	2195	human	OrganismTaxon	9606	Photochemoprevention has been appreciated as a viable approach to reduce the occurrence of skin cancer and in recent years, the use of agents, especially botanical antioxidants, present in the common diet and beverages consumed by human population have gained considerable attention as photochemopreventive agents for human use.
BC8_BioRED_Task1_Doc195	2784	2795	skin cancer	Disease	D012878	We suggest that the use of skin care products supplemented with proven chemopreventive agents in conjunction with the use of sunscreens along with educational efforts may be an effective strategy for reducing UV-induced photodamage and skin cancer in humans.
BC8_BioRED_Task1_Doc195	2799	2805	humans	OrganismTaxon	9606	We suggest that the use of skin care products supplemented with proven chemopreventive agents in conjunction with the use of sunscreens along with educational efforts may be an effective strategy for reducing UV-induced photodamage and skin cancer in humans.
BC8_BioRED_Task1_Doc196	25	32	GADD45A	Gene	13197	DNA-damage response gene GADD45A induces differentiation in hematopoietic stem cells without inhibiting cell cycle or survival.
BC8_BioRED_Task1_Doc196	293	340	Growth arrest and DNA-damage-inducible 45 alpha	Gene	13197	Growth arrest and DNA-damage-inducible 45 alpha (GADD45A) is induced by genotoxic stress in HSCs.
BC8_BioRED_Task1_Doc196	342	349	GADD45A	Gene	13197	Growth arrest and DNA-damage-inducible 45 alpha (GADD45A) is induced by genotoxic stress in HSCs.
BC8_BioRED_Task1_Doc196	391	398	GADD45A	Gene	13197	GADD45A has been implicated in cell cycle control, cell death and senescence, as well as in DNA-damage repair.
BC8_BioRED_Task1_Doc196	514	521	GADD45A	Gene	13197	In general, GADD45A provides cellular stability by either arresting the cell cycle progression until DNA damage is repaired or, in cases of fatal damage, by inducing apoptosis.
BC8_BioRED_Task1_Doc196	704	711	GADD45A	Gene	13197	However, the function of GADD45A in hematopoiesis remains controversial.
BC8_BioRED_Task1_Doc196	779	785	murine	OrganismTaxon	10090	We revealed the changes in murine HSC fate control orchestrated by the expression of GADD45A at single cell resolution.
BC8_BioRED_Task1_Doc196	837	844	GADD45A	Gene	13197	We revealed the changes in murine HSC fate control orchestrated by the expression of GADD45A at single cell resolution.
BC8_BioRED_Task1_Doc196	911	918	GADD45A	Gene	13197	In contrast to other cellular systems, GADD45A expression did not cause a cell cycle arrest or an alteration in the decision between cell survival and apoptosis in HSCs.
BC8_BioRED_Task1_Doc196	1054	1061	GADD45A	Gene	13197	Strikingly, GADD45A strongly induced and accelerated the differentiation program in HSCs.
BC8_BioRED_Task1_Doc196	1236	1243	GADD45A	Gene	13197	Continuous tracking of individual HSCs and their progeny via time-lapse microscopy elucidated that once GADD45A was expressed, HSCs differentiate into committed progenitors within 29 hours.
BC8_BioRED_Task1_Doc196	1322	1329	GADD45A	Gene	13197	GADD45A-expressing HSCs failed to long-term reconstitute the blood of recipients by inducing multilineage differentiation in vivo.
BC8_BioRED_Task1_Doc196	1545	1552	GADD45A	Gene	13197	Importantly, g-irradiation of HSCs induced their differentiation by upregulating endogenous GADD45A.
BC8_BioRED_Task1_Doc196	1587	1594	GADD45A	Gene	13197	The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages.
BC8_BioRED_Task1_Doc196	1625	1661	p38 Mitogen-activated protein kinase	Gene	26416	The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages.
BC8_BioRED_Task1_Doc196	1663	1667	MAPK	Gene	26416	The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages.
BC8_BioRED_Task1_Doc196	1817	1824	GADD45A	Gene	13197	These data indicate that genotoxic stress-induced GADD45A expression in HSCs prevents their fatal transformation by directing them into differentiation and thereby clearing them from the system.
BC8_BioRED_Task1_Doc197	18	28	ritanserin	Chemical	D016713	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
BC8_BioRED_Task1_Doc197	73	84	scopolamine	Chemical	D012601	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
BC8_BioRED_Task1_Doc197	93	100	amnesia	Disease	D000647	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
BC8_BioRED_Task1_Doc197	115	119	rats	OrganismTaxon	10116	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.
BC8_BioRED_Task1_Doc197	135	145	ritanserin	Chemical	D016713	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
BC8_BioRED_Task1_Doc197	147	152	5-HT2	Gene	29595	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
BC8_BioRED_Task1_Doc197	168	179	scopolamine	Chemical	D012601	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
BC8_BioRED_Task1_Doc197	181	203	muscarinic cholinergic	Gene	25229	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
BC8_BioRED_Task1_Doc197	224	231	amnesia	Disease	D000647	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.
BC8_BioRED_Task1_Doc197	277	281	Rats	OrganismTaxon	10116	Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus.
BC8_BioRED_Task1_Doc197	435	439	DMSO	Chemical	D004121	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	448	452	DMSO	Chemical	D004121	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	455	466	scopolamine	Chemical	D012601	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	526	536	ritanserin	Chemical	D016713	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	567	571	DMSO	Chemical	D004121	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	606	617	scopolamine	Chemical	D012601	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	654	664	ritanserin	Chemical	D016713	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	676	686	ritanserin	Chemical	D016713	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	708	712	DMSO	Chemical	D004121	One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.
BC8_BioRED_Task1_Doc197	1129	1140	scopolamine	Chemical	D012601	The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine-treated group as compared to saline group.
BC8_BioRED_Task1_Doc197	1184	1194	Ritanserin	Chemical	D016713	Ritanserin-treated rats (4 microg/0.5 microl/side) showed a significant decrease in the mentioned parameters as compared to DMSO-treated group.
BC8_BioRED_Task1_Doc197	1203	1207	rats	OrganismTaxon	10116	Ritanserin-treated rats (4 microg/0.5 microl/side) showed a significant decrease in the mentioned parameters as compared to DMSO-treated group.
BC8_BioRED_Task1_Doc197	1308	1312	DMSO	Chemical	D004121	Ritanserin-treated rats (4 microg/0.5 microl/side) showed a significant decrease in the mentioned parameters as compared to DMSO-treated group.
BC8_BioRED_Task1_Doc197	1337	1348	scopolamine	Chemical	D012601	However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
BC8_BioRED_Task1_Doc197	1353	1363	ritanserin	Chemical	D016713	However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
BC8_BioRED_Task1_Doc197	1479	1490	scopolamine	Chemical	D012601	However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
BC8_BioRED_Task1_Doc197	1499	1503	rats	OrganismTaxon	10116	However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
BC8_BioRED_Task1_Doc197	1546	1556	ritanserin	Chemical	D016713	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.
BC8_BioRED_Task1_Doc197	1609	1620	scopolamine	Chemical	D012601	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.
BC8_BioRED_Task1_Doc197	1629	1636	amnesia	Disease	D000647	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.
BC8_BioRED_Task1_Doc198	0	9	Valproate	Chemical	D014635	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
BC8_BioRED_Task1_Doc198	18	24	chorea	Disease	D002819	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
BC8_BioRED_Task1_Doc198	29	43	encephalopathy	Disease	D001927	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
BC8_BioRED_Task1_Doc198	56	82	nonketotic hyperglycinemia	Disease	D020158	Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
BC8_BioRED_Task1_Doc198	84	110	Nonketotic hyperglycinemia	Disease	D020158	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
BC8_BioRED_Task1_Doc198	116	149	disorder of amino acid metabolism	Disease	D000592	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
BC8_BioRED_Task1_Doc198	175	182	glycine	Chemical	D005998	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
BC8_BioRED_Task1_Doc198	227	234	glycine	Chemical	D005998	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
BC8_BioRED_Task1_Doc198	323	328	apnea	Disease	D001049	In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
BC8_BioRED_Task1_Doc198	342	350	seizures	Disease	D012640	In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
BC8_BioRED_Task1_Doc198	356	365	hypotonia	Disease	D009123	In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
BC8_BioRED_Task1_Doc198	391	414	psychomotor retardation	Disease	D011596	In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
BC8_BioRED_Task1_Doc198	453	479	nonketotic hyperglycinemia	Disease	D020158	An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
BC8_BioRED_Task1_Doc198	565	572	patient	OrganismTaxon	9606	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc198	583	597	language delay	Disease	D007805	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc198	602	620	mental retardation	Disease	D008607	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc198	644	670	nonketotic hyperglycinemia	Disease	D020158	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc198	709	723	encephalopathy	Disease	D001927	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc198	728	734	chorea	Disease	D002819	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc198	763	772	valproate	Chemical	D014635	This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.
BC8_BioRED_Task1_Doc199	66	71	human	OrganismTaxon	9606	cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed.
BC8_BioRED_Task1_Doc199	72	135	nuclear encoded iron sulphur protein (IP) subunits of complex I	Gene	4720,4722,4726	cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed.
BC8_BioRED_Task1_Doc199	141	146	human	OrganismTaxon	9606	cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed.
BC8_BioRED_Task1_Doc199	147	149	IP	Gene	4720,4722,4726	cDNA sequence and chromosomal localization of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed.
BC8_BioRED_Task1_Doc199	173	215	NADH:ubiquinone oxidoreductase (complex I)	Gene	4720,4722,4726	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	278	290	flavoprotein	Gene	-	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	292	294	FP	Gene	-	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	297	316	iron-sulfur protein	Gene	4720,4722,4726	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	318	320	IP	Gene	4720,4722,4726	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	327	346	hydrophobic protein	Gene	-	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	348	350	HP	Gene	-	NADH:ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a flavoprotein (FP), iron-sulfur protein (IP), and hydrophobic protein (HP) subfraction.
BC8_BioRED_Task1_Doc199	369	371	IP	Gene	4720,4722,4726	The IP subfraction is hypothesized to be significant, since it contains important prosthetic groups highly conserved among species.
BC8_BioRED_Task1_Doc199	535	540	human	OrganismTaxon	9606	We cloned the cDNA of three remaining human NADH:ubiquinone oxidoreductase subunits of this IP fraction: the NDUFS2 (49 kDa), NDUFS3 (30 kDa), and NDUFS6 (13 kDa) subunits.
BC8_BioRED_Task1_Doc199	541	580	NADH:ubiquinone oxidoreductase subunits	Gene	4720,4722,4726	We cloned the cDNA of three remaining human NADH:ubiquinone oxidoreductase subunits of this IP fraction: the NDUFS2 (49 kDa), NDUFS3 (30 kDa), and NDUFS6 (13 kDa) subunits.
BC8_BioRED_Task1_Doc199	589	591	IP	Gene	4720,4722,4726	We cloned the cDNA of three remaining human NADH:ubiquinone oxidoreductase subunits of this IP fraction: the NDUFS2 (49 kDa), NDUFS3 (30 kDa), and NDUFS6 (13 kDa) subunits.
BC8_BioRED_Task1_Doc199	606	612	NDUFS2	Gene	4720	We cloned the cDNA of three remaining human NADH:ubiquinone oxidoreductase subunits of this IP fraction: the NDUFS2 (49 kDa), NDUFS3 (30 kDa), and NDUFS6 (13 kDa) subunits.
BC8_BioRED_Task1_Doc199	623	629	NDUFS3	Gene	4722	We cloned the cDNA of three remaining human NADH:ubiquinone oxidoreductase subunits of this IP fraction: the NDUFS2 (49 kDa), NDUFS3 (30 kDa), and NDUFS6 (13 kDa) subunits.
BC8_BioRED_Task1_Doc199	644	650	NDUFS6	Gene	4726	We cloned the cDNA of three remaining human NADH:ubiquinone oxidoreductase subunits of this IP fraction: the NDUFS2 (49 kDa), NDUFS3 (30 kDa), and NDUFS6 (13 kDa) subunits.
BC8_BioRED_Task1_Doc199	905	911	bovine	OrganismTaxon	9913	The latter show 96, 90, and 83% homology with the corresponding bovine translation products.
BC8_BioRED_Task1_Doc199	1068	1073	human	OrganismTaxon	9606	Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template gave a human-specific signal which mapped the NDUFS2 and NDUFS3 subunits to chromosomes 1 and 11, respectively.
BC8_BioRED_Task1_Doc199	1113	1118	human	OrganismTaxon	9606	Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template gave a human-specific signal which mapped the NDUFS2 and NDUFS3 subunits to chromosomes 1 and 11, respectively.
BC8_BioRED_Task1_Doc199	1150	1155	human	OrganismTaxon	9606	Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template gave a human-specific signal which mapped the NDUFS2 and NDUFS3 subunits to chromosomes 1 and 11, respectively.
BC8_BioRED_Task1_Doc199	1189	1195	NDUFS2	Gene	4720	Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template gave a human-specific signal which mapped the NDUFS2 and NDUFS3 subunits to chromosomes 1 and 11, respectively.
BC8_BioRED_Task1_Doc199	1200	1206	NDUFS3	Gene	4722	Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template gave a human-specific signal which mapped the NDUFS2 and NDUFS3 subunits to chromosomes 1 and 11, respectively.
BC8_BioRED_Task1_Doc199	1274	1280	NDUFS6	Gene	4726	In the case of the NDUFS6 subunit a pseudogene may be present since signals were seen in the lanes containing chromosomes 5 and 6.
BC8_BioRED_Task1_Doc199	1390	1396	NDUFS2	Gene	4720	The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.
BC8_BioRED_Task1_Doc199	1425	1441	protein kinase C	Gene	5578	The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.
BC8_BioRED_Task1_Doc199	1471	1477	NDUFS3	Gene	4722	The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.
BC8_BioRED_Task1_Doc199	1514	1530	casein kinase II	Gene	1457	The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.
BC8_BioRED_Task1_Doc199	1627	1656	enzymatic complex I-deficient	Disease	C537475	The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.
BC8_BioRED_Task1_Doc199	1657	1665	patients	OrganismTaxon	9606	The NDUFS2 contains a highly conserved protein kinase C phosphorylation site and the NDUFS3 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I-deficient patients.
BC8_BioRED_Task1_Doc200	10	14	CCR5	Gene	1234	Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.
BC8_BioRED_Task1_Doc200	14	21	delta32	SequenceVariant	c|DEL||32	Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.
BC8_BioRED_Task1_Doc200	73	78	HIV-1	OrganismTaxon	11676	Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.
BC8_BioRED_Task1_Doc200	206	235	C-C chemokine receptor type 5	Gene	1234	The interplay between C-C chemokine receptor type 5 (CCR5) host genetic background, disease progression, and intrahost HIV-1 evolutionary dynamics remains unclear because differences in viral evolution between hosts limit the ability to draw conclusions across hosts stratified into clinically relevant populations.
BC8_BioRED_Task1_Doc200	237	241	CCR5	Gene	1234	The interplay between C-C chemokine receptor type 5 (CCR5) host genetic background, disease progression, and intrahost HIV-1 evolutionary dynamics remains unclear because differences in viral evolution between hosts limit the ability to draw conclusions across hosts stratified into clinically relevant populations.
BC8_BioRED_Task1_Doc200	303	308	HIV-1	OrganismTaxon	11676	The interplay between C-C chemokine receptor type 5 (CCR5) host genetic background, disease progression, and intrahost HIV-1 evolutionary dynamics remains unclear because differences in viral evolution between hosts limit the ability to draw conclusions across hosts stratified into clinically relevant populations.
BC8_BioRED_Task1_Doc200	933	937	CCR5	Gene	1234	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1028	1033	gp120	Gene	3700	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1065	1070	HIV-1	OrganismTaxon	11676	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1130	1139	infection	Disease	D007239	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1160	1174	HIV-1-infected	Disease	D015658	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1205	1209	CCR5	Gene	1234	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1216	1221	HIV-1	OrganismTaxon	11676	To clarify the role of CCR5 host genetic background and disease progression on viral evolutionary patterns, we obtain gp120 envelope sequences from clonal HIV-1 variants isolated at multiple time points in the course of infection from populations of HIV-1-infected individuals who only harbored CCR5-using HIV-1 variants at all time points.
BC8_BioRED_Task1_Doc200	1276	1280	CCR5	Gene	1234	Presence or absence of a CCR5 wt/DD32 genotype and progressive or long-term nonprogressive course of infection stratify the clinical populations in a two-way design.
BC8_BioRED_Task1_Doc200	1284	1288	DD32	SequenceVariant	c|DEL||32	Presence or absence of a CCR5 wt/DD32 genotype and progressive or long-term nonprogressive course of infection stratify the clinical populations in a two-way design.
BC8_BioRED_Task1_Doc200	1352	1361	infection	Disease	D007239	Presence or absence of a CCR5 wt/DD32 genotype and progressive or long-term nonprogressive course of infection stratify the clinical populations in a two-way design.
BC8_BioRED_Task1_Doc200	1489	1496	patient	OrganismTaxon	9606	As compared with the standard approach of analyzing sequences from each patient independently, the HPM provides more efficient estimation of evolutionary parameters such as nucleotide substitution rates and d(N)/d(S) rate ratios, as shown by significant shrinkage of the estimator variance.
BC8_BioRED_Task1_Doc200	1839	1846	patient	OrganismTaxon	9606	The fixed effects also correct for nonindependence of data between populations and results in even further shrinkage of individual patient estimates.
BC8_BioRED_Task1_Doc200	1975	1979	CCR5	Gene	1234	Model selection suggests an association between nucleotide substitution rate and disease progression, but a role for CCR5 genotype remains elusive.
BC8_BioRED_Task1_Doc200	2063	2070	patient	OrganismTaxon	9606	Given the absence of clear d(N)/d(S) differences between patient groups, delayed onset of AIDS symptoms appears to be solely associated with lower viral replication rates rather than with differences in selection on amino acid fixation.
BC8_BioRED_Task1_Doc200	2096	2100	AIDS	Disease	D000163	Given the absence of clear d(N)/d(S) differences between patient groups, delayed onset of AIDS symptoms appears to be solely associated with lower viral replication rates rather than with differences in selection on amino acid fixation.
BC8_BioRED_Task1_Doc201	0	6	RNASEL	Gene	6041	RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.
BC8_BioRED_Task1_Doc201	11	17	RNASEL	Gene	6041	RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.
BC8_BioRED_Task1_Doc201	42	57	prostate cancer	Disease	D011471	RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.
BC8_BioRED_Task1_Doc201	154	169	prostate cancer	Disease	D011471	BACKGROUND: Afro-Caribbeans from Tobago are at high risk of developing prostate cancer.
BC8_BioRED_Task1_Doc201	193	208	prostate cancer	Disease	D011471	This elevated risk of prostate cancer is shared by populations of African ancestry living in diverse environments in the Western hemisphere.
BC8_BioRED_Task1_Doc201	329	343	ribonuclease L	Gene	6041	Variation in the ribonuclease L (RNASEL) gene has recently been reported to be associated with an increased risk of prostate cancer.
BC8_BioRED_Task1_Doc201	345	351	RNASEL	Gene	6041	Variation in the ribonuclease L (RNASEL) gene has recently been reported to be associated with an increased risk of prostate cancer.
BC8_BioRED_Task1_Doc201	428	443	prostate cancer	Disease	D011471	Variation in the ribonuclease L (RNASEL) gene has recently been reported to be associated with an increased risk of prostate cancer.
BC8_BioRED_Task1_Doc201	462	468	RNASEL	Gene	6041	However, whether RNASEL variation contributes to the increased risk of prostate cancer observed in populations of African ancestry remains unclear.
BC8_BioRED_Task1_Doc201	516	531	prostate cancer	Disease	D011471	However, whether RNASEL variation contributes to the increased risk of prostate cancer observed in populations of African ancestry remains unclear.
BC8_BioRED_Task1_Doc201	647	653	RNASEL	Gene	6041	METHODS: We resequenced the positional candidate gene RNASEL in 48 prostate cancer cases and genotyped the previously reported R462Q and D541E polymorphisms in 230 prostate cancer cases and 458 controls.
BC8_BioRED_Task1_Doc201	660	675	prostate cancer	Disease	D011471	METHODS: We resequenced the positional candidate gene RNASEL in 48 prostate cancer cases and genotyped the previously reported R462Q and D541E polymorphisms in 230 prostate cancer cases and 458 controls.
BC8_BioRED_Task1_Doc201	720	725	R462Q	SequenceVariant	rs486907	METHODS: We resequenced the positional candidate gene RNASEL in 48 prostate cancer cases and genotyped the previously reported R462Q and D541E polymorphisms in 230 prostate cancer cases and 458 controls.
BC8_BioRED_Task1_Doc201	730	735	D541E	SequenceVariant	rs627928	METHODS: We resequenced the positional candidate gene RNASEL in 48 prostate cancer cases and genotyped the previously reported R462Q and D541E polymorphisms in 230 prostate cancer cases and 458 controls.
BC8_BioRED_Task1_Doc201	757	772	prostate cancer	Disease	D011471	METHODS: We resequenced the positional candidate gene RNASEL in 48 prostate cancer cases and genotyped the previously reported R462Q and D541E polymorphisms in 230 prostate cancer cases and 458 controls.
BC8_BioRED_Task1_Doc201	831	837	RNASEL	Gene	6041	We also examined the inhibitor of RNASEL (ABCE1) for variation associated with prostate cancer risk.
BC8_BioRED_Task1_Doc201	839	844	ABCE1	Gene	6059	We also examined the inhibitor of RNASEL (ABCE1) for variation associated with prostate cancer risk.
BC8_BioRED_Task1_Doc201	876	891	prostate cancer	Disease	D011471	We also examined the inhibitor of RNASEL (ABCE1) for variation associated with prostate cancer risk.
BC8_BioRED_Task1_Doc201	951	956	R462Q	SequenceVariant	rs486907	RESULTS: We found no evidence of association between R462Q and D541E polymorphisms and prostate cancer risk in our case/control analysis.
BC8_BioRED_Task1_Doc201	961	966	D541E	SequenceVariant	rs627928	RESULTS: We found no evidence of association between R462Q and D541E polymorphisms and prostate cancer risk in our case/control analysis.
BC8_BioRED_Task1_Doc201	985	1000	prostate cancer	Disease	D011471	RESULTS: We found no evidence of association between R462Q and D541E polymorphisms and prostate cancer risk in our case/control analysis.
BC8_BioRED_Task1_Doc201	1053	1058	K294E	SequenceVariant	rs143544690	A novel variant (K294E) was identified in a single heterozygous individual with prostate cancer.
BC8_BioRED_Task1_Doc201	1116	1131	prostate cancer	Disease	D011471	A novel variant (K294E) was identified in a single heterozygous individual with prostate cancer.
BC8_BioRED_Task1_Doc201	1152	1231	20 bp insertion/deletion polymorphism 1,109 bp upstream of the initiation codon	SequenceVariant	c|INDEL|1109|20	We also observed a 20 bp insertion/deletion polymorphism 1,109 bp upstream of the initiation codon, but this variant was not associated with prostate cancer.
BC8_BioRED_Task1_Doc201	1274	1289	prostate cancer	Disease	D011471	We also observed a 20 bp insertion/deletion polymorphism 1,109 bp upstream of the initiation codon, but this variant was not associated with prostate cancer.
BC8_BioRED_Task1_Doc201	1347	1352	ABCE1	Gene	6059	We identified 16 single nucleotide polymorphisms in the ABCE1 gene, only 3 of which had a minor allele frequency >5%.
BC8_BioRED_Task1_Doc201	1418	1442	A/G transition -1,071 bp	SequenceVariant	c|SUB|A|-1071|G	A common A/G transition -1,071 bp from the transcriptional start site was genotyped and showed no evidence of association with prostate cancer.
BC8_BioRED_Task1_Doc201	1536	1551	prostate cancer	Disease	D011471	A common A/G transition -1,071 bp from the transcriptional start site was genotyped and showed no evidence of association with prostate cancer.
BC8_BioRED_Task1_Doc201	1624	1639	prostate cancer	Disease	D011471	CONCLUSIONS: Our results suggest that common variation in the putative prostate cancer susceptibility gene, RNASEL, or its inhibitor does not contribute significantly to prostate cancer risk in this Afro-Caribbean population.
BC8_BioRED_Task1_Doc201	1661	1667	RNASEL	Gene	6041	CONCLUSIONS: Our results suggest that common variation in the putative prostate cancer susceptibility gene, RNASEL, or its inhibitor does not contribute significantly to prostate cancer risk in this Afro-Caribbean population.
BC8_BioRED_Task1_Doc201	1723	1738	prostate cancer	Disease	D011471	CONCLUSIONS: Our results suggest that common variation in the putative prostate cancer susceptibility gene, RNASEL, or its inhibitor does not contribute significantly to prostate cancer risk in this Afro-Caribbean population.
BC8_BioRED_Task1_Doc202	56	60	ETV6	Gene	2120	Identification of the nuclear localization motif in the ETV6 (TEL) protein.
BC8_BioRED_Task1_Doc202	62	65	TEL	Gene	2120	Identification of the nuclear localization motif in the ETV6 (TEL) protein.
BC8_BioRED_Task1_Doc202	76	80	ETV6	Gene	2120	ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer.
BC8_BioRED_Task1_Doc202	85	111	Translocation-Ets-Leukemia	Gene	2120	ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer.
BC8_BioRED_Task1_Doc202	113	116	TEL	Gene	2120	ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer.
BC8_BioRED_Task1_Doc202	296	301	human	OrganismTaxon	9606	ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer.
BC8_BioRED_Task1_Doc202	302	308	cancer	Disease	D009369	ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer.
BC8_BioRED_Task1_Doc202	310	314	ETV6	Gene	2120	ETV6 is predominantly a nuclear phosphoprotein that represses transcription by binding directly to the promoters of target genes.
BC8_BioRED_Task1_Doc202	478	482	ETV6	Gene	2120	The nuclear localization mechanism of ETV6, however, is not well understood.
BC8_BioRED_Task1_Doc202	629	633	ETV6	Gene	2120	In this report, we provide evidence that a nuclear localization signal (NLS) exists in the C-terminal region of ETV6.
BC8_BioRED_Task1_Doc202	635	639	ETV6	Gene	2120	ETV6 proteins with mutations outside of amino acids 332-452 localize to the nucleus, whereas proteins with mutations within amino acids 332-452 remain in the cytoplasm.
BC8_BioRED_Task1_Doc202	836	840	ETV6	Gene	2120	Furthermore, when a fragment of ETV6 comprised of amino acids 332-452 was fused to cytoplasmic beta-galactosidase protein, the fusion protein was able to enter the nucleus.
BC8_BioRED_Task1_Doc202	899	917	beta-galactosidase	Gene	2720	Furthermore, when a fragment of ETV6 comprised of amino acids 332-452 was fused to cytoplasmic beta-galactosidase protein, the fusion protein was able to enter the nucleus.
BC8_BioRED_Task1_Doc202	1063	1067	ETV6	Gene	2120	These results strongly indicate that residues 332-452 mediate nuclear localization of ETV6.
BC8_BioRED_Task1_Doc203	0	27	Hepatocyte nuclear factor-6	Gene	3175	Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion.
BC8_BioRED_Task1_Doc203	74	90	type II diabetes	Disease	D003924	Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion.
BC8_BioRED_Task1_Doc203	140	147	insulin	Gene	3630	Hepatocyte nuclear factor-6: associations between genetic variability and type II diabetes and between genetic variability and estimates of insulin secretion.
BC8_BioRED_Task1_Doc203	184	217	hepatocyte nuclear factor (HNF)-6	Gene	3175	The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young.
BC8_BioRED_Task1_Doc203	292	315	maturity-onset diabetes	Disease	D003924	The transcription factor hepatocyte nuclear factor (HNF)-6 is an upstream regulator of several genes involved in the pathogenesis of maturity-onset diabetes of the young.
BC8_BioRED_Task1_Doc203	389	394	HNF-6	Gene	3175	We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects.
BC8_BioRED_Task1_Doc203	430	479	Type II (non-insulin-dependent) diabetes mellitus	Disease	D003924	We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects.
BC8_BioRED_Task1_Doc203	497	504	insulin	Gene	3630	We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects.
BC8_BioRED_Task1_Doc203	518	525	glucose	Chemical	D005947	We therefore tested the hypothesis that variability in the HNF-6 gene is associated with subsets of Type II (non-insulin-dependent) diabetes mellitus and estimates of insulin secretion in glucose tolerant subjects.
BC8_BioRED_Task1_Doc203	620	625	HNF-6	Gene	3175	We cloned the coding region as well as the intron-exon boundaries of the HNF-6 gene.
BC8_BioRED_Task1_Doc203	676	680	MODY	Gene	3172,3651,6927	We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants.
BC8_BioRED_Task1_Doc203	715	720	MODY1	Gene	3172	We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants.
BC8_BioRED_Task1_Doc203	722	727	MODY3	Gene	6927	We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants.
BC8_BioRED_Task1_Doc203	732	737	MODY4	Gene	3651	We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants.
BC8_BioRED_Task1_Doc203	754	762	patients	OrganismTaxon	9606	We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants.
BC8_BioRED_Task1_Doc203	779	795	Type II diabetes	Disease	D003924	We then examined them on genomic DNA in six MODY probands without mutations in the MODY1, MODY3 and MODY4 genes and in 54 patients with late-onset Type II diabetes by combined single strand conformational polymorphism-heteroduplex analysis followed by direct sequencing of identified variants.
BC8_BioRED_Task1_Doc203	1070	1079	Pro75 Ala	SequenceVariant	rs74805019	We identified two silent and one missense (Pro75 Ala) variant.
BC8_BioRED_Task1_Doc203	1143	1151	Pro75Ala	SequenceVariant	rs74805019	In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects.
BC8_BioRED_Task1_Doc203	1216	1224	patients	OrganismTaxon	9606	In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects.
BC8_BioRED_Task1_Doc203	1230	1255	Type II diabetes mellitus	Disease	D003924	In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects.
BC8_BioRED_Task1_Doc203	1304	1311	glucose	Chemical	D005947	In an association study the allelic frequency of the Pro75Ala polymorphism was 3.2% (95% confidence interval, 1.9-4.5) in 330 patients with Type II diabetes mellitus compared with 4.2% (2.4-6.0) in 238 age-matched glucose tolerant control subjects.
BC8_BioRED_Task1_Doc203	1379	1386	glucose	Chemical	D005947	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1413	1420	glucose	Chemical	D005947	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1443	1459	Type II diabetic	Disease	D003924	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1460	1468	patients	OrganismTaxon	9606	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1573	1580	glucose	Chemical	D005947	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1595	1602	insulin	Gene	3630	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1606	1615	C-peptide	Gene	3630	Moreover, in studies of 238 middle-aged glucose tolerant subjects, of 226 glucose tolerant offspring of Type II diabetic patients and of 367 young healthy subjects, the carriers of the polymorphism did not differ from non-carriers in glucose induced serum insulin or C-peptide responses.
BC8_BioRED_Task1_Doc203	1667	1672	HNF-6	Gene	3175	Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.
BC8_BioRED_Task1_Doc203	1702	1718	Type II diabetes	Disease	D003924	Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.
BC8_BioRED_Task1_Doc203	1738	1745	insulin	Gene	3630	Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.
BC8_BioRED_Task1_Doc203	1759	1766	glucose	Chemical	D005947	Mutations in the coding region of the HNF-6 gene are not associated with Type II diabetes or with changes in insulin responses to glucose among the Caucasians examined.
BC8_BioRED_Task1_Doc204	46	59	Daucus carota	OrganismTaxon	4039	Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.
BC8_BioRED_Task1_Doc204	81	103	cognitive dysfunctions	Disease	D003072	Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.
BC8_BioRED_Task1_Doc204	165	178	Daucus carota	OrganismTaxon	4039	The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.
BC8_BioRED_Task1_Doc204	221	232	cholesterol	Chemical	D002784	The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.
BC8_BioRED_Task1_Doc204	250	264	cholinesterase	Gene	12038	The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.
BC8_BioRED_Task1_Doc204	277	281	mice	OrganismTaxon	10090	The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.
BC8_BioRED_Task1_Doc204	297	327	extract of Daucus carota seeds	Chemical	D010936	The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.
BC8_BioRED_Task1_Doc204	329	332	DCE	Chemical	D010936	The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.
BC8_BioRED_Task1_Doc204	459	463	mice	OrganismTaxon	10090	The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.
BC8_BioRED_Task1_Doc204	582	590	Diazepam	Chemical	D003975	Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.
BC8_BioRED_Task1_Doc204	593	604	scopolamine	Chemical	D012601	Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.
BC8_BioRED_Task1_Doc204	625	632	amnesia	Disease	D000647	Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.
BC8_BioRED_Task1_Doc204	680	683	DCE	Chemical	D010936	DCE (200, 400 mg/kg, p.o.)
BC8_BioRED_Task1_Doc204	773	777	mice	OrganismTaxon	10090	showed significant improvement in memory scores of young and aged mice.
BC8_BioRED_Task1_Doc204	822	825	DCE	Chemical	D010936	The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.
BC8_BioRED_Task1_Doc204	901	905	mice	OrganismTaxon	10090	The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.
BC8_BioRED_Task1_Doc204	1042	1046	mice	OrganismTaxon	10090	Similarly, significant improvements in memory scores were observed using passive avoidance apparatus and aged mice.
BC8_BioRED_Task1_Doc204	1061	1064	DCE	Chemical	D010936	Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.)
BC8_BioRED_Task1_Doc204	1078	1085	amnesia	Disease	D000647	Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.)
BC8_BioRED_Task1_Doc204	1097	1108	scopolamine	Chemical	D012601	Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.)
BC8_BioRED_Task1_Doc204	1131	1139	diazepam	Chemical	D003975	and diazepam (1 mg/kg, i.p.).
BC8_BioRED_Task1_Doc204	1157	1178	Daucus carota extract	Chemical	D010936	Daucus carota extract (200, 400 mg/kg, p.o.)
BC8_BioRED_Task1_Doc204	1234	1254	acetylcholinesterase	Gene	11423	reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.
BC8_BioRED_Task1_Doc204	1268	1279	cholesterol	Chemical	D002784	reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.
BC8_BioRED_Task1_Doc204	1305	1309	mice	OrganismTaxon	10090	reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.
BC8_BioRED_Task1_Doc204	1345	1359	cholinesterase	Gene	12038	The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.
BC8_BioRED_Task1_Doc204	1379	1382	DCE	Chemical	D010936	The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.
BC8_BioRED_Task1_Doc204	1441	1445	mice	OrganismTaxon	10090	The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.
BC8_BioRED_Task1_Doc204	1489	1500	cholesterol	Chemical	D002784	There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.
BC8_BioRED_Task1_Doc204	1588	1591	DCE	Chemical	D010936	There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.
BC8_BioRED_Task1_Doc204	1604	1607	DCE	Chemical	D010936	Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.
BC8_BioRED_Task1_Doc204	1662	1684	cognitive dysfunctions	Disease	D003072	Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.
BC8_BioRED_Task1_Doc204	1771	1782	cholesterol	Chemical	D002784	Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.
BC8_BioRED_Task1_Doc205	0	18	Chloroacetaldehyde	Chemical	C004656	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
BC8_BioRED_Task1_Doc205	24	42	sulfhydryl reagent	Chemical	D013439	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
BC8_BioRED_Task1_Doc205	65	70	thiol	Chemical	D013438	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
BC8_BioRED_Task1_Doc205	81	91	ifosfamide	Chemical	D007069	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
BC8_BioRED_Task1_Doc205	92	103	nephropathy	Disease	D007674	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
BC8_BioRED_Task1_Doc205	105	123	Chloroacetaldehyde	Chemical	C004656	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	125	128	CAA	Chemical	C004656	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	153	169	alkylating agent	Chemical	D000477	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	170	180	ifosfamide	Chemical	D007069	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	182	185	IFO	Chemical	D007069	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	218	230	renal damage	Disease	D007674	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	246	251	tumor	Disease	D009369	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	265	268	IFO	Chemical	D007069	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
BC8_BioRED_Task1_Doc205	283	293	sulfhydryl	Chemical	D013439	Depletion of sulfhydryl (SH) groups has been reported from cell culture, animal and clinical studies.
BC8_BioRED_Task1_Doc205	295	297	SH	Chemical	D013439	Depletion of sulfhydryl (SH) groups has been reported from cell culture, animal and clinical studies.
BC8_BioRED_Task1_Doc205	399	402	CAA	Chemical	C004656	In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated.
BC8_BioRED_Task1_Doc205	406	411	human	OrganismTaxon	9606	In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated.
BC8_BioRED_Task1_Doc205	454	460	hRPTEC	CellLine	CVCL_K278	In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated.
BC8_BioRED_Task1_Doc205	480	488	Toxicity	Disease	D064420	Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
BC8_BioRED_Task1_Doc205	492	495	CAA	Chemical	C004656	Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
BC8_BioRED_Task1_Doc205	544	547	LDH	Chemical	D007770	Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
BC8_BioRED_Task1_Doc205	557	568	trypan blue	Chemical	D014343	Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
BC8_BioRED_Task1_Doc205	589	598	caspase-3	Gene	836	Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
BC8_BioRED_Task1_Doc205	614	620	thiols	Chemical	D013438	Free thiols were measured by the method of Ellman.
BC8_BioRED_Task1_Doc205	660	663	CAA	Chemical	C004656	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
BC8_BioRED_Task1_Doc205	672	678	hRPTEC	CellLine	CVCL_K278	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
BC8_BioRED_Task1_Doc205	741	747	thiols	Chemical	D013438	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
BC8_BioRED_Task1_Doc205	767	775	necrosis	Disease	D009336	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
BC8_BioRED_Task1_Doc205	785	788	CAA	Chemical	C004656	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	797	805	acrolein	Chemical	D000171	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	820	838	cysteine proteases	Gene	1508,836,841	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	839	848	caspase-3	Gene	836	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	850	859	caspase-8	Gene	841	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	864	875	cathepsin B	Gene	1508	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	877	884	Caspase	Gene	836,841	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	899	908	cisplatin	Chemical	D002945	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	926	929	CAA	Chemical	C004656	CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by cisplatin was inhibited by CAA.
BC8_BioRED_Task1_Doc205	991	994	CAA	Chemical	C004656	In cells stained with fluorescent dyes targeting lysosomes, CAA induced an increase in lysosomal size and lysosomal leakage.
BC8_BioRED_Task1_Doc205	1071	1074	CAA	Chemical	C004656	The effects of CAA on cysteine protease activities and thiols could be reproduced in cell lysate.
BC8_BioRED_Task1_Doc205	1078	1095	cysteine protease	Gene	1508,836,841	The effects of CAA on cysteine protease activities and thiols could be reproduced in cell lysate.
BC8_BioRED_Task1_Doc205	1111	1117	thiols	Chemical	D013438	The effects of CAA on cysteine protease activities and thiols could be reproduced in cell lysate.
BC8_BioRED_Task1_Doc205	1198	1201	CAA	Chemical	C004656	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
BC8_BioRED_Task1_Doc205	1207	1212	thiol	Chemical	D013438	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
BC8_BioRED_Task1_Doc205	1253	1256	CAA	Chemical	C004656	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
BC8_BioRED_Task1_Doc205	1260	1268	necrosis	Disease	D009336	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
BC8_BioRED_Task1_Doc205	1278	1283	thiol	Chemical	D013438	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
BC8_BioRED_Task1_Doc205	1298	1315	cysteine protease	Gene	1508,836,841	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
BC8_BioRED_Task1_Doc205	1350	1353	CAA	Chemical	C004656	Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.
BC8_BioRED_Task1_Doc205	1408	1414	thiols	Chemical	D013438	Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.
BC8_BioRED_Task1_Doc205	1430	1438	toxicity	Disease	D064420	Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.
BC8_BioRED_Task1_Doc205	1442	1448	hRPTEC	CellLine	CVCL_K278	Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.
BC8_BioRED_Task1_Doc205	1558	1561	IFO	Chemical	D007069	Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.
BC8_BioRED_Task1_Doc205	1562	1573	nephropathy	Disease	D007674	Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.
BC8_BioRED_Task1_Doc205	1577	1585	patients	OrganismTaxon	9606	Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.
BC8_BioRED_Task1_Doc206	63	68	FGFR3	Gene	2261	An improved tetra-primer PCR approach for the detection of the FGFR3 G380R mutation responsible for achondroplasia.
BC8_BioRED_Task1_Doc206	69	74	G380R	SequenceVariant	rs28931614	An improved tetra-primer PCR approach for the detection of the FGFR3 G380R mutation responsible for achondroplasia.
BC8_BioRED_Task1_Doc206	100	114	achondroplasia	Disease	D000130	An improved tetra-primer PCR approach for the detection of the FGFR3 G380R mutation responsible for achondroplasia.
BC8_BioRED_Task1_Doc206	116	130	Achondroplasia	Disease	D000130	Achondroplasia is the most common form of dwarfism and has an incidence of approximately 1/7500.
BC8_BioRED_Task1_Doc206	158	166	dwarfism	Disease	D004392	Achondroplasia is the most common form of dwarfism and has an incidence of approximately 1/7500.
BC8_BioRED_Task1_Doc206	273	330	G to A or G to C substitution at nucleotide position 1138	SequenceVariant	rs28931614	In more than 98% of cases, the disease is associated with a G to A or G to C substitution at nucleotide position 1138 (p.G380R) of the fibroblast growth factor receptor 3 (FGFR3) gene.
BC8_BioRED_Task1_Doc206	332	339	p.G380R	SequenceVariant	rs28931614	In more than 98% of cases, the disease is associated with a G to A or G to C substitution at nucleotide position 1138 (p.G380R) of the fibroblast growth factor receptor 3 (FGFR3) gene.
BC8_BioRED_Task1_Doc206	348	383	fibroblast growth factor receptor 3	Gene	2261	In more than 98% of cases, the disease is associated with a G to A or G to C substitution at nucleotide position 1138 (p.G380R) of the fibroblast growth factor receptor 3 (FGFR3) gene.
BC8_BioRED_Task1_Doc206	385	390	FGFR3	Gene	2261	In more than 98% of cases, the disease is associated with a G to A or G to C substitution at nucleotide position 1138 (p.G380R) of the fibroblast growth factor receptor 3 (FGFR3) gene.
BC8_BioRED_Task1_Doc206	482	491	c.1138G>A	SequenceVariant	rs28931614	We have developed a sensitive single tube tetra-primer PCR assay to detect both the c.1138G>A and c.1138G>C mutations and can successfully distinguish DNA samples that are homozygous and heterozygous for the c.1138G>A mutation.
BC8_BioRED_Task1_Doc206	496	505	c.1138G>C	SequenceVariant	rs28931614	We have developed a sensitive single tube tetra-primer PCR assay to detect both the c.1138G>A and c.1138G>C mutations and can successfully distinguish DNA samples that are homozygous and heterozygous for the c.1138G>A mutation.
BC8_BioRED_Task1_Doc206	606	615	c.1138G>A	SequenceVariant	rs28931614	We have developed a sensitive single tube tetra-primer PCR assay to detect both the c.1138G>A and c.1138G>C mutations and can successfully distinguish DNA samples that are homozygous and heterozygous for the c.1138G>A mutation.
BC8_BioRED_Task1_Doc206	811	819	patients	OrganismTaxon	9606	The assay has been tested in 50 healthy controls, 3 known patients with achondroplasia, and 5 amniotic fluids suspected of having achondroplasia and for whom we had previously determined the genotypes for the c.1138G>A mutation by PCR-RFLP.
BC8_BioRED_Task1_Doc206	825	839	achondroplasia	Disease	D000130	The assay has been tested in 50 healthy controls, 3 known patients with achondroplasia, and 5 amniotic fluids suspected of having achondroplasia and for whom we had previously determined the genotypes for the c.1138G>A mutation by PCR-RFLP.
BC8_BioRED_Task1_Doc206	883	897	achondroplasia	Disease	D000130	The assay has been tested in 50 healthy controls, 3 known patients with achondroplasia, and 5 amniotic fluids suspected of having achondroplasia and for whom we had previously determined the genotypes for the c.1138G>A mutation by PCR-RFLP.
BC8_BioRED_Task1_Doc206	962	971	c.1138G>A	SequenceVariant	rs28931614	The assay has been tested in 50 healthy controls, 3 known patients with achondroplasia, and 5 amniotic fluids suspected of having achondroplasia and for whom we had previously determined the genotypes for the c.1138G>A mutation by PCR-RFLP.
BC8_BioRED_Task1_Doc206	1127	1132	FGFR3	Gene	2261	Our tetra-primer PCR assay is sensitive, low-cost, and easy to use method for FGFR3 p.G380R genotyping, which could be used even in "low-tech" laboratories.
BC8_BioRED_Task1_Doc206	1133	1140	p.G380R	SequenceVariant	rs28931614	Our tetra-primer PCR assay is sensitive, low-cost, and easy to use method for FGFR3 p.G380R genotyping, which could be used even in "low-tech" laboratories.
BC8_BioRED_Task1_Doc207	24	26	F5	Gene	2153	Identification of three F5 gene mutations associated with inherited coagulation factor V deficiency in two Chinese pedigrees.
BC8_BioRED_Task1_Doc207	58	99	inherited coagulation factor V deficiency	Disease	D005166	Identification of three F5 gene mutations associated with inherited coagulation factor V deficiency in two Chinese pedigrees.
BC8_BioRED_Task1_Doc207	193	227	inherited factor V (FV) deficiency	Disease	D005166	To investigate the molecular defects in two Chinese pedigrees with inherited factor V (FV) deficiency.
BC8_BioRED_Task1_Doc207	314	349	inherited coagulation FV deficiency	Disease	D005166	A 37-year-old male (proband 1) and an 18-month-old boy (proband 2) were diagnosed as inherited coagulation FV deficiency by severely reduced plasma levels of FV activity and antigen.
BC8_BioRED_Task1_Doc207	387	389	FV	Gene	2153	A 37-year-old male (proband 1) and an 18-month-old boy (proband 2) were diagnosed as inherited coagulation FV deficiency by severely reduced plasma levels of FV activity and antigen.
BC8_BioRED_Task1_Doc207	456	458	F5	Gene	2153	All 25 exons and their flanking sequence of F5 gene were amplified by polymerase chain reaction (PCR) for both probands and the PCR products were directly sequenced.
BC8_BioRED_Task1_Doc207	712	722	IVS8 -2A>G	SequenceVariant	c|SUB|A|IVS8-2|G	The homozygous deletion IVS8 -2A>G was identified in the F5 gene of proband 1 and complementary DNA (cDNA) analysis revealed the abolishment of the canonical splicing site by the mutation and the activation of the cryptic acceptor site 24 bp upstream instead.
BC8_BioRED_Task1_Doc207	745	747	F5	Gene	2153	The homozygous deletion IVS8 -2A>G was identified in the F5 gene of proband 1 and complementary DNA (cDNA) analysis revealed the abolishment of the canonical splicing site by the mutation and the activation of the cryptic acceptor site 24 bp upstream instead.
BC8_BioRED_Task1_Doc207	952	1001	insertion introduced eight additional amino acids	SequenceVariant	p|INS||8	The insertion introduced eight additional amino acids (AA) into the FV protein.
BC8_BioRED_Task1_Doc207	1016	1018	FV	Gene	2153	The insertion introduced eight additional amino acids (AA) into the FV protein.
BC8_BioRED_Task1_Doc207	1058	1060	F5	Gene	2153	Two heterozygous mutations of F5 gene were discovered in proband 2.
BC8_BioRED_Task1_Doc207	1100	1112	2238-9del AG	SequenceVariant	c|DEL|2238_2239|AG	The 2238-9del AG in exon 13 introduced a premature termination code at 689 AA and the substitution of G6410 by T in exon 23 lead to the missense mutation Gly2079Val.
BC8_BioRED_Task1_Doc207	1167	1173	689 AA	SequenceVariant	c|Allele|A|689	The 2238-9del AG in exon 13 introduced a premature termination code at 689 AA and the substitution of G6410 by T in exon 23 lead to the missense mutation Gly2079Val.
BC8_BioRED_Task1_Doc207	1198	1208	G6410 by T	SequenceVariant	g|SUB|G|6410|T	The 2238-9del AG in exon 13 introduced a premature termination code at 689 AA and the substitution of G6410 by T in exon 23 lead to the missense mutation Gly2079Val.
BC8_BioRED_Task1_Doc207	1250	1260	Gly2079Val	SequenceVariant	p|SUB|G|2079|V	The 2238-9del AG in exon 13 introduced a premature termination code at 689 AA and the substitution of G6410 by T in exon 23 lead to the missense mutation Gly2079Val.
BC8_BioRED_Task1_Doc207	1268	1270	F5	Gene	2153	Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with congenital FV deficiency, respectively.
BC8_BioRED_Task1_Doc207	1287	1297	IVS8 -2A>G	SequenceVariant	c|SUB|A|IVS8-2|G	Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with congenital FV deficiency, respectively.
BC8_BioRED_Task1_Doc207	1299	1311	2238-9del AG	SequenceVariant	c|DEL|2238_2239|AG	Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with congenital FV deficiency, respectively.
BC8_BioRED_Task1_Doc207	1316	1322	G6410T	SequenceVariant	g|SUB|G|6410|T	Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with congenital FV deficiency, respectively.
BC8_BioRED_Task1_Doc207	1374	1398	congenital FV deficiency	Disease	D005166	Three F5 gene mutations, IVS8 -2A>G, 2238-9del AG and G6410T, have been identified in two Chinese pedigree with congenital FV deficiency, respectively.
BC8_BioRED_Task1_Doc208	13	17	IL10	Gene	3586	Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.
BC8_BioRED_Task1_Doc208	87	102	prostate cancer	Disease	D011471	Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.
BC8_BioRED_Task1_Doc208	216	220	IL10	Gene	3586	BACKGROUND: To evaluate the association of variation in genes involved in immune response, including IL10, production and detoxification of reactive oxygen species, and repair of oxidative DNA damage with risk of recurrence after surgery for localized prostate cancer.
BC8_BioRED_Task1_Doc208	255	278	reactive oxygen species	Chemical	D017382	BACKGROUND: To evaluate the association of variation in genes involved in immune response, including IL10, production and detoxification of reactive oxygen species, and repair of oxidative DNA damage with risk of recurrence after surgery for localized prostate cancer.
BC8_BioRED_Task1_Doc208	367	382	prostate cancer	Disease	D011471	BACKGROUND: To evaluate the association of variation in genes involved in immune response, including IL10, production and detoxification of reactive oxygen species, and repair of oxidative DNA damage with risk of recurrence after surgery for localized prostate cancer.
BC8_BioRED_Task1_Doc208	437	440	men	OrganismTaxon	9606	METHODS: We conducted a nested case-control study of men who had a radical prostatectomy in 1993 to 2001.
BC8_BioRED_Task1_Doc208	630	638	paraffin	Chemical	D010232	Germline DNA was extracted from paraffin-embedded unaffected lymph nodes.
BC8_BioRED_Task1_Doc208	736	740	IL10	Gene	3586	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	742	745	CRP	Gene	1401	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	747	751	GPX1	Gene	2876	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	753	756	GSR	Gene	2936	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	758	763	GSTP1	Gene	2950	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	765	770	hOGG1	Gene	4968	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	772	776	IL1B	Gene	3553	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	778	783	IL1RN	Gene	3557	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	785	788	IL6	Gene	3569	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	790	793	IL8	Gene	3576	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	795	798	MPO	Gene	4353	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	800	804	NOS2	Gene	4843	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	806	810	NOS3	Gene	4846	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	812	816	SOD1	Gene	6647	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	818	822	SOD2	Gene	6648	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	824	828	SOD3	Gene	6649	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	830	834	TLR4	Gene	7099	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	840	843	TNF	Gene	7124	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	864	868	IL10	Gene	3586	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	870	873	CRP	Gene	1401	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	875	878	GSR	Gene	2936	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	880	885	IL1RN	Gene	3557	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	887	890	IL6	Gene	3569	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	892	896	NOS2	Gene	4843	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	902	906	NOS3	Gene	4846	We genotyped candidate single-nucleotide polymorphisms (SNP) in IL10, CRP, GPX1, GSR, GSTP1, hOGG1, IL1B, IL1RN, IL6, IL8, MPO, NOS2, NOS3, SOD1, SOD2, SOD3, TLR4, and TNF and tagging SNPs in IL10, CRP, GSR, IL1RN, IL6, NOS2, and NOS3.
BC8_BioRED_Task1_Doc208	1031	1035	IL10	Gene	3586	RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91).
BC8_BioRED_Task1_Doc208	1036	1045	rs1800872	SequenceVariant	rs1800872	RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91).
BC8_BioRED_Task1_Doc208	1069	1083	interleukin-10	Gene	3586	RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91).
BC8_BioRED_Task1_Doc208	1085	1090	IL-10	Gene	3586	RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91).
BC8_BioRED_Task1_Doc208	1201	1210	rs1800896	SequenceVariant	rs1800896	RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91).
BC8_BioRED_Task1_Doc208	1234	1239	IL-10	Gene	3586	RESULTS: The minor allele (A) in IL10 rs1800872, known to produce less interleukin-10 (IL-10), was associated with a higher risk of recurrence (OR = 1.76, 95% CI: 1.00-3.10), and the minor allele (G) in rs1800896, known to produce more IL-10, was associated with a lower risk of recurrence (OR = 0.66, 95% CI: 0.48-0.91).
BC8_BioRED_Task1_Doc208	1372	1375	CRP	Gene	1401	We also observed associations for candidate SNPs in CRP, GSTP1, and IL1B.
BC8_BioRED_Task1_Doc208	1377	1382	GSTP1	Gene	2950	We also observed associations for candidate SNPs in CRP, GSTP1, and IL1B.
BC8_BioRED_Task1_Doc208	1388	1392	IL1B	Gene	3553	We also observed associations for candidate SNPs in CRP, GSTP1, and IL1B.
BC8_BioRED_Task1_Doc208	1403	1407	IL10	Gene	3586	A common IL10 haplotype and 2 common NOS2 haplotypes were associated with recurrence.
BC8_BioRED_Task1_Doc208	1431	1435	NOS2	Gene	4843	A common IL10 haplotype and 2 common NOS2 haplotypes were associated with recurrence.
BC8_BioRED_Task1_Doc208	1505	1509	IL10	Gene	3586	CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors.
BC8_BioRED_Task1_Doc208	1511	1514	CRP	Gene	1401	CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors.
BC8_BioRED_Task1_Doc208	1516	1521	GSTP1	Gene	2950	CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors.
BC8_BioRED_Task1_Doc208	1523	1527	IL1B	Gene	3553	CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors.
BC8_BioRED_Task1_Doc208	1533	1537	NOS2	Gene	4843	CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors.
BC8_BioRED_Task1_Doc208	1558	1573	prostate cancer	Disease	D011471	CONCLUSION: Variation in IL10, CRP, GSTP1, IL1B, and NOS2 was associated with prostate cancer recurrence independent of pathologic prognostic factors.
BC8_BioRED_Task1_Doc208	1725	1740	prostate cancer	Disease	D011471	IMPACT: This study supports that genetic variation in immune response and oxidation influence prostate cancer recurrence risk and suggests genetic variation in these pathways may inform prognosis.
BC8_BioRED_Task1_Doc209	4	8	G51S	SequenceVariant	rs1049564	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients.
BC8_BioRED_Task1_Doc209	9	40	purine nucleoside phosphorylase	Gene	4860	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients.
BC8_BioRED_Task1_Doc209	73	90	cognitive decline	Disease	D003072	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients.
BC8_BioRED_Task1_Doc209	94	113	Alzheimer's disease	Disease	D000544	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients.
BC8_BioRED_Task1_Doc209	114	122	patients	OrganismTaxon	9606	The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients.
BC8_BioRED_Task1_Doc209	124	143	Alzheimer's disease	Disease	D000544	Alzheimer's disease (AD) is a polygenic and multifactorial complex disease, whose etiopathology is still unclear, however several genetic factors have shown to increase the risk of developing the disease.
BC8_BioRED_Task1_Doc209	145	147	AD	Disease	D000544	Alzheimer's disease (AD) is a polygenic and multifactorial complex disease, whose etiopathology is still unclear, however several genetic factors have shown to increase the risk of developing the disease.
BC8_BioRED_Task1_Doc209	522	534	inflammatory	Disease	D007249	Besides their role in neurotransmission and neuromodulation, they are involved in trophic factor release, apoptosis, and inflammatory responses.
BC8_BioRED_Task1_Doc209	653	655	AD	Disease	D000544	These mediators may also have a pivotal role in the control of neurodegenerative processes associated with AD.
BC8_BioRED_Task1_Doc209	703	706	G/A	SequenceVariant	rs1049564	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	747	778	purine nucleoside phosphorylase	Gene	4860	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	780	783	PNP	Gene	4860	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	832	864	serine to glycine at position 51	SequenceVariant	rs1049564	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	866	870	G51S	SequenceVariant	rs1049564	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	915	917	AD	Disease	D000544	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	918	926	patients	OrganismTaxon	9606	In this report the distribution of the exonic G/A single nucleotide polymorphism (SNP) in purine nucleoside phosphorylase (PNP) gene, resulting in the amino acid substitution serine to glycine at position 51 (G51S), was investigated in a large population of AD patients (n=321) and non-demented control (n=208).
BC8_BioRED_Task1_Doc209	973	976	PNP	Gene	4860	The PNP polymorphism distribution was not different between patients and controls.
BC8_BioRED_Task1_Doc209	1029	1037	patients	OrganismTaxon	9606	The PNP polymorphism distribution was not different between patients and controls.
BC8_BioRED_Task1_Doc209	1103	1105	AD	Disease	D000544	The polymorphism distribution was also analyzed in AD patients stratified according to differential progressive rate of cognitive decline during a 2-year follow-up.
BC8_BioRED_Task1_Doc209	1106	1114	patients	OrganismTaxon	9606	The polymorphism distribution was also analyzed in AD patients stratified according to differential progressive rate of cognitive decline during a 2-year follow-up.
BC8_BioRED_Task1_Doc209	1172	1189	cognitive decline	Disease	D003072	The polymorphism distribution was also analyzed in AD patients stratified according to differential progressive rate of cognitive decline during a 2-year follow-up.
BC8_BioRED_Task1_Doc209	1252	1255	PNP	Gene	4860	An increased representation of the PNP AA genotype was observed in AD patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate.
BC8_BioRED_Task1_Doc209	1284	1286	AD	Disease	D000544	An increased representation of the PNP AA genotype was observed in AD patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate.
BC8_BioRED_Task1_Doc209	1287	1295	patients	OrganismTaxon	9606	An increased representation of the PNP AA genotype was observed in AD patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate.
BC8_BioRED_Task1_Doc209	1306	1329	cognitive deterioration	Disease	D003072	An increased representation of the PNP AA genotype was observed in AD patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate.
BC8_BioRED_Task1_Doc209	1359	1367	patients	OrganismTaxon	9606	An increased representation of the PNP AA genotype was observed in AD patients with fast cognitive deterioration in comparison with that from patients with slow deterioration rate.
BC8_BioRED_Task1_Doc209	1428	1432	G51S	SequenceVariant	rs1049564	Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.
BC8_BioRED_Task1_Doc209	1433	1436	PNP	Gene	4860	Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.
BC8_BioRED_Task1_Doc209	1486	1503	cognitive decline	Disease	D003072	Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.
BC8_BioRED_Task1_Doc209	1507	1509	AD	Disease	D000544	Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.
BC8_BioRED_Task1_Doc209	1510	1518	patients	OrganismTaxon	9606	Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.
BC8_BioRED_Task1_Doc209	1600	1626	neurodegenerative disorder	Disease	D019636	Our findings suggest that the G51S PNP polymorphism is associated with a faster rate of cognitive decline in AD patients, highlighting the important role of purine metabolism in the progression of this neurodegenerative disorder.
BC8_BioRED_Task1_Doc210	39	51	Delta-like 4	Gene	54485	Context- and cell-dependent effects of Delta-like 4 targeting in the bone marrow microenvironment.
BC8_BioRED_Task1_Doc210	99	111	Delta-like 4	Gene	54485	Delta-like 4 (Dll4) is a ligand of the Notch pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.
BC8_BioRED_Task1_Doc210	113	117	Dll4	Gene	54485	Delta-like 4 (Dll4) is a ligand of the Notch pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.
BC8_BioRED_Task1_Doc210	138	143	Notch	Gene	18128	Delta-like 4 (Dll4) is a ligand of the Notch pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.
BC8_BioRED_Task1_Doc210	207	212	tumor	Disease	D009369	Delta-like 4 (Dll4) is a ligand of the Notch pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.
BC8_BioRED_Task1_Doc210	298	303	tumor	Disease	D009369	Delta-like 4 (Dll4) is a ligand of the Notch pathway family which has been widely studied in the context of tumor angiogenesis, its blockade shown to result in non-productive angiogenesis and halted tumor growth.
BC8_BioRED_Task1_Doc210	315	319	Dll4	Gene	54485	As Dll4 inhibitors enter the clinic, there is an emerging need to understand their side effects, namely the systemic consequences of Dll4:Notch blockade in tissues other than tumors.
BC8_BioRED_Task1_Doc210	445	449	Dll4	Gene	54485	As Dll4 inhibitors enter the clinic, there is an emerging need to understand their side effects, namely the systemic consequences of Dll4:Notch blockade in tissues other than tumors.
BC8_BioRED_Task1_Doc210	450	455	Notch	Gene	18128	As Dll4 inhibitors enter the clinic, there is an emerging need to understand their side effects, namely the systemic consequences of Dll4:Notch blockade in tissues other than tumors.
BC8_BioRED_Task1_Doc210	487	493	tumors	Disease	D009369	As Dll4 inhibitors enter the clinic, there is an emerging need to understand their side effects, namely the systemic consequences of Dll4:Notch blockade in tissues other than tumors.
BC8_BioRED_Task1_Doc210	553	557	Dll4	Gene	54485	The present study focused on the effects of systemic anti-Dll4 targeting in the bone marrow (BM) microenvironment.
BC8_BioRED_Task1_Doc210	628	632	Dll4	Gene	54485	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	727	731	mice	OrganismTaxon	10090	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	756	760	CD31	Gene	18613	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	765	776	VE-Cadherin	Gene	12562	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	784	789	c-kit	Gene	16590	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	852	857	CD105	Gene	13805	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	862	868	VEGFR3	Gene	14257	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	873	876	SMA	Gene	11475	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	884	890	lectin	Gene	-	Here we show that Dll4 blockade with monoclonal antibodies perturbs the BM vascular niche of sub-lethally irradiated mice, resulting in increased CD31(+), VE-Cadherin(+) and c-kit(+) vessel density, and also increased megakaryocytes, whereas CD105(+), VEGFR3(+), SMA(+) and lectin(+) vessel density remained unaltered.
BC8_BioRED_Task1_Doc210	990	994	Dll4	Gene	54485	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1035	1041	IGFbp2	Gene	16008	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1043	1049	IGFbp3	Gene	16009	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1051	1057	Angpt2	Gene	11601	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1059	1063	Dll4	Gene	54485	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1065	1068	DHH	Gene	13363	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1073	1079	VEGF-A	Gene	22339	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1103	1107	FGF1	Gene	14164	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1112	1116	CSF2	Gene	12981	We investigated also the expression of angiocrine genes upon Dll4 treatment in vivo, and demonstrate that IGFbp2, IGFbp3, Angpt2, Dll4, DHH and VEGF-A are upregulated, while FGF1 and CSF2 are reduced.
BC8_BioRED_Task1_Doc210	1180	1184	Dll4	Gene	54485	In vitro treatment of endothelial cells with anti-Dll4 reduced Akt phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.
BC8_BioRED_Task1_Doc210	1193	1196	Akt	Gene	11651	In vitro treatment of endothelial cells with anti-Dll4 reduced Akt phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.
BC8_BioRED_Task1_Doc210	1249	1256	Erk 1/2	Gene	26413,26417	In vitro treatment of endothelial cells with anti-Dll4 reduced Akt phosphorylation while maintaining similar levels of Erk 1/2 phosphorylation.
BC8_BioRED_Task1_Doc210	1325	1329	Dll4	Gene	54485	Besides its effects in the BM vascular niche, anti-Dll4 treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.
BC8_BioRED_Task1_Doc210	1400	1405	CD11b	Gene	16409	Besides its effects in the BM vascular niche, anti-Dll4 treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.
BC8_BioRED_Task1_Doc210	1424	1428	B220	Gene	19264	Besides its effects in the BM vascular niche, anti-Dll4 treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.
BC8_BioRED_Task1_Doc210	1440	1443	CD3	Gene	12501	Besides its effects in the BM vascular niche, anti-Dll4 treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.
BC8_BioRED_Task1_Doc210	1479	1483	mice	OrganismTaxon	10090	Besides its effects in the BM vascular niche, anti-Dll4 treatment perturbed hematopoiesis, as evidenced by increased myeloid (CD11b(+)), decreased B (B220(+)) and T (CD3(+)) lymphoid BM content of treated mice, with a corresponding increase in myeloid circulating cells.
BC8_BioRED_Task1_Doc210	1560	1564	Dll4	Gene	54485	Moreover, anti-Dll4 treatment also increased the number of CFU-M and -G colonies in methylcellulose assays, independently of Notch1.
BC8_BioRED_Task1_Doc210	1670	1676	Notch1	Gene	18128	Moreover, anti-Dll4 treatment also increased the number of CFU-M and -G colonies in methylcellulose assays, independently of Notch1.
BC8_BioRED_Task1_Doc210	1692	1696	Dll4	Gene	54485	Finally, anti-Dll4 treatment of donor BM improved the hematopoietic recovery of lethally irradiated recipients in a transplant setting.
BC8_BioRED_Task1_Doc210	1889	1893	Dll4	Gene	54485	Together, our data reveals the hematopoietic (BM) effects of systemic anti-Dll4 treatment result from qualitative vascular changes and also direct hematopoietic cell modulation, which may be favorable in a transplant setting.
BC8_BioRED_Task1_Doc211	13	19	ADAM10	Gene	29650	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	21	27	ADAM17	Gene	57027	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	29	34	MMP-2	Gene	81686	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	39	44	MMP-9	Gene	81687	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	89	94	CaCl2	Chemical	D002122	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	103	127	thoracic aortic aneurysm	Disease	D017545	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	133	136	rat	OrganismTaxon	10116	Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
BC8_BioRED_Task1_Doc211	192	195	rat	OrganismTaxon	10116	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	205	229	thoracic aortic aneurysm	Disease	D017545	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	231	234	TAA	Disease	D017545	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	239	255	calcium chloride	Chemical	D002122	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	257	264	CaCl(2)	Chemical	D002122	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	274	289	arterial injury	Disease	D014652	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	327	362	a disintegrin and metalloproteinase	Gene	29650,57027	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	364	368	ADAM	Gene	29650,57027	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	371	396	matrix metalloproteinases	Gene	81686,81687	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	398	402	MMPs	Gene	81686,81687	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	447	450	TAA	Disease	D017545	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
BC8_BioRED_Task1_Doc211	509	513	rats	OrganismTaxon	10116	METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).
BC8_BioRED_Task1_Doc211	534	541	CaCl(2)	Chemical	D002122	METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).
BC8_BioRED_Task1_Doc211	560	564	NaCl	Chemical	D012965	METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).
BC8_BioRED_Task1_Doc211	611	618	CaCl(2)	Chemical	D002122	After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.
BC8_BioRED_Task1_Doc211	628	635	CaCl(2)	Chemical	D002122	After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.
BC8_BioRED_Task1_Doc211	657	661	NaCl	Chemical	D012965	After 12weeks, animals were euthanized, and CaCl(2)-treated, CaCl(2)-untreated (n=12) and NaCl-treated aortic segments (n=12) were collected for histological and molecular assessments.
BC8_BioRED_Task1_Doc211	752	755	MMP	Gene	81686,81687	MMP-TIMP and ADAM mRNAs were semi-quantitatively analyzed and protein expressions were determined by immunohistochemistry.
BC8_BioRED_Task1_Doc211	756	760	TIMP	Gene	116510	MMP-TIMP and ADAM mRNAs were semi-quantitatively analyzed and protein expressions were determined by immunohistochemistry.
BC8_BioRED_Task1_Doc211	765	769	ADAM	Gene	29650,57027	MMP-TIMP and ADAM mRNAs were semi-quantitatively analyzed and protein expressions were determined by immunohistochemistry.
BC8_BioRED_Task1_Doc211	925	932	CaCl(2)	Chemical	D002122	RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	946	953	CaCl(2)	Chemical	D002122	RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	966	970	NaCl	Chemical	D012965	RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1167	1174	CaCl(2)	Chemical	D002122	RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1193	1198	MMP-2	Gene	81686	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1200	1205	MMP-9	Gene	81687	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1207	1214	ADAM-10	Gene	29650	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1219	1226	ADAM-17	Gene	57027	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1257	1264	CaCl(2)	Chemical	D002122	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1324	1331	CaCl(2)	Chemical	D002122	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1369	1373	NaCl	Chemical	D012965	MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.
BC8_BioRED_Task1_Doc211	1462	1467	MMP-2	Gene	81686	Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1469	1474	MMP-9	Gene	81687	Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1476	1483	ADAM-10	Gene	29650	Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1488	1495	ADAM-17	Gene	57027	Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1533	1540	CaCl(2)	Chemical	D002122	Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.
BC8_BioRED_Task1_Doc211	1559	1563	TIMP	Gene	116510	TIMP mRNA and tissue levels did not differ obviously among the three aortic segments.
BC8_BioRED_Task1_Doc211	1682	1685	TAA	Disease	D017545	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc211	1708	1715	CaCl(2)	Chemical	D002122	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc211	1728	1732	rats	OrganismTaxon	10116	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc211	1792	1797	MMP-2	Gene	81686	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc211	1799	1804	MMP-9	Gene	81687	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc211	1806	1812	ADAM10	Gene	29650	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc211	1817	1823	ADAM17	Gene	57027	CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.
BC8_BioRED_Task1_Doc212	69	77	Asn45Ser	SequenceVariant	rs5030764	Compound heterozygosity for a novel nine-nucleotide deletion and the Asn45Ser missense mutation in the glycoprotein IX gene in a patient with Bernard-Soulier syndrome.
BC8_BioRED_Task1_Doc212	103	118	glycoprotein IX	Gene	2815	Compound heterozygosity for a novel nine-nucleotide deletion and the Asn45Ser missense mutation in the glycoprotein IX gene in a patient with Bernard-Soulier syndrome.
BC8_BioRED_Task1_Doc212	129	136	patient	OrganismTaxon	9606	Compound heterozygosity for a novel nine-nucleotide deletion and the Asn45Ser missense mutation in the glycoprotein IX gene in a patient with Bernard-Soulier syndrome.
BC8_BioRED_Task1_Doc212	142	166	Bernard-Soulier syndrome	Disease	D001606	Compound heterozygosity for a novel nine-nucleotide deletion and the Asn45Ser missense mutation in the glycoprotein IX gene in a patient with Bernard-Soulier syndrome.
BC8_BioRED_Task1_Doc212	168	192	Bernard-Soulier syndrome	Disease	D001606	Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein (GP) Ib/IX/V complex, the major von Willebrand factor receptor.
BC8_BioRED_Task1_Doc212	194	197	BSS	Disease	D001606	Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein (GP) Ib/IX/V complex, the major von Willebrand factor receptor.
BC8_BioRED_Task1_Doc212	209	236	inherited bleeding disorder	Disease	D025861	Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein (GP) Ib/IX/V complex, the major von Willebrand factor receptor.
BC8_BioRED_Task1_Doc212	302	327	glycoprotein (GP) Ib/IX/V	Gene	2811,2814,2815	Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein (GP) Ib/IX/V complex, the major von Willebrand factor receptor.
BC8_BioRED_Task1_Doc212	347	368	von Willebrand factor	Gene	7450	Bernard-Soulier syndrome (BSS) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein (GP) Ib/IX/V complex, the major von Willebrand factor receptor.
BC8_BioRED_Task1_Doc212	524	527	GPV	Gene	2814	Several mutations have been described for each of the subunits, except for GPV, as a cause of BSS.
BC8_BioRED_Task1_Doc212	543	546	BSS	Disease	D001606	Several mutations have been described for each of the subunits, except for GPV, as a cause of BSS.
BC8_BioRED_Task1_Doc212	615	618	BSS	Disease	D001606	We describe here the genetic basis of the disorder in a child with BSS.
BC8_BioRED_Task1_Doc212	652	659	patient	OrganismTaxon	9606	Flow-cytometric analysis of the patient's platelets showed a markedly reduced surface expression of all three glycoproteins of the GPIb/IX/V complex.
BC8_BioRED_Task1_Doc212	730	743	glycoproteins	Gene	2811,2814,2815	Flow-cytometric analysis of the patient's platelets showed a markedly reduced surface expression of all three glycoproteins of the GPIb/IX/V complex.
BC8_BioRED_Task1_Doc212	751	760	GPIb/IX/V	Gene	2811,2814,2815	Flow-cytometric analysis of the patient's platelets showed a markedly reduced surface expression of all three glycoproteins of the GPIb/IX/V complex.
BC8_BioRED_Task1_Doc212	805	812	patient	OrganismTaxon	9606	DNA sequencing analysis showed the patient to be a compound heterozygote for two mutations in the GPIX gene, a novel nine-nucleotide deletion starting at position 1952 of the gene that changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) and a previously reported point mutation that changes the codon asparagine (AAC) for serine (AGC) at residue 45.
BC8_BioRED_Task1_Doc212	868	872	GPIX	Gene	2815	DNA sequencing analysis showed the patient to be a compound heterozygote for two mutations in the GPIX gene, a novel nine-nucleotide deletion starting at position 1952 of the gene that changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) and a previously reported point mutation that changes the codon asparagine (AAC) for serine (AGC) at residue 45.
BC8_BioRED_Task1_Doc212	887	937	nine-nucleotide deletion starting at position 1952	SequenceVariant	c|DEL|1952|9	DNA sequencing analysis showed the patient to be a compound heterozygote for two mutations in the GPIX gene, a novel nine-nucleotide deletion starting at position 1952 of the gene that changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) and a previously reported point mutation that changes the codon asparagine (AAC) for serine (AGC) at residue 45.
BC8_BioRED_Task1_Doc212	955	1065	changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline)	SequenceVariant	p|SUB|NRTP|86_89|A	DNA sequencing analysis showed the patient to be a compound heterozygote for two mutations in the GPIX gene, a novel nine-nucleotide deletion starting at position 1952 of the gene that changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) and a previously reported point mutation that changes the codon asparagine (AAC) for serine (AGC) at residue 45.
BC8_BioRED_Task1_Doc212	1130	1177	asparagine (AAC) for serine (AGC) at residue 45	SequenceVariant	rs5030764	DNA sequencing analysis showed the patient to be a compound heterozygote for two mutations in the GPIX gene, a novel nine-nucleotide deletion starting at position 1952 of the gene that changes asparagine 86 for alanine and eliminates amino acids 87, 88, and 89 (arginine, threonine, and proline) and a previously reported point mutation that changes the codon asparagine (AAC) for serine (AGC) at residue 45.
BC8_BioRED_Task1_Doc212	1215	1223	Asn45Ser	SequenceVariant	rs5030764	Her mother was heterozygous for the Asn45Ser mutation, and her father, for the nine-nucleotide deletion.
BC8_BioRED_Task1_Doc212	1356	1360	GPIX	Gene	2815	Our findings suggest that the additive effects of both mutations in the GPIX gene are responsible for the BSS phenotype of the patient.
BC8_BioRED_Task1_Doc212	1390	1393	BSS	Disease	D001606	Our findings suggest that the additive effects of both mutations in the GPIX gene are responsible for the BSS phenotype of the patient.
BC8_BioRED_Task1_Doc212	1411	1418	patient	OrganismTaxon	9606	Our findings suggest that the additive effects of both mutations in the GPIX gene are responsible for the BSS phenotype of the patient.
BC8_BioRED_Task1_Doc213	18	23	IL-10	Gene	3586	Analysis of -1082 IL-10 gene polymorphism in Iranian patients with generalized aggressive periodontitis.
BC8_BioRED_Task1_Doc213	53	61	patients	OrganismTaxon	9606	Analysis of -1082 IL-10 gene polymorphism in Iranian patients with generalized aggressive periodontitis.
BC8_BioRED_Task1_Doc213	79	103	aggressive periodontitis	Disease	D010520	Analysis of -1082 IL-10 gene polymorphism in Iranian patients with generalized aggressive periodontitis.
BC8_BioRED_Task1_Doc213	117	130	Periodontitis	Disease	D010518	BACKGROUND: Periodontitis is a multifactorial disease and its severe forms, such as aggressive periodontitis, are suggested to have a genetic basis.
BC8_BioRED_Task1_Doc213	189	213	aggressive periodontitis	Disease	D010520	BACKGROUND: Periodontitis is a multifactorial disease and its severe forms, such as aggressive periodontitis, are suggested to have a genetic basis.
BC8_BioRED_Task1_Doc213	363	376	periodontitis	Disease	D010518	Among the genetic factors, polymorphisms in cytokine genes have recently been described in susceptibility to periodontitis.
BC8_BioRED_Task1_Doc213	378	383	IL-10	Gene	3586	IL-10 is a multi-functional cytokine thought to play a role in the pathogenesis of periodontitis.
BC8_BioRED_Task1_Doc213	461	474	periodontitis	Disease	D010518	IL-10 is a multi-functional cytokine thought to play a role in the pathogenesis of periodontitis.
BC8_BioRED_Task1_Doc213	491	494	G/A	SequenceVariant	c|SUB|G||A	A substitution G/A polymorphism in the promoter region of the IL-10 gene at position -1082 has been associated with different amounts of IL-10 production.
BC8_BioRED_Task1_Doc213	538	543	IL-10	Gene	3586	A substitution G/A polymorphism in the promoter region of the IL-10 gene at position -1082 has been associated with different amounts of IL-10 production.
BC8_BioRED_Task1_Doc213	613	618	IL-10	Gene	3586	A substitution G/A polymorphism in the promoter region of the IL-10 gene at position -1082 has been associated with different amounts of IL-10 production.
BC8_BioRED_Task1_Doc213	706	716	-1082(G/A)	SequenceVariant	c|SUB|G|-1082|A	The aim of the present study was to investigate the possible links between -1082(G/A) polymorphism of the IL-10 gene and the generalized form of aggressive periodontitis.
BC8_BioRED_Task1_Doc213	737	742	IL-10	Gene	3586	The aim of the present study was to investigate the possible links between -1082(G/A) polymorphism of the IL-10 gene and the generalized form of aggressive periodontitis.
BC8_BioRED_Task1_Doc213	776	800	aggressive periodontitis	Disease	D010520	The aim of the present study was to investigate the possible links between -1082(G/A) polymorphism of the IL-10 gene and the generalized form of aggressive periodontitis.
BC8_BioRED_Task1_Doc213	929	953	aggressive periodontitis	Disease	D010520	MATERIAL/METHODS: This study included 52 Iranian Khorasanian (north-east province of Iran) subjects suffering from generalized aggressive periodontitis referred to the Periodontology Department of Mashhad Dental School.
BC8_BioRED_Task1_Doc213	1426	1450	aggressive periodontitis	Disease	D010520	RESULTS: There was no marked difference in genotype frequencies between the controls and generalized aggressive periodontitis patients (p=0.585).
BC8_BioRED_Task1_Doc213	1451	1459	patients	OrganismTaxon	9606	RESULTS: There was no marked difference in genotype frequencies between the controls and generalized aggressive periodontitis patients (p=0.585).
BC8_BioRED_Task1_Doc213	1504	1512	patients	OrganismTaxon	9606	Moreover, no association between patients and normal subjects was found in their allele frequency (p=0.329).
BC8_BioRED_Task1_Doc213	1637	1656	A at position -1082	SequenceVariant	c|Allele|A|-1082	CONCLUSIONS: We conclude that the polymorphic nucleotide A at position -1082 of the IL-10 gene is not associated with generalized aggressive periodontitis in the Iranian population.
BC8_BioRED_Task1_Doc213	1664	1669	IL-10	Gene	3586	CONCLUSIONS: We conclude that the polymorphic nucleotide A at position -1082 of the IL-10 gene is not associated with generalized aggressive periodontitis in the Iranian population.
BC8_BioRED_Task1_Doc213	1710	1734	aggressive periodontitis	Disease	D010520	CONCLUSIONS: We conclude that the polymorphic nucleotide A at position -1082 of the IL-10 gene is not associated with generalized aggressive periodontitis in the Iranian population.
BC8_BioRED_Task1_Doc214	0	5	Human	OrganismTaxon	9606	Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions.
BC8_BioRED_Task1_Doc214	6	10	TBX1	Gene	6899	Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions.
BC8_BioRED_Task1_Doc214	88	105	22q11.2 deletions	Disease	D004062	Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions.
BC8_BioRED_Task1_Doc214	107	132	Deletion 22q11.2 syndrome	Disease	D004062	Deletion 22q11.2 syndrome is the most frequent known microdeletion syndrome and is associated with a highly variable phenotype, including DiGeorge and Shprintzen (velocardiofacial) syndromes.
BC8_BioRED_Task1_Doc214	245	297	DiGeorge and Shprintzen (velocardiofacial) syndromes	Disease	D004062	Deletion 22q11.2 syndrome is the most frequent known microdeletion syndrome and is associated with a highly variable phenotype, including DiGeorge and Shprintzen (velocardiofacial) syndromes.
BC8_BioRED_Task1_Doc214	334	360	T-box transcription factor	Gene	6899	Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome.
BC8_BioRED_Task1_Doc214	366	370	TBX1	Gene	6899	Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome.
BC8_BioRED_Task1_Doc214	454	458	TBX1	Gene	6899	Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome.
BC8_BioRED_Task1_Doc214	527	552	22q11.2 deletion syndrome	Disease	D004062	Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome.
BC8_BioRED_Task1_Doc214	749	754	H194Q	SequenceVariant	rs74315522	We report a novel heterozygous missense mutation, H194Q, in a familial case of Shprintzen syndrome and show that this and the two previously reported missense mutations result in gain of function, possibly through stabilization of the protein dimer DNA complex.
BC8_BioRED_Task1_Doc214	778	797	Shprintzen syndrome	Disease	D004062	We report a novel heterozygous missense mutation, H194Q, in a familial case of Shprintzen syndrome and show that this and the two previously reported missense mutations result in gain of function, possibly through stabilization of the protein dimer DNA complex.
BC8_BioRED_Task1_Doc214	988	992	TBX1	Gene	6899	We therefore conclude that TBX1 gain-of-function mutations can result in the same phenotypic spectrum as haploinsufficiency caused by loss-of-function mutations or deletions.
BC8_BioRED_Task1_Doc215	24	53	T-cell immunoglobulin mucin 1	Gene	26762	Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population.
BC8_BioRED_Task1_Doc215	66	95	T-cell immunoglobulin mucin 3	Gene	84868	Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population.
BC8_BioRED_Task1_Doc215	121	127	asthma	Disease	D001249	Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population.
BC8_BioRED_Task1_Doc215	179	206	T-cell immunoglobulin mucin	Gene	26762,84868	BACKGROUND: The T-cell immunoglobulin mucin ( TIM ) proteins and their genetic variants have been suggested to play a role in regulating allergic diseases.
BC8_BioRED_Task1_Doc215	209	212	TIM	Gene	26762,84868	BACKGROUND: The T-cell immunoglobulin mucin ( TIM ) proteins and their genetic variants have been suggested to play a role in regulating allergic diseases.
BC8_BioRED_Task1_Doc215	300	317	allergic diseases	Disease	D004342	BACKGROUND: The T-cell immunoglobulin mucin ( TIM ) proteins and their genetic variants have been suggested to play a role in regulating allergic diseases.
BC8_BioRED_Task1_Doc215	379	384	TIM-1	Gene	26762	OBJECTIVE: Genetic association of the sequence variants for TIM-1 and TIM-3 genes with asthma in an African American population was investigated.
BC8_BioRED_Task1_Doc215	389	394	TIM-3	Gene	84868	OBJECTIVE: Genetic association of the sequence variants for TIM-1 and TIM-3 genes with asthma in an African American population was investigated.
BC8_BioRED_Task1_Doc215	406	412	asthma	Disease	D001249	OBJECTIVE: Genetic association of the sequence variants for TIM-1 and TIM-3 genes with asthma in an African American population was investigated.
BC8_BioRED_Task1_Doc215	672	683	TIM-1 and 3	Gene	26762,84868	METHODS: Both case-control and family-based association analyses were performed for a total of 7 polymorphisms, including 3 single nucleotide polymorphism (SNPs) and 1 insertion/deletion polymorphism in the TIM-1 and 3 SNPs in the TIM-3 genes.
BC8_BioRED_Task1_Doc215	696	701	TIM-3	Gene	84868	METHODS: Both case-control and family-based association analyses were performed for a total of 7 polymorphisms, including 3 single nucleotide polymorphism (SNPs) and 1 insertion/deletion polymorphism in the TIM-1 and 3 SNPs in the TIM-3 genes.
BC8_BioRED_Task1_Doc215	725	742	hepatitis A virus	OrganismTaxon	208726	The exposure to hepatitis A virus as judged by seropositivity was also examined.
BC8_BioRED_Task1_Doc215	870	879	rs2277025	SequenceVariant	rs2277025	RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).
BC8_BioRED_Task1_Doc215	917	929	157delMTTTVP	SequenceVariant	p|DEL|157|MTTTVP	RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).
BC8_BioRED_Task1_Doc215	957	962	TIM-1	Gene	26762	RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).
BC8_BioRED_Task1_Doc215	986	994	patients	OrganismTaxon	9606	RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).
BC8_BioRED_Task1_Doc215	1000	1008	patients	OrganismTaxon	9606	RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).
BC8_BioRED_Task1_Doc215	1014	1020	asthma	Disease	D001249	RESULTS: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157delMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P = .016; and OR, 3.09, P = .022, respectively).
BC8_BioRED_Task1_Doc215	1301	1313	157delMTTTVP	SequenceVariant	p|DEL|157|MTTTVP	This association was substantiated by haplotype analysis of these and 2 additional SNPs (OR, 2.48; P = .004), and also by family-based tests for the allele and haplotype carrying 157delMTTTVP (P = .009 and P = .048, respectively).
BC8_BioRED_Task1_Doc215	1410	1427	hepatitis A virus	OrganismTaxon	208726	Furthermore, this association seems to exist even in the hepatitis A virus-seronegative subjects in our data.
BC8_BioRED_Task1_Doc215	1489	1494	TIM-3	Gene	84868	None of the 3 variants in TIM-3 genes yielded significant association with either asthma or asthma-related phenotypes.
BC8_BioRED_Task1_Doc215	1545	1551	asthma	Disease	D001249	None of the 3 variants in TIM-3 genes yielded significant association with either asthma or asthma-related phenotypes.
BC8_BioRED_Task1_Doc215	1555	1561	asthma	Disease	D001249	None of the 3 variants in TIM-3 genes yielded significant association with either asthma or asthma-related phenotypes.
BC8_BioRED_Task1_Doc215	1648	1653	TIM-1	Gene	26762	CONCLUSION: Our findings suggest that the genetic variants of the TIM-1 but not the TIM-3 gene contribute to asthma susceptibility in this African-American population.
BC8_BioRED_Task1_Doc215	1666	1671	TIM-3	Gene	84868	CONCLUSION: Our findings suggest that the genetic variants of the TIM-1 but not the TIM-3 gene contribute to asthma susceptibility in this African-American population.
BC8_BioRED_Task1_Doc215	1691	1697	asthma	Disease	D001249	CONCLUSION: Our findings suggest that the genetic variants of the TIM-1 but not the TIM-3 gene contribute to asthma susceptibility in this African-American population.
BC8_BioRED_Task1_Doc216	24	39	tranexamic acid	Chemical	D014148	The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
BC8_BioRED_Task1_Doc216	44	63	convulsive seizures	Disease	D012640	The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
BC8_BioRED_Task1_Doc216	121	129	patients	OrganismTaxon	9606	The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
BC8_BioRED_Task1_Doc216	180	188	seizures	Disease	D012640	Because of a lack of contemporary data regarding seizures after cardiac surgery, we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010.
BC8_BioRED_Task1_Doc216	294	302	patients	OrganismTaxon	9606	Because of a lack of contemporary data regarding seizures after cardiac surgery, we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010.
BC8_BioRED_Task1_Doc216	381	399	convulsive seizure	Disease	D012640	A convulsive seizure was defined as a transient episode of disturbed brain function characterised by abnormal involuntary motor movements.
BC8_BioRED_Task1_Doc216	480	516	abnormal involuntary motor movements	Disease	D004409	A convulsive seizure was defined as a transient episode of disturbed brain function characterised by abnormal involuntary motor movements.
BC8_BioRED_Task1_Doc216	617	625	seizures	Disease	D012640	Multivariate regression analysis was performed to identify independent predictors of postoperative seizures.
BC8_BioRED_Task1_Doc216	649	657	patients	OrganismTaxon	9606	A total of 100 (0.9%) patients developed postoperative convulsive seizures.
BC8_BioRED_Task1_Doc216	682	701	convulsive seizures	Disease	D012640	A total of 100 (0.9%) patients developed postoperative convulsive seizures.
BC8_BioRED_Task1_Doc216	703	733	Generalised and focal seizures	Disease	D012640	Generalised and focal seizures were identified in 68 and 32 patients, respectively.
BC8_BioRED_Task1_Doc216	763	771	patients	OrganismTaxon	9606	Generalised and focal seizures were identified in 68 and 32 patients, respectively.
BC8_BioRED_Task1_Doc216	840	847	seizure	Disease	D012640	The median (IQR [range]) time after surgery when the seizure occurred was 7 (6-12 [1-216]) h and 8 (6-11 [4-18]) h, respectively.
BC8_BioRED_Task1_Doc216	981	989	patients	OrganismTaxon	9606	Epileptiform findings on electroencephalography were seen in 19 patients.
BC8_BioRED_Task1_Doc216	1031	1039	seizures	Disease	D012640	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
BC8_BioRED_Task1_Doc216	1088	1120	calcification of ascending aorta	Disease	D001018	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
BC8_BioRED_Task1_Doc216	1122	1146	congestive heart failure	Disease	D006333	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
BC8_BioRED_Task1_Doc216	1153	1164	hypothermic	Disease	D007035	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
BC8_BioRED_Task1_Doc216	1220	1235	tranexamic acid	Chemical	D014148	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
BC8_BioRED_Task1_Doc216	1288	1303	tranexamic acid	Chemical	D014148	When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).
BC8_BioRED_Task1_Doc216	1342	1350	seizures	Disease	D012640	When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).
BC8_BioRED_Task1_Doc216	1390	1398	Patients	OrganismTaxon	9606	Patients with convulsive seizures had 2.5 times higher in-hospital mortality rates and twice the length of hospital stay compared with patients without convulsive seizures.
BC8_BioRED_Task1_Doc216	1404	1423	convulsive seizures	Disease	D012640	Patients with convulsive seizures had 2.5 times higher in-hospital mortality rates and twice the length of hospital stay compared with patients without convulsive seizures.
BC8_BioRED_Task1_Doc216	1525	1533	patients	OrganismTaxon	9606	Patients with convulsive seizures had 2.5 times higher in-hospital mortality rates and twice the length of hospital stay compared with patients without convulsive seizures.
BC8_BioRED_Task1_Doc216	1542	1561	convulsive seizures	Disease	D012640	Patients with convulsive seizures had 2.5 times higher in-hospital mortality rates and twice the length of hospital stay compared with patients without convulsive seizures.
BC8_BioRED_Task1_Doc216	1655	1663	patients	OrganismTaxon	9606	Mean (IQR [range]) length of stay in the intensive care unit was 115 (49-228 [32-481]) h in patients with convulsive seizures compared with 26 (22-69 [14-1080]) h in patients without seizures (p < 0.001).
BC8_BioRED_Task1_Doc216	1669	1688	convulsive seizures	Disease	D012640	Mean (IQR [range]) length of stay in the intensive care unit was 115 (49-228 [32-481]) h in patients with convulsive seizures compared with 26 (22-69 [14-1080]) h in patients without seizures (p < 0.001).
BC8_BioRED_Task1_Doc216	1729	1737	patients	OrganismTaxon	9606	Mean (IQR [range]) length of stay in the intensive care unit was 115 (49-228 [32-481]) h in patients with convulsive seizures compared with 26 (22-69 [14-1080]) h in patients without seizures (p < 0.001).
BC8_BioRED_Task1_Doc216	1746	1754	seizures	Disease	D012640	Mean (IQR [range]) length of stay in the intensive care unit was 115 (49-228 [32-481]) h in patients with convulsive seizures compared with 26 (22-69 [14-1080]) h in patients without seizures (p < 0.001).
BC8_BioRED_Task1_Doc216	1768	1787	Convulsive seizures	Disease	D012640	Convulsive seizures are a serious postoperative complication after cardiac surgery.
BC8_BioRED_Task1_Doc216	1802	1828	postoperative complication	Disease	D011183	Convulsive seizures are a serious postoperative complication after cardiac surgery.
BC8_BioRED_Task1_Doc216	1855	1870	tranexamic acid	Chemical	D014148	As tranexamic acid is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative seizures.
BC8_BioRED_Task1_Doc216	2020	2028	seizures	Disease	D012640	As tranexamic acid is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative seizures.
BC8_BioRED_Task1_Doc217	0	34	Angiotensin II subtype 1a receptor	Gene	11607	Angiotensin II subtype 1a receptor signaling in resident hepatic macrophages induces liver metastasis formation.
BC8_BioRED_Task1_Doc217	85	101	liver metastasis	Disease	D008113	Angiotensin II subtype 1a receptor signaling in resident hepatic macrophages induces liver metastasis formation.
BC8_BioRED_Task1_Doc217	113	129	Liver metastases	Disease	D008113	Liver metastases from colorectal cancer (CRC) are a clinically significant problem.
BC8_BioRED_Task1_Doc217	135	152	colorectal cancer	Disease	D015179	Liver metastases from colorectal cancer (CRC) are a clinically significant problem.
BC8_BioRED_Task1_Doc217	154	157	CRC	Disease	D015179	Liver metastases from colorectal cancer (CRC) are a clinically significant problem.
BC8_BioRED_Task1_Doc217	201	206	renin	Gene	19701	The renin-angiotensin system is involved in tumor growth and metastases.
BC8_BioRED_Task1_Doc217	207	218	angiotensin	Gene	11606	The renin-angiotensin system is involved in tumor growth and metastases.
BC8_BioRED_Task1_Doc217	241	246	tumor	Disease	D009369	The renin-angiotensin system is involved in tumor growth and metastases.
BC8_BioRED_Task1_Doc217	258	268	metastases	Disease	D009362	The renin-angiotensin system is involved in tumor growth and metastases.
BC8_BioRED_Task1_Doc217	318	352	angiotensin II subtype receptor 1a	Gene	11607	This study was designed to evaluate the role of angiotensin II subtype receptor 1a (AT1a) in the formation of liver metastasis in CRC.
BC8_BioRED_Task1_Doc217	354	358	AT1a	Gene	11607	This study was designed to evaluate the role of angiotensin II subtype receptor 1a (AT1a) in the formation of liver metastasis in CRC.
BC8_BioRED_Task1_Doc217	380	396	liver metastasis	Disease	D008113	This study was designed to evaluate the role of angiotensin II subtype receptor 1a (AT1a) in the formation of liver metastasis in CRC.
BC8_BioRED_Task1_Doc217	400	403	CRC	Disease	D015179	This study was designed to evaluate the role of angiotensin II subtype receptor 1a (AT1a) in the formation of liver metastasis in CRC.
BC8_BioRED_Task1_Doc217	416	432	liver metastasis	Disease	D008113	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	476	481	mouse	OrganismTaxon	10090	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	482	494	colon cancer	Disease	D015179	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	496	502	CMT-93	CellLine	CVCL_1986	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	509	513	AT1a	Gene	11607	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	523	527	mice	OrganismTaxon	10090	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	529	533	AT1a	Gene	11607	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	552	559	C57BL/6	CellLine	CVCL_5746	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	561	565	mice	OrganismTaxon	10090	A model of liver metastasis was developed by intrasplenic injection of mouse colon cancer (CMT-93) into AT1a knockout mice (AT1aKO) and wild-type (C57BL/6) mice (WT).
BC8_BioRED_Task1_Doc217	589	593	mice	OrganismTaxon	10090	Compared with WT mice, the liver weight and liver metastatic rate were significantly lower in AT1aKO.
BC8_BioRED_Task1_Doc217	616	632	liver metastatic	Disease	D008113	Compared with WT mice, the liver weight and liver metastatic rate were significantly lower in AT1aKO.
BC8_BioRED_Task1_Doc217	666	670	AT1a	Gene	11607	Compared with WT mice, the liver weight and liver metastatic rate were significantly lower in AT1aKO.
BC8_BioRED_Task1_Doc217	693	697	CD31	Gene	18613	The mRNA levels of CD31, transforming growth factor- b1 (TGF-b1), and F4/80 were suppressed in AT1aKO compared with WT.
BC8_BioRED_Task1_Doc217	699	729	transforming growth factor- b1	Gene	21803	The mRNA levels of CD31, transforming growth factor- b1 (TGF-b1), and F4/80 were suppressed in AT1aKO compared with WT.
BC8_BioRED_Task1_Doc217	731	737	TGF-b1	Gene	21803	The mRNA levels of CD31, transforming growth factor- b1 (TGF-b1), and F4/80 were suppressed in AT1aKO compared with WT.
BC8_BioRED_Task1_Doc217	744	749	F4/80	Gene	13733	The mRNA levels of CD31, transforming growth factor- b1 (TGF-b1), and F4/80 were suppressed in AT1aKO compared with WT.
BC8_BioRED_Task1_Doc217	769	773	AT1a	Gene	11607	The mRNA levels of CD31, transforming growth factor- b1 (TGF-b1), and F4/80 were suppressed in AT1aKO compared with WT.
BC8_BioRED_Task1_Doc217	867	872	F4/80	Gene	13733	Double immunofluorescence analysis showed that the number of accumulated F4/80(+) cells expressing TGF-b1 in metastatic areas was higher in WT than in AT1aKO.
BC8_BioRED_Task1_Doc217	893	899	TGF-b1	Gene	21803	Double immunofluorescence analysis showed that the number of accumulated F4/80(+) cells expressing TGF-b1 in metastatic areas was higher in WT than in AT1aKO.
BC8_BioRED_Task1_Doc217	945	949	AT1a	Gene	11607	Double immunofluorescence analysis showed that the number of accumulated F4/80(+) cells expressing TGF-b1 in metastatic areas was higher in WT than in AT1aKO.
BC8_BioRED_Task1_Doc217	957	961	AT1a	Gene	11607	The AT1aKO bone marrow (BM) (AT1aKO-BM)>WT showed suppressed formation of liver metastasis compared with WT-BM>WT.
BC8_BioRED_Task1_Doc217	982	986	AT1a	Gene	11607	The AT1aKO bone marrow (BM) (AT1aKO-BM)>WT showed suppressed formation of liver metastasis compared with WT-BM>WT.
BC8_BioRED_Task1_Doc217	1027	1043	liver metastasis	Disease	D008113	The AT1aKO bone marrow (BM) (AT1aKO-BM)>WT showed suppressed formation of liver metastasis compared with WT-BM>WT.
BC8_BioRED_Task1_Doc217	1094	1104	metastasis	Disease	D009362	However, the formation of metastasis was further suppressed in WT-BM>AT1aKO compared with AT1aKO-BM>WT.
BC8_BioRED_Task1_Doc217	1137	1141	AT1a	Gene	11607	However, the formation of metastasis was further suppressed in WT-BM>AT1aKO compared with AT1aKO-BM>WT.
BC8_BioRED_Task1_Doc217	1158	1162	AT1a	Gene	11607	However, the formation of metastasis was further suppressed in WT-BM>AT1aKO compared with AT1aKO-BM>WT.
BC8_BioRED_Task1_Doc217	1197	1202	F4/80	Gene	13733	In addition, accumulated F4/80(+) cells in the liver metastasis were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for TGF-b1.
BC8_BioRED_Task1_Doc217	1219	1235	liver metastasis	Disease	D008113	In addition, accumulated F4/80(+) cells in the liver metastasis were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for TGF-b1.
BC8_BioRED_Task1_Doc217	1256	1261	F4/80	Gene	13733	In addition, accumulated F4/80(+) cells in the liver metastasis were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for TGF-b1.
BC8_BioRED_Task1_Doc217	1300	1305	F4/80	Gene	13733	In addition, accumulated F4/80(+) cells in the liver metastasis were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for TGF-b1.
BC8_BioRED_Task1_Doc217	1343	1348	F4/80	Gene	13733	In addition, accumulated F4/80(+) cells in the liver metastasis were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for TGF-b1.
BC8_BioRED_Task1_Doc217	1376	1382	TGF-b1	Gene	21803	In addition, accumulated F4/80(+) cells in the liver metastasis were not BM-derived F4/80(+) cells, but mainly resident hepatic F4/80(+) cells, and these resident hepatic F4/80(+) cells were positive for TGF-b1.
BC8_BioRED_Task1_Doc217	1384	1398	Angiotensin II	Gene	11606	Angiotensin II enhanced TGF-b1 expression in Kupffer cells.
BC8_BioRED_Task1_Doc217	1408	1414	TGF-b1	Gene	21803	Angiotensin II enhanced TGF-b1 expression in Kupffer cells.
BC8_BioRED_Task1_Doc217	1465	1475	clodronate	Chemical	D004002	Treatment of WT with clodronate liposomes suppressed liver metastasis by diminishing TGF-b1(+) F4/80(+) cells accumulation.
BC8_BioRED_Task1_Doc217	1497	1513	liver metastasis	Disease	D008113	Treatment of WT with clodronate liposomes suppressed liver metastasis by diminishing TGF-b1(+) F4/80(+) cells accumulation.
BC8_BioRED_Task1_Doc217	1529	1535	TGF-b1	Gene	21803	Treatment of WT with clodronate liposomes suppressed liver metastasis by diminishing TGF-b1(+) F4/80(+) cells accumulation.
BC8_BioRED_Task1_Doc217	1539	1544	F4/80	Gene	13733	Treatment of WT with clodronate liposomes suppressed liver metastasis by diminishing TGF-b1(+) F4/80(+) cells accumulation.
BC8_BioRED_Task1_Doc217	1585	1601	liver metastasis	Disease	D008113	The formation of liver metastasis correlated with collagen deposition in the metastatic area, which was dependent on AT1a signaling.
BC8_BioRED_Task1_Doc217	1618	1626	collagen	Gene	12842	The formation of liver metastasis correlated with collagen deposition in the metastatic area, which was dependent on AT1a signaling.
BC8_BioRED_Task1_Doc217	1685	1689	AT1a	Gene	11607	The formation of liver metastasis correlated with collagen deposition in the metastatic area, which was dependent on AT1a signaling.
BC8_BioRED_Task1_Doc217	1767	1783	liver metastasis	Disease	D008113	These results suggested that resident hepatic macrophages induced liver metastasis formation by induction of TGF-b1 through AT1a signaling.
BC8_BioRED_Task1_Doc217	1810	1816	TGF-b1	Gene	21803	These results suggested that resident hepatic macrophages induced liver metastasis formation by induction of TGF-b1 through AT1a signaling.
BC8_BioRED_Task1_Doc217	1825	1829	AT1a	Gene	11607	These results suggested that resident hepatic macrophages induced liver metastasis formation by induction of TGF-b1 through AT1a signaling.
BC8_BioRED_Task1_Doc218	22	26	iron	Chemical	D007501	Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
BC8_BioRED_Task1_Doc218	50	61	deferasirox	Chemical	D000077588	Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
BC8_BioRED_Task1_Doc218	65	83	aceruloplasminemia	Disease	C536004	Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
BC8_BioRED_Task1_Doc218	137	155	Aceruloplasminemia	Disease	C536004	BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.
BC8_BioRED_Task1_Doc218	166	211	autosomal recessive neurodegenerative disease	Disease	D020271	BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.
BC8_BioRED_Task1_Doc218	244	248	iron	Chemical	D007501	BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.
BC8_BioRED_Task1_Doc218	292	310	movement disorders	Disease	D009069	BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.
BC8_BioRED_Task1_Doc218	312	332	retinal degeneration	Disease	D012162	BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.
BC8_BioRED_Task1_Doc218	338	355	diabetes mellitus	Disease	D003920	BACKGROUND _#38; AIMS: Aceruloplasminemia is a rare autosomal recessive neurodegenerative disease associated with brain and liver iron accumulation which typically presents with movement disorders, retinal degeneration, and diabetes mellitus.
BC8_BioRED_Task1_Doc218	357	370	Ceruloplasmin	Gene	1356	Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin.
BC8_BioRED_Task1_Doc218	389	400	ferroxidase	Chemical	-	Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin.
BC8_BioRED_Task1_Doc218	455	459	iron	Chemical	D007501	Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin.
BC8_BioRED_Task1_Doc218	471	475	iron	Chemical	D007501	Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin.
BC8_BioRED_Task1_Doc218	487	498	transferrin	Gene	7018	Ceruloplasmin is a multi-copper ferroxidase that is secreted into plasma and facilitates cellular iron export and iron binding to transferrin.
BC8_BioRED_Task1_Doc218	528	541	ceruloplasmin	Gene	1356	RESULTS: A novel homozygous ceruloplasmin gene mutation, c.2554+1G>T, was identified as the cause of aceruloplasminemia in three affected siblings.
BC8_BioRED_Task1_Doc218	557	568	c.2554+1G>T	SequenceVariant	c|SUB|G|2554+1|T	RESULTS: A novel homozygous ceruloplasmin gene mutation, c.2554+1G>T, was identified as the cause of aceruloplasminemia in three affected siblings.
BC8_BioRED_Task1_Doc218	601	619	aceruloplasminemia	Disease	C536004	RESULTS: A novel homozygous ceruloplasmin gene mutation, c.2554+1G>T, was identified as the cause of aceruloplasminemia in three affected siblings.
BC8_BioRED_Task1_Doc218	676	694	movement disorders	Disease	D009069	Two siblings presented with movement disorders and diabetes.
BC8_BioRED_Task1_Doc218	699	707	diabetes	Disease	D003920	Two siblings presented with movement disorders and diabetes.
BC8_BioRED_Task1_Doc218	795	826	deletion of amino acids 809-852	SequenceVariant	c|DEL|809_852|	Complementary DNA sequencing showed that this mutation causes skipping of exon 14 and deletion of amino acids 809-852 while preserving the open reading frame.
BC8_BioRED_Task1_Doc218	924	932	patients	OrganismTaxon	9606	Western blotting of liver extracts and sera of affected patients showed retention of the abnormal protein in the liver.
BC8_BioRED_Task1_Doc218	988	1006	Aceruloplasminemia	Disease	C536004	Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.
BC8_BioRED_Task1_Doc218	1050	1063	iron overload	Disease	D019190	Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.
BC8_BioRED_Task1_Doc218	1102	1106	iron	Chemical	D007501	Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.
BC8_BioRED_Task1_Doc218	1115	1123	hepcidin	Gene	57817	Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.
BC8_BioRED_Task1_Doc218	1170	1183	iron overload	Disease	D019190	Aceruloplasminemia was associated with severe brain and liver iron overload, where hepatic mRNA expression of the iron hormone hepcidin was increased, corresponding to the degree of iron overload.
BC8_BioRED_Task1_Doc218	1193	1197	iron	Chemical	D007501	Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox, which was also associated with reduced insulin demands.
BC8_BioRED_Task1_Doc218	1246	1250	iron	Chemical	D007501	Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox, which was also associated with reduced insulin demands.
BC8_BioRED_Task1_Doc218	1274	1285	deferasirox	Chemical	D000077588	Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox, which was also associated with reduced insulin demands.
BC8_BioRED_Task1_Doc218	1326	1333	insulin	Gene	3630	Hepatic iron concentration normalized after 3 and 5months of iron chelation therapy with deferasirox, which was also associated with reduced insulin demands.
BC8_BioRED_Task1_Doc218	1446	1459	iron overload	Disease	D019190	During short term treatment there was no clinical or imaging evidence for significant effects on brain iron overload.
BC8_BioRED_Task1_Doc218	1474	1492	Aceruloplasminemia	Disease	C536004	CONCLUSIONS: Aceruloplasminemia can show an incomplete clinical penetrance but is invariably associated with iron accumulation in the liver and in the brain.
BC8_BioRED_Task1_Doc218	1570	1574	iron	Chemical	D007501	CONCLUSIONS: Aceruloplasminemia can show an incomplete clinical penetrance but is invariably associated with iron accumulation in the liver and in the brain.
BC8_BioRED_Task1_Doc218	1619	1623	Iron	Chemical	D007501	Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload.
BC8_BioRED_Task1_Doc218	1640	1658	aceruloplasminemia	Disease	C536004	Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload.
BC8_BioRED_Task1_Doc218	1693	1697	iron	Chemical	D007501	Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload.
BC8_BioRED_Task1_Doc218	1712	1720	hepcidin	Gene	57817	Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload.
BC8_BioRED_Task1_Doc218	1765	1778	iron overload	Disease	D019190	Iron accumulation in aceruloplasminemia is a result of defective cellular iron export, where hepcidin regulation is appropriate for the degree of iron overload.
BC8_BioRED_Task1_Doc218	1780	1784	Iron	Chemical	D007501	Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron.
BC8_BioRED_Task1_Doc218	1800	1811	deferasirox	Chemical	D000077588	Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron.
BC8_BioRED_Task1_Doc218	1848	1852	iron	Chemical	D007501	Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron.
BC8_BioRED_Task1_Doc218	1880	1884	iron	Chemical	D007501	Iron chelation with deferasirox was effective in mobilizing hepatic iron but has no effect on brain iron.
BC8_BioRED_Task1_Doc219	0	10	Fluoxetine	Chemical	D005473	Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
BC8_BioRED_Task1_Doc219	24	39	memory deficits	Disease	D008569	Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
BC8_BioRED_Task1_Doc219	73	87	5-fluorouracil	Chemical	D005472	Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
BC8_BioRED_Task1_Doc219	89	95	Cancer	Disease	D009369	Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition.
BC8_BioRED_Task1_Doc219	96	104	patients	OrganismTaxon	9606	Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition.
BC8_BioRED_Task1_Doc219	258	272	5-fluorouracil	Chemical	D005472	A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function.
BC8_BioRED_Task1_Doc219	274	278	5-FU	Chemical	D005472	A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function.
BC8_BioRED_Task1_Doc219	592	596	SSRI	Chemical	D017367	In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the SSRI antidepressant Fluoxetine.
BC8_BioRED_Task1_Doc219	612	622	Fluoxetine	Chemical	D005473	In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the SSRI antidepressant Fluoxetine.
BC8_BioRED_Task1_Doc219	707	711	5-FU	Chemical	D005472	In this investigation the behavioural effects of chronic (two week) treatment with 5-FU and (three weeks) with Fluoxetine either separately or in combination with 5-FU were tested on adult Lister hooded rats.
BC8_BioRED_Task1_Doc219	735	745	Fluoxetine	Chemical	D005473	In this investigation the behavioural effects of chronic (two week) treatment with 5-FU and (three weeks) with Fluoxetine either separately or in combination with 5-FU were tested on adult Lister hooded rats.
BC8_BioRED_Task1_Doc219	787	791	5-FU	Chemical	D005472	In this investigation the behavioural effects of chronic (two week) treatment with 5-FU and (three weeks) with Fluoxetine either separately or in combination with 5-FU were tested on adult Lister hooded rats.
BC8_BioRED_Task1_Doc219	827	831	rats	OrganismTaxon	10116	In this investigation the behavioural effects of chronic (two week) treatment with 5-FU and (three weeks) with Fluoxetine either separately or in combination with 5-FU were tested on adult Lister hooded rats.
BC8_BioRED_Task1_Doc219	972	976	5-FU	Chemical	D005472	Behavioural effects were tested using a context dependent conditioned emotional response test (CER) which showed that animals treated with 5-FU had a significant reduction in freezing time compared to controls.
BC8_BioRED_Task1_Doc219	1212	1216	5-FU	Chemical	D005472	Animals treated only with 5-FU showed significant deficits in their ability to carry out the OLR task but co administration of Fluoxetine improved their performance.
BC8_BioRED_Task1_Doc219	1313	1323	Fluoxetine	Chemical	D005473	Animals treated only with 5-FU showed significant deficits in their ability to carry out the OLR task but co administration of Fluoxetine improved their performance.
BC8_BioRED_Task1_Doc219	1352	1356	5-FU	Chemical	D005472	5-FU chemotherapy caused a significant reduction in the number of proliferating cells in the sub granular zone of the dentate gyrus compared to controls.
BC8_BioRED_Task1_Doc219	1541	1551	Fluoxetine	Chemical	D005473	This reduction was eliminated when Fluoxetine was co administered with 5-FU.
BC8_BioRED_Task1_Doc219	1577	1581	5-FU	Chemical	D005472	This reduction was eliminated when Fluoxetine was co administered with 5-FU.
BC8_BioRED_Task1_Doc219	1583	1593	Fluoxetine	Chemical	D005473	Fluoxetine on its own had no effect on proliferating cell number or behaviour.
BC8_BioRED_Task1_Doc219	1690	1694	5-FU	Chemical	D005472	These findings suggest that 5-FU can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant Fluoxetine.
BC8_BioRED_Task1_Doc219	1879	1889	Fluoxetine	Chemical	D005473	These findings suggest that 5-FU can negatively affect both cell proliferation and hippocampal dependent working memory and that these deficits can be reversed by the simultaneous administration of the antidepressant Fluoxetine.
BC8_BioRED_Task1_Doc220	10	34	Bernard-Soulier Syndrome	Disease	D001606	A case of Bernard-Soulier Syndrome due to a homozygous four bases deletion (TGAG) of GPIbalpha gene: lack of GPIbalpha but absence of bleeding.
BC8_BioRED_Task1_Doc220	66	81	deletion (TGAG)	SequenceVariant	c|DEL||TGAG	A case of Bernard-Soulier Syndrome due to a homozygous four bases deletion (TGAG) of GPIbalpha gene: lack of GPIbalpha but absence of bleeding.
BC8_BioRED_Task1_Doc220	85	94	GPIbalpha	Gene	2811	A case of Bernard-Soulier Syndrome due to a homozygous four bases deletion (TGAG) of GPIbalpha gene: lack of GPIbalpha but absence of bleeding.
BC8_BioRED_Task1_Doc220	109	118	GPIbalpha	Gene	2811	A case of Bernard-Soulier Syndrome due to a homozygous four bases deletion (TGAG) of GPIbalpha gene: lack of GPIbalpha but absence of bleeding.
BC8_BioRED_Task1_Doc220	134	142	bleeding	Disease	D006470	A case of Bernard-Soulier Syndrome due to a homozygous four bases deletion (TGAG) of GPIbalpha gene: lack of GPIbalpha but absence of bleeding.
BC8_BioRED_Task1_Doc220	229	237	patients	OrganismTaxon	9606	More than 20 DNA mutations with different inheritance pattern have been described in patients with Bernard-Soulier Syndrome (BSS), leading to abnormal or absent synthesis and/or expression of GPIbalpha.
BC8_BioRED_Task1_Doc220	243	267	Bernard-Soulier Syndrome	Disease	D001606	More than 20 DNA mutations with different inheritance pattern have been described in patients with Bernard-Soulier Syndrome (BSS), leading to abnormal or absent synthesis and/or expression of GPIbalpha.
BC8_BioRED_Task1_Doc220	269	272	BSS	Disease	D001606	More than 20 DNA mutations with different inheritance pattern have been described in patients with Bernard-Soulier Syndrome (BSS), leading to abnormal or absent synthesis and/or expression of GPIbalpha.
BC8_BioRED_Task1_Doc220	336	345	GPIbalpha	Gene	2811	More than 20 DNA mutations with different inheritance pattern have been described in patients with Bernard-Soulier Syndrome (BSS), leading to abnormal or absent synthesis and/or expression of GPIbalpha.
BC8_BioRED_Task1_Doc220	424	432	bleeding	Disease	D006470	Clinical phenotype shows considerable variation between individuals, such as bleeding, platelet count and the percentage of large platelets.
BC8_BioRED_Task1_Doc220	505	508	BSS	Disease	D001606	We describe in a BSS patient the first case of homozygous four bases deletion (TGAG) in the gpIbalpha gene coding sequence, leading to a premature stop codon.
BC8_BioRED_Task1_Doc220	509	516	patient	OrganismTaxon	9606	We describe in a BSS patient the first case of homozygous four bases deletion (TGAG) in the gpIbalpha gene coding sequence, leading to a premature stop codon.
BC8_BioRED_Task1_Doc220	557	572	deletion (TGAG)	SequenceVariant	c|DEL||TGAG	We describe in a BSS patient the first case of homozygous four bases deletion (TGAG) in the gpIbalpha gene coding sequence, leading to a premature stop codon.
BC8_BioRED_Task1_Doc220	580	589	gpIbalpha	Gene	2811	We describe in a BSS patient the first case of homozygous four bases deletion (TGAG) in the gpIbalpha gene coding sequence, leading to a premature stop codon.
BC8_BioRED_Task1_Doc220	760	770	ristocetin	Chemical	D012310	In the propositus, blood smears revealed giant platelets (30 x 10(9) platelets/L), and platelet agglutination to ristocetin was absent.
BC8_BioRED_Task1_Doc220	873	889	thrombocytopenia	Disease	D013921	His father and paternal grandmother showed a mild thrombocytopenia (108 x 10(9)/L and 120 x 10(9)/L platelets respectively) while mothers and sister's referred normal platelet counts.
BC8_BioRED_Task1_Doc220	1033	1042	GPIbalpha	Gene	2811	The surface expression of GPIbalpha was practically undetectable by flow-cytometry and western blot in the patient and was reduced in the father.
BC8_BioRED_Task1_Doc220	1114	1121	patient	OrganismTaxon	9606	The surface expression of GPIbalpha was practically undetectable by flow-cytometry and western blot in the patient and was reduced in the father.
BC8_BioRED_Task1_Doc220	1213	1228	deletion (TGAG)	SequenceVariant	c|DEL||TGAG	Proband's DNA analysis revealed a homozygous four-base-pair deletion (TGAG), starting from the last base of the codon for Ser39, leading to a coding frame shift with a new termination codon after 11 novel amino acids.
BC8_BioRED_Task1_Doc220	1460	1469	GPIbalpha	Gene	2811	This is the first report of GPIbalpha TGAG deletion in homozygous state even if the defect has already been described in a case of compound heterozygosis.
BC8_BioRED_Task1_Doc220	1470	1483	TGAG deletion	SequenceVariant	c|DEL||TGAG	This is the first report of GPIbalpha TGAG deletion in homozygous state even if the defect has already been described in a case of compound heterozygosis.
BC8_BioRED_Task1_Doc220	1648	1665	bleeding tendency	Disease	D006470	Surprisingly, the propositus does not report any spontaneous bleeding tendency.
BC8_BioRED_Task1_Doc221	64	92	systemic lupus erythematosus	Disease	D008180	Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform.
BC8_BioRED_Task1_Doc221	179	207	systemic lupus erythematosus	Disease	D008180	OBJECTIVE: Childhood-onset systemic lupus erythematosus (SLE) presents a unique subgroup of patients for genetic study.
BC8_BioRED_Task1_Doc221	209	212	SLE	Disease	D008180	OBJECTIVE: Childhood-onset systemic lupus erythematosus (SLE) presents a unique subgroup of patients for genetic study.
BC8_BioRED_Task1_Doc221	244	252	patients	OrganismTaxon	9606	OBJECTIVE: Childhood-onset systemic lupus erythematosus (SLE) presents a unique subgroup of patients for genetic study.
BC8_BioRED_Task1_Doc221	354	357	SLE	Disease	D008180	The present study was undertaken to identify susceptibility genes contributing to SLE, using a novel candidate gene pathway microarray platform to investigate gene expression in patients with childhood-onset SLE and both of their parents.
BC8_BioRED_Task1_Doc221	450	458	patients	OrganismTaxon	9606	The present study was undertaken to identify susceptibility genes contributing to SLE, using a novel candidate gene pathway microarray platform to investigate gene expression in patients with childhood-onset SLE and both of their parents.
BC8_BioRED_Task1_Doc221	480	483	SLE	Disease	D008180	The present study was undertaken to identify susceptibility genes contributing to SLE, using a novel candidate gene pathway microarray platform to investigate gene expression in patients with childhood-onset SLE and both of their parents.
BC8_BioRED_Task1_Doc221	839	842	SLE	Disease	D008180	Seven hundred fifty three subjects, corresponding to 251 full trios of childhood-onset SLE families, were genotyped and analyzed using transmission disequilibrium testing (TDT) and multitest corrections.
BC8_BioRED_Task1_Doc221	1018	1021	SLE	Disease	D008180	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1029	1034	N673S	SequenceVariant	rs3917815	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1055	1065	P-selectin	Gene	6403	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1072	1076	SELP	Gene	6403	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1104	1109	C203S	SequenceVariant	rs10127175	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1130	1172	interleukin-1 receptor-associated kinase 1	Gene	3654	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1179	1184	IRAK1	Gene	3654	RESULTS: Family-based TDT showed a significant association of SLE with a N673S polymorphism in the P-selectin gene (SELP) (P = 5.74 x 10(-6)) and a C203S polymorphism in the interleukin-1 receptor-associated kinase 1 gene (IRAK1) (P = 9.58 x 10(-6)).
BC8_BioRED_Task1_Doc221	1430	1433	SLE	Disease	D008180	Furthermore, 7 additional SNPs showed q values of <0.5, suggesting association with SLE and providing a direction for followup studies.
BC8_BioRED_Task1_Doc221	1522	1529	TNFRSF6	Gene	355	These additional genes notably included TNFRSF6 (Fas) and IRF5, supporting previous findings of their association with SLE pathogenesis.
BC8_BioRED_Task1_Doc221	1531	1534	Fas	Gene	355	These additional genes notably included TNFRSF6 (Fas) and IRF5, supporting previous findings of their association with SLE pathogenesis.
BC8_BioRED_Task1_Doc221	1540	1544	IRF5	Gene	3663	These additional genes notably included TNFRSF6 (Fas) and IRF5, supporting previous findings of their association with SLE pathogenesis.
BC8_BioRED_Task1_Doc221	1601	1604	SLE	Disease	D008180	These additional genes notably included TNFRSF6 (Fas) and IRF5, supporting previous findings of their association with SLE pathogenesis.
BC8_BioRED_Task1_Doc221	1631	1635	SELP	Gene	6403	CONCLUSION: SELP and IRAK1 were identified as novel SLE-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of SLE.
BC8_BioRED_Task1_Doc221	1640	1645	IRAK1	Gene	3654	CONCLUSION: SELP and IRAK1 were identified as novel SLE-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of SLE.
BC8_BioRED_Task1_Doc221	1671	1674	SLE	Disease	D008180	CONCLUSION: SELP and IRAK1 were identified as novel SLE-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of SLE.
BC8_BioRED_Task1_Doc221	1791	1794	SLE	Disease	D008180	CONCLUSION: SELP and IRAK1 were identified as novel SLE-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of SLE.
BC8_BioRED_Task1_Doc222	0	5	hOGG1	Gene	4968	hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type.
BC8_BioRED_Task1_Doc222	6	15	Ser326Cys	SequenceVariant	rs1052133	hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type.
BC8_BioRED_Task1_Doc222	41	52	lung cancer	Disease	D008175	hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type.
BC8_BioRED_Task1_Doc222	75	80	Human	OrganismTaxon	9606	Human 8-oxoguanine DNA glycosylase 1 (hOGG1) has a major role in the repair of 8-hydroxyguanine, a major promutagenic DNA lesion.
BC8_BioRED_Task1_Doc222	81	111	8-oxoguanine DNA glycosylase 1	Gene	4968	Human 8-oxoguanine DNA glycosylase 1 (hOGG1) has a major role in the repair of 8-hydroxyguanine, a major promutagenic DNA lesion.
BC8_BioRED_Task1_Doc222	113	118	hOGG1	Gene	4968	Human 8-oxoguanine DNA glycosylase 1 (hOGG1) has a major role in the repair of 8-hydroxyguanine, a major promutagenic DNA lesion.
BC8_BioRED_Task1_Doc222	154	170	8-hydroxyguanine	Chemical	C024829	Human 8-oxoguanine DNA glycosylase 1 (hOGG1) has a major role in the repair of 8-hydroxyguanine, a major promutagenic DNA lesion.
BC8_BioRED_Task1_Doc222	230	239	rs1052133	SequenceVariant	rs1052133	The genetic polymorphism rs1052133, which leads to substitution of the amino acid at codon 326 from Ser to Cys, shows functional differences, namely a decrease in enzyme activity in hOGG1-Cys326.
BC8_BioRED_Task1_Doc222	296	315	326 from Ser to Cys	SequenceVariant	rs1052133	The genetic polymorphism rs1052133, which leads to substitution of the amino acid at codon 326 from Ser to Cys, shows functional differences, namely a decrease in enzyme activity in hOGG1-Cys326.
BC8_BioRED_Task1_Doc222	387	392	hOGG1	Gene	4968	The genetic polymorphism rs1052133, which leads to substitution of the amino acid at codon 326 from Ser to Cys, shows functional differences, namely a decrease in enzyme activity in hOGG1-Cys326.
BC8_BioRED_Task1_Doc222	393	399	Cys326	SequenceVariant	rs1052133	The genetic polymorphism rs1052133, which leads to substitution of the amino acid at codon 326 from Ser to Cys, shows functional differences, namely a decrease in enzyme activity in hOGG1-Cys326.
BC8_BioRED_Task1_Doc222	468	477	rs1052133	SequenceVariant	rs1052133	Although several studies have investigated the association between rs1052133 and lung cancer susceptibility, the effect of this locus on lung cancer according to histology remains unclear.
BC8_BioRED_Task1_Doc222	482	493	lung cancer	Disease	D008175	Although several studies have investigated the association between rs1052133 and lung cancer susceptibility, the effect of this locus on lung cancer according to histology remains unclear.
BC8_BioRED_Task1_Doc222	538	549	lung cancer	Disease	D008175	Although several studies have investigated the association between rs1052133 and lung cancer susceptibility, the effect of this locus on lung cancer according to histology remains unclear.
BC8_BioRED_Task1_Doc222	652	663	lung cancer	Disease	D008175	We therefore conducted a case-control study with 515 incident lung cancer cases and 1030 age- and sex-matched controls without cancer, and further conducted a meta-analysis.
BC8_BioRED_Task1_Doc222	717	723	cancer	Disease	D009369	We therefore conducted a case-control study with 515 incident lung cancer cases and 1030 age- and sex-matched controls without cancer, and further conducted a meta-analysis.
BC8_BioRED_Task1_Doc222	855	866	lung cancer	Disease	D008175	In overall analysis, the homozygous Cys/Cys genotype showed a significant association with lung cancer compared to Ser allele carrier status (odds ratio (OR)=1.31, 95% confidence interval (CI)=1.02-1.69).
BC8_BioRED_Task1_Doc222	1068	1088	small-cell carcinoma	Disease	D018288	By histology-based analysis, the Cys/Cys genotype showed a significantly positive association with small-cell carcinoma (OR=2.40, 95% CI=1.32-4.49) and marginally significant association with adenocarcinoma (OR=1.32, 95% CI=0.98-1.77).
BC8_BioRED_Task1_Doc222	1161	1175	adenocarcinoma	Disease	D000230	By histology-based analysis, the Cys/Cys genotype showed a significantly positive association with small-cell carcinoma (OR=2.40, 95% CI=1.32-4.49) and marginally significant association with adenocarcinoma (OR=1.32, 95% CI=0.98-1.77).
BC8_BioRED_Task1_Doc222	1317	1331	adenocarcinoma	Disease	D000230	A meta-analysis of previous and our present study revealed that this polymorphism is positively associated with adenocarcinoma, although suggestive associations were also found for squamous- and small-cell lung cancers.
BC8_BioRED_Task1_Doc222	1386	1423	squamous- and small-cell lung cancers	Disease	D002289,D055752	A meta-analysis of previous and our present study revealed that this polymorphism is positively associated with adenocarcinoma, although suggestive associations were also found for squamous- and small-cell lung cancers.
BC8_BioRED_Task1_Doc222	1453	1462	rs1052133	SequenceVariant	rs1052133	These results indicate that rs1052133 contributes to the risk of adenocarcinoma of lung.
BC8_BioRED_Task1_Doc222	1490	1512	adenocarcinoma of lung	Disease	D000077192	These results indicate that rs1052133 contributes to the risk of adenocarcinoma of lung.
BC8_BioRED_Task1_Doc223	32	44	LIF Receptor	Gene	16880	Tissue-Specific Ablation of the LIF Receptor in the Murine Uterine Epithelium Results in Implantation Failure.
BC8_BioRED_Task1_Doc223	52	58	Murine	OrganismTaxon	10090	Tissue-Specific Ablation of the LIF Receptor in the Murine Uterine Epithelium Results in Implantation Failure.
BC8_BioRED_Task1_Doc223	124	150	leukemia inhibitory factor	Gene	16878	The cytokine leukemia inhibitory factor (LIF) is essential for rendering the uterus receptive for blastocyst implantation.
BC8_BioRED_Task1_Doc223	152	155	LIF	Gene	16878	The cytokine leukemia inhibitory factor (LIF) is essential for rendering the uterus receptive for blastocyst implantation.
BC8_BioRED_Task1_Doc223	237	241	mice	OrganismTaxon	10090	In mice, LIF receptor expression (LIFR) is largely restricted to the uterine luminal epithelium (LE).
BC8_BioRED_Task1_Doc223	243	255	LIF receptor	Gene	16880	In mice, LIF receptor expression (LIFR) is largely restricted to the uterine luminal epithelium (LE).
BC8_BioRED_Task1_Doc223	268	272	LIFR	Gene	16880	In mice, LIF receptor expression (LIFR) is largely restricted to the uterine luminal epithelium (LE).
BC8_BioRED_Task1_Doc223	336	339	LIF	Gene	16878	LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.
BC8_BioRED_Task1_Doc223	398	402	LIFR	Gene	16880	LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.
BC8_BioRED_Task1_Doc223	419	431	Janus kinase	Gene	16452	LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.
BC8_BioRED_Task1_Doc223	432	490	signal transducer and activation of transcription (STAT) 3	Gene	20848	LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.
BC8_BioRED_Task1_Doc223	492	495	Jak	Gene	16452	LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.
BC8_BioRED_Task1_Doc223	496	501	Stat3	Gene	20848	LIF, secreted from the endometrial glands (GEs), binds to the LIFR, activating the Janus kinase-signal transducer and activation of transcription (STAT) 3 (Jak-Stat3) signaling pathway in the LE.
BC8_BioRED_Task1_Doc223	532	535	JAK	Gene	16452	JAK-STAT activation converts the LE to a receptive state so that juxtaposed blastocysts begin to implant.
BC8_BioRED_Task1_Doc223	536	540	STAT	Gene	20848	JAK-STAT activation converts the LE to a receptive state so that juxtaposed blastocysts begin to implant.
BC8_BioRED_Task1_Doc223	665	669	LIFR	Gene	16880	To specifically delete the LIFR in the LE, we derived a line of mice in which Cre recombinase was inserted into the endogenous lactoferrin gene (Ltf-Cre).
BC8_BioRED_Task1_Doc223	702	706	mice	OrganismTaxon	10090	To specifically delete the LIFR in the LE, we derived a line of mice in which Cre recombinase was inserted into the endogenous lactoferrin gene (Ltf-Cre).
BC8_BioRED_Task1_Doc223	765	776	lactoferrin	Gene	17002	To specifically delete the LIFR in the LE, we derived a line of mice in which Cre recombinase was inserted into the endogenous lactoferrin gene (Ltf-Cre).
BC8_BioRED_Task1_Doc223	783	786	Ltf	Gene	16878	To specifically delete the LIFR in the LE, we derived a line of mice in which Cre recombinase was inserted into the endogenous lactoferrin gene (Ltf-Cre).
BC8_BioRED_Task1_Doc223	793	804	Lactoferrin	Gene	17002	Lactoferrin expression in the LE is induced by E2, and we demonstrate that Cre recombinase activity is restricted to the LE and GE.
BC8_BioRED_Task1_Doc223	961	965	LIFR	Gene	16880	To determine the requirement of the LIFR in implantation, we derived an additional mouse line carrying a conditional (floxed) Lifr flx/flx gene.
BC8_BioRED_Task1_Doc223	1008	1013	mouse	OrganismTaxon	10090	To determine the requirement of the LIFR in implantation, we derived an additional mouse line carrying a conditional (floxed) Lifr flx/flx gene.
BC8_BioRED_Task1_Doc223	1051	1055	Lifr	Gene	16880	To determine the requirement of the LIFR in implantation, we derived an additional mouse line carrying a conditional (floxed) Lifr flx/flx gene.
BC8_BioRED_Task1_Doc223	1079	1082	Ltf	Gene	16878	Crossing Ltf-Cre mice with Lifr flx/flx mice generated Lifr flx/D:Ltf Cre/+ females that were overtly normal but infertile.
BC8_BioRED_Task1_Doc223	1087	1091	mice	OrganismTaxon	10090	Crossing Ltf-Cre mice with Lifr flx/flx mice generated Lifr flx/D:Ltf Cre/+ females that were overtly normal but infertile.
BC8_BioRED_Task1_Doc223	1097	1101	Lifr	Gene	16880	Crossing Ltf-Cre mice with Lifr flx/flx mice generated Lifr flx/D:Ltf Cre/+ females that were overtly normal but infertile.
BC8_BioRED_Task1_Doc223	1110	1114	mice	OrganismTaxon	10090	Crossing Ltf-Cre mice with Lifr flx/flx mice generated Lifr flx/D:Ltf Cre/+ females that were overtly normal but infertile.
BC8_BioRED_Task1_Doc223	1125	1129	Lifr	Gene	16880	Crossing Ltf-Cre mice with Lifr flx/flx mice generated Lifr flx/D:Ltf Cre/+ females that were overtly normal but infertile.
BC8_BioRED_Task1_Doc223	1136	1139	Ltf	Gene	16878	Crossing Ltf-Cre mice with Lifr flx/flx mice generated Lifr flx/D:Ltf Cre/+ females that were overtly normal but infertile.
BC8_BioRED_Task1_Doc223	1316	1320	Lifr	Gene	16880	Unimplanted blastocysts were recovered from the Lifr flx/D:Ltf Cre/+ uteri and, when transferred to wild-type recipients, implanted normally, indicating that uterine receptivity rather than the embryo's competency is compromised.
BC8_BioRED_Task1_Doc223	1327	1330	Ltf	Gene	16878	Unimplanted blastocysts were recovered from the Lifr flx/D:Ltf Cre/+ uteri and, when transferred to wild-type recipients, implanted normally, indicating that uterine receptivity rather than the embryo's competency is compromised.
BC8_BioRED_Task1_Doc223	1510	1514	Lifr	Gene	16880	The loss of Lifr results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the LIF regulated gene Msx1 that regulates uterine receptivity.
BC8_BioRED_Task1_Doc223	1547	1552	STAT3	Gene	20848	The loss of Lifr results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the LIF regulated gene Msx1 that regulates uterine receptivity.
BC8_BioRED_Task1_Doc223	1626	1629	LIF	Gene	16878	The loss of Lifr results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the LIF regulated gene Msx1 that regulates uterine receptivity.
BC8_BioRED_Task1_Doc223	1645	1649	Msx1	Gene	17701	The loss of Lifr results in both the failure for STAT3 to translocate to the LE nuclei and a reduction in the expression of the LIF regulated gene Msx1 that regulates uterine receptivity.
BC8_BioRED_Task1_Doc223	1738	1742	LIFR	Gene	16880	These results reveal that uterine expression of the LIFR is essential for embryo implantation and further define the components of the LIF signaling pathway necessary for effective implantation.
BC8_BioRED_Task1_Doc223	1821	1824	LIF	Gene	16878	These results reveal that uterine expression of the LIFR is essential for embryo implantation and further define the components of the LIF signaling pathway necessary for effective implantation.
BC8_BioRED_Task1_Doc224	73	81	migraine	Disease	D008881	A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach.
BC8_BioRED_Task1_Doc224	112	120	Migraine	Disease	D008881	Migraine is a common debilitating primary headache disorder with significant mental, physical and social health implications.
BC8_BioRED_Task1_Doc224	154	171	headache disorder	Disease	D020773	Migraine is a common debilitating primary headache disorder with significant mental, physical and social health implications.
BC8_BioRED_Task1_Doc224	248	264	neurotransmitter	Chemical	D018377	The brain neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) is involved in nociceptive pathways and has been implicated in the pathophysiology of migraine.
BC8_BioRED_Task1_Doc224	265	284	5-hydroxytryptamine	Chemical	D012701	The brain neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) is involved in nociceptive pathways and has been implicated in the pathophysiology of migraine.
BC8_BioRED_Task1_Doc224	286	290	5-HT	Chemical	D012701	The brain neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) is involved in nociceptive pathways and has been implicated in the pathophysiology of migraine.
BC8_BioRED_Task1_Doc224	292	301	serotonin	Chemical	D012701	The brain neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) is involved in nociceptive pathways and has been implicated in the pathophysiology of migraine.
BC8_BioRED_Task1_Doc224	389	397	migraine	Disease	D008881	The brain neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) is involved in nociceptive pathways and has been implicated in the pathophysiology of migraine.
BC8_BioRED_Task1_Doc224	495	499	5-HT	Chemical	D012701	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	535	543	migraine	Disease	D008881	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	618	623	human	OrganismTaxon	9606	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	624	646	tryptophan hydroxylase	Gene	7166	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	648	651	TPH	Gene	7166	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	654	678	amino acid decarboxylase	Gene	1644	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	680	684	AADC	Gene	1644	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	690	709	monoamine oxidase A	Gene	4128	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	711	715	MAOA	Gene	4128	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	726	734	migraine	Disease	D008881	With few genetic studies investigating biosynthetic and metabolic enzymes governing the rate of 5-HT activity and their relationship to migraine, it was the objective of this study to assess genetic variants within the human tryptophan hydroxylase (TPH), amino acid decarboxylase (AADC) and monoamine oxidase A (MAOA) genes in migraine susceptibility.
BC8_BioRED_Task1_Doc224	1340	1343	TPH	Gene	7166	Despite the application of this high-throughput genotyping method, negative results from the two-stage DNA pooling design used to screen loci within the TPH, AADC and MAOA genes did not support their role in migraine susceptibility.
BC8_BioRED_Task1_Doc224	1345	1349	AADC	Gene	1644	Despite the application of this high-throughput genotyping method, negative results from the two-stage DNA pooling design used to screen loci within the TPH, AADC and MAOA genes did not support their role in migraine susceptibility.
BC8_BioRED_Task1_Doc224	1354	1358	MAOA	Gene	4128	Despite the application of this high-throughput genotyping method, negative results from the two-stage DNA pooling design used to screen loci within the TPH, AADC and MAOA genes did not support their role in migraine susceptibility.
BC8_BioRED_Task1_Doc224	1395	1403	migraine	Disease	D008881	Despite the application of this high-throughput genotyping method, negative results from the two-stage DNA pooling design used to screen loci within the TPH, AADC and MAOA genes did not support their role in migraine susceptibility.
BC8_BioRED_Task1_Doc225	0	5	FGFR4	Gene	2264	FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
BC8_BioRED_Task1_Doc225	6	15	Gly388Arg	SequenceVariant	rs351855	FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
BC8_BioRED_Task1_Doc225	33	48	prostate cancer	Disease	D011471	FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
BC8_BioRED_Task1_Doc225	66	69	men	OrganismTaxon	9606	FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
BC8_BioRED_Task1_Doc225	71	106	Fibroblast growth factor receptor 4	Gene	2264	Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells.
BC8_BioRED_Task1_Doc225	108	113	FGFR4	Gene	2264	Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells.
BC8_BioRED_Task1_Doc225	132	158	fibroblast growth receptor	Gene	2264	Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells.
BC8_BioRED_Task1_Doc225	318	323	FGFR4	Gene	2264	A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients.
BC8_BioRED_Task1_Doc225	375	408	glycine (Gly) with arginine (Arg)	SequenceVariant	rs351855	A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients.
BC8_BioRED_Task1_Doc225	477	492	prostate cancer	Disease	D011471	A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients.
BC8_BioRED_Task1_Doc225	493	501	patients	OrganismTaxon	9606	A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients.
BC8_BioRED_Task1_Doc225	551	566	prostate cancer	Disease	D011471	DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls.
BC8_BioRED_Task1_Doc225	567	575	patients	OrganismTaxon	9606	DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls.
BC8_BioRED_Task1_Doc225	581	584	BPH	Disease	D011470	DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls.
BC8_BioRED_Task1_Doc225	585	593	patients	OrganismTaxon	9606	DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls.
BC8_BioRED_Task1_Doc225	711	716	FGFR4	Gene	2264	Polymerase chain reaction was carried out and single nucleotide polymorphisms of FGFR4 were identified by restriction enzyme digestion.
BC8_BioRED_Task1_Doc225	840	855	prostate cancer	Disease	D011471	No overall association is detectable between the Arg allele and increased prostate cancer risk.
BC8_BioRED_Task1_Doc225	944	950	cancer	Disease	D009369	Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls.
BC8_BioRED_Task1_Doc225	987	990	BPH	Disease	D011470	Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls.
BC8_BioRED_Task1_Doc225	1067	1073	cancer	Disease	D009369	Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls.
BC8_BioRED_Task1_Doc225	1078	1081	BPH	Disease	D011470	Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls.
BC8_BioRED_Task1_Doc225	1082	1090	patients	OrganismTaxon	9606	Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls.
BC8_BioRED_Task1_Doc225	1107	1113	cancer	Disease	D009369	Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls.
BC8_BioRED_Task1_Doc225	1179	1190	Gly(388)Arg	SequenceVariant	rs351855	The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men.
BC8_BioRED_Task1_Doc225	1194	1199	FGFR4	Gene	2264	The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men.
BC8_BioRED_Task1_Doc225	1241	1256	prostate cancer	Disease	D011471	The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men.
BC8_BioRED_Task1_Doc225	1269	1272	men	OrganismTaxon	9606	The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men.
BC8_BioRED_Task1_Doc226	0	11	Amisulpride	Chemical	D000077582	Amisulpride related tic-like symptoms in an adolescent schizophrenic.
BC8_BioRED_Task1_Doc226	20	37	tic-like symptoms	Disease	-	Amisulpride related tic-like symptoms in an adolescent schizophrenic.
BC8_BioRED_Task1_Doc226	55	68	schizophrenic	Disease	D012559	Amisulpride related tic-like symptoms in an adolescent schizophrenic.
BC8_BioRED_Task1_Doc226	70	83	Tic disorders	Disease	D013981	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
BC8_BioRED_Task1_Doc226	123	137	antipsychotics	Chemical	D014150	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
BC8_BioRED_Task1_Doc226	146	157	risperidone	Chemical	D018967	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
BC8_BioRED_Task1_Doc226	159	169	olanzapine	Chemical	D000077152	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
BC8_BioRED_Task1_Doc226	174	185	ziprasidone	Chemical	C092292	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
BC8_BioRED_Task1_Doc226	233	250	tic-like symptoms	Disease	-	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
BC8_BioRED_Task1_Doc226	321	331	quetiapine	Chemical	D000069348	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
BC8_BioRED_Task1_Doc226	335	344	clozapine	Chemical	D003024	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
BC8_BioRED_Task1_Doc226	376	389	schizophrenic	Disease	D012559	We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).
BC8_BioRED_Task1_Doc226	413	447	involuntary eye-blinking movements	Disease	D020820	We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).
BC8_BioRED_Task1_Doc226	466	477	amisulpride	Chemical	D000077582	We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).
BC8_BioRED_Task1_Doc226	511	528	tic-like symptoms	Disease	-	The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
BC8_BioRED_Task1_Doc226	578	589	amisulpride	Chemical	D000077582	The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
BC8_BioRED_Task1_Doc226	627	636	psychosis	Disease	D011605	However, her psychosis recurred after the dose reduction.
BC8_BioRED_Task1_Doc226	726	736	quetiapine	Chemical	D000069348	We then placed her on an additional 100 mg per day of quetiapine.
BC8_BioRED_Task1_Doc226	871	888	tic-like symptoms	Disease	-	No more tic-like symptoms or other side effects have been reported.
BC8_BioRED_Task1_Doc226	976	983	patient	OrganismTaxon	9606	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
BC8_BioRED_Task1_Doc226	998	1015	tic-like symptoms	Disease	-	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
BC8_BioRED_Task1_Doc226	1093	1107	antipsychotics	Chemical	D014150	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
BC8_BioRED_Task1_Doc226	1116	1126	quetiapine	Chemical	D000069348	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
BC8_BioRED_Task1_Doc226	1128	1137	clozapine	Chemical	D003024	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
BC8_BioRED_Task1_Doc226	1142	1153	amisulpride	Chemical	D000077582	Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.
BC8_BioRED_Task1_Doc227	47	58	hippocalcin	Gene	3208	Biophysical and functional characterization of hippocalcin mutants responsible for human dystonia.
BC8_BioRED_Task1_Doc227	83	88	human	OrganismTaxon	9606	Biophysical and functional characterization of hippocalcin mutants responsible for human dystonia.
BC8_BioRED_Task1_Doc227	89	97	dystonia	Disease	D004421	Biophysical and functional characterization of hippocalcin mutants responsible for human dystonia.
BC8_BioRED_Task1_Doc227	99	107	Dystonia	Disease	D004421	Dystonia is a neurological movement disorder that forces the body into twisting, repetitive movements or sometimes painful abnormal postures.
BC8_BioRED_Task1_Doc227	113	143	neurological movement disorder	Disease	D009069	Dystonia is a neurological movement disorder that forces the body into twisting, repetitive movements or sometimes painful abnormal postures.
BC8_BioRED_Task1_Doc227	326	330	T71N	SequenceVariant	rs775863165	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	335	340	A190T	SequenceVariant	rs550921485	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	348	371	neuronal calcium sensor	Gene	3208	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	373	376	NCS	Gene	3208	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	378	389	hippocalcin	Gene	3208	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	430	455	primary isolated dystonia	Disease	D004421	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	457	461	DYT2	Gene	3208	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	462	470	dystonia	Disease	D004421	With the advent of next-generation sequencing technologies, the homozygous mutations T71N and A190T in the neuronal calcium sensor (NCS) hippocalcin were identified as the genetic cause of primary isolated dystonia (DYT2 dystonia).
BC8_BioRED_Task1_Doc227	541	552	hippocalcin	Gene	3208	However, the effect of these mutations on the physiological role of hippocalcin has not yet been elucidated.
BC8_BioRED_Task1_Doc227	639	650	hippocalcin	Gene	3208	Using a multidisciplinary approach, we demonstrated that hippocalcin oligomerises in a calcium-dependent manner and binds to voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	669	676	calcium	Chemical	D002118	Using a multidisciplinary approach, we demonstrated that hippocalcin oligomerises in a calcium-dependent manner and binds to voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	707	737	voltage-gated calcium channels	Gene	783	Using a multidisciplinary approach, we demonstrated that hippocalcin oligomerises in a calcium-dependent manner and binds to voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	749	753	T71N	SequenceVariant	rs775863165	Mutations T71N and A190T in hippocalcin did not affect stability, calcium-binding affinity or translocation to cellular membranes (Ca2+/myristoyl switch).
BC8_BioRED_Task1_Doc227	758	763	A190T	SequenceVariant	rs550921485	Mutations T71N and A190T in hippocalcin did not affect stability, calcium-binding affinity or translocation to cellular membranes (Ca2+/myristoyl switch).
BC8_BioRED_Task1_Doc227	767	778	hippocalcin	Gene	3208	Mutations T71N and A190T in hippocalcin did not affect stability, calcium-binding affinity or translocation to cellular membranes (Ca2+/myristoyl switch).
BC8_BioRED_Task1_Doc227	805	812	calcium	Chemical	D002118	Mutations T71N and A190T in hippocalcin did not affect stability, calcium-binding affinity or translocation to cellular membranes (Ca2+/myristoyl switch).
BC8_BioRED_Task1_Doc227	870	874	Ca2+	Chemical	D000069285	Mutations T71N and A190T in hippocalcin did not affect stability, calcium-binding affinity or translocation to cellular membranes (Ca2+/myristoyl switch).
BC8_BioRED_Task1_Doc227	937	948	hippocalcin	Gene	3208	We obtained the first crystal structure of hippocalcin and alignment with other NCS proteins showed significant variability in the orientation of the C-terminal part of the molecule, the region expected to be important for target binding.
BC8_BioRED_Task1_Doc227	974	977	NCS	Gene	3208	We obtained the first crystal structure of hippocalcin and alignment with other NCS proteins showed significant variability in the orientation of the C-terminal part of the molecule, the region expected to be important for target binding.
BC8_BioRED_Task1_Doc227	1324	1331	calcium	Chemical	D002118	In addition, we observed an increased calcium influx in KCl-depolarised cells expressing mutated hippocalcin, mostly driven by N-type voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	1342	1345	KCl	Chemical	D011189	In addition, we observed an increased calcium influx in KCl-depolarised cells expressing mutated hippocalcin, mostly driven by N-type voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	1383	1394	hippocalcin	Gene	3208	In addition, we observed an increased calcium influx in KCl-depolarised cells expressing mutated hippocalcin, mostly driven by N-type voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	1413	1450	N-type voltage-gated calcium channels	Gene	774	In addition, we observed an increased calcium influx in KCl-depolarised cells expressing mutated hippocalcin, mostly driven by N-type voltage-gated calcium channels.
BC8_BioRED_Task1_Doc227	1482	1490	dystonia	Disease	D004421	Our data demonstrate that the dystonia-causing mutations strongly affect hippocalcin cellular functions which suggest a central role for perturbed calcium signalling in DYT2 dystonia.
BC8_BioRED_Task1_Doc227	1525	1536	hippocalcin	Gene	3208	Our data demonstrate that the dystonia-causing mutations strongly affect hippocalcin cellular functions which suggest a central role for perturbed calcium signalling in DYT2 dystonia.
BC8_BioRED_Task1_Doc227	1599	1606	calcium	Chemical	D002118	Our data demonstrate that the dystonia-causing mutations strongly affect hippocalcin cellular functions which suggest a central role for perturbed calcium signalling in DYT2 dystonia.
BC8_BioRED_Task1_Doc227	1621	1625	DYT2	Gene	3208	Our data demonstrate that the dystonia-causing mutations strongly affect hippocalcin cellular functions which suggest a central role for perturbed calcium signalling in DYT2 dystonia.
BC8_BioRED_Task1_Doc227	1626	1634	dystonia	Disease	D004421	Our data demonstrate that the dystonia-causing mutations strongly affect hippocalcin cellular functions which suggest a central role for perturbed calcium signalling in DYT2 dystonia.
BC8_BioRED_Task1_Doc228	75	80	HIV-1	OrganismTaxon	11676	A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17.
BC8_BioRED_Task1_Doc228	96	99	p17	Gene	155348	A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17.
BC8_BioRED_Task1_Doc228	140	158	HIV-1-seropositive	Disease	D006679	Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis.
BC8_BioRED_Task1_Doc228	159	167	patients	OrganismTaxon	9606	Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis.
BC8_BioRED_Task1_Doc228	173	181	lymphoma	Disease	D008223	Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis.
BC8_BioRED_Task1_Doc228	186	189	p17	Gene	155348	Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis.
BC8_BioRED_Task1_Doc228	272	287	lymphomagenesis	Disease	D008223	Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis.
BC8_BioRED_Task1_Doc228	392	395	p17	Gene	155348	We investigated the mechanisms responsible for the functional disparity on B cells between a wild-type p17 (refp17) and a vp17 named S75X.
BC8_BioRED_Task1_Doc228	422	426	S75X	SequenceVariant	p|SUB|S|75|X	We investigated the mechanisms responsible for the functional disparity on B cells between a wild-type p17 (refp17) and a vp17 named S75X.
BC8_BioRED_Task1_Doc228	456	507	Arginine (R) to Glycine (G) mutation at position 76	SequenceVariant	p|SUB|R|76|G	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	532	535	p17	Gene	155348	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	535	539	R76G	SequenceVariant	p|SUB|R|76|G	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	552	556	S75X	SequenceVariant	p|SUB|S|75|X	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	688	692	PTEN	Gene	5728	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	693	697	PI3K	Gene	5291	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	698	701	Akt	Gene	207	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	775	781	CASP-9	Gene	842	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	783	789	CASP-7	Gene	840	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	791	797	DFF-45	Gene	1676	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	799	802	NPM	Gene	4869	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	804	809	YWHAZ	Gene	7534	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	811	814	Src	Gene	6714	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	816	820	PAX2	Gene	5076	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	822	827	MAPK8	Gene	5599	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	855	861	cancer	Disease	D009369	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	875	879	CDK1	Gene	983	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	881	885	CDK2	Gene	1017	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	887	891	CDK8	Gene	1024	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	893	898	CHEK1	Gene	1111	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	900	905	CHEK2	Gene	11200	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	907	917	GSK-3 beta	Gene	2932	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	919	922	NPM	Gene	4869	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	924	928	PAK1	Gene	5058	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	930	940	PP2C-alpha	Gene	5494	Here, we show that a single Arginine (R) to Glycine (G) mutation at position 76 in the refp17 backbone (p17R76G), as in the S75X variant, is per se sufficient to confer a B-cell clonogenic potential to the viral protein and modulate, through activation of the PTEN/PI3K/Akt signaling pathway, different molecules involved in apoptosis inhibition (CASP-9, CASP-7, DFF-45, NPM, YWHAZ, Src, PAX2, MAPK8), cell cycle promotion and cancer progression (CDK1, CDK2, CDK8, CHEK1, CHEK2, GSK-3 beta, NPM, PAK1, PP2C-alpha).
BC8_BioRED_Task1_Doc228	962	992	R to G mutation at position 76	SequenceVariant	p|SUB|R|76|G	Moreover, the only R to G mutation at position 76 was found to strongly impact on protein folding and oligomerization by altering the hydrogen bond network.
BC8_BioRED_Task1_Doc228	1145	1148	p17	Gene	155348	This generates a conformational shift in the p17 R76G mutant which enables a functional epitope(s), masked in refp17, to elicit B-cell growth-promoting signals after its interaction with a still unknown receptor(s).
BC8_BioRED_Task1_Doc228	1149	1153	R76G	SequenceVariant	p|SUB|R|76|G	This generates a conformational shift in the p17 R76G mutant which enables a functional epitope(s), masked in refp17, to elicit B-cell growth-promoting signals after its interaction with a still unknown receptor(s).
BC8_BioRED_Task1_Doc229	0	19	Acute renal failure	Disease	D058186	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
BC8_BioRED_Task1_Doc229	23	31	patients	OrganismTaxon	9606	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
BC8_BioRED_Task1_Doc229	37	41	AIDS	Disease	D000163	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
BC8_BioRED_Task1_Doc229	45	54	tenofovir	Chemical	D000068698	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
BC8_BioRED_Task1_Doc229	81	91	vancomycin	Chemical	D014640	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
BC8_BioRED_Task1_Doc229	103	116	osteomyelitis	Disease	D010019	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
BC8_BioRED_Task1_Doc229	118	131	Renal failure	Disease	D051437	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
BC8_BioRED_Task1_Doc229	170	180	vancomycin	Chemical	D014640	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
BC8_BioRED_Task1_Doc229	194	202	patients	OrganismTaxon	9606	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
BC8_BioRED_Task1_Doc229	222	251	tenofovir disoproxil fumarate	Chemical	D000068698	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
BC8_BioRED_Task1_Doc229	290	299	Tenofovir	Chemical	D000068698	Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
BC8_BioRED_Task1_Doc229	342	358	Fanconi syndrome	Disease	D005198	Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
BC8_BioRED_Task1_Doc229	363	382	renal insufficiency	Disease	D051437	Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
BC8_BioRED_Task1_Doc229	436	446	Vancomycin	Chemical	D014640	Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
BC8_BioRED_Task1_Doc229	447	461	nephrotoxicity	Disease	D007674	Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
BC8_BioRED_Task1_Doc229	520	531	nephrotoxic	Disease	D007674	Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
BC8_BioRED_Task1_Doc229	571	580	tenofovir	Chemical	D000068698	Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.
BC8_BioRED_Task1_Doc229	603	616	renal failure	Disease	D051437	Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.
BC8_BioRED_Task1_Doc229	652	662	vancomycin	Chemical	D014640	Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.
BC8_BioRED_Task1_Doc230	15	31	cyclooxygenase-2	Gene	5743	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
BC8_BioRED_Task1_Doc230	51	61	valdecoxib	Chemical	C406224	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
BC8_BioRED_Task1_Doc230	69	105	nonsteroidal antiinflammatory agents	Chemical	D000894	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
BC8_BioRED_Task1_Doc230	136	146	thrombotic	Disease	D013927	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
BC8_BioRED_Task1_Doc230	157	165	patients	OrganismTaxon	9606	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
BC8_BioRED_Task1_Doc230	171	180	arthritis	Disease	D001168	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
BC8_BioRED_Task1_Doc230	239	249	thrombotic	Disease	D013927	There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc230	276	298	cyclooxygenase (COX)-2	Gene	5743	There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc230	337	372	nonsteroidal antiinflammatory drugs	Chemical	D000894	There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc230	374	380	NSAIDs	Chemical	D000894	There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc230	426	436	valdecoxib	Chemical	C406224	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
BC8_BioRED_Task1_Doc230	444	449	COX-2	Gene	5743	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
BC8_BioRED_Task1_Doc230	491	499	patients	OrganismTaxon	9606	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
BC8_BioRED_Task1_Doc230	505	519	osteoarthritis	Disease	D010003	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
BC8_BioRED_Task1_Doc230	524	544	rheumatoid arthritis	Disease	D001172	We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
BC8_BioRED_Task1_Doc230	632	642	thrombotic	Disease	D013927	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	713	723	thrombotic	Disease	D013927	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	760	770	valdecoxib	Chemical	C406224	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	802	807	NSAID	Chemical	D000894	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	809	819	diclofenac	Chemical	D004008	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	831	840	ibuprofen	Chemical	D007052	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	856	864	naproxen	Chemical	D009288	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	913	927	osteoarthritis	Disease	D010003	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	932	952	rheumatoid arthritis	Disease	D001172	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
BC8_BioRED_Task1_Doc230	1047	1055	patients	OrganismTaxon	9606	The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
BC8_BioRED_Task1_Doc230	1113	1120	aspirin	Chemical	D001241	The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
BC8_BioRED_Task1_Doc230	1148	1155	aspirin	Chemical	D001241	The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
BC8_BioRED_Task1_Doc230	1210	1220	thrombotic	Disease	D013927	Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.
BC8_BioRED_Task1_Doc230	1245	1255	valdecoxib	Chemical	C406224	Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.
BC8_BioRED_Task1_Doc230	1257	1263	NSAIDs	Chemical	D000894	Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.
BC8_BioRED_Task1_Doc230	1298	1308	thrombotic	Disease	D013927	The risk of serious thrombotic events was also similar for each valdecoxib dose.
BC8_BioRED_Task1_Doc230	1342	1352	valdecoxib	Chemical	C406224	The risk of serious thrombotic events was also similar for each valdecoxib dose.
BC8_BioRED_Task1_Doc230	1359	1369	Thrombotic	Disease	D013927	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
BC8_BioRED_Task1_Doc230	1412	1419	aspirin	Chemical	D001241	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
BC8_BioRED_Task1_Doc230	1443	1450	aspirin	Chemical	D001241	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
BC8_BioRED_Task1_Doc230	1474	1484	valdecoxib	Chemical	C406224	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
BC8_BioRED_Task1_Doc230	1501	1507	NSAIDs	Chemical	D000894	Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
BC8_BioRED_Task1_Doc230	1557	1564	aspirin	Chemical	D001241	The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.
BC8_BioRED_Task1_Doc230	1616	1626	valdecoxib	Chemical	C406224	The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses.
BC8_BioRED_Task1_Doc230	1751	1761	valdecoxib	Chemical	C406224	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
BC8_BioRED_Task1_Doc230	1818	1828	thrombotic	Disease	D013927	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
BC8_BioRED_Task1_Doc230	1861	1867	NSAIDs	Chemical	D000894	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
BC8_BioRED_Task1_Doc230	1882	1896	osteoarthritis	Disease	D010003	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
BC8_BioRED_Task1_Doc230	1901	1921	rheumatoid arthritis	Disease	D001172	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
BC8_BioRED_Task1_Doc230	1922	1930	patients	OrganismTaxon	9606	Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.
BC8_BioRED_Task1_Doc231	4	25	glycine transporter-1	Gene	14664	The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
BC8_BioRED_Task1_Doc231	36	45	SSR103800	Chemical	-	The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
BC8_BioRED_Task1_Doc231	132	136	mice	OrganismTaxon	10090	The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
BC8_BioRED_Task1_Doc231	138	151	Schizophrenia	Disease	D012559	Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.
BC8_BioRED_Task1_Doc231	202	210	dopamine	Chemical	D004298	Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.
BC8_BioRED_Task1_Doc231	279	325	glutamate N-methyl-D-aspartate (NMDA) receptor	Gene	14810	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
BC8_BioRED_Task1_Doc231	334	347	schizophrenic	Disease	D012559	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
BC8_BioRED_Task1_Doc231	365	371	humans	OrganismTaxon	9606	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
BC8_BioRED_Task1_Doc231	448	461	NMDA receptor	Gene	14810	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
BC8_BioRED_Task1_Doc231	667	680	NMDA receptor	Gene	14810	As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.
BC8_BioRED_Task1_Doc231	697	718	glycine transporter-1	Gene	14664	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.
BC8_BioRED_Task1_Doc231	720	725	GlyT1	Gene	14664	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.
BC8_BioRED_Task1_Doc231	746	755	SSR103800	Chemical	-	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.
BC8_BioRED_Task1_Doc231	782	795	NMDA receptor	Gene	14810	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.
BC8_BioRED_Task1_Doc231	823	830	glycine	Chemical	D005998	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.
BC8_BioRED_Task1_Doc231	853	866	NMDA receptor	Gene	14810	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.
BC8_BioRED_Task1_Doc231	972	981	SSR103800	Chemical	-	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1020	1033	hyperactivity	Disease	D006948	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1072	1083	amphetamine	Chemical	D000661	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1088	1094	MK-801	Chemical	D016291	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1110	1114	mice	OrganismTaxon	10090	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1120	1128	NMDA Nr1	Gene	14810	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1141	1144	DAT	Gene	13162	This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
BC8_BioRED_Task1_Doc231	1172	1181	SSR103800	Chemical	-	Results showed that SSR103800 (10-30 mg/kg p.o.)
BC8_BioRED_Task1_Doc231	1209	1222	hyperactivity	Disease	D006948	blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
BC8_BioRED_Task1_Doc231	1254	1267	NMDA receptor	Gene	14810	blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
BC8_BioRED_Task1_Doc231	1280	1286	MK-801	Chemical	D016291	blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
BC8_BioRED_Task1_Doc231	1322	1335	hyperactivity	Disease	D006948	blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
BC8_BioRED_Task1_Doc231	1339	1347	NMDA Nr1	Gene	14810	blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
BC8_BioRED_Task1_Doc231	1356	1360	mice	OrganismTaxon	10090	blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
BC8_BioRED_Task1_Doc231	1375	1384	SSR103800	Chemical	-	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
BC8_BioRED_Task1_Doc231	1402	1415	hyperactivity	Disease	D006948	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
BC8_BioRED_Task1_Doc231	1427	1438	amphetamine	Chemical	D000661	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
BC8_BioRED_Task1_Doc231	1464	1484	dopamine transporter	Gene	13162	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
BC8_BioRED_Task1_Doc231	1486	1489	DAT	Gene	13162	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
BC8_BioRED_Task1_Doc231	1505	1509	mice	OrganismTaxon	10090	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
BC8_BioRED_Task1_Doc231	1559	1570	haloperidol	Chemical	D006220	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
BC8_BioRED_Task1_Doc231	1586	1596	olanzapine	Chemical	C076029	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
BC8_BioRED_Task1_Doc231	1598	1607	clozapine	Chemical	D003024	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
BC8_BioRED_Task1_Doc231	1612	1624	aripiprazole	Chemical	C094645	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
BC8_BioRED_Task1_Doc231	1679	1692	hyperactivity	Disease	D006948	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
BC8_BioRED_Task1_Doc231	1724	1733	SSR103800	Chemical	-	However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.
BC8_BioRED_Task1_Doc231	1750	1759	catalepsy	Disease	D002375	However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.
BC8_BioRED_Task1_Doc231	1846	1851	GlyT1	Gene	14664	Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.
BC8_BioRED_Task1_Doc231	1863	1872	SSR103800	Chemical	-	Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.
BC8_BioRED_Task1_Doc231	1983	1995	dopaminergic	Chemical	D004298	Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.
BC8_BioRED_Task1_Doc232	10	21	hypothermia	Disease	D007036	Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure.
BC8_BioRED_Task1_Doc232	50	64	cerebral edema	Disease	D001929	Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure.
BC8_BioRED_Task1_Doc232	69	94	intracranial hypertension	Disease	D019586	Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure.
BC8_BioRED_Task1_Doc232	111	136	fulminant hepatic failure	Disease	D017114	Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure.
BC8_BioRED_Task1_Doc232	196	204	patients	OrganismTaxon	9606	BACKGROUND: To review evidence-based treatment options in patients with cerebral edema complicating fulminant hepatic failure (FHF) and discuss the potential applications of hypothermia.
BC8_BioRED_Task1_Doc232	210	224	cerebral edema	Disease	D001929	BACKGROUND: To review evidence-based treatment options in patients with cerebral edema complicating fulminant hepatic failure (FHF) and discuss the potential applications of hypothermia.
BC8_BioRED_Task1_Doc232	238	263	fulminant hepatic failure	Disease	D017114	BACKGROUND: To review evidence-based treatment options in patients with cerebral edema complicating fulminant hepatic failure (FHF) and discuss the potential applications of hypothermia.
BC8_BioRED_Task1_Doc232	265	268	FHF	Disease	D017114	BACKGROUND: To review evidence-based treatment options in patients with cerebral edema complicating fulminant hepatic failure (FHF) and discuss the potential applications of hypothermia.
BC8_BioRED_Task1_Doc232	312	323	hypothermia	Disease	D007036	BACKGROUND: To review evidence-based treatment options in patients with cerebral edema complicating fulminant hepatic failure (FHF) and discuss the potential applications of hypothermia.
BC8_BioRED_Task1_Doc232	456	459	FHF	Disease	D017114	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
BC8_BioRED_Task1_Doc232	465	478	acetaminophen	Chemical	D000082	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
BC8_BioRED_Task1_Doc232	493	507	cerebral edema	Disease	D001929	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
BC8_BioRED_Task1_Doc232	522	529	patient	OrganismTaxon	9606	RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period.
BC8_BioRED_Task1_Doc232	600	608	toxicity	Disease	D064420	RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period.
BC8_BioRED_Task1_Doc232	614	627	acetaminophen	Chemical	D000082	RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period.
BC8_BioRED_Task1_Doc232	672	679	patient	OrganismTaxon	9606	The patient had depressed of mental status lasting at least 24 h prior to admission.
BC8_BioRED_Task1_Doc232	684	693	depressed	Disease	D003866	The patient had depressed of mental status lasting at least 24 h prior to admission.
BC8_BioRED_Task1_Doc232	782	785	FHF	Disease	D017114	Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
BC8_BioRED_Task1_Doc232	791	804	acetaminophen	Chemical	D000082	Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
BC8_BioRED_Task1_Doc232	809	823	cerebral edema	Disease	D001929	Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
BC8_BioRED_Task1_Doc232	829	836	patient	OrganismTaxon	9606	The patient was treated with hyperosmolar therapy, hyperventilation, sedation, and chemical paralysis.
BC8_BioRED_Task1_Doc232	876	892	hyperventilation	Disease	D006985	The patient was treated with hyperosmolar therapy, hyperventilation, sedation, and chemical paralysis.
BC8_BioRED_Task1_Doc232	917	926	paralysis	Disease	D010243	The patient was treated with hyperosmolar therapy, hyperventilation, sedation, and chemical paralysis.
BC8_BioRED_Task1_Doc232	1035	1046	hypothermia	Disease	D007036	We then initiated therapeutic hypothermia which was continued for 5 days.
BC8_BioRED_Task1_Doc232	1094	1101	patient	OrganismTaxon	9606	At re-warming, patient had resolution of her cerebral edema and intracranial hypertension.
BC8_BioRED_Task1_Doc232	1124	1138	cerebral edema	Disease	D001929	At re-warming, patient had resolution of her cerebral edema and intracranial hypertension.
BC8_BioRED_Task1_Doc232	1143	1168	intracranial hypertension	Disease	D019586	At re-warming, patient had resolution of her cerebral edema and intracranial hypertension.
BC8_BioRED_Task1_Doc232	1264	1272	patients	OrganismTaxon	9606	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
BC8_BioRED_Task1_Doc232	1278	1281	FHF	Disease	D017114	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
BC8_BioRED_Task1_Doc232	1286	1300	cerebral edema	Disease	D001929	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
BC8_BioRED_Task1_Doc232	1306	1319	acetaminophen	Chemical	D000082	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
BC8_BioRED_Task1_Doc232	1352	1363	hypothermia	Disease	D007036	CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
BC8_BioRED_Task1_Doc232	1486	1497	hypothermia	Disease	D007036	A clinical trial of hypothermia in patients with this condition is warranted.
BC8_BioRED_Task1_Doc232	1501	1509	patients	OrganismTaxon	9606	A clinical trial of hypothermia in patients with this condition is warranted.
BC8_BioRED_Task1_Doc233	0	5	FGFR2	Gene	14183	FGFR2 is required for airway basal cell self-renewal and terminal differentiation.
BC8_BioRED_Task1_Doc233	287	293	cancer	Disease	D009369	Mutations in the molecular regulators of these processes may drive cancer or degenerative disease, but are also potential therapeutic targets.
BC8_BioRED_Task1_Doc233	297	317	degenerative disease	Disease	D019636	Mutations in the molecular regulators of these processes may drive cancer or degenerative disease, but are also potential therapeutic targets.
BC8_BioRED_Task1_Doc233	398	412	FGF receptor 2	Gene	14183	Conditionally deleting one copy of FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation phenotypes.
BC8_BioRED_Task1_Doc233	414	419	FGFR2	Gene	14183	Conditionally deleting one copy of FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation phenotypes.
BC8_BioRED_Task1_Doc233	430	435	mouse	OrganismTaxon	10090	Conditionally deleting one copy of FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation phenotypes.
BC8_BioRED_Task1_Doc233	524	529	FGFR2	Gene	14183	We show that FGFR2 signalling correlates with maintenance of expression of a key transcription factor for basal cell self-renewal and differentiation: SOX2.
BC8_BioRED_Task1_Doc233	662	666	SOX2	Gene	20674	We show that FGFR2 signalling correlates with maintenance of expression of a key transcription factor for basal cell self-renewal and differentiation: SOX2.
BC8_BioRED_Task1_Doc233	731	755	receptor tyrosine kinase	Gene	14183	This heterozygous phenotype illustrates that subtle changes in receptor tyrosine kinase signalling can have significant effects, perhaps providing an explanation for the numerous changes seen in cancer.
BC8_BioRED_Task1_Doc233	863	869	cancer	Disease	D009369	This heterozygous phenotype illustrates that subtle changes in receptor tyrosine kinase signalling can have significant effects, perhaps providing an explanation for the numerous changes seen in cancer.
BC8_BioRED_Task1_Doc234	53	58	CASP8	Gene	841	The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck.
BC8_BioRED_Task1_Doc234	112	156	squamous cell carcinoma of the head and neck	Disease	D000077195	The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck.
BC8_BioRED_Task1_Doc234	158	167	Caspase 8	Gene	841	Caspase 8 (CASP8) is an apoptosis-related cysteine peptidase involved in the death receptor pathway and likely in the mitochondrial pathway.
BC8_BioRED_Task1_Doc234	169	174	CASP8	Gene	841	Caspase 8 (CASP8) is an apoptosis-related cysteine peptidase involved in the death receptor pathway and likely in the mitochondrial pathway.
BC8_BioRED_Task1_Doc234	301	306	CASP8	Gene	841	A CASP8 promoter region six-nucleotide deletion/insertion (-652 6N ins/del) variant and a coding region D302H polymorphism are reportedly important in cancer development, but no reported study has assessed the associations of these genetic variations with risk of head and neck cancer.
BC8_BioRED_Task1_Doc234	358	373	-652 6N ins/del	SequenceVariant	c|INDEL|-652|6	A CASP8 promoter region six-nucleotide deletion/insertion (-652 6N ins/del) variant and a coding region D302H polymorphism are reportedly important in cancer development, but no reported study has assessed the associations of these genetic variations with risk of head and neck cancer.
BC8_BioRED_Task1_Doc234	403	408	D302H	SequenceVariant	rs1045485	A CASP8 promoter region six-nucleotide deletion/insertion (-652 6N ins/del) variant and a coding region D302H polymorphism are reportedly important in cancer development, but no reported study has assessed the associations of these genetic variations with risk of head and neck cancer.
BC8_BioRED_Task1_Doc234	450	456	cancer	Disease	D009369	A CASP8 promoter region six-nucleotide deletion/insertion (-652 6N ins/del) variant and a coding region D302H polymorphism are reportedly important in cancer development, but no reported study has assessed the associations of these genetic variations with risk of head and neck cancer.
BC8_BioRED_Task1_Doc234	563	583	head and neck cancer	Disease	D006258	A CASP8 promoter region six-nucleotide deletion/insertion (-652 6N ins/del) variant and a coding region D302H polymorphism are reportedly important in cancer development, but no reported study has assessed the associations of these genetic variations with risk of head and neck cancer.
BC8_BioRED_Task1_Doc234	648	653	CASP8	Gene	841	In a hospital-based study of non-Hispanic whites, we genotyped CASP8 -652 6N del and 302H variants in 1,023 patients with squamous cell carcinoma of the head and neck (SCCHN) and 1,052 cancer-free controls.
BC8_BioRED_Task1_Doc234	654	665	-652 6N del	SequenceVariant	c|DEL|-652|6	In a hospital-based study of non-Hispanic whites, we genotyped CASP8 -652 6N del and 302H variants in 1,023 patients with squamous cell carcinoma of the head and neck (SCCHN) and 1,052 cancer-free controls.
BC8_BioRED_Task1_Doc234	670	674	302H	SequenceVariant	rs1045485	In a hospital-based study of non-Hispanic whites, we genotyped CASP8 -652 6N del and 302H variants in 1,023 patients with squamous cell carcinoma of the head and neck (SCCHN) and 1,052 cancer-free controls.
BC8_BioRED_Task1_Doc234	693	701	patients	OrganismTaxon	9606	In a hospital-based study of non-Hispanic whites, we genotyped CASP8 -652 6N del and 302H variants in 1,023 patients with squamous cell carcinoma of the head and neck (SCCHN) and 1,052 cancer-free controls.
BC8_BioRED_Task1_Doc234	707	751	squamous cell carcinoma of the head and neck	Disease	D000077195	In a hospital-based study of non-Hispanic whites, we genotyped CASP8 -652 6N del and 302H variants in 1,023 patients with squamous cell carcinoma of the head and neck (SCCHN) and 1,052 cancer-free controls.
BC8_BioRED_Task1_Doc234	753	758	SCCHN	Disease	D000077195	In a hospital-based study of non-Hispanic whites, we genotyped CASP8 -652 6N del and 302H variants in 1,023 patients with squamous cell carcinoma of the head and neck (SCCHN) and 1,052 cancer-free controls.
BC8_BioRED_Task1_Doc234	929	934	CASP8	Gene	841	The CASP8 -652 6N del variant genotypes or haplotypes were inversely associated with SCCHN risk (adjusted OR, 0.70; 95% CI, 0.57-0.85 for the ins/del + del/del genotypes compared with the ins/ins genotype; adjusted OR, 0.73; 95% CI, 0.55-0.97 for the del-D haplotype compared with the ins-D haplotype).
BC8_BioRED_Task1_Doc234	935	946	-652 6N del	SequenceVariant	c|DEL|-652|6	The CASP8 -652 6N del variant genotypes or haplotypes were inversely associated with SCCHN risk (adjusted OR, 0.70; 95% CI, 0.57-0.85 for the ins/del + del/del genotypes compared with the ins/ins genotype; adjusted OR, 0.73; 95% CI, 0.55-0.97 for the del-D haplotype compared with the ins-D haplotype).
BC8_BioRED_Task1_Doc234	1010	1015	SCCHN	Disease	D000077195	The CASP8 -652 6N del variant genotypes or haplotypes were inversely associated with SCCHN risk (adjusted OR, 0.70; 95% CI, 0.57-0.85 for the ins/del + del/del genotypes compared with the ins/ins genotype; adjusted OR, 0.73; 95% CI, 0.55-0.97 for the del-D haplotype compared with the ins-D haplotype).
BC8_BioRED_Task1_Doc234	1259	1264	CASP8	Gene	841	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.
BC8_BioRED_Task1_Doc234	1265	1276	-652 6N del	SequenceVariant	c|DEL|-652|6	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.
BC8_BioRED_Task1_Doc234	1286	1290	302H	SequenceVariant	rs1045485	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.
BC8_BioRED_Task1_Doc234	1352	1364	camptothecin	Chemical	D002166	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.
BC8_BioRED_Task1_Doc234	1373	1376	p53	Gene	7157	Furthermore, the number of the CASP8 -652 6N del (but not 302H) variant allele tended to correlate with increased levels of camptothecin-induced p53-mediated apoptosis in T lymphocytes from 170 cancer-free controls.
BC8_BioRED_Task1_Doc234	1466	1471	CASP8	Gene	841	We concluded that the CASP8 -652 6N del variant allele may contribute to the risk of developing SCCHN in non-Hispanic white populations.
BC8_BioRED_Task1_Doc234	1472	1483	-652 6N del	SequenceVariant	c|DEL|-652|6	We concluded that the CASP8 -652 6N del variant allele may contribute to the risk of developing SCCHN in non-Hispanic white populations.
BC8_BioRED_Task1_Doc234	1540	1545	SCCHN	Disease	D000077195	We concluded that the CASP8 -652 6N del variant allele may contribute to the risk of developing SCCHN in non-Hispanic white populations.
BC8_BioRED_Task1_Doc235	22	38	COX-2 inhibitors	Chemical	D052246	Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit?
BC8_BioRED_Task1_Doc235	56	62	NSAIDs	Chemical	D000894	Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit?
BC8_BioRED_Task1_Doc235	188	215	acute myocardial infarction	Disease	D009203	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc235	217	220	AMI	Disease	D009203	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc235	227	243	COX-2 inhibitors	Chemical	D052246	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc235	324	361	non-steroidal anti-inflammatory drugs	Chemical	D000894	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc235	363	369	NSAIDs	Chemical	D000894	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
BC8_BioRED_Task1_Doc235	425	428	AMI	Disease	D009203	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
BC8_BioRED_Task1_Doc235	433	444	GI bleeding	Disease	D006471	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
BC8_BioRED_Task1_Doc235	459	467	patients	OrganismTaxon	9606	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
BC8_BioRED_Task1_Doc235	474	490	COX-2 inhibitors	Chemical	D052246	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
BC8_BioRED_Task1_Doc235	495	501	NSAIDs	Chemical	D000894	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
BC8_BioRED_Task1_Doc235	506	519	acetaminophen	Chemical	D000082	We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
BC8_BioRED_Task1_Doc235	601	609	patients	OrganismTaxon	9606	METHODS: We conducted a retrospective cohort study using administrative data of patients > or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002.
BC8_BioRED_Task1_Doc235	662	667	NSAID	Chemical	D000894	METHODS: We conducted a retrospective cohort study using administrative data of patients > or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002.
BC8_BioRED_Task1_Doc235	671	684	acetaminophen	Chemical	D000082	METHODS: We conducted a retrospective cohort study using administrative data of patients > or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002.
BC8_BioRED_Task1_Doc235	838	845	aspirin	Chemical	D001241	RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.
BC8_BioRED_Task1_Doc235	862	875	acetaminophen	Chemical	D000082	RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.
BC8_BioRED_Task1_Doc235	887	896	rofecoxib	Chemical	C116926	RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.
BC8_BioRED_Task1_Doc235	907	916	celecoxib	Chemical	C105934	RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.
BC8_BioRED_Task1_Doc235	935	941	NSAIDs	Chemical	D000894	RESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs.
BC8_BioRED_Task1_Doc235	958	965	aspirin	Chemical	D001241	Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.
BC8_BioRED_Task1_Doc235	988	997	rofecoxib	Chemical	C116926	Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.
BC8_BioRED_Task1_Doc235	1009	1018	celecoxib	Chemical	C105934	Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.
BC8_BioRED_Task1_Doc235	1032	1038	NSAIDs	Chemical	D000894	Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.
BC8_BioRED_Task1_Doc235	1053	1066	acetaminophen	Chemical	D000082	Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen.
BC8_BioRED_Task1_Doc235	1087	1094	aspirin	Chemical	D001241	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1172	1175	AMI	Disease	D009203	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1186	1199	acetaminophen	Chemical	D000082	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1209	1216	aspirin	Chemical	D001241	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1230	1239	rofecoxib	Chemical	C116926	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1259	1268	celecoxib	Chemical	C105934	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1288	1296	naproxen	Chemical	D009288	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1316	1326	diclofenac	Chemical	D004008	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1349	1358	ibuprofen	Chemical	D007052	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
BC8_BioRED_Task1_Doc235	1393	1400	aspirin	Chemical	D001241	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1413	1422	rofecoxib	Chemical	C116926	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1442	1451	celecoxib	Chemical	C105934	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1471	1480	ibuprofen	Chemical	D007052	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1500	1510	diclofenac	Chemical	D004008	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1530	1538	naproxen	Chemical	D009288	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1561	1574	acetaminophen	Chemical	D000082	Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).
BC8_BioRED_Task1_Doc235	1625	1632	aspirin	Chemical	D001241	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
BC8_BioRED_Task1_Doc235	1634	1642	naproxen	Chemical	D009288	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
BC8_BioRED_Task1_Doc235	1680	1683	AMI	Disease	D009203	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
BC8_BioRED_Task1_Doc235	1684	1695	GI bleeding	Disease	D006471	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
BC8_BioRED_Task1_Doc235	1701	1704	AMI	Disease	D009203	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
BC8_BioRED_Task1_Doc235	1705	1716	GI toxicity	Disease	D005767	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
BC8_BioRED_Task1_Doc235	1720	1729	celecoxib	Chemical	C105934	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
BC8_BioRED_Task1_Doc235	1753	1766	acetaminophen	Chemical	D000082	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
BC8_BioRED_Task1_Doc235	1805	1814	rofecoxib	Chemical	C116926	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
BC8_BioRED_Task1_Doc235	1822	1828	NSAIDs	Chemical	D000894	The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
BC8_BioRED_Task1_Doc235	1845	1852	aspirin	Chemical	D001241	Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic.
BC8_BioRED_Task1_Doc235	1859	1868	celecoxib	Chemical	C105934	Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic.
BC8_BioRED_Task1_Doc235	1873	1881	naproxen	Chemical	D009288	Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic.
BC8_BioRED_Task1_Doc236	0	9	Cisplatin	Chemical	D002945	Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
BC8_BioRED_Task1_Doc236	61	64	TLR	Gene	13982	Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
BC8_BioRED_Task1_Doc236	105	110	IL-10	Gene	16153	Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
BC8_BioRED_Task1_Doc236	203	212	cisplatin	Chemical	D002945	Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
BC8_BioRED_Task1_Doc236	214	242	cis-diamminedichloroplatinum	Chemical	D002945	Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
BC8_BioRED_Task1_Doc236	249	253	CDDP	Chemical	D002945	Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
BC8_BioRED_Task1_Doc236	277	283	cancer	Disease	D009369	Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
BC8_BioRED_Task1_Doc236	323	332	cisplatin	Chemical	D002945	Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood.
BC8_BioRED_Task1_Doc236	462	471	cisplatin	Chemical	D002945	Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation.
BC8_BioRED_Task1_Doc236	553	571	toll-like receptor	Gene	13982	Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation.
BC8_BioRED_Task1_Doc236	573	576	TLR	Gene	13982	Here, we investigated the effect of cisplatin on the functionality of DCs and the changes in signaling pathways activated upon toll-like receptor (TLR) stimulation.
BC8_BioRED_Task1_Doc236	591	600	Cisplatin	Chemical	D002945	Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
BC8_BioRED_Task1_Doc236	670	674	CD80	Gene	12519	Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
BC8_BioRED_Task1_Doc236	676	680	CD86	Gene	12524	Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
BC8_BioRED_Task1_Doc236	682	700	MHC class I and II	Gene	14961,14972	Cisplatin-treated DCs down-regulated the expression of cell surface molecules (CD80, CD86, MHC class I and II) and up-regulated endocytic capacity in a dose-dependent manner.
BC8_BioRED_Task1_Doc236	796	799	TLR	Gene	13982	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	810	819	cisplatin	Chemical	D002945	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	858	863	IL-10	Gene	16153	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	901	909	p38 MAPK	Gene	26416	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	914	923	NF-kappaB	Gene	18033	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	974	983	TNF-alpha	Gene	21926	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	988	996	IL-12p70	Gene	16185	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	1013	1022	cisplatin	Chemical	D002945	Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-kappaB signaling pathways without altering the levels of TNF-alpha and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
BC8_BioRED_Task1_Doc236	1109	1114	IL-10	Gene	16153	This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
BC8_BioRED_Task1_Doc236	1154	1159	IL-10	Gene	16153	This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
BC8_BioRED_Task1_Doc236	1163	1167	mice	OrganismTaxon	10090	This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
BC8_BioRED_Task1_Doc236	1172	1177	IL-10	Gene	16153	This effect was dependent on the production of IL-10 from DCs, as neither DCs isolated from IL-10-/- mice nor IL-10-neutralized DCs generated tolerogenic DCs.
BC8_BioRED_Task1_Doc236	1266	1275	cisplatin	Chemical	D002945	Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.
BC8_BioRED_Task1_Doc236	1280	1298	lipopolysaccharide	Chemical	D008070	Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.
BC8_BioRED_Task1_Doc236	1300	1303	LPS	Chemical	D008070	Interestingly, DCs that were co-treated with cisplatin and lipopolysaccharide (LPS) exhibited a decreased immunostimulatory capacity for inducing the proliferation of Th1- and Th17-type T cells; instead, these DCs contributed to Th2-type T cell immunity.
BC8_BioRED_Task1_Doc236	1562	1567	IL-10	Gene	16153	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1578	1581	CD3	Gene	12501	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1582	1585	CD4	Gene	12504	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1586	1591	LAG-3	Gene	16768	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1592	1597	CD49b	Gene	16398	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1598	1602	CD25	Gene	16184	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1603	1608	Foxp3	Gene	20371	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1675	1680	Foxp3	Gene	20371	Furthermore, in vitro and in vivo investigations revealed a unique T cell population, IL-10-producing CD3+CD4+LAG-3+CD49b+CD25-Foxp3- Tr1 cells, that was significantly increased without altering the Foxp3+ regulatory T cell population.
BC8_BioRED_Task1_Doc236	1753	1762	cisplatin	Chemical	D002945	Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
BC8_BioRED_Task1_Doc236	1809	1820	TLR agonist	Chemical	-	Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
BC8_BioRED_Task1_Doc236	1829	1841	inflammatory	Disease	D007249	Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
BC8_BioRED_Task1_Doc236	1866	1871	IL-10	Gene	16153	Taken together, our results suggest that cisplatin induces immune-suppressive tolerogenic DCs in TLR agonist-induced inflammatory conditions via abundant IL-10 production, thereby skewing Th cell differentiation towards Th2 and Tr1 cells.
BC8_BioRED_Task1_Doc236	1981	1987	cancer	Disease	D009369	This relationship may provide cancer cells with an opportunity to evade the immune system.
BC8_BioRED_Task1_Doc237	0	6	SLURP1	Gene	57152	SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda.
BC8_BioRED_Task1_Doc237	60	73	mal de Meleda	Disease	D007645	SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda.
BC8_BioRED_Task1_Doc237	87	100	Mal de Meleda	Disease	D007645	BACKGROUND: Mal de Meleda (MDM) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1).
BC8_BioRED_Task1_Doc237	102	105	MDM	Disease	D007645	BACKGROUND: Mal de Meleda (MDM) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1).
BC8_BioRED_Task1_Doc237	110	141	palmoplantar erythrokeratoderma	Disease	C563781	BACKGROUND: Mal de Meleda (MDM) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1).
BC8_BioRED_Task1_Doc237	231	238	SLURP-1	Gene	57152	BACKGROUND: Mal de Meleda (MDM) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1).
BC8_BioRED_Task1_Doc237	240	260	lymphocyte antigen 6	Gene	57152	BACKGROUND: Mal de Meleda (MDM) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1).
BC8_BioRED_Task1_Doc237	261	324	urokinase-type plasminogen activator receptor related protein-1	Gene	57152	BACKGROUND: Mal de Meleda (MDM) is palmoplantar erythrokeratoderma with an autosomal recessive inheritance and is caused by a mutation in the gene encoding SLURP-1 (lymphocyte antigen 6/urokinase-type plasminogen activator receptor related protein-1).
BC8_BioRED_Task1_Doc237	327	334	SLURP-1	Gene	57152	SLURP-1 is an allosteric agonist to the nicotinic acetylcholine receptor (nAchR) and it regulates epidermal homeostasis.
BC8_BioRED_Task1_Doc237	367	399	nicotinic acetylcholine receptor	Gene	1137	SLURP-1 is an allosteric agonist to the nicotinic acetylcholine receptor (nAchR) and it regulates epidermal homeostasis.
BC8_BioRED_Task1_Doc237	401	406	nAchR	Gene	1137	SLURP-1 is an allosteric agonist to the nicotinic acetylcholine receptor (nAchR) and it regulates epidermal homeostasis.
BC8_BioRED_Task1_Doc237	461	467	murine	OrganismTaxon	10090	In addition, murine studies have shown that nAchR signalling is important for the regulation of T-cell function.
BC8_BioRED_Task1_Doc237	492	497	nAchR	Gene	11441	In addition, murine studies have shown that nAchR signalling is important for the regulation of T-cell function.
BC8_BioRED_Task1_Doc237	587	595	patients	OrganismTaxon	9606	Among the family members, patients with the homozygous SLURP1 (previously known as ARS component B) mutation are prone to melanoma and viral infection, which might link to defective T-cell function as well as a derangement of epidermal homeostasis.
BC8_BioRED_Task1_Doc237	616	622	SLURP1	Gene	57152	Among the family members, patients with the homozygous SLURP1 (previously known as ARS component B) mutation are prone to melanoma and viral infection, which might link to defective T-cell function as well as a derangement of epidermal homeostasis.
BC8_BioRED_Task1_Doc237	683	691	melanoma	Disease	D008545	Among the family members, patients with the homozygous SLURP1 (previously known as ARS component B) mutation are prone to melanoma and viral infection, which might link to defective T-cell function as well as a derangement of epidermal homeostasis.
BC8_BioRED_Task1_Doc237	696	711	viral infection	Disease	D014777	Among the family members, patients with the homozygous SLURP1 (previously known as ARS component B) mutation are prone to melanoma and viral infection, which might link to defective T-cell function as well as a derangement of epidermal homeostasis.
BC8_BioRED_Task1_Doc237	860	866	SLURP1	Gene	57152	OBJECTIVES: To investigate the association of the SLURP1 gene mutation with T-cell activation in a Taiwanese family with MDM.
BC8_BioRED_Task1_Doc237	931	934	MDM	Disease	D007645	OBJECTIVES: To investigate the association of the SLURP1 gene mutation with T-cell activation in a Taiwanese family with MDM.
BC8_BioRED_Task1_Doc237	949	956	SLURP-1	Gene	57152	To test that SLURP-1 is essential for T-cell activation.
BC8_BioRED_Task1_Doc237	1002	1007	Human	OrganismTaxon	9606	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1082	1085	MDM	Disease	D007645	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1105	1142	G to A substitution in nucleotide 256	SequenceVariant	rs28937888	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1150	1156	SLURP1	Gene	57152	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1182	1231	glycine to arginine substitution at amino acid 86	SequenceVariant	rs28937888	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1233	1237	G86R	SequenceVariant	rs28937888	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1246	1253	SLURP-1	Gene	57152	METHODS: Human peripheral blood mononuclear cells (PBMCs) were isolated from a Taiwanese MDM family bearing the G to A substitution in nucleotide 256 in the SLURP1 gene, corresponding to a glycine to arginine substitution at amino acid 86 (G86R) in the SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1335	1338	CD3	Gene	915	PBMCs from homozygotes and wild-type controls were stimulated with anti-CD3/anti-CD28 antibodies and the level of T-cell activation was determined by the stimulation index.
BC8_BioRED_Task1_Doc237	1344	1348	CD28	Gene	940	PBMCs from homozygotes and wild-type controls were stimulated with anti-CD3/anti-CD28 antibodies and the level of T-cell activation was determined by the stimulation index.
BC8_BioRED_Task1_Doc237	1488	1495	SLURP-1	Gene	57152	RESULTS: PBMCs with the heterozygous and homozygous SLURP-1 G86R mutation had defective T-cell activation.
BC8_BioRED_Task1_Doc237	1496	1500	G86R	SequenceVariant	rs28937888	RESULTS: PBMCs with the heterozygous and homozygous SLURP-1 G86R mutation had defective T-cell activation.
BC8_BioRED_Task1_Doc237	1606	1611	human	OrganismTaxon	9606	This was restored by the addition of 0 5 ug mL(-1) recombinant human SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1612	1619	SLURP-1	Gene	57152	This was restored by the addition of 0 5 ug mL(-1) recombinant human SLURP-1 protein.
BC8_BioRED_Task1_Doc237	1642	1650	Patients	OrganismTaxon	9606	CONCLUSIONS: Patients with MDM with the homozygous SLURP-1 G86R mutation may have an impaired T-cell activation.
BC8_BioRED_Task1_Doc237	1656	1659	MDM	Disease	D007645	CONCLUSIONS: Patients with MDM with the homozygous SLURP-1 G86R mutation may have an impaired T-cell activation.
BC8_BioRED_Task1_Doc237	1680	1687	SLURP-1	Gene	57152	CONCLUSIONS: Patients with MDM with the homozygous SLURP-1 G86R mutation may have an impaired T-cell activation.
BC8_BioRED_Task1_Doc237	1688	1692	G86R	SequenceVariant	rs28937888	CONCLUSIONS: Patients with MDM with the homozygous SLURP-1 G86R mutation may have an impaired T-cell activation.
BC8_BioRED_Task1_Doc237	1768	1775	SLURP-1	Gene	57152	The presence of wild-type SLURP-1 is essential for normal T-cell activation.
BC8_BioRED_Task1_Doc238	56	83	Aristaless-related homeobox	Gene	170302	Screening and cell-based assessment of mutations in the Aristaless-related homeobox (ARX) gene.
BC8_BioRED_Task1_Doc238	85	88	ARX	Gene	170302	Screening and cell-based assessment of mutations in the Aristaless-related homeobox (ARX) gene.
BC8_BioRED_Task1_Doc238	96	99	ARX	Gene	170302	ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID).
BC8_BioRED_Task1_Doc238	138	143	human	OrganismTaxon	9606	ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID).
BC8_BioRED_Task1_Doc238	175	206	brain and genital malformations	Disease	D000013	ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID).
BC8_BioRED_Task1_Doc238	224	247	intellectual disability	Disease	D008607	ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID).
BC8_BioRED_Task1_Doc238	249	251	ID	Disease	D008607	ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID).
BC8_BioRED_Task1_Doc238	254	257	ARX	Gene	170302	ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations.
BC8_BioRED_Task1_Doc238	324	335	polyalanine	Chemical	C019529	ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations.
BC8_BioRED_Task1_Doc238	337	339	pA	Chemical	C019529	ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations.
BC8_BioRED_Task1_Doc238	474	476	ID	Disease	D008607	We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2).
BC8_BioRED_Task1_Doc238	509	512	ARX	Gene	170302	We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2).
BC8_BioRED_Task1_Doc238	524	540	c.304ins(GCG)(7)	SequenceVariant	c|INS|304|GCG(7)	We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2).
BC8_BioRED_Task1_Doc238	563	575	c.429_452dup	SequenceVariant	c|DUP|429_452||	We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2).
BC8_BioRED_Task1_Doc238	577	584	dup24bp	SequenceVariant	c|DUP||24|	We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2).
BC8_BioRED_Task1_Doc238	660	663	ARX	Gene	170302	Five hundred samples without pA1 or pA2 mutations had the entire ARX ORF screened by single stranded polymorphism conformation (SSCP) and/or denaturing high pressure liquid chromatography (dHPLC) analysis.
BC8_BioRED_Task1_Doc238	847	850	ARX	Gene	170302	Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T).
BC8_BioRED_Task1_Doc238	971	978	dup24bp	SequenceVariant	c|DUP||24|	Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T).
BC8_BioRED_Task1_Doc238	1016	1023	dup24bp	SequenceVariant	c|DUP||24|	Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T).
BC8_BioRED_Task1_Doc238	1045	1052	dup27bp	SequenceVariant	c|DUP||27|	Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T).
BC8_BioRED_Task1_Doc238	1054	1061	dup33bp	SequenceVariant	c|DUP||33|	Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T).
BC8_BioRED_Task1_Doc238	1147	1156	c.1074G>T	SequenceVariant	c|SUB|G|1074|T	Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T).
BC8_BioRED_Task1_Doc238	1197	1200	ARX	Gene	170302	Four ultraconserved regions distal to ARX (uc466-469) were also screened in a subset of 94 patients, with three unique nucleotide changes identified in two (uc466, uc467).
BC8_BioRED_Task1_Doc238	1250	1258	patients	OrganismTaxon	9606	Four ultraconserved regions distal to ARX (uc466-469) were also screened in a subset of 94 patients, with three unique nucleotide changes identified in two (uc466, uc467).
BC8_BioRED_Task1_Doc238	1375	1378	ARX	Gene	170302	The subcellular localization of full length ARX proteins was assessed for 11 variants.
BC8_BioRED_Task1_Doc239	0	44	Ectodermal dysplasia-skin fragility syndrome	Disease	C536183	Ectodermal dysplasia-skin fragility syndrome resulting from a new homozygous mutation, 888delC, in the desmosomal protein plakophilin 1.
BC8_BioRED_Task1_Doc239	87	94	888delC	SequenceVariant	c|DEL888|C	Ectodermal dysplasia-skin fragility syndrome resulting from a new homozygous mutation, 888delC, in the desmosomal protein plakophilin 1.
BC8_BioRED_Task1_Doc239	122	135	plakophilin 1	Gene	5317	Ectodermal dysplasia-skin fragility syndrome resulting from a new homozygous mutation, 888delC, in the desmosomal protein plakophilin 1.
BC8_BioRED_Task1_Doc239	169	187	inherited disorder	Disease	D030342	We report an unusual case of an inherited disorder of the desmosomal protein plakophilin 1, resulting in ectodermal dysplasia-skin fragility syndrome.
BC8_BioRED_Task1_Doc239	214	227	plakophilin 1	Gene	5317	We report an unusual case of an inherited disorder of the desmosomal protein plakophilin 1, resulting in ectodermal dysplasia-skin fragility syndrome.
BC8_BioRED_Task1_Doc239	242	286	ectodermal dysplasia-skin fragility syndrome	Disease	C536183	We report an unusual case of an inherited disorder of the desmosomal protein plakophilin 1, resulting in ectodermal dysplasia-skin fragility syndrome.
BC8_BioRED_Task1_Doc239	365	379	skin fragility	Disease	C536183	The affected 6-year-old boy had red skin at birth and subsequently developed skin fragility, progressive plantar keratoderma, nail dystrophy, and alopecia.
BC8_BioRED_Task1_Doc239	393	412	plantar keratoderma	Disease	D017499	The affected 6-year-old boy had red skin at birth and subsequently developed skin fragility, progressive plantar keratoderma, nail dystrophy, and alopecia.
BC8_BioRED_Task1_Doc239	414	428	nail dystrophy	Disease	D009260	The affected 6-year-old boy had red skin at birth and subsequently developed skin fragility, progressive plantar keratoderma, nail dystrophy, and alopecia.
BC8_BioRED_Task1_Doc239	434	442	alopecia	Disease	D000505	The affected 6-year-old boy had red skin at birth and subsequently developed skin fragility, progressive plantar keratoderma, nail dystrophy, and alopecia.
BC8_BioRED_Task1_Doc239	597	610	plakophilin 1	Gene	5317	Mutation analysis of the plakophilin 1 gene PKP1 revealed a homozygous deletion of C at nucleotide 888 within exon 5.
BC8_BioRED_Task1_Doc239	616	620	PKP1	Gene	5317	Mutation analysis of the plakophilin 1 gene PKP1 revealed a homozygous deletion of C at nucleotide 888 within exon 5.
BC8_BioRED_Task1_Doc239	643	674	deletion of C at nucleotide 888	SequenceVariant	c|DEL888|C	Mutation analysis of the plakophilin 1 gene PKP1 revealed a homozygous deletion of C at nucleotide 888 within exon 5.
BC8_BioRED_Task1_Doc239	721	725	PKP1	Gene	5317	This mutation differs from the PKP1 gene pathology reported in 8 previously published individuals with this rare genodermatosis.
BC8_BioRED_Task1_Doc239	803	817	genodermatosis	Disease	D012873	This mutation differs from the PKP1 gene pathology reported in 8 previously published individuals with this rare genodermatosis.
BC8_BioRED_Task1_Doc239	912	925	plakophilin 1	Gene	5317	However, all cases show similar clinical features, highlighting the importance of functional plakophilin 1 in maintaining desmosomal adhesion in skin, as well as the role of this protein in aspects of ectodermal development.
BC8_BioRED_Task1_Doc240	52	58	BMPR1A	Gene	657	A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis.
BC8_BioRED_Task1_Doc240	67	85	juvenile polyposis	Disease	C537702	A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis.
BC8_BioRED_Task1_Doc240	128	134	BMPR1A	Gene	657	We describe a novel germline mutation of BMPR1A in a family with juvenile polyposis and colon cancer.
BC8_BioRED_Task1_Doc240	152	170	juvenile polyposis	Disease	C537702	We describe a novel germline mutation of BMPR1A in a family with juvenile polyposis and colon cancer.
BC8_BioRED_Task1_Doc240	175	187	colon cancer	Disease	D003110	We describe a novel germline mutation of BMPR1A in a family with juvenile polyposis and colon cancer.
BC8_BioRED_Task1_Doc240	246	257	735-6 TG>AT	SequenceVariant	c|SUB|TG|735_736|AT	This mutation consists of two consecutive substitutions (735-6 TG>AT) that cause two nonsense mutations (Y245X, G246X), inherited in an autosomal dominant fashion, on one parental chromosome.
BC8_BioRED_Task1_Doc240	294	299	Y245X	SequenceVariant	p|SUB|Y|245|X	This mutation consists of two consecutive substitutions (735-6 TG>AT) that cause two nonsense mutations (Y245X, G246X), inherited in an autosomal dominant fashion, on one parental chromosome.
BC8_BioRED_Task1_Doc240	301	306	G246X	SequenceVariant	p|SUB|G|246|X	This mutation consists of two consecutive substitutions (735-6 TG>AT) that cause two nonsense mutations (Y245X, G246X), inherited in an autosomal dominant fashion, on one parental chromosome.
BC8_BioRED_Task1_Doc240	487	492	human	OrganismTaxon	9606	This mutation caused protein truncation, and represents a novel case of consecutive nonsense mutations in human disease.
BC8_BioRED_Task1_Doc241	11	23	ginsenosides	Chemical	D036145	Effects of ginsenosides on opioid-induced hyperalgesia in mice.
BC8_BioRED_Task1_Doc241	27	33	opioid	Chemical	D000701	Effects of ginsenosides on opioid-induced hyperalgesia in mice.
BC8_BioRED_Task1_Doc241	42	54	hyperalgesia	Disease	D006930	Effects of ginsenosides on opioid-induced hyperalgesia in mice.
BC8_BioRED_Task1_Doc241	58	62	mice	OrganismTaxon	10090	Effects of ginsenosides on opioid-induced hyperalgesia in mice.
BC8_BioRED_Task1_Doc241	64	70	Opioid	Chemical	D000701	Opioid-induced hyperalgesia (OIH) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use.
BC8_BioRED_Task1_Doc241	79	91	hyperalgesia	Disease	D006930	Opioid-induced hyperalgesia (OIH) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use.
BC8_BioRED_Task1_Doc241	93	96	OIH	Disease	D006930	Opioid-induced hyperalgesia (OIH) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use.
BC8_BioRED_Task1_Doc241	179	185	opioid	Chemical	D000701	Opioid-induced hyperalgesia (OIH) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use.
BC8_BioRED_Task1_Doc241	191	194	OIH	Disease	D006930	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from opioid addiction.
BC8_BioRED_Task1_Doc241	225	231	opioid	Chemical	D000701	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from opioid addiction.
BC8_BioRED_Task1_Doc241	274	290	opioid addiction	Disease	D009293	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from opioid addiction.
BC8_BioRED_Task1_Doc241	338	367	Re, Rg1, and Rb1 ginsenosides	Chemical	C035054,C049864,C442759	In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.
BC8_BioRED_Task1_Doc241	397	404	ginseng	OrganismTaxon	4054	In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.
BC8_BioRED_Task1_Doc241	409	412	OIH	Disease	D006930	In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.
BC8_BioRED_Task1_Doc241	414	417	OIH	Disease	D006930	OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.
BC8_BioRED_Task1_Doc241	434	438	mice	OrganismTaxon	10090	OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.
BC8_BioRED_Task1_Doc241	476	484	morphine	Chemical	D009020	OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.
BC8_BioRED_Task1_Doc241	569	573	mice	OrganismTaxon	10090	During withdrawal (days 8 and 9), these mice were administered Re, Rg1, or Rb1 intragastrically two times per day.
BC8_BioRED_Task1_Doc241	592	594	Re	Chemical	C049864	During withdrawal (days 8 and 9), these mice were administered Re, Rg1, or Rb1 intragastrically two times per day.
BC8_BioRED_Task1_Doc241	596	599	Rg1	Chemical	C035054	During withdrawal (days 8 and 9), these mice were administered Re, Rg1, or Rb1 intragastrically two times per day.
BC8_BioRED_Task1_Doc241	604	607	Rb1	Chemical	C442759	During withdrawal (days 8 and 9), these mice were administered Re, Rg1, or Rb1 intragastrically two times per day.
BC8_BioRED_Task1_Doc241	670	674	mice	OrganismTaxon	10090	On the test day (day 10), mice were subjected to the thermal sensitivity test and the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	730	741	acetic acid	Chemical	D019342	On the test day (day 10), mice were subjected to the thermal sensitivity test and the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	765	767	Re	Chemical	C049864	Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	790	793	OIH	Disease	D006930	Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	839	850	acetic acid	Chemical	D019342	Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	887	911	Rg1 and Rb1 ginsenosides	Chemical	C035054,C442759	However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.
BC8_BioRED_Task1_Doc241	930	933	OIH	Disease	D006930	However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.
BC8_BioRED_Task1_Doc241	963	966	Rg1	Chemical	C035054	Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	998	1001	OIH	Disease	D006930	Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	1009	1020	acetic acid	Chemical	D019342	Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.
BC8_BioRED_Task1_Doc241	1072	1086	ginsenoside Re	Chemical	C049864	Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.
BC8_BioRED_Task1_Doc241	1096	1099	Rg1	Chemical	C035054	Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.
BC8_BioRED_Task1_Doc241	1103	1106	Rb1	Chemical	C442759	Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.
BC8_BioRED_Task1_Doc241	1142	1145	OIH	Disease	D006930	Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.
BC8_BioRED_Task1_Doc242	0	26	Nijmegen breakage syndrome	Disease	D049932	Nijmegen breakage syndrome in 13% of age-matched Czech children with primary microcephaly.
BC8_BioRED_Task1_Doc242	69	89	primary microcephaly	Disease	D008831	Nijmegen breakage syndrome in 13% of age-matched Czech children with primary microcephaly.
BC8_BioRED_Task1_Doc242	95	121	Nijmegen breakage syndrome	Disease	D049932	The Nijmegen breakage syndrome is a rare autosomal recessive chromosomal instability disorder characterized by early growth retardation, congenital microcephaly, immunodeficiency, borderline mental development, and a high tendency to lymphoreticular malignancies.
BC8_BioRED_Task1_Doc242	132	184	autosomal recessive chromosomal instability disorder	Disease	D043171	The Nijmegen breakage syndrome is a rare autosomal recessive chromosomal instability disorder characterized by early growth retardation, congenital microcephaly, immunodeficiency, borderline mental development, and a high tendency to lymphoreticular malignancies.
BC8_BioRED_Task1_Doc242	208	226	growth retardation	Disease	D006130	The Nijmegen breakage syndrome is a rare autosomal recessive chromosomal instability disorder characterized by early growth retardation, congenital microcephaly, immunodeficiency, borderline mental development, and a high tendency to lymphoreticular malignancies.
BC8_BioRED_Task1_Doc242	228	251	congenital microcephaly	Disease	D008831	The Nijmegen breakage syndrome is a rare autosomal recessive chromosomal instability disorder characterized by early growth retardation, congenital microcephaly, immunodeficiency, borderline mental development, and a high tendency to lymphoreticular malignancies.
BC8_BioRED_Task1_Doc242	253	269	immunodeficiency	Disease	D007153	The Nijmegen breakage syndrome is a rare autosomal recessive chromosomal instability disorder characterized by early growth retardation, congenital microcephaly, immunodeficiency, borderline mental development, and a high tendency to lymphoreticular malignancies.
BC8_BioRED_Task1_Doc242	325	353	lymphoreticular malignancies	Disease	D049932	The Nijmegen breakage syndrome is a rare autosomal recessive chromosomal instability disorder characterized by early growth retardation, congenital microcephaly, immunodeficiency, borderline mental development, and a high tendency to lymphoreticular malignancies.
BC8_BioRED_Task1_Doc242	360	386	Nijmegen breakage syndrome	Disease	D049932	Most Nijmegen breakage syndrome patients are of Slavonic origin, and all of them known so far carry a founder homozygous 5 nucleotide deletion in the NBS1 gene.
BC8_BioRED_Task1_Doc242	387	395	patients	OrganismTaxon	9606	Most Nijmegen breakage syndrome patients are of Slavonic origin, and all of them known so far carry a founder homozygous 5 nucleotide deletion in the NBS1 gene.
BC8_BioRED_Task1_Doc242	476	497	5 nucleotide deletion	SequenceVariant	c|DEL||5	Most Nijmegen breakage syndrome patients are of Slavonic origin, and all of them known so far carry a founder homozygous 5 nucleotide deletion in the NBS1 gene.
BC8_BioRED_Task1_Doc242	505	509	NBS1	Gene	4683	Most Nijmegen breakage syndrome patients are of Slavonic origin, and all of them known so far carry a founder homozygous 5 nucleotide deletion in the NBS1 gene.
BC8_BioRED_Task1_Doc242	516	528	Microcephaly	Disease	D008831	Microcephaly was present in 100% of Nijmegen breakage syndrome patients in a recent large international cooperative study.
BC8_BioRED_Task1_Doc242	552	578	Nijmegen breakage syndrome	Disease	D049932	Microcephaly was present in 100% of Nijmegen breakage syndrome patients in a recent large international cooperative study.
BC8_BioRED_Task1_Doc242	579	587	patients	OrganismTaxon	9606	Microcephaly was present in 100% of Nijmegen breakage syndrome patients in a recent large international cooperative study.
BC8_BioRED_Task1_Doc242	656	682	Nijmegen breakage syndrome	Disease	D049932	The frequency of Nijmegen breakage syndrome among children with primary microcephaly was not known.
BC8_BioRED_Task1_Doc242	703	723	primary microcephaly	Disease	D008831	The frequency of Nijmegen breakage syndrome among children with primary microcephaly was not known.
BC8_BioRED_Task1_Doc242	854	862	patients	OrganismTaxon	9606	We tested 67 Czech patients of different ages with simple microcephaly for the presence of the most common mutation in the NBS1 gene.
BC8_BioRED_Task1_Doc242	958	962	NBS1	Gene	4683	We tested 67 Czech patients of different ages with simple microcephaly for the presence of the most common mutation in the NBS1 gene.
BC8_BioRED_Task1_Doc242	979	1005	Nijmegen breakage syndrome	Disease	D049932	Three new Nijmegen breakage syndrome cases were detected in this cohort, representing 4.5% of the cohort.
BC8_BioRED_Task1_Doc242	1101	1127	Nijmegen breakage syndrome	Disease	D049932	All these newly diagnosed Nijmegen breakage syndrome patients were younger than 10 months at the time of diagnosis.
BC8_BioRED_Task1_Doc242	1128	1136	patients	OrganismTaxon	9606	All these newly diagnosed Nijmegen breakage syndrome patients were younger than 10 months at the time of diagnosis.
BC8_BioRED_Task1_Doc242	1353	1379	Nijmegen breakage syndrome	Disease	D049932	Twenty-three of the 67 children in the cohort were born within this 2.5-year period, representing a 13% incidence of Nijmegen breakage syndrome.
BC8_BioRED_Task1_Doc242	1394	1420	Nijmegen breakage syndrome	Disease	D049932	Frequency of Nijmegen breakage syndrome heterozygotes among infants in the Czech Republic is 1: 130-158 and the birth rate is 90,000 per year, therefore in the time span of 2.5 years, three new Nijmegen breakage syndrome homozygotes are expected to be born.
BC8_BioRED_Task1_Doc242	1575	1601	Nijmegen breakage syndrome	Disease	D049932	Frequency of Nijmegen breakage syndrome heterozygotes among infants in the Czech Republic is 1: 130-158 and the birth rate is 90,000 per year, therefore in the time span of 2.5 years, three new Nijmegen breakage syndrome homozygotes are expected to be born.
BC8_BioRED_Task1_Doc242	1748	1774	Nijmegen breakage syndrome	Disease	D049932	Therefore we assume that by DNA testing of Czech primary microcephalic children it is possible to detect all Nijmegen breakage syndrome patients to be expected.
BC8_BioRED_Task1_Doc242	1775	1783	patients	OrganismTaxon	9606	Therefore we assume that by DNA testing of Czech primary microcephalic children it is possible to detect all Nijmegen breakage syndrome patients to be expected.
BC8_BioRED_Task1_Doc242	1925	1951	Nijmegen breakage syndrome	Disease	D049932	All new Nijmegen breakage syndrome patients could receive appropriate preventive care, which should significantly improve their life expectancy and prognosis.
BC8_BioRED_Task1_Doc242	1952	1960	patients	OrganismTaxon	9606	All new Nijmegen breakage syndrome patients could receive appropriate preventive care, which should significantly improve their life expectancy and prognosis.
BC8_BioRED_Task1_Doc243	56	60	ETS2	Gene	2114	Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome.
BC8_BioRED_Task1_Doc243	65	69	SIM2	Gene	6493	Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome.
BC8_BioRED_Task1_Doc243	79	92	Down syndrome	Disease	D004314	Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome.
BC8_BioRED_Task1_Doc243	182	195	Down syndrome	Disease	D004314	Trisomy of the 21{st} chromosome leads to an over dosage of several regulatory genes in Down syndrome (DS).
BC8_BioRED_Task1_Doc243	197	199	DS	Disease	D004314	Trisomy of the 21{st} chromosome leads to an over dosage of several regulatory genes in Down syndrome (DS).
BC8_BioRED_Task1_Doc243	341	343	DS	Disease	D004314	Though allelic and genotypic combinations formed between genes are interesting, till date, this particular area has never been explored in DS.
BC8_BioRED_Task1_Doc243	414	429	Single minded 2	Gene	6493	In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS.
BC8_BioRED_Task1_Doc243	431	435	SIM2	Gene	6493	In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS.
BC8_BioRED_Task1_Doc243	441	491	V-ets erythroblastosis virus E26 oncogene homolog2	Gene	2114	In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS.
BC8_BioRED_Task1_Doc243	493	497	ETS2	Gene	2114	In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS.
BC8_BioRED_Task1_Doc243	576	578	DS	Disease	D004314	In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS.
BC8_BioRED_Task1_Doc243	624	626	DS	Disease	D004314	Genomic DNA of eastern Indian probands with DS (N=132), their parents (N=209) and ethnically matched controls (N=149) was subjected to PCR-based analyses of functionally important SNPs followed by statistical analyses.
BC8_BioRED_Task1_Doc243	799	803	ETS2	Gene	2114	ETS2 rs461155 showed high heterozygosity in DS.
BC8_BioRED_Task1_Doc243	804	812	rs461155	SequenceVariant	rs461155	ETS2 rs461155 showed high heterozygosity in DS.
BC8_BioRED_Task1_Doc243	843	845	DS	Disease	D004314	ETS2 rs461155 showed high heterozygosity in DS.
BC8_BioRED_Task1_Doc243	880	884	SIM2	Gene	6493	Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185).
BC8_BioRED_Task1_Doc243	900	909	rs2073601	SequenceVariant	rs2073601	Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185).
BC8_BioRED_Task1_Doc243	910	919	rs2073416	SequenceVariant	rs2073416	Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185).
BC8_BioRED_Task1_Doc243	953	955	DS	Disease	D004314	Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185).
BC8_BioRED_Task1_Doc243	1135	1137	DS	Disease	D004314	Significantly lower frequency of the A-C-C-G with higher frequency of A-C-A-G haplotypes was also noticed in subjects with DS (P value =0.02089 and 0.00588 respectively).
BC8_BioRED_Task1_Doc243	1215	1224	rs2073601	SequenceVariant	rs2073601	Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.
BC8_BioRED_Task1_Doc243	1283	1304	leucine to methionine	SequenceVariant	rs2073601	Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.
BC8_BioRED_Task1_Doc243	1328	1330	DS	Disease	D004314	Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.
BC8_BioRED_Task1_Doc244	0	14	Retinoblastoma	Disease	D012175	Retinoblastoma in India : microsatellite analysis and its application in genetic counseling.
BC8_BioRED_Task1_Doc244	230	233	RB1	Gene	5925	The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India.
BC8_BioRED_Task1_Doc244	278	284	tumors	Disease	D009369	The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India.
BC8_BioRED_Task1_Doc244	288	296	patients	OrganismTaxon	9606	The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India.
BC8_BioRED_Task1_Doc244	344	347	RB1	Gene	5925	The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB).
BC8_BioRED_Task1_Doc244	474	488	retinoblastoma	Disease	D012175	The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB).
BC8_BioRED_Task1_Doc244	490	492	RB	Disease	D012175	The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB).
BC8_BioRED_Task1_Doc244	548	554	tumors	Disease	D009369	METHODS: DNA was extracted from peripheral blood and tumors of 54 RB patients and their relatives.
BC8_BioRED_Task1_Doc244	561	563	RB	Disease	D012175	METHODS: DNA was extracted from peripheral blood and tumors of 54 RB patients and their relatives.
BC8_BioRED_Task1_Doc244	564	572	patients	OrganismTaxon	9606	METHODS: DNA was extracted from peripheral blood and tumors of 54 RB patients and their relatives.
BC8_BioRED_Task1_Doc244	669	672	RB1	Gene	5925	Eight fluorescent microsatellite markers, both intragenic and flanking the RB1 gene, were used.
BC8_BioRED_Task1_Doc244	867	872	tumor	Disease	D009369	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	895	897	RB	Disease	D012175	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	898	906	patients	OrganismTaxon	9606	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	914	922	patients	OrganismTaxon	9606	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	1026	1028	RB	Disease	D012175	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	1029	1037	patients	OrganismTaxon	9606	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	1070	1073	RB1	Gene	5925	RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH.
BC8_BioRED_Task1_Doc244	1112	1114	RB	Disease	D012175	Seven germline deletions (13% of RB patients) were identified, and the maternal allele was more frequently lost (p=0.01).
BC8_BioRED_Task1_Doc244	1115	1123	patients	OrganismTaxon	9606	Seven germline deletions (13% of RB patients) were identified, and the maternal allele was more frequently lost (p=0.01).
BC8_BioRED_Task1_Doc244	1316	1319	RB1	Gene	5925	CONCLUSION: LOH of the RB1 gene could play an important role in tumor formation.
BC8_BioRED_Task1_Doc244	1357	1362	tumor	Disease	D009369	CONCLUSION: LOH of the RB1 gene could play an important role in tumor formation.
BC8_BioRED_Task1_Doc244	1400	1403	RB1	Gene	5925	Large deletions involving RB1 were observed, and a disease co-segregating haplotype was used for indirect genetic testing.
BC8_BioRED_Task1_Doc244	1578	1580	RB	Disease	D012175	This is the first report from India where molecular testing has been applied for RB families in conjunction with genetic counseling.
BC8_BioRED_Task1_Doc245	9	32	glucocorticoid receptor	Gene	2908	Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.
BC8_BioRED_Task1_Doc245	86	105	adrenal hyperplasia	Disease	D000312	Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.
BC8_BioRED_Task1_Doc245	110	143	apparent mineralocorticoid excess	Disease	C537422	Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.
BC8_BioRED_Task1_Doc245	153	178	glucocorticoid resistance	Disease	C564221	Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).
BC8_BioRED_Task1_Doc245	180	191	OMIM 138040	Disease	OMIM:138040	Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).
BC8_BioRED_Task1_Doc245	203	221	hereditary disease	Disease	D030342	Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).
BC8_BioRED_Task1_Doc245	273	287	glucocorticoid	Chemical	D005938	Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).
BC8_BioRED_Task1_Doc245	330	353	glucocorticoid receptor	Gene	2908	Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).
BC8_BioRED_Task1_Doc245	355	357	GR	Gene	2908	Primary glucocorticoid resistance (OMIM 138040) is a rare hereditary disease that causes a generalized partial insensitivity to glucocorticoid action, due to genetic alterations of the glucocorticoid receptor (GR).
BC8_BioRED_Task1_Doc245	377	399	adrenal incidentalomas	Disease	C538238	Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenal hyperplasia, arterial hypertension and hypokalemia.
BC8_BioRED_Task1_Doc245	499	518	cortisol resistance	Disease	C535280	Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenal hyperplasia, arterial hypertension and hypokalemia.
BC8_BioRED_Task1_Doc245	520	549	bilateral adrenal hyperplasia	Disease	D000312	Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenal hyperplasia, arterial hypertension and hypokalemia.
BC8_BioRED_Task1_Doc245	560	572	hypertension	Disease	D006973	Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenal hyperplasia, arterial hypertension and hypokalemia.
BC8_BioRED_Task1_Doc245	577	588	hypokalemia	Disease	D007008	Investigation of adrenal incidentalomas led to the discovery of a family (eight affected individuals spanning three generations), prone to cortisol resistance, bilateral adrenal hyperplasia, arterial hypertension and hypokalemia.
BC8_BioRED_Task1_Doc245	687	698	p.R469[R,X]	SequenceVariant	p|SUB|R|469|X	This phenotype exacerbated over time, cosegregates with the first heterozygous nonsense mutation p.R469[R,X] reported to date for the GR, replacing an arginine (CGA) by a stop (TGA) at amino-acid 469 in the second zinc finger of the DNA-binding domain of the receptor.
BC8_BioRED_Task1_Doc245	724	726	GR	Gene	2908	This phenotype exacerbated over time, cosegregates with the first heterozygous nonsense mutation p.R469[R,X] reported to date for the GR, replacing an arginine (CGA) by a stop (TGA) at amino-acid 469 in the second zinc finger of the DNA-binding domain of the receptor.
BC8_BioRED_Task1_Doc245	741	789	arginine (CGA) by a stop (TGA) at amino-acid 469	SequenceVariant	p|SUB|R|469|X	This phenotype exacerbated over time, cosegregates with the first heterozygous nonsense mutation p.R469[R,X] reported to date for the GR, replacing an arginine (CGA) by a stop (TGA) at amino-acid 469 in the second zinc finger of the DNA-binding domain of the receptor.
BC8_BioRED_Task1_Doc245	911	913	GR	Gene	2908	In vitro, this mutation leads to a truncated 50-kDa GR lacking hormone and DNA binding capacity, devoid of hormone-dependent nuclear translocation and transactivation properties.
BC8_BioRED_Task1_Doc245	1183	1185	GR	Gene	2908	The absence of detectable mutated GR mRNA was accompanied by a 50% reduction in wild type GR transcript and protein.
BC8_BioRED_Task1_Doc245	1239	1241	GR	Gene	2908	The absence of detectable mutated GR mRNA was accompanied by a 50% reduction in wild type GR transcript and protein.
BC8_BioRED_Task1_Doc245	1279	1281	GR	Gene	2908	This reduced GR expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, FKBP5 in fibroblasts.
BC8_BioRED_Task1_Doc245	1344	1358	glucocorticoid	Chemical	D005938	This reduced GR expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, FKBP5 in fibroblasts.
BC8_BioRED_Task1_Doc245	1381	1386	FKBP5	Gene	2289	This reduced GR expression leads to a significantly below-normal induction of glucocorticoid-induced target genes, FKBP5 in fibroblasts.
BC8_BioRED_Task1_Doc245	1452	1466	glucocorticoid	Chemical	D005938	We demonstrated that the molecular mechanisms of glucocorticoid signaling dysfunction involved GR haploinsufficiency due to the selective degradation of the mutated GR transcript through a nonsense-mediated mRNA Decay that was experimentally validated on emetine-treated propositus' fibroblasts.
BC8_BioRED_Task1_Doc245	1498	1500	GR	Gene	2908	We demonstrated that the molecular mechanisms of glucocorticoid signaling dysfunction involved GR haploinsufficiency due to the selective degradation of the mutated GR transcript through a nonsense-mediated mRNA Decay that was experimentally validated on emetine-treated propositus' fibroblasts.
BC8_BioRED_Task1_Doc245	1568	1570	GR	Gene	2908	We demonstrated that the molecular mechanisms of glucocorticoid signaling dysfunction involved GR haploinsufficiency due to the selective degradation of the mutated GR transcript through a nonsense-mediated mRNA Decay that was experimentally validated on emetine-treated propositus' fibroblasts.
BC8_BioRED_Task1_Doc245	1658	1665	emetine	Chemical	D004640	We demonstrated that the molecular mechanisms of glucocorticoid signaling dysfunction involved GR haploinsufficiency due to the selective degradation of the mutated GR transcript through a nonsense-mediated mRNA Decay that was experimentally validated on emetine-treated propositus' fibroblasts.
BC8_BioRED_Task1_Doc245	1699	1701	GR	Gene	2908	GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
BC8_BioRED_Task1_Doc245	1730	1742	hypertension	Disease	D006973	GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
BC8_BioRED_Task1_Doc245	1778	1804	mineralocorticoid receptor	Gene	4306	GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
BC8_BioRED_Task1_Doc245	1817	1825	cortisol	Chemical	D006854	GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
BC8_BioRED_Task1_Doc245	1851	1868	mineralocorticoid	Chemical	D008901	GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
BC8_BioRED_Task1_Doc245	1900	1925	glucocorticoid resistance	Disease	C564221	GR haploinsufficiency leads to hypertension due to illicit occupation of renal mineralocorticoid receptor by elevated cortisol rather than to increased mineralocorticoid production reported in primary glucocorticoid resistance.
BC8_BioRED_Task1_Doc245	1935	1968	apparent mineralocorticoid excess	Disease	C537422	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2011	2030	tetrahydrocortisone	Chemical	D013761	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2031	2049	tetrahydrocortisol	Chemical	D013760	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2068	2076	patients	OrganismTaxon	9606	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2096	2110	glucocorticoid	Chemical	D005938	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2148	2187	11b-hydroxysteroid dehydrogenase type 2	Gene	3291	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2191	2193	GR	Gene	2908	Indeed, apparent mineralocorticoid excess was demonstrated by a decrease in urinary tetrahydrocortisone-tetrahydrocortisol ratio in affected patients, revealing reduced glucocorticoid degradation by renal activity of the 11b-hydroxysteroid dehydrogenase type 2, a GR regulated gene.
BC8_BioRED_Task1_Doc245	2231	2233	GR	Gene	2908	We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.
BC8_BioRED_Task1_Doc245	2265	2279	glucocorticoid	Chemical	D005938	We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.
BC8_BioRED_Task1_Doc245	2347	2363	hypercortisolism	Disease	D003480	We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.
BC8_BioRED_Task1_Doc245	2387	2416	bilateral adrenal hyperplasia	Disease	D000312	We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.
BC8_BioRED_Task1_Doc245	2421	2438	mineralocorticoid	Chemical	D008901	We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.
BC8_BioRED_Task1_Doc245	2451	2463	hypertension	Disease	D006973	We propose thus that GR haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenal hyperplasia and mineralocorticoid-independent hypertension.
BC8_BioRED_Task1_Doc246	8	19	adiponectin	Gene	11450	Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	97	104	ALDH1A1	Gene	11668	Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	117	139	retinoic acid receptor	Gene	19401,19411,20181	Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	169	180	Adiponectin	Gene	11450	Adiponectin is an adipocyte-derived adipokine with potent antidiabetic, anti-inflammatory, and antiatherogenic activity.
BC8_BioRED_Task1_Doc246	205	214	adipokine	Gene	11450	Adiponectin is an adipocyte-derived adipokine with potent antidiabetic, anti-inflammatory, and antiatherogenic activity.
BC8_BioRED_Task1_Doc246	246	258	inflammatory	Disease	D007249	Adiponectin is an adipocyte-derived adipokine with potent antidiabetic, anti-inflammatory, and antiatherogenic activity.
BC8_BioRED_Task1_Doc246	347	356	adiposity	Disease	D009765	Long-term, high-fat diet results in gain of body weight, adiposity, further inflammatory-based cardiovascular diseases, and reduced adiponectin secretion.
BC8_BioRED_Task1_Doc246	366	378	inflammatory	Disease	D007249	Long-term, high-fat diet results in gain of body weight, adiposity, further inflammatory-based cardiovascular diseases, and reduced adiponectin secretion.
BC8_BioRED_Task1_Doc246	385	408	cardiovascular diseases	Disease	D002318	Long-term, high-fat diet results in gain of body weight, adiposity, further inflammatory-based cardiovascular diseases, and reduced adiponectin secretion.
BC8_BioRED_Task1_Doc246	422	433	adiponectin	Gene	11450	Long-term, high-fat diet results in gain of body weight, adiposity, further inflammatory-based cardiovascular diseases, and reduced adiponectin secretion.
BC8_BioRED_Task1_Doc246	445	454	Vitamin A	Chemical	D014801	Vitamin A derivatives/retinoids are involved in several of these processes, which mainly take place in white adipose tissue (WAT).
BC8_BioRED_Task1_Doc246	467	476	retinoids	Chemical	D012176	Vitamin A derivatives/retinoids are involved in several of these processes, which mainly take place in white adipose tissue (WAT).
BC8_BioRED_Task1_Doc246	603	614	adiponectin	Gene	11450	In this study, we examined adiponectin expression as a function of dietary high-fat and high-vitamin A conditions in mice.
BC8_BioRED_Task1_Doc246	669	678	vitamin A	Chemical	D014801	In this study, we examined adiponectin expression as a function of dietary high-fat and high-vitamin A conditions in mice.
BC8_BioRED_Task1_Doc246	693	697	mice	OrganismTaxon	10090	In this study, we examined adiponectin expression as a function of dietary high-fat and high-vitamin A conditions in mice.
BC8_BioRED_Task1_Doc246	713	724	adiponectin	Gene	11450	A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.
BC8_BioRED_Task1_Doc246	771	796	aldehyde dehydrogenase A1	Gene	11668	A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.
BC8_BioRED_Task1_Doc246	798	805	ALDH1A1	Gene	11668	A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.
BC8_BioRED_Task1_Doc246	832	845	retinoic acid	Chemical	D014212	A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.
BC8_BioRED_Task1_Doc246	908	912	mice	OrganismTaxon	10090	A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.
BC8_BioRED_Task1_Doc246	926	935	vitamin A	Chemical	D014801	A decrease of adiponectin expression in addition to an up-regulation of aldehyde dehydrogenase A1 (ALDH1A1), retinoid signaling, and retinoic acid response element signaling was selectively observed in WAT of mice fed a normal-vitamin A, high-fat diet.
BC8_BioRED_Task1_Doc246	960	971	adiponectin	Gene	11450	Reduced adiponectin expression in WAT was also observed in mice fed a high-vitamin A diet.
BC8_BioRED_Task1_Doc246	1011	1015	mice	OrganismTaxon	10090	Reduced adiponectin expression in WAT was also observed in mice fed a high-vitamin A diet.
BC8_BioRED_Task1_Doc246	1027	1036	vitamin A	Chemical	D014801	Reduced adiponectin expression in WAT was also observed in mice fed a high-vitamin A diet.
BC8_BioRED_Task1_Doc246	1105	1134	retinoic acid receptor (RAR)a	Gene	19401	Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.
BC8_BioRED_Task1_Doc246	1140	1144	RARg	Gene	19411	Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.
BC8_BioRED_Task1_Doc246	1188	1207	retinoid X receptor	Gene	20181	Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.
BC8_BioRED_Task1_Doc246	1237	1248	adiponectin	Gene	11450	Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.
BC8_BioRED_Task1_Doc246	1269	1276	ALDH1A1	Gene	11668	Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.
BC8_BioRED_Task1_Doc246	1308	1311	RAR	Gene	19401,19411,20181	Adipocyte cell culture revealed that endogenous and synthetic retinoic acid receptor (RAR)a- and RARg-selective agonists, as well as a synthetic retinoid X receptor agonist, efficiently reduced adiponectin expression, whereas ALDH1A1 expression only increased with RAR agonists.
BC8_BioRED_Task1_Doc246	1347	1358	adiponectin	Gene	11450	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1433	1440	ALDH1A1	Gene	11668	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1501	1514	retinoic acid	Chemical	D014212	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1534	1537	RAR	Gene	19401,19411,20181	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1579	1592	retinoic acid	Chemical	D014212	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1637	1640	RAR	Gene	19401,19411,20181	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1671	1682	adiponectin	Gene	11450	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1852	1863	adiponectin	Gene	11450	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1941	1948	ALDH1A1	Gene	11668	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc246	1961	1983	retinoic acid receptor	Gene	19401,19411,20181	We conclude that reduced adiponectin expression under high-fat dietary conditions is dependent on 1) increased ALDH1A1 expression in adipocytes, which does not increase all-trans-retinoic acid levels; 2) further RAR ligand-induced, WAT-selective, increased retinoic acid response element-mediated signaling; and 3) RAR ligand-dependent reduction of adiponectin expression.-Landrier, J.-F., Kasiri, E., Karkeni, E., Mihaly, J., Beke, G., Weiss, K., Lucas, R., Aydemir, G., Salles, J., Walrand, S., de Lera, A. R., Ruhl, R. Reduced adiponectin expression after high-fat diet is associated with selective up-regulation of ALDH1A1 and further retinoic acid receptor signaling in adipose tissue.
BC8_BioRED_Task1_Doc247	18	44	C-to-T substitution at -31	SequenceVariant	rs1143627	A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population.
BC8_BioRED_Task1_Doc247	45	49	IL1B	Gene	3553	A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population.
BC8_BioRED_Task1_Doc247	90	112	gastric adenocarcinoma	Disease	D013274	A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population.
BC8_BioRED_Task1_Doc247	139	163	Proinflammatory cytokine	Gene	3553	Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.
BC8_BioRED_Task1_Doc247	224	238	gastric cancer	Disease	D013274	Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.
BC8_BioRED_Task1_Doc247	254	258	IL1B	Gene	3553	Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.
BC8_BioRED_Task1_Doc247	258	264	-31T/C	SequenceVariant	rs1143627	Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.
BC8_BioRED_Task1_Doc247	269	276	-511C/T	SequenceVariant	rs1143634	Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.
BC8_BioRED_Task1_Doc247	360	364	IL1B	Gene	3553	Proinflammatory cytokine gene polymorphisms have been demonstrated to associate with gastric cancer risk, of which IL1B-31T/C and -511C/T changes have been well investigated due to the possibility that they may alter the IL1B transcription.
BC8_BioRED_Task1_Doc247	416	434	interleukin 1 beta	Gene	3553	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	436	443	IL1beta	Gene	3553	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	462	487	nuclear factor of kappa B	Gene	4790	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	489	497	NFkappaB	Gene	4790	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	520	526	cancer	Disease	D009369	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	584	625	FS-7 cell-associated cell surface antigen	Gene	355	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	627	630	FAS	Gene	355	The signal transduction target upon interleukin 1 beta (IL1beta) stimulation, the nuclear factor of kappa B (NFkappaB) activation, supports cancer development, signal transduction in which is mediated by FS-7 cell-associated cell surface antigen (FAS) signaling.
BC8_BioRED_Task1_Doc247	727	735	NFkappaB	Gene	4790	Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.
BC8_BioRED_Task1_Doc247	749	755	cancer	Disease	D009369	Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.
BC8_BioRED_Task1_Doc247	804	818	gastric cancer	Disease	D013274	Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.
BC8_BioRED_Task1_Doc247	819	827	patients	OrganismTaxon	9606	Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.
BC8_BioRED_Task1_Doc247	849	853	IL1B	Gene	3553	Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.
BC8_BioRED_Task1_Doc247	867	870	FAS	Gene	355	Based on recent papers describing the prognostic roles of the polymorphisms and the NFkappaB functions on cancer development, we sought to determine if Japanese gastric cancer patients were affected by the IL1B -31/-511 and FAS-670 polymorphisms.
BC8_BioRED_Task1_Doc247	937	959	gastric adenocarcinoma	Disease	D013274	A case-control study was conducted on incident gastric adenocarcinoma patients (n=271) and age-gender frequency-matched control subjects (n=271).
BC8_BioRED_Task1_Doc247	960	968	patients	OrganismTaxon	9606	A case-control study was conducted on incident gastric adenocarcinoma patients (n=271) and age-gender frequency-matched control subjects (n=271).
BC8_BioRED_Task1_Doc247	1090	1106	T allele at -511	SequenceVariant	rs1143634	We observed strong linkage disequilibrium between the T allele at -511 and the C allele at -31 and between the C allele at -511 and the T allele at -31 in IL1B in both the cases and controls (R (2)=0.94).
BC8_BioRED_Task1_Doc247	1115	1130	C allele at -31	SequenceVariant	rs1143627	We observed strong linkage disequilibrium between the T allele at -511 and the C allele at -31 and between the C allele at -511 and the T allele at -31 in IL1B in both the cases and controls (R (2)=0.94).
BC8_BioRED_Task1_Doc247	1147	1163	C allele at -511	SequenceVariant	rs1143634	We observed strong linkage disequilibrium between the T allele at -511 and the C allele at -31 and between the C allele at -511 and the T allele at -31 in IL1B in both the cases and controls (R (2)=0.94).
BC8_BioRED_Task1_Doc247	1172	1187	T allele at -31	SequenceVariant	rs1143627	We observed strong linkage disequilibrium between the T allele at -511 and the C allele at -31 and between the C allele at -511 and the T allele at -31 in IL1B in both the cases and controls (R (2)=0.94).
BC8_BioRED_Task1_Doc247	1191	1195	IL1B	Gene	3553	We observed strong linkage disequilibrium between the T allele at -511 and the C allele at -31 and between the C allele at -511 and the T allele at -31 in IL1B in both the cases and controls (R (2)=0.94).
BC8_BioRED_Task1_Doc247	1249	1253	IL1B	Gene	3553	Neither IL1B-31, -511 nor FAS-670 polymorphisms showed significantly different risks of gastric adenocarcinoma.
BC8_BioRED_Task1_Doc247	1267	1270	FAS	Gene	355	Neither IL1B-31, -511 nor FAS-670 polymorphisms showed significantly different risks of gastric adenocarcinoma.
BC8_BioRED_Task1_Doc247	1329	1351	gastric adenocarcinoma	Disease	D013274	Neither IL1B-31, -511 nor FAS-670 polymorphisms showed significantly different risks of gastric adenocarcinoma.
BC8_BioRED_Task1_Doc247	1360	1363	FAS	Gene	355	Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B-31TT (or IL1B-511CC) increased according to stage (trend P=0.019).
BC8_BioRED_Task1_Doc247	1455	1459	IL1B	Gene	3553	Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B-31TT (or IL1B-511CC) increased according to stage (trend P=0.019).
BC8_BioRED_Task1_Doc247	1459	1464	-31TT	SequenceVariant	rs1143627	Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B-31TT (or IL1B-511CC) increased according to stage (trend P=0.019).
BC8_BioRED_Task1_Doc247	1469	1473	IL1B	Gene	3553	Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B-31TT (or IL1B-511CC) increased according to stage (trend P=0.019).
BC8_BioRED_Task1_Doc247	1473	1479	-511CC	SequenceVariant	rs1143634	Though FAS-670 polymorphisms did not show any significant difference, the proportion of subjects with IL1B-31TT (or IL1B-511CC) increased according to stage (trend P=0.019).
BC8_BioRED_Task1_Doc247	1617	1621	IL1B	Gene	3553	In particular, subjects with stage IV had a two times higher probability of having either IL1B-31TT (or IL1B-511CC) genotype compared with stage I subjects.
BC8_BioRED_Task1_Doc247	1621	1626	-31TT	SequenceVariant	rs1143627	In particular, subjects with stage IV had a two times higher probability of having either IL1B-31TT (or IL1B-511CC) genotype compared with stage I subjects.
BC8_BioRED_Task1_Doc247	1631	1635	IL1B	Gene	3553	In particular, subjects with stage IV had a two times higher probability of having either IL1B-31TT (or IL1B-511CC) genotype compared with stage I subjects.
BC8_BioRED_Task1_Doc247	1635	1641	-511CC	SequenceVariant	rs1143634	In particular, subjects with stage IV had a two times higher probability of having either IL1B-31TT (or IL1B-511CC) genotype compared with stage I subjects.
BC8_BioRED_Task1_Doc247	1716	1720	IL1B	Gene	3553	These observations suggest that IL1B-31TT and IL1B-511CC are associated with disease progression.
BC8_BioRED_Task1_Doc247	1720	1725	-31TT	SequenceVariant	rs1143627	These observations suggest that IL1B-31TT and IL1B-511CC are associated with disease progression.
BC8_BioRED_Task1_Doc247	1730	1734	IL1B	Gene	3553	These observations suggest that IL1B-31TT and IL1B-511CC are associated with disease progression.
BC8_BioRED_Task1_Doc247	1734	1740	-511CC	SequenceVariant	rs1143634	These observations suggest that IL1B-31TT and IL1B-511CC are associated with disease progression.
BC8_BioRED_Task1_Doc248	42	48	HOMER1	Gene	9456	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
BC8_BioRED_Task1_Doc248	59	67	levodopa	Chemical	D007980	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
BC8_BioRED_Task1_Doc248	87	106	Parkinson's disease	Disease	D010300	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
BC8_BioRED_Task1_Doc248	107	115	patients	OrganismTaxon	9606	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
BC8_BioRED_Task1_Doc248	117	125	Levodopa	Chemical	D007980	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
BC8_BioRED_Task1_Doc248	172	191	Parkinson's disease	Disease	D010300	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
BC8_BioRED_Task1_Doc248	281	291	dyskinesia	Disease	D004409	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
BC8_BioRED_Task1_Doc248	296	317	visual hallucinations	Disease	D006212	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
BC8_BioRED_Task1_Doc248	319	325	HOMER1	Gene	9456	HOMER1 is a protein with pivotal function in glutamate transmission, which has been related to the pathogenesis of these complications.
BC8_BioRED_Task1_Doc248	364	373	glutamate	Chemical	D018698	HOMER1 is a protein with pivotal function in glutamate transmission, which has been related to the pathogenesis of these complications.
BC8_BioRED_Task1_Doc248	508	514	HOMER1	Gene	9456	This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy.
BC8_BioRED_Task1_Doc248	603	611	levodopa	Chemical	D007980	This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy.
BC8_BioRED_Task1_Doc248	636	644	patients	OrganismTaxon	9606	A total of 205 patients with idiopathic Parkinson's disease were investigated.
BC8_BioRED_Task1_Doc248	650	680	idiopathic Parkinson's disease	Disease	D010300	A total of 205 patients with idiopathic Parkinson's disease were investigated.
BC8_BioRED_Task1_Doc248	700	708	Patients	OrganismTaxon	9606	Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays.
BC8_BioRED_Task1_Doc248	728	737	rs4704559	SequenceVariant	rs4704559	Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays.
BC8_BioRED_Task1_Doc248	739	749	rs10942891	SequenceVariant	rs10942891	Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays.
BC8_BioRED_Task1_Doc248	754	763	rs4704560	SequenceVariant	rs4704560	Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays.
BC8_BioRED_Task1_Doc248	814	823	rs4704559	SequenceVariant	rs4704559	The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020).
BC8_BioRED_Task1_Doc248	875	885	dyskinesia	Disease	D004409	The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020).
BC8_BioRED_Task1_Doc248	971	992	visual hallucinations	Disease	D006212	The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020).
BC8_BioRED_Task1_Doc248	1056	1062	HOMER1	Gene	9456	Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.
BC8_BioRED_Task1_Doc248	1063	1072	rs4704559	SequenceVariant	rs4704559	Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.
BC8_BioRED_Task1_Doc248	1127	1135	levodopa	Chemical	D007980	Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.
BC8_BioRED_Task1_Doc249	0	44	Cone dystrophy with supernormal rod response	Disease	C563678	Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2.
BC8_BioRED_Task1_Doc249	86	91	KCNV2	Gene	169522	Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2.
BC8_BioRED_Task1_Doc249	102	146	Cone dystrophy with supernormal rod response	Disease	C563678	PURPOSE: Cone dystrophy with supernormal rod response (CDSRR) is a retinal disorder characterized by reduced visual acuity, color vision defects, and specific alterations of ERG responses that feature elevated scotopic b-wave amplitudes at high luminance intensities.
BC8_BioRED_Task1_Doc249	148	153	CDSRR	Disease	C563678	PURPOSE: Cone dystrophy with supernormal rod response (CDSRR) is a retinal disorder characterized by reduced visual acuity, color vision defects, and specific alterations of ERG responses that feature elevated scotopic b-wave amplitudes at high luminance intensities.
BC8_BioRED_Task1_Doc249	160	176	retinal disorder	Disease	D012164	PURPOSE: Cone dystrophy with supernormal rod response (CDSRR) is a retinal disorder characterized by reduced visual acuity, color vision defects, and specific alterations of ERG responses that feature elevated scotopic b-wave amplitudes at high luminance intensities.
BC8_BioRED_Task1_Doc249	217	237	color vision defects	Disease	D003117	PURPOSE: Cone dystrophy with supernormal rod response (CDSRR) is a retinal disorder characterized by reduced visual acuity, color vision defects, and specific alterations of ERG responses that feature elevated scotopic b-wave amplitudes at high luminance intensities.
BC8_BioRED_Task1_Doc249	374	379	PDE6H	Gene	5149	Mutations in PDE6H and in KCNV2 have been described in CDSRR.
BC8_BioRED_Task1_Doc249	387	392	KCNV2	Gene	169522	Mutations in PDE6H and in KCNV2 have been described in CDSRR.
BC8_BioRED_Task1_Doc249	416	421	CDSRR	Disease	C563678	Mutations in PDE6H and in KCNV2 have been described in CDSRR.
BC8_BioRED_Task1_Doc249	490	498	patients	OrganismTaxon	9606	A combined clinical and genetic study was conducted in a cohort of patients with CDSRR, to substantiate these prior RESULTS: Seventeen patients from 13 families underwent a detailed ophthalmic examination including color vision testing, Goldmann visual fields, fundus photography, Ganzfeld and multifocal ERGs, and optical coherence tomography.
BC8_BioRED_Task1_Doc249	504	509	CDSRR	Disease	C563678	A combined clinical and genetic study was conducted in a cohort of patients with CDSRR, to substantiate these prior RESULTS: Seventeen patients from 13 families underwent a detailed ophthalmic examination including color vision testing, Goldmann visual fields, fundus photography, Ganzfeld and multifocal ERGs, and optical coherence tomography.
BC8_BioRED_Task1_Doc249	558	566	patients	OrganismTaxon	9606	A combined clinical and genetic study was conducted in a cohort of patients with CDSRR, to substantiate these prior RESULTS: Seventeen patients from 13 families underwent a detailed ophthalmic examination including color vision testing, Goldmann visual fields, fundus photography, Ganzfeld and multifocal ERGs, and optical coherence tomography.
BC8_BioRED_Task1_Doc249	826	831	PDE6C	Gene	5146	The coding sequences and flanking intron/UTR sequences of PDE6C and KCNV2 were screened for mutations by means of DHPLC and direct DNA sequencing of PCR-amplified genomic DNA.
BC8_BioRED_Task1_Doc249	836	841	KCNV2	Gene	169522	The coding sequences and flanking intron/UTR sequences of PDE6C and KCNV2 were screened for mutations by means of DHPLC and direct DNA sequencing of PCR-amplified genomic DNA.
BC8_BioRED_Task1_Doc249	995	1000	PDE6H	Gene	5149	Whereas no mutations were detected in the PDE6H gene, mutations in KCNV2 were identified in all patients, in either the homozygous or compound heterozygous state.
BC8_BioRED_Task1_Doc249	1020	1025	KCNV2	Gene	169522	Whereas no mutations were detected in the PDE6H gene, mutations in KCNV2 were identified in all patients, in either the homozygous or compound heterozygous state.
BC8_BioRED_Task1_Doc249	1049	1057	patients	OrganismTaxon	9606	Whereas no mutations were detected in the PDE6H gene, mutations in KCNV2 were identified in all patients, in either the homozygous or compound heterozygous state.
BC8_BioRED_Task1_Doc249	1351	1356	CDSRR	Disease	C563678	The CDSRR phenotype was associated with reduced visual acuity of variable degree and color vision defects.
BC8_BioRED_Task1_Doc249	1432	1452	color vision defects	Disease	D003117	The CDSRR phenotype was associated with reduced visual acuity of variable degree and color vision defects.
BC8_BioRED_Task1_Doc249	1526	1533	atrophy	Disease	D001284	Macular defects ranging from mild pigmentary changes to distinct foveal atrophy were present in nine patients.
BC8_BioRED_Task1_Doc249	1555	1563	patients	OrganismTaxon	9606	Macular defects ranging from mild pigmentary changes to distinct foveal atrophy were present in nine patients.
BC8_BioRED_Task1_Doc249	1628	1636	patients	OrganismTaxon	9606	Progression of the disease was observed in only three of seven patients with follow-up data.
BC8_BioRED_Task1_Doc249	1688	1732	cone dystrophy with supernormal rod response	Disease	C563678	CONCLUSIONS: The phenotype of cone dystrophy with supernormal rod response is tightly linked with mutations in KCNV2.
BC8_BioRED_Task1_Doc249	1769	1774	KCNV2	Gene	169522	CONCLUSIONS: The phenotype of cone dystrophy with supernormal rod response is tightly linked with mutations in KCNV2.
BC8_BioRED_Task1_Doc250	32	37	PQBP1	Gene	10084	A two base pair deletion in the PQBP1 gene is associated with microphthalmia, microcephaly, and mental retardation.
BC8_BioRED_Task1_Doc250	62	76	microphthalmia	Disease	D008850	A two base pair deletion in the PQBP1 gene is associated with microphthalmia, microcephaly, and mental retardation.
BC8_BioRED_Task1_Doc250	78	90	microcephaly	Disease	D008831	A two base pair deletion in the PQBP1 gene is associated with microphthalmia, microcephaly, and mental retardation.
BC8_BioRED_Task1_Doc250	96	114	mental retardation	Disease	D008607	A two base pair deletion in the PQBP1 gene is associated with microphthalmia, microcephaly, and mental retardation.
BC8_BioRED_Task1_Doc250	116	143	X-linked mental retardation	Disease	D038901	X-linked mental retardation has been traditionally divided into syndromic (S-XLMR) and non-syndromic forms (NS-XLMR), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example PQBP1, can cause S-XLMR as well as NS-XLMR.
BC8_BioRED_Task1_Doc250	193	197	XLMR	Disease	D038901	X-linked mental retardation has been traditionally divided into syndromic (S-XLMR) and non-syndromic forms (NS-XLMR), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example PQBP1, can cause S-XLMR as well as NS-XLMR.
BC8_BioRED_Task1_Doc250	227	231	XLMR	Disease	D038901	X-linked mental retardation has been traditionally divided into syndromic (S-XLMR) and non-syndromic forms (NS-XLMR), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example PQBP1, can cause S-XLMR as well as NS-XLMR.
BC8_BioRED_Task1_Doc250	344	349	PQBP1	Gene	10084	X-linked mental retardation has been traditionally divided into syndromic (S-XLMR) and non-syndromic forms (NS-XLMR), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example PQBP1, can cause S-XLMR as well as NS-XLMR.
BC8_BioRED_Task1_Doc250	363	367	XLMR	Disease	D038901	X-linked mental retardation has been traditionally divided into syndromic (S-XLMR) and non-syndromic forms (NS-XLMR), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example PQBP1, can cause S-XLMR as well as NS-XLMR.
BC8_BioRED_Task1_Doc250	382	386	XLMR	Disease	D038901	X-linked mental retardation has been traditionally divided into syndromic (S-XLMR) and non-syndromic forms (NS-XLMR), although the borderlines between these phenotypes begin to vanish and mutations in a single gene, for example PQBP1, can cause S-XLMR as well as NS-XLMR.
BC8_BioRED_Task1_Doc250	444	484	X-linked phenotype of mental retardation	Disease	D038901	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	486	488	MR	Disease	D008607	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	491	505	microphthalmia	Disease	D008850	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	507	523	choroid coloboma	Disease	D003103	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	525	537	microcephaly	Disease	D008831	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	539	555	renal hypoplasia	Disease	D007674	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	561	579	spastic paraplegia	Disease	D010264	Here, we report two maternal cousins with an apparently X-linked phenotype of mental retardation (MR), microphthalmia, choroid coloboma, microcephaly, renal hypoplasia, and spastic paraplegia.
BC8_BioRED_Task1_Doc250	745	749	BCOR	Gene	54880	By multipoint linkage analysis with markers spanning the entire X-chromosome we mapped the disease locus to a 28-Mb interval between Xp11.4 and Xq12, including the BCOR gene.
BC8_BioRED_Task1_Doc250	779	783	BCOR	Gene	54880	A missense mutation in BCOR was described in a family with Lenz microphthalmia syndrome, a phenotype showing substantial overlapping features with that described in the two cousins.
BC8_BioRED_Task1_Doc250	815	843	Lenz microphthalmia syndrome	Disease	C537464	A missense mutation in BCOR was described in a family with Lenz microphthalmia syndrome, a phenotype showing substantial overlapping features with that described in the two cousins.
BC8_BioRED_Task1_Doc250	966	970	BCOR	Gene	54880	However, no mutation in the BCOR gene was found in both patients.
BC8_BioRED_Task1_Doc250	994	1002	patients	OrganismTaxon	9606	However, no mutation in the BCOR gene was found in both patients.
BC8_BioRED_Task1_Doc250	1036	1041	PQBP1	Gene	10084	Subsequent mutation analysis of PQBP1, located within the delineated linkage interval in Xp11.23, revealed a 2-bp deletion, c.461_462delAG, that cosegregated with the disease.
BC8_BioRED_Task1_Doc250	1128	1142	c.461_462delAG	SequenceVariant	rs606231195	Subsequent mutation analysis of PQBP1, located within the delineated linkage interval in Xp11.23, revealed a 2-bp deletion, c.461_462delAG, that cosegregated with the disease.
BC8_BioRED_Task1_Doc250	1230	1265	Hamel cerebropalatocardiac syndrome	Disease	C537761	Notably, the same mutation is associated with the Hamel cerebropalatocardiac syndrome, another form of S-XLMR.
BC8_BioRED_Task1_Doc250	1285	1289	XLMR	Disease	D038901	Notably, the same mutation is associated with the Hamel cerebropalatocardiac syndrome, another form of S-XLMR.
BC8_BioRED_Task1_Doc250	1493	1498	PQBP1	Gene	10084	In summary, our findings demonstrate for the first time that mutations in PQBP1 are associated with an S-XLMR phenotype including microphthalmia, thereby further extending the clinical spectrum of phenotypes associated with PQBP1 mutations.
BC8_BioRED_Task1_Doc250	1524	1528	XLMR	Disease	D038901	In summary, our findings demonstrate for the first time that mutations in PQBP1 are associated with an S-XLMR phenotype including microphthalmia, thereby further extending the clinical spectrum of phenotypes associated with PQBP1 mutations.
BC8_BioRED_Task1_Doc250	1549	1563	microphthalmia	Disease	D008850	In summary, our findings demonstrate for the first time that mutations in PQBP1 are associated with an S-XLMR phenotype including microphthalmia, thereby further extending the clinical spectrum of phenotypes associated with PQBP1 mutations.
BC8_BioRED_Task1_Doc250	1643	1648	PQBP1	Gene	10084	In summary, our findings demonstrate for the first time that mutations in PQBP1 are associated with an S-XLMR phenotype including microphthalmia, thereby further extending the clinical spectrum of phenotypes associated with PQBP1 mutations.
BC8_BioRED_Task1_Doc251	18	27	Lys198Asn	SequenceVariant	rs5370	Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene.
BC8_BioRED_Task1_Doc251	32	40	-134delA	SequenceVariant	rs1800997	Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene.
BC8_BioRED_Task1_Doc251	70	82	endothelin-1	Gene	1906	Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene.
BC8_BioRED_Task1_Doc251	89	101	Endothelin-1	Gene	1906	Endothelin-1 (ET-1) is a potent vasoconstrictor and shows various pharmacological responses.
BC8_BioRED_Task1_Doc251	103	107	ET-1	Gene	1906	Endothelin-1 (ET-1) is a potent vasoconstrictor and shows various pharmacological responses.
BC8_BioRED_Task1_Doc251	225	229	ET-1	Gene	1906	Two single nucleotide polymorphisms in the ET-1 gene (EDN1) have been reported to be associated with blood pressure (BP).
BC8_BioRED_Task1_Doc251	236	240	EDN1	Gene	1906	Two single nucleotide polymorphisms in the ET-1 gene (EDN1) have been reported to be associated with blood pressure (BP).
BC8_BioRED_Task1_Doc251	315	324	Lys198Asn	SequenceVariant	rs5370	One is the Lys198Asn polymorphism, which showed a positive association with BP in overweight people.
BC8_BioRED_Task1_Doc251	386	396	overweight	Disease	D050177	One is the Lys198Asn polymorphism, which showed a positive association with BP in overweight people.
BC8_BioRED_Task1_Doc251	440	448	-134delA	SequenceVariant	rs1800997	Another is the 3A/4A polymorphism (-134delA) located in the 5'-untranslated region.
BC8_BioRED_Task1_Doc251	542	551	Lys198Asn	SequenceVariant	rs5370	In this study, we investigated the expression of the Lys198Asn polymorphism in ET-1 in vitro, as well as the association between either of the two polymorphisms and the plasma ET-1 level.
BC8_BioRED_Task1_Doc251	568	572	ET-1	Gene	1906	In this study, we investigated the expression of the Lys198Asn polymorphism in ET-1 in vitro, as well as the association between either of the two polymorphisms and the plasma ET-1 level.
BC8_BioRED_Task1_Doc251	665	669	ET-1	Gene	1906	In this study, we investigated the expression of the Lys198Asn polymorphism in ET-1 in vitro, as well as the association between either of the two polymorphisms and the plasma ET-1 level.
BC8_BioRED_Task1_Doc251	748	752	ET-1	Gene	1906	We expressed both the major (Lys-type) and minor type (Asn-type) preproET-1 in three different cell lines, and measured the levels of ET-1 and big ET-1 in the culture supernatant.
BC8_BioRED_Task1_Doc251	811	815	ET-1	Gene	1906	We expressed both the major (Lys-type) and minor type (Asn-type) preproET-1 in three different cell lines, and measured the levels of ET-1 and big ET-1 in the culture supernatant.
BC8_BioRED_Task1_Doc251	824	828	ET-1	Gene	1906	We expressed both the major (Lys-type) and minor type (Asn-type) preproET-1 in three different cell lines, and measured the levels of ET-1 and big ET-1 in the culture supernatant.
BC8_BioRED_Task1_Doc251	910	914	ET-1	Gene	1906	There was no significant difference in the levels of ET-1 or big ET-1 between the Asn-type and Lys-type transfectant.
BC8_BioRED_Task1_Doc251	922	926	ET-1	Gene	1906	There was no significant difference in the levels of ET-1 or big ET-1 between the Asn-type and Lys-type transfectant.
BC8_BioRED_Task1_Doc251	939	973	Asn-type and Lys-type transfectant	SequenceVariant	rs5370	There was no significant difference in the levels of ET-1 or big ET-1 between the Asn-type and Lys-type transfectant.
BC8_BioRED_Task1_Doc251	1022	1026	ET-1	Gene	1906	In the association study, the plasma levels of ET-1 in 54 hypertensive patients having an amino acid substitution from Lys to Asn at position 198 were not different from those of hypertensives without the substitution.
BC8_BioRED_Task1_Doc251	1033	1045	hypertensive	Disease	D006973	In the association study, the plasma levels of ET-1 in 54 hypertensive patients having an amino acid substitution from Lys to Asn at position 198 were not different from those of hypertensives without the substitution.
BC8_BioRED_Task1_Doc251	1046	1054	patients	OrganismTaxon	9606	In the association study, the plasma levels of ET-1 in 54 hypertensive patients having an amino acid substitution from Lys to Asn at position 198 were not different from those of hypertensives without the substitution.
BC8_BioRED_Task1_Doc251	1094	1120	Lys to Asn at position 198	SequenceVariant	rs5370	In the association study, the plasma levels of ET-1 in 54 hypertensive patients having an amino acid substitution from Lys to Asn at position 198 were not different from those of hypertensives without the substitution.
BC8_BioRED_Task1_Doc251	1154	1167	hypertensives	Disease	D006973	In the association study, the plasma levels of ET-1 in 54 hypertensive patients having an amino acid substitution from Lys to Asn at position 198 were not different from those of hypertensives without the substitution.
BC8_BioRED_Task1_Doc251	1240	1244	ET-1	Gene	1906	However, we found a significant difference in ET-1 levels between individuals with the 3A/3A and 3A/4A genotypes.
BC8_BioRED_Task1_Doc251	1358	1367	Lys198Asn	SequenceVariant	rs5370	Our transient expression study indicates that the Lys198Asn polymorphism may not directly affect ET-1 and big ET-1 production.
BC8_BioRED_Task1_Doc251	1405	1409	ET-1	Gene	1906	Our transient expression study indicates that the Lys198Asn polymorphism may not directly affect ET-1 and big ET-1 production.
BC8_BioRED_Task1_Doc251	1418	1422	ET-1	Gene	1906	Our transient expression study indicates that the Lys198Asn polymorphism may not directly affect ET-1 and big ET-1 production.
BC8_BioRED_Task1_Doc251	1458	1462	EDN1	Gene	1906	Another variant in the EDN1 gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity may be involved in the mechanisms elevating BP in vivo.
BC8_BioRED_Task1_Doc251	1503	1512	Lys198Asn	SequenceVariant	rs5370	Another variant in the EDN1 gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity may be involved in the mechanisms elevating BP in vivo.
BC8_BioRED_Task1_Doc251	1605	1609	EDN1	Gene	1906	Another variant in the EDN1 gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity may be involved in the mechanisms elevating BP in vivo.
BC8_BioRED_Task1_Doc251	1610	1619	Lys198Asn	SequenceVariant	rs5370	Another variant in the EDN1 gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity may be involved in the mechanisms elevating BP in vivo.
BC8_BioRED_Task1_Doc251	1659	1666	obesity	Disease	D009765	Another variant in the EDN1 gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity may be involved in the mechanisms elevating BP in vivo.
BC8_BioRED_Task1_Doc252	0	14	Norepinephrine	Chemical	D009638	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	33	58	beta-adrenergic receptors	Gene	11554	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	89	96	cocaine	Chemical	D003042	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	105	112	anxiety	Disease	D001008	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	126	133	Cocaine	Chemical	D003042	BACKGROUND: Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties.
BC8_BioRED_Task1_Doc252	250	257	cocaine	Chemical	D003042	While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.
BC8_BioRED_Task1_Doc252	385	392	cocaine	Chemical	D003042	While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.
BC8_BioRED_Task1_Doc252	402	409	anxiety	Disease	D001008	While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.
BC8_BioRED_Task1_Doc252	467	492	dopamine beta-hydroxylase	Gene	13166	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	503	506	Dbh	Gene	13166	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	512	516	mice	OrganismTaxon	10090	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	529	543	norepinephrine	Chemical	D009638	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	545	547	NE	Chemical	D009638	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	640	647	cocaine	Chemical	D003042	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	656	663	anxiety	Disease	D001008	METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.
BC8_BioRED_Task1_Doc252	688	695	cocaine	Chemical	D003042	RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.
BC8_BioRED_Task1_Doc252	723	730	anxiety	Disease	D001008	RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.
BC8_BioRED_Task1_Doc252	757	760	Dbh	Gene	13166	RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.
BC8_BioRED_Task1_Doc252	766	770	mice	OrganismTaxon	10090	RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.
BC8_BioRED_Task1_Doc252	827	830	Dbh	Gene	13166	The Dbh -/- mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine.
BC8_BioRED_Task1_Doc252	835	839	mice	OrganismTaxon	10090	The Dbh -/- mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine.
BC8_BioRED_Task1_Doc252	942	949	cocaine	Chemical	D003042	The Dbh -/- mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine.
BC8_BioRED_Task1_Doc252	951	958	Cocaine	Chemical	D003042	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	967	974	anxiety	Disease	D001008	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	998	1001	Dbh	Gene	13166	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	1006	1010	mice	OrganismTaxon	10090	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	1039	1049	disulfiram	Chemical	D004221	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	1053	1078	dopamine beta-hydroxylase	Gene	13166	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	1080	1083	DBH	Gene	13166	Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
BC8_BioRED_Task1_Doc252	1126	1148	adrenergic antagonists	Chemical	D018674	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1186	1210	beta-adrenergic receptor	Gene	11554	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1222	1233	propranolol	Chemical	D011433	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1242	1249	cocaine	Chemical	D003042	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1258	1265	anxiety	Disease	D001008	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1283	1286	Dbh	Gene	13166	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1314	1318	mice	OrganismTaxon	10090	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1330	1338	alpha(1)	Gene	11549	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1350	1358	prazosin	Chemical	D011224	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1367	1375	alpha(2)	Gene	11551	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1387	1396	yohimbine	Chemical	D015016	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
BC8_BioRED_Task1_Doc252	1481	1506	beta-adrenergic receptors	Gene	11554	CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.
BC8_BioRED_Task1_Doc252	1523	1530	cocaine	Chemical	D003042	CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.
BC8_BioRED_Task1_Doc252	1539	1546	anxiety	Disease	D001008	CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.
BC8_BioRED_Task1_Doc252	1550	1554	mice	OrganismTaxon	10090	CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.
BC8_BioRED_Task1_Doc253	0	38	Plasminogen activator inhibitor type 1	Gene	5054	Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
BC8_BioRED_Task1_Doc253	92	97	obese	Disease	D009765	Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
BC8_BioRED_Task1_Doc253	107	115	patients	OrganismTaxon	9606	Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
BC8_BioRED_Task1_Doc253	121	154	non-alcoholic fatty liver disease	Disease	D065626	Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
BC8_BioRED_Task1_Doc253	172	210	plasminogen activator inhibitor type-1	Gene	5054	BACKGROUND: The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components.
BC8_BioRED_Task1_Doc253	212	217	PAI-1	Gene	5054	BACKGROUND: The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components.
BC8_BioRED_Task1_Doc253	413	418	PAI-1	Gene	5054	The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis.
BC8_BioRED_Task1_Doc253	435	440	PAI-1	Gene	5054	The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis.
BC8_BioRED_Task1_Doc253	468	488	hepatic fibrogenesis	Disease	D008107	The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis.
BC8_BioRED_Task1_Doc253	524	529	PAI-1	Gene	5054	AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.
BC8_BioRED_Task1_Doc253	581	595	liver fibrosis	Disease	D008103	AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.
BC8_BioRED_Task1_Doc253	610	643	non-alcoholic fatty liver disease	Disease	D065626	AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.
BC8_BioRED_Task1_Doc253	645	650	NAFLD	Disease	D065626	AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.
BC8_BioRED_Task1_Doc253	664	669	obese	Disease	D009765	AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.
BC8_BioRED_Task1_Doc253	670	678	patients	OrganismTaxon	9606	AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.
BC8_BioRED_Task1_Doc253	727	732	obese	Disease	D009765	MATERIAL AND METHODS: Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex.
BC8_BioRED_Task1_Doc253	733	741	patients	OrganismTaxon	9606	MATERIAL AND METHODS: Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex.
BC8_BioRED_Task1_Doc253	782	787	obese	Disease	D009765	MATERIAL AND METHODS: Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex.
BC8_BioRED_Task1_Doc253	891	896	PAI-1	Gene	5054	Anthropometric and biochemical measurements were performed, including PAI-1 serum levels.
BC8_BioRED_Task1_Doc253	1009	1022	triglycerides	Chemical	D014280	RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects.
BC8_BioRED_Task1_Doc253	1033	1045	hypertension	Disease	D006973	RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects.
BC8_BioRED_Task1_Doc253	1050	1058	diabetes	Disease	D003920	RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects.
BC8_BioRED_Task1_Doc253	1088	1093	obese	Disease	D009765	RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects.
BC8_BioRED_Task1_Doc253	1094	1102	patients	OrganismTaxon	9606	RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects.
BC8_BioRED_Task1_Doc253	1133	1138	PAI-1	Gene	5054	PAI-1 serum levels observed in obese patients were significantly lower (10.63 4.82) compared to controls (14.26 11.4; p < 0.05).
BC8_BioRED_Task1_Doc253	1164	1169	obese	Disease	D009765	PAI-1 serum levels observed in obese patients were significantly lower (10.63 4.82) compared to controls (14.26 11.4; p < 0.05).
BC8_BioRED_Task1_Doc253	1170	1178	patients	OrganismTaxon	9606	PAI-1 serum levels observed in obese patients were significantly lower (10.63 4.82) compared to controls (14.26 11.4; p < 0.05).
BC8_BioRED_Task1_Doc253	1298	1303	PAI-1	Gene	5054	No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12).
BC8_BioRED_Task1_Doc253	1385	1390	PAI-1	Gene	5054	No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985).
BC8_BioRED_Task1_Doc253	1411	1416	obese	Disease	D009765	No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985).
BC8_BioRED_Task1_Doc253	1417	1425	patients	OrganismTaxon	9606	No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985).
BC8_BioRED_Task1_Doc253	1431	1445	liver fibrosis	Disease	D008103	No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985).
BC8_BioRED_Task1_Doc253	1471	1479	patients	OrganismTaxon	9606	No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985).
BC8_BioRED_Task1_Doc253	1488	1502	liver fibrosis	Disease	D008103	No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985).
BC8_BioRED_Task1_Doc253	1527	1532	PAI-1	Gene	5054	PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6).
BC8_BioRED_Task1_Doc253	1586	1594	patients	OrganismTaxon	9606	PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6).
BC8_BioRED_Task1_Doc253	1611	1625	liver fibrosis	Disease	D008103	PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6).
BC8_BioRED_Task1_Doc253	1640	1644	NASH	Disease	D065626	PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6).
BC8_BioRED_Task1_Doc253	1678	1683	obese	Disease	D009765	CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects.
BC8_BioRED_Task1_Doc253	1684	1692	patients	OrganismTaxon	9606	CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects.
BC8_BioRED_Task1_Doc253	1717	1722	PAI-1	Gene	5054	CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects.
BC8_BioRED_Task1_Doc253	1749	1754	PAI-1	Gene	5054	CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects.
BC8_BioRED_Task1_Doc253	1799	1804	obese	Disease	D009765	CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects.
BC8_BioRED_Task1_Doc253	1970	1975	PAI-1	Gene	5054	No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
BC8_BioRED_Task1_Doc253	2012	2026	liver fibrosis	Disease	D008103	No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
BC8_BioRED_Task1_Doc253	2030	2035	obese	Disease	D009765	No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
BC8_BioRED_Task1_Doc253	2036	2044	patients	OrganismTaxon	9606	No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.
BC8_BioRED_Task1_Doc254	8	24	apolipoprotein E	Gene	348	A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc254	35	39	ApoE	Gene	348	A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc254	47	57	Arg158 Pro	SequenceVariant	p|SUB|R|158|P	A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc254	65	77	dyslipidemic	Disease	D050171	A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc254	78	85	patient	OrganismTaxon	9606	A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc254	91	117	lipoprotein glomerulopathy	Disease	C567089	A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc254	119	145	Lipoprotein glomerulopathy	Disease	C567089	Lipoprotein glomerulopathy (LPG) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum apolipoprotein E (apoE) level.
BC8_BioRED_Task1_Doc254	147	150	LPG	Disease	C567089	Lipoprotein glomerulopathy (LPG) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum apolipoprotein E (apoE) level.
BC8_BioRED_Task1_Doc254	317	333	apolipoprotein E	Gene	348	Lipoprotein glomerulopathy (LPG) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum apolipoprotein E (apoE) level.
BC8_BioRED_Task1_Doc254	335	339	apoE	Gene	348	Lipoprotein glomerulopathy (LPG) is a rare disease characterized by the presence of thrombuslike deposition in markedly dilated glomerular capillaries and is often accompanied by an increased serum apolipoprotein E (apoE) level.
BC8_BioRED_Task1_Doc254	374	378	apoE	Gene	348	Several gene mutations of apoE have been reported to be associated with LPG.
BC8_BioRED_Task1_Doc254	420	423	LPG	Disease	C567089	Several gene mutations of apoE have been reported to be associated with LPG.
BC8_BioRED_Task1_Doc254	460	463	LPG	Disease	C567089	In the current study, we report an LPG patient with a novel apoE mutation, apoE Osaka.
BC8_BioRED_Task1_Doc254	464	471	patient	OrganismTaxon	9606	In the current study, we report an LPG patient with a novel apoE mutation, apoE Osaka.
BC8_BioRED_Task1_Doc254	485	489	apoE	Gene	348	In the current study, we report an LPG patient with a novel apoE mutation, apoE Osaka.
BC8_BioRED_Task1_Doc254	500	504	apoE	Gene	348	In the current study, we report an LPG patient with a novel apoE mutation, apoE Osaka.
BC8_BioRED_Task1_Doc254	516	523	patient	OrganismTaxon	9606	The patient was a 45-year-old man who was hospitalized due to nephrotic syndrome.
BC8_BioRED_Task1_Doc254	542	545	man	OrganismTaxon	9606	The patient was a 45-year-old man who was hospitalized due to nephrotic syndrome.
BC8_BioRED_Task1_Doc254	574	592	nephrotic syndrome	Disease	D009404	The patient was a 45-year-old man who was hospitalized due to nephrotic syndrome.
BC8_BioRED_Task1_Doc254	696	699	LPG	Disease	C567089	Light and electron microscopic observations of renal biopsy clearly showed characteristic findings of LPG, including lamellate thrombi in the lumen of dilated glomerular capillaries.
BC8_BioRED_Task1_Doc254	711	728	lamellate thrombi	Disease	D013927	Light and electron microscopic observations of renal biopsy clearly showed characteristic findings of LPG, including lamellate thrombi in the lumen of dilated glomerular capillaries.
BC8_BioRED_Task1_Doc254	781	785	apoE	Gene	348	His apoE phenotype was apoE3/2 and he had mild dyslipidemia with a mid-band on polyacrylamide gel electrophoresis.
BC8_BioRED_Task1_Doc254	800	807	apoE3/2	Gene	348	His apoE phenotype was apoE3/2 and he had mild dyslipidemia with a mid-band on polyacrylamide gel electrophoresis.
BC8_BioRED_Task1_Doc254	824	836	dyslipidemia	Disease	D050171	His apoE phenotype was apoE3/2 and he had mild dyslipidemia with a mid-band on polyacrylamide gel electrophoresis.
BC8_BioRED_Task1_Doc254	856	870	polyacrylamide	Chemical	-	His apoE phenotype was apoE3/2 and he had mild dyslipidemia with a mid-band on polyacrylamide gel electrophoresis.
BC8_BioRED_Task1_Doc254	924	928	apoE	Gene	348	It is intriguing that the serum apoE level was within normal limits.
BC8_BioRED_Task1_Doc254	995	999	apoE	Gene	348	We determined the sequence of the apoE gene using direct sequencing of the polymerase chain reaction (PCR) products.
BC8_BioRED_Task1_Doc254	1078	1082	ApoE	Gene	348	ApoE gene analysis showed a nucleotide substitution of G to C at codon 158 of exon 4.
BC8_BioRED_Task1_Doc254	1133	1152	G to C at codon 158	SequenceVariant	c|SUB|G|CODON158|C	ApoE gene analysis showed a nucleotide substitution of G to C at codon 158 of exon 4.
BC8_BioRED_Task1_Doc254	1216	1272	arginine residue for the proline residue at position 158	SequenceVariant	p|SUB|R|158|P	This mutation denoted an amino acid substitution of arginine residue for the proline residue at position 158 of apoE.
BC8_BioRED_Task1_Doc254	1276	1280	apoE	Gene	348	This mutation denoted an amino acid substitution of arginine residue for the proline residue at position 158 of apoE.
BC8_BioRED_Task1_Doc254	1437	1441	apoE	Gene	348	It is possible that apoE Osaka mutation causes a conformational change of apoE protein and affects the interaction between abnormal apoE-containing lipoproteins and the endothelial cells of glomerular capillaries.
BC8_BioRED_Task1_Doc254	1491	1495	apoE	Gene	348	It is possible that apoE Osaka mutation causes a conformational change of apoE protein and affects the interaction between abnormal apoE-containing lipoproteins and the endothelial cells of glomerular capillaries.
BC8_BioRED_Task1_Doc254	1549	1553	apoE	Gene	348	It is possible that apoE Osaka mutation causes a conformational change of apoE protein and affects the interaction between abnormal apoE-containing lipoproteins and the endothelial cells of glomerular capillaries.
BC8_BioRED_Task1_Doc254	1656	1659	LPG	Disease	C567089	The precise mechanism of LPG related with apoE Osaka, however, remains to be elucidated.
BC8_BioRED_Task1_Doc254	1673	1677	apoE	Gene	348	The precise mechanism of LPG related with apoE Osaka, however, remains to be elucidated.
BC8_BioRED_Task1_Doc255	38	53	liver kinase B1	Gene	20869	Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
BC8_BioRED_Task1_Doc255	81	86	tumor	Disease	D009369	Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
BC8_BioRED_Task1_Doc255	98	132	vascular endothelial growth factor	Gene	22339	Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
BC8_BioRED_Task1_Doc255	134	149	Liver kinase B1	Gene	20869	Liver kinase B1 (LKB1) is a serine/threonine protein kinase ubiquitously expressed in mammalian cells.
BC8_BioRED_Task1_Doc255	151	155	LKB1	Gene	20869	Liver kinase B1 (LKB1) is a serine/threonine protein kinase ubiquitously expressed in mammalian cells.
BC8_BioRED_Task1_Doc255	162	193	serine/threonine protein kinase	Gene	20869	Liver kinase B1 (LKB1) is a serine/threonine protein kinase ubiquitously expressed in mammalian cells.
BC8_BioRED_Task1_Doc255	264	286	Peutz-Jeghers syndrome	Disease	D010580	It was first identified in Peutz-Jeghers syndrome as a tumor suppressor gene.
BC8_BioRED_Task1_Doc255	292	297	tumor	Disease	D009369	It was first identified in Peutz-Jeghers syndrome as a tumor suppressor gene.
BC8_BioRED_Task1_Doc255	335	339	LKB1	Gene	20869	Whether endothelial LKB1 regulates angiogenesis and tumor growth is unknown.
BC8_BioRED_Task1_Doc255	367	372	tumor	Disease	D009369	Whether endothelial LKB1 regulates angiogenesis and tumor growth is unknown.
BC8_BioRED_Task1_Doc255	446	450	LKB1	Gene	20869	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	461	465	LKB1	Gene	20869	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	476	480	mice	OrganismTaxon	10090	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	498	527	vascular endothelial-cadherin	Gene	12562	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	532	536	mice	OrganismTaxon	10090	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	542	546	LKB1	Gene	20869	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	558	562	mice	OrganismTaxon	10090	In this study, we generated endothelial cell-specific LKB1-knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelial-cadherin-Cre mice with LKB1(flox/flox) mice.
BC8_BioRED_Task1_Doc255	564	598	Vascular endothelial growth factor	Gene	22339	Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1(endo-/-) mice.
BC8_BioRED_Task1_Doc255	600	604	VEGF	Gene	22339	Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1(endo-/-) mice.
BC8_BioRED_Task1_Doc255	681	685	LKB1	Gene	20869	Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1(endo-/-) mice.
BC8_BioRED_Task1_Doc255	695	699	mice	OrganismTaxon	10090	Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1(endo-/-) mice.
BC8_BioRED_Task1_Doc255	715	719	LKB1	Gene	20869	Consistently, LKB1(endo-/-) mouse tissues including the lung, skin, kidney and liver showed increased vascular permeability.
BC8_BioRED_Task1_Doc255	729	734	mouse	OrganismTaxon	10090	Consistently, LKB1(endo-/-) mouse tissues including the lung, skin, kidney and liver showed increased vascular permeability.
BC8_BioRED_Task1_Doc255	826	832	Tumors	Disease	D009369	Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.
BC8_BioRED_Task1_Doc255	846	850	LKB1	Gene	20869	Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.
BC8_BioRED_Task1_Doc255	860	864	mice	OrganismTaxon	10090	Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.
BC8_BioRED_Task1_Doc255	893	897	LKB1	Gene	20869	Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.
BC8_BioRED_Task1_Doc255	907	911	mice	OrganismTaxon	10090	Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.
BC8_BioRED_Task1_Doc255	1039	1043	mice	OrganismTaxon	10090	Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1-knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wild-type mice.
BC8_BioRED_Task1_Doc255	1058	1062	VEGF	Gene	22339	Injection of VEGF-neutralizing antibody but not the isotype-matched control antibody decreased endothelial-cell angiogenesis and tumor growth in vivo.
BC8_BioRED_Task1_Doc255	1174	1179	tumor	Disease	D009369	Injection of VEGF-neutralizing antibody but not the isotype-matched control antibody decreased endothelial-cell angiogenesis and tumor growth in vivo.
BC8_BioRED_Task1_Doc255	1209	1213	LKB1	Gene	20869	Furthermore, LKB1 deletion enhanced mouse retinal and cell angiogenesis, and knockdown of VEGF by small-interfering RNA decreased endothelial cell proliferation and migration.
BC8_BioRED_Task1_Doc255	1232	1237	mouse	OrganismTaxon	10090	Furthermore, LKB1 deletion enhanced mouse retinal and cell angiogenesis, and knockdown of VEGF by small-interfering RNA decreased endothelial cell proliferation and migration.
BC8_BioRED_Task1_Doc255	1286	1290	VEGF	Gene	22339	Furthermore, LKB1 deletion enhanced mouse retinal and cell angiogenesis, and knockdown of VEGF by small-interfering RNA decreased endothelial cell proliferation and migration.
BC8_BioRED_Task1_Doc255	1389	1393	LKB1	Gene	20869	Re-expression of LKB1 or knockdown of VEGF receptor 2 decreased the overproliferation and -migration observed in LKB1(endo-/-) cells.
BC8_BioRED_Task1_Doc255	1410	1425	VEGF receptor 2	Gene	16542	Re-expression of LKB1 or knockdown of VEGF receptor 2 decreased the overproliferation and -migration observed in LKB1(endo-/-) cells.
BC8_BioRED_Task1_Doc255	1485	1489	LKB1	Gene	20869	Re-expression of LKB1 or knockdown of VEGF receptor 2 decreased the overproliferation and -migration observed in LKB1(endo-/-) cells.
BC8_BioRED_Task1_Doc255	1523	1527	LKB1	Gene	20869	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1546	1550	VEGF	Gene	22339	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1573	1594	specificity protein 1	Gene	20683	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1596	1599	Sp1	Gene	20683	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1638	1641	Sp1	Gene	20683	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1649	1653	VEGF	Gene	22339	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1673	1677	VEGF	Gene	22339	Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression.
BC8_BioRED_Task1_Doc255	1702	1706	LKB1	Gene	20869	Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.
BC8_BioRED_Task1_Doc255	1749	1754	tumor	Disease	D009369	Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.
BC8_BioRED_Task1_Doc255	1776	1779	Sp1	Gene	20683	Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.
BC8_BioRED_Task1_Doc255	1789	1793	VEGF	Gene	22339	Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.
BC8_BioRED_Task1_Doc256	0	9	Clonidine	Chemical	D003000	Clonidine for attention-deficit/hyperactivity disorder: II.
BC8_BioRED_Task1_Doc256	14	54	attention-deficit/hyperactivity disorder	Disease	D001289	Clonidine for attention-deficit/hyperactivity disorder: II.
BC8_BioRED_Task1_Doc256	154	163	clonidine	Chemical	D003000	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
BC8_BioRED_Task1_Doc256	183	198	methylphenidate	Chemical	D008774	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
BC8_BioRED_Task1_Doc256	216	256	attention-deficit/hyperactivity disorder	Disease	D001289	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
BC8_BioRED_Task1_Doc256	258	262	ADHD	Disease	D001289	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
BC8_BioRED_Task1_Doc256	337	341	ADHD	Disease	D001289	METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
BC8_BioRED_Task1_Doc256	368	377	clonidine	Chemical	D003000	METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
BC8_BioRED_Task1_Doc256	388	403	methylphenidate	Chemical	D008774	METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
BC8_BioRED_Task1_Doc256	414	423	clonidine	Chemical	D003000	METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
BC8_BioRED_Task1_Doc256	428	443	methylphenidate	Chemical	D008774	METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
BC8_BioRED_Task1_Doc256	525	534	clonidine	Chemical	D003000	Doses were flexibly titrated up to 0.6 mg/day for clonidine and 60 mg/day for methylphenidate (both with divided dosing).
BC8_BioRED_Task1_Doc256	553	568	methylphenidate	Chemical	D008774	Doses were flexibly titrated up to 0.6 mg/day for clonidine and 60 mg/day for methylphenidate (both with divided dosing).
BC8_BioRED_Task1_Doc256	757	768	bradycardia	Disease	D001919	RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.
BC8_BioRED_Task1_Doc256	794	803	clonidine	Chemical	D003000	RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.
BC8_BioRED_Task1_Doc256	841	850	clonidine	Chemical	D003000	RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.
BC8_BioRED_Task1_Doc256	1036	1045	clonidine	Chemical	D003000	There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes.
BC8_BioRED_Task1_Doc256	1050	1065	methylphenidate	Chemical	D008774	There were no suggestions of interactions between clonidine and methylphenidate regarding cardiovascular outcomes.
BC8_BioRED_Task1_Doc256	1167	1176	clonidine	Chemical	D003000	Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.
BC8_BioRED_Task1_Doc256	1272	1282	Drowsiness	Disease	D006970	Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.
BC8_BioRED_Task1_Doc256	1297	1306	clonidine	Chemical	D003000	Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.
BC8_BioRED_Task1_Doc256	1361	1370	Clonidine	Chemical	D003000	CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.
BC8_BioRED_Task1_Doc256	1391	1406	methylphenidate	Chemical	D008774	CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.
BC8_BioRED_Task1_Doc256	1453	1457	ADHD	Disease	D001289	CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.
BC8_BioRED_Task1_Doc256	1482	1491	clonidine	Chemical	D003000	Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.
BC8_BioRED_Task1_Doc256	1511	1522	bradycardia	Disease	D001919	Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.
BC8_BioRED_Task1_Doc256	1534	1542	patients	OrganismTaxon	9606	Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.
BC8_BioRED_Task1_Doc256	1580	1590	drowsiness	Disease	D006970	Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness.
BC8_BioRED_Task1_Doc257	10	22	capecitabine	Chemical	D000069287	Safety of capecitabine: a review.
BC8_BioRED_Task1_Doc257	59	76	Fluoropyrimidines	Chemical	-	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
BC8_BioRED_Task1_Doc257	92	106	5-fluorouracil	Chemical	D005472	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
BC8_BioRED_Task1_Doc257	108	112	5-FU	Chemical	D005472	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
BC8_BioRED_Task1_Doc257	169	175	tumors	Disease	D009369	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
BC8_BioRED_Task1_Doc257	187	231	colorectal, breast and head and neck cancers	Disease	D001943,D006258,D015179	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
BC8_BioRED_Task1_Doc257	333	345	capecitabine	Chemical	D000069287	AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.
BC8_BioRED_Task1_Doc257	467	479	capecitabine	Chemical	D000069287	WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.
BC8_BioRED_Task1_Doc257	511	519	patients	OrganismTaxon	9606	WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.
BC8_BioRED_Task1_Doc257	539	563	renal and kidney disease	Disease	D007674	WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.
BC8_BioRED_Task1_Doc257	615	627	capecitabine	Chemical	D000069287	We also explore different dosing and schedules of capecitabine administration.
BC8_BioRED_Task1_Doc257	663	675	Capecitabine	Chemical	D000069287	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.
BC8_BioRED_Task1_Doc257	698	702	5-FU	Chemical	D005472	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.
BC8_BioRED_Task1_Doc257	913	998	colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers	Disease	D001943,D002292,D006258,D010190,D013274,D015179	It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.
BC8_BioRED_Task1_Doc257	1044	1056	capecitabine	Chemical	D000069287	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
BC8_BioRED_Task1_Doc257	1061	1069	diarrhea	Disease	D003967	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
BC8_BioRED_Task1_Doc257	1071	1077	nausea	Disease	D009325	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
BC8_BioRED_Task1_Doc257	1079	1087	vomiting	Disease	D014839	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
BC8_BioRED_Task1_Doc257	1089	1099	stomatitis	Disease	D013280	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
BC8_BioRED_Task1_Doc257	1104	1122	hand-foot syndrome	Disease	D060831	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
BC8_BioRED_Task1_Doc257	1124	1136	Capecitabine	Chemical	D000069287	Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.
BC8_BioRED_Task1_Doc257	1202	1210	patients	OrganismTaxon	9606	Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.
BC8_BioRED_Task1_Doc257	1230	1260	hepatic and renal dysfunctions	Disease	D007674,D008107	Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.
BC8_BioRED_Task1_Doc258	0	28	Cardiovascular complications	Disease	D002318	Cardiovascular complications associated with terbutaline treatment for preterm labor.
BC8_BioRED_Task1_Doc258	45	56	terbutaline	Chemical	D013726	Cardiovascular complications associated with terbutaline treatment for preterm labor.
BC8_BioRED_Task1_Doc258	71	84	preterm labor	Disease	D007752	Cardiovascular complications associated with terbutaline treatment for preterm labor.
BC8_BioRED_Task1_Doc258	93	121	cardiovascular complications	Disease	D002318	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.
BC8_BioRED_Task1_Doc258	147	155	patients	OrganismTaxon	9606	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.
BC8_BioRED_Task1_Doc258	169	180	terbutaline	Chemical	D013726	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.
BC8_BioRED_Task1_Doc258	185	198	preterm labor	Disease	D007752	Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.
BC8_BioRED_Task1_Doc258	211	225	corticosteroid	Chemical	D000305	Associated corticosteroid therapy and twin gestations appear to be predisposing factors.
BC8_BioRED_Task1_Doc259	0	5	XRCC1	Gene	7515	XRCC1 Arg399Gln gene polymorphism and the risk of systemic lupus erythematosus in the Polish population.
BC8_BioRED_Task1_Doc259	6	15	Arg399Gln	SequenceVariant	rs25487	XRCC1 Arg399Gln gene polymorphism and the risk of systemic lupus erythematosus in the Polish population.
BC8_BioRED_Task1_Doc259	50	78	systemic lupus erythematosus	Disease	D008180	XRCC1 Arg399Gln gene polymorphism and the risk of systemic lupus erythematosus in the Polish population.
BC8_BioRED_Task1_Doc259	153	161	patients	OrganismTaxon	9606	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	167	195	systemic lupus erythematosus	Disease	D008180	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	197	200	SLE	Disease	D008180	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	215	247	X-ray repair cross-complementing	Gene	7515	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	249	254	XRCC1	Gene	7515	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	256	265	Arg399Gln	SequenceVariant	rs25487	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	267	274	rs25487	SequenceVariant	rs25487	It has been shown that DNA repair is reduced in patients with systemic lupus erythematosus (SLE) and that the X-ray repair cross-complementing (XRCC1) Arg399Gln (rs25487) polymorphism may contribute to DNA repair.
BC8_BioRED_Task1_Doc259	353	358	XRCC1	Gene	7515	We evaluated the frequency of the XRCC1 Arg399Gln substitution in patients with SLE (n=265) and controls (n=360) in a sample of the Polish population.
BC8_BioRED_Task1_Doc259	359	368	Arg399Gln	SequenceVariant	rs25487	We evaluated the frequency of the XRCC1 Arg399Gln substitution in patients with SLE (n=265) and controls (n=360) in a sample of the Polish population.
BC8_BioRED_Task1_Doc259	385	393	patients	OrganismTaxon	9606	We evaluated the frequency of the XRCC1 Arg399Gln substitution in patients with SLE (n=265) and controls (n=360) in a sample of the Polish population.
BC8_BioRED_Task1_Doc259	399	402	SLE	Disease	D008180	We evaluated the frequency of the XRCC1 Arg399Gln substitution in patients with SLE (n=265) and controls (n=360) in a sample of the Polish population.
BC8_BioRED_Task1_Doc259	494	497	SLE	Disease	D008180	The odds ratio (OR) for SLE patients with the Gln/Gln versus Gln/Arg or Arg/Arg genotypes was 1.553 (95% confidence interval [CI]=0.9573-2.520; p=0.0729).
BC8_BioRED_Task1_Doc259	498	506	patients	OrganismTaxon	9606	The odds ratio (OR) for SLE patients with the Gln/Gln versus Gln/Arg or Arg/Arg genotypes was 1.553 (95% confidence interval [CI]=0.9573-2.520; p=0.0729).
BC8_BioRED_Task1_Doc259	736	743	399 Gln	SequenceVariant	rs25487	The OR for the 399 Gln allele in patients with SLE was 1.406 (95% CI=1.111-1.779, p=0.0045).
BC8_BioRED_Task1_Doc259	754	762	patients	OrganismTaxon	9606	The OR for the 399 Gln allele in patients with SLE was 1.406 (95% CI=1.111-1.779, p=0.0045).
BC8_BioRED_Task1_Doc259	768	771	SLE	Disease	D008180	The OR for the 399 Gln allele in patients with SLE was 1.406 (95% CI=1.111-1.779, p=0.0045).
BC8_BioRED_Task1_Doc259	911	916	XRCC1	Gene	7515	There was also a statistically significant p-value of the (2) test for the trend observed in the XRCC1 Arg399Gln polymorphism (ptrend=0.0048).
BC8_BioRED_Task1_Doc259	917	926	Arg399Gln	SequenceVariant	rs25487	There was also a statistically significant p-value of the (2) test for the trend observed in the XRCC1 Arg399Gln polymorphism (ptrend=0.0048).
BC8_BioRED_Task1_Doc259	1078	1088	malar rash	Disease	D005076	We also found a significant contribution of the Gln/Gln or Arg/Gln versus Arg/Arg genotype to the presence of either the malar rash or photosensitivity manifestations of SLE OR=2.241 (1.328-3.781, p=0.0023, pcorr=0.0414).
BC8_BioRED_Task1_Doc259	1127	1130	SLE	Disease	D008180	We also found a significant contribution of the Gln/Gln or Arg/Gln versus Arg/Arg genotype to the presence of either the malar rash or photosensitivity manifestations of SLE OR=2.241 (1.328-3.781, p=0.0023, pcorr=0.0414).
BC8_BioRED_Task1_Doc259	1347	1350	SLE	Disease	D008180	Moreover, the meta-analysis of Taiwanese Han Chinese, Brazilian, and Polish populations showed that the Gln/Gln or Gln/Arg genotype and Gln allele were associated with SLE incidence.
BC8_BioRED_Task1_Doc259	1553	1558	XRCC1	Gene	7515	Our studies may confirm that the XRCC1 Arg399Gln polymorphism may increase the risk of incidence of SLE and the occurrence of some SLE manifestations.
BC8_BioRED_Task1_Doc259	1559	1568	Arg399Gln	SequenceVariant	rs25487	Our studies may confirm that the XRCC1 Arg399Gln polymorphism may increase the risk of incidence of SLE and the occurrence of some SLE manifestations.
BC8_BioRED_Task1_Doc259	1620	1623	SLE	Disease	D008180	Our studies may confirm that the XRCC1 Arg399Gln polymorphism may increase the risk of incidence of SLE and the occurrence of some SLE manifestations.
BC8_BioRED_Task1_Doc259	1651	1654	SLE	Disease	D008180	Our studies may confirm that the XRCC1 Arg399Gln polymorphism may increase the risk of incidence of SLE and the occurrence of some SLE manifestations.
BC8_BioRED_Task1_Doc260	25	30	LYRM7	Gene	90624	A homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity.
BC8_BioRED_Task1_Doc260	31	36	MZM1L	Gene	90624	A homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity.
BC8_BioRED_Task1_Doc260	65	79	encephalopathy	Disease	D001927	A homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity.
BC8_BioRED_Task1_Doc260	81	96	lactic acidosis	Disease	D000140	A homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity.
BC8_BioRED_Task1_Doc260	109	147	reduction of mitochondrial complex III	Disease	C565128	A homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity.
BC8_BioRED_Task1_Doc260	201	250	defective complex III (cIII) of the mitochondrial	Disease	C565128	Mutations in nuclear genes associated with defective complex III (cIII) of the mitochondrial respiratory chain are rare, having been found in only two cIII assembly factors and, as private changes in single families, three cIII structural subunits.
BC8_BioRED_Task1_Doc260	309	313	cIII	Gene	617	Mutations in nuclear genes associated with defective complex III (cIII) of the mitochondrial respiratory chain are rare, having been found in only two cIII assembly factors and, as private changes in single families, three cIII structural subunits.
BC8_BioRED_Task1_Doc260	381	385	cIII	Gene	617	Mutations in nuclear genes associated with defective complex III (cIII) of the mitochondrial respiratory chain are rare, having been found in only two cIII assembly factors and, as private changes in single families, three cIII structural subunits.
BC8_BioRED_Task1_Doc260	417	422	human	OrganismTaxon	9606	Recently, human LYRM7/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for cIII.
BC8_BioRED_Task1_Doc260	423	428	LYRM7	Gene	90624	Recently, human LYRM7/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for cIII.
BC8_BioRED_Task1_Doc260	429	434	MZM1L	Gene	90624	Recently, human LYRM7/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for cIII.
BC8_BioRED_Task1_Doc260	452	457	yeast	OrganismTaxon	4932	Recently, human LYRM7/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for cIII.
BC8_BioRED_Task1_Doc260	458	462	MZM1	Gene	852104	Recently, human LYRM7/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for cIII.
BC8_BioRED_Task1_Doc260	513	517	cIII	Gene	617	Recently, human LYRM7/MZM1L, the ortholog of yeast MZM1, has been identified as a new assembly factor for cIII.
BC8_BioRED_Task1_Doc260	529	536	patient	OrganismTaxon	9606	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	562	576	encephalopathy	Disease	D001927	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	578	593	lactic acidosis	Disease	D000140	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	617	632	cIII deficiency	Disease	C565128	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	710	717	c.73G>A	SequenceVariant	rs587777433	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	722	727	LYRM7	Gene	90624	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	728	733	MZM1L	Gene	90624	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	805	815	p.Asp25Asn	SequenceVariant	rs587777433	In a baby patient with early onset, severe encephalopathy, lactic acidosis and profound, isolated cIII deficiency in skeletal muscle, we identified a disease-segregating homozygous mutation (c.73G>A) in LYRM7/MZM1L, predicting a drastic change in a highly conserved amino-acid residue (p.Asp25Asn).
BC8_BioRED_Task1_Doc260	823	828	mzm1D	Gene	852104	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	829	834	yeast	OrganismTaxon	4932	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	863	867	mzm1	Gene	852104	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	868	872	D25N	SequenceVariant	rs587777433	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	917	942	respiratory growth defect	Disease	D012131	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	954	960	oxygen	Chemical	D010100	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	1015	1034	Rieske Fe-S protein	Gene	856689	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	1048	1059	complex III	Gene	617	In a mzm1D yeast strain, the expression of a mzm1(D25N) mutant allele caused temperature-sensitive respiratory growth defect, decreased oxygen consumption, impaired maturation/stabilization of the Rieske Fe-S protein, and reduced complex III activity and amount.
BC8_BioRED_Task1_Doc260	1081	1086	LYRM7	Gene	90624	LYRM7/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe mitochondrial encephalopathy.
BC8_BioRED_Task1_Doc260	1087	1092	MZM1L	Gene	90624	LYRM7/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe mitochondrial encephalopathy.
BC8_BioRED_Task1_Doc260	1126	1140	cIII-defective	Disease	C565128	LYRM7/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe mitochondrial encephalopathy.
BC8_BioRED_Task1_Doc260	1162	1190	mitochondrial encephalopathy	Disease	C538525	LYRM7/MZM1L is a novel disease gene, causing cIII-defective, early onset, severe mitochondrial encephalopathy.
BC8_BioRED_Task1_Doc261	13	17	EGFR	Gene	1956	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
BC8_BioRED_Task1_Doc261	47	58	lung cancer	Disease	D008175	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
BC8_BioRED_Task1_Doc261	59	67	patients	OrganismTaxon	9606	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
BC8_BioRED_Task1_Doc261	117	122	tumor	Disease	D009369	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
BC8_BioRED_Task1_Doc261	123	127	EGFR	Gene	1956	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
BC8_BioRED_Task1_Doc261	151	155	EGFR	Gene	1956	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
BC8_BioRED_Task1_Doc261	174	178	EGFR	Gene	1956	AIMS: EGFR mutations now guide the clinical use of EGFR-targeted therapy in lung cancer.
BC8_BioRED_Task1_Doc261	219	223	EGFR	Gene	1956	AIMS: EGFR mutations now guide the clinical use of EGFR-targeted therapy in lung cancer.
BC8_BioRED_Task1_Doc261	244	255	lung cancer	Disease	D008175	AIMS: EGFR mutations now guide the clinical use of EGFR-targeted therapy in lung cancer.
BC8_BioRED_Task1_Doc261	275	279	EGFR	Gene	1956	However, standard EGFR mutation analysis requires a minimum amount of tumor tissue, which may not be available in certain situations.
BC8_BioRED_Task1_Doc261	327	332	tumor	Disease	D009369	However, standard EGFR mutation analysis requires a minimum amount of tumor tissue, which may not be available in certain situations.
BC8_BioRED_Task1_Doc261	512	516	EGFR	Gene	1956	In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect EGFR mutations in free plasma DNA from patients with lung cancer.
BC8_BioRED_Task1_Doc261	551	559	patients	OrganismTaxon	9606	In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect EGFR mutations in free plasma DNA from patients with lung cancer.
BC8_BioRED_Task1_Doc261	565	576	lung cancer	Disease	D008175	In this study, we combined a mass spectrometry genotyping assay (Sequenom) with a mutant-enriched PCR (ME-PCR) to detect EGFR mutations in free plasma DNA from patients with lung cancer.
BC8_BioRED_Task1_Doc261	637	645	patients	OrganismTaxon	9606	METHOD: DNAs were extracted from 31 plasma samples from 31 patients and analyzed by both methods for EGFR Exon 19 deletion and EGFR L858R mutation.
BC8_BioRED_Task1_Doc261	679	683	EGFR	Gene	1956	METHOD: DNAs were extracted from 31 plasma samples from 31 patients and analyzed by both methods for EGFR Exon 19 deletion and EGFR L858R mutation.
BC8_BioRED_Task1_Doc261	705	709	EGFR	Gene	1956	METHOD: DNAs were extracted from 31 plasma samples from 31 patients and analyzed by both methods for EGFR Exon 19 deletion and EGFR L858R mutation.
BC8_BioRED_Task1_Doc261	710	715	L858R	SequenceVariant	rs121434568	METHOD: DNAs were extracted from 31 plasma samples from 31 patients and analyzed by both methods for EGFR Exon 19 deletion and EGFR L858R mutation.
BC8_BioRED_Task1_Doc261	775	779	EGFR	Gene	1956	Results in plasma DNA samples were compared with EGFR mutation status obtained in tumor DNA (18/31 EGFR mutant).
BC8_BioRED_Task1_Doc261	808	813	tumor	Disease	D009369	Results in plasma DNA samples were compared with EGFR mutation status obtained in tumor DNA (18/31 EGFR mutant).
BC8_BioRED_Task1_Doc261	825	829	EGFR	Gene	1956	Results in plasma DNA samples were compared with EGFR mutation status obtained in tumor DNA (18/31 EGFR mutant).
BC8_BioRED_Task1_Doc261	859	863	EGFR	Gene	1956	The relationship of EGFR mutation status in tumor and/or plasma samples to overall survival was assessed.
BC8_BioRED_Task1_Doc261	883	888	tumor	Disease	D009369	The relationship of EGFR mutation status in tumor and/or plasma samples to overall survival was assessed.
BC8_BioRED_Task1_Doc261	958	962	EGFR	Gene	1956	RESULTS: The EGFR mutation status in plasma DNA was identical to the primary tumor in 61% of patients (19/31).
BC8_BioRED_Task1_Doc261	1022	1027	tumor	Disease	D009369	RESULTS: The EGFR mutation status in plasma DNA was identical to the primary tumor in 61% of patients (19/31).
BC8_BioRED_Task1_Doc261	1038	1046	patients	OrganismTaxon	9606	RESULTS: The EGFR mutation status in plasma DNA was identical to the primary tumor in 61% of patients (19/31).
BC8_BioRED_Task1_Doc261	1151	1155	EGFR	Gene	1956	By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR L858R mutations previously diagnosed in the matched tumors.
BC8_BioRED_Task1_Doc261	1182	1186	EGFR	Gene	1956	By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR L858R mutations previously diagnosed in the matched tumors.
BC8_BioRED_Task1_Doc261	1187	1192	L858R	SequenceVariant	rs121434568	By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR L858R mutations previously diagnosed in the matched tumors.
BC8_BioRED_Task1_Doc261	1239	1245	tumors	Disease	D009369	By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR L858R mutations previously diagnosed in the matched tumors.
BC8_BioRED_Task1_Doc261	1311	1316	tumor	Disease	D009369	Two samples were positive in plasma DNA but negative in primary tumor tissue.
BC8_BioRED_Task1_Doc261	1381	1389	patients	OrganismTaxon	9606	For patients treated with erlotinib, overall survival was correlated with the presence of EGFR mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.
BC8_BioRED_Task1_Doc261	1403	1412	erlotinib	Chemical	D000069347	For patients treated with erlotinib, overall survival was correlated with the presence of EGFR mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.
BC8_BioRED_Task1_Doc261	1467	1471	EGFR	Gene	1956	For patients treated with erlotinib, overall survival was correlated with the presence of EGFR mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.
BC8_BioRED_Task1_Doc261	1498	1503	tumor	Disease	D009369	For patients treated with erlotinib, overall survival was correlated with the presence of EGFR mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.
BC8_BioRED_Task1_Doc261	1535	1543	patients	OrganismTaxon	9606	For patients treated with erlotinib, overall survival was correlated with the presence of EGFR mutation in plasma and/or tumor tissue (p=0.002), with the two patients positive only in plasma DNA showing responses and favorable outcomes.
BC8_BioRED_Task1_Doc261	1643	1647	EGFR	Gene	1956	CONCLUSION: The detection of EGFR mutations in plasma DNA samples by mass spectrometry genotyping and ME-PCR is feasible.
BC8_BioRED_Task1_Doc261	1747	1751	EGFR	Gene	1956	A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens.
BC8_BioRED_Task1_Doc261	1805	1810	tumor	Disease	D009369	A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens.
BC8_BioRED_Task1_Doc261	1811	1815	EGFR	Gene	1956	A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens.
BC8_BioRED_Task1_Doc261	1860	1864	EGFR	Gene	1956	A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens.
BC8_BioRED_Task1_Doc261	1945	1953	patients	OrganismTaxon	9606	A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens.
BC8_BioRED_Task1_Doc261	1987	1992	tumor	Disease	D009369	A positive EGFR result in plasma DNA has a high predictive value for tumor EGFR status and for favorable clinical course on EGFR-targeted therapy and could therefore be useful in guiding clinical decisions in patients with insufficient or unavailable tumor specimens.
BC8_BioRED_Task1_Doc262	0	28	Bone morphogenetic protein-4	Gene	652	Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.
BC8_BioRED_Task1_Doc262	44	51	activin	Gene	3624,83729	Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.
BC8_BioRED_Task1_Doc262	56	60	GnRH	Gene	14714	Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.
BC8_BioRED_Task1_Doc262	73	86	gonadotrophin	Gene	12640,14308	Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.
BC8_BioRED_Task1_Doc262	100	107	LbetaT2	CellLine	CVCL_0398	Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.
BC8_BioRED_Task1_Doc262	156	161	sheep	OrganismTaxon	9940	We have shown previously that, in sheep primary pituitary cells, bone morphogenetic proteins (BMP)-4 inhibits FSHbeta mRNA expression and FSH release.
BC8_BioRED_Task1_Doc262	187	222	bone morphogenetic proteins (BMP)-4	Gene	443502	We have shown previously that, in sheep primary pituitary cells, bone morphogenetic proteins (BMP)-4 inhibits FSHbeta mRNA expression and FSH release.
BC8_BioRED_Task1_Doc262	232	239	FSHbeta	Gene	443387	We have shown previously that, in sheep primary pituitary cells, bone morphogenetic proteins (BMP)-4 inhibits FSHbeta mRNA expression and FSH release.
BC8_BioRED_Task1_Doc262	260	263	FSH	Gene	443387,443538	We have shown previously that, in sheep primary pituitary cells, bone morphogenetic proteins (BMP)-4 inhibits FSHbeta mRNA expression and FSH release.
BC8_BioRED_Task1_Doc262	289	294	mouse	OrganismTaxon	10090	In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or activin-stimulated FSHbeta promoter-driven transcription.
BC8_BioRED_Task1_Doc262	295	302	LbetaT2	CellLine	CVCL_0398	In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or activin-stimulated FSHbeta promoter-driven transcription.
BC8_BioRED_Task1_Doc262	359	363	BMPs	Gene	652	In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or activin-stimulated FSHbeta promoter-driven transcription.
BC8_BioRED_Task1_Doc262	376	383	activin	Gene	16323	In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or activin-stimulated FSHbeta promoter-driven transcription.
BC8_BioRED_Task1_Doc262	395	402	FSHbeta	Gene	14308	In contrast, in mouse LbetaT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or activin-stimulated FSHbeta promoter-driven transcription.
BC8_BioRED_Task1_Doc262	493	500	LbetaT2	CellLine	CVCL_0398	As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by activin and GnRH.
BC8_BioRED_Task1_Doc262	537	542	BMP-4	Gene	652	As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by activin and GnRH.
BC8_BioRED_Task1_Doc262	546	559	gonadotrophin	Gene	12640,14308	As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by activin and GnRH.
BC8_BioRED_Task1_Doc262	592	599	activin	Gene	16323	As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by activin and GnRH.
BC8_BioRED_Task1_Doc262	604	608	GnRH	Gene	14714	As a species comparison with our previous results, we used LbetaT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by activin and GnRH.
BC8_BioRED_Task1_Doc262	610	615	BMP-4	Gene	652	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	639	642	FSH	Gene	443387,443538	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	672	679	activin	Gene	16323	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	680	684	GnRH	Gene	14714	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	708	715	FSHbeta	Gene	14308	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	725	728	FSH	Gene	443387,443538	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	762	773	follistatin	Gene	14313	BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHbeta mRNA and FSH secretion, without any effect on follistatin mRNA.
BC8_BioRED_Task1_Doc262	780	785	BMP-4	Gene	652	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	794	800	LHbeta	Gene	16866	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	835	839	GnRH	Gene	14714	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	844	851	activin	Gene	16323	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	867	880	GnRH receptor	Gene	14715	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	912	915	FSH	Gene	443387,443538	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	929	931	LH	Gene	12640,16866	BMP-4 reduced LHbeta mRNA up-regulation in response to GnRH (+/-activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion.
BC8_BioRED_Task1_Doc262	973	978	sheep	OrganismTaxon	9940	In contrast to sheep pituitary gonadotrophs, which express only BMP receptor types IA (BMPRIA) and II (BMPRII), LbetaT2 cells also express BMPRIB.
BC8_BioRED_Task1_Doc262	1022	1068	BMP receptor types IA (BMPRIA) and II (BMPRII)	Gene	101103793,101112282	In contrast to sheep pituitary gonadotrophs, which express only BMP receptor types IA (BMPRIA) and II (BMPRII), LbetaT2 cells also express BMPRIB.
BC8_BioRED_Task1_Doc262	1070	1077	LbetaT2	CellLine	CVCL_0398	In contrast to sheep pituitary gonadotrophs, which express only BMP receptor types IA (BMPRIA) and II (BMPRII), LbetaT2 cells also express BMPRIB.
BC8_BioRED_Task1_Doc262	1097	1103	BMPRIB	Gene	12167	In contrast to sheep pituitary gonadotrophs, which express only BMP receptor types IA (BMPRIA) and II (BMPRII), LbetaT2 cells also express BMPRIB.
BC8_BioRED_Task1_Doc262	1105	1112	Smad1/5	Gene	17125,17129	Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.
BC8_BioRED_Task1_Doc262	1140	1145	BMP-4	Gene	652	Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.
BC8_BioRED_Task1_Doc262	1172	1175	BMP	Gene	12159	Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.
BC8_BioRED_Task1_Doc262	1209	1214	BMP-4	Gene	652	Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.
BC8_BioRED_Task1_Doc262	1247	1254	activin	Gene	16323	Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.
BC8_BioRED_Task1_Doc262	1257	1261	GnRH	Gene	14714	Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin+/-GnRH.
BC8_BioRED_Task1_Doc262	1284	1291	activin	Gene	16323	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1299	1303	GnRH	Gene	14714	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1333	1338	BMP-4	Gene	652	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1356	1363	activin	Gene	16323	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1394	1401	Smad2/3	Gene	17126,17127	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1410	1414	GnRH	Gene	14714	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1423	1429	ERK1/2	Gene	26413,26417	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1433	1462	cAMP response element-binding	Gene	12912	We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified.
BC8_BioRED_Task1_Doc262	1507	1511	GnRH	Gene	14714	However, the GnRH-induced activation of p38 MAPK was decreased by BMP-4.
BC8_BioRED_Task1_Doc262	1534	1542	p38 MAPK	Gene	26416	However, the GnRH-induced activation of p38 MAPK was decreased by BMP-4.
BC8_BioRED_Task1_Doc262	1560	1565	BMP-4	Gene	652	However, the GnRH-induced activation of p38 MAPK was decreased by BMP-4.
BC8_BioRED_Task1_Doc262	1602	1609	FSHbeta	Gene	14308	This was associated with increased FSHbeta mRNA levels and FSH secretion, but decreased LHbeta mRNA levels.
BC8_BioRED_Task1_Doc262	1626	1629	FSH	Gene	443387,443538	This was associated with increased FSHbeta mRNA levels and FSH secretion, but decreased LHbeta mRNA levels.
BC8_BioRED_Task1_Doc262	1655	1661	LHbeta	Gene	16866	This was associated with increased FSHbeta mRNA levels and FSH secretion, but decreased LHbeta mRNA levels.
BC8_BioRED_Task1_Doc262	1700	1704	BMPs	Gene	652	BMPs as important modulators of activin and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.
BC8_BioRED_Task1_Doc262	1732	1739	activin	Gene	16323	BMPs as important modulators of activin and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.
BC8_BioRED_Task1_Doc262	1747	1751	GnRH	Gene	14714	BMPs as important modulators of activin and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.
BC8_BioRED_Task1_Doc262	1763	1776	gonadotrophin	Gene	12640,14308	BMPs as important modulators of activin and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.
BC8_BioRED_Task1_Doc262	1891	1903	BMP receptor	Gene	101103793,101112282,12167	BMPs as important modulators of activin and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.
BC8_BioRED_Task1_Doc263	10	14	CCL2	Gene	24770	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.
BC8_BioRED_Task1_Doc263	32	36	CCR2	Gene	60463	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.
BC8_BioRED_Task1_Doc263	80	91	pilocarpine	Chemical	D010862	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.
BC8_BioRED_Task1_Doc263	100	118	status epilepticus	Disease	D013226	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.
BC8_BioRED_Task1_Doc263	132	149	Neuroinflammation	Disease	D007249	BACKGROUND: Neuroinflammation occurs after seizures and is implicated in epileptogenesis.
BC8_BioRED_Task1_Doc263	163	171	seizures	Disease	D012640	BACKGROUND: Neuroinflammation occurs after seizures and is implicated in epileptogenesis.
BC8_BioRED_Task1_Doc263	210	214	CCR2	Gene	60463	CCR2 is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies.
BC8_BioRED_Task1_Doc263	220	238	chemokine receptor	Gene	60463	CCR2 is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies.
BC8_BioRED_Task1_Doc263	243	247	CCL2	Gene	24770	CCR2 is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies.
BC8_BioRED_Task1_Doc263	308	325	neuroinflammatory	Disease	D007249	CCR2 is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies.
BC8_BioRED_Task1_Doc263	389	393	CCR2	Gene	60463	In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	398	402	CCL2	Gene	24770	In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	438	456	status epilepticus	Disease	D013226	In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	458	460	SE	Disease	D013226	In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	473	484	pilocarpine	Chemical	D010862	In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	505	507	SE	Disease	D013226	METHODS: SE was induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	523	534	pilocarpine	Chemical	D010862	METHODS: SE was induced by pilocarpine injection.
BC8_BioRED_Task1_Doc263	554	558	rats	OrganismTaxon	10116	Control rats were injected with saline instead of pilocarpine.
BC8_BioRED_Task1_Doc263	596	607	pilocarpine	Chemical	D010862	Control rats were injected with saline instead of pilocarpine.
BC8_BioRED_Task1_Doc263	625	627	SE	Disease	D013226	Five days after SE, CCR2 staining in neurons and glial cells was examined using imunohistochemical analyses.
BC8_BioRED_Task1_Doc263	629	633	CCR2	Gene	60463	Five days after SE, CCR2 staining in neurons and glial cells was examined using imunohistochemical analyses.
BC8_BioRED_Task1_Doc263	732	736	CCR2	Gene	60463	The number of CCR2 positive cells was determined using stereology probes in the hippocampus.
BC8_BioRED_Task1_Doc263	811	815	CCL2	Gene	24770	CCL2 expression in the hippocampus was examined by molecular assay.
BC8_BioRED_Task1_Doc263	898	902	CCR2	Gene	60463	RESULTS: Increased CCR2 was observed in the hippocampus after SE.
BC8_BioRED_Task1_Doc263	941	943	SE	Disease	D013226	RESULTS: Increased CCR2 was observed in the hippocampus after SE.
BC8_BioRED_Task1_Doc263	945	953	Seizures	Disease	D012640	Seizures also resulted in alterations to the cell types expressing CCR2.
BC8_BioRED_Task1_Doc263	1012	1016	CCR2	Gene	60463	Seizures also resulted in alterations to the cell types expressing CCR2.
BC8_BioRED_Task1_Doc263	1062	1066	CCR2	Gene	60463	Increased numbers of neurons that expressed CCR2 was observed following SE.
BC8_BioRED_Task1_Doc263	1090	1092	SE	Disease	D013226	Increased numbers of neurons that expressed CCR2 was observed following SE.
BC8_BioRED_Task1_Doc263	1144	1148	CCR2	Gene	60463	Microglial cells were more closely apposed to the CCR2-labeled cells in SE rats.
BC8_BioRED_Task1_Doc263	1166	1168	SE	Disease	D013226	Microglial cells were more closely apposed to the CCR2-labeled cells in SE rats.
BC8_BioRED_Task1_Doc263	1169	1173	rats	OrganismTaxon	10116	Microglial cells were more closely apposed to the CCR2-labeled cells in SE rats.
BC8_BioRED_Task1_Doc263	1188	1192	rats	OrganismTaxon	10116	In addition, rats that experienced SE exhibited CCR2-labeling in populations of hypertrophied astrocytes, especially in CA1 and dentate gyrus.
BC8_BioRED_Task1_Doc263	1210	1212	SE	Disease	D013226	In addition, rats that experienced SE exhibited CCR2-labeling in populations of hypertrophied astrocytes, especially in CA1 and dentate gyrus.
BC8_BioRED_Task1_Doc263	1223	1227	CCR2	Gene	60463	In addition, rats that experienced SE exhibited CCR2-labeling in populations of hypertrophied astrocytes, especially in CA1 and dentate gyrus.
BC8_BioRED_Task1_Doc263	1324	1328	CCR2	Gene	60463	These CCR2+ astroctytes were not observed in control rats.
BC8_BioRED_Task1_Doc263	1371	1375	rats	OrganismTaxon	10116	These CCR2+ astroctytes were not observed in control rats.
BC8_BioRED_Task1_Doc263	1392	1396	CCL2	Gene	24770	Examination of CCL2 expression showed that it was elevated in the hippocampus following SE.
BC8_BioRED_Task1_Doc263	1465	1467	SE	Disease	D013226	Examination of CCL2 expression showed that it was elevated in the hippocampus following SE.
BC8_BioRED_Task1_Doc263	1500	1504	CCR2	Gene	60463	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.
BC8_BioRED_Task1_Doc263	1509	1513	CCL2	Gene	24770	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.
BC8_BioRED_Task1_Doc263	1556	1567	pilocarpine	Chemical	D010862	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.
BC8_BioRED_Task1_Doc263	1576	1578	SE	Disease	D013226	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.
BC8_BioRED_Task1_Doc263	1580	1588	Seizures	Disease	D012640	Seizures also result in changes to CCR2 receptor expression in neurons and astrocytes.
BC8_BioRED_Task1_Doc263	1615	1619	CCR2	Gene	60463	Seizures also result in changes to CCR2 receptor expression in neurons and astrocytes.
BC8_BioRED_Task1_Doc263	1734	1751	neuroinflammatory	Disease	D007249	These changes might be involved in detrimental neuroplasticity and neuroinflammatory changes that occur following seizures.
BC8_BioRED_Task1_Doc263	1781	1789	seizures	Disease	D012640	These changes might be involved in detrimental neuroplasticity and neuroinflammatory changes that occur following seizures.
BC8_BioRED_Task1_Doc264	7	21	rhabdomyolysis	Disease	D012206	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
BC8_BioRED_Task1_Doc264	26	45	acute renal failure	Disease	D058186	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
BC8_BioRED_Task1_Doc264	78	89	simvastatin	Chemical	D019821	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
BC8_BioRED_Task1_Doc264	91	101	amiodarone	Chemical	D000638	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
BC8_BioRED_Task1_Doc264	107	117	atazanavir	Chemical	C413408	Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
BC8_BioRED_Task1_Doc264	179	190	simvastatin	Chemical	D019821	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
BC8_BioRED_Task1_Doc264	192	202	amiodarone	Chemical	D000638	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
BC8_BioRED_Task1_Doc264	208	218	atazanavir	Chemical	C413408	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
BC8_BioRED_Task1_Doc264	232	246	rhabdomyolysis	Disease	D012206	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
BC8_BioRED_Task1_Doc264	251	270	acute renal failure	Disease	D058186	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
BC8_BioRED_Task1_Doc264	304	307	man	OrganismTaxon	9606	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	324	352	human immunodeficiency virus	OrganismTaxon	12721	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	354	373	atrial fibrillation	Disease	D001281	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	375	398	coronary artery disease	Disease	D003324	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	404	418	hyperlipidemia	Disease	D006949	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	446	450	pain	Disease	D010146	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	452	459	fatigue	Disease	D005221	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.
BC8_BioRED_Task1_Doc264	499	506	patient	OrganismTaxon	9606	The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).
BC8_BioRED_Task1_Doc264	524	535	simvastatin	Chemical	D019821	The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).
BC8_BioRED_Task1_Doc264	576	586	amiodarone	Chemical	D000638	The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).
BC8_BioRED_Task1_Doc264	683	693	atazanavir	Chemical	C413408	The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).
BC8_BioRED_Task1_Doc264	783	798	creatine kinase	Chemical	D003402	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.
BC8_BioRED_Task1_Doc264	809	828	blood urea nitrogen	Chemical	D001806	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.
BC8_BioRED_Task1_Doc264	840	850	creatinine	Chemical	D003404	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.
BC8_BioRED_Task1_Doc264	861	887	aspartate aminotransferase	Chemical	D001219	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.
BC8_BioRED_Task1_Doc264	901	925	alanine aminotransferase	Chemical	D000410	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.
BC8_BioRED_Task1_Doc264	927	938	Simvastatin	Chemical	D019821	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
BC8_BioRED_Task1_Doc264	940	950	amiodarone	Chemical	D000638	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
BC8_BioRED_Task1_Doc264	960	967	patient	OrganismTaxon	9606	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
BC8_BioRED_Task1_Doc264	970	998	human immunodeficiency virus	OrganismTaxon	12721	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
BC8_BioRED_Task1_Doc264	1053	1060	patient	OrganismTaxon	9606	Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
BC8_BioRED_Task1_Doc264	1141	1148	patient	OrganismTaxon	9606	Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL.
BC8_BioRED_Task1_Doc264	1151	1166	creatine kinase	Chemical	D003402	Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL.
BC8_BioRED_Task1_Doc264	1195	1205	creatinine	Chemical	D003404	Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL.
BC8_BioRED_Task1_Doc264	1225	1232	patient	OrganismTaxon	9606	The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.
BC8_BioRED_Task1_Doc264	1262	1272	outpatient	OrganismTaxon	9606	The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.
BC8_BioRED_Task1_Doc264	1354	1368	rhabdomyolysis	Disease	D012206	DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.
BC8_BioRED_Task1_Doc264	1432	1443	simvastatin	Chemical	D019821	DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.
BC8_BioRED_Task1_Doc264	1456	1467	Simvastatin	Chemical	D019821	Simvastatin is metabolized by CYP3A4.
BC8_BioRED_Task1_Doc264	1486	1492	CYP3A4	Gene	1576	Simvastatin is metabolized by CYP3A4.
BC8_BioRED_Task1_Doc264	1494	1504	Amiodarone	Chemical	D000638	Amiodarone and atazanavir are recognized CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1509	1519	atazanavir	Chemical	C413408	Amiodarone and atazanavir are recognized CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1535	1541	CYP3A4	Gene	1576	Amiodarone and atazanavir are recognized CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1598	1605	statins	Chemical	D019821	CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions.
BC8_BioRED_Task1_Doc264	1695	1703	patients	OrganismTaxon	9606	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1736	1743	statins	Chemical	D019821	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1748	1754	CYP3A4	Gene	1576	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1767	1778	pravastatin	Chemical	D017035	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1780	1791	fluvastatin	Chemical	C065180	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1797	1809	rosuvastatin	Chemical	C422923	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1854	1866	atorvastatin	Chemical	C065179	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1898	1909	simvastatin	Chemical	D019821	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1914	1924	lovastatin	Chemical	D008148	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	1972	1980	patients	OrganismTaxon	9606	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc264	2000	2017	CYP3A4 inhibitors	Chemical	D065692	In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.
BC8_BioRED_Task1_Doc265	15	22	obesity	Disease	D009765	Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion.
BC8_BioRED_Task1_Doc265	36	41	PCSK1	Gene	5122	Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion.
BC8_BioRED_Task1_Doc265	47	54	insulin	Gene	3630	Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion.
BC8_BioRED_Task1_Doc265	71	81	proinsulin	Chemical	D011384	Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion.
BC8_BioRED_Task1_Doc265	106	129	Prohormone convertase 1	Gene	5122	BACKGROUND: Prohormone convertase 1 is involved in maturation of peptides.
BC8_BioRED_Task1_Doc265	192	197	PCSK1	Gene	5122	Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations.
BC8_BioRED_Task1_Doc265	237	244	obesity	Disease	D009765	Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations.
BC8_BioRED_Task1_Doc265	249	277	abnormal glucose homeostasis	Disease	D044882	Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations.
BC8_BioRED_Task1_Doc265	292	302	proinsulin	Chemical	D011384	Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations.
BC8_BioRED_Task1_Doc265	383	389	rs6232	SequenceVariant	rs6232	Common single nucleotide polymorphisms (SNPs) within this gene, rs6232 and rs6235, are associated with obesity.
BC8_BioRED_Task1_Doc265	394	400	rs6235	SequenceVariant	rs6235	Common single nucleotide polymorphisms (SNPs) within this gene, rs6232 and rs6235, are associated with obesity.
BC8_BioRED_Task1_Doc265	422	429	obesity	Disease	D009765	Common single nucleotide polymorphisms (SNPs) within this gene, rs6232 and rs6235, are associated with obesity.
BC8_BioRED_Task1_Doc265	494	512	insulin resistance	Disease	D007333	We studied whether these SNPs influence the prediabetic traits insulin resistance, beta-cell dysfunction, or glucose intolerance.
BC8_BioRED_Task1_Doc265	514	535	beta-cell dysfunction	Disease	-	We studied whether these SNPs influence the prediabetic traits insulin resistance, beta-cell dysfunction, or glucose intolerance.
BC8_BioRED_Task1_Doc265	540	559	glucose intolerance	Disease	D018149	We studied whether these SNPs influence the prediabetic traits insulin resistance, beta-cell dysfunction, or glucose intolerance.
BC8_BioRED_Task1_Doc265	613	619	rs6232	SequenceVariant	rs6232	METHODS: We genotyped 1498 German subjects for SNPs rs6232 and rs6235 within PCSK1.
BC8_BioRED_Task1_Doc265	624	630	rs6235	SequenceVariant	rs6235	METHODS: We genotyped 1498 German subjects for SNPs rs6232 and rs6235 within PCSK1.
BC8_BioRED_Task1_Doc265	638	643	PCSK1	Gene	5122	METHODS: We genotyped 1498 German subjects for SNPs rs6232 and rs6235 within PCSK1.
BC8_BioRED_Task1_Doc265	699	706	glucose	Chemical	D005947	The subjects were metabolically characterized by oral glucose tolerance test with glucose, insulin, proinsulin, and C-peptide measurements.
BC8_BioRED_Task1_Doc265	727	734	glucose	Chemical	D005947	The subjects were metabolically characterized by oral glucose tolerance test with glucose, insulin, proinsulin, and C-peptide measurements.
BC8_BioRED_Task1_Doc265	736	743	insulin	Gene	3630	The subjects were metabolically characterized by oral glucose tolerance test with glucose, insulin, proinsulin, and C-peptide measurements.
BC8_BioRED_Task1_Doc265	745	755	proinsulin	Chemical	D011384	The subjects were metabolically characterized by oral glucose tolerance test with glucose, insulin, proinsulin, and C-peptide measurements.
BC8_BioRED_Task1_Doc265	761	770	C-peptide	Chemical	D002096	The subjects were metabolically characterized by oral glucose tolerance test with glucose, insulin, proinsulin, and C-peptide measurements.
BC8_BioRED_Task1_Doc265	824	851	hyperinsulinemic-euglycemic	Disease	D044903	A subgroup of 512 subjects underwent a hyperinsulinemic-euglycemic clamp.
BC8_BioRED_Task1_Doc265	916	922	rs6235	SequenceVariant	rs6235	RESULTS: The minor allele frequencies were 25.8% for SNP rs6235 and 6.0% for rs6232.
BC8_BioRED_Task1_Doc265	936	942	rs6232	SequenceVariant	rs6232	RESULTS: The minor allele frequencies were 25.8% for SNP rs6235 and 6.0% for rs6232.
BC8_BioRED_Task1_Doc265	1010	1016	rs6235	SequenceVariant	rs6235	After adjustment for sex and age, we found no association of SNPs rs6235 and rs6232 with BMI or other weight-related traits (all p >or= 0.07).
BC8_BioRED_Task1_Doc265	1021	1027	rs6232	SequenceVariant	rs6232	After adjustment for sex and age, we found no association of SNPs rs6235 and rs6232 with BMI or other weight-related traits (all p >or= 0.07).
BC8_BioRED_Task1_Doc265	1138	1145	insulin	Gene	3630	Both minor alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUCinsulin (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).
BC8_BioRED_Task1_Doc265	1191	1201	proinsulin	Chemical	D011384	Both minor alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUCinsulin (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).
BC8_BioRED_Task1_Doc265	1209	1219	proinsulin	Chemical	D011384	Both minor alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUCinsulin (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).
BC8_BioRED_Task1_Doc265	1223	1230	insulin	Gene	3630	Both minor alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUCinsulin (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).
BC8_BioRED_Task1_Doc265	1232	1238	rs6235	SequenceVariant	rs6235	Both minor alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUCinsulin (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).
BC8_BioRED_Task1_Doc265	1289	1295	rs6232	SequenceVariant	rs6232	Both minor alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/AUCinsulin (rs6235: p(additive) model <or= 0.009, effect sizes 8/8%, rs6232: pdominant model <or= 0.01, effect sizes 10/21%).
BC8_BioRED_Task1_Doc265	1346	1353	Insulin	Gene	3630	Insulin secretion was not affected by the variants (different secretion parameters, all p >or= 0.08).
BC8_BioRED_Task1_Doc265	1472	1478	rs6232	SequenceVariant	rs6232	The minor allele of SNP rs6232 was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and proinsulin conversion.
BC8_BioRED_Task1_Doc265	1565	1572	insulin	Gene	3630	The minor allele of SNP rs6232 was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and proinsulin conversion.
BC8_BioRED_Task1_Doc265	1660	1667	glucose	Chemical	D005947	The minor allele of SNP rs6232 was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and proinsulin conversion.
BC8_BioRED_Task1_Doc265	1709	1719	proinsulin	Chemical	D011384	The minor allele of SNP rs6232 was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom <or= 0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and proinsulin conversion.
BC8_BioRED_Task1_Doc265	1736	1742	rs6235	SequenceVariant	rs6235	SNP rs6235 was not associated with parameters of glucose metabolism.
BC8_BioRED_Task1_Doc265	1837	1842	PCSK1	Gene	5122	CONCLUSIONS: Like rare mutations in PCSK1, the more common variants tested determine glucose-stimulated proinsulin conversion, but not insulin secretion.
BC8_BioRED_Task1_Doc265	1886	1893	glucose	Chemical	D005947	CONCLUSIONS: Like rare mutations in PCSK1, the more common variants tested determine glucose-stimulated proinsulin conversion, but not insulin secretion.
BC8_BioRED_Task1_Doc265	1905	1915	proinsulin	Chemical	D011384	CONCLUSIONS: Like rare mutations in PCSK1, the more common variants tested determine glucose-stimulated proinsulin conversion, but not insulin secretion.
BC8_BioRED_Task1_Doc265	1936	1943	insulin	Gene	3630	CONCLUSIONS: Like rare mutations in PCSK1, the more common variants tested determine glucose-stimulated proinsulin conversion, but not insulin secretion.
BC8_BioRED_Task1_Doc265	1968	1974	rs6232	SequenceVariant	rs6232	In addition, rs6232, encoding the amino acid exchange N221D, influences insulin sensitivity and glucose homeostasis.
BC8_BioRED_Task1_Doc265	2009	2014	N221D	SequenceVariant	rs6232	In addition, rs6232, encoding the amino acid exchange N221D, influences insulin sensitivity and glucose homeostasis.
BC8_BioRED_Task1_Doc265	2027	2034	insulin	Gene	3630	In addition, rs6232, encoding the amino acid exchange N221D, influences insulin sensitivity and glucose homeostasis.
BC8_BioRED_Task1_Doc265	2051	2058	glucose	Chemical	D005947	In addition, rs6232, encoding the amino acid exchange N221D, influences insulin sensitivity and glucose homeostasis.
BC8_BioRED_Task1_Doc266	17	25	amikacin	Chemical	D000583	An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
BC8_BioRED_Task1_Doc266	26	40	nephrotoxicity	Disease	D007674	An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
BC8_BioRED_Task1_Doc266	80	88	Amikacin	Chemical	D000583	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
BC8_BioRED_Task1_Doc266	95	109	aminoglycoside	Chemical	D000617	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
BC8_BioRED_Task1_Doc266	180	199	febrile neutropenia	Disease	D009503	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
BC8_BioRED_Task1_Doc266	220	230	infections	Disease	D007239	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
BC8_BioRED_Task1_Doc266	460	468	amikacin	Chemical	D000583	To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.
BC8_BioRED_Task1_Doc266	480	494	nephrotoxicity	Disease	D007674	To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.
BC8_BioRED_Task1_Doc266	646	654	patients	OrganismTaxon	9606	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
BC8_BioRED_Task1_Doc266	690	720	hematologic/oncologic disorder	Disease	D006402,D009369	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
BC8_BioRED_Task1_Doc266	753	767	aminoglycoside	Chemical	D000617	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
BC8_BioRED_Task1_Doc266	828	836	amikacin	Chemical	D000583	Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.
BC8_BioRED_Task1_Doc266	856	870	nephrotoxicity	Disease	D007674	The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.
BC8_BioRED_Task1_Doc266	904	914	creatinine	Chemical	D003404	The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.
BC8_BioRED_Task1_Doc266	946	954	amikacin	Chemical	D000583	The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.
BC8_BioRED_Task1_Doc266	1035	1049	nephrotoxicity	Disease	D007674	The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).
BC8_BioRED_Task1_Doc266	1161	1169	patients	OrganismTaxon	9606	Six patients in the conventional group had a positive culture, compared with none in the extended-interval group (P = 0.002).
BC8_BioRED_Task1_Doc266	1301	1315	nephrotoxicity	Disease	D007674	The occurrence of nephrotoxicity was similar between the two dosing regimens, but the distribution of risk factors was variable between the two groups.
BC8_BioRED_Task1_Doc267	13	55	N-acetylglucosamine (O-GlcNAc) transferase	Gene	8473	Mutations in N-acetylglucosamine (O-GlcNAc) transferase in patients with X-linked intellectual disability.
BC8_BioRED_Task1_Doc267	59	67	patients	OrganismTaxon	9606	Mutations in N-acetylglucosamine (O-GlcNAc) transferase in patients with X-linked intellectual disability.
BC8_BioRED_Task1_Doc267	73	105	X-linked intellectual disability	Disease	D038901	Mutations in N-acetylglucosamine (O-GlcNAc) transferase in patients with X-linked intellectual disability.
BC8_BioRED_Task1_Doc267	107	149	N-Acetylglucosamine (O-GlcNAc) transferase	Gene	8473	N-Acetylglucosamine (O-GlcNAc) transferase (OGT) regulates protein O-GlcNAcylation, an essential and dynamic post-translational modification.
BC8_BioRED_Task1_Doc267	151	154	OGT	Gene	8473	N-Acetylglucosamine (O-GlcNAc) transferase (OGT) regulates protein O-GlcNAcylation, an essential and dynamic post-translational modification.
BC8_BioRED_Task1_Doc267	174	189	O-GlcNAcylation	Gene	8473	N-Acetylglucosamine (O-GlcNAc) transferase (OGT) regulates protein O-GlcNAcylation, an essential and dynamic post-translational modification.
BC8_BioRED_Task1_Doc267	253	261	O-GlcNAc	Gene	8473	The O-GlcNAc modification is present on numerous nuclear and cytosolic proteins and has been implicated in essential cellular functions such as signaling and gene expression.
BC8_BioRED_Task1_Doc267	463	478	O-GlcNAcylation	Gene	8473	Accordingly, altered levels of protein O-GlcNAcylation have been associated with developmental defects and neurodegeneration.
BC8_BioRED_Task1_Doc267	505	526	developmental defects	Disease	D003147	Accordingly, altered levels of protein O-GlcNAcylation have been associated with developmental defects and neurodegeneration.
BC8_BioRED_Task1_Doc267	531	548	neurodegeneration	Disease	D019636	Accordingly, altered levels of protein O-GlcNAcylation have been associated with developmental defects and neurodegeneration.
BC8_BioRED_Task1_Doc267	576	579	OGT	Gene	8473	However, mutations in the OGT gene have not yet been functionally confirmed in humans.
BC8_BioRED_Task1_Doc267	629	635	humans	OrganismTaxon	9606	However, mutations in the OGT gene have not yet been functionally confirmed in humans.
BC8_BioRED_Task1_Doc267	684	687	OGT	Gene	8473	Here, we report on two hemizygous mutations in OGT in individuals with X-linked intellectual disability (XLID) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (c.463-6T>G).
BC8_BioRED_Task1_Doc267	708	740	X-linked intellectual disability	Disease	D038901	Here, we report on two hemizygous mutations in OGT in individuals with X-linked intellectual disability (XLID) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (c.463-6T>G).
BC8_BioRED_Task1_Doc267	742	746	XLID	Disease	D038901	Here, we report on two hemizygous mutations in OGT in individuals with X-linked intellectual disability (XLID) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (c.463-6T>G).
BC8_BioRED_Task1_Doc267	796	807	p.Arg284Pro	SequenceVariant	rs1114167891	Here, we report on two hemizygous mutations in OGT in individuals with X-linked intellectual disability (XLID) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (c.463-6T>G).
BC8_BioRED_Task1_Doc267	856	866	c.463-6T>G	SequenceVariant	c|SUB|T463-6|G	Here, we report on two hemizygous mutations in OGT in individuals with X-linked intellectual disability (XLID) and dysmorphic features: one missense mutation (p.Arg284Pro) and one mutation leading to a splicing defect (c.463-6T>G).
BC8_BioRED_Task1_Doc267	927	930	OGT	Gene	8473	Both mutations reside in the tetratricopeptide repeats of OGT that are essential for substrate recognition.
BC8_BioRED_Task1_Doc267	1016	1019	OGT	Gene	8473	We observed slightly reduced levels of OGT protein and reduced levels of its opposing enzyme O-GlcNAcase in both patient-derived fibroblasts, but global O-GlcNAc levels appeared to be unaffected.
BC8_BioRED_Task1_Doc267	1070	1081	O-GlcNAcase	Gene	10724	We observed slightly reduced levels of OGT protein and reduced levels of its opposing enzyme O-GlcNAcase in both patient-derived fibroblasts, but global O-GlcNAc levels appeared to be unaffected.
BC8_BioRED_Task1_Doc267	1090	1097	patient	OrganismTaxon	9606	We observed slightly reduced levels of OGT protein and reduced levels of its opposing enzyme O-GlcNAcase in both patient-derived fibroblasts, but global O-GlcNAc levels appeared to be unaffected.
BC8_BioRED_Task1_Doc267	1130	1138	O-GlcNAc	Gene	8473	We observed slightly reduced levels of OGT protein and reduced levels of its opposing enzyme O-GlcNAcase in both patient-derived fibroblasts, but global O-GlcNAc levels appeared to be unaffected.
BC8_BioRED_Task1_Doc267	1235	1250	O-GlcNAcylation	Gene	8473	Our data suggest that mutant cells attempt to maintain global O-GlcNAcylation by down-regulating O-GlcNAcase expression.
BC8_BioRED_Task1_Doc267	1270	1281	O-GlcNAcase	Gene	10724	Our data suggest that mutant cells attempt to maintain global O-GlcNAcylation by down-regulating O-GlcNAcase expression.
BC8_BioRED_Task1_Doc267	1317	1327	c.463-6T>G	SequenceVariant	c|SUB|T463-6|G	We also found that the c.463-6T>G mutation leads to aberrant mRNA splicing, but no stable truncated protein was detected in the corresponding patient-derived fibroblasts.
BC8_BioRED_Task1_Doc267	1436	1443	patient	OrganismTaxon	9606	We also found that the c.463-6T>G mutation leads to aberrant mRNA splicing, but no stable truncated protein was detected in the corresponding patient-derived fibroblasts.
BC8_BioRED_Task1_Doc267	1477	1480	OGT	Gene	8473	Recombinant OGT bearing the p.Arg284Pro mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor host cell factor 1, which is also encoded by an XLID-associated gene.
BC8_BioRED_Task1_Doc267	1493	1504	p.Arg284Pro	SequenceVariant	rs1114167891	Recombinant OGT bearing the p.Arg284Pro mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor host cell factor 1, which is also encoded by an XLID-associated gene.
BC8_BioRED_Task1_Doc267	1689	1707	host cell factor 1	Gene	3054	Recombinant OGT bearing the p.Arg284Pro mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor host cell factor 1, which is also encoded by an XLID-associated gene.
BC8_BioRED_Task1_Doc267	1737	1741	XLID	Disease	D038901	Recombinant OGT bearing the p.Arg284Pro mutation was prone to unfolding and exhibited reduced glycosylation activity against a complex array of glycosylation substrates and proteolytic processing of the transcription factor host cell factor 1, which is also encoded by an XLID-associated gene.
BC8_BioRED_Task1_Doc267	1787	1795	O-GlcNAc	Gene	8473	We conclude that defects in O-GlcNAc homeostasis and host cell factor 1 proteolysis may play roles in mediation of XLID in individuals with OGT mutations.
BC8_BioRED_Task1_Doc267	1812	1830	host cell factor 1	Gene	3054	We conclude that defects in O-GlcNAc homeostasis and host cell factor 1 proteolysis may play roles in mediation of XLID in individuals with OGT mutations.
BC8_BioRED_Task1_Doc267	1874	1878	XLID	Disease	D038901	We conclude that defects in O-GlcNAc homeostasis and host cell factor 1 proteolysis may play roles in mediation of XLID in individuals with OGT mutations.
BC8_BioRED_Task1_Doc267	1899	1902	OGT	Gene	8473	We conclude that defects in O-GlcNAc homeostasis and host cell factor 1 proteolysis may play roles in mediation of XLID in individuals with OGT mutations.
BC8_BioRED_Task1_Doc268	8	39	angiotensin II type 1a receptor	Gene	11607	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
BC8_BioRED_Task1_Doc268	43	55	renal injury	Disease	D007674	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
BC8_BioRED_Task1_Doc268	67	94	deoxycorticosterone acetate	Chemical	D064791	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
BC8_BioRED_Task1_Doc268	100	112	hypertension	Disease	D006973	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.	Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
BC8_BioRED_Task1_Doc268	175	213	angiotensin II type 1a (AT1a) receptor	Gene	11607	The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.
BC8_BioRED_Task1_Doc268	217	229	renal damage	Disease	D007674	The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.
BC8_BioRED_Task1_Doc268	245	257	hypertension	Disease	D006973	The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.
BC8_BioRED_Task1_Doc268	278	282	mice	OrganismTaxon	10090	The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.
BC8_BioRED_Task1_Doc268	288	301	AT1a receptor	Gene	11607	The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption.
BC8_BioRED_Task1_Doc268	330	334	mice	OrganismTaxon	10090	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	348	353	human	OrganismTaxon	9606	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	354	391	liver-type fatty acid binding protein	Gene	2168	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	393	399	L-FABP	Gene	2168	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	435	448	AT1a receptor	Gene	11607	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	455	461	L-FABP	Gene	2168	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	467	471	AT1a	Gene	11607	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	482	488	L-FABP	Gene	2168	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	494	498	AT1a	Gene	11607	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	542	548	L-FABP	Gene	2168	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	568	593	tubulointerstitial damage	Disease	D007674	Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage.
BC8_BioRED_Task1_Doc268	608	612	mice	OrganismTaxon	10090	Those female mice were administered subcutaneously deoxycorticosterone acetate (DOCA)-salt tablets plus drinking water that contained 1% saline for 28 d after uninephrectomy.
BC8_BioRED_Task1_Doc268	646	673	deoxycorticosterone acetate	Chemical	D064791	Those female mice were administered subcutaneously deoxycorticosterone acetate (DOCA)-salt tablets plus drinking water that contained 1% saline for 28 d after uninephrectomy.
BC8_BioRED_Task1_Doc268	675	679	DOCA	Chemical	D064791	Those female mice were administered subcutaneously deoxycorticosterone acetate (DOCA)-salt tablets plus drinking water that contained 1% saline for 28 d after uninephrectomy.
BC8_BioRED_Task1_Doc268	773	779	L-FABP	Gene	2168	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	785	789	AT1a	Gene	11607	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	795	799	mice	OrganismTaxon	10090	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	814	818	DOCA	Chemical	D064791	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	835	847	hypertension	Disease	D006973	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	901	921	glomerular sclerosis	Disease	D007674	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	927	952	tubulointerstitial damage	Disease	D007674	In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed.
BC8_BioRED_Task1_Doc268	971	977	L-FABP	Gene	2168	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	983	987	AT1a	Gene	11607	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	993	997	mice	OrganismTaxon	10090	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1012	1016	DOCA	Chemical	D064791	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1033	1045	hypertension	Disease	D006973	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1086	1103	glomerular damage	Disease	D007674	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1142	1148	L-FABP	Gene	2168	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1154	1158	AT1a	Gene	11607	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1164	1168	DOCA	Chemical	D064791	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1169	1173	mice	OrganismTaxon	10090	In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1183	1189	L-FABP	Gene	2168	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1226	1232	L-FABP	Gene	2168	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1238	1242	AT1a	Gene	11607	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1248	1252	DOCA	Chemical	D064791	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1253	1257	mice	OrganismTaxon	10090	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1281	1287	L-FABP	Gene	2168	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1293	1297	AT1a	Gene	11607	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1303	1307	DOCA	Chemical	D064791	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1308	1312	mice	OrganismTaxon	10090	Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice.
BC8_BioRED_Task1_Doc268	1314	1325	Hydralazine	Chemical	D006830	Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.
BC8_BioRED_Task1_Doc268	1361	1373	renal damage	Disease	D007674	Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.
BC8_BioRED_Task1_Doc268	1392	1398	L-FABP	Gene	2168	Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.
BC8_BioRED_Task1_Doc268	1404	1408	AT1a	Gene	11607	Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.
BC8_BioRED_Task1_Doc268	1414	1418	DOCA	Chemical	D064791	Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.
BC8_BioRED_Task1_Doc268	1419	1423	mice	OrganismTaxon	10090	Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure.
BC8_BioRED_Task1_Doc268	1496	1509	AT1a receptor	Gene	11607	In summary, activation of the AT1a receptor may contribute to maintenance of the glomerular structure against hypertensive renal damage.-Hisamichi, M., Kamijo-Ikemori, A., Sugaya, T., Ichikawa, D., Natsuki, T., Hoshino, S., Kimura, K., Shibagaki, Y.
BC8_BioRED_Task1_Doc268	1576	1601	hypertensive renal damage	Disease	D006973,D007674	In summary, activation of the AT1a receptor may contribute to maintenance of the glomerular structure against hypertensive renal damage.-Hisamichi, M., Kamijo-Ikemori, A., Sugaya, T., Ichikawa, D., Natsuki, T., Hoshino, S., Kimura, K., Shibagaki, Y.
BC8_BioRED_Task1_Doc268	1724	1755	angiotensin II type 1a receptor	Gene	11607
BC8_BioRED_Task1_Doc268	1759	1771	renal injury	Disease	D007674
BC8_BioRED_Task1_Doc268	1783	1810	deoxycorticosterone acetate	Chemical	D064791
BC8_BioRED_Task1_Doc268	1816	1828	hypertension	Disease	D006973
BC8_BioRED_Task1_Doc269	0	4	CTR9	Gene	22083	CTR9/PAF1c regulates molecular lineage identity, histone H3K36 trimethylation and genomic imprinting during preimplantation development.
BC8_BioRED_Task1_Doc269	5	10	PAF1c	Gene	22083,54624,76246	CTR9/PAF1c regulates molecular lineage identity, histone H3K36 trimethylation and genomic imprinting during preimplantation development.
BC8_BioRED_Task1_Doc269	49	59	histone H3	Gene	260423	CTR9/PAF1c regulates molecular lineage identity, histone H3K36 trimethylation and genomic imprinting during preimplantation development.
BC8_BioRED_Task1_Doc269	428	507	RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex	Gene	22083,54624,76246	Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.
BC8_BioRED_Task1_Doc269	509	521	PAF1 complex	Gene	22083,54624,76246	Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.
BC8_BioRED_Task1_Doc269	535	539	Ctr9	Gene	22083	Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.
BC8_BioRED_Task1_Doc269	544	548	Rtf1	Gene	76246	Here we report that two members of the RNA polymerase II associated factor, homolog (Saccharomyces cerevisiae) complex (PAF1 complex) components, Ctr9 and Rtf1, are required during mammalian preimplantation development.
BC8_BioRED_Task1_Doc269	629	633	Ctr9	Gene	22083	We demonstrate that Ctr9-deficient embryos fail to correctly specify lineages at the blastocyst stage.
BC8_BioRED_Task1_Doc269	779	783	Ctr9	Gene	22083	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	813	818	Eomes	Gene	13813	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	820	824	Elf5	Gene	13711	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	829	833	Sox2	Gene	20674	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	879	883	Oct4	Gene	18999	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	885	890	Nanog	Gene	71950	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	892	897	Gata6	Gene	14465	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	899	903	Fgf4	Gene	14175	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	908	913	Sox17	Gene	20671	Expression of some lineage specific factors is markedly reduced in Ctr9 knockdown embryos, including Eomes, Elf5 and Sox2, while others are inappropriately expressed (Oct4, Nanog, Gata6, Fgf4 and Sox17).
BC8_BioRED_Task1_Doc269	959	963	Mest	Gene	17294	We also show that several imprinted genes (Mest, Peg3, Snrpn and Meg3) are aberrantly expressed although allele specific DNA methylation is not altered.
BC8_BioRED_Task1_Doc269	965	969	Peg3	Gene	18616	We also show that several imprinted genes (Mest, Peg3, Snrpn and Meg3) are aberrantly expressed although allele specific DNA methylation is not altered.
BC8_BioRED_Task1_Doc269	971	976	Snrpn	Gene	20646	We also show that several imprinted genes (Mest, Peg3, Snrpn and Meg3) are aberrantly expressed although allele specific DNA methylation is not altered.
BC8_BioRED_Task1_Doc269	981	985	Meg3	Gene	17263	We also show that several imprinted genes (Mest, Peg3, Snrpn and Meg3) are aberrantly expressed although allele specific DNA methylation is not altered.
BC8_BioRED_Task1_Doc269	1091	1101	histone H3	Gene	260423	We document a loss of histone H3 lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.
BC8_BioRED_Task1_Doc269	1128	1130	H3	Gene	260423	We document a loss of histone H3 lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.
BC8_BioRED_Task1_Doc269	1141	1145	Ctr9	Gene	22083	We document a loss of histone H3 lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.
BC8_BioRED_Task1_Doc269	1201	1206	Setd2	Gene	235626	We document a loss of histone H3 lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.
BC8_BioRED_Task1_Doc269	1210	1214	Rtf1	Gene	76246	We document a loss of histone H3 lysine 36 trimethylation (H3K36me3) in Ctr9-deficient embryos and confirm that knockdown of either Setd2 or Rtf1 results in similar phenotypes.
BC8_BioRED_Task1_Doc269	1275	1287	PAF1 complex	Gene	22083,54624,76246	These findings show that the PAF1 complex is required for mammalian development, likely through regulation of H3K36me3, and indicate functional conservation of the PAF1 complex from yeast to mammals in vivo.
BC8_BioRED_Task1_Doc269	1356	1358	H3	Gene	260423	These findings show that the PAF1 complex is required for mammalian development, likely through regulation of H3K36me3, and indicate functional conservation of the PAF1 complex from yeast to mammals in vivo.
BC8_BioRED_Task1_Doc269	1410	1422	PAF1 complex	Gene	22083,54624,76246	These findings show that the PAF1 complex is required for mammalian development, likely through regulation of H3K36me3, and indicate functional conservation of the PAF1 complex from yeast to mammals in vivo.
BC8_BioRED_Task1_Doc269	1428	1433	yeast	OrganismTaxon	4932	These findings show that the PAF1 complex is required for mammalian development, likely through regulation of H3K36me3, and indicate functional conservation of the PAF1 complex from yeast to mammals in vivo.
BC8_BioRED_Task1_Doc270	54	59	OPHN1	Gene	4983	Delineation of the clinical phenotype associated with OPHN1 mutations based on the clinical and neuropsychological evaluation of three families.
BC8_BioRED_Task1_Doc270	200	205	OPHN1	Gene	4983	Recent reports have demonstrated that mutations in the OPHN1 gene were responsible for a syndromic rather than non-specific mental retardation.
BC8_BioRED_Task1_Doc270	269	287	mental retardation	Disease	D008607	Recent reports have demonstrated that mutations in the OPHN1 gene were responsible for a syndromic rather than non-specific mental retardation.
BC8_BioRED_Task1_Doc270	331	352	cerebellar hypoplasia	Disease	C562568	Abnormalities of the posterior fossa with cerebellar hypoplasia have been demonstrated in all male patients reported to date.
BC8_BioRED_Task1_Doc270	388	396	patients	OrganismTaxon	9606	Abnormalities of the posterior fossa with cerebellar hypoplasia have been demonstrated in all male patients reported to date.
BC8_BioRED_Task1_Doc270	448	475	X-linked mental retardation	Disease	D038901	We report here a new family with X-linked mental retardation due to mutation in OPHN1 and present unpublished data about two families previously reported, concerning the facial and psychological phenotype of affected males and carrier females.
BC8_BioRED_Task1_Doc270	495	500	OPHN1	Gene	4983	We report here a new family with X-linked mental retardation due to mutation in OPHN1 and present unpublished data about two families previously reported, concerning the facial and psychological phenotype of affected males and carrier females.
BC8_BioRED_Task1_Doc270	683	704	cerebellar hypoplasia	Disease	C562568	Our study confirms that cerebellar hypoplasia is a hallmark of this syndrome.
BC8_BioRED_Task1_Doc270	853	871	mental retardation	Disease	D008607	Most carrier females have mild mental retardation and subtle facial changes.
BC8_BioRED_Task1_Doc271	0	11	Apomorphine	Chemical	D001058	Apomorphine: an underutilized therapy for Parkinson's disease.
BC8_BioRED_Task1_Doc271	42	61	Parkinson's disease	Disease	D010300	Apomorphine: an underutilized therapy for Parkinson's disease.
BC8_BioRED_Task1_Doc271	63	74	Apomorphine	Chemical	D001058	Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.
BC8_BioRED_Task1_Doc271	89	106	dopaminergic drug	Chemical	D004298	Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.
BC8_BioRED_Task1_Doc271	138	157	Parkinson's disease	Disease	D010300	Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.
BC8_BioRED_Task1_Doc271	273	292	Parkinson's disease	Disease	D010300	While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.
BC8_BioRED_Task1_Doc271	327	338	apomorphine	Chemical	D001058	While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.
BC8_BioRED_Task1_Doc271	493	504	apomorphine	Chemical	D001058	A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.
BC8_BioRED_Task1_Doc271	590	598	levodopa	Chemical	D007980	A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.
BC8_BioRED_Task1_Doc271	608	619	apomorphine	Chemical	D001058	A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.
BC8_BioRED_Task1_Doc271	678	686	patients	OrganismTaxon	9606	A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.
BC8_BioRED_Task1_Doc271	745	756	apomorphine	Chemical	D001058	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.
BC8_BioRED_Task1_Doc271	827	835	patients	OrganismTaxon	9606	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.
BC8_BioRED_Task1_Doc271	930	947	dopamine agonists	Chemical	D018491	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.
BC8_BioRED_Task1_Doc271	951	966	COMT inhibitors	Chemical	D065098	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.
BC8_BioRED_Task1_Doc271	1055	1066	apomorphine	Chemical	D001058	Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.
BC8_BioRED_Task1_Doc271	1174	1185	apomorphine	Chemical	D001058	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc271	1248	1256	levodopa	Chemical	D007980	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc271	1265	1276	dyskinesias	Disease	D004409	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias.
BC8_BioRED_Task1_Doc271	1316	1327	apomorphine	Chemical	D001058	The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
BC8_BioRED_Task1_Doc271	1407	1432	psychiatric complications	Disease	D001523	The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
BC8_BioRED_Task1_Doc271	1505	1516	apomorphine	Chemical	D001058	Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.
BC8_BioRED_Task1_Doc271	1542	1561	Parkinson's disease	Disease	D010300	Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.
BC8_BioRED_Task1_Doc272	45	55	daptomycin	Chemical	D017576	Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
BC8_BioRED_Task1_Doc272	69	90	Staphylococcus aureus	OrganismTaxon	1280	Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
BC8_BioRED_Task1_Doc272	91	101	meningitis	Disease	D008581	Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
BC8_BioRED_Task1_Doc272	134	145	methicillin	Chemical	D008712	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
BC8_BioRED_Task1_Doc272	156	177	Staphylococcus aureus	OrganismTaxon	1280	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
BC8_BioRED_Task1_Doc272	185	195	bacteremia	Disease	D016470	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
BC8_BioRED_Task1_Doc272	216	226	meningitis	Disease	D008581	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
BC8_BioRED_Task1_Doc272	250	260	daptomycin	Chemical	D017576	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
BC8_BioRED_Task1_Doc272	426	434	weakness	Disease	D018908	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph.
BC8_BioRED_Task1_Doc272	471	480	pneumonia	Disease	D011014	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph.
BC8_BioRED_Task1_Doc272	549	559	vancomycin	Chemical	D014640	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam.
BC8_BioRED_Task1_Doc272	561	573	levofloxacin	Chemical	D064704	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam.
BC8_BioRED_Task1_Doc272	579	602	piperacillin/tazobactam	Chemical	D000077725	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam.
BC8_BioRED_Task1_Doc272	628	637	S. aureus	OrganismTaxon	1280	Blood cultures revealed S. aureus susceptible to oxacillin.
BC8_BioRED_Task1_Doc272	653	662	oxacillin	Chemical	D010068	Blood cultures revealed S. aureus susceptible to oxacillin.
BC8_BioRED_Task1_Doc272	672	682	antibiotic	Chemical	D000900	Empiric antibiotic treatment was narrowed to nafcillin on day 4.
BC8_BioRED_Task1_Doc272	709	718	nafcillin	Chemical	D009254	Empiric antibiotic treatment was narrowed to nafcillin on day 4.
BC8_BioRED_Task1_Doc272	743	750	patient	OrganismTaxon	9606	On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).
BC8_BioRED_Task1_Doc272	761	780	acute renal failure	Disease	D058186	On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).
BC8_BioRED_Task1_Doc272	788	798	creatinine	Chemical	D003404	On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).
BC8_BioRED_Task1_Doc272	885	892	patient	OrganismTaxon	9606	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10.
BC8_BioRED_Task1_Doc272	903	907	Coma	Disease	D003128	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10.
BC8_BioRED_Task1_Doc272	1021	1035	cardiac arrest	Disease	D006323	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10.
BC8_BioRED_Task1_Doc272	1051	1058	patient	OrganismTaxon	9606	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection.
BC8_BioRED_Task1_Doc272	1086	1096	bacteremia	Disease	D016470	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection.
BC8_BioRED_Task1_Doc272	1138	1176	central nervous system (CNS) infection	Disease	D002494	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection.
BC8_BioRED_Task1_Doc272	1178	1187	Nafcillin	Chemical	D009254	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
BC8_BioRED_Task1_Doc272	1209	1219	daptomycin	Chemical	D017576	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
BC8_BioRED_Task1_Doc272	1262	1272	meningitis	Disease	D008581	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
BC8_BioRED_Task1_Doc272	1301	1308	patient	OrganismTaxon	9606	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
BC8_BioRED_Task1_Doc272	1311	1316	death	Disease	D003643	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
BC8_BioRED_Task1_Doc272	1328	1338	Daptomycin	Chemical	D017576	Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose.
BC8_BioRED_Task1_Doc272	1543	1558	Creatine kinase	Gene	1152	Creatine kinase levels were normal prior to daptomycin therapy and were not reassessed.
BC8_BioRED_Task1_Doc272	1587	1597	daptomycin	Chemical	D017576	Creatine kinase levels were normal prior to daptomycin therapy and were not reassessed.
BC8_BioRED_Task1_Doc272	1643	1653	Daptomycin	Chemical	D017576	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
BC8_BioRED_Task1_Doc272	1675	1682	patient	OrganismTaxon	9606	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
BC8_BioRED_Task1_Doc272	1705	1714	nafcillin	Chemical	D009254	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
BC8_BioRED_Task1_Doc272	1729	1751	interstitial nephritis	Disease	D009395	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
BC8_BioRED_Task1_Doc272	1766	1776	bacteremia	Disease	D016470	DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.
BC8_BioRED_Task1_Doc272	1928	1938	daptomycin	Chemical	D017576	CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.
BC8_BioRED_Task1_Doc272	1977	1987	bacteremia	Disease	D016470	CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.
BC8_BioRED_Task1_Doc272	2020	2028	patients	OrganismTaxon	9606	CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.
BC8_BioRED_Task1_Doc272	2113	2121	patients	OrganismTaxon	9606	Further clinical evaluation in patients with confirmed meningitis is warranted.
BC8_BioRED_Task1_Doc272	2137	2147	meningitis	Disease	D008581	Further clinical evaluation in patients with confirmed meningitis is warranted.
BC8_BioRED_Task1_Doc273	4	26	dopamine b-hydroxylase	Gene	1621	The dopamine b-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project.
BC8_BioRED_Task1_Doc273	27	35	-1021C/T	SequenceVariant	rs1611115	The dopamine b-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project.
BC8_BioRED_Task1_Doc273	80	99	Alzheimer's disease	Disease	D000544	The dopamine b-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project.
BC8_BioRED_Task1_Doc273	218	237	Alzheimer's disease	Disease	D000544	BACKGROUND: The loss of noradrenergic neurones of the locus coeruleus is a major feature of Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc273	239	241	AD	Disease	D000544	BACKGROUND: The loss of noradrenergic neurones of the locus coeruleus is a major feature of Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc273	244	266	Dopamine b-hydroxylase	Gene	1621	Dopamine b-hydroxylase (DBH) catalyses the conversion of dopamine to noradrenaline.
BC8_BioRED_Task1_Doc273	268	271	DBH	Gene	1621	Dopamine b-hydroxylase (DBH) catalyses the conversion of dopamine to noradrenaline.
BC8_BioRED_Task1_Doc273	301	309	dopamine	Chemical	D004298	Dopamine b-hydroxylase (DBH) catalyses the conversion of dopamine to noradrenaline.
BC8_BioRED_Task1_Doc273	313	326	noradrenaline	Chemical	D009638	Dopamine b-hydroxylase (DBH) catalyses the conversion of dopamine to noradrenaline.
BC8_BioRED_Task1_Doc273	385	391	-1021T	SequenceVariant	rs1611115	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	400	409	rs1611115	SequenceVariant	rs1611115	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	414	417	DBH	Gene	1621	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	447	459	inflammatory	Disease	D007249	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	476	480	IL1A	Gene	3552	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	485	488	IL6	Gene	3569	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	518	520	AD	Disease	D000544	Interactions have been reported between the low-activity -1021T allele (rs1611115) of DBH and polymorphisms of the pro-inflammatory cytokine genes, IL1A and IL6, contributing to the risk of AD.
BC8_BioRED_Task1_Doc273	566	568	AD	Disease	D000544	We therefore examined the associations with AD of the DBH -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of AD and 6294 elderly controls.
BC8_BioRED_Task1_Doc273	576	579	DBH	Gene	1621	We therefore examined the associations with AD of the DBH -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of AD and 6294 elderly controls.
BC8_BioRED_Task1_Doc273	580	586	-1021T	SequenceVariant	rs1611115	We therefore examined the associations with AD of the DBH -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of AD and 6294 elderly controls.
BC8_BioRED_Task1_Doc273	669	671	AD	Disease	D000544	We therefore examined the associations with AD of the DBH -1021T allele and of the above interactions in the Epistasis Project, with 1757 cases of AD and 6294 elderly controls.
BC8_BioRED_Task1_Doc273	786	789	DBH	Gene	1621	METHODS: We genotyped eight single nucleotide polymorphisms (SNPs) in the three genes, DBH, IL1A and IL6.
BC8_BioRED_Task1_Doc273	791	795	IL1A	Gene	3552	METHODS: We genotyped eight single nucleotide polymorphisms (SNPs) in the three genes, DBH, IL1A and IL6.
BC8_BioRED_Task1_Doc273	800	803	IL6	Gene	3569	METHODS: We genotyped eight single nucleotide polymorphisms (SNPs) in the three genes, DBH, IL1A and IL6.
BC8_BioRED_Task1_Doc273	924	926	AD	Disease	D000544	We used logistic regression models and synergy factor analysis to examine potential interactions and associations with AD.
BC8_BioRED_Task1_Doc273	971	977	-1021T	SequenceVariant	rs1611115	RESULTS: We found that the presence of the -1021T allele was associated with AD: odds ratio = 1.2 (95% confidence interval: 1.06-1.4, p = 0.005).
BC8_BioRED_Task1_Doc273	1005	1007	AD	Disease	D000544	RESULTS: We found that the presence of the -1021T allele was associated with AD: odds ratio = 1.2 (95% confidence interval: 1.06-1.4, p = 0.005).
BC8_BioRED_Task1_Doc273	1116	1119	men	OrganismTaxon	9606	This association was nearly restricted to men < 75 years old: odds ratio = 2.2 (1.4-3.3, 0.0004).
BC8_BioRED_Task1_Doc273	1225	1228	DBH	Gene	1621	We also found an interaction between the presence of DBH -1021T and the -889TT genotype (rs1800587) of IL1A: synergy factor = 1.9 (1.2-3.1, 0.005).
BC8_BioRED_Task1_Doc273	1229	1235	-1021T	SequenceVariant	rs1611115	We also found an interaction between the presence of DBH -1021T and the -889TT genotype (rs1800587) of IL1A: synergy factor = 1.9 (1.2-3.1, 0.005).
BC8_BioRED_Task1_Doc273	1244	1250	-889TT	SequenceVariant	rs1800587	We also found an interaction between the presence of DBH -1021T and the -889TT genotype (rs1800587) of IL1A: synergy factor = 1.9 (1.2-3.1, 0.005).
BC8_BioRED_Task1_Doc273	1261	1270	rs1800587	SequenceVariant	rs1800587	We also found an interaction between the presence of DBH -1021T and the -889TT genotype (rs1800587) of IL1A: synergy factor = 1.9 (1.2-3.1, 0.005).
BC8_BioRED_Task1_Doc273	1275	1279	IL1A	Gene	3552	We also found an interaction between the presence of DBH -1021T and the -889TT genotype (rs1800587) of IL1A: synergy factor = 1.9 (1.2-3.1, 0.005).
BC8_BioRED_Task1_Doc273	1482	1495	noradrenaline	Chemical	D009638	CONCLUSIONS: Extensive, previous evidence (reviewed here) indicates an important role for noradrenaline in the control of inflammation in the brain.
BC8_BioRED_Task1_Doc273	1514	1526	inflammation	Disease	D007249	CONCLUSIONS: Extensive, previous evidence (reviewed here) indicates an important role for noradrenaline in the control of inflammation in the brain.
BC8_BioRED_Task1_Doc273	1551	1557	-1021T	SequenceVariant	rs1611115	Thus, the -1021T allele with presumed low activity may be associated with misregulation of inflammation, which could contribute to the onset of AD.
BC8_BioRED_Task1_Doc273	1632	1644	inflammation	Disease	D007249	Thus, the -1021T allele with presumed low activity may be associated with misregulation of inflammation, which could contribute to the onset of AD.
BC8_BioRED_Task1_Doc273	1685	1687	AD	Disease	D000544	Thus, the -1021T allele with presumed low activity may be associated with misregulation of inflammation, which could contribute to the onset of AD.
BC8_BioRED_Task1_Doc274	44	51	CYP11B2	Gene	1585	Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas.
BC8_BioRED_Task1_Doc274	52	59	CYP11B1	Gene	1584	Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas.
BC8_BioRED_Task1_Doc274	84	96	hypertension	Disease	D006973	Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas.
BC8_BioRED_Task1_Doc274	109	117	patients	OrganismTaxon	9606	Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas.
BC8_BioRED_Task1_Doc274	123	153	aldosterone-producing adenomas	Disease	D000236	Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas.
BC8_BioRED_Task1_Doc274	167	179	Hypertension	Disease	D006973	OBJECTIVES: Hypertension often persists after adrenalectomy for primary aldosteronism.
BC8_BioRED_Task1_Doc274	292	304	hypertension	Disease	D006973	Traditional factors associated with postoperative hypertension were evaluated, but whether genetic determinants were involved remains poorly understood.
BC8_BioRED_Task1_Doc274	480	503	steroid synthesis genes	Gene	1584,1585	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	505	512	CYP11B2	Gene	1585	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	514	521	CYP11B1	Gene	1584	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	559	571	hypertension	Disease	D006973	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	583	591	patients	OrganismTaxon	9606	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	621	651	aldosterone-producing adenomas	Disease	D000236	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	653	656	APA	Disease	D000236	The aim of this study was to investigate the association of DNA polymorphisms within steroid synthesis genes (CYP11B2, CYP11B1) and the postoperative resolution of hypertension in Chinese patients undergoing adrenalectomy for aldosterone-producing adenomas (APA).
BC8_BioRED_Task1_Doc274	681	689	patients	OrganismTaxon	9606	METHODS: Ninety-three patients with APA were assessed for postoperative resolution of hypertension.
BC8_BioRED_Task1_Doc274	695	698	APA	Disease	D000236	METHODS: Ninety-three patients with APA were assessed for postoperative resolution of hypertension.
BC8_BioRED_Task1_Doc274	745	757	hypertension	Disease	D006973	METHODS: Ninety-three patients with APA were assessed for postoperative resolution of hypertension.
BC8_BioRED_Task1_Doc274	763	771	patients	OrganismTaxon	9606	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	791	800	rs1799998	SequenceVariant	rs1799998	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	802	809	C-344 T	SequenceVariant	rs1799998	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	833	839	rs4539	SequenceVariant	rs4539	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	841	847	A2718G	SequenceVariant	rs4539	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	856	863	CYP11B2	Gene	1585	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	868	874	rs6410	SequenceVariant	rs6410	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	876	882	G22 5A	SequenceVariant	rs6410	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	885	891	rs6387	SequenceVariant	rs6387	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	893	899	A2803G	SequenceVariant	rs6387	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	908	915	CYP11B1	Gene	1584	All patients were genotyped for rs1799998 (C-344 T), intron 2 conversion, rs4539 (A2718G) within CYP11B2 and rs6410 (G22 5A), rs6387 (A2803G) within CYP11B1.
BC8_BioRED_Task1_Doc274	942	950	CYPB11B2	Gene	1585	The associations between CYPB11B2/CYP11B1 polymorphisms and persistent postoperative hypertension were assessed by multivariate analysis.
BC8_BioRED_Task1_Doc274	951	958	CYP11B1	Gene	1584	The associations between CYPB11B2/CYP11B1 polymorphisms and persistent postoperative hypertension were assessed by multivariate analysis.
BC8_BioRED_Task1_Doc274	1002	1014	hypertension	Disease	D006973	The associations between CYPB11B2/CYP11B1 polymorphisms and persistent postoperative hypertension were assessed by multivariate analysis.
BC8_BioRED_Task1_Doc274	1064	1071	CYP11B2	Gene	1585	RESULTS: CYP11B2-CYP11B1 haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with APA (P = .006).
BC8_BioRED_Task1_Doc274	1072	1079	CYP11B1	Gene	1584	RESULTS: CYP11B2-CYP11B1 haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with APA (P = .006).
BC8_BioRED_Task1_Doc274	1135	1147	hypertension	Disease	D006973	RESULTS: CYP11B2-CYP11B1 haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with APA (P = .006).
BC8_BioRED_Task1_Doc274	1159	1167	patients	OrganismTaxon	9606	RESULTS: CYP11B2-CYP11B1 haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with APA (P = .006).
BC8_BioRED_Task1_Doc274	1198	1201	APA	Disease	D000236	RESULTS: CYP11B2-CYP11B1 haplotype was associated with persistent postoperative hypertension in Chinese patients undergoing adrenalectomy with APA (P = .006).
BC8_BioRED_Task1_Doc274	1232	1238	rs4539	SequenceVariant	rs4539	Specifically, the rs4539 (AA) polymorphism was associated with persistent postoperative hypertension (P = .002).
BC8_BioRED_Task1_Doc274	1302	1314	hypertension	Disease	D006973	Specifically, the rs4539 (AA) polymorphism was associated with persistent postoperative hypertension (P = .002).
BC8_BioRED_Task1_Doc274	1480	1492	hypertension	Disease	D006973	Multivariate logistic regression revealed the common haplotypes H1 (AGACT), H2 (AGAWT), and H3 (AGAWC) were associated with the persistent postoperative hypertension (P = .01, 0.03, 0.005 after Bonferroni correction).
BC8_BioRED_Task1_Doc274	1595	1607	hypertension	Disease	D006973	Additional predictors of persistent postoperative hypertension included duration of hypertension (P <.0005), family history of hypertension (P = .001), and elevated systolic blood pressure (P = .015).
BC8_BioRED_Task1_Doc274	1629	1641	hypertension	Disease	D006973	Additional predictors of persistent postoperative hypertension included duration of hypertension (P <.0005), family history of hypertension (P = .001), and elevated systolic blood pressure (P = .015).
BC8_BioRED_Task1_Doc274	1672	1684	hypertension	Disease	D006973	Additional predictors of persistent postoperative hypertension included duration of hypertension (P <.0005), family history of hypertension (P = .001), and elevated systolic blood pressure (P = .015).
BC8_BioRED_Task1_Doc274	1763	1769	rs4539	SequenceVariant	rs4539	CONCLUSIONS: The rs4539 (AA), H1, H2, and H3 are genetic predictors for postoperative persistence of hypertension for Chinese patients treated by adrenalectomy with APA.
BC8_BioRED_Task1_Doc274	1847	1859	hypertension	Disease	D006973	CONCLUSIONS: The rs4539 (AA), H1, H2, and H3 are genetic predictors for postoperative persistence of hypertension for Chinese patients treated by adrenalectomy with APA.
BC8_BioRED_Task1_Doc274	1872	1880	patients	OrganismTaxon	9606	CONCLUSIONS: The rs4539 (AA), H1, H2, and H3 are genetic predictors for postoperative persistence of hypertension for Chinese patients treated by adrenalectomy with APA.
BC8_BioRED_Task1_Doc274	1911	1914	APA	Disease	D000236	CONCLUSIONS: The rs4539 (AA), H1, H2, and H3 are genetic predictors for postoperative persistence of hypertension for Chinese patients treated by adrenalectomy with APA.
BC8_BioRED_Task1_Doc274	1937	1947	CYP11B2/B1	Gene	1584,1585	DNA polymorphisms at CYP11B2/B1 locus may confer susceptibility to postoperative hypertension of patients with APA.
BC8_BioRED_Task1_Doc274	1997	2009	hypertension	Disease	D006973	DNA polymorphisms at CYP11B2/B1 locus may confer susceptibility to postoperative hypertension of patients with APA.
BC8_BioRED_Task1_Doc274	2013	2021	patients	OrganismTaxon	9606	DNA polymorphisms at CYP11B2/B1 locus may confer susceptibility to postoperative hypertension of patients with APA.
BC8_BioRED_Task1_Doc274	2027	2030	APA	Disease	D000236	DNA polymorphisms at CYP11B2/B1 locus may confer susceptibility to postoperative hypertension of patients with APA.
BC8_BioRED_Task1_Doc275	0	13	Valproic acid	Chemical	D014635	Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
BC8_BioRED_Task1_Doc275	32	37	lipid	Chemical	D008055	Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
BC8_BioRED_Task1_Doc275	63	77	liver toxicity	Disease	D056486	Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
BC8_BioRED_Task1_Doc275	83	96	valproic acid	Chemical	D014635	Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
BC8_BioRED_Task1_Doc275	118	122	rats	OrganismTaxon	10116	Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
BC8_BioRED_Task1_Doc275	141	154	valproic acid	Chemical	D014635	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).
BC8_BioRED_Task1_Doc275	156	159	VPA	Chemical	D014635	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).
BC8_BioRED_Task1_Doc275	185	203	antiepileptic drug	Chemical	D000927	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).
BC8_BioRED_Task1_Doc275	244	248	rats	OrganismTaxon	10116	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).
BC8_BioRED_Task1_Doc275	297	317	15-F(2t)-isoprostane	Chemical	C075750	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).
BC8_BioRED_Task1_Doc275	319	332	15-F(2t)-IsoP	Chemical	C075750	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).
BC8_BioRED_Task1_Doc275	398	401	VPA	Chemical	D014635	To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.
BC8_BioRED_Task1_Doc275	434	448	hepatotoxicity	Disease	D056486	To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.
BC8_BioRED_Task1_Doc275	476	480	rats	OrganismTaxon	10116	To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.
BC8_BioRED_Task1_Doc275	502	505	VPA	Chemical	D014635	To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.
BC8_BioRED_Task1_Doc275	655	668	15-F(2t)-IsoP	Chemical	C075750	Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).
BC8_BioRED_Task1_Doc275	670	690	lipid hydroperoxides	Chemical	D008054	Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).
BC8_BioRED_Task1_Doc275	692	695	LPO	Chemical	D008054	Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).
BC8_BioRED_Task1_Doc275	702	741	thiobarbituric acid reactive substances	Chemical	D017392	Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).
BC8_BioRED_Task1_Doc275	743	748	TBARs	Chemical	D017392	Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).
BC8_BioRED_Task1_Doc275	768	781	15-F(2t)-IsoP	Chemical	C075750	Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.
BC8_BioRED_Task1_Doc275	833	836	VPA	Chemical	D014635	Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.
BC8_BioRED_Task1_Doc275	874	877	LPO	Chemical	D008054	Liver LPO levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).
BC8_BioRED_Task1_Doc275	982	987	TBARs	Chemical	D017392	Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
BC8_BioRED_Task1_Doc275	1053	1067	Liver toxicity	Disease	D056486	Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
BC8_BioRED_Task1_Doc275	1107	1138	alpha-glutathione S-transferase	Gene	24421	Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
BC8_BioRED_Task1_Doc275	1140	1149	alpha-GST	Gene	24421	Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
BC8_BioRED_Task1_Doc275	1175	1184	alpha-GST	Gene	24421	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
BC8_BioRED_Task1_Doc275	1252	1266	hepatotoxicity	Disease	D056486	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
BC8_BioRED_Task1_Doc275	1307	1340	inflammation of the liver capsule	Disease	D006505	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
BC8_BioRED_Task1_Doc275	1342	1350	necrosis	Disease	D009336	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
BC8_BioRED_Task1_Doc275	1356	1365	steatosis	Disease	D005234	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
BC8_BioRED_Task1_Doc275	1438	1441	VPA	Chemical	D014635	The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
BC8_BioRED_Task1_Doc275	1488	1497	4-ene-VPA	Chemical	C045022	The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
BC8_BioRED_Task1_Doc275	1506	1519	2,4-diene-VPA	Chemical	C556631	The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
BC8_BioRED_Task1_Doc275	1598	1601	VPA	Chemical	D014635	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
BC8_BioRED_Task1_Doc275	1666	1679	15-F(2t)-IsoP	Chemical	C075750	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
BC8_BioRED_Task1_Doc275	1709	1717	necrosis	Disease	D009336	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
BC8_BioRED_Task1_Doc275	1719	1728	steatosis	Disease	D005234	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
BC8_BioRED_Task1_Doc275	1759	1768	alpha-GST	Gene	24421	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.
BC8_BioRED_Task1_Doc276	24	35	connexin 26	Gene	2706	A novel mutation in the connexin 26 gene (GJB2) in a child with clinical and histological features of keratitis-ichthyosis-deafness (KID) syndrome.
BC8_BioRED_Task1_Doc276	42	46	GJB2	Gene	2706	A novel mutation in the connexin 26 gene (GJB2) in a child with clinical and histological features of keratitis-ichthyosis-deafness (KID) syndrome.
BC8_BioRED_Task1_Doc276	102	146	keratitis-ichthyosis-deafness (KID) syndrome	Disease	C536168	A novel mutation in the connexin 26 gene (GJB2) in a child with clinical and histological features of keratitis-ichthyosis-deafness (KID) syndrome.
BC8_BioRED_Task1_Doc276	160	204	Keratitis-ichthyosis-deafness (KID) syndrome	Disease	C536168	BACKGROUND: Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital ectodermal disorder, caused by heterozygous missense mutation in GJB2, encoding the gap junction protein connexin 26.
BC8_BioRED_Task1_Doc276	215	245	congenital ectodermal disorder	Disease	D004476	BACKGROUND: Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital ectodermal disorder, caused by heterozygous missense mutation in GJB2, encoding the gap junction protein connexin 26.
BC8_BioRED_Task1_Doc276	291	295	GJB2	Gene	2706	BACKGROUND: Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital ectodermal disorder, caused by heterozygous missense mutation in GJB2, encoding the gap junction protein connexin 26.
BC8_BioRED_Task1_Doc276	331	342	connexin 26	Gene	2706	BACKGROUND: Keratitis-ichthyosis-deafness (KID) syndrome is a rare congenital ectodermal disorder, caused by heterozygous missense mutation in GJB2, encoding the gap junction protein connexin 26.
BC8_BioRED_Task1_Doc276	374	384	p.Asp50Asn	SequenceVariant	rs28931594	The commonest mutation is the p.Asp50Asn mutation, and only a few other mutations have been described to date.
BC8_BioRED_Task1_Doc276	611	623	KID syndrome	Disease	C536168	AIM: To report the fatal clinical course and characterize the genetic background of a premature male neonate with the clinical and histological features of KID syndrome.
BC8_BioRED_Task1_Doc276	720	724	GJB2	Gene	2706	METHODS: Genomic DNA was extracted from peripheral blood and used for PCR amplification of the GJB2 gene.
BC8_BioRED_Task1_Doc276	821	839	hearing impairment	Disease	D034381	RESULTS: The clinical features included hearing impairment, ichthyosiform erythroderma with hyperkeratotic plaques, palmoplantar keratoderma, alopecia of the scalp and eyelashes, and a thick vernix caseosa-like covering of the scalp.
BC8_BioRED_Task1_Doc276	841	867	ichthyosiform erythroderma	Disease	D016113	RESULTS: The clinical features included hearing impairment, ichthyosiform erythroderma with hyperkeratotic plaques, palmoplantar keratoderma, alopecia of the scalp and eyelashes, and a thick vernix caseosa-like covering of the scalp.
BC8_BioRED_Task1_Doc276	897	921	palmoplantar keratoderma	Disease	D007645	RESULTS: The clinical features included hearing impairment, ichthyosiform erythroderma with hyperkeratotic plaques, palmoplantar keratoderma, alopecia of the scalp and eyelashes, and a thick vernix caseosa-like covering of the scalp.
BC8_BioRED_Task1_Doc276	923	958	alopecia of the scalp and eyelashes	Disease	D000505	RESULTS: The clinical features included hearing impairment, ichthyosiform erythroderma with hyperkeratotic plaques, palmoplantar keratoderma, alopecia of the scalp and eyelashes, and a thick vernix caseosa-like covering of the scalp.
BC8_BioRED_Task1_Doc276	1068	1080	KID syndrome	Disease	C536168	On histological analysis, features characteristic of KID syndrome, such as acanthosis and papillomatosis of the epidermis with basket-weave hyperkeratosis, were seen.
BC8_BioRED_Task1_Doc276	1090	1100	acanthosis	Disease	D000052	On histological analysis, features characteristic of KID syndrome, such as acanthosis and papillomatosis of the epidermis with basket-weave hyperkeratosis, were seen.
BC8_BioRED_Task1_Doc276	1105	1119	papillomatosis	Disease	D010212	On histological analysis, features characteristic of KID syndrome, such as acanthosis and papillomatosis of the epidermis with basket-weave hyperkeratosis, were seen.
BC8_BioRED_Task1_Doc276	1155	1169	hyperkeratosis	Disease	D017488	On histological analysis, features characteristic of KID syndrome, such as acanthosis and papillomatosis of the epidermis with basket-weave hyperkeratosis, were seen.
BC8_BioRED_Task1_Doc276	1231	1240	acitretin	Chemical	D017255	The skin symptoms were treated successfully with acitretin 0.5 mg/kg.
BC8_BioRED_Task1_Doc276	1270	1316	intraventricular and intracerebral haemorrhage	Disease	D000074042,D002543	The boy developed intraventricular and intracerebral haemorrhage, leading to hydrocephalus.
BC8_BioRED_Task1_Doc276	1329	1342	hydrocephalus	Disease	D006849	The boy developed intraventricular and intracerebral haemorrhage, leading to hydrocephalus.
BC8_BioRED_Task1_Doc276	1385	1396	septicaemia	Disease	D018805	His condition was further complicated by septicaemia and meningitis caused by infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
BC8_BioRED_Task1_Doc276	1401	1411	meningitis	Disease	D008581	His condition was further complicated by septicaemia and meningitis caused by infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
BC8_BioRED_Task1_Doc276	1422	1431	infection	Disease	D007239	His condition was further complicated by septicaemia and meningitis caused by infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
BC8_BioRED_Task1_Doc276	1480	1501	Klebsiella pneumoniae	Disease	D007710	His condition was further complicated by septicaemia and meningitis caused by infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
BC8_BioRED_Task1_Doc276	1510	1529	respiratory failure	Disease	D012131	Severe respiratory failure followed, and the child died at 46 weeks of gestational age (13 weeks postnatally).
BC8_BioRED_Task1_Doc276	1632	1636	GJB2	Gene	2706	Sequencing of the GJB2 gene showed that the child was heterozygous for a novel nucleotide change, c.263C>T, in exon 2, leading to a substitution of alanine for valine at position 88 (p.Ala88Val).
BC8_BioRED_Task1_Doc276	1712	1720	c.263C>T	SequenceVariant	c|SUB|C|263|T	Sequencing of the GJB2 gene showed that the child was heterozygous for a novel nucleotide change, c.263C>T, in exon 2, leading to a substitution of alanine for valine at position 88 (p.Ala88Val).
BC8_BioRED_Task1_Doc276	1762	1795	alanine for valine at position 88	SequenceVariant	p|SUB|A|88|V	Sequencing of the GJB2 gene showed that the child was heterozygous for a novel nucleotide change, c.263C>T, in exon 2, leading to a substitution of alanine for valine at position 88 (p.Ala88Val).
BC8_BioRED_Task1_Doc276	1797	1807	p.Ala88Val	SequenceVariant	p|SUB|A|88|V	Sequencing of the GJB2 gene showed that the child was heterozygous for a novel nucleotide change, c.263C>T, in exon 2, leading to a substitution of alanine for valine at position 88 (p.Ala88Val).
BC8_BioRED_Task1_Doc276	1892	1896	Cx26	Gene	2706	CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the Cx26 gene (c.263C>T; p.Ala88Val) leading to KID syndrome.
BC8_BioRED_Task1_Doc276	1903	1911	c.263C>T	SequenceVariant	c|SUB|C|263|T	CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the Cx26 gene (c.263C>T; p.Ala88Val) leading to KID syndrome.
BC8_BioRED_Task1_Doc276	1913	1923	p.Ala88Val	SequenceVariant	p|SUB|A|88|V	CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the Cx26 gene (c.263C>T; p.Ala88Val) leading to KID syndrome.
BC8_BioRED_Task1_Doc276	1936	1948	KID syndrome	Disease	C536168	CONCLUSIONS: This study has identified a new heterozygous de novo mutation in the Cx26 gene (c.263C>T; p.Ala88Val) leading to KID syndrome.
BC8_BioRED_Task1_Doc277	27	35	estrogen	Chemical	D004967	Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
BC8_BioRED_Task1_Doc277	39	84	alpha2-adrenergic and I1-imidazoline receptor	Gene	25083,64652	Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
BC8_BioRED_Task1_Doc277	94	105	hypotension	Disease	D007022	Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
BC8_BioRED_Task1_Doc277	116	120	rats	OrganismTaxon	10116	Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
BC8_BioRED_Task1_Doc277	150	158	estrogen	Chemical	D004967	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
BC8_BioRED_Task1_Doc277	184	195	hypotensive	Disease	D007022	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
BC8_BioRED_Task1_Doc277	206	215	clonidine	Chemical	D003000	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
BC8_BioRED_Task1_Doc277	223	242	alpha2-/I1-receptor	Gene	25083,64652	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
BC8_BioRED_Task1_Doc277	262	266	rats	OrganismTaxon	10116	We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
BC8_BioRED_Task1_Doc277	394	402	estrogen	Chemical	D004967	The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.
BC8_BioRED_Task1_Doc277	429	456	alpha2- and/or I1-receptors	Gene	25083,64652	The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.
BC8_BioRED_Task1_Doc277	514	525	rilmenidine	Chemical	C032302	Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.
BC8_BioRED_Task1_Doc277	545	561	alpha-methyldopa	Chemical	D008750	Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.
BC8_BioRED_Task1_Doc277	585	608	I1- and alpha2-receptor	Gene	25083,64652	Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.
BC8_BioRED_Task1_Doc277	795	799	rats	OrganismTaxon	10116	Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.
BC8_BioRED_Task1_Doc277	822	830	estrogen	Chemical	D004967	Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.
BC8_BioRED_Task1_Doc277	1201	1205	rats	OrganismTaxon	10116	In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
BC8_BioRED_Task1_Doc277	1207	1218	rilmenidine	Chemical	C032302	In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
BC8_BioRED_Task1_Doc277	1222	1238	alpha-methyldopa	Chemical	D008750	In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
BC8_BioRED_Task1_Doc277	1256	1267	hypotension	Disease	D007022	In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
BC8_BioRED_Task1_Doc277	1402	1418	alpha-methyldopa	Chemical	D008750	SDRR was reduced only by alpha-methyldopa.
BC8_BioRED_Task1_Doc277	1451	1462	hypotensive	Disease	D007022	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
BC8_BioRED_Task1_Doc277	1475	1491	alpha-methyldopa	Chemical	D008750	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
BC8_BioRED_Task1_Doc277	1521	1532	rilmenidine	Chemical	C032302	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
BC8_BioRED_Task1_Doc277	1533	1544	hypotension	Disease	D007022	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
BC8_BioRED_Task1_Doc277	1559	1575	alpha-methyldopa	Chemical	D008750	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
BC8_BioRED_Task1_Doc277	1576	1587	hypotension	Disease	D007022	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
BC8_BioRED_Task1_Doc277	1595	1599	rats	OrganismTaxon	10116	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
BC8_BioRED_Task1_Doc277	1650	1678	a reduced locomotor activity	Disease	D001523	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
BC8_BioRED_Task1_Doc277	1702	1718	17beta-estradiol	Chemical	D004958	Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.
BC8_BioRED_Task1_Doc277	1771	1775	rats	OrganismTaxon	10116	Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.
BC8_BioRED_Task1_Doc277	1826	1842	alpha-methyldopa	Chemical	D008750	Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.
BC8_BioRED_Task1_Doc277	1896	1904	estrogen	Chemical	D004967	These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.
BC8_BioRED_Task1_Doc277	1919	1946	alpha2- but not I1-receptor	Gene	25083	These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.
BC8_BioRED_Task1_Doc277	1956	1967	hypotension	Disease	D007022	These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.
BC8_BioRED_Task1_Doc277	2026	2042	alpha-methyldopa	Chemical	D008750	These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.
BC8_BioRED_Task1_Doc277	2043	2051	estrogen	Chemical	D004967	These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.
BC8_BioRED_Task1_Doc278	12	16	EPOR	Gene	13857	Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.
BC8_BioRED_Task1_Doc278	77	87	Tnfr-sf13c	Gene	72049	Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.
BC8_BioRED_Task1_Doc278	111	114	EPO	Gene	13856	Defining an EPOR- regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO- dependent erythroblast formation.
BC8_BioRED_Task1_Doc278	178	181	EPO	Gene	13856	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	182	186	EPOR	Gene	13857	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	241	246	Bcl-x	Gene	12048	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	334	338	EPOR	Gene	13857	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	365	373	p85/PI3K	Gene	18708	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	411	423	polycythemia	Disease	D011086	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	429	433	Erk1	Gene	26417	Certain concepts concerning EPO/EPOR action modes have been challenged by in vivo studies: Bcl-x levels are elevated in maturing erythroblasts, but not in their progenitors; truncated EPOR alleles that lack a major p85/PI3K recruitment site nonetheless promote polycythemia; and Erk1 disruption unexpectedly bolsters erythropoiesis.
BC8_BioRED_Task1_Doc278	501	504	EPO	Gene	13856	To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors.
BC8_BioRED_Task1_Doc278	505	509	EPOR	Gene	13857	To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors.
BC8_BioRED_Task1_Doc278	592	595	EPO	Gene	13856	To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors.
BC8_BioRED_Task1_Doc278	596	600	EPOR	Gene	13857	To discover novel EPO/EPOR action routes, global transcriptome analyses presently are applied to interrogate EPO/EPOR effects on primary bone marrow-derived CFUe-like progenitors.
BC8_BioRED_Task1_Doc278	676	679	EPO	Gene	13856	Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold.
BC8_BioRED_Task1_Doc278	680	684	EPOR	Gene	13857	Overall, 160 EPO/EPOR target transcripts were significantly modulated 2-to 21.8-fold.
BC8_BioRED_Task1_Doc278	765	768	EPO	Gene	13856	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	805	809	Lyl1	Gene	17095	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	811	815	Gas5	Gene	14455	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	817	821	Pim3	Gene	223775	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	823	827	Pim1	Gene	18712	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	829	832	Bim	Gene	12125	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	834	839	Trib3	Gene	228775	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	844	854	Serpina 3g	Gene	20715	A unique set of EPO-regulated survival factors included Lyl1, Gas5, Pim3, Pim1, Bim, Trib3 and Serpina 3g.
BC8_BioRED_Task1_Doc278	856	859	EPO	Gene	13856	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	860	864	EPOR	Gene	13857	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	905	911	Cdc25a	Gene	12530	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	913	917	Btg3	Gene	12228	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	919	928	Cyclin-d2	Gene	12444	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	930	938	p27-kip1	Gene	12576	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	940	949	Cyclin-g2	Gene	12452	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	954	967	CyclinB1-IP-1	Gene	239083	EPO/EPOR-modulated cell cycle mediators included Cdc25a, Btg3, Cyclin-d2, p27-kip1, Cyclin-g2 and CyclinB1-IP-1.
BC8_BioRED_Task1_Doc278	969	972	EPO	Gene	13856	EPO regulation of signal transduction factors was also interestingly complex.
BC8_BioRED_Task1_Doc278	1069	1074	Socs3	Gene	12702	For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components.
BC8_BioRED_Task1_Doc278	1080	1085	Socs2	Gene	216233	For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components.
BC8_BioRED_Task1_Doc278	1095	1101	Spred2	Gene	114716	For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components.
BC8_BioRED_Task1_Doc278	1103	1109	Spred1	Gene	114715	For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components.
BC8_BioRED_Task1_Doc278	1114	1118	Eaf1	Gene	74427	For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components.
BC8_BioRED_Task1_Doc278	1124	1127	EPO	Gene	13856	For example, not only Socs3 plus Socs2 but also Spred2, Spred1 and Eaf1 were EPO-induced as negative-feedback components.
BC8_BioRED_Task1_Doc278	1169	1174	Socs2	Gene	216233	Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia).
BC8_BioRED_Task1_Doc278	1237	1241	EPOR	Gene	13857	Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia).
BC8_BioRED_Task1_Doc278	1242	1246	Jak2	Gene	16452	Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia).
BC8_BioRED_Task1_Doc278	1247	1252	Stat5	Gene	20850	Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia).
BC8_BioRED_Task1_Doc278	1315	1321	anemia	Disease	D000740	Socs2, plus five additional targets, further proved to comprise new EPOR/Jak2/Stat5 response genes (which are important for erythropoiesis during anemia).
BC8_BioRED_Task1_Doc278	1353	1365	TNF-receptor	Gene	72049	Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated    >5-fold by EPO.
BC8_BioRED_Task1_Doc278	1366	1376	Tnfr-sf13c	Gene	72049	Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated    >5-fold by EPO.
BC8_BioRED_Task1_Doc278	1408	1411	EPO	Gene	13856	Among receptors, an atypical TNF-receptor Tnfr-sf13c was up-modulated    >5-fold by EPO.
BC8_BioRED_Task1_Doc278	1427	1437	Tnfr-sf13c	Gene	72049	Functionally, Tnfr-sf13c ligation proved to both promote proerythroblast survival, and substantially enhance erythroblast formation.
BC8_BioRED_Task1_Doc278	1550	1554	EPOR	Gene	13857	The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation.
BC8_BioRED_Task1_Doc278	1634	1644	Tnfr-sf13c	Gene	72049	The EPOR therefore engages a sophisticated set of transcriptome response circuits, with Tnfr-sf13c deployed as one novel positive regulator of proerythroblast formation.
BC8_BioRED_Task1_Doc279	97	105	patients	OrganismTaxon	9606	Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease.
BC8_BioRED_Task1_Doc279	111	137	inflammatory bowel disease	Disease	D015212	Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease.
BC8_BioRED_Task1_Doc279	253	268	Crohn's disease	Disease	D003424	BACKGROUND AND AIMS: A number of antibodies against microbial epitopes or self-antigens have been associated with Crohn's disease.
BC8_BioRED_Task1_Doc279	343	351	bacteria	OrganismTaxon	2	The development of antibodies reflects a loss of tolerance to intestinal bacteria that underlies Crohn's disease, resulting in an exaggerated adaptive immune response to these bacteria.
BC8_BioRED_Task1_Doc279	367	382	Crohn's disease	Disease	D003424	The development of antibodies reflects a loss of tolerance to intestinal bacteria that underlies Crohn's disease, resulting in an exaggerated adaptive immune response to these bacteria.
BC8_BioRED_Task1_Doc279	446	454	bacteria	OrganismTaxon	2	The development of antibodies reflects a loss of tolerance to intestinal bacteria that underlies Crohn's disease, resulting in an exaggerated adaptive immune response to these bacteria.
BC8_BioRED_Task1_Doc279	701	723	innate immune receptor	Gene	10333,10392,22900,64127,7096,7097,7099	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	731	772	nucleotide oligomerisation domain (NOD) 2	Gene	64127	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	773	809	caspase recruitment domain (CARD) 15	Gene	64127	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	811	815	NOD1	Gene	10392	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	816	821	CARD4	Gene	10392	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	823	828	TUCAN	Gene	22900	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	829	837	CARDINAL	Gene	22900	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	838	843	CARD8	Gene	22900	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	845	871	Toll-like receptor (TLR) 4	Gene	7099	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	873	877	TLR2	Gene	7097	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	879	883	TLR1	Gene	7096	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	888	892	TLR6	Gene	10333	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	959	985	inflammatory bowel disease	Disease	D015212	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	987	990	IBD	Disease	D015212	The aim of this study was therefore to investigate the influence of mutations in these innate immune receptor genes (nucleotide oligomerisation domain (NOD) 2/caspase recruitment domain (CARD) 15, NOD1/CARD4, TUCAN/CARDINAL/CARD8, Toll-like receptor (TLR) 4, TLR2, TLR1 and TLR6) on the development of antimicrobial and antiglycan antibodies in inflammatory bowel disease (IBD).
BC8_BioRED_Task1_Doc279	1043	1051	patients	OrganismTaxon	9606	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1057	1060	IBD	Disease	D015212	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1066	1081	Crohn's disease	Disease	D003424	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1087	1105	ulcerative colitis	Disease	D003093	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1124	1131	colitis	Disease	D003092	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1173	1197	Saccharomyces cerevisiae	OrganismTaxon	4932	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1417	1421	NOD2	Gene	64127	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1422	1428	CARD15	Gene	64127	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1430	1435	TUCAN	Gene	22900	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1436	1444	CARDINAL	Gene	22900	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1445	1450	CARD8	Gene	22900	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1452	1456	NOD1	Gene	10392	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1457	1462	CARD4	Gene	10392	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1464	1468	TLR4	Gene	7099	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1470	1474	TLR1	Gene	7096	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1476	1480	TLR2	Gene	7097	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1485	1489	TLR6	Gene	10333	Materials and METHODS: A cohort of 1163 unrelated patients with IBD (874 Crohn's disease, 259 ulcerative colitis, 30 indeterminate colitis) and 312 controls were analysed for anti-Saccharomyces cerevisiae antibodies (gASCA) IgG, anti-laminaribioside antibodies (ALCA) IgG, anti-chitobioside antibodies (ACCA) IgA, anti-mannobioside antibodies (AMCA) IgG and outer membrane porin (Omp) IgA and were genotyped for variants in NOD2/CARD15, TUCAN/CARDINAL/CARD8, NOD1/CARD4, TLR4, TLR1, TLR2 and TLR6.
BC8_BioRED_Task1_Doc279	1519	1534	Crohn's disease	Disease	D003424	RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.
BC8_BioRED_Task1_Doc279	1535	1543	patients	OrganismTaxon	9606	RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.
BC8_BioRED_Task1_Doc279	1552	1558	CARD15	Gene	64127	RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.
BC8_BioRED_Task1_Doc279	1599	1605	CARD15	Gene	64127	RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.
BC8_BioRED_Task1_Doc279	1617	1632	Crohn's disease	Disease	D003424	RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.
BC8_BioRED_Task1_Doc279	1633	1641	patients	OrganismTaxon	9606	RESULTS: When compared with Crohn's disease patients without CARD15 mutations, the presence of at least one CARD15 variant in Crohn's disease patients more frequently led to gASCA positivity (66.1% versus 51.5%, p < 0.0001) and ALCA positivity (43.3% versus 34.9%, p = 0.018) and higher gASCA titers (85.7 versus 51.8 ELISA units, p < 0.0001), independent of ileal involvement.
BC8_BioRED_Task1_Doc279	1937	1945	patients	OrganismTaxon	9606	A gene dosage effect, with increasing gASCA and ALCA positivity for patients carrying none, one and two CARD15 variants, respectively, was seen for both markers.
BC8_BioRED_Task1_Doc279	1973	1979	CARD15	Gene	64127	A gene dosage effect, with increasing gASCA and ALCA positivity for patients carrying none, one and two CARD15 variants, respectively, was seen for both markers.
BC8_BioRED_Task1_Doc279	2042	2057	Crohn's disease	Disease	D003424	Similarly, Crohn's disease patients carrying NOD1/CARD4 indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect.
BC8_BioRED_Task1_Doc279	2058	2066	patients	OrganismTaxon	9606	Similarly, Crohn's disease patients carrying NOD1/CARD4 indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect.
BC8_BioRED_Task1_Doc279	2076	2080	NOD1	Gene	10392	Similarly, Crohn's disease patients carrying NOD1/CARD4 indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect.
BC8_BioRED_Task1_Doc279	2081	2086	CARD4	Gene	10392	Similarly, Crohn's disease patients carrying NOD1/CARD4 indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect.
BC8_BioRED_Task1_Doc279	2152	2160	patients	OrganismTaxon	9606	Similarly, Crohn's disease patients carrying NOD1/CARD4 indel had a higher prevalence of gASCA antibodies than wild-type patients (63.8% versus 55.2%, p = 0.014), also with a gene dosage effect.
BC8_BioRED_Task1_Doc279	2266	2270	TLR4	Gene	7099	An opposite effect was observed for the TLR4 D299G and TLR2 P631H variants, with a lower prevalence of ACCA antibodies (23.4% versus 35%, p = 0.013) and Omp antibodies (20.5% versus 34.6%, p = 0.009), respectively.
BC8_BioRED_Task1_Doc279	2271	2276	D299G	SequenceVariant	rs4986790	An opposite effect was observed for the TLR4 D299G and TLR2 P631H variants, with a lower prevalence of ACCA antibodies (23.4% versus 35%, p = 0.013) and Omp antibodies (20.5% versus 34.6%, p = 0.009), respectively.
BC8_BioRED_Task1_Doc279	2281	2285	TLR2	Gene	7097	An opposite effect was observed for the TLR4 D299G and TLR2 P631H variants, with a lower prevalence of ACCA antibodies (23.4% versus 35%, p = 0.013) and Omp antibodies (20.5% versus 34.6%, p = 0.009), respectively.
BC8_BioRED_Task1_Doc279	2286	2291	P631H	SequenceVariant	p|SUB|P|631|H	An opposite effect was observed for the TLR4 D299G and TLR2 P631H variants, with a lower prevalence of ACCA antibodies (23.4% versus 35%, p = 0.013) and Omp antibodies (20.5% versus 34.6%, p = 0.009), respectively.
BC8_BioRED_Task1_Doc279	2465	2487	innate immune receptor	Gene	10333,10392,22900,64127,7096,7097,7099	CONCLUSION: Variants in innate immune receptor genes were found to influence antibody formation against microbial epitopes.
BC8_BioRED_Task1_Doc279	2626	2632	CARD15	Gene	64127	In this respect, it is intriguing that an opposite effect of CARD15 and TLR4 variants was observed.
BC8_BioRED_Task1_Doc279	2637	2641	TLR4	Gene	7099	In this respect, it is intriguing that an opposite effect of CARD15 and TLR4 variants was observed.
BC8_BioRED_Task1_Doc279	2766	2769	IBD	Disease	D015212	These findings may contribute to an understanding of the aetiology of the seroreactivity observed in IBD.
BC8_BioRED_Task1_Doc280	17	22	M404V	SequenceVariant	rs771966860	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.
BC8_BioRED_Task1_Doc280	39	42	p62	Gene	8878	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.
BC8_BioRED_Task1_Doc280	43	57	sequestosome 1	Gene	8878	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.
BC8_BioRED_Task1_Doc280	59	62	p62	Gene	8878	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.
BC8_BioRED_Task1_Doc280	63	69	SQSTM1	Gene	8878	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.
BC8_BioRED_Task1_Doc280	93	116	Paget's disease of bone	Disease	C538098	Segregation of a M404V mutation of the p62/sequestosome 1 (p62/SQSTM1) gene with polyostotic Paget's disease of bone in an Italian family.
BC8_BioRED_Task1_Doc280	156	159	p62	Gene	8878	Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of Paget's disease of bone (PDB).
BC8_BioRED_Task1_Doc280	160	174	Sequestosome 1	Gene	8878	Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of Paget's disease of bone (PDB).
BC8_BioRED_Task1_Doc280	181	184	p62	Gene	8878	Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of Paget's disease of bone (PDB).
BC8_BioRED_Task1_Doc280	185	191	SQSTM1	Gene	8878	Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of Paget's disease of bone (PDB).
BC8_BioRED_Task1_Doc280	241	264	Paget's disease of bone	Disease	C538098	Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of Paget's disease of bone (PDB).
BC8_BioRED_Task1_Doc280	266	269	PDB	Disease	C538098	Mutations of the p62/Sequestosome 1 gene (p62/SQSTM1) account for both sporadic and familial forms of Paget's disease of bone (PDB).
BC8_BioRED_Task1_Doc280	298	343	methionine-->valine substitution at codon 404	SequenceVariant	rs771966860	We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian PDB patient.
BC8_BioRED_Task1_Doc280	345	350	M404V	SequenceVariant	rs771966860	We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian PDB patient.
BC8_BioRED_Task1_Doc280	406	409	p62	Gene	8878	We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian PDB patient.
BC8_BioRED_Task1_Doc280	410	416	SQSTM1	Gene	8878	We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian PDB patient.
BC8_BioRED_Task1_Doc280	436	439	PDB	Disease	C538098	We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian PDB patient.
BC8_BioRED_Task1_Doc280	440	447	patient	OrganismTaxon	9606	We originally described a methionine-->valine substitution at codon 404 (M404V) of exon 8, in the ubiquitin protein-binding domain of p62/SQSTM1 gene in an Italian PDB patient.
BC8_BioRED_Task1_Doc280	481	488	patient	OrganismTaxon	9606	The collection of data from the patient's pedigree provided evidence for a familial form of PDB.
BC8_BioRED_Task1_Doc280	541	544	PDB	Disease	C538098	The collection of data from the patient's pedigree provided evidence for a familial form of PDB.
BC8_BioRED_Task1_Doc280	646	651	M404V	SequenceVariant	rs771966860	Extension of the genetic analysis to other relatives in this family demonstrated segregation of the M404V mutation with the polyostotic PDB phenotype and provided the identification of six asymptomatic gene carriers.
BC8_BioRED_Task1_Doc280	682	685	PDB	Disease	C538098	Extension of the genetic analysis to other relatives in this family demonstrated segregation of the M404V mutation with the polyostotic PDB phenotype and provided the identification of six asymptomatic gene carriers.
BC8_BioRED_Task1_Doc280	854	857	PDB	Disease	C538098	DNA for mutational analysis of the exon 8 coding sequence was obtained from 22 subjects, 4 PDB patients and 18 clinically unaffected members.
BC8_BioRED_Task1_Doc280	858	866	patients	OrganismTaxon	9606	DNA for mutational analysis of the exon 8 coding sequence was obtained from 22 subjects, 4 PDB patients and 18 clinically unaffected members.
BC8_BioRED_Task1_Doc280	991	996	M404V	SequenceVariant	rs771966860	Of the five clinically ascertained affected members of the family, four possessed the M404V mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a polyostotic disease who had died several years before the DNA analysis.
BC8_BioRED_Task1_Doc280	1044	1047	PDB	Disease	C538098	Of the five clinically ascertained affected members of the family, four possessed the M404V mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a polyostotic disease who had died several years before the DNA analysis.
BC8_BioRED_Task1_Doc280	1060	1067	patient	OrganismTaxon	9606	Of the five clinically ascertained affected members of the family, four possessed the M404V mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a polyostotic disease who had died several years before the DNA analysis.
BC8_BioRED_Task1_Doc280	1134	1153	polyostotic disease	Disease	D005357	Of the five clinically ascertained affected members of the family, four possessed the M404V mutation and exhibited the polyostotic form of PDB, except one patient with a single X-ray-assessed skeletal localization and one with a polyostotic disease who had died several years before the DNA analysis.
BC8_BioRED_Task1_Doc280	1317	1322	M404V	SequenceVariant	rs771966860	By both reconstitution and mutational analysis of the pedigree, six unaffected subjects were shown to bear the M404V mutation, representing potential asymptomatic gene carriers whose circulating levels of alkaline phosphatase were recently assessed as still within the normal range.
BC8_BioRED_Task1_Doc280	1411	1431	alkaline phosphatase	Chemical	D000469	By both reconstitution and mutational analysis of the pedigree, six unaffected subjects were shown to bear the M404V mutation, representing potential asymptomatic gene carriers whose circulating levels of alkaline phosphatase were recently assessed as still within the normal range.
BC8_BioRED_Task1_Doc280	1572	1577	M404V	SequenceVariant	rs771966860	Taken together, these results support a genotype-phenotype correlation between the M404V mutation in the p62/SQSTM1 gene and a polyostotic form of PDB in this family.
BC8_BioRED_Task1_Doc280	1594	1597	p62	Gene	8878	Taken together, these results support a genotype-phenotype correlation between the M404V mutation in the p62/SQSTM1 gene and a polyostotic form of PDB in this family.
BC8_BioRED_Task1_Doc280	1598	1604	SQSTM1	Gene	8878	Taken together, these results support a genotype-phenotype correlation between the M404V mutation in the p62/SQSTM1 gene and a polyostotic form of PDB in this family.
BC8_BioRED_Task1_Doc280	1636	1639	PDB	Disease	C538098	Taken together, these results support a genotype-phenotype correlation between the M404V mutation in the p62/SQSTM1 gene and a polyostotic form of PDB in this family.
BC8_BioRED_Task1_Doc280	1683	1686	PDB	Disease	C538098	The high penetrance of the PDB trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype-phenotype correlation and to evaluate the potential use of mutational analysis of the p62/SQSTM1 gene in the early detection of relatives at risk for PDB.
BC8_BioRED_Task1_Doc280	1899	1902	p62	Gene	8878	The high penetrance of the PDB trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype-phenotype correlation and to evaluate the potential use of mutational analysis of the p62/SQSTM1 gene in the early detection of relatives at risk for PDB.
BC8_BioRED_Task1_Doc280	1903	1909	SQSTM1	Gene	8878	The high penetrance of the PDB trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype-phenotype correlation and to evaluate the potential use of mutational analysis of the p62/SQSTM1 gene in the early detection of relatives at risk for PDB.
BC8_BioRED_Task1_Doc280	1963	1966	PDB	Disease	C538098	The high penetrance of the PDB trait in this family together with the study of the asymptomatic gene carriers will allow us to confirm the proposed genotype-phenotype correlation and to evaluate the potential use of mutational analysis of the p62/SQSTM1 gene in the early detection of relatives at risk for PDB.
BC8_BioRED_Task1_Doc281	28	36	thiazide	Chemical	D049971	Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome.
BC8_BioRED_Task1_Doc281	47	67	Na-Cl co-transporter	Gene	6559	Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome.
BC8_BioRED_Task1_Doc281	85	93	patients	OrganismTaxon	9606	Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome.
BC8_BioRED_Task1_Doc281	99	118	Gitelman's syndrome	Disease	D053579	Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome.
BC8_BioRED_Task1_Doc281	132	151	Gitelman's syndrome	Disease	D053579	BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (NCCT) gene.
BC8_BioRED_Task1_Doc281	153	155	GS	Disease	D053579	BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (NCCT) gene.
BC8_BioRED_Task1_Doc281	163	191	autosomal recessive disorder	Disease	D030342	BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (NCCT) gene.
BC8_BioRED_Task1_Doc281	237	245	thiazide	Chemical	D049971	BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (NCCT) gene.
BC8_BioRED_Task1_Doc281	256	276	Na-Cl co-transporter	Gene	6559	BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (NCCT) gene.
BC8_BioRED_Task1_Doc281	278	282	NCCT	Gene	6559	BACKGROUND: Gitelman's syndrome (GS) is an autosomal recessive disorder resulting from inactivating mutations in the thiazide-sensitive Na-Cl co-transporter (NCCT) gene.
BC8_BioRED_Task1_Doc281	463	467	NCCT	Gene	6559	In this study, we analysed mutations in the NCCT gene of seven Japanese patients with GS.
BC8_BioRED_Task1_Doc281	491	499	patients	OrganismTaxon	9606	In this study, we analysed mutations in the NCCT gene of seven Japanese patients with GS.
BC8_BioRED_Task1_Doc281	505	507	GS	Disease	D053579	In this study, we analysed mutations in the NCCT gene of seven Japanese patients with GS.
BC8_BioRED_Task1_Doc281	572	580	patients	OrganismTaxon	9606	METHODS: Peripheral blood mononuclear cells were isolated from patients with GS, their family members and healthy control subjects.
BC8_BioRED_Task1_Doc281	586	588	GS	Disease	D053579	METHODS: Peripheral blood mononuclear cells were isolated from patients with GS, their family members and healthy control subjects.
BC8_BioRED_Task1_Doc281	668	672	NCCT	Gene	6559	A mutation analysis of the NCCT gene was performed completely by direct automated sequencing of polymerase chain reaction-amplified DNA products.
BC8_BioRED_Task1_Doc281	790	798	patients	OrganismTaxon	9606	In patients with a deletion or splice site mutation, we undertook cDNA sequence analysis.
BC8_BioRED_Task1_Doc281	930	938	c.185C>T	SequenceVariant	rs371443644	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	940	948	Thr60Met	SequenceVariant	rs371443644	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	951	960	c.1712C>T	SequenceVariant	rs79351185	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	962	971	Ala569Val	SequenceVariant	rs79351185	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	974	983	c.1930C>T	SequenceVariant	rs200697179	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	985	994	Arg642Cys	SequenceVariant	rs200697179	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	997	1006	c.2552T>A	SequenceVariant	rs185927948	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	1008	1017	Leu849His	SequenceVariant	rs185927948	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	1023	1033	c.1932delC	SequenceVariant	c|DEL|1932|C	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	1066	1074	patients	OrganismTaxon	9606	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	1087	1089	GS	Disease	D053579	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	1090	1098	patients	OrganismTaxon	9606	Five of them [c.185C>T (Thr60Met), c.1712C>T (Ala569Val), c.1930C>T (Arg642Cys), c.2552T>A (Leu849His) and c.1932delC] have been reported in Japanese patients, but not in GS patients from other ethnic groups.
BC8_BioRED_Task1_Doc281	1155	1161	c.7A>T	SequenceVariant	c|SUB|A|7|T	The remaining four mutations [c.7A>T (Met1Leu), c.1181_1186+20del26, c.1811_1812delAT and IVS16+1G>A] were novel.
BC8_BioRED_Task1_Doc281	1163	1170	Met1Leu	SequenceVariant	p|SUB|M|1|L	The remaining four mutations [c.7A>T (Met1Leu), c.1181_1186+20del26, c.1811_1812delAT and IVS16+1G>A] were novel.
BC8_BioRED_Task1_Doc281	1173	1192	c.1181_1186+20del26	SequenceVariant	c|DEL|1181_1186+20|26	The remaining four mutations [c.7A>T (Met1Leu), c.1181_1186+20del26, c.1811_1812delAT and IVS16+1G>A] were novel.
BC8_BioRED_Task1_Doc281	1194	1210	c.1811_1812delAT	SequenceVariant	c|DEL|1811_1812|AT	The remaining four mutations [c.7A>T (Met1Leu), c.1181_1186+20del26, c.1811_1812delAT and IVS16+1G>A] were novel.
BC8_BioRED_Task1_Doc281	1215	1225	IVS16+1G>A	SequenceVariant	c|SUB|G|IVS16+1|A	The remaining four mutations [c.7A>T (Met1Leu), c.1181_1186+20del26, c.1811_1812delAT and IVS16+1G>A] were novel.
BC8_BioRED_Task1_Doc281	1262	1269	patient	OrganismTaxon	9606	In cDNA derived from a patient with c.1181_1186+20del26, a deletion of exon 9 and a frameshift at the start of exon 10 were observed.
BC8_BioRED_Task1_Doc281	1275	1294	c.1181_1186+20del26	SequenceVariant	c|DEL|1181_1186+20|26	In cDNA derived from a patient with c.1181_1186+20del26, a deletion of exon 9 and a frameshift at the start of exon 10 were observed.
BC8_BioRED_Task1_Doc281	1394	1402	patients	OrganismTaxon	9606	In cDNA derived from patients with IVS16+1G>A, an additional 96 bp insertion between exons 16 and 17 was observed.
BC8_BioRED_Task1_Doc281	1408	1418	IVS16+1G>A	SequenceVariant	c|SUB|G|IVS16+1|A	In cDNA derived from patients with IVS16+1G>A, an additional 96 bp insertion between exons 16 and 17 was observed.
BC8_BioRED_Task1_Doc281	1434	1449	96 bp insertion	SequenceVariant	c|INS||96	In cDNA derived from patients with IVS16+1G>A, an additional 96 bp insertion between exons 16 and 17 was observed.
BC8_BioRED_Task1_Doc281	1505	1513	patients	OrganismTaxon	9606	Six out of seven patients were compound heterozygotes, and the remaining one carried a single heterozygous mutation.
BC8_BioRED_Task1_Doc281	1655	1659	NCCT	Gene	6559	CONCLUSIONS: We found four novel mutations in the NCCT gene in seven Japanese patients with GS.
BC8_BioRED_Task1_Doc281	1683	1691	patients	OrganismTaxon	9606	CONCLUSIONS: We found four novel mutations in the NCCT gene in seven Japanese patients with GS.
BC8_BioRED_Task1_Doc281	1697	1699	GS	Disease	D053579	CONCLUSIONS: We found four novel mutations in the NCCT gene in seven Japanese patients with GS.
BC8_BioRED_Task1_Doc281	1772	1776	NCCT	Gene	6559	Moreover, our study suggests that the distribution of mutations in the NCCT gene in Japanese GS patients potentially differs from that in other populations.
BC8_BioRED_Task1_Doc281	1794	1796	GS	Disease	D053579	Moreover, our study suggests that the distribution of mutations in the NCCT gene in Japanese GS patients potentially differs from that in other populations.
BC8_BioRED_Task1_Doc281	1797	1805	patients	OrganismTaxon	9606	Moreover, our study suggests that the distribution of mutations in the NCCT gene in Japanese GS patients potentially differs from that in other populations.
BC8_BioRED_Task1_Doc282	28	39	bupivacaine	Chemical	D002045	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
BC8_BioRED_Task1_Doc282	44	53	lidocaine	Chemical	D008012	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
BC8_BioRED_Task1_Doc282	57	73	prostaglandin E2	Gene	5732	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
BC8_BioRED_Task1_Doc282	83	97	cyclooxygenase	Gene	4512,4513	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
BC8_BioRED_Task1_Doc282	118	122	pain	Disease	D010146	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
BC8_BioRED_Task1_Doc282	137	141	pain	Disease	D010146	The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
BC8_BioRED_Task1_Doc282	278	290	inflammation	Disease	D007249	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate inflammation.
BC8_BioRED_Task1_Doc282	357	368	bupivacaine	Chemical	D002045	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	378	394	prostaglandin E2	Gene	5732	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	396	400	PGE2	Gene	5732	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	417	431	cyclooxygenase	Gene	4512,4513	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	433	436	COX	Gene	4512,4513	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	469	487	postoperative pain	Disease	D010149	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	491	496	human	OrganismTaxon	9606	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
BC8_BioRED_Task1_Doc282	601	610	lidocaine	Chemical	D008012	METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery.
BC8_BioRED_Task1_Doc282	619	630	bupivacaine	Chemical	D002045	METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery.
BC8_BioRED_Task1_Doc282	657	666	rofecoxib	Chemical	C116926	METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery.
BC8_BioRED_Task1_Doc282	889	893	PGE2	Gene	5732	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements.
BC8_BioRED_Task1_Doc282	898	912	thromboxane B2	Chemical	D013929	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements.
BC8_BioRED_Task1_Doc282	914	918	TXB2	Chemical	D013929	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 (TXB2) measurements.
BC8_BioRED_Task1_Doc282	947	958	bupivacaine	Chemical	D002045	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
BC8_BioRED_Task1_Doc282	959	968	rofecoxib	Chemical	C116926	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
BC8_BioRED_Task1_Doc282	1003	1007	pain	Disease	D010146	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
BC8_BioRED_Task1_Doc282	1127	1138	bupivacaine	Chemical	D002045	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
BC8_BioRED_Task1_Doc282	1181	1185	pain	Disease	D010146	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
BC8_BioRED_Task1_Doc282	1198	1202	PGE2	Gene	5732	RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
BC8_BioRED_Task1_Doc282	1306	1317	bupivacaine	Chemical	D002045	Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group.
BC8_BioRED_Task1_Doc282	1342	1347	COX-2	Gene	4513	Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group.
BC8_BioRED_Task1_Doc282	1393	1402	lidocaine	Chemical	D008012	Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group.
BC8_BioRED_Task1_Doc282	1418	1429	Thromboxane	Chemical	D013931	Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1.
BC8_BioRED_Task1_Doc282	1563	1568	COX-2	Gene	4513	Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1.
BC8_BioRED_Task1_Doc282	1578	1583	COX-1	Gene	4512	Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1.
BC8_BioRED_Task1_Doc282	1625	1636	bupivacaine	Chemical	D002045	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
BC8_BioRED_Task1_Doc282	1648	1653	COX-2	Gene	4513	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
BC8_BioRED_Task1_Doc282	1676	1689	tissue injury	Disease	D017695	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
BC8_BioRED_Task1_Doc282	1723	1727	PGE2	Gene	5732	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
BC8_BioRED_Task1_Doc282	1743	1747	pain	Disease	D010146	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.
BC8_BioRED_Task1_Doc283	22	59	luteinizing hormone-releasing hormone	Gene	2796	Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.
BC8_BioRED_Task1_Doc283	67	78	haloperidol	Chemical	D006220	Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.
BC8_BioRED_Task1_Doc283	87	105	hyperprolactinemia	Disease	D006966	Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.
BC8_BioRED_Task1_Doc283	145	156	haloperidol	Chemical	D006220	The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects.
BC8_BioRED_Task1_Doc283	166	175	prolactin	Gene	5617	The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects.
BC8_BioRED_Task1_Doc283	180	199	luteinizing hormone	Gene	1081	The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects.
BC8_BioRED_Task1_Doc283	201	203	LH	Gene	1081	The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects.
BC8_BioRED_Task1_Doc283	332	352	LH-releasing hormone	Gene	2796	Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out.
BC8_BioRED_Task1_Doc283	354	359	LH-RH	Gene	2796	Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out.
BC8_BioRED_Task1_Doc283	386	394	patients	OrganismTaxon	9606	Control patients received infusions of 0.9% NaCl solution.
BC8_BioRED_Task1_Doc283	422	426	NaCl	Chemical	D012965	Control patients received infusions of 0.9% NaCl solution.
BC8_BioRED_Task1_Doc283	458	469	haloperidol	Chemical	D006220	During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.
BC8_BioRED_Task1_Doc283	493	511	hyperprolactinemia	Disease	D006966	During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.
BC8_BioRED_Task1_Doc283	572	577	LH-RH	Gene	2796	During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.
BC8_BioRED_Task1_Doc284	53	58	renin	Gene	5972	Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	77	83	anemia	Disease	D000740	Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	85	98	hyperuricemia	Disease	D033461	Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	104	107	CKD	Disease	D051436	Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	158	163	renin	Gene	5972	Homozygous or compound heterozygous mutations in renin (REN) cause renal tubular dysgenesis, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.
BC8_BioRED_Task1_Doc284	165	168	REN	Gene	5972	Homozygous or compound heterozygous mutations in renin (REN) cause renal tubular dysgenesis, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.
BC8_BioRED_Task1_Doc284	176	200	renal tubular dysgenesis	Disease	C537048	Homozygous or compound heterozygous mutations in renin (REN) cause renal tubular dysgenesis, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.
BC8_BioRED_Task1_Doc284	228	233	death	Disease	D003643	Homozygous or compound heterozygous mutations in renin (REN) cause renal tubular dysgenesis, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.
BC8_BioRED_Task1_Doc284	250	264	kidney failure	Disease	D051437	Homozygous or compound heterozygous mutations in renin (REN) cause renal tubular dysgenesis, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.
BC8_BioRED_Task1_Doc284	269	289	pulmonary hypoplasia	Disease	D008171	Homozygous or compound heterozygous mutations in renin (REN) cause renal tubular dysgenesis, which is characterized by death in utero due to kidney failure and pulmonary hypoplasia.
BC8_BioRED_Task1_Doc284	319	328	fetopathy	Disease	C576203	The phenotype resembles the fetopathy caused by angiotensin-converting enzyme inhibitor or angiotensin receptor blocker intake during pregnancy.
BC8_BioRED_Task1_Doc284	339	378	angiotensin-converting enzyme inhibitor	Chemical	D000806	The phenotype resembles the fetopathy caused by angiotensin-converting enzyme inhibitor or angiotensin receptor blocker intake during pregnancy.
BC8_BioRED_Task1_Doc284	382	410	angiotensin receptor blocker	Chemical	D057911	The phenotype resembles the fetopathy caused by angiotensin-converting enzyme inhibitor or angiotensin receptor blocker intake during pregnancy.
BC8_BioRED_Task1_Doc284	459	462	REN	Gene	5972	Recently, heterozygous REN mutations were shown to result in early-onset hyperuricemia, anemia, and chronic kidney disease (CKD).
BC8_BioRED_Task1_Doc284	509	522	hyperuricemia	Disease	D033461	Recently, heterozygous REN mutations were shown to result in early-onset hyperuricemia, anemia, and chronic kidney disease (CKD).
BC8_BioRED_Task1_Doc284	524	530	anemia	Disease	D000740	Recently, heterozygous REN mutations were shown to result in early-onset hyperuricemia, anemia, and chronic kidney disease (CKD).
BC8_BioRED_Task1_Doc284	536	558	chronic kidney disease	Disease	D051436	Recently, heterozygous REN mutations were shown to result in early-onset hyperuricemia, anemia, and chronic kidney disease (CKD).
BC8_BioRED_Task1_Doc284	560	563	CKD	Disease	D051436	Recently, heterozygous REN mutations were shown to result in early-onset hyperuricemia, anemia, and chronic kidney disease (CKD).
BC8_BioRED_Task1_Doc284	605	608	REN	Gene	5972	To date, only 3 different heterozygous REN mutations have been published.
BC8_BioRED_Task1_Doc284	675	678	REN	Gene	5972	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	704	717	hyperuricemia	Disease	D033461	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	722	725	CKD	Disease	D051436	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	778	782	UMOD	Gene	7369	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	784	794	uromodulin	Gene	7369	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	800	805	HNF1B	Gene	6928	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	807	835	hepatocyte nuclear factor 1b	Gene	6928	We report mutation analysis of the REN gene in 39 kindreds with hyperuricemia and CKD who previously tested negative for mutations in the UMOD (uromodulin) and HNF1B (hepatocyte nuclear factor 1b) genes.
BC8_BioRED_Task1_Doc284	883	928	thymidine to cytosine mutation at position 28	SequenceVariant	c|SUB|T|28|C	We identified one kindred with a novel thymidine to cytosine mutation at position 28 in the REN complementary DNA, corresponding to a tryptophan to arginine substitution at amino acid 10, which is found within the signal sequence (c.28T>C; p.W10R).
BC8_BioRED_Task1_Doc284	936	939	REN	Gene	5972	We identified one kindred with a novel thymidine to cytosine mutation at position 28 in the REN complementary DNA, corresponding to a tryptophan to arginine substitution at amino acid 10, which is found within the signal sequence (c.28T>C; p.W10R).
BC8_BioRED_Task1_Doc284	978	1030	tryptophan to arginine substitution at amino acid 10	SequenceVariant	p|SUB|W|10|R	We identified one kindred with a novel thymidine to cytosine mutation at position 28 in the REN complementary DNA, corresponding to a tryptophan to arginine substitution at amino acid 10, which is found within the signal sequence (c.28T>C; p.W10R).
BC8_BioRED_Task1_Doc284	1075	1082	c.28T>C	SequenceVariant	c|SUB|T|28|C	We identified one kindred with a novel thymidine to cytosine mutation at position 28 in the REN complementary DNA, corresponding to a tryptophan to arginine substitution at amino acid 10, which is found within the signal sequence (c.28T>C; p.W10R).
BC8_BioRED_Task1_Doc284	1084	1090	p.W10R	SequenceVariant	p|SUB|W|10|R	We identified one kindred with a novel thymidine to cytosine mutation at position 28 in the REN complementary DNA, corresponding to a tryptophan to arginine substitution at amino acid 10, which is found within the signal sequence (c.28T>C; p.W10R).
BC8_BioRED_Task1_Doc284	1125	1128	REN	Gene	5972	On this basis, we conclude that REN mutations are rare events in patients with CKD.
BC8_BioRED_Task1_Doc284	1158	1166	patients	OrganismTaxon	9606	On this basis, we conclude that REN mutations are rare events in patients with CKD.
BC8_BioRED_Task1_Doc284	1172	1175	CKD	Disease	D051436	On this basis, we conclude that REN mutations are rare events in patients with CKD.
BC8_BioRED_Task1_Doc284	1268	1271	REN	Gene	5972	Within the kindred, we found affected individuals over 4 generations who carried the novel REN mutation and were characterized by significant anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	1319	1325	anemia	Disease	D000740	Within the kindred, we found affected individuals over 4 generations who carried the novel REN mutation and were characterized by significant anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	1327	1340	hyperuricemia	Disease	D033461	Within the kindred, we found affected individuals over 4 generations who carried the novel REN mutation and were characterized by significant anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	1346	1349	CKD	Disease	D051436	Within the kindred, we found affected individuals over 4 generations who carried the novel REN mutation and were characterized by significant anemia, hyperuricemia, and CKD.
BC8_BioRED_Task1_Doc284	1351	1357	Anemia	Disease	D000740	Anemia was severe and disproportional to the degree of decreased kidney function.
BC8_BioRED_Task1_Doc284	1458	1461	REN	Gene	5972	Because all heterozygous REN mutations that have been described are localized in the signal sequence, screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.
BC8_BioRED_Task1_Doc284	1552	1555	REN	Gene	5972	Because all heterozygous REN mutations that have been described are localized in the signal sequence, screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.
BC8_BioRED_Task1_Doc284	1565	1573	patients	OrganismTaxon	9606	Because all heterozygous REN mutations that have been described are localized in the signal sequence, screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.
BC8_BioRED_Task1_Doc284	1579	1582	CKD	Disease	D051436	Because all heterozygous REN mutations that have been described are localized in the signal sequence, screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.
BC8_BioRED_Task1_Doc284	1588	1601	hyperuricemia	Disease	D033461	Because all heterozygous REN mutations that have been described are localized in the signal sequence, screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.
BC8_BioRED_Task1_Doc284	1606	1612	anemia	Disease	D000740	Because all heterozygous REN mutations that have been described are localized in the signal sequence, screening of the REN gene for patients with CKD with hyperuricemia and anemia may best be focused on sequencing of exon 1, which encodes the signal peptide.
BC8_BioRED_Task1_Doc285	0	8	Star-PAP	Gene	64852	Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthotopic human breast cancer model.
BC8_BioRED_Task1_Doc285	12	30	poly(A) polymerase	Gene	64852	Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthotopic human breast cancer model.
BC8_BioRED_Task1_Doc285	47	52	tumor	Disease	D009369	Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthotopic human breast cancer model.
BC8_BioRED_Task1_Doc285	81	86	human	OrganismTaxon	9606	Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthotopic human breast cancer model.
BC8_BioRED_Task1_Doc285	87	100	breast cancer	Disease	D001943	Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthotopic human breast cancer model.
BC8_BioRED_Task1_Doc285	108	116	Star-PAP	Gene	64852	Star-PAP is a noncanonical poly(A) polymerase and required for the expression of a select set of mRNAs.
BC8_BioRED_Task1_Doc285	135	153	poly(A) polymerase	Gene	64852	Star-PAP is a noncanonical poly(A) polymerase and required for the expression of a select set of mRNAs.
BC8_BioRED_Task1_Doc285	246	254	Star-PAP	Gene	64852	However, the pathological role of Star-PAP in cancer largely remains unknown.
BC8_BioRED_Task1_Doc285	258	264	cancer	Disease	D009369	However, the pathological role of Star-PAP in cancer largely remains unknown.
BC8_BioRED_Task1_Doc285	341	349	Star-PAP	Gene	64852	In this study, we observed decreased expression of Star-PAP in breast cancer cell lines and tissues.
BC8_BioRED_Task1_Doc285	353	366	breast cancer	Disease	D001943	In this study, we observed decreased expression of Star-PAP in breast cancer cell lines and tissues.
BC8_BioRED_Task1_Doc285	399	407	Star-PAP	Gene	64852	Ectopic Star-PAP expression inhibited proliferation as well as colony-forming ability of breast cancer cells.
BC8_BioRED_Task1_Doc285	480	493	breast cancer	Disease	D001943	Ectopic Star-PAP expression inhibited proliferation as well as colony-forming ability of breast cancer cells.
BC8_BioRED_Task1_Doc285	504	517	breast cancer	Disease	D001943	In breast cancer patients, high levels of Star-PAP correlated with an improved prognosis.
BC8_BioRED_Task1_Doc285	518	526	patients	OrganismTaxon	9606	In breast cancer patients, high levels of Star-PAP correlated with an improved prognosis.
BC8_BioRED_Task1_Doc285	543	551	Star-PAP	Gene	64852	In breast cancer patients, high levels of Star-PAP correlated with an improved prognosis.
BC8_BioRED_Task1_Doc285	633	636	BIK	Gene	638	Moreover, by regulating the expression of BIK (BCL2-interacting killer), Star-PAP induced apoptosis of breast cancer cells through the mitochondrial pathway.
BC8_BioRED_Task1_Doc285	638	661	BCL2-interacting killer	Gene	638	Moreover, by regulating the expression of BIK (BCL2-interacting killer), Star-PAP induced apoptosis of breast cancer cells through the mitochondrial pathway.
BC8_BioRED_Task1_Doc285	664	672	Star-PAP	Gene	64852	Moreover, by regulating the expression of BIK (BCL2-interacting killer), Star-PAP induced apoptosis of breast cancer cells through the mitochondrial pathway.
BC8_BioRED_Task1_Doc285	694	707	breast cancer	Disease	D001943	Moreover, by regulating the expression of BIK (BCL2-interacting killer), Star-PAP induced apoptosis of breast cancer cells through the mitochondrial pathway.
BC8_BioRED_Task1_Doc285	763	776	breast cancer	Disease	D001943	The growth of breast cancer xenografts in NOD/SCID mice was also inhibited by the doxycycline-induced Star-PAP overexpression.
BC8_BioRED_Task1_Doc285	795	799	SCID	Disease	D016511	The growth of breast cancer xenografts in NOD/SCID mice was also inhibited by the doxycycline-induced Star-PAP overexpression.
BC8_BioRED_Task1_Doc285	800	804	mice	OrganismTaxon	10090	The growth of breast cancer xenografts in NOD/SCID mice was also inhibited by the doxycycline-induced Star-PAP overexpression.
BC8_BioRED_Task1_Doc285	831	842	doxycycline	Chemical	D004318	The growth of breast cancer xenografts in NOD/SCID mice was also inhibited by the doxycycline-induced Star-PAP overexpression.
BC8_BioRED_Task1_Doc285	851	859	Star-PAP	Gene	64852	The growth of breast cancer xenografts in NOD/SCID mice was also inhibited by the doxycycline-induced Star-PAP overexpression.
BC8_BioRED_Task1_Doc285	889	897	Star-PAP	Gene	64852	Furthermore, Star-PAP sensitized breast cancer cells to chemotherapy drugs both in vitro and in vivo.
BC8_BioRED_Task1_Doc285	909	922	breast cancer	Disease	D001943	Furthermore, Star-PAP sensitized breast cancer cells to chemotherapy drugs both in vitro and in vivo.
BC8_BioRED_Task1_Doc285	1007	1015	Star-PAP	Gene	64852	In mammary epithelial cells, Star-PAP knockdown partially transformed these cells and induced them to undergo epithelial-mesenchymal transition (EMT).
BC8_BioRED_Task1_Doc285	1159	1167	Star-PAP	Gene	64852	These findings suggested that Star-PAP possesses tumor-suppressing activity and can be a valuable target for developing new cancer therapeutic strategies.
BC8_BioRED_Task1_Doc285	1178	1183	tumor	Disease	D009369	These findings suggested that Star-PAP possesses tumor-suppressing activity and can be a valuable target for developing new cancer therapeutic strategies.
BC8_BioRED_Task1_Doc285	1253	1259	cancer	Disease	D009369	These findings suggested that Star-PAP possesses tumor-suppressing activity and can be a valuable target for developing new cancer therapeutic strategies.
BC8_BioRED_Task1_Doc286	0	23	Desmin-related myopathy	Disease	C563319	Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene.
BC8_BioRED_Task1_Doc286	88	103	selenoprotein N	Gene	57190	Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene.
BC8_BioRED_Task1_Doc286	110	135	Desmin-related myopathies	Disease	C563319	Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin.
BC8_BioRED_Task1_Doc286	137	141	DRMs	Disease	C563319	Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin.
BC8_BioRED_Task1_Doc286	172	188	muscle disorders	Disease	D009135	Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin.
BC8_BioRED_Task1_Doc286	249	255	desmin	Gene	1674	Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin.
BC8_BioRED_Task1_Doc286	274	280	desmin	Gene	1674	Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases.
BC8_BioRED_Task1_Doc286	289	307	alpha-B crystallin	Gene	1410	Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases.
BC8_BioRED_Task1_Doc286	357	360	DRM	Disease	C563319	Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases.
BC8_BioRED_Task1_Doc286	501	505	DRMs	Disease	C563319	The genetic basis of the other forms remain unknown, including the early-onset, recessive form with Mallory body-like inclusions (MB-DRMs), first described in five related German patients.
BC8_BioRED_Task1_Doc286	547	555	patients	OrganismTaxon	9606	The genetic basis of the other forms remain unknown, including the early-onset, recessive form with Mallory body-like inclusions (MB-DRMs), first described in five related German patients.
BC8_BioRED_Task1_Doc286	585	600	selenoprotein N	Gene	57190	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	607	612	SEPN1	Gene	57190	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	633	654	SEPN-related myopathy	Disease	D009135	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	656	663	SEPN-RM	Disease	D009135	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	687	695	myopathy	Disease	D009135	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	754	784	rigid spine muscular dystrophy	Disease	C535683	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	818	839	multiminicore disease	Disease	C564969	Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease.
BC8_BioRED_Task1_Doc286	924	931	SEPN-RM	Disease	D009135	The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1.
BC8_BioRED_Task1_Doc286	976	979	DRM	Disease	C563319	The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1.
BC8_BioRED_Task1_Doc286	984	989	SEPN1	Gene	57190	The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1.
BC8_BioRED_Task1_Doc286	1010	1013	DRM	Disease	C563319	In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients.
BC8_BioRED_Task1_Doc286	1077	1082	SEPN1	Gene	57190	In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients.
BC8_BioRED_Task1_Doc286	1127	1132	SEPN1	Gene	57190	In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients.
BC8_BioRED_Task1_Doc286	1143	1168	del 92 nucleotide -19/+73	SequenceVariant	c|DEL|-19_+73|92	In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients.
BC8_BioRED_Task1_Doc286	1186	1194	patients	OrganismTaxon	9606	In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients.
BC8_BioRED_Task1_Doc286	1238	1241	DRM	Disease	C563319	A comparative reevaluation showed that MB-DRM and SEPN-RM share identical clinical features.
BC8_BioRED_Task1_Doc286	1246	1253	SEPN-RM	Disease	D009135	A comparative reevaluation showed that MB-DRM and SEPN-RM share identical clinical features.
BC8_BioRED_Task1_Doc286	1319	1322	DRM	Disease	C563319	Therefore, we propose that MB-DRM should be categorized as SEPN-RM.
BC8_BioRED_Task1_Doc286	1348	1355	SEPN-RM	Disease	D009135	Therefore, we propose that MB-DRM should be categorized as SEPN-RM.
BC8_BioRED_Task1_Doc286	1416	1419	DRM	Disease	C563319	These findings substantiate the molecular heterogeneity of DRM, expand the morphological spectrum of SEPN-RM, and implicate a necessary reassessment of the nosological boundaries in early-onset myopathies.
BC8_BioRED_Task1_Doc286	1458	1465	SEPN-RM	Disease	D009135	These findings substantiate the molecular heterogeneity of DRM, expand the morphological spectrum of SEPN-RM, and implicate a necessary reassessment of the nosological boundaries in early-onset myopathies.
BC8_BioRED_Task1_Doc286	1551	1561	myopathies	Disease	D009135	These findings substantiate the molecular heterogeneity of DRM, expand the morphological spectrum of SEPN-RM, and implicate a necessary reassessment of the nosological boundaries in early-onset myopathies.
BC8_BioRED_Task1_Doc287	0	13	Paraoxonase 1	Gene	5444	Paraoxonase 1 polymorphisms and survival.
BC8_BioRED_Task1_Doc287	65	78	paraoxonase 1	Gene	5444	The antioxidant enzyme paraoxonase 1 (PON1) has previously been suggested to confer protection against coronary heart disease (CHD), one of the main causes of death in the Western world.
BC8_BioRED_Task1_Doc287	80	84	PON1	Gene	5444	The antioxidant enzyme paraoxonase 1 (PON1) has previously been suggested to confer protection against coronary heart disease (CHD), one of the main causes of death in the Western world.
BC8_BioRED_Task1_Doc287	145	167	coronary heart disease	Disease	D003327	The antioxidant enzyme paraoxonase 1 (PON1) has previously been suggested to confer protection against coronary heart disease (CHD), one of the main causes of death in the Western world.
BC8_BioRED_Task1_Doc287	169	172	CHD	Disease	D003327	The antioxidant enzyme paraoxonase 1 (PON1) has previously been suggested to confer protection against coronary heart disease (CHD), one of the main causes of death in the Western world.
BC8_BioRED_Task1_Doc287	201	206	death	Disease	D003643	The antioxidant enzyme paraoxonase 1 (PON1) has previously been suggested to confer protection against coronary heart disease (CHD), one of the main causes of death in the Western world.
BC8_BioRED_Task1_Doc287	255	260	55M/L	SequenceVariant	p|SUB|M|55|L	Two coding polymorphisms, 55M/L and 192Q/R, and a promoter variant, -107C/T, has been extensively studied with respect to susceptibility to CHD.
BC8_BioRED_Task1_Doc287	265	271	192Q/R	SequenceVariant	p|SUB|Q|192|R	Two coding polymorphisms, 55M/L and 192Q/R, and a promoter variant, -107C/T, has been extensively studied with respect to susceptibility to CHD.
BC8_BioRED_Task1_Doc287	297	304	-107C/T	SequenceVariant	c|SUB|C|-107|T	Two coding polymorphisms, 55M/L and 192Q/R, and a promoter variant, -107C/T, has been extensively studied with respect to susceptibility to CHD.
BC8_BioRED_Task1_Doc287	369	372	CHD	Disease	D003327	Two coding polymorphisms, 55M/L and 192Q/R, and a promoter variant, -107C/T, has been extensively studied with respect to susceptibility to CHD.
BC8_BioRED_Task1_Doc287	843	848	192RR	SequenceVariant	p|Allele|R|192	However, a longitudinal follow-up study on survival in the same sample indicated that 192RR homozygotes have a poorer survival compared to QQ homozygotes (hazard rate: 1.38, P = 0.04).
BC8_BioRED_Task1_Doc287	1148	1153	women	OrganismTaxon	9606	In both samples, the effect was most pronounced in women.
BC8_BioRED_Task1_Doc287	1183	1205	ischemic heart disease	Disease	D017202	Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.
BC8_BioRED_Task1_Doc287	1236	1239	PON	Gene	5444	Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.
BC8_BioRED_Task1_Doc287	1240	1246	192Q/R	SequenceVariant	p|SUB|Q|192|R	Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.
BC8_BioRED_Task1_Doc287	1281	1284	CHD	Disease	D003327	Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.
BC8_BioRED_Task1_Doc287	1326	1331	192RR	SequenceVariant	p|Allele|R|192	Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.
BC8_BioRED_Task1_Doc287	1348	1353	women	OrganismTaxon	9606	Using self-reported data on ischemic heart disease to evaluate the impact of the PON 192Q/R polymorphism on susceptibility to CHD, we found only a nonsignificant trend of 192RR homozygosity in women being a risk factor.
BC8_BioRED_Task1_Doc287	1407	1411	PON1	Gene	5444	Our results thus indicates that PON1 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to CHD severity and survival after CHD rather than susceptibility to development of CHD.
BC8_BioRED_Task1_Doc287	1412	1417	192RR	SequenceVariant	p|Allele|R|192	Our results thus indicates that PON1 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to CHD severity and survival after CHD rather than susceptibility to development of CHD.
BC8_BioRED_Task1_Doc287	1473	1478	women	OrganismTaxon	9606	Our results thus indicates that PON1 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to CHD severity and survival after CHD rather than susceptibility to development of CHD.
BC8_BioRED_Task1_Doc287	1563	1566	CHD	Disease	D003327	Our results thus indicates that PON1 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to CHD severity and survival after CHD rather than susceptibility to development of CHD.
BC8_BioRED_Task1_Doc287	1595	1598	CHD	Disease	D003327	Our results thus indicates that PON1 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to CHD severity and survival after CHD rather than susceptibility to development of CHD.
BC8_BioRED_Task1_Doc287	1644	1647	CHD	Disease	D003327	Our results thus indicates that PON1 192RR homozygosity is associated with increased mortality in women in the second half of life and that this increased mortality is possibly related to CHD severity and survival after CHD rather than susceptibility to development of CHD.
BC8_BioRED_Task1_Doc288	15	41	thyroid hormone resistance	Disease	D018382	Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene.
BC8_BioRED_Task1_Doc288	47	54	patient	OrganismTaxon	9606	Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene.
BC8_BioRED_Task1_Doc288	94	105	T3 receptor	Gene	7068	Severe form of thyroid hormone resistance in a patient with homozygous/hemizygous mutation of T3 receptor gene.
BC8_BioRED_Task1_Doc288	112	150	Resistance to thyroid hormone syndrome	Disease	D018382	Resistance to thyroid hormone syndrome (RTH) is a rare disorder, usually inherited as an autosomal dominant trait.
BC8_BioRED_Task1_Doc288	152	155	RTH	Disease	D018382	Resistance to thyroid hormone syndrome (RTH) is a rare disorder, usually inherited as an autosomal dominant trait.
BC8_BioRED_Task1_Doc288	227	235	Patients	OrganismTaxon	9606	Patients with RTH are usually euthyroid but can occasionally present with signs and symptoms of thyrotoxicosis or rarely with hypothyroidism.
BC8_BioRED_Task1_Doc288	241	244	RTH	Disease	D018382	Patients with RTH are usually euthyroid but can occasionally present with signs and symptoms of thyrotoxicosis or rarely with hypothyroidism.
BC8_BioRED_Task1_Doc288	323	337	thyrotoxicosis	Disease	D013971	Patients with RTH are usually euthyroid but can occasionally present with signs and symptoms of thyrotoxicosis or rarely with hypothyroidism.
BC8_BioRED_Task1_Doc288	353	367	hypothyroidism	Disease	D007037	Patients with RTH are usually euthyroid but can occasionally present with signs and symptoms of thyrotoxicosis or rarely with hypothyroidism.
BC8_BioRED_Task1_Doc288	436	465	thyroid hormone receptor beta	Gene	7068	Affected individuals are usually heterozygous for mutations in the thyroid hormone receptor beta gene (TR-beta).
BC8_BioRED_Task1_Doc288	472	479	TR-beta	Gene	7068	Affected individuals are usually heterozygous for mutations in the thyroid hormone receptor beta gene (TR-beta).
BC8_BioRED_Task1_Doc288	495	502	patient	OrganismTaxon	9606	We present a patient with RTH found to be homo-/hemizygous for a mutation in the TR-beta gene.
BC8_BioRED_Task1_Doc288	508	511	RTH	Disease	D018382	We present a patient with RTH found to be homo-/hemizygous for a mutation in the TR-beta gene.
BC8_BioRED_Task1_Doc288	563	570	TR-beta	Gene	7068	We present a patient with RTH found to be homo-/hemizygous for a mutation in the TR-beta gene.
BC8_BioRED_Task1_Doc288	612	617	I280S	SequenceVariant	p|SUB|I|280|S	The single nucleotide substitution I280S (1123T-->G) was present either on both alleles or in a hemizygous form with complete deletion of the second allele.
BC8_BioRED_Task1_Doc288	619	628	1123T-->G	SequenceVariant	g|SUB|T|1123|G	The single nucleotide substitution I280S (1123T-->G) was present either on both alleles or in a hemizygous form with complete deletion of the second allele.
BC8_BioRED_Task1_Doc288	738	743	I280S	SequenceVariant	p|SUB|I|280|S	The I280S mutation was recently reported in a heterozygous patient.
BC8_BioRED_Task1_Doc288	793	800	patient	OrganismTaxon	9606	The I280S mutation was recently reported in a heterozygous patient.
BC8_BioRED_Task1_Doc288	838	871	impaired intellectual development	Disease	D008607	The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional TR-beta.
BC8_BioRED_Task1_Doc288	873	885	hyperkinetic	Disease	D006948	The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional TR-beta.
BC8_BioRED_Task1_Doc288	897	908	tachycardia	Disease	D013610	The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional TR-beta.
BC8_BioRED_Task1_Doc288	910	939	hearing and visual impairment	Disease	D006311,D014786	The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional TR-beta.
BC8_BioRED_Task1_Doc288	995	1000	I280S	SequenceVariant	p|SUB|I|280|S	The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional TR-beta.
BC8_BioRED_Task1_Doc288	1050	1057	TR-beta	Gene	7068	The severe phenotype with seriously impaired intellectual development, hyperkinetic behaviour, tachycardia, hearing and visual impairment is probably due to the dominant negative effect of the I280S mutant protein and the absence of any functional TR-beta.
BC8_BioRED_Task1_Doc289	59	67	patients	OrganismTaxon	9606	Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations.
BC8_BioRED_Task1_Doc289	73	78	POLG1	Gene	5428	Depletion of mitochondrial DNA in fibroblast cultures from patients with POLG1 mutations is a consequence of catalytic mutations.
BC8_BioRED_Task1_Doc289	249	291	mitochondrial DNA (mtDNA) gamma polymerase	Gene	5428	We investigated clinical and cellular phenotypes of 24 children with mutations in the catalytic (alpha) subunit of the mitochondrial DNA (mtDNA) gamma polymerase (POLG1).
BC8_BioRED_Task1_Doc289	293	298	POLG1	Gene	5428	We investigated clinical and cellular phenotypes of 24 children with mutations in the catalytic (alpha) subunit of the mitochondrial DNA (mtDNA) gamma polymerase (POLG1).
BC8_BioRED_Task1_Doc289	316	331	Alpers syndrome	Disease	D002549	Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion.
BC8_BioRED_Task1_Doc289	354	359	POLG1	Gene	5428	Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion.
BC8_BioRED_Task1_Doc289	402	422	hepatoencephalopathy	Disease	C563797	Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion.
BC8_BioRED_Task1_Doc289	541	549	Patients	OrganismTaxon	9606	Patients with tissue depletion of mtDNA all had at least one allele with either a missense mutation in a catalytic domain or a nonsense mutation.
BC8_BioRED_Task1_Doc289	702	710	patients	OrganismTaxon	9606	Four out of 12 patients exhibited a progressive, mosaic pattern of mtDNA depletion in cultured fibroblasts.
BC8_BioRED_Task1_Doc289	805	813	patients	OrganismTaxon	9606	All these patients had mutations in a catalytic domain in both POLG1 alleles, in either the polymerase or exonuclease domain or both.
BC8_BioRED_Task1_Doc289	858	863	POLG1	Gene	5428	All these patients had mutations in a catalytic domain in both POLG1 alleles, in either the polymerase or exonuclease domain or both.
BC8_BioRED_Task1_Doc289	957	965	patients	OrganismTaxon	9606	The tissue mtDNA content of patients who had two linker mutations was normal, and their phenotypes the mildest.
BC8_BioRED_Task1_Doc289	1041	1049	Epilepsy	Disease	D004827	Epilepsy and/or movement disorder were major features in all 21.
BC8_BioRED_Task1_Doc289	1057	1074	movement disorder	Disease	D009069	Epilepsy and/or movement disorder were major features in all 21.
BC8_BioRED_Task1_Doc289	1328	1335	patient	OrganismTaxon	9606	One patient with a severe cellular and clinical phenotype was a compound heterozygote with POLG1 mutations in the polymerase and exonuclease domain intrans.
BC8_BioRED_Task1_Doc289	1415	1420	POLG1	Gene	5428	One patient with a severe cellular and clinical phenotype was a compound heterozygote with POLG1 mutations in the polymerase and exonuclease domain intrans.
BC8_BioRED_Task1_Doc289	1500	1505	POLG1	Gene	5428	This suggests that POLG1 requires both polymerase and 3'-5' exonuclease activity in the same molecule.
BC8_BioRED_Task1_Doc290	25	46	Sulfonylurea Receptor	Gene	6833	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease.
BC8_BioRED_Task1_Doc290	48	63	Type 2 Diabetes	Disease	D003924	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease.
BC8_BioRED_Task1_Doc290	69	91	Coronary Heart Disease	Disease	D003324	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease.
BC8_BioRED_Task1_Doc290	145	160	type 2 diabetes	Disease	D003924	Despite widespread clinical use in the treatment of type 2 diabetes, the impact of sulfonylurea therapy on cardiovascular outcomes remains uncertain.
BC8_BioRED_Task1_Doc290	176	188	sulfonylurea	Chemical	D013453	Despite widespread clinical use in the treatment of type 2 diabetes, the impact of sulfonylurea therapy on cardiovascular outcomes remains uncertain.
BC8_BioRED_Task1_Doc290	449	470	sulfonylurea receptor	Gene	6833	A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy.
BC8_BioRED_Task1_Doc290	472	477	ABCC8	Gene	6833	A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy.
BC8_BioRED_Task1_Doc290	478	486	p.A1369S	SequenceVariant	rs757110	A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy.
BC8_BioRED_Task1_Doc290	530	542	sulfonylurea	Chemical	D013453	A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy.
BC8_BioRED_Task1_Doc290	584	591	insulin	Gene	3630	A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy.
BC8_BioRED_Task1_Doc290	633	645	sulfonylurea	Chemical	D013453	A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin secretion, thus mimicking the effects of sulfonylurea therapy.
BC8_BioRED_Task1_Doc290	880	895	type 2 diabetes	Disease	D003924	Using individual-level data from 120,286 participants in the UK Biobank and summary association results from four large-scale genome-wide association studies, we examined the impact of this variant on cardiometabolic traits, type 2 diabetes, and coronary heart disease.
BC8_BioRED_Task1_Doc290	901	923	coronary heart disease	Disease	D003324	Using individual-level data from 120,286 participants in the UK Biobank and summary association results from four large-scale genome-wide association studies, we examined the impact of this variant on cardiometabolic traits, type 2 diabetes, and coronary heart disease.
BC8_BioRED_Task1_Doc290	929	937	p.A1369S	SequenceVariant	rs757110	The p.A1369S variant was associated with a significantly lower risk of type 2 diabetes (odds ratio [OR] 0.93; 95% CI 0.91, 0.95; P = 1.2 x 10(-11)).
BC8_BioRED_Task1_Doc290	996	1011	type 2 diabetes	Disease	D003924	The p.A1369S variant was associated with a significantly lower risk of type 2 diabetes (odds ratio [OR] 0.93; 95% CI 0.91, 0.95; P = 1.2 x 10(-11)).
BC8_BioRED_Task1_Doc290	1276	1284	p.A1369S	SequenceVariant	rs757110	Furthermore, p.A1369S was associated with a reduced risk of coronary heart disease (OR 0.98; 95% CI 0.96, 0.99; P = 5.9 x 10(-4)).
BC8_BioRED_Task1_Doc290	1323	1345	coronary heart disease	Disease	D003324	Furthermore, p.A1369S was associated with a reduced risk of coronary heart disease (OR 0.98; 95% CI 0.96, 0.99; P = 5.9 x 10(-4)).
BC8_BioRED_Task1_Doc290	1483	1495	sulfonylurea	Chemical	D013453	These results suggest that, despite a known association with increased weight, long-term sulfonylurea therapy may reduce the risk of coronary heart disease.
BC8_BioRED_Task1_Doc290	1527	1549	coronary heart disease	Disease	D003324	These results suggest that, despite a known association with increased weight, long-term sulfonylurea therapy may reduce the risk of coronary heart disease.
BC8_BioRED_Task1_Doc291	66	78	HIV-infected	Disease	D015658	Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
BC8_BioRED_Task1_Doc291	79	87	patients	OrganismTaxon	9606	Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
BC8_BioRED_Task1_Doc291	249	261	HIV-infected	Disease	D015658	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India.
BC8_BioRED_Task1_Doc291	326	338	HIV-infected	Disease	D015658	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India.
BC8_BioRED_Task1_Doc291	528	531	3TC	Chemical	D019259	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	534	537	d4T	Chemical	D018119	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	540	550	nevirapine	Chemical	D019829	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	552	555	NVP	Chemical	D019829	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	566	576	zidovudine	Chemical	D015215	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	578	581	AZT	Chemical	D015215	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	585	588	3TC	Chemical	D019259	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	591	594	NVP	Chemical	D019829	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	604	607	3TC	Chemical	D019259	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	610	613	d4T	Chemical	D018119	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	616	625	efavirenz	Chemical	C098320	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	627	630	EFV	Chemical	C098320	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	645	648	AZT	Chemical	D015215	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	651	654	3TC	Chemical	D019259	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	657	660	EFV	Chemical	C098320	The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%).
BC8_BioRED_Task1_Doc291	711	714	CD4	Gene	920	The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL).
BC8_BioRED_Task1_Doc291	737	741	rash	Disease	D005076	The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL).
BC8_BioRED_Task1_Doc291	750	753	CD4	Gene	920	The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL).
BC8_BioRED_Task1_Doc291	777	798	peripheral neuropathy	Disease	D010523	The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL).
BC8_BioRED_Task1_Doc291	851	857	anemia	Disease	D000740	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	859	869	hemoglobin	Gene	3039	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	903	911	patients	OrganismTaxon	9606	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	913	916	CD4	Gene	920	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	940	949	hepatitis	Disease	D056486	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	960	968	jaundice	Disease	D007565	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	974	998	alanine aminotransferase	Chemical	D000410	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	1044	1052	patients	OrganismTaxon	9606	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	1054	1057	CD4	Gene	920	Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
BC8_BioRED_Task1_Doc291	1078	1083	Women	OrganismTaxon	9606	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05).
BC8_BioRED_Task1_Doc291	1129	1144	lactic acidosis	Disease	D000140	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05).
BC8_BioRED_Task1_Doc291	1152	1155	men	OrganismTaxon	9606	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05).
BC8_BioRED_Task1_Doc291	1201	1231	immune reconstitution syndrome	Disease	D054019	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05).
BC8_BioRED_Task1_Doc291	1254	1262	patients	OrganismTaxon	9606	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
BC8_BioRED_Task1_Doc291	1289	1292	NVP	Chemical	D019829	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
BC8_BioRED_Task1_Doc291	1346	1350	rash	Disease	D005076	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
BC8_BioRED_Task1_Doc291	1355	1358	d4T	Chemical	D018119	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
BC8_BioRED_Task1_Doc291	1383	1404	peripheral neuropathy	Disease	D010523	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
BC8_BioRED_Task1_Doc291	1417	1423	Anemia	Disease	D000740	Anemia and hepatitis often occur within 12 weeks of initiating generic HAART.
BC8_BioRED_Task1_Doc291	1428	1437	hepatitis	Disease	D056486	Anemia and hepatitis often occur within 12 weeks of initiating generic HAART.
BC8_BioRED_Task1_Doc291	1535	1545	toxicities	Disease	D064420	Frequent and early monitoring for these toxicities is warranted in developing countries where generic HAART is increasingly available.
BC8_BioRED_Task1_Doc292	23	35	hypertension	Disease	D006973	Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.
BC8_BioRED_Task1_Doc292	49	66	cerebral ischemia	Disease	D002545	Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.
BC8_BioRED_Task1_Doc292	78	89	brain edema	Disease	D001929	Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.
BC8_BioRED_Task1_Doc292	113	125	hypertension	Disease	D006973	The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
BC8_BioRED_Task1_Doc292	165	197	middle cerebral artery occlusion	Disease	D020244	The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
BC8_BioRED_Task1_Doc292	199	203	MCAO	Disease	D020244	The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
BC8_BioRED_Task1_Doc292	208	219	brain edema	Disease	D001929	The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
BC8_BioRED_Task1_Doc292	274	284	isoflurane	Chemical	D007530	Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
BC8_BioRED_Task1_Doc292	325	337	hypertensive	Disease	D006973	Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
BC8_BioRED_Task1_Doc292	338	342	rats	OrganismTaxon	10116	Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
BC8_BioRED_Task1_Doc292	448	460	hypertensive	Disease	D006973	In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.
BC8_BioRED_Task1_Doc292	532	536	MCAO	Disease	D020244	In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.
BC8_BioRED_Task1_Doc292	555	559	MCAO	Disease	D020244	Four hours after MCAO, the rats were killed and the brains harvested.
BC8_BioRED_Task1_Doc292	565	569	rats	OrganismTaxon	10116	Four hours after MCAO, the rats were killed and the brains harvested.
BC8_BioRED_Task1_Doc292	684	692	ischemia	Disease	D007511	The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.
BC8_BioRED_Task1_Doc292	705	709	MCAO	Disease	D020244	The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.
BC8_BioRED_Task1_Doc292	823	831	ischemic	Disease	D007511	Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).
BC8_BioRED_Task1_Doc292	858	873	neuronal injury	Disease	D009410	The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.
BC8_BioRED_Task1_Doc292	892	918	2,3,5-triphenyltetrazolium	Chemical	C009591	The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.
BC8_BioRED_Task1_Doc292	936	944	ischemic	Disease	D007511	In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
BC8_BioRED_Task1_Doc292	1052	1060	ischemic	Disease	D007511	In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).
BC8_BioRED_Task1_Doc292	1107	1112	edema	Disease	D004487	In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).
BC8_BioRED_Task1_Doc292	1134	1146	hypertensive	Disease	D006973	In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).
BC8_BioRED_Task1_Doc292	1319	1331	hypertensive	Disease	D006973	The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).
BC8_BioRED_Task1_Doc292	1405	1418	phenylephrine	Chemical	D010656	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1427	1439	hypertension	Disease	D006973	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1461	1465	MCAO	Disease	D020244	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1485	1490	edema	Disease	D004487	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1498	1506	ischemic	Disease	D007511	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1530	1535	edema	Disease	D004487	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1560	1568	ischemic	Disease	D007511	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc292	1626	1646	neuronal dysfunction	Disease	D009410	The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.
BC8_BioRED_Task1_Doc293	0	45	Aryl hydrocarbon receptor interacting protein	Gene	9049	Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
BC8_BioRED_Task1_Doc293	47	50	AIP	Gene	9049	Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
BC8_BioRED_Task1_Doc293	117	135	pituitary adenomas	Disease	D010911	Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
BC8_BioRED_Task1_Doc293	148	166	Pituitary adenomas	Disease	D010911	OBJECTIVE: Pituitary adenomas occur rarely in childhood and adolescence.
BC8_BioRED_Task1_Doc293	210	227	Pituitary adenoma	Disease	D010911	Pituitary adenoma predisposition (PAP) has been recently associated with germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.
BC8_BioRED_Task1_Doc293	309	354	aryl hydrocarbon receptor interacting protein	Gene	9049	Pituitary adenoma predisposition (PAP) has been recently associated with germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.
BC8_BioRED_Task1_Doc293	356	359	AIP	Gene	9049	Pituitary adenoma predisposition (PAP) has been recently associated with germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.
BC8_BioRED_Task1_Doc293	430	433	AIP	Gene	9049	The aim of the study was to examine the proportion of germline AIP mutations in apparently sporadic paediatric pituitary adenomas.
BC8_BioRED_Task1_Doc293	478	496	pituitary adenomas	Disease	D010911	The aim of the study was to examine the proportion of germline AIP mutations in apparently sporadic paediatric pituitary adenomas.
BC8_BioRED_Task1_Doc293	552	555	AIP	Gene	9049	DESIGN: Genomic DNA was analysed for mutations in the AIP gene, by PCR amplification and direct sequencing.
BC8_BioRED_Task1_Doc293	606	614	PATIENTS	OrganismTaxon	9606	PATIENTS: A population-based cohort consisting of 36 apparently sporadic paediatric pituitary adenoma patients, referred to two medical centres in Italy, was included in the study.
BC8_BioRED_Task1_Doc293	690	707	pituitary adenoma	Disease	D010911	PATIENTS: A population-based cohort consisting of 36 apparently sporadic paediatric pituitary adenoma patients, referred to two medical centres in Italy, was included in the study.
BC8_BioRED_Task1_Doc293	708	716	patients	OrganismTaxon	9606	PATIENTS: A population-based cohort consisting of 36 apparently sporadic paediatric pituitary adenoma patients, referred to two medical centres in Italy, was included in the study.
BC8_BioRED_Task1_Doc293	787	795	Patients	OrganismTaxon	9606	Patients were either less than 18 years at diagnosis, or showed clinical evidence of adenoma development before the age of 18 years.
BC8_BioRED_Task1_Doc293	872	879	adenoma	Disease	D000236	Patients were either less than 18 years at diagnosis, or showed clinical evidence of adenoma development before the age of 18 years.
BC8_BioRED_Task1_Doc293	962	969	Y248del	SequenceVariant	rs267606574	RESULTS: A heterozygous in-frame deletion Y248del (c.742_744delTAC) was identified in one GH-secreting adenoma patient.
BC8_BioRED_Task1_Doc293	971	986	c.742_744delTAC	SequenceVariant	rs267606574	RESULTS: A heterozygous in-frame deletion Y248del (c.742_744delTAC) was identified in one GH-secreting adenoma patient.
BC8_BioRED_Task1_Doc293	1010	1030	GH-secreting adenoma	Disease	D049912	RESULTS: A heterozygous in-frame deletion Y248del (c.742_744delTAC) was identified in one GH-secreting adenoma patient.
BC8_BioRED_Task1_Doc293	1031	1038	patient	OrganismTaxon	9606	RESULTS: A heterozygous in-frame deletion Y248del (c.742_744delTAC) was identified in one GH-secreting adenoma patient.
BC8_BioRED_Task1_Doc293	1081	1087	tumour	Disease	D009369	Loss of heterozygosity (LOH) analysis of tumour DNA revealed the loss of the wild-type allele.
BC8_BioRED_Task1_Doc293	1256	1276	GH-secreting adenoma	Disease	D049912	CONCLUSIONS: While mutations were absent in non-GH-secreting adenoma patients, germline AIP mutations can be found in children and adolescents with GH-secreting tumours, even in the absence of family history.
BC8_BioRED_Task1_Doc293	1277	1285	patients	OrganismTaxon	9606	CONCLUSIONS: While mutations were absent in non-GH-secreting adenoma patients, germline AIP mutations can be found in children and adolescents with GH-secreting tumours, even in the absence of family history.
BC8_BioRED_Task1_Doc293	1296	1299	AIP	Gene	9049	CONCLUSIONS: While mutations were absent in non-GH-secreting adenoma patients, germline AIP mutations can be found in children and adolescents with GH-secreting tumours, even in the absence of family history.
BC8_BioRED_Task1_Doc293	1356	1376	GH-secreting tumours	Disease	D049912	CONCLUSIONS: While mutations were absent in non-GH-secreting adenoma patients, germline AIP mutations can be found in children and adolescents with GH-secreting tumours, even in the absence of family history.
BC8_BioRED_Task1_Doc293	1447	1450	AIP	Gene	9049	The present study reports the AIP mutation analysis results on patients of a single ethnic origin.
BC8_BioRED_Task1_Doc293	1480	1488	patients	OrganismTaxon	9606	The present study reports the AIP mutation analysis results on patients of a single ethnic origin.
BC8_BioRED_Task1_Doc293	1592	1595	AIP	Gene	9049	Clearly, further studies are needed to improve our knowledge on the role of AIP in paediatric pituitary adenomas.
BC8_BioRED_Task1_Doc293	1610	1628	pituitary adenomas	Disease	D010911	Clearly, further studies are needed to improve our knowledge on the role of AIP in paediatric pituitary adenomas.
BC8_BioRED_Task1_Doc294	0	11	Clopidogrel	Chemical	D000077144	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
BC8_BioRED_Task1_Doc294	123	134	clopidogrel	Chemical	D000077144	Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention.
BC8_BioRED_Task1_Doc294	171	194	coronary artery disease	Disease	D003324	Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention.
BC8_BioRED_Task1_Doc294	195	203	patients	OrganismTaxon	9606	Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention.
BC8_BioRED_Task1_Doc294	283	291	patients	OrganismTaxon	9606	However, approximately 25% of patients experience a subtherapeutic antiplatelet response.
BC8_BioRED_Task1_Doc294	343	354	Clopidogrel	Chemical	D000077144	Clopidogrel is a prodrug that undergoes hepatic biotransformation by CYP2C19 into its active metabolite.
BC8_BioRED_Task1_Doc294	412	419	CYP2C19	Gene	1557	Clopidogrel is a prodrug that undergoes hepatic biotransformation by CYP2C19 into its active metabolite.
BC8_BioRED_Task1_Doc294	521	528	CYP2C19	Gene	1557	Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events.
BC8_BioRED_Task1_Doc294	606	617	clopidogrel	Chemical	D000077144	Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events.
BC8_BioRED_Task1_Doc294	805	816	clopidogrel	Chemical	D000077144	Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response.
BC8_BioRED_Task1_Doc294	870	877	CYP2C19	Gene	1557	Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response.
BC8_BioRED_Task1_Doc294	890	901	clopidogrel	Chemical	D000077144	Consequently, the US FDA has recently changed clopidogrel's prescribing information to highlight the impact of CYP2C19 genotype on clopidogrel pharmacokinetics, pharmacodynamics and clinical response.
BC8_BioRED_Task1_Doc294	1053	1060	CYP2C19	Gene	1557	Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness.
BC8_BioRED_Task1_Doc294	1119	1130	clopidogrel	Chemical	D000077144	Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness.
BC8_BioRED_Task1_Doc295	74	90	cyclophosphamide	Chemical	D003520	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.
BC8_BioRED_Task1_Doc295	99	107	cystitis	Disease	D003556	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.
BC8_BioRED_Task1_Doc295	115	118	rat	OrganismTaxon	10116	In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat.
BC8_BioRED_Task1_Doc295	123	139	cyclophosphamide	Chemical	D003520	In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.
BC8_BioRED_Task1_Doc295	148	156	cystitis	Disease	D003556	In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.
BC8_BioRED_Task1_Doc295	164	167	rat	OrganismTaxon	10116	In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.
BC8_BioRED_Task1_Doc295	233	253	muscarinic receptors	Gene	25229	In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.
BC8_BioRED_Task1_Doc295	323	331	cystitis	Disease	D003556	Whether or not the neuronal transmission may be affected by cystitis was presently investigated.
BC8_BioRED_Task1_Doc295	417	433	cyclophosphamide	Chemical	D003520	Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.
BC8_BioRED_Task1_Doc295	445	449	rats	OrganismTaxon	10116	Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.
BC8_BioRED_Task1_Doc295	543	601	muscarinic, adrenergic and purinergic receptor antagonists	Chemical	D018674,D018727,D058914	Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.
BC8_BioRED_Task1_Doc295	614	622	atropine	Chemical	D001285	Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.
BC8_BioRED_Task1_Doc295	830	876	alpha,beta-methylene adenosine-5'-triphosphate	Chemical	C002630	In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).
BC8_BioRED_Task1_Doc295	878	894	alpha,beta-meATP	Chemical	C002630	In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).
BC8_BioRED_Task1_Doc295	955	974	muscarinic receptor	Gene	25229	The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.
BC8_BioRED_Task1_Doc295	987	995	atropine	Chemical	D001285	The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.
BC8_BioRED_Task1_Doc295	997	1033	4-diphenylacetoxy-N-methylpiperidine	Chemical	C042375	The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.
BC8_BioRED_Task1_Doc295	1035	1041	4-DAMP	Chemical	C042375	The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.
BC8_BioRED_Task1_Doc295	1073	1086	methoctramine	Chemical	C054938	The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.
BC8_BioRED_Task1_Doc295	1110	1121	pirenzepine	Chemical	D010890	The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.
BC8_BioRED_Task1_Doc295	1278	1284	4-DAMP	Chemical	C042375	4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.
BC8_BioRED_Task1_Doc295	1349	1362	methoctramine	Chemical	C054938	4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.
BC8_BioRED_Task1_Doc295	1367	1378	pirenzepine	Chemical	D010890	4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.
BC8_BioRED_Task1_Doc295	1410	1440	muscarinic receptor antagonism	Chemical	D018674	In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.
BC8_BioRED_Task1_Doc295	1542	1553	pirenzepine	Chemical	D010890	In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.
BC8_BioRED_Task1_Doc295	1558	1564	4-DAMP	Chemical	C042375	In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.
BC8_BioRED_Task1_Doc295	1666	1679	methoctramine	Chemical	C054938	In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.
BC8_BioRED_Task1_Doc295	1780	1789	carbachol	Chemical	D002217	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.
BC8_BioRED_Task1_Doc295	1794	1797	ATP	Chemical	D000255	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.
BC8_BioRED_Task1_Doc295	1874	1883	potassium	Chemical	D011188	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.
BC8_BioRED_Task1_Doc295	1894	1906	isoprenaline	Chemical	D007545	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.
BC8_BioRED_Task1_Doc295	1969	1977	cystitis	Disease	D003556	Thus, in cystitis substantial changes of the efferent functional responses occur.
BC8_BioRED_Task1_Doc295	2063	2080	beta-adrenoceptor	Gene	24925	While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.
BC8_BioRED_Task1_Doc295	2151	2171	muscarinic receptors	Gene	25229	While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.
BC8_BioRED_Task1_Doc296	0	37	Insulin-like growth factor 1 receptor	Gene	16001	Insulin-like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	64	71	hypoxia	Disease	D000860	Insulin-like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	133	137	PI3K	Gene	18706	Insulin-like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	138	141	Akt	Gene	11651	Insulin-like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	142	146	mTOR	Gene	56717	Insulin-like growth factor 1 receptor-mediated cell survival in hypoxia depends on the promotion of autophagy via suppression of the PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	166	173	Hypoxia	Disease	D000860	Hypoxia is widely accepted as a fundamental biological phenomenon, which is strongly associated with tissue damage and cell viability under stress conditions.
BC8_BioRED_Task1_Doc296	325	353	Insulin-like growth factor-1	Gene	16000	Insulin-like growth factor-1 (IGF-1) is known to protect tissues from multiple types of damage, and protect cells from apoptosis.
BC8_BioRED_Task1_Doc296	355	360	IGF-1	Gene	16000	Insulin-like growth factor-1 (IGF-1) is known to protect tissues from multiple types of damage, and protect cells from apoptosis.
BC8_BioRED_Task1_Doc296	455	462	Hypoxia	Disease	D000860	Hypoxia is a regulatory factor of the IGF system, however the role of the IGF-1 receptor (IGF-1R) in hypoxia-induced apoptosis remains unclear.
BC8_BioRED_Task1_Doc296	493	496	IGF	Gene	16000	Hypoxia is a regulatory factor of the IGF system, however the role of the IGF-1 receptor (IGF-1R) in hypoxia-induced apoptosis remains unclear.
BC8_BioRED_Task1_Doc296	529	543	IGF-1 receptor	Gene	16001	Hypoxia is a regulatory factor of the IGF system, however the role of the IGF-1 receptor (IGF-1R) in hypoxia-induced apoptosis remains unclear.
BC8_BioRED_Task1_Doc296	545	551	IGF-1R	Gene	16001	Hypoxia is a regulatory factor of the IGF system, however the role of the IGF-1 receptor (IGF-1R) in hypoxia-induced apoptosis remains unclear.
BC8_BioRED_Task1_Doc296	556	563	hypoxia	Disease	D000860	Hypoxia is a regulatory factor of the IGF system, however the role of the IGF-1 receptor (IGF-1R) in hypoxia-induced apoptosis remains unclear.
BC8_BioRED_Task1_Doc296	671	677	IGF-1R	Gene	16001	The present study investigated the potential mechanisms associated with IGF-1R-associated apoptosis under hypoxic conditions.
BC8_BioRED_Task1_Doc296	705	712	hypoxic	Disease	D000860	The present study investigated the potential mechanisms associated with IGF-1R-associated apoptosis under hypoxic conditions.
BC8_BioRED_Task1_Doc296	725	730	Mouse	OrganismTaxon	10090	Mouse embryonic fibroblasts exhibiting disruption or overexpression of IGF-1R (R- cells and R+ cells) were used to examine the level of apoptosis, autophagy, and production of reactive oxygen species (ROS).
BC8_BioRED_Task1_Doc296	796	802	IGF-1R	Gene	16001	Mouse embryonic fibroblasts exhibiting disruption or overexpression of IGF-1R (R- cells and R+ cells) were used to examine the level of apoptosis, autophagy, and production of reactive oxygen species (ROS).
BC8_BioRED_Task1_Doc296	901	924	reactive oxygen species	Chemical	D017382	Mouse embryonic fibroblasts exhibiting disruption or overexpression of IGF-1R (R- cells and R+ cells) were used to examine the level of apoptosis, autophagy, and production of reactive oxygen species (ROS).
BC8_BioRED_Task1_Doc296	926	929	ROS	Chemical	D017382	Mouse embryonic fibroblasts exhibiting disruption or overexpression of IGF-1R (R- cells and R+ cells) were used to examine the level of apoptosis, autophagy, and production of reactive oxygen species (ROS).
BC8_BioRED_Task1_Doc296	956	971	3-methyladenine	Chemical	C025946	The autophagy inhibitor 3-methyladenine was used to assess the effect of autophagy on ROS production and apoptosis under hypoxic conditions.
BC8_BioRED_Task1_Doc296	1018	1021	ROS	Chemical	D017382	The autophagy inhibitor 3-methyladenine was used to assess the effect of autophagy on ROS production and apoptosis under hypoxic conditions.
BC8_BioRED_Task1_Doc296	1053	1060	hypoxic	Disease	D000860	The autophagy inhibitor 3-methyladenine was used to assess the effect of autophagy on ROS production and apoptosis under hypoxic conditions.
BC8_BioRED_Task1_Doc296	1124	1153	phosphatidylinositol 3-kinase	Gene	18706	A potential downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3K)/threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR) was identifiedby western blot analysis.
BC8_BioRED_Task1_Doc296	1155	1159	PI3K	Gene	18706	A potential downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3K)/threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR) was identifiedby western blot analysis.
BC8_BioRED_Task1_Doc296	1161	1187	threonine protein kinase B	Gene	11651	A potential downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3K)/threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR) was identifiedby western blot analysis.
BC8_BioRED_Task1_Doc296	1189	1192	Akt	Gene	11651	A potential downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3K)/threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR) was identifiedby western blot analysis.
BC8_BioRED_Task1_Doc296	1194	1223	mammalian target of rapamycin	Gene	56717	A potential downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3K)/threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR) was identifiedby western blot analysis.
BC8_BioRED_Task1_Doc296	1225	1229	mTOR	Gene	56717	A potential downstream signaling pathway involving phosphatidylinositol 3-kinase (PI3K)/threonine protein kinase B (Akt)/mammalian target of rapamycin (mTOR) was identifiedby western blot analysis.
BC8_BioRED_Task1_Doc296	1301	1308	hypoxia	Disease	D000860	The results demonstrated that hypoxia induced apoptosis, increased ROS production, and promoted autophagy in a time-dependent manner relative to that observed under normoxia.
BC8_BioRED_Task1_Doc296	1338	1341	ROS	Chemical	D017382	The results demonstrated that hypoxia induced apoptosis, increased ROS production, and promoted autophagy in a time-dependent manner relative to that observed under normoxia.
BC8_BioRED_Task1_Doc296	1510	1513	ROS	Chemical	D017382	R+ cells exhibited a lower percentage of apoptotic cells, lower ROS production, and higher levels of autophagy when compared to that of R- cells.
BC8_BioRED_Task1_Doc296	1646	1649	ROS	Chemical	D017382	In addition, inhibition of autophagy led to increased ROS production and a higher percentage of apoptotic cells in the two cell types.
BC8_BioRED_Task1_Doc296	1740	1746	IGF-1R	Gene	16001	Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.
BC8_BioRED_Task1_Doc296	1763	1767	PI3K	Gene	18706	Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.
BC8_BioRED_Task1_Doc296	1768	1771	Akt	Gene	11651	Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.
BC8_BioRED_Task1_Doc296	1772	1776	mTOR	Gene	56717	Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.
BC8_BioRED_Task1_Doc296	1897	1901	PI3K	Gene	18706	Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.
BC8_BioRED_Task1_Doc296	1912	1920	LY294002	Chemical	C085911	Furthermore, IGF-1R is related with PI3K/Akt/mTOR signaling pathway and enhanced autophagy-associated protein expression, which was verified following treatment with the PI3K inhibitor LY294002.
BC8_BioRED_Task1_Doc296	1951	1957	IGF-1R	Gene	16001	These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	1992	1999	hypoxic	Disease	D000860	These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	2049	2052	ROS	Chemical	D017382	These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	2086	2090	PI3K	Gene	18706	These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	2091	2094	Akt	Gene	11651	These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc296	2095	2099	mTOR	Gene	56717	These results indicated that IGF-1R may increase cell viability under hypoxic conditions by promoting autophagy and scavenging ROS production, which is closed with PI3K/Akt/mTOR signaling pathway.
BC8_BioRED_Task1_Doc297	30	39	trazodone	Chemical	D014196	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats.
BC8_BioRED_Task1_Doc297	43	62	5-HT 2A/2C receptor	Gene	25187,29595	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats.
BC8_BioRED_Task1_Doc297	78	86	dopamine	Chemical	D004298	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats.
BC8_BioRED_Task1_Doc297	110	114	rats	OrganismTaxon	10116	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats.
BC8_BioRED_Task1_Doc297	127	146	5-Hydroxytryptamine	Chemical	D012701	RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission.
BC8_BioRED_Task1_Doc297	167	184	5-HT 2C receptors	Gene	25187	RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission.
BC8_BioRED_Task1_Doc297	279	296	5-HT 2A receptors	Gene	29595	RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission.
BC8_BioRED_Task1_Doc297	363	372	trazodone	Chemical	D014196	The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist.
BC8_BioRED_Task1_Doc297	378	397	5-HT 2A/2C receptor	Gene	25187,29595	The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist.
BC8_BioRED_Task1_Doc297	448	457	trazodone	Chemical	D014196	OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system.
BC8_BioRED_Task1_Doc297	594	603	trazodone	Chemical	D014196	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	607	621	dexamphetamine	Chemical	D003913	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	627	638	apomorphine	Chemical	D001058	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	647	664	oral stereotypies	Disease	D009062	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	669	678	catalepsy	Disease	D002375	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	690	701	haloperidol	Chemical	D006220	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	706	717	apomorphine	Chemical	D001058	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.
BC8_BioRED_Task1_Doc297	741	752	ergometrine	Chemical	D004874	), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
BC8_BioRED_Task1_Doc297	794	804	fluoxetine	Chemical	D005473	), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
BC8_BioRED_Task1_Doc297	845	849	rats	OrganismTaxon	10116	), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.
BC8_BioRED_Task1_Doc297	880	889	trazodone	Chemical	D014196	We also investigated whether trazodone induces catalepsy in rats.
BC8_BioRED_Task1_Doc297	898	907	catalepsy	Disease	D002375	We also investigated whether trazodone induces catalepsy in rats.
BC8_BioRED_Task1_Doc297	911	915	rats	OrganismTaxon	10116	We also investigated whether trazodone induces catalepsy in rats.
BC8_BioRED_Task1_Doc297	926	935	Trazodone	Chemical	D014196	RESULTS: Trazodone at 2.5-20 mg/kg i.p.
BC8_BioRED_Task1_Doc297	972	981	catalepsy	Disease	D002375	did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.
BC8_BioRED_Task1_Doc297	1006	1017	apomorphine	Chemical	D001058	did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.
BC8_BioRED_Task1_Doc297	1051	1062	apomorphine	Chemical	D001058	did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.
BC8_BioRED_Task1_Doc297	1084	1093	catalepsy	Disease	D002375	did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.
BC8_BioRED_Task1_Doc297	1146	1155	trazodone	Chemical	D014196	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
BC8_BioRED_Task1_Doc297	1165	1179	dexamphetamine	Chemical	D003913	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
BC8_BioRED_Task1_Doc297	1208	1219	haloperidol	Chemical	D006220	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
BC8_BioRED_Task1_Doc297	1220	1229	catalepsy	Disease	D002375	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
BC8_BioRED_Task1_Doc297	1231	1242	ergometrine	Chemical	D004874	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
BC8_BioRED_Task1_Doc297	1268	1278	fluoxetine	Chemical	D005473	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.
BC8_BioRED_Task1_Doc297	1305	1314	Trazodone	Chemical	D014196	Trazodone at 30, 40 and 50 mg/kg i.p.
BC8_BioRED_Task1_Doc297	1351	1360	catalepsy	Disease	D002375	induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
BC8_BioRED_Task1_Doc297	1377	1388	apomorphine	Chemical	D001058	induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
BC8_BioRED_Task1_Doc297	1393	1407	dexamphetamine	Chemical	D003913	induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
BC8_BioRED_Task1_Doc297	1461	1470	trazodone	Chemical	D014196	CONCLUSIONS: Our results indicate that trazodone at 2.5-20 mg/kg does not block pre- and postsynaptic striatal D2 DA receptors, while at 30, 40 and 50 mg/kg it blocks postsynaptic striatal D2 DA receptors.
BC8_BioRED_Task1_Doc297	1533	1548	D2 DA receptors	Gene	24318	CONCLUSIONS: Our results indicate that trazodone at 2.5-20 mg/kg does not block pre- and postsynaptic striatal D2 DA receptors, while at 30, 40 and 50 mg/kg it blocks postsynaptic striatal D2 DA receptors.
BC8_BioRED_Task1_Doc297	1611	1626	D2 DA receptors	Gene	24318	CONCLUSIONS: Our results indicate that trazodone at 2.5-20 mg/kg does not block pre- and postsynaptic striatal D2 DA receptors, while at 30, 40 and 50 mg/kg it blocks postsynaptic striatal D2 DA receptors.
BC8_BioRED_Task1_Doc297	1664	1673	trazodone	Chemical	D014196	Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors.
BC8_BioRED_Task1_Doc297	1681	1710	5-HT 2A and 5-HT 2C receptors	Gene	25187,29595	Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors.
BC8_BioRED_Task1_Doc297	1728	1737	trazodone	Chemical	D014196	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
BC8_BioRED_Task1_Doc297	1776	1793	5-HT 2C receptors	Gene	25187	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
BC8_BioRED_Task1_Doc297	1870	1874	5-HT	Chemical	D012701	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
BC8_BioRED_Task1_Doc297	1900	1914	dexamphetamine	Chemical	D003913	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
BC8_BioRED_Task1_Doc297	1942	1953	haloperidol	Chemical	D006220	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
BC8_BioRED_Task1_Doc297	1954	1963	catalepsy	Disease	D002375	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.
BC8_BioRED_Task1_Doc298	28	56	glutathione-S-transferase P1	Gene	2950	Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population.
BC8_BioRED_Task1_Doc298	63	68	GSTP1	Gene	2950	Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population.
BC8_BioRED_Task1_Doc298	92	107	prostate cancer	Disease	D011471	Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population.
BC8_BioRED_Task1_Doc298	136	164	Glutathione-S-transferase P1	Gene	2950	Glutathione-S-transferase P1 (GSTP1) is a critical enzyme of the phase II detoxification pathway.
BC8_BioRED_Task1_Doc298	166	171	GSTP1	Gene	2950	Glutathione-S-transferase P1 (GSTP1) is a critical enzyme of the phase II detoxification pathway.
BC8_BioRED_Task1_Doc298	280	285	GSTP1	Gene	2950	One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1.
BC8_BioRED_Task1_Doc298	289	312	A > G at nucleotide 313	SequenceVariant	rs1695	One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1.
BC8_BioRED_Task1_Doc298	359	368	Ile105Val	SequenceVariant	rs1695	One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1.
BC8_BioRED_Task1_Doc298	403	408	GSTP1	Gene	2950	One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1.
BC8_BioRED_Task1_Doc298	443	448	GSTP1	Gene	2950	One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1.
BC8_BioRED_Task1_Doc298	469	474	GSTP1	Gene	2950	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	475	484	Ile105Val	SequenceVariant	rs1695	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	507	522	prostate cancer	Disease	D011471	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	603	618	prostate cancer	Disease	D011471	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	632	659	benign prostate hyperplasia	Disease	D011470	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	683	688	GSTP1	Gene	2950	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	689	698	Ile105Val	SequenceVariant	rs1695	To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique.
BC8_BioRED_Task1_Doc298	865	870	GSTP1	Gene	2950	We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively.
BC8_BioRED_Task1_Doc298	871	880	Ile105Val	SequenceVariant	rs1695	We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively.
BC8_BioRED_Task1_Doc298	984	999	prostate cancer	Disease	D011471	We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively.
BC8_BioRED_Task1_Doc298	1032	1059	benign prostate hyperplasia	Disease	D011470	We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively.
BC8_BioRED_Task1_Doc298	1177	1182	GSTP1	Gene	2950	There was a significant association between the GSTP1 Ile/Val genotype and the advanced age group among the cases.
BC8_BioRED_Task1_Doc298	1183	1190	Ile/Val	SequenceVariant	rs1695	There was a significant association between the GSTP1 Ile/Val genotype and the advanced age group among the cases.
BC8_BioRED_Task1_Doc298	1261	1266	GSTP1	Gene	2950	We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.
BC8_BioRED_Task1_Doc298	1267	1274	Ile/Val	SequenceVariant	rs1695	We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.
BC8_BioRED_Task1_Doc298	1315	1330	prostate cancer	Disease	D011471	We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.
BC8_BioRED_Task1_Doc299	0	25	Adrenoleukodystrophy gene	Gene	215	Adrenoleukodystrophy gene encodes an 80 kDa membrane protein.
BC8_BioRED_Task1_Doc299	166	195	X-linked adrenoleukodystrophy	Disease	D000326	An antibody against the synthetic C-terminal peptides deduced from the cDNA of the gene responsible for X-linked adrenoleukodystrophy (ALD) was produced to characterize the product of the ALD gene.
BC8_BioRED_Task1_Doc299	197	200	ALD	Disease	D000326	An antibody against the synthetic C-terminal peptides deduced from the cDNA of the gene responsible for X-linked adrenoleukodystrophy (ALD) was produced to characterize the product of the ALD gene.
BC8_BioRED_Task1_Doc299	250	253	ALD	Gene	215	An antibody against the synthetic C-terminal peptides deduced from the cDNA of the gene responsible for X-linked adrenoleukodystrophy (ALD) was produced to characterize the product of the ALD gene.
BC8_BioRED_Task1_Doc299	389	396	patient	OrganismTaxon	9606	The antibody reacted with the 80 kDa band protein in control fibroblasts, while no bands were detected in the fibroblasts from a patient with ALD (# 163), in which mRNA of the ALD gene was undetectable based on Northern blot analysis.
BC8_BioRED_Task1_Doc299	402	405	ALD	Disease	D000326	The antibody reacted with the 80 kDa band protein in control fibroblasts, while no bands were detected in the fibroblasts from a patient with ALD (# 163), in which mRNA of the ALD gene was undetectable based on Northern blot analysis.
BC8_BioRED_Task1_Doc299	436	439	ALD	Gene	215	The antibody reacted with the 80 kDa band protein in control fibroblasts, while no bands were detected in the fibroblasts from a patient with ALD (# 163), in which mRNA of the ALD gene was undetectable based on Northern blot analysis.
BC8_BioRED_Task1_Doc299	499	503	293T	CellLine	CVCL_0063	The 293T cells transfected with the full-coding cDNA inserted in the expression vector produced a new 80 kDa protein, as detected by Western blot.
BC8_BioRED_Task1_Doc299	834	837	ALD	Gene	215	These data thus indicate that the ALD gene encodes an 80 kDa membrane protein..
BC8_BioRED_Task1_Doc300	23	26	SRY	Gene	6736	Two novel mutations in SRY gene form Chinese sex reversal XY females.
BC8_BioRED_Task1_Doc300	45	60	sex reversal XY	Disease	OMIM:400044	Two novel mutations in SRY gene form Chinese sex reversal XY females.
BC8_BioRED_Task1_Doc300	74	77	SRY	Gene	6736	The SRY gene (sex determining region on Y chromosome) acts as TDF and is required for regulating male sex determination.
BC8_BioRED_Task1_Doc300	191	194	SRY	Gene	6736	SRY represents a transcription factor belonging to the superfamily of genes sharing the HMG-box motif (high-mobility group-box), which acts as DNA binding region.
BC8_BioRED_Task1_Doc300	393	396	SRY	Gene	6736	Deletion and inactivating mutations of SRY are among the known causes of XY sex reversal.
BC8_BioRED_Task1_Doc300	427	442	XY sex reversal	Disease	OMIM:400044	Deletion and inactivating mutations of SRY are among the known causes of XY sex reversal.
BC8_BioRED_Task1_Doc300	483	491	patients	OrganismTaxon	9606	Here, we described the screening of 10 patients who presented with 46,XY sex reversal for mutations in open reading frame (ORF) of SRY gene.
BC8_BioRED_Task1_Doc300	511	529	46,XY sex reversal	Disease	OMIM:400044	Here, we described the screening of 10 patients who presented with 46,XY sex reversal for mutations in open reading frame (ORF) of SRY gene.
BC8_BioRED_Task1_Doc300	575	578	SRY	Gene	6736	Here, we described the screening of 10 patients who presented with 46,XY sex reversal for mutations in open reading frame (ORF) of SRY gene.
BC8_BioRED_Task1_Doc300	698	701	SRY	Gene	6736	A 609 bp fragment from the central portion of the SRY gene was amplified, using primers XES-2 and XES-7.
BC8_BioRED_Task1_Doc300	1014	1022	patients	OrganismTaxon	9606	In two patients,de novo mutations led to an amino acid substitution.
BC8_BioRED_Task1_Doc300	1079	1112	A was replaced by a G in codon 38	SequenceVariant	c|SUB|A|CODON38|G	An A was replaced by a G in codon 38 upstream of the 5' border outside the HMG box of the SRY gene, resulting in the replacement of the amino acid glutamate by glycine.
BC8_BioRED_Task1_Doc300	1166	1169	SRY	Gene	6736	An A was replaced by a G in codon 38 upstream of the 5' border outside the HMG box of the SRY gene, resulting in the replacement of the amino acid glutamate by glycine.
BC8_BioRED_Task1_Doc300	1223	1243	glutamate by glycine	SequenceVariant	p|SUB|E||G	An A was replaced by a G in codon 38 upstream of the 5' border outside the HMG box of the SRY gene, resulting in the replacement of the amino acid glutamate by glycine.
BC8_BioRED_Task1_Doc300	1266	1315	T to A transition at the nucleotide position +387	SequenceVariant	c|SUB|T|387|A	Another heterozygous T to A transition at the nucleotide position +387 which encodes for a Tyrosine (Tyr) instead of a Term, whereas her father was proven to have the wild-type sequence.
BC8_BioRED_Task1_Doc300	1336	1368	Tyrosine (Tyr) instead of a Term	SequenceVariant	c|SUB|Y||X	Another heterozygous T to A transition at the nucleotide position +387 which encodes for a Tyrosine (Tyr) instead of a Term, whereas her father was proven to have the wild-type sequence.
BC8_BioRED_Task1_Doc300	1530	1535	Human	OrganismTaxon	9606	As demonstrated by the Human Gene Mutation Database analysis,homology search, and review of the literature, these two mutations were not described previously and brought the total number of SRY gene nucleotide substitutions (missense/nonsense) to 45.
BC8_BioRED_Task1_Doc300	1697	1700	SRY	Gene	6736	As demonstrated by the Human Gene Mutation Database analysis,homology search, and review of the literature, these two mutations were not described previously and brought the total number of SRY gene nucleotide substitutions (missense/nonsense) to 45.
BC8_BioRED_Task1_Doc300	1846	1858	sex reversal	Disease	OMIM:400044	These findings indicated that these amino acid substitutions may be responsible for the sex reversal,not only inside the HMG-box but also outside the HMG-box.
BC8_BioRED_Task1_Doc300	1944	1947	SRY	Gene	6736	The two novel mutations in SRY gene provided valuable information for understanding the molecular mechanism of the patient with 46,XY female sex reversal.
BC8_BioRED_Task1_Doc300	2032	2039	patient	OrganismTaxon	9606	The two novel mutations in SRY gene provided valuable information for understanding the molecular mechanism of the patient with 46,XY female sex reversal.
BC8_BioRED_Task1_Doc300	2045	2070	46,XY female sex reversal	Disease	OMIM:400044	The two novel mutations in SRY gene provided valuable information for understanding the molecular mechanism of the patient with 46,XY female sex reversal.
BC8_BioRED_Task1_Doc301	0	4	IL-3	Gene	16187	IL-3 and CSF-1 interact to promote generation of CD11c+ IL-10-producing macrophages.
BC8_BioRED_Task1_Doc301	9	14	CSF-1	Gene	12977	IL-3 and CSF-1 interact to promote generation of CD11c+ IL-10-producing macrophages.
BC8_BioRED_Task1_Doc301	49	54	CD11c	Gene	16411	IL-3 and CSF-1 interact to promote generation of CD11c+ IL-10-producing macrophages.
BC8_BioRED_Task1_Doc301	56	61	IL-10	Gene	16153	IL-3 and CSF-1 interact to promote generation of CD11c+ IL-10-producing macrophages.
BC8_BioRED_Task1_Doc301	195	199	IL-3	Gene	16187	IL-3 is an allergic cytokine with the multilineage potential, while CSF-1 is produced in the steady state with restricted lineage coverage.
BC8_BioRED_Task1_Doc301	263	268	CSF-1	Gene	12977	IL-3 is an allergic cytokine with the multilineage potential, while CSF-1 is produced in the steady state with restricted lineage coverage.
BC8_BioRED_Task1_Doc301	377	382	CSF-1	Gene	12977	Here, we uncovered an instructive role of CSF-1 in IL-3-mediated hematopoiesis.
BC8_BioRED_Task1_Doc301	386	390	IL-3	Gene	16187	Here, we uncovered an instructive role of CSF-1 in IL-3-mediated hematopoiesis.
BC8_BioRED_Task1_Doc301	415	420	CSF-1	Gene	12977	CSF-1 significantly promoted IL-3-driven CD11c+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.
BC8_BioRED_Task1_Doc301	444	448	IL-3	Gene	16187	CSF-1 significantly promoted IL-3-driven CD11c+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.
BC8_BioRED_Task1_Doc301	456	461	CD11c	Gene	16411	CSF-1 significantly promoted IL-3-driven CD11c+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.
BC8_BioRED_Task1_Doc301	530	537	C57BL/6	CellLine	CVCL_5746	CSF-1 significantly promoted IL-3-driven CD11c+ cell expansion and dampened basophil and mast cell generation from C57BL/6 bone marrow.
BC8_BioRED_Task1_Doc301	586	591	CSF-1	Gene	12977	Further studies indicated that the CSF-1/CSF-1R axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.
BC8_BioRED_Task1_Doc301	592	598	CSF-1R	Gene	12978	Further studies indicated that the CSF-1/CSF-1R axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.
BC8_BioRED_Task1_Doc301	633	637	IL-3	Gene	16187	Further studies indicated that the CSF-1/CSF-1R axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.
BC8_BioRED_Task1_Doc301	646	651	CD11c	Gene	16411	Further studies indicated that the CSF-1/CSF-1R axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.
BC8_BioRED_Task1_Doc301	687	692	c-Fos	Gene	14281	Further studies indicated that the CSF-1/CSF-1R axis contributed significantly to IL-3-induced CD11c+ cell generation through enhancing c-Fos-associated monopoiesis.
BC8_BioRED_Task1_Doc301	717	722	CD11c	Gene	16411	CD11c+ cells induced by IL-3 or IL-3/CSF-1 were competent in cellular maturation and endocytosis.
BC8_BioRED_Task1_Doc301	741	745	IL-3	Gene	16187	CD11c+ cells induced by IL-3 or IL-3/CSF-1 were competent in cellular maturation and endocytosis.
BC8_BioRED_Task1_Doc301	749	753	IL-3	Gene	16187	CD11c+ cells induced by IL-3 or IL-3/CSF-1 were competent in cellular maturation and endocytosis.
BC8_BioRED_Task1_Doc301	754	759	CSF-1	Gene	12977	CD11c+ cells induced by IL-3 or IL-3/CSF-1 were competent in cellular maturation and endocytosis.
BC8_BioRED_Task1_Doc301	820	824	IL-3	Gene	16187	Both IL-3 and IL-3/CSF-1 cells lacked classical dendritic cell appearance and resembled macrophages in morphology.
BC8_BioRED_Task1_Doc301	829	833	IL-3	Gene	16187	Both IL-3 and IL-3/CSF-1 cells lacked classical dendritic cell appearance and resembled macrophages in morphology.
BC8_BioRED_Task1_Doc301	834	839	CSF-1	Gene	12977	Both IL-3 and IL-3/CSF-1 cells lacked classical dendritic cell appearance and resembled macrophages in morphology.
BC8_BioRED_Task1_Doc301	972	977	IL-10	Gene	16153	Both populations produced a high level of IL-10, in addition to IL-1, IL-6 and TNFa, in response to LPS, and were relatively poor T cell stimulators.
BC8_BioRED_Task1_Doc301	994	998	IL-1	Gene	111343	Both populations produced a high level of IL-10, in addition to IL-1, IL-6 and TNFa, in response to LPS, and were relatively poor T cell stimulators.
BC8_BioRED_Task1_Doc301	1000	1004	IL-6	Gene	16193	Both populations produced a high level of IL-10, in addition to IL-1, IL-6 and TNFa, in response to LPS, and were relatively poor T cell stimulators.
BC8_BioRED_Task1_Doc301	1009	1013	TNFa	Gene	21926	Both populations produced a high level of IL-10, in addition to IL-1, IL-6 and TNFa, in response to LPS, and were relatively poor T cell stimulators.
BC8_BioRED_Task1_Doc301	1030	1033	LPS	Chemical	D008070	Both populations produced a high level of IL-10, in addition to IL-1, IL-6 and TNFa, in response to LPS, and were relatively poor T cell stimulators.
BC8_BioRED_Task1_Doc301	1127	1132	CSF-1	Gene	12977	Collectively, these findings reveal a role for CSF-1 in mediating the IL-3 hematopoietic pathway through monopoiesis, which regulates expansion of CD11c+ macrophages.
BC8_BioRED_Task1_Doc301	1150	1154	IL-3	Gene	16187	Collectively, these findings reveal a role for CSF-1 in mediating the IL-3 hematopoietic pathway through monopoiesis, which regulates expansion of CD11c+ macrophages.
BC8_BioRED_Task1_Doc301	1227	1232	CD11c	Gene	16411	Collectively, these findings reveal a role for CSF-1 in mediating the IL-3 hematopoietic pathway through monopoiesis, which regulates expansion of CD11c+ macrophages.
BC8_BioRED_Task1_Doc302	39	54	arylsulfatase B	Gene	411	Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient.
BC8_BioRED_Task1_Doc302	94	123	mucopolysaccharidosis type VI	Disease	D009087	Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient.
BC8_BioRED_Task1_Doc302	124	131	patient	OrganismTaxon	9606	Large deletion involving exon 5 of the arylsulfatase B gene caused apparent homozygosity in a mucopolysaccharidosis type VI patient.
BC8_BioRED_Task1_Doc302	172	179	p.R315X	SequenceVariant	p|SUB|R|315|X	Apparent homozygosity for the mutation p.R315X present on exon 5 of the arylsulfatase B (ARSB) gene in a mucopolysaccharidosis type VI patient was solved in this study by further testing for a second mutation.
BC8_BioRED_Task1_Doc302	205	220	arylsulfatase B	Gene	411	Apparent homozygosity for the mutation p.R315X present on exon 5 of the arylsulfatase B (ARSB) gene in a mucopolysaccharidosis type VI patient was solved in this study by further testing for a second mutation.
BC8_BioRED_Task1_Doc302	222	226	ARSB	Gene	411	Apparent homozygosity for the mutation p.R315X present on exon 5 of the arylsulfatase B (ARSB) gene in a mucopolysaccharidosis type VI patient was solved in this study by further testing for a second mutation.
BC8_BioRED_Task1_Doc302	238	267	mucopolysaccharidosis type VI	Disease	D009087	Apparent homozygosity for the mutation p.R315X present on exon 5 of the arylsulfatase B (ARSB) gene in a mucopolysaccharidosis type VI patient was solved in this study by further testing for a second mutation.
BC8_BioRED_Task1_Doc302	268	275	patient	OrganismTaxon	9606	Apparent homozygosity for the mutation p.R315X present on exon 5 of the arylsulfatase B (ARSB) gene in a mucopolysaccharidosis type VI patient was solved in this study by further testing for a second mutation.
BC8_BioRED_Task1_Doc302	343	350	Patient	OrganismTaxon	9606	Patient cDNA analysis revealed that the entire exon 5 of the ARSB gene was lacking; this new mutation was identified as c.899-1142del.
BC8_BioRED_Task1_Doc302	404	408	ARSB	Gene	411	Patient cDNA analysis revealed that the entire exon 5 of the ARSB gene was lacking; this new mutation was identified as c.899-1142del.
BC8_BioRED_Task1_Doc302	463	476	c.899-1142del	SequenceVariant	c|DEL|899_1142|	Patient cDNA analysis revealed that the entire exon 5 of the ARSB gene was lacking; this new mutation was identified as c.899-1142del.
BC8_BioRED_Task1_Doc302	660	664	ARSB	Gene	411	As the genomic DNA sequencing excluded the presence of splicing mutations, polymerase chain reaction analysis was performed for polymorphisms listed in the NCBI SNP database for the ARSB gene.
BC8_BioRED_Task1_Doc302	742	759	g.99367-102002del	SequenceVariant	g|DEL|99367_102002|	This allowed the mutation at the genomic DNA level to be identified as g.99367-102002del; this gross deletion, involving the entire exon 5 of the gene and parts of introns 4 and 5 led to a frameshift starting at amino acid 300 and resulting in a protein with 39% amino acids different from the normal enzyme.
BC8_BioRED_Task1_Doc303	0	7	Cocaine	Chemical	D003042	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
BC8_BioRED_Task1_Doc303	15	46	memory and learning impairments	Disease	D007859,D008569	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
BC8_BioRED_Task1_Doc303	50	54	rats	OrganismTaxon	10116	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
BC8_BioRED_Task1_Doc303	71	93	nuclear factor kappa B	Gene	81736	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
BC8_BioRED_Task1_Doc303	134	144	topiramate	Chemical	D000077236	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
BC8_BioRED_Task1_Doc303	191	198	cocaine	Chemical	D003042	Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.
BC8_BioRED_Task1_Doc303	199	207	toxicity	Disease	D064420	Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.
BC8_BioRED_Task1_Doc303	312	319	cocaine	Chemical	D003042	Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.
BC8_BioRED_Task1_Doc303	360	382	Nuclear factor kappa B	Gene	81736	Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.
BC8_BioRED_Task1_Doc303	384	392	NFkappaB	Gene	81736	Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.
BC8_BioRED_Task1_Doc303	494	502	toxicity	Disease	D064420	Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.
BC8_BioRED_Task1_Doc303	539	547	NFkappaB	Gene	81736	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	576	606	neuronal nitric oxide synthase	Gene	24598	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	608	612	nNOS	Gene	24598	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	677	687	topiramate	Chemical	D000077236	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	723	740	cocaine addiction	Disease	D019970	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	785	792	cocaine	Chemical	D003042	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	811	815	rats	OrganismTaxon	10116	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
BC8_BioRED_Task1_Doc303	817	825	NFkappaB	Gene	81736	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.
BC8_BioRED_Task1_Doc303	874	881	cocaine	Chemical	D003042	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.
BC8_BioRED_Task1_Doc303	890	894	rats	OrganismTaxon	10116	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.
BC8_BioRED_Task1_Doc303	907	910	GSH	Chemical	D005978	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.
BC8_BioRED_Task1_Doc303	929	951	glutathione peroxidase	Gene	2876	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.
BC8_BioRED_Task1_Doc303	989	993	nNOS	Gene	24598	NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.
BC8_BioRED_Task1_Doc303	1087	1094	cocaine	Chemical	D003042	Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.
BC8_BioRED_Task1_Doc303	1154	1162	NFkappaB	Gene	81736	Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.
BC8_BioRED_Task1_Doc303	1279	1283	nNOS	Gene	24598	In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.
BC8_BioRED_Task1_Doc303	1313	1335	glutathione peroxidase	Gene	2876	In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.
BC8_BioRED_Task1_Doc303	1440	1448	NFkappaB	Gene	81736	These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.
BC8_BioRED_Task1_Doc303	1479	1486	cocaine	Chemical	D003042	These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.
BC8_BioRED_Task1_Doc303	1488	1498	Topiramate	Chemical	D000077236	Topiramate prevented all the alterations observed, showing novel neuroprotective properties.
BC8_BioRED_Task1_Doc304	39	45	SRD5A2	Gene	6716	Compound heterozygous mutations in the SRD5A2 gene exon 4 in a male pseudohermaphrodite patient of Chinese origin.
BC8_BioRED_Task1_Doc304	63	87	male pseudohermaphrodite	Disease	D058490	Compound heterozygous mutations in the SRD5A2 gene exon 4 in a male pseudohermaphrodite patient of Chinese origin.
BC8_BioRED_Task1_Doc304	88	95	patient	OrganismTaxon	9606	Compound heterozygous mutations in the SRD5A2 gene exon 4 in a male pseudohermaphrodite patient of Chinese origin.
BC8_BioRED_Task1_Doc304	153	177	5-alpha-reductase type 2	Gene	6716	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	184	190	SRD5A2	Gene	6716	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	206	230	male pseudohermaphrodite	Disease	D058490	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	232	235	MPH	Disease	D058490	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	237	244	patient	OrganismTaxon	9606	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	257	269	testosterone	Chemical	D013739	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	271	272	T	Chemical	D013739	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	296	313	androgen receptor	Gene	367	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	315	317	AR	Gene	367	The goal of this study was to perform 5-alpha-reductase type 2 gene (SRD5A2) analysis in a male pseudohermaphrodite (MPH) patient with normal testosterone (T) production and normal androgen receptor (AR) gene coding sequences.
BC8_BioRED_Task1_Doc304	344	351	patient	OrganismTaxon	9606	A patient of Chinese origin with ambiguous genitalia at 14 months, a 46,XY karyotype, and normal T secretion under human chorionic gonadotropin (hCG) stimulation underwent a gonadectomy at 20 months.
BC8_BioRED_Task1_Doc304	439	440	T	Chemical	D013739	A patient of Chinese origin with ambiguous genitalia at 14 months, a 46,XY karyotype, and normal T secretion under human chorionic gonadotropin (hCG) stimulation underwent a gonadectomy at 20 months.
BC8_BioRED_Task1_Doc304	457	485	human chorionic gonadotropin	Chemical	D006063	A patient of Chinese origin with ambiguous genitalia at 14 months, a 46,XY karyotype, and normal T secretion under human chorionic gonadotropin (hCG) stimulation underwent a gonadectomy at 20 months.
BC8_BioRED_Task1_Doc304	487	490	hCG	Chemical	D006063	A patient of Chinese origin with ambiguous genitalia at 14 months, a 46,XY karyotype, and normal T secretion under human chorionic gonadotropin (hCG) stimulation underwent a gonadectomy at 20 months.
BC8_BioRED_Task1_Doc304	559	561	AR	Gene	367	Exons 1-8 of the AR gene and exons 1-5 of the SRD5A2 gene were sequenced from peripheral blood DNA.
BC8_BioRED_Task1_Doc304	588	594	SRD5A2	Gene	6716	Exons 1-8 of the AR gene and exons 1-5 of the SRD5A2 gene were sequenced from peripheral blood DNA.
BC8_BioRED_Task1_Doc304	642	644	AR	Gene	367	AR gene coding sequences were normal.
BC8_BioRED_Task1_Doc304	680	686	SRD5A2	Gene	6716	SRD5A2 gene analysis revealed 2 consecutive mutations in exon 4, each located in a different allele: 1) a T nucleotide deletion, which predicts a frameshift mutation from codon 219, and 2) a missense mutation at codon 227, where the substitution of guanine (CGA) by adenine (CAA) predicts a glutamine replacement of arginine (R227Q).
BC8_BioRED_Task1_Doc304	786	860	T nucleotide deletion, which predicts a frameshift mutation from codon 219	SequenceVariant	c|DEL|CODON219|T	SRD5A2 gene analysis revealed 2 consecutive mutations in exon 4, each located in a different allele: 1) a T nucleotide deletion, which predicts a frameshift mutation from codon 219, and 2) a missense mutation at codon 227, where the substitution of guanine (CGA) by adenine (CAA) predicts a glutamine replacement of arginine (R227Q).
BC8_BioRED_Task1_Doc304	929	959	guanine (CGA) by adenine (CAA)	SequenceVariant	rs9332964	SRD5A2 gene analysis revealed 2 consecutive mutations in exon 4, each located in a different allele: 1) a T nucleotide deletion, which predicts a frameshift mutation from codon 219, and 2) a missense mutation at codon 227, where the substitution of guanine (CGA) by adenine (CAA) predicts a glutamine replacement of arginine (R227Q).
BC8_BioRED_Task1_Doc304	971	1004	glutamine replacement of arginine	SequenceVariant	rs9332964	SRD5A2 gene analysis revealed 2 consecutive mutations in exon 4, each located in a different allele: 1) a T nucleotide deletion, which predicts a frameshift mutation from codon 219, and 2) a missense mutation at codon 227, where the substitution of guanine (CGA) by adenine (CAA) predicts a glutamine replacement of arginine (R227Q).
BC8_BioRED_Task1_Doc304	1006	1011	R227Q	SequenceVariant	rs9332964	SRD5A2 gene analysis revealed 2 consecutive mutations in exon 4, each located in a different allele: 1) a T nucleotide deletion, which predicts a frameshift mutation from codon 219, and 2) a missense mutation at codon 227, where the substitution of guanine (CGA) by adenine (CAA) predicts a glutamine replacement of arginine (R227Q).
BC8_BioRED_Task1_Doc304	1091	1098	patient	OrganismTaxon	9606	The patient was a compound heterozygote for SRD5A2 mutations, carrying 2 mutations in exon 4.
BC8_BioRED_Task1_Doc304	1131	1137	SRD5A2	Gene	6716	The patient was a compound heterozygote for SRD5A2 mutations, carrying 2 mutations in exon 4.
BC8_BioRED_Task1_Doc304	1185	1192	patient	OrganismTaxon	9606	The patient showed an R227Q mutation that has been described in an Asian population and MPH patients, along with a novel frameshift mutation, Tdel219.
BC8_BioRED_Task1_Doc304	1203	1208	R227Q	SequenceVariant	rs9332964	The patient showed an R227Q mutation that has been described in an Asian population and MPH patients, along with a novel frameshift mutation, Tdel219.
BC8_BioRED_Task1_Doc304	1269	1272	MPH	Disease	D058490	The patient showed an R227Q mutation that has been described in an Asian population and MPH patients, along with a novel frameshift mutation, Tdel219.
BC8_BioRED_Task1_Doc304	1273	1281	patients	OrganismTaxon	9606	The patient showed an R227Q mutation that has been described in an Asian population and MPH patients, along with a novel frameshift mutation, Tdel219.
BC8_BioRED_Task1_Doc304	1323	1330	Tdel219	SequenceVariant	c|DEL|CODON219|T	The patient showed an R227Q mutation that has been described in an Asian population and MPH patients, along with a novel frameshift mutation, Tdel219.
BC8_BioRED_Task1_Doc304	1389	1406	5-alpha-reductase	Gene	6716	Testis morphology showed that, during early infancy, the 5-alpha-reductase enzyme deficiency may not have affected interstitial or tubular development.
BC8_BioRED_Task1_Doc305	0	10	Anxiogenic	Disease	D001008	Anxiogenic potential of ciprofloxacin and norfloxacin in rats.
BC8_BioRED_Task1_Doc305	24	37	ciprofloxacin	Chemical	D002939	Anxiogenic potential of ciprofloxacin and norfloxacin in rats.
BC8_BioRED_Task1_Doc305	42	53	norfloxacin	Chemical	D009643	Anxiogenic potential of ciprofloxacin and norfloxacin in rats.
BC8_BioRED_Task1_Doc305	57	61	rats	OrganismTaxon	10116	Anxiogenic potential of ciprofloxacin and norfloxacin in rats.
BC8_BioRED_Task1_Doc305	90	100	anxiogenic	Disease	D001008	INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.
BC8_BioRED_Task1_Doc305	112	128	fluoroquinolones	Chemical	D024841	INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.
BC8_BioRED_Task1_Doc305	137	150	ciprofloxacin	Chemical	D002939	INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.
BC8_BioRED_Task1_Doc305	155	166	norfloxacin	Chemical	D009643	INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.
BC8_BioRED_Task1_Doc305	217	221	rats	OrganismTaxon	10116	INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.
BC8_BioRED_Task1_Doc305	595	608	ciprofloxacin	Chemical	D002939	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
BC8_BioRED_Task1_Doc305	614	625	norfloxacin	Chemical	D009643	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
BC8_BioRED_Task1_Doc305	634	638	rats	OrganismTaxon	10116	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
BC8_BioRED_Task1_Doc305	646	663	anxious behaviour	Disease	D001008	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
BC8_BioRED_Task1_Doc305	689	693	rats	OrganismTaxon	10116	RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
BC8_BioRED_Task1_Doc305	734	747	ciprofloxacin	Chemical	D002939	However, ciprofloxacin- and norfloxacin-treated rats did not differ significantly from each other in various behavioural parameters.
BC8_BioRED_Task1_Doc305	753	764	norfloxacin	Chemical	D009643	However, ciprofloxacin- and norfloxacin-treated rats did not differ significantly from each other in various behavioural parameters.
BC8_BioRED_Task1_Doc305	773	777	rats	OrganismTaxon	10116	However, ciprofloxacin- and norfloxacin-treated rats did not differ significantly from each other in various behavioural parameters.
BC8_BioRED_Task1_Doc305	941	951	anxiogenic	Disease	D001008	CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.
BC8_BioRED_Task1_Doc305	965	978	ciprofloxacin	Chemical	D002939	CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.
BC8_BioRED_Task1_Doc305	983	994	norfloxacin	Chemical	D009643	CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.
BC8_BioRED_Task1_Doc306	0	21	Simvastatin-ezetimibe	Chemical	D000069499	Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.
BC8_BioRED_Task1_Doc306	30	45	hepatic failure	Disease	D017093	Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.
BC8_BioRED_Task1_Doc306	92	114	Serum aminotransferase	Chemical	D001219	Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.
BC8_BioRED_Task1_Doc306	165	212	3-hydroxy-3-methylglutaryl coenzyme A reductase	Gene	3156	Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.
BC8_BioRED_Task1_Doc306	224	230	statin	Chemical	D019821	Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.
BC8_BioRED_Task1_Doc306	250	261	hepatotoxic	Disease	D056486	However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.
BC8_BioRED_Task1_Doc306	305	314	ezetimibe	Chemical	D000069438	However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.
BC8_BioRED_Task1_Doc306	340	361	simvastatin-ezetimibe	Chemical	D000069499	However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.
BC8_BioRED_Task1_Doc306	398	403	woman	OrganismTaxon	9606	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
BC8_BioRED_Task1_Doc306	418	443	fulminant hepatic failure	Disease	D017114	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
BC8_BioRED_Task1_Doc306	511	522	simvastatin	Chemical	D019821	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
BC8_BioRED_Task1_Doc306	536	547	simvastatin	Chemical	D019821	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
BC8_BioRED_Task1_Doc306	554	563	ezetimibe	Chemical	D000069438	We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
BC8_BioRED_Task1_Doc306	579	586	patient	OrganismTaxon	9606	The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.
BC8_BioRED_Task1_Doc306	589	594	lipid	Chemical	D008055	The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.
BC8_BioRED_Task1_Doc306	626	637	simvastatin	Chemical	D019821	The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.
BC8_BioRED_Task1_Doc306	694	708	hepatotoxicity	Disease	D056486	The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.
BC8_BioRED_Task1_Doc306	783	805	serum aminotransferase	Chemical	D001219	A routine laboratory work-up 10 weeks after conversion revealed elevated serum aminotransferase levels.
BC8_BioRED_Task1_Doc306	814	834	Simvastatinezetimibe	Chemical	D000069499	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
BC8_BioRED_Task1_Doc306	839	851	escitalopram	Chemical	D015283	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
BC8_BioRED_Task1_Doc306	878	888	depression	Disease	D003866	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
BC8_BioRED_Task1_Doc306	939	953	hepatotoxicity	Disease	D056486	Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
BC8_BioRED_Task1_Doc306	1017	1033	aminotransferase	Chemical	D000637	A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.
BC8_BioRED_Task1_Doc306	1099	1112	drug toxicity	Disease	D064420	A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.
BC8_BioRED_Task1_Doc306	1195	1211	aminotransferase	Chemical	D000637	Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events.
BC8_BioRED_Task1_Doc306	1314	1323	Ezetimibe	Chemical	D000069438	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
BC8_BioRED_Task1_Doc306	1363	1407	uridine diphosphate glucoronosyltransferases	Gene	7361	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
BC8_BioRED_Task1_Doc306	1409	1412	UGT	Gene	7361	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
BC8_BioRED_Task1_Doc306	1487	1511	simvastatin hydroxy acid	Chemical	C532833	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
BC8_BioRED_Task1_Doc306	1536	1547	simvastatin	Chemical	D019821	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
BC8_BioRED_Task1_Doc306	1572	1586	hepatotoxicity	Disease	D056486	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
BC8_BioRED_Task1_Doc306	1639	1660	simvastatin-ezetimibe	Chemical	D000069499	To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.
BC8_BioRED_Task1_Doc306	1669	1682	liver failure	Disease	D017093	To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.
BC8_BioRED_Task1_Doc306	1762	1782	simvastatinezetimibe	Chemical	D000069499	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
BC8_BioRED_Task1_Doc306	1791	1805	hepatotoxicity	Disease	D056486	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
BC8_BioRED_Task1_Doc306	1823	1834	simvastatin	Chemical	D019821	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
BC8_BioRED_Task1_Doc306	1847	1856	ezetimibe	Chemical	D000069438	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
BC8_BioRED_Task1_Doc306	1871	1874	UGT	Gene	7361	We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
BC8_BioRED_Task1_Doc306	1924	1938	hepatotoxicity	Disease	D056486	Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.
BC8_BioRED_Task1_Doc306	1944	1965	simvastatin-ezetimibe	Chemical	D000069499	Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.
BC8_BioRED_Task1_Doc306	1988	1996	patients	OrganismTaxon	9606	Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.
BC8_BioRED_Task1_Doc306	2026	2048	serum aminotransferase	Chemical	D001219	Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.
BC8_BioRED_Task1_Doc307	23	32	modafinil	Chemical	C048833	Normalizing effects of modafinil on sleep in chronic cocaine users.
BC8_BioRED_Task1_Doc307	53	60	cocaine	Chemical	D003042	Normalizing effects of modafinil on sleep in chronic cocaine users.
BC8_BioRED_Task1_Doc307	157	166	modafinil	Chemical	C048833	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.
BC8_BioRED_Task1_Doc307	180	198	daytime sleepiness	Disease	D012893	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.
BC8_BioRED_Task1_Doc307	210	217	cocaine	Chemical	D003042	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.
BC8_BioRED_Task1_Doc307	240	247	cocaine	Chemical	D003042	METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.
BC8_BioRED_Task1_Doc307	305	314	modafinil	Chemical	C048833	METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.
BC8_BioRED_Task1_Doc307	394	403	inpatient	OrganismTaxon	9606	METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.
BC8_BioRED_Task1_Doc307	919	926	cocaine	Chemical	D003042	RESULTS: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes.
BC8_BioRED_Task1_Doc307	1029	1038	modafinil	Chemical	C048833	Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.
BC8_BioRED_Task1_Doc307	1111	1118	cocaine	Chemical	D003042	Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.
BC8_BioRED_Task1_Doc307	1157	1166	modafinil	Chemical	C048833	The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.
BC8_BioRED_Task1_Doc307	1389	1396	cocaine	Chemical	D003042	Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.
BC8_BioRED_Task1_Doc307	1465	1474	modafinil	Chemical	C048833	Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.
BC8_BioRED_Task1_Doc307	1478	1485	cocaine	Chemical	D003042	Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.
BC8_BioRED_Task1_Doc307	1510	1519	Modafinil	Chemical	C048833	Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.
BC8_BioRED_Task1_Doc307	1669	1687	daytime sleepiness	Disease	D012893	Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.
BC8_BioRED_Task1_Doc307	1716	1725	modafinil	Chemical	C048833	CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.
BC8_BioRED_Task1_Doc307	1797	1815	daytime sleepiness	Disease	D012893	CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.
BC8_BioRED_Task1_Doc307	1829	1836	cocaine	Chemical	D003042	CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.
BC8_BioRED_Task1_Doc307	1894	1901	cocaine	Chemical	D003042	These effects may be relevant in the treatment of cocaine dependence.
BC8_BioRED_Task1_Doc308	0	5	Tumor	Disease	D009369	Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
BC8_BioRED_Task1_Doc308	6	26	thymidylate synthase	Gene	7298	Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
BC8_BioRED_Task1_Doc308	27	35	1494del6	SequenceVariant	c|DEL|1494|6	Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
BC8_BioRED_Task1_Doc308	71	88	colorectal cancer	Disease	D015179	Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
BC8_BioRED_Task1_Doc308	89	97	patients	OrganismTaxon	9606	Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
BC8_BioRED_Task1_Doc308	108	120	fluorouracil	Chemical	D005472	Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
BC8_BioRED_Task1_Doc308	223	228	tumor	Disease	D009369	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	229	249	thymidylate synthase	Gene	7298	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	251	253	TS	Gene	7298	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	304	321	colorectal cancer	Disease	D015179	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	322	330	patients	OrganismTaxon	9606	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	350	362	fluorouracil	Chemical	D005472	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	364	366	FU	Chemical	D005472	PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment.
BC8_BioRED_Task1_Doc308	386	394	PATIENTS	OrganismTaxon	9606	PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included.
BC8_BioRED_Task1_Doc308	432	449	colorectal cancer	Disease	D015179	PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included.
BC8_BioRED_Task1_Doc308	450	458	patients	OrganismTaxon	9606	PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included.
BC8_BioRED_Task1_Doc308	486	488	FU	Chemical	D005472	PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included.
BC8_BioRED_Task1_Doc308	494	504	levamisole	Chemical	D007978	PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included.
BC8_BioRED_Task1_Doc308	508	518	leucovorin	Chemical	D002955	PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included.
BC8_BioRED_Task1_Doc308	558	560	TS	Gene	7298	TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and tumor.
BC8_BioRED_Task1_Doc308	581	586	G > C	SequenceVariant	c|SUB|G||C	TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and tumor.
BC8_BioRED_Task1_Doc308	629	631	TS	Gene	7298	TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and tumor.
BC8_BioRED_Task1_Doc308	632	640	1494del6	SequenceVariant	c|DEL|1494|6	TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and tumor.
BC8_BioRED_Task1_Doc308	708	713	tumor	Disease	D009369	TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and tumor.
BC8_BioRED_Task1_Doc308	738	740	TS	Gene	7298	Mutational analyses of TS and allelic imbalances were studied in all primary tumors and in 18 additional metachronic metastases.
BC8_BioRED_Task1_Doc308	792	798	tumors	Disease	D009369	Mutational analyses of TS and allelic imbalances were studied in all primary tumors and in 18 additional metachronic metastases.
BC8_BioRED_Task1_Doc308	832	842	metastases	Disease	D009362	Mutational analyses of TS and allelic imbalances were studied in all primary tumors and in 18 additional metachronic metastases.
BC8_BioRED_Task1_Doc308	844	846	TS	Gene	7298	TS protein immunostaining was assessed in an expanded series of 214 tumors.
BC8_BioRED_Task1_Doc308	912	918	tumors	Disease	D009369	TS protein immunostaining was assessed in an expanded series of 214 tumors.
BC8_BioRED_Task1_Doc308	1009	1014	Tumor	Disease	D009369	RESULTS: Tumor genotyping (frequency of allelic loss, 26%) showed that the 3R/3R genotype was associated with a better outcome (hazard ratio [HR] = 0.38; 95% CI, 0.16 to 0.93; P = .020 for the recessive model).
BC8_BioRED_Task1_Doc308	1214	1219	G > C	SequenceVariant	c|SUB|G||C	3R G > C SNP genotyping did not add prognostic information.
BC8_BioRED_Task1_Doc308	1271	1276	Tumor	Disease	D009369	Tumor TS 1494del6 allele (frequency of allelic loss, 36%) was protective (for each allele with the deletion, based on an additive model, HR = 0.42; 95% CI, 0.22 to 0.82; P = .0034).
BC8_BioRED_Task1_Doc308	1277	1279	TS	Gene	7298	Tumor TS 1494del6 allele (frequency of allelic loss, 36%) was protective (for each allele with the deletion, based on an additive model, HR = 0.42; 95% CI, 0.22 to 0.82; P = .0034).
BC8_BioRED_Task1_Doc308	1280	1288	1494del6	SequenceVariant	c|DEL|1494|6	Tumor TS 1494del6 allele (frequency of allelic loss, 36%) was protective (for each allele with the deletion, based on an additive model, HR = 0.42; 95% CI, 0.22 to 0.82; P = .0034).
BC8_BioRED_Task1_Doc308	1717	1719	TS	Gene	7298	No TS point mutation was detected in primary tumors or metastases.
BC8_BioRED_Task1_Doc308	1759	1765	tumors	Disease	D009369	No TS point mutation was detected in primary tumors or metastases.
BC8_BioRED_Task1_Doc308	1769	1779	metastases	Disease	D009362	No TS point mutation was detected in primary tumors or metastases.
BC8_BioRED_Task1_Doc308	1781	1783	TS	Gene	7298	TS protein immunostaining was not associated with survival or any of the genotypes analyzed.
BC8_BioRED_Task1_Doc308	1886	1891	Tumor	Disease	D009369	CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.
BC8_BioRED_Task1_Doc308	1892	1894	TS	Gene	7298	CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.
BC8_BioRED_Task1_Doc308	1895	1903	1494del6	SequenceVariant	c|DEL|1494|6	CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.
BC8_BioRED_Task1_Doc308	1943	1945	FU	Chemical	D005472	CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.
BC8_BioRED_Task1_Doc308	1974	1991	colorectal cancer	Disease	D015179	CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.
BC8_BioRED_Task1_Doc308	1992	2000	patients	OrganismTaxon	9606	CONCLUSION: Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.
BC8_BioRED_Task1_Doc309	0	23	Focal dermal hypoplasia	Disease	D005489	Focal dermal hypoplasia resulting from a new nonsense mutation, p.E300X, in the PORCN gene.
BC8_BioRED_Task1_Doc309	64	71	p.E300X	SequenceVariant	p|SUB|E|300|X	Focal dermal hypoplasia resulting from a new nonsense mutation, p.E300X, in the PORCN gene.
BC8_BioRED_Task1_Doc309	80	85	PORCN	Gene	64840	Focal dermal hypoplasia resulting from a new nonsense mutation, p.E300X, in the PORCN gene.
BC8_BioRED_Task1_Doc309	104	127	Focal dermal hypoplasia	Disease	D005489	BACKGROUND: Focal dermal hypoplasia (FDH) (OMIM 305600) is an X-linked dominant disorder of ecto-mesodermal development.
BC8_BioRED_Task1_Doc309	129	132	FDH	Disease	D005489	BACKGROUND: Focal dermal hypoplasia (FDH) (OMIM 305600) is an X-linked dominant disorder of ecto-mesodermal development.
BC8_BioRED_Task1_Doc309	135	146	OMIM 305600	Disease	D005489	BACKGROUND: Focal dermal hypoplasia (FDH) (OMIM 305600) is an X-linked dominant disorder of ecto-mesodermal development.
BC8_BioRED_Task1_Doc309	154	180	X-linked dominant disorder	Disease	D040181	BACKGROUND: Focal dermal hypoplasia (FDH) (OMIM 305600) is an X-linked dominant disorder of ecto-mesodermal development.
BC8_BioRED_Task1_Doc309	227	241	Goltz syndrome	Disease	D005489	Also known as Goltz syndrome, FDH presents with characteristic linear streaks of hypoplastic dermis and variable abnormalities of bone, nails, hair, limbs, teeth and eyes.
BC8_BioRED_Task1_Doc309	243	246	FDH	Disease	D005489	Also known as Goltz syndrome, FDH presents with characteristic linear streaks of hypoplastic dermis and variable abnormalities of bone, nails, hair, limbs, teeth and eyes.
BC8_BioRED_Task1_Doc309	294	312	hypoplastic dermis	Disease	D005489	Also known as Goltz syndrome, FDH presents with characteristic linear streaks of hypoplastic dermis and variable abnormalities of bone, nails, hair, limbs, teeth and eyes.
BC8_BioRED_Task1_Doc309	408	411	FDH	Disease	D005489	The molecular basis of FDH involves mutations in the PORCN gene, which encodes an enzyme that allows membrane targeting and secretion of several Wnt proteins critical for normal tissue development.
BC8_BioRED_Task1_Doc309	438	443	PORCN	Gene	64840	The molecular basis of FDH involves mutations in the PORCN gene, which encodes an enzyme that allows membrane targeting and secretion of several Wnt proteins critical for normal tissue development.
BC8_BioRED_Task1_Doc309	633	636	FDH	Disease	D005489	OBJECTIVES: To investigate the molecular basis of FDH in a 2-year-old Thai girl who presented at birth with depressed, pale linear scars on the trunk and limbs, sparse brittle hair, syndactyly of the right middle and ring fingers, dental caries and radiological features of osteopathia striata.
BC8_BioRED_Task1_Doc309	691	700	depressed	Disease	D003866	OBJECTIVES: To investigate the molecular basis of FDH in a 2-year-old Thai girl who presented at birth with depressed, pale linear scars on the trunk and limbs, sparse brittle hair, syndactyly of the right middle and ring fingers, dental caries and radiological features of osteopathia striata.
BC8_BioRED_Task1_Doc309	814	827	dental caries	Disease	D003731	OBJECTIVES: To investigate the molecular basis of FDH in a 2-year-old Thai girl who presented at birth with depressed, pale linear scars on the trunk and limbs, sparse brittle hair, syndactyly of the right middle and ring fingers, dental caries and radiological features of osteopathia striata.
BC8_BioRED_Task1_Doc309	997	1002	PORCN	Gene	64840	METHODS: Sequencing of genomic DNA from the affected individual and both parents to search for pathogenic mutations in PORCN gene.
BC8_BioRED_Task1_Doc309	1058	1094	G>T substitution at nucleotide c.898	SequenceVariant	c|SUB|G|898|T	RESULTS: DNA sequencing disclosed a heterozygous G>T substitution at nucleotide c.898 within exon 10 (NM_203475.1), converting a glutamic acid residue (GAA) to a premature termination codon (TAA).
BC8_BioRED_Task1_Doc309	1138	1204	glutamic acid residue (GAA) to a premature termination codon (TAA)	SequenceVariant	p|SUB|E||X	RESULTS: DNA sequencing disclosed a heterozygous G>T substitution at nucleotide c.898 within exon 10 (NM_203475.1), converting a glutamic acid residue (GAA) to a premature termination codon (TAA).
BC8_BioRED_Task1_Doc309	1232	1239	p.E300X	SequenceVariant	p|SUB|E|300|X	This mutation, designated p.E300X, was not detected in DNA from either parent or in 100 control chromosomes.
BC8_BioRED_Task1_Doc309	1406	1409	FDH	Disease	D005489	CONCLUSION: Identification of this new de novo nonsense mutation confirms the diagnosis of FDH in this child and highlights the clinical importance of PORCN and Wnt signalling pathways in embryogenesis.
BC8_BioRED_Task1_Doc309	1466	1471	PORCN	Gene	64840	CONCLUSION: Identification of this new de novo nonsense mutation confirms the diagnosis of FDH in this child and highlights the clinical importance of PORCN and Wnt signalling pathways in embryogenesis.
BC8_BioRED_Task1_Doc310	12	16	MLH1	Gene	4292	Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.
BC8_BioRED_Task1_Doc310	29	35	cancer	Disease	D009369	Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.
BC8_BioRED_Task1_Doc310	71	87	Hodgkin lymphoma	Disease	D006689	Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.
BC8_BioRED_Task1_Doc310	172	188	Hodgkin lymphoma	Disease	D006689	BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers.
BC8_BioRED_Task1_Doc310	248	255	cancers	Disease	D009369	BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers.
BC8_BioRED_Task1_Doc310	257	269	Cytotoxicity	Disease	D064420	Cytotoxicity of methylating agents is mediated primarily by the DNA mismatch repair (MMR) system.
BC8_BioRED_Task1_Doc310	363	367	MLH1	Gene	4292	Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells at high risk of malignant transformation.
BC8_BioRED_Task1_Doc310	427	436	cytotoxic	Disease	D064420	Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells at high risk of malignant transformation.
BC8_BioRED_Task1_Doc310	614	618	MLH1	Gene	4292	We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy.
BC8_BioRED_Task1_Doc310	634	643	rs1800734	SequenceVariant	rs1800734	We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy.
BC8_BioRED_Task1_Doc310	666	672	cancer	Disease	D009369	We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy.
BC8_BioRED_Task1_Doc310	718	726	patients	OrganismTaxon	9606	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	741	747	cancer	Disease	D009369	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	806	814	patients	OrganismTaxon	9606	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	838	855	myeloid leukaemia	Disease	D007938	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	861	869	patients	OrganismTaxon	9606	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	885	909	primary Hodgkin lymphoma	Disease	D006689	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	960	964	MLH1	Gene	4292	METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay.
BC8_BioRED_Task1_Doc310	1137	1143	cancer	Disease	D009369	Odds ratios and 95% confidence intervals for cancer risk by MLH1 -93 polymorphism status, and stratified by previous exposure to methylating chemotherapy, were calculated using unconditional logistic regression.
BC8_BioRED_Task1_Doc310	1152	1156	MLH1	Gene	4292	Odds ratios and 95% confidence intervals for cancer risk by MLH1 -93 polymorphism status, and stratified by previous exposure to methylating chemotherapy, were calculated using unconditional logistic regression.
BC8_BioRED_Task1_Doc310	1338	1342	MLH1	Gene	4292	RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%.
BC8_BioRED_Task1_Doc310	1369	1377	patients	OrganismTaxon	9606	RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%.
BC8_BioRED_Task1_Doc310	1408	1431	acute myeloid leukaemia	Disease	D015470	RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%.
BC8_BioRED_Task1_Doc310	1435	1438	AML	Disease	D015470	RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%.
BC8_BioRED_Task1_Doc310	1459	1472	breast cancer	Disease	D001943	RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%.
BC8_BioRED_Task1_Doc310	1524	1540	Hodgkin lymphoma	Disease	D006689	n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
BC8_BioRED_Task1_Doc310	1553	1561	patients	OrganismTaxon	9606	n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
BC8_BioRED_Task1_Doc310	1603	1606	AML	Disease	D015470	n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
BC8_BioRED_Task1_Doc310	1623	1636	breast cancer	Disease	D001943	n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
BC8_BioRED_Task1_Doc310	1637	1645	patients	OrganismTaxon	9606	n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
BC8_BioRED_Task1_Doc310	1667	1671	MLH1	Gene	4292	The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent.
BC8_BioRED_Task1_Doc310	1722	1725	AML	Disease	D015470	The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent.
BC8_BioRED_Task1_Doc310	1757	1760	AML	Disease	D015470	The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent.
BC8_BioRED_Task1_Doc310	1894	1897	AML	Disease	D015470	The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent.
BC8_BioRED_Task1_Doc310	1968	1976	patients	OrganismTaxon	9606	The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent.
BC8_BioRED_Task1_Doc310	2138	2142	MLH1	Gene	4292	CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma.
BC8_BioRED_Task1_Doc310	2188	2194	cancer	Disease	D009369	CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma.
BC8_BioRED_Task1_Doc310	2230	2246	Hodgkin lymphoma	Disease	D006689	CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma.
BC8_BioRED_Task1_Doc311	49	64	phenylketonuria	Disease	D010661	Two distinct mutations at a single BamHI site in phenylketonuria.
BC8_BioRED_Task1_Doc311	66	91	Classical phenylketonuria	Disease	D010661	Classical phenylketonuria is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (PAH).
BC8_BioRED_Task1_Doc311	98	125	autosomal recessive disease	Disease	D030342	Classical phenylketonuria is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (PAH).
BC8_BioRED_Task1_Doc311	138	185	deficiency of hepatic phenylalanine hydroxylase	Disease	OMIM:261600	Classical phenylketonuria is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (PAH).
BC8_BioRED_Task1_Doc311	187	190	PAH	Gene	5053	Classical phenylketonuria is an autosomal recessive disease caused by a deficiency of hepatic phenylalanine hydroxylase (PAH).
BC8_BioRED_Task1_Doc311	272	275	PAH	Gene	5053	The abolition of an invariant BamHI site located in the coding sequence of the PAH gene (exon 7) led to the recognition of two new point mutations at codon 272 and 273 (272gly----stop and 273ser----phe, respectively).
BC8_BioRED_Task1_Doc311	362	376	272gly----stop	SequenceVariant	rs62514952	The abolition of an invariant BamHI site located in the coding sequence of the PAH gene (exon 7) led to the recognition of two new point mutations at codon 272 and 273 (272gly----stop and 273ser----phe, respectively).
BC8_BioRED_Task1_Doc311	381	394	273ser----phe	SequenceVariant	rs62514953	The abolition of an invariant BamHI site located in the coding sequence of the PAH gene (exon 7) led to the recognition of two new point mutations at codon 272 and 273 (272gly----stop and 273ser----phe, respectively).
BC8_BioRED_Task1_Doc311	606	609	PKU	Disease	D010661	The present study supports the view that the clinical heterogeneity in PKU is accounted for by the large variety of mutant genotypes associated with PAH deficiencies..
BC8_BioRED_Task1_Doc311	684	700	PAH deficiencies	Disease	OMIM:261600	The present study supports the view that the clinical heterogeneity in PKU is accounted for by the large variety of mutant genotypes associated with PAH deficiencies..
BC8_BioRED_Task1_Doc312	10	25	tranexamic Acid	Chemical	D014148	High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
BC8_BioRED_Task1_Doc312	66	74	seizures	Disease	D012640	High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
BC8_BioRED_Task1_Doc312	95	103	patients	OrganismTaxon	9606	High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
BC8_BioRED_Task1_Doc312	205	224	convulsive seizures	Disease	D012640	BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.
BC8_BioRED_Task1_Doc312	246	254	patients	OrganismTaxon	9606	BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.
BC8_BioRED_Task1_Doc312	381	396	tranexamic acid	Chemical	D014148	These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.
BC8_BioRED_Task1_Doc312	398	401	TXA	Chemical	D014148	These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.
BC8_BioRED_Task1_Doc312	585	588	TXA	Chemical	D014148	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.
BC8_BioRED_Task1_Doc312	599	607	seizures	Disease	D012640	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.
BC8_BioRED_Task1_Doc312	690	698	patients	OrganismTaxon	9606	METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative seizures.
BC8_BioRED_Task1_Doc312	727	735	seizures	Disease	D012640	METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative seizures.
BC8_BioRED_Task1_Doc312	798	806	patients	OrganismTaxon	9606	Electroencephalographic activity was recorded in 11 of these patients, and all patients had a formal neurological evaluation and brain imaging studies.
BC8_BioRED_Task1_Doc312	816	824	patients	OrganismTaxon	9606	Electroencephalographic activity was recorded in 11 of these patients, and all patients had a formal neurological evaluation and brain imaging studies.
BC8_BioRED_Task1_Doc312	919	927	patients	OrganismTaxon	9606	RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.
BC8_BioRED_Task1_Doc312	957	981	cerebral ischemic injury	Disease	D001930	RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.
BC8_BioRED_Task1_Doc312	987	995	seizures	Disease	D012640	RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.
BC8_BioRED_Task1_Doc312	1015	1036	ischemic brain injury	Disease	D001930	RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.
BC8_BioRED_Task1_Doc312	1042	1050	patients	OrganismTaxon	9606	RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.
BC8_BioRED_Task1_Doc312	1056	1064	patients	OrganismTaxon	9606	All patients with seizures did not have permanent neurological abnormalities.
BC8_BioRED_Task1_Doc312	1070	1078	seizures	Disease	D012640	All patients with seizures did not have permanent neurological abnormalities.
BC8_BioRED_Task1_Doc312	1102	1128	neurological abnormalities	Disease	D009422	All patients with seizures did not have permanent neurological abnormalities.
BC8_BioRED_Task1_Doc312	1137	1145	patients	OrganismTaxon	9606	All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
BC8_BioRED_Task1_Doc312	1151	1159	seizures	Disease	D012640	All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
BC8_BioRED_Task1_Doc312	1183	1186	TXA	Chemical	D014148	All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
BC8_BioRED_Task1_Doc312	1356	1363	patient	OrganismTaxon	9606	All but one patient were managed using cardiopulmonary bypass.
BC8_BioRED_Task1_Doc312	1422	1436	brain ischemic	Disease	D002546	No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.
BC8_BioRED_Task1_Doc312	1452	1464	hyperthermia	Disease	D005334	No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.
BC8_BioRED_Task1_Doc312	1490	1498	seizures	Disease	D012640	No evidence of brain ischemic, metabolic, or hyperthermia-induced causes for their seizures was apparent.
BC8_BioRED_Task1_Doc312	1567	1570	TXA	Chemical	D014148	CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.
BC8_BioRED_Task1_Doc312	1580	1588	patients	OrganismTaxon	9606	CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.
BC8_BioRED_Task1_Doc312	1693	1701	seizures	Disease	D012640	CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.
BC8_BioRED_Task1_Doc312	1717	1725	patients	OrganismTaxon	9606	CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.
BC8_BioRED_Task1_Doc313	76	134	UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit	Gene	84572	Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma.
BC8_BioRED_Task1_Doc313	136	141	GNPTG	Gene	84572	Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma.
BC8_BioRED_Task1_Doc313	151	159	patients	OrganismTaxon	9606	Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma.
BC8_BioRED_Task1_Doc313	165	188	mucolipidosis III gamma	Disease	C565367	Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma.
BC8_BioRED_Task1_Doc313	190	212	Mucolipidosis type III	Disease	D009081	Mucolipidosis type III (MLIII) is an autosomal recessive disorder affecting lysosomal hydrolase trafficking.
BC8_BioRED_Task1_Doc313	214	219	MLIII	Disease	D009081	Mucolipidosis type III (MLIII) is an autosomal recessive disorder affecting lysosomal hydrolase trafficking.
BC8_BioRED_Task1_Doc313	227	255	autosomal recessive disorder	Disease	D030342	Mucolipidosis type III (MLIII) is an autosomal recessive disorder affecting lysosomal hydrolase trafficking.
BC8_BioRED_Task1_Doc313	316	324	patients	OrganismTaxon	9606	In a study of 10 patients from seven families with a clinical phenotype and enzymatic diagnosis of MLIII, six novel GNPTG gene mutations were identified.
BC8_BioRED_Task1_Doc313	398	403	MLIII	Disease	D009081	In a study of 10 patients from seven families with a clinical phenotype and enzymatic diagnosis of MLIII, six novel GNPTG gene mutations were identified.
BC8_BioRED_Task1_Doc313	415	420	GNPTG	Gene	84572	In a study of 10 patients from seven families with a clinical phenotype and enzymatic diagnosis of MLIII, six novel GNPTG gene mutations were identified.
BC8_BioRED_Task1_Doc313	478	485	p.T286M	SequenceVariant	rs193302860	These included missense (p.T286M) and nonsense (p.W111X) mutations and a transition in the obligate AG-dinucleotide of the intron 8 acceptor splice site (c.610-2A>G).
BC8_BioRED_Task1_Doc313	501	508	p.W111X	SequenceVariant	rs137852884	These included missense (p.T286M) and nonsense (p.W111X) mutations and a transition in the obligate AG-dinucleotide of the intron 8 acceptor splice site (c.610-2A>G).
BC8_BioRED_Task1_Doc313	553	568	AG-dinucleotide	SequenceVariant	rs193302855	These included missense (p.T286M) and nonsense (p.W111X) mutations and a transition in the obligate AG-dinucleotide of the intron 8 acceptor splice site (c.610-2A>G).
BC8_BioRED_Task1_Doc313	607	617	c.610-2A>G	SequenceVariant	rs193302855	These included missense (p.T286M) and nonsense (p.W111X) mutations and a transition in the obligate AG-dinucleotide of the intron 8 acceptor splice site (c.610-2A>G).
BC8_BioRED_Task1_Doc313	677	686	c.611delG	SequenceVariant	rs193302856	Three microdeletions were also identified, two of which (c.611delG and c.640_667del28) were located within the coding region whereas one (c.609+28_610-16del) was located entirely within intron 8.
BC8_BioRED_Task1_Doc313	691	705	c.640_667del28	SequenceVariant	rs193302859	Three microdeletions were also identified, two of which (c.611delG and c.640_667del28) were located within the coding region whereas one (c.609+28_610-16del) was located entirely within intron 8.
BC8_BioRED_Task1_Doc313	758	776	c.609+28_610-16del	SequenceVariant	c|DEL|609+28_610-16|	Three microdeletions were also identified, two of which (c.611delG and c.640_667del28) were located within the coding region whereas one (c.609+28_610-16del) was located entirely within intron 8.
BC8_BioRED_Task1_Doc313	839	849	c.610-2A>G	SequenceVariant	rs193302855	RT-PCR analysis of the c.610-2A>G transition demonstrated that the change altered splicing, leading to the production of two distinct aberrantly spliced forms, viz.
BC8_BioRED_Task1_Doc313	1005	1019	p.G204_K247del	SequenceVariant	p|DEL|204_247|	the skipping of exon 9 (p.G204_K247del) or the retention of introns 8 and 9 (p.G204VfsX28).
BC8_BioRED_Task1_Doc313	1058	1070	p.G204VfsX28	SequenceVariant	p|FS|G|204|V|28	the skipping of exon 9 (p.G204_K247del) or the retention of introns 8 and 9 (p.G204VfsX28).
BC8_BioRED_Task1_Doc313	1105	1112	patient	OrganismTaxon	9606	RT-PCR analysis, performed on a patient homozygous for the intronic deletion (c.609+28_610-16del), failed to detect any GNPTG RNA transcripts.
BC8_BioRED_Task1_Doc313	1151	1169	c.609+28_610-16del	SequenceVariant	c|DEL|609+28_610-16|	RT-PCR analysis, performed on a patient homozygous for the intronic deletion (c.609+28_610-16del), failed to detect any GNPTG RNA transcripts.
BC8_BioRED_Task1_Doc313	1193	1198	GNPTG	Gene	84572	RT-PCR analysis, performed on a patient homozygous for the intronic deletion (c.609+28_610-16del), failed to detect any GNPTG RNA transcripts.
BC8_BioRED_Task1_Doc313	1237	1255	c.609+28_610-16del	SequenceVariant	c|DEL|609+28_610-16|	To determine whether c.609+28_610-16del allele-derived transcripts were subject to nonsense-mediated mRNA decay (NMD), patient fibroblasts were incubated with the protein synthesis inhibitor anisomycin.
BC8_BioRED_Task1_Doc313	1335	1342	patient	OrganismTaxon	9606	To determine whether c.609+28_610-16del allele-derived transcripts were subject to nonsense-mediated mRNA decay (NMD), patient fibroblasts were incubated with the protein synthesis inhibitor anisomycin.
BC8_BioRED_Task1_Doc313	1407	1417	anisomycin	Chemical	D000841	To determine whether c.609+28_610-16del allele-derived transcripts were subject to nonsense-mediated mRNA decay (NMD), patient fibroblasts were incubated with the protein synthesis inhibitor anisomycin.
BC8_BioRED_Task1_Doc313	1512	1534	33-bp genomic deletion	SequenceVariant	g|DEL||33	An RT-PCR fragment retaining 43 bp of intron 8 was consistently detected suggesting that the 33-bp genomic deletion had elicited NMD.
BC8_BioRED_Task1_Doc313	1584	1589	GNPTG	Gene	84572	Quantitative real-time PCR and GNPTG western blot analysis confirmed that the homozygous microdeletion p.G204VfsX17 had elicited NMD resulting in failure to synthesize GNPTG protein.
BC8_BioRED_Task1_Doc313	1656	1668	p.G204VfsX17	SequenceVariant	p|FS|G|204|V|17	Quantitative real-time PCR and GNPTG western blot analysis confirmed that the homozygous microdeletion p.G204VfsX17 had elicited NMD resulting in failure to synthesize GNPTG protein.
BC8_BioRED_Task1_Doc313	1721	1726	GNPTG	Gene	84572	Quantitative real-time PCR and GNPTG western blot analysis confirmed that the homozygous microdeletion p.G204VfsX17 had elicited NMD resulting in failure to synthesize GNPTG protein.
BC8_BioRED_Task1_Doc313	2083	2088	GNPTG	Gene	84572	This is consistent with these repeats having mediated the microdeletions via replication slippage and supports the view that the mutational spectrum of the GNPTG gene is strongly influenced by the properties of the local DNA sequence environment.
BC8_BioRED_Task1_Doc314	6	13	CACNA1S	Gene	779	Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a South American family.
BC8_BioRED_Task1_Doc314	49	79	hypokalemic periodic paralysis	Disease	D020514	Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a South American family.
BC8_BioRED_Task1_Doc314	108	139	Hypokalaemic periodic paralysis	Disease	D020514	Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant disorder, which is characterized by periodic attacks of muscle weakness associated with a decrease in the serum potassium level.
BC8_BioRED_Task1_Doc314	141	147	HypoPP	Disease	D020514	Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant disorder, which is characterized by periodic attacks of muscle weakness associated with a decrease in the serum potassium level.
BC8_BioRED_Task1_Doc314	155	182	autosomal dominant disorder	Disease	D030342	Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant disorder, which is characterized by periodic attacks of muscle weakness associated with a decrease in the serum potassium level.
BC8_BioRED_Task1_Doc314	230	245	muscle weakness	Disease	D018908	Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant disorder, which is characterized by periodic attacks of muscle weakness associated with a decrease in the serum potassium level.
BC8_BioRED_Task1_Doc314	286	295	potassium	Chemical	D011188	Hypokalaemic periodic paralysis (HypoPP) is an autosomal dominant disorder, which is characterized by periodic attacks of muscle weakness associated with a decrease in the serum potassium level.
BC8_BioRED_Task1_Doc314	336	342	HypoPP	Disease	D020514	A major disease-causing gene for HypoPP has been identified as CACNA1S, which encodes the skeletal muscle calcium channel alpha-subunit with four transmembrane domains (I-IV), each with six transmembrane segments (S1-S6).
BC8_BioRED_Task1_Doc314	366	373	CACNA1S	Gene	779	A major disease-causing gene for HypoPP has been identified as CACNA1S, which encodes the skeletal muscle calcium channel alpha-subunit with four transmembrane domains (I-IV), each with six transmembrane segments (S1-S6).
BC8_BioRED_Task1_Doc314	393	438	skeletal muscle calcium channel alpha-subunit	Gene	779	A major disease-causing gene for HypoPP has been identified as CACNA1S, which encodes the skeletal muscle calcium channel alpha-subunit with four transmembrane domains (I-IV), each with six transmembrane segments (S1-S6).
BC8_BioRED_Task1_Doc314	538	545	CACNA1S	Gene	779	To date, all CACNA1S mutations identified in HypoPP patients are located within the voltage-sensor S4 segment.
BC8_BioRED_Task1_Doc314	570	576	HypoPP	Disease	D020514	To date, all CACNA1S mutations identified in HypoPP patients are located within the voltage-sensor S4 segment.
BC8_BioRED_Task1_Doc314	577	585	patients	OrganismTaxon	9606	To date, all CACNA1S mutations identified in HypoPP patients are located within the voltage-sensor S4 segment.
BC8_BioRED_Task1_Doc314	668	675	CACNA1S	Gene	779	In this study we report a novel CACNA1S mutation in a new region of the protein, the S3 segment of domain III.
BC8_BioRED_Task1_Doc314	809	815	HypoPP	Disease	D020514	We characterized a four-generation South American family with HypoPP.
BC8_BioRED_Task1_Doc314	853	858	V876E	SequenceVariant	rs267606698	Genetic analysis identified a novel V876E mutation in all HypoPP patients in the family, but not in normal family members or 160 control people.
BC8_BioRED_Task1_Doc314	875	881	HypoPP	Disease	D020514	Genetic analysis identified a novel V876E mutation in all HypoPP patients in the family, but not in normal family members or 160 control people.
BC8_BioRED_Task1_Doc314	882	890	patients	OrganismTaxon	9606	Genetic analysis identified a novel V876E mutation in all HypoPP patients in the family, but not in normal family members or 160 control people.
BC8_BioRED_Task1_Doc314	1004	1009	V876E	SequenceVariant	rs267606698	Clinical analysis indicates that mutation V876E is associated with a severe outcome as characterized by a very early age of onset, complete penetrance and a severe prognosis including death.
BC8_BioRED_Task1_Doc314	1146	1151	death	Disease	D003643	Clinical analysis indicates that mutation V876E is associated with a severe outcome as characterized by a very early age of onset, complete penetrance and a severe prognosis including death.
BC8_BioRED_Task1_Doc314	1194	1201	CACNA1S	Gene	779	These results identify a new mutation in CACNA1S and expand the spectrum of CACNA1S mutations associated with HypoPP.
BC8_BioRED_Task1_Doc314	1229	1236	CACNA1S	Gene	779	These results identify a new mutation in CACNA1S and expand the spectrum of CACNA1S mutations associated with HypoPP.
BC8_BioRED_Task1_Doc314	1263	1269	HypoPP	Disease	D020514	These results identify a new mutation in CACNA1S and expand the spectrum of CACNA1S mutations associated with HypoPP.
BC8_BioRED_Task1_Doc315	2	8	G1103R	SequenceVariant	rs62636275	A G1103R mutation in CRB1 is co-inherited with high hyperopia and Leber congenital amaurosis.
BC8_BioRED_Task1_Doc315	21	25	CRB1	Gene	23418	A G1103R mutation in CRB1 is co-inherited with high hyperopia and Leber congenital amaurosis.
BC8_BioRED_Task1_Doc315	52	61	hyperopia	Disease	D006956	A G1103R mutation in CRB1 is co-inherited with high hyperopia and Leber congenital amaurosis.
BC8_BioRED_Task1_Doc315	66	92	Leber congenital amaurosis	Disease	D057130	A G1103R mutation in CRB1 is co-inherited with high hyperopia and Leber congenital amaurosis.
BC8_BioRED_Task1_Doc315	161	175	high hyperopia	Disease	C565497	PURPOSE: To identify the genetic basis of recessive inheritance of high hyperopia and Leber congenital amaurosis (LCA) in a family of Middle Eastern origin.
BC8_BioRED_Task1_Doc315	180	206	Leber congenital amaurosis	Disease	D057130	PURPOSE: To identify the genetic basis of recessive inheritance of high hyperopia and Leber congenital amaurosis (LCA) in a family of Middle Eastern origin.
BC8_BioRED_Task1_Doc315	208	211	LCA	Disease	D057130	PURPOSE: To identify the genetic basis of recessive inheritance of high hyperopia and Leber congenital amaurosis (LCA) in a family of Middle Eastern origin.
BC8_BioRED_Task1_Doc315	278	286	patients	OrganismTaxon	9606	MATERIALS AND METHODS: The patients were examined using standard ophthalmic techniques.
BC8_BioRED_Task1_Doc315	465	468	LCA	Disease	D057130	DNA samples were obtained and genetic linkage was carried out using polymorphic markers flanking the known genes and loci for LCA.
BC8_BioRED_Task1_Doc315	559	562	LCA	Disease	D057130	RESULTS: All four members of this family affected by LCA showed high to extreme hyperopia, with average spherical refractive errors ranging from +5.00 to +10.00.
BC8_BioRED_Task1_Doc315	586	595	hyperopia	Disease	D006956	RESULTS: All four members of this family affected by LCA showed high to extreme hyperopia, with average spherical refractive errors ranging from +5.00 to +10.00.
BC8_BioRED_Task1_Doc315	770	774	CRB1	Gene	23418	Linkage was obtained to 1q31.3 with a maximal LOD score of 5.20 and a mutation found in exon 9 of the CRB1 gene, causing a G1103R substitution at a highly conserved site in the protein.
BC8_BioRED_Task1_Doc315	791	797	G1103R	SequenceVariant	rs62636275	Linkage was obtained to 1q31.3 with a maximal LOD score of 5.20 and a mutation found in exon 9 of the CRB1 gene, causing a G1103R substitution at a highly conserved site in the protein.
BC8_BioRED_Task1_Doc315	854	858	CRB1	Gene	23418	CRB1 is a vertebrate homolog of the Drosophila crumbs gene, which is required for photoreceptor morphogenesis, and has been associated with either retinitis pigmentosa (RP) or LCA.
BC8_BioRED_Task1_Doc315	890	900	Drosophila	OrganismTaxon	7227	CRB1 is a vertebrate homolog of the Drosophila crumbs gene, which is required for photoreceptor morphogenesis, and has been associated with either retinitis pigmentosa (RP) or LCA.
BC8_BioRED_Task1_Doc315	901	907	crumbs	Gene	42896	CRB1 is a vertebrate homolog of the Drosophila crumbs gene, which is required for photoreceptor morphogenesis, and has been associated with either retinitis pigmentosa (RP) or LCA.
BC8_BioRED_Task1_Doc315	1001	1021	retinitis pigmentosa	Disease	D012174	CRB1 is a vertebrate homolog of the Drosophila crumbs gene, which is required for photoreceptor morphogenesis, and has been associated with either retinitis pigmentosa (RP) or LCA.
BC8_BioRED_Task1_Doc315	1023	1025	RP	Disease	D012174	CRB1 is a vertebrate homolog of the Drosophila crumbs gene, which is required for photoreceptor morphogenesis, and has been associated with either retinitis pigmentosa (RP) or LCA.
BC8_BioRED_Task1_Doc315	1030	1033	LCA	Disease	D057130	CRB1 is a vertebrate homolog of the Drosophila crumbs gene, which is required for photoreceptor morphogenesis, and has been associated with either retinitis pigmentosa (RP) or LCA.
BC8_BioRED_Task1_Doc315	1129	1132	LCA	Disease	D057130	This sequence variant has previously been reported as a compound heterozygote in one sporadic LCA patient.
BC8_BioRED_Task1_Doc315	1133	1140	patient	OrganismTaxon	9606	This sequence variant has previously been reported as a compound heterozygote in one sporadic LCA patient.
BC8_BioRED_Task1_Doc315	1163	1172	hyperopia	Disease	D006956	CONCLUSION: Although hyperopia has been associated with LCA, it is typically moderate and variable between patients with the same mutation.
BC8_BioRED_Task1_Doc315	1198	1201	LCA	Disease	D057130	CONCLUSION: Although hyperopia has been associated with LCA, it is typically moderate and variable between patients with the same mutation.
BC8_BioRED_Task1_Doc315	1249	1257	patients	OrganismTaxon	9606	CONCLUSION: Although hyperopia has been associated with LCA, it is typically moderate and variable between patients with the same mutation.
BC8_BioRED_Task1_Doc315	1300	1304	CRB1	Gene	23418	In addition, some CRB1 mutations can be associated with either RP or LCA.
BC8_BioRED_Task1_Doc315	1345	1347	RP	Disease	D012174	In addition, some CRB1 mutations can be associated with either RP or LCA.
BC8_BioRED_Task1_Doc315	1351	1354	LCA	Disease	D057130	In addition, some CRB1 mutations can be associated with either RP or LCA.
BC8_BioRED_Task1_Doc315	1375	1384	hyperopia	Disease	D006956	We have shown that hyperopia and LCA are linked to the mutant CRB1 gene itself and are not dependent on unlinked modifiers.
BC8_BioRED_Task1_Doc315	1389	1392	LCA	Disease	D057130	We have shown that hyperopia and LCA are linked to the mutant CRB1 gene itself and are not dependent on unlinked modifiers.
BC8_BioRED_Task1_Doc315	1418	1422	CRB1	Gene	23418	We have shown that hyperopia and LCA are linked to the mutant CRB1 gene itself and are not dependent on unlinked modifiers.
BC8_BioRED_Task1_Doc316	0	28	Catechol-O-methyltransferase	Gene	1312	Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
BC8_BioRED_Task1_Doc316	30	34	COMT	Gene	1312	Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
BC8_BioRED_Task1_Doc316	79	88	Val158Met	SequenceVariant	rs4680	Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
BC8_BioRED_Task1_Doc316	102	118	opiate addiction	Disease	D009293	Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
BC8_BioRED_Task1_Doc316	131	136	women	OrganismTaxon	9606	Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.
BC8_BioRED_Task1_Doc316	138	166	Catechol-O-methyltransferase	Gene	1312	Catechol-O-methyltransferase (COMT) catalyzes the breakdown of catechol neurotransmitters, including dopamine, which plays a prominent role in drug reward.
BC8_BioRED_Task1_Doc316	168	172	COMT	Gene	1312	Catechol-O-methyltransferase (COMT) catalyzes the breakdown of catechol neurotransmitters, including dopamine, which plays a prominent role in drug reward.
BC8_BioRED_Task1_Doc316	201	227	catechol neurotransmitters	Chemical	D002395	Catechol-O-methyltransferase (COMT) catalyzes the breakdown of catechol neurotransmitters, including dopamine, which plays a prominent role in drug reward.
BC8_BioRED_Task1_Doc316	239	247	dopamine	Chemical	D004298	Catechol-O-methyltransferase (COMT) catalyzes the breakdown of catechol neurotransmitters, including dopamine, which plays a prominent role in drug reward.
BC8_BioRED_Task1_Doc316	341	346	G472A	SequenceVariant	rs4680	A common single nucleotide polymorphism (SNP), G472A, codes for a Val158Met substitution and results in a fourfold down regulation of enzyme activity.
BC8_BioRED_Task1_Doc316	360	369	Val158Met	SequenceVariant	rs4680	A common single nucleotide polymorphism (SNP), G472A, codes for a Val158Met substitution and results in a fourfold down regulation of enzyme activity.
BC8_BioRED_Task1_Doc316	469	473	COMT	Gene	1312	We sequenced exon IV of COMT gene in search for novel polymorphisms and then genotyped four out of five identified by direct sequencing, using TaqMan assay on 266 opioid-dependent and 173 control subjects.
BC8_BioRED_Task1_Doc316	608	614	opioid	Chemical	D018847	We sequenced exon IV of COMT gene in search for novel polymorphisms and then genotyped four out of five identified by direct sequencing, using TaqMan assay on 266 opioid-dependent and 173 control subjects.
BC8_BioRED_Task1_Doc316	679	684	G472A	SequenceVariant	rs4680	Genotype frequencies of the G472A SNP varied significantly (P = 0.029) among the three main ethnic/cultural groups (Caucasians, Hispanics, and African Americans).
BC8_BioRED_Task1_Doc316	899	904	G472A	SequenceVariant	rs4680	Using a genotype test, we found a trend to point-wise association (P = 0.053) of the G472A SNP in Hispanic subjects with opiate addiction.
BC8_BioRED_Task1_Doc316	935	951	opiate addiction	Disease	D009293	Using a genotype test, we found a trend to point-wise association (P = 0.053) of the G472A SNP in Hispanic subjects with opiate addiction.
BC8_BioRED_Task1_Doc316	973	978	G472A	SequenceVariant	rs4680	Further analysis of G472A genotypes in Hispanic subjects with data stratified by gender identified a point-wise significant (P = 0.049) association of G/A and A/A genotypes with opiate addiction in women, but not men.
BC8_BioRED_Task1_Doc316	1131	1147	opiate addiction	Disease	D009293	Further analysis of G472A genotypes in Hispanic subjects with data stratified by gender identified a point-wise significant (P = 0.049) association of G/A and A/A genotypes with opiate addiction in women, but not men.
BC8_BioRED_Task1_Doc316	1151	1156	women	OrganismTaxon	9606	Further analysis of G472A genotypes in Hispanic subjects with data stratified by gender identified a point-wise significant (P = 0.049) association of G/A and A/A genotypes with opiate addiction in women, but not men.
BC8_BioRED_Task1_Doc316	1166	1169	men	OrganismTaxon	9606	Further analysis of G472A genotypes in Hispanic subjects with data stratified by gender identified a point-wise significant (P = 0.049) association of G/A and A/A genotypes with opiate addiction in women, but not men.
BC8_BioRED_Task1_Doc317	33	38	DISC1	Gene	27185	Families with the risk allele of DISC1 reveal a link between schizophrenia and another component of the same molecular pathway, NDE1.
BC8_BioRED_Task1_Doc317	61	74	schizophrenia	Disease	D012559	Families with the risk allele of DISC1 reveal a link between schizophrenia and another component of the same molecular pathway, NDE1.
BC8_BioRED_Task1_Doc317	128	132	NDE1	Gene	54820	Families with the risk allele of DISC1 reveal a link between schizophrenia and another component of the same molecular pathway, NDE1.
BC8_BioRED_Task1_Doc317	216	244	Disrupted in Schizophrenia 1	Gene	27185	We have previously reported a robust association between an allelic haplotype of 'Disrupted in Schizophrenia 1' (DISC1) and schizophrenia in a nationwide collection of Finnish schizophrenia families.
BC8_BioRED_Task1_Doc317	247	252	DISC1	Gene	27185	We have previously reported a robust association between an allelic haplotype of 'Disrupted in Schizophrenia 1' (DISC1) and schizophrenia in a nationwide collection of Finnish schizophrenia families.
BC8_BioRED_Task1_Doc317	258	271	schizophrenia	Disease	D012559	We have previously reported a robust association between an allelic haplotype of 'Disrupted in Schizophrenia 1' (DISC1) and schizophrenia in a nationwide collection of Finnish schizophrenia families.
BC8_BioRED_Task1_Doc317	310	323	schizophrenia	Disease	D012559	We have previously reported a robust association between an allelic haplotype of 'Disrupted in Schizophrenia 1' (DISC1) and schizophrenia in a nationwide collection of Finnish schizophrenia families.
BC8_BioRED_Task1_Doc317	348	353	DISC1	Gene	27185	This specific DISC1 allele was later identified to associate with visual working memory, selectively in males.
BC8_BioRED_Task1_Doc317	445	450	DISC1	Gene	27185	DISC1 association to schizophrenia has since been replicated in multiple independent study samples from different populations.
BC8_BioRED_Task1_Doc317	466	479	schizophrenia	Disease	D012559	DISC1 association to schizophrenia has since been replicated in multiple independent study samples from different populations.
BC8_BioRED_Task1_Doc317	691	696	DISC1	Gene	27185	In this study, we conditioned our sample of Finnish families for the presence of the Finnish tentative risk allele for DISC1 and re-analyzed our genome-wide scan data of 443 markers on the basis of this stratification.
BC8_BioRED_Task1_Doc317	915	919	NDE1	Gene	54820	Two additional loci displayed an evidence of linkage (LOD > 3) and included a locus on 16p13, proximal to the gene encoding NDE1, which has been shown to biologically interact with DISC1.
BC8_BioRED_Task1_Doc317	972	977	DISC1	Gene	27185	Two additional loci displayed an evidence of linkage (LOD > 3) and included a locus on 16p13, proximal to the gene encoding NDE1, which has been shown to biologically interact with DISC1.
BC8_BioRED_Task1_Doc317	1110	1114	NDE1	Gene	54820	Although none of the observed linkages remained significant after multiple test correction through simulation, further analysis of NDE1 revealed an association between a tag-haplotype and schizophrenia (P = 0.00046) specific to females, which proved to be significant (P = 0.011) after multiple test correction.
BC8_BioRED_Task1_Doc317	1167	1180	schizophrenia	Disease	D012559	Although none of the observed linkages remained significant after multiple test correction through simulation, further analysis of NDE1 revealed an association between a tag-haplotype and schizophrenia (P = 0.00046) specific to females, which proved to be significant (P = 0.011) after multiple test correction.
BC8_BioRED_Task1_Doc317	1547	1552	DISC1	Gene	27185	Notably, this and other converging lines of evidence underline the importance of DISC1-related functional pathways in the etiology of schizophrenia.
BC8_BioRED_Task1_Doc317	1600	1613	schizophrenia	Disease	D012559	Notably, this and other converging lines of evidence underline the importance of DISC1-related functional pathways in the etiology of schizophrenia.
BC8_BioRED_Task1_Doc318	0	6	L1503R	SequenceVariant	rs61750097	L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
BC8_BioRED_Task1_Doc318	100	103	VWF	Gene	7450	L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
BC8_BioRED_Task1_Doc318	134	142	patients	OrganismTaxon	9606	L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
BC8_BioRED_Task1_Doc318	148	178	type 2A von Willebrand disease	Disease	D056728	L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
BC8_BioRED_Task1_Doc318	180	210	Type 2A von Willebrand disease	Disease	D056728	Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF); this in turn is associated with an absence of high-molecular-weight multimers.
BC8_BioRED_Task1_Doc318	212	215	VWD	Disease	D014842	Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF); this in turn is associated with an absence of high-molecular-weight multimers.
BC8_BioRED_Task1_Doc318	278	299	von Willebrand factor	Gene	7450	Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF); this in turn is associated with an absence of high-molecular-weight multimers.
BC8_BioRED_Task1_Doc318	301	304	VWF	Gene	7450	Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF); this in turn is associated with an absence of high-molecular-weight multimers.
BC8_BioRED_Task1_Doc318	411	414	VWF	Gene	7450	Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain.
BC8_BioRED_Task1_Doc318	439	450	type 2A VWD	Disease	D056728	Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain.
BC8_BioRED_Task1_Doc318	451	459	patients	OrganismTaxon	9606	Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain.
BC8_BioRED_Task1_Doc318	501	538	T-->G transversion at nucleotide 4508	SequenceVariant	rs61750097	Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain.
BC8_BioRED_Task1_Doc318	573	579	L1503R	SequenceVariant	rs61750097	Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain.
BC8_BioRED_Task1_Doc318	587	590	VWF	Gene	7450	Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain.
BC8_BioRED_Task1_Doc318	711	714	VWF	Gene	7450	This substitution, which was not found in 60 unrelated normal individuals, was introduced into a full-length VWF cDNA and subsequently expressed in 293T cells.
BC8_BioRED_Task1_Doc318	750	754	293T	CellLine	CVCL_0063	This substitution, which was not found in 60 unrelated normal individuals, was introduced into a full-length VWF cDNA and subsequently expressed in 293T cells.
BC8_BioRED_Task1_Doc318	794	797	VWF	Gene	7450	Only trace amount of the mutant VWF protein was secreted but most of the same was retained in 293T cells.
BC8_BioRED_Task1_Doc318	856	860	293T	CellLine	CVCL_0063	Only trace amount of the mutant VWF protein was secreted but most of the same was retained in 293T cells.
BC8_BioRED_Task1_Doc318	1038	1041	VWF	Gene	7450	Co-transfection experiment of both wild-type and mutant plasmids indicated the dominant-negative mechanism of disease development; as more of mutant DNA was transfected, VWF secretion was impaired in the media, whereas more of VWF was stored in the cell lysates.
BC8_BioRED_Task1_Doc318	1095	1098	VWF	Gene	7450	Co-transfection experiment of both wild-type and mutant plasmids indicated the dominant-negative mechanism of disease development; as more of mutant DNA was transfected, VWF secretion was impaired in the media, whereas more of VWF was stored in the cell lysates.
BC8_BioRED_Task1_Doc318	1194	1200	L1503R	SequenceVariant	rs61750097	Molecular dynamic simulations of structural changes induced by L1503R indicated that the mean value of all-atom root-mean-squared-deviation was shifted from those with wild type or another mutation L1503Q that has been reported to be a group II mutation, which is susceptible to ADAMTS13 proteolysis.
BC8_BioRED_Task1_Doc318	1329	1335	L1503Q	SequenceVariant	rs61750097	Molecular dynamic simulations of structural changes induced by L1503R indicated that the mean value of all-atom root-mean-squared-deviation was shifted from those with wild type or another mutation L1503Q that has been reported to be a group II mutation, which is susceptible to ADAMTS13 proteolysis.
BC8_BioRED_Task1_Doc318	1410	1418	ADAMTS13	Gene	11093	Molecular dynamic simulations of structural changes induced by L1503R indicated that the mean value of all-atom root-mean-squared-deviation was shifted from those with wild type or another mutation L1503Q that has been reported to be a group II mutation, which is susceptible to ADAMTS13 proteolysis.
BC8_BioRED_Task1_Doc318	1455	1461	L1503R	SequenceVariant	rs61750097	Protein instability of L1503R may be responsible for its intracellular retention and perhaps the larger VWF multimers, containing more mutant VWF subunits, are likely to be mal-processed and retained within the cell.
BC8_BioRED_Task1_Doc318	1536	1539	VWF	Gene	7450	Protein instability of L1503R may be responsible for its intracellular retention and perhaps the larger VWF multimers, containing more mutant VWF subunits, are likely to be mal-processed and retained within the cell.
BC8_BioRED_Task1_Doc318	1574	1577	VWF	Gene	7450	Protein instability of L1503R may be responsible for its intracellular retention and perhaps the larger VWF multimers, containing more mutant VWF subunits, are likely to be mal-processed and retained within the cell.
BC8_BioRED_Task1_Doc319	21	30	verapamil	Chemical	D014700	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
BC8_BioRED_Task1_Doc319	34	60	gastric hemorrhagic ulcers	Disease	D006471,D013276	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
BC8_BioRED_Task1_Doc319	71	86	atherosclerotic	Disease	D050197	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
BC8_BioRED_Task1_Doc319	87	91	rats	OrganismTaxon	10116	Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
BC8_BioRED_Task1_Doc319	133	151	gastric hemorrhage	Disease	D006471	Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.
BC8_BioRED_Task1_Doc319	187	202	atherosclerotic	Disease	D050197	Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.
BC8_BioRED_Task1_Doc319	203	207	rats	OrganismTaxon	10116	Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.
BC8_BioRED_Task1_Doc319	308	317	histamine	Chemical	D006632	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	327	341	lipid peroxide	Chemical	D008054	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	343	346	LPO	Chemical	D008054	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	412	440	gastric hemorrhage and ulcer	Disease	D006471,D013276	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	444	448	rats	OrganismTaxon	10116	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	454	469	atherosclerosis	Disease	D050197	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	501	511	vitamin D2	Chemical	D004872	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	516	527	cholesterol	Chemical	D002784	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
BC8_BioRED_Task1_Doc319	568	577	verapamil	Chemical	D014700	Additionally, the protective effect of verapamil on this ulcer model was evaluated.
BC8_BioRED_Task1_Doc319	586	591	ulcer	Disease	D013276	Additionally, the protective effect of verapamil on this ulcer model was evaluated.
BC8_BioRED_Task1_Doc319	625	629	rats	OrganismTaxon	10116	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
BC8_BioRED_Task1_Doc319	703	711	corn oil	Chemical	D003314	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
BC8_BioRED_Task1_Doc319	723	733	vitamin D2	Chemical	D004872	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
BC8_BioRED_Task1_Doc319	738	749	cholesterol	Chemical	D002784	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
BC8_BioRED_Task1_Doc319	760	775	atherosclerosis	Disease	D050197	Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
BC8_BioRED_Task1_Doc319	785	789	rats	OrganismTaxon	10116	Control rats received corn oil only.
BC8_BioRED_Task1_Doc319	799	807	corn oil	Chemical	D003314	Control rats received corn oil only.
BC8_BioRED_Task1_Doc319	837	840	rat	OrganismTaxon	10116	After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.
BC8_BioRED_Task1_Doc319	964	967	LPO	Chemical	D008054	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
BC8_BioRED_Task1_Doc319	980	989	histamine	Chemical	D006632	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
BC8_BioRED_Task1_Doc319	1033	1040	luminal	Chemical	D010634	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
BC8_BioRED_Task1_Doc319	1041	1051	hemoglobin	Gene	25632	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
BC8_BioRED_Task1_Doc319	1064	1069	ulcer	Disease	D013276	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
BC8_BioRED_Task1_Doc319	1102	1117	atherosclerotic	Disease	D050197	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1144	1151	calcium	Chemical	D002118	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1159	1170	cholesterol	Chemical	D002784	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1175	1198	low-density lipoprotein	Chemical	D008077	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1230	1245	atherosclerotic	Disease	D050197	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1246	1250	rats	OrganismTaxon	10116	Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1259	1273	gastric ulcers	Disease	D013276	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
BC8_BioRED_Task1_Doc319	1361	1370	histamine	Chemical	D006632	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
BC8_BioRED_Task1_Doc319	1380	1383	LPO	Chemical	D008054	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
BC8_BioRED_Task1_Doc319	1399	1406	luminal	Chemical	D010634	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
BC8_BioRED_Task1_Doc319	1407	1417	hemoglobin	Gene	25632	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
BC8_BioRED_Task1_Doc319	1454	1458	rats	OrganismTaxon	10116	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
BC8_BioRED_Task1_Doc319	1496	1505	histamine	Chemical	D006632	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1509	1527	gastric hemorrhage	Disease	D006471	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1535	1540	ulcer	Disease	D013276	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1560	1575	atherosclerotic	Disease	D050197	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1576	1580	rats	OrganismTaxon	10116	Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
BC8_BioRED_Task1_Doc319	1587	1604	hemorrhagic ulcer	Disease	D006471,D013276	This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.
BC8_BioRED_Task1_Doc319	1696	1705	verapamil	Chemical	D014700	This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.
BC8_BioRED_Task1_Doc319	1707	1722	Atherosclerosis	Disease	D050197	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
BC8_BioRED_Task1_Doc319	1737	1762	gastric hemorrhagic ulcer	Disease	D006471,D013276	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
BC8_BioRED_Task1_Doc319	1811	1814	LPO	Chemical	D008054	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
BC8_BioRED_Task1_Doc319	1827	1836	histamine	Chemical	D006632	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
BC8_BioRED_Task1_Doc319	1905	1914	verapamil	Chemical	D014700	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
BC8_BioRED_Task1_Doc319	1918	1922	rats	OrganismTaxon	10116	Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.
BC8_BioRED_Task1_Doc320	0	5	TIPE2	Gene	79626	TIPE2 Inhibits Lung Cancer Growth Attributing to Promotion of Apoptosis by Regulating Some Apoptotic Molecules Expression.
BC8_BioRED_Task1_Doc320	15	26	Lung Cancer	Disease	D008175	TIPE2 Inhibits Lung Cancer Growth Attributing to Promotion of Apoptosis by Regulating Some Apoptotic Molecules Expression.
BC8_BioRED_Task1_Doc320	149	154	TIPE2	Gene	79626	Recent studies found that TIPE2 was involved in cancer development.
BC8_BioRED_Task1_Doc320	171	177	cancer	Disease	D009369	Recent studies found that TIPE2 was involved in cancer development.
BC8_BioRED_Task1_Doc320	222	227	TIPE2	Gene	79626	However, little is known about TIPE2 in lung cancer.
BC8_BioRED_Task1_Doc320	231	242	lung cancer	Disease	D008175	However, little is known about TIPE2 in lung cancer.
BC8_BioRED_Task1_Doc320	282	287	TIPE2	Gene	79626	Our study aims to clarify the role of TIPE2 in lung carcinogenesis.
BC8_BioRED_Task1_Doc320	291	310	lung carcinogenesis	Disease	D008175	Our study aims to clarify the role of TIPE2 in lung carcinogenesis.
BC8_BioRED_Task1_Doc320	342	347	TIPE2	Gene	79626	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	351	371	lung squamous cancer	Disease	D002289	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	373	376	LSC	Disease	D002289	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	379	401	small cell lung cancer	Disease	D055752	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	406	425	lung adenocarcinoma	Disease	D000077192	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	427	430	AdC	Disease	D000077192	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	455	460	TIPE2	Gene	79626	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	484	506	small cell lung cancer	Disease	D055752	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	535	540	tumor	Disease	D009369	We examined the expression of TIPE2 in lung squamous cancer (LSC), small cell lung cancer and lung adenocarcinoma (AdC) tissues and found that TIPE2 expression was lost in small cell lung cancer, compared with adjacent non-tumor tissues.
BC8_BioRED_Task1_Doc320	568	573	TIPE2	Gene	79626	Overexpression of TIPE2 significantly inhibited the growth of lung cancer cell H446 in vitro and even suppressed tumor formation in vivo.
BC8_BioRED_Task1_Doc320	612	623	lung cancer	Disease	D008175	Overexpression of TIPE2 significantly inhibited the growth of lung cancer cell H446 in vitro and even suppressed tumor formation in vivo.
BC8_BioRED_Task1_Doc320	629	633	H446	CellLine	CVCL_1562	Overexpression of TIPE2 significantly inhibited the growth of lung cancer cell H446 in vitro and even suppressed tumor formation in vivo.
BC8_BioRED_Task1_Doc320	663	668	tumor	Disease	D009369	Overexpression of TIPE2 significantly inhibited the growth of lung cancer cell H446 in vitro and even suppressed tumor formation in vivo.
BC8_BioRED_Task1_Doc320	718	723	TIPE2	Gene	79626	Flow cytometry analysis found TIPE2 overexpression promoted apoptosis of H446.
BC8_BioRED_Task1_Doc320	761	765	H446	CellLine	CVCL_1562	Flow cytometry analysis found TIPE2 overexpression promoted apoptosis of H446.
BC8_BioRED_Task1_Doc320	770	775	TIPE2	Gene	79626	In TIPE2 over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated.
BC8_BioRED_Task1_Doc320	799	808	caspase-3	Gene	836	In TIPE2 over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated.
BC8_BioRED_Task1_Doc320	810	819	caspase-9	Gene	842	In TIPE2 over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated.
BC8_BioRED_Task1_Doc320	825	828	Bax	Gene	581	In TIPE2 over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated.
BC8_BioRED_Task1_Doc320	867	872	Bcl-2	Gene	596	In TIPE2 over-expression cells, caspase-3, caspase-9, and Bax were significantly up-regulated while Bcl-2 was down-regulated.
BC8_BioRED_Task1_Doc320	960	966	tumors	Disease	D009369	Moreover, coincident results were shown by immunohistochemistry in tumors from nude mice.
BC8_BioRED_Task1_Doc320	977	981	mice	OrganismTaxon	10090	Moreover, coincident results were shown by immunohistochemistry in tumors from nude mice.
BC8_BioRED_Task1_Doc320	983	988	TIPE2	Gene	79626	TIPE2 inhibited the phosphorylation of Akt, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway.
BC8_BioRED_Task1_Doc320	1022	1025	Akt	Gene	207	TIPE2 inhibited the phosphorylation of Akt, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway.
BC8_BioRED_Task1_Doc320	1066	1069	P38	Gene	1432	TIPE2 inhibited the phosphorylation of Akt, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway.
BC8_BioRED_Task1_Doc320	1092	1096	IkBa	Gene	4792	TIPE2 inhibited the phosphorylation of Akt, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway.
BC8_BioRED_Task1_Doc320	1101	1104	ERK	Gene	5594	TIPE2 inhibited the phosphorylation of Akt, while promoting the phosphorylation of P38, but had no effect on IkBa and ERK pathway.
BC8_BioRED_Task1_Doc320	1130	1135	TIPE2	Gene	79626	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1145	1156	lung cancer	Disease	D008175	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1218	1227	caspase-3	Gene	836	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1229	1238	caspase-9	Gene	842	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1240	1245	Bcl-2	Gene	596	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1250	1253	Bax	Gene	581	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1279	1282	P38	Gene	1432	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1287	1290	Akt	Gene	207	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1317	1322	TIPE2	Gene	79626	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc320	1351	1362	lung cancer	Disease	D008175	Taken together, TIPE2 promoted lung cancer cell apoptosis through affecting apoptosis-related molecules caspase-3, caspase-9, Bcl-2 and Bax, possibly via regulating P38 and Akt pathways, indicating that TIPE2 might be a novel marker for lung cancer diagnosis and therapy.
BC8_BioRED_Task1_Doc321	4	6	FH	Gene	2271	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
BC8_BioRED_Task1_Doc321	48	66	fumarate hydratase	Gene	2271	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
BC8_BioRED_Task1_Doc321	93	97	MCUL	Disease	C535516	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
BC8_BioRED_Task1_Doc321	99	104	HLRCC	Disease	C535516	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
BC8_BioRED_Task1_Doc321	106	120	tumor syndrome	Disease	D009369	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
BC8_BioRED_Task1_Doc321	136	155	fumarase deficiency	Disease	C538191	The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
BC8_BioRED_Task1_Doc321	169	187	Fumarate hydratase	Gene	2271	BACKGROUND: Fumarate hydratase (HGNC approved gene symbol - FH), also known as fumarase, is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy production.
BC8_BioRED_Task1_Doc321	217	219	FH	Gene	2271	BACKGROUND: Fumarate hydratase (HGNC approved gene symbol - FH), also known as fumarase, is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy production.
BC8_BioRED_Task1_Doc321	236	244	fumarase	Gene	2271	BACKGROUND: Fumarate hydratase (HGNC approved gene symbol - FH), also known as fumarase, is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy production.
BC8_BioRED_Task1_Doc321	266	284	tricarboxylic acid	Chemical	D014233	BACKGROUND: Fumarate hydratase (HGNC approved gene symbol - FH), also known as fumarase, is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy production.
BC8_BioRED_Task1_Doc321	286	289	TCA	Chemical	D014233	BACKGROUND: Fumarate hydratase (HGNC approved gene symbol - FH), also known as fumarase, is an enzyme of the tricarboxylic acid (TCA) cycle, involved in fundamental cellular energy production.
BC8_BioRED_Task1_Doc321	389	405	deficiency of FH	Disease	C538191	First described by Zinn et al in 1986, deficiency of FH results in early onset, severe encephalopathy.
BC8_BioRED_Task1_Doc321	437	451	encephalopathy	Disease	D001927	First described by Zinn et al in 1986, deficiency of FH results in early onset, severe encephalopathy.
BC8_BioRED_Task1_Doc321	475	484	Leiomyoma	Disease	D007889	In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800).
BC8_BioRED_Task1_Doc321	542	544	FH	Gene	2271	In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800).
BC8_BioRED_Task1_Doc321	548	556	patients	OrganismTaxon	9606	In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800).
BC8_BioRED_Task1_Doc321	562	603	multiple cutaneous and uterine leiomyomas	Disease	C535516	In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800).
BC8_BioRED_Task1_Doc321	606	610	MCUL	Disease	C535516	In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800).
BC8_BioRED_Task1_Doc321	612	623	OMIM 150800	Disease	C535516	In 2002, the Multiple Leiomyoma Consortium identified heterozygous germline mutations of FH in patients with multiple cutaneous and uterine leiomyomas, (MCUL: OMIM 150800).
BC8_BioRED_Task1_Doc321	643	660	renal cell cancer	Disease	D002292	In some families renal cell cancer also forms a component of the complex and as such has been described as hereditary leiomyomatosis and renal cell cancer (HLRCC: OMIM 605839).
BC8_BioRED_Task1_Doc321	733	780	hereditary leiomyomatosis and renal cell cancer	Disease	C535516	In some families renal cell cancer also forms a component of the complex and as such has been described as hereditary leiomyomatosis and renal cell cancer (HLRCC: OMIM 605839).
BC8_BioRED_Task1_Doc321	782	787	HLRCC	Disease	C535516	In some families renal cell cancer also forms a component of the complex and as such has been described as hereditary leiomyomatosis and renal cell cancer (HLRCC: OMIM 605839).
BC8_BioRED_Task1_Doc321	789	800	OMIM 605839	Disease	C535516	In some families renal cell cancer also forms a component of the complex and as such has been described as hereditary leiomyomatosis and renal cell cancer (HLRCC: OMIM 605839).
BC8_BioRED_Task1_Doc321	825	827	FH	Gene	2271	The identification of FH as a tumor suppressor was an unexpected finding and following the identification of subunits of succinate dehydrogenase in 2000 and 2001, was only the second description of the involvement of an enzyme of intermediary metabolism in tumorigenesis.
BC8_BioRED_Task1_Doc321	833	838	tumor	Disease	D009369	The identification of FH as a tumor suppressor was an unexpected finding and following the identification of subunits of succinate dehydrogenase in 2000 and 2001, was only the second description of the involvement of an enzyme of intermediary metabolism in tumorigenesis.
BC8_BioRED_Task1_Doc321	1060	1073	tumorigenesis	Disease	D009369	The identification of FH as a tumor suppressor was an unexpected finding and following the identification of subunits of succinate dehydrogenase in 2000 and 2001, was only the second description of the involvement of an enzyme of intermediary metabolism in tumorigenesis.
BC8_BioRED_Task1_Doc321	1092	1094	FH	Gene	2271	DESCRIPTION: The FH mutation database is a part of the TCA cycle gene mutation database (formerly the succinate dehydrogenase gene mutation database) and is based on the Leiden Open (source) Variation Database (LOVD) system.
BC8_BioRED_Task1_Doc321	1130	1133	TCA	Chemical	D014233	DESCRIPTION: The FH mutation database is a part of the TCA cycle gene mutation database (formerly the succinate dehydrogenase gene mutation database) and is based on the Leiden Open (source) Variation Database (LOVD) system.
BC8_BioRED_Task1_Doc321	1444	1446	FH	Gene	2271	The FH database applies HGVS nomenclature guidelines, and will assist researchers in applying these guidelines when directly submitting new sequence variants online.
BC8_BioRED_Task1_Doc321	1655	1657	FH	Gene	2271	Since the first molecular characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.
BC8_BioRED_Task1_Doc321	1723	1736	FH deficiency	Disease	C538191	Since the first molecular characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.
BC8_BioRED_Task1_Doc321	1737	1745	patients	OrganismTaxon	9606	Since the first molecular characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.
BC8_BioRED_Task1_Doc321	1750	1758	patients	OrganismTaxon	9606	Since the first molecular characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.
BC8_BioRED_Task1_Doc321	1764	1768	MCUL	Disease	C535516	Since the first molecular characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.
BC8_BioRED_Task1_Doc321	1769	1774	HLRRC	Disease	C535516	Since the first molecular characterization of an FH mutation by Bourgeron et al in 1994, a series of reports of both FH deficiency patients and patients with MCUL/HLRRC have described 107 variants, of which 93 are thought to be pathogenic.
BC8_BioRED_Task1_Doc321	2052	2054	FH	Gene	2271	Here we introduce an online database detailing all reported FH sequence variants.
BC8_BioRED_Task1_Doc321	2090	2092	FH	Gene	2271	CONCLUSION: The FH mutation database strives to systematically unify all current genetic knowledge of FH variants.
BC8_BioRED_Task1_Doc321	2176	2178	FH	Gene	2271	CONCLUSION: The FH mutation database strives to systematically unify all current genetic knowledge of FH variants.
BC8_BioRED_Task1_Doc321	2291	2299	patients	OrganismTaxon	9606	We believe that this knowledge will assist clinical geneticists and treating physicians when advising patients and their families, will provide a rapid and convenient resource for research scientists, and may eventually assist in gaining novel insights into FH and its related clinical syndromes.
BC8_BioRED_Task1_Doc321	2447	2449	FH	Gene	2271	We believe that this knowledge will assist clinical geneticists and treating physicians when advising patients and their families, will provide a rapid and convenient resource for research scientists, and may eventually assist in gaining novel insights into FH and its related clinical syndromes.
BC8_BioRED_Task1_Doc322	531	546	cystic fibrosis	Disease	D003550	We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients homozygous for the E831X mutation (2623G>T) in the CFTR gene.
BC8_BioRED_Task1_Doc322	547	555	patients	OrganismTaxon	9606	We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients homozygous for the E831X mutation (2623G>T) in the CFTR gene.
BC8_BioRED_Task1_Doc322	575	580	E831X	SequenceVariant	rs397508387	We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients homozygous for the E831X mutation (2623G>T) in the CFTR gene.
BC8_BioRED_Task1_Doc322	591	598	2623G>T	SequenceVariant	rs397508387	We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients homozygous for the E831X mutation (2623G>T) in the CFTR gene.
BC8_BioRED_Task1_Doc322	607	611	CFTR	Gene	1080	We identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients homozygous for the E831X mutation (2623G>T) in the CFTR gene.
BC8_BioRED_Task1_Doc323	33	43	etoricoxib	Chemical	D000077613	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
BC8_BioRED_Task1_Doc323	47	67	rheumatoid arthritis	Disease	D001172	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
BC8_BioRED_Task1_Doc323	68	76	patients	OrganismTaxon	9606	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
BC8_BioRED_Task1_Doc323	93	103	etoricoxib	Chemical	D000077613	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
BC8_BioRED_Task1_Doc323	107	124	diclofenac sodium	Chemical	D004008	Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
BC8_BioRED_Task1_Doc323	308	318	etoricoxib	Chemical	D000077613	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc323	323	333	diclofenac	Chemical	D004008	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc323	337	345	patients	OrganismTaxon	9606	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc323	351	371	rheumatoid arthritis	Disease	D001172	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc323	373	375	RA	Disease	D001172	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc323	378	386	PATIENTS	OrganismTaxon	9606	PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
BC8_BioRED_Task1_Doc323	416	424	patients	OrganismTaxon	9606	PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
BC8_BioRED_Task1_Doc323	462	464	RA	Disease	D001172	PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
BC8_BioRED_Task1_Doc323	492	502	etoricoxib	Chemical	D000077613	PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
BC8_BioRED_Task1_Doc323	529	539	diclofenac	Chemical	D004008	PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
BC8_BioRED_Task1_Doc323	614	621	aspirin	Chemical	D001241	Use of gastroprotective agents and low-dose aspirin was allowed.
BC8_BioRED_Task1_Doc323	706	713	patient	OrganismTaxon	9606	The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
BC8_BioRED_Task1_Doc323	762	784	GI adverse experiences	Disease	D005767	The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
BC8_BioRED_Task1_Doc323	848	873	thrombotic cardiovascular	Disease	D002318	General safety was also assessed, including adjudicated thrombotic cardiovascular event data.
BC8_BioRED_Task1_Doc323	919	926	Patient	OrganismTaxon	9606	Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
BC8_BioRED_Task1_Doc323	1097	1107	etoricoxib	Chemical	D000077613	RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
BC8_BioRED_Task1_Doc323	1112	1122	diclofenac	Chemical	D004008	RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.
BC8_BioRED_Task1_Doc323	1188	1194	GI AEs	Disease	D005767	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
BC8_BioRED_Task1_Doc323	1224	1234	etoricoxib	Chemical	D000077613	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
BC8_BioRED_Task1_Doc323	1240	1250	diclofenac	Chemical	D004008	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
BC8_BioRED_Task1_Doc323	1278	1285	patient	OrganismTaxon	9606	The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
BC8_BioRED_Task1_Doc323	1398	1410	hypertension	Disease	D006973	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
BC8_BioRED_Task1_Doc323	1423	1429	oedema	Disease	D004487	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
BC8_BioRED_Task1_Doc323	1473	1483	etoricoxib	Chemical	D000077613	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
BC8_BioRED_Task1_Doc323	1527	1537	diclofenac	Chemical	D004008	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
BC8_BioRED_Task1_Doc323	1579	1591	hypertension	Disease	D006973	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
BC8_BioRED_Task1_Doc323	1607	1613	oedema	Disease	D004487	The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
BC8_BioRED_Task1_Doc323	1616	1626	Etoricoxib	Chemical	D000077613	Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
BC8_BioRED_Task1_Doc323	1631	1641	diclofenac	Chemical	D004008	Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
BC8_BioRED_Task1_Doc323	1759	1769	Etoricoxib	Chemical	D000077613	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
BC8_BioRED_Task1_Doc323	1851	1857	GI AEs	Disease	D005767	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
BC8_BioRED_Task1_Doc323	1872	1882	diclofenac	Chemical	D004008	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
BC8_BioRED_Task1_Doc323	1979	1985	GI AEs	Disease	D005767	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
BC8_BioRED_Task1_Doc323	2018	2028	etoricoxib	Chemical	D000077613	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.
BC8_BioRED_Task1_Doc324	8	12	IRF6	Gene	3664	A novel IRF6 nonsense mutation (Y67X) in a German family with Van der Woude syndrome.
BC8_BioRED_Task1_Doc324	32	36	Y67X	SequenceVariant	p|SUB|Y|67|X	A novel IRF6 nonsense mutation (Y67X) in a German family with Van der Woude syndrome.
BC8_BioRED_Task1_Doc324	62	84	Van der Woude syndrome	Disease	C536528	A novel IRF6 nonsense mutation (Y67X) in a German family with Van der Woude syndrome.
BC8_BioRED_Task1_Doc324	86	108	Van der Woude syndrome	Disease	C536528	Van der Woude syndrome (VWS) is the most common type of syndromic orofacial cleft, which accounts for approximately 2% of all cleft lip and palate cases.
BC8_BioRED_Task1_Doc324	110	113	VWS	Disease	C536528	Van der Woude syndrome (VWS) is the most common type of syndromic orofacial cleft, which accounts for approximately 2% of all cleft lip and palate cases.
BC8_BioRED_Task1_Doc324	142	167	syndromic orofacial cleft	Disease	D002972	Van der Woude syndrome (VWS) is the most common type of syndromic orofacial cleft, which accounts for approximately 2% of all cleft lip and palate cases.
BC8_BioRED_Task1_Doc324	212	232	cleft lip and palate	Disease	D002971,D002972	Van der Woude syndrome (VWS) is the most common type of syndromic orofacial cleft, which accounts for approximately 2% of all cleft lip and palate cases.
BC8_BioRED_Task1_Doc324	293	301	lip pits	Disease	C536528	It is characterised by variable association of lower lip pits, cleft lip and cleft palate, and hypodontia.
BC8_BioRED_Task1_Doc324	303	312	cleft lip	Disease	D002971	It is characterised by variable association of lower lip pits, cleft lip and cleft palate, and hypodontia.
BC8_BioRED_Task1_Doc324	317	329	cleft palate	Disease	D002972	It is characterised by variable association of lower lip pits, cleft lip and cleft palate, and hypodontia.
BC8_BioRED_Task1_Doc324	335	345	hypodontia	Disease	D000848	It is characterised by variable association of lower lip pits, cleft lip and cleft palate, and hypodontia.
BC8_BioRED_Task1_Doc324	347	350	VWS	Disease	C536528	VWS arises as the result of mutations in the gene encoding interferon regulatory factor 6 (IRF6).
BC8_BioRED_Task1_Doc324	406	436	interferon regulatory factor 6	Gene	3664	VWS arises as the result of mutations in the gene encoding interferon regulatory factor 6 (IRF6).
BC8_BioRED_Task1_Doc324	438	442	IRF6	Gene	3664	VWS arises as the result of mutations in the gene encoding interferon regulatory factor 6 (IRF6).
BC8_BioRED_Task1_Doc324	586	590	IRF6	Gene	3664	Very recently, mutations of the IRF6 gene in exons 2-9 have been found in VWS patients, suggesting that this gene plays an important role in orofacial development.
BC8_BioRED_Task1_Doc324	628	631	VWS	Disease	C536528	Very recently, mutations of the IRF6 gene in exons 2-9 have been found in VWS patients, suggesting that this gene plays an important role in orofacial development.
BC8_BioRED_Task1_Doc324	632	640	patients	OrganismTaxon	9606	Very recently, mutations of the IRF6 gene in exons 2-9 have been found in VWS patients, suggesting that this gene plays an important role in orofacial development.
BC8_BioRED_Task1_Doc324	752	756	IRF6	Gene	3664	We report a novel mutation of the IRF6 gene in a German family.
BC8_BioRED_Task1_Doc324	904	908	IRF6	Gene	3664	The mutation produced a stop codon within exon 4 of the IRF6 gene.
BC8_BioRED_Task1_Doc324	921	929	patients	OrganismTaxon	9606	All 5 patients were heterozygous for a base substitution c.201C>A changing the tyrosine codon at amino acid position 67 into a stop codon (p.Y67X) in exon 4.
BC8_BioRED_Task1_Doc324	972	980	c.201C>A	SequenceVariant	c|SUB|C|201|A	All 5 patients were heterozygous for a base substitution c.201C>A changing the tyrosine codon at amino acid position 67 into a stop codon (p.Y67X) in exon 4.
BC8_BioRED_Task1_Doc324	994	1046	tyrosine codon at amino acid position 67 into a stop	SequenceVariant	p|SUB|Y|67|X	All 5 patients were heterozygous for a base substitution c.201C>A changing the tyrosine codon at amino acid position 67 into a stop codon (p.Y67X) in exon 4.
BC8_BioRED_Task1_Doc324	1054	1060	p.Y67X	SequenceVariant	p|SUB|Y|67|X	All 5 patients were heterozygous for a base substitution c.201C>A changing the tyrosine codon at amino acid position 67 into a stop codon (p.Y67X) in exon 4.
BC8_BioRED_Task1_Doc324	1196	1200	Smad	Gene	4086	The premature stop codon was responsible for a truncated protein lacking parts of the DNA- binding domain and the complete Smad-interferon regulatory factor-binding domain probably essential for interactions with the Smad transcription factors.
BC8_BioRED_Task1_Doc324	1201	1229	interferon regulatory factor	Gene	3664	The premature stop codon was responsible for a truncated protein lacking parts of the DNA- binding domain and the complete Smad-interferon regulatory factor-binding domain probably essential for interactions with the Smad transcription factors.
BC8_BioRED_Task1_Doc324	1290	1294	Smad	Gene	4086	The premature stop codon was responsible for a truncated protein lacking parts of the DNA- binding domain and the complete Smad-interferon regulatory factor-binding domain probably essential for interactions with the Smad transcription factors.
BC8_BioRED_Task1_Doc325	0	17	Neuregulin-1 beta	Gene	3084	Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.
BC8_BioRED_Task1_Doc325	22	40	neuregulin-1 alpha	Gene	3084	Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.
BC8_BioRED_Task1_Doc325	93	132	malignant peripheral nerve sheath tumor	Disease	D018319	Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.
BC8_BioRED_Task1_Doc325	140	180	Malignant peripheral nerve sheath tumors	Disease	D018319	Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with neurofibromatosis Type 1 (NF1).
BC8_BioRED_Task1_Doc325	182	188	MPNSTs	Disease	D018319	Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with neurofibromatosis Type 1 (NF1).
BC8_BioRED_Task1_Doc325	210	220	malignancy	Disease	D009369	Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with neurofibromatosis Type 1 (NF1).
BC8_BioRED_Task1_Doc325	237	261	neurofibromatosis Type 1	Gene	4763	Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with neurofibromatosis Type 1 (NF1).
BC8_BioRED_Task1_Doc325	263	266	NF1	Gene	4763	Malignant peripheral nerve sheath tumors (MPNSTs) are the most common malignancy associated with neurofibromatosis Type 1 (NF1).
BC8_BioRED_Task1_Doc325	304	312	sarcomas	Disease	D012509	These Schwann cell lineage-derived sarcomas aggressively invade adjacent nerve and soft tissue, frequently precluding surgical resection.
BC8_BioRED_Task1_Doc325	502	508	MPNSTs	Disease	D018319	We have shown that MPNSTs express neuregulin-1 (NRG-1) beta isoforms, which promote Schwann cell migration during development, and NRG-1 alpha isoforms, whose effects on Schwann cells are poorly understood.
BC8_BioRED_Task1_Doc325	517	542	neuregulin-1 (NRG-1) beta	Gene	3084	We have shown that MPNSTs express neuregulin-1 (NRG-1) beta isoforms, which promote Schwann cell migration during development, and NRG-1 alpha isoforms, whose effects on Schwann cells are poorly understood.
BC8_BioRED_Task1_Doc325	614	625	NRG-1 alpha	Gene	3084	We have shown that MPNSTs express neuregulin-1 (NRG-1) beta isoforms, which promote Schwann cell migration during development, and NRG-1 alpha isoforms, whose effects on Schwann cells are poorly understood.
BC8_BioRED_Task1_Doc325	709	719	NRG-1 beta	Gene	3084	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	727	738	NRG-1 alpha	Gene	3084	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	747	752	MPNST	Disease	D018319	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	777	787	NRG-1 beta	Gene	3084	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	797	802	MPNST	Disease	D018319	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	877	884	laminin	Gene	16777	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	896	911	collagen type I	Gene	1277,1278	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	915	926	fibronectin	Gene	2335	Hypothesizing that NRG-1 beta and/or NRG-1 alpha promote MPNST invasion, we found that NRG-1 beta promoted MPNST migration in a substrate-specific manner, markedly enhancing migration on laminin but not on collagen type I or fibronectin.
BC8_BioRED_Task1_Doc325	932	937	NRG-1	Gene	3084	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	948	953	erbB3	Gene	13867,2065	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	958	963	erbB4	Gene	13869,2066	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	980	985	MPNST	Disease	D018319	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	1057	1078	focal adhesion kinase	Gene	5747	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	1087	1103	laminin receptor	Gene	3688	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	1104	1120	beta(1)-integrin	Gene	3688	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	1151	1167	beta(1)-integrin	Gene	3688	The NRG-1 receptors erbB3 and erbB4 were present in MPNST invadopodia (processes mediating invasion), partially colocalized with focal adhesion kinase and the laminin receptor beta(1)-integrin and coimmunoprecipitated with beta(1)-integrin.
BC8_BioRED_Task1_Doc325	1169	1179	NRG-1 beta	Gene	3084	NRG-1 beta stimulated human and murine MPNST cell migration and invasion in a concentration-dependent manner in three-dimensional migration assays, acting as a chemotactic factor.
BC8_BioRED_Task1_Doc325	1191	1196	human	OrganismTaxon	9606	NRG-1 beta stimulated human and murine MPNST cell migration and invasion in a concentration-dependent manner in three-dimensional migration assays, acting as a chemotactic factor.
BC8_BioRED_Task1_Doc325	1201	1207	murine	OrganismTaxon	10090	NRG-1 beta stimulated human and murine MPNST cell migration and invasion in a concentration-dependent manner in three-dimensional migration assays, acting as a chemotactic factor.
BC8_BioRED_Task1_Doc325	1208	1213	MPNST	Disease	D018319	NRG-1 beta stimulated human and murine MPNST cell migration and invasion in a concentration-dependent manner in three-dimensional migration assays, acting as a chemotactic factor.
BC8_BioRED_Task1_Doc325	1367	1377	NRG-1 beta	Gene	3084	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1401	1405	erbB	Gene	13867,13869,2065,2066	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1443	1450	MEK 1/2	Gene	26395,26396,5604,5605	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1452	1456	SAPK	Gene	26419,5599	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1457	1460	JNK	Gene	26419,5599	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1462	1473	PI-3 kinase	Gene	30955,5290	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1475	1493	Src family kinases	Gene	20779,6714	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1498	1507	ROCK-I/II	Gene	19877,19878,6093,9475	Both baseline and NRG-1 beta-induced migration were erbB-dependent and required the action of MEK 1/2, SAPK/JNK, PI-3 kinase, Src family kinases and ROCK-I/II.
BC8_BioRED_Task1_Doc325	1522	1533	NRG-1 alpha	Gene	3084	In contrast, NRG-1 alpha had no effect on the migration and invasion of some MPNST lines and inhibited the migration of others.
BC8_BioRED_Task1_Doc325	1586	1591	MPNST	Disease	D018319	In contrast, NRG-1 alpha had no effect on the migration and invasion of some MPNST lines and inhibited the migration of others.
BC8_BioRED_Task1_Doc325	1643	1653	NRG-1 beta	Gene	3084	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1690	1697	Erk 1/2	Gene	26413,26417,5594,5595	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1699	1703	SAPK	Gene	26419,5599	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1704	1707	JNK	Gene	26419,5599	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1709	1712	Akt	Gene	11651,207	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1717	1735	Src family kinases	Gene	20779,6714	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1737	1748	NRG-1 alpha	Gene	3084	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1766	1769	Akt	Gene	11651,207	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1849	1859	NRG-1 beta	Gene	3084	While NRG-1 beta potently and persistently activated Erk 1/2, SAPK/JNK, Akt and Src family kinases, NRG-1 alpha did not activate Akt and activated these other kinases with kinetics distinct from those evident in NRG-1 beta-stimulated cells.
BC8_BioRED_Task1_Doc325	1906	1916	NRG-1 beta	Gene	3084	These findings suggest that NRG-1 beta enhances MPNST migration and that NRG-1 beta and NRG-1 alpha differentially modulate this process.
BC8_BioRED_Task1_Doc325	1926	1931	MPNST	Disease	D018319	These findings suggest that NRG-1 beta enhances MPNST migration and that NRG-1 beta and NRG-1 alpha differentially modulate this process.
BC8_BioRED_Task1_Doc325	1951	1961	NRG-1 beta	Gene	3084	These findings suggest that NRG-1 beta enhances MPNST migration and that NRG-1 beta and NRG-1 alpha differentially modulate this process.
BC8_BioRED_Task1_Doc325	1966	1977	NRG-1 alpha	Gene	3084	These findings suggest that NRG-1 beta enhances MPNST migration and that NRG-1 beta and NRG-1 alpha differentially modulate this process.
BC8_BioRED_Task1_Doc326	26	47	nitric oxide synthase	Gene	4843	The promoter of inducible nitric oxide synthase implicated in glaucoma based on genetic analysis and nuclear factor binding.
BC8_BioRED_Task1_Doc326	62	70	glaucoma	Disease	D005901	The promoter of inducible nitric oxide synthase implicated in glaucoma based on genetic analysis and nuclear factor binding.
BC8_BioRED_Task1_Doc326	134	146	Nitric oxide	Chemical	D009569	PURPOSE: Nitric oxide has many beneficial functions in the human body at the right amounts, but it can also be hazardous if it is produced in amounts more than needed and has therefore been studied in relation to several neurological and non-neurological disorders.
BC8_BioRED_Task1_Doc326	184	189	human	OrganismTaxon	9606	PURPOSE: Nitric oxide has many beneficial functions in the human body at the right amounts, but it can also be hazardous if it is produced in amounts more than needed and has therefore been studied in relation to several neurological and non-neurological disorders.
BC8_BioRED_Task1_Doc326	346	389	neurological and non-neurological disorders	Disease	D009422	PURPOSE: Nitric oxide has many beneficial functions in the human body at the right amounts, but it can also be hazardous if it is produced in amounts more than needed and has therefore been studied in relation to several neurological and non-neurological disorders.
BC8_BioRED_Task1_Doc326	475	496	Nitric Oxide Synthase	Gene	4843	In vitro and in vivo studies demonstrate a connection between the inducible form of Nitric Oxide Synthase, iNOS, and the neuropathological disorder glaucoma, one of the major causes of blindness in the world.
BC8_BioRED_Task1_Doc326	498	502	iNOS	Gene	4843	In vitro and in vivo studies demonstrate a connection between the inducible form of Nitric Oxide Synthase, iNOS, and the neuropathological disorder glaucoma, one of the major causes of blindness in the world.
BC8_BioRED_Task1_Doc326	512	547	neuropathological disorder glaucoma	Disease	D005901	In vitro and in vivo studies demonstrate a connection between the inducible form of Nitric Oxide Synthase, iNOS, and the neuropathological disorder glaucoma, one of the major causes of blindness in the world.
BC8_BioRED_Task1_Doc326	576	585	blindness	Disease	D001766	In vitro and in vivo studies demonstrate a connection between the inducible form of Nitric Oxide Synthase, iNOS, and the neuropathological disorder glaucoma, one of the major causes of blindness in the world.
BC8_BioRED_Task1_Doc326	670	674	iNOS	Gene	4843	In this study, we sought to establish the genetic association between iNOS and primary open angle glaucoma, POAG, and to find the functional element(s) connected with the pathogenesis of the disease.
BC8_BioRED_Task1_Doc326	679	706	primary open angle glaucoma	Disease	D005902	In this study, we sought to establish the genetic association between iNOS and primary open angle glaucoma, POAG, and to find the functional element(s) connected with the pathogenesis of the disease.
BC8_BioRED_Task1_Doc326	708	712	POAG	Disease	D005902	In this study, we sought to establish the genetic association between iNOS and primary open angle glaucoma, POAG, and to find the functional element(s) connected with the pathogenesis of the disease.
BC8_BioRED_Task1_Doc326	925	929	iNOS	Gene	4843	METHODS: Two microsatellites, 1 insertion/deletion, and 8 single nucleotide polymorphisms (SNPs) in the regulatory region of iNOS were genotyped in 200 POAG patients and 200 age-matched controls.
BC8_BioRED_Task1_Doc326	952	956	POAG	Disease	D005902	METHODS: Two microsatellites, 1 insertion/deletion, and 8 single nucleotide polymorphisms (SNPs) in the regulatory region of iNOS were genotyped in 200 POAG patients and 200 age-matched controls.
BC8_BioRED_Task1_Doc326	957	965	patients	OrganismTaxon	9606	METHODS: Two microsatellites, 1 insertion/deletion, and 8 single nucleotide polymorphisms (SNPs) in the regulatory region of iNOS were genotyped in 200 POAG patients and 200 age-matched controls.
BC8_BioRED_Task1_Doc326	1229	1237	patients	OrganismTaxon	9606	RESULTS: There was a significant difference in allele distribution of the CCTTT-microsatellite, between patients and controls.
BC8_BioRED_Task1_Doc326	1252	1261	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14	(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in POAG patients, while (CCTTT)10 and (CCTTT)13 were less common.
BC8_BioRED_Task1_Doc326	1373	1377	POAG	Disease	D005902	(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in POAG patients, while (CCTTT)10 and (CCTTT)13 were less common.
BC8_BioRED_Task1_Doc326	1378	1386	patients	OrganismTaxon	9606	(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in POAG patients, while (CCTTT)10 and (CCTTT)13 were less common.
BC8_BioRED_Task1_Doc326	1394	1403	(CCTTT)10	SequenceVariant	c|DUP||CCTTT|10	(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in POAG patients, while (CCTTT)10 and (CCTTT)13 were less common.
BC8_BioRED_Task1_Doc326	1408	1417	(CCTTT)13	SequenceVariant	c|DUP||CCTTT|13	(CCTTT)14, which has been reported to have a higher activity in a reporter-construct, was significantly more abundant in POAG patients, while (CCTTT)10 and (CCTTT)13 were less common.
BC8_BioRED_Task1_Doc326	1449	1458	(CCTTT)14	SequenceVariant	c|DUP||CCTTT|14	In EMSA, the (CCTTT)14 allele exhibited specific binding of nuclear proteins.
BC8_BioRED_Task1_Doc326	1669	1673	iNOS	Gene	4843	CONCLUSIONS: These results, together with other studies on this gene and the CCTTT-microsatellite, establish, for the first time, a genetic association of iNOS with POAG and suggest a regulatory function for the microsatellite.
BC8_BioRED_Task1_Doc326	1679	1683	POAG	Disease	D005902	CONCLUSIONS: These results, together with other studies on this gene and the CCTTT-microsatellite, establish, for the first time, a genetic association of iNOS with POAG and suggest a regulatory function for the microsatellite.
BC8_BioRED_Task1_Doc327	24	50	Type I Interferon Receptor	Gene	288264,686326	A Critical Role for the Type I Interferon Receptor in Virus-Induced Autoimmune Diabetes in Rats.
BC8_BioRED_Task1_Doc327	68	87	Autoimmune Diabetes	Disease	D003922	A Critical Role for the Type I Interferon Receptor in Virus-Induced Autoimmune Diabetes in Rats.
BC8_BioRED_Task1_Doc327	91	95	Rats	OrganismTaxon	10116	A Critical Role for the Type I Interferon Receptor in Virus-Induced Autoimmune Diabetes in Rats.
BC8_BioRED_Task1_Doc327	117	122	human	OrganismTaxon	9606	The pathogenesis of human type 1 diabetes, characterized by immune-mediated damage of insulin-producing b-cells of pancreatic islets, may involve viral infection.
BC8_BioRED_Task1_Doc327	123	138	type 1 diabetes	Disease	D003922	The pathogenesis of human type 1 diabetes, characterized by immune-mediated damage of insulin-producing b-cells of pancreatic islets, may involve viral infection.
BC8_BioRED_Task1_Doc327	183	190	insulin	Gene	3630	The pathogenesis of human type 1 diabetes, characterized by immune-mediated damage of insulin-producing b-cells of pancreatic islets, may involve viral infection.
BC8_BioRED_Task1_Doc327	243	258	viral infection	Disease	D014777	The pathogenesis of human type 1 diabetes, characterized by immune-mediated damage of insulin-producing b-cells of pancreatic islets, may involve viral infection.
BC8_BioRED_Task1_Doc327	332	349	type I interferon	Gene	3456	Essential components of the innate immune antiviral response, including type I interferon (IFN) and IFN receptor-mediated signaling pathways, are candidates for determining susceptibility to human type 1 diabetes.
BC8_BioRED_Task1_Doc327	351	354	IFN	Gene	3439	Essential components of the innate immune antiviral response, including type I interferon (IFN) and IFN receptor-mediated signaling pathways, are candidates for determining susceptibility to human type 1 diabetes.
BC8_BioRED_Task1_Doc327	360	372	IFN receptor	Gene	3454	Essential components of the innate immune antiviral response, including type I interferon (IFN) and IFN receptor-mediated signaling pathways, are candidates for determining susceptibility to human type 1 diabetes.
BC8_BioRED_Task1_Doc327	451	456	human	OrganismTaxon	9606	Essential components of the innate immune antiviral response, including type I interferon (IFN) and IFN receptor-mediated signaling pathways, are candidates for determining susceptibility to human type 1 diabetes.
BC8_BioRED_Task1_Doc327	457	472	type 1 diabetes	Disease	D003922	Essential components of the innate immune antiviral response, including type I interferon (IFN) and IFN receptor-mediated signaling pathways, are candidates for determining susceptibility to human type 1 diabetes.
BC8_BioRED_Task1_Doc327	494	499	human	OrganismTaxon	9606	Numerous aspects of human type 1 diabetes pathogenesis are recapitulated in the LEW.1WR1 rat model.
BC8_BioRED_Task1_Doc327	500	515	type 1 diabetes	Disease	D003922	Numerous aspects of human type 1 diabetes pathogenesis are recapitulated in the LEW.1WR1 rat model.
BC8_BioRED_Task1_Doc327	563	566	rat	OrganismTaxon	10116	Numerous aspects of human type 1 diabetes pathogenesis are recapitulated in the LEW.1WR1 rat model.
BC8_BioRED_Task1_Doc327	574	582	Diabetes	Disease	D003920	Diabetes can be induced in LEW.1WR1 weanling rats challenged with virus or with the viral mimetic polyinosinic:polycytidylic acid (poly I:C).
BC8_BioRED_Task1_Doc327	619	623	rats	OrganismTaxon	10116	Diabetes can be induced in LEW.1WR1 weanling rats challenged with virus or with the viral mimetic polyinosinic:polycytidylic acid (poly I:C).
BC8_BioRED_Task1_Doc327	672	703	polyinosinic:polycytidylic acid	Chemical	D011070	Diabetes can be induced in LEW.1WR1 weanling rats challenged with virus or with the viral mimetic polyinosinic:polycytidylic acid (poly I:C).
BC8_BioRED_Task1_Doc327	705	713	poly I:C	Chemical	D011070	Diabetes can be induced in LEW.1WR1 weanling rats challenged with virus or with the viral mimetic polyinosinic:polycytidylic acid (poly I:C).
BC8_BioRED_Task1_Doc327	760	779	type I IFN receptor	Gene	288264,686326	We hypothesized that disrupting the cognate type I IFN receptor (type I IFN a/b receptor [IFNAR]) to interrupt IFN signaling would prevent or delay the development of virus-induced diabetes.
BC8_BioRED_Task1_Doc327	781	804	type I IFN a/b receptor	Gene	288264,686326	We hypothesized that disrupting the cognate type I IFN receptor (type I IFN a/b receptor [IFNAR]) to interrupt IFN signaling would prevent or delay the development of virus-induced diabetes.
BC8_BioRED_Task1_Doc327	806	811	IFNAR	Gene	288264,686326	We hypothesized that disrupting the cognate type I IFN receptor (type I IFN a/b receptor [IFNAR]) to interrupt IFN signaling would prevent or delay the development of virus-induced diabetes.
BC8_BioRED_Task1_Doc327	827	830	IFN	Gene	25712	We hypothesized that disrupting the cognate type I IFN receptor (type I IFN a/b receptor [IFNAR]) to interrupt IFN signaling would prevent or delay the development of virus-induced diabetes.
BC8_BioRED_Task1_Doc327	897	905	diabetes	Disease	D003920	We hypothesized that disrupting the cognate type I IFN receptor (type I IFN a/b receptor [IFNAR]) to interrupt IFN signaling would prevent or delay the development of virus-induced diabetes.
BC8_BioRED_Task1_Doc327	920	926	IFNAR1	Gene	288264	We generated IFNAR1 subunit-deficient LEW.1WR1 rats using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) genome editing and confirmed functional disruption of the Ifnar1 gene.
BC8_BioRED_Task1_Doc327	954	958	rats	OrganismTaxon	10116	We generated IFNAR1 subunit-deficient LEW.1WR1 rats using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) genome editing and confirmed functional disruption of the Ifnar1 gene.
BC8_BioRED_Task1_Doc327	1116	1122	Ifnar1	Gene	288264	We generated IFNAR1 subunit-deficient LEW.1WR1 rats using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) genome editing and confirmed functional disruption of the Ifnar1 gene.
BC8_BioRED_Task1_Doc327	1129	1135	IFNAR1	Gene	288264	IFNAR1 deficiency significantly delayed the onset and frequency of diabetes and greatly reduced the intensity of insulitis after poly I:C treatment.
BC8_BioRED_Task1_Doc327	1196	1204	diabetes	Disease	D003920	IFNAR1 deficiency significantly delayed the onset and frequency of diabetes and greatly reduced the intensity of insulitis after poly I:C treatment.
BC8_BioRED_Task1_Doc327	1242	1251	insulitis	Disease	D007410	IFNAR1 deficiency significantly delayed the onset and frequency of diabetes and greatly reduced the intensity of insulitis after poly I:C treatment.
BC8_BioRED_Task1_Doc327	1258	1266	poly I:C	Chemical	D011070	IFNAR1 deficiency significantly delayed the onset and frequency of diabetes and greatly reduced the intensity of insulitis after poly I:C treatment.
BC8_BioRED_Task1_Doc327	1296	1312	Kilham rat virus	OrganismTaxon	12441	The occurrence of Kilham rat virus-induced diabetes was also diminished in IFNAR1-deficient animals.
BC8_BioRED_Task1_Doc327	1321	1329	diabetes	Disease	D003920	The occurrence of Kilham rat virus-induced diabetes was also diminished in IFNAR1-deficient animals.
BC8_BioRED_Task1_Doc327	1353	1359	IFNAR1	Gene	288264	The occurrence of Kilham rat virus-induced diabetes was also diminished in IFNAR1-deficient animals.
BC8_BioRED_Task1_Doc327	1471	1490	autoimmune diabetes	Disease	D003922	These findings firmly establish that alterations in innate immunity influence the course of autoimmune diabetes and support the use of targeted strategies to limit or prevent the development of type 1 diabetes.
BC8_BioRED_Task1_Doc327	1573	1588	type 1 diabetes	Disease	D003922	These findings firmly establish that alterations in innate immunity influence the course of autoimmune diabetes and support the use of targeted strategies to limit or prevent the development of type 1 diabetes.
BC8_BioRED_Task1_Doc328	0	17	Metallothionein-1	Gene	4495	Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
BC8_BioRED_Task1_Doc328	64	88	hepatocellular carcinoma	Disease	D006528	Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
BC8_BioRED_Task1_Doc328	106	115	sorafenib	Chemical	D000077157	Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
BC8_BioRED_Task1_Doc328	129	138	Sorafenib	Chemical	D000077157	BACKGROUND: Sorafenib, a kinase inhibitor active against various solid tumours, induces oxidative stress and ferroptosis, a new form of oxidative necrosis, in some cancer cells.
BC8_BioRED_Task1_Doc328	188	195	tumours	Disease	D009369	BACKGROUND: Sorafenib, a kinase inhibitor active against various solid tumours, induces oxidative stress and ferroptosis, a new form of oxidative necrosis, in some cancer cells.
BC8_BioRED_Task1_Doc328	263	271	necrosis	Disease	D009336	BACKGROUND: Sorafenib, a kinase inhibitor active against various solid tumours, induces oxidative stress and ferroptosis, a new form of oxidative necrosis, in some cancer cells.
BC8_BioRED_Task1_Doc328	281	287	cancer	Disease	D009369	BACKGROUND: Sorafenib, a kinase inhibitor active against various solid tumours, induces oxidative stress and ferroptosis, a new form of oxidative necrosis, in some cancer cells.
BC8_BioRED_Task1_Doc328	355	364	sorafenib	Chemical	D000077157	Clinically-applicable biomarkers that reflect the impact of sorafenib on the redox metabolism of cancer cells are lacking.
BC8_BioRED_Task1_Doc328	392	398	cancer	Disease	D009369	Clinically-applicable biomarkers that reflect the impact of sorafenib on the redox metabolism of cancer cells are lacking.
BC8_BioRED_Task1_Doc328	611	617	cancer	Disease	D009369	METHODS: We used gene expression microarrays, real-time PCR, immunoblot, protein-specific ELISA, and gene reporter constructs encoding the enzyme luciferase to study the response of a panel of cancer cells to sorafenib.
BC8_BioRED_Task1_Doc328	627	636	sorafenib	Chemical	D000077157	METHODS: We used gene expression microarrays, real-time PCR, immunoblot, protein-specific ELISA, and gene reporter constructs encoding the enzyme luciferase to study the response of a panel of cancer cells to sorafenib.
BC8_BioRED_Task1_Doc328	638	644	Tumour	Disease	D009369	Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used.
BC8_BioRED_Task1_Doc328	677	701	hepatocellular carcinoma	Disease	D006528	Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used.
BC8_BioRED_Task1_Doc328	703	706	HCC	Disease	D006528	Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used.
BC8_BioRED_Task1_Doc328	748	751	HCC	Disease	D006528	Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used.
BC8_BioRED_Task1_Doc328	752	760	patients	OrganismTaxon	9606	Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used.
BC8_BioRED_Task1_Doc328	771	780	sorafenib	Chemical	D000077157	Tumour explants prepared from surgical hepatocellular carcinoma (HCC) samples and serum samples obtained from HCC patients receiving sorafenib were also used.
BC8_BioRED_Task1_Doc328	836	853	metallothionein-1	Gene	4495	RESULTS: We observed that genes of the metallothionein-1 (MT1) family are induced in the HCC cell line Huh7 exposed to sorafenib.
BC8_BioRED_Task1_Doc328	855	858	MT1	Gene	4495	RESULTS: We observed that genes of the metallothionein-1 (MT1) family are induced in the HCC cell line Huh7 exposed to sorafenib.
BC8_BioRED_Task1_Doc328	886	889	HCC	Disease	D006528	RESULTS: We observed that genes of the metallothionein-1 (MT1) family are induced in the HCC cell line Huh7 exposed to sorafenib.
BC8_BioRED_Task1_Doc328	900	904	Huh7	CellLine	CVCL_0336	RESULTS: We observed that genes of the metallothionein-1 (MT1) family are induced in the HCC cell line Huh7 exposed to sorafenib.
BC8_BioRED_Task1_Doc328	916	925	sorafenib	Chemical	D000077157	RESULTS: We observed that genes of the metallothionein-1 (MT1) family are induced in the HCC cell line Huh7 exposed to sorafenib.
BC8_BioRED_Task1_Doc328	927	936	Sorafenib	Chemical	D000077157	Sorafenib increased the expression of MT1G mRNA in a panel of human cancer cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.
BC8_BioRED_Task1_Doc328	965	969	MT1G	Gene	4495	Sorafenib increased the expression of MT1G mRNA in a panel of human cancer cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.
BC8_BioRED_Task1_Doc328	989	994	human	OrganismTaxon	9606	Sorafenib increased the expression of MT1G mRNA in a panel of human cancer cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.
BC8_BioRED_Task1_Doc328	995	1001	cancer	Disease	D009369	Sorafenib increased the expression of MT1G mRNA in a panel of human cancer cells, an effect that was not observed with eight other clinically-approved kinase inhibitors.
BC8_BioRED_Task1_Doc328	1137	1141	MT1G	Gene	4495	We identified the minimal region of the MT1G promoter that confers inducibility by sorafenib to a 133 base pair region containing an Anti-oxidant Response Element (ARE) and showed the essential role of the transcription factor NRF2 (Nuclear factor erythroid 2-Related Factor 2).
BC8_BioRED_Task1_Doc328	1180	1189	sorafenib	Chemical	D000077157	We identified the minimal region of the MT1G promoter that confers inducibility by sorafenib to a 133 base pair region containing an Anti-oxidant Response Element (ARE) and showed the essential role of the transcription factor NRF2 (Nuclear factor erythroid 2-Related Factor 2).
BC8_BioRED_Task1_Doc328	1324	1328	NRF2	Gene	4780	We identified the minimal region of the MT1G promoter that confers inducibility by sorafenib to a 133 base pair region containing an Anti-oxidant Response Element (ARE) and showed the essential role of the transcription factor NRF2 (Nuclear factor erythroid 2-Related Factor 2).
BC8_BioRED_Task1_Doc328	1330	1373	Nuclear factor erythroid 2-Related Factor 2	Gene	4780	We identified the minimal region of the MT1G promoter that confers inducibility by sorafenib to a 133 base pair region containing an Anti-oxidant Response Element (ARE) and showed the essential role of the transcription factor NRF2 (Nuclear factor erythroid 2-Related Factor 2).
BC8_BioRED_Task1_Doc328	1458	1462	MT1G	Gene	4495	We examined the clinical relevance of our findings by analysing the regulation of MT1G in five tumour explants prepared from surgical HCC samples.
BC8_BioRED_Task1_Doc328	1471	1477	tumour	Disease	D009369	We examined the clinical relevance of our findings by analysing the regulation of MT1G in five tumour explants prepared from surgical HCC samples.
BC8_BioRED_Task1_Doc328	1510	1513	HCC	Disease	D006528	We examined the clinical relevance of our findings by analysing the regulation of MT1G in five tumour explants prepared from surgical HCC samples.
BC8_BioRED_Task1_Doc328	1569	1572	MT1	Gene	4495	Finally, we showed that the protein levels of MT1 increase in the serum of some HCC patients receiving sorafenib, and found an association with reduced overall survival.
BC8_BioRED_Task1_Doc328	1603	1606	HCC	Disease	D006528	Finally, we showed that the protein levels of MT1 increase in the serum of some HCC patients receiving sorafenib, and found an association with reduced overall survival.
BC8_BioRED_Task1_Doc328	1607	1615	patients	OrganismTaxon	9606	Finally, we showed that the protein levels of MT1 increase in the serum of some HCC patients receiving sorafenib, and found an association with reduced overall survival.
BC8_BioRED_Task1_Doc328	1626	1635	sorafenib	Chemical	D000077157	Finally, we showed that the protein levels of MT1 increase in the serum of some HCC patients receiving sorafenib, and found an association with reduced overall survival.
BC8_BioRED_Task1_Doc328	1734	1737	MT1	Gene	4495	CONCLUSION: These findings indicate that MT1 constitute a biomarker adapted for exploring the impact of sorafenib on the redox metabolism of cancer cells.
BC8_BioRED_Task1_Doc328	1797	1806	sorafenib	Chemical	D000077157	CONCLUSION: These findings indicate that MT1 constitute a biomarker adapted for exploring the impact of sorafenib on the redox metabolism of cancer cells.
BC8_BioRED_Task1_Doc328	1834	1840	cancer	Disease	D009369	CONCLUSION: These findings indicate that MT1 constitute a biomarker adapted for exploring the impact of sorafenib on the redox metabolism of cancer cells.
BC8_BioRED_Task1_Doc329	0	12	Coenzyme Q10	Chemical	C024989	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
BC8_BioRED_Task1_Doc329	41	50	cisplatin	Chemical	D002945	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
BC8_BioRED_Task1_Doc329	51	65	nephrotoxicity	Disease	D007674	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
BC8_BioRED_Task1_Doc329	69	73	mice	OrganismTaxon	10090	Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
BC8_BioRED_Task1_Doc329	106	118	coenzyme Q10	Chemical	C024989	The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.
BC8_BioRED_Task1_Doc329	139	143	mice	OrganismTaxon	10090	The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.
BC8_BioRED_Task1_Doc329	149	167	acute renal injury	Disease	D058186	The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.
BC8_BioRED_Task1_Doc329	206	215	cisplatin	Chemical	D002945	injection of cisplatin (5 mg/kg).
BC8_BioRED_Task1_Doc329	227	239	Coenzyme Q10	Chemical	C024989	Coenzyme Q10 treatment (10 mg/kg/day, i.p.)
BC8_BioRED_Task1_Doc329	329	338	cisplatin	Chemical	D002945	was applied for 6 consecutive days, starting 1 day before cisplatin administration.
BC8_BioRED_Task1_Doc329	355	367	Coenzyme Q10	Chemical	C024989	Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.
BC8_BioRED_Task1_Doc329	390	409	blood urea nitrogen	Chemical	D001806	Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.
BC8_BioRED_Task1_Doc329	420	430	creatinine	Chemical	D003404	Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.
BC8_BioRED_Task1_Doc329	462	471	cisplatin	Chemical	D002945	Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.
BC8_BioRED_Task1_Doc329	473	485	Coenzyme Q10	Chemical	C024989	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	568	579	glutathione	Chemical	D005978	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	590	610	superoxide dismutase	Gene	20655	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	633	638	lipid	Chemical	D008055	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	681	708	tumor necrosis factor-alpha	Gene	21926	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	710	722	nitric oxide	Chemical	D009569	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	727	735	platinum	Chemical	D010984	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	788	796	selenium	Chemical	D012643	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	801	805	zinc	Chemical	D015032	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	841	850	cisplatin	Chemical	D002945	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
BC8_BioRED_Task1_Doc329	891	910	renal tissue damage	Disease	D007674	Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
BC8_BioRED_Task1_Doc329	923	932	cisplatin	Chemical	D002945	Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
BC8_BioRED_Task1_Doc329	952	964	coenzyme Q10	Chemical	C024989	Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
BC8_BioRED_Task1_Doc329	1019	1031	coenzyme Q10	Chemical	C024989	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.
BC8_BioRED_Task1_Doc329	1060	1069	cisplatin	Chemical	D002945	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.
BC8_BioRED_Task1_Doc329	1106	1127	nitric oxide synthase	Gene	18125	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.
BC8_BioRED_Task1_Doc329	1129	1150	nuclear factor-kappaB	Gene	18033	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.
BC8_BioRED_Task1_Doc329	1152	1161	caspase-3	Gene	12367	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.
BC8_BioRED_Task1_Doc329	1166	1169	p53	Gene	22060	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.
BC8_BioRED_Task1_Doc329	1209	1221	coenzyme Q10	Chemical	C024989	It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.
BC8_BioRED_Task1_Doc329	1289	1298	cisplatin	Chemical	D002945	It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.
BC8_BioRED_Task1_Doc329	1299	1313	nephrotoxicity	Disease	D007674	It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.
BC8_BioRED_Task1_Doc330	14	18	MEN1	Gene	4221	Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics.
BC8_BioRED_Task1_Doc330	48	75	primary hyperparathyroidism	Disease	D049950	Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics.
BC8_BioRED_Task1_Doc330	123	150	Primary hyperparathyroidism	Disease	D049950	Primary hyperparathyroidism (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (MEN1 and 2).
BC8_BioRED_Task1_Doc330	152	156	pHPT	Disease	D049950	Primary hyperparathyroidism (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (MEN1 and 2).
BC8_BioRED_Task1_Doc330	170	187	endocrine disease	Disease	D004700	Primary hyperparathyroidism (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (MEN1 and 2).
BC8_BioRED_Task1_Doc330	267	286	inherited disorders	Disease	D030342	Primary hyperparathyroidism (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (MEN1 and 2).
BC8_BioRED_Task1_Doc330	311	339	multiple endocrine neoplasia	Disease	D009377	Primary hyperparathyroidism (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (MEN1 and 2).
BC8_BioRED_Task1_Doc330	341	351	MEN1 and 2	Disease	D018761,D018813	Primary hyperparathyroidism (pHPT) is a common endocrine disease that in more than 95% of cases is sporadic and only in some cases is caused by inherited disorders, isolated or as part of multiple endocrine neoplasia (MEN1 and 2).
BC8_BioRED_Task1_Doc330	375	379	MEN1	Gene	4221	Somatic mutations of MEN1 gene have also been described in sporadic parathyroid tumors.
BC8_BioRED_Task1_Doc330	422	440	parathyroid tumors	Disease	D010282	Somatic mutations of MEN1 gene have also been described in sporadic parathyroid tumors.
BC8_BioRED_Task1_Doc330	499	503	MEN1	Gene	4221	In our study, we examined the presence of alterations in MEN1 gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a carcinoma).
BC8_BioRED_Task1_Doc330	527	535	patients	OrganismTaxon	9606	In our study, we examined the presence of alterations in MEN1 gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a carcinoma).
BC8_BioRED_Task1_Doc330	575	579	pHPT	Disease	D049950	In our study, we examined the presence of alterations in MEN1 gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a carcinoma).
BC8_BioRED_Task1_Doc330	589	623	parathyroid adenoma or hyperplasia	Disease	D010282	In our study, we examined the presence of alterations in MEN1 gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a carcinoma).
BC8_BioRED_Task1_Doc330	634	643	carcinoma	Disease	D002277	In our study, we examined the presence of alterations in MEN1 gene in a series of 39 patients who had undergone surgery for sporadic pHPT (35 with parathyroid adenoma or hyperplasia, 4 with a carcinoma).
BC8_BioRED_Task1_Doc330	724	732	paraffin	Chemical	D010232	After DNA extraction from paraffin-embedded tissues, we amplified by PCR and sequenced the exons 2-10 of the MEN1 gene.
BC8_BioRED_Task1_Doc330	807	811	MEN1	Gene	4221	After DNA extraction from paraffin-embedded tissues, we amplified by PCR and sequenced the exons 2-10 of the MEN1 gene.
BC8_BioRED_Task1_Doc330	826	830	MEN1	Gene	4221	Somatic MEN1 mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined (17.1%), whereas no alterations were found in the carcinomas.
BC8_BioRED_Task1_Doc330	870	878	patients	OrganismTaxon	9606	Somatic MEN1 mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined (17.1%), whereas no alterations were found in the carcinomas.
BC8_BioRED_Task1_Doc330	886	911	benign parathyroid lesion	Disease	D010279	Somatic MEN1 mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined (17.1%), whereas no alterations were found in the carcinomas.
BC8_BioRED_Task1_Doc330	971	981	carcinomas	Disease	D002277	Somatic MEN1 mutations were detected in 6 of the 35 patients with a benign parathyroid lesion examined (17.1%), whereas no alterations were found in the carcinomas.
BC8_BioRED_Task1_Doc330	994	998	MEN1	Gene	4221	Four novel MEN1 gene mutations were identified as follows: one frameshift mutation (222insT, exon 2), one frameshift deletion (912delTA, exon 5), one in-frame deletion (835del18, exon 4) and one missense mutation (P291A, exon 6).
BC8_BioRED_Task1_Doc330	1067	1074	222insT	SequenceVariant	c|INS|222|T	Four novel MEN1 gene mutations were identified as follows: one frameshift mutation (222insT, exon 2), one frameshift deletion (912delTA, exon 5), one in-frame deletion (835del18, exon 4) and one missense mutation (P291A, exon 6).
BC8_BioRED_Task1_Doc330	1110	1118	912delTA	SequenceVariant	c|DEL|912|TA	Four novel MEN1 gene mutations were identified as follows: one frameshift mutation (222insT, exon 2), one frameshift deletion (912delTA, exon 5), one in-frame deletion (835del18, exon 4) and one missense mutation (P291A, exon 6).
BC8_BioRED_Task1_Doc330	1152	1160	835del18	SequenceVariant	c|DEL|835|18	Four novel MEN1 gene mutations were identified as follows: one frameshift mutation (222insT, exon 2), one frameshift deletion (912delTA, exon 5), one in-frame deletion (835del18, exon 4) and one missense mutation (P291A, exon 6).
BC8_BioRED_Task1_Doc330	1197	1202	P291A	SequenceVariant	p|SUB|P|291|A	Four novel MEN1 gene mutations were identified as follows: one frameshift mutation (222insT, exon 2), one frameshift deletion (912delTA, exon 5), one in-frame deletion (835del18, exon 4) and one missense mutation (P291A, exon 6).
BC8_BioRED_Task1_Doc330	1249	1253	L89R	SequenceVariant	p|SUB|L|89|R	In addition, one missense mutation (L89R, exon 2) and one nonsense mutation (Q536X, exon 10) were previously reported.
BC8_BioRED_Task1_Doc330	1290	1295	Q536X	SequenceVariant	p|SUB|Q|536|X	In addition, one missense mutation (L89R, exon 2) and one nonsense mutation (Q536X, exon 10) were previously reported.
BC8_BioRED_Task1_Doc330	1398	1403	R171Q	SequenceVariant	rs607969	Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 tumors), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.
BC8_BioRED_Task1_Doc330	1423	1429	tumors	Disease	D009369	Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 tumors), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.
BC8_BioRED_Task1_Doc330	1440	1445	D418D	SequenceVariant	rs2071313	Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 tumors), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.
BC8_BioRED_Task1_Doc330	1460	1467	GAC/GAT	SequenceVariant	rs2071313	Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 tumors), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.
BC8_BioRED_Task1_Doc330	1491	1497	tumors	Disease	D009369	Moreover, two polymorphisms were also found: one allele carried a R171Q polymorphism (1/39 tumors), while a D418D polymorphism (GAC/GAT) was found in 15 and 8 tumors in hetero (CT) and homozygosity (TT), respectively.
BC8_BioRED_Task1_Doc330	1719	1723	MEN1	Gene	4221	In conclusion, our data demonstrate the presence of somatic alterations of the MEN1 tumor suppressor gene in about one fifth of benign sporadic parathyroid tumors.
BC8_BioRED_Task1_Doc330	1724	1729	tumor	Disease	D009369	In conclusion, our data demonstrate the presence of somatic alterations of the MEN1 tumor suppressor gene in about one fifth of benign sporadic parathyroid tumors.
BC8_BioRED_Task1_Doc330	1784	1802	parathyroid tumors	Disease	D010282	In conclusion, our data demonstrate the presence of somatic alterations of the MEN1 tumor suppressor gene in about one fifth of benign sporadic parathyroid tumors.
BC8_BioRED_Task1_Doc331	2	30	recessive skeletal dysplasia	Disease	D010009	A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan.
BC8_BioRED_Task1_Doc331	32	36	SEMD	Disease	D010009	A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan.
BC8_BioRED_Task1_Doc331	37	45	aggrecan	Gene	176	A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan.
BC8_BioRED_Task1_Doc331	123	131	aggrecan	Gene	176	A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan.
BC8_BioRED_Task1_Doc331	234	266	spondyloepimetaphyseal dysplasia	Disease	D010009	Analysis of a nuclear family with three affected offspring identified an autosomal-recessive form of spondyloepimetaphyseal dysplasia characterized by severe short stature and a unique constellation of radiographic findings.
BC8_BioRED_Task1_Doc331	291	304	short stature	Disease	D006130	Analysis of a nuclear family with three affected offspring identified an autosomal-recessive form of spondyloepimetaphyseal dysplasia characterized by severe short stature and a unique constellation of radiographic findings.
BC8_BioRED_Task1_Doc331	704	712	aggrecan	Gene	176	These genes were assessed and ranked by cartilage selectivity with whole-genome microarray data, revealing only two genes, encoding aggrecan and chondroitin sulfate proteoglycan 4, that were selectively expressed in cartilage.
BC8_BioRED_Task1_Doc331	717	751	chondroitin sulfate proteoglycan 4	Gene	1464	These genes were assessed and ranked by cartilage selectivity with whole-genome microarray data, revealing only two genes, encoding aggrecan and chondroitin sulfate proteoglycan 4, that were selectively expressed in cartilage.
BC8_BioRED_Task1_Doc331	820	828	aggrecan	Gene	176	Sequence analysis of aggrecan complementary DNA from an affected individual revealed homozygosity for a missense mutation (c.6799G --> A) that predicts a p.D2267N amino acid substitution in the C-type lectin domain within the G3 domain of aggrecan.
BC8_BioRED_Task1_Doc331	922	935	c.6799G --> A	SequenceVariant	rs545688154	Sequence analysis of aggrecan complementary DNA from an affected individual revealed homozygosity for a missense mutation (c.6799G --> A) that predicts a p.D2267N amino acid substitution in the C-type lectin domain within the G3 domain of aggrecan.
BC8_BioRED_Task1_Doc331	953	961	p.D2267N	SequenceVariant	rs545688154	Sequence analysis of aggrecan complementary DNA from an affected individual revealed homozygosity for a missense mutation (c.6799G --> A) that predicts a p.D2267N amino acid substitution in the C-type lectin domain within the G3 domain of aggrecan.
BC8_BioRED_Task1_Doc331	1038	1046	aggrecan	Gene	176	Sequence analysis of aggrecan complementary DNA from an affected individual revealed homozygosity for a missense mutation (c.6799G --> A) that predicts a p.D2267N amino acid substitution in the C-type lectin domain within the G3 domain of aggrecan.
BC8_BioRED_Task1_Doc331	1052	1057	D2267	SequenceVariant	rs545688154	The D2267 residue is predicted to coordinate binding of a calcium ion, which influences the conformational binding loops of the C-type lectin domain that mediate interactions with tenascins and other extracellular-matrix proteins.
BC8_BioRED_Task1_Doc331	1106	1113	calcium	Chemical	D002118	The D2267 residue is predicted to coordinate binding of a calcium ion, which influences the conformational binding loops of the C-type lectin domain that mediate interactions with tenascins and other extracellular-matrix proteins.
BC8_BioRED_Task1_Doc331	1603	1611	aggrecan	Gene	176	Surface-plasmon-resonance studies showed that the mutation influenced the binding and kinetics of the interactions between the aggrecan G3 domain and tenascin-C.
BC8_BioRED_Task1_Doc331	1626	1636	tenascin-C	Gene	3371	Surface-plasmon-resonance studies showed that the mutation influenced the binding and kinetics of the interactions between the aggrecan G3 domain and tenascin-C.
BC8_BioRED_Task1_Doc331	1665	1703	autosomal-recessive skeletal dysplasia	Disease	D010009	These findings identify an autosomal-recessive skeletal dysplasia and a significant role for the aggrecan C-type lectin domain in regulating endochondral ossification and, thereby, height.
BC8_BioRED_Task1_Doc331	1735	1743	aggrecan	Gene	176	These findings identify an autosomal-recessive skeletal dysplasia and a significant role for the aggrecan C-type lectin domain in regulating endochondral ossification and, thereby, height.
BC8_BioRED_Task1_Doc332	0	4	CD72	Gene	971	CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.
BC8_BioRED_Task1_Doc332	81	86	human	OrganismTaxon	9606	CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.
BC8_BioRED_Task1_Doc332	87	115	systemic lupus erythematosus	Disease	D008180	CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.
BC8_BioRED_Task1_Doc332	151	157	FCGR2B	Gene	2213	CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.
BC8_BioRED_Task1_Doc332	197	203	FCGR2B	Gene	2213	We previously reported association of FCGR2B-Ile232Thr with systemic lupus erythematosus (SLE) in three Asian populations.
BC8_BioRED_Task1_Doc332	204	213	Ile232Thr	SequenceVariant	rs1050501	We previously reported association of FCGR2B-Ile232Thr with systemic lupus erythematosus (SLE) in three Asian populations.
BC8_BioRED_Task1_Doc332	219	247	systemic lupus erythematosus	Disease	D008180	We previously reported association of FCGR2B-Ile232Thr with systemic lupus erythematosus (SLE) in three Asian populations.
BC8_BioRED_Task1_Doc332	249	252	SLE	Disease	D008180	We previously reported association of FCGR2B-Ile232Thr with systemic lupus erythematosus (SLE) in three Asian populations.
BC8_BioRED_Task1_Doc332	306	310	CD72	Gene	12517	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	372	378	murine	OrganismTaxon	10090	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	379	382	SLE	Disease	D008180	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	398	403	human	OrganismTaxon	9606	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	404	408	CD72	Gene	971	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	454	457	SLE	Disease	D008180	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	496	502	FCGR2B	Gene	2213	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	524	527	SLE	Disease	D008180	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	554	557	SLE	Disease	D008180	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	612	615	SLE	Disease	D008180	Because polymorphism of CD72, another inhibitory receptor of B cells, was associated with murine SLE, we identified human CD72 polymorphisms, tested their association with SLE and examined genetic interaction with FCGR2B in the Japanese (160 SLE, 277 controls), Thais (87 SLE, 187 controls) and Caucasians (94 families containing SLE members).
BC8_BioRED_Task1_Doc332	877	880	SLE	Disease	D008180	Although association with susceptibility to SLE was not detected, the *1 allele was significantly associated with nephritis among the Japanese patients (P=0.024).
BC8_BioRED_Task1_Doc332	947	956	nephritis	Disease	D009393	Although association with susceptibility to SLE was not detected, the *1 allele was significantly associated with nephritis among the Japanese patients (P=0.024).
BC8_BioRED_Task1_Doc332	976	984	patients	OrganismTaxon	9606	Although association with susceptibility to SLE was not detected, the *1 allele was significantly associated with nephritis among the Japanese patients (P=0.024).
BC8_BioRED_Task1_Doc332	1103	1108	COS-7	CellLine	CVCL_0224	RT-PCR identified a novel alternatively spliced (AS) transcript that was expressed at the protein level in COS-7 transfectants.
BC8_BioRED_Task1_Doc332	1341	1347	FCGR2B	Gene	2213	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1348	1354	232Thr	SequenceVariant	rs1050501	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1364	1367	SLE	Disease	D008180	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1405	1409	CD72	Gene	971	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1468	1474	FCGR2B	Gene	2213	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1475	1481	232Ile	SequenceVariant	rs1050501	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1491	1495	CD72	Gene	971	Using the two Asian cohorts, significant association of FCGR2B-232Thr/Thr with SLE was observed only in the presence of CD72-*1/*1 genotype (OR 4.63, 95% CI 1.47-14.6, P=0.009 versus FCGR2B-232Ile/Ile plus CD72-*2/*2).
BC8_BioRED_Task1_Doc332	1844	1848	CD72	Gene	12517	The AS isoform lacks exon 8, and is deduced to contain 49 amino acid changes in the membrane-distal portion of the extracellular domain, where considerable amino acid changes are known in CD72(c) allele associated with murine SLE.
BC8_BioRED_Task1_Doc332	1875	1881	murine	OrganismTaxon	10090	The AS isoform lacks exon 8, and is deduced to contain 49 amino acid changes in the membrane-distal portion of the extracellular domain, where considerable amino acid changes are known in CD72(c) allele associated with murine SLE.
BC8_BioRED_Task1_Doc332	1882	1885	SLE	Disease	D008180	The AS isoform lacks exon 8, and is deduced to contain 49 amino acid changes in the membrane-distal portion of the extracellular domain, where considerable amino acid changes are known in CD72(c) allele associated with murine SLE.
BC8_BioRED_Task1_Doc332	1932	1936	CD72	Gene	971	These results indicated that the presence of CD72-*2 allele decreases risk for human SLE conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of CD72.
BC8_BioRED_Task1_Doc332	1966	1971	human	OrganismTaxon	9606	These results indicated that the presence of CD72-*2 allele decreases risk for human SLE conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of CD72.
BC8_BioRED_Task1_Doc332	1972	1975	SLE	Disease	D008180	These results indicated that the presence of CD72-*2 allele decreases risk for human SLE conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of CD72.
BC8_BioRED_Task1_Doc332	1989	1995	FCGR2B	Gene	2213	These results indicated that the presence of CD72-*2 allele decreases risk for human SLE conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of CD72.
BC8_BioRED_Task1_Doc332	1996	2002	232Thr	SequenceVariant	rs1050501	These results indicated that the presence of CD72-*2 allele decreases risk for human SLE conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of CD72.
BC8_BioRED_Task1_Doc332	2045	2049	CD72	Gene	971	These results indicated that the presence of CD72-*2 allele decreases risk for human SLE conferred by FCGR2B-232Thr, possibly by increasing the AS isoform of CD72.
BC8_BioRED_Task1_Doc333	8	19	proteinuria	Disease	D011507	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
BC8_BioRED_Task1_Doc333	24	43	acute renal failure	Disease	D058186	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
BC8_BioRED_Task1_Doc333	55	69	bisphosphonate	Chemical	D004164	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
BC8_BioRED_Task1_Doc333	71	82	alendronate	Chemical	D019386	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
BC8_BioRED_Task1_Doc333	104	111	patient	OrganismTaxon	9606	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
BC8_BioRED_Task1_Doc333	117	151	focal segmental glomerulosclerosis	Disease	D005923	Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
BC8_BioRED_Task1_Doc333	176	179	man	OrganismTaxon	9606	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
BC8_BioRED_Task1_Doc333	185	203	nephrotic syndrome	Disease	D009404	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
BC8_BioRED_Task1_Doc333	211	245	focal segmental glomerulosclerosis	Disease	D005923	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
BC8_BioRED_Task1_Doc333	279	286	steroid	Chemical	D013256	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
BC8_BioRED_Task1_Doc333	389	403	bisphosphonate	Chemical	D004164	The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.
BC8_BioRED_Task1_Doc333	405	423	alendronate sodium	Chemical	D019386	The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.
BC8_BioRED_Task1_Doc333	513	532	acute renal failure	Disease	D058186	The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.
BC8_BioRED_Task1_Doc333	563	574	alendronate	Chemical	D019386	After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.
BC8_BioRED_Task1_Doc333	580	587	patient	OrganismTaxon	9606	After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.
BC8_BioRED_Task1_Doc333	684	694	creatinine	Chemical	D003404	Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days.
BC8_BioRED_Task1_Doc333	860	875	bisphosphonates	Chemical	D004164	This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.
BC8_BioRED_Task1_Doc333	890	901	proteinuria	Disease	D011507	This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.
BC8_BioRED_Task1_Doc333	906	925	acute renal failure	Disease	D058186	This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.
BC8_BioRED_Task1_Doc334	31	38	SLCO1B1	Gene	10599	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	40	46	OATP-C	Gene	10599	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	58	65	SLCO1B1	Gene	10599	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	69	76	SLCO1B1	Gene	10599	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	84	91	SLCO1B1	Gene	10599	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	95	101	C1007G	SequenceVariant	rs72559747	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	144	148	HeLa	CellLine	CVCL_0030	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	153	159	HEK293	CellLine	CVCL_0045	Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
BC8_BioRED_Task1_Doc334	179	186	SLCO1B1	Gene	10599	OBJECTIVES: SLCO1B1*5 and SLCO1B1*15 have been reported to reduce the clearance of pravastatin in healthy volunteers.
BC8_BioRED_Task1_Doc334	193	200	SLCO1B1	Gene	10599	OBJECTIVES: SLCO1B1*5 and SLCO1B1*15 have been reported to reduce the clearance of pravastatin in healthy volunteers.
BC8_BioRED_Task1_Doc334	250	261	pravastatin	Chemical	D017035	OBJECTIVES: SLCO1B1*5 and SLCO1B1*15 have been reported to reduce the clearance of pravastatin in healthy volunteers.
BC8_BioRED_Task1_Doc334	338	345	SLCO1B1	Gene	10599	However, there remains controversy in the effects of SLCO1B1*5 on the activity of OATP1B1 in vitro.
BC8_BioRED_Task1_Doc334	367	374	OATP1B1	Gene	10599	However, there remains controversy in the effects of SLCO1B1*5 on the activity of OATP1B1 in vitro.
BC8_BioRED_Task1_Doc334	412	419	SLCO1B1	Gene	10599	In addition, the effect of SLCO1B1*15 on the function of OATP1B1 has not been studied using cDNA-expression systems.
BC8_BioRED_Task1_Doc334	442	449	OATP1B1	Gene	10599	In addition, the effect of SLCO1B1*15 on the function of OATP1B1 has not been studied using cDNA-expression systems.
BC8_BioRED_Task1_Doc334	560	567	SLCO1B1	Gene	10599	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	583	589	C1007G	SequenceVariant	rs72559747	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	620	627	patient	OrganismTaxon	9606	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	633	644	pravastatin	Chemical	D017035	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	653	661	myopathy	Disease	D009135	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	695	702	OATP1B1	Gene	10599	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	738	744	HEK293	CellLine	CVCL_0045	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	749	753	HeLa	CellLine	CVCL_0030	Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates.
BC8_BioRED_Task1_Doc334	891	898	tritium	Chemical	D014316	METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate.
BC8_BioRED_Task1_Doc334	907	937	estradiol-17beta-D-glucuronide	Chemical	C025483	METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate.
BC8_BioRED_Task1_Doc334	942	959	estrone-3-sulfate	Chemical	C017296	METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate.
BC8_BioRED_Task1_Doc334	977	988	pravastatin	Chemical	D017035	Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry.
BC8_BioRED_Task1_Doc334	990	1002	atorvastatin	Chemical	D000069059	Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry.
BC8_BioRED_Task1_Doc334	1004	1016	cerivastatin	Chemical	C086276	Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry.
BC8_BioRED_Task1_Doc334	1021	1032	simvastatin	Chemical	D019821	Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry.
BC8_BioRED_Task1_Doc334	1144	1151	SLCO1B1	Gene	10599	RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin.
BC8_BioRED_Task1_Doc334	1167	1173	C1007G	SequenceVariant	rs72559747	RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin.
BC8_BioRED_Task1_Doc334	1211	1218	SLCO1B1	Gene	10599	RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin.
BC8_BioRED_Task1_Doc334	1227	1233	C1007G	SequenceVariant	rs72559747	RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin.
BC8_BioRED_Task1_Doc334	1242	1248	C1007G	SequenceVariant	rs72559747	RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin.
BC8_BioRED_Task1_Doc334	1310	1321	simvastatin	Chemical	D019821	RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin.
BC8_BioRED_Task1_Doc334	1343	1354	pravastatin	Chemical	D017035	Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G.
BC8_BioRED_Task1_Doc334	1359	1371	atorvastatin	Chemical	D000069059	Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G.
BC8_BioRED_Task1_Doc334	1471	1478	SLCO1B1	Gene	10599	Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G.
BC8_BioRED_Task1_Doc334	1494	1500	C1007G	SequenceVariant	rs72559747	Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G.
BC8_BioRED_Task1_Doc334	1539	1546	SLCO1B1	Gene	10599	Immunocytochemical study showed that SLCO1B1*5, *15 and *15+C1007G proteins are localized not only at the plasma membrane but also in the intracellular space.
BC8_BioRED_Task1_Doc334	1562	1568	C1007G	SequenceVariant	rs72559747	Immunocytochemical study showed that SLCO1B1*5, *15 and *15+C1007G proteins are localized not only at the plasma membrane but also in the intracellular space.
BC8_BioRED_Task1_Doc334	1702	1708	521T>C	SequenceVariant	c|SUB|T|521|C	CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.
BC8_BioRED_Task1_Doc334	1731	1738	SLCO1B1	Gene	10599	CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.
BC8_BioRED_Task1_Doc334	1754	1760	C1007G	SequenceVariant	rs72559747	CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.
BC8_BioRED_Task1_Doc334	1855	1862	SLCO1B1	Gene	10599	CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.
BC8_BioRED_Task1_Doc334	1878	1884	C1007G	SequenceVariant	rs72559747	CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.
BC8_BioRED_Task1_Doc335	23	33	adriamycin	Chemical	D004317	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
BC8_BioRED_Task1_Doc335	34	45	nephropathy	Disease	D007674	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
BC8_BioRED_Task1_Doc335	63	75	hypertensive	Disease	D006973	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
BC8_BioRED_Task1_Doc335	76	80	rats	OrganismTaxon	10116	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
BC8_BioRED_Task1_Doc335	92	100	losartan	Chemical	D019808	Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
BC8_BioRED_Task1_Doc335	186	216	angiotensin II type-1 receptor	Gene	24180	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	226	234	losartan	Chemical	D019808	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	270	283	renal disease	Disease	D007674	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	313	325	hypertensive	Disease	D006973	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	326	330	rats	OrganismTaxon	10116	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	342	352	adriamycin	Chemical	D004317	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	354	357	ADR	Chemical	D004317	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	359	370	nephropathy	Disease	D007674	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
BC8_BioRED_Task1_Doc335	504	507	ADR	Chemical	D004317	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	512	515	ADR	Chemical	D004317	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	516	519	LOS	Chemical	D019808	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	527	530	ADR	Chemical	D004317	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	540	543	ADR	Chemical	D004317	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	544	547	LOS	Chemical	D019808	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	561	564	ADR	Chemical	D004317	Groups ADR(6), ADR+LOS(6) and ADR(12), and ADR+LOS(12) received ADR (2 mg/kg/b.w.
BC8_BioRED_Task1_Doc335	619	622	ADR	Chemical	D004317	Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR.
BC8_BioRED_Task1_Doc335	623	626	LOS	Chemical	D019808	Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR.
BC8_BioRED_Task1_Doc335	639	647	losartan	Chemical	D019808	Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR.
BC8_BioRED_Task1_Doc335	701	704	ADR	Chemical	D004317	Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR.
BC8_BioRED_Task1_Doc335	705	708	LOS	Chemical	D019808	Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR.
BC8_BioRED_Task1_Doc335	752	755	ADR	Chemical	D004317	Group ADR+LOS(6) received losartan (10 mg/kg/b.w./day by gavages) for 6 weeks and group ADR+LOS(12) for 12 weeks after second injection of ADR.
BC8_BioRED_Task1_Doc335	1020	1028	losartan	Chemical	D019808	RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.
BC8_BioRED_Task1_Doc335	1125	1143	glomerulosclerosis	Disease	D005921	RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.
BC8_BioRED_Task1_Doc335	1167	1178	proteinuria	Disease	D011507	RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.
BC8_BioRED_Task1_Doc335	1205	1213	losartan	Chemical	D019808	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
BC8_BioRED_Task1_Doc335	1242	1260	glomerulosclerosis	Disease	D005921	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
BC8_BioRED_Task1_Doc335	1308	1315	atrophy	Disease	D001284	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
BC8_BioRED_Task1_Doc335	1320	1341	interstitial fibrosis	Disease	D005355	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
BC8_BioRED_Task1_Doc335	1365	1376	proteinuria	Disease	D011507	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
BC8_BioRED_Task1_Doc335	1381	1402	chronic renal failure	Disease	D007676	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
BC8_BioRED_Task1_Doc335	1404	1412	Losartan	Chemical	D019808	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
BC8_BioRED_Task1_Doc335	1421	1428	uraemia	Disease	D014511	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
BC8_BioRED_Task1_Doc335	1443	1447	urea	Chemical	D014508	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
BC8_BioRED_Task1_Doc335	1470	1473	ADR	Chemical	D004317	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
BC8_BioRED_Task1_Doc335	1474	1485	nephropathy	Disease	D007674	Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
BC8_BioRED_Task1_Doc335	1531	1539	losartan	Chemical	D019808	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
BC8_BioRED_Task1_Doc335	1562	1569	atrophy	Disease	D001284	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
BC8_BioRED_Task1_Doc335	1601	1609	fibrosis	Disease	D005355	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
BC8_BioRED_Task1_Doc335	1613	1616	ADR	Chemical	D004317	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
BC8_BioRED_Task1_Doc335	1617	1628	nephropathy	Disease	D007674	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
BC8_BioRED_Task1_Doc335	1642	1650	Losartan	Chemical	D019808	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
BC8_BioRED_Task1_Doc335	1686	1689	ADR	Chemical	D004317	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
BC8_BioRED_Task1_Doc335	1698	1732	focal segmental glomerulosclerosis	Disease	D005923	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
BC8_BioRED_Task1_Doc335	1736	1759	end-stage renal disease	Disease	D007676	CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.
BC8_BioRED_Task1_Doc336	23	49	Solidago virgaurea extract	Chemical	D010936	Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity.
BC8_BioRED_Task1_Doc336	66	80	cardiotoxicity	Disease	D066126	Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity.
BC8_BioRED_Task1_Doc336	82	105	Cardiovascular diseases	Disease	D002318	Cardiovascular diseases (CVDs) are the major health problem of advanced as well as developing countries of the world.
BC8_BioRED_Task1_Doc336	107	111	CVDs	Disease	D002318	Cardiovascular diseases (CVDs) are the major health problem of advanced as well as developing countries of the world.
BC8_BioRED_Task1_Doc336	277	303	Solidago virgaurea extract	Chemical	D010936	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.
BC8_BioRED_Task1_Doc336	307	320	isoproterenol	Chemical	D007545	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.
BC8_BioRED_Task1_Doc336	329	343	cardiotoxicity	Disease	D066126	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.
BC8_BioRED_Task1_Doc336	347	351	rats	OrganismTaxon	10116	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.
BC8_BioRED_Task1_Doc336	383	396	isoproterenol	Chemical	D007545	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	413	417	rats	OrganismTaxon	10116	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	513	534	lactate dehydrogenase	Gene	24533	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	536	558	creatine phosphokinase	Gene	24264	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	560	580	alanine transaminase	Gene	81670	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	582	604	aspartate transaminase	Gene	25721	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	610	639	angiotensin-converting enzyme	Gene	24310	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	658	669	cholesterol	Chemical	D002784	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	671	684	triglycerides	Chemical	D014280	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	697	707	fatty acid	Chemical	D005227	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	724	739	malondialdehyde	Chemical	D008315	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	741	744	MDA	Chemical	D008315	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	751	763	nitric oxide	Chemical	D009569	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	811	822	glutathione	Chemical	D005978	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	827	847	superoxide dismutase	Gene	24786	The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05).
BC8_BioRED_Task1_Doc336	936	956	S. virgaurea extract	Chemical	D010936	Pretreatment with S. virgaurea extract for 5 weeks at a dose of 250 mg/kg followed by isoproterenol injection significantly prevented the observed alterations.
BC8_BioRED_Task1_Doc336	1004	1017	isoproterenol	Chemical	D007545	Pretreatment with S. virgaurea extract for 5 weeks at a dose of 250 mg/kg followed by isoproterenol injection significantly prevented the observed alterations.
BC8_BioRED_Task1_Doc336	1078	1087	Captopril	Chemical	D002216	Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study.
BC8_BioRED_Task1_Doc336	1134	1163	angiotensin-converting enzyme	Gene	24310	Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study.
BC8_BioRED_Task1_Doc336	1183	1204	cardioprotective drug	Chemical	D002316	Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study.
BC8_BioRED_Task1_Doc336	1295	1315	S. virgaurea extract	Chemical	D010936	The data of the present study suggest that S. virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc336	1359	1362	MDA	Chemical	D008315	The data of the present study suggest that S. virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc336	1410	1423	isoproterenol	Chemical	D007545	The data of the present study suggest that S. virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc336	1432	1436	rats	OrganismTaxon	10116	The data of the present study suggest that S. virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc336	1484	1504	S. virgaurea extract	Chemical	D010936	The study emphasizes the beneficial action of S. virgaurea extract as a cardioprotective agent.
BC8_BioRED_Task1_Doc336	1510	1532	cardioprotective agent	Chemical	D002316	The study emphasizes the beneficial action of S. virgaurea extract as a cardioprotective agent.
BC8_BioRED_Task1_Doc337	17	32	cystic fibrosis	Disease	D003550	Gene therapy for cystic fibrosis airway disease- is clinical success imminent?
BC8_BioRED_Task1_Doc337	79	94	Cystic fibrosis	Disease	D003550	Cystic fibrosis (CF) was one of the first inherited disorders for which gene therapy was seriously considered as a realistic option for treatment, and as such, it has long provided a paradigm for gene therapy of inherited diseases.
BC8_BioRED_Task1_Doc337	96	98	CF	Disease	D003550	Cystic fibrosis (CF) was one of the first inherited disorders for which gene therapy was seriously considered as a realistic option for treatment, and as such, it has long provided a paradigm for gene therapy of inherited diseases.
BC8_BioRED_Task1_Doc337	121	140	inherited disorders	Disease	D030342	Cystic fibrosis (CF) was one of the first inherited disorders for which gene therapy was seriously considered as a realistic option for treatment, and as such, it has long provided a paradigm for gene therapy of inherited diseases.
BC8_BioRED_Task1_Doc337	291	309	inherited diseases	Disease	D030342	Cystic fibrosis (CF) was one of the first inherited disorders for which gene therapy was seriously considered as a realistic option for treatment, and as such, it has long provided a paradigm for gene therapy of inherited diseases.
BC8_BioRED_Task1_Doc337	347	398	cystic fibrosis transmembrane conductance regulator	Gene	1080	However, despite the cloning of the cystic fibrosis transmembrane conductance regulator gene in 1989, over 15 years later a practical gene therapy for CF has not eventuated.
BC8_BioRED_Task1_Doc337	462	464	CF	Disease	D003550	However, despite the cloning of the cystic fibrosis transmembrane conductance regulator gene in 1989, over 15 years later a practical gene therapy for CF has not eventuated.
BC8_BioRED_Task1_Doc337	626	628	CF	Disease	D003550	There are a number of reasons for this, and analysis of the specific issues that have delayed the successful development of gene therapy for CF also provides general insights into the practical complexities involved in the development of gene therapy for inherited disorders.
BC8_BioRED_Task1_Doc337	740	759	inherited disorders	Disease	D030342	There are a number of reasons for this, and analysis of the specific issues that have delayed the successful development of gene therapy for CF also provides general insights into the practical complexities involved in the development of gene therapy for inherited disorders.
BC8_BioRED_Task1_Doc337	829	831	CF	Disease	D003550	The issues which have prevented the application of gene therapy for CF to date include the lack of suitable gene delivery technologies, the complexities of the interactions between the host and vector, the biology of the lung airways, and the nature of the pathology found in individuals with CF.
BC8_BioRED_Task1_Doc337	1054	1056	CF	Disease	D003550	The issues which have prevented the application of gene therapy for CF to date include the lack of suitable gene delivery technologies, the complexities of the interactions between the host and vector, the biology of the lung airways, and the nature of the pathology found in individuals with CF.
BC8_BioRED_Task1_Doc337	1089	1091	CF	Disease	D003550	We will discuss the history of CF gene therapy with specific reference to these and other issues that pre-occupy the field at present: namely, the question of what vectors appear to be suitable for airway gene delivery in CF, what cells must be targeted, how airway epithelium defences can be overcome or eluded to allow efficient gene delivery, how to ensure safe and long-term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in CF patients.
BC8_BioRED_Task1_Doc337	1280	1282	CF	Disease	D003550	We will discuss the history of CF gene therapy with specific reference to these and other issues that pre-occupy the field at present: namely, the question of what vectors appear to be suitable for airway gene delivery in CF, what cells must be targeted, how airway epithelium defences can be overcome or eluded to allow efficient gene delivery, how to ensure safe and long-term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in CF patients.
BC8_BioRED_Task1_Doc337	1577	1579	CF	Disease	D003550	We will discuss the history of CF gene therapy with specific reference to these and other issues that pre-occupy the field at present: namely, the question of what vectors appear to be suitable for airway gene delivery in CF, what cells must be targeted, how airway epithelium defences can be overcome or eluded to allow efficient gene delivery, how to ensure safe and long-term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in CF patients.
BC8_BioRED_Task1_Doc337	1580	1588	patients	OrganismTaxon	9606	We will discuss the history of CF gene therapy with specific reference to these and other issues that pre-occupy the field at present: namely, the question of what vectors appear to be suitable for airway gene delivery in CF, what cells must be targeted, how airway epithelium defences can be overcome or eluded to allow efficient gene delivery, how to ensure safe and long-term transgene expression and the need to identify relevant surrogate success measures that can be used to assess the outcome of gene therapy in CF patients.
BC8_BioRED_Task1_Doc338	0	3	Myc	Gene	17869	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
BC8_BioRED_Task1_Doc338	13	28	B-cell receptor	Gene	16019	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
BC8_BioRED_Task1_Doc338	42	54	precancerous	Disease	D011230	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
BC8_BioRED_Task1_Doc338	89	92	Btk	Gene	12229	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
BC8_BioRED_Task1_Doc338	157	160	MYC	Gene	17869	Dysregulation of the oncogenic transcription factor MYC induces B-cell transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL).
BC8_BioRED_Task1_Doc338	211	238	B-cell non-Hodgkin lymphoma	Disease	D016393	Dysregulation of the oncogenic transcription factor MYC induces B-cell transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL).
BC8_BioRED_Task1_Doc338	240	245	B-NHL	Disease	D016393	Dysregulation of the oncogenic transcription factor MYC induces B-cell transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL).
BC8_BioRED_Task1_Doc338	248	251	MYC	Gene	17869	MYC overexpression in B-NHL is associated with more aggressive phenotypes and poor prognosis.
BC8_BioRED_Task1_Doc338	270	275	B-NHL	Disease	D016393	MYC overexpression in B-NHL is associated with more aggressive phenotypes and poor prognosis.
BC8_BioRED_Task1_Doc338	390	393	MYC	Gene	17869	Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated.
BC8_BioRED_Task1_Doc338	413	428	B-cell receptor	Gene	16019	Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated.
BC8_BioRED_Task1_Doc338	430	433	BCR	Gene	16019	Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated.
BC8_BioRED_Task1_Doc338	458	463	B-NHL	Disease	D016393	Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated.
BC8_BioRED_Task1_Doc338	497	500	Myc	Gene	17869	Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated.
BC8_BioRED_Task1_Doc338	653	656	Myc	Gene	17869	We utilized intracellular phospho-flow cytometry to investigate the relationship between Myc and BCR signaling in pre-malignant B cells.
BC8_BioRED_Task1_Doc338	661	664	BCR	Gene	16019	We utilized intracellular phospho-flow cytometry to investigate the relationship between Myc and BCR signaling in pre-malignant B cells.
BC8_BioRED_Task1_Doc338	718	721	myc	Gene	17869	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	722	727	mouse	OrganismTaxon	10090	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	741	744	Myc	Gene	17869	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	813	816	BCR	Gene	16019	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	845	857	precancerous	Disease	D011230	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	880	883	myc	Gene	17869	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	884	888	mice	OrganismTaxon	10090	Utilizing the Eu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from Eu-myc mice compared with wild-type littermates.
BC8_BioRED_Task1_Doc338	949	952	Myc	Gene	17869	B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plcg2 and Erk1/2.
BC8_BioRED_Task1_Doc338	1005	1010	CD79a	Gene	12518	B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plcg2 and Erk1/2.
BC8_BioRED_Task1_Doc338	1012	1015	Btk	Gene	12229	B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plcg2 and Erk1/2.
BC8_BioRED_Task1_Doc338	1017	1022	Plcg2	Gene	234779	B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plcg2 and Erk1/2.
BC8_BioRED_Task1_Doc338	1027	1033	Erk1/2	Gene	26413,26417	B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plcg2 and Erk1/2.
BC8_BioRED_Task1_Doc338	1044	1047	Myc	Gene	17869	Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.
BC8_BioRED_Task1_Doc338	1091	1094	BCR	Gene	16019	Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.
BC8_BioRED_Task1_Doc338	1128	1137	ibrutinib	Chemical	C551803	Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.
BC8_BioRED_Task1_Doc338	1141	1165	Bruton's tyrosine kinase	Gene	695	Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.
BC8_BioRED_Task1_Doc338	1190	1194	PI3K	Gene	18708	Furthermore, PI3K/Akt pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with ibrutinib.
BC8_BioRED_Task1_Doc338	1195	1198	Akt	Gene	11651	Furthermore, PI3K/Akt pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with ibrutinib.
BC8_BioRED_Task1_Doc338	1242	1245	myc	Gene	17869	Furthermore, PI3K/Akt pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with ibrutinib.
BC8_BioRED_Task1_Doc338	1303	1312	ibrutinib	Chemical	C551803	Furthermore, PI3K/Akt pathway signaling was also increased in Eu-myc B cells, and this increase was partially suppressed with ibrutinib.
BC8_BioRED_Task1_Doc338	1344	1347	Btk	Gene	12229	In addition, experiments with Btk-null B cells revealed off-target effects of ibrutinib on BCR signaling.
BC8_BioRED_Task1_Doc338	1392	1401	ibrutinib	Chemical	C551803	In addition, experiments with Btk-null B cells revealed off-target effects of ibrutinib on BCR signaling.
BC8_BioRED_Task1_Doc338	1405	1408	BCR	Gene	16019	In addition, experiments with Btk-null B cells revealed off-target effects of ibrutinib on BCR signaling.
BC8_BioRED_Task1_Doc338	1465	1468	Myc	Gene	17869	Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation.
BC8_BioRED_Task1_Doc338	1510	1513	BCR	Gene	16019	Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation.
BC8_BioRED_Task1_Doc338	1518	1522	PI3K	Gene	18708	Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation.
BC8_BioRED_Task1_Doc338	1523	1526	Akt	Gene	11651	Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation.
BC8_BioRED_Task1_Doc338	1587	1590	BCR	Gene	16019	Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation.
BC8_BioRED_Task1_Doc338	1638	1650	precancerous	Disease	D011230	Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.
BC8_BioRED_Task1_Doc338	1764	1767	MYC	Gene	17869	Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.
BC8_BioRED_Task1_Doc338	1824	1827	BCR	Gene	16019	Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.
BC8_BioRED_Task1_Doc338	1878	1883	B-NHL	Disease	D016393	Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.
BC8_BioRED_Task1_Doc339	12	22	everolimus	Chemical	D000068338	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
BC8_BioRED_Task1_Doc339	24	30	RAD001	Chemical	D000068338	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
BC8_BioRED_Task1_Doc339	35	43	patients	OrganismTaxon	9606	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
BC8_BioRED_Task1_Doc339	58	63	NSCLC	Disease	D002289	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
BC8_BioRED_Task1_Doc339	132	136	EGFR	Gene	1956	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
BC8_BioRED_Task1_Doc339	213	239	non-small-cell lung cancer	Disease	D002289	BACKGROUND: Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients.
BC8_BioRED_Task1_Doc339	241	246	NSCLC	Disease	D002289	BACKGROUND: Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients.
BC8_BioRED_Task1_Doc339	248	256	patients	OrganismTaxon	9606	BACKGROUND: Treatment options are scarce in pretreated advanced non-small-cell lung cancer (NSCLC) patients.
BC8_BioRED_Task1_Doc339	258	264	RAD001	Chemical	D000068338	RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
BC8_BioRED_Task1_Doc339	291	320	mammalian target of rapamycin	Gene	2475	RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
BC8_BioRED_Task1_Doc339	322	326	mTOR	Gene	2475	RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
BC8_BioRED_Task1_Doc339	359	364	NSCLC	Disease	D002289	RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
BC8_BioRED_Task1_Doc339	392	397	NSCLC	Disease	D002289	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
BC8_BioRED_Task1_Doc339	398	406	patients	OrganismTaxon	9606	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
BC8_BioRED_Task1_Doc339	459	467	platinum	Chemical	D010984	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
BC8_BioRED_Task1_Doc339	511	559	epidermal growth factor receptor tyrosine kinase	Gene	1956	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
BC8_BioRED_Task1_Doc339	593	599	RAD001	Chemical	D000068338	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
BC8_BioRED_Task1_Doc339	644	652	toxicity	Disease	D064420	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
BC8_BioRED_Task1_Doc339	745	749	mTOR	Gene	2475	Analyses of markers associated with the mTOR pathway were carried out on archival tumor from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing.
BC8_BioRED_Task1_Doc339	787	792	tumor	Disease	D009369	Analyses of markers associated with the mTOR pathway were carried out on archival tumor from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing.
BC8_BioRED_Task1_Doc339	895	903	patients	OrganismTaxon	9606	RESULTS: Eighty-five patients were enrolled, 42 in stratum 1 and 43 in stratum.
BC8_BioRED_Task1_Doc339	1164	1171	fatigue	Disease	D005221	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia.
BC8_BioRED_Task1_Doc339	1173	1180	dyspnea	Disease	D004417	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia.
BC8_BioRED_Task1_Doc339	1182	1192	stomatitis	Disease	D013280	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia.
BC8_BioRED_Task1_Doc339	1194	1200	anemia	Disease	D000740	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia.
BC8_BioRED_Task1_Doc339	1206	1222	thrombocytopenia	Disease	D013921	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and thrombocytopenia.
BC8_BioRED_Task1_Doc339	1224	1235	Pneumonitis	Disease	D011014	Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%.
BC8_BioRED_Task1_Doc339	1364	1367	AKT	Gene	207	Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS.
BC8_BioRED_Task1_Doc339	1369	1373	pAKT	Gene	207	Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS.
BC8_BioRED_Task1_Doc339	1442	1448	RAD001	Chemical	D000068338	CONCLUSIONS: RAD001 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC.
BC8_BioRED_Task1_Doc339	1526	1531	NSCLC	Disease	D002289	CONCLUSIONS: RAD001 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC.
BC8_BioRED_Task1_Doc339	1547	1553	RAD001	Chemical	D000068338	Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues.
BC8_BioRED_Task1_Doc339	1591	1596	NSCLC	Disease	D002289	Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues.
BC8_BioRED_Task1_Doc340	21	27	emodin	Chemical	D004642	Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
BC8_BioRED_Task1_Doc340	31	50	fatty acid synthase	Gene	2194	Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
BC8_BioRED_Task1_Doc340	52	64	colon cancer	Disease	D015179	Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
BC8_BioRED_Task1_Doc340	94	113	Fatty acid synthase	Gene	2194	Fatty acid synthase (FASN) is a key anabolic enzyme for de novo fatty acid synthesis, which is important in the development of colon carcinoma.
BC8_BioRED_Task1_Doc340	115	119	FASN	Gene	2194	Fatty acid synthase (FASN) is a key anabolic enzyme for de novo fatty acid synthesis, which is important in the development of colon carcinoma.
BC8_BioRED_Task1_Doc340	158	168	fatty acid	Chemical	D005227	Fatty acid synthase (FASN) is a key anabolic enzyme for de novo fatty acid synthesis, which is important in the development of colon carcinoma.
BC8_BioRED_Task1_Doc340	221	236	colon carcinoma	Disease	D015179	Fatty acid synthase (FASN) is a key anabolic enzyme for de novo fatty acid synthesis, which is important in the development of colon carcinoma.
BC8_BioRED_Task1_Doc340	261	265	FASN	Gene	2194	The high expression of FASN is considered a promising molecular target for colon cancer therapy.
BC8_BioRED_Task1_Doc340	313	325	colon cancer	Disease	D015179	The high expression of FASN is considered a promising molecular target for colon cancer therapy.
BC8_BioRED_Task1_Doc340	335	341	Emodin	Chemical	D004642	Emodin, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including colon cancer; however, the molecular mechanisms remain to be fully elucidated.
BC8_BioRED_Task1_Doc340	365	378	anthraquinone	Chemical	D000880	Emodin, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including colon cancer; however, the molecular mechanisms remain to be fully elucidated.
BC8_BioRED_Task1_Doc340	430	435	human	OrganismTaxon	9606	Emodin, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including colon cancer; however, the molecular mechanisms remain to be fully elucidated.
BC8_BioRED_Task1_Doc340	436	442	cancer	Disease	D009369	Emodin, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including colon cancer; however, the molecular mechanisms remain to be fully elucidated.
BC8_BioRED_Task1_Doc340	454	466	colon cancer	Disease	D015179	Emodin, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including colon cancer; however, the molecular mechanisms remain to be fully elucidated.
BC8_BioRED_Task1_Doc340	669	678	Annexin V	Gene	308	The apoptosis rate of cells was quantified via flow cytometry following Annexin V/propidium iodide staining.
BC8_BioRED_Task1_Doc340	679	695	propidium iodide	Chemical	D011419	The apoptosis rate of cells was quantified via flow cytometry following Annexin V/propidium iodide staining.
BC8_BioRED_Task1_Doc340	706	710	FASN	Gene	2194	FASN activity was measured by monitoring oxidation of nicotinamide adenine dinucleotide phosphate at a wavelength of 340 nm, and intracellular free fatty acid levels were detected using a Free Fatty Acid Quantification kit.
BC8_BioRED_Task1_Doc340	760	803	nicotinamide adenine dinucleotide phosphate	Chemical	D009249	FASN activity was measured by monitoring oxidation of nicotinamide adenine dinucleotide phosphate at a wavelength of 340 nm, and intracellular free fatty acid levels were detected using a Free Fatty Acid Quantification kit.
BC8_BioRED_Task1_Doc340	849	864	free fatty acid	Chemical	D005230	FASN activity was measured by monitoring oxidation of nicotinamide adenine dinucleotide phosphate at a wavelength of 340 nm, and intracellular free fatty acid levels were detected using a Free Fatty Acid Quantification kit.
BC8_BioRED_Task1_Doc340	894	909	Free Fatty Acid	Chemical	D005230	FASN activity was measured by monitoring oxidation of nicotinamide adenine dinucleotide phosphate at a wavelength of 340 nm, and intracellular free fatty acid levels were detected using a Free Fatty Acid Quantification kit.
BC8_BioRED_Task1_Doc340	1138	1142	FASN	Gene	2194	The present study was performed to investigate whether the gene expression of FASN and its enzymatic activity are regulated by emodin in a human colon cancer cell line.
BC8_BioRED_Task1_Doc340	1187	1193	emodin	Chemical	D004642	The present study was performed to investigate whether the gene expression of FASN and its enzymatic activity are regulated by emodin in a human colon cancer cell line.
BC8_BioRED_Task1_Doc340	1199	1204	human	OrganismTaxon	9606	The present study was performed to investigate whether the gene expression of FASN and its enzymatic activity are regulated by emodin in a human colon cancer cell line.
BC8_BioRED_Task1_Doc340	1205	1217	colon cancer	Disease	D015179	The present study was performed to investigate whether the gene expression of FASN and its enzymatic activity are regulated by emodin in a human colon cancer cell line.
BC8_BioRED_Task1_Doc340	1229	1235	Emodin	Chemical	D004642	Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.
BC8_BioRED_Task1_Doc340	1276	1282	HCT116	CellLine	CVCL_0291	Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.
BC8_BioRED_Task1_Doc340	1319	1323	FASN	Gene	2194	Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.
BC8_BioRED_Task1_Doc340	1361	1366	SW480	CellLine	CVCL_0546	Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.
BC8_BioRED_Task1_Doc340	1368	1375	SNU-C2A	CellLine	CVCL_1709	Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.
BC8_BioRED_Task1_Doc340	1379	1385	SNU-C5	CellLine	CVCL_5112	Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells.
BC8_BioRED_Task1_Doc340	1393	1399	Emodin	Chemical	D004642	Emodin significantly downregulated the protein expression of FASN in HCT116 cells, which was caused by protein degradation due to elevated protein ubiquitination.
BC8_BioRED_Task1_Doc340	1454	1458	FASN	Gene	2194	Emodin significantly downregulated the protein expression of FASN in HCT116 cells, which was caused by protein degradation due to elevated protein ubiquitination.
BC8_BioRED_Task1_Doc340	1462	1468	HCT116	CellLine	CVCL_0291	Emodin significantly downregulated the protein expression of FASN in HCT116 cells, which was caused by protein degradation due to elevated protein ubiquitination.
BC8_BioRED_Task1_Doc340	1556	1562	Emodin	Chemical	D004642	Emodin also inhibited intracellular FASN enzymatic activity and reduced the levels of intracellular free fatty acids.
BC8_BioRED_Task1_Doc340	1592	1596	FASN	Gene	2194	Emodin also inhibited intracellular FASN enzymatic activity and reduced the levels of intracellular free fatty acids.
BC8_BioRED_Task1_Doc340	1656	1672	free fatty acids	Chemical	D005230	Emodin also inhibited intracellular FASN enzymatic activity and reduced the levels of intracellular free fatty acids.
BC8_BioRED_Task1_Doc340	1674	1680	Emodin	Chemical	D004642	Emodin enhanced antiproliferation and apoptosis in a dose- and time-dependent manner.
BC8_BioRED_Task1_Doc340	1786	1792	emodin	Chemical	D004642	The combined treatment of emodin and cerulenin, a commercial FASN inhibitor, had an additive effect on these activities.
BC8_BioRED_Task1_Doc340	1797	1806	cerulenin	Chemical	D002569	The combined treatment of emodin and cerulenin, a commercial FASN inhibitor, had an additive effect on these activities.
BC8_BioRED_Task1_Doc340	1821	1825	FASN	Gene	2194	The combined treatment of emodin and cerulenin, a commercial FASN inhibitor, had an additive effect on these activities.
BC8_BioRED_Task1_Doc340	1881	1890	Palmitate	Chemical	D010168	Palmitate, the final product of the FASN reaction, rescued emodin-induced viability and apoptosis.
BC8_BioRED_Task1_Doc340	1917	1921	FASN	Gene	2194	Palmitate, the final product of the FASN reaction, rescued emodin-induced viability and apoptosis.
BC8_BioRED_Task1_Doc340	1940	1946	emodin	Chemical	D004642	Palmitate, the final product of the FASN reaction, rescued emodin-induced viability and apoptosis.
BC8_BioRED_Task1_Doc340	1993	1999	emodin	Chemical	D004642	In addition, emodin altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.
BC8_BioRED_Task1_Doc340	2008	2012	FASN	Gene	2194	In addition, emodin altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.
BC8_BioRED_Task1_Doc340	2052	2081	phosphatidylinositol 3-kinase	Gene	5291	In addition, emodin altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.
BC8_BioRED_Task1_Doc340	2082	2085	Akt	Gene	207	In addition, emodin altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.
BC8_BioRED_Task1_Doc340	2090	2166	mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2	Gene	5594,5595	In addition, emodin altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2.
BC8_BioRED_Task1_Doc340	2197	2203	emodin	Chemical	D004642	These results suggested that emodin-regulated cell growth and apoptosis were mediated by inhibiting FASN and provide a molecular basis for colon cancer therapy.
BC8_BioRED_Task1_Doc340	2268	2272	FASN	Gene	2194	These results suggested that emodin-regulated cell growth and apoptosis were mediated by inhibiting FASN and provide a molecular basis for colon cancer therapy.
BC8_BioRED_Task1_Doc340	2307	2319	colon cancer	Disease	D015179	These results suggested that emodin-regulated cell growth and apoptosis were mediated by inhibiting FASN and provide a molecular basis for colon cancer therapy.
BC8_BioRED_Task1_Doc341	61	67	RAB-28	Gene	189429	Whole-Organism Developmental Expression Profiling Identifies RAB-28 as a Novel Ciliary GTPase Associated with the BBSome and Intraflagellar Transport.
BC8_BioRED_Task1_Doc341	87	93	GTPase	Gene	189429	Whole-Organism Developmental Expression Profiling Identifies RAB-28 as a Novel Ciliary GTPase Associated with the BBSome and Intraflagellar Transport.
BC8_BioRED_Task1_Doc341	114	120	BBSome	Gene	260219	Whole-Organism Developmental Expression Profiling Identifies RAB-28 as a Novel Ciliary GTPase Associated with the BBSome and Intraflagellar Transport.
BC8_BioRED_Task1_Doc341	313	338	inherited human disorders	Disease	D030342	Defects in these organelles cause inherited human disorders (ciliopathies) such as retinitis pigmentosa and Bardet-Biedl syndrome (BBS), frequently affecting many physiological and developmental processes across multiple organs.
BC8_BioRED_Task1_Doc341	340	352	ciliopathies	Disease	D000072661	Defects in these organelles cause inherited human disorders (ciliopathies) such as retinitis pigmentosa and Bardet-Biedl syndrome (BBS), frequently affecting many physiological and developmental processes across multiple organs.
BC8_BioRED_Task1_Doc341	362	382	retinitis pigmentosa	Disease	D012174	Defects in these organelles cause inherited human disorders (ciliopathies) such as retinitis pigmentosa and Bardet-Biedl syndrome (BBS), frequently affecting many physiological and developmental processes across multiple organs.
BC8_BioRED_Task1_Doc341	387	408	Bardet-Biedl syndrome	Disease	D020788	Defects in these organelles cause inherited human disorders (ciliopathies) such as retinitis pigmentosa and Bardet-Biedl syndrome (BBS), frequently affecting many physiological and developmental processes across multiple organs.
BC8_BioRED_Task1_Doc341	410	413	BBS	Disease	D020788	Defects in these organelles cause inherited human disorders (ciliopathies) such as retinitis pigmentosa and Bardet-Biedl syndrome (BBS), frequently affecting many physiological and developmental processes across multiple organs.
BC8_BioRED_Task1_Doc341	652	661	kinesin-2	Gene	177685	Cilium formation, maintenance and function depend on intracellular transport systems such as intraflagellar transport (IFT), which is driven by kinesin-2 and IFT-dynein motors and regulated by the Bardet-Biedl syndrome (BBS) cargo-adaptor protein complex, or BBSome.
BC8_BioRED_Task1_Doc341	670	676	dynein	Gene	172041	Cilium formation, maintenance and function depend on intracellular transport systems such as intraflagellar transport (IFT), which is driven by kinesin-2 and IFT-dynein motors and regulated by the Bardet-Biedl syndrome (BBS) cargo-adaptor protein complex, or BBSome.
BC8_BioRED_Task1_Doc341	705	762	Bardet-Biedl syndrome (BBS) cargo-adaptor protein complex	Gene	260219	Cilium formation, maintenance and function depend on intracellular transport systems such as intraflagellar transport (IFT), which is driven by kinesin-2 and IFT-dynein motors and regulated by the Bardet-Biedl syndrome (BBS) cargo-adaptor protein complex, or BBSome.
BC8_BioRED_Task1_Doc341	767	773	BBSome	Gene	260219	Cilium formation, maintenance and function depend on intracellular transport systems such as intraflagellar transport (IFT), which is driven by kinesin-2 and IFT-dynein motors and regulated by the Bardet-Biedl syndrome (BBS) cargo-adaptor protein complex, or BBSome.
BC8_BioRED_Task1_Doc341	841	851	C. elegans	OrganismTaxon	6239	To identify new cilium-associated genes, we employed the nematode C. elegans, where ciliogenesis occurs within a short timespan during late embryogenesis when most sensory neurons differentiate.
BC8_BioRED_Task1_Doc341	1124	1131	FAM-161	Gene	189695	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1133	1140	FAM161A	Gene	84140	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1154	1162	CCDC-104	Gene	112942	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1164	1171	CCDC104	Gene	112942	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1178	1183	RPI-1	Gene	189281	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1185	1188	RP1	Gene	6101	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1189	1194	RP1L1	Gene	94137	Using whole-organism RNA-Seq libraries, we discovered a signature expression profile highly enriched for transcripts of known ciliary proteins, including FAM-161 (FAM161A orthologue), CCDC-104 (CCDC104), and RPI-1 (RP1/RP1L1), which we confirm are cilium-localised in worms.
BC8_BioRED_Task1_Doc341	1315	1320	human	OrganismTaxon	9606	From a list of 185 candidate ciliary genes, we uncover orthologues of human MAP9, YAP, CCDC149, and RAB28 as conserved cilium-associated components.
BC8_BioRED_Task1_Doc341	1321	1325	MAP9	Gene	79884	From a list of 185 candidate ciliary genes, we uncover orthologues of human MAP9, YAP, CCDC149, and RAB28 as conserved cilium-associated components.
BC8_BioRED_Task1_Doc341	1327	1330	YAP	Gene	10413	From a list of 185 candidate ciliary genes, we uncover orthologues of human MAP9, YAP, CCDC149, and RAB28 as conserved cilium-associated components.
BC8_BioRED_Task1_Doc341	1332	1339	CCDC149	Gene	91050	From a list of 185 candidate ciliary genes, we uncover orthologues of human MAP9, YAP, CCDC149, and RAB28 as conserved cilium-associated components.
BC8_BioRED_Task1_Doc341	1345	1350	RAB28	Gene	9364	From a list of 185 candidate ciliary genes, we uncover orthologues of human MAP9, YAP, CCDC149, and RAB28 as conserved cilium-associated components.
BC8_BioRED_Task1_Doc341	1414	1424	C. elegans	OrganismTaxon	6239	Further analyses of C. elegans RAB-28, recently associated with autosomal-recessive cone-rod dystrophy, reveal that this small GTPase is exclusively expressed in ciliated neurons where it dynamically associates with IFT trains.
BC8_BioRED_Task1_Doc341	1425	1431	RAB-28	Gene	189429	Further analyses of C. elegans RAB-28, recently associated with autosomal-recessive cone-rod dystrophy, reveal that this small GTPase is exclusively expressed in ciliated neurons where it dynamically associates with IFT trains.
BC8_BioRED_Task1_Doc341	1478	1496	cone-rod dystrophy	Disease	D000071700	Further analyses of C. elegans RAB-28, recently associated with autosomal-recessive cone-rod dystrophy, reveal that this small GTPase is exclusively expressed in ciliated neurons where it dynamically associates with IFT trains.
BC8_BioRED_Task1_Doc341	1521	1527	GTPase	Gene	189429	Further analyses of C. elegans RAB-28, recently associated with autosomal-recessive cone-rod dystrophy, reveal that this small GTPase is exclusively expressed in ciliated neurons where it dynamically associates with IFT trains.
BC8_BioRED_Task1_Doc341	1639	1642	GDP	Chemical	D006153	Whereas inactive GDP-bound RAB-28 displays no IFT movement and diffuse localisation, GTP-bound (activated) RAB-28 concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.
BC8_BioRED_Task1_Doc341	1649	1655	RAB-28	Gene	189429	Whereas inactive GDP-bound RAB-28 displays no IFT movement and diffuse localisation, GTP-bound (activated) RAB-28 concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.
BC8_BioRED_Task1_Doc341	1707	1710	GTP	Chemical	D006160	Whereas inactive GDP-bound RAB-28 displays no IFT movement and diffuse localisation, GTP-bound (activated) RAB-28 concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.
BC8_BioRED_Task1_Doc341	1729	1735	RAB-28	Gene	189429	Whereas inactive GDP-bound RAB-28 displays no IFT movement and diffuse localisation, GTP-bound (activated) RAB-28 concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.
BC8_BioRED_Task1_Doc341	1782	1788	BBSome	Gene	260219	Whereas inactive GDP-bound RAB-28 displays no IFT movement and diffuse localisation, GTP-bound (activated) RAB-28 concentrates at the periciliary membrane in a BBSome-dependent manner and undergoes bidirectional IFT.
BC8_BioRED_Task1_Doc341	1947	1953	rab-28	Gene	189429	Functional analyses reveal that whilst cilium structure, sensory function and IFT are seemingly normal in a rab-28 null allele, overexpression of predicted GDP or GTP locked variants of RAB-28 perturbs cilium and sensory pore morphogenesis and function.
BC8_BioRED_Task1_Doc341	1995	1998	GDP	Chemical	D006153	Functional analyses reveal that whilst cilium structure, sensory function and IFT are seemingly normal in a rab-28 null allele, overexpression of predicted GDP or GTP locked variants of RAB-28 perturbs cilium and sensory pore morphogenesis and function.
BC8_BioRED_Task1_Doc341	2002	2005	GTP	Chemical	D006160	Functional analyses reveal that whilst cilium structure, sensory function and IFT are seemingly normal in a rab-28 null allele, overexpression of predicted GDP or GTP locked variants of RAB-28 perturbs cilium and sensory pore morphogenesis and function.
BC8_BioRED_Task1_Doc341	2025	2031	RAB-28	Gene	189429	Functional analyses reveal that whilst cilium structure, sensory function and IFT are seemingly normal in a rab-28 null allele, overexpression of predicted GDP or GTP locked variants of RAB-28 perturbs cilium and sensory pore morphogenesis and function.
BC8_BioRED_Task1_Doc341	2188	2193	RAB28	Gene	9364	Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the BBS protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.
BC8_BioRED_Task1_Doc341	2197	2203	GTPase	Gene	9364	Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the BBS protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.
BC8_BioRED_Task1_Doc341	2232	2235	BBS	Disease	D020788	Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the BBS protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.
BC8_BioRED_Task1_Doc341	2244	2249	RABL4	Gene	11020	Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the BBS protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.
BC8_BioRED_Task1_Doc341	2250	2255	IFT27	Gene	11020	Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the BBS protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.
BC8_BioRED_Task1_Doc341	2289	2295	BBSome	Gene	260219	Collectively, our findings present a new approach for identifying ciliary proteins, and unveil RAB28, a GTPase most closely related to the BBS protein RABL4/IFT27, as an IFT-associated cargo with BBSome-dependent cell autonomous and non-autonomous functions at the ciliary base.
BC8_BioRED_Task1_Doc342	31	58	anabolic androgenic steroid	Chemical	D045165	Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.
BC8_BioRED_Task1_Doc342	76	80	rats	OrganismTaxon	10116	Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.
BC8_BioRED_Task1_Doc342	90	99	serotonin	Chemical	D012701	Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.
BC8_BioRED_Task1_Doc342	173	200	anabolic androgenic steroid	Chemical	D045165	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.
BC8_BioRED_Task1_Doc342	202	205	AAS	Chemical	D045165	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.
BC8_BioRED_Task1_Doc342	226	235	serotonin	Chemical	D012701	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.
BC8_BioRED_Task1_Doc342	237	256	5-hydroxytryptamine	Chemical	D012701	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.
BC8_BioRED_Task1_Doc342	258	262	5-HT	Chemical	D012701	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.
BC8_BioRED_Task1_Doc342	303	307	rats	OrganismTaxon	10116	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.
BC8_BioRED_Task1_Doc342	309	318	Serotonin	Chemical	D012701	Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
BC8_BioRED_Task1_Doc342	367	390	parachlorophenylalanine	Chemical	D010134	Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
BC8_BioRED_Task1_Doc342	392	396	PCPA	Chemical	D010134	Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
BC8_BioRED_Task1_Doc342	479	483	PCPA	Chemical	D010134	At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).
BC8_BioRED_Task1_Doc342	492	496	rats	OrganismTaxon	10116	At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).
BC8_BioRED_Task1_Doc342	525	529	rats	OrganismTaxon	10116	At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).
BC8_BioRED_Task1_Doc342	551	563	testosterone	Chemical	D013739	At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).
BC8_BioRED_Task1_Doc342	565	566	T	Chemical	D013739	At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).
BC8_BioRED_Task1_Doc342	632	644	irritability	Disease	D001523	Behavioral measures included locomotion, irritability, copulation, partner preference, and aggression.
BC8_BioRED_Task1_Doc342	682	692	aggression	Disease	D001523	Behavioral measures included locomotion, irritability, copulation, partner preference, and aggression.
BC8_BioRED_Task1_Doc342	718	728	aggression	Disease	D001523	Animals were tested for aggression in their home cage, both with and without physical provocation (mild tail pinch).
BC8_BioRED_Task1_Doc342	827	831	5-HT	Chemical	D012701	Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.
BC8_BioRED_Task1_Doc342	852	878	5-hydroxyindoleacetic acid	Chemical	D006897	Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.
BC8_BioRED_Task1_Doc342	880	886	5-HIAA	Chemical	D006897	Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.
BC8_BioRED_Task1_Doc342	917	921	PCPA	Chemical	D010134	PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.
BC8_BioRED_Task1_Doc342	963	967	5-HT	Chemical	D012701	PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.
BC8_BioRED_Task1_Doc342	972	978	5-HIAA	Chemical	D006897	PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.
BC8_BioRED_Task1_Doc342	1018	1019	T	Chemical	D013739	Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.
BC8_BioRED_Task1_Doc342	1054	1058	5-HT	Chemical	D012701	Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.
BC8_BioRED_Task1_Doc342	1063	1069	5-HIAA	Chemical	D006897	Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.
BC8_BioRED_Task1_Doc342	1127	1131	PCPA	Chemical	D010134	Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.
BC8_BioRED_Task1_Doc342	1153	1157	PCPA	Chemical	D010134	Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
BC8_BioRED_Task1_Doc342	1221	1233	irritability	Disease	D001523	Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
BC8_BioRED_Task1_Doc342	1295	1305	aggression	Disease	D001523	Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
BC8_BioRED_Task1_Doc342	1307	1308	T	Chemical	D013739	T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.
BC8_BioRED_Task1_Doc342	1344	1356	irritability	Disease	D001523	T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.
BC8_BioRED_Task1_Doc342	1414	1424	aggression	Disease	D001523	T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.
BC8_BioRED_Task1_Doc342	1464	1465	T	Chemical	D013739	The most striking effect of combining T+PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.
BC8_BioRED_Task1_Doc342	1466	1470	PCPA	Chemical	D010134	The most striking effect of combining T+PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.
BC8_BioRED_Task1_Doc342	1679	1682	AAS	Chemical	D045165	Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.
BC8_BioRED_Task1_Doc342	1706	1710	5-HT	Chemical	D012701	Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.
BC8_BioRED_Task1_Doc342	1746	1765	aggressive behavior	Disease	D001523	Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit aggressive behavior.
BC8_BioRED_Task1_Doc343	40	44	mice	OrganismTaxon	10090	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
BC8_BioRED_Task1_Doc343	61	80	garcinielliptone FC	Chemical	C573355	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
BC8_BioRED_Task1_Doc343	84	95	pilocarpine	Chemical	D010862	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
BC8_BioRED_Task1_Doc343	104	112	seizures	Disease	D012640	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.
BC8_BioRED_Task1_Doc343	114	133	Garcinielliptone FC	Chemical	C573355	Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart.
BC8_BioRED_Task1_Doc343	135	138	GFC	Chemical	C573355	Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart.
BC8_BioRED_Task1_Doc343	195	217	Platonia insignis Mart	OrganismTaxon	198787	Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart.
BC8_BioRED_Task1_Doc343	263	276	skin diseases	Disease	D012871	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases.
BC8_BioRED_Task1_Doc343	285	291	humans	OrganismTaxon	9606	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases.
BC8_BioRED_Task1_Doc343	357	366	diarrheas	Disease	D003967	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases.
BC8_BioRED_Task1_Doc343	371	392	inflammatory diseases	Disease	D007249	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases.
BC8_BioRED_Task1_Doc343	427	430	GFC	Chemical	C573355	However, there is no research on GFC effects in the central nervous system of rodents.
BC8_BioRED_Task1_Doc343	521	524	GFC	Chemical	C573355	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	567	574	seizure	Disease	D012640	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	660	679	r-aminobutyric acid	Chemical	D005680	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	681	685	GABA	Chemical	D005680	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	688	697	glutamine	Chemical	D018698	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	699	708	aspartate	Chemical	D001224	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	713	724	glutathione	Chemical	D005978	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	747	767	acetylcholinesterase	Gene	11423	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	769	773	AChE	Gene	11423	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	787	791	mice	OrganismTaxon	10090	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	810	818	seizures	Disease	D012640	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
BC8_BioRED_Task1_Doc343	820	823	GFC	Chemical	C573355	GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.
BC8_BioRED_Task1_Doc343	863	870	seizure	Disease	D012640	GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.
BC8_BioRED_Task1_Doc343	993	997	mice	OrganismTaxon	10090	GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.
BC8_BioRED_Task1_Doc343	1012	1016	GABA	Chemical	D005680	In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice.
BC8_BioRED_Task1_Doc343	1028	1032	mice	OrganismTaxon	10090	In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice.
BC8_BioRED_Task1_Doc343	1058	1063	GFC75	Chemical	C573355	In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice.
BC8_BioRED_Task1_Doc343	1069	1073	P400	Chemical	D010862	In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice.
BC8_BioRED_Task1_Doc343	1129	1133	mice	OrganismTaxon	10090	In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice.
BC8_BioRED_Task1_Doc343	1138	1147	aspartate	Chemical	D001224	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1149	1158	glutamine	Chemical	D018698	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1163	1172	glutamate	Chemical	D018698	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1245	1249	mice	OrganismTaxon	10090	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1275	1280	GFC75	Chemical	C573355	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1286	1290	P400	Chemical	D010862	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1317	1321	mice	OrganismTaxon	10090	In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice.
BC8_BioRED_Task1_Doc343	1335	1339	mice	OrganismTaxon	10090	Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice.
BC8_BioRED_Task1_Doc343	1353	1358	GFC75	Chemical	C573355	Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice.
BC8_BioRED_Task1_Doc343	1364	1368	P400	Chemical	D010862	Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice.
BC8_BioRED_Task1_Doc343	1391	1395	AChE	Gene	11423	Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice.
BC8_BioRED_Task1_Doc343	1440	1444	mice	OrganismTaxon	10090	Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice.
BC8_BioRED_Task1_Doc343	1472	1475	GFC	Chemical	C573355	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
BC8_BioRED_Task1_Doc343	1554	1565	pilocarpine	Chemical	D010862	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
BC8_BioRED_Task1_Doc343	1574	1592	status epilepticus	Disease	D013226	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
BC8_BioRED_Task1_Doc343	1642	1649	seizure	Disease	D012640	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
BC8_BioRED_Task1_Doc343	1730	1733	GFC	Chemical	C573355	In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.
BC8_BioRED_Task1_Doc343	1805	1816	pilocarpine	Chemical	D010862	In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.
BC8_BioRED_Task1_Doc343	1841	1845	GABA	Chemical	D005680	In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.
BC8_BioRED_Task1_Doc343	1850	1859	glutamate	Chemical	D018698	In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.
BC8_BioRED_Task1_Doc343	1876	1880	AChE	Gene	11423	In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.
BC8_BioRED_Task1_Doc343	1900	1904	mice	OrganismTaxon	10090	In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and glutamate contents and of AChE activity in seized mice hippocampus.
BC8_BioRED_Task1_Doc344	57	66	b-catenin	Gene	12387	Disruption of the temporally regulated cloaca endodermal b-catenin signaling causes anorectal malformations.
BC8_BioRED_Task1_Doc344	84	107	anorectal malformations	Disease	D000071056	Disruption of the temporally regulated cloaca endodermal b-catenin signaling causes anorectal malformations.
BC8_BioRED_Task1_Doc344	254	278	congenital malformations	Disease	D000013	Although congenital malformations, such as anorectal malformations (ARMs), are frequently observed during this process, the underlying pathogenic mechanisms remain unclear.
BC8_BioRED_Task1_Doc344	288	311	anorectal malformations	Disease	D000071056	Although congenital malformations, such as anorectal malformations (ARMs), are frequently observed during this process, the underlying pathogenic mechanisms remain unclear.
BC8_BioRED_Task1_Doc344	313	317	ARMs	Disease	D000071056	Although congenital malformations, such as anorectal malformations (ARMs), are frequently observed during this process, the underlying pathogenic mechanisms remain unclear.
BC8_BioRED_Task1_Doc344	418	427	b-Catenin	Gene	12387	b-Catenin is a critical component of canonical Wnt signaling and is essential for the regulation of cell differentiation and morphogenesis during embryogenesis.
BC8_BioRED_Task1_Doc344	465	468	Wnt	Gene	22408	b-Catenin is a critical component of canonical Wnt signaling and is essential for the regulation of cell differentiation and morphogenesis during embryogenesis.
BC8_BioRED_Task1_Doc344	597	606	b-catenin	Gene	12387	The expression of b-catenin is observed in endodermal epithelia, including URS epithelia.
BC8_BioRED_Task1_Doc344	686	695	b-catenin	Gene	12387	We modulated the b-catenin gene conditionally in endodermal epithelia by utilizing tamoxifen-inducible Cre driver line (Shh(CreERT2)).
BC8_BioRED_Task1_Doc344	752	761	tamoxifen	Chemical	D013629	We modulated the b-catenin gene conditionally in endodermal epithelia by utilizing tamoxifen-inducible Cre driver line (Shh(CreERT2)).
BC8_BioRED_Task1_Doc344	789	792	Shh	Gene	20423	We modulated the b-catenin gene conditionally in endodermal epithelia by utilizing tamoxifen-inducible Cre driver line (Shh(CreERT2)).
BC8_BioRED_Task1_Doc344	809	818	b-catenin	Gene	12387	Both b-catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
BC8_BioRED_Task1_Doc344	921	932	hypoplastic	Disease	D029502	Both b-catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
BC8_BioRED_Task1_Doc344	1050	1059	b-catenin	Gene	12387	In addition, the b-catenin GOF mutants displayed reduced apoptosis and subsequently increased apoptosis in the URS epithelium.
BC8_BioRED_Task1_Doc344	1260	1269	keratin 1	Gene	16678	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
BC8_BioRED_Task1_Doc344	1274	1283	filaggrin	Gene	14246	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
BC8_BioRED_Task1_Doc344	1330	1356	bone morphogenetic protein	Gene	12159,12162	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1358	1361	Bmp	Gene	12159,12162	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1378	1382	Bmp4	Gene	12159	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1387	1391	Bmp7	Gene	12162	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1457	1466	b-catenin	Gene	12387	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1502	1506	Msx2	Gene	17702	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
BC8_BioRED_Task1_Doc344	1531	1540	Smad1/5/8	Gene	17125,17129,55994	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
BC8_BioRED_Task1_Doc344	1563	1566	Bmp	Gene	12159,12162	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
BC8_BioRED_Task1_Doc344	1666	1678	Bmp receptor	Gene	12166	Moreover, we introduced an additional mutation for a Bmp receptor gene: BmprIA.
BC8_BioRED_Task1_Doc344	1685	1691	BmprIA	Gene	12166	Moreover, we introduced an additional mutation for a Bmp receptor gene: BmprIA.
BC8_BioRED_Task1_Doc344	1697	1700	Shh	Gene	20423	The Shh(CreERT2/+); b-catenin(flox(ex3)/+); BmprIA(flox/-) mutants displayed partial restoration of URS elongation compared with the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1713	1722	b-catenin	Gene	12387	The Shh(CreERT2/+); b-catenin(flox(ex3)/+); BmprIA(flox/-) mutants displayed partial restoration of URS elongation compared with the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1737	1743	BmprIA	Gene	12166	The Shh(CreERT2/+); b-catenin(flox(ex3)/+); BmprIA(flox/-) mutants displayed partial restoration of URS elongation compared with the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1826	1835	b-catenin	Gene	12387	The Shh(CreERT2/+); b-catenin(flox(ex3)/+); BmprIA(flox/-) mutants displayed partial restoration of URS elongation compared with the b-catenin GOF mutants.
BC8_BioRED_Task1_Doc344	1882	1885	ARM	Disease	D000071056	These results indicate that some ARM phenotypes in the b-catenin GOF mutants were caused by abnormal Bmp signaling.
BC8_BioRED_Task1_Doc344	1904	1913	b-catenin	Gene	12387	These results indicate that some ARM phenotypes in the b-catenin GOF mutants were caused by abnormal Bmp signaling.
BC8_BioRED_Task1_Doc344	1950	1953	Bmp	Gene	12159,12162	These results indicate that some ARM phenotypes in the b-catenin GOF mutants were caused by abnormal Bmp signaling.
BC8_BioRED_Task1_Doc344	2028	2037	b-catenin	Gene	12387	The current analysis revealed the close relation of endodermal b-catenin signaling to the ARM phenotypes.
BC8_BioRED_Task1_Doc344	2055	2058	ARM	Disease	D000071056	The current analysis revealed the close relation of endodermal b-catenin signaling to the ARM phenotypes.
BC8_BioRED_Task1_Doc344	2146	2151	human	OrganismTaxon	9606	These results are considered to shed light on the pathogenic mechanisms of human ARMs.
BC8_BioRED_Task1_Doc344	2152	2156	ARMs	Disease	D000071056	These results are considered to shed light on the pathogenic mechanisms of human ARMs.
BC8_BioRED_Task1_Doc345	0	5	VPAC2	Gene	22355	VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
BC8_BioRED_Task1_Doc345	7	52	vasoactive intestinal peptide receptor type 2	Gene	22355	VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
BC8_BioRED_Task1_Doc345	73	77	mice	OrganismTaxon	10090	VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
BC8_BioRED_Task1_Doc345	98	139	experimental autoimmune encephalomyelitis	Disease	D004681	VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.
BC8_BioRED_Task1_Doc345	196	225	Vasoactive intestinal peptide	Gene	22353	Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems.
BC8_BioRED_Task1_Doc345	227	230	VIP	Gene	22353	Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems.
BC8_BioRED_Task1_Doc345	236	285	pituitary adenylyl cyclase-activating polypeptide	Gene	11516	Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems.
BC8_BioRED_Task1_Doc345	287	292	PACAP	Gene	11516	Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems.
BC8_BioRED_Task1_Doc345	483	495	inflammatory	Disease	D007249	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	542	562	inflammatory disease	Disease	D007249	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	564	568	mice	OrganismTaxon	10090	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	582	585	VIP	Gene	22353	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	590	595	PACAP	Gene	11516	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	707	748	experimental autoimmune encephalomyelitis	Disease	D004681	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	750	753	EAE	Disease	D004681	Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE).
BC8_BioRED_Task1_Doc345	867	872	VPAC1	Gene	22354	Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical.
BC8_BioRED_Task1_Doc345	874	879	VPAC2	Gene	22355	Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical.
BC8_BioRED_Task1_Doc345	885	889	PAC1	Gene	11517	Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical.
BC8_BioRED_Task1_Doc345	933	937	mice	OrganismTaxon	10090	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	965	970	VIPR2	Gene	22355	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	985	999	VPAC2 receptor	Gene	22355	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1024	1032	MOG35-55	Gene	4340	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1042	1045	EAE	Disease	D004681	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1068	1072	mice	OrganismTaxon	10090	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1151	1176	proinflammatory cytokines	Gene	15978,16171,16193,21926	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1178	1187	TNF-alpha	Gene	21926	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1189	1193	IL-6	Gene	16193	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1195	1204	IFN-gamma	Gene	15978	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1216	1221	IL-17	Gene	16171	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1242	1269	anti-inflammatory cytokines	Gene	16153,16189,21803	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1271	1276	IL-10	Gene	16153	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1278	1285	TGFbeta	Gene	21803	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1291	1295	IL-4	Gene	16189	In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes.
BC8_BioRED_Task1_Doc345	1409	1412	CD4	Gene	12504	Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE.
BC8_BioRED_Task1_Doc345	1415	1419	CD25	Gene	16184	Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE.
BC8_BioRED_Task1_Doc345	1422	1427	FoxP3	Gene	20371	Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE.
BC8_BioRED_Task1_Doc345	1464	1469	VPAC2	Gene	22355	Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE.
BC8_BioRED_Task1_Doc345	1480	1484	mice	OrganismTaxon	10090	Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE.
BC8_BioRED_Task1_Doc345	1490	1493	EAE	Disease	D004681	Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE.
BC8_BioRED_Task1_Doc345	1575	1580	VPAC2	Gene	22355	Finally, the in vitro suppressive activity of lymph node and splenic Tregs from VPAC2-deficient mice was impaired.
BC8_BioRED_Task1_Doc345	1591	1595	mice	OrganismTaxon	10090	Finally, the in vitro suppressive activity of lymph node and splenic Tregs from VPAC2-deficient mice was impaired.
BC8_BioRED_Task1_Doc345	1673	1678	PACAP	Gene	11516	Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool.
BC8_BioRED_Task1_Doc345	1687	1701	VPAC2 receptor	Gene	22355	Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool.
BC8_BioRED_Task1_Doc346	11	39	metachromatic leukodystrophy	Disease	D007966	Late-onset metachromatic leukodystrophy: molecular pathology in two siblings.
BC8_BioRED_Task1_Doc346	111	126	arylsulfatase A	Gene	410	We report on a new allele at the arylsulfatase A (ARSA) locus causing late-onset metachromatic leukodystrophy (MLD).
BC8_BioRED_Task1_Doc346	128	132	ARSA	Gene	410	We report on a new allele at the arylsulfatase A (ARSA) locus causing late-onset metachromatic leukodystrophy (MLD).
BC8_BioRED_Task1_Doc346	159	187	metachromatic leukodystrophy	Disease	D007966	We report on a new allele at the arylsulfatase A (ARSA) locus causing late-onset metachromatic leukodystrophy (MLD).
BC8_BioRED_Task1_Doc346	189	192	MLD	Disease	D007966	We report on a new allele at the arylsulfatase A (ARSA) locus causing late-onset metachromatic leukodystrophy (MLD).
BC8_BioRED_Task1_Doc346	210	220	arginine84	SequenceVariant	rs74315458	In that allele arginine84, a residue that is highly conserved in the arylsulfatase gene family, is replaced by glutamine.
BC8_BioRED_Task1_Doc346	264	277	arylsulfatase	Gene	410	In that allele arginine84, a residue that is highly conserved in the arylsulfatase gene family, is replaced by glutamine.
BC8_BioRED_Task1_Doc346	363	366	MLD	Disease	D007966	In contrast to alleles that cause early-onset MLD, the arginine84 to glutamine substitution is associated with some residual ARSA activity.
BC8_BioRED_Task1_Doc346	372	395	arginine84 to glutamine	SequenceVariant	rs74315458	In contrast to alleles that cause early-onset MLD, the arginine84 to glutamine substitution is associated with some residual ARSA activity.
BC8_BioRED_Task1_Doc346	442	446	ARSA	Gene	410	In contrast to alleles that cause early-onset MLD, the arginine84 to glutamine substitution is associated with some residual ARSA activity.
BC8_BioRED_Task1_Doc346	484	488	ARSA	Gene	410	A comparison of genotypes, ARSA activities, and clinical data on 4 individuals carrying the allele of 81 patients with MLD examined, further validates the concept that different degrees of residual ARSA activity are the basis of phenotypical variation in MLD..
BC8_BioRED_Task1_Doc346	562	570	patients	OrganismTaxon	9606	A comparison of genotypes, ARSA activities, and clinical data on 4 individuals carrying the allele of 81 patients with MLD examined, further validates the concept that different degrees of residual ARSA activity are the basis of phenotypical variation in MLD..
BC8_BioRED_Task1_Doc346	576	579	MLD	Disease	D007966	A comparison of genotypes, ARSA activities, and clinical data on 4 individuals carrying the allele of 81 patients with MLD examined, further validates the concept that different degrees of residual ARSA activity are the basis of phenotypical variation in MLD..
BC8_BioRED_Task1_Doc346	655	659	ARSA	Gene	410	A comparison of genotypes, ARSA activities, and clinical data on 4 individuals carrying the allele of 81 patients with MLD examined, further validates the concept that different degrees of residual ARSA activity are the basis of phenotypical variation in MLD..
BC8_BioRED_Task1_Doc346	712	715	MLD	Disease	D007966	A comparison of genotypes, ARSA activities, and clinical data on 4 individuals carrying the allele of 81 patients with MLD examined, further validates the concept that different degrees of residual ARSA activity are the basis of phenotypical variation in MLD..
BC8_BioRED_Task1_Doc347	18	22	PVT1	Gene	5820	Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.
BC8_BioRED_Task1_Doc347	47	70	end-stage renal disease	Disease	D007676	Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.
BC8_BioRED_Task1_Doc347	74	89	type 2 diabetes	Disease	D003924	Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study.
BC8_BioRED_Task1_Doc347	219	242	end-stage renal disease	Disease	D007676	To identify genetic variants contributing to end-stage renal disease (ESRD) in type 2 diabetes, we performed a genome-wide analysis of 115,352 single nucleotide polymorphisms (SNPs) in pools of 105 unrelated case subjects with ESRD and 102 unrelated control subjects who have had type 2 diabetes for > or =10 years without macroalbuminuria.
BC8_BioRED_Task1_Doc347	244	248	ESRD	Disease	D007676	To identify genetic variants contributing to end-stage renal disease (ESRD) in type 2 diabetes, we performed a genome-wide analysis of 115,352 single nucleotide polymorphisms (SNPs) in pools of 105 unrelated case subjects with ESRD and 102 unrelated control subjects who have had type 2 diabetes for > or =10 years without macroalbuminuria.
BC8_BioRED_Task1_Doc347	253	268	type 2 diabetes	Disease	D003924	To identify genetic variants contributing to end-stage renal disease (ESRD) in type 2 diabetes, we performed a genome-wide analysis of 115,352 single nucleotide polymorphisms (SNPs) in pools of 105 unrelated case subjects with ESRD and 102 unrelated control subjects who have had type 2 diabetes for > or =10 years without macroalbuminuria.
BC8_BioRED_Task1_Doc347	401	405	ESRD	Disease	D007676	To identify genetic variants contributing to end-stage renal disease (ESRD) in type 2 diabetes, we performed a genome-wide analysis of 115,352 single nucleotide polymorphisms (SNPs) in pools of 105 unrelated case subjects with ESRD and 102 unrelated control subjects who have had type 2 diabetes for > or =10 years without macroalbuminuria.
BC8_BioRED_Task1_Doc347	454	469	type 2 diabetes	Disease	D003924	To identify genetic variants contributing to end-stage renal disease (ESRD) in type 2 diabetes, we performed a genome-wide analysis of 115,352 single nucleotide polymorphisms (SNPs) in pools of 105 unrelated case subjects with ESRD and 102 unrelated control subjects who have had type 2 diabetes for > or =10 years without macroalbuminuria.
BC8_BioRED_Task1_Doc347	822	831	rs2720709	SequenceVariant	rs2720709	These SNPs were genotyped in individuals comprising each pool, and strong evidence for association was found with rs2720709 (P = 0.000021; odds ratio 2.57 [95% CI 1.66-3.96]), which is located in the plasmacytoma variant translocation gene PVT1.
BC8_BioRED_Task1_Doc347	948	952	PVT1	Gene	5820	These SNPs were genotyped in individuals comprising each pool, and strong evidence for association was found with rs2720709 (P = 0.000021; odds ratio 2.57 [95% CI 1.66-3.96]), which is located in the plasmacytoma variant translocation gene PVT1.
BC8_BioRED_Task1_Doc347	1022	1026	PVT1	Gene	5820	We sequenced all exons, exon-intron boundaries, and the promoter of PVT1 and identified 47 variants, 11 of which represented nonredundant markers with minor allele frequency > or =0.05.
BC8_BioRED_Task1_Doc347	1265	1274	rs2720709	SequenceVariant	rs2720709	We subsequently genotyped these 11 variants and an additional 87 SNPs identified through public databases in 319-kb flanking rs2720709 ( approximately 1 SNP/3.5 kb); 23 markers were associated with ESRD at P < 0.01.
BC8_BioRED_Task1_Doc347	1338	1342	ESRD	Disease	D007676	We subsequently genotyped these 11 variants and an additional 87 SNPs identified through public databases in 319-kb flanking rs2720709 ( approximately 1 SNP/3.5 kb); 23 markers were associated with ESRD at P < 0.01.
BC8_BioRED_Task1_Doc347	1409	1418	rs2648875	SequenceVariant	rs2648875	The strongest evidence for association was found for rs2648875 (P = 0.0000018; 2.97 [1.90-4.65]), which maps to intron 8 of PVT1.
BC8_BioRED_Task1_Doc347	1480	1484	PVT1	Gene	5820	The strongest evidence for association was found for rs2648875 (P = 0.0000018; 2.97 [1.90-4.65]), which maps to intron 8 of PVT1.
BC8_BioRED_Task1_Doc347	1523	1527	PVT1	Gene	5820	Together, these results suggest that PVT1 may contribute to ESRD susceptibility in diabetes.
BC8_BioRED_Task1_Doc347	1546	1550	ESRD	Disease	D007676	Together, these results suggest that PVT1 may contribute to ESRD susceptibility in diabetes.
BC8_BioRED_Task1_Doc347	1569	1577	diabetes	Disease	D003920	Together, these results suggest that PVT1 may contribute to ESRD susceptibility in diabetes.
BC8_BioRED_Task1_Doc348	11	20	serotonin	Chemical	D012701	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
BC8_BioRED_Task1_Doc348	31	34	rat	OrganismTaxon	10116	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
BC8_BioRED_Task1_Doc348	59	70	hypotensive	Disease	D007022	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
BC8_BioRED_Task1_Doc348	81	91	methyldopa	Chemical	D008750	Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
BC8_BioRED_Task1_Doc348	167	177	methyldopa	Chemical	D008750	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.
BC8_BioRED_Task1_Doc348	217	226	serotonin	Chemical	D012701	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.
BC8_BioRED_Task1_Doc348	260	271	hypotensive	Disease	D007022	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.
BC8_BioRED_Task1_Doc348	432	441	serotonin	Chemical	D012701	The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla, coinciding with the raphe magnus.
BC8_BioRED_Task1_Doc348	517	529	hypertensive	Disease	D006973	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	531	537	stroke	Disease	D020521	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	544	548	rats	OrganismTaxon	10116	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	568	578	methyldopa	Chemical	D008750	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	611	620	serotonin	Chemical	D012701	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	671	682	hypotension	Disease	D007022	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	769	778	serotonin	Chemical	D012701	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	790	813	5,7-dihydroxytryptamine	Chemical	D015116	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	815	822	5,7-DHT	Chemical	D015116	In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
BC8_BioRED_Task1_Doc348	894	901	5,7-DHT	Chemical	D015116	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
BC8_BioRED_Task1_Doc348	956	965	serotonin	Chemical	D012701	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
BC8_BioRED_Task1_Doc348	1017	1028	hypotension	Disease	D007022	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
BC8_BioRED_Task1_Doc348	1039	1046	5,7-DHT	Chemical	D015116	Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.
BC8_BioRED_Task1_Doc348	1057	1066	serotonin	Chemical	D012701	Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.
BC8_BioRED_Task1_Doc348	1164	1173	serotonin	Chemical	D012701	Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.
BC8_BioRED_Task1_Doc348	1252	1261	serotonin	Chemical	D012701	Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.
BC8_BioRED_Task1_Doc348	1262	1272	methyldopa	Chemical	D008750	Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.
BC8_BioRED_Task1_Doc348	1366	1376	methyldopa	Chemical	D008750	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
BC8_BioRED_Task1_Doc348	1385	1396	hypotension	Disease	D007022	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
BC8_BioRED_Task1_Doc348	1437	1446	serotonin	Chemical	D012701	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
BC8_BioRED_Task1_Doc348	1489	1500	hypotensive	Disease	D007022	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
BC8_BioRED_Task1_Doc348	1511	1521	methyldopa	Chemical	D008750	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.
BC8_BioRED_Task1_Doc349	21	26	FOXP3	Gene	50943	Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients.
BC8_BioRED_Task1_Doc349	47	56	psoriasis	Disease	D011565	Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients.
BC8_BioRED_Task1_Doc349	57	65	patients	OrganismTaxon	9606	Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients.
BC8_BioRED_Task1_Doc349	79	88	Psoriasis	Disease	D011565	BACKGROUND: Psoriasis is a common dermatological disorder, in which autoimmunity plays an important role.
BC8_BioRED_Task1_Doc349	101	124	dermatological disorder	Disease	D012871	BACKGROUND: Psoriasis is a common dermatological disorder, in which autoimmunity plays an important role.
BC8_BioRED_Task1_Doc349	173	176	CD4	Gene	920	CD4(+)CD25(+) regulatory T cells (T-regs) have been suggested to be involved in the pathogenesis of some autoimmune diseases.
BC8_BioRED_Task1_Doc349	179	183	CD25	Gene	3559	CD4(+)CD25(+) regulatory T cells (T-regs) have been suggested to be involved in the pathogenesis of some autoimmune diseases.
BC8_BioRED_Task1_Doc349	278	297	autoimmune diseases	Disease	D001327	CD4(+)CD25(+) regulatory T cells (T-regs) have been suggested to be involved in the pathogenesis of some autoimmune diseases.
BC8_BioRED_Task1_Doc349	363	368	FOXP3	Gene	50943	T-regs express the fork head/winged helix transcription factor, FOXP3, which appears to be of key importance in the development and function of T-regs.
BC8_BioRED_Task1_Doc349	521	526	FOXP3	Gene	50943	Studies have found that single-nucleotide polymorphisms (SNPs) in the FOXP3 gene contribute to susceptibility to some autoimmune disorders.
BC8_BioRED_Task1_Doc349	569	589	autoimmune disorders	Disease	D001327	Studies have found that single-nucleotide polymorphisms (SNPs) in the FOXP3 gene contribute to susceptibility to some autoimmune disorders.
BC8_BioRED_Task1_Doc349	618	623	FOXP3	Gene	50943	However, information about FOXP3 gene in psoriasis is limited.
BC8_BioRED_Task1_Doc349	632	641	psoriasis	Disease	D011565	However, information about FOXP3 gene in psoriasis is limited.
BC8_BioRED_Task1_Doc349	710	715	FOXP3	Gene	50943	OBJECTIVE: This study evaluated the association between FOXP3 gene SNPs and susceptibility to psoriasis in a Han Chinese population.
BC8_BioRED_Task1_Doc349	748	757	psoriasis	Disease	D011565	OBJECTIVE: This study evaluated the association between FOXP3 gene SNPs and susceptibility to psoriasis in a Han Chinese population.
BC8_BioRED_Task1_Doc349	840	848	patients	OrganismTaxon	9606	METHODS: In a hospital-based case-control study, 524 patients with psoriasis and 549 psoriasis-free controls were recruited according to age and gender.
BC8_BioRED_Task1_Doc349	854	863	psoriasis	Disease	D011565	METHODS: In a hospital-based case-control study, 524 patients with psoriasis and 549 psoriasis-free controls were recruited according to age and gender.
BC8_BioRED_Task1_Doc349	872	881	psoriasis	Disease	D011565	METHODS: In a hospital-based case-control study, 524 patients with psoriasis and 549 psoriasis-free controls were recruited according to age and gender.
BC8_BioRED_Task1_Doc349	973	978	FOXP3	Gene	50943	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	985	1004	-6054, deletion/ATT	SequenceVariant	c|DEL|-6054|ATT	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1006	1016	-3279, A/C	SequenceVariant	c|SUB|A|-3279|C	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1018	1027	-924, A/G	SequenceVariant	c|SUB|A|-924|G	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1029	1042	IVS9+459, A/G	SequenceVariant	c|SUB|A|IVS9+459|G	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1047	1056	psoriatic	Disease	D011565	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1057	1065	patients	OrganismTaxon	9606	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1115	1124	psoriatic	Disease	D011565	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1125	1133	patients	OrganismTaxon	9606	We investigated four SNPs in the FOXP3 gene (-6054, deletion/ATT; -3279, A/C; -924, A/G; IVS9+459, A/G) in psoriatic patients, and assessed allele and genotype frequencies in psoriatic patients (237 females, 287 males) and normal controls (272 females, 277 males).
BC8_BioRED_Task1_Doc349	1404	1413	psoriasis	Disease	D011565	RESULTS: We found that increased risk of psoriasis was associated with the FOXP3 -3279 AC genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.
BC8_BioRED_Task1_Doc349	1438	1443	FOXP3	Gene	50943	RESULTS: We found that increased risk of psoriasis was associated with the FOXP3 -3279 AC genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.
BC8_BioRED_Task1_Doc349	1444	1452	-3279 AC	SequenceVariant	c|Allele|AC|-3297	RESULTS: We found that increased risk of psoriasis was associated with the FOXP3 -3279 AC genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.
BC8_BioRED_Task1_Doc349	1591	1599	-3279 CC	SequenceVariant	c|Allele|CC|-3279	RESULTS: We found that increased risk of psoriasis was associated with the FOXP3 -3279 AC genotype (adjusted OR, 1.32; 95% CI, 1.01-1.74) and the combined AC+AA genotype (adjusted OR, 1.38; 95% CI, 1.07-1.78), compared with the -3279 CC genotype.
BC8_BioRED_Task1_Doc349	1650	1659	psoriasis	Disease	D011565	We also found that an increased risk of psoriasis was associated with the FOXP3 IVS9+459 GG genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).
BC8_BioRED_Task1_Doc349	1684	1689	FOXP3	Gene	50943	We also found that an increased risk of psoriasis was associated with the FOXP3 IVS9+459 GG genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).
BC8_BioRED_Task1_Doc349	1690	1701	IVS9+459 GG	SequenceVariant	c|Allele|GG|IVS9+459	We also found that an increased risk of psoriasis was associated with the FOXP3 IVS9+459 GG genotype (adjusted OR, 2.24; 95% CI, 1.41-3.58).
BC8_BioRED_Task1_Doc349	1869	1880	IVS9+459 AA	SequenceVariant	c|Allele|AA|IVS9+459	However, the combined GA+GG genotype showed no such tendency (adjusted OR=1.28; 95% CI, 1.00-1.64), compared with the IVS9+459 AA genotype.
BC8_BioRED_Task1_Doc349	1954	1959	FOXP3	Gene	50943	There was no evidence of an increased risk associated with the FOXP3-6054 deletion/ATT or FOXP3-924 A/G genotype.
BC8_BioRED_Task1_Doc349	1959	1977	-6054 deletion/ATT	SequenceVariant	c|DEL|-6054|ATT	There was no evidence of an increased risk associated with the FOXP3-6054 deletion/ATT or FOXP3-924 A/G genotype.
BC8_BioRED_Task1_Doc349	1981	1986	FOXP3	Gene	50943	There was no evidence of an increased risk associated with the FOXP3-6054 deletion/ATT or FOXP3-924 A/G genotype.
BC8_BioRED_Task1_Doc349	1986	1994	-924 A/G	SequenceVariant	c|SUB|A|-924|G	There was no evidence of an increased risk associated with the FOXP3-6054 deletion/ATT or FOXP3-924 A/G genotype.
BC8_BioRED_Task1_Doc349	2040	2045	FOXP3	Gene	50943	In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).
BC8_BioRED_Task1_Doc349	2045	2056	-3279 AC+AA	SequenceVariant	c|Allele|AC|-3279	In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).
BC8_BioRED_Task1_Doc349	2153	2162	psoriasis	Disease	D011565	In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).
BC8_BioRED_Task1_Doc349	2163	2171	patients	OrganismTaxon	9606	In combined genotype analyses, the FOXP3-3279 AC+AA genotype was more obviously associated in males (adjusted OR=1.60, 95% CI=1.11-2.31) and severe psoriasis patients (PASI score >20; adjusted OR=1.97, 95% CI=1.41-2.75).
BC8_BioRED_Task1_Doc349	2241	2246	FOXP3	Gene	50943	Meanwhile, the FOXP3 IVS9+459 GA+GG genotype was also associated with severe psoriasis patients (adjusted OR=1.69, 95% CI=1.21-2.36).
BC8_BioRED_Task1_Doc349	2247	2261	IVS9+459 GA+GG	SequenceVariant	c|Allele|GA|IVS9+459	Meanwhile, the FOXP3 IVS9+459 GA+GG genotype was also associated with severe psoriasis patients (adjusted OR=1.69, 95% CI=1.21-2.36).
BC8_BioRED_Task1_Doc349	2303	2312	psoriasis	Disease	D011565	Meanwhile, the FOXP3 IVS9+459 GA+GG genotype was also associated with severe psoriasis patients (adjusted OR=1.69, 95% CI=1.21-2.36).
BC8_BioRED_Task1_Doc349	2313	2321	patients	OrganismTaxon	9606	Meanwhile, the FOXP3 IVS9+459 GA+GG genotype was also associated with severe psoriasis patients (adjusted OR=1.69, 95% CI=1.21-2.36).
BC8_BioRED_Task1_Doc349	2373	2378	FOXP3	Gene	50943	CONCLUSIONS: FOXP3 polymorphisms appear to contribute to the risk of psoriasis in a Han Chinese population.
BC8_BioRED_Task1_Doc349	2429	2438	psoriasis	Disease	D011565	CONCLUSIONS: FOXP3 polymorphisms appear to contribute to the risk of psoriasis in a Han Chinese population.
BC8_BioRED_Task1_Doc350	0	8	Curcumin	Chemical	D003474	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
BC8_BioRED_Task1_Doc350	18	25	maleate	Chemical	C030272	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
BC8_BioRED_Task1_Doc350	34	48	nephrotoxicity	Disease	D007674	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
BC8_BioRED_Task1_Doc350	119	125	oxygen	Chemical	D010100	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
BC8_BioRED_Task1_Doc350	154	175	respiratory complex I	Chemical	D042967	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
BC8_BioRED_Task1_Doc350	236	244	curcumin	Chemical	D003474	The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.
BC8_BioRED_Task1_Doc350	284	296	renal injury	Disease	D007674	The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.
BC8_BioRED_Task1_Doc350	308	315	maleate	Chemical	C030272	The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.
BC8_BioRED_Task1_Doc350	339	350	proteinuria	Disease	D011507	Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.
BC8_BioRED_Task1_Doc350	410	417	maleate	Chemical	C030272	Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.
BC8_BioRED_Task1_Doc350	433	437	rats	OrganismTaxon	10116	Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.
BC8_BioRED_Task1_Doc350	439	446	Maleate	Chemical	C030272	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	455	467	renal injury	Disease	D007674	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	562	569	glucose	Chemical	D005947	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	571	577	sodium	Chemical	D012964	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	579	621	neutrophil gelatinase-associated lipocalin	Gene	170496	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	623	627	NGAL	Gene	170496	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	633	661	N-acetyl b-D-glucosaminidase	Gene	-	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	663	666	NAG	Gene	-	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	685	715	kidney injury molecule (KIM)-1	Gene	286934	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	750	759	claudin-2	Gene	733684	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	782	821	necrosis and apoptosis of tubular cells	Disease	D007673	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	893	899	lipids	Chemical	D008055	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	937	941	Nrf2	Gene	83619	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.
BC8_BioRED_Task1_Doc350	998	1005	LLC-PK1	CellLine	CVCL_0391	Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups.
BC8_BioRED_Task1_Doc350	1086	1093	Maleate	Chemical	C030272	Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture.
BC8_BioRED_Task1_Doc350	1118	1141	reactive oxygen species	Chemical	D017382	Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture.
BC8_BioRED_Task1_Doc350	1143	1146	ROS	Chemical	D017382	Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture.
BC8_BioRED_Task1_Doc350	1162	1169	LLC-PK1	CellLine	CVCL_0391	Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture.
BC8_BioRED_Task1_Doc350	1201	1208	maleate	Chemical	C030272	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.
BC8_BioRED_Task1_Doc350	1227	1233	oxygen	Chemical	D010100	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.
BC8_BioRED_Task1_Doc350	1249	1252	ADP	Chemical	D000244	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.
BC8_BioRED_Task1_Doc350	1329	1335	malate	Chemical	C030298	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.
BC8_BioRED_Task1_Doc350	1336	1345	glutamate	Chemical	D018698	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate.
BC8_BioRED_Task1_Doc350	1397	1406	aconitase	Gene	50655	The activities of both complex I and aconitase were also diminished.
BC8_BioRED_Task1_Doc350	1483	1491	curcumin	Chemical	D003474	All the above-described alterations were prevented by curcumin.
BC8_BioRED_Task1_Doc350	1514	1522	curcumin	Chemical	D003474	It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.
BC8_BioRED_Task1_Doc350	1552	1559	maleate	Chemical	C030272	It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.
BC8_BioRED_Task1_Doc350	1568	1579	nephropathy	Disease	D007674	It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.
BC8_BioRED_Task1_Doc350	1716	1722	oxygen	Chemical	D010100	The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I, and the in vitro protection was associated to the prevention of ROS production.
BC8_BioRED_Task1_Doc350	1751	1772	respiratory complex I	Chemical	D042967	The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I, and the in vitro protection was associated to the prevention of ROS production.
BC8_BioRED_Task1_Doc350	1838	1841	ROS	Chemical	D017382	The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I, and the in vitro protection was associated to the prevention of ROS production.
BC8_BioRED_Task1_Doc351	96	100	mTOR	Gene	56717	Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.
BC8_BioRED_Task1_Doc351	137	142	tumor	Disease	D009369	Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance.
BC8_BioRED_Task1_Doc351	161	165	VEGF	Gene	22339,7422	Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance.
BC8_BioRED_Task1_Doc351	237	242	human	OrganismTaxon	9606	Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance.
BC8_BioRED_Task1_Doc351	243	249	tumors	Disease	D009369	Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance.
BC8_BioRED_Task1_Doc351	254	259	mouse	OrganismTaxon	10090	Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance.
BC8_BioRED_Task1_Doc351	270	276	cancer	Disease	D009369	Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance.
BC8_BioRED_Task1_Doc351	354	359	mouse	OrganismTaxon	10090	In one such mouse model, potent angiogenesis inhibitors elicit compartmental reorganization of cancer cells around remaining blood vessels.
BC8_BioRED_Task1_Doc351	437	443	cancer	Disease	D009369	In one such mouse model, potent angiogenesis inhibitors elicit compartmental reorganization of cancer cells around remaining blood vessels.
BC8_BioRED_Task1_Doc351	519	524	GLUT1	Gene	20525	The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis.
BC8_BioRED_Task1_Doc351	529	533	MCT4	Gene	80879	The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis.
BC8_BioRED_Task1_Doc351	556	563	hypoxic	Disease	D000860	The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis.
BC8_BioRED_Task1_Doc351	575	580	HIF1a	Gene	15251	The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis.
BC8_BioRED_Task1_Doc351	626	631	Tumor	Disease	D009369	Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling.
BC8_BioRED_Task1_Doc351	704	708	MCT1	Gene	20501	Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling.
BC8_BioRED_Task1_Doc351	714	718	p-S6	Gene	72508	Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling.
BC8_BioRED_Task1_Doc351	742	746	mTOR	Gene	56717	Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling.
BC8_BioRED_Task1_Doc351	758	773	Normoxic cancer	Disease	D009369	Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism.
BC8_BioRED_Task1_Doc351	802	809	lactate	Chemical	D019344	Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism.
BC8_BioRED_Task1_Doc351	840	844	mTOR	Gene	56717	Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism.
BC8_BioRED_Task1_Doc351	859	868	glutamine	Chemical	D005973	Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism.
BC8_BioRED_Task1_Doc351	892	899	lactate	Chemical	D019344	Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism.
BC8_BioRED_Task1_Doc351	1009	1015	cancer	Disease	D009369	Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate.
BC8_BioRED_Task1_Doc351	1029	1036	glucose	Chemical	D005947	Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate.
BC8_BioRED_Task1_Doc351	1048	1055	lactate	Chemical	D019344	Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate.
BC8_BioRED_Task1_Doc351	1100	1107	lactate	Chemical	D019344	Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate.
BC8_BioRED_Task1_Doc351	1109	1113	mTOR	Gene	56717	mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.
BC8_BioRED_Task1_Doc351	1226	1231	GLUT2	Gene	20526	mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.
BC8_BioRED_Task1_Doc352	0	44	Serum- and glucocorticoid-inducible kinase 1	Gene	20393	Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc352	48	59	doxorubicin	Chemical	D004317	Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc352	68	86	nephrotic syndrome	Disease	D009404	Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc352	88	99	Doxorubicin	Chemical	D004317	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
BC8_BioRED_Task1_Doc352	108	119	nephropathy	Disease	D007674	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
BC8_BioRED_Task1_Doc352	140	146	sodium	Chemical	D012964	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
BC8_BioRED_Task1_Doc352	172	188	volume retention	Disease	D016055	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
BC8_BioRED_Task1_Doc352	193	207	renal fibrosis	Disease	D007674	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
BC8_BioRED_Task1_Doc352	213	224	aldosterone	Chemical	D000450	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
BC8_BioRED_Task1_Doc352	235	277	serum- and glucocorticoid-inducible kinase	Gene	20393	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
BC8_BioRED_Task1_Doc352	278	282	SGK1	Gene	20393	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
BC8_BioRED_Task1_Doc352	355	369	renal fibrosis	Disease	D007674	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
BC8_BioRED_Task1_Doc352	380	397	mineralocorticoid	Chemical	D008901	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
BC8_BioRED_Task1_Doc352	402	406	salt	Chemical	D012492	The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
BC8_BioRED_Task1_Doc352	472	476	SGK1	Gene	20393	The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.
BC8_BioRED_Task1_Doc352	484	500	volume retention	Disease	D016055	The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.
BC8_BioRED_Task1_Doc352	505	513	fibrosis	Disease	D005355	The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.
BC8_BioRED_Task1_Doc352	521	539	nephrotic syndrome	Disease	D009404	The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.
BC8_BioRED_Task1_Doc352	554	565	doxorubicin	Chemical	D004317	To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).
BC8_BioRED_Task1_Doc352	631	635	mice	OrganismTaxon	10090	To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).
BC8_BioRED_Task1_Doc352	644	648	SGK1	Gene	20393	To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).
BC8_BioRED_Task1_Doc352	650	654	sgk1	Gene	20393	To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).
BC8_BioRED_Task1_Doc352	694	698	sgk1	Gene	20393	To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).
BC8_BioRED_Task1_Doc352	706	717	Doxorubicin	Chemical	D004317	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	746	757	proteinuria	Disease	D011507	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	778	782	crea	Chemical	D003404	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	796	800	sgk1	Gene	20393	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	819	823	sgk1	Gene	20393	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	829	833	mice	OrganismTaxon	10090	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	852	870	nephrotic syndrome	Disease	D009404	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	876	883	ascites	Disease	D001201	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	885	894	lipidemia	Disease	D006949	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	900	915	hypoalbuminemia	Disease	D034141	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
BC8_BioRED_Task1_Doc352	942	953	aldosterone	Chemical	D000450	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
BC8_BioRED_Task1_Doc352	974	983	nephrotic	Disease	D009404	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
BC8_BioRED_Task1_Doc352	984	988	mice	OrganismTaxon	10090	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
BC8_BioRED_Task1_Doc352	1037	1041	SGK1	Gene	20393	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
BC8_BioRED_Task1_Doc352	1064	1068	sgk1	Gene	20393	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
BC8_BioRED_Task1_Doc352	1074	1078	mice	OrganismTaxon	10090	Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
BC8_BioRED_Task1_Doc352	1088	1094	sodium	Chemical	D012964	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1142	1146	sgk1	Gene	20393	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1152	1156	mice	OrganismTaxon	10090	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1176	1180	crea	Chemical	D003404	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1190	1194	sgk1	Gene	20393	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1200	1204	mice	OrganismTaxon	10090	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1224	1228	crea	Chemical	D003404	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1282	1293	weight gain	Disease	D015430	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1297	1301	sgk1	Gene	20393	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1321	1325	sgk1	Gene	20393	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1331	1335	mice	OrganismTaxon	10090	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
BC8_BioRED_Task1_Doc352	1392	1410	nephrotic syndrome	Disease	D009404	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1418	1422	urea	Chemical	D014508	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1472	1476	sgk1	Gene	20393	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1482	1486	mice	OrganismTaxon	10090	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1495	1499	sgk1	Gene	20393	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1505	1509	mice	OrganismTaxon	10090	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1521	1527	uremia	Disease	D014511	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1561	1565	sgk1	Gene	20393	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1571	1575	mice	OrganismTaxon	10090	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1595	1599	sgk1	Gene	20393	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1605	1609	mice	OrganismTaxon	10090	During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
BC8_BioRED_Task1_Doc352	1641	1645	mice	OrganismTaxon	10090	In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.
BC8_BioRED_Task1_Doc352	1654	1658	SGK1	Gene	20393	In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.
BC8_BioRED_Task1_Doc352	1674	1690	volume retention	Disease	D016055	In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.
BC8_BioRED_Task1_Doc352	1723	1737	renal fibrosis	Disease	D007674	In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.
BC8_BioRED_Task1_Doc352	1758	1776	nephrotic syndrome	Disease	D009404	In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.
BC8_BioRED_Task1_Doc353	4	13	autotaxin	Gene	84050	The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair.
BC8_BioRED_Task1_Doc353	14	18	LPA2	Gene	498609,53978	The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair.
BC8_BioRED_Task1_Doc353	19	23	GPCR	Gene	295589	The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair.
BC8_BioRED_Task1_Doc353	144	160	radiation injury	Disease	D011832	In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis.
BC8_BioRED_Task1_Doc353	199	208	autotaxin	Gene	84050	In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis.
BC8_BioRED_Task1_Doc353	210	213	ATX	Gene	84050	In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis.
BC8_BioRED_Task1_Doc353	215	219	LPA2	Gene	498609	In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis.
BC8_BioRED_Task1_Doc353	220	224	GPCR	Gene	295589	In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis.
BC8_BioRED_Task1_Doc353	234	239	IEC-6	CellLine	CVCL_0343	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	344	348	lpa2	Gene	498609	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	420	429	NF-kappaB	Gene	81736	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	442	446	lpa2	Gene	498609	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	476	491	ATM/ATR kinases	Gene	300711,685055	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	497	504	CGK-733	Chemical	C512273	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	522	526	lpa2	Gene	498609	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	572	575	ATM	Gene	300711	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	580	589	NF-kappaB	Gene	81736	In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB.
BC8_BioRED_Task1_Doc353	640	650	gamma-H2AX	Gene	500987	The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX.
BC8_BioRED_Task1_Doc353	654	657	LPA	Gene	53978	The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX.
BC8_BioRED_Task1_Doc353	666	671	IEC-6	CellLine	CVCL_0343	The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX.
BC8_BioRED_Task1_Doc353	782	786	LPA2	Gene	498609	The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX.
BC8_BioRED_Task1_Doc353	813	823	gamma-H2AX	Gene	500987	The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX.
BC8_BioRED_Task1_Doc353	828	832	LPA2	Gene	53978	In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained.
BC8_BioRED_Task1_Doc353	847	850	MEF	CellLine	CVCL_9115	In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained.
BC8_BioRED_Task1_Doc353	865	875	LPA1    '3	Gene	14745,65086	In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained.
BC8_BioRED_Task1_Doc353	890	900	gamma-H2AX	Gene	15270	In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained.
BC8_BioRED_Task1_Doc353	938	941	MEF	CellLine	CVCL_9115	In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained.
BC8_BioRED_Task1_Doc353	990	1000	ERK1    '2	Gene	26413,26417	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1004	1008	PI3K	Gene	18708	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1009	1012	AKT	Gene	11651	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1054	1059	C311A	SequenceVariant	p|SUB|C|311|A	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1060	1065	C314A	SequenceVariant	p|SUB|C|314|A	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1066	1071	L351A	SequenceVariant	p|SUB|L|351|A	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1102	1106	LPA2	Gene	53978	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1131	1134	LPA	Gene	53978	Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair.
BC8_BioRED_Task1_Doc353	1150	1154	LPA2	Gene	53978	LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively.
BC8_BioRED_Task1_Doc353	1170	1173	Lin	Gene	83557	LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively.
BC8_BioRED_Task1_Doc353	1176	1181	Sca-1	Gene	110454	LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively.
BC8_BioRED_Task1_Doc353	1184	1189	c-Kit	Gene	16590	LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively.
BC8_BioRED_Task1_Doc353	1365	1375	gamma-H2AX	Gene	15270	Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice.
BC8_BioRED_Task1_Doc353	1441	1445	LPA2	Gene	53978	Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice.
BC8_BioRED_Task1_Doc353	1449	1453	mice	OrganismTaxon	10090	Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice.
BC8_BioRED_Task1_Doc353	1469	1473	mice	OrganismTaxon	10090	Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice.
BC8_BioRED_Task1_Doc353	1524	1527	ATX	Gene	84050	We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha.
BC8_BioRED_Task1_Doc353	1541	1544	LPA	Gene	53978	We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha.
BC8_BioRED_Task1_Doc353	1635	1643	TNFalpha	Gene	21926	We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha.
BC8_BioRED_Task1_Doc353	1669	1672	ATX	Gene	18606,84050	These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair.
BC8_BioRED_Task1_Doc353	1677	1681	LPA2	Gene	498609,53978	These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair.
BC8_BioRED_Task1_Doc354	0	5	Human	OrganismTaxon	9606	Human mu opiate receptor.
BC8_BioRED_Task1_Doc354	6	24	mu opiate receptor	Gene	4988	Human mu opiate receptor.
BC8_BioRED_Task1_Doc354	112	117	human	OrganismTaxon	9606	A human mu opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat mu opiate receptor cDNA.
BC8_BioRED_Task1_Doc354	118	136	mu opiate receptor	Gene	4988	A human mu opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat mu opiate receptor cDNA.
BC8_BioRED_Task1_Doc354	225	228	rat	OrganismTaxon	10116	A human mu opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat mu opiate receptor cDNA.
BC8_BioRED_Task1_Doc354	229	247	mu opiate receptor	Gene	25601	A human mu opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat mu opiate receptor cDNA.
BC8_BioRED_Task1_Doc354	258	263	human	OrganismTaxon	9606	The human mu opiate receptor (h mu OR1) shares 95% amino acid identity with the rat sequence.
BC8_BioRED_Task1_Doc354	264	282	mu opiate receptor	Gene	4988	The human mu opiate receptor (h mu OR1) shares 95% amino acid identity with the rat sequence.
BC8_BioRED_Task1_Doc354	284	292	h mu OR1	Gene	4988	The human mu opiate receptor (h mu OR1) shares 95% amino acid identity with the rat sequence.
BC8_BioRED_Task1_Doc354	334	337	rat	OrganismTaxon	10116	The human mu opiate receptor (h mu OR1) shares 95% amino acid identity with the rat sequence.
BC8_BioRED_Task1_Doc354	362	368	mu OR1	Gene	25601	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	387	393	opiate	Chemical	D053610	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	404	419	opioid peptides	Chemical	D018847	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	425	431	sodium	Chemical	D012964	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	437	440	GTP	Chemical	D006160	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	521	524	rat	OrganismTaxon	10116	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	525	543	mu opiate receptor	Gene	25601	The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	556	566	cyclic AMP	Chemical	D000242	Effects on cyclic AMP are similar to those noted for the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	602	605	rat	OrganismTaxon	10116	Effects on cyclic AMP are similar to those noted for the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	606	624	mu opiate receptor	Gene	25601	Effects on cyclic AMP are similar to those noted for the rat mu opiate receptor.
BC8_BioRED_Task1_Doc354	670	678	h mu OR1	Gene	4988	An 18 kb genomic clone hybridizing with the h mu OR1 cDNA contains 63 and 489 bp exonic sequences flanked by splice donor/acceptor sequences.
BC8_BioRED_Task1_Doc354	815	820	human	OrganismTaxon	9606	Analysis of hybridization to DNA prepared from human rodent hybrid cell lines and chromosomal in situ hybridization studies indicate localization to 6q24-25.
BC8_BioRED_Task1_Doc354	1030	1056	neuropsychiatric disorders	Disease	D001523	An MspI polymorphism, producing a 3.7 kb band, may prove useful in assessing this gene's involvement in neuropsychiatric disorders involving opiatergic systems.
BC8_BioRED_Task1_Doc355	0	18	Cytochrome p4501A1	Gene	1543	Cytochrome p4501A1 gene variants as susceptibility marker for prostate cancer.
BC8_BioRED_Task1_Doc355	62	77	prostate cancer	Disease	D011471	Cytochrome p4501A1 gene variants as susceptibility marker for prostate cancer.
BC8_BioRED_Task1_Doc355	79	85	CYP1A1	Gene	1543	CYP1A1 activates environmental procarcinogens and catalyzes oxidative metabolism of estrogens and is likely to play an important role in the etiology of prostate cancer.
BC8_BioRED_Task1_Doc355	232	247	prostate cancer	Disease	D011471	CYP1A1 activates environmental procarcinogens and catalyzes oxidative metabolism of estrogens and is likely to play an important role in the etiology of prostate cancer.
BC8_BioRED_Task1_Doc355	339	345	A to G	SequenceVariant	rs1048943	To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of CYP1A1 gene in prostate cancer were analyzed in a case-control study of 100 individuals in South Indian population.
BC8_BioRED_Task1_Doc355	401	410	Ile462Val	SequenceVariant	rs1048943	To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of CYP1A1 gene in prostate cancer were analyzed in a case-control study of 100 individuals in South Indian population.
BC8_BioRED_Task1_Doc355	415	421	T3801C	SequenceVariant	g|SUB|T|3801|C	To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of CYP1A1 gene in prostate cancer were analyzed in a case-control study of 100 individuals in South Indian population.
BC8_BioRED_Task1_Doc355	435	441	CYP1A1	Gene	1543	To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of CYP1A1 gene in prostate cancer were analyzed in a case-control study of 100 individuals in South Indian population.
BC8_BioRED_Task1_Doc355	450	465	prostate cancer	Disease	D011471	To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of CYP1A1 gene in prostate cancer were analyzed in a case-control study of 100 individuals in South Indian population.
BC8_BioRED_Task1_Doc355	650	656	CYP1A1	Gene	1543	The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of CYP1A1 gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the CYP1A1 Ile/Val genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for prostate cancer (OR-0.17; 95%CI = 0.02-0.89; P=0.03).
BC8_BioRED_Task1_Doc355	714	720	CYP1A1	Gene	1543	The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of CYP1A1 gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the CYP1A1 Ile/Val genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for prostate cancer (OR-0.17; 95%CI = 0.02-0.89; P=0.03).
BC8_BioRED_Task1_Doc355	721	728	Ile/Val	SequenceVariant	rs1048943	The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of CYP1A1 gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the CYP1A1 Ile/Val genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for prostate cancer (OR-0.17; 95%CI = 0.02-0.89; P=0.03).
BC8_BioRED_Task1_Doc355	809	824	prostate cancer	Disease	D011471	The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of CYP1A1 gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the CYP1A1 Ile/Val genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for prostate cancer (OR-0.17; 95%CI = 0.02-0.89; P=0.03).
BC8_BioRED_Task1_Doc355	924	929	tumor	Disease	D009369	A Stratified analysis of the genotypes with age of onset and tumor grade showed the w1/m1 genotype to be significantly associated with an early age of onset; however the tumor grades did not have significant association with the variant genotypes.
BC8_BioRED_Task1_Doc355	1033	1038	tumor	Disease	D009369	A Stratified analysis of the genotypes with age of onset and tumor grade showed the w1/m1 genotype to be significantly associated with an early age of onset; however the tumor grades did not have significant association with the variant genotypes.
BC8_BioRED_Task1_Doc355	1280	1295	prostate cancer	Disease	D011471	Thus the present study indicates that individuals with the variant w1/m1 genotype exhibit an increased risk while those with w2/m2 genotype exhibit a decreased risk for prostate cancer.
BC8_BioRED_Task1_Doc356	42	52	hemorrhage	Disease	D006470	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.
BC8_BioRED_Task1_Doc356	65	70	mouse	OrganismTaxon	10090	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.
BC8_BioRED_Task1_Doc356	80	88	warfarin	Chemical	D014859	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.
BC8_BioRED_Task1_Doc356	100	124	intracerebral hemorrhage	Disease	D002543	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.
BC8_BioRED_Task1_Doc356	126	134	Warfarin	Chemical	D014859	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
BC8_BioRED_Task1_Doc356	146	170	intracerebral hemorrhage	Disease	D002543	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
BC8_BioRED_Task1_Doc356	172	173	W	Chemical	D014859	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
BC8_BioRED_Task1_Doc356	174	177	ICH	Disease	D002543	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
BC8_BioRED_Task1_Doc356	199	205	stroke	Disease	D020521	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
BC8_BioRED_Task1_Doc356	258	259	W	Chemical	D014859	There is no consensus on the optimal treatment for W-ICH.
BC8_BioRED_Task1_Doc356	260	263	ICH	Disease	D002543	There is no consensus on the optimal treatment for W-ICH.
BC8_BioRED_Task1_Doc356	273	278	mouse	OrganismTaxon	10090	Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	348	353	human	OrganismTaxon	9606	Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	354	385	prothrombin complex concentrate	Chemical	C025667	Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	387	390	PCC	Chemical	C025667	Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	439	443	mice	OrganismTaxon	10090	Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.)
BC8_BioRED_Task1_Doc356	462	470	warfarin	Chemical	D014859	Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.)
BC8_BioRED_Task1_Doc356	622	627	human	OrganismTaxon	9606	First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.
BC8_BioRED_Task1_Doc356	628	631	PCC	Chemical	C025667	First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.
BC8_BioRED_Task1_Doc356	668	672	mice	OrganismTaxon	10090	First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.
BC8_BioRED_Task1_Doc356	710	721	collagenase	Chemical	D017364	Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum.
BC8_BioRED_Task1_Doc356	749	759	hemorrhage	Disease	D006470	Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum.
BC8_BioRED_Task1_Doc356	848	851	PCC	Chemical	C025667	Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v.
BC8_BioRED_Task1_Doc356	920	930	hemorrhage	Disease	D006470	Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.
BC8_BioRED_Task1_Doc356	1069	1072	PCC	Chemical	C025667	The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).
BC8_BioRED_Task1_Doc356	1201	1205	mice	OrganismTaxon	10090	In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).
BC8_BioRED_Task1_Doc356	1222	1231	hematomas	Disease	D006406	In the saline group, 45% of the mice developed large hematomas (i.e., >15 microL).
BC8_BioRED_Task1_Doc356	1312	1315	PCC	Chemical	C025667	In contrast, such extensive lesions were never found in the PCC group.
BC8_BioRED_Task1_Doc356	1363	1366	PCC	Chemical	C025667	We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	1406	1407	W	Chemical	D014859	We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	1408	1411	ICH	Disease	D002543	We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.
BC8_BioRED_Task1_Doc356	1551	1556	human	OrganismTaxon	9606	Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH.
BC8_BioRED_Task1_Doc356	1557	1558	W	Chemical	D014859	Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH.
BC8_BioRED_Task1_Doc356	1559	1562	ICH	Disease	D002543	Future studies are needed to assess the therapeutic potential emerging from our finding for human W-ICH.
BC8_BioRED_Task1_Doc357	25	30	BRCA1	Gene	672	Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
BC8_BioRED_Task1_Doc357	60	81	breast-ovarian cancer	Disease	D061325	Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.
BC8_BioRED_Task1_Doc357	147	152	BRCA1	Gene	672	We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population.
BC8_BioRED_Task1_Doc357	157	162	BRCA2	Gene	675	We have undertaken a hospital-based study, to identify possible BRCA1 and BRCA2 founder mutations in the Polish population.
BC8_BioRED_Task1_Doc357	260	266	cancer	Disease	D009369	The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years.
BC8_BioRED_Task1_Doc357	321	345	breast or ovarian cancer	Disease	D001943,D010051	The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years.
BC8_BioRED_Task1_Doc357	358	364	cancer	Disease	D009369	The study group consisted of 66 Polish families with cancer who have at least three related females affected with breast or ovarian cancer and who had cancer diagnosed, in at least one of the three affected females, at age < 50 years.
BC8_BioRED_Task1_Doc357	474	500	breast and ovarian cancers	Disease	D001943,D010051	A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only.
BC8_BioRED_Task1_Doc357	517	532	ovarian cancers	Disease	D010051	A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only.
BC8_BioRED_Task1_Doc357	559	573	breast cancers	Disease	D001943	A total of 26 families had both breast and ovarian cancers, 4 families had ovarian cancers only, and 36 families had breast cancers only.
BC8_BioRED_Task1_Doc357	667	672	woman	OrganismTaxon	9606	Genomic DNA was prepared from the peripheral blood leukocytes of at least one affected woman from each family.
BC8_BioRED_Task1_Doc357	719	724	BRCA1	Gene	672	The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants.
BC8_BioRED_Task1_Doc357	729	734	BRCA2	Gene	675	The entire coding region of BRCA1 and BRCA2 was screened for the presence of germline mutations, by use of SSCP followed by direct sequencing of observed variants.
BC8_BioRED_Task1_Doc357	970	975	BRCA1	Gene	672	All but one of the mutations were detected within the BRCA1 gene.
BC8_BioRED_Task1_Doc357	982	1001	BRCA1 abnormalities	Disease	OMIM:604370	BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only.
BC8_BioRED_Task1_Doc357	1044	1058	ovarian cancer	Disease	D010051	BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only.
BC8_BioRED_Task1_Doc357	1097	1122	breast and ovarian cancer	Disease	D001943,D010051	BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only.
BC8_BioRED_Task1_Doc357	1155	1168	breast cancer	Disease	D001943	BRCA1 abnormalities were identified in all four families with ovarian cancer only, in 67% of 27 families with both breast and ovarian cancer, and in 34% of 35 families with breast cancer only.
BC8_BioRED_Task1_Doc357	1200	1205	BRCA2	Gene	675	The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome.
BC8_BioRED_Task1_Doc357	1223	1253	breast-ovarian cancer syndrome	Disease	D061325	The single family with a BRCA2 mutation had the breast-ovarian cancer syndrome.
BC8_BioRED_Task1_Doc357	1448	1467	BRCA1 abnormalities	Disease	OMIM:604370	Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively..
BC8_BioRED_Task1_Doc357	1470	1478	5382insC	SequenceVariant	c|INS|5382|C	Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively..
BC8_BioRED_Task1_Doc357	1480	1484	C61G	SequenceVariant	rs28897672	Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively..
BC8_BioRED_Task1_Doc357	1490	1498	4153delA	SequenceVariant	c|DEL|4153|A	Three BRCA1 abnormalities - 5382insC, C61G, and 4153delA - accounted for 51%, 20%, and 11% of the identified mutations, respectively..
BC8_BioRED_Task1_Doc358	0	5	NF-kB	Gene	4790	NF-kB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	44	49	tumor	Disease	D009369	NF-kB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	83	88	tumor	Disease	D009369	NF-kB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	134	139	tumor	Disease	D009369	NF-kB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	178	183	tumor	Disease	D009369	Radiation modulates both tumor cells and immune cells in the tumor microenvironment to exert its anti-tumor activity; however, the molecular connection between tumor cells and immune cells that mediates radiation-exerted tumor suppression activity in the tumor microenvironment is largely unknown.
BC8_BioRED_Task1_Doc358	214	219	tumor	Disease	D009369	Radiation modulates both tumor cells and immune cells in the tumor microenvironment to exert its anti-tumor activity; however, the molecular connection between tumor cells and immune cells that mediates radiation-exerted tumor suppression activity in the tumor microenvironment is largely unknown.
BC8_BioRED_Task1_Doc358	255	260	tumor	Disease	D009369	Radiation modulates both tumor cells and immune cells in the tumor microenvironment to exert its anti-tumor activity; however, the molecular connection between tumor cells and immune cells that mediates radiation-exerted tumor suppression activity in the tumor microenvironment is largely unknown.
BC8_BioRED_Task1_Doc358	313	318	tumor	Disease	D009369	Radiation modulates both tumor cells and immune cells in the tumor microenvironment to exert its anti-tumor activity; however, the molecular connection between tumor cells and immune cells that mediates radiation-exerted tumor suppression activity in the tumor microenvironment is largely unknown.
BC8_BioRED_Task1_Doc358	374	379	tumor	Disease	D009369	Radiation modulates both tumor cells and immune cells in the tumor microenvironment to exert its anti-tumor activity; however, the molecular connection between tumor cells and immune cells that mediates radiation-exerted tumor suppression activity in the tumor microenvironment is largely unknown.
BC8_BioRED_Task1_Doc358	408	413	tumor	Disease	D009369	Radiation modulates both tumor cells and immune cells in the tumor microenvironment to exert its anti-tumor activity; however, the molecular connection between tumor cells and immune cells that mediates radiation-exerted tumor suppression activity in the tumor microenvironment is largely unknown.
BC8_BioRED_Task1_Doc358	513	516	p65	Gene	5970	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	517	520	p50	Gene	4790	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	525	528	p50	Gene	4790	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	529	532	p50	Gene	4790	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	533	538	NF-kB	Gene	4790	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	552	557	human	OrganismTaxon	9606	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	558	577	soft tissue sarcoma	Disease	D012509	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	579	582	STS	Disease	D012509	We report here that radiation induces rapid activation of the p65/p50 and p50/p50 NF-kB complexes in human soft tissue sarcoma (STS) cells.
BC8_BioRED_Task1_Doc358	611	614	p65	Gene	5970	Radiation-activated p65/p50 and p50/p50 bind to the TNFa promoter to activate its transcription in STS cells.
BC8_BioRED_Task1_Doc358	615	618	p50	Gene	4790	Radiation-activated p65/p50 and p50/p50 bind to the TNFa promoter to activate its transcription in STS cells.
BC8_BioRED_Task1_Doc358	623	626	p50	Gene	4790	Radiation-activated p65/p50 and p50/p50 bind to the TNFa promoter to activate its transcription in STS cells.
BC8_BioRED_Task1_Doc358	627	630	p50	Gene	4790	Radiation-activated p65/p50 and p50/p50 bind to the TNFa promoter to activate its transcription in STS cells.
BC8_BioRED_Task1_Doc358	643	647	TNFa	Gene	7124	Radiation-activated p65/p50 and p50/p50 bind to the TNFa promoter to activate its transcription in STS cells.
BC8_BioRED_Task1_Doc358	690	693	STS	Disease	D012509	Radiation-activated p65/p50 and p50/p50 bind to the TNFa promoter to activate its transcription in STS cells.
BC8_BioRED_Task1_Doc358	719	723	TNFa	Gene	7124	Radiation-induced TNFa induces tumor cell death in an autocrine manner.
BC8_BioRED_Task1_Doc358	732	737	tumor	Disease	D009369	Radiation-induced TNFa induces tumor cell death in an autocrine manner.
BC8_BioRED_Task1_Doc358	793	797	Smac	Gene	56616	A sublethal dose of Smac mimetic BV6 induces cIAP1 and cIAP2 degradation to increase tumor cell sensitivity to radiation-induced cell death in vitro and to enhance radiation-mediated suppression of STS xenografts in vivo.
BC8_BioRED_Task1_Doc358	806	809	BV6	Chemical	C582180	A sublethal dose of Smac mimetic BV6 induces cIAP1 and cIAP2 degradation to increase tumor cell sensitivity to radiation-induced cell death in vitro and to enhance radiation-mediated suppression of STS xenografts in vivo.
BC8_BioRED_Task1_Doc358	818	823	cIAP1	Gene	329	A sublethal dose of Smac mimetic BV6 induces cIAP1 and cIAP2 degradation to increase tumor cell sensitivity to radiation-induced cell death in vitro and to enhance radiation-mediated suppression of STS xenografts in vivo.
BC8_BioRED_Task1_Doc358	828	833	cIAP2	Gene	330	A sublethal dose of Smac mimetic BV6 induces cIAP1 and cIAP2 degradation to increase tumor cell sensitivity to radiation-induced cell death in vitro and to enhance radiation-mediated suppression of STS xenografts in vivo.
BC8_BioRED_Task1_Doc358	858	863	tumor	Disease	D009369	A sublethal dose of Smac mimetic BV6 induces cIAP1 and cIAP2 degradation to increase tumor cell sensitivity to radiation-induced cell death in vitro and to enhance radiation-mediated suppression of STS xenografts in vivo.
BC8_BioRED_Task1_Doc358	971	974	STS	Disease	D012509	A sublethal dose of Smac mimetic BV6 induces cIAP1 and cIAP2 degradation to increase tumor cell sensitivity to radiation-induced cell death in vitro and to enhance radiation-mediated suppression of STS xenografts in vivo.
BC8_BioRED_Task1_Doc358	1009	1017	caspases	Gene	836	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1019	1023	RIP1	Gene	8737	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1028	1032	RIP3	Gene	11035	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1050	1054	TNFa	Gene	7124	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1097	1101	RIP1	Gene	8737	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1109	1113	TNFa	Gene	7124	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1122	1129	caspase	Gene	836	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1158	1166	caspases	Gene	836	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1171	1175	RIP1	Gene	8737	Inhibition of caspases, RIP1, or RIP3 blocks radiation/TNFa-induced cell death, whereas inhibition of RIP1 blocks TNFa-induced caspase activation, suggesting that caspases and RIP1 act sequentially to mediate the non-compensatory cell death pathways.
BC8_BioRED_Task1_Doc358	1288	1295	sarcoma	Disease	D012509	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1296	1301	mouse	OrganismTaxon	10090	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1336	1340	IRF3	Gene	54131	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1342	1346	IFNb	Gene	15977	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1363	1373	chemokines	Gene	20296,20304	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1374	1378	CCL2	Gene	20296	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1383	1387	CCL5	Gene	20304	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1395	1400	tumor	Disease	D009369	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1509	1514	tumor	Disease	D009369	Furthermore, we determined in a syngeneic sarcoma mouse model that radiation up-regulates IRF3, IFNb, and the T cell chemokines CCL2 and CCL5 in the tumor microenvironment, which are associated with activation and increased infiltration of Th1/Tc1 T cells in the tumor microenvironment.
BC8_BioRED_Task1_Doc358	1543	1548	tumor	Disease	D009369	Moreover, tumor-infiltrating T cells are in their active form since both the perforin and FasL pathways are activated in irradiated tumor tissues.
BC8_BioRED_Task1_Doc358	1610	1618	perforin	Gene	18646	Moreover, tumor-infiltrating T cells are in their active form since both the perforin and FasL pathways are activated in irradiated tumor tissues.
BC8_BioRED_Task1_Doc358	1623	1627	FasL	Gene	14103	Moreover, tumor-infiltrating T cells are in their active form since both the perforin and FasL pathways are activated in irradiated tumor tissues.
BC8_BioRED_Task1_Doc358	1665	1670	tumor	Disease	D009369	Moreover, tumor-infiltrating T cells are in their active form since both the perforin and FasL pathways are activated in irradiated tumor tissues.
BC8_BioRED_Task1_Doc358	1703	1706	BV6	Chemical	C582180	Consequently, combined BV6 and radiation completely suppressed tumor growth in vivo.
BC8_BioRED_Task1_Doc358	1743	1748	tumor	Disease	D009369	Consequently, combined BV6 and radiation completely suppressed tumor growth in vivo.
BC8_BioRED_Task1_Doc358	1794	1799	NF-kB	Gene	4790	Therefore, radiation-induced NF-kB functions as a molecular link between tumor cells and immune cells in the tumor microenvironment for radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	1838	1843	tumor	Disease	D009369	Therefore, radiation-induced NF-kB functions as a molecular link between tumor cells and immune cells in the tumor microenvironment for radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	1874	1879	tumor	Disease	D009369	Therefore, radiation-induced NF-kB functions as a molecular link between tumor cells and immune cells in the tumor microenvironment for radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc358	1920	1925	tumor	Disease	D009369	Therefore, radiation-induced NF-kB functions as a molecular link between tumor cells and immune cells in the tumor microenvironment for radiation-mediated tumor suppression.
BC8_BioRED_Task1_Doc359	0	7	Dextran	Chemical	D003911	Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.
BC8_BioRED_Task1_Doc359	8	16	etodolac	Chemical	D017308	Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.
BC8_BioRED_Task1_Doc359	73	81	Etodolac	Chemical	D017308	Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.
BC8_BioRED_Task1_Doc359	83	84	E	Chemical	D017308	Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.
BC8_BioRED_Task1_Doc359	119	140	antiinflammatory drug	Chemical	D000893	Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.
BC8_BioRED_Task1_Doc359	166	173	dextran	Chemical	D003911	A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.
BC8_BioRED_Task1_Doc359	222	230	etodolac	Chemical	D017308	A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.
BC8_BioRED_Task1_Doc359	231	238	dextran	Chemical	D003911	A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.
BC8_BioRED_Task1_Doc359	251	253	ED	Chemical	D003911,D017308	A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.
BC8_BioRED_Task1_Doc359	357	372	N-acylimidazole	Chemical	-	N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).
BC8_BioRED_Task1_Doc359	387	395	etodolac	Chemical	D017308	N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).
BC8_BioRED_Task1_Doc359	397	400	EAI	Chemical	-	N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).
BC8_BioRED_Task1_Doc359	449	456	dextran	Chemical	D003911	N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).
BC8_BioRED_Task1_Doc359	563	568	ester	Chemical	D004952	IR spectral data confirmed formation of ester bonding in the conjugates.
BC8_BioRED_Task1_Doc359	596	604	Etodolac	Chemical	D017308	Etodolac contents were evaluated by UV-spectrophotometric analysis.
BC8_BioRED_Task1_Doc359	789	791	ED	Chemical	D003911,D017308	In vitro hydrolysis of ED was done in aqueous buffers (pH 1.2, 7.4, 9) and in 80% (v/v) human plasma (pH 7.4).
BC8_BioRED_Task1_Doc359	854	859	human	OrganismTaxon	9606	In vitro hydrolysis of ED was done in aqueous buffers (pH 1.2, 7.4, 9) and in 80% (v/v) human plasma (pH 7.4).
BC8_BioRED_Task1_Doc359	903	911	etodolac	Chemical	D017308	At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.
BC8_BioRED_Task1_Doc359	925	927	ED	Chemical	D003911,D017308	At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.
BC8_BioRED_Task1_Doc359	989	994	human	OrganismTaxon	9606	At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.
BC8_BioRED_Task1_Doc359	1165	1176	acetic acid	Chemical	D019342	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
BC8_BioRED_Task1_Doc359	1201	1205	mice	OrganismTaxon	10090	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
BC8_BioRED_Task1_Doc359	1211	1222	carrageenan	Chemical	D002351	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
BC8_BioRED_Task1_Doc359	1231	1234	rat	OrganismTaxon	10116	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
BC8_BioRED_Task1_Doc359	1239	1244	edema	Disease	D004487	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.
BC8_BioRED_Task1_Doc359	1292	1293	E	Chemical	D017308	In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).
BC8_BioRED_Task1_Doc359	1579	1587	etodolac	Chemical	D017308	Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.
BC8_BioRED_Task1_Doc360	0	11	Antioxidant	Chemical	D000975	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
BC8_BioRED_Task1_Doc360	23	29	bovine	OrganismTaxon	9913	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
BC8_BioRED_Task1_Doc360	30	41	lactoferrin	Gene	301034	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
BC8_BioRED_Task1_Doc360	45	58	dexamethasone	Chemical	D003907	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
BC8_BioRED_Task1_Doc360	67	79	hypertension	Disease	D006973	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
BC8_BioRED_Task1_Doc360	83	86	rat	OrganismTaxon	10116	Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.
BC8_BioRED_Task1_Doc360	88	101	Dexamethasone	Chemical	D003907	Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.
BC8_BioRED_Task1_Doc360	104	107	Dex	Chemical	D003907	Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.
BC8_BioRED_Task1_Doc360	118	130	hypertension	Disease	D006973	Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.
BC8_BioRED_Task1_Doc360	177	188	Lactoferrin	Gene	301034	Lactoferrin (LF) is an iron-binding glycoprotein with antihypertensive properties.
BC8_BioRED_Task1_Doc360	190	192	LF	Gene	301034	Lactoferrin (LF) is an iron-binding glycoprotein with antihypertensive properties.
BC8_BioRED_Task1_Doc360	200	204	iron	Chemical	D007501	Lactoferrin (LF) is an iron-binding glycoprotein with antihypertensive properties.
BC8_BioRED_Task1_Doc360	213	225	glycoprotein	Gene	11820	Lactoferrin (LF) is an iron-binding glycoprotein with antihypertensive properties.
BC8_BioRED_Task1_Doc360	331	333	LF	Gene	301034	In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.
BC8_BioRED_Task1_Doc360	358	370	hypertension	Disease	D006973	In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.
BC8_BioRED_Task1_Doc360	376	379	Dex	Chemical	D003907	In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.
BC8_BioRED_Task1_Doc360	408	412	rats	OrganismTaxon	10116	Male Wistar rats were treated by Dex (30  u g/kg/day subcutaneously) or saline for 14 days.
BC8_BioRED_Task1_Doc360	429	432	Dex	Chemical	D003907	Male Wistar rats were treated by Dex (30  u g/kg/day subcutaneously) or saline for 14 days.
BC8_BioRED_Task1_Doc360	493	499	bovine	OrganismTaxon	9913	Oral bovine LF (30, 100, 300 mg/kg) was given from day 8 to 14 in a reversal study.
BC8_BioRED_Task1_Doc360	500	502	LF	Gene	301034	Oral bovine LF (30, 100, 300 mg/kg) was given from day 8 to 14 in a reversal study.
BC8_BioRED_Task1_Doc360	595	599	rats	OrganismTaxon	10116	In a prevention study, rats received 4 days of LF treatment followed by Dex and continued during the test period.
BC8_BioRED_Task1_Doc360	619	621	LF	Gene	301034	In a prevention study, rats received 4 days of LF treatment followed by Dex and continued during the test period.
BC8_BioRED_Task1_Doc360	644	647	Dex	Chemical	D003907	In a prevention study, rats received 4 days of LF treatment followed by Dex and continued during the test period.
BC8_BioRED_Task1_Doc360	791	805	glucocorticoid	Chemical	D005938	Thymus weight was used as a marker of glucocorticoid activity.
BC8_BioRED_Task1_Doc360	823	840	hydrogen peroxide	Chemical	D006861	Plasma hydrogen peroxide (H2O2) concentration and ferric reducing antioxidant power (FRAP) value were determined.
BC8_BioRED_Task1_Doc360	842	846	H2O2	Chemical	D006861	Plasma hydrogen peroxide (H2O2) concentration and ferric reducing antioxidant power (FRAP) value were determined.
BC8_BioRED_Task1_Doc360	866	872	ferric	Chemical	D007501	Plasma hydrogen peroxide (H2O2) concentration and ferric reducing antioxidant power (FRAP) value were determined.
BC8_BioRED_Task1_Doc360	930	943	Dexamethasone	Chemical	D003907	Dexamethasone significantly increased SBP and plasma H2O2 level and decreased thymus and body weights.
BC8_BioRED_Task1_Doc360	983	987	H2O2	Chemical	D006861	Dexamethasone significantly increased SBP and plasma H2O2 level and decreased thymus and body weights.
BC8_BioRED_Task1_Doc360	1033	1035	LF	Gene	301034	LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.
BC8_BioRED_Task1_Doc360	1098	1101	Dex	Chemical	D003907	LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.
BC8_BioRED_Task1_Doc360	1110	1122	hypertension	Disease	D006973	LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.
BC8_BioRED_Task1_Doc360	1124	1126	LF	Gene	301034	LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.
BC8_BioRED_Task1_Doc360	1142	1153	weight loss	Disease	D015431	LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.
BC8_BioRED_Task1_Doc360	1200	1204	H2O2	Chemical	D006861	LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.
BC8_BioRED_Task1_Doc360	1258	1260	LF	Gene	301034	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
BC8_BioRED_Task1_Doc360	1315	1318	ROS	Chemical	D017382	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
BC8_BioRED_Task1_Doc360	1356	1359	Dex	Chemical	D003907	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
BC8_BioRED_Task1_Doc360	1368	1380	hypertension	Disease	D006973	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
BC8_BioRED_Task1_Doc360	1487	1489	LF	Gene	301034	Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.
BC8_BioRED_Task1_Doc361	9	39	neuroleptic malignant syndrome	Disease	D009459	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
BC8_BioRED_Task1_Doc361	78	88	paroxetine	Chemical	D017374	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
BC8_BioRED_Task1_Doc361	93	103	alprazolam	Chemical	D000525	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
BC8_BioRED_Task1_Doc361	119	122	man	OrganismTaxon	9606	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
BC8_BioRED_Task1_Doc361	128	147	depressive symptoms	Disease	D003866	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
BC8_BioRED_Task1_Doc361	166	177	psychiatric	Disease	D001523	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
BC8_BioRED_Task1_Doc361	194	202	insomnia	Disease	D007319	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
BC8_BioRED_Task1_Doc361	204	220	loss of appetite	Disease	D001068	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
BC8_BioRED_Task1_Doc361	238	247	agitation	Disease	D011595	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.
BC8_BioRED_Task1_Doc361	306	316	paroxetine	Chemical	D017374	Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
BC8_BioRED_Task1_Doc361	328	338	alprazolam	Chemical	D000525	Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
BC8_BioRED_Task1_Doc361	359	369	paroxetine	Chemical	D017374	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
BC8_BioRED_Task1_Doc361	374	384	alprazolam	Chemical	D000525	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
BC8_BioRED_Task1_Doc361	400	407	patient	OrganismTaxon	9606	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
BC8_BioRED_Task1_Doc361	425	448	psychomotor retardation	Disease	D011596	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
BC8_BioRED_Task1_Doc361	477	492	muscle rigidity	Disease	D009127	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
BC8_BioRED_Task1_Doc361	498	505	tremors	Disease	D014202	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
BC8_BioRED_Task1_Doc361	511	518	patient	OrganismTaxon	9606	The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
BC8_BioRED_Task1_Doc361	525	530	fever	Disease	D005334	The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
BC8_BioRED_Task1_Doc361	625	648	extrapyramidal symptoms	Disease	D001480	The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
BC8_BioRED_Task1_Doc361	690	712	creatine phosphokinase	Chemical	D003402	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
BC8_BioRED_Task1_Doc361	726	752	aspartate aminotransferase	Chemical	D001219	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
BC8_BioRED_Task1_Doc361	765	789	alanine aminotransferase	Chemical	D000410	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
BC8_BioRED_Task1_Doc361	834	841	patient	OrganismTaxon	9606	The patient received bromocriptine and diazepam to treat his symptoms.
BC8_BioRED_Task1_Doc361	851	864	bromocriptine	Chemical	D001971	The patient received bromocriptine and diazepam to treat his symptoms.
BC8_BioRED_Task1_Doc361	869	877	diazepam	Chemical	D003975	The patient received bromocriptine and diazepam to treat his symptoms.
BC8_BioRED_Task1_Doc361	919	924	fever	Disease	D005334	7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
BC8_BioRED_Task1_Doc361	945	952	patient	OrganismTaxon	9606	7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
BC8_BioRED_Task1_Doc361	961	964	CPK	Chemical	D003402	7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
BC8_BioRED_Task1_Doc361	1005	1012	patient	OrganismTaxon	9606	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
BC8_BioRED_Task1_Doc361	1040	1070	neuroleptic malignant syndrome	Disease	D009459	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
BC8_BioRED_Task1_Doc361	1072	1075	NMS	Disease	D009459	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
BC8_BioRED_Task1_Doc361	1102	1105	NMS	Disease	D009459	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
BC8_BioRED_Task1_Doc361	1145	1155	paroxetine	Chemical	D017374	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
BC8_BioRED_Task1_Doc361	1160	1170	alprazolam	Chemical	D000525	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
BC8_BioRED_Task1_Doc361	1314	1321	patient	OrganismTaxon	9606	The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
BC8_BioRED_Task1_Doc361	1324	1327	NMS	Disease	D009459	The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
BC8_BioRED_Task1_Doc361	1470	1477	patient	OrganismTaxon	9606	The involvement of physiologic and environmental aspects specific to this patient was suspected.
BC8_BioRED_Task1_Doc361	1518	1521	NMS	Disease	D009459	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
BC8_BioRED_Task1_Doc361	1549	1559	depressive	Disease	D003866	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
BC8_BioRED_Task1_Doc361	1560	1568	patients	OrganismTaxon	9606	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
BC8_BioRED_Task1_Doc361	1598	1609	dehydration	Disease	D003681	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
BC8_BioRED_Task1_Doc361	1611	1620	agitation	Disease	D011595	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
BC8_BioRED_Task1_Doc361	1622	1634	malnutrition	Disease	D044342	Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.
BC8_BioRED_Task1_Doc361	1725	1733	patients	OrganismTaxon	9606	Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.
BC8_BioRED_Task1_Doc361	1750	1760	depression	Disease	D003866	Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression.
BC8_BioRED_Task1_Doc362	15	26	sevoflurane	Chemical	C009250	The effects of sevoflurane on lidocaine-induced convulsions.
BC8_BioRED_Task1_Doc362	30	39	lidocaine	Chemical	D008012	The effects of sevoflurane on lidocaine-induced convulsions.
BC8_BioRED_Task1_Doc362	48	59	convulsions	Disease	D012640	The effects of sevoflurane on lidocaine-induced convulsions.
BC8_BioRED_Task1_Doc362	78	89	sevoflurane	Chemical	C009250	The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.
BC8_BioRED_Task1_Doc362	93	102	lidocaine	Chemical	D008012	The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.
BC8_BioRED_Task1_Doc362	111	122	convulsions	Disease	D012640	The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.
BC8_BioRED_Task1_Doc362	138	142	cats	OrganismTaxon	9685	The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.
BC8_BioRED_Task1_Doc362	148	158	convulsive	Disease	D012640	The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.
BC8_BioRED_Task1_Doc362	215	224	lidocaine	Chemical	D008012	The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.
BC8_BioRED_Task1_Doc362	345	356	sevoflurane	Chemical	C009250	The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.
BC8_BioRED_Task1_Doc362	427	438	sevoflurane	Chemical	C009250	However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.
BC8_BioRED_Task1_Doc362	481	492	sevoflurane	Chemical	C009250	However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.
BC8_BioRED_Task1_Doc362	566	576	convulsive	Disease	D012640	There was no significant difference in the convulsive threshold between sevoflurane and enflurane.
BC8_BioRED_Task1_Doc362	595	606	sevoflurane	Chemical	C009250	There was no significant difference in the convulsive threshold between sevoflurane and enflurane.
BC8_BioRED_Task1_Doc362	611	620	enflurane	Chemical	D004737	There was no significant difference in the convulsive threshold between sevoflurane and enflurane.
BC8_BioRED_Task1_Doc362	698	709	sevoflurane	Chemical	C009250	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
BC8_BioRED_Task1_Doc362	713	722	enflurane	Chemical	D004737	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
BC8_BioRED_Task1_Doc362	767	778	convulsions	Disease	D012640	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
BC8_BioRED_Task1_Doc362	811	822	sevoflurane	Chemical	C009250	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
BC8_BioRED_Task1_Doc362	845	854	enflurane	Chemical	D004737	The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
BC8_BioRED_Task1_Doc362	908	917	lidocaine	Chemical	D008012	However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg.
BC8_BioRED_Task1_Doc362	991	997	Apamin	Chemical	D001030	Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.
BC8_BioRED_Task1_Doc362	1022	1029	calcium	Chemical	D002118	Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.
BC8_BioRED_Task1_Doc362	1040	1049	potassium	Chemical	D011188	Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.
BC8_BioRED_Task1_Doc362	1106	1110	rats	OrganismTaxon	10116	Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.
BC8_BioRED_Task1_Doc362	1134	1145	sevoflurane	Chemical	C009250	Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.
BC8_BioRED_Task1_Doc362	1206	1212	Apamin	Chemical	D001030	Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.
BC8_BioRED_Task1_Doc362	1252	1262	convulsive	Disease	D012640	Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.
BC8_BioRED_Task1_Doc362	1379	1390	sevoflurane	Chemical	C009250	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
BC8_BioRED_Task1_Doc362	1403	1413	convulsive	Disease	D012640	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
BC8_BioRED_Task1_Doc362	1424	1433	lidocaine	Chemical	D008012	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
BC8_BioRED_Task1_Doc362	1434	1442	toxicity	Disease	D064420	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
BC8_BioRED_Task1_Doc362	1484	1494	depression	Disease	D003866	It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.
BC8_BioRED_Task1_Doc363	0	11	Salidroside	Chemical	C009172	Salidroside Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/NF-kappaB and MAPK Signaling Pathways.
BC8_BioRED_Task1_Doc363	24	51	Renal Interstitial Fibrosis	Disease	D007674	Salidroside Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/NF-kappaB and MAPK Signaling Pathways.
BC8_BioRED_Task1_Doc363	70	74	TLR4	Gene	21898,7099	Salidroside Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/NF-kappaB and MAPK Signaling Pathways.
BC8_BioRED_Task1_Doc363	75	84	NF-kappaB	Gene	18033,4790	Salidroside Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/NF-kappaB and MAPK Signaling Pathways.
BC8_BioRED_Task1_Doc363	89	93	MAPK	Gene	26413,5594	Salidroside Ameliorates Renal Interstitial Fibrosis by Inhibiting the TLR4/NF-kappaB and MAPK Signaling Pathways.
BC8_BioRED_Task1_Doc363	114	125	Salidroside	Chemical	C009172	Salidroside (Sal) is an active ingredient that is isolated from Rhodiola rosea, which has been reported to have anti-inflammatory activities and a renal protective effect.
BC8_BioRED_Task1_Doc363	127	130	Sal	Chemical	C009172	Salidroside (Sal) is an active ingredient that is isolated from Rhodiola rosea, which has been reported to have anti-inflammatory activities and a renal protective effect.
BC8_BioRED_Task1_Doc363	178	192	Rhodiola rosea	OrganismTaxon	203015	Salidroside (Sal) is an active ingredient that is isolated from Rhodiola rosea, which has been reported to have anti-inflammatory activities and a renal protective effect.
BC8_BioRED_Task1_Doc363	231	243	inflammatory	Disease	D007249	Salidroside (Sal) is an active ingredient that is isolated from Rhodiola rosea, which has been reported to have anti-inflammatory activities and a renal protective effect.
BC8_BioRED_Task1_Doc363	307	310	Sal	Chemical	C009172	However, the role of Sal on renal fibrosis has not yet been elucidated.
BC8_BioRED_Task1_Doc363	314	328	renal fibrosis	Disease	D007674	However, the role of Sal on renal fibrosis has not yet been elucidated.
BC8_BioRED_Task1_Doc363	434	437	Sal	Chemical	C009172	Here, the purpose of the current study is to test the protective effects of Sal against renal interstitial fibrosis (RIF), and to explore the underlying mechanisms using both in vivo and in vitro models.
BC8_BioRED_Task1_Doc363	446	473	renal interstitial fibrosis	Disease	D007674	Here, the purpose of the current study is to test the protective effects of Sal against renal interstitial fibrosis (RIF), and to explore the underlying mechanisms using both in vivo and in vitro models.
BC8_BioRED_Task1_Doc363	475	478	RIF	Disease	D007674	Here, the purpose of the current study is to test the protective effects of Sal against renal interstitial fibrosis (RIF), and to explore the underlying mechanisms using both in vivo and in vitro models.
BC8_BioRED_Task1_Doc363	594	625	unilateral ureteric obstruction	Disease	D014517	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	627	630	UUO	Disease	D014517	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	635	645	folic acid	Chemical	D005492	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	647	649	FA	Chemical	D005492	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	659	663	mice	OrganismTaxon	10090	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	664	691	renal interstitial fibrosis	Disease	D007674	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	708	746	transforming growth factor (TGF)-beta1	Gene	21803	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	758	763	human	OrganismTaxon	9606	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	798	802	HK-2	CellLine	CVCL_0302	In this study, we establish the unilateral ureteric obstruction (UUO) or folic acid (FA)-induced mice renal interstitial fibrosis in vivo and the transforming growth factor (TGF)-beta1-stimulated human proximal tubular epithelial cell (HK-2) model in vitro.
BC8_BioRED_Task1_Doc363	867	879	inflammatory	Disease	D007249	The levels of kidney functional parameters and inflammatory cytokines in serum are examined.
BC8_BioRED_Task1_Doc363	927	939	renal damage	Disease	D007674	The degree of renal damage and fibrosis is determined by histological assessment.
BC8_BioRED_Task1_Doc363	944	952	fibrosis	Disease	D005355	The degree of renal damage and fibrosis is determined by histological assessment.
BC8_BioRED_Task1_Doc363	1077	1080	Sal	Chemical	C009172	Immunohistochemistry and western blotting are used to determine the mechanisms of Sal against RIF.
BC8_BioRED_Task1_Doc363	1089	1092	RIF	Disease	D007674	Immunohistochemistry and western blotting are used to determine the mechanisms of Sal against RIF.
BC8_BioRED_Task1_Doc363	1131	1134	Sal	Chemical	C009172	Our results show that treatment with Sal can ameliorate tubular injury and deposition of the extracellular matrix (ECM) components (including collagen SH and collagen I).
BC8_BioRED_Task1_Doc363	1150	1164	tubular injury	Disease	D007674	Our results show that treatment with Sal can ameliorate tubular injury and deposition of the extracellular matrix (ECM) components (including collagen SH and collagen I).
BC8_BioRED_Task1_Doc363	1236	1247	collagen SH	Gene	1281,12825	Our results show that treatment with Sal can ameliorate tubular injury and deposition of the extracellular matrix (ECM) components (including collagen SH and collagen I).
BC8_BioRED_Task1_Doc363	1252	1262	collagen I	Gene	1277,1278,12842,12843	Our results show that treatment with Sal can ameliorate tubular injury and deposition of the extracellular matrix (ECM) components (including collagen SH and collagen I).
BC8_BioRED_Task1_Doc363	1278	1281	Sal	Chemical	C009172	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1405	1414	alpha-SMA	Gene	11475,59	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1416	1424	vimentin	Gene	22352,7431	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1426	1435	TGF-beta1	Gene	21803,7040	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1437	1442	snail	Gene	20613,6615	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1444	1448	slug	Gene	20583,6591	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1487	1497	E-cadherin	Gene	12550,999	Furthermore, Sal administration significantly suppresses epithelial-mesenchymal transition (EMT), as evidenced by a decreased expression of alpha-SMA, vimentin, TGF-beta1, snail, slug, and a largely restored expression of E-cadherin.
BC8_BioRED_Task1_Doc363	1513	1516	Sal	Chemical	C009172	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1577	1587	creatinine	Chemical	D003404	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1600	1604	urea	Chemical	D014508	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1605	1613	nitrogen	Chemical	D009584	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1624	1633	uric acid	Chemical	D014527	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1635	1637	UA	Chemical	D014527	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1668	1680	inflammatory	Disease	D007249	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1692	1700	IL-1beta	Gene	16176,3553	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1702	1706	IL-6	Gene	16193,3569	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1708	1717	TNF-alpha	Gene	21926,7124	Additionally, Sal also reduces the levels of serum biochemical markers (serum creatinine, Scr; blood urea nitrogen, BUN; and uric acid, UA) and decreases the release of inflammatory cytokines (IL-1beta, IL-6, TNF-alpha).
BC8_BioRED_Task1_Doc363	1762	1765	Sal	Chemical	C009172	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1769	1796	renal interstitial fibrosis	Disease	D007674	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1840	1844	TLR4	Gene	21898,7099	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1848	1860	IkappaBalpha	Gene	18035,4792	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1864	1873	NF-kappaB	Gene	18033,4790	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1878	1911	mitogen-activated protein kinases	Gene	26413,5594	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1913	1917	MAPK	Gene	26413,5594	Further study revealed that the effect of Sal on renal interstitial fibrosis is associated with the lower expression of TLR4, p-IkappaBalpha, p-NF-kappaB and mitogen-activated protein kinases (MAPK), both in vivo and in vitro.
BC8_BioRED_Task1_Doc363	1962	1965	Sal	Chemical	C009172	In conclusion, Sal treatment improves kidney function, ameliorates the deposition of the ECM components and relieves the protein levels of EMT markers in mouse kidneys and HK-2 cells.
BC8_BioRED_Task1_Doc363	2101	2106	mouse	OrganismTaxon	10090	In conclusion, Sal treatment improves kidney function, ameliorates the deposition of the ECM components and relieves the protein levels of EMT markers in mouse kidneys and HK-2 cells.
BC8_BioRED_Task1_Doc363	2119	2123	HK-2	CellLine	CVCL_0302	In conclusion, Sal treatment improves kidney function, ameliorates the deposition of the ECM components and relieves the protein levels of EMT markers in mouse kidneys and HK-2 cells.
BC8_BioRED_Task1_Doc363	2144	2147	Sal	Chemical	C009172	Furthermore, Sal treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/NF-kappaB and MAPK signaling pathways.
BC8_BioRED_Task1_Doc363	2197	2209	inflammatory	Disease	D007249	Furthermore, Sal treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/NF-kappaB and MAPK signaling pathways.
BC8_BioRED_Task1_Doc363	2237	2241	TLR4	Gene	21898,7099	Furthermore, Sal treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/NF-kappaB and MAPK signaling pathways.
BC8_BioRED_Task1_Doc363	2242	2251	NF-kappaB	Gene	18033,4790	Furthermore, Sal treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/NF-kappaB and MAPK signaling pathways.
BC8_BioRED_Task1_Doc363	2256	2260	MAPK	Gene	26413,5594	Furthermore, Sal treatment significantly decreases the release of inflammatory cytokines and inhibits the TLR4/NF-kappaB and MAPK signaling pathways.
BC8_BioRED_Task1_Doc363	2344	2347	Sal	Chemical	C009172	Collectively, these results suggest that the administration of Sal could be a novel therapeutic strategy in treating renal fibrosis.
BC8_BioRED_Task1_Doc363	2398	2412	renal fibrosis	Disease	D007674	Collectively, these results suggest that the administration of Sal could be a novel therapeutic strategy in treating renal fibrosis.
BC8_BioRED_Task1_Doc364	0	22	Superoxide dismutase 1	Gene	20655	Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	41	45	mice	OrganismTaxon	10090	Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	56	73	maternal diabetes	Disease	D016640	Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	114	122	diabetic	Disease	D003920	Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	123	134	embryopathy	Disease	D005315	Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes-induced endoplasmic reticulum stress in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	235	243	diabetic	Disease	D003920	OBJECTIVE: Both oxidative stress and endoplasmic reticulum stress (ER stress) are causal events in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	244	255	embryopathy	Disease	D005315	OBJECTIVE: Both oxidative stress and endoplasmic reticulum stress (ER stress) are causal events in diabetic embryopathy.
BC8_BioRED_Task1_Doc364	343	365	superoxide dismutase 1	Gene	20655	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	367	371	SOD1	Gene	20655	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	438	442	SOD1	Gene	20655	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	463	471	diabetic	Disease	D003920	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	487	491	SOD1	Gene	20655	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	545	569	C/EBP-homologous protein	Gene	13198	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	571	575	CHOP	Gene	13198	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	578	586	calnexin	Gene	12330	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	588	619	eukaryotic initiation factor 2a	Gene	229317	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	621	626	eIF2a	Gene	229317	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	629	681	protein kinase ribonucleic acid (RNA)-like ER kinase	Gene	13666	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	683	687	PERK	Gene	13666	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	690	720	binding immunoglobulin protein	Gene	14828	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	722	767	protein disulfide isomerase family A member 3	Gene	14827	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	769	806	kinases inositol-requiring protein-1a	Gene	78943	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	808	813	IRE1a	Gene	78943	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	824	845	X-box binding protein	Gene	22433	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	847	851	XBP1	Gene	22433	STUDY DESIGN: Wild-type (WT) and superoxide dismutase 1 (SOD1)-overexpressing day 8.75 embryos from nondiabetic WT control with SOD1 transgenic male and diabetic WT female with SOD1 transgenic male were analyzed for ER stress markers: C/EBP-homologous protein (CHOP), calnexin, eukaryotic initiation factor 2a (eIF2a), protein kinase ribonucleic acid (RNA)-like ER kinase (PERK), binding immunoglobulin protein, protein disulfide isomerase family A member 3, kinases inositol-requiring protein-1a (IRE1a), and the X-box binding protein (XBP1) messenger RNA (mRNA) splicing.
BC8_BioRED_Task1_Doc364	893	910	Maternal diabetes	Disease	D016640	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	949	953	CHOP	Gene	13198	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	955	963	calnexin	Gene	12330	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	984	989	eIF2a	Gene	229317	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	993	997	PERK	Gene	13666	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	1005	1010	IRE1a	Gene	78943	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	1022	1026	XBP1	Gene	22433	RESULTS: Maternal diabetes significantly increased the levels of CHOP, calnexin, phosphorylated (p)-eIF2a, p-PERK, and p-IRE1a; triggered XBP1 mRNA splicing; and enhanced ER chaperone gene expression in WT embryos.
BC8_BioRED_Task1_Doc364	1099	1103	SOD1	Gene	20655	SOD1 overexpression blocked these diabetes-induced ER stress markers.
BC8_BioRED_Task1_Doc364	1133	1141	diabetes	Disease	D003920	SOD1 overexpression blocked these diabetes-induced ER stress markers.
BC8_BioRED_Task1_Doc364	1213	1217	SOD1	Gene	20655	CONCLUSION: Mitigating oxidative stress via SOD1 overexpression blocks maternal diabetes-induced ER stress in vivo.
BC8_BioRED_Task1_Doc364	1240	1257	maternal diabetes	Disease	D016640	CONCLUSION: Mitigating oxidative stress via SOD1 overexpression blocks maternal diabetes-induced ER stress in vivo.
BC8_BioRED_Task1_Doc365	0	49	Peroxisomal proliferator activated receptor-gamma	Gene	5468	Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
BC8_BioRED_Task1_Doc365	88	125	familial partial lipodystrophy type 3	Disease	D052496	Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
BC8_BioRED_Task1_Doc365	127	132	FPLD3	Disease	D052496	Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
BC8_BioRED_Task1_Doc365	147	195	Familial partial lipodystrophy (Dunnigan) type 3	Disease	D052496	BACKGROUND: Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated receptor-gamma.
BC8_BioRED_Task1_Doc365	197	202	FPLD3	Disease	D052496	BACKGROUND: Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated receptor-gamma.
BC8_BioRED_Task1_Doc365	204	245	Mendelian Inheritance in Man [MIM] 604367	Disease	D052496	BACKGROUND: Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated receptor-gamma.
BC8_BioRED_Task1_Doc365	286	291	PPARG	Gene	5468	BACKGROUND: Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated receptor-gamma.
BC8_BioRED_Task1_Doc365	301	350	peroxisomal proliferator-activated receptor-gamma	Gene	5468	BACKGROUND: Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated receptor-gamma.
BC8_BioRED_Task1_Doc365	480	485	FPLD3	Disease	D052496	METHODS: We present a Canadian FPLD3 kindred with an affected mother who had loss of fat on arms and legs, but no increase in facial, neck, suprascapular or abdominal fat.
BC8_BioRED_Task1_Doc365	638	656	insulin resistance	Disease	D007333	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	658	666	diabetes	Disease	D003920	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	675	695	hypertriglyceridemia	Disease	D015228	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	710	722	pancreatitis	Disease	D010195	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	805	818	triglycerides	Chemical	D014280	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	823	832	C-peptide	Chemical	D002096	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	847	883	high-density lipoprotein cholesterol	Chemical	D008076	She had profound insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and depressed high-density lipoprotein cholesterol.
BC8_BioRED_Task1_Doc365	945	950	PPARG	Gene	5468	RESULTS: The mother and daughter were each heterozygous for PPARG nonsense mutation Y355X, whose protein product in vitro was transcriptionally inactive with no dominant-negative activity against the wild-type receptor.
BC8_BioRED_Task1_Doc365	969	974	Y355X	SequenceVariant	p|SUB|Y|355|X	RESULTS: The mother and daughter were each heterozygous for PPARG nonsense mutation Y355X, whose protein product in vitro was transcriptionally inactive with no dominant-negative activity against the wild-type receptor.
BC8_BioRED_Task1_Doc365	1222	1227	human	OrganismTaxon	9606	CONCLUSION: Taken together with previous studies of human PPARG mutations, these findings suggest that PPAR-gamma deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product's function can each contribute to the FPLD3 phenotype.
BC8_BioRED_Task1_Doc365	1228	1233	PPARG	Gene	5468	CONCLUSION: Taken together with previous studies of human PPARG mutations, these findings suggest that PPAR-gamma deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product's function can each contribute to the FPLD3 phenotype.
BC8_BioRED_Task1_Doc365	1273	1283	PPAR-gamma	Gene	5468	CONCLUSION: Taken together with previous studies of human PPARG mutations, these findings suggest that PPAR-gamma deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product's function can each contribute to the FPLD3 phenotype.
BC8_BioRED_Task1_Doc365	1465	1470	FPLD3	Disease	D052496	CONCLUSION: Taken together with previous studies of human PPARG mutations, these findings suggest that PPAR-gamma deficiency due either to haploinsufficiency or to substantial activity loss due to dominant negative interference of the normal allele product's function can each contribute to the FPLD3 phenotype.
BC8_BioRED_Task1_Doc366	27	32	F826Y	SequenceVariant	rs13306592	A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes.
BC8_BioRED_Task1_Doc366	41	67	mineralocorticoid receptor	Gene	4306	A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes.
BC8_BioRED_Task1_Doc366	85	98	hypertensives	Disease	D006973	A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes.
BC8_BioRED_Task1_Doc366	187	192	S810L	SequenceVariant	rs41511344	A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy.
BC8_BioRED_Task1_Doc366	254	280	mineralocorticoid receptor	Gene	4306	A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy.
BC8_BioRED_Task1_Doc366	282	284	MR	Gene	4306	A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy.
BC8_BioRED_Task1_Doc366	299	304	NR3C2	Gene	4306	A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy.
BC8_BioRED_Task1_Doc366	337	349	hypertension	Disease	D006973	A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy.
BC8_BioRED_Task1_Doc366	519	531	hypertension	Disease	D006973	The objective of this study was to test whether other types of missense mutations in the hormone-binding domain could be implicated in hypertension in Japanese.
BC8_BioRED_Task1_Doc366	576	584	patients	OrganismTaxon	9606	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	590	602	hypertension	Disease	D006973	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	611	616	S810L	SequenceVariant	rs41511344	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	643	645	MR	Gene	4306	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	671	676	S810L	SequenceVariant	rs41511344	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	693	705	hypertensive	Disease	D006973	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	734	739	S810L	SequenceVariant	rs41511344	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	786	808	essential hypertension	Disease	D000075222	Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR. We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese.
BC8_BioRED_Task1_Doc366	872	877	F826Y	SequenceVariant	rs13306592	However, we identified a novel missense mutation, F826Y, in three patients in a heterozygous state, in addition to four single nucleotide polymorphisms, including one synonymous mutation (L809L).
BC8_BioRED_Task1_Doc366	888	896	patients	OrganismTaxon	9606	However, we identified a novel missense mutation, F826Y, in three patients in a heterozygous state, in addition to four single nucleotide polymorphisms, including one synonymous mutation (L809L).
BC8_BioRED_Task1_Doc366	1010	1015	L809L	SequenceVariant	rs145670736	However, we identified a novel missense mutation, F826Y, in three patients in a heterozygous state, in addition to four single nucleotide polymorphisms, including one synonymous mutation (L809L).
BC8_BioRED_Task1_Doc366	1022	1027	F826Y	SequenceVariant	rs13306592	The F826Y mutation is present in the MR hormone-binding domain and might affect the ligand affinity.
BC8_BioRED_Task1_Doc366	1055	1057	MR	Gene	4306	The F826Y mutation is present in the MR hormone-binding domain and might affect the ligand affinity.
BC8_BioRED_Task1_Doc366	1123	1128	F826Y	SequenceVariant	rs13306592	The F826Y mutation was also identified in 13 individuals (5 hypertensives and 8 normotensives) in a Japanese general population (n=3,655).
BC8_BioRED_Task1_Doc366	1179	1192	hypertensives	Disease	D006973	The F826Y mutation was also identified in 13 individuals (5 hypertensives and 8 normotensives) in a Japanese general population (n=3,655).
BC8_BioRED_Task1_Doc366	1315	1320	F826Y	SequenceVariant	rs13306592	The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension.
BC8_BioRED_Task1_Doc366	1337	1349	hypertensive	Disease	D006973	The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension.
BC8_BioRED_Task1_Doc366	1380	1392	hypertensive	Disease	D006973	The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension.
BC8_BioRED_Task1_Doc366	1561	1573	hypertension	Disease	D006973	The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension.
BC8_BioRED_Task1_Doc366	1628	1633	F826Y	SequenceVariant	rs13306592	Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.
BC8_BioRED_Task1_Doc366	1683	1709	mineralocorticoid receptor	Gene	4306	Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.
BC8_BioRED_Task1_Doc366	1821	1823	MR	Gene	4306	Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.
BC8_BioRED_Task1_Doc367	16	19	Sag	Gene	19823	Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
BC8_BioRED_Task1_Doc367	20	24	Rbx2	Gene	19823	Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
BC8_BioRED_Task1_Doc367	25	29	Roc2	Gene	19823	Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
BC8_BioRED_Task1_Doc367	30	49	e3 ubiquitin ligase	Gene	19823	Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
BC8_BioRED_Task1_Doc367	83	87	kras	Gene	16653	Inactivation of Sag/Rbx2/Roc2 e3 ubiquitin ligase triggers senescence and inhibits kras-induced immortalization.
BC8_BioRED_Task1_Doc367	142	145	SAG	Gene	19823	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	146	150	RBX2	Gene	19823	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	151	170	E3 ubiquitin ligase	Gene	19823	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	238	242	NOXA	Gene	58801	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	247	250	NF1	Gene	18015	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	273	277	Kras	Gene	16653	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	289	307	lung tumorigenesis	Disease	D008175	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	322	330	NFkappaB	Gene	18033	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	335	339	mTOR	Gene	56717	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	377	382	tumor	Disease	D009369	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	416	423	IkappaB	Gene	18033	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	425	431	DEPTOR	Gene	97998	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	433	436	p21	Gene	12575	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	441	444	p27	Gene	12576	Our recent study showed that SAG/RBX2 E3 ubiquitin ligase regulates apoptosis and vasculogenesis by promoting degradation of NOXA and NF1, and co-operates with Kras to promote lung tumorigenesis by activating NFkappaB and mTOR pathways via targeted degradation of tumor suppressive substrates including IkappaB, DEPTOR, p21 and p27.
BC8_BioRED_Task1_Doc367	479	482	Sag	Gene	19823	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	483	487	Rbx2	Gene	19823	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	488	497	E3 ligase	Gene	19823	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	544	549	mouse	OrganismTaxon	10090	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	595	598	Sag	Gene	19823	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	645	649	Kras	Gene	16653	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	650	654	G12D	SequenceVariant	rs121913529	Here we investigated the role of Sag/Rbx2 E3 ligase in cellular senescence and immortalization of mouse embryonic fibroblasts (MEFs) and report that Sag is required for proper cell proliferation and Kras(G12D)-induced immortalization.
BC8_BioRED_Task1_Doc367	681	684	Sag	Gene	19823	Sag inactivation by genetic deletion remarkably suppresses cell proliferation by inducing senescence, which is associated with accumulation of p16, but not p53.
BC8_BioRED_Task1_Doc367	824	827	p16	Gene	12578	Sag inactivation by genetic deletion remarkably suppresses cell proliferation by inducing senescence, which is associated with accumulation of p16, but not p53.
BC8_BioRED_Task1_Doc367	837	840	p53	Gene	22059	Sag inactivation by genetic deletion remarkably suppresses cell proliferation by inducing senescence, which is associated with accumulation of p16, but not p53.
BC8_BioRED_Task1_Doc367	859	862	Sag	Gene	19823	Mechanistically, Sag deletion caused accumulation of Jun-B, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives p16 transcription.
BC8_BioRED_Task1_Doc367	895	900	Jun-B	Gene	16477	Mechanistically, Sag deletion caused accumulation of Jun-B, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives p16 transcription.
BC8_BioRED_Task1_Doc367	917	920	Sag	Gene	19823	Mechanistically, Sag deletion caused accumulation of Jun-B, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives p16 transcription.
BC8_BioRED_Task1_Doc367	921	926	Fbxw7	Gene	50754	Mechanistically, Sag deletion caused accumulation of Jun-B, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives p16 transcription.
BC8_BioRED_Task1_Doc367	927	936	E3 ligase	Gene	19823	Mechanistically, Sag deletion caused accumulation of Jun-B, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives p16 transcription.
BC8_BioRED_Task1_Doc367	976	979	p16	Gene	12578	Mechanistically, Sag deletion caused accumulation of Jun-B, a substrate of Sag-Fbxw7 E3 ligase and a transcription factor that drives p16 transcription.
BC8_BioRED_Task1_Doc367	1032	1035	Sag	Gene	19823	Importantly, senescence triggered by Sag deletion can be largely rescued by simultaneous deletion of Cdkn2a, the p16 encoding gene, indicating its causal role.
BC8_BioRED_Task1_Doc367	1096	1102	Cdkn2a	Gene	12578	Importantly, senescence triggered by Sag deletion can be largely rescued by simultaneous deletion of Cdkn2a, the p16 encoding gene, indicating its causal role.
BC8_BioRED_Task1_Doc367	1108	1111	p16	Gene	12578	Importantly, senescence triggered by Sag deletion can be largely rescued by simultaneous deletion of Cdkn2a, the p16 encoding gene, indicating its causal role.
BC8_BioRED_Task1_Doc367	1168	1172	Kras	Gene	16653	Furthermore, Kras(G12D)-induced immortalization can also be abrogated by Sag deletion via senescence induction, which is again rescued by simultaneous deletion of Cdkn2a.
BC8_BioRED_Task1_Doc367	1173	1177	G12D	SequenceVariant	rs121913529	Furthermore, Kras(G12D)-induced immortalization can also be abrogated by Sag deletion via senescence induction, which is again rescued by simultaneous deletion of Cdkn2a.
BC8_BioRED_Task1_Doc367	1228	1231	Sag	Gene	19823	Furthermore, Kras(G12D)-induced immortalization can also be abrogated by Sag deletion via senescence induction, which is again rescued by simultaneous deletion of Cdkn2a.
BC8_BioRED_Task1_Doc367	1318	1324	Cdkn2a	Gene	12578	Furthermore, Kras(G12D)-induced immortalization can also be abrogated by Sag deletion via senescence induction, which is again rescued by simultaneous deletion of Cdkn2a.
BC8_BioRED_Task1_Doc367	1349	1352	Sag	Gene	19823	Finally, we found that Sag deletion inactivates Kras(G12D) activity and block the MAPK signaling pathway, together with accumulated p16, to induce senescence.
BC8_BioRED_Task1_Doc367	1374	1378	Kras	Gene	16653	Finally, we found that Sag deletion inactivates Kras(G12D) activity and block the MAPK signaling pathway, together with accumulated p16, to induce senescence.
BC8_BioRED_Task1_Doc367	1379	1383	G12D	SequenceVariant	rs121913529	Finally, we found that Sag deletion inactivates Kras(G12D) activity and block the MAPK signaling pathway, together with accumulated p16, to induce senescence.
BC8_BioRED_Task1_Doc367	1408	1412	MAPK	Gene	26413	Finally, we found that Sag deletion inactivates Kras(G12D) activity and block the MAPK signaling pathway, together with accumulated p16, to induce senescence.
BC8_BioRED_Task1_Doc367	1458	1461	p16	Gene	12578	Finally, we found that Sag deletion inactivates Kras(G12D) activity and block the MAPK signaling pathway, together with accumulated p16, to induce senescence.
BC8_BioRED_Task1_Doc367	1531	1534	Sag	Gene	19823	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1540	1544	Kras	Gene	16653	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1545	1549	G12D	SequenceVariant	rs121913529	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1585	1589	Kras	Gene	16653	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1590	1594	G12D	SequenceVariant	rs121913529	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1654	1657	SAG	Gene	19823	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1658	1661	SCF	Gene	50754	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1662	1671	E3 ligase	Gene	19823	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc367	1732	1738	cancer	Disease	D009369	Taken together, our results demonstrated that Sag is a Kras(G12D)-cooperating oncogene required for Kras(G12D)-induced immortalization and transformation, and targeting SAG-SCF E3 ligase may, therefore, have therapeutic value for senescence-based cancer treatment.
BC8_BioRED_Task1_Doc368	6	19	carbamazepine	Chemical	D002220	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
BC8_BioRED_Task1_Doc368	52	68	hypersensitivity	Disease	D006967	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
BC8_BioRED_Task1_Doc368	70	81	myocarditis	Disease	D009205	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
BC8_BioRED_Task1_Doc368	167	188	drug hypersensitivity	Disease	D004342	Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
BC8_BioRED_Task1_Doc368	254	267	carbamazepine	Chemical	D002220	The most severe adverse reactions to carbamazepine have been observed in the haemopoietic system, the liver and the cardiovascular system.
BC8_BioRED_Task1_Doc368	419	432	carbamazepine	Chemical	D002220	A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
BC8_BioRED_Task1_Doc368	462	478	hypersensitivity	Disease	D006967	A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
BC8_BioRED_Task1_Doc368	480	491	myocarditis	Disease	D009205	A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
BC8_BioRED_Task1_Doc368	513	529	hypersensitivity	Disease	D006967	We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
BC8_BioRED_Task1_Doc368	530	541	myocarditis	Disease	D009205	We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
BC8_BioRED_Task1_Doc368	573	586	carbamazepine	Chemical	D002220	We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
BC8_BioRED_Task1_Doc368	594	610	hypersensitivity	Disease	D006967	Acute hypersensitivity myocarditis was not suspected clinically, and the diagnosis was made post-mortem.
BC8_BioRED_Task1_Doc368	611	622	myocarditis	Disease	D009205	Acute hypersensitivity myocarditis was not suspected clinically, and the diagnosis was made post-mortem.
BC8_BioRED_Task1_Doc368	815	820	death	Disease	D003643	Clinically, death was due to cardiogenic shock.
BC8_BioRED_Task1_Doc368	832	849	cardiogenic shock	Disease	D012770	Clinically, death was due to cardiogenic shock.
BC8_BioRED_Task1_Doc368	909	922	carbamazepine	Chemical	D002220	To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature.
BC8_BioRED_Task1_Doc368	931	942	myocarditis	Disease	D009205	To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature.
BC8_BioRED_Task1_Doc369	11	24	crack cocaine	Chemical	D016578	Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs.
BC8_BioRED_Task1_Doc369	46	59	HIV infection	Disease	D015658	Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs.
BC8_BioRED_Task1_Doc369	163	176	crack cocaine	Chemical	D016578	BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection.
BC8_BioRED_Task1_Doc369	201	214	HIV infection	Disease	D015658	BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection.
BC8_BioRED_Task1_Doc369	244	257	crack cocaine	Chemical	D016578	Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection.
BC8_BioRED_Task1_Doc369	342	355	HIV infection	Disease	D015658	Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection.
BC8_BioRED_Task1_Doc369	577	580	HIV	Disease	D015658	METHODS: We included data from people participating in the Vancouver Injection Drug Users Study who reported injecting illicit drugs at least once in the month before enrolment, lived in the greater Vancouver area, were HIV-negative at enrolment and completed at least 1 follow-up study visit.
BC8_BioRED_Task1_Doc369	684	702	HIV seroconversion	Disease	D006679	To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).
BC8_BioRED_Task1_Doc369	726	739	crack cocaine	Chemical	D016578	To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).
BC8_BioRED_Task1_Doc369	1065	1078	HIV infection	Disease	D015658	Of these, 137 acquired HIV infection during follow-up.
BC8_BioRED_Task1_Doc369	1163	1176	crack cocaine	Chemical	D016578	The mean proportion of participants who reported daily smoking of crack cocaine increased from 11.6% in period 1 to 39.7% in period 3.
BC8_BioRED_Task1_Doc369	1301	1319	HIV seroconversion	Disease	D006679	After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).
BC8_BioRED_Task1_Doc369	1365	1378	crack cocaine	Chemical	D016578	After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).
BC8_BioRED_Task1_Doc369	1580	1593	crack cocaine	Chemical	D016578	INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users.
BC8_BioRED_Task1_Doc369	1641	1659	HIV seroconversion	Disease	D006679	INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users.
BC8_BioRED_Task1_Doc369	1817	1830	crack cocaine	Chemical	D016578	This finding points to the urgent need for evidence-based public health initiatives targeted at people who smoke crack cocaine.
BC8_BioRED_Task1_Doc370	0	5	TGFBI	Gene	7045	TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients.
BC8_BioRED_Task1_Doc370	29	69	lattice and granular corneal dystrophies	Disease	C537881,D003317	TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients.
BC8_BioRED_Task1_Doc370	80	88	patients	OrganismTaxon	9606	TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients.
BC8_BioRED_Task1_Doc370	128	133	TGFBI	Gene	7045	PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations.
BC8_BioRED_Task1_Doc370	149	157	patients	OrganismTaxon	9606	PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations.
BC8_BioRED_Task1_Doc370	163	188	lattice corneal dystrophy	Disease	C537881	PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations.
BC8_BioRED_Task1_Doc370	190	193	LCD	Disease	C537881	PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations.
BC8_BioRED_Task1_Doc370	198	224	granular corneal dystrophy	Disease	D003317	PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations.
BC8_BioRED_Task1_Doc370	226	229	GCD	Disease	D003317	PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations.
BC8_BioRED_Task1_Doc370	312	320	patients	OrganismTaxon	9606	METHODS: Thirty-seven unrelated patients were studied, 18 with LCD and 19 with GCD.
BC8_BioRED_Task1_Doc370	343	346	LCD	Disease	C537881	METHODS: Thirty-seven unrelated patients were studied, 18 with LCD and 19 with GCD.
BC8_BioRED_Task1_Doc370	359	362	GCD	Disease	D003317	METHODS: Thirty-seven unrelated patients were studied, 18 with LCD and 19 with GCD.
BC8_BioRED_Task1_Doc370	381	384	LCD	Disease	C537881	The diagnosis of LCD or GCD was made on the basis of clinical and/or histopathological evaluation.
BC8_BioRED_Task1_Doc370	388	391	GCD	Disease	D003317	The diagnosis of LCD or GCD was made on the basis of clinical and/or histopathological evaluation.
BC8_BioRED_Task1_Doc370	506	511	TGFBI	Gene	7045	Exons and flanking intron sequences of the TGFBI gene were amplified by PCR with specific primers.
BC8_BioRED_Task1_Doc370	803	811	patients	OrganismTaxon	9606	RESULTS: Mutations were identified in 14 of 18 patients with LCD and in all 19 patients with GCD.
BC8_BioRED_Task1_Doc370	817	820	LCD	Disease	C537881	RESULTS: Mutations were identified in 14 of 18 patients with LCD and in all 19 patients with GCD.
BC8_BioRED_Task1_Doc370	835	843	patients	OrganismTaxon	9606	RESULTS: Mutations were identified in 14 of 18 patients with LCD and in all 19 patients with GCD.
BC8_BioRED_Task1_Doc370	849	852	GCD	Disease	D003317	RESULTS: Mutations were identified in 14 of 18 patients with LCD and in all 19 patients with GCD.
BC8_BioRED_Task1_Doc370	857	860	LCD	Disease	C537881	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	908	926	glycine-594-valine	SequenceVariant	p|SUB|G|594|V	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	928	937	Gly594Val	SequenceVariant	p|SUB|G|594|V	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	950	958	patients	OrganismTaxon	9606	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	960	984	valine-539-aspartic acid	SequenceVariant	p|SUB|V|539|D	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	986	995	Val539Asp	SequenceVariant	p|SUB|V|539|D	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	1002	1009	patient	OrganismTaxon	9606	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	1015	1049	deletion of valine 624, valine 625	SequenceVariant	p|DEL|624_625|VV	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	1051	1067	Val624-Val625del	SequenceVariant	p|DEL|624_625|VV	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	1074	1081	patient	OrganismTaxon	9606	In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient.
BC8_BioRED_Task1_Doc370	1108	1132	arginine 124-to-cysteine	SequenceVariant	rs121909210	In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients.
BC8_BioRED_Task1_Doc370	1134	1143	Arg124Cys	SequenceVariant	rs121909210	In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients.
BC8_BioRED_Task1_Doc370	1166	1174	patients	OrganismTaxon	9606	In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients.
BC8_BioRED_Task1_Doc370	1179	1204	histidine 626-to-arginine	SequenceVariant	p|SUB|H|626|R	In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients.
BC8_BioRED_Task1_Doc370	1206	1215	His626Arg	SequenceVariant	p|SUB|H|626|R	In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients.
BC8_BioRED_Task1_Doc370	1228	1236	patients	OrganismTaxon	9606	In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients.
BC8_BioRED_Task1_Doc370	1269	1272	LCD	Disease	C537881	Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations.
BC8_BioRED_Task1_Doc370	1287	1295	patients	OrganismTaxon	9606	Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations.
BC8_BioRED_Task1_Doc370	1305	1314	Gly594Val	SequenceVariant	p|SUB|G|594|V	Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations.
BC8_BioRED_Task1_Doc370	1319	1335	Val624-Val625del	SequenceVariant	p|DEL|624_625|VV	Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations.
BC8_BioRED_Task1_Doc370	1350	1353	GCD	Disease	D003317	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1358	1366	patients	OrganismTaxon	9606	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1372	1382	GCD type I	Disease	C537304	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1401	1427	arginine 555-to-tryptophan	SequenceVariant	rs121909208	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1429	1438	Arg555Trp	SequenceVariant	rs121909208	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1446	1453	patient	OrganismTaxon	9606	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1459	1471	GCD type III	Disease	C535476	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1473	1496	Reis-Bucklers dystrophy	Disease	C535476	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1507	1516	Arg124Leu	SequenceVariant	rs121909211	In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation.
BC8_BioRED_Task1_Doc370	1616	1644	leucine 269 to phenylalanine	SequenceVariant	rs199852470	Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation.
BC8_BioRED_Task1_Doc370	1646	1655	Leu269Phe	SequenceVariant	rs199852470	Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation.
BC8_BioRED_Task1_Doc370	1679	1687	patients	OrganismTaxon	9606	Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation.
BC8_BioRED_Task1_Doc370	1697	1706	Arg555Trp	SequenceVariant	rs121909208	Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation.
BC8_BioRED_Task1_Doc370	1730	1739	Arg124Cys	SequenceVariant	rs121909210	CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied.
BC8_BioRED_Task1_Doc370	1744	1753	Arg555Trp	SequenceVariant	rs121909208	CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied.
BC8_BioRED_Task1_Doc370	1801	1804	LCD	Disease	C537881	CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied.
BC8_BioRED_Task1_Doc370	1809	1812	GCD	Disease	D003317	CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied.
BC8_BioRED_Task1_Doc371	48	60	inflammatory	Disease	D007249	Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor.
BC8_BioRED_Task1_Doc371	74	90	prostaglandin A2	Chemical	C100008	Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor.
BC8_BioRED_Task1_Doc371	100	112	EP4 receptor	Gene	19219	Regulation of lung endothelial permeability and inflammatory responses by prostaglandin A2: role of EP4 receptor.
BC8_BioRED_Task1_Doc371	126	142	prostaglandin A2	Chemical	C100008	The role of prostaglandin A2 (PGA2) in modulation of vascular endothelial function is unknown.
BC8_BioRED_Task1_Doc371	144	148	PGA2	Chemical	C100008	The role of prostaglandin A2 (PGA2) in modulation of vascular endothelial function is unknown.
BC8_BioRED_Task1_Doc371	236	240	PGA2	Chemical	C100008	We investigated effects of PGA2 on pulmonary endothelial cell (EC) permeability and inflammatory activation and identified a receptor mediating these effects.
BC8_BioRED_Task1_Doc371	293	305	inflammatory	Disease	D007249	We investigated effects of PGA2 on pulmonary endothelial cell (EC) permeability and inflammatory activation and identified a receptor mediating these effects.
BC8_BioRED_Task1_Doc371	368	372	PGA2	Chemical	C100008	PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall lipopolysaccharide (LPS).
BC8_BioRED_Task1_Doc371	468	476	thrombin	Gene	14061	PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall lipopolysaccharide (LPS).
BC8_BioRED_Task1_Doc371	481	496	proinflammatory	Disease	D007249	PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall lipopolysaccharide (LPS).
BC8_BioRED_Task1_Doc371	512	530	lipopolysaccharide	Chemical	D008070	PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall lipopolysaccharide (LPS).
BC8_BioRED_Task1_Doc371	532	535	LPS	Chemical	D008070	PGA2 enhanced the EC barrier and protected against barrier dysfunction caused by vasoactive peptide thrombin and proinflammatory bacterial wall lipopolysaccharide (LPS).
BC8_BioRED_Task1_Doc371	626	629	EP4	Gene	5734	Receptor screening using pharmacological and molecular inhibitory approaches identified EP4 as a novel PGA2 receptor.
BC8_BioRED_Task1_Doc371	641	654	PGA2 receptor	Gene	5734	Receptor screening using pharmacological and molecular inhibitory approaches identified EP4 as a novel PGA2 receptor.
BC8_BioRED_Task1_Doc371	656	659	EP4	Gene	5734	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	699	703	PGA2	Chemical	C100008	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	718	734	Rap1/Rac1 GTPase	Gene	5879,5906	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	739	755	protein kinase A	Gene	5566	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	800	811	VE-cadherin	Gene	1003	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	813	825	p120-catenin	Gene	1500	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	827	831	ZO-1	Gene	7082	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	833	842	cortactin	Gene	2017	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	848	852	VASP	Gene	7408	EP4 mediated barrier-protective effects of PGA2 by activating Rap1/Rac1 GTPase and protein kinase A targets at cell adhesions and cytoskeleton: VE-cadherin, p120-catenin, ZO-1, cortactin, and VASP.
BC8_BioRED_Task1_Doc371	854	858	PGA2	Chemical	C100008	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	875	878	LPS	Chemical	D008070	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	887	899	inflammatory	Disease	D007249	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	928	932	NFkB	Gene	19697	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	959	980	EC adhesion molecules	Gene	3383,7412	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	981	986	ICAM1	Gene	3383	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	991	996	VCAM1	Gene	7412	PGA2 also suppressed LPS-induced inflammatory signaling by inhibiting the NFkB pathway and expression of EC adhesion molecules ICAM1 and VCAM1.
BC8_BioRED_Task1_Doc371	1073	1076	EP4	Gene	5734	These effects were abolished by pharmacological or molecular inhibition of EP4.
BC8_BioRED_Task1_Doc371	1087	1091	PGA2	Chemical	C100008	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1133	1150	acute lung injury	Disease	D055371	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1152	1155	ALI	Disease	D055371	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1158	1161	LPS	Chemical	D008070	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1170	1189	inflammatory injury	Disease	D007249	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1202	1205	ALI	Disease	D055371	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1267	1284	thrombin receptor	Gene	14062	In vivo, PGA2 was protective in two distinct models of acute lung injury (ALI): LPS-induced inflammatory injury and two-hit ALI caused by suboptimal mechanical ventilation and injection of thrombin receptor-activating peptide.
BC8_BioRED_Task1_Doc371	1348	1352	mice	OrganismTaxon	10090	These protective effects were abolished in mice with endothelial-specific EP4 knockout.
BC8_BioRED_Task1_Doc371	1379	1382	EP4	Gene	19219	These protective effects were abolished in mice with endothelial-specific EP4 knockout.
BC8_BioRED_Task1_Doc371	1434	1438	PGA2	Chemical	C100008	The results suggest a novel role for the PGA2-EP4 axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and inflammation.
BC8_BioRED_Task1_Doc371	1439	1442	EP4	Gene	5734	The results suggest a novel role for the PGA2-EP4 axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and inflammation.
BC8_BioRED_Task1_Doc371	1577	1589	inflammation	Disease	D007249	The results suggest a novel role for the PGA2-EP4 axis in vascular EC protection that is critical for improvement of pathological states associated with increased vascular leakage and inflammation.
BC8_BioRED_Task1_Doc372	0	5	FGFR1	Gene	2260	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
BC8_BioRED_Task1_Doc372	10	15	NTRK3	Gene	4916	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
BC8_BioRED_Task1_Doc372	54	85	gastrointestinal stromal tumors	Disease	D046152	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
BC8_BioRED_Task1_Doc372	142	173	gastrointestinal stromal tumors	Disease	D046152	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	175	179	GIST	Disease	D046152	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	199	202	KIT	Gene	3815	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	204	210	PDGFRA	Gene	5156	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	212	216	SDHx	Gene	6390	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	221	224	RAS	Gene	3845	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	245	249	KRAS	Gene	3845	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	251	255	BRAF	Gene	673	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	257	260	NF1	Gene	4763	BACKGROUND: About 10-15% of adult, and most pediatric, gastrointestinal stromal tumors (GIST) lack mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF1).
BC8_BioRED_Task1_Doc372	333	339	tumors	Disease	D009369	The identification of additional mutated genes in this rare subset of tumors can have important clinical benefit to identify altered biological pathways and select targeted therapies.
BC8_BioRED_Task1_Doc372	543	549	cancer	Disease	D009369	METHODS: We performed comprehensive genomic profiling (CGP) for coding regions in more than 300 cancer-related genes of 186 GISTs to assess for their somatic alterations.
BC8_BioRED_Task1_Doc372	571	576	GISTs	Disease	D046152	METHODS: We performed comprehensive genomic profiling (CGP) for coding regions in more than 300 cancer-related genes of 186 GISTs to assess for their somatic alterations.
BC8_BioRED_Task1_Doc372	644	648	GIST	Disease	D046152	RESULTS: We identified 24 GIST lacking alterations in the canonical KIT/PDGFRA/RAS pathways, including 12 without SDHx alterations.
BC8_BioRED_Task1_Doc372	686	689	KIT	Gene	3815	RESULTS: We identified 24 GIST lacking alterations in the canonical KIT/PDGFRA/RAS pathways, including 12 without SDHx alterations.
BC8_BioRED_Task1_Doc372	690	696	PDGFRA	Gene	5156	RESULTS: We identified 24 GIST lacking alterations in the canonical KIT/PDGFRA/RAS pathways, including 12 without SDHx alterations.
BC8_BioRED_Task1_Doc372	697	700	RAS	Gene	3845	RESULTS: We identified 24 GIST lacking alterations in the canonical KIT/PDGFRA/RAS pathways, including 12 without SDHx alterations.
BC8_BioRED_Task1_Doc372	732	736	SDHx	Gene	6390	RESULTS: We identified 24 GIST lacking alterations in the canonical KIT/PDGFRA/RAS pathways, including 12 without SDHx alterations.
BC8_BioRED_Task1_Doc372	759	767	patients	OrganismTaxon	9606	These 24 patients were mostly adults (96%).
BC8_BioRED_Task1_Doc372	798	804	tumors	Disease	D009369	The tumors had a 46% rate of nodal metastases.
BC8_BioRED_Task1_Doc372	823	839	nodal metastases	Disease	D009362	The tumors had a 46% rate of nodal metastases.
BC8_BioRED_Task1_Doc372	850	854	GIST	Disease	D046152	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	894	900	ARID1B	Gene	57492	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	902	905	ATR	Gene	545	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	907	912	FGFR1	Gene	2260	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	914	917	LTK	Gene	4058	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	919	923	SUFU	Gene	51684	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	925	930	PARK2	Gene	5071	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	935	941	ZNF217	Gene	7764	These 24 GIST were more commonly mutated at 7 genes: ARID1B, ATR, FGFR1, LTK, SUFU, PARK2 and ZNF217.
BC8_BioRED_Task1_Doc372	947	953	tumors	Disease	D009369	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	963	968	FGFR1	Gene	2260	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	983	988	FGFR1	Gene	2260	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	989	994	HOOK3	Gene	84376	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	996	1001	FGFR1	Gene	2260	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	1002	1007	TACC1	Gene	6867	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	1029	1033	ETV6	Gene	2120	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	1034	1039	NTRK3	Gene	4916	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	1065	1068	TRK	Gene	4914	Two tumors harbored FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1) and one harbored an ETV6-NTRK3 fusion that responded to TRK inhibition.
BC8_BioRED_Task1_Doc372	1127	1131	GIST	Disease	D046152	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1165	1168	KIT	Gene	3815	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1169	1175	PDGFRA	Gene	5156	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1176	1180	SDHx	Gene	6390	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1181	1184	RAS	Gene	3845	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1231	1236	FGFR1	Gene	2260	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1237	1242	TACC1	Gene	6867	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1247	1251	ETV6	Gene	2120	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1252	1257	NTRK3	Gene	4916	In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.
BC8_BioRED_Task1_Doc372	1286	1293	patient	OrganismTaxon	9606	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1308	1313	tumor	Disease	D009369	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1353	1357	GIST	Disease	D046152	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1414	1422	patients	OrganismTaxon	9606	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1435	1461	metastasize to lymph nodes	Disease	D009362	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1546	1551	FGFR1	Gene	2260	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1556	1561	NTRK3	Gene	4916	CONCLUSIONS: Using patient demographics, tumor characteristics, and CGP, we show that GIST lacking alterations in canonical genes occur in younger patients, frequently metastasize to lymph nodes, and most contain deleterious genomic alterations, including gene fusions involving FGFR1 and NTRK3.
BC8_BioRED_Task1_Doc372	1671	1675	GIST	Disease	D046152	If confirmed in larger series, routine testing for these translocations may be indicated for this subset of GIST.
BC8_BioRED_Task1_Doc372	1751	1759	patients	OrganismTaxon	9606	Moreover, these findings can be used to guide personalized treatments for patients with GIST.
BC8_BioRED_Task1_Doc372	1765	1769	GIST	Disease	D046152	Moreover, these findings can be used to guide personalized treatments for patients with GIST.
BC8_BioRED_Task1_Doc373	0	5	PTCH1	Gene	5727	PTCH1 gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas.
BC8_BioRED_Task1_Doc373	110	115	human	OrganismTaxon	9606	PTCH1 gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas.
BC8_BioRED_Task1_Doc373	116	137	basal cell carcinomas	Disease	D002280	PTCH1 gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas.
BC8_BioRED_Task1_Doc373	151	172	Basal cell carcinomas	Disease	D002280	BACKGROUND: Basal cell carcinomas (BCCs) are the most frequent human cancer that results from malignant transformation of basal cells in the epidermis.
BC8_BioRED_Task1_Doc373	174	178	BCCs	Disease	D002280	BACKGROUND: Basal cell carcinomas (BCCs) are the most frequent human cancer that results from malignant transformation of basal cells in the epidermis.
BC8_BioRED_Task1_Doc373	202	207	human	OrganismTaxon	9606	BACKGROUND: Basal cell carcinomas (BCCs) are the most frequent human cancer that results from malignant transformation of basal cells in the epidermis.
BC8_BioRED_Task1_Doc373	208	214	cancer	Disease	D009369	BACKGROUND: Basal cell carcinomas (BCCs) are the most frequent human cancer that results from malignant transformation of basal cells in the epidermis.
BC8_BioRED_Task1_Doc373	291	306	Gorlin syndrome	Disease	D001478	Gorlin syndrome is a rare inherited autosomal dominant disease that predisposes with multiple BCCs and other birth defects.
BC8_BioRED_Task1_Doc373	317	353	inherited autosomal dominant disease	Disease	D030342	Gorlin syndrome is a rare inherited autosomal dominant disease that predisposes with multiple BCCs and other birth defects.
BC8_BioRED_Task1_Doc373	385	389	BCCs	Disease	D002280	Gorlin syndrome is a rare inherited autosomal dominant disease that predisposes with multiple BCCs and other birth defects.
BC8_BioRED_Task1_Doc373	400	413	birth defects	Disease	D000013	Gorlin syndrome is a rare inherited autosomal dominant disease that predisposes with multiple BCCs and other birth defects.
BC8_BioRED_Task1_Doc373	443	447	BCCs	Disease	D002280	Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2.
BC8_BioRED_Task1_Doc373	485	490	tumor	Disease	D009369	Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2.
BC8_BioRED_Task1_Doc373	507	512	PTCH1	Gene	5727	Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2.
BC8_BioRED_Task1_Doc373	572	577	PTCH2	Gene	8643	Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2.
BC8_BioRED_Task1_Doc373	665	669	BCCs	Disease	D002280	OBJECTIVES: To search for mutations and genomic instability in sporadic and inherited BCCs.
BC8_BioRED_Task1_Doc373	713	718	tumor	Disease	D009369	METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites.
BC8_BioRED_Task1_Doc373	792	797	PTCH1	Gene	5727	METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites.
BC8_BioRED_Task1_Doc373	802	807	PTCH2	Gene	8643	METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites.
BC8_BioRED_Task1_Doc373	987	991	BCCs	Disease	D002280	RESULTS: Only D9S180, of six microsatellites, showed loss of heterozygosity in three BCCs (two sporadic and one inherited).
BC8_BioRED_Task1_Doc373	1039	1042	BCC	Disease	D002280	One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein.
BC8_BioRED_Task1_Doc373	1066	1075	g.2885G>C	SequenceVariant	g|SUB|G|2885|C	One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein.
BC8_BioRED_Task1_Doc373	1090	1095	PTCH1	Gene	5727	One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein.
BC8_BioRED_Task1_Doc373	1129	1136	p.R962T	SequenceVariant	p|SUB|R|962|T	One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein.
BC8_BioRED_Task1_Doc373	1207	1212	tumor	Disease	D009369	In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein.
BC8_BioRED_Task1_Doc373	1226	1233	patient	OrganismTaxon	9606	In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein.
BC8_BioRED_Task1_Doc373	1239	1254	Gorlin syndrome	Disease	D001478	In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein.
BC8_BioRED_Task1_Doc373	1275	1284	g.2839T>G	SequenceVariant	g|SUB|T|2839|G	In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein.
BC8_BioRED_Task1_Doc373	1329	1339	p.E947stop	SequenceVariant	p|SUB|E|947|X	In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein.
BC8_BioRED_Task1_Doc373	1379	1384	tumor	Disease	D009369	All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1.
BC8_BioRED_Task1_Doc373	1403	1414	IVS9 + 217T	SequenceVariant	c|Allele|T|IVS9+217	All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1.
BC8_BioRED_Task1_Doc373	1430	1435	PTCH1	Gene	5727	All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1.
BC8_BioRED_Task1_Doc373	1472	1477	PTCH1	Gene	5727	CONCLUSION: Mutations found in the PTCH1 gene and neighboring repetitive sequences may have contributed to the development of the studied BCCs.
BC8_BioRED_Task1_Doc373	1575	1579	BCCs	Disease	D002280	CONCLUSION: Mutations found in the PTCH1 gene and neighboring repetitive sequences may have contributed to the development of the studied BCCs.
BC8_BioRED_Task1_Doc374	0	8	Langerin	Gene	50489	Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules.
BC8_BioRED_Task1_Doc374	18	31	C-type lectin	Gene	50489	Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules.
BC8_BioRED_Task1_Doc374	156	185	type II Ca2+-dependent lectin	Gene	50489	We have identified a type II Ca2+-dependent lectin displaying mannose-binding specificity, exclusively expressed by Langerhans cells (LC), and named Langerin.
BC8_BioRED_Task1_Doc374	197	204	mannose	Chemical	D008358	We have identified a type II Ca2+-dependent lectin displaying mannose-binding specificity, exclusively expressed by Langerhans cells (LC), and named Langerin.
BC8_BioRED_Task1_Doc374	284	292	Langerin	Gene	50489	We have identified a type II Ca2+-dependent lectin displaying mannose-binding specificity, exclusively expressed by Langerhans cells (LC), and named Langerin.
BC8_BioRED_Task1_Doc374	447	455	Langerin	Gene	50489	Here, we have shown that Langerin is constitutively associated with BG and that antibody to Langerin is internalized into these structures.
BC8_BioRED_Task1_Doc374	514	522	Langerin	Gene	50489	Here, we have shown that Langerin is constitutively associated with BG and that antibody to Langerin is internalized into these structures.
BC8_BioRED_Task1_Doc374	590	598	Langerin	Gene	50489	Remarkably, transfection of Langerin cDNA into fibroblasts created a compact network of membrane structures with typical features of BG.
BC8_BioRED_Task1_Doc374	699	707	Langerin	Gene	50489	Langerin is thus a potent inducer of membrane superimposition and zippering leading to BG formation.
BC8_BioRED_Task1_Doc374	890	898	Langerin	Gene	50489	Our data suggest that induction of BG is a consequence of the antigen-capture function of Langerin, allowing routing into these organelles and providing access to a nonclassical antigen-processing pathway.
BC8_BioRED_Task1_Doc375	0	12	Testosterone	Chemical	D013739	Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	25	39	streptozotocin	Chemical	D013311	Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	48	65	memory impairment	Disease	D008569	Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	74	78	rats	OrganismTaxon	10116	Testosterone ameliorates streptozotocin-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	109	121	testosterone	Chemical	D013739	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	125	139	streptozotocin	Chemical	D013311	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	141	144	STZ	Chemical	D013311	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	154	171	memory impairment	Disease	D008569	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	180	184	rats	OrganismTaxon	10116	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.
BC8_BioRED_Task1_Doc375	213	217	rats	OrganismTaxon	10116	METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ.
BC8_BioRED_Task1_Doc375	268	271	STZ	Chemical	D013311	METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ.
BC8_BioRED_Task1_Doc375	376	379	STZ	Chemical	D013311	METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ.
BC8_BioRED_Task1_Doc375	434	438	rats	OrganismTaxon	10116	Castration surgery was performed in another group of rats, and the passive avoidance task was assessed 4 weeks after the operation.
BC8_BioRED_Task1_Doc375	513	525	Testosterone	Chemical	D013739	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	555	572	androgen receptor	Gene	367	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	584	593	flutamide	Chemical	D005485	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	624	641	estrogen receptor	Gene	2099	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	653	662	tamoxifen	Chemical	D013629	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	694	703	aromatase	Gene	25147	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	714	723	letrozole	Chemical	C067431	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	803	806	STZ	Chemical	D013311	Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the estrogen receptor antagonist tamoxifen (1 mg.kg(-1).d(-1), ip) or the aromatase inhibitor letrozole (4 mg.kg(-1).d(-1), ip) were administered for 6 d after the first injection of STZ.
BC8_BioRED_Task1_Doc375	817	820	STZ	Chemical	D013311	RESULTS: STZ administration and castration markedly decreased both STL1 (the short memory) and STL2 (the long memory) in passive avoidance tests.
BC8_BioRED_Task1_Doc375	875	879	STL1	Gene	369068	RESULTS: STZ administration and castration markedly decreased both STL1 (the short memory) and STL2 (the long memory) in passive avoidance tests.
BC8_BioRED_Task1_Doc375	903	907	STL2	Gene	369140	RESULTS: STZ administration and castration markedly decreased both STL1 (the short memory) and STL2 (the long memory) in passive avoidance tests.
BC8_BioRED_Task1_Doc375	954	966	Testosterone	Chemical	D013739	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	999	1003	STL1	Gene	369068	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1008	1012	STL2	Gene	369140	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1026	1030	rats	OrganismTaxon	10116	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1064	1068	STL1	Gene	369068	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1073	1077	STL2	Gene	369140	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1081	1084	STZ	Chemical	D013311	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1093	1097	rats	OrganismTaxon	10116	Testosterone replacement almost restored the STL1 and STL2 in castrated rats, and significantly prolonged the STL1 and STL2 in STZ-treated rats.
BC8_BioRED_Task1_Doc375	1117	1126	flutamide	Chemical	D005485	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1128	1137	letrozole	Chemical	C067431	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1141	1150	tamoxifen	Chemical	D013629	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1195	1199	rats	OrganismTaxon	10116	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1234	1246	testosterone	Chemical	D013739	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1272	1275	STZ	Chemical	D013311	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1300	1317	memory impairment	Disease	D008569	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.
BC8_BioRED_Task1_Doc375	1331	1343	Testosterone	Chemical	D013739	CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
BC8_BioRED_Task1_Doc375	1371	1374	STZ	Chemical	D013311	CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
BC8_BioRED_Task1_Doc375	1399	1416	memory impairment	Disease	D008569	CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
BC8_BioRED_Task1_Doc375	1432	1436	rats	OrganismTaxon	10116	CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.
BC8_BioRED_Task1_Doc376	23	45	Chromosome Instability	Disease	D043171	Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth.
BC8_BioRED_Task1_Doc376	57	61	Mad2	Gene	56150	Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth.
BC8_BioRED_Task1_Doc376	83	96	Breast Cancer	Disease	D001943	Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth.
BC8_BioRED_Task1_Doc376	144	166	Chromosome instability	Disease	D043171	Chromosome instability (CIN) is associated with poor survival and therapeutic outcome in a number of malignancies.
BC8_BioRED_Task1_Doc376	168	171	CIN	Disease	D043171	Chromosome instability (CIN) is associated with poor survival and therapeutic outcome in a number of malignancies.
BC8_BioRED_Task1_Doc376	245	257	malignancies	Disease	D009369	Chromosome instability (CIN) is associated with poor survival and therapeutic outcome in a number of malignancies.
BC8_BioRED_Task1_Doc376	285	288	CIN	Disease	D043171	Despite this correlation, CIN can also lead to growth disadvantages.
BC8_BioRED_Task1_Doc376	409	413	Mad2	Gene	56150	Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.
BC8_BioRED_Task1_Doc376	419	423	Kras	Gene	16653	Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.
BC8_BioRED_Task1_Doc376	424	428	G12D	Gene	16653	Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.
BC8_BioRED_Task1_Doc376	433	437	Her2	Gene	13866	Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.
BC8_BioRED_Task1_Doc376	465	469	mice	OrganismTaxon	10090	Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.
BC8_BioRED_Task1_Doc376	530	535	tumor	Disease	D009369	Here, we show that simultaneous overexpression of the mitotic checkpoint protein Mad2 with Kras(G12D) or Her2 in mammary glands of adult mice results in mitotic checkpoint overactivation and a delay in tumor onset.
BC8_BioRED_Task1_Doc376	619	624	tumor	Disease	D009369	Time-lapse imaging of organotypic cultures and pathologic analysis prior to tumor establishment reveals error-prone mitosis, mitotic arrest, and cell death.
BC8_BioRED_Task1_Doc376	713	717	Mad2	Gene	56150	Nonetheless, Mad2 expression persists and increases karyotype complexity in Kras tumors.
BC8_BioRED_Task1_Doc376	776	780	Kras	Gene	16653	Nonetheless, Mad2 expression persists and increases karyotype complexity in Kras tumors.
BC8_BioRED_Task1_Doc376	781	787	tumors	Disease	D009369	Nonetheless, Mad2 expression persists and increases karyotype complexity in Kras tumors.
BC8_BioRED_Task1_Doc376	847	851	Mad2	Gene	56150	Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow.
BC8_BioRED_Task1_Doc376	861	867	tumors	Disease	D009369	Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow.
BC8_BioRED_Task1_Doc377	26	36	lamivudine	Chemical	D019259	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
BC8_BioRED_Task1_Doc377	66	98	hepatitis B virus (HBV) infected	Disease	D006509	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
BC8_BioRED_Task1_Doc377	99	107	patients	OrganismTaxon	9606	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
BC8_BioRED_Task1_Doc377	125	141	HIV co-infection	Disease	D015658	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
BC8_BioRED_Task1_Doc377	186	209	HBV and HIV co-infected	Disease	D006509,D015658	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
BC8_BioRED_Task1_Doc377	224	232	patients	OrganismTaxon	9606	Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
BC8_BioRED_Task1_Doc377	279	289	lamivudine	Chemical	D019259	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	300	317	hepatitis B virus	OrganismTaxon	10407	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	319	322	HBV	OrganismTaxon	10407	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	344	354	lamivudine	Chemical	D019259	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	362	365	HBV	OrganismTaxon	10407	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	392	439	human immunodeficiency virus (HIV) co-infection	Disease	D015658	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	457	465	patients	OrganismTaxon	9606	This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
BC8_BioRED_Task1_Doc377	479	489	lamivudine	Chemical	D019259	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	497	509	HBV infected	Disease	D006509	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	510	518	patients	OrganismTaxon	9606	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	535	551	HIV co-infection	Disease	D015658	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	577	594	HBV mono-infected	Disease	D006509	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	595	603	patients	OrganismTaxon	9606	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	611	630	HBV-HIV co-infected	Disease	D006509,D015658	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	631	639	patients	OrganismTaxon	9606	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	697	700	HBV	OrganismTaxon	10407	The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.
BC8_BioRED_Task1_Doc377	702	707	HBsAg	Chemical	D006514	The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.
BC8_BioRED_Task1_Doc377	730	733	HBV	OrganismTaxon	10407	The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.
BC8_BioRED_Task1_Doc377	735	740	HBsAg	Chemical	D006514	The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.
BC8_BioRED_Task1_Doc377	752	760	patients	OrganismTaxon	9606	The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.
BC8_BioRED_Task1_Doc377	762	767	HBsAg	Chemical	D006514	HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).
BC8_BioRED_Task1_Doc377	798	805	HIV 1/2	OrganismTaxon	11676,11709	HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).
BC8_BioRED_Task1_Doc377	950	953	HBV	OrganismTaxon	10407	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.
BC8_BioRED_Task1_Doc377	1137	1140	HBV	OrganismTaxon	10407	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.
BC8_BioRED_Task1_Doc377	1152	1155	HBV	OrganismTaxon	10407	HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).
BC8_BioRED_Task1_Doc377	1195	1198	HBV	OrganismTaxon	10407	HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).
BC8_BioRED_Task1_Doc377	1257	1260	HBV	OrganismTaxon	10407	HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1261	1271	lamivudine	Chemical	D019259	HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1337	1348	hepatitis B	Disease	D006509	HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1349	1357	patients	OrganismTaxon	9606	HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1371	1390	HBV-HIV co-infected	Disease	D006509,D015658	HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1391	1399	patients	OrganismTaxon	9606	HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1468	1471	HBV	OrganismTaxon	10407	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1472	1482	lamivudine	Chemical	D019259	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1519	1538	HBV-HIV co-infected	Disease	D006509,D015658	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1539	1547	patients	OrganismTaxon	9606	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1553	1556	HBV	OrganismTaxon	10407	The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.
BC8_BioRED_Task1_Doc377	1603	1611	patients	OrganismTaxon	9606	The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.
BC8_BioRED_Task1_Doc377	1811	1814	HBV	OrganismTaxon	10407	It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	1838	1848	lamivudine	Chemical	D019259	It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	2031	2050	HBV-HIV co-infected	Disease	D006509,D015658	It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc377	2051	2059	patients	OrganismTaxon	9606	It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
BC8_BioRED_Task1_Doc378	23	32	asenapine	Chemical	C522667	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
BC8_BioRED_Task1_Doc378	51	62	haloperidol	Chemical	D006220	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
BC8_BioRED_Task1_Doc378	83	91	patients	OrganismTaxon	9606	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
BC8_BioRED_Task1_Doc378	119	132	schizophrenia	Disease	D012559	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
BC8_BioRED_Task1_Doc378	134	143	Asenapine	Chemical	C522667	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
BC8_BioRED_Task1_Doc378	226	239	schizophrenia	Disease	D012559	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
BC8_BioRED_Task1_Doc378	246	251	manic	Disease	D001714	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
BC8_BioRED_Task1_Doc378	286	304	bipolar I disorder	Disease	D001714	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
BC8_BioRED_Task1_Doc378	321	330	psychotic	Disease	D011618	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
BC8_BioRED_Task1_Doc378	377	385	patients	OrganismTaxon	9606	In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
BC8_BioRED_Task1_Doc378	397	410	schizophrenia	Disease	D012559	In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
BC8_BioRED_Task1_Doc378	463	472	asenapine	Chemical	C522667	In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
BC8_BioRED_Task1_Doc378	500	509	asenapine	Chemical	C522667	In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
BC8_BioRED_Task1_Doc378	536	547	haloperidol	Chemical	D006220	In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
BC8_BioRED_Task1_Doc378	761	770	asenapine	Chemical	C522667	With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).
BC8_BioRED_Task1_Doc378	795	806	haloperidol	Chemical	D006220	With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).
BC8_BioRED_Task1_Doc378	950	959	asenapine	Chemical	C522667	With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).
BC8_BioRED_Task1_Doc378	1015	1026	haloperidol	Chemical	D006220	With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).
BC8_BioRED_Task1_Doc378	1194	1203	asenapine	Chemical	C522667	On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.
BC8_BioRED_Task1_Doc378	1423	1432	asenapine	Chemical	C522667	Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
BC8_BioRED_Task1_Doc378	1453	1464	haloperidol	Chemical	D006220	Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
BC8_BioRED_Task1_Doc378	1500	1523	Extrapyramidal symptoms	Disease	D001480	Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
BC8_BioRED_Task1_Doc378	1585	1594	asenapine	Chemical	C522667	Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
BC8_BioRED_Task1_Doc378	1615	1626	haloperidol	Chemical	D006220	Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
BC8_BioRED_Task1_Doc378	1700	1708	patients	OrganismTaxon	9606	Across all groups, no more than 5% of patients had clinically significant weight change.
BC8_BioRED_Task1_Doc378	1810	1819	asenapine	Chemical	C522667	Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.
BC8_BioRED_Task1_Doc378	1824	1835	haloperidol	Chemical	D006220	Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.
BC8_BioRED_Task1_Doc378	1884	1907	extrapyramidal symptoms	Disease	D001480	Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.
BC8_BioRED_Task1_Doc379	17	28	bupivacaine	Chemical	D002045	Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
BC8_BioRED_Task1_Doc379	37	62	cardiovascular depression	Disease	D002318	Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
BC8_BioRED_Task1_Doc379	79	84	lipid	Chemical	D008055	Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
BC8_BioRED_Task1_Doc379	101	109	propofol	Chemical	D015742	Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
BC8_BioRED_Task1_Doc379	142	157	lipid emulsions	Chemical	D005217	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	201	212	bupivacaine	Chemical	D002045	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	222	227	lipid	Chemical	D008055	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	239	247	propofol	Chemical	D015742	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	262	273	bupivacaine	Chemical	D002045	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	282	296	cardiotoxicity	Disease	D066126	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	353	361	propofol	Chemical	D015742	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	365	375	intralipid	Chemical	C545823	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	379	389	medialipid	Chemical	D008055	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	403	414	bupivacaine	Chemical	D002045	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	423	437	cardiotoxicity	Disease	D066126	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.
BC8_BioRED_Task1_Doc379	448	452	Rats	OrganismTaxon	10116	METHODS: Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min.
BC8_BioRED_Task1_Doc379	477	485	ketamine	Chemical	D007649	METHODS: Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min.
BC8_BioRED_Task1_Doc379	515	523	propofol	Chemical	D015742	METHODS: Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min.
BC8_BioRED_Task1_Doc379	527	537	intralipid	Chemical	C545823	METHODS: Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min.
BC8_BioRED_Task1_Doc379	549	557	propofol	Chemical	D015742	METHODS: Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min.
BC8_BioRED_Task1_Doc379	561	571	medialipid	Chemical	D008055	METHODS: Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min.
BC8_BioRED_Task1_Doc379	640	651	bupivacaine	Chemical	D002045	Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused.
BC8_BioRED_Task1_Doc379	696	707	dysrhythmia	Disease	D001145	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
BC8_BioRED_Task1_Doc379	825	833	asystole	Disease	D006323	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
BC8_BioRED_Task1_Doc379	854	865	bupivacaine	Chemical	D002045	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
BC8_BioRED_Task1_Doc379	929	937	asystole	Disease	D006323	Blood and tissue samples were collected following asystole.
BC8_BioRED_Task1_Doc379	966	977	dysrhythmia	Disease	D001145	RESULTS: The time to first dysrhythmia occurrence, time to 25% and 50% reductions in HR, and time to asystole were longer in Group P than the other groups.
BC8_BioRED_Task1_Doc379	1040	1048	asystole	Disease	D006323	RESULTS: The time to first dysrhythmia occurrence, time to 25% and 50% reductions in HR, and time to asystole were longer in Group P than the other groups.
BC8_BioRED_Task1_Doc379	1110	1121	bupivacaine	Chemical	D002045	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1184	1195	bupivacaine	Chemical	D002045	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1256	1267	Bupivacaine	Chemical	D002045	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1411	1419	propofol	Chemical	D015742	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1423	1433	intralipid	Chemical	C545823	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1449	1457	propofol	Chemical	D015742	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1461	1471	medialipid	Chemical	D008055	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1504	1515	bupivacaine	Chemical	D002045	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1524	1535	cardiotoxic	Disease	D066126	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1570	1581	bupivacaine	Chemical	D002045	The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
BC8_BioRED_Task1_Doc379	1635	1646	bupivacaine	Chemical	D002045	Further studies are needed to explore tissue bupivacaine levels of propofol in medialipid and adapt these results to clinical practice.
BC8_BioRED_Task1_Doc379	1657	1665	propofol	Chemical	D015742	Further studies are needed to explore tissue bupivacaine levels of propofol in medialipid and adapt these results to clinical practice.
BC8_BioRED_Task1_Doc379	1669	1679	medialipid	Chemical	D008055	Further studies are needed to explore tissue bupivacaine levels of propofol in medialipid and adapt these results to clinical practice.
BC8_BioRED_Task1_Doc380	23	32	46,XY DSD	Disease	D058490	Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene.
BC8_BioRED_Task1_Doc380	63	84	8 nucleotide deletion	SequenceVariant	c|DEL||8	Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene.
BC8_BioRED_Task1_Doc380	102	108	SRD5A2	Gene	6716	Molecular diagnosis of 46,XY DSD and identification of a novel 8 nucleotide deletion in exon 1 of the SRD5A2 gene.
BC8_BioRED_Task1_Doc380	142	151	46,XY DSD	Disease	D058490	Phenotypic presentation of 46,XY DSD depends on the underlying defects.
BC8_BioRED_Task1_Doc380	407	424	androgen receptor	Gene	367	Mutational analysis of androgen receptor (AR) and SRD5A2 genes was performed in 29 patients with 46,XY DSD, by PCR-SSCP.
BC8_BioRED_Task1_Doc380	426	428	AR	Gene	367	Mutational analysis of androgen receptor (AR) and SRD5A2 genes was performed in 29 patients with 46,XY DSD, by PCR-SSCP.
BC8_BioRED_Task1_Doc380	434	440	SRD5A2	Gene	6716	Mutational analysis of androgen receptor (AR) and SRD5A2 genes was performed in 29 patients with 46,XY DSD, by PCR-SSCP.
BC8_BioRED_Task1_Doc380	467	475	patients	OrganismTaxon	9606	Mutational analysis of androgen receptor (AR) and SRD5A2 genes was performed in 29 patients with 46,XY DSD, by PCR-SSCP.
BC8_BioRED_Task1_Doc380	481	490	46,XY DSD	Disease	D058490	Mutational analysis of androgen receptor (AR) and SRD5A2 genes was performed in 29 patients with 46,XY DSD, by PCR-SSCP.
BC8_BioRED_Task1_Doc380	610	618	patients	OrganismTaxon	9606	Interestingly, six patients from 4 unrelated families (a pair of sibs, uncle/nephew and other two isolated) were identified with mutations in SRD5A2 gene.
BC8_BioRED_Task1_Doc380	733	739	SRD5A2	Gene	6716	Interestingly, six patients from 4 unrelated families (a pair of sibs, uncle/nephew and other two isolated) were identified with mutations in SRD5A2 gene.
BC8_BioRED_Task1_Doc380	754	762	patients	OrganismTaxon	9606	In five patients p.R246Q missense mutation was detected, of which four were homozygous and one was compound heterozygous: g.80_87delT CGCGAAG (p.A27fsX132) and p.R246Q.
BC8_BioRED_Task1_Doc380	763	770	p.R246Q	SequenceVariant	rs9332967	In five patients p.R246Q missense mutation was detected, of which four were homozygous and one was compound heterozygous: g.80_87delT CGCGAAG (p.A27fsX132) and p.R246Q.
BC8_BioRED_Task1_Doc380	868	887	g.80_87delT CGCGAAG	SequenceVariant	g|DEL|80_87|TCGCGAAG	In five patients p.R246Q missense mutation was detected, of which four were homozygous and one was compound heterozygous: g.80_87delT CGCGAAG (p.A27fsX132) and p.R246Q.
BC8_BioRED_Task1_Doc380	889	900	p.A27fsX132	SequenceVariant	p|FS|A|27||132	In five patients p.R246Q missense mutation was detected, of which four were homozygous and one was compound heterozygous: g.80_87delT CGCGAAG (p.A27fsX132) and p.R246Q.
BC8_BioRED_Task1_Doc380	906	913	p.R246Q	SequenceVariant	rs9332967	In five patients p.R246Q missense mutation was detected, of which four were homozygous and one was compound heterozygous: g.80_87delT CGCGAAG (p.A27fsX132) and p.R246Q.
BC8_BioRED_Task1_Doc380	923	930	patient	OrganismTaxon	9606	Another patient with isolated micropenis harbored a heterozygous p.G196S missense mutation.
BC8_BioRED_Task1_Doc380	936	955	isolated micropenis	Disease	C536649	Another patient with isolated micropenis harbored a heterozygous p.G196S missense mutation.
BC8_BioRED_Task1_Doc380	980	987	p.G196S	SequenceVariant	rs121434250	Another patient with isolated micropenis harbored a heterozygous p.G196S missense mutation.
BC8_BioRED_Task1_Doc380	1010	1012	AR	Gene	367	No AR gene mutation was detected.
BC8_BioRED_Task1_Doc380	1080	1087	p.R246Q	SequenceVariant	rs9332967	In conclusion, our study suggests that p.R246Q mutation is common amongst patients with SRD5A2 gene defect from the Northern states of India.
BC8_BioRED_Task1_Doc380	1115	1123	patients	OrganismTaxon	9606	In conclusion, our study suggests that p.R246Q mutation is common amongst patients with SRD5A2 gene defect from the Northern states of India.
BC8_BioRED_Task1_Doc380	1129	1135	SRD5A2	Gene	6716	In conclusion, our study suggests that p.R246Q mutation is common amongst patients with SRD5A2 gene defect from the Northern states of India.
BC8_BioRED_Task1_Doc380	1230	1236	SRD5A2	Gene	6716	Also, it records a novel deletion in exon 1 of SRD5A2 gene in a patient with severe hypospadias.
BC8_BioRED_Task1_Doc380	1247	1254	patient	OrganismTaxon	9606	Also, it records a novel deletion in exon 1 of SRD5A2 gene in a patient with severe hypospadias.
BC8_BioRED_Task1_Doc380	1267	1278	hypospadias	Disease	D007021	Also, it records a novel deletion in exon 1 of SRD5A2 gene in a patient with severe hypospadias.
BC8_BioRED_Task1_Doc381	0	5	R58fs	SequenceVariant	p|FS|R|58||	R58fs mutation in the HGD gene in a family with alkaptonuria in the UAE.
BC8_BioRED_Task1_Doc381	22	25	HGD	Gene	3081	R58fs mutation in the HGD gene in a family with alkaptonuria in the UAE.
BC8_BioRED_Task1_Doc381	48	60	alkaptonuria	Disease	D000474	R58fs mutation in the HGD gene in a family with alkaptonuria in the UAE.
BC8_BioRED_Task1_Doc381	129	141	alkaptonuria	Disease	D000474	This study was conducted to determine the prevalence of alkaptonuria in the UAE population and to identify the genotype of affected individuals.
BC8_BioRED_Task1_Doc381	436	453	homogentisic acid	Chemical	D006713	Urine collected was analysed for homogentisic acid by gas chromatography-mass spectrometry.
BC8_BioRED_Task1_Doc381	698	701	HGD	Gene	3081	Specific PRC primers were designed to amplify all 14 exons of the HGD gene with the flanking intronic sequences including the splice site sequences.
BC8_BioRED_Task1_Doc381	864	881	homogentisic acid	Chemical	D006713	2857 children returned a viable urine sample, of which one was highly positive for homogentisic acid.
BC8_BioRED_Task1_Doc381	986	989	HGA	Chemical	D006713	All 12 members of this girl's family were studied and one, a 22 year old brother, was found to excrete HGA.
BC8_BioRED_Task1_Doc381	1109	1119	joint pain	Disease	D018771	There were no complaints of joint pain or other symptoms in any member of this family.
BC8_BioRED_Task1_Doc381	1234	1243	c.342delA	SequenceVariant	c|DEL|342|A	We found a single nucleotide deletion c.342delA, located in exon 3, which resulted in a frameshift at amino acid position 58 (p.Arg58fs or p.R58fs).
BC8_BioRED_Task1_Doc381	1322	1331	p.Arg58fs	SequenceVariant	p|FS|R|58||	We found a single nucleotide deletion c.342delA, located in exon 3, which resulted in a frameshift at amino acid position 58 (p.Arg58fs or p.R58fs).
BC8_BioRED_Task1_Doc381	1335	1342	p.R58fs	SequenceVariant	p|FS|R|58||	We found a single nucleotide deletion c.342delA, located in exon 3, which resulted in a frameshift at amino acid position 58 (p.Arg58fs or p.R58fs).
BC8_BioRED_Task1_Doc381	1345	1357	Alkaptonuria	Disease	D000474	Alkaptonuria may be more common than it is thought to be with an allele prevalence estimated at 0.0107 (95% CI 0.000392-0.03473).
BC8_BioRED_Task1_Doc381	1479	1484	R58fs	SequenceVariant	p|FS|R|58||	The R58fs mutation is old, perhaps having occurred several thousand years ago, and has spread over a large geographical area.
BC8_BioRED_Task1_Doc382	10	19	celecoxib	Chemical	C105934	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	23	31	patients	OrganismTaxon	9606	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	45	59	skin reactions	Disease	D003875	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	63	76	acetaminophen	Chemical	D000082	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	78	89	paracetamol	Chemical	D000082	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	95	105	nimesulide	Chemical	C012655	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	136	173	non-steroidal anti-inflammatory drugs	Chemical	D000894	Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	187	200	Acetaminophen	Chemical	D000082	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	202	213	paracetamol	Chemical	D000082	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	215	216	P	Chemical	D000082	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	222	232	Nimesulide	Chemical	C012655	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	234	235	N	Chemical	C012655	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	263	274	antipyretic	Chemical	D058633	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	275	298	anti-inflammatory drugs	Chemical	D000893	BACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs.
BC8_BioRED_Task1_Doc382	320	336	hypersensitivity	Disease	D004342	The rate of adverse hypersensitivity reactions to these agents is generally low.
BC8_BioRED_Task1_Doc382	397	434	non-steroidal anti-inflammatory drugs	Chemical	D000894	On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions.
BC8_BioRED_Task1_Doc382	436	442	NSAIDs	Chemical	D000894	On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions.
BC8_BioRED_Task1_Doc382	485	494	Celecoxib	Chemical	C105934	Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.
BC8_BioRED_Task1_Doc382	496	498	CE	Chemical	C105934	Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.
BC8_BioRED_Task1_Doc382	556	561	COX-2	Gene	4513	Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.
BC8_BioRED_Task1_Doc382	614	616	CE	Chemical	C105934	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
BC8_BioRED_Task1_Doc382	631	639	patients	OrganismTaxon	9606	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
BC8_BioRED_Task1_Doc382	675	694	cutaneous reactions	Disease	D003875	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
BC8_BioRED_Task1_Doc382	698	699	P	Chemical	D000082	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
BC8_BioRED_Task1_Doc382	704	705	N	Chemical	C012655	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
BC8_BioRED_Task1_Doc382	735	741	NSAIDs	Chemical	D000894	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
BC8_BioRED_Task1_Doc382	765	773	patients	OrganismTaxon	9606	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
BC8_BioRED_Task1_Doc382	779	795	hypersensitivity	Disease	D004342	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
BC8_BioRED_Task1_Doc382	799	800	P	Chemical	D000082	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
BC8_BioRED_Task1_Doc382	805	806	N	Chemical	C012655	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
BC8_BioRED_Task1_Doc382	855	861	NSAIDs	Chemical	D000894	METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
BC8_BioRED_Task1_Doc382	880	881	P	Chemical	D000082	The diagnosis of P and N-induced skin reactions was based in vivo challenge.
BC8_BioRED_Task1_Doc382	886	887	N	Chemical	C012655	The diagnosis of P and N-induced skin reactions was based in vivo challenge.
BC8_BioRED_Task1_Doc382	896	910	skin reactions	Disease	D003875	The diagnosis of P and N-induced skin reactions was based in vivo challenge.
BC8_BioRED_Task1_Doc382	1064	1066	CE	Chemical	C105934	After three days, a cumulative dosage of 200 mg of CE in refracted doses were given.
BC8_BioRED_Task1_Doc382	1160	1168	patients	OrganismTaxon	9606	All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions.
BC8_BioRED_Task1_Doc382	1363	1371	erythema	Disease	D004890	The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.
BC8_BioRED_Task1_Doc382	1381	1390	urticaria	Disease	D014581	The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.
BC8_BioRED_Task1_Doc382	1391	1401	angioedema	Disease	D000799	The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.
BC8_BioRED_Task1_Doc382	1460	1468	patients	OrganismTaxon	9606	RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE.
BC8_BioRED_Task1_Doc382	1487	1489	CE	Chemical	C105934	RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE.
BC8_BioRED_Task1_Doc382	1500	1507	patient	OrganismTaxon	9606	Only one patient developed a moderate angioedema of the lips.
BC8_BioRED_Task1_Doc382	1529	1539	angioedema	Disease	D000799	Only one patient developed a moderate angioedema of the lips.
BC8_BioRED_Task1_Doc382	1574	1590	hypersensitivity	Disease	D004342	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
BC8_BioRED_Task1_Doc382	1603	1605	CE	Chemical	C105934	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
BC8_BioRED_Task1_Doc382	1629	1630	P	Chemical	D000082	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
BC8_BioRED_Task1_Doc382	1635	1636	N	Chemical	C012655	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
BC8_BioRED_Task1_Doc382	1644	1650	NSAIDs	Chemical	D000894	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
BC8_BioRED_Task1_Doc382	1662	1670	patients	OrganismTaxon	9606	CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
BC8_BioRED_Task1_Doc382	1695	1697	CE	Chemical	C105934	Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N.
BC8_BioRED_Task1_Doc382	1774	1775	P	Chemical	D000082	Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N.
BC8_BioRED_Task1_Doc382	1780	1781	N	Chemical	C012655	Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N.
BC8_BioRED_Task1_Doc383	0	8	Dopamine	Chemical	D004298	Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.
BC8_BioRED_Task1_Doc383	49	64	methamphetamine	Chemical	D008694	Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.
BC8_BioRED_Task1_Doc383	73	86	neurotoxicity	Disease	D020258	Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.
BC8_BioRED_Task1_Doc383	115	123	dopamine	Chemical	D004298	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	125	127	DA	Chemical	D004298	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	138	153	methamphetamine	Chemical	D008694	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	155	159	METH	Chemical	D008694	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	169	177	toxicity	Disease	D064420	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	243	245	DA	Chemical	D004298	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	273	281	toxicity	Disease	D064420	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	311	313	DA	Chemical	D004298	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	340	348	toxicity	Disease	D064420	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
BC8_BioRED_Task1_Doc383	428	430	DA	Chemical	D004298	However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
BC8_BioRED_Task1_Doc383	537	561	L-dihydroxyphenylalanine	Chemical	D007980	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
BC8_BioRED_Task1_Doc383	598	624	alpha-methyl-para-tyrosine	Chemical	D019805	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
BC8_BioRED_Task1_Doc383	628	632	METH	Chemical	D008694	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
BC8_BioRED_Task1_Doc383	641	643	DA	Chemical	D004298	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
BC8_BioRED_Task1_Doc383	644	657	neurotoxicity	Disease	D020258	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.
BC8_BioRED_Task1_Doc383	736	740	mice	OrganismTaxon	10090	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
BC8_BioRED_Task1_Doc383	789	791	DA	Chemical	D004298	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
BC8_BioRED_Task1_Doc383	800	804	METH	Chemical	D008694	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
BC8_BioRED_Task1_Doc383	805	818	neurotoxicity	Disease	D020258	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
BC8_BioRED_Task1_Doc383	854	858	METH	Chemical	D008694	Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
BC8_BioRED_Task1_Doc383	907	911	mice	OrganismTaxon	10090	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
BC8_BioRED_Task1_Doc383	960	962	DA	Chemical	D004298	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
BC8_BioRED_Task1_Doc383	980	984	METH	Chemical	D008694	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
BC8_BioRED_Task1_Doc383	993	1014	dopaminergic deficits	Disease	D009461	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
BC8_BioRED_Task1_Doc383	1124	1126	DA	Chemical	D004298	Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.
BC8_BioRED_Task1_Doc383	1167	1171	METH	Chemical	D008694	Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.
BC8_BioRED_Task1_Doc383	1193	1206	neurotoxicity	Disease	D020258	Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.
BC8_BioRED_Task1_Doc383	1250	1252	DA	Chemical	D004298	Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.
BC8_BioRED_Task1_Doc384	27	36	-1123 G>C	SequenceVariant	rs2488457	No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
BC8_BioRED_Task1_Doc384	40	49	+2740 A>G	SequenceVariant	rs1217412	No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
BC8_BioRED_Task1_Doc384	81	87	PTPN22	Gene	26191	No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
BC8_BioRED_Task1_Doc384	93	108	type 1 diabetes	Disease	D003922	No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
BC8_BioRED_Task1_Doc384	113	142	juvenile idiopathic arthritis	Disease	D001171	No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations.
BC8_BioRED_Task1_Doc384	191	197	PTPN22	Gene	26191	INTRODUCTION: The PTPN22 is a negative regulator of the T cell response.
BC8_BioRED_Task1_Doc384	250	258	+1858C>T	SequenceVariant	rs2476601	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	260	265	R620W	SequenceVariant	rs2476601	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	333	352	autoimmune diseases	Disease	D001327	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	364	379	type 1 diabetes	Disease	D003922	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	381	384	T1D	Disease	D003922	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	390	419	juvenile idiopathic arthritis	Disease	D001171	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	421	424	JIA	Disease	D001171	Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA).
BC8_BioRED_Task1_Doc384	712	718	PTPN22	Gene	26191	AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D).
BC8_BioRED_Task1_Doc384	789	792	T1D	Disease	D003922	AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D).
BC8_BioRED_Task1_Doc384	802	805	JIA	Disease	D001171	AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D).
BC8_BioRED_Task1_Doc384	823	826	T1D	Disease	D003922	AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D).
BC8_BioRED_Task1_Doc384	900	909	rs2488457	SequenceVariant	rs2488457	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	919	928	rs2476601	SequenceVariant	rs2476601	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	934	939	R620W	SequenceVariant	rs2476601	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	966	975	rs1217412	SequenceVariant	rs1217412	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	1049	1052	T1D	Disease	D003922	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	1072	1075	JIA	Disease	D001171	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	1144	1147	T1D	Disease	D003922	METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin.
BC8_BioRED_Task1_Doc384	1549	1572	(W) allele at codon 620	SequenceVariant	rs2476601	Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs).
BC8_BioRED_Task1_Doc384	1593	1596	T1D	Disease	D003922	Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs).
BC8_BioRED_Task1_Doc384	1672	1675	JIA	Disease	D001171	Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs).
BC8_BioRED_Task1_Doc384	1751	1774	(R) allele at codon 620	SequenceVariant	rs2476601	The haplotypes having the wild-type (R) allele at codon 620 and minor alleles at -1123 and/or +2740 were neutral as to the risk of autoimmune conditions in both populations.
BC8_BioRED_Task1_Doc384	1846	1867	autoimmune conditions	Disease	D001327	The haplotypes having the wild-type (R) allele at codon 620 and minor alleles at -1123 and/or +2740 were neutral as to the risk of autoimmune conditions in both populations.
BC8_BioRED_Task1_Doc384	2099	2105	PTPN22	Gene	26191	CONCLUSIONS: In two different Caucasian populations, the Czechs and the Azeri, no independent contribution can be detected either of the -1123 promoter SNP or the +2740 3'-UTR SNP, and only the minor allele at PTPN22 codon 620 contributes to the risk of autoimmunity.
BC8_BioRED_Task1_Doc385	25	57	lattice corneal dystrophy type I	Disease	C537881	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.
BC8_BioRED_Task1_Doc385	63	68	R124C	SequenceVariant	rs121909210	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.
BC8_BioRED_Task1_Doc385	85	90	TGFBI	Gene	7045	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.
BC8_BioRED_Task1_Doc385	92	97	BIGH3	Gene	7045	Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.
BC8_BioRED_Task1_Doc385	182	214	lattice corneal dystrophy type I	Disease	C537881	PURPOSE: To report the clinical, ophthalmic, and genetic characteristics for lattice corneal dystrophy type I (LCDI) in a Chilean family.
BC8_BioRED_Task1_Doc385	216	220	LCDI	Disease	C537881	PURPOSE: To report the clinical, ophthalmic, and genetic characteristics for lattice corneal dystrophy type I (LCDI) in a Chilean family.
BC8_BioRED_Task1_Doc385	513	545	lattice corneal dystrophy type I	Disease	C537881	Genomic DNA was extracted from peripheral leukocytes from six affected and three unaffected members of a family with lattice corneal dystrophy type I. Exon 4 of the transforming growth factor-induced gene (TGFBI) was screened for the most frequent mutation, R124C, in the proband by sequencing.
BC8_BioRED_Task1_Doc385	561	600	transforming growth factor-induced gene	Gene	7045	Genomic DNA was extracted from peripheral leukocytes from six affected and three unaffected members of a family with lattice corneal dystrophy type I. Exon 4 of the transforming growth factor-induced gene (TGFBI) was screened for the most frequent mutation, R124C, in the proband by sequencing.
BC8_BioRED_Task1_Doc385	602	607	TGFBI	Gene	7045	Genomic DNA was extracted from peripheral leukocytes from six affected and three unaffected members of a family with lattice corneal dystrophy type I. Exon 4 of the transforming growth factor-induced gene (TGFBI) was screened for the most frequent mutation, R124C, in the proband by sequencing.
BC8_BioRED_Task1_Doc385	654	659	R124C	SequenceVariant	rs121909210	Genomic DNA was extracted from peripheral leukocytes from six affected and three unaffected members of a family with lattice corneal dystrophy type I. Exon 4 of the transforming growth factor-induced gene (TGFBI) was screened for the most frequent mutation, R124C, in the proband by sequencing.
BC8_BioRED_Task1_Doc385	868	872	PstI	Gene	6690	We also designed a rapid polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to analyze the same mutation, amplifying exon 4 and digesting with PstI restriction enzyme.
BC8_BioRED_Task1_Doc385	1065	1090	lattice corneal dystrophy	Disease	C537881	RESULTS: Three generations of family members were positively diagnosed with lattice corneal dystrophy.
BC8_BioRED_Task1_Doc385	1122	1126	LCD1	Disease	C537881	Six participants demonstrated LCD1 in both eyes, most of whom were symmetric.
BC8_BioRED_Task1_Doc385	1408	1416	patients	OrganismTaxon	9606	Two patients, ages 69 and 44 years old, demonstrated a degree of severity "Bad" according to best-corrected vision and corneal commitment.
BC8_BioRED_Task1_Doc385	1566	1571	TGFBI	Gene	7045	The exon 4 sequence of TGFBI of the proband exhibits the heterozygous single-nucleotide mutation, C417T, leading to amino acid substitution (R124C) in the encoded TGF-induced protein.
BC8_BioRED_Task1_Doc385	1641	1646	C417T	SequenceVariant	rs121909210	The exon 4 sequence of TGFBI of the proband exhibits the heterozygous single-nucleotide mutation, C417T, leading to amino acid substitution (R124C) in the encoded TGF-induced protein.
BC8_BioRED_Task1_Doc385	1684	1689	R124C	SequenceVariant	rs121909210	The exon 4 sequence of TGFBI of the proband exhibits the heterozygous single-nucleotide mutation, C417T, leading to amino acid substitution (R124C) in the encoded TGF-induced protein.
BC8_BioRED_Task1_Doc385	1706	1725	TGF-induced protein	Gene	7045	The exon 4 sequence of TGFBI of the proband exhibits the heterozygous single-nucleotide mutation, C417T, leading to amino acid substitution (R124C) in the encoded TGF-induced protein.
BC8_BioRED_Task1_Doc385	1872	1877	R124C	SequenceVariant	rs121909210	CONCLUSIONS: The R124C mutation in TGFBI cosegregated with LCD type I in the investigated family.
BC8_BioRED_Task1_Doc385	1890	1895	TGFBI	Gene	7045	CONCLUSIONS: The R124C mutation in TGFBI cosegregated with LCD type I in the investigated family.
BC8_BioRED_Task1_Doc385	1914	1924	LCD type I	Disease	C537881	CONCLUSIONS: The R124C mutation in TGFBI cosegregated with LCD type I in the investigated family.
BC8_BioRED_Task1_Doc385	2005	2015	LCD type I	Disease	C537881	This is the first report of a molecular analysis of LCD type I in Chilean patients.
BC8_BioRED_Task1_Doc385	2027	2035	patients	OrganismTaxon	9606	This is the first report of a molecular analysis of LCD type I in Chilean patients.
BC8_BioRED_Task1_Doc386	0	5	Bach1	Gene	12013	Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice.
BC8_BioRED_Task1_Doc386	23	32	bleomycin	Chemical	D001761	Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice.
BC8_BioRED_Task1_Doc386	41	59	pulmonary fibrosis	Disease	D011658	Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice.
BC8_BioRED_Task1_Doc386	94	98	mice	OrganismTaxon	10090	Bach1 siRNA attenuates bleomycin-induced pulmonary fibrosis by modulating oxidative stress in mice.
BC8_BioRED_Task1_Doc386	144	156	inflammation	Disease	D007249	Oxidative stress plays an essential role in inflammation and fibrosis.
BC8_BioRED_Task1_Doc386	161	169	fibrosis	Disease	D005355	Oxidative stress plays an essential role in inflammation and fibrosis.
BC8_BioRED_Task1_Doc386	171	176	Bach1	Gene	12013	Bach1 is an important transcriptional repressor that acts by modulating oxidative stress and represents a potential target in the treatment of pulmonary fibrosis (PF).
BC8_BioRED_Task1_Doc386	314	332	pulmonary fibrosis	Disease	D011658	Bach1 is an important transcriptional repressor that acts by modulating oxidative stress and represents a potential target in the treatment of pulmonary fibrosis (PF).
BC8_BioRED_Task1_Doc386	334	336	PF	Disease	D011658	Bach1 is an important transcriptional repressor that acts by modulating oxidative stress and represents a potential target in the treatment of pulmonary fibrosis (PF).
BC8_BioRED_Task1_Doc386	370	375	Bach1	Gene	12013	In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced PF.
BC8_BioRED_Task1_Doc386	464	469	Bach1	Gene	12013	In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced PF.
BC8_BioRED_Task1_Doc386	516	520	mice	OrganismTaxon	10090	In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced PF.
BC8_BioRED_Task1_Doc386	526	535	bleomycin	Chemical	D001761	In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced PF.
BC8_BioRED_Task1_Doc386	537	540	BLM	Chemical	D001761	In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced PF.
BC8_BioRED_Task1_Doc386	550	552	PF	Disease	D011658	In this study, we knocked down Bach1 using adenovirus-mediated small interfering RNA (siRNA) to determine whether the use of Bach1 siRNA is an effective therapeutic strategy in mice with bleomycin (BLM)-induced PF.
BC8_BioRED_Task1_Doc386	554	559	Mouse	OrganismTaxon	10090	Mouse lung fibroblasts (MLFs) were incubated with transforming growth factor (TGF)-b1 (5 ng/ml) and subsequently infected with recombined adenovirus-like Bach1 siRNA1 and Bach1 siRNA2, while an empty adenovirus vector was used as the negative control.
BC8_BioRED_Task1_Doc386	604	639	transforming growth factor (TGF)-b1	Gene	21803	Mouse lung fibroblasts (MLFs) were incubated with transforming growth factor (TGF)-b1 (5 ng/ml) and subsequently infected with recombined adenovirus-like Bach1 siRNA1 and Bach1 siRNA2, while an empty adenovirus vector was used as the negative control.
BC8_BioRED_Task1_Doc386	708	713	Bach1	Gene	12013	Mouse lung fibroblasts (MLFs) were incubated with transforming growth factor (TGF)-b1 (5 ng/ml) and subsequently infected with recombined adenovirus-like Bach1 siRNA1 and Bach1 siRNA2, while an empty adenovirus vector was used as the negative control.
BC8_BioRED_Task1_Doc386	725	730	Bach1	Gene	12013	Mouse lung fibroblasts (MLFs) were incubated with transforming growth factor (TGF)-b1 (5 ng/ml) and subsequently infected with recombined adenovirus-like Bach1 siRNA1 and Bach1 siRNA2, while an empty adenovirus vector was used as the negative control.
BC8_BioRED_Task1_Doc386	819	824	Bach1	Gene	12013	The selected Bach1 siRNA with higher interference efficiency was used for the animal experiments.
BC8_BioRED_Task1_Doc386	906	911	mouse	OrganismTaxon	10090	A mouse model of BLM-induced PF was established, and Bach1 siRNA (1x109 pfu) was administered to the mice via the tail vein.
BC8_BioRED_Task1_Doc386	921	924	BLM	Chemical	D001761	A mouse model of BLM-induced PF was established, and Bach1 siRNA (1x109 pfu) was administered to the mice via the tail vein.
BC8_BioRED_Task1_Doc386	933	935	PF	Disease	D011658	A mouse model of BLM-induced PF was established, and Bach1 siRNA (1x109 pfu) was administered to the mice via the tail vein.
BC8_BioRED_Task1_Doc386	957	962	Bach1	Gene	12013	A mouse model of BLM-induced PF was established, and Bach1 siRNA (1x109 pfu) was administered to the mice via the tail vein.
BC8_BioRED_Task1_Doc386	1005	1009	mice	OrganismTaxon	10090	A mouse model of BLM-induced PF was established, and Bach1 siRNA (1x109 pfu) was administered to the mice via the tail vein.
BC8_BioRED_Task1_Doc386	1059	1064	Bach1	Gene	12013	The results revealed that the Bach1 mRNA and protein levels were significantly downregulated by Bach1 siRNA.
BC8_BioRED_Task1_Doc386	1125	1130	Bach1	Gene	12013	The results revealed that the Bach1 mRNA and protein levels were significantly downregulated by Bach1 siRNA.
BC8_BioRED_Task1_Doc386	1174	1179	Bach1	Gene	12013	Furthermore, the MLFs infected with Bach1 siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.
BC8_BioRED_Task1_Doc386	1244	1260	heme oxygenase-1	Gene	15368	Furthermore, the MLFs infected with Bach1 siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.
BC8_BioRED_Task1_Doc386	1265	1289	glutathione peroxidase 1	Gene	14775	Furthermore, the MLFs infected with Bach1 siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.
BC8_BioRED_Task1_Doc386	1315	1321	TGF-b1	Gene	21803	Furthermore, the MLFs infected with Bach1 siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.
BC8_BioRED_Task1_Doc386	1326	1339	interleukin-6	Gene	16193	Furthermore, the MLFs infected with Bach1 siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.
BC8_BioRED_Task1_Doc386	1400	1406	TGF-b1	Gene	21803	Furthermore, the MLFs infected with Bach1 siRNA exhibited increased mRNA and protein expression levels of heme oxygenase-1 and glutathione peroxidase 1, but decreased levels of TGF-b1 and interleukin-6 in the cell supernatants compared with the cells exposed to TGF-b1 alone.
BC8_BioRED_Task1_Doc386	1414	1419	Bach1	Gene	12013	Bach1 knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of fibrosis-related cytokines in mice compared with the BLM group.
BC8_BioRED_Task1_Doc386	1471	1490	antioxidant factors	Gene	14775,15368	Bach1 knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of fibrosis-related cytokines in mice compared with the BLM group.
BC8_BioRED_Task1_Doc386	1515	1523	fibrosis	Disease	D005355	Bach1 knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of fibrosis-related cytokines in mice compared with the BLM group.
BC8_BioRED_Task1_Doc386	1545	1549	mice	OrganismTaxon	10090	Bach1 knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of fibrosis-related cytokines in mice compared with the BLM group.
BC8_BioRED_Task1_Doc386	1568	1571	BLM	Chemical	D001761	Bach1 knockdown by siRNA also enhanced the expression of antioxidant factors, but suppressed that of fibrosis-related cytokines in mice compared with the BLM group.
BC8_BioRED_Task1_Doc386	1592	1604	inflammatory	Disease	D007249	Finally, the inflammatory infiltration of alveolar and interstitial cells and the destruction of lung structure were significantly attenuated in the mide administered Bach1 siRNA compared with those in the BLM group.
BC8_BioRED_Task1_Doc386	1746	1751	Bach1	Gene	12013	Finally, the inflammatory infiltration of alveolar and interstitial cells and the destruction of lung structure were significantly attenuated in the mide administered Bach1 siRNA compared with those in the BLM group.
BC8_BioRED_Task1_Doc386	1785	1788	BLM	Chemical	D001761	Finally, the inflammatory infiltration of alveolar and interstitial cells and the destruction of lung structure were significantly attenuated in the mide administered Bach1 siRNA compared with those in the BLM group.
BC8_BioRED_Task1_Doc386	1840	1845	Bach1	Gene	12013	On the whole, our findings demonstrate that Bach1 siRNA exerts protective effects against BLM-induced PF in mice.
BC8_BioRED_Task1_Doc386	1886	1889	BLM	Chemical	D001761	On the whole, our findings demonstrate that Bach1 siRNA exerts protective effects against BLM-induced PF in mice.
BC8_BioRED_Task1_Doc386	1898	1900	PF	Disease	D011658	On the whole, our findings demonstrate that Bach1 siRNA exerts protective effects against BLM-induced PF in mice.
BC8_BioRED_Task1_Doc386	1904	1908	mice	OrganismTaxon	10090	On the whole, our findings demonstrate that Bach1 siRNA exerts protective effects against BLM-induced PF in mice.
BC8_BioRED_Task1_Doc386	2006	2008	PF	Disease	D011658	Our data may provide the basis for the development of novel targeted therapeutic strategies for PF.
BC8_BioRED_Task1_Doc387	53	71	prolactin receptor	Gene	5618	Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
BC8_BioRED_Task1_Doc387	75	80	women	OrganismTaxon	9606	Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
BC8_BioRED_Task1_Doc387	86	106	benign breast tumors	Disease	D001943	Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
BC8_BioRED_Task1_Doc387	136	151	genetic disease	Disease	D030342	There is currently no known genetic disease linked to prolactin (Prl) or its receptor (PrlR) in humans.
BC8_BioRED_Task1_Doc387	162	171	prolactin	Gene	5617	There is currently no known genetic disease linked to prolactin (Prl) or its receptor (PrlR) in humans.
BC8_BioRED_Task1_Doc387	173	176	Prl	Gene	5617	There is currently no known genetic disease linked to prolactin (Prl) or its receptor (PrlR) in humans.
BC8_BioRED_Task1_Doc387	195	199	PrlR	Gene	5618	There is currently no known genetic disease linked to prolactin (Prl) or its receptor (PrlR) in humans.
BC8_BioRED_Task1_Doc387	204	210	humans	OrganismTaxon	9606	There is currently no known genetic disease linked to prolactin (Prl) or its receptor (PrlR) in humans.
BC8_BioRED_Task1_Doc387	321	324	Prl	Gene	5617	Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
BC8_BioRED_Task1_Doc387	325	329	PrlR	Gene	5618	Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
BC8_BioRED_Task1_Doc387	372	387	breast diseases	Disease	D001941	Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
BC8_BioRED_Task1_Doc387	423	445	Multiple fibroadenomas	Disease	D018226	Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
BC8_BioRED_Task1_Doc387	447	450	MFA	Disease	D018226	Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
BC8_BioRED_Task1_Doc387	456	476	benign breast tumors	Disease	D001943	Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
BC8_BioRED_Task1_Doc387	515	520	women	OrganismTaxon	9606	Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
BC8_BioRED_Task1_Doc387	549	552	Prl	Gene	5617	Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
BC8_BioRED_Task1_Doc387	646	649	MFA	Disease	D018226	In a prospective study involving 74 MFA patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding Ile(146)-->Leu substitution in its extracellular domain.
BC8_BioRED_Task1_Doc387	650	658	patients	OrganismTaxon	9606	In a prospective study involving 74 MFA patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding Ile(146)-->Leu substitution in its extracellular domain.
BC8_BioRED_Task1_Doc387	704	712	patients	OrganismTaxon	9606	In a prospective study involving 74 MFA patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding Ile(146)-->Leu substitution in its extracellular domain.
BC8_BioRED_Task1_Doc387	786	790	PrlR	Gene	5618	In a prospective study involving 74 MFA patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding Ile(146)-->Leu substitution in its extracellular domain.
BC8_BioRED_Task1_Doc387	806	820	Ile(146)-->Leu	SequenceVariant	rs72478580	In a prospective study involving 74 MFA patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding Ile(146)-->Leu substitution in its extracellular domain.
BC8_BioRED_Task1_Doc387	958	962	PrlR	Gene	19116	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	963	968	I146L	SequenceVariant	rs72478580	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1020	1025	Ba/F3	CellLine	CVCL_0161	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1027	1033	HEK293	CellLine	CVCL_0045	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1038	1043	MCF-7	CellLine	CVCL_0031	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1054	1057	Prl	Gene	5617	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1074	1078	PrlR	Gene	5618	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1124	1174	signal transducer and activator of transcription 5	Gene	6776	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1176	1181	STAT5	Gene	6776	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1234	1237	Prl	Gene	5617	This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
BC8_BioRED_Task1_Doc387	1349	1353	PrlR	Gene	5618	Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
BC8_BioRED_Task1_Doc387	1354	1359	I146L	SequenceVariant	rs72478580	Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
BC8_BioRED_Task1_Doc387	1389	1396	patient	OrganismTaxon	9606	Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
BC8_BioRED_Task1_Doc387	1424	1429	STAT5	Gene	6776	Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
BC8_BioRED_Task1_Doc387	1502	1506	PrlR	Gene	5618	This is a unique description of a functional mutation of the PrlR associated with a human disease.
BC8_BioRED_Task1_Doc387	1525	1530	human	OrganismTaxon	9606	This is a unique description of a functional mutation of the PrlR associated with a human disease.
BC8_BioRED_Task1_Doc387	1607	1622	PrlR antagonist	Chemical	-	Hallmarks of constitutive activity were all reversed by a specific PrlR antagonist, which opens potential therapeutic approaches for MFA, or any other disease that could be associated with this mutation in future.
BC8_BioRED_Task1_Doc387	1673	1676	MFA	Disease	D018226	Hallmarks of constitutive activity were all reversed by a specific PrlR antagonist, which opens potential therapeutic approaches for MFA, or any other disease that could be associated with this mutation in future.
BC8_BioRED_Task1_Doc388	4	8	GALT	Gene	2592	The GALT rush: high carrier frequency of an unusual deletion mutation of the GALT gene in the Ashkenazi population.
BC8_BioRED_Task1_Doc388	77	81	GALT	Gene	2592	The GALT rush: high carrier frequency of an unusual deletion mutation of the GALT gene in the Ashkenazi population.
BC8_BioRED_Task1_Doc388	116	136	Classic galactosemia	Disease	D005693	Classic galactosemia is an autosomal recessive disorder of galactose metabolism manifesting in the first weeks of life following exposure to a milk-based diet.
BC8_BioRED_Task1_Doc388	143	195	autosomal recessive disorder of galactose metabolism	Disease	D005693	Classic galactosemia is an autosomal recessive disorder of galactose metabolism manifesting in the first weeks of life following exposure to a milk-based diet.
BC8_BioRED_Task1_Doc388	312	319	lactose	Chemical	D007785	Despite the benefit of avoidance of lactose, many patients suffer from long-term complications including neurological deficits and ovarian failure.
BC8_BioRED_Task1_Doc388	326	334	patients	OrganismTaxon	9606	Despite the benefit of avoidance of lactose, many patients suffer from long-term complications including neurological deficits and ovarian failure.
BC8_BioRED_Task1_Doc388	381	402	neurological deficits	Disease	D009461	Despite the benefit of avoidance of lactose, many patients suffer from long-term complications including neurological deficits and ovarian failure.
BC8_BioRED_Task1_Doc388	407	422	ovarian failure	Disease	D016649	Despite the benefit of avoidance of lactose, many patients suffer from long-term complications including neurological deficits and ovarian failure.
BC8_BioRED_Task1_Doc388	479	483	GALT	Gene	2592	To date, over 230 mutations have been described in the GALT gene resulting in galactosemia.
BC8_BioRED_Task1_Doc388	502	514	galactosemia	Disease	D005693	To date, over 230 mutations have been described in the GALT gene resulting in galactosemia.
BC8_BioRED_Task1_Doc388	574	589	5.5 kb deletion	SequenceVariant	c|DEL||5.5K	Recently, an unusual mutation was characterized causing a 5.5 kb deletion, with a relatively high carrier rate in subjects of Ashkenazi Jewish (AJ) descent.
BC8_BioRED_Task1_Doc388	1132	1136	GALT	Gene	2592	DNA samples of 760 anonymous AJ subjects were submitted for analysis, subsequently detecting six individuals heterozygous for the GALT deletion mutation, giving a carrier frequency of 1 in 127 (0.79%).
BC8_BioRED_Task1_Doc388	1425	1437	galactosemia	Disease	D005693	Based on these results, we suggest that the method described here provides a basis for genetic screening and prenatal counseling and can potentially reduce the morbidity and mortality associated with delayed diagnosis of galactosemia in this patient population.
BC8_BioRED_Task1_Doc388	1446	1453	patient	OrganismTaxon	9606	Based on these results, we suggest that the method described here provides a basis for genetic screening and prenatal counseling and can potentially reduce the morbidity and mortality associated with delayed diagnosis of galactosemia in this patient population.
BC8_BioRED_Task1_Doc389	25	33	meckelin	Gene	91147	Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	35	39	MKS3	Gene	91147	Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	40	46	TMEM67	Gene	91147	Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	54	90	nephronophthisis with liver fibrosis	Disease	OMIM:613550	Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	92	98	NPHP11	Disease	OMIM:613550	Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	113	129	Nephronophthisis	Disease	C537699	BACKGROUND: Nephronophthisis (NPHP), a rare recessive cystic kidney disease, is the most frequent genetic cause of chronic renal failure in children and young adults.
BC8_BioRED_Task1_Doc389	131	135	NPHP	Disease	C537699	BACKGROUND: Nephronophthisis (NPHP), a rare recessive cystic kidney disease, is the most frequent genetic cause of chronic renal failure in children and young adults.
BC8_BioRED_Task1_Doc389	155	176	cystic kidney disease	Disease	D052177	BACKGROUND: Nephronophthisis (NPHP), a rare recessive cystic kidney disease, is the most frequent genetic cause of chronic renal failure in children and young adults.
BC8_BioRED_Task1_Doc389	216	237	chronic renal failure	Disease	D007676	BACKGROUND: Nephronophthisis (NPHP), a rare recessive cystic kidney disease, is the most frequent genetic cause of chronic renal failure in children and young adults.
BC8_BioRED_Task1_Doc389	293	300	NPHP1-9	Gene	23322,261734,27031,27130,284086,4867,80184,84662,9657	Mutations in nine genes (NPHP1-9) have been identified.
BC8_BioRED_Task1_Doc389	324	328	NPHP	Disease	C537699	NPHP can be associated with retinal degeneration (Senior-Loken syndrome), brainstem and cerebellar anomalies (Joubert syndrome), or liver fibrosis.
BC8_BioRED_Task1_Doc389	352	372	retinal degeneration	Disease	D012162	NPHP can be associated with retinal degeneration (Senior-Loken syndrome), brainstem and cerebellar anomalies (Joubert syndrome), or liver fibrosis.
BC8_BioRED_Task1_Doc389	374	395	Senior-Loken syndrome	Disease	C537580	NPHP can be associated with retinal degeneration (Senior-Loken syndrome), brainstem and cerebellar anomalies (Joubert syndrome), or liver fibrosis.
BC8_BioRED_Task1_Doc389	412	432	cerebellar anomalies	Disease	D002526	NPHP can be associated with retinal degeneration (Senior-Loken syndrome), brainstem and cerebellar anomalies (Joubert syndrome), or liver fibrosis.
BC8_BioRED_Task1_Doc389	434	450	Joubert syndrome	Disease	C536293	NPHP can be associated with retinal degeneration (Senior-Loken syndrome), brainstem and cerebellar anomalies (Joubert syndrome), or liver fibrosis.
BC8_BioRED_Task1_Doc389	456	470	liver fibrosis	Disease	D008103	NPHP can be associated with retinal degeneration (Senior-Loken syndrome), brainstem and cerebellar anomalies (Joubert syndrome), or liver fibrosis.
BC8_BioRED_Task1_Doc389	528	536	patients	OrganismTaxon	9606	METHODS: To identify a causative gene for the subset of patients with associated liver fibrosis, the authors performed a genome wide linkage search in a consanguineous family with three affected patients using 50K SNP microarrays and homozygosity mapping.
BC8_BioRED_Task1_Doc389	553	567	liver fibrosis	Disease	D008103	METHODS: To identify a causative gene for the subset of patients with associated liver fibrosis, the authors performed a genome wide linkage search in a consanguineous family with three affected patients using 50K SNP microarrays and homozygosity mapping.
BC8_BioRED_Task1_Doc389	667	675	patients	OrganismTaxon	9606	METHODS: To identify a causative gene for the subset of patients with associated liver fibrosis, the authors performed a genome wide linkage search in a consanguineous family with three affected patients using 50K SNP microarrays and homozygosity mapping.
BC8_BioRED_Task1_Doc389	915	919	MKS3	Gene	91147	RESULTS: The authors obtained a significant maximum parametric LOD (logarithm of odds) score of Z(max) = 3.72 on chromosome 8q22 and identified a homozygous missense mutation in the gene MKS3/TMEM67.
BC8_BioRED_Task1_Doc389	920	926	TMEM67	Gene	91147	RESULTS: The authors obtained a significant maximum parametric LOD (logarithm of odds) score of Z(max) = 3.72 on chromosome 8q22 and identified a homozygous missense mutation in the gene MKS3/TMEM67.
BC8_BioRED_Task1_Doc389	980	988	patients	OrganismTaxon	9606	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	994	998	NPHP	Disease	C537699	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	1014	1028	liver fibrosis	Disease	D008103	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	1076	1083	p.W290L	SequenceVariant	rs267607117	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	1085	1092	p.C615R	SequenceVariant	rs201893408	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	1094	1101	p.G821S	SequenceVariant	rs267607116	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	1107	1114	p.G821R	SequenceVariant	rs267607116	When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
BC8_BioRED_Task1_Doc389	1146	1150	MKS3	Gene	91147	Mutations of MKS3/TMEM67, found recently in Meckel-Gruber syndrome (MKS) type 3 and Joubert syndrome (JBTS) type 6, are predominantly truncating mutations.
BC8_BioRED_Task1_Doc389	1151	1157	TMEM67	Gene	91147	Mutations of MKS3/TMEM67, found recently in Meckel-Gruber syndrome (MKS) type 3 and Joubert syndrome (JBTS) type 6, are predominantly truncating mutations.
BC8_BioRED_Task1_Doc389	1177	1212	Meckel-Gruber syndrome (MKS) type 3	Disease	C536132	Mutations of MKS3/TMEM67, found recently in Meckel-Gruber syndrome (MKS) type 3 and Joubert syndrome (JBTS) type 6, are predominantly truncating mutations.
BC8_BioRED_Task1_Doc389	1217	1247	Joubert syndrome (JBTS) type 6	Disease	C537689	Mutations of MKS3/TMEM67, found recently in Meckel-Gruber syndrome (MKS) type 3 and Joubert syndrome (JBTS) type 6, are predominantly truncating mutations.
BC8_BioRED_Task1_Doc389	1333	1341	patients	OrganismTaxon	9606	In contrast, the mutations detected here in patients with NPHP and associated liver fibrosis are exclusively missense mutations.
BC8_BioRED_Task1_Doc389	1347	1351	NPHP	Disease	C537699	In contrast, the mutations detected here in patients with NPHP and associated liver fibrosis are exclusively missense mutations.
BC8_BioRED_Task1_Doc389	1367	1381	liver fibrosis	Disease	D008103	In contrast, the mutations detected here in patients with NPHP and associated liver fibrosis are exclusively missense mutations.
BC8_BioRED_Task1_Doc389	1537	1540	MKS	Disease	C536133	This suggests that they may represent hypomorphic alleles, leading to a milder phenotype compared with the more severe MKS or JBTS phenotype.
BC8_BioRED_Task1_Doc389	1544	1548	JBTS	Disease	C536293	This suggests that they may represent hypomorphic alleles, leading to a milder phenotype compared with the more severe MKS or JBTS phenotype.
BC8_BioRED_Task1_Doc389	1596	1600	MKS3	Gene	91147	Additionally, mutation analysis for MKS3/TMEM67 in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.
BC8_BioRED_Task1_Doc389	1601	1607	TMEM67	Gene	91147	Additionally, mutation analysis for MKS3/TMEM67 in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.
BC8_BioRED_Task1_Doc389	1615	1623	patients	OrganismTaxon	9606	Additionally, mutation analysis for MKS3/TMEM67 in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.
BC8_BioRED_Task1_Doc389	1629	1633	JBTS	Disease	C536293	Additionally, mutation analysis for MKS3/TMEM67 in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.
BC8_BioRED_Task1_Doc389	1689	1697	patients	OrganismTaxon	9606	Additionally, mutation analysis for MKS3/TMEM67 in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.
BC8_BioRED_Task1_Doc389	1743	1757	liver fibrosis	Disease	D008103	Additionally, mutation analysis for MKS3/TMEM67 in 120 patients with JBTS yielded seven different (four novel) mutations in five patients, four of whom also presented with congenital liver fibrosis.
BC8_BioRED_Task1_Doc389	1784	1788	MKS3	Gene	91147	CONCLUSIONS: Hypomorphic MKS3/TMEM67 mutations cause NPHP with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	1789	1795	TMEM67	Gene	91147	CONCLUSIONS: Hypomorphic MKS3/TMEM67 mutations cause NPHP with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	1812	1836	NPHP with liver fibrosis	Disease	OMIM:613550	CONCLUSIONS: Hypomorphic MKS3/TMEM67 mutations cause NPHP with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	1838	1844	NPHP11	Disease	OMIM:613550	CONCLUSIONS: Hypomorphic MKS3/TMEM67 mutations cause NPHP with liver fibrosis (NPHP11).
BC8_BioRED_Task1_Doc389	1875	1879	MKS3	Gene	91147	This is the first report of MKS3 mutations in patients with no vermian agenesis and without neurological signs.
BC8_BioRED_Task1_Doc389	1893	1901	patients	OrganismTaxon	9606	This is the first report of MKS3 mutations in patients with no vermian agenesis and without neurological signs.
BC8_BioRED_Task1_Doc389	1964	1968	NPHP	Disease	C537699	Thus NPHP, JBTS, and MKS represent allelic disorders.
BC8_BioRED_Task1_Doc389	1970	1974	JBTS	Disease	C536293	Thus NPHP, JBTS, and MKS represent allelic disorders.
BC8_BioRED_Task1_Doc389	1980	1983	MKS	Disease	C536133	Thus NPHP, JBTS, and MKS represent allelic disorders.
BC8_BioRED_Task1_Doc389	1994	2011	allelic disorders	Disease	D030342	Thus NPHP, JBTS, and MKS represent allelic disorders.
BC8_BioRED_Task1_Doc390	67	71	SOD1	Gene	6647	Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.
BC8_BioRED_Task1_Doc390	73	77	SOD2	Gene	6648	Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.
BC8_BioRED_Task1_Doc390	83	86	CAT	Gene	847	Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.
BC8_BioRED_Task1_Doc390	90	100	Erysipelas	Disease	D004886	Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.
BC8_BioRED_Task1_Doc390	101	109	Patients	OrganismTaxon	9606	Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients.
BC8_BioRED_Task1_Doc390	193	216	streptococcus infection	Disease	D013290	Increased free radical production had been documented in group A (beta-hemolytic) streptococcus infection cases.
BC8_BioRED_Task1_Doc390	237	247	erysipelas	Disease	D004886	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	248	256	patients	OrganismTaxon	9606	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	310	313	CAT	Gene	847	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	315	319	SOD1	Gene	6647	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	325	329	SOD2	Gene	6648	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	384	394	erysipelas	Disease	D004886	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	473	493	erysipelas infection	Disease	D004886	Comparing 71 erysipelas patients to 55 age-matched healthy individuals, we sought for CAT, SOD1, and SOD2 single polymorphism mutation (SNPs) interactions with erysipelas' predisposition and serum cytokine levels in the acute and recovery phases of erysipelas infection.
BC8_BioRED_Task1_Doc390	510	518	patients	OrganismTaxon	9606	Whereas female patients had a higher predisposition to erysipelas, male patients were prone to having a facial localization of the infection.
BC8_BioRED_Task1_Doc390	550	560	erysipelas	Disease	D004886	Whereas female patients had a higher predisposition to erysipelas, male patients were prone to having a facial localization of the infection.
BC8_BioRED_Task1_Doc390	567	575	patients	OrganismTaxon	9606	Whereas female patients had a higher predisposition to erysipelas, male patients were prone to having a facial localization of the infection.
BC8_BioRED_Task1_Doc390	626	635	infection	Disease	D007239	Whereas female patients had a higher predisposition to erysipelas, male patients were prone to having a facial localization of the infection.
BC8_BioRED_Task1_Doc390	653	657	SOD1	Gene	6647	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	658	663	G7958	SequenceVariant	c|Aelle|G|7958	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	665	669	SOD2	Gene	6648	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	670	675	T2734	SequenceVariant	c|Aelle|T|2734	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	681	684	CAT	Gene	847	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	685	689	C262	SequenceVariant	c|Aelle|C|262	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	712	722	erysipelas	Disease	D004886	The presence of SOD1 G7958, SOD2 T2734, and CAT C262 alleles was linked to erysipelas' predisposition.
BC8_BioRED_Task1_Doc390	759	763	SOD2	Gene	6648	T and C alleles of SOD2 T2734C individually were linked to patients with bullous and erythematous erysipelas, respectively.
BC8_BioRED_Task1_Doc390	764	770	T2734C	SequenceVariant	c|SYB|T2734|C	T and C alleles of SOD2 T2734C individually were linked to patients with bullous and erythematous erysipelas, respectively.
BC8_BioRED_Task1_Doc390	799	807	patients	OrganismTaxon	9606	T and C alleles of SOD2 T2734C individually were linked to patients with bullous and erythematous erysipelas, respectively.
BC8_BioRED_Task1_Doc390	825	848	erythematous erysipelas	Disease	D004886	T and C alleles of SOD2 T2734C individually were linked to patients with bullous and erythematous erysipelas, respectively.
BC8_BioRED_Task1_Doc390	883	887	SOD1	Gene	6647	G and A alleles of SOD1 G7958A individually were associated with lower limbs and higher body part localizations of the infection, respectively.
BC8_BioRED_Task1_Doc390	888	894	G7958A	SequenceVariant	rs4998557	G and A alleles of SOD1 G7958A individually were associated with lower limbs and higher body part localizations of the infection, respectively.
BC8_BioRED_Task1_Doc390	983	992	infection	Disease	D007239	G and A alleles of SOD1 G7958A individually were associated with lower limbs and higher body part localizations of the infection, respectively.
BC8_BioRED_Task1_Doc390	1024	1032	IL-1beta	Gene	3553	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1034	1039	CCL11	Gene	6356	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1041	1051	IL-2Ralpha	Gene	3559	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1053	1058	CXCL9	Gene	4283	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1060	1065	TRAIL	Gene	8743	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1067	1074	PDGF-BB	Gene	5155	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1080	1084	CCL4	Gene	6351	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1132	1141	infection	Disease	D007239	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1149	1153	IL-6	Gene	3569	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1155	1159	IL-9	Gene	3578	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1161	1166	IL-10	Gene	3586	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1168	1173	IL-13	Gene	3596	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1175	1180	IL-15	Gene	3600	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1182	1187	IL-17	Gene	3605	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1189	1194	G-CSF	Gene	1440	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1200	1204	VEGF	Gene	7422	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1259	1269	erysipelas	Disease	D004886	Serum levels of IL-1beta, CCL11, IL-2Ralpha, CXCL9, TRAIL, PDGF-BB, and CCL4 were associated with symptoms accompanying the infection, while IL-6, IL-9, IL-10, IL-13, IL-15, IL-17, G-CSF, and VEGF were associated with predisposition and recurrence of erysipelas.
BC8_BioRED_Task1_Doc390	1291	1299	IL-1beta	Gene	3553	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1301	1305	IL-7	Gene	3574	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1307	1311	IL-8	Gene	3576	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1313	1318	IL-17	Gene	3605	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1320	1324	CCL5	Gene	6352	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1330	1333	HGF	Gene	3082	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1359	1363	SOD2	Gene	6648	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1364	1370	T2734C	SequenceVariant	c|SYB|T2734|C	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1390	1397	PDFG-BB	Gene	5155	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1402	1406	CCL2	Gene	6347	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1432	1435	CAT	Gene	847	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc390	1436	1441	C262T	SequenceVariant	c|SUB|C|262|T	While variations of IL-1beta, IL-7, IL-8, IL-17, CCL5, and HGF were associated with the SOD2 T2734C SNP, variations of PDFG-BB and CCL2 were associated with the CAT C262T SNP.
BC8_BioRED_Task1_Doc391	25	39	gastric cancer	Disease	D013274	DNA damage and repair in gastric cancer--a correlation with the hOGG1 and RAD51 genes polymorphisms.
BC8_BioRED_Task1_Doc391	64	69	hOGG1	Gene	4968	DNA damage and repair in gastric cancer--a correlation with the hOGG1 and RAD51 genes polymorphisms.
BC8_BioRED_Task1_Doc391	74	79	RAD51	Gene	5888	DNA damage and repair in gastric cancer--a correlation with the hOGG1 and RAD51 genes polymorphisms.
BC8_BioRED_Task1_Doc391	195	201	cancer	Disease	D009369	The cell's susceptibility to mutagens and its ability to repair DNA lesions are important for cancer induction, promotion and progression.
BC8_BioRED_Task1_Doc391	381	386	hOGG1	Gene	4968	The hOGG1 gene encodes glycosylase of base excision repair and RAD51 specifies a key protein in homologues recombination repair.
BC8_BioRED_Task1_Doc391	440	445	RAD51	Gene	5888	The hOGG1 gene encodes glycosylase of base excision repair and RAD51 specifies a key protein in homologues recombination repair.
BC8_BioRED_Task1_Doc391	591	605	stomach cancer	Disease	D013274	Both can be involved in the repair of oxidative DNA lesions, which can contribute to stomach cancer.
BC8_BioRED_Task1_Doc391	738	755	hydrogen peroxide	Chemical	D006861	In the present work we determined the level of basal and oxidative DNA damage and the kinetics of removal of DNA damage induced by hydrogen peroxide in peripheral blood lymphocytes of 30 gastric cancer patients and 30 healthy individuals.
BC8_BioRED_Task1_Doc391	794	808	gastric cancer	Disease	D013274	In the present work we determined the level of basal and oxidative DNA damage and the kinetics of removal of DNA damage induced by hydrogen peroxide in peripheral blood lymphocytes of 30 gastric cancer patients and 30 healthy individuals.
BC8_BioRED_Task1_Doc391	809	817	patients	OrganismTaxon	9606	In the present work we determined the level of basal and oxidative DNA damage and the kinetics of removal of DNA damage induced by hydrogen peroxide in peripheral blood lymphocytes of 30 gastric cancer patients and 30 healthy individuals.
BC8_BioRED_Task1_Doc391	957	962	hOGG1	Gene	4968	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	967	972	RAD51	Gene	5888	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	982	1017	G-->C transversion at 1245 position	SequenceVariant	rs1052133	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1025	1030	hOGG1	Gene	4968	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1048	1087	Ser-->Cys substitution at the codon 326	SequenceVariant	rs1052133	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1093	1102	Ser326Cys	SequenceVariant	rs1052133	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1123	1157	G-->C substitution at position 135	SequenceVariant	g|SUB|G|135|C	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1190	1195	RAD51	Gene	5888	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1206	1211	G135C	SequenceVariant	g|SUB|G|135|C	The metrics from DNA damage and repair study were correlated with the genotypes of common polymorphisms of the hOGG1 and RAD51 genes: a G-->C transversion at 1245 position of the hOGG1 gene producing a Ser-->Cys substitution at the codon 326 (the Ser326Cys polymorphism) and a G-->C substitution at position 135 (5'-untranslated region) of the RAD51 gene (the G135C polymorphism).
BC8_BioRED_Task1_Doc391	1354	1370	endonuclease III	Gene	4913	DNA damage and repair were evaluated by alkaline single cell gel electrophoresis (comet assay) assisted by DNA repair enzymes: endonuclease III (Nth) and formamidopyrimidine-DNA glycosylase (Fpg), preferentially recognizing oxidized DNA bases.
BC8_BioRED_Task1_Doc391	1372	1375	Nth	Gene	4913	DNA damage and repair were evaluated by alkaline single cell gel electrophoresis (comet assay) assisted by DNA repair enzymes: endonuclease III (Nth) and formamidopyrimidine-DNA glycosylase (Fpg), preferentially recognizing oxidized DNA bases.
BC8_BioRED_Task1_Doc391	1381	1416	formamidopyrimidine-DNA glycosylase	Gene	79661	DNA damage and repair were evaluated by alkaline single cell gel electrophoresis (comet assay) assisted by DNA repair enzymes: endonuclease III (Nth) and formamidopyrimidine-DNA glycosylase (Fpg), preferentially recognizing oxidized DNA bases.
BC8_BioRED_Task1_Doc391	1418	1421	Fpg	Gene	79661	DNA damage and repair were evaluated by alkaline single cell gel electrophoresis (comet assay) assisted by DNA repair enzymes: endonuclease III (Nth) and formamidopyrimidine-DNA glycosylase (Fpg), preferentially recognizing oxidized DNA bases.
BC8_BioRED_Task1_Doc391	1611	1625	gastric cancer	Disease	D013274	We observed a strong association between gastric cancer occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the G135C polymorphism of the RAD51 gene.
BC8_BioRED_Task1_Doc391	1661	1666	human	OrganismTaxon	9606	We observed a strong association between gastric cancer occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the G135C polymorphism of the RAD51 gene.
BC8_BioRED_Task1_Doc391	1687	1690	G/C	SequenceVariant	g|SUB|G||C	We observed a strong association between gastric cancer occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the G135C polymorphism of the RAD51 gene.
BC8_BioRED_Task1_Doc391	1707	1712	G135C	SequenceVariant	g|SUB|G|135|C	We observed a strong association between gastric cancer occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the G135C polymorphism of the RAD51 gene.
BC8_BioRED_Task1_Doc391	1733	1738	RAD51	Gene	5888	We observed a strong association between gastric cancer occurrence, impaired DNA repair in human lymphocytes and the G/C genotype of the G135C polymorphism of the RAD51 gene.
BC8_BioRED_Task1_Doc391	1812	1826	stomach cancer	Disease	D013274	Moreover, there was a strong correlation between that genotype and stomach cancer occurrence in subjects with high level of oxidatively damaged DNA.
BC8_BioRED_Task1_Doc391	1941	1951	Ser1245Cys	SequenceVariant	rs1052133	We did not observe any correlation between the Ser1245Cys polymorphism of the hOGG1 gene and gastric cancer, including subjects with impaired DNA repair and/or high levels of endogenous oxidative DNA lesions.
BC8_BioRED_Task1_Doc391	1972	1977	hOGG1	Gene	4968	We did not observe any correlation between the Ser1245Cys polymorphism of the hOGG1 gene and gastric cancer, including subjects with impaired DNA repair and/or high levels of endogenous oxidative DNA lesions.
BC8_BioRED_Task1_Doc391	1987	2001	gastric cancer	Disease	D013274	We did not observe any correlation between the Ser1245Cys polymorphism of the hOGG1 gene and gastric cancer, including subjects with impaired DNA repair and/or high levels of endogenous oxidative DNA lesions.
BC8_BioRED_Task1_Doc391	2142	2147	G135C	SequenceVariant	g|SUB|G|135|C	Therefore, our result suggest that the G135C polymorphism of the RAD51 gene may be linked with gastric cancer by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or/and environmental indicators of oxidative stress.
BC8_BioRED_Task1_Doc391	2168	2173	RAD51	Gene	5888	Therefore, our result suggest that the G135C polymorphism of the RAD51 gene may be linked with gastric cancer by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or/and environmental indicators of oxidative stress.
BC8_BioRED_Task1_Doc391	2198	2212	gastric cancer	Disease	D013274	Therefore, our result suggest that the G135C polymorphism of the RAD51 gene may be linked with gastric cancer by the modulation of the cellular response to oxidative stress and this polymorphism may be a useful additional marker in this disease along with the genetic or/and environmental indicators of oxidative stress.
BC8_BioRED_Task1_Doc392	27	51	beta adrenergic receptor	Gene	153,154,155	Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans.
BC8_BioRED_Task1_Doc392	102	127	beta-adrenergic receptors	Gene	153,154,155	The beta-adrenergic receptors (beta-AR) are G protein-coupled receptors activated by epinephrine and norepinephrine and are involved in a variety of their physiological functions.
BC8_BioRED_Task1_Doc392	129	136	beta-AR	Gene	153,154,155	The beta-adrenergic receptors (beta-AR) are G protein-coupled receptors activated by epinephrine and norepinephrine and are involved in a variety of their physiological functions.
BC8_BioRED_Task1_Doc392	183	194	epinephrine	Chemical	D004837	The beta-adrenergic receptors (beta-AR) are G protein-coupled receptors activated by epinephrine and norepinephrine and are involved in a variety of their physiological functions.
BC8_BioRED_Task1_Doc392	199	213	norepinephrine	Chemical	D009638	The beta-adrenergic receptors (beta-AR) are G protein-coupled receptors activated by epinephrine and norepinephrine and are involved in a variety of their physiological functions.
BC8_BioRED_Task1_Doc392	296	303	beta-AR	Gene	153,154,155	Previously, three beta-AR genes (ADRB1, ADRB2 and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of cardiovascular and metabolic disorders.
BC8_BioRED_Task1_Doc392	311	316	ADRB1	Gene	153	Previously, three beta-AR genes (ADRB1, ADRB2 and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of cardiovascular and metabolic disorders.
BC8_BioRED_Task1_Doc392	318	323	ADRB2	Gene	154	Previously, three beta-AR genes (ADRB1, ADRB2 and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of cardiovascular and metabolic disorders.
BC8_BioRED_Task1_Doc392	328	333	ADRB3	Gene	155	Previously, three beta-AR genes (ADRB1, ADRB2 and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of cardiovascular and metabolic disorders.
BC8_BioRED_Task1_Doc392	428	466	cardiovascular and metabolic disorders	Disease	D002318,D008659	Previously, three beta-AR genes (ADRB1, ADRB2 and ADRB3) were resequenced, identifying polymorphisms that were used in genetic association studies of cardiovascular and metabolic disorders.
BC8_BioRED_Task1_Doc392	584	589	ADRB1	Gene	153	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	590	599	Arg389Gly	SequenceVariant	p|SUB|R|389|G	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	604	612	Gly49Ser	SequenceVariant	p|SUB|G|49|S	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	614	619	ADRB2	Gene	154	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	620	628	Arg16Gly	SequenceVariant	p|SUB|R|16|G	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	633	641	Gln27Glu	SequenceVariant	p|SUB|Q|27|E	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	647	652	ADRB3	Gene	155	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	653	661	Arg64Trp	SequenceVariant	p|SUB|R|64|W	These studies have produced intriguing but inconsistent results, potentially because the known functional variants: ADRB1 Arg389Gly and Gly49Ser, ADRB2 Arg16Gly and Gln27Glu, and ADRB3 Arg64Trp provided an incomplete picture of the total functional diversity at these genes.
BC8_BioRED_Task1_Doc392	788	795	beta-AR	Gene	153,154,155	Therefore, we created marker panels for each beta-AR gene that included the known functional markers and also other markers evenly spaced and with sufficient density to identify haplotype block structure and to maximize haplotype diversity.
BC8_BioRED_Task1_Doc392	1479	1486	beta-AR	Gene	153,154,155	This study demonstrates the utility of using beta-AR gene haplotype maps and marker panels as tools for linkage studies on beta-AR function.
BC8_BioRED_Task1_Doc392	1557	1564	beta-AR	Gene	153,154,155	This study demonstrates the utility of using beta-AR gene haplotype maps and marker panels as tools for linkage studies on beta-AR function.
BC8_BioRED_Task1_Doc393	12	23	skin cancer	Disease	D012878	Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
BC8_BioRED_Task1_Doc393	74	82	patients	OrganismTaxon	9606	Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
BC8_BioRED_Task1_Doc393	123	131	CC to TT	SequenceVariant	c|SUB|C||T	Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
BC8_BioRED_Task1_Doc393	149	152	p53	Gene	7157	Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
BC8_BioRED_Task1_Doc393	230	255	non-melanoma skin cancers	Disease	D012878	Immunosuppressed renal transplant recipients (RTRs) are predisposed to non-melanoma skin cancers (NMSCs), predominantly squamous cell carcinomas (SCCs).
BC8_BioRED_Task1_Doc393	257	262	NMSCs	Disease	D012878	Immunosuppressed renal transplant recipients (RTRs) are predisposed to non-melanoma skin cancers (NMSCs), predominantly squamous cell carcinomas (SCCs).
BC8_BioRED_Task1_Doc393	279	303	squamous cell carcinomas	Disease	D002294	Immunosuppressed renal transplant recipients (RTRs) are predisposed to non-melanoma skin cancers (NMSCs), predominantly squamous cell carcinomas (SCCs).
BC8_BioRED_Task1_Doc393	305	309	SCCs	Disease	D002294	Immunosuppressed renal transplant recipients (RTRs) are predisposed to non-melanoma skin cancers (NMSCs), predominantly squamous cell carcinomas (SCCs).
BC8_BioRED_Task1_Doc393	329	341	skin lesions	Disease	D012871	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	368	374	tumors	Disease	D009369	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	379	382	p53	Gene	7157	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	419	441	Human Papillomas Virus	OrganismTaxon	10566	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	443	446	HPV	OrganismTaxon	10566	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	471	474	p53	Gene	7157	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	518	521	XPD	Gene	2068	We have analyzed skin lesions from RTRs with aggressive tumors for p53 gene modifications, the presence of Human Papillomas Virus (HPV) DNA in relation to the p53 codon 72 genotype and polymorphisms of the XPD repair gene.
BC8_BioRED_Task1_Doc393	550	553	p53	Gene	7157	We detected 24 p53 mutations in 15/25 (60%) NMSCs, 1 deletion and 23 base substitutions, the majority (78%) being UV-specific C to T transitions at bipyrimidine sites.
BC8_BioRED_Task1_Doc393	579	584	NMSCs	Disease	D012878	We detected 24 p53 mutations in 15/25 (60%) NMSCs, 1 deletion and 23 base substitutions, the majority (78%) being UV-specific C to T transitions at bipyrimidine sites.
BC8_BioRED_Task1_Doc393	661	667	C to T	SequenceVariant	c|SUB|C||T	We detected 24 p53 mutations in 15/25 (60%) NMSCs, 1 deletion and 23 base substitutions, the majority (78%) being UV-specific C to T transitions at bipyrimidine sites.
BC8_BioRED_Task1_Doc393	774	782	CC to TT	SequenceVariant	c|SUB|C||T	Importantly, 35% (6/17) are tandem mutations, including 4 UV signature CC to TT transitions possibly linked to modulated DNA repair caused by the immunosuppressive drug cyclosporin A (CsA).
BC8_BioRED_Task1_Doc393	872	885	cyclosporin A	Chemical	D016572	Importantly, 35% (6/17) are tandem mutations, including 4 UV signature CC to TT transitions possibly linked to modulated DNA repair caused by the immunosuppressive drug cyclosporin A (CsA).
BC8_BioRED_Task1_Doc393	887	890	CsA	Chemical	D016572	Importantly, 35% (6/17) are tandem mutations, including 4 UV signature CC to TT transitions possibly linked to modulated DNA repair caused by the immunosuppressive drug cyclosporin A (CsA).
BC8_BioRED_Task1_Doc393	904	907	p53	Gene	7157	We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
BC8_BioRED_Task1_Doc393	932	944	precancerous	Disease	D011230	We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
BC8_BioRED_Task1_Doc393	945	962	actinic keratosis	Disease	D055623	We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
BC8_BioRED_Task1_Doc393	964	966	AK	Disease	D055623	We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
BC8_BioRED_Task1_Doc393	985	988	p53	Gene	7157	We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
BC8_BioRED_Task1_Doc393	1023	1042	skin carcinogenesis	Disease	D012878	We found 8 p53 mutations in 7/17 (41%) precancerous actinic keratosis (AK), suggesting that p53 mutations are early events in RTR skin carcinogenesis.
BC8_BioRED_Task1_Doc393	1106	1109	p53	Gene	7157	Immunohistochemical analysis shows a good correlation between p53 accumulation and mutations.
BC8_BioRED_Task1_Doc393	1138	1141	HPV	OrganismTaxon	10566	HPV DNA was detected in 78% of skin lesions (60% Basal Cell Carcinomas, 82%AK and 79% SCCs).
BC8_BioRED_Task1_Doc393	1169	1181	skin lesions	Disease	D012871	HPV DNA was detected in 78% of skin lesions (60% Basal Cell Carcinomas, 82%AK and 79% SCCs).
BC8_BioRED_Task1_Doc393	1187	1208	Basal Cell Carcinomas	Disease	D002280	HPV DNA was detected in 78% of skin lesions (60% Basal Cell Carcinomas, 82%AK and 79% SCCs).
BC8_BioRED_Task1_Doc393	1213	1215	AK	Disease	D055623	HPV DNA was detected in 78% of skin lesions (60% Basal Cell Carcinomas, 82%AK and 79% SCCs).
BC8_BioRED_Task1_Doc393	1224	1228	SCCs	Disease	D002294	HPV DNA was detected in 78% of skin lesions (60% Basal Cell Carcinomas, 82%AK and 79% SCCs).
BC8_BioRED_Task1_Doc393	1281	1291	infections	Disease	D007239	Thus, immunosuppression has increased the risk of infections by HPVs, predominantly epidermodysplasia verruciformis, speculated to play a role in skin cancer development.
BC8_BioRED_Task1_Doc393	1295	1299	HPVs	OrganismTaxon	10566	Thus, immunosuppression has increased the risk of infections by HPVs, predominantly epidermodysplasia verruciformis, speculated to play a role in skin cancer development.
BC8_BioRED_Task1_Doc393	1315	1346	epidermodysplasia verruciformis	Disease	D004819	Thus, immunosuppression has increased the risk of infections by HPVs, predominantly epidermodysplasia verruciformis, speculated to play a role in skin cancer development.
BC8_BioRED_Task1_Doc393	1377	1388	skin cancer	Disease	D012878	Thus, immunosuppression has increased the risk of infections by HPVs, predominantly epidermodysplasia verruciformis, speculated to play a role in skin cancer development.
BC8_BioRED_Task1_Doc393	1434	1437	HPV	OrganismTaxon	10566	No association is found between HPV status and p53 mutation.
BC8_BioRED_Task1_Doc393	1449	1452	p53	Gene	7157	No association is found between HPV status and p53 mutation.
BC8_BioRED_Task1_Doc393	1473	1476	p53	Gene	7157	Moreover, p53 codon 72 or frequencies of three XPD genotypes of RTRs are comparable with control populations.
BC8_BioRED_Task1_Doc393	1510	1513	XPD	Gene	2068	Moreover, p53 codon 72 or frequencies of three XPD genotypes of RTRs are comparable with control populations.
BC8_BioRED_Task1_Doc393	1577	1580	p53	Gene	7157	The p53 mutation spectrum, presenting a high level of CC to TT mutations, shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the skin carcinogenesis of RTRs.
BC8_BioRED_Task1_Doc393	1627	1635	CC to TT	SequenceVariant	c|SUB|C||T	The p53 mutation spectrum, presenting a high level of CC to TT mutations, shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the skin carcinogenesis of RTRs.
BC8_BioRED_Task1_Doc393	1799	1818	skin carcinogenesis	Disease	D012878	The p53 mutation spectrum, presenting a high level of CC to TT mutations, shows that the UV component of sunlight is the major risk factor and modulated DNA repair by immunosuppressive drug treatment may be significant in the skin carcinogenesis of RTRs.
BC8_BioRED_Task1_Doc394	0	14	Erythropoietin	Gene	2056	Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo.
BC8_BioRED_Task1_Doc394	33	56	erythropoietin receptor	Gene	2057	Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo.
BC8_BioRED_Task1_Doc394	92	97	human	OrganismTaxon	9606	Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo.
BC8_BioRED_Task1_Doc394	153	167	Erythropoietin	Gene	13856	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	169	172	Epo	Gene	13856	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	229	233	mice	OrganismTaxon	10090	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	284	290	humans	OrganismTaxon	9606	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	291	294	Epo	Gene	2056	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	349	354	lipid	Chemical	D008055	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	385	388	Epo	Gene	2056	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	392	397	human	OrganismTaxon	9606	BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented.
BC8_BioRED_Task1_Doc394	489	492	Epo	Gene	2056	We therefore investigated the effects of acute and prolonged Epo exposure on human WAT in vivo.
BC8_BioRED_Task1_Doc394	505	510	human	OrganismTaxon	9606	We therefore investigated the effects of acute and prolonged Epo exposure on human WAT in vivo.
BC8_BioRED_Task1_Doc394	586	589	Epo	Gene	2056	METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha.
BC8_BioRED_Task1_Doc394	689	721	erythropoiesis-stimulating agent	Chemical	D006397	METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha.
BC8_BioRED_Task1_Doc394	723	726	ESA	Chemical	D006397	METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha.
BC8_BioRED_Task1_Doc394	728	746	Darbepoietin-alpha	Chemical	-	METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha.
BC8_BioRED_Task1_Doc394	782	794	Epo receptor	Gene	2057	Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA.
BC8_BioRED_Task1_Doc394	796	801	Epo-R	Gene	2057	Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA.
BC8_BioRED_Task1_Doc394	894	899	Epo-R	Gene	2057	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	940	945	Epo-R	Gene	2057	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	966	969	Akt	Gene	207	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	971	976	STAT5	Gene	6776	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	978	984	p70s6k	Gene	6198	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	986	989	LYN	Gene	4067	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	995	1002	p38MAPK	Gene	1432	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1039	1043	ATGL	Gene	57104	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1045	1048	HSL	Gene	3991	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1050	1056	CGI-58	Gene	51099	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1058	1062	G0S2	Gene	50486	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1064	1073	Perilipin	Gene	5346	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1075	1080	Cidea	Gene	1149	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1082	1087	Cidec	Gene	63924	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1089	1093	AMPK	Gene	5562	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1099	1102	ACC	Gene	31	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1135	1139	VDAC	Gene	7416	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1141	1146	HSP90	Gene	3320	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1148	1151	PDH	Gene	54704	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1157	1161	SDHA	Gene	6389	A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA).
BC8_BioRED_Task1_Doc394	1214	1219	Epo-R	Gene	2057	RESULTS: No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA.
BC8_BioRED_Task1_Doc394	1276	1281	Epo-R	Gene	2057	RESULTS: No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA.
BC8_BioRED_Task1_Doc394	1342	1345	Epo	Gene	2056	CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.
BC8_BioRED_Task1_Doc394	1397	1403	humans	OrganismTaxon	9606	CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.
BC8_BioRED_Task1_Doc395	50	55	DOCK8	Gene	81704	Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.
BC8_BioRED_Task1_Doc395	64	69	human	OrganismTaxon	9606	Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.
BC8_BioRED_Task1_Doc395	70	81	lung cancer	Disease	D008175	Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.
BC8_BioRED_Task1_Doc395	112	117	DOCK8	Gene	81704	A homozygous deletion of the DOCK8 (dedicator of cytokinesis 8) locus at chromosome 9p24 was found in a lung cancer cell line by array-CGH analysis.
BC8_BioRED_Task1_Doc395	119	145	dedicator of cytokinesis 8	Gene	81704	A homozygous deletion of the DOCK8 (dedicator of cytokinesis 8) locus at chromosome 9p24 was found in a lung cancer cell line by array-CGH analysis.
BC8_BioRED_Task1_Doc395	187	198	lung cancer	Disease	D008175	A homozygous deletion of the DOCK8 (dedicator of cytokinesis 8) locus at chromosome 9p24 was found in a lung cancer cell line by array-CGH analysis.
BC8_BioRED_Task1_Doc395	259	264	DOCK8	Gene	81704	Cloning of the full-length DOCK8 cDNA led us to define that the DOCK8 gene encodes a protein consisting of 2,099 amino acids.
BC8_BioRED_Task1_Doc395	296	301	DOCK8	Gene	81704	Cloning of the full-length DOCK8 cDNA led us to define that the DOCK8 gene encodes a protein consisting of 2,099 amino acids.
BC8_BioRED_Task1_Doc395	358	363	DOCK8	Gene	81704	DOCK8 was expressed in a variety of human organs, including the lungs, and was also expressed in type II alveolar, bronchiolar epithelial and bronchial epithelial cells, which are considered as being progenitors for lung cancer cells.
BC8_BioRED_Task1_Doc395	394	399	human	OrganismTaxon	9606	DOCK8 was expressed in a variety of human organs, including the lungs, and was also expressed in type II alveolar, bronchiolar epithelial and bronchial epithelial cells, which are considered as being progenitors for lung cancer cells.
BC8_BioRED_Task1_Doc395	574	585	lung cancer	Disease	D008175	DOCK8 was expressed in a variety of human organs, including the lungs, and was also expressed in type II alveolar, bronchiolar epithelial and bronchial epithelial cells, which are considered as being progenitors for lung cancer cells.
BC8_BioRED_Task1_Doc395	593	598	DOCK8	Gene	81704	DOCK8 expression was reduced in 62/71 (87%) primary lung cancers compared with normal lung tissue, and the reduction occurred irrespective of the histological type of lung cancer.
BC8_BioRED_Task1_Doc395	645	657	lung cancers	Disease	D008175	DOCK8 expression was reduced in 62/71 (87%) primary lung cancers compared with normal lung tissue, and the reduction occurred irrespective of the histological type of lung cancer.
BC8_BioRED_Task1_Doc395	760	771	lung cancer	Disease	D008175	DOCK8 expression was reduced in 62/71 (87%) primary lung cancers compared with normal lung tissue, and the reduction occurred irrespective of the histological type of lung cancer.
BC8_BioRED_Task1_Doc395	773	796	5-Aza-2'-deoxy-cytidine	Chemical	D000077209	5-Aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced DOCK8 expression in lung cancer cell lines with reduced DOCK8 expression.
BC8_BioRED_Task1_Doc395	804	818	Trichostatin A	Chemical	C012589	5-Aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced DOCK8 expression in lung cancer cell lines with reduced DOCK8 expression.
BC8_BioRED_Task1_Doc395	838	843	DOCK8	Gene	81704	5-Aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced DOCK8 expression in lung cancer cell lines with reduced DOCK8 expression.
BC8_BioRED_Task1_Doc395	858	869	lung cancer	Disease	D008175	5-Aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced DOCK8 expression in lung cancer cell lines with reduced DOCK8 expression.
BC8_BioRED_Task1_Doc395	894	899	DOCK8	Gene	81704	5-Aza-2'-deoxy-cytidine and/or Trichostatin A treatments induced DOCK8 expression in lung cancer cell lines with reduced DOCK8 expression.
BC8_BioRED_Task1_Doc395	1032	1037	DOCK8	Gene	81704	Therefore, epigenetic mechanisms, including DNA methylation and histone deacetylation, were indicated to be involved in DOCK8 down-regulation in lung cancer cells.
BC8_BioRED_Task1_Doc395	1057	1068	lung cancer	Disease	D008175	Therefore, epigenetic mechanisms, including DNA methylation and histone deacetylation, were indicated to be involved in DOCK8 down-regulation in lung cancer cells.
BC8_BioRED_Task1_Doc395	1131	1136	DOCK8	Gene	81704	Further screening revealed homozygous deletions of the DOCK8 gene in a gastric and a breast cancer cell line.
BC8_BioRED_Task1_Doc395	1161	1174	breast cancer	Disease	D001943	Further screening revealed homozygous deletions of the DOCK8 gene in a gastric and a breast cancer cell line.
BC8_BioRED_Task1_Doc395	1186	1190	DOCK	Gene	81704	DOCK family proteins have been shown to play roles in regulation of migration, morphology, adhesion and growth of cells.
BC8_BioRED_Task1_Doc395	1385	1390	DOCK8	Gene	81704	Thus, the present results suggest that genetic and epigenetic inactivation of DOCK8 is involved in the development and/or progression of lung and other cancers by disturbing such regulations.
BC8_BioRED_Task1_Doc395	1444	1466	lung and other cancers	Disease	D008175,D009369	Thus, the present results suggest that genetic and epigenetic inactivation of DOCK8 is involved in the development and/or progression of lung and other cancers by disturbing such regulations.
BC8_BioRED_Task1_Doc396	43	50	Osterix	Gene	121340	Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	56	63	patient	OrganismTaxon	9606	Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	69	102	recessive osteogenesis imperfecta	Disease	D010013	Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	104	127	Osteogenesis imperfecta	Disease	D010013	Osteogenesis imperfecta, or "brittle bone disease," is a type I collagen-related condition associated with osteoporosis and increased risk of bone fractures.
BC8_BioRED_Task1_Doc396	133	153	brittle bone disease	Disease	D010013	Osteogenesis imperfecta, or "brittle bone disease," is a type I collagen-related condition associated with osteoporosis and increased risk of bone fractures.
BC8_BioRED_Task1_Doc396	161	176	type I collagen	Gene	1278	Osteogenesis imperfecta, or "brittle bone disease," is a type I collagen-related condition associated with osteoporosis and increased risk of bone fractures.
BC8_BioRED_Task1_Doc396	211	223	osteoporosis	Disease	D010024	Osteogenesis imperfecta, or "brittle bone disease," is a type I collagen-related condition associated with osteoporosis and increased risk of bone fractures.
BC8_BioRED_Task1_Doc396	246	260	bone fractures	Disease	D050723	Osteogenesis imperfecta, or "brittle bone disease," is a type I collagen-related condition associated with osteoporosis and increased risk of bone fractures.
BC8_BioRED_Task1_Doc396	367	392	single base pair deletion	SequenceVariant	rs137853893	Using a combination of homozygosity mapping and candidate gene approach, we have identified a homozygous single base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	394	404	c.1052delA	SequenceVariant	rs137853893	Using a combination of homozygosity mapping and candidate gene approach, we have identified a homozygous single base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	409	412	SP7	Gene	121340	Using a combination of homozygosity mapping and candidate gene approach, we have identified a homozygous single base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	413	420	Osterix	Gene	121340	Using a combination of homozygosity mapping and candidate gene approach, we have identified a homozygous single base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	422	425	OSX	Gene	121340	Using a combination of homozygosity mapping and candidate gene approach, we have identified a homozygous single base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	453	486	recessive osteogenesis imperfecta	Disease	D010013	Using a combination of homozygosity mapping and candidate gene approach, we have identified a homozygous single base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta.
BC8_BioRED_Task1_Doc396	520	527	patient	OrganismTaxon	9606	The clinical findings from this patient include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing, and white sclera.
BC8_BioRED_Task1_Doc396	546	555	fractures	Disease	D050723	The clinical findings from this patient include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing, and white sclera.
BC8_BioRED_Task1_Doc396	562	578	bone deformities	Disease	D001847	The clinical findings from this patient include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing, and white sclera.
BC8_BioRED_Task1_Doc396	588	602	tooth eruption	Disease	D014079	The clinical findings from this patient include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing, and white sclera.
BC8_BioRED_Task1_Doc396	638	641	OSX	Gene	121340	OSX encodes a transcription factor containing three Cys2-His2 zinc-finger DNA-binding domains at its C terminus, which, in mice, has been shown to be essential for bone formation.
BC8_BioRED_Task1_Doc396	761	765	mice	OrganismTaxon	10090	OSX encodes a transcription factor containing three Cys2-His2 zinc-finger DNA-binding domains at its C terminus, which, in mice, has been shown to be essential for bone formation.
BC8_BioRED_Task1_Doc396	847	857	c.1052delA	SequenceVariant	rs137853893	The frameshift caused by the c.1052delA deletion removes the last 81 amino acids of the protein, including the third zinc-finger motif.
BC8_BioRED_Task1_Doc396	1027	1050	osteogenesis imperfecta	Disease	D010013	This finding adds another locus to the spectrum of genes associated with osteogenesis imperfecta and reveals that SP7/OSX also plays a key role in human bone development.
BC8_BioRED_Task1_Doc396	1068	1071	SP7	Gene	121340	This finding adds another locus to the spectrum of genes associated with osteogenesis imperfecta and reveals that SP7/OSX also plays a key role in human bone development.
BC8_BioRED_Task1_Doc396	1072	1075	OSX	Gene	121340	This finding adds another locus to the spectrum of genes associated with osteogenesis imperfecta and reveals that SP7/OSX also plays a key role in human bone development.
BC8_BioRED_Task1_Doc396	1101	1106	human	OrganismTaxon	9606	This finding adds another locus to the spectrum of genes associated with osteogenesis imperfecta and reveals that SP7/OSX also plays a key role in human bone development.
BC8_BioRED_Task1_Doc397	34	40	PTPN22	Gene	26191	A haplotype-based analysis of the PTPN22 locus in type 1 diabetes.
BC8_BioRED_Task1_Doc397	50	65	type 1 diabetes	Disease	D003922	A haplotype-based analysis of the PTPN22 locus in type 1 diabetes.
BC8_BioRED_Task1_Doc397	117	132	type 1 diabetes	Disease	D003922	A recent addition to the list of widely confirmed type 1 diabetes risk loci is the PTPN22 gene encoding a lymphoid-specific phosphatase (Lyp).
BC8_BioRED_Task1_Doc397	150	156	PTPN22	Gene	26191	A recent addition to the list of widely confirmed type 1 diabetes risk loci is the PTPN22 gene encoding a lymphoid-specific phosphatase (Lyp).
BC8_BioRED_Task1_Doc397	173	202	lymphoid-specific phosphatase	Gene	26191	A recent addition to the list of widely confirmed type 1 diabetes risk loci is the PTPN22 gene encoding a lymphoid-specific phosphatase (Lyp).
BC8_BioRED_Task1_Doc397	204	207	Lyp	Gene	26191	A recent addition to the list of widely confirmed type 1 diabetes risk loci is the PTPN22 gene encoding a lymphoid-specific phosphatase (Lyp).
BC8_BioRED_Task1_Doc397	250	256	PTPN22	Gene	26191	However, evidence supporting a role for PTPN22 in type 1 diabetes derives entirely from the study of just one coding single nucleotide polymorphism, 1858C/T.
BC8_BioRED_Task1_Doc397	260	275	type 1 diabetes	Disease	D003922	However, evidence supporting a role for PTPN22 in type 1 diabetes derives entirely from the study of just one coding single nucleotide polymorphism, 1858C/T.
BC8_BioRED_Task1_Doc397	359	366	1858C/T	SequenceVariant	rs2476601	However, evidence supporting a role for PTPN22 in type 1 diabetes derives entirely from the study of just one coding single nucleotide polymorphism, 1858C/T.
BC8_BioRED_Task1_Doc397	421	427	PTPN22	Gene	26191	In the current study, the haplotype structure of the PTPN22 region was determined, and individual haplotypes were tested for association with type 1 diabetes in family-based tests.
BC8_BioRED_Task1_Doc397	510	525	type 1 diabetes	Disease	D003922	In the current study, the haplotype structure of the PTPN22 region was determined, and individual haplotypes were tested for association with type 1 diabetes in family-based tests.
BC8_BioRED_Task1_Doc397	553	558	1858T	SequenceVariant	rs2476601	The 1858T risk allele occurred on only a single haplotype that was strongly associated with type 1 diabetes (P = 7.9 x 10(-5)).
BC8_BioRED_Task1_Doc397	641	656	type 1 diabetes	Disease	D003922	The 1858T risk allele occurred on only a single haplotype that was strongly associated with type 1 diabetes (P = 7.9 x 10(-5)).
BC8_BioRED_Task1_Doc397	791	806	type 1 diabetes	Disease	D003922	After controlling for the effects of this allele, two other haplotypes were observed to be weakly associated with type 1 diabetes (P < 0.05).
BC8_BioRED_Task1_Doc397	854	860	PTPN22	Gene	26191	Sequencing of the coding region of PTPN22 on these haplotypes revealed a novel variant (2250G/C) predicted to result in a nonsynonymous amino acid substitution.
BC8_BioRED_Task1_Doc397	907	914	2250G/C	SequenceVariant	rs56048322	Sequencing of the coding region of PTPN22 on these haplotypes revealed a novel variant (2250G/C) predicted to result in a nonsynonymous amino acid substitution.
BC8_BioRED_Task1_Doc397	992	998	PTPN22	Gene	26191	Analysis of PTPN22 transcripts from a subject heterozygous for this variant indicated that it interfered with normal mRNA splicing, resulting in a premature termination codon after exon 17.
BC8_BioRED_Task1_Doc397	1216	1223	1858C/T	SequenceVariant	rs2476601	These results support the conclusion that the 1858C/T allele is the major risk variant for type 1 diabetes in the PTPN22 locus, but they suggest that additional infrequent coding variants at PTPN22 may also contribute to type 1 diabetes risk.
BC8_BioRED_Task1_Doc397	1261	1276	type 1 diabetes	Disease	D003922	These results support the conclusion that the 1858C/T allele is the major risk variant for type 1 diabetes in the PTPN22 locus, but they suggest that additional infrequent coding variants at PTPN22 may also contribute to type 1 diabetes risk.
BC8_BioRED_Task1_Doc397	1284	1290	PTPN22	Gene	26191	These results support the conclusion that the 1858C/T allele is the major risk variant for type 1 diabetes in the PTPN22 locus, but they suggest that additional infrequent coding variants at PTPN22 may also contribute to type 1 diabetes risk.
BC8_BioRED_Task1_Doc397	1361	1367	PTPN22	Gene	26191	These results support the conclusion that the 1858C/T allele is the major risk variant for type 1 diabetes in the PTPN22 locus, but they suggest that additional infrequent coding variants at PTPN22 may also contribute to type 1 diabetes risk.
BC8_BioRED_Task1_Doc397	1391	1406	type 1 diabetes	Disease	D003922	These results support the conclusion that the 1858C/T allele is the major risk variant for type 1 diabetes in the PTPN22 locus, but they suggest that additional infrequent coding variants at PTPN22 may also contribute to type 1 diabetes risk.
BC8_BioRED_Task1_Doc398	13	18	mouse	OrganismTaxon	10090	An inducible mouse model of podocin-mutation-related nephrotic syndrome.
BC8_BioRED_Task1_Doc398	28	35	podocin	Gene	170484	An inducible mouse model of podocin-mutation-related nephrotic syndrome.
BC8_BioRED_Task1_Doc398	53	71	nephrotic syndrome	Disease	D009404	An inducible mouse model of podocin-mutation-related nephrotic syndrome.
BC8_BioRED_Task1_Doc398	90	95	NPHS2	Gene	7827	Mutations in the NPHS2 gene, encoding podocin, cause hereditary nephrotic syndrome.
BC8_BioRED_Task1_Doc398	111	118	podocin	Gene	7827	Mutations in the NPHS2 gene, encoding podocin, cause hereditary nephrotic syndrome.
BC8_BioRED_Task1_Doc398	137	155	nephrotic syndrome	Disease	D009404	Mutations in the NPHS2 gene, encoding podocin, cause hereditary nephrotic syndrome.
BC8_BioRED_Task1_Doc398	173	180	podocin	Gene	7827	The most common podocin mutation, R138Q, is associated with early disease onset and rapid progression to end-stage renal disease.
BC8_BioRED_Task1_Doc398	191	196	R138Q	SequenceVariant	rs74315342	The most common podocin mutation, R138Q, is associated with early disease onset and rapid progression to end-stage renal disease.
BC8_BioRED_Task1_Doc398	272	285	renal disease	Disease	D007674	The most common podocin mutation, R138Q, is associated with early disease onset and rapid progression to end-stage renal disease.
BC8_BioRED_Task1_Doc398	296	300	mice	OrganismTaxon	10090	Knock-in mice carrying a R140Q mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal renal failure at neonatal age.
BC8_BioRED_Task1_Doc398	312	317	R140Q	SequenceVariant	p|SUB|R|140|Q	Knock-in mice carrying a R140Q mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal renal failure at neonatal age.
BC8_BioRED_Task1_Doc398	332	337	mouse	OrganismTaxon	10090	Knock-in mice carrying a R140Q mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal renal failure at neonatal age.
BC8_BioRED_Task1_Doc398	350	355	human	OrganismTaxon	9606	Knock-in mice carrying a R140Q mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal renal failure at neonatal age.
BC8_BioRED_Task1_Doc398	356	361	R138Q	SequenceVariant	rs74315342	Knock-in mice carrying a R140Q mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal renal failure at neonatal age.
BC8_BioRED_Task1_Doc398	413	426	renal failure	Disease	D051437	Knock-in mice carrying a R140Q mutation, the mouse analogue of human R138Q, show developmental arrest of podocytes and lethal renal failure at neonatal age.
BC8_BioRED_Task1_Doc398	474	481	podocin	Gene	170484	Here we created a conditional podocin knock-in model named NPHS2 R140Q/-, using a tamoxifen-inducible Cre recombinase, which permits to study the effects of the mutation in postnatal life.
BC8_BioRED_Task1_Doc398	503	508	NPHS2	Gene	170484	Here we created a conditional podocin knock-in model named NPHS2 R140Q/-, using a tamoxifen-inducible Cre recombinase, which permits to study the effects of the mutation in postnatal life.
BC8_BioRED_Task1_Doc398	509	514	R140Q	SequenceVariant	p|SUB|R|140|Q	Here we created a conditional podocin knock-in model named NPHS2 R140Q/-, using a tamoxifen-inducible Cre recombinase, which permits to study the effects of the mutation in postnatal life.
BC8_BioRED_Task1_Doc398	526	535	tamoxifen	Chemical	D013629	Here we created a conditional podocin knock-in model named NPHS2 R140Q/-, using a tamoxifen-inducible Cre recombinase, which permits to study the effects of the mutation in postnatal life.
BC8_BioRED_Task1_Doc398	658	663	R140Q	SequenceVariant	p|SUB|R|140|Q	Within the first week of R140Q hemizygosity induction the animals developed proteinuria, which peaked after 4-5 weeks.
BC8_BioRED_Task1_Doc398	709	720	proteinuria	Disease	D011507	Within the first week of R140Q hemizygosity induction the animals developed proteinuria, which peaked after 4-5 weeks.
BC8_BioRED_Task1_Doc398	799	812	renal failure	Disease	D051437	Subsequently the animals developed progressive renal failure, with a median survival time of 12 (95% CI: 11-13) weeks.
BC8_BioRED_Task1_Doc398	1231	1258	tubulointerstitial fibrosis	Disease	D007674	Severe tubulointerstitial fibrosis was present at later disease stage and was correlated quantitatively with the level of proteinuria at early disease stages.
BC8_BioRED_Task1_Doc398	1346	1357	proteinuria	Disease	D011507	Severe tubulointerstitial fibrosis was present at later disease stage and was correlated quantitatively with the level of proteinuria at early disease stages.
BC8_BioRED_Task1_Doc398	1389	1394	R140Q	SequenceVariant	p|SUB|R|140|Q	While R140Q podocin mRNA expression was elevated, protein abundance was reduced by more than 50% within one week following induction.
BC8_BioRED_Task1_Doc398	1395	1402	podocin	Gene	170484	While R140Q podocin mRNA expression was elevated, protein abundance was reduced by more than 50% within one week following induction.
BC8_BioRED_Task1_Doc398	1525	1532	miRNA21	Gene	406991	Whereas miRNA21 expression persistently increased during the first 4 weeks, miRNA-193a expression peaked 2 weeks after induction.
BC8_BioRED_Task1_Doc398	1593	1603	miRNA-193a	Gene	406968	Whereas miRNA21 expression persistently increased during the first 4 weeks, miRNA-193a expression peaked 2 weeks after induction.
BC8_BioRED_Task1_Doc398	1676	1681	R140Q	SequenceVariant	p|SUB|R|140|Q	In conclusion, the inducible R140Q-podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome, with a spontaneous disease course strongly reminiscent of the human disorder.
BC8_BioRED_Task1_Doc398	1682	1689	podocin	Gene	170484	In conclusion, the inducible R140Q-podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome, with a spontaneous disease course strongly reminiscent of the human disorder.
BC8_BioRED_Task1_Doc398	1690	1695	mouse	OrganismTaxon	10090	In conclusion, the inducible R140Q-podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome, with a spontaneous disease course strongly reminiscent of the human disorder.
BC8_BioRED_Task1_Doc398	1761	1766	human	OrganismTaxon	9606	In conclusion, the inducible R140Q-podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome, with a spontaneous disease course strongly reminiscent of the human disorder.
BC8_BioRED_Task1_Doc398	1767	1785	nephrotic syndrome	Disease	D009404	In conclusion, the inducible R140Q-podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome, with a spontaneous disease course strongly reminiscent of the human disorder.
BC8_BioRED_Task1_Doc398	1849	1854	human	OrganismTaxon	9606	In conclusion, the inducible R140Q-podocin mouse model is an auspicious model of the most common genetic cause of human nephrotic syndrome, with a spontaneous disease course strongly reminiscent of the human disorder.
BC8_BioRED_Task1_Doc398	2027	2038	proteinuria	Disease	D011507	This model constitutes a valuable tool to test the efficacy of novel pharmacological interventions aimed to improve podocyte function and viability and attenuate proteinuria, glomerulosclerosis and progressive renal failure.
BC8_BioRED_Task1_Doc398	2040	2058	glomerulosclerosis	Disease	D005921	This model constitutes a valuable tool to test the efficacy of novel pharmacological interventions aimed to improve podocyte function and viability and attenuate proteinuria, glomerulosclerosis and progressive renal failure.
BC8_BioRED_Task1_Doc398	2075	2088	renal failure	Disease	D051437	This model constitutes a valuable tool to test the efficacy of novel pharmacological interventions aimed to improve podocyte function and viability and attenuate proteinuria, glomerulosclerosis and progressive renal failure.
BC8_BioRED_Task1_Doc399	30	36	PTPN11	Gene	5781	Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	43	61	metachondromatosis	Disease	C562938	Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	71	85	Ollier disease	Disease	D004687	Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	89	106	Maffucci syndrome	Disease	D004687	Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	108	126	Metachondromatosis	Disease	C562938	Metachondromatosis (MC) is a rare, autosomal dominant, incompletely penetrant combined exostosis and enchondromatosis tumor syndrome.
BC8_BioRED_Task1_Doc399	128	130	MC	Disease	C562938	Metachondromatosis (MC) is a rare, autosomal dominant, incompletely penetrant combined exostosis and enchondromatosis tumor syndrome.
BC8_BioRED_Task1_Doc399	195	204	exostosis	Disease	D005096	Metachondromatosis (MC) is a rare, autosomal dominant, incompletely penetrant combined exostosis and enchondromatosis tumor syndrome.
BC8_BioRED_Task1_Doc399	209	240	enchondromatosis tumor syndrome	Disease	D004687	Metachondromatosis (MC) is a rare, autosomal dominant, incompletely penetrant combined exostosis and enchondromatosis tumor syndrome.
BC8_BioRED_Task1_Doc399	242	244	MC	Disease	C562938	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	279	297	multiple exostosis	Disease	D005097	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	301	336	multiple enchondromatosis syndromes	Disease	D004687	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	356	360	EXT1	Gene	2131	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	365	369	EXT2	Gene	2132	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	416	440	multiple osteochondromas	Disease	D005097	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	442	444	MO	Disease	D005097	MC is clinically distinct from other multiple exostosis or multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for autosomal dominant multiple osteochondromas (MO).
BC8_BioRED_Task1_Doc399	470	472	MC	Disease	C562938	To identify a gene for MC, we performed linkage analysis with high-density SNP arrays in a single family, used a targeted array to capture exons and promoter sequences from the linked interval in 16 participants from 11 MC families, and sequenced the captured DNA using high-throughput parallel sequencing technologies.
BC8_BioRED_Task1_Doc399	667	669	MC	Disease	C562938	To identify a gene for MC, we performed linkage analysis with high-density SNP arrays in a single family, used a targeted array to capture exons and promoter sequences from the linked interval in 16 participants from 11 MC families, and sequenced the captured DNA using high-throughput parallel sequencing technologies.
BC8_BioRED_Task1_Doc399	866	872	PTPN11	Gene	5781	DNA capture and parallel sequencing identified heterozygous putative loss-of-function mutations in PTPN11 in 4 of the 11 families.
BC8_BioRED_Task1_Doc399	926	932	PTPN11	Gene	5781	Sanger sequence analysis of PTPN11 coding regions in a total of 17 MC families identified mutations in 10 of them (5 frameshift, 2 nonsense, and 3 splice-site mutations).
BC8_BioRED_Task1_Doc399	965	967	MC	Disease	C562938	Sanger sequence analysis of PTPN11 coding regions in a total of 17 MC families identified mutations in 10 of them (5 frameshift, 2 nonsense, and 3 splice-site mutations).
BC8_BioRED_Task1_Doc399	1166	1172	PTPN11	Gene	5781	Copy number analysis of sequencing reads from a second targeted capture that included the entire PTPN11 gene identified an additional family with a 15 kb deletion spanning exon 7 of PTPN11.
BC8_BioRED_Task1_Doc399	1217	1231	15 kb deletion	SequenceVariant	c|DEL||15K	Copy number analysis of sequencing reads from a second targeted capture that included the entire PTPN11 gene identified an additional family with a 15 kb deletion spanning exon 7 of PTPN11.
BC8_BioRED_Task1_Doc399	1251	1257	PTPN11	Gene	5781	Copy number analysis of sequencing reads from a second targeted capture that included the entire PTPN11 gene identified an additional family with a 15 kb deletion spanning exon 7 of PTPN11.
BC8_BioRED_Task1_Doc399	1274	1276	MC	Disease	C562938	Microdissected MC lesions from two patients with PTPN11 mutations demonstrated loss-of-heterozygosity for the wild-type allele.
BC8_BioRED_Task1_Doc399	1294	1302	patients	OrganismTaxon	9606	Microdissected MC lesions from two patients with PTPN11 mutations demonstrated loss-of-heterozygosity for the wild-type allele.
BC8_BioRED_Task1_Doc399	1308	1314	PTPN11	Gene	5781	Microdissected MC lesions from two patients with PTPN11 mutations demonstrated loss-of-heterozygosity for the wild-type allele.
BC8_BioRED_Task1_Doc399	1405	1411	PTPN11	Gene	5781	We next sequenced PTPN11 in DNA samples from 54 patients with the multiple enchondromatosis disorders Ollier disease or Maffucci syndrome, but found no coding sequence PTPN11 mutations.
BC8_BioRED_Task1_Doc399	1435	1443	patients	OrganismTaxon	9606	We next sequenced PTPN11 in DNA samples from 54 patients with the multiple enchondromatosis disorders Ollier disease or Maffucci syndrome, but found no coding sequence PTPN11 mutations.
BC8_BioRED_Task1_Doc399	1462	1503	enchondromatosis disorders Ollier disease	Disease	D004687	We next sequenced PTPN11 in DNA samples from 54 patients with the multiple enchondromatosis disorders Ollier disease or Maffucci syndrome, but found no coding sequence PTPN11 mutations.
BC8_BioRED_Task1_Doc399	1507	1524	Maffucci syndrome	Disease	D004687	We next sequenced PTPN11 in DNA samples from 54 patients with the multiple enchondromatosis disorders Ollier disease or Maffucci syndrome, but found no coding sequence PTPN11 mutations.
BC8_BioRED_Task1_Doc399	1555	1561	PTPN11	Gene	5781	We next sequenced PTPN11 in DNA samples from 54 patients with the multiple enchondromatosis disorders Ollier disease or Maffucci syndrome, but found no coding sequence PTPN11 mutations.
BC8_BioRED_Task1_Doc399	1633	1639	PTPN11	Gene	5781	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1664	1666	MC	Disease	C562938	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1684	1692	patients	OrganismTaxon	9606	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1698	1700	MC	Disease	C562938	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1748	1750	MC	Disease	C562938	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1861	1867	PTPN11	Gene	5781	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1888	1894	PTPN11	Gene	5781	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1931	1945	Ollier disease	Disease	D004687	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc399	1949	1966	Maffucci syndrome	Disease	D004687	We conclude that heterozygous loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear to arise following a "second hit," that MC may be locus heterogeneous since 1 familial and 5 sporadically occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not a common cause of Ollier disease or Maffucci syndrome.
BC8_BioRED_Task1_Doc400	9	17	fentanyl	Chemical	D005283	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
BC8_BioRED_Task1_Doc400	26	32	nausea	Disease	D009325	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
BC8_BioRED_Task1_Doc400	37	45	vomiting	Disease	D014839	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
BC8_BioRED_Task1_Doc400	66	70	pain	Disease	D010146	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
BC8_BioRED_Task1_Doc400	78	89	sevoflurane	Chemical	C009250	Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
BC8_BioRED_Task1_Doc400	201	212	sevoflurane	Chemical	C009250	BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.
BC8_BioRED_Task1_Doc400	214	247	postoperative nausea and vomiting	Disease	D020250	BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.
BC8_BioRED_Task1_Doc400	267	275	Fentanyl	Chemical	D005283	Fentanyl is a commonly used supplement that may contribute to this, although it may also improve analgesia.
BC8_BioRED_Task1_Doc400	447	489	postoperative nausea and vomiting and pain	Disease	D010149,D020250	METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.
BC8_BioRED_Task1_Doc400	514	525	sevoflurane	Chemical	C009250	METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.
BC8_BioRED_Task1_Doc400	563	571	patients	OrganismTaxon	9606	METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.
BC8_BioRED_Task1_Doc400	573	581	Patients	OrganismTaxon	9606	Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.
BC8_BioRED_Task1_Doc400	643	651	fentanyl	Chemical	D005283	Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.
BC8_BioRED_Task1_Doc400	682	695	dexamethasone	Chemical	D003907	Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.
BC8_BioRED_Task1_Doc400	711	719	fentanyl	Chemical	D005283	Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received dexamethasone in addition to fentanyl.
BC8_BioRED_Task1_Doc400	742	750	fentanyl	Chemical	D005283	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	791	824	postoperative nausea and vomiting	Disease	D020250	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	858	866	vomiting	Disease	D014839	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	893	899	nausea	Disease	D009325	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	941	949	fentanyl	Chemical	D005283	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	954	962	fentanyl	Chemical	D005283	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	963	976	dexamethasone	Chemical	D003907	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
BC8_BioRED_Task1_Doc400	1085	1098	Dexamethasone	Chemical	D003907	Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.
BC8_BioRED_Task1_Doc400	1157	1190	postoperative nausea and vomiting	Disease	D020250	Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.
BC8_BioRED_Task1_Doc400	1210	1218	fentanyl	Chemical	D005283	Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).
BC8_BioRED_Task1_Doc400	1304	1337	postoperative nausea and vomiting	Disease	D020250	Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).
BC8_BioRED_Task1_Doc400	1342	1348	nausea	Disease	D009325	Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).
BC8_BioRED_Task1_Doc400	1447	1453	nausea	Disease	D009325	Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).
BC8_BioRED_Task1_Doc400	1515	1519	Pain	Disease	D010146	Pain severity and analgesic requirements were unaffected by the omission of fentanyl.
BC8_BioRED_Task1_Doc400	1591	1599	fentanyl	Chemical	D005283	Pain severity and analgesic requirements were unaffected by the omission of fentanyl.
BC8_BioRED_Task1_Doc400	1601	1609	Fentanyl	Chemical	D005283	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
BC8_BioRED_Task1_Doc400	1662	1673	sevoflurane	Chemical	C009250	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
BC8_BioRED_Task1_Doc400	1703	1725	respiratory depression	Disease	D012131	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
BC8_BioRED_Task1_Doc400	1727	1738	hypotension	Disease	D007022	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
BC8_BioRED_Task1_Doc400	1743	1754	bradycardia	Disease	D001919	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
BC8_BioRED_Task1_Doc400	1771	1779	fentanyl	Chemical	D005283	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
BC8_BioRED_Task1_Doc400	1792	1825	postoperative nausea and vomiting	Disease	D020250	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
BC8_BioRED_Task1_Doc400	1852	1870	postoperative pain	Disease	D010149	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
BC8_BioRED_Task1_Doc400	1990	2001	sevoflurane	Chemical	C009250	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.
BC8_BioRED_Task1_Doc401	26	36	ifosfamide	Chemical	D007069	The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.
BC8_BioRED_Task1_Doc401	38	43	mesna	Chemical	D015080	The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.
BC8_BioRED_Task1_Doc401	81	87	rabbit	OrganismTaxon	9986	The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.
BC8_BioRED_Task1_Doc401	140	150	Ifosfamide	Chemical	D007069	Ifosfamide (IFO) is an alkylating nitrogen mustard, administrated as an antineoplasmic agent.
BC8_BioRED_Task1_Doc401	152	155	IFO	Chemical	D007069	Ifosfamide (IFO) is an alkylating nitrogen mustard, administrated as an antineoplasmic agent.
BC8_BioRED_Task1_Doc401	163	190	alkylating nitrogen mustard	Chemical	D008357	Ifosfamide (IFO) is an alkylating nitrogen mustard, administrated as an antineoplasmic agent.
BC8_BioRED_Task1_Doc401	297	308	hemorrhagic	Disease	D006470	It is characterized by its intense urotoxic action, leading to hemorrhagic cystitis.
BC8_BioRED_Task1_Doc401	309	317	cystitis	Disease	D003556	It is characterized by its intense urotoxic action, leading to hemorrhagic cystitis.
BC8_BioRED_Task1_Doc401	339	342	IFO	Chemical	D007069	This side effect of IFO raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect.
BC8_BioRED_Task1_Doc401	397	429	sodium 2-sulfanylethanesulfonate	Chemical	D015080	This side effect of IFO raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect.
BC8_BioRED_Task1_Doc401	431	436	Mesna	Chemical	D015080	This side effect of IFO raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect.
BC8_BioRED_Task1_Doc401	479	482	IFO	Chemical	D007069	IFO and Mesna were administrated separately on rabbit's lymphocytes in vivo, which were later developed in vitro.
BC8_BioRED_Task1_Doc401	487	492	Mesna	Chemical	D015080	IFO and Mesna were administrated separately on rabbit's lymphocytes in vivo, which were later developed in vitro.
BC8_BioRED_Task1_Doc401	526	532	rabbit	OrganismTaxon	9986	IFO and Mesna were administrated separately on rabbit's lymphocytes in vivo, which were later developed in vitro.
BC8_BioRED_Task1_Doc401	716	721	Mesna	Chemical	D015080	Mesna's action, in conjunction with IFO reduces the frequency of SCEs, in comparison with the SCEs recordings obtained when IFO is administered alone.
BC8_BioRED_Task1_Doc401	752	755	IFO	Chemical	D007069	Mesna's action, in conjunction with IFO reduces the frequency of SCEs, in comparison with the SCEs recordings obtained when IFO is administered alone.
BC8_BioRED_Task1_Doc401	840	843	IFO	Chemical	D007069	Mesna's action, in conjunction with IFO reduces the frequency of SCEs, in comparison with the SCEs recordings obtained when IFO is administered alone.
BC8_BioRED_Task1_Doc401	916	921	Mesna	Chemical	D015080	In addition to this, when high concentrations of Mesna were administered alone significant reductions of the PRI were noted, than with IFO acting at the same concentration on the lymphocytes.
BC8_BioRED_Task1_Doc401	1002	1005	IFO	Chemical	D007069	In addition to this, when high concentrations of Mesna were administered alone significant reductions of the PRI were noted, than with IFO acting at the same concentration on the lymphocytes.
BC8_BioRED_Task1_Doc401	1059	1064	Mesna	Chemical	D015080	Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.
BC8_BioRED_Task1_Doc401	1087	1090	IFO	Chemical	D007069	Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.
BC8_BioRED_Task1_Doc401	1093	1105	genotoxicity	Disease	D030342	Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.
BC8_BioRED_Task1_Doc402	0	15	Methamphetamine	Chemical	D008694	Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.
BC8_BioRED_Task1_Doc402	24	37	neurotoxicity	Disease	D020258	Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.
BC8_BioRED_Task1_Doc402	84	104	fractalkine receptor	Gene	13051	Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.
BC8_BioRED_Task1_Doc402	116	131	Methamphetamine	Chemical	D008694	Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.
BC8_BioRED_Task1_Doc402	133	137	METH	Chemical	D008694	Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.
BC8_BioRED_Task1_Doc402	147	155	dopamine	Chemical	D004298	Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.
BC8_BioRED_Task1_Doc402	157	159	DA	Chemical	D004298	Methamphetamine (METH) damages dopamine (DA) nerve endings by a process that has been linked to microglial activation but the signaling pathways that mediate this response have not yet been delineated.
BC8_BioRED_Task1_Doc402	408	428	fractalkine receptor	Gene	13051	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
BC8_BioRED_Task1_Doc402	430	436	CX3CR1	Gene	13051	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
BC8_BioRED_Task1_Doc402	466	470	MPTP	Chemical	D015632	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
BC8_BioRED_Task1_Doc402	479	496	neurodegeneration	Disease	D009422	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
BC8_BioRED_Task1_Doc402	500	502	DA	Chemical	D004298	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.
BC8_BioRED_Task1_Doc402	524	534	CNS damage	Disease	D009422	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	545	549	METH	Chemical	D008694	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	554	558	MPTP	Chemical	D015632	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	587	589	DA	Chemical	D004298	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	609	614	mouse	OrganismTaxon	10090	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	625	638	neurotoxicity	Disease	D020258	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	665	671	CX3CR1	Gene	13051	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	688	692	METH	Chemical	D008694	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	701	714	neurotoxicity	Disease	D020258	Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.
BC8_BioRED_Task1_Doc402	742	746	Mice	OrganismTaxon	10090	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
BC8_BioRED_Task1_Doc402	760	766	CX3CR1	Gene	13051	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
BC8_BioRED_Task1_Doc402	823	857	enhanced green fluorescent protein	Chemical	C485184	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
BC8_BioRED_Task1_Doc402	859	863	eGFP	Chemical	C485184	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
BC8_BioRED_Task1_Doc402	883	887	METH	Chemical	D008694	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
BC8_BioRED_Task1_Doc402	914	927	neurotoxicity	Disease	D020258	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
BC8_BioRED_Task1_Doc402	929	933	METH	Chemical	D008694	METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.
BC8_BioRED_Task1_Doc402	943	945	DA	Chemical	D004298	METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.
BC8_BioRED_Task1_Doc402	1011	1017	CX3CR1	Gene	13051	METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.
BC8_BioRED_Task1_Doc402	1027	1031	mice	OrganismTaxon	10090	METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.
BC8_BioRED_Task1_Doc402	1124	1128	METH	Chemical	D008694	The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.
BC8_BioRED_Task1_Doc402	1132	1138	CX3CR1	Gene	13051	The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.
BC8_BioRED_Task1_Doc402	1148	1152	mice	OrganismTaxon	10090	The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.
BC8_BioRED_Task1_Doc402	1249	1253	eGFP	Chemical	C485184	Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.
BC8_BioRED_Task1_Doc402	1302	1306	METH	Chemical	D008694	Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.
BC8_BioRED_Task1_Doc402	1432	1436	eGFP	Chemical	C485184	This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.
BC8_BioRED_Task1_Doc402	1498	1502	METH	Chemical	D008694	This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.
BC8_BioRED_Task1_Doc402	1540	1546	CX3CR1	Gene	13051	We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.
BC8_BioRED_Task1_Doc402	1575	1579	METH	Chemical	D008694	We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.
BC8_BioRED_Task1_Doc402	1580	1593	neurotoxicity	Disease	D020258	We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.
BC8_BioRED_Task1_Doc402	1688	1692	METH	Chemical	D008694	Furthermore, it appears that striatal-resident microglia respond to METH with an activation cascade and then return to a surveying state without undergoing apoptosis or migration.
BC8_BioRED_Task1_Doc403	35	48	neurotoxicity	Disease	D020258	Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
BC8_BioRED_Task1_Doc403	68	82	Streptozotocin	Chemical	D013311	Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
BC8_BioRED_Task1_Doc403	97	114	memory impairment	Disease	D008569	Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
BC8_BioRED_Task1_Doc403	118	122	rats	OrganismTaxon	10116	Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
BC8_BioRED_Task1_Doc403	192	200	toxicity	Disease	D064420	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
BC8_BioRED_Task1_Doc403	208	222	Streptozotocin	Chemical	D013311	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
BC8_BioRED_Task1_Doc403	224	227	STZ	Chemical	D013311	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
BC8_BioRED_Task1_Doc403	237	252	memory impaired	Disease	D008569	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
BC8_BioRED_Task1_Doc403	253	257	rats	OrganismTaxon	10116	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
BC8_BioRED_Task1_Doc403	296	310	Memory deficit	Disease	D008569	In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.
BC8_BioRED_Task1_Doc403	367	370	STZ	Chemical	D013311	In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.
BC8_BioRED_Task1_Doc403	401	404	STZ	Chemical	D013311	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
BC8_BioRED_Task1_Doc403	436	440	GFAP	Gene	24387	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
BC8_BioRED_Task1_Doc403	442	447	CD11b	Gene	25021	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
BC8_BioRED_Task1_Doc403	452	457	TNF-a	Gene	24835	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
BC8_BioRED_Task1_Doc403	490	507	neuroinflammation	Disease	D007249	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
BC8_BioRED_Task1_Doc403	509	512	STZ	Chemical	D013311	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
BC8_BioRED_Task1_Doc403	555	558	ROS	Chemical	D017382	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
BC8_BioRED_Task1_Doc403	560	567	nitrite	Chemical	D009573	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
BC8_BioRED_Task1_Doc403	569	575	Ca(2+)	Chemical	D002118	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
BC8_BioRED_Task1_Doc403	684	698	excitotoxicity	Disease	D064420	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
BC8_BioRED_Task1_Doc403	737	746	Caspase-3	Gene	25402	Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex.
BC8_BioRED_Task1_Doc403	768	771	STZ	Chemical	D013311	Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex.
BC8_BioRED_Task1_Doc403	780	783	rat	OrganismTaxon	10116	Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex.
BC8_BioRED_Task1_Doc403	846	849	STZ	Chemical	D013311	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
BC8_BioRED_Task1_Doc403	912	919	CaMKIIa	Gene	25400	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
BC8_BioRED_Task1_Doc403	924	930	PSD-95	Gene	29495	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
BC8_BioRED_Task1_Doc403	975	988	synaptophysin	Gene	24804	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
BC8_BioRED_Task1_Doc403	993	1000	SNAP-25	Gene	25012	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
BC8_BioRED_Task1_Doc403	1055	1068	neurotoxicity	Disease	D020258	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
BC8_BioRED_Task1_Doc403	1090	1099	Memantine	Chemical	D008559	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
BC8_BioRED_Task1_Doc403	1114	1123	Ibuprofen	Chemical	D007052	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
BC8_BioRED_Task1_Doc403	1164	1167	STZ	Chemical	D013311	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
BC8_BioRED_Task1_Doc403	1233	1246	neurotoxicity	Disease	D020258	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
BC8_BioRED_Task1_Doc403	1250	1253	rat	OrganismTaxon	10116	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
BC8_BioRED_Task1_Doc403	1353	1356	STZ	Chemical	D013311	7-9 days after STZ treatment.
BC8_BioRED_Task1_Doc403	1381	1385	GFAP	Gene	24387	The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased.
BC8_BioRED_Task1_Doc403	1387	1392	CD11b	Gene	25021	The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased.
BC8_BioRED_Task1_Doc403	1394	1399	TNF-a	Gene	24835	The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased.
BC8_BioRED_Task1_Doc403	1401	1404	ROS	Chemical	D017382	The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased.
BC8_BioRED_Task1_Doc403	1409	1416	nitrite	Chemical	D009573	The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased.
BC8_BioRED_Task1_Doc403	1522	1528	Ca(2+)	Chemical	D002118	On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and Ca(2+) levels remained unaffected.
BC8_BioRED_Task1_Doc403	1588	1605	neuroinflammatory	Disease	D007249	Collective data indicates that neuroinflammatory process and oxidative stress occurs earlier to apoptosis and does not affect memory function.
BC8_BioRED_Task1_Doc403	1771	1784	neurotoxicity	Disease	D020258	Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.
BC8_BioRED_Task1_Doc403	1808	1811	STZ	Chemical	D013311	Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.
BC8_BioRED_Task1_Doc403	1820	1837	memory impairment	Disease	D008569	Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.
BC8_BioRED_Task1_Doc404	3	39	autosomal dominant cerebellar ataxia	Disease	OMIM:604121	An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains.
BC8_BioRED_Task1_Doc404	207	245	Rho guanine-nucleotide exchange-factor	Gene	9138	An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains.
BC8_BioRED_Task1_Doc404	255	291	Autosomal dominant cerebellar ataxia	Disease	OMIM:604121	Autosomal dominant cerebellar ataxia (ADCA) is a group of heterogeneous neurodegenerative disorders.
BC8_BioRED_Task1_Doc404	293	297	ADCA	Disease	OMIM:604121	Autosomal dominant cerebellar ataxia (ADCA) is a group of heterogeneous neurodegenerative disorders.
BC8_BioRED_Task1_Doc404	327	354	neurodegenerative disorders	Disease	D019636	Autosomal dominant cerebellar ataxia (ADCA) is a group of heterogeneous neurodegenerative disorders.
BC8_BioRED_Task1_Doc404	442	461	degenerative ataxia	Disease	D001259	By positional cloning, we have identified the gene strongly associated with a form of degenerative ataxia (chromosome 16q22.1-linked ADCA) that clinically shows progressive pure cerebellar ataxia.
BC8_BioRED_Task1_Doc404	489	493	ADCA	Disease	OMIM:604121	By positional cloning, we have identified the gene strongly associated with a form of degenerative ataxia (chromosome 16q22.1-linked ADCA) that clinically shows progressive pure cerebellar ataxia.
BC8_BioRED_Task1_Doc404	534	551	cerebellar ataxia	Disease	D002524	By positional cloning, we have identified the gene strongly associated with a form of degenerative ataxia (chromosome 16q22.1-linked ADCA) that clinically shows progressive pure cerebellar ataxia.
BC8_BioRED_Task1_Doc404	609	641	sensorineural hearing impairment	Disease	D034381	Detailed examination by use of audiogram suggested that sensorineural hearing impairment may be associated with ataxia in our families.
BC8_BioRED_Task1_Doc404	665	671	ataxia	Disease	D001259	Detailed examination by use of audiogram suggested that sensorineural hearing impairment may be associated with ataxia in our families.
BC8_BioRED_Task1_Doc404	791	799	patients	OrganismTaxon	9606	After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called "puratrophin-1" (Purkinje cell atrophy associated protein-1).
BC8_BioRED_Task1_Doc404	858	863	C-->T	SequenceVariant	c|SUB|C||T	After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called "puratrophin-1" (Purkinje cell atrophy associated protein-1).
BC8_BioRED_Task1_Doc404	994	1006	DKFZP434I216	Gene	25894	After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called "puratrophin-1" (Purkinje cell atrophy associated protein-1).
BC8_BioRED_Task1_Doc404	1030	1043	puratrophin-1	Gene	25894	After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called "puratrophin-1" (Purkinje cell atrophy associated protein-1).
BC8_BioRED_Task1_Doc404	1046	1088	Purkinje cell atrophy associated protein-1	Gene	25894	After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called "puratrophin-1" (Purkinje cell atrophy associated protein-1).
BC8_BioRED_Task1_Doc404	1107	1120	puratrophin-1	Gene	25894	The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus.
BC8_BioRED_Task1_Doc404	1243	1277	guanine-nucleotide exchange factor	Gene	9138	The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus.
BC8_BioRED_Task1_Doc404	1279	1282	GEF	Gene	9138	The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus.
BC8_BioRED_Task1_Doc404	1288	1299	Rho GTPases	Gene	387	The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus.
BC8_BioRED_Task1_Doc404	1368	1381	puratrophin-1	Gene	25894	The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus.
BC8_BioRED_Task1_Doc404	1413	1418	actin	Gene	60	The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus.
BC8_BioRED_Task1_Doc404	1452	1465	Puratrophin-1	Gene	25894	Puratrophin-1--normally expressed in a wide range of cells, including epithelial hair cells in the cochlea--was aggregated in Purkinje cells of the chromosome 16q22.1-linked ADCA brains.
BC8_BioRED_Task1_Doc404	1626	1630	ADCA	Disease	OMIM:604121	Puratrophin-1--normally expressed in a wide range of cells, including epithelial hair cells in the cochlea--was aggregated in Purkinje cells of the chromosome 16q22.1-linked ADCA brains.
BC8_BioRED_Task1_Doc404	1686	1699	puratrophin-1	Gene	25894	Consistent with the protein prediction data of puratrophin-1, the Golgi-apparatus membrane protein and spectrin also formed aggregates in Purkinje cells.
BC8_BioRED_Task1_Doc404	1903	1908	human	OrganismTaxon	9606	The present study highlights the importance of the 5' untranslated region (UTR) in identification of genes of human disease, suggests that a single-nucleotide substitution in the 5' UTR could be associated with protein aggregation, and indicates that the GEF protein is associated with cerebellar degeneration in humans.
BC8_BioRED_Task1_Doc404	2048	2051	GEF	Gene	9138	The present study highlights the importance of the 5' untranslated region (UTR) in identification of genes of human disease, suggests that a single-nucleotide substitution in the 5' UTR could be associated with protein aggregation, and indicates that the GEF protein is associated with cerebellar degeneration in humans.
BC8_BioRED_Task1_Doc404	2079	2102	cerebellar degeneration	Disease	D013132	The present study highlights the importance of the 5' untranslated region (UTR) in identification of genes of human disease, suggests that a single-nucleotide substitution in the 5' UTR could be associated with protein aggregation, and indicates that the GEF protein is associated with cerebellar degeneration in humans.
BC8_BioRED_Task1_Doc404	2106	2112	humans	OrganismTaxon	9606	The present study highlights the importance of the 5' untranslated region (UTR) in identification of genes of human disease, suggests that a single-nucleotide substitution in the 5' UTR could be associated with protein aggregation, and indicates that the GEF protein is associated with cerebellar degeneration in humans.
BC8_BioRED_Task1_Doc405	22	29	677 C>T	SequenceVariant	rs1801133	Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis.
BC8_BioRED_Task1_Doc405	50	55	MTHFR	Gene	4524	Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis.
BC8_BioRED_Task1_Doc405	66	82	male infertility	Disease	D007248	Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis.
BC8_BioRED_Task1_Doc405	149	184	Methylenetetrahydrofolate reductase	Gene	4524	BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.
BC8_BioRED_Task1_Doc405	186	191	MTHFR	Gene	4524	BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.
BC8_BioRED_Task1_Doc405	219	225	folate	Chemical	D005492	BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.
BC8_BioRED_Task1_Doc405	230	240	methionine	Chemical	D008715	BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation.
BC8_BioRED_Task1_Doc405	349	354	MTHFR	Gene	4524	The objective of this study was to analyze MTHFR gene 677C>T polymorphism in infertile male individuals from North India, followed by a meta-analysis on our data and published studies.
BC8_BioRED_Task1_Doc405	360	366	677C>T	SequenceVariant	rs1801133	The objective of this study was to analyze MTHFR gene 677C>T polymorphism in infertile male individuals from North India, followed by a meta-analysis on our data and published studies.
BC8_BioRED_Task1_Doc405	938	944	677C>T	SequenceVariant	rs1801133	Those studies analyzing 677C>T polymorphism in male infertility and presenting all relevant data were included in meta-analysis.
BC8_BioRED_Task1_Doc405	961	977	male infertility	Disease	D007248	Those studies analyzing 677C>T polymorphism in male infertility and presenting all relevant data were included in meta-analysis.
BC8_BioRED_Task1_Doc405	1639	1645	677C>T	SequenceVariant	rs1801133	The overall summary estimate (OR) for allele and genotype meta-analysis were 1.304 (p=0.000), 1.310 (p=0.000), respectively, establishing significant association of 677C>T polymorphism with male infertility.
BC8_BioRED_Task1_Doc405	1664	1680	male infertility	Disease	D007248	The overall summary estimate (OR) for allele and genotype meta-analysis were 1.304 (p=0.000), 1.310 (p=0.000), respectively, establishing significant association of 677C>T polymorphism with male infertility.
BC8_BioRED_Task1_Doc405	1708	1714	677C>T	SequenceVariant	rs1801133	CONCLUSIONS/SIGNIFICANCE: 677C>T substitution associated strongly with male infertility in Indian population.
BC8_BioRED_Task1_Doc405	1753	1769	male infertility	Disease	D007248	CONCLUSIONS/SIGNIFICANCE: 677C>T substitution associated strongly with male infertility in Indian population.
BC8_BioRED_Task1_Doc405	1869	1885	male infertility	Disease	D007248	Allele and genotype meta-analysis also supported its strong correlation with male infertility, thus establishing it as a risk factor.
BC8_BioRED_Task1_Doc406	34	39	ABCG2	Gene	9429	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
BC8_BioRED_Task1_Doc406	59	69	irinotecan	Chemical	D000077146	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
BC8_BioRED_Task1_Doc406	85	101	myelosuppression	Disease	D001855	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
BC8_BioRED_Task1_Doc406	103	113	Irinotecan	Chemical	D000077146	Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea.
BC8_BioRED_Task1_Doc406	175	202	colorectal and lung cancers	Disease	D008175,D015179	Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea.
BC8_BioRED_Task1_Doc406	221	231	toxicities	Disease	D064420	Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea.
BC8_BioRED_Task1_Doc406	247	263	myelosuppression	Disease	D001855	Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea.
BC8_BioRED_Task1_Doc406	268	276	diarrhea	Disease	D003967	Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea.
BC8_BioRED_Task1_Doc406	353	363	irinotecan	Chemical	D000077146	In this study, we performed a two-stage case-control association study for irinotecan-induced severe myelosuppression (grades 3 and 4).
BC8_BioRED_Task1_Doc406	379	395	myelosuppression	Disease	D001855	In this study, we performed a two-stage case-control association study for irinotecan-induced severe myelosuppression (grades 3 and 4).
BC8_BioRED_Task1_Doc406	437	445	patients	OrganismTaxon	9606	In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan.
BC8_BioRED_Task1_Doc406	467	483	myelosuppression	Disease	D001855	In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan.
BC8_BioRED_Task1_Doc406	491	499	patients	OrganismTaxon	9606	In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan.
BC8_BioRED_Task1_Doc406	524	532	toxicity	Disease	D064420	In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan.
BC8_BioRED_Task1_Doc406	650	660	irinotecan	Chemical	D000077146	In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan.
BC8_BioRED_Task1_Doc406	744	760	myelosuppression	Disease	D001855	A total of five SNPs were identified to show the possible association with severe myelosuppression (P(Fisher)<0.01) and were further examined in 7 cases and 20 controls in the second stage of the study.
BC8_BioRED_Task1_Doc406	882	891	rs2622604	SequenceVariant	rs2622604	An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036).
BC8_BioRED_Task1_Doc406	896	901	ABCG2	Gene	9429	An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036).
BC8_BioRED_Task1_Doc406	998	1014	myelosuppression	Disease	D001855	An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036).
BC8_BioRED_Task1_Doc406	1182	1187	ABCG2	Gene	9429	Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.
BC8_BioRED_Task1_Doc406	1282	1292	irinotecan	Chemical	D000077146	Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.
BC8_BioRED_Task1_Doc406	1312	1328	myelosuppression	Disease	D001855	Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.
BC8_BioRED_Task1_Doc407	18	23	E333D	SequenceVariant	p|SUB|E|333|D	A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.
BC8_BioRED_Task1_Doc407	32	61	thyroid hormone beta receptor	Gene	6955	A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.
BC8_BioRED_Task1_Doc407	70	108	resistance to thyroid hormone syndrome	Disease	D018382	A novel mutation (E333D) in the thyroid hormone beta receptor causing resistance to thyroid hormone syndrome.
BC8_BioRED_Task1_Doc407	110	139	Resistance to thyroid hormone	Disease	D018382	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	141	144	RTH	Disease	D018382	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	203	219	thyroid hormones	Chemical	D013963	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	221	223	TH	Chemical	D013963	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	256	283	thyroid stimulating hormone	Gene	1081	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	285	288	TSH	Gene	1081	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	350	352	TH	Chemical	D013963	Resistance to thyroid hormone (RTH) is an inherited syndrome characterized by elevated serum thyroid hormones (TH), failure to suppress pituitary thyroid stimulating hormone (TSH) secretion, and variable peripheral tissue responsiveness to TH.
BC8_BioRED_Task1_Doc407	411	440	thyroid hormone beta receptor	Gene	6955	The disorder is associated with diverse mutations in the thyroid hormone beta receptor (TRbeta).
BC8_BioRED_Task1_Doc407	442	448	TRbeta	Gene	6955	The disorder is associated with diverse mutations in the thyroid hormone beta receptor (TRbeta).
BC8_BioRED_Task1_Doc407	483	486	RTH	Disease	D018382	Here, we report a novel natural RTH mutation (E333D) located in the large carboxy-terminal ligand binding domain of TRbeta.
BC8_BioRED_Task1_Doc407	497	502	E333D	SequenceVariant	p|SUB|E|333|D	Here, we report a novel natural RTH mutation (E333D) located in the large carboxy-terminal ligand binding domain of TRbeta.
BC8_BioRED_Task1_Doc407	567	573	TRbeta	Gene	6955	Here, we report a novel natural RTH mutation (E333D) located in the large carboxy-terminal ligand binding domain of TRbeta.
BC8_BioRED_Task1_Doc407	627	632	woman	OrganismTaxon	9606	The mutation was identified in a 22-year-old French woman coming to medical attention because of an increasing overweight.
BC8_BioRED_Task1_Doc407	686	696	overweight	Disease	D050177	The mutation was identified in a 22-year-old French woman coming to medical attention because of an increasing overweight.
BC8_BioRED_Task1_Doc407	737	746	thyroxine	Chemical	D013974	Biochemical tests showed elevated free thyroxine (T4: 20.8 pg/ml (normal, 8.5-18)) and triiodothyronine (T3: 5.7 pg/ml (normal, 1.4-4)) in the serum, together with an inappropriately nonsuppressed TSH level of 4.7 mU/ml (normal, 0.4-4).
BC8_BioRED_Task1_Doc407	748	750	T4	Chemical	D013974	Biochemical tests showed elevated free thyroxine (T4: 20.8 pg/ml (normal, 8.5-18)) and triiodothyronine (T3: 5.7 pg/ml (normal, 1.4-4)) in the serum, together with an inappropriately nonsuppressed TSH level of 4.7 mU/ml (normal, 0.4-4).
BC8_BioRED_Task1_Doc407	785	801	triiodothyronine	Chemical	D014284	Biochemical tests showed elevated free thyroxine (T4: 20.8 pg/ml (normal, 8.5-18)) and triiodothyronine (T3: 5.7 pg/ml (normal, 1.4-4)) in the serum, together with an inappropriately nonsuppressed TSH level of 4.7 mU/ml (normal, 0.4-4).
BC8_BioRED_Task1_Doc407	803	805	T3	Chemical	D014284	Biochemical tests showed elevated free thyroxine (T4: 20.8 pg/ml (normal, 8.5-18)) and triiodothyronine (T3: 5.7 pg/ml (normal, 1.4-4)) in the serum, together with an inappropriately nonsuppressed TSH level of 4.7 mU/ml (normal, 0.4-4).
BC8_BioRED_Task1_Doc407	895	898	TSH	Gene	1081	Biochemical tests showed elevated free thyroxine (T4: 20.8 pg/ml (normal, 8.5-18)) and triiodothyronine (T3: 5.7 pg/ml (normal, 1.4-4)) in the serum, together with an inappropriately nonsuppressed TSH level of 4.7 mU/ml (normal, 0.4-4).
BC8_BioRED_Task1_Doc407	1030	1033	RTH	Disease	D018382	Her father and her brother's serum tests also showed biochemical abnormalities consistent with RTH.
BC8_BioRED_Task1_Doc407	1060	1066	TRbeta	Gene	6955	Direct sequencing of the TRbeta gene revealed a heterozygous transition 1284A>C in exon 9 resulting in substitution of glutamic acid 333 by aspartic acid residue (E333D).
BC8_BioRED_Task1_Doc407	1107	1114	1284A>C	SequenceVariant	c|SUB|A|1284|C	Direct sequencing of the TRbeta gene revealed a heterozygous transition 1284A>C in exon 9 resulting in substitution of glutamic acid 333 by aspartic acid residue (E333D).
BC8_BioRED_Task1_Doc407	1154	1188	glutamic acid 333 by aspartic acid	SequenceVariant	p|SUB|E|333|D	Direct sequencing of the TRbeta gene revealed a heterozygous transition 1284A>C in exon 9 resulting in substitution of glutamic acid 333 by aspartic acid residue (E333D).
BC8_BioRED_Task1_Doc407	1198	1203	E333D	SequenceVariant	p|SUB|E|333|D	Direct sequencing of the TRbeta gene revealed a heterozygous transition 1284A>C in exon 9 resulting in substitution of glutamic acid 333 by aspartic acid residue (E333D).
BC8_BioRED_Task1_Doc407	1247	1253	TRbeta	Gene	6955	Further functional analyses of the novel TRbeta mutant were conducted.
BC8_BioRED_Task1_Doc407	1295	1300	E333D	SequenceVariant	p|SUB|E|333|D	We found that the E333D mutation neither significantly affected the affinity of the receptor for T3 nor modified heterodimer formation with retinoid X receptor (RXR) when bound to DNA.
BC8_BioRED_Task1_Doc407	1374	1376	T3	Chemical	D014284	We found that the E333D mutation neither significantly affected the affinity of the receptor for T3 nor modified heterodimer formation with retinoid X receptor (RXR) when bound to DNA.
BC8_BioRED_Task1_Doc407	1417	1436	retinoid X receptor	Gene	6256	We found that the E333D mutation neither significantly affected the affinity of the receptor for T3 nor modified heterodimer formation with retinoid X receptor (RXR) when bound to DNA.
BC8_BioRED_Task1_Doc407	1438	1441	RXR	Gene	6256	We found that the E333D mutation neither significantly affected the affinity of the receptor for T3 nor modified heterodimer formation with retinoid X receptor (RXR) when bound to DNA.
BC8_BioRED_Task1_Doc407	1509	1514	E333D	SequenceVariant	p|SUB|E|333|D	However, in transient transfection assays, the E333D TRbeta mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements (F2- and DR4-TREs) as well as on the negatively regulated human TSHalpha promoter.
BC8_BioRED_Task1_Doc407	1515	1521	TRbeta	Gene	6955	However, in transient transfection assays, the E333D TRbeta mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements (F2- and DR4-TREs) as well as on the negatively regulated human TSHalpha promoter.
BC8_BioRED_Task1_Doc407	1696	1701	human	OrganismTaxon	9606	However, in transient transfection assays, the E333D TRbeta mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements (F2- and DR4-TREs) as well as on the negatively regulated human TSHalpha promoter.
BC8_BioRED_Task1_Doc407	1702	1710	TSHalpha	Gene	1081	However, in transient transfection assays, the E333D TRbeta mutant exhibited impaired transcriptional regulation on two distinct positively regulated thyroid response elements (F2- and DR4-TREs) as well as on the negatively regulated human TSHalpha promoter.
BC8_BioRED_Task1_Doc407	1770	1776	TRbeta	Gene	6955	Moreover, a dominant inhibition of the wild-type TRbeta counterpart transactivation function was observed on both a positive (F2-TRE) and a negative (TSHalpha) promoter.
BC8_BioRED_Task1_Doc407	1871	1879	TSHalpha	Gene	1081	Moreover, a dominant inhibition of the wild-type TRbeta counterpart transactivation function was observed on both a positive (F2-TRE) and a negative (TSHalpha) promoter.
BC8_BioRED_Task1_Doc407	1931	1936	E333D	SequenceVariant	p|SUB|E|333|D	These results strongly suggest that the E333D TRbeta mutation is responsible for the RTH phenotype in the proposita's family.
BC8_BioRED_Task1_Doc407	1937	1943	TRbeta	Gene	6955	These results strongly suggest that the E333D TRbeta mutation is responsible for the RTH phenotype in the proposita's family.
BC8_BioRED_Task1_Doc407	1976	1979	RTH	Disease	D018382	These results strongly suggest that the E333D TRbeta mutation is responsible for the RTH phenotype in the proposita's family.
BC8_BioRED_Task1_Doc408	44	58	NMDA receptors	Gene	24408	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
BC8_BioRED_Task1_Doc408	99	110	haloperidol	Chemical	D006220	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
BC8_BioRED_Task1_Doc408	119	128	catalepsy	Disease	D002375	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
BC8_BioRED_Task1_Doc408	742	751	catalepsy	Disease	D002375	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
BC8_BioRED_Task1_Doc408	767	784	dopamine receptor	Gene	24316	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
BC8_BioRED_Task1_Doc408	793	804	haloperidol	Chemical	D006220	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
BC8_BioRED_Task1_Doc408	851	855	rats	OrganismTaxon	10116	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
BC8_BioRED_Task1_Doc408	857	868	Haloperidol	Chemical	D006220	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	877	886	catalepsy	Disease	D002375	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	948	971	glutamate NMDA receptor	Gene	24408	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	985	991	MK-801	Chemical	D016291	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	1023	1026	AP7	Chemical	C031231	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	1065	1078	NMDA receptor	Gene	24408	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	1087	1107	N-methyl-d-aspartate	Chemical	D016202	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	1109	1113	NMDA	Chemical	D016202	Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
BC8_BioRED_Task1_Doc408	1200	1206	MK-801	Chemical	D016291	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
BC8_BioRED_Task1_Doc408	1211	1214	AP7	Chemical	C031231	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
BC8_BioRED_Task1_Doc408	1250	1261	haloperidol	Chemical	D006220	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
BC8_BioRED_Task1_Doc408	1291	1300	catalepsy	Disease	D002375	The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
BC8_BioRED_Task1_Doc408	1419	1423	NMDA	Chemical	D016202	Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
BC8_BioRED_Task1_Doc408	1496	1505	glutamate	Chemical	D018698	These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.
BC8_BioRED_Task1_Doc408	1575	1586	haloperidol	Chemical	D006220	These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.
BC8_BioRED_Task1_Doc408	1595	1604	catalepsy	Disease	D002375	These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.
BC8_BioRED_Task1_Doc409	22	34	antithrombin	Chemical	D000991	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
BC8_BioRED_Task1_Doc409	38	63	puromycin aminonucleoside	Chemical	D011692	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
BC8_BioRED_Task1_Doc409	64	73	nephrosis	Disease	D009401	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
BC8_BioRED_Task1_Doc409	77	81	rats	OrganismTaxon	10116	Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
BC8_BioRED_Task1_Doc409	114	126	antithrombin	Chemical	D000991	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
BC8_BioRED_Task1_Doc409	174	178	rats	OrganismTaxon	10116	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
BC8_BioRED_Task1_Doc409	184	209	puromycin aminonucleoside	Chemical	D011692	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
BC8_BioRED_Task1_Doc409	218	227	nephrosis	Disease	D009401	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
BC8_BioRED_Task1_Doc409	263	268	human	OrganismTaxon	9606	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
BC8_BioRED_Task1_Doc409	269	287	nephrotic syndrome	Disease	D009404	We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.
BC8_BioRED_Task1_Doc409	289	301	Antithrombin	Chemical	D000991	Antithrombin (50 or 500 IU/kg/i.v.)
BC8_BioRED_Task1_Doc409	345	349	rats	OrganismTaxon	10116	was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).
BC8_BioRED_Task1_Doc409	408	433	puromycin aminonucleoside	Chemical	D011692	was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).
BC8_BioRED_Task1_Doc409	466	478	antithrombin	Chemical	D000991	Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.
BC8_BioRED_Task1_Doc409	494	519	puromycin aminonucleoside	Chemical	D011692	Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.
BC8_BioRED_Task1_Doc409	528	555	hematological abnormalities	Disease	D006402	Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.
BC8_BioRED_Task1_Doc409	557	582	Puromycin aminonucleoside	Chemical	D011692	Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
BC8_BioRED_Task1_Doc409	591	608	renal dysfunction	Disease	D007674	Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
BC8_BioRED_Task1_Doc409	613	627	hyperlipidemia	Disease	D006949	Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
BC8_BioRED_Task1_Doc409	696	708	renal damage	Disease	D007674	Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.
BC8_BioRED_Task1_Doc409	794	798	rats	OrganismTaxon	10116	Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.
BC8_BioRED_Task1_Doc409	847	859	antithrombin	Chemical	D000991	Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.
BC8_BioRED_Task1_Doc409	868	872	rats	OrganismTaxon	10116	Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.
BC8_BioRED_Task1_Doc409	887	899	antithrombin	Chemical	D000991	In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.
BC8_BioRED_Task1_Doc409	930	955	puromycin aminonucleoside	Chemical	D011692	In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.
BC8_BioRED_Task1_Doc409	1022	1047	puromycin aminonucleoside	Chemical	D011692	Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.
BC8_BioRED_Task1_Doc409	1141	1149	thrombin	Gene	29251	These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc409	1197	1222	puromycin aminonucleoside	Chemical	D011692	These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc409	1231	1249	nephrotic syndrome	Disease	D009404	These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.
BC8_BioRED_Task1_Doc409	1266	1278	antithrombin	Chemical	D000991	Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.
BC8_BioRED_Task1_Doc409	1310	1318	patients	OrganismTaxon	9606	Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.
BC8_BioRED_Task1_Doc409	1324	1342	nephrotic syndrome	Disease	D009404	Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.
BC8_BioRED_Task1_Doc410	0	27	Cholecystokinin-octapeptide	Chemical	D012844	Cholecystokinin-octapeptide restored morphine-induced hippocampal long-term potentiation impairment in rats.
BC8_BioRED_Task1_Doc410	37	45	morphine	Chemical	D009020	Cholecystokinin-octapeptide restored morphine-induced hippocampal long-term potentiation impairment in rats.
BC8_BioRED_Task1_Doc410	103	107	rats	OrganismTaxon	10116	Cholecystokinin-octapeptide restored morphine-induced hippocampal long-term potentiation impairment in rats.
BC8_BioRED_Task1_Doc410	109	136	Cholecystokinin-octapeptide	Chemical	D012844	Cholecystokinin-octapeptide (CCK-8), which is a typical brain-gut peptide, exerts a wide range of biological activities on the central nervous system.
BC8_BioRED_Task1_Doc410	138	143	CCK-8	Chemical	D012844	Cholecystokinin-octapeptide (CCK-8), which is a typical brain-gut peptide, exerts a wide range of biological activities on the central nervous system.
BC8_BioRED_Task1_Doc410	293	298	CCK-8	Chemical	D012844	We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
BC8_BioRED_Task1_Doc410	324	332	morphine	Chemical	D009020	We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
BC8_BioRED_Task1_Doc410	341	348	amnesia	Disease	D000647	We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
BC8_BioRED_Task1_Doc410	426	434	morphine	Chemical	D009020	We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
BC8_BioRED_Task1_Doc410	489	494	CCK-8	Chemical	D012844	Here, we investigated the effects of CCK-8 on long-term potentiation (LTP) in the lateral perforant path (LPP)-granule cell synapse of rat dentate gyrus (DG) in acute saline or morphine-treated rats.
BC8_BioRED_Task1_Doc410	587	590	rat	OrganismTaxon	10116	Here, we investigated the effects of CCK-8 on long-term potentiation (LTP) in the lateral perforant path (LPP)-granule cell synapse of rat dentate gyrus (DG) in acute saline or morphine-treated rats.
BC8_BioRED_Task1_Doc410	629	637	morphine	Chemical	D009020	Here, we investigated the effects of CCK-8 on long-term potentiation (LTP) in the lateral perforant path (LPP)-granule cell synapse of rat dentate gyrus (DG) in acute saline or morphine-treated rats.
BC8_BioRED_Task1_Doc410	646	650	rats	OrganismTaxon	10116	Here, we investigated the effects of CCK-8 on long-term potentiation (LTP) in the lateral perforant path (LPP)-granule cell synapse of rat dentate gyrus (DG) in acute saline or morphine-treated rats.
BC8_BioRED_Task1_Doc410	759	767	morphine	Chemical	D009020	Acute morphine (30mg/kg, s.c.) treatment significantly attenuated hippocampal LTP and CCK-8 (1ug, i.c.v.)
BC8_BioRED_Task1_Doc410	839	844	CCK-8	Chemical	D012844	Acute morphine (30mg/kg, s.c.) treatment significantly attenuated hippocampal LTP and CCK-8 (1ug, i.c.v.)
BC8_BioRED_Task1_Doc410	911	919	morphine	Chemical	D009020	restored the amplitude of PS that was attenuated by morphine injection.
BC8_BioRED_Task1_Doc410	962	967	CCK-8	Chemical	D012844	Furthermore, microinjection of CCK-8 (0.1 and 1ug, i.c.v.)
BC8_BioRED_Task1_Doc410	1068	1072	rats	OrganismTaxon	10116	also significantly augmented hippocampal LTP in saline-treated (1ml/kg, s.c.) rats.
BC8_BioRED_Task1_Doc410	1095	1108	CCK2 receptor	Gene	25706	Pre-treatment of the CCK2 receptor antagonist L-365,260 (10ug, i.c.v) reversed the effects of CCK-8, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.
BC8_BioRED_Task1_Doc410	1120	1129	L-365,260	Chemical	C058121	Pre-treatment of the CCK2 receptor antagonist L-365,260 (10ug, i.c.v) reversed the effects of CCK-8, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.
BC8_BioRED_Task1_Doc410	1168	1173	CCK-8	Chemical	D012844	Pre-treatment of the CCK2 receptor antagonist L-365,260 (10ug, i.c.v) reversed the effects of CCK-8, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.
BC8_BioRED_Task1_Doc410	1183	1196	CCK1 receptor	Gene	24889	Pre-treatment of the CCK2 receptor antagonist L-365,260 (10ug, i.c.v) reversed the effects of CCK-8, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.
BC8_BioRED_Task1_Doc410	1208	1217	L-364,718	Chemical	D020109	Pre-treatment of the CCK2 receptor antagonist L-365,260 (10ug, i.c.v) reversed the effects of CCK-8, but the CCK1 receptor antagonist L-364,718 (10ug, i.c.v) did not.
BC8_BioRED_Task1_Doc410	1278	1283	CCK-8	Chemical	D012844	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
BC8_BioRED_Task1_Doc410	1309	1317	morphine	Chemical	D009020	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
BC8_BioRED_Task1_Doc410	1345	1359	CCK2 receptors	Gene	25706	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
BC8_BioRED_Task1_Doc410	1400	1405	CCK-8	Chemical	D012844	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
BC8_BioRED_Task1_Doc410	1409	1417	morphine	Chemical	D009020	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
BC8_BioRED_Task1_Doc410	1426	1443	memory impairment	Disease	D008569	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.
BC8_BioRED_Task1_Doc411	0	28	Learning and memory deficits	Disease	D007859,D008569	Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.
BC8_BioRED_Task1_Doc411	32	39	ecstasy	Chemical	D018817	Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.
BC8_BioRED_Task1_Doc411	139	146	ecstasy	Chemical	D018817	It has been consistently shown that ecstasy users display impairments in learning and memory performance.
BC8_BioRED_Task1_Doc411	161	195	impairments in learning and memory	Disease	D007859,D008569	It has been consistently shown that ecstasy users display impairments in learning and memory performance.
BC8_BioRED_Task1_Doc411	251	258	ecstasy	Chemical	D018817	In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).
BC8_BioRED_Task1_Doc411	616	623	ecstasy	Chemical	D018817	Using functional imaging and a face-learning task, we investigated neural correlates of encoding and recalling face-name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls.
BC8_BioRED_Task1_Doc411	693	701	cannabis	Chemical	D002188	To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.
BC8_BioRED_Task1_Doc411	713	720	ecstasy	Chemical	D018817	To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.
BC8_BioRED_Task1_Doc411	782	790	cannabis	Chemical	D002188	To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested cannabis users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008.
BC8_BioRED_Task1_Doc411	854	885	Deficits in learning and memory	Disease	D007859,D008569	Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
BC8_BioRED_Task1_Doc411	903	916	hyperactivity	Disease	D006948	Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
BC8_BioRED_Task1_Doc411	952	960	cannabis	Chemical	D002188	Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
BC8_BioRED_Task1_Doc411	995	1002	Ecstasy	Chemical	D018817	Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users.
BC8_BioRED_Task1_Doc411	1087	1095	cannabis	Chemical	D002188	Ecstasy users performed significantly worse in learning and memory compared to controls and cannabis users.
BC8_BioRED_Task1_Doc411	1179	1186	ecstasy	Chemical	D018817	A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.
BC8_BioRED_Task1_Doc411	1196	1209	hyperactivity	Disease	D006948	A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.
BC8_BioRED_Task1_Doc411	1330	1337	Ecstasy	Chemical	D018817	Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.
BC8_BioRED_Task1_Doc411	1471	1478	ecstasy	Chemical	D018817	In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.
BC8_BioRED_Task1_Doc411	1483	1491	cannabis	Chemical	D002188	In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.
BC8_BioRED_Task1_Doc411	1665	1672	ecstasy	Chemical	D018817	These results elucidated ecstasy-related deficits, only some of which might be attributed to cannabis use.
BC8_BioRED_Task1_Doc411	1733	1741	cannabis	Chemical	D002188	These results elucidated ecstasy-related deficits, only some of which might be attributed to cannabis use.
BC8_BioRED_Task1_Doc411	1753	1760	ecstasy	Chemical	D018817	These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.
BC8_BioRED_Task1_Doc411	1861	1871	neurotoxic	Disease	D020258	These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.
BC8_BioRED_Task1_Doc411	1883	1890	ecstasy	Chemical	D018817	These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.
BC8_BioRED_Task1_Doc412	0	15	Metallothionein	Chemical	D008668	Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.
BC8_BioRED_Task1_Doc412	34	43	caspase-3	Gene	25402	Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.
BC8_BioRED_Task1_Doc412	57	65	TNFalpha	Gene	24835	Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.
BC8_BioRED_Task1_Doc412	147	157	carmustine	Chemical	D002330	Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.
BC8_BioRED_Task1_Doc412	166	170	rats	OrganismTaxon	10116	Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats.
BC8_BioRED_Task1_Doc412	264	279	metallothionein	Chemical	D008668	On the other hand, induction of metallothionein (MT) by ZnSO(4) and its role in neuroprotection has been documented.
BC8_BioRED_Task1_Doc412	281	283	MT	Chemical	D008668	On the other hand, induction of metallothionein (MT) by ZnSO(4) and its role in neuroprotection has been documented.
BC8_BioRED_Task1_Doc412	288	295	ZnSO(4)	Chemical	D019287	On the other hand, induction of metallothionein (MT) by ZnSO(4) and its role in neuroprotection has been documented.
BC8_BioRED_Task1_Doc412	398	400	MT	Chemical	D008668	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
BC8_BioRED_Task1_Doc412	414	424	carmustine	Chemical	D002330	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
BC8_BioRED_Task1_Doc412	426	430	BCNU	Chemical	D002330	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
BC8_BioRED_Task1_Doc412	452	473	cognitive dysfunction	Disease	D003072	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
BC8_BioRED_Task1_Doc412	477	481	rats	OrganismTaxon	10116	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.
BC8_BioRED_Task1_Doc412	516	520	rats	OrganismTaxon	10116	A total of 60 male Wistar albino rats were randomly divided into four groups (15/group): The control group injected with single doses of normal saline (i.c.v) followed 24 h later by BCNU solvent (i.v).
BC8_BioRED_Task1_Doc412	665	669	BCNU	Chemical	D002330	A total of 60 male Wistar albino rats were randomly divided into four groups (15/group): The control group injected with single doses of normal saline (i.c.v) followed 24 h later by BCNU solvent (i.v).
BC8_BioRED_Task1_Doc412	715	722	ZnSO(4)	Chemical	D019287	The second group administered ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v, once) then BCNU solvent (i.v) after 24 h. Third group received BCNU (20 mg/kg, i.v, once) 24 h after injection with normal saline (i.c.v).
BC8_BioRED_Task1_Doc412	780	784	BCNU	Chemical	D002330	The second group administered ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v, once) then BCNU solvent (i.v) after 24 h. Third group received BCNU (20 mg/kg, i.v, once) 24 h after injection with normal saline (i.c.v).
BC8_BioRED_Task1_Doc412	832	836	BCNU	Chemical	D002330	The second group administered ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v, once) then BCNU solvent (i.v) after 24 h. Third group received BCNU (20 mg/kg, i.v, once) 24 h after injection with normal saline (i.c.v).
BC8_BioRED_Task1_Doc412	947	954	ZnSO(4)	Chemical	D019287	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1006	1010	BCNU	Chemical	D002330	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1077	1081	BCNU	Chemical	D002330	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1109	1156	deterioration of learning and short-term memory	Disease	D007859,D008569	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1247	1268	glutathione reductase	Gene	116686	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1270	1272	GR	Gene	116686	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1295	1306	glutathione	Chemical	D005978	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1308	1311	GSH	Chemical	D005978	Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
BC8_BioRED_Task1_Doc412	1328	1332	BCNU	Chemical	D002330	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1364	1391	tumor necrosis factor-alpha	Gene	24835	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1393	1401	TNFalpha	Gene	24835	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1416	1418	MT	Chemical	D008668	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1423	1438	malondialdehyde	Chemical	D008315	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1440	1443	MDA	Chemical	D008315	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1465	1474	caspase-3	Gene	25402	Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
BC8_BioRED_Task1_Doc412	1525	1532	ZnSO(4)	Chemical	D019287	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1559	1563	BCNU	Chemical	D002330	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1586	1588	GR	Gene	116686	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1606	1609	GSH	Chemical	D005978	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1665	1668	MDA	Chemical	D008315	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1673	1681	TNFalpha	Gene	24835	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1709	1718	caspase-3	Gene	25402	ZnSO(4) pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3.
BC8_BioRED_Task1_Doc412	1778	1782	rats	OrganismTaxon	10116	The histological features were improved in hippocampus of rats treated with ZnSO(4) + BCNU compared to only BCNU-treated animals.
BC8_BioRED_Task1_Doc412	1796	1803	ZnSO(4)	Chemical	D019287	The histological features were improved in hippocampus of rats treated with ZnSO(4) + BCNU compared to only BCNU-treated animals.
BC8_BioRED_Task1_Doc412	1806	1810	BCNU	Chemical	D002330	The histological features were improved in hippocampus of rats treated with ZnSO(4) + BCNU compared to only BCNU-treated animals.
BC8_BioRED_Task1_Doc412	1828	1832	BCNU	Chemical	D002330	The histological features were improved in hippocampus of rats treated with ZnSO(4) + BCNU compared to only BCNU-treated animals.
BC8_BioRED_Task1_Doc412	1865	1867	MT	Chemical	D008668	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	1884	1888	BCNU	Chemical	D002330	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	1909	1917	toxicity	Disease	D064420	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	1934	1936	GR	Gene	116686	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	1952	1955	GSH	Chemical	D005978	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	2007	2015	TNFalpha	Gene	24835	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	2017	2020	MDA	Chemical	D008315	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc412	2025	2034	caspase-3	Gene	25402	In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.
BC8_BioRED_Task1_Doc413	0	33	Brain-derived neurotrophic factor	Gene	24225	Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
BC8_BioRED_Task1_Doc413	45	56	doxorubicin	Chemical	D004317	Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
BC8_BioRED_Task1_Doc413	65	84	cardiac dysfunction	Disease	D006331	Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
BC8_BioRED_Task1_Doc413	104	107	Akt	Gene	24185	Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
BC8_BioRED_Task1_Doc413	122	126	rats	OrganismTaxon	10116	Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
BC8_BioRED_Task1_Doc413	156	167	doxorubicin	Chemical	D004317	The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity.
BC8_BioRED_Task1_Doc413	169	172	Dox	Chemical	D004317	The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity.
BC8_BioRED_Task1_Doc413	210	224	cardiotoxicity	Disease	D066126	The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity.
BC8_BioRED_Task1_Doc413	289	322	brain-derived neurotrophic factor	Gene	24225	Previous studies have suggested the cardioprotective effect of brain-derived neurotrophic factor (BDNF).
BC8_BioRED_Task1_Doc413	324	328	BDNF	Gene	24225	Previous studies have suggested the cardioprotective effect of brain-derived neurotrophic factor (BDNF).
BC8_BioRED_Task1_Doc413	351	355	BDNF	Gene	24225	We hypothesize that BDNF could protect against Dox-induced cardiotoxicity.
BC8_BioRED_Task1_Doc413	378	381	Dox	Chemical	D004317	We hypothesize that BDNF could protect against Dox-induced cardiotoxicity.
BC8_BioRED_Task1_Doc413	390	404	cardiotoxicity	Disease	D066126	We hypothesize that BDNF could protect against Dox-induced cardiotoxicity.
BC8_BioRED_Task1_Doc413	421	425	rats	OrganismTaxon	10116	Sprague Dawley rats were injected with Dox (2.5 mg/kg, 3 times/week, i.p.
BC8_BioRED_Task1_Doc413	445	448	Dox	Chemical	D004317	Sprague Dawley rats were injected with Dox (2.5 mg/kg, 3 times/week, i.p.
BC8_BioRED_Task1_Doc413	524	528	BDNF	Gene	24225	), in the presence or absence of recombinant BDNF (0.4 ug/kg, i.v.)
BC8_BioRED_Task1_Doc413	560	564	H9c2	CellLine	CVCL_0286	H9c2 cells were treated with Dox (1 uM) and/or BDNF (400 ng/ml) for 24 hrs.
BC8_BioRED_Task1_Doc413	589	592	Dox	Chemical	D004317	H9c2 cells were treated with Dox (1 uM) and/or BDNF (400 ng/ml) for 24 hrs.
BC8_BioRED_Task1_Doc413	607	611	BDNF	Gene	24225	H9c2 cells were treated with Dox (1 uM) and/or BDNF (400 ng/ml) for 24 hrs.
BC8_BioRED_Task1_Doc413	656	660	BDNF	Gene	24225	Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro.
BC8_BioRED_Task1_Doc413	669	672	Dox	Chemical	D004317	Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro.
BC8_BioRED_Task1_Doc413	681	695	cardiac injury	Disease	D006331	Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro.
BC8_BioRED_Task1_Doc413	754	758	BDNF	Gene	24225	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	774	777	Dox	Chemical	D004317	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	786	789	rat	OrganismTaxon	10116	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	810	814	BDNF	Gene	24225	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	832	860	tropomyosin-related kinase B	Gene	25054	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	862	866	TrkB	Gene	25054	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	901	905	BDNF	Gene	24225	Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration.
BC8_BioRED_Task1_Doc413	922	955	Brain-derived neurotrophic factor	Gene	24225	Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats.
BC8_BioRED_Task1_Doc413	980	983	Dox	Chemical	D004317	Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats.
BC8_BioRED_Task1_Doc413	1038	1057	cardiac dysfunction	Disease	D006331	Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats.
BC8_BioRED_Task1_Doc413	1061	1065	rats	OrganismTaxon	10116	Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats.
BC8_BioRED_Task1_Doc413	1078	1082	BDNF	Gene	24225	Meanwhile, BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells.
BC8_BioRED_Task1_Doc413	1147	1150	Dox	Chemical	D004317	Meanwhile, BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells.
BC8_BioRED_Task1_Doc413	1159	1163	H9c2	CellLine	CVCL_0286	Meanwhile, BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells.
BC8_BioRED_Task1_Doc413	1229	1233	BDNF	Gene	24225	Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways.
BC8_BioRED_Task1_Doc413	1244	1247	Akt	Gene	24185	Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways.
BC8_BioRED_Task1_Doc413	1281	1310	mammalian target of rapamycin	Gene	56718	Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways.
BC8_BioRED_Task1_Doc413	1315	1318	Bad	Gene	64639	Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways.
BC8_BioRED_Task1_Doc413	1337	1373	p38 mitogen-activated protein kinase	Gene	81649	Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways.
BC8_BioRED_Task1_Doc413	1378	1416	extracellular regulated protein kinase	Gene	116590	Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways.
BC8_BioRED_Task1_Doc413	1465	1469	BDNF	Gene	24225	Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor.
BC8_BioRED_Task1_Doc413	1487	1491	BDNF	Gene	24225	Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor.
BC8_BioRED_Task1_Doc413	1502	1506	TrkB	Gene	25054	Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor.
BC8_BioRED_Task1_Doc413	1513	1516	Akt	Gene	24185	Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor.
BC8_BioRED_Task1_Doc413	1591	1595	BDNF	Gene	24225	In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.
BC8_BioRED_Task1_Doc413	1604	1607	Dox	Chemical	D004317	In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.
BC8_BioRED_Task1_Doc413	1616	1630	cardiotoxicity	Disease	D066126	In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.
BC8_BioRED_Task1_Doc413	1645	1648	Akt	Gene	24185	In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.
BC8_BioRED_Task1_Doc413	1698	1701	Dox	Chemical	D004317	In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.
BC8_BioRED_Task1_Doc413	1705	1711	cancer	Disease	D009369	In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.
BC8_BioRED_Task1_Doc414	8	44	protein arginine methyltransferase 5	Gene	10419	Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
BC8_BioRED_Task1_Doc414	48	60	inflammation	Disease	D007249	Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
BC8_BioRED_Task1_Doc414	110	130	rheumatoid arthritis	Disease	D001172	Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
BC8_BioRED_Task1_Doc414	153	189	protein arginine methyltransferase 5	Gene	10419	To probe the role of protein arginine methyltransferase 5 (PRMT5) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc414	191	196	PRMT5	Gene	10419	To probe the role of protein arginine methyltransferase 5 (PRMT5) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc414	212	224	inflammation	Disease	D007249	To probe the role of protein arginine methyltransferase 5 (PRMT5) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc414	313	321	patients	OrganismTaxon	9606	To probe the role of protein arginine methyltransferase 5 (PRMT5) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc414	327	347	rheumatoid arthritis	Disease	D001172	To probe the role of protein arginine methyltransferase 5 (PRMT5) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc414	349	351	RA	Disease	D001172	To probe the role of protein arginine methyltransferase 5 (PRMT5) in regulating inflammation, cell proliferation, migration and invasion of fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA).
BC8_BioRED_Task1_Doc414	407	415	patients	OrganismTaxon	9606	FLSs were separated from synovial tissues (STs) from patients with RA and osteoarthritis (OA).
BC8_BioRED_Task1_Doc414	421	423	RA	Disease	D001172	FLSs were separated from synovial tissues (STs) from patients with RA and osteoarthritis (OA).
BC8_BioRED_Task1_Doc414	428	442	osteoarthritis	Disease	D010003	FLSs were separated from synovial tissues (STs) from patients with RA and osteoarthritis (OA).
BC8_BioRED_Task1_Doc414	444	446	OA	Disease	D010003	FLSs were separated from synovial tissues (STs) from patients with RA and osteoarthritis (OA).
BC8_BioRED_Task1_Doc414	465	470	PRMT5	Gene	10419	An inhibitor of PRMT5 (EPZ015666) and short interference RNA (siRNA) against PRMT5 were used to inhibit PRMT5 expression.
BC8_BioRED_Task1_Doc414	472	481	EPZ015666	Chemical	C000599896	An inhibitor of PRMT5 (EPZ015666) and short interference RNA (siRNA) against PRMT5 were used to inhibit PRMT5 expression.
BC8_BioRED_Task1_Doc414	526	531	PRMT5	Gene	10419	An inhibitor of PRMT5 (EPZ015666) and short interference RNA (siRNA) against PRMT5 were used to inhibit PRMT5 expression.
BC8_BioRED_Task1_Doc414	553	558	PRMT5	Gene	10419	An inhibitor of PRMT5 (EPZ015666) and short interference RNA (siRNA) against PRMT5 were used to inhibit PRMT5 expression.
BC8_BioRED_Task1_Doc414	687	699	inflammatory	Disease	D007249	The excretion and genetic expression of inflammatory factors were, respectively, estimated by enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (PCR).
BC8_BioRED_Task1_Doc414	966	971	PRMT5	Gene	10419	Increased PRMT5 was discovered in STs and FLSs from patients with RA.
BC8_BioRED_Task1_Doc414	1008	1016	patients	OrganismTaxon	9606	Increased PRMT5 was discovered in STs and FLSs from patients with RA.
BC8_BioRED_Task1_Doc414	1022	1024	RA	Disease	D001172	Increased PRMT5 was discovered in STs and FLSs from patients with RA.
BC8_BioRED_Task1_Doc414	1029	1031	RA	Disease	D001172	In RA FLSs, the level of PRMT5 was up-regulated by stimulation with IL-1b and TNF-a.
BC8_BioRED_Task1_Doc414	1051	1056	PRMT5	Gene	10419	In RA FLSs, the level of PRMT5 was up-regulated by stimulation with IL-1b and TNF-a.
BC8_BioRED_Task1_Doc414	1094	1099	IL-1b	Gene	3553	In RA FLSs, the level of PRMT5 was up-regulated by stimulation with IL-1b and TNF-a.
BC8_BioRED_Task1_Doc414	1104	1109	TNF-a	Gene	7124	In RA FLSs, the level of PRMT5 was up-regulated by stimulation with IL-1b and TNF-a.
BC8_BioRED_Task1_Doc414	1125	1130	PRMT5	Gene	10419	Inhibition of PRMT5 by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of RA FLSs.
BC8_BioRED_Task1_Doc414	1134	1143	EPZ015666	Chemical	C000599896	Inhibition of PRMT5 by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of RA FLSs.
BC8_BioRED_Task1_Doc414	1181	1185	IL-6	Gene	3569	Inhibition of PRMT5 by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of RA FLSs.
BC8_BioRED_Task1_Doc414	1190	1194	IL-8	Gene	3576	Inhibition of PRMT5 by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of RA FLSs.
BC8_BioRED_Task1_Doc414	1228	1230	RA	Disease	D001172	Inhibition of PRMT5 by EPZ015666 and siRNA-mediated knockdown reduced IL-6 and IL-8 production, and proliferation of RA FLSs.
BC8_BioRED_Task1_Doc414	1264	1269	PRMT5	Gene	10419	In addition, inhibition of PRMT5 decreased in vitro migration and invasion of RA FLSs.
BC8_BioRED_Task1_Doc414	1315	1317	RA	Disease	D001172	In addition, inhibition of PRMT5 decreased in vitro migration and invasion of RA FLSs.
BC8_BioRED_Task1_Doc414	1337	1346	EPZ015666	Chemical	C000599896	Furthermore, EPZ015666 restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of p65 as well as AKT in FLSs.
BC8_BioRED_Task1_Doc414	1381	1392	IkB kinaseb	Gene	3551	Furthermore, EPZ015666 restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of p65 as well as AKT in FLSs.
BC8_BioRED_Task1_Doc414	1397	1401	IkBa	Gene	4792	Furthermore, EPZ015666 restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of p65 as well as AKT in FLSs.
BC8_BioRED_Task1_Doc414	1440	1443	p65	Gene	5970	Furthermore, EPZ015666 restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of p65 as well as AKT in FLSs.
BC8_BioRED_Task1_Doc414	1455	1458	AKT	Gene	207	Furthermore, EPZ015666 restrained the phosphorylation of IkB kinaseb and IkBa, as well as nucleus transsituation of p65 as well as AKT in FLSs.
BC8_BioRED_Task1_Doc414	1468	1473	PRMT5	Gene	10419	PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and AKT pathways.
BC8_BioRED_Task1_Doc414	1502	1514	inflammatory	Disease	D007249	PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and AKT pathways.
BC8_BioRED_Task1_Doc414	1570	1572	RA	Disease	D001172	PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and AKT pathways.
BC8_BioRED_Task1_Doc414	1604	1609	NF-kB	Gene	5970	PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and AKT pathways.
BC8_BioRED_Task1_Doc414	1614	1617	AKT	Gene	207	PRMT5 regulated the production of inflammatory factors, cell proliferation, migration and invasion of RA FLS, which was mediated by the NF-kB and AKT pathways.
BC8_BioRED_Task1_Doc414	1662	1667	PRMT5	Gene	10419	Our data suggested that targeting PRMT5 to prevent synovial inflammation and destruction might be a promising therapy for RA.
BC8_BioRED_Task1_Doc414	1679	1700	synovial inflammation	Disease	D013585	Our data suggested that targeting PRMT5 to prevent synovial inflammation and destruction might be a promising therapy for RA.
BC8_BioRED_Task1_Doc414	1750	1752	RA	Disease	D001172	Our data suggested that targeting PRMT5 to prevent synovial inflammation and destruction might be a promising therapy for RA.
BC8_BioRED_Task1_Doc415	0	21	H3 histamine receptor	Gene	11255	H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
BC8_BioRED_Task1_Doc415	45	66	protein kinase Calpha	Gene	5578	H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
BC8_BioRED_Task1_Doc415	90	108	cholangiocarcinoma	Disease	D018281	H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.
BC8_BioRED_Task1_Doc415	131	140	Histamine	Chemical	D006632	Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4).
BC8_BioRED_Task1_Doc415	181	185	HRH1	Gene	3269	Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4).
BC8_BioRED_Task1_Doc415	187	191	HRH2	Gene	3274	Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4).
BC8_BioRED_Task1_Doc415	193	197	HRH3	Gene	11255	Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4).
BC8_BioRED_Task1_Doc415	203	207	HRH4	Gene	59340	Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4).
BC8_BioRED_Task1_Doc415	214	248	d-myo-inositol 1,4,5-trisphosphate	Chemical	D015544	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	250	255	IP(3)	Chemical	D015544	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	257	263	Ca(2+)	Chemical	D002118	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	264	280	protein kinase C	Gene	5578	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	282	285	PKC	Gene	5578	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	287	319	mitogen-activated protein kinase	Gene	5594,5595	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	338	356	cholangiocarcinoma	Disease	D018281	The d-myo-inositol 1,4,5-trisphosphate (IP(3))/Ca(2+)/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	390	394	HRH3	Gene	11255	We evaluated the role of HRH3 in the regulation of cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	416	434	cholangiocarcinoma	Disease	D018281	We evaluated the role of HRH3 in the regulation of cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	457	461	HRH3	Gene	11255	Expression of HRH3 in intrahepatic and extrahepatic cell lines, normal cholangiocytes, and human tissue arrays was measured.
BC8_BioRED_Task1_Doc415	534	539	human	OrganismTaxon	9606	Expression of HRH3 in intrahepatic and extrahepatic cell lines, normal cholangiocytes, and human tissue arrays was measured.
BC8_BioRED_Task1_Doc415	571	579	Mz-ChA-1	CellLine	CVCL_6932	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	602	648	(R)-(alpha)-(-)-methylhistamine dihydrobromide	Chemical	C069357	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	650	654	RAMH	Chemical	C069357	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	690	695	IP(3)	Chemical	D015544	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	700	710	cyclic AMP	Chemical	D000242	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	746	749	PKC	Gene	5578	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	754	786	mitogen-activated protein kinase	Gene	5594,5595	In Mz-ChA-1 cells stimulated with (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP(3) and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms.
BC8_BioRED_Task1_Doc415	813	821	PKCalpha	Gene	5578	Localization of PKCalpha was visualized by immunofluorescence in cell smears and immunoblotting for PKCalpha in cytosol and membrane fractions.
BC8_BioRED_Task1_Doc415	897	905	PKCalpha	Gene	5578	Localization of PKCalpha was visualized by immunofluorescence in cell smears and immunoblotting for PKCalpha in cytosol and membrane fractions.
BC8_BioRED_Task1_Doc415	964	972	PKCalpha	Gene	5578	Following knockdown of PKCalpha, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	974	982	Mz-ChA-1	CellLine	CVCL_6932	Following knockdown of PKCalpha, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1010	1014	RAMH	Chemical	C069357	Following knockdown of PKCalpha, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1049	1096	extracellular signal-regulated kinase (ERK)-1/2	Gene	5595,5594	Following knockdown of PKCalpha, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1147	1153	BALB/c	CellLine	CVCL_9101	In vivo experiments were done in BALB/c nude mice.
BC8_BioRED_Task1_Doc415	1159	1163	mice	OrganismTaxon	10090	In vivo experiments were done in BALB/c nude mice.
BC8_BioRED_Task1_Doc415	1165	1169	Mice	OrganismTaxon	10090	Mice were treated with saline or RAMH for 44 days and tumor volume was measured.
BC8_BioRED_Task1_Doc415	1198	1202	RAMH	Chemical	C069357	Mice were treated with saline or RAMH for 44 days and tumor volume was measured.
BC8_BioRED_Task1_Doc415	1219	1224	tumor	Disease	D009369	Mice were treated with saline or RAMH for 44 days and tumor volume was measured.
BC8_BioRED_Task1_Doc415	1246	1252	Tumors	Disease	D009369	Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3.
BC8_BioRED_Task1_Doc415	1328	1336	PKCalpha	Gene	5578	Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3.
BC8_BioRED_Task1_Doc415	1338	1381	vascular endothelial growth factor (VEGF)-A	Gene	7422	Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3.
BC8_BioRED_Task1_Doc415	1383	1389	VEGF-C	Gene	7424	Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3.
BC8_BioRED_Task1_Doc415	1391	1406	VEGF receptor 2	Gene	3791	Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3.
BC8_BioRED_Task1_Doc415	1412	1427	VEGF receptor 3	Gene	2324	Tumors were excised and evaluated for proliferation, apoptosis, and expression of PKCalpha, vascular endothelial growth factor (VEGF)-A, VEGF-C, VEGF receptor 2, and VEGF receptor 3.
BC8_BioRED_Task1_Doc415	1429	1433	HRH3	Gene	11255	HRH3 expression was found in all cells.
BC8_BioRED_Task1_Doc415	1469	1473	RAMH	Chemical	C069357	RAMH inhibited the growth of cholangiocarcinoma cells.
BC8_BioRED_Task1_Doc415	1498	1516	cholangiocarcinoma	Disease	D018281	RAMH inhibited the growth of cholangiocarcinoma cells.
BC8_BioRED_Task1_Doc415	1524	1528	RAMH	Chemical	C069357	RAMH increased IP(3) levels and PKCalpha phosphorylation and decreased ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1539	1544	IP(3)	Chemical	D015544	RAMH increased IP(3) levels and PKCalpha phosphorylation and decreased ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1556	1564	PKCalpha	Gene	5578	RAMH increased IP(3) levels and PKCalpha phosphorylation and decreased ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1595	1601	ERK1/2	Gene	5595,5594	RAMH increased IP(3) levels and PKCalpha phosphorylation and decreased ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1619	1623	RAMH	Chemical	C069357	RAMH induced a shift in the localization of PKCalpha expression from the cytosolic domain into the membrane region of Mz-ChA-1 cells.
BC8_BioRED_Task1_Doc415	1663	1671	PKCalpha	Gene	5578	RAMH induced a shift in the localization of PKCalpha expression from the cytosolic domain into the membrane region of Mz-ChA-1 cells.
BC8_BioRED_Task1_Doc415	1737	1745	Mz-ChA-1	CellLine	CVCL_6932	RAMH induced a shift in the localization of PKCalpha expression from the cytosolic domain into the membrane region of Mz-ChA-1 cells.
BC8_BioRED_Task1_Doc415	1766	1774	PKCalpha	Gene	5578	Silencing of PKCalpha prevented RAMH inhibition of Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1785	1789	RAMH	Chemical	C069357	Silencing of PKCalpha prevented RAMH inhibition of Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1804	1812	Mz-ChA-1	CellLine	CVCL_6932	Silencing of PKCalpha prevented RAMH inhibition of Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1837	1841	RAMH	Chemical	C069357	Silencing of PKCalpha prevented RAMH inhibition of Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1853	1859	ERK1/2	Gene	5595,5594	Silencing of PKCalpha prevented RAMH inhibition of Mz-ChA-1 cell growth and ablated RAMH effects on ERK1/2 phosphorylation.
BC8_BioRED_Task1_Doc415	1886	1890	RAMH	Chemical	C069357	In vivo, RAMH decreased tumor growth and expression of VEGF and its receptors; PKCalpha expression was increased.
BC8_BioRED_Task1_Doc415	1901	1906	tumor	Disease	D009369	In vivo, RAMH decreased tumor growth and expression of VEGF and its receptors; PKCalpha expression was increased.
BC8_BioRED_Task1_Doc415	1932	1936	VEGF	Gene	7422,7424	In vivo, RAMH decreased tumor growth and expression of VEGF and its receptors; PKCalpha expression was increased.
BC8_BioRED_Task1_Doc415	1956	1964	PKCalpha	Gene	5578	In vivo, RAMH decreased tumor growth and expression of VEGF and its receptors; PKCalpha expression was increased.
BC8_BioRED_Task1_Doc415	1991	1995	RAMH	Chemical	C069357	RAMH inhibits cholangiocarcinoma growth by PKCalpha-dependent ERK1/2 dephosphorylation.
BC8_BioRED_Task1_Doc415	2005	2023	cholangiocarcinoma	Disease	D018281	RAMH inhibits cholangiocarcinoma growth by PKCalpha-dependent ERK1/2 dephosphorylation.
BC8_BioRED_Task1_Doc415	2034	2042	PKCalpha	Gene	5578	RAMH inhibits cholangiocarcinoma growth by PKCalpha-dependent ERK1/2 dephosphorylation.
BC8_BioRED_Task1_Doc415	2053	2059	ERK1/2	Gene	5595,5594	RAMH inhibits cholangiocarcinoma growth by PKCalpha-dependent ERK1/2 dephosphorylation.
BC8_BioRED_Task1_Doc415	2093	2101	PKCalpha	Gene	5578	Modulation of PKCalpha by histamine receptors may be important in regulating cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	2105	2124	histamine receptors	Gene	11255,3269,3274,59340	Modulation of PKCalpha by histamine receptors may be important in regulating cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc415	2156	2174	cholangiocarcinoma	Disease	D018281	Modulation of PKCalpha by histamine receptors may be important in regulating cholangiocarcinoma growth.
BC8_BioRED_Task1_Doc416	27	50	extrapyramidal symptoms	Disease	D001480	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
BC8_BioRED_Task1_Doc416	52	55	EPS	Disease	D001480	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
BC8_BioRED_Task1_Doc416	62	72	quetiapine	Chemical	C069541	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
BC8_BioRED_Task1_Doc416	98	106	patients	OrganismTaxon	9606	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
BC8_BioRED_Task1_Doc416	112	125	bipolar mania	Disease	D001714	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
BC8_BioRED_Task1_Doc416	151	174	extrapyramidal symptoms	Disease	D001480	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
BC8_BioRED_Task1_Doc416	176	179	EPS	Disease	D001480	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
BC8_BioRED_Task1_Doc416	192	201	akathisia	Disease	D017109	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
BC8_BioRED_Task1_Doc416	208	218	quetiapine	Chemical	C069541	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
BC8_BioRED_Task1_Doc416	222	230	patients	OrganismTaxon	9606	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
BC8_BioRED_Task1_Doc416	236	249	bipolar mania	Disease	D001714	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
BC8_BioRED_Task1_Doc416	380	390	quetiapine	Chemical	C069541	Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.
BC8_BioRED_Task1_Doc416	463	470	lithium	Chemical	D008094	Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.
BC8_BioRED_Task1_Doc416	474	485	haloperidol	Chemical	D006220	Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.
BC8_BioRED_Task1_Doc416	551	561	quetiapine	Chemical	C069541	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	620	627	lithium	Chemical	D008094	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	631	641	divalproex	Chemical	D014635	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	643	646	QTP	Chemical	C069541	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	649	651	Li	Chemical	D008094	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	652	655	DVP	Chemical	D014635	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	714	716	Li	Chemical	D008094	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	717	720	DVP	Chemical	D014635	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).
BC8_BioRED_Task1_Doc416	733	756	Extrapyramidal symptoms	Disease	D001480	Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.
BC8_BioRED_Task1_Doc416	877	897	anticholinergic drug	Chemical	D018680	Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.
BC8_BioRED_Task1_Doc416	931	934	EPS	Disease	D001480	RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).
BC8_BioRED_Task1_Doc416	969	978	akathisia	Disease	D017109	RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).
BC8_BioRED_Task1_Doc416	1002	1012	quetiapine	Chemical	C069541	RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).
BC8_BioRED_Task1_Doc416	1071	1074	EPS	Disease	D001480	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
BC8_BioRED_Task1_Doc416	1103	1106	QTP	Chemical	C069541	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
BC8_BioRED_Task1_Doc416	1109	1111	Li	Chemical	D008094	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
BC8_BioRED_Task1_Doc416	1112	1115	DVP	Chemical	D014635	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
BC8_BioRED_Task1_Doc416	1158	1160	Li	Chemical	D008094	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
BC8_BioRED_Task1_Doc416	1161	1164	DVP	Chemical	D014635	Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
BC8_BioRED_Task1_Doc416	1200	1203	EPS	Disease	D001480	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
BC8_BioRED_Task1_Doc416	1225	1233	patients	OrganismTaxon	9606	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
BC8_BioRED_Task1_Doc416	1247	1258	haloperidol	Chemical	D006220	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
BC8_BioRED_Task1_Doc416	1298	1306	patients	OrganismTaxon	9606	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
BC8_BioRED_Task1_Doc416	1320	1327	lithium	Chemical	D008094	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
BC8_BioRED_Task1_Doc416	1387	1390	EPS	Disease	D001480	Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
BC8_BioRED_Task1_Doc416	1409	1418	akathisia	Disease	D017109	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1444	1454	quetiapine	Chemical	C069541	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1503	1506	QTP	Chemical	C069541	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1509	1511	Li	Chemical	D008094	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1512	1515	DVP	Chemical	D014635	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1533	1535	Li	Chemical	D008094	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1536	1539	DVP	Chemical	D014635	The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
BC8_BioRED_Task1_Doc416	1548	1555	Lithium	Chemical	D008094	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1623	1629	tremor	Disease	D014202	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1643	1653	quetiapine	Chemical	C069541	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1673	1679	tremor	Disease	D014202	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1716	1723	lithium	Chemical	D008094	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1770	1776	tremor	Disease	D014202	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1780	1788	patients	OrganismTaxon	9606	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1799	1806	lithium	Chemical	D008094	Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
BC8_BioRED_Task1_Doc416	1816	1827	Haloperidol	Chemical	D006220	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
BC8_BioRED_Task1_Doc416	1884	1893	akathisia	Disease	D017109	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
BC8_BioRED_Task1_Doc416	1915	1921	tremor	Disease	D014202	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
BC8_BioRED_Task1_Doc416	1947	1970	extrapyramidal syndrome	Disease	D001480	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
BC8_BioRED_Task1_Doc416	1996	2006	quetiapine	Chemical	C069541	Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
BC8_BioRED_Task1_Doc416	2057	2067	quetiapine	Chemical	C069541	No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
BC8_BioRED_Task1_Doc416	2104	2119	Anticholinergic	Chemical	D018680	Anticholinergic use was low and similar with quetiapine or placebo.
BC8_BioRED_Task1_Doc416	2149	2159	quetiapine	Chemical	C069541	Anticholinergic use was low and similar with quetiapine or placebo.
BC8_BioRED_Task1_Doc416	2188	2201	bipolar mania	Disease	D001714	CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.
BC8_BioRED_Task1_Doc416	2220	2223	EPS	Disease	D001480	CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.
BC8_BioRED_Task1_Doc416	2235	2244	akathisia	Disease	D017109	CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.
BC8_BioRED_Task1_Doc416	2251	2261	quetiapine	Chemical	C069541	CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.
BC8_BioRED_Task1_Doc417	32	39	Ghrelin	Gene	58991	Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
BC8_BioRED_Task1_Doc417	44	61	Glucagon Receptor	Gene	14527	Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade.
BC8_BioRED_Task1_Doc417	72	89	Glucagon receptor	Gene	2642	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	91	95	GcgR	Gene	2642	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	145	152	insulin	Gene	3630	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	178	193	type 1 diabetes	Disease	D003922	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	226	231	GcgRs	Gene	2642	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	241	254	hyperglycemia	Disease	D006943	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	268	276	diabetes	Disease	D003920	Glucagon receptor (GcgR) blockade has been proposed as an alternative to insulin monotherapy for treating type 1 diabetes since deletion or inhibition of GcgRs corrects hyperglycemia in models of diabetes.
BC8_BioRED_Task1_Doc417	301	309	glycemia	Chemical	D001786	The factors regulating glycemia in a setting devoid of insulin and glucagon function remain unclear but may include the hormone ghrelin.
BC8_BioRED_Task1_Doc417	333	340	insulin	Gene	3630	The factors regulating glycemia in a setting devoid of insulin and glucagon function remain unclear but may include the hormone ghrelin.
BC8_BioRED_Task1_Doc417	345	353	glucagon	Gene	2641	The factors regulating glycemia in a setting devoid of insulin and glucagon function remain unclear but may include the hormone ghrelin.
BC8_BioRED_Task1_Doc417	406	413	ghrelin	Gene	51738	The factors regulating glycemia in a setting devoid of insulin and glucagon function remain unclear but may include the hormone ghrelin.
BC8_BioRED_Task1_Doc417	427	434	ghrelin	Gene	51738	Not only is ghrelin release controlled by glucose but also ghrelin has many actions that can raise or reduce falls in blood glucose level.
BC8_BioRED_Task1_Doc417	457	464	glucose	Chemical	D005947	Not only is ghrelin release controlled by glucose but also ghrelin has many actions that can raise or reduce falls in blood glucose level.
BC8_BioRED_Task1_Doc417	474	481	ghrelin	Gene	51738	Not only is ghrelin release controlled by glucose but also ghrelin has many actions that can raise or reduce falls in blood glucose level.
BC8_BioRED_Task1_Doc417	533	546	blood glucose	Chemical	D001786	Not only is ghrelin release controlled by glucose but also ghrelin has many actions that can raise or reduce falls in blood glucose level.
BC8_BioRED_Task1_Doc417	590	597	ghrelin	Gene	58991	Here, we tested the hypothesis that ghrelin rises to prevent hypoglycemia in the absence of glucagon function.
BC8_BioRED_Task1_Doc417	615	627	hypoglycemia	Disease	D007003	Here, we tested the hypothesis that ghrelin rises to prevent hypoglycemia in the absence of glucagon function.
BC8_BioRED_Task1_Doc417	646	654	glucagon	Gene	14526	Here, we tested the hypothesis that ghrelin rises to prevent hypoglycemia in the absence of glucagon function.
BC8_BioRED_Task1_Doc417	670	674	GcgR	Gene	14527	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	685	689	Gcgr	Gene	14527	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	696	700	mice	OrganismTaxon	10090	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	711	715	mice	OrganismTaxon	10090	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	739	743	GcgR	Gene	14527	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	780	793	blood glucose	Chemical	D001786	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	832	839	ghrelin	Gene	58991	Both GcgR knockout (Gcgr(-/-)) mice and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghrelin levels.
BC8_BioRED_Task1_Doc417	900	914	streptozotocin	Chemical	D013311	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	923	936	hyperglycemia	Disease	D006943	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	955	962	ghrelin	Gene	58991	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	983	987	mice	OrganismTaxon	10090	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	989	1002	hyperglycemia	Disease	D006943	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	1036	1040	Gcgr	Gene	14527	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	1046	1050	mice	OrganismTaxon	10090	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	1066	1073	ghrelin	Gene	58991	Although treatment with the pancreatic b-cell toxin streptozotocin induced hyperglycemia and raised plasma ghrelin levels in wild-type mice, hyperglycemia was averted in similarly treated Gcgr(-/-) mice and the plasma ghrelin level was further increased.
BC8_BioRED_Task1_Doc417	1132	1148	ghrelin receptor	Gene	208188	Notably, administration of a ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.
BC8_BioRED_Task1_Doc417	1176	1189	blood glucose	Chemical	D001786	Notably, administration of a ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.
BC8_BioRED_Task1_Doc417	1255	1269	streptozotocin	Chemical	D013311	Notably, administration of a ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.
BC8_BioRED_Task1_Doc417	1278	1282	Gcgr	Gene	14527	Notably, administration of a ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.
BC8_BioRED_Task1_Doc417	1288	1292	mice	OrganismTaxon	10090	Notably, administration of a ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.
BC8_BioRED_Task1_Doc417	1304	1317	blood glucose	Chemical	D001786	A lowered blood glucose level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that were administered GcgR monoclonal antibody.
BC8_BioRED_Task1_Doc417	1363	1377	streptozotocin	Chemical	D013311	A lowered blood glucose level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that were administered GcgR monoclonal antibody.
BC8_BioRED_Task1_Doc417	1386	1402	ghrelin receptor	Gene	208188	A lowered blood glucose level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that were administered GcgR monoclonal antibody.
BC8_BioRED_Task1_Doc417	1408	1412	mice	OrganismTaxon	10090	A lowered blood glucose level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that were administered GcgR monoclonal antibody.
BC8_BioRED_Task1_Doc417	1436	1440	GcgR	Gene	14527	A lowered blood glucose level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that were administered GcgR monoclonal antibody.
BC8_BioRED_Task1_Doc417	1491	1499	glucagon	Gene	14526	These data suggest that when glucagon activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, preventing hypoglycemia.
BC8_BioRED_Task1_Doc417	1538	1553	type 1 diabetes	Disease	D003922	These data suggest that when glucagon activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, preventing hypoglycemia.
BC8_BioRED_Task1_Doc417	1566	1573	ghrelin	Gene	58991	These data suggest that when glucagon activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, preventing hypoglycemia.
BC8_BioRED_Task1_Doc417	1598	1610	hypoglycemia	Disease	D007003	These data suggest that when glucagon activity is blocked in the setting of type 1 diabetes, the plasma ghrelin level rises, preventing hypoglycemia.
BC8_BioRED_Task1_Doc418	0	15	mToR inhibitors	Chemical	-	mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
BC8_BioRED_Task1_Doc418	24	35	proteinuria	Disease	D011507	mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
BC8_BioRED_Task1_Doc418	153	175	calcineurin inhibitors	Chemical	D065095	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.
BC8_BioRED_Task1_Doc418	179	226	mammalian target of rapamycin (mToR) inhibitors	Chemical	-	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.
BC8_BioRED_Task1_Doc418	239	248	sirolimus	Chemical	D020123	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.
BC8_BioRED_Task1_Doc418	286	315	chronic allograft nephropathy	Disease	D051436	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.
BC8_BioRED_Task1_Doc418	325	336	proteinuria	Disease	D011507	Because proteinuria is a major predictive factor of poor transplantation outcome, many studies focused on this adverse event during the past years.
BC8_BioRED_Task1_Doc418	473	484	proteinuria	Disease	D011507	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	496	505	sirolimus	Chemical	D020123	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	531	553	calcineurin inhibitors	Chemical	D065095	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	600	611	proteinuria	Disease	D011507	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	637	646	sirolimus	Chemical	D020123	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	687	695	patients	OrganismTaxon	9606	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	709	718	sirolimus	Chemical	D020123	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
BC8_BioRED_Task1_Doc418	764	782	glomerulosclerosis	Disease	D005921	Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.
BC8_BioRED_Task1_Doc418	804	808	mToR	Gene	2475	Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.
BC8_BioRED_Task1_Doc418	828	836	patients	OrganismTaxon	9606	Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.
BC8_BioRED_Task1_Doc418	965	969	mToR	Gene	2475	We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.
BC8_BioRED_Task1_Doc418	987	998	proteinuria	Disease	D011507	We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.
BC8_BioRED_Task1_Doc419	42	54	temsirolimus	Chemical	C401859	Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
BC8_BioRED_Task1_Doc419	69	89	mantle cell lymphoma	Disease	D020522	Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
BC8_BioRED_Task1_Doc419	91	111	Mantle cell lymphoma	Disease	D020522	Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
BC8_BioRED_Task1_Doc419	113	116	MCL	Disease	D020522	Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
BC8_BioRED_Task1_Doc419	151	180	B-cell non-Hodgkin's lymphoma	Disease	D008228	Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell non-Hodgkin's lymphoma.
BC8_BioRED_Task1_Doc419	182	190	Patients	OrganismTaxon	9606	Patients become progressively refractory to conventional chemotherapy, and their prognosis is poor.
BC8_BioRED_Task1_Doc419	353	356	MCL	Disease	D020522	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
BC8_BioRED_Task1_Doc419	370	382	temsirolimus	Chemical	C401859	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
BC8_BioRED_Task1_Doc419	386	390	mTOR	Gene	2475	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
BC8_BioRED_Task1_Doc419	459	462	MCL	Disease	D020522	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
BC8_BioRED_Task1_Doc419	471	476	tumor	Disease	D009369	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
BC8_BioRED_Task1_Doc419	505	517	temsirolimus	Chemical	C401859	However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
BC8_BioRED_Task1_Doc419	652	664	temsirolimus	Chemical	C401859	In this case, lymph node biopsies were performed before and six months after temsirolimus therapy.
BC8_BioRED_Task1_Doc419	717	729	temsirolimus	Chemical	C401859	Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
BC8_BioRED_Task1_Doc419	740	745	tumor	Disease	D009369	Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
BC8_BioRED_Task1_Doc419	849	854	tumor	Disease	D009369	Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
BC8_BioRED_Task1_Doc419	897	909	temsirolimus	Chemical	C401859	Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
BC8_BioRED_Task1_Doc419	956	961	tumor	Disease	D009369	Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
BC8_BioRED_Task1_Doc419	989	993	VEGF	Gene	7422	Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
BC8_BioRED_Task1_Doc419	1083	1091	necrotic	Disease	D009336	Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
BC8_BioRED_Task1_Doc419	1132	1144	temsirolimus	Chemical	C401859	Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
BC8_BioRED_Task1_Doc419	1160	1172	temsirolimus	Chemical	C401859	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
BC8_BioRED_Task1_Doc419	1181	1186	tumor	Disease	D009369	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
BC8_BioRED_Task1_Doc419	1272	1284	temsirolimus	Chemical	C401859	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
BC8_BioRED_Task1_Doc419	1288	1293	tumor	Disease	D009369	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
BC8_BioRED_Task1_Doc419	1368	1371	MCL	Disease	D020522	Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.
BC8_BioRED_Task1_Doc420	18	69	left ventricular systolic and diastolic dysfunction	Disease	D018487	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.
BC8_BioRED_Task1_Doc420	99	110	epinephrine	Chemical	D004837	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.
BC8_BioRED_Task1_Doc420	121	134	Catecholamine	Chemical	D002395	Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.
BC8_BioRED_Task1_Doc420	143	157	cardiomyopathy	Disease	D009202	Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.
BC8_BioRED_Task1_Doc420	194	208	catecholamines	Chemical	D002395	Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.
BC8_BioRED_Task1_Doc420	291	313	myocardial dysfunction	Disease	D009202	In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.
BC8_BioRED_Task1_Doc420	371	376	woman	OrganismTaxon	9606	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
BC8_BioRED_Task1_Doc420	436	447	epinephrine	Chemical	D004837	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
BC8_BioRED_Task1_Doc420	458	477	myocardial stunning	Disease	D017682	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
BC8_BioRED_Task1_Doc420	563	614	left ventricular systolic and diastolic dysfunction	Disease	D018487	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
BC8_BioRED_Task1_Doc420	666	685	myocardial necrosis	Disease	D009202	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.
BC8_BioRED_Task1_Doc421	17	25	deafness	Disease	D003638	Low frequency of deafness-associated GJB2 variants in Kenya and Sudan and novel GJB2 variants.
BC8_BioRED_Task1_Doc421	37	41	GJB2	Gene	2706	Low frequency of deafness-associated GJB2 variants in Kenya and Sudan and novel GJB2 variants.
BC8_BioRED_Task1_Doc421	80	84	GJB2	Gene	2706	Low frequency of deafness-associated GJB2 variants in Kenya and Sudan and novel GJB2 variants.
BC8_BioRED_Task1_Doc421	117	159	non-syndromic autosomal recessive deafness	Disease	C567134	A large proportion of non-syndromic autosomal recessive deafness (NSARD) in many populations is caused by variants of the GJB2 gene.
BC8_BioRED_Task1_Doc421	161	166	NSARD	Disease	C567134	A large proportion of non-syndromic autosomal recessive deafness (NSARD) in many populations is caused by variants of the GJB2 gene.
BC8_BioRED_Task1_Doc421	217	221	GJB2	Gene	2706	A large proportion of non-syndromic autosomal recessive deafness (NSARD) in many populations is caused by variants of the GJB2 gene.
BC8_BioRED_Task1_Doc421	251	255	GJB2	Gene	2706	Here, the frequency of GJB2 variants was studied in 406 and 183 apparently unrelated children from Kenya and Sudan, respectively, with mostly severe to profound non-syndromic deafness.
BC8_BioRED_Task1_Doc421	389	411	non-syndromic deafness	Disease	D003638	Here, the frequency of GJB2 variants was studied in 406 and 183 apparently unrelated children from Kenya and Sudan, respectively, with mostly severe to profound non-syndromic deafness.
BC8_BioRED_Task1_Doc421	538	542	GJB2	Gene	2706	Nine (2.2 %) Kenyan and 12 (6.6 %) of the Sudanese children only were carriers of variants within the coding sequence of the GJB2 gene.
BC8_BioRED_Task1_Doc421	729	733	GJB2	Gene	2706	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	749	760	g.3318-6T>A	SequenceVariant	g|SUB|T|3318-6|A	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	762	774	g.3318-15C>T	SequenceVariant	g|SUB|C|3318-15|T	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	776	788	g.3318-34C>T	SequenceVariant	g|SUB|C|3318-34|T	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	790	802	g.3318-35T>G	SequenceVariant	g|SUB|T|3318-35|G	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	829	843	g.3455_3460del	SequenceVariant	g|DEL|3455_3460|	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	845	867	p.Asp46_Gln48delinsGlu	SequenceVariant	p|INDEL|46_48|Glu	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	906	915	g.3512C>A	SequenceVariant	rs763572195	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	917	925	p.Tyr65X	SequenceVariant	rs763572195	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	950	959	g.3395C>T	SequenceVariant	g|SUB|C|3395|T	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	961	968	p.Thr26	SequenceVariant	p|Allele|T|26	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	971	980	g.3503C>T	SequenceVariant	g|SUB|C|3503|T	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	982	989	p.Asn62	SequenceVariant	p|Allele|N|62	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	992	1001	g.3627A>C	SequenceVariant	g|SUB|A|3627|C	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	1003	1011	p.Arg104	SequenceVariant	p|Allele|R|104	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	1047	1056	g.3816C>A	SequenceVariant	rs111033360	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	1058	1069	p.Val167Met	SequenceVariant	rs111033360	A total of 10 novel variants was recognized, among them four variants in the adjacent 5'-region of the GJB2 coding exon 2 (g.3318-6T>A, g.3318-15C>T, g.3318-34C>T, g.3318-35T>G), a 6 base-pair deletion (g.3455_3460del [p.Asp46_Gln48delinsGlu]), a variant leading to a stop codon (g.3512C>A [p.Tyr65X]), synonymous variants (g.3395C>T [p.Thr26], g.3503C>T [p.Asn62], g.3627A>C [p.Arg104]), and one non-synonymous variant (g.3816C>A [p.Val167Met]).
BC8_BioRED_Task1_Doc421	1120	1130	g.3352delG	SequenceVariant	g|DEL|3352|G	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1152	1158	30delG	SequenceVariant	c|DEL|30|G	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1162	1169	35 delG	SequenceVariant	c|DEL|35|G	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1172	1181	g.3426G>A	SequenceVariant	rs72474224	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1183	1193	p.Val37Ile	SequenceVariant	rs72474224	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1196	1205	g.3697G>A	SequenceVariant	rs111033196	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1207	1218	p.Arg127His	SequenceVariant	rs111033196	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1221	1230	g.3774G>A	SequenceVariant	rs111033186	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1232	1243	p.Val153Ile	SequenceVariant	rs111033186	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1250	1259	g.3795G>A	SequenceVariant	rs34988750	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1261	1272	p.Gly160Ser	SequenceVariant	rs34988750	In addition, the previously described variants g.3352delG (commonly designated 30delG or 35 delG), g.3426G>A [p.Val37Ile], g.3697G>A [p.Arg127His], g.3774G>A [p.Val153Ile], and g.3795G>A [p.Gly160Ser] were identified.
BC8_BioRED_Task1_Doc421	1313	1325	g.3318-34C>T	SequenceVariant	g|SUB|C|3318-34|T	With the exception of g.3318-34C>T and g.3352delG, all variants occurred heterozygously.
BC8_BioRED_Task1_Doc421	1330	1340	g.3352delG	SequenceVariant	g|DEL|3352|G	With the exception of g.3318-34C>T and g.3352delG, all variants occurred heterozygously.
BC8_BioRED_Task1_Doc421	1490	1495	NSARD	Disease	C567134	For most of the variants identified in the Kenyan and Sudanese study population, a causative association with NSARD appears to be unlikely.
BC8_BioRED_Task1_Doc421	1558	1566	deafness	Disease	D003638	Compared to many other ethnic groups, deafness-associated variants of the coding region of GJB2 are rare in Sudan and Kenya, suggesting a role of other genetic, or epigenetic factors as a cause for deafness in these countries.
BC8_BioRED_Task1_Doc421	1611	1615	GJB2	Gene	2706	Compared to many other ethnic groups, deafness-associated variants of the coding region of GJB2 are rare in Sudan and Kenya, suggesting a role of other genetic, or epigenetic factors as a cause for deafness in these countries.
BC8_BioRED_Task1_Doc421	1718	1726	deafness	Disease	D003638	Compared to many other ethnic groups, deafness-associated variants of the coding region of GJB2 are rare in Sudan and Kenya, suggesting a role of other genetic, or epigenetic factors as a cause for deafness in these countries.
BC8_BioRED_Task1_Doc422	0	8	Curcumin	Chemical	D003474	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
BC8_BioRED_Task1_Doc422	21	42	cognitive dysfunction	Disease	D003072	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
BC8_BioRED_Task1_Doc422	67	81	phenobarbitone	Chemical	D010634	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
BC8_BioRED_Task1_Doc422	86	99	carbamazepine	Chemical	D002220	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
BC8_BioRED_Task1_Doc422	113	117	rats	OrganismTaxon	10116	Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
BC8_BioRED_Task1_Doc422	123	142	antiepileptic drugs	Chemical	D000927	The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
BC8_BioRED_Task1_Doc422	144	158	phenobarbitone	Chemical	D010634	The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
BC8_BioRED_Task1_Doc422	163	176	carbamazepine	Chemical	D002220	The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
BC8_BioRED_Task1_Doc422	201	221	cognitive impairment	Disease	D003072	The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
BC8_BioRED_Task1_Doc422	336	356	cognitive impairment	Disease	D003072	The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.
BC8_BioRED_Task1_Doc422	360	379	antiepileptic drugs	Chemical	D000927	The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.
BC8_BioRED_Task1_Doc422	381	389	Curcumin	Chemical	D003474	Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.
BC8_BioRED_Task1_Doc422	400	411	antioxidant	Chemical	D000975	Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.
BC8_BioRED_Task1_Doc422	418	430	inflammatory	Disease	D007249	Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.
BC8_BioRED_Task1_Doc422	546	554	curcumin	Chemical	D003474	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
BC8_BioRED_Task1_Doc422	573	587	phenobarbitone	Chemical	D010634	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
BC8_BioRED_Task1_Doc422	593	606	carbamazepine	Chemical	D002220	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
BC8_BioRED_Task1_Doc422	615	635	cognitive impairment	Disease	D003072	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
BC8_BioRED_Task1_Doc422	660	664	rats	OrganismTaxon	10116	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.
BC8_BioRED_Task1_Doc422	698	706	curcumin	Chemical	D003474	Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.
BC8_BioRED_Task1_Doc422	712	726	phenobarbitone	Chemical	D010634	Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.
BC8_BioRED_Task1_Doc422	731	744	carbamazepine	Chemical	D002220	Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.
BC8_BioRED_Task1_Doc422	828	832	rats	OrganismTaxon	10116	Vehicle/drugs were administered daily for 21days to male Wistar rats.
BC8_BioRED_Task1_Doc422	963	977	phenobarbitone	Chemical	D010634	At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.
BC8_BioRED_Task1_Doc422	982	995	carbamazepine	Chemical	D002220	At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.
BC8_BioRED_Task1_Doc422	1009	1024	malondialdehyde	Chemical	D008315	At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.
BC8_BioRED_Task1_Doc422	1037	1048	glutathione	Chemical	D005978	At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.
BC8_BioRED_Task1_Doc422	1094	1108	phenobarbitone	Chemical	D010634	The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.
BC8_BioRED_Task1_Doc422	1113	1126	carbamazepine	Chemical	D002220	The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.
BC8_BioRED_Task1_Doc422	1159	1192	impairment of learning and memory	Disease	D003072	The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.
BC8_BioRED_Task1_Doc422	1247	1255	curcumin	Chemical	D003474	Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.
BC8_BioRED_Task1_Doc422	1285	1305	cognitive impairment	Disease	D003072	Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.
BC8_BioRED_Task1_Doc422	1368	1387	antiepileptic drugs	Chemical	D000927	Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.
BC8_BioRED_Task1_Doc422	1389	1397	Curcumin	Chemical	D003474	Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.
BC8_BioRED_Task1_Doc422	1493	1507	phenobarbitone	Chemical	D010634	Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.
BC8_BioRED_Task1_Doc422	1519	1532	carbamazepine	Chemical	D002220	Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.
BC8_BioRED_Task1_Doc422	1558	1566	curcumin	Chemical	D003474	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
BC8_BioRED_Task1_Doc422	1607	1643	deterioration of cognitive functions	Disease	D003072	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
BC8_BioRED_Task1_Doc422	1668	1672	rats	OrganismTaxon	10116	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
BC8_BioRED_Task1_Doc422	1686	1700	phenobarbitone	Chemical	D010634	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
BC8_BioRED_Task1_Doc422	1705	1718	carbamazepine	Chemical	D002220	These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
BC8_BioRED_Task1_Doc422	1804	1812	curcumin	Chemical	D003474	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.
BC8_BioRED_Task1_Doc422	1877	1891	phenobarbitone	Chemical	D010634	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.
BC8_BioRED_Task1_Doc422	1896	1909	carbamazepine	Chemical	D002220	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.
BC8_BioRED_Task1_Doc422	1932	1952	cognitive impairment	Disease	D003072	The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.
BC8_BioRED_Task1_Doc423	0	17	Alpha-lipoic acid	Chemical	D008063	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
BC8_BioRED_Task1_Doc423	27	47	mitochondrial damage	Disease	D028361	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
BC8_BioRED_Task1_Doc423	52	65	neurotoxicity	Disease	D020258	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
BC8_BioRED_Task1_Doc423	95	105	neuropathy	Disease	D009422	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
BC8_BioRED_Task1_Doc423	133	150	alpha-lipoic acid	Chemical	D008063	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
BC8_BioRED_Task1_Doc423	199	212	neurotoxicity	Disease	D020258	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
BC8_BioRED_Task1_Doc423	217	237	mitochondrial damage	Disease	D028361	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
BC8_BioRED_Task1_Doc423	263	294	toxic neurodegenerative cascade	Disease	D009410	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
BC8_BioRED_Task1_Doc423	330	347	alpha-lipoic acid	Chemical	D008063	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
BC8_BioRED_Task1_Doc423	433	454	peripheral neuropathy	Disease	D010523	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.
BC8_BioRED_Task1_Doc423	574	584	paclitaxel	Chemical	D017239	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.
BC8_BioRED_Task1_Doc423	589	598	cisplatin	Chemical	D002945	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.
BC8_BioRED_Task1_Doc423	713	730	alpha-lipoic acid	Chemical	D008063	This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.
BC8_BioRED_Task1_Doc423	745	758	axonal damage	Disease	D020833	This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.
BC8_BioRED_Task1_Doc423	872	889	alpha-lipoic acid	Chemical	D008063	This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.
BC8_BioRED_Task1_Doc423	925	934	cisplatin	Chemical	D002945	Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.
BC8_BioRED_Task1_Doc423	939	949	paclitaxel	Chemical	D017239	Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.
BC8_BioRED_Task1_Doc423	962	986	mitochondrial impairment	Disease	D028361	Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.
BC8_BioRED_Task1_Doc423	1068	1085	Alpha-lipoic acid	Chemical	D008063	Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.
BC8_BioRED_Task1_Doc423	1146	1159	neurotoxicity	Disease	D020258	Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.
BC8_BioRED_Task1_Doc423	1195	1217	mitochondrial toxicity	Disease	D028361	Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.
BC8_BioRED_Task1_Doc423	1248	1256	frataxin	Gene	2395	Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.
BC8_BioRED_Task1_Doc423	1351	1373	mitochondrial toxicity	Disease	D028361	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
BC8_BioRED_Task1_Doc423	1407	1417	paclitaxel	Chemical	D017239	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
BC8_BioRED_Task1_Doc423	1422	1431	cisplatin	Chemical	D002945	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
BC8_BioRED_Task1_Doc423	1440	1453	neurotoxicity	Disease	D020258	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
BC8_BioRED_Task1_Doc423	1455	1472	Alpha-lipoic acid	Chemical	D008063	Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.
BC8_BioRED_Task1_Doc423	1599	1607	frataxin	Gene	2395	Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.
BC8_BioRED_Task1_Doc423	1637	1654	alpha-lipoic acid	Chemical	D008063	These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.
BC8_BioRED_Task1_Doc423	1691	1716	peripheral nerve toxicity	Disease	D010523	These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.
BC8_BioRED_Task1_Doc423	1720	1728	patients	OrganismTaxon	9606	These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.
BC8_BioRED_Task1_Doc424	0	4	Brat	Gene	35197	Brat promotes stem cell differentiation via control of a bistable switch that restricts BMP signaling.
BC8_BioRED_Task1_Doc424	88	91	BMP	Gene	33432	Brat promotes stem cell differentiation via control of a bistable switch that restricts BMP signaling.
BC8_BioRED_Task1_Doc424	103	113	Drosophila	OrganismTaxon	7227	Drosophila ovarian germline stem cells (GSCs) are maintained by Dpp signaling and the Pumilio (Pum) and Nanos (Nos) translational repressors.
BC8_BioRED_Task1_Doc424	167	170	Dpp	Gene	33432	Drosophila ovarian germline stem cells (GSCs) are maintained by Dpp signaling and the Pumilio (Pum) and Nanos (Nos) translational repressors.
BC8_BioRED_Task1_Doc424	189	196	Pumilio	Gene	41094	Drosophila ovarian germline stem cells (GSCs) are maintained by Dpp signaling and the Pumilio (Pum) and Nanos (Nos) translational repressors.
BC8_BioRED_Task1_Doc424	198	201	Pum	Gene	41094	Drosophila ovarian germline stem cells (GSCs) are maintained by Dpp signaling and the Pumilio (Pum) and Nanos (Nos) translational repressors.
BC8_BioRED_Task1_Doc424	207	212	Nanos	Gene	42297	Drosophila ovarian germline stem cells (GSCs) are maintained by Dpp signaling and the Pumilio (Pum) and Nanos (Nos) translational repressors.
BC8_BioRED_Task1_Doc424	214	217	Nos	Gene	42297	Drosophila ovarian germline stem cells (GSCs) are maintained by Dpp signaling and the Pumilio (Pum) and Nanos (Nos) translational repressors.
BC8_BioRED_Task1_Doc424	260	263	Dpp	Gene	33432	Upon division, Dpp signaling is extinguished, and Nos is downregulated in one daughter cell, causing it to switch to a differentiating cystoblast (CB).
BC8_BioRED_Task1_Doc424	295	298	Nos	Gene	42297	Upon division, Dpp signaling is extinguished, and Nos is downregulated in one daughter cell, causing it to switch to a differentiating cystoblast (CB).
BC8_BioRED_Task1_Doc424	430	433	Pum	Gene	41094	However, downstream effectors of Pum-Nos remain unknown, and how CBs lose their responsiveness to Dpp is unclear.
BC8_BioRED_Task1_Doc424	434	437	Nos	Gene	42297	However, downstream effectors of Pum-Nos remain unknown, and how CBs lose their responsiveness to Dpp is unclear.
BC8_BioRED_Task1_Doc424	495	498	Dpp	Gene	33432	However, downstream effectors of Pum-Nos remain unknown, and how CBs lose their responsiveness to Dpp is unclear.
BC8_BioRED_Task1_Doc424	529	540	Brain Tumor	Gene	35197	Here, we identify Brain Tumor (Brat) as a potent differentiation factor and target of Pum-Nos regulation.
BC8_BioRED_Task1_Doc424	542	546	Brat	Gene	35197	Here, we identify Brain Tumor (Brat) as a potent differentiation factor and target of Pum-Nos regulation.
BC8_BioRED_Task1_Doc424	597	600	Pum	Gene	41094	Here, we identify Brain Tumor (Brat) as a potent differentiation factor and target of Pum-Nos regulation.
BC8_BioRED_Task1_Doc424	601	604	Nos	Gene	42297	Here, we identify Brain Tumor (Brat) as a potent differentiation factor and target of Pum-Nos regulation.
BC8_BioRED_Task1_Doc424	617	621	Brat	Gene	35197	Brat is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.
BC8_BioRED_Task1_Doc424	647	650	Pum	Gene	41094	Brat is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.
BC8_BioRED_Task1_Doc424	651	654	Nos	Gene	42297	Brat is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.
BC8_BioRED_Task1_Doc424	674	677	Pum	Gene	41094	Brat is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.
BC8_BioRED_Task1_Doc424	744	747	Mad	Gene	33529	Brat is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.
BC8_BioRED_Task1_Doc424	752	756	dMyc	Gene	31310	Brat is excluded from GSCs by Pum-Nos but functions with Pum in CBs to translationally repress distinct targets, including the Mad and dMyc mRNAs.
BC8_BioRED_Task1_Doc424	840	843	Dpp	Gene	33432	Regulation of both targets simultaneously lowers cellular responsiveness to Dpp signaling, forcing the cell to become refractory to the self-renewal signal.
BC8_BioRED_Task1_Doc424	986	990	Brat	Gene	35197	Mathematical modeling elucidates bistability of cell fate in the Brat-mediated system, revealing how autoregulation of GSC number can arise from Brat coupling extracellular Dpp regulation to intracellular interpretation.
BC8_BioRED_Task1_Doc424	1066	1070	Brat	Gene	35197	Mathematical modeling elucidates bistability of cell fate in the Brat-mediated system, revealing how autoregulation of GSC number can arise from Brat coupling extracellular Dpp regulation to intracellular interpretation.
BC8_BioRED_Task1_Doc424	1094	1097	Dpp	Gene	33432	Mathematical modeling elucidates bistability of cell fate in the Brat-mediated system, revealing how autoregulation of GSC number can arise from Brat coupling extracellular Dpp regulation to intracellular interpretation.
BC8_BioRED_Task1_Doc425	46	50	MSH2	Gene	4436	Screening for exonic copy number mutations at MSH2 and MLH1 by MAPH.
BC8_BioRED_Task1_Doc425	55	59	MLH1	Gene	4292	Screening for exonic copy number mutations at MSH2 and MLH1 by MAPH.
BC8_BioRED_Task1_Doc425	101	105	MSH2	Gene	4436	BACKGROUND: Exonic deletions in MSH2 and MLH1 are significant contributors to the mutation spectrum in HNPCC, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.
BC8_BioRED_Task1_Doc425	110	114	MLH1	Gene	4292	BACKGROUND: Exonic deletions in MSH2 and MLH1 are significant contributors to the mutation spectrum in HNPCC, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.
BC8_BioRED_Task1_Doc425	172	177	HNPCC	Disease	D003123	BACKGROUND: Exonic deletions in MSH2 and MLH1 are significant contributors to the mutation spectrum in HNPCC, and heterozygous changes in exon copy number are not detected by conventional mutation screening methods.
BC8_BioRED_Task1_Doc425	377	381	MLH1	Gene	4292	AIMS: We aimed to develop methods for screening copy number changes in all the exons of the MLH1 and MSH2 genes using a single multiplex amplifiable probe hybridisation (MAPH) assay.
BC8_BioRED_Task1_Doc425	386	390	MSH2	Gene	4436	AIMS: We aimed to develop methods for screening copy number changes in all the exons of the MLH1 and MSH2 genes using a single multiplex amplifiable probe hybridisation (MAPH) assay.
BC8_BioRED_Task1_Doc425	544	548	MLH1	Gene	4292	METHODS: We developed a probe set consisting of probes from the 19 exons of MLH1 and 16 exons of MSH2, and 3 control probes, and applied it to screening for deletions and duplications using fluorescent detection of amplified fragments.
BC8_BioRED_Task1_Doc425	565	569	MSH2	Gene	4436	METHODS: We developed a probe set consisting of probes from the 19 exons of MLH1 and 16 exons of MSH2, and 3 control probes, and applied it to screening for deletions and duplications using fluorescent detection of amplified fragments.
BC8_BioRED_Task1_Doc425	764	769	HNPCC	Disease	D003123	RESULTS: We tested 73 DNA samples from controls and 50 from HNPCC patients in whom no point mutations had been found, and detected 10 copy number changes among the patient samples.
BC8_BioRED_Task1_Doc425	770	778	patients	OrganismTaxon	9606	RESULTS: We tested 73 DNA samples from controls and 50 from HNPCC patients in whom no point mutations had been found, and detected 10 copy number changes among the patient samples.
BC8_BioRED_Task1_Doc425	868	875	patient	OrganismTaxon	9606	RESULTS: We tested 73 DNA samples from controls and 50 from HNPCC patients in whom no point mutations had been found, and detected 10 copy number changes among the patient samples.
BC8_BioRED_Task1_Doc425	932	936	MSH2	Gene	4436	A deletion of about 1.4 kb including exon 3 of MSH2 was confirmed by amplification of a junction fragment, and was shown to be the result of an unequal recombination between intronic Alu elements.
BC8_BioRED_Task1_Doc425	1141	1145	MLH1	Gene	4292	CONCLUSIONS: MAPH can detect exonic copy number changes in MLH1 and MSH2 in DNA from HNPCC patients.
BC8_BioRED_Task1_Doc425	1150	1154	MSH2	Gene	4436	CONCLUSIONS: MAPH can detect exonic copy number changes in MLH1 and MSH2 in DNA from HNPCC patients.
BC8_BioRED_Task1_Doc425	1167	1172	HNPCC	Disease	D003123	CONCLUSIONS: MAPH can detect exonic copy number changes in MLH1 and MSH2 in DNA from HNPCC patients.
BC8_BioRED_Task1_Doc425	1173	1181	patients	OrganismTaxon	9606	CONCLUSIONS: MAPH can detect exonic copy number changes in MLH1 and MSH2 in DNA from HNPCC patients.
BC8_BioRED_Task1_Doc426	15	19	DRD2	Gene	1813	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
BC8_BioRED_Task1_Doc426	38	52	chlorpromazine	Chemical	D002746	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
BC8_BioRED_Task1_Doc426	61	84	extrapyramidal syndrome	Disease	D001480	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
BC8_BioRED_Task1_Doc426	96	109	schizophrenic	Disease	D012559	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
BC8_BioRED_Task1_Doc426	110	118	patients	OrganismTaxon	9606	Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
BC8_BioRED_Task1_Doc426	125	148	Extrapyramidal syndrome	Disease	D001480	AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor.
BC8_BioRED_Task1_Doc426	150	153	EPS	Disease	D001480	AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor.
BC8_BioRED_Task1_Doc426	192	211	antipsychotic drugs	Chemical	D014150	AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor.
BC8_BioRED_Task1_Doc426	247	258	D2 receptor	Gene	1813	AIM: Extrapyramidal syndrome (EPS) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor.
BC8_BioRED_Task1_Doc426	372	376	DRD2	Gene	1813	Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression.
BC8_BioRED_Task1_Doc426	414	427	schizophrenia	Disease	D012559	Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression.
BC8_BioRED_Task1_Doc426	428	436	patients	OrganismTaxon	9606	Recently, many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression.
BC8_BioRED_Task1_Doc426	562	566	DRD2	Gene	1813	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
BC8_BioRED_Task1_Doc426	576	590	chlorpromazine	Chemical	D002746	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
BC8_BioRED_Task1_Doc426	599	602	EPS	Disease	D001480	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
BC8_BioRED_Task1_Doc426	606	619	schizophrenic	Disease	D012559	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
BC8_BioRED_Task1_Doc426	620	628	patients	OrganismTaxon	9606	In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.
BC8_BioRED_Task1_Doc426	696	708	-141Cins>del	SequenceVariant	c|INDEL|0141|C	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	724	733	Ser311Cys	SequenceVariant	c|SUB|S|311|C	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	735	741	rs6275	SequenceVariant	rs6275	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	743	749	rs6277	SequenceVariant	rs6277	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	768	772	DRD2	Gene	1813	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	785	798	schizophrenic	Disease	D012559	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	799	809	inpatients	OrganismTaxon	9606	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	819	822	EPS	Disease	D001480	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	838	841	EPS	Disease	D001480	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	893	907	chlorpromazine	Chemical	D002746	METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
BC8_BioRED_Task1_Doc426	1029	1038	Ser311Cys	SequenceVariant	c|SUB|S|311|C	RESULTS: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study.
BC8_BioRED_Task1_Doc426	1043	1049	rs6277	SequenceVariant	rs6277	RESULTS: Polymorphisms TaqID, Ser311Cys and rs6277 were not polymorphic in the population recruited in the present study.
BC8_BioRED_Task1_Doc426	1189	1201	-141Cins>del	SequenceVariant	c|INDEL|0141|C	No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups.
BC8_BioRED_Task1_Doc426	1210	1216	rs6275	SequenceVariant	rs6275	No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups.
BC8_BioRED_Task1_Doc426	1281	1287	rs6275	SequenceVariant	rs6275	No statistical significance was found in the allele distribution of -141Cins>del, TaqIB, rs6275 and TaqIA or in the estimated haplotypes (constituted by TaqIB, rs6275 and TaqIA) in linkage disequilibrium between the two groups.
BC8_BioRED_Task1_Doc426	1447	1451	DRD2	Gene	1813	CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.
BC8_BioRED_Task1_Doc426	1531	1545	chlorpromazine	Chemical	D002746	CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.
BC8_BioRED_Task1_Doc426	1567	1575	patients	OrganismTaxon	9606	CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.
BC8_BioRED_Task1_Doc426	1581	1594	schizophrenia	Disease	D012559	CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.
BC8_BioRED_Task1_Doc426	1663	1667	DRD2	Gene	1813	Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
BC8_BioRED_Task1_Doc426	1672	1675	EPS	Disease	D001480	Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians.
BC8_BioRED_Task1_Doc427	0	5	Tumor	Disease	D009369	Tumor associated antigen recognition by autologous serum in patients with breast cancer.
BC8_BioRED_Task1_Doc427	60	68	patients	OrganismTaxon	9606	Tumor associated antigen recognition by autologous serum in patients with breast cancer.
BC8_BioRED_Task1_Doc427	74	87	breast cancer	Disease	D001943	Tumor associated antigen recognition by autologous serum in patients with breast cancer.
BC8_BioRED_Task1_Doc427	89	102	Breast cancer	Disease	D001943	Breast cancer accounts for 30-40% of all deaths from cancers in females.
BC8_BioRED_Task1_Doc427	142	149	cancers	Disease	D009369	Breast cancer accounts for 30-40% of all deaths from cancers in females.
BC8_BioRED_Task1_Doc427	187	192	tumor	Disease	D009369	In an effort to identify tumor associated antigens that may be useful for immunotherapy, we utilized serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify breast cancer-associated antigens.
BC8_BioRED_Task1_Doc427	355	368	breast cancer	Disease	D001943	In an effort to identify tumor associated antigens that may be useful for immunotherapy, we utilized serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify breast cancer-associated antigens.
BC8_BioRED_Task1_Doc427	450	463	breast cancer	Disease	D001943	SEREX screening of cDNA expression libraries derived from 3 breast cancer patients identified a total of 88 positive clones (bcg-1 to bcg-88), including 27 hitherto unknown sequences.
BC8_BioRED_Task1_Doc427	464	472	patients	OrganismTaxon	9606	SEREX screening of cDNA expression libraries derived from 3 breast cancer patients identified a total of 88 positive clones (bcg-1 to bcg-88), including 27 hitherto unknown sequences.
BC8_BioRED_Task1_Doc427	709	722	breast cancer	Disease	D001943	Seroreactivity of the SEREX clones were determined in sera from 75 breast cancer patients, 75 colon cancer patients, and 25 healthy donors.
BC8_BioRED_Task1_Doc427	723	731	patients	OrganismTaxon	9606	Seroreactivity of the SEREX clones were determined in sera from 75 breast cancer patients, 75 colon cancer patients, and 25 healthy donors.
BC8_BioRED_Task1_Doc427	736	748	colon cancer	Disease	D015179	Seroreactivity of the SEREX clones were determined in sera from 75 breast cancer patients, 75 colon cancer patients, and 25 healthy donors.
BC8_BioRED_Task1_Doc427	749	757	patients	OrganismTaxon	9606	Seroreactivity of the SEREX clones were determined in sera from 75 breast cancer patients, 75 colon cancer patients, and 25 healthy donors.
BC8_BioRED_Task1_Doc427	1286	1298	colon cancer	Disease	D015179	Serologic assay revealed that 7 out of the 88 clones showed reactivity to at least one serum from either 75 breast or 75 colon cancer patients.
BC8_BioRED_Task1_Doc427	1299	1307	patients	OrganismTaxon	9606	Serologic assay revealed that 7 out of the 88 clones showed reactivity to at least one serum from either 75 breast or 75 colon cancer patients.
BC8_BioRED_Task1_Doc427	1486	1491	tumor	Disease	D009369	Our results demonstrate the utility of the SEREX approach for the identification of potential tumor associated antigens in human breast cancer.
BC8_BioRED_Task1_Doc427	1515	1520	human	OrganismTaxon	9606	Our results demonstrate the utility of the SEREX approach for the identification of potential tumor associated antigens in human breast cancer.
BC8_BioRED_Task1_Doc427	1521	1534	breast cancer	Disease	D001943	Our results demonstrate the utility of the SEREX approach for the identification of potential tumor associated antigens in human breast cancer.
BC8_BioRED_Task1_Doc428	11	21	Fas ligand	Gene	356	Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.
BC8_BioRED_Task1_Doc428	61	64	AZT	Chemical	D015215	Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.
BC8_BioRED_Task1_Doc428	73	87	cardiomyopathy	Disease	D009202	Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.
BC8_BioRED_Task1_Doc428	101	123	Dilated cardiomyopathy	Disease	D002311	BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.
BC8_BioRED_Task1_Doc428	125	128	DCM	Disease	D002311	BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.
BC8_BioRED_Task1_Doc428	134	145	myocarditis	Disease	D009205	BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.
BC8_BioRED_Task1_Doc428	160	172	HIV-infected	Disease	D015658	BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.
BC8_BioRED_Task1_Doc428	211	224	heart failure	Disease	D006333	BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.
BC8_BioRED_Task1_Doc428	240	248	patients	OrganismTaxon	9606	BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.
BC8_BioRED_Task1_Doc428	348	382	acquired immunodeficiency syndrome	Disease	D000163	Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
BC8_BioRED_Task1_Doc428	384	388	AIDS	Disease	D000163	Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
BC8_BioRED_Task1_Doc428	426	457	cardiac and skeletal myopathies	Disease	C538496	Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
BC8_BioRED_Task1_Doc428	532	542	zidovudine	Chemical	D015215	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	544	573	3'-azido-2',3'-deoxythymidine	Chemical	D015215	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	575	578	AZT	Chemical	D015215	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	593	596	Fas	Gene	355	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	665	671	murine	OrganismTaxon	10090	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	681	684	DCM	Disease	D002311	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	720	730	Fas ligand	Gene	356	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	750	754	FasL	Gene	14103	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	784	788	mice	OrganismTaxon	10090	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	854	857	AZT	Chemical	D015215	METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
BC8_BioRED_Task1_Doc428	1052	1056	FasL	Gene	14103	NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.
BC8_BioRED_Task1_Doc428	1060	1064	mice	OrganismTaxon	10090	NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.
BC8_BioRED_Task1_Doc428	1139	1142	AZT	Chemical	D015215	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
BC8_BioRED_Task1_Doc428	1151	1155	FasL	Gene	14103	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
BC8_BioRED_Task1_Doc428	1159	1163	mice	OrganismTaxon	10090	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
BC8_BioRED_Task1_Doc428	1174	1190	cardiac dilation	Disease	D002311	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
BC8_BioRED_Task1_Doc428	1195	1221	depressed cardiac function	Disease	D000275	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
BC8_BioRED_Task1_Doc428	1267	1279	inflammatory	Disease	D007249	In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
BC8_BioRED_Task1_Doc428	1387	1390	Fas	Gene	355	These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.
BC8_BioRED_Task1_Doc428	1395	1399	FasL	Gene	14103	These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.
BC8_BioRED_Task1_Doc428	1436	1445	caspase 3	Gene	12367	These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.
BC8_BioRED_Task1_Doc428	1464	1473	calpain 1	Gene	12333	These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.
BC8_BioRED_Task1_Doc428	1598	1608	dystrophin	Gene	13405	These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.
BC8_BioRED_Task1_Doc428	1613	1631	cardiac troponin I	Gene	21954	These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.
BC8_BioRED_Task1_Doc428	1719	1729	Fas ligand	Gene	356	CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.
BC8_BioRED_Task1_Doc428	1766	1769	HIV	OrganismTaxon	11676	CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.
BC8_BioRED_Task1_Doc428	1779	1787	patients	OrganismTaxon	9606	CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.
BC8_BioRED_Task1_Doc428	1840	1854	cardiomyopathy	Disease	D009202	CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.
BC8_BioRED_Task1_Doc428	1909	1941	cardiac dilation and dysfunction	Disease	D002311,D006331	CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.
BC8_BioRED_Task1_Doc429	13	31	prolactin receptor	Gene	24684	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
BC8_BioRED_Task1_Doc429	42	58	ribonucleic acid	Chemical	D012313	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
BC8_BioRED_Task1_Doc429	67	76	prolactin	Gene	24683	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
BC8_BioRED_Task1_Doc429	92	110	hyperprolactinemic	Disease	D006966	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
BC8_BioRED_Task1_Doc429	135	154	luteinizing hormone	Chemical	D007986	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
BC8_BioRED_Task1_Doc429	182	191	estradiol	Chemical	D004958	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
BC8_BioRED_Task1_Doc429	193	211	Hyperprolactinemia	Disease	D006966	Hyperprolactinemia can reduce fertility and libido.
BC8_BioRED_Task1_Doc429	262	271	prolactin	Gene	24683	Although central prolactin actions are thought to contribute to this, the mechanisms are poorly understood.
BC8_BioRED_Task1_Doc429	385	403	hyperprolactinemia	Disease	D006966	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.
BC8_BioRED_Task1_Doc429	486	488	LH	Chemical	D007986	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.
BC8_BioRED_Task1_Doc429	507	515	estrogen	Chemical	D004967	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.
BC8_BioRED_Task1_Doc429	524	526	LH	Chemical	D007986	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.
BC8_BioRED_Task1_Doc429	542	560	hyperprolactinemia	Disease	D006966	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
BC8_BioRED_Task1_Doc429	576	584	dopamine	Chemical	D004298	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
BC8_BioRED_Task1_Doc429	596	605	sulpiride	Chemical	D013469	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
BC8_BioRED_Task1_Doc429	629	631	LH	Chemical	D007986	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
BC8_BioRED_Task1_Doc429	666	670	rats	OrganismTaxon	10116	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
BC8_BioRED_Task1_Doc429	722	731	estradiol	Chemical	D004958	Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
BC8_BioRED_Task1_Doc429	733	742	Sulpiride	Chemical	D013469	Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.
BC8_BioRED_Task1_Doc429	777	784	steroid	Chemical	D013256	Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.
BC8_BioRED_Task1_Doc429	793	795	LH	Chemical	D007986	Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.
BC8_BioRED_Task1_Doc429	864	873	Estradiol	Chemical	D004958	Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.
BC8_BioRED_Task1_Doc429	927	946	prolactin receptors	Gene	24684	Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.
BC8_BioRED_Task1_Doc429	948	953	PRL-R	Gene	24684	Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.
BC8_BioRED_Task1_Doc429	973	982	prolactin	Gene	24683	Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.
BC8_BioRED_Task1_Doc429	1032	1040	estrogen	Chemical	D004967	To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.
BC8_BioRED_Task1_Doc429	1051	1056	PRL-R	Gene	24684	To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.
BC8_BioRED_Task1_Doc429	1087	1096	prolactin	Gene	24683	To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.
BC8_BioRED_Task1_Doc429	1124	1133	estradiol	Chemical	D004958	To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.
BC8_BioRED_Task1_Doc429	1151	1160	prolactin	Gene	24683	To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.
BC8_BioRED_Task1_Doc429	1169	1174	STAT5	Gene	24918	To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.
BC8_BioRED_Task1_Doc429	1207	1212	PRL-R	Gene	24684	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1217	1249	suppressor of cytokine signaling	Gene	252971,83681,89829	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1251	1264	SOCS-1 and -3	Gene	252971,89829	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1269	1272	CIS	Gene	83681	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1301	1310	prolactin	Gene	24683	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1343	1352	sulpiride	Chemical	D013469	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1357	1366	estradiol	Chemical	D004958	Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.
BC8_BioRED_Task1_Doc429	1368	1377	Sulpiride	Chemical	D013469	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.
BC8_BioRED_Task1_Doc429	1391	1397	SOCS-1	Gene	252971	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.
BC8_BioRED_Task1_Doc429	1508	1513	PRL-R	Gene	24684	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.
BC8_BioRED_Task1_Doc429	1515	1521	SOCS-3	Gene	89829	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.
BC8_BioRED_Task1_Doc429	1527	1530	CIS	Gene	83681	Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.
BC8_BioRED_Task1_Doc429	1562	1571	Estradiol	Chemical	D004958	Estradiol enhanced these effects on SOCS-3 and CIS.
BC8_BioRED_Task1_Doc429	1598	1604	SOCS-3	Gene	89829	Estradiol enhanced these effects on SOCS-3 and CIS.
BC8_BioRED_Task1_Doc429	1609	1612	CIS	Gene	83681	Estradiol enhanced these effects on SOCS-3 and CIS.
BC8_BioRED_Task1_Doc429	1629	1638	estradiol	Chemical	D004958	Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.
BC8_BioRED_Task1_Doc429	1652	1657	PRL-R	Gene	24684	Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.
BC8_BioRED_Task1_Doc429	1659	1665	SOCS-3	Gene	89829	Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.
BC8_BioRED_Task1_Doc429	1671	1674	CIS	Gene	83681	Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.
BC8_BioRED_Task1_Doc429	1768	1786	hyperprolactinemia	Disease	D006966	These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.
BC8_BioRED_Task1_Doc429	1792	1799	steroid	Chemical	D013256	These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.
BC8_BioRED_Task1_Doc429	1849	1858	estradiol	Chemical	D004958	They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.
BC8_BioRED_Task1_Doc429	1909	1914	PRL-R	Gene	24684	They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.
BC8_BioRED_Task1_Doc429	1953	1962	prolactin	Gene	24683	They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.
BC8_BioRED_Task1_Doc430	0	25	Congenital hypothyroidism	Disease	D003409	Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein.
BC8_BioRED_Task1_Doc430	55	78	sodium/iodide symporter	Gene	6528	Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein.
BC8_BioRED_Task1_Doc430	99	122	Iodide transport defect	Disease	C564766	OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.
BC8_BioRED_Task1_Doc430	124	127	ITD	Disease	C564766	OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.
BC8_BioRED_Task1_Doc430	168	192	inability of the thyroid	Disease	D050033	OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.
BC8_BioRED_Task1_Doc430	208	214	iodide	Chemical	D007454	OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.
BC8_BioRED_Task1_Doc430	307	332	congenital hypothyroidism	Disease	D003409	OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism.
BC8_BioRED_Task1_Doc430	471	494	sodium/iodide symporter	Gene	6528	When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS).
BC8_BioRED_Task1_Doc430	496	499	NIS	Gene	6528	When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS).
BC8_BioRED_Task1_Doc430	502	509	PATIENT	OrganismTaxon	9606	PATIENT: We describe a woman with hypothyroidism identified at the 3rd month of life.
BC8_BioRED_Task1_Doc430	525	530	woman	OrganismTaxon	9606	PATIENT: We describe a woman with hypothyroidism identified at the 3rd month of life.
BC8_BioRED_Task1_Doc430	536	550	hypothyroidism	Disease	D007037	PATIENT: We describe a woman with hypothyroidism identified at the 3rd month of life.
BC8_BioRED_Task1_Doc430	605	608	ITD	Disease	C564766	The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands.
BC8_BioRED_Task1_Doc430	634	648	nodular goitre	Disease	D020518	The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands.
BC8_BioRED_Task1_Doc430	668	674	iodide	Chemical	D007454	The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands.
BC8_BioRED_Task1_Doc430	733	739	iodide	Chemical	D007454	Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started.
BC8_BioRED_Task1_Doc430	764	778	hypothyroidism	Disease	D007037	Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started.
BC8_BioRED_Task1_Doc430	825	836	L-thyroxine	Chemical	D013974	Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started.
BC8_BioRED_Task1_Doc430	872	883	radioiodide	Chemical	D007454	MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH.
BC8_BioRED_Task1_Doc430	968	973	human	OrganismTaxon	9606	MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH.
BC8_BioRED_Task1_Doc430	974	977	TSH	Gene	7200	MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH.
BC8_BioRED_Task1_Doc430	1000	1002	I-	Chemical	D007454	The saliva to plasma I- ratio was 1.1 indicating that the inability of the thyroid gland to concentrate I- was also present in the salivary glands.
BC8_BioRED_Task1_Doc430	1083	1085	I-	Chemical	D007454	The saliva to plasma I- ratio was 1.1 indicating that the inability of the thyroid gland to concentrate I- was also present in the salivary glands.
BC8_BioRED_Task1_Doc430	1152	1159	patient	OrganismTaxon	9606	RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron.
BC8_BioRED_Task1_Doc430	1162	1165	NIS	Gene	6528	RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron.
BC8_BioRED_Task1_Doc430	1201	1258	deletion of the coding sequence (nt 1314 through nt 1328)	SequenceVariant	c|DEL|1314_1328|	RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron.
BC8_BioRED_Task1_Doc430	1267	1310	insertion of 15 nt duplicating the first 15	SequenceVariant	c|DUP||15	RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron.
BC8_BioRED_Task1_Doc430	1342	1349	patient	OrganismTaxon	9606	The patient was homozygous for this insertion/deletion, while both consanguineous parents were heterozygous.
BC8_BioRED_Task1_Doc430	1498	1556	lacking the five terminal amino acids of exon XI (439-443)	SequenceVariant	p|DEL|439_443|	This deletion predicts the production of a protein lacking the five terminal amino acids of exon XI (439-443) which are located in the 6th intracellular loop.
BC8_BioRED_Task1_Doc430	1606	1611	COS-7	CellLine	CVCL_0224	COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient.
BC8_BioRED_Task1_Doc430	1666	1679	del-(439-443)	SequenceVariant	p|DEL|439_443|	COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient.
BC8_BioRED_Task1_Doc430	1680	1683	NIS	Gene	6528	COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient.
BC8_BioRED_Task1_Doc430	1706	1712	iodide	Chemical	D007454	COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient.
BC8_BioRED_Task1_Doc430	1771	1774	ITD	Disease	C564766	COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient.
BC8_BioRED_Task1_Doc430	1783	1790	patient	OrganismTaxon	9606	COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient.
BC8_BioRED_Task1_Doc430	1856	1881	congenital hypothyroidism	Disease	D003409	CONCLUSION: In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene.
BC8_BioRED_Task1_Doc430	1911	1914	NIS	Gene	6528	CONCLUSION: In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene.
BC8_BioRED_Task1_Doc431	14	28	5-HT6 receptor	Gene	64354	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
BC8_BioRED_Task1_Doc431	40	49	Ro4368554	Chemical	C507242	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
BC8_BioRED_Task1_Doc431	81	92	cholinergic	Chemical	D018678	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
BC8_BioRED_Task1_Doc431	97	109	serotonergic	Chemical	D018490	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
BC8_BioRED_Task1_Doc431	120	137	memory deficiency	Disease	D008569	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
BC8_BioRED_Task1_Doc431	145	148	rat	OrganismTaxon	10116	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
BC8_BioRED_Task1_Doc431	165	201	serotonin type 6 (5-HT(6)) receptors	Gene	64354	Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory.
BC8_BioRED_Task1_Doc431	353	366	acetylcholine	Chemical	D000109	Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.
BC8_BioRED_Task1_Doc431	368	371	ACh	Chemical	D000109	Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.
BC8_BioRED_Task1_Doc431	461	468	5-HT(6)	Gene	64354	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	480	489	Ro4368554	Chemical	C507242	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	491	545	3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole	Chemical	C507242	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	552	555	rat	OrganismTaxon	10116	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	592	603	cholinergic	Chemical	D018678	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	605	616	scopolamine	Chemical	D012601	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	637	649	serotonergic	Chemical	D018490	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	652	662	tryptophan	Chemical	D014364	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	664	667	TRP	Chemical	D014364	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	749	769	acetylcholinesterase	Gene	83817	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	780	791	metrifonate	Chemical	D014236	The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.
BC8_BioRED_Task1_Doc431	909	920	metrifonate	Chemical	D014236	Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.
BC8_BioRED_Task1_Doc431	985	994	Ro4368554	Chemical	C507242	), whereas Ro4368554 was inactive.
BC8_BioRED_Task1_Doc431	1015	1024	Ro4368554	Chemical	C507242	Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.))
BC8_BioRED_Task1_Doc431	1072	1083	metrifonate	Chemical	D014236	and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
BC8_BioRED_Task1_Doc431	1124	1139	memory deficits	Disease	D008569	and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
BC8_BioRED_Task1_Doc431	1151	1162	scopolamine	Chemical	D012601	and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
BC8_BioRED_Task1_Doc431	1167	1170	TRP	Chemical	D014364	and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
BC8_BioRED_Task1_Doc431	1256	1265	Ro4368554	Chemical	C507242	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
BC8_BioRED_Task1_Doc431	1330	1341	cholinergic	Chemical	D018678	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
BC8_BioRED_Task1_Doc431	1348	1360	serotonergic	Chemical	D018490	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
BC8_BioRED_Task1_Doc431	1361	1375	memory deficit	Disease	D008569	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
BC8_BioRED_Task1_Doc431	1465	1474	Ro4368554	Chemical	C507242	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
BC8_BioRED_Task1_Doc431	1496	1524	5-HT(6) receptor antagonists	Chemical	D012702	In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.
BC8_BioRED_Task1_Doc432	23	29	CYP2C8	Gene	1558	Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography.
BC8_BioRED_Task1_Doc432	33	45	hypertensive	Disease	D006973	Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography.
BC8_BioRED_Task1_Doc432	46	54	patients	OrganismTaxon	9606	Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography.
BC8_BioRED_Task1_Doc432	141	147	CYP2C8	Gene	1558	WHAT IS KNOWN AND OBJECTIVE: CYP2C8 is involved in the cytochrome P450 (CYP) epoxygenase pathway.
BC8_BioRED_Task1_Doc432	167	200	cytochrome P450 (CYP) epoxygenase	Gene	1558	WHAT IS KNOWN AND OBJECTIVE: CYP2C8 is involved in the cytochrome P450 (CYP) epoxygenase pathway.
BC8_BioRED_Task1_Doc432	210	226	Arachidonic acid	Chemical	D016718	Arachidonic acid metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids, produced may have a role in hypertension.
BC8_BioRED_Task1_Doc432	247	274	epoxyeicosatrienenoic acids	Chemical	-	Arachidonic acid metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids, produced may have a role in hypertension.
BC8_BioRED_Task1_Doc432	279	307	hydroxyeicosatetrenoic acids	Chemical	-	Arachidonic acid metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids, produced may have a role in hypertension.
BC8_BioRED_Task1_Doc432	337	349	hypertension	Disease	D006973	Arachidonic acid metabolites such as epoxyeicosatrienenoic acids and hydroxyeicosatetrenoic acids, produced may have a role in hypertension.
BC8_BioRED_Task1_Doc432	451	457	CYP2C8	Gene	1558	We aimed to develop a medium through-put method for screening samples of known and new mutations of CYP2C8 using denaturing high performance liquid chromatography (DHPLC).
BC8_BioRED_Task1_Doc432	563	575	hypertensive	Disease	D006973	METHODS: DNA samples from 200 subjects (hypertensive patients and healthy controls) were screened for SNPs in CYP2C8 using DHPLC.
BC8_BioRED_Task1_Doc432	576	584	patients	OrganismTaxon	9606	METHODS: DNA samples from 200 subjects (hypertensive patients and healthy controls) were screened for SNPs in CYP2C8 using DHPLC.
BC8_BioRED_Task1_Doc432	633	639	CYP2C8	Gene	1558	METHODS: DNA samples from 200 subjects (hypertensive patients and healthy controls) were screened for SNPs in CYP2C8 using DHPLC.
BC8_BioRED_Task1_Doc432	690	696	CYP2C8	Gene	1558	Genotypes and allelic frequencies of CYP2C8 between the healthy controls and patients with hypertension were compared.
BC8_BioRED_Task1_Doc432	730	738	patients	OrganismTaxon	9606	Genotypes and allelic frequencies of CYP2C8 between the healthy controls and patients with hypertension were compared.
BC8_BioRED_Task1_Doc432	744	756	hypertension	Disease	D006973	Genotypes and allelic frequencies of CYP2C8 between the healthy controls and patients with hypertension were compared.
BC8_BioRED_Task1_Doc432	842	860	T deletion at 5063	SequenceVariant	c|DEL|5063|T	RESULTS AND DISCUSSIONS: Six variants were detected and two were new; T deletion at 5063 and substitution of C to T at 33468 in exon 8.
BC8_BioRED_Task1_Doc432	881	896	C to T at 33468	SequenceVariant	c|SUB|C|33468|T	RESULTS AND DISCUSSIONS: Six variants were detected and two were new; T deletion at 5063 and substitution of C to T at 33468 in exon 8.
BC8_BioRED_Task1_Doc432	982	994	hypertensive	Disease	D006973	Differences in variant frequencies were detected between the controls and hypertensive patients.
BC8_BioRED_Task1_Doc432	995	1003	patients	OrganismTaxon	9606	Differences in variant frequencies were detected between the controls and hypertensive patients.
BC8_BioRED_Task1_Doc432	1058	1065	C35322C	SequenceVariant	c|SUB|C|35322|C	The controls have significantly higher prevalence of C35322C compared to the patients.
BC8_BioRED_Task1_Doc432	1082	1090	patients	OrganismTaxon	9606	The controls have significantly higher prevalence of C35322C compared to the patients.
BC8_BioRED_Task1_Doc432	1182	1189	C35322C	SequenceVariant	c|SUB|C|35322|C	Having homozygous C35322C could be a protective factor for hypertension.
BC8_BioRED_Task1_Doc432	1223	1235	hypertension	Disease	D006973	Having homozygous C35322C could be a protective factor for hypertension.
BC8_BioRED_Task1_Doc432	1411	1418	C35322T	SequenceVariant	c|SUB|C|35322|T	A higher frequency of the C35322T SNP was observed among hypertensive patients than control subjects.
BC8_BioRED_Task1_Doc432	1442	1454	hypertensive	Disease	D006973	A higher frequency of the C35322T SNP was observed among hypertensive patients than control subjects.
BC8_BioRED_Task1_Doc432	1455	1463	patients	OrganismTaxon	9606	A higher frequency of the C35322T SNP was observed among hypertensive patients than control subjects.
BC8_BioRED_Task1_Doc433	0	21	Serotonin transporter	Gene	6532	Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy.
BC8_BioRED_Task1_Doc433	47	55	5-HTTLPR	Gene	6532	Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy.
BC8_BioRED_Task1_Doc433	87	106	Parkinson's disease	Disease	D010300	Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy.
BC8_BioRED_Task1_Doc433	117	136	Parkinson's disease	Disease	D010300	Parkinson's disease (PD) is a neurodegenerative disorder causing muscular rigidity, resting tremor and bradykinesia.
BC8_BioRED_Task1_Doc433	138	140	PD	Disease	D010300	Parkinson's disease (PD) is a neurodegenerative disorder causing muscular rigidity, resting tremor and bradykinesia.
BC8_BioRED_Task1_Doc433	147	173	neurodegenerative disorder	Disease	D019636	Parkinson's disease (PD) is a neurodegenerative disorder causing muscular rigidity, resting tremor and bradykinesia.
BC8_BioRED_Task1_Doc433	182	199	muscular rigidity	Disease	D009127	Parkinson's disease (PD) is a neurodegenerative disorder causing muscular rigidity, resting tremor and bradykinesia.
BC8_BioRED_Task1_Doc433	201	215	resting tremor	Disease	D014202	Parkinson's disease (PD) is a neurodegenerative disorder causing muscular rigidity, resting tremor and bradykinesia.
BC8_BioRED_Task1_Doc433	220	232	bradykinesia	Disease	D018476	Parkinson's disease (PD) is a neurodegenerative disorder causing muscular rigidity, resting tremor and bradykinesia.
BC8_BioRED_Task1_Doc433	282	284	PD	Disease	D010300	We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region.
BC8_BioRED_Task1_Doc433	321	342	serotonin transporter	Gene	6532	We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region.
BC8_BioRED_Task1_Doc433	349	355	SLC6A4	Gene	6532	We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region.
BC8_BioRED_Task1_Doc433	376	384	5-HTTLPR	Gene	6532	We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region.
BC8_BioRED_Task1_Doc433	403	461	insertion/deletion (long allele-L/short allele-S) of 43 bp	SequenceVariant	c|INDEL||43	We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region.
BC8_BioRED_Task1_Doc433	469	475	SLC6A4	Gene	6532	We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region.
BC8_BioRED_Task1_Doc433	497	503	SLC6A4	Gene	6532	The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too.
BC8_BioRED_Task1_Doc433	544	551	rs25531	SequenceVariant	rs25531	The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too.
BC8_BioRED_Task1_Doc433	552	557	A-->G	SequenceVariant	rs25531	The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too.
BC8_BioRED_Task1_Doc433	621	623	PD	Disease	D010300	We collected 837 independent subjects (393 PD, 444 controls).
BC8_BioRED_Task1_Doc433	667	675	5-HTTLPR	Gene	6532	An association between the 5-HTTLPR polymorphism and risk of PD (S/S genotype OR [95% CI]: 1.7[1.2-2.5], p = 0.002) was found.
BC8_BioRED_Task1_Doc433	701	703	PD	Disease	D010300	An association between the 5-HTTLPR polymorphism and risk of PD (S/S genotype OR [95% CI]: 1.7[1.2-2.5], p = 0.002) was found.
BC8_BioRED_Task1_Doc433	771	778	rs25531	SequenceVariant	rs25531	The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD.
BC8_BioRED_Task1_Doc433	797	805	5-HTTLPR	Gene	6532	The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD.
BC8_BioRED_Task1_Doc433	806	813	rs25531	SequenceVariant	rs25531	The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD.
BC8_BioRED_Task1_Doc433	845	847	PD	Disease	D010300	The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD.
BC8_BioRED_Task1_Doc433	876	884	5-HTTLPR	Gene	6532	Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.
BC8_BioRED_Task1_Doc433	916	922	SLC6A4	Gene	6532	Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.
BC8_BioRED_Task1_Doc433	963	965	PD	Disease	D010300	Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.
BC8_BioRED_Task1_Doc434	28	32	PHEX	Gene	5251	Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets.
BC8_BioRED_Task1_Doc434	51	59	patients	OrganismTaxon	9606	Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets.
BC8_BioRED_Task1_Doc434	65	89	hypophosphatemic rickets	Disease	D063730	Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets.
BC8_BioRED_Task1_Doc434	117	195	phosphate-regulating gene with homologies to endopeptidase on the X chromosome	Gene	5251	Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) have been identified as a cause of X-linked hypophosphatemic rickets (XLH; OMIM 307800).
BC8_BioRED_Task1_Doc434	197	201	PHEX	Gene	5251	Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) have been identified as a cause of X-linked hypophosphatemic rickets (XLH; OMIM 307800).
BC8_BioRED_Task1_Doc434	238	271	X-linked hypophosphatemic rickets	Disease	D053098	Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) have been identified as a cause of X-linked hypophosphatemic rickets (XLH; OMIM 307800).
BC8_BioRED_Task1_Doc434	273	276	XLH	Disease	D053098	Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) have been identified as a cause of X-linked hypophosphatemic rickets (XLH; OMIM 307800).
BC8_BioRED_Task1_Doc434	278	289	OMIM 307800	Disease	D053098	Inactivating mutations in phosphate-regulating gene with homologies to endopeptidase on the X chromosome (PHEX) have been identified as a cause of X-linked hypophosphatemic rickets (XLH; OMIM 307800).
BC8_BioRED_Task1_Doc434	329	337	patients	OrganismTaxon	9606	In the present study, we enrolled 43 patients from 18 unrelated families clinically diagnosed with hypophosphatemic rickets and 250 healthy controls.
BC8_BioRED_Task1_Doc434	391	415	hypophosphatemic rickets	Disease	D063730	In the present study, we enrolled 43 patients from 18 unrelated families clinically diagnosed with hypophosphatemic rickets and 250 healthy controls.
BC8_BioRED_Task1_Doc434	527	531	PHEX	Gene	5251	For each available individual, all 22 exons with their exon-intron boundaries of the PHEX gene were directly sequenced.
BC8_BioRED_Task1_Doc434	582	609	fibroblast growth factor 23	Gene	8074	The levels of serum fibroblast growth factor 23 (FGF23) were measured as well.
BC8_BioRED_Task1_Doc434	611	616	FGF23	Gene	8074	The levels of serum fibroblast growth factor 23 (FGF23) were measured as well.
BC8_BioRED_Task1_Doc434	683	687	PHEX	Gene	5251	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	777	785	c.304G>A	SequenceVariant	c|SUB|G|304|A	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	787	798	p.Gly102Arg	SequenceVariant	p|SUB|G|102|R	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	811	819	c.229T>C	SequenceVariant	c|SUB|T|229|C	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	821	831	p.Cys77Arg	SequenceVariant	p|SUB|C|77|R	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	847	855	c.824T>C	SequenceVariant	c|SUB|T|284|C	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	857	868	p.Leu275Pro	SequenceVariant	p|SUB|L|275|P	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	913	922	c.528delT	SequenceVariant	c|DEL|528|T	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	924	940	p.Glu177LysfsX44	SequenceVariant	p|SUB|E|177|K|44	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	956	966	c.1234delA	SequenceVariant	c|DEL|1234|A	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	968	984	p.Ser412ValfsX12	SequenceVariant	p|SUB|S|412|V|12	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	1046	1062	c.436_436+1delAG	SequenceVariant	c|DEL|436_436+1|AG	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	1103	1114	c.1483-1G>C	SequenceVariant	c|SUB|G|1483-1|C	Sequencing analysis detected 17 different PHEX gene mutations, and 7 of these were identified as novel: 3 missense mutations, including c.304G>A (p.Gly102Arg) in exon 3, c.229T>C (p.Cys77Arg) in exon 3 and c.824T>C (p.Leu275Pro) in exon 7; 2 deletion mutations, including c.528delT (p.Glu177LysfsX44) in exon 5 and c.1234delA (p.Ser412ValfsX12) in exon 11; and 2 alternative splicing mutations, including c.436_436+1delAG in intron 4 at splicing donor sites and c.1483-1G>C in intron 13 at splicing acceptor sites.
BC8_BioRED_Task1_Doc434	1332	1337	FGF23	Gene	8074	The serum levels of FGF23 varied widely among the patients with XLH, and no significant difference was found when compared with those of the healthy controls.
BC8_BioRED_Task1_Doc434	1362	1370	patients	OrganismTaxon	9606	The serum levels of FGF23 varied widely among the patients with XLH, and no significant difference was found when compared with those of the healthy controls.
BC8_BioRED_Task1_Doc434	1376	1379	XLH	Disease	D053098	The serum levels of FGF23 varied widely among the patients with XLH, and no significant difference was found when compared with those of the healthy controls.
BC8_BioRED_Task1_Doc434	1553	1557	PHEX	Gene	5251	On the whole, the findings of this study provide new insight into the spectrum of PHEX mutations and provide potential evidence of a critical domain in PHEX protein.
BC8_BioRED_Task1_Doc434	1623	1627	PHEX	Gene	5251	On the whole, the findings of this study provide new insight into the spectrum of PHEX mutations and provide potential evidence of a critical domain in PHEX protein.
BC8_BioRED_Task1_Doc434	1689	1694	FGF23	Gene	8074	In addition, the finding of an overlap of the serum FGF23 levels between the patients with XLH and the healthy controls indicates its limited diagnostic value in XLH.
BC8_BioRED_Task1_Doc434	1714	1722	patients	OrganismTaxon	9606	In addition, the finding of an overlap of the serum FGF23 levels between the patients with XLH and the healthy controls indicates its limited diagnostic value in XLH.
BC8_BioRED_Task1_Doc434	1728	1731	XLH	Disease	D053098	In addition, the finding of an overlap of the serum FGF23 levels between the patients with XLH and the healthy controls indicates its limited diagnostic value in XLH.
BC8_BioRED_Task1_Doc434	1799	1802	XLH	Disease	D053098	In addition, the finding of an overlap of the serum FGF23 levels between the patients with XLH and the healthy controls indicates its limited diagnostic value in XLH.
BC8_BioRED_Task1_Doc435	16	38	interstitial nephritis	Disease	D009395	Recurrent acute interstitial nephritis induced by azithromycin.
BC8_BioRED_Task1_Doc435	50	62	azithromycin	Chemical	D017963	Recurrent acute interstitial nephritis induced by azithromycin.
BC8_BioRED_Task1_Doc435	111	123	azithromycin	Chemical	D017963	A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.
BC8_BioRED_Task1_Doc435	139	161	interstitial nephritis	Disease	D009395	A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.
BC8_BioRED_Task1_Doc435	260	274	corticosteroid	Chemical	D000305	The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.
BC8_BioRED_Task1_Doc435	341	351	antibiotic	Chemical	D000900	Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.
BC8_BioRED_Task1_Doc435	366	388	interstitial nephritis	Disease	D009395	Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.
BC8_BioRED_Task1_Doc435	423	431	patients	OrganismTaxon	9606	Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.
BC8_BioRED_Task1_Doc435	458	470	renal injury	Disease	D007674	Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.
BC8_BioRED_Task1_Doc436	9	15	G1359A	SequenceVariant	rs1049353	Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet.
BC8_BioRED_Task1_Doc436	36	56	cannabinoid receptor	Gene	1268	Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet.
BC8_BioRED_Task1_Doc436	63	67	CNR1	Gene	1268	Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet.
BC8_BioRED_Task1_Doc436	72	83	weight loss	Disease	D015431	Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet.
BC8_BioRED_Task1_Doc436	178	186	1359 G/A	SequenceVariant	rs1049353	BACKGROUND: A intragenic biallelic polymorphism (1359 G/A) of the CB1 gene resulting in the substitution of the G to A at nucleotide position 1359 in codon 435 (Thr), was reported as a common polymorphism in Caucasian populations.
BC8_BioRED_Task1_Doc436	195	198	CB1	Gene	1268	BACKGROUND: A intragenic biallelic polymorphism (1359 G/A) of the CB1 gene resulting in the substitution of the G to A at nucleotide position 1359 in codon 435 (Thr), was reported as a common polymorphism in Caucasian populations.
BC8_BioRED_Task1_Doc436	241	275	G to A at nucleotide position 1359	SequenceVariant	rs1049353	BACKGROUND: A intragenic biallelic polymorphism (1359 G/A) of the CB1 gene resulting in the substitution of the G to A at nucleotide position 1359 in codon 435 (Thr), was reported as a common polymorphism in Caucasian populations.
BC8_BioRED_Task1_Doc436	279	294	codon 435 (Thr)	SequenceVariant	rs1049353	BACKGROUND: A intragenic biallelic polymorphism (1359 G/A) of the CB1 gene resulting in the substitution of the G to A at nucleotide position 1359 in codon 435 (Thr), was reported as a common polymorphism in Caucasian populations.
BC8_BioRED_Task1_Doc436	495	501	G1359A	SequenceVariant	rs1049353	OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of CB1 receptor gene on adipocytokines response and weight loss secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
BC8_BioRED_Task1_Doc436	506	518	CB1 receptor	Gene	1268	OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of CB1 receptor gene on adipocytokines response and weight loss secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
BC8_BioRED_Task1_Doc436	555	566	weight loss	Disease	D015431	OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of CB1 receptor gene on adipocytokines response and weight loss secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
BC8_BioRED_Task1_Doc436	654	659	obese	Disease	D009765	OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of CB1 receptor gene on adipocytokines response and weight loss secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
BC8_BioRED_Task1_Doc436	660	668	patients	OrganismTaxon	9606	OBJECTIVE: We decided to investigate the role of the polymorphism (G1359A) of CB1 receptor gene on adipocytokines response and weight loss secondary to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
BC8_BioRED_Task1_Doc436	697	705	patients	OrganismTaxon	9606	DESIGN: A population of 94 patients with obesity was analyzed.
BC8_BioRED_Task1_Doc436	711	718	obesity	Disease	D009765	DESIGN: A population of 94 patients with obesity was analyzed.
BC8_BioRED_Task1_Doc436	947	953	G1359A	SequenceVariant	rs1049353	The statistical analysis was performed for the combined G1359A and A1359A as a group and wild type G1359G as second group, with a dominant model.
BC8_BioRED_Task1_Doc436	958	964	A1359A	SequenceVariant	rs1049353	The statistical analysis was performed for the combined G1359A and A1359A as a group and wild type G1359G as second group, with a dominant model.
BC8_BioRED_Task1_Doc436	990	996	G1359G	SequenceVariant	rs1049353	The statistical analysis was performed for the combined G1359A and A1359A as a group and wild type G1359G as second group, with a dominant model.
BC8_BioRED_Task1_Doc436	1058	1066	patients	OrganismTaxon	9606	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1090	1096	G1359G	SequenceVariant	rs1049353	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1128	1136	patients	OrganismTaxon	9606	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1137	1143	G1359A	SequenceVariant	rs1049353	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1148	1156	patients	OrganismTaxon	9606	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1168	1174	A1359A	SequenceVariant	rs1049353	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1178	1186	patients	OrganismTaxon	9606	Results: Forty seven patients (50%) had the genotype G1359G (wild type group) and 47 (50%) patients G1359A (41 patients, 43.6%) or A1359A (6 patients, 6.4%) (mutant type group) had the genotype.
BC8_BioRED_Task1_Doc436	1380	1388	resistin	Gene	56729	In mutant type group, resistin (4.15 1.7 ng/ml vs. 3.90 2.1 ng/ml: P < 0.05), leptin (78.4 69 ng/ml vs 66.2 32 ng/ml: P < 0.05) and IL-6 (1.40 1.9 pg/ml vs 0.81 1.5 pg/ml: P < 0.05) levels decreased after dietary treatment.
BC8_BioRED_Task1_Doc436	1436	1442	leptin	Gene	3952	In mutant type group, resistin (4.15 1.7 ng/ml vs. 3.90 2.1 ng/ml: P < 0.05), leptin (78.4 69 ng/ml vs 66.2 32 ng/ml: P < 0.05) and IL-6 (1.40 1.9 pg/ml vs 0.81 1.5 pg/ml: P < 0.05) levels decreased after dietary treatment.
BC8_BioRED_Task1_Doc436	1490	1494	IL-6	Gene	3569	In mutant type group, resistin (4.15 1.7 ng/ml vs. 3.90 2.1 ng/ml: P < 0.05), leptin (78.4 69 ng/ml vs 66.2 32 ng/ml: P < 0.05) and IL-6 (1.40 1.9 pg/ml vs 0.81 1.5 pg/ml: P < 0.05) levels decreased after dietary treatment.
BC8_BioRED_Task1_Doc436	1667	1672	A1359	SequenceVariant	rs1049353	CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, leptin and interleukin-6 secondary to weight loss.
BC8_BioRED_Task1_Doc436	1693	1701	resistin	Gene	56729	CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, leptin and interleukin-6 secondary to weight loss.
BC8_BioRED_Task1_Doc436	1703	1709	leptin	Gene	3952	CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, leptin and interleukin-6 secondary to weight loss.
BC8_BioRED_Task1_Doc436	1714	1727	interleukin-6	Gene	3569	CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, leptin and interleukin-6 secondary to weight loss.
BC8_BioRED_Task1_Doc436	1741	1752	weight loss	Disease	D015431	CONCLUSION: The novel finding of this study is the association of the mutant allele (A1359) with a decrease of resistin, leptin and interleukin-6 secondary to weight loss.
BC8_BioRED_Task1_Doc437	16	30	calbindin-D28k	Gene	12307	Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model.
BC8_BioRED_Task1_Doc437	54	73	Alzheimer's disease	Disease	D000544	Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model.
BC8_BioRED_Task1_Doc437	74	79	mouse	OrganismTaxon	10090	Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model.
BC8_BioRED_Task1_Doc437	87	101	Calbindin-D28k	Gene	12307	Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis.
BC8_BioRED_Task1_Doc437	103	105	CB	Gene	12307	Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis.
BC8_BioRED_Task1_Doc437	125	132	calcium	Chemical	D002118	Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis.
BC8_BioRED_Task1_Doc437	201	215	neuronal death	Disease	D009410	Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis.
BC8_BioRED_Task1_Doc437	239	246	calcium	Chemical	D002118	Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis.
BC8_BioRED_Task1_Doc437	290	292	CB	Gene	12307,793	Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction.
BC8_BioRED_Task1_Doc437	340	344	mice	OrganismTaxon	10090	Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction.
BC8_BioRED_Task1_Doc437	349	355	humans	OrganismTaxon	9606	Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction.
BC8_BioRED_Task1_Doc437	361	378	Alzheimer disease	Disease	D000544	Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction.
BC8_BioRED_Task1_Doc437	380	382	AD	Disease	D000544	Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction.
BC8_BioRED_Task1_Doc437	435	437	AD	Disease	D000544	Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction.
BC8_BioRED_Task1_Doc437	501	503	CB	Gene	12307	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	518	520	AD	Disease	D000544	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	551	553	AD	Disease	D000544	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	568	570	AD	Disease	D000544	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	576	580	mice	OrganismTaxon	10090	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	586	588	CB	Gene	12307	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	600	602	CB	Gene	12307	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	606	610	mice	OrganismTaxon	10090	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	638	640	CB	Gene	12307	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	646	648	AD	Disease	D000544	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	650	652	CB	Gene	12307	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	658	662	mice	OrganismTaxon	10090	To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice.
BC8_BioRED_Task1_Doc437	776	778	CB	Gene	12307	We first identified the change of signaling pathways and differentially expressed proteins globally by removing CB in Tg mice using mass spectrometry and antibody microarray.
BC8_BioRED_Task1_Doc437	785	789	mice	OrganismTaxon	10090	We first identified the change of signaling pathways and differentially expressed proteins globally by removing CB in Tg mice using mass spectrometry and antibody microarray.
BC8_BioRED_Task1_Doc437	872	874	CB	Gene	12307	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	879	883	mice	OrganismTaxon	10090	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	900	913	neuronal loss	Disease	D009410	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	979	996	amyloid b-peptide	Gene	11820	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	998	1000	Ab	Gene	11820	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	1069	1094	mitochondrial dysfunction	Disease	D028361	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	1112	1116	mice	OrganismTaxon	10090	Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice.
BC8_BioRED_Task1_Doc437	1128	1130	CB	Gene	12307	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1135	1139	mice	OrganismTaxon	10090	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1173	1205	mitogen-activated protein kinase	Gene	26413,26417	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1207	1249	extracellular signal-regulated kinase) 1/2	Gene	26413,26417	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1254	1291	cAMP response element-binding protein	Gene	12912	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1334	1365	N-methyl-D-aspartate receptor 1	Gene	14810	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1367	1382	NMDA receptor 1	Gene	14810	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1385	1401	NMDA receptor 2A	Gene	14811	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1403	1409	PSD-95	Gene	13385	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1414	1427	synaptophysin	Gene	20977	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1462	1466	mice	OrganismTaxon	10090	Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice.
BC8_BioRED_Task1_Doc437	1537	1539	CB	Gene	12307	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc437	1545	1570	amyloid precursor protein	Gene	11820	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc437	1571	1581	presenilin	Gene	19164	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc437	1593	1597	mice	OrganismTaxon	10090	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc437	1609	1611	AD	Disease	D000544	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc437	1642	1644	CB	Gene	12307	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc437	1668	1670	AD	Disease	D000544	Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.
BC8_BioRED_Task1_Doc438	26	38	inflammatory	Disease	D007249	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	52	85	vasoactive intestinal polypeptide	Gene	22353	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	96	99	VIP	Gene	22353	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	104	108	mice	OrganismTaxon	10090	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	114	130	cyclophosphamide	Chemical	D003520	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	132	135	CYP	Chemical	D003520	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	145	153	cystitis	Disease	D003556	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	155	188	Vasoactive intestinal polypeptide	Gene	22353	Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways.
BC8_BioRED_Task1_Doc438	190	193	VIP	Gene	22353	Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways.
BC8_BioRED_Task1_Doc438	268	271	VIP	Gene	22353	VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	277	281	mice	OrganismTaxon	10090	VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	374	390	cyclophosphamide	Chemical	D003520	VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	392	395	CYP	Chemical	D003520	VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	405	413	cystitis	Disease	D003556	VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.
BC8_BioRED_Task1_Doc438	421	424	VIP	Gene	22353	Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.
BC8_BioRED_Task1_Doc438	443	455	inflammatory	Disease	D007249	Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.
BC8_BioRED_Task1_Doc438	487	490	VIP	Gene	22353	Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.
BC8_BioRED_Task1_Doc438	496	500	mice	OrganismTaxon	10090	Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.
BC8_BioRED_Task1_Doc438	524	536	inflammatory	Disease	D007249	Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.
BC8_BioRED_Task1_Doc438	563	571	cystitis	Disease	D003556	Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.
BC8_BioRED_Task1_Doc438	575	580	mouse	OrganismTaxon	10090	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.
BC8_BioRED_Task1_Doc438	581	593	inflammatory	Disease	D007249	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.
BC8_BioRED_Task1_Doc438	724	727	VIP	Gene	22353	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.
BC8_BioRED_Task1_Doc438	733	737	mice	OrganismTaxon	10090	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.
BC8_BioRED_Task1_Doc438	754	757	CYP	Chemical	D003520	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.
BC8_BioRED_Task1_Doc438	766	774	cystitis	Disease	D003556	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.
BC8_BioRED_Task1_Doc438	853	856	CYP	Chemical	D003520	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	875	878	VIP	Gene	22353	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	899	902	CYP	Chemical	D003520	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	939	942	VIP	Gene	22353	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	969	972	CYP	Chemical	D003520	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	997	1000	VIP	Gene	22353	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	1011	1014	CYP	Chemical	D003520	Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).
BC8_BioRED_Task1_Doc438	1267	1275	IL-1beta	Gene	16176	Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.
BC8_BioRED_Task1_Doc438	1280	1285	CXCL1	Gene	14825	Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.
BC8_BioRED_Task1_Doc438	1287	1290	CYP	Chemical	D003520	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1356	1361	CXCL1	Gene	14825	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1366	1374	IL-1beta	Gene	16176	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1408	1411	VIP	Gene	22353	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1417	1421	mice	OrganismTaxon	10090	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1441	1444	VIP	Gene	22353	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1450	1454	mice	OrganismTaxon	10090	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1460	1463	CYP	Chemical	D003520	CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).
BC8_BioRED_Task1_Doc438	1637	1640	VIP	Gene	22353	The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.
BC8_BioRED_Task1_Doc438	1646	1650	mice	OrganismTaxon	10090	The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.
BC8_BioRED_Task1_Doc438	1656	1676	bladder inflammation	Disease	D003556	The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.
BC8_BioRED_Task1_Doc438	1678	1690	inflammatory	Disease	D007249	The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.
BC8_BioRED_Task1_Doc438	1746	1749	CYP	Chemical	D003520	The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.
BC8_BioRED_Task1_Doc438	1801	1820	bladder dysfunction	Disease	D001745	This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.
BC8_BioRED_Task1_Doc438	1824	1827	VIP	Gene	22353	This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.
BC8_BioRED_Task1_Doc438	1833	1837	mice	OrganismTaxon	10090	This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.
BC8_BioRED_Task1_Doc438	1843	1863	bladder inflammation	Disease	D003556	This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.
BC8_BioRED_Task1_Doc439	77	83	Klotho	Gene	9365	A potential regulatory single nucleotide polymorphism in the promoter of the Klotho gene may be associated with essential hypertension in the Chinese Han population.
BC8_BioRED_Task1_Doc439	112	134	essential hypertension	Disease	D000075222	A potential regulatory single nucleotide polymorphism in the promoter of the Klotho gene may be associated with essential hypertension in the Chinese Han population.
BC8_BioRED_Task1_Doc439	178	182	Mice	OrganismTaxon	10090	BACKGROUND: Mice with defects in the Klotho gene exhibit multiple aging phenotypes including arteriosclerosis.
BC8_BioRED_Task1_Doc439	203	209	Klotho	Gene	16591	BACKGROUND: Mice with defects in the Klotho gene exhibit multiple aging phenotypes including arteriosclerosis.
BC8_BioRED_Task1_Doc439	259	275	arteriosclerosis	Disease	D001161	BACKGROUND: Mice with defects in the Klotho gene exhibit multiple aging phenotypes including arteriosclerosis.
BC8_BioRED_Task1_Doc439	302	308	G-395A	SequenceVariant	rs1207568	We hypothesised that the G-395A polymorphism in the promoter region of the human Klotho gene may contribute to the prevalence of Essential Hypertension (EH).
BC8_BioRED_Task1_Doc439	352	357	human	OrganismTaxon	9606	We hypothesised that the G-395A polymorphism in the promoter region of the human Klotho gene may contribute to the prevalence of Essential Hypertension (EH).
BC8_BioRED_Task1_Doc439	358	364	Klotho	Gene	9365	We hypothesised that the G-395A polymorphism in the promoter region of the human Klotho gene may contribute to the prevalence of Essential Hypertension (EH).
BC8_BioRED_Task1_Doc439	406	428	Essential Hypertension	Disease	D000075222	We hypothesised that the G-395A polymorphism in the promoter region of the human Klotho gene may contribute to the prevalence of Essential Hypertension (EH).
BC8_BioRED_Task1_Doc439	430	432	EH	Disease	D000075222	We hypothesised that the G-395A polymorphism in the promoter region of the human Klotho gene may contribute to the prevalence of Essential Hypertension (EH).
BC8_BioRED_Task1_Doc439	471	477	G-395A	SequenceVariant	rs1207568	METHODS: We investigate whether the G-395A polymorphism of Klotho is associated with EH in a population consisting of 215 patients with EH and 220 non-hypertensive subjects.
BC8_BioRED_Task1_Doc439	494	500	Klotho	Gene	9365	METHODS: We investigate whether the G-395A polymorphism of Klotho is associated with EH in a population consisting of 215 patients with EH and 220 non-hypertensive subjects.
BC8_BioRED_Task1_Doc439	520	522	EH	Disease	D000075222	METHODS: We investigate whether the G-395A polymorphism of Klotho is associated with EH in a population consisting of 215 patients with EH and 220 non-hypertensive subjects.
BC8_BioRED_Task1_Doc439	557	565	patients	OrganismTaxon	9606	METHODS: We investigate whether the G-395A polymorphism of Klotho is associated with EH in a population consisting of 215 patients with EH and 220 non-hypertensive subjects.
BC8_BioRED_Task1_Doc439	571	573	EH	Disease	D000075222	METHODS: We investigate whether the G-395A polymorphism of Klotho is associated with EH in a population consisting of 215 patients with EH and 220 non-hypertensive subjects.
BC8_BioRED_Task1_Doc439	586	598	hypertensive	Disease	D006973	METHODS: We investigate whether the G-395A polymorphism of Klotho is associated with EH in a population consisting of 215 patients with EH and 220 non-hypertensive subjects.
BC8_BioRED_Task1_Doc439	634	637	G/A	SequenceVariant	rs1207568	We also tested whether a G/A substitution at the G-395A site affected the transcription level in vitro through the dual-luciferase reporter assay.
BC8_BioRED_Task1_Doc439	658	664	G-395A	SequenceVariant	rs1207568	We also tested whether a G/A substitution at the G-395A site affected the transcription level in vitro through the dual-luciferase reporter assay.
BC8_BioRED_Task1_Doc439	814	820	G-395A	SequenceVariant	rs1207568	RESULTS: Differences in the genotype distributions of the G-395A polymorphism between the EH and non-hypertension groups are statistically significant (P=0.032).
BC8_BioRED_Task1_Doc439	846	848	EH	Disease	D000075222	RESULTS: Differences in the genotype distributions of the G-395A polymorphism between the EH and non-hypertension groups are statistically significant (P=0.032).
BC8_BioRED_Task1_Doc439	857	869	hypertension	Disease	D006973	RESULTS: Differences in the genotype distributions of the G-395A polymorphism between the EH and non-hypertension groups are statistically significant (P=0.032).
BC8_BioRED_Task1_Doc439	1009	1015	G-395A	SequenceVariant	rs1207568	There are differential effects of age, gender and smoking status on the association of the G-395A polymorphism with EH; the G-395A polymorphism is significantly associated with EH in subjects over 60years old, in females and in nonsmokers.
BC8_BioRED_Task1_Doc439	1034	1036	EH	Disease	D000075222	There are differential effects of age, gender and smoking status on the association of the G-395A polymorphism with EH; the G-395A polymorphism is significantly associated with EH in subjects over 60years old, in females and in nonsmokers.
BC8_BioRED_Task1_Doc439	1042	1048	G-395A	SequenceVariant	rs1207568	There are differential effects of age, gender and smoking status on the association of the G-395A polymorphism with EH; the G-395A polymorphism is significantly associated with EH in subjects over 60years old, in females and in nonsmokers.
BC8_BioRED_Task1_Doc439	1095	1097	EH	Disease	D000075222	There are differential effects of age, gender and smoking status on the association of the G-395A polymorphism with EH; the G-395A polymorphism is significantly associated with EH in subjects over 60years old, in females and in nonsmokers.
BC8_BioRED_Task1_Doc439	1232	1234	EH	Disease	D000075222	A multiple logistic regression analysis indicated that the odds ratio for EH in the -395A allele carriers as compared with the control group was 0.593 (P=0.024) after adjusting for current traditional risk factors.
BC8_BioRED_Task1_Doc439	1242	1247	-395A	SequenceVariant	rs1207568	A multiple logistic regression analysis indicated that the odds ratio for EH in the -395A allele carriers as compared with the control group was 0.593 (P=0.024) after adjusting for current traditional risk factors.
BC8_BioRED_Task1_Doc439	1426	1431	-395A	SequenceVariant	rs1207568	The dual-luciferase reporter assay revealed that the -395A carrier of a 498-bp DNA fragment (containing the G-395A site) upstream of the Klotho gene has higher relative luciferase activity than the -395G carrier.
BC8_BioRED_Task1_Doc439	1481	1487	G-395A	SequenceVariant	rs1207568	The dual-luciferase reporter assay revealed that the -395A carrier of a 498-bp DNA fragment (containing the G-395A site) upstream of the Klotho gene has higher relative luciferase activity than the -395G carrier.
BC8_BioRED_Task1_Doc439	1510	1516	Klotho	Gene	9365	The dual-luciferase reporter assay revealed that the -395A carrier of a 498-bp DNA fragment (containing the G-395A site) upstream of the Klotho gene has higher relative luciferase activity than the -395G carrier.
BC8_BioRED_Task1_Doc439	1571	1576	-395G	SequenceVariant	rs1207568	The dual-luciferase reporter assay revealed that the -395A carrier of a 498-bp DNA fragment (containing the G-395A site) upstream of the Klotho gene has higher relative luciferase activity than the -395G carrier.
BC8_BioRED_Task1_Doc439	1603	1609	G-395A	SequenceVariant	rs1207568	CONCLUSIONS: The G-395A polymorphism of the human Klotho gene is associated with EH and may be a potential regulatory site.
BC8_BioRED_Task1_Doc439	1630	1635	human	OrganismTaxon	9606	CONCLUSIONS: The G-395A polymorphism of the human Klotho gene is associated with EH and may be a potential regulatory site.
BC8_BioRED_Task1_Doc439	1636	1642	Klotho	Gene	9365	CONCLUSIONS: The G-395A polymorphism of the human Klotho gene is associated with EH and may be a potential regulatory site.
BC8_BioRED_Task1_Doc439	1667	1669	EH	Disease	D000075222	CONCLUSIONS: The G-395A polymorphism of the human Klotho gene is associated with EH and may be a potential regulatory site.
BC8_BioRED_Task1_Doc440	58	76	opioid receptor u1	Gene	4988	Genome-wide loss-of-function genetic screening identifies opioid receptor u1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
BC8_BioRED_Task1_Doc440	99	113	L-asparaginase	Chemical	D001215	Genome-wide loss-of-function genetic screening identifies opioid receptor u1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
BC8_BioRED_Task1_Doc440	138	166	acute lymphoblastic leukemia	Disease	D054198	Genome-wide loss-of-function genetic screening identifies opioid receptor u1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
BC8_BioRED_Task1_Doc440	168	182	L-asparaginase	Chemical	D001215	L-asparaginase is a critical chemotherapeutic agent for acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc440	224	252	acute lymphoblastic leukemia	Disease	D054198	L-asparaginase is a critical chemotherapeutic agent for acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc440	254	257	ALL	Disease	D054198	L-asparaginase is a critical chemotherapeutic agent for acute lymphoblastic leukemia (ALL).
BC8_BioRED_Task1_Doc440	281	291	asparagine	Chemical	D001216	It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.
BC8_BioRED_Task1_Doc440	297	306	aspartate	Chemical	D001224	It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.
BC8_BioRED_Task1_Doc440	311	314	NH3	Chemical	D000641	It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.
BC8_BioRED_Task1_Doc440	324	342	asparagine deficit	Disease	OMIM:615574	It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.
BC8_BioRED_Task1_Doc440	395	403	leukemic	Disease	D007938	It hydrolyzes plasma asparagine into aspartate and NH3, causing asparagine deficit and inhibition of protein synthesis and eventually, leukemic cell death.
BC8_BioRED_Task1_Doc440	425	432	patient	OrganismTaxon	9606	However, patient relapse often occurs due to development of resistance.
BC8_BioRED_Task1_Doc440	521	524	ALL	Disease	D054198	The molecular mechanism by which ALL cells acquire resistance to L-asparaginase is unknown.
BC8_BioRED_Task1_Doc440	553	567	L-asparaginase	Chemical	D001215	The molecular mechanism by which ALL cells acquire resistance to L-asparaginase is unknown.
BC8_BioRED_Task1_Doc440	640	654	L-asparaginase	Chemical	D001215	Therefore, we sought to identify genes that are involved in L-asparaginase resistance in primary leukemic cells.
BC8_BioRED_Task1_Doc440	677	685	leukemic	Disease	D007938	Therefore, we sought to identify genes that are involved in L-asparaginase resistance in primary leukemic cells.
BC8_BioRED_Task1_Doc440	766	769	ALL	Disease	D054198	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	796	816	opioid receptor mu 1	Gene	4988	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	818	823	oprm1	Gene	4988	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	844	864	carbonic anhydrase 1	Gene	759	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	866	869	ca1	Gene	759	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	901	933	ubiquitin-conjugating enzyme E2C	Gene	11065	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	935	940	ube2c	Gene	11065	By unbiased genome-wide RNAi screening, we found that among 10 resistant ALL clones, six hits were for opioid receptor mu 1 (oprm1), two hits were for carbonic anhydrase 1 (ca1) and another two hits were for ubiquitin-conjugating enzyme E2C (ube2c).
BC8_BioRED_Task1_Doc440	962	967	OPRM1	Gene	4988	We also found that OPRM1 is expressed in all leukemic cells tested.
BC8_BioRED_Task1_Doc440	988	996	leukemic	Disease	D007938	We also found that OPRM1 is expressed in all leukemic cells tested.
BC8_BioRED_Task1_Doc440	1033	1038	OPRM1	Gene	4988	Specific knockdown of OPRM1 confers L-asparaginase resistance, validating our genome-wide retroviral shRNA library screening data.
BC8_BioRED_Task1_Doc440	1047	1061	L-asparaginase	Chemical	D001215	Specific knockdown of OPRM1 confers L-asparaginase resistance, validating our genome-wide retroviral shRNA library screening data.
BC8_BioRED_Task1_Doc440	1142	1151	Methadone	Chemical	D008691	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1167	1172	OPRM1	Gene	4988	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1211	1219	leukemic	Disease	D007938	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1235	1240	OPRM1	Gene	4988	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1260	1274	L-asparaginase	Chemical	D001215	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1302	1307	OPRM1	Gene	4988	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1350	1364	L-asparaginase	Chemical	D001215	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1369	1378	methadone	Chemical	D008691	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1389	1394	OPRM1	Gene	4988	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1409	1417	leukemic	Disease	D007938	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1469	1474	OPRM1	Gene	4988	Methadone, an agonist of OPRM1, enhances the sensitivity of parental leukemic cells, but not OPRM1-depleted cells, to L-asparaginase treatment, indicating that OPRM1 is required for the synergistic action of L-asparaginase and methadone, and that OPRM1 loss promotes leukemic cell survival likely through downregulation of the OPRM1-mediated apoptotic pathway.
BC8_BioRED_Task1_Doc440	1533	1540	patient	OrganismTaxon	9606	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1541	1549	leukemic	Disease	D007938	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1587	1592	OPRM1	Gene	4988	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1615	1629	L-asparaginase	Chemical	D001215	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1652	1657	OPRM1	Gene	4988	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1667	1675	leukemic	Disease	D007938	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1707	1712	OPRM1	Gene	4988	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1740	1754	L-asparaginase	Chemical	D001215	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1769	1777	leukemic	Disease	D007938	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1778	1786	patients	OrganismTaxon	9606	Consistent with this premise, patient leukemic cells with relatively high levels of OPRM1 are more sensitive to L-asparaginase treatment compared to OPRM1-depleted leukemic cells, further indicating that OPRM1 loss has a crucial role in L-asparaginase resistance in leukemic patients.
BC8_BioRED_Task1_Doc440	1845	1850	OPRM1	Gene	4988	Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for L-asparaginase resistance in ALL, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.
BC8_BioRED_Task1_Doc440	1874	1888	L-asparaginase	Chemical	D001215	Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for L-asparaginase resistance in ALL, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.
BC8_BioRED_Task1_Doc440	1903	1906	ALL	Disease	D054198	Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for L-asparaginase resistance in ALL, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.
BC8_BioRED_Task1_Doc440	1923	1928	OPRM1	Gene	4988	Thus, our study demonstrates for the first time, a novel OPRM1-mediated mechanism for L-asparaginase resistance in ALL, and identifies OPRM1 as a functional biomarker for defining high-risk subpopulations and for the detection of evolving resistant clones.
BC8_BioRED_Task1_Doc440	2045	2050	Oprm1	Gene	4988	Oprm1 may also be utilized for effective treatment of L-asparaginase-resistant ALL.Oncogene advance online publication, 26 June 2017; doi:10.1038/onc.2017.211.
BC8_BioRED_Task1_Doc440	2099	2113	L-asparaginase	Chemical	D001215	Oprm1 may also be utilized for effective treatment of L-asparaginase-resistant ALL.Oncogene advance online publication, 26 June 2017; doi:10.1038/onc.2017.211.
BC8_BioRED_Task1_Doc440	2124	2127	ALL	Disease	D054198	Oprm1 may also be utilized for effective treatment of L-asparaginase-resistant ALL.Oncogene advance online publication, 26 June 2017; doi:10.1038/onc.2017.211.
BC8_BioRED_Task1_Doc441	17	22	CXCR1	Gene	3577	Variation in the CXCR1 gene (IL8RA) is not associated with susceptibility to chronic periodontitis.
BC8_BioRED_Task1_Doc441	29	34	IL8RA	Gene	3577	Variation in the CXCR1 gene (IL8RA) is not associated with susceptibility to chronic periodontitis.
BC8_BioRED_Task1_Doc441	77	98	chronic periodontitis	Disease	D055113	Variation in the CXCR1 gene (IL8RA) is not associated with susceptibility to chronic periodontitis.
BC8_BioRED_Task1_Doc441	116	143	chemokine receptor 1 CXCR-1	Gene	3577	BACKGROUND: The chemokine receptor 1 CXCR-1 (or IL8R-alpha) is a specific receptor for the interleukin 8 (IL-8), which is chemoattractant for neutrophils and has an important role in the inflammatory response.
BC8_BioRED_Task1_Doc441	148	158	IL8R-alpha	Gene	3577	BACKGROUND: The chemokine receptor 1 CXCR-1 (or IL8R-alpha) is a specific receptor for the interleukin 8 (IL-8), which is chemoattractant for neutrophils and has an important role in the inflammatory response.
BC8_BioRED_Task1_Doc441	191	204	interleukin 8	Gene	3576	BACKGROUND: The chemokine receptor 1 CXCR-1 (or IL8R-alpha) is a specific receptor for the interleukin 8 (IL-8), which is chemoattractant for neutrophils and has an important role in the inflammatory response.
BC8_BioRED_Task1_Doc441	206	210	IL-8	Gene	3576	BACKGROUND: The chemokine receptor 1 CXCR-1 (or IL8R-alpha) is a specific receptor for the interleukin 8 (IL-8), which is chemoattractant for neutrophils and has an important role in the inflammatory response.
BC8_BioRED_Task1_Doc441	287	299	inflammatory	Disease	D007249	BACKGROUND: The chemokine receptor 1 CXCR-1 (or IL8R-alpha) is a specific receptor for the interleukin 8 (IL-8), which is chemoattractant for neutrophils and has an important role in the inflammatory response.
BC8_BioRED_Task1_Doc441	327	336	rs2234671	SequenceVariant	rs2234671	The polymorphism rs2234671 at position Ex2+860G>C of the CXCR1 gene causes a conservative amino acid substitution (S276T).
BC8_BioRED_Task1_Doc441	349	359	Ex2+860G>C	SequenceVariant	rs2234671	The polymorphism rs2234671 at position Ex2+860G>C of the CXCR1 gene causes a conservative amino acid substitution (S276T).
BC8_BioRED_Task1_Doc441	367	372	CXCR1	Gene	3577	The polymorphism rs2234671 at position Ex2+860G>C of the CXCR1 gene causes a conservative amino acid substitution (S276T).
BC8_BioRED_Task1_Doc441	425	430	S276T	SequenceVariant	rs2234671	The polymorphism rs2234671 at position Ex2+860G>C of the CXCR1 gene causes a conservative amino acid substitution (S276T).
BC8_BioRED_Task1_Doc441	535	546	lung cancer	Disease	D008175	This single nucleotide polymorphism (SNP) seemed to be functional as it was associated with decreased lung cancer risk.
BC8_BioRED_Task1_Doc441	622	625	IL8	Gene	3576	Previous studies of our group found association of haplotypes in the IL8 and in the CXCR2 genes with the multifactorial disease chronic periodontitis.
BC8_BioRED_Task1_Doc441	637	642	CXCR2	Gene	3579	Previous studies of our group found association of haplotypes in the IL8 and in the CXCR2 genes with the multifactorial disease chronic periodontitis.
BC8_BioRED_Task1_Doc441	681	702	chronic periodontitis	Disease	D055113	Previous studies of our group found association of haplotypes in the IL8 and in the CXCR2 genes with the multifactorial disease chronic periodontitis.
BC8_BioRED_Task1_Doc441	751	760	rs2234671	SequenceVariant	rs2234671	In this study we investigated the polymorphism rs2234671 in 395 Brazilian subjects with and without chronic periodontitis.
BC8_BioRED_Task1_Doc441	804	825	chronic periodontitis	Disease	D055113	In this study we investigated the polymorphism rs2234671 in 395 Brazilian subjects with and without chronic periodontitis.
BC8_BioRED_Task1_Doc441	972	981	rs2234671	SequenceVariant	rs2234671	CONCLUSIONS: The polymorphism rs2234671 in the CXCR1 gene was not associated with the susceptibility to chronic periodontitis in the studied Brazilian population.
BC8_BioRED_Task1_Doc441	989	994	CXCR1	Gene	3577	CONCLUSIONS: The polymorphism rs2234671 in the CXCR1 gene was not associated with the susceptibility to chronic periodontitis in the studied Brazilian population.
BC8_BioRED_Task1_Doc441	1046	1067	chronic periodontitis	Disease	D055113	CONCLUSIONS: The polymorphism rs2234671 in the CXCR1 gene was not associated with the susceptibility to chronic periodontitis in the studied Brazilian population.
BC8_BioRED_Task1_Doc442	8	18	mangiferin	Chemical	C013592	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc442	72	85	isoproterenol	Chemical	D007545	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc442	94	115	myocardial infarction	Disease	D009203	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc442	119	123	rats	OrganismTaxon	10116	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc442	177	187	mangiferin	Chemical	C013592	The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn.
BC8_BioRED_Task1_Doc442	191	201	polyphenol	Chemical	D059808	The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn.
BC8_BioRED_Task1_Doc442	207	228	Mangifera indica Linn	OrganismTaxon	29780	The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn.
BC8_BioRED_Task1_Doc442	250	263	isoproterenol	Chemical	D007545	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
BC8_BioRED_Task1_Doc442	265	269	ISPH	Chemical	D007545	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
BC8_BioRED_Task1_Doc442	279	300	myocardial infarction	Disease	D009203	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
BC8_BioRED_Task1_Doc442	302	304	MI	Disease	D009203	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
BC8_BioRED_Task1_Doc442	309	313	rats	OrganismTaxon	10116	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
BC8_BioRED_Task1_Doc442	377	381	ISPH	Chemical	D007545	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	424	428	rats	OrganismTaxon	10116	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	459	476	myocardial damage	Disease	D009202	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	480	483	rat	OrganismTaxon	10116	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	547	568	lactate dehydrogenase	Gene	24533	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	570	573	LDH	Gene	24533	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	579	612	creatine phosphokinase isoenzymes	Gene	24264	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	614	619	CK-MB	Gene	24264	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	632	641	uric acid	Chemical	D014527	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	667	671	iron	Chemical	D007501	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
BC8_BioRED_Task1_Doc442	713	723	mangiferin	Chemical	C013592	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
BC8_BioRED_Task1_Doc442	740	770	triphenyl tetrazolium chloride	Chemical	C009591	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
BC8_BioRED_Task1_Doc442	772	775	TTC	Chemical	C009591	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
BC8_BioRED_Task1_Doc442	831	850	ischemic myocardium	Disease	D017202	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
BC8_BioRED_Task1_Doc442	897	917	superoxide dismutase	Gene	24786	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	919	927	catalase	Gene	24248	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	929	951	glutathione peroxidase	Gene	24404	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	953	976	glutathione transferase	Gene	24421	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	981	1002	glutathione reductase	Gene	116686	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1048	1062	cerruloplasmin	Gene	1356	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1064	1073	Vitamin C	Chemical	D001205	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1075	1084	Vitamin E	Chemical	D014810	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1089	1100	glutathione	Chemical	D005978	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1124	1126	MI	Disease	D009203	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1127	1131	rats	OrganismTaxon	10116	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
BC8_BioRED_Task1_Doc442	1156	1166	mangiferin	Chemical	C013592	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
BC8_BioRED_Task1_Doc442	1211	1230	dimethyl sulphoxide	Chemical	D004121	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
BC8_BioRED_Task1_Doc442	1271	1273	MI	Disease	D009203	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
BC8_BioRED_Task1_Doc442	1274	1278	rats	OrganismTaxon	10116	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
BC8_BioRED_Task1_Doc442	1466	1476	mangiferin	Chemical	C013592	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
BC8_BioRED_Task1_Doc442	1507	1511	ISPH	Chemical	D007545	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
BC8_BioRED_Task1_Doc442	1520	1522	MI	Disease	D009203	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
BC8_BioRED_Task1_Doc442	1523	1527	rats	OrganismTaxon	10116	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
BC8_BioRED_Task1_Doc442	1573	1583	mangiferin	Chemical	C013592	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
BC8_BioRED_Task1_Doc442	1619	1623	ISPH	Chemical	D007545	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
BC8_BioRED_Task1_Doc442	1632	1634	MI	Disease	D009203	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
BC8_BioRED_Task1_Doc442	1720	1734	cardiac damage	Disease	D006331	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.
BC8_BioRED_Task1_Doc443	39	48	HNF4alpha	Gene	3172	Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	92	116	type 2 diabetes mellitus	Disease	D003924	Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	140	172	Hepatocyte nuclear factor 4alpha	Gene	3172	Hepatocyte nuclear factor 4alpha (HNF4alpha) is a transcription factor, which is necessary for normal function of human liver and pancreatic islets.
BC8_BioRED_Task1_Doc443	174	183	HNF4alpha	Gene	3172	Hepatocyte nuclear factor 4alpha (HNF4alpha) is a transcription factor, which is necessary for normal function of human liver and pancreatic islets.
BC8_BioRED_Task1_Doc443	254	259	human	OrganismTaxon	9606	Hepatocyte nuclear factor 4alpha (HNF4alpha) is a transcription factor, which is necessary for normal function of human liver and pancreatic islets.
BC8_BioRED_Task1_Doc443	355	360	HNF4A	Gene	3172	We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to type 2 diabetes mellitus in subjects of the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	371	380	HNF4alpha	Gene	3172	We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to type 2 diabetes mellitus in subjects of the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	413	439	impaired glucose tolerance	Disease	D018149	We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to type 2 diabetes mellitus in subjects of the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	441	444	IGT	Disease	D018149	We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to type 2 diabetes mellitus in subjects of the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	449	473	type 2 diabetes mellitus	Disease	D003924	We investigated whether single nucleotide polymorphisms (SNPs) of HNF4A, encoding HNF4alpha, influenced the conversion from impaired glucose tolerance (IGT) to type 2 diabetes mellitus in subjects of the STOP-NIDDM trial.
BC8_BioRED_Task1_Doc443	556	564	acarbose	Chemical	D020909	This trial aimed at evaluating the effect of acarbose compared to placebo in the prevention of type 2 diabetes mellitus.
BC8_BioRED_Task1_Doc443	606	630	type 2 diabetes mellitus	Disease	D003924	This trial aimed at evaluating the effect of acarbose compared to placebo in the prevention of type 2 diabetes mellitus.
BC8_BioRED_Task1_Doc443	704	709	HNF4A	Gene	3172	Eight SNPs covering the intragenic and alternate P2 promoter regions of HNF4A were genotyped in study samples using the TaqMan Allelic Discrimination Assays.
BC8_BioRED_Task1_Doc443	828	837	rs4810424	SequenceVariant	rs4810424	Three SNPs in the P2 promoter region (rs4810424, rs1884614, and rs2144908) were in almost complete association (D'>0.97, r (2)>0.95) and, therefore, only rs4810424 was included in further analyses.
BC8_BioRED_Task1_Doc443	839	848	rs1884614	SequenceVariant	rs1884614	Three SNPs in the P2 promoter region (rs4810424, rs1884614, and rs2144908) were in almost complete association (D'>0.97, r (2)>0.95) and, therefore, only rs4810424 was included in further analyses.
BC8_BioRED_Task1_Doc443	854	863	rs2144908	SequenceVariant	rs2144908	Three SNPs in the P2 promoter region (rs4810424, rs1884614, and rs2144908) were in almost complete association (D'>0.97, r (2)>0.95) and, therefore, only rs4810424 was included in further analyses.
BC8_BioRED_Task1_Doc443	944	953	rs4810424	SequenceVariant	rs4810424	Three SNPs in the P2 promoter region (rs4810424, rs1884614, and rs2144908) were in almost complete association (D'>0.97, r (2)>0.95) and, therefore, only rs4810424 was included in further analyses.
BC8_BioRED_Task1_Doc443	1037	1046	rs4810424	SequenceVariant	rs4810424	Female carriers of the less frequent C allele of rs4810424 had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to diabetes compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.
BC8_BioRED_Task1_Doc443	1148	1156	diabetes	Disease	D003920	Female carriers of the less frequent C allele of rs4810424 had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to diabetes compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.
BC8_BioRED_Task1_Doc443	1169	1174	women	OrganismTaxon	9606	Female carriers of the less frequent C allele of rs4810424 had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to diabetes compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.
BC8_BioRED_Task1_Doc443	1258	1266	acarbose	Chemical	D020909	Female carriers of the less frequent C allele of rs4810424 had a 1.7-fold elevated risk [95% confidence interval (CI) 1.09-2.66; P=0.020] for the conversion to diabetes compared to women with the common genotype after the adjustment for age, treatment group (placebo or acarbose), smoking, weight at baseline, and weight change.
BC8_BioRED_Task1_Doc443	1345	1348	men	OrganismTaxon	9606	No association was found in men.
BC8_BioRED_Task1_Doc443	1390	1399	rs4810424	SequenceVariant	rs4810424	Haplotype analysis based on three SNPs (rs4810424, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.
BC8_BioRED_Task1_Doc443	1401	1410	rs2071197	SequenceVariant	rs2071197	Haplotype analysis based on three SNPs (rs4810424, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.
BC8_BioRED_Task1_Doc443	1416	1425	rs3818247	SequenceVariant	rs3818247	Haplotype analysis based on three SNPs (rs4810424, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.
BC8_BioRED_Task1_Doc443	1531	1555	type 2 diabetes mellitus	Disease	D003924	Haplotype analysis based on three SNPs (rs4810424, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.
BC8_BioRED_Task1_Doc443	1627	1632	women	OrganismTaxon	9606	Haplotype analysis based on three SNPs (rs4810424, rs2071197, and rs3818247) representing the linkage disequilibrium blocks in our study population indicated that the conversion to type 2 diabetes mellitus was dependent on the number of risk alleles in different haplotypes in women.
BC8_BioRED_Task1_Doc443	1667	1672	HNF4A	Gene	3172	Our results suggest that SNPs of HNF4A and their haplotypes predispose to type 2 diabetes mellitus in female subjects of the STOP-NIDDM study population.
BC8_BioRED_Task1_Doc443	1708	1732	type 2 diabetes mellitus	Disease	D003924	Our results suggest that SNPs of HNF4A and their haplotypes predispose to type 2 diabetes mellitus in female subjects of the STOP-NIDDM study population.
BC8_BioRED_Task1_Doc444	69	76	Arsenic	Chemical	D001151	Mechanisms Underlying Latent Disease Risk Associated with Early-Life Arsenic Exposure: Current Research Trends and Scientific Gaps.
BC8_BioRED_Task1_Doc444	269	286	inorganic arsenic	Chemical	D001152	BACKGROUND: Millions of individuals worldwide, particularly those living in rural and developing areas, are exposed to harmful levels of inorganic arsenic (iAs) in their drinking water.
BC8_BioRED_Task1_Doc444	288	291	iAs	Chemical	D001152	BACKGROUND: Millions of individuals worldwide, particularly those living in rural and developing areas, are exposed to harmful levels of inorganic arsenic (iAs) in their drinking water.
BC8_BioRED_Task1_Doc444	318	330	Inorganic As	Chemical	D001152	Inorganic As exposure during key developmental periods is associated with a variety of adverse health effects including those that are evident in adulthood.
BC8_BioRED_Task1_Doc444	569	572	iAs	Chemical	D001152	There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to cancer.
BC8_BioRED_Task1_Doc444	659	665	cancer	Disease	D009369	There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to cancer.
BC8_BioRED_Task1_Doc444	773	779	cancer	Disease	D009369	OBJECTIVES: This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early-life iAs exposure.
BC8_BioRED_Task1_Doc444	840	843	iAs	Chemical	D001152	OBJECTIVES: This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early-life iAs exposure.
BC8_BioRED_Task1_Doc444	962	968	cancer	Disease	D009369	DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by which early-life iAs exposure elicits latent carcinogenic effects.
BC8_BioRED_Task1_Doc444	1058	1061	iAs	Chemical	D001152	DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by which early-life iAs exposure elicits latent carcinogenic effects.
BC8_BioRED_Task1_Doc444	1086	1098	carcinogenic	Disease	D009369	DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by which early-life iAs exposure elicits latent carcinogenic effects.
BC8_BioRED_Task1_Doc444	1166	1169	iAs	Chemical	D001152	CONCLUSIONS: Evidence is mounting that relates early-life iAs exposure and cancer development later in life.
BC8_BioRED_Task1_Doc444	1183	1189	cancer	Disease	D009369	CONCLUSIONS: Evidence is mounting that relates early-life iAs exposure and cancer development later in life.
BC8_BioRED_Task1_Doc444	1314	1319	human	OrganismTaxon	9606	Future research should include animal studies that address mechanistic hypotheses and studies of human populations that integrate early-life exposure, molecular alterations, and latent disease outcomes.
BC8_BioRED_Task1_Doc445	8	31	coronary artery disease	Disease	D003324	Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
BC8_BioRED_Task1_Doc445	56	69	sulphonylurea	Chemical	D013453	Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
BC8_BioRED_Task1_Doc445	83	91	patients	OrganismTaxon	9606	Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
BC8_BioRED_Task1_Doc445	97	112	type 2 diabetes	Disease	D003924	Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
BC8_BioRED_Task1_Doc445	201	224	coronary artery disease	Disease	D003324	AIMS: This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas.
BC8_BioRED_Task1_Doc445	226	229	CAD	Disease	D003324	AIMS: This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas.
BC8_BioRED_Task1_Doc445	268	283	type 2 diabetes	Disease	D003924	AIMS: This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas.
BC8_BioRED_Task1_Doc445	299	313	sulphonylureas	Chemical	D013453	AIMS: This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas.
BC8_BioRED_Task1_Doc445	327	342	type 2 diabetic	Disease	D003924	METHODS: In type 2 diabetic patients, cases who developed CAD were compared retrospectively with controls that did not.
BC8_BioRED_Task1_Doc445	343	351	patients	OrganismTaxon	9606	METHODS: In type 2 diabetic patients, cases who developed CAD were compared retrospectively with controls that did not.
BC8_BioRED_Task1_Doc445	373	376	CAD	Disease	D003324	METHODS: In type 2 diabetic patients, cases who developed CAD were compared retrospectively with controls that did not.
BC8_BioRED_Task1_Doc445	455	458	CAD	Disease	D003324	The 20-year risk of CAD at diagnosis of diabetes, using the UKPDS risk engine, was used to match cases with controls.
BC8_BioRED_Task1_Doc445	475	483	diabetes	Disease	D003920	The 20-year risk of CAD at diagnosis of diabetes, using the UKPDS risk engine, was used to match cases with controls.
BC8_BioRED_Task1_Doc445	578	581	CAD	Disease	D003324	RESULTS: The 76 cases of CAD were compared with 152 controls.
BC8_BioRED_Task1_Doc445	640	643	CAD	Disease	D003324	The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
BC8_BioRED_Task1_Doc445	733	746	glibenclamide	Chemical	D005905	The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
BC8_BioRED_Task1_Doc445	779	788	glipizide	Chemical	D005913	The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
BC8_BioRED_Task1_Doc445	854	863	metformin	Chemical	D008687	The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
BC8_BioRED_Task1_Doc445	919	930	glimepiride	Chemical	C057619	The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with glimepiride, 0.4-fold (0.7-1.3, P=0.192) with gliclazide, and 0.4-fold (0.7-1.1, P=0.09) with either.
BC8_BioRED_Task1_Doc445	965	975	gliclazide	Chemical	D005907	The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with glimepiride, 0.4-fold (0.7-1.3, P=0.192) with gliclazide, and 0.4-fold (0.7-1.1, P=0.09) with either.
BC8_BioRED_Task1_Doc445	1058	1073	type 2 diabetes	Disease	D003924	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
BC8_BioRED_Task1_Doc445	1079	1092	glibenclamide	Chemical	D005905	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
BC8_BioRED_Task1_Doc445	1096	1105	glipizide	Chemical	D005913	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
BC8_BioRED_Task1_Doc445	1143	1146	CAD	Disease	D003324	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
BC8_BioRED_Task1_Doc445	1164	1174	gliclazide	Chemical	D005907	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
BC8_BioRED_Task1_Doc445	1178	1189	glimepiride	Chemical	C057619	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
BC8_BioRED_Task1_Doc445	1247	1255	patients	OrganismTaxon	9606	If confirmed, this may be important because most Indian patients receive the cheaper older sulphonylureas, and present guidelines do not distinguish between individual agents.
BC8_BioRED_Task1_Doc445	1282	1296	sulphonylureas	Chemical	D013453	If confirmed, this may be important because most Indian patients receive the cheaper older sulphonylureas, and present guidelines do not distinguish between individual agents.
BC8_BioRED_Task1_Doc446	0	8	Succimer	Chemical	D004113	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
BC8_BioRED_Task1_Doc446	75	79	lead	Chemical	D007854	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
BC8_BioRED_Task1_Doc446	88	92	rats	OrganismTaxon	10116	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
BC8_BioRED_Task1_Doc446	114	134	cognitive impairment	Disease	D003072	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
BC8_BioRED_Task1_Doc446	153	157	lead	Chemical	D007854	Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
BC8_BioRED_Task1_Doc446	284	288	lead	Chemical	D007854	BACKGROUND: There is growing pressure for clinicians to prescribe chelation therapy at only slightly elevated blood lead levels.
BC8_BioRED_Task1_Doc446	387	389	Pb	Chemical	D007854	However, very few studies have evaluated whether chelation improves cognitive outcomes in Pb-exposed children, or whether these agents have adverse effects that may affect brain development in the absence of Pb exposure.
BC8_BioRED_Task1_Doc446	505	507	Pb	Chemical	D007854	However, very few studies have evaluated whether chelation improves cognitive outcomes in Pb-exposed children, or whether these agents have adverse effects that may affect brain development in the absence of Pb exposure.
BC8_BioRED_Task1_Doc446	628	630	Pb	Chemical	D007854	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
BC8_BioRED_Task1_Doc446	659	667	succimer	Chemical	D004113	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
BC8_BioRED_Task1_Doc446	720	732	Pb poisoning	Disease	D007855	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
BC8_BioRED_Task1_Doc446	743	745	Pb	Chemical	D007854	RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
BC8_BioRED_Task1_Doc446	772	850	impairments in learning, attention, inhibitory control, and arousal regulation	Disease	D007859,D019958	RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
BC8_BioRED_Task1_Doc446	897	899	Pb	Chemical	D007854	RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
BC8_BioRED_Task1_Doc446	918	926	Succimer	Chemical	D004113	Succimer treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit.
BC8_BioRED_Task1_Doc446	944	946	Pb	Chemical	D007854	Succimer treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit.
BC8_BioRED_Task1_Doc446	955	959	rats	OrganismTaxon	10116	Succimer treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit.
BC8_BioRED_Task1_Doc446	1095	1097	Pb	Chemical	D007854	Succimer treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit.
BC8_BioRED_Task1_Doc446	1163	1171	succimer	Chemical	D004113	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
BC8_BioRED_Task1_Doc446	1185	1189	rats	OrganismTaxon	10116	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
BC8_BioRED_Task1_Doc446	1216	1218	Pb	Chemical	D007854	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
BC8_BioRED_Task1_Doc446	1250	1285	cognitive and affective dysfunction	Disease	D003072,D019964	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
BC8_BioRED_Task1_Doc446	1341	1343	Pb	Chemical	D007854	In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
BC8_BioRED_Task1_Doc446	1481	1499	cognitive deficits	Disease	D003072	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure.
BC8_BioRED_Task1_Doc446	1507	1509	Pb	Chemical	D007854	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure.
BC8_BioRED_Task1_Doc446	1581	1589	succimer	Chemical	D004113	These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb-exposed children.
BC8_BioRED_Task1_Doc446	1645	1647	Pb	Chemical	D007854	These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb-exposed children.
BC8_BioRED_Task1_Doc446	1698	1706	succimer	Chemical	D004113	However, they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals.
BC8_BioRED_Task1_Doc446	1803	1805	Pb	Chemical	D007854	However, they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals.
BC8_BioRED_Task1_Doc447	14	18	RGS4	Gene	5999	Evaluation of RGS4 as a candidate gene for schizophrenia.
BC8_BioRED_Task1_Doc447	43	56	schizophrenia	Disease	D012559	Evaluation of RGS4 as a candidate gene for schizophrenia.
BC8_BioRED_Task1_Doc447	98	132	regulator of G-protein signaling 4	Gene	5999	Several studies have suggested that the regulator of G-protein signaling 4 (RGS4) may be a positional and functional candidate gene for schizophrenia.
BC8_BioRED_Task1_Doc447	134	138	RGS4	Gene	5999	Several studies have suggested that the regulator of G-protein signaling 4 (RGS4) may be a positional and functional candidate gene for schizophrenia.
BC8_BioRED_Task1_Doc447	194	207	schizophrenia	Disease	D012559	Several studies have suggested that the regulator of G-protein signaling 4 (RGS4) may be a positional and functional candidate gene for schizophrenia.
BC8_BioRED_Task1_Doc447	328	332	RGS4	Gene	5999	Three single nucleotide polymorphisms (SNP) located at the promoter region (SNP4 and SNP7) and the intron 1 (SNP18) of RGS4 have been verified in different ethnic groups.
BC8_BioRED_Task1_Doc447	545	558	schizophrenia	Disease	D012559	In this study, these three SNP markers were genotyped in 218 schizophrenia pedigrees of Taiwan (864 individuals) for association analysis.
BC8_BioRED_Task1_Doc447	712	725	schizophrenia	Disease	D012559	Among these three SNPs, neither SNP4, SNP7, SNP18 has shown significant association with schizophrenia in single locus association analysis, nor any compositions of the three SNP haplotypes has shown significantly associations with the DSM-IV diagnosed schizophrenia.
BC8_BioRED_Task1_Doc447	876	889	schizophrenia	Disease	D012559	Among these three SNPs, neither SNP4, SNP7, SNP18 has shown significant association with schizophrenia in single locus association analysis, nor any compositions of the three SNP haplotypes has shown significantly associations with the DSM-IV diagnosed schizophrenia.
BC8_BioRED_Task1_Doc447	923	927	RGS4	Gene	5999	Our results fail to support the RGS4 as a candidate gene for schizophrenia when evaluated from these three SNP markers.
BC8_BioRED_Task1_Doc447	952	965	schizophrenia	Disease	D012559	Our results fail to support the RGS4 as a candidate gene for schizophrenia when evaluated from these three SNP markers.
BC8_BioRED_Task1_Doc448	0	5	HIV-1	OrganismTaxon	11676	HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner.
BC8_BioRED_Task1_Doc448	6	9	Tat	Gene	155871	HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner.
BC8_BioRED_Task1_Doc448	20	47	indoleamine 2,3 dioxygenase	Gene	15930	HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner.
BC8_BioRED_Task1_Doc448	51	57	murine	OrganismTaxon	10090	HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner.
BC8_BioRED_Task1_Doc448	102	138	p38 mitogen-activated protein kinase	Gene	26416	HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner.
BC8_BioRED_Task1_Doc448	212	222	tryptophan	Chemical	D014364	BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior.
BC8_BioRED_Task1_Doc448	240	267	indoleamine 2,3 dioxygenase	Gene	15930	BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior.
BC8_BioRED_Task1_Doc448	269	272	IDO	Gene	15930	BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior.
BC8_BioRED_Task1_Doc448	337	347	depressive	Disease	D000275	BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior.
BC8_BioRED_Task1_Doc448	371	406	human immunodeficiency virus type 1	OrganismTaxon	11676	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	408	413	HIV-1	OrganismTaxon	11676	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	415	418	Tat	Gene	155871	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	434	444	depressive	Disease	D000275	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	462	466	mice	OrganismTaxon	10090	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	508	511	IDO	Gene	15930	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	584	591	C57BL/6	CellLine	CVCL_5746	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	592	596	mice	OrganismTaxon	10090	Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice.
BC8_BioRED_Task1_Doc448	607	617	Depressive	Disease	D000275	METHODS: Depressive-like behavior in C57BL/6J mice was assessed by the forced swim test.
BC8_BioRED_Task1_Doc448	635	643	C57BL/6J	CellLine	CVCL_5U84	METHODS: Depressive-like behavior in C57BL/6J mice was assessed by the forced swim test.
BC8_BioRED_Task1_Doc448	644	648	mice	OrganismTaxon	10090	METHODS: Depressive-like behavior in C57BL/6J mice was assessed by the forced swim test.
BC8_BioRED_Task1_Doc448	715	718	IDO	Gene	15930	Expression of cytokines and IDO mRNA in OHSCs was measured by real-time RT-PCR and cytokine protein was measured by enzyme-linked immunosorbent assays (ELISAs).
BC8_BioRED_Task1_Doc448	848	856	p38 MAPK	Gene	26416	p38 MAPK phosphorylation was analyzed by western blot.
BC8_BioRED_Task1_Doc448	963	966	Tat	Gene	155871	administration of Tat (40 ng) induced depressive-like behavior in the absence of sickness.
BC8_BioRED_Task1_Doc448	983	993	depressive	Disease	D000275	administration of Tat (40 ng) induced depressive-like behavior in the absence of sickness.
BC8_BioRED_Task1_Doc448	1048	1051	Tat	Gene	155871	Addition of Tat (40 ng/slice) to the medium of OHSCs induced IDO steady-state mRNA that peaked at 6 h. This effect was potentiated by pretreatment with IFNg.
BC8_BioRED_Task1_Doc448	1097	1100	IDO	Gene	15930	Addition of Tat (40 ng/slice) to the medium of OHSCs induced IDO steady-state mRNA that peaked at 6 h. This effect was potentiated by pretreatment with IFNg.
BC8_BioRED_Task1_Doc448	1188	1192	IFNg	Gene	15978	Addition of Tat (40 ng/slice) to the medium of OHSCs induced IDO steady-state mRNA that peaked at 6 h. This effect was potentiated by pretreatment with IFNg.
BC8_BioRED_Task1_Doc448	1194	1197	Tat	Gene	155871	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1240	1244	TNFa	Gene	21926	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1249	1253	IL-6	Gene	16193	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1327	1369	inducible isoform of nitric oxide synthase	Gene	18126	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1371	1375	iNOS	Gene	18126	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1385	1406	serotonin transporter	Gene	15567	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1408	1412	SERT	Gene	15567	Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT).
BC8_BioRED_Task1_Doc448	1415	1418	Tat	Gene	155871	Tat had no effect on endogenous synthesis of IFNg.
BC8_BioRED_Task1_Doc448	1460	1464	IFNg	Gene	15978	Tat had no effect on endogenous synthesis of IFNg.
BC8_BioRED_Task1_Doc448	1495	1498	Tat	Gene	155871	To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment.
BC8_BioRED_Task1_Doc448	1507	1510	IDO	Gene	15930	To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment.
BC8_BioRED_Task1_Doc448	1555	1591	p38 mitogen-activated protein kinase	Gene	26416	To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment.
BC8_BioRED_Task1_Doc448	1593	1597	MAPK	Gene	26416	To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment.
BC8_BioRED_Task1_Doc448	1609	1618	SB 202190	Chemical	C090942	To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment.
BC8_BioRED_Task1_Doc448	1637	1640	Tat	Gene	155871	To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment.
BC8_BioRED_Task1_Doc448	1652	1661	SB 202190	Chemical	C090942	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1686	1689	IDO	Gene	15930	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1712	1715	Tat	Gene	155871	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1767	1770	Tat	Gene	155871	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1793	1797	TNFa	Gene	21926	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1799	1803	IL-6	Gene	16193	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1805	1809	iNOS	Gene	18126	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1814	1818	SERT	Gene	15567	SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT.
BC8_BioRED_Task1_Doc448	1858	1861	Tat	Gene	155871	CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK.
BC8_BioRED_Task1_Doc448	1870	1873	IDO	Gene	15930	CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK.
BC8_BioRED_Task1_Doc448	1892	1896	IFNg	Gene	15978	CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK.
BC8_BioRED_Task1_Doc448	1951	1959	p38 MAPK	Gene	26416	CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK.
BC8_BioRED_Task1_Doc448	1971	1974	IDO	Gene	3620	Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.
BC8_BioRED_Task1_Doc448	1989	1997	p38 MAPK	Gene	26416	Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.
BC8_BioRED_Task1_Doc448	2059	2079	depressive disorders	Disease	D000275	Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.
BC8_BioRED_Task1_Doc448	2083	2097	HIV-1-infected	Disease	D015658	Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.
BC8_BioRED_Task1_Doc448	2098	2106	patients	OrganismTaxon	9606	Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.
BC8_BioRED_Task1_Doc449	0	19	Atrial fibrillation	Disease	D001281	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).
BC8_BioRED_Task1_Doc449	79	95	gastric lymphoma	Disease	C535648	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).
BC8_BioRED_Task1_Doc449	101	108	patient	OrganismTaxon	9606	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).
BC8_BioRED_Task1_Doc449	114	132	myotonic dystrophy	Disease	D009223	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).
BC8_BioRED_Task1_Doc449	134	152	Steinert's disease	Disease	D009223	Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).
BC8_BioRED_Task1_Doc449	223	239	gastric lymphoma	Disease	C535648	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
BC8_BioRED_Task1_Doc449	244	262	myotonic dystrophy	Disease	D009223	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
BC8_BioRED_Task1_Doc449	294	312	muscular dystrophy	Disease	D009136	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
BC8_BioRED_Task1_Doc449	325	344	atrial fibrillation	Disease	D001281	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
BC8_BioRED_Task1_Doc449	368	379	doxorubicin	Chemical	D004317	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
BC8_BioRED_Task1_Doc449	411	418	patient	OrganismTaxon	9606	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
BC8_BioRED_Task1_Doc449	420	439	Atrial fibrillation	Disease	D001281	Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
BC8_BioRED_Task1_Doc449	449	468	cardiac arrhythmias	Disease	D001145	Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
BC8_BioRED_Task1_Doc449	498	506	patients	OrganismTaxon	9606	Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
BC8_BioRED_Task1_Doc449	538	554	cardiac toxicity	Disease	D066126	The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.
BC8_BioRED_Task1_Doc449	668	678	arrhythmia	Disease	D001145	The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.
BC8_BioRED_Task1_Doc449	717	724	patient	OrganismTaxon	9606	The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.
BC8_BioRED_Task1_Doc450	0	7	Syncope	Disease	D013575	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
BC8_BioRED_Task1_Doc450	12	27	QT prolongation	Disease	D008133	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
BC8_BioRED_Task1_Doc450	34	42	patients	OrganismTaxon	9606	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
BC8_BioRED_Task1_Doc450	56	65	methadone	Chemical	D008691	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
BC8_BioRED_Task1_Doc450	70	87	heroin dependence	Disease	D006556	Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
BC8_BioRED_Task1_Doc450	127	136	Methadone	Chemical	D008691	BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.
BC8_BioRED_Task1_Doc450	154	168	heroin addicts	Disease	D006556	BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.
BC8_BioRED_Task1_Doc450	189	195	opioid	Chemical	D000701	BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.
BC8_BioRED_Task1_Doc450	201	232	Prolongation of the QT interval	Disease	D008133	Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
BC8_BioRED_Task1_Doc450	247	255	patients	OrganismTaxon	9606	Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
BC8_BioRED_Task1_Doc450	261	279	torsade de pointes	Disease	D016171	Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
BC8_BioRED_Task1_Doc450	281	284	TdP	Disease	D016171	Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
BC8_BioRED_Task1_Doc450	307	316	methadone	Chemical	D008691	Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
BC8_BioRED_Task1_Doc450	327	341	heroin addicts	Disease	D006556	As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.
BC8_BioRED_Task1_Doc450	430	437	syncope	Disease	D013575	As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.
BC8_BioRED_Task1_Doc450	501	504	TdP	Disease	D016171	As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.
BC8_BioRED_Task1_Doc450	630	639	methadone	Chemical	D008691	As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.
BC8_BioRED_Task1_Doc450	754	768	heroin addicts	Disease	D006556	METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
BC8_BioRED_Task1_Doc450	782	791	methadone	Chemical	D008691	METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
BC8_BioRED_Task1_Doc450	795	808	buprenorphine	Chemical	D002047	METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
BC8_BioRED_Task1_Doc450	834	842	patients	OrganismTaxon	9606	Of the patients at the Drug Addiction Service in the municipal of Copenhagen, 450 (approximately 52%) were included.
BC8_BioRED_Task1_Doc450	1051	1058	syncope	Disease	D013575	All participants were interviewed about any experience of syncope.
BC8_BioRED_Task1_Doc450	1084	1090	opioid	Chemical	D000701	The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.
BC8_BioRED_Task1_Doc450	1108	1117	methadone	Chemical	D008691	The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.
BC8_BioRED_Task1_Doc450	1140	1147	syncope	Disease	D013575	The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.
BC8_BioRED_Task1_Doc450	1246	1255	Methadone	Chemical	D008691	RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).
BC8_BioRED_Task1_Doc450	1281	1299	longer QT interval	Disease	D008133	RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).
BC8_BioRED_Task1_Doc450	1351	1364	buprenorphine	Chemical	D002047	No association between buprenorphine and QTc was found.
BC8_BioRED_Task1_Doc450	1416	1425	methadone	Chemical	D008691	Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.
BC8_BioRED_Task1_Doc450	1431	1434	men	OrganismTaxon	9606	Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.
BC8_BioRED_Task1_Doc450	1443	1448	women	OrganismTaxon	9606	Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.
BC8_BioRED_Task1_Doc450	1453	1475	prolonged QTc interval	Disease	D008133	Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.
BC8_BioRED_Task1_Doc450	1511	1524	buprenorphine	Chemical	D002047	None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).
BC8_BioRED_Task1_Doc450	1574	1583	methadone	Chemical	D008691	A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
BC8_BioRED_Task1_Doc450	1657	1664	syncope	Disease	D013575	A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
BC8_BioRED_Task1_Doc450	1679	1688	Methadone	Chemical	D008691	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
BC8_BioRED_Task1_Doc450	1708	1723	QT prolongation	Disease	D008133	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
BC8_BioRED_Task1_Doc450	1748	1755	syncope	Disease	D013575	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
BC8_BioRED_Task1_Doc450	1775	1789	heroin addicts	Disease	D006556	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts.
BC8_BioRED_Task1_Doc451	27	45	salvianolic acid A	Chemical	C066201	Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	49	62	isoproterenol	Chemical	D007545	Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	71	92	myocardial infarction	Disease	D009203	Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	96	100	rats	OrganismTaxon	10116	Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	179	197	salvianolic acid A	Chemical	C066201	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	201	214	isoproterenol	Chemical	D007545	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	223	244	myocardial infarction	Disease	D009203	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	248	252	rats	OrganismTaxon	10116	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc451	556	569	Isoproterenol	Chemical	D007545	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	578	582	rats	OrganismTaxon	10116	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	629	650	lactate dehydrogenase	Gene	24533	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	652	674	aspartate transaminase	Gene	25721	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	676	691	creatine kinase	Gene	24264	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	696	711	malondialdehyde	Chemical	D008315	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	759	779	superoxide dismutase	Gene	24786	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	781	789	catalase	Gene	24248	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	794	816	glutathione peroxidase	Gene	24404	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.
BC8_BioRED_Task1_Doc451	843	847	rats	OrganismTaxon	10116	These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment.
BC8_BioRED_Task1_Doc451	1059	1096	mitochondrial respiratory dysfunction	Disease	D028361	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc451	1154	1157	ADP	Chemical	D000244	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc451	1176	1189	isoproterenol	Chemical	D007545	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc451	1198	1202	rats	OrganismTaxon	10116	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
BC8_BioRED_Task1_Doc451	1222	1240	salvianolic acid A	Chemical	C066201	Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
BC8_BioRED_Task1_Doc451	1289	1302	isoproterenol	Chemical	D007545	Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
BC8_BioRED_Task1_Doc451	1311	1330	cardiac dysfunction	Disease	D006331	Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
BC8_BioRED_Task1_Doc451	1335	1352	myocardial injury	Disease	D009202	Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
BC8_BioRED_Task1_Doc451	1425	1443	salvianolic acid A	Chemical	C066201	The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.
BC8_BioRED_Task1_Doc451	1452	1465	isoproterenol	Chemical	D007545	The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.
BC8_BioRED_Task1_Doc451	1474	1491	myocardial damage	Disease	D009202	The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.
BC8_BioRED_Task1_Doc451	1586	1604	salvianolic acid A	Chemical	C066201	The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.
BC8_BioRED_Task1_Doc451	1681	1694	isoproterenol	Chemical	D007545	The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.
BC8_BioRED_Task1_Doc451	1703	1724	myocardial infarction	Disease	D009203	The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.
BC8_BioRED_Task1_Doc452	0	8	Curcumin	Chemical	D003474	Curcumin decreases specificity protein expression in bladder cancer cells.
BC8_BioRED_Task1_Doc452	19	38	specificity protein	Gene	6667,6670,6671	Curcumin decreases specificity protein expression in bladder cancer cells.
BC8_BioRED_Task1_Doc452	53	67	bladder cancer	Disease	D001749	Curcumin decreases specificity protein expression in bladder cancer cells.
BC8_BioRED_Task1_Doc452	75	83	Curcumin	Chemical	D003474	Curcumin is the active component of tumeric, and this polyphenolic compound has been extensively investigated as an anticancer drug that modulates multiple pathways and genes.
BC8_BioRED_Task1_Doc452	286	294	curcumin	Chemical	D003474	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	305	312	253JB-V	CellLine	CVCL_7937	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	317	320	KU7	CellLine	CVCL_4714	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	321	335	bladder cancer	Disease	D001749	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	432	452	proapoptotic protein	Gene	332	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	453	461	survivin	Gene	332	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	470	489	angiogenic proteins	Gene	2321,7422	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	490	524	vascular endothelial growth factor	Gene	7422	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	526	530	VEGF	Gene	7422	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	536	551	VEGF receptor 1	Gene	2321	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	553	559	VEGFR1	Gene	2321	In this study, 10 to 25 micromol/L curcumin inhibited 253JB-V and KU7 bladder cancer cell growth, and this was accompanied by induction of apoptosis and decreased expression of the proapoptotic protein survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) and VEGF receptor 1 (VEGFR1).
BC8_BioRED_Task1_Doc452	584	592	survivin	Gene	332	Because expression of survivin, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of curcumin on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.
BC8_BioRED_Task1_Doc452	594	598	VEGF	Gene	7422	Because expression of survivin, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of curcumin on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.
BC8_BioRED_Task1_Doc452	604	610	VEGFR1	Gene	2321	Because expression of survivin, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of curcumin on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.
BC8_BioRED_Task1_Doc452	628	674	specificity protein (Sp) transcription factors	Gene	6667,6670,6671	Because expression of survivin, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of curcumin on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.
BC8_BioRED_Task1_Doc452	712	720	curcumin	Chemical	D003474	Because expression of survivin, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of curcumin on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.
BC8_BioRED_Task1_Doc452	724	726	Sp	Gene	6667,6670,6671	Because expression of survivin, VEGF, and VEGFR1 are dependent on specificity protein (Sp) transcription factors, we also investigated the effects of curcumin on Sp protein expression as an underlying mechanism for the apoptotic and antiangiogenic activity of this compound.
BC8_BioRED_Task1_Doc452	859	867	curcumin	Chemical	D003474	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	876	886	proteasome	Gene	5698	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	916	919	Sp1	Gene	6667	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	921	924	Sp3	Gene	6670	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	930	933	Sp4	Gene	6671	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	937	944	253JB-V	CellLine	CVCL_7937	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	949	952	KU7	CellLine	CVCL_4714	The results show that curcumin induced proteasome-dependent down-regulation of Sp1, Sp3, and Sp4 in 253JB-V and KU7 cells.
BC8_BioRED_Task1_Doc452	1024	1027	Sp1	Gene	6667	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1029	1032	Sp3	Gene	6670	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1038	1041	Sp4	Gene	6671	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1060	1068	curcumin	Chemical	D003474	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1093	1114	nuclear factor kappaB	Gene	4790	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1116	1125	NF-kappaB	Gene	4790	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1152	1157	bcl-2	Gene	596	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1159	1167	survivin	Gene	332	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1173	1182	cyclin D1	Gene	595	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1218	1220	Sp	Gene	6667,6670,6671	Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3, and Sp4, we observed that curcumin-dependent inhibition of nuclear factor kappaB (NF-kappaB)-dependent genes, such as bcl-2, survivin, and cyclin D1, was also due, in part, to loss of Sp proteins.
BC8_BioRED_Task1_Doc452	1231	1239	Curcumin	Chemical	D003474	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1255	1268	bladder tumor	Disease	D001749	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1292	1296	mice	OrganismTaxon	10090	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1305	1308	KU7	CellLine	CVCL_4714	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1367	1370	Sp1	Gene	20683	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1372	1375	Sp3	Gene	20687	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1381	1384	Sp4	Gene	20688	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1403	1409	tumors	Disease	D009369	Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 cells as xenografts and this was accompanied by decreased Sp1, Sp3, and Sp4 protein levels in tumors.
BC8_BioRED_Task1_Doc452	1500	1508	curcumin	Chemical	D003474	These results show for the first time that one of the underlying mechanisms of action of curcumin as a cancer chemotherapeutic agent is due, in part, to decreased expression of Sp transcription factors in bladder cancer cells.
BC8_BioRED_Task1_Doc452	1514	1520	cancer	Disease	D009369	These results show for the first time that one of the underlying mechanisms of action of curcumin as a cancer chemotherapeutic agent is due, in part, to decreased expression of Sp transcription factors in bladder cancer cells.
BC8_BioRED_Task1_Doc452	1588	1612	Sp transcription factors	Gene	6667,6670,6671	These results show for the first time that one of the underlying mechanisms of action of curcumin as a cancer chemotherapeutic agent is due, in part, to decreased expression of Sp transcription factors in bladder cancer cells.
BC8_BioRED_Task1_Doc452	1616	1630	bladder cancer	Disease	D001749	These results show for the first time that one of the underlying mechanisms of action of curcumin as a cancer chemotherapeutic agent is due, in part, to decreased expression of Sp transcription factors in bladder cancer cells.
BC8_BioRED_Task1_Doc453	47	67	mantle cell lymphoma	Disease	D020522	Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes.
BC8_BioRED_Task1_Doc453	126	146	Mantle cell lymphoma	Disease	D020522	Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation and several other cytogenetic aberrations, including heterozygous loss of chromosomal arms 1p, 6q, 11q and 13q and/or gains of 3q and 8q.
BC8_BioRED_Task1_Doc453	148	151	MCL	Disease	D020522	Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation and several other cytogenetic aberrations, including heterozygous loss of chromosomal arms 1p, 6q, 11q and 13q and/or gains of 3q and 8q.
BC8_BioRED_Task1_Doc453	554	557	MCL	Disease	D020522	However, the chromosomal intervals still contain many genes potentially involved in MCL pathogeny.
BC8_BioRED_Task1_Doc453	655	666	MCL tumours	Disease	D020522	Combined analysis of tiling-resolution array-CGH with gene expression profiling on 11 MCL tumours enabled the identification of genomic alterations and their corresponding gene expression profiles.
BC8_BioRED_Task1_Doc453	1019	1022	MCL	Disease	D020522	The genes that showed consistent correlation between DNA copy number and RNA expression levels are likely to be important in MCL pathology.
BC8_BioRED_Task1_Doc453	1155	1185	cyclic adenosine monophosphate	Chemical	D000242	Besides several 'anonymous genes', we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate-regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29).
BC8_BioRED_Task1_Doc453	1206	1212	PRKACB	Gene	5567	Besides several 'anonymous genes', we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate-regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29).
BC8_BioRED_Task1_Doc453	1303	1306	ATM	Gene	472	Besides several 'anonymous genes', we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate-regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29).
BC8_BioRED_Task1_Doc453	1308	1313	ERCC5	Gene	2073	Besides several 'anonymous genes', we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate-regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29).
BC8_BioRED_Task1_Doc453	1315	1320	FBXO5	Gene	26271	Besides several 'anonymous genes', we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate-regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29).
BC8_BioRED_Task1_Doc453	1465	1473	ARHGAP29	Gene	9411	Besides several 'anonymous genes', we also identified various fully annotated genes, whose gene products are involved in cyclic adenosine monophosphate-regulated pathways (PRKACB), DNA damage repair, maintenance of chromosome stability and prevention of rereplication (ATM, ERCC5, FBXO5), energy metabolism (such as genes that are involved in the synthesis of proteins encoded by the mitochondrial genome) and signal transduction (ARHGAP29).
BC8_BioRED_Task1_Doc453	1576	1586	MCL tumour	Disease	D020522	Deregulation of these gene products may interfere with the signalling pathways that are involved in MCL tumour development and maintenance.
BC8_BioRED_Task1_Doc454	37	64	tumor necrosis factor-alpha	Gene	21926,7124	Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
BC8_BioRED_Task1_Doc454	66	87	nuclear factor-kappaB	Gene	18033,4790	Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
BC8_BioRED_Task1_Doc454	93	121	bone morphogenetic protein-2	Gene	12156,650	Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
BC8_BioRED_Task1_Doc454	139	149	metastasis	Disease	D009362	Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
BC8_BioRED_Task1_Doc454	170	185	prostate cancer	Disease	D011471	Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
BC8_BioRED_Task1_Doc454	234	242	MC3T3-E1	CellLine	CVCL_0409	Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
BC8_BioRED_Task1_Doc454	303	334	prostate cancer (PC) metastasis	Disease	D009362,D011471	The molecular mechanisms involved in prostate cancer (PC) metastasis and bone remodeling are poorly understood.
BC8_BioRED_Task1_Doc454	404	453	phosphoinositide 3-kinase (PI3K)/protein kinase B	Gene	207	We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells.
BC8_BioRED_Task1_Doc454	455	458	Akt	Gene	207	We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells.
BC8_BioRED_Task1_Doc454	514	548	bone morphogenetic protein (BMP)-2	Gene	650	We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells.
BC8_BioRED_Task1_Doc454	562	588	nuclear factor (NF)-kappaB	Gene	4790	We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells.
BC8_BioRED_Task1_Doc454	608	623	prostate cancer	Disease	D011471	We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells.
BC8_BioRED_Task1_Doc454	673	682	NF-kappaB	Gene	4790	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	717	722	human	OrganismTaxon	9606	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	723	756	tumor necrosis factor (TNF)-alpha	Gene	7124	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	789	792	p65	Gene	5970	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	875	879	PC-3	CellLine	CVCL_0035	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	884	889	C4-2B	CellLine	CVCL_4784	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	899	904	LNCaP	CellLine	CVCL_0395	In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells.
BC8_BioRED_Task1_Doc454	999	1010	osteopontin	Gene	6696	The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells.
BC8_BioRED_Task1_Doc454	1012	1023	osteocalcin	Gene	632	The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells.
BC8_BioRED_Task1_Doc454	1029	1041	collagen IA1	Gene	1277	The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells.
BC8_BioRED_Task1_Doc454	1057	1059	PC	Disease	D011471	The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells.
BC8_BioRED_Task1_Doc454	1108	1110	PC	Disease	D011471	The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells.
BC8_BioRED_Task1_Doc454	1125	1130	BMP-4	Gene	652	Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells.
BC8_BioRED_Task1_Doc454	1132	1137	BMP-2	Gene	650	Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells.
BC8_BioRED_Task1_Doc454	1182	1187	C4-2B	CellLine	CVCL_4784	Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells.
BC8_BioRED_Task1_Doc454	1206	1211	LNCaP	CellLine	CVCL_0395	Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells.
BC8_BioRED_Task1_Doc454	1254	1260	Noggin	Gene	9241	Also, this effect was nullified by Noggin.
BC8_BioRED_Task1_Doc454	1275	1280	BMP-2	Gene	650	In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion.
BC8_BioRED_Task1_Doc454	1290	1299	TNF-alpha	Gene	7124	In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion.
BC8_BioRED_Task1_Doc454	1320	1325	C4-2B	CellLine	CVCL_4784	In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion.
BC8_BioRED_Task1_Doc454	1337	1346	NF-kappaB	Gene	4790	In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion.
BC8_BioRED_Task1_Doc454	1366	1375	TNF-alpha	Gene	7124	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1405	1414	TNF-alpha	Gene	7124	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1426	1431	C4-2B	CellLine	CVCL_4784	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1450	1455	BMP-2	Gene	12156	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1460	1463	BMP	Gene	12156	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1474	1478	Smad	Gene	17127	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1505	1543	receptor activator of NF-kappaB ligand	Gene	21943	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1559	1568	RAW 264.7	CellLine	CVCL_0493	TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms.
BC8_BioRED_Task1_Doc454	1738	1747	TNF-alpha	Gene	7124	In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively.
BC8_BioRED_Task1_Doc454	1761	1765	BMP2	Gene	650	In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively.
BC8_BioRED_Task1_Doc454	1777	1782	C4-2B	CellLine	CVCL_4784	In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively.
BC8_BioRED_Task1_Doc454	1824	1832	MC3T3-E1	CellLine	CVCL_0409	In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively.
BC8_BioRED_Task1_Doc454	1855	1860	BMP-2	Gene	12156	In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively.
BC8_BioRED_Task1_Doc454	1875	1884	NF-kappaB	Gene	4790	In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively.
BC8_BioRED_Task1_Doc454	2082	2084	PC	Disease	D011471	Taken together, the results suggest that mutual interactions between these factors may be pivotal not only in enhancing the osteomimicry and metastatic potential of PC cells, but also in bone remodeling and in shifting the balance from osteoclastogenesis towards osteoblastogenesis.
BC8_BioRED_Task1_Doc455	33	67	oculopharyngeal muscular dystrophy	Disease	D039141	Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
BC8_BioRED_Task1_Doc455	81	115	Oculopharyngeal muscular dystrophy	Disease	D039141	BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late onset autosomal dominant muscle disorder.
BC8_BioRED_Task1_Doc455	117	121	OPMD	Disease	D039141	BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late onset autosomal dominant muscle disorder.
BC8_BioRED_Task1_Doc455	139	173	autosomal dominant muscle disorder	Disease	D030342	BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late onset autosomal dominant muscle disorder.
BC8_BioRED_Task1_Doc455	175	179	OPMD	Disease	D039141	OPMD is caused by a short trinucleotide repeat expansion encoding an expanded polyalanine tract in the polyadenylate binding-protein nuclear 1 (PABPN1) gene.
BC8_BioRED_Task1_Doc455	253	264	polyalanine	Chemical	C019529	OPMD is caused by a short trinucleotide repeat expansion encoding an expanded polyalanine tract in the polyadenylate binding-protein nuclear 1 (PABPN1) gene.
BC8_BioRED_Task1_Doc455	278	317	polyadenylate binding-protein nuclear 1	Gene	8106	OPMD is caused by a short trinucleotide repeat expansion encoding an expanded polyalanine tract in the polyadenylate binding-protein nuclear 1 (PABPN1) gene.
BC8_BioRED_Task1_Doc455	319	325	PABPN1	Gene	8106	OPMD is caused by a short trinucleotide repeat expansion encoding an expanded polyalanine tract in the polyadenylate binding-protein nuclear 1 (PABPN1) gene.
BC8_BioRED_Task1_Doc455	367	373	PABPN1	Gene	8106	We identified and characterized a PABPN1 mutation in a Taiwanese family with OPMD.
BC8_BioRED_Task1_Doc455	410	414	OPMD	Disease	D039141	We identified and characterized a PABPN1 mutation in a Taiwanese family with OPMD.
BC8_BioRED_Task1_Doc455	516	520	OPMD	Disease	D039141	METHODS: The phenotypic and genotypic characteristics of all subjects were evaluated in a Taiwanese OPMD family.
BC8_BioRED_Task1_Doc455	556	562	PABPN1	Gene	8106	Genetic alterations in the PABPN1 gene were identified using PCR and DNA sequencing.
BC8_BioRED_Task1_Doc455	641	645	OPMD	Disease	D039141	RESULTS: Ten subjects with OPMD (6 symptomatic and 4 asymptomatic) within the Taiwanese family carried a novel mutation in the PABPN1 gene.
BC8_BioRED_Task1_Doc455	741	747	PABPN1	Gene	8106	RESULTS: Ten subjects with OPMD (6 symptomatic and 4 asymptomatic) within the Taiwanese family carried a novel mutation in the PABPN1 gene.
BC8_BioRED_Task1_Doc455	765	832	(GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG	SequenceVariant	c|SUB|(GCG)6(GCA)3GCG||(GCG)6(GCA)(GCG)4(GCA)3GCG	The normal (GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG due to an insertion of (GCG)4GCA into the normal allele in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	843	865	insertion of (GCG)4GCA	SequenceVariant	c|INS|(GCG)4GCA	The normal (GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG due to an insertion of (GCG)4GCA into the normal allele in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	906	910	OPMD	Disease	D039141	The normal (GCG)6(GCA)3GCG sequence was replaced by (GCG)6(GCA)(GCG)4(GCA)3GCG due to an insertion of (GCG)4GCA into the normal allele in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	983	987	OPMD	Disease	D039141	CONCLUSIONS: In contrast to a single GCG expansion in most of OPMD patients in the literature, an insertion of (GCG)4GCA in the PABPN1 gene was found in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	988	996	patients	OrganismTaxon	9606	CONCLUSIONS: In contrast to a single GCG expansion in most of OPMD patients in the literature, an insertion of (GCG)4GCA in the PABPN1 gene was found in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	1019	1041	insertion of (GCG)4GCA	SequenceVariant	c|INS|(GCG)4GCA	CONCLUSIONS: In contrast to a single GCG expansion in most of OPMD patients in the literature, an insertion of (GCG)4GCA in the PABPN1 gene was found in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	1049	1055	PABPN1	Gene	8106	CONCLUSIONS: In contrast to a single GCG expansion in most of OPMD patients in the literature, an insertion of (GCG)4GCA in the PABPN1 gene was found in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	1088	1092	OPMD	Disease	D039141	CONCLUSIONS: In contrast to a single GCG expansion in most of OPMD patients in the literature, an insertion of (GCG)4GCA in the PABPN1 gene was found in the Taiwanese OPMD subjects.
BC8_BioRED_Task1_Doc455	1211	1217	PABPN1	Gene	8106	The identification of this mutation appears to support the molecular mechanism of unequal cross-over of two PABPN1 alleles.
BC8_BioRED_Task1_Doc456	4	9	M235T	SequenceVariant	rs699	The M235T polymorphism of the angiotensinogen gene in South Indian patients of hypertrophic cardiomyopathy.
BC8_BioRED_Task1_Doc456	30	45	angiotensinogen	Gene	183	The M235T polymorphism of the angiotensinogen gene in South Indian patients of hypertrophic cardiomyopathy.
BC8_BioRED_Task1_Doc456	67	75	patients	OrganismTaxon	9606	The M235T polymorphism of the angiotensinogen gene in South Indian patients of hypertrophic cardiomyopathy.
BC8_BioRED_Task1_Doc456	79	106	hypertrophic cardiomyopathy	Disease	D002312	The M235T polymorphism of the angiotensinogen gene in South Indian patients of hypertrophic cardiomyopathy.
BC8_BioRED_Task1_Doc456	122	149	Hypertrophic cardiomyopathy	Disease	D002312	INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is a complex disorder and genetically transmitted cardiac disease with a diverse clinical course.
BC8_BioRED_Task1_Doc456	151	154	HCM	Disease	D002312	INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is a complex disorder and genetically transmitted cardiac disease with a diverse clinical course.
BC8_BioRED_Task1_Doc456	206	221	cardiac disease	Disease	D006331	INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is a complex disorder and genetically transmitted cardiac disease with a diverse clinical course.
BC8_BioRED_Task1_Doc456	327	332	T704C	SequenceVariant	rs699	The objective of the present study was to examine the association of the T704C polymorphism of exon 2 of the angiotensinogen (AGT) gene with HCM in a South Indian population from Andhra Pradesh.
BC8_BioRED_Task1_Doc456	363	378	angiotensinogen	Gene	183	The objective of the present study was to examine the association of the T704C polymorphism of exon 2 of the angiotensinogen (AGT) gene with HCM in a South Indian population from Andhra Pradesh.
BC8_BioRED_Task1_Doc456	380	383	AGT	Gene	183	The objective of the present study was to examine the association of the T704C polymorphism of exon 2 of the angiotensinogen (AGT) gene with HCM in a South Indian population from Andhra Pradesh.
BC8_BioRED_Task1_Doc456	395	398	HCM	Disease	D002312	The objective of the present study was to examine the association of the T704C polymorphism of exon 2 of the angiotensinogen (AGT) gene with HCM in a South Indian population from Andhra Pradesh.
BC8_BioRED_Task1_Doc456	493	496	HCM	Disease	D002312	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	501	537	sporadic hypertrophic cardiomyopathy	Disease	D002312	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	539	543	SHCM	Disease	D002312	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	552	588	familial hypertrophic cardiomyopathy	Disease	D024741	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	590	594	FHCM	Disease	D024741	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	597	605	patients	OrganismTaxon	9606	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	673	685	hypertension	Disease	D006973	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	690	718	left ventricular hypertrophy	Disease	D017379	One-hundred and fifty HCM (90 sporadic hypertrophic cardiomyopathy [SHCM] and 60 familial hypertrophic cardiomyopathy [FHCM]) patients and 165 age- and sex-matched normal healthy controls without known hypertension and left ventricular hypertrophy were included in the study.
BC8_BioRED_Task1_Doc456	825	828	AGT	Gene	183	DNA was isolated from peripheral leukocytes and the region of interest in the AGT gene bearing a missense mutation methionine to threonine substitution at codon 235 (M235T) of exon 2, was amplified by polymerase chain reaction (PCR).
BC8_BioRED_Task1_Doc456	862	911	methionine to threonine substitution at codon 235	SequenceVariant	rs699	DNA was isolated from peripheral leukocytes and the region of interest in the AGT gene bearing a missense mutation methionine to threonine substitution at codon 235 (M235T) of exon 2, was amplified by polymerase chain reaction (PCR).
BC8_BioRED_Task1_Doc456	913	918	M235T	SequenceVariant	rs699	DNA was isolated from peripheral leukocytes and the region of interest in the AGT gene bearing a missense mutation methionine to threonine substitution at codon 235 (M235T) of exon 2, was amplified by polymerase chain reaction (PCR).
BC8_BioRED_Task1_Doc456	1054	1059	SfaNI	Chemical	-	The PCR products were subjected to restriction digestion with the enzyme SfaNI.
BC8_BioRED_Task1_Doc456	1202	1206	SHCM	Disease	D002312	RESULTS: Significant differences were detected in genotypic distribution (p = 0.04) as well as the allelic frequency (p = 0.003) between the SHCM patients and controls.
BC8_BioRED_Task1_Doc456	1207	1215	patients	OrganismTaxon	9606	RESULTS: Significant differences were detected in genotypic distribution (p = 0.04) as well as the allelic frequency (p = 0.003) between the SHCM patients and controls.
BC8_BioRED_Task1_Doc456	1281	1285	FHCM	Disease	D024741	The polymorphism did not show any association with FHCM.
BC8_BioRED_Task1_Doc456	1344	1347	AGT	Gene	183	CONCLUSION: Our results suggest that the T allele of the AGT gene is significantly associated with SHCM in a South Indian population from Andhra Pradesh.
BC8_BioRED_Task1_Doc456	1386	1390	SHCM	Disease	D002312	CONCLUSION: Our results suggest that the T allele of the AGT gene is significantly associated with SHCM in a South Indian population from Andhra Pradesh.
BC8_BioRED_Task1_Doc456	1516	1520	FHCM	Disease	D024741	However, we did not find significant association of this polymorphism with FHCM.
BC8_BioRED_Task1_Doc457	23	28	PPARa	Gene	19013	On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	59	66	hypoxia	Disease	D000860	On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	101	108	hypoxic	Disease	D000860	On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	129	173	peroxisome proliferator-activated receptor a	Gene	19013	The role of peroxisome proliferator-activated receptor a (PPARa)-mediated metabolic remodeling in cardiac adaptation to hypoxia has yet to be defined.
BC8_BioRED_Task1_Doc457	175	180	PPARa	Gene	19013	The role of peroxisome proliferator-activated receptor a (PPARa)-mediated metabolic remodeling in cardiac adaptation to hypoxia has yet to be defined.
BC8_BioRED_Task1_Doc457	237	244	hypoxia	Disease	D000860	The role of peroxisome proliferator-activated receptor a (PPARa)-mediated metabolic remodeling in cardiac adaptation to hypoxia has yet to be defined.
BC8_BioRED_Task1_Doc457	274	278	mice	OrganismTaxon	10090	Here, mice were housed in hypoxia for 3 wk before in vivo contractile function was measured using cine MRI.
BC8_BioRED_Task1_Doc457	294	301	hypoxia	Disease	D000860	Here, mice were housed in hypoxia for 3 wk before in vivo contractile function was measured using cine MRI.
BC8_BioRED_Task1_Doc457	501	511	fatty acid	Chemical	D005227	In isolated, perfused hearts, energetics were measured using (31)P magnetic resonance spectroscopy (MRS), and glycolysis and fatty acid oxidation were measured using [(3)H] labeling.
BC8_BioRED_Task1_Doc457	543	547	(3)H	Chemical	D014316	In isolated, perfused hearts, energetics were measured using (31)P magnetic resonance spectroscopy (MRS), and glycolysis and fatty acid oxidation were measured using [(3)H] labeling.
BC8_BioRED_Task1_Doc457	602	607	mouse	OrganismTaxon	10090	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	615	622	hypoxia	Disease	D000860	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	633	638	PPARa	Gene	19013	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	651	661	fatty acid	Chemical	D005227	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	677	711	mitochondrial uncoupling protein 3	Gene	22229	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	713	717	UCP3	Gene	22229	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	795	798	ATP	Chemical	D000255	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	816	819	ATP	Chemical	D000255	Compared with a normoxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial uncoupling protein 3 (UCP3) levels, while increasing glycolysis, all of which served to maintain normal ATP concentrations ([ATP]) and thereby, ejection fractions.
BC8_BioRED_Task1_Doc457	889	894	PPARa	Gene	19013	A high-fat diet increased cardiac PPARa expression, fatty acid oxidation, and UCP3 levels with decreased glycolysis.
BC8_BioRED_Task1_Doc457	907	917	fatty acid	Chemical	D005227	A high-fat diet increased cardiac PPARa expression, fatty acid oxidation, and UCP3 levels with decreased glycolysis.
BC8_BioRED_Task1_Doc457	933	937	UCP3	Gene	22229	A high-fat diet increased cardiac PPARa expression, fatty acid oxidation, and UCP3 levels with decreased glycolysis.
BC8_BioRED_Task1_Doc457	972	979	Hypoxia	Disease	D000860	Hypoxia was unable to alter the high PPARa expression or reverse the metabolic changes caused by the high-fat diet, with the result that [ATP] and contractile function decreased significantly.
BC8_BioRED_Task1_Doc457	1009	1014	PPARa	Gene	19013	Hypoxia was unable to alter the high PPARa expression or reverse the metabolic changes caused by the high-fat diet, with the result that [ATP] and contractile function decreased significantly.
BC8_BioRED_Task1_Doc457	1110	1113	ATP	Chemical	D000255	Hypoxia was unable to alter the high PPARa expression or reverse the metabolic changes caused by the high-fat diet, with the result that [ATP] and contractile function decreased significantly.
BC8_BioRED_Task1_Doc457	1206	1213	hypoxia	Disease	D000860	The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient (PPARa(-/-)) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling.
BC8_BioRED_Task1_Doc457	1225	1230	mouse	OrganismTaxon	10090	The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient (PPARa(-/-)) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling.
BC8_BioRED_Task1_Doc457	1277	1282	PPARa	Gene	19013	The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient (PPARa(-/-)) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling.
BC8_BioRED_Task1_Doc457	1294	1299	PPARa	Gene	19013	The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient (PPARa(-/-)) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling.
BC8_BioRED_Task1_Doc457	1306	1311	mouse	OrganismTaxon	10090	The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient (PPARa(-/-)) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling.
BC8_BioRED_Task1_Doc457	1345	1352	hypoxia	Disease	D000860	The adaptive metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient (PPARa(-/-)) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling.
BC8_BioRED_Task1_Doc457	1443	1448	PPARa	Gene	19013	We conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K. On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	1510	1517	hypoxia	Disease	D000860	We conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K. On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	1875	1880	PPARa	Gene	19013	We conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K. On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	1911	1918	hypoxia	Disease	D000860	We conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K. On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc457	1953	1960	hypoxic	Disease	D000860	We conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia, but is prevented by dietary fat.-Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., Neubauer, S., Robbins, P. A., Clarke, K. On the pivotal role of PPARa in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.
BC8_BioRED_Task1_Doc458	70	75	hPER2	Gene	8864	A single-nucleotide polymorphism in the 5'-untranslated region of the hPER2 gene is associated with diurnal preference.
BC8_BioRED_Task1_Doc458	124	131	PERIOD2	Gene	8864	The PERIOD2 (PER2) gene is a key component of the molecular mechanism that generates circadian rhythms in mammals.
BC8_BioRED_Task1_Doc458	133	137	PER2	Gene	8864	The PERIOD2 (PER2) gene is a key component of the molecular mechanism that generates circadian rhythms in mammals.
BC8_BioRED_Task1_Doc458	262	267	human	OrganismTaxon	9606	A missense mutation in the human PER2 gene has previously been linked to advanced sleep phase syndrome (ASPS).
BC8_BioRED_Task1_Doc458	268	272	PER2	Gene	8864	A missense mutation in the human PER2 gene has previously been linked to advanced sleep phase syndrome (ASPS).
BC8_BioRED_Task1_Doc458	308	337	advanced sleep phase syndrome	Disease	C565789	A missense mutation in the human PER2 gene has previously been linked to advanced sleep phase syndrome (ASPS).
BC8_BioRED_Task1_Doc458	339	343	ASPS	Disease	C565789	A missense mutation in the human PER2 gene has previously been linked to advanced sleep phase syndrome (ASPS).
BC8_BioRED_Task1_Doc458	418	423	hPER2	Gene	8864	We have investigated three other single-nucleotide polymorphisms in the hPER2 gene, one downstream of the transcription start site (C-1228T), one in exon 2 in the 5'-untranslated region (5'-UTR) (C111G), and one missense mutation (G3853A) causing a glycine to glutamine substitution in the predicted protein.
BC8_BioRED_Task1_Doc458	478	485	C-1228T	SequenceVariant	c|SUB|C|-1228|T	We have investigated three other single-nucleotide polymorphisms in the hPER2 gene, one downstream of the transcription start site (C-1228T), one in exon 2 in the 5'-untranslated region (5'-UTR) (C111G), and one missense mutation (G3853A) causing a glycine to glutamine substitution in the predicted protein.
BC8_BioRED_Task1_Doc458	542	547	C111G	SequenceVariant	c|SUB|C|111|G	We have investigated three other single-nucleotide polymorphisms in the hPER2 gene, one downstream of the transcription start site (C-1228T), one in exon 2 in the 5'-untranslated region (5'-UTR) (C111G), and one missense mutation (G3853A) causing a glycine to glutamine substitution in the predicted protein.
BC8_BioRED_Task1_Doc458	577	583	G3853A	SequenceVariant	c|SUB|G|3853|A	We have investigated three other single-nucleotide polymorphisms in the hPER2 gene, one downstream of the transcription start site (C-1228T), one in exon 2 in the 5'-untranslated region (5'-UTR) (C111G), and one missense mutation (G3853A) causing a glycine to glutamine substitution in the predicted protein.
BC8_BioRED_Task1_Doc458	595	615	glycine to glutamine	SequenceVariant	p|SUB|G||Q	We have investigated three other single-nucleotide polymorphisms in the hPER2 gene, one downstream of the transcription start site (C-1228T), one in exon 2 in the 5'-untranslated region (5'-UTR) (C111G), and one missense mutation (G3853A) causing a glycine to glutamine substitution in the predicted protein.
BC8_BioRED_Task1_Doc458	978	982	111G	SequenceVariant	c|Allele|G|111	Whereas allele frequencies for the other two polymorphisms did not differ significantly between any of the groups, the 111G allele frequency was significantly higher in subjects with extreme morning preference (0.14) than in subjects with extreme evening preference (0.03) (Fisher's exact test, two-sided P value=0.031, odds ratio=5.67).
BC8_BioRED_Task1_Doc458	1226	1230	111G	SequenceVariant	c|Allele|G|111	No significant difference in 111G allele frequency was observed between either of these groups and subjects with intermediate diurnal preference.
BC8_BioRED_Task1_Doc458	1382	1387	C111G	SequenceVariant	c|SUB|C|111|G	Computer prediction indicated that the C111G polymorphism, which occurs 12 bases upstream from the translation start codon, might alter the secondary structure of the transcript.
BC8_BioRED_Task1_Doc458	1526	1530	PER2	Gene	8864	The PER2 111G allele associates with morning preference and is a potential candidate allele for ASPS.
BC8_BioRED_Task1_Doc458	1531	1535	111G	SequenceVariant	c|Allele|G|111	The PER2 111G allele associates with morning preference and is a potential candidate allele for ASPS.
BC8_BioRED_Task1_Doc458	1618	1622	ASPS	Disease	C565789	The PER2 111G allele associates with morning preference and is a potential candidate allele for ASPS.
BC8_BioRED_Task1_Doc459	12	27	NADPH oxidase 4	Gene	85431	Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.
BC8_BioRED_Task1_Doc459	37	82	vascular endothelial growth factor receptor 2	Gene	25589	Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.
BC8_BioRED_Task1_Doc459	128	131	rat	OrganismTaxon	10116	Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.
BC8_BioRED_Task1_Doc459	141	167	retinopathy of prematurity	Disease	D012178	Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity.
BC8_BioRED_Task1_Doc459	178	191	NADPH oxidase	Gene	114243,50507,66021,85431	PURPOSE: NADPH oxidase-generated reactive oxygen species (ROS) are implicated in angiogenesis.
BC8_BioRED_Task1_Doc459	202	225	reactive oxygen species	Chemical	D017382	PURPOSE: NADPH oxidase-generated reactive oxygen species (ROS) are implicated in angiogenesis.
BC8_BioRED_Task1_Doc459	227	230	ROS	Chemical	D017382	PURPOSE: NADPH oxidase-generated reactive oxygen species (ROS) are implicated in angiogenesis.
BC8_BioRED_Task1_Doc459	276	289	NADPH oxidase	Gene	114243,50507,66021,85431	Isoforms of NADPH oxidase NOX1, NOX2, and NOX4 are reported to be expressed in endothelial cells (ECs).
BC8_BioRED_Task1_Doc459	290	294	NOX1	Gene	114243	Isoforms of NADPH oxidase NOX1, NOX2, and NOX4 are reported to be expressed in endothelial cells (ECs).
BC8_BioRED_Task1_Doc459	296	300	NOX2	Gene	66021	Isoforms of NADPH oxidase NOX1, NOX2, and NOX4 are reported to be expressed in endothelial cells (ECs).
BC8_BioRED_Task1_Doc459	306	310	NOX4	Gene	85431	Isoforms of NADPH oxidase NOX1, NOX2, and NOX4 are reported to be expressed in endothelial cells (ECs).
BC8_BioRED_Task1_Doc459	378	382	NOX1	Gene	114243	Of these, NOX1 and NOX2 have been reported to contribute to intravitreal neovascularization (IVNV) in oxygen-induced retinopathy (OIR) models.
BC8_BioRED_Task1_Doc459	387	391	NOX2	Gene	66021	Of these, NOX1 and NOX2 have been reported to contribute to intravitreal neovascularization (IVNV) in oxygen-induced retinopathy (OIR) models.
BC8_BioRED_Task1_Doc459	470	476	oxygen	Chemical	D010100	Of these, NOX1 and NOX2 have been reported to contribute to intravitreal neovascularization (IVNV) in oxygen-induced retinopathy (OIR) models.
BC8_BioRED_Task1_Doc459	485	496	retinopathy	Disease	D012164	Of these, NOX1 and NOX2 have been reported to contribute to intravitreal neovascularization (IVNV) in oxygen-induced retinopathy (OIR) models.
BC8_BioRED_Task1_Doc459	498	501	OIR	Disease	D012164	Of these, NOX1 and NOX2 have been reported to contribute to intravitreal neovascularization (IVNV) in oxygen-induced retinopathy (OIR) models.
BC8_BioRED_Task1_Doc459	568	572	NOX4	Gene	85431	In this study, we tested the hypothesis that the isoform NOX4 in ECs contributed to vascular endothelial growth factor (VEGF)-induced angiogenesis and IVNV.
BC8_BioRED_Task1_Doc459	595	629	vascular endothelial growth factor	Gene	83785	In this study, we tested the hypothesis that the isoform NOX4 in ECs contributed to vascular endothelial growth factor (VEGF)-induced angiogenesis and IVNV.
BC8_BioRED_Task1_Doc459	631	635	VEGF	Gene	83785	In this study, we tested the hypothesis that the isoform NOX4 in ECs contributed to vascular endothelial growth factor (VEGF)-induced angiogenesis and IVNV.
BC8_BioRED_Task1_Doc459	689	702	NADPH oxidase	Gene	114243,50507,66021,85431	METHODS: Isoforms of NADPH oxidase MRNA were measured in several types of cultured vascular ecs: human retinal microvascular ECs (hRMVECs), choroidal ECs (CECs), and human umbilical vascular ECs (HUVECs) using real-time PCR.
BC8_BioRED_Task1_Doc459	765	770	human	OrganismTaxon	9606	METHODS: Isoforms of NADPH oxidase MRNA were measured in several types of cultured vascular ecs: human retinal microvascular ECs (hRMVECs), choroidal ECs (CECs), and human umbilical vascular ECs (HUVECs) using real-time PCR.
BC8_BioRED_Task1_Doc459	834	839	human	OrganismTaxon	9606	METHODS: Isoforms of NADPH oxidase MRNA were measured in several types of cultured vascular ecs: human retinal microvascular ECs (hRMVECs), choroidal ECs (CECs), and human umbilical vascular ECs (HUVECs) using real-time PCR.
BC8_BioRED_Task1_Doc459	901	904	rat	OrganismTaxon	10116	Newborn rat pups and dams were placed into an OIR model that cycled oxygen concentration between 50% and 10% every 24 h for 14 days, and then were placed in room air (RA) for an additional 4 days (rat OIR model).
BC8_BioRED_Task1_Doc459	939	942	OIR	Disease	D012164	Newborn rat pups and dams were placed into an OIR model that cycled oxygen concentration between 50% and 10% every 24 h for 14 days, and then were placed in room air (RA) for an additional 4 days (rat OIR model).
BC8_BioRED_Task1_Doc459	961	967	oxygen	Chemical	D010100	Newborn rat pups and dams were placed into an OIR model that cycled oxygen concentration between 50% and 10% every 24 h for 14 days, and then were placed in room air (RA) for an additional 4 days (rat OIR model).
BC8_BioRED_Task1_Doc459	1090	1093	rat	OrganismTaxon	10116	Newborn rat pups and dams were placed into an OIR model that cycled oxygen concentration between 50% and 10% every 24 h for 14 days, and then were placed in room air (RA) for an additional 4 days (rat OIR model).
BC8_BioRED_Task1_Doc459	1094	1097	OIR	Disease	D012164	Newborn rat pups and dams were placed into an OIR model that cycled oxygen concentration between 50% and 10% every 24 h for 14 days, and then were placed in room air (RA) for an additional 4 days (rat OIR model).
BC8_BioRED_Task1_Doc459	1106	1110	NOX4	Gene	85431	NOX4 expression in retinal lysates from the RA-raised pups at postnatal day 0 (P0), P14, and P18 was determined with western blots.
BC8_BioRED_Task1_Doc459	1238	1243	STAT3	Gene	25125	STAT3 activation was determined as the ratio of phosphorylated STAT3 to total STAT3 with western blot analysis of retinal lysates from pups raised in RA or from the rat OIR model at P18.
BC8_BioRED_Task1_Doc459	1301	1306	STAT3	Gene	25125	STAT3 activation was determined as the ratio of phosphorylated STAT3 to total STAT3 with western blot analysis of retinal lysates from pups raised in RA or from the rat OIR model at P18.
BC8_BioRED_Task1_Doc459	1316	1321	STAT3	Gene	25125	STAT3 activation was determined as the ratio of phosphorylated STAT3 to total STAT3 with western blot analysis of retinal lysates from pups raised in RA or from the rat OIR model at P18.
BC8_BioRED_Task1_Doc459	1403	1406	rat	OrganismTaxon	10116	STAT3 activation was determined as the ratio of phosphorylated STAT3 to total STAT3 with western blot analysis of retinal lysates from pups raised in RA or from the rat OIR model at P18.
BC8_BioRED_Task1_Doc459	1407	1410	OIR	Disease	D012164	STAT3 activation was determined as the ratio of phosphorylated STAT3 to total STAT3 with western blot analysis of retinal lysates from pups raised in RA or from the rat OIR model at P18.
BC8_BioRED_Task1_Doc459	1471	1475	NOX4	Gene	85431	Semiquantitative assessment of the density of NOX4 colabeling with lectin-stained retinal ECs was determined by immunolabeling of retinal cryosections from P18 pups in OIR or in RA.
BC8_BioRED_Task1_Doc459	1492	1498	lectin	Gene	-	Semiquantitative assessment of the density of NOX4 colabeling with lectin-stained retinal ECs was determined by immunolabeling of retinal cryosections from P18 pups in OIR or in RA.
BC8_BioRED_Task1_Doc459	1593	1596	OIR	Disease	D012164	Semiquantitative assessment of the density of NOX4 colabeling with lectin-stained retinal ECs was determined by immunolabeling of retinal cryosections from P18 pups in OIR or in RA.
BC8_BioRED_Task1_Doc459	1635	1639	NOX4	Gene	50507	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1663	1667	VEGF	Gene	7422	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1683	1686	ROS	Chemical	D017382	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1721	1800	5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester	Chemical	-	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1842	1857	VEGF receptor 2	Gene	3791	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1862	1867	STAT3	Gene	6774	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1879	1885	VEGFR2	Gene	3791	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1890	1895	STAT3	Gene	6774	In hRMVECs transfected with NOX4 siRNA and treated with VEGF or control, 1) ROS generation was measured using the 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester fluorescence assay and 2) phosphorylated VEGF receptor 2 and STAT3, and total VEGFR2 and STAT3 were measured in western blot analyses.
BC8_BioRED_Task1_Doc459	1936	1940	VEGF	Gene	7422	VEGF-stimulated hRMVEC proliferation was measured following transfection with NOX4 siRNA or STAT3 siRNA, or respective controls.
BC8_BioRED_Task1_Doc459	2014	2018	NOX4	Gene	50507	VEGF-stimulated hRMVEC proliferation was measured following transfection with NOX4 siRNA or STAT3 siRNA, or respective controls.
BC8_BioRED_Task1_Doc459	2028	2033	STAT3	Gene	6774	VEGF-stimulated hRMVEC proliferation was measured following transfection with NOX4 siRNA or STAT3 siRNA, or respective controls.
BC8_BioRED_Task1_Doc459	2074	2078	NOX4	Gene	50507	RESULTS: NOX4 was the most prevalent isoform of NADPH oxidase in vascular ECs.
BC8_BioRED_Task1_Doc459	2113	2126	NADPH oxidase	Gene	114243,50507,66021,85431	RESULTS: NOX4 was the most prevalent isoform of NADPH oxidase in vascular ECs.
BC8_BioRED_Task1_Doc459	2144	2148	NOX4	Gene	85431	NOX4 expression in retinal lysates was significantly decreased during development in RA.
BC8_BioRED_Task1_Doc459	2275	2279	NOX4	Gene	85431	Compared to RA, the expression of retinal NOX4 increased at P18.
BC8_BioRED_Task1_Doc459	2305	2308	OIR	Disease	D012164	At p18 OIR, semiquantitative assessment of the density of lectin and NOX4 colabeling in retinal vascular ECs was greater in retinal cryosections and activated STAT3 was greater in retinal lysates when compared to the RA-raised pups.
BC8_BioRED_Task1_Doc459	2356	2362	lectin	Gene	-	At p18 OIR, semiquantitative assessment of the density of lectin and NOX4 colabeling in retinal vascular ECs was greater in retinal cryosections and activated STAT3 was greater in retinal lysates when compared to the RA-raised pups.
BC8_BioRED_Task1_Doc459	2367	2371	NOX4	Gene	85431	At p18 OIR, semiquantitative assessment of the density of lectin and NOX4 colabeling in retinal vascular ECs was greater in retinal cryosections and activated STAT3 was greater in retinal lysates when compared to the RA-raised pups.
BC8_BioRED_Task1_Doc459	2457	2462	STAT3	Gene	25125	At p18 OIR, semiquantitative assessment of the density of lectin and NOX4 colabeling in retinal vascular ECs was greater in retinal cryosections and activated STAT3 was greater in retinal lysates when compared to the RA-raised pups.
BC8_BioRED_Task1_Doc459	2565	2569	NOX4	Gene	50507	In cultured hRMVECs, knockdown of NOX4 by siRNA transfection inhibited VEGF-induced ROS generation.
BC8_BioRED_Task1_Doc459	2602	2606	VEGF	Gene	7422	In cultured hRMVECs, knockdown of NOX4 by siRNA transfection inhibited VEGF-induced ROS generation.
BC8_BioRED_Task1_Doc459	2615	2618	ROS	Chemical	D017382	In cultured hRMVECs, knockdown of NOX4 by siRNA transfection inhibited VEGF-induced ROS generation.
BC8_BioRED_Task1_Doc459	2631	2635	VEGF	Gene	7422	VEGF induced a physical interaction of phosphorylated-VEGFR2 and NOX4.
BC8_BioRED_Task1_Doc459	2685	2691	VEGFR2	Gene	3791	VEGF induced a physical interaction of phosphorylated-VEGFR2 and NOX4.
BC8_BioRED_Task1_Doc459	2696	2700	NOX4	Gene	50507	VEGF induced a physical interaction of phosphorylated-VEGFR2 and NOX4.
BC8_BioRED_Task1_Doc459	2715	2719	NOX4	Gene	50507	Knockdown of NOX4: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished STAT3 activation in response to VEGF.
BC8_BioRED_Task1_Doc459	2732	2738	VEGFR2	Gene	3791	Knockdown of NOX4: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished STAT3 activation in response to VEGF.
BC8_BioRED_Task1_Doc459	2790	2795	STAT3	Gene	6774	Knockdown of NOX4: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished STAT3 activation in response to VEGF.
BC8_BioRED_Task1_Doc459	2822	2826	VEGF	Gene	7422	Knockdown of NOX4: 1) reduced VEGFR2 activation but did not abolish it and 2) abolished STAT3 activation in response to VEGF.
BC8_BioRED_Task1_Doc459	2848	2852	NOX4	Gene	50507	Knockdown of either NOX4 or STAT3 inhibited VEGF-induced EC proliferation.
BC8_BioRED_Task1_Doc459	2856	2861	STAT3	Gene	6774	Knockdown of either NOX4 or STAT3 inhibited VEGF-induced EC proliferation.
BC8_BioRED_Task1_Doc459	2872	2876	VEGF	Gene	7422	Knockdown of either NOX4 or STAT3 inhibited VEGF-induced EC proliferation.
BC8_BioRED_Task1_Doc459	2967	2972	human	OrganismTaxon	9606	CONCLUSIONS: Our data suggest that in a model representative of human retinopathy of prematurity, NOX4 was increased at a time point when IVNV developed.
BC8_BioRED_Task1_Doc459	2973	2999	retinopathy of prematurity	Disease	D012178	CONCLUSIONS: Our data suggest that in a model representative of human retinopathy of prematurity, NOX4 was increased at a time point when IVNV developed.
BC8_BioRED_Task1_Doc459	3001	3005	NOX4	Gene	85431	CONCLUSIONS: Our data suggest that in a model representative of human retinopathy of prematurity, NOX4 was increased at a time point when IVNV developed.
BC8_BioRED_Task1_Doc459	3057	3061	VEGF	Gene	7422	VEGF-activated NOX4 led to an interaction between VEGF-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of STAT3.
BC8_BioRED_Task1_Doc459	3072	3076	NOX4	Gene	50507	VEGF-activated NOX4 led to an interaction between VEGF-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of STAT3.
BC8_BioRED_Task1_Doc459	3107	3111	VEGF	Gene	7422	VEGF-activated NOX4 led to an interaction between VEGF-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of STAT3.
BC8_BioRED_Task1_Doc459	3122	3128	VEGFR2	Gene	3791	VEGF-activated NOX4 led to an interaction between VEGF-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of STAT3.
BC8_BioRED_Task1_Doc459	3133	3137	NOX4	Gene	50507	VEGF-activated NOX4 led to an interaction between VEGF-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of STAT3.
BC8_BioRED_Task1_Doc459	3187	3192	STAT3	Gene	6774	VEGF-activated NOX4 led to an interaction between VEGF-activated VEGFR2 and NOX4 that mediated EC proliferation via activation of STAT3.
BC8_BioRED_Task1_Doc459	3231	3235	NOX4	Gene	85431	Altogether, our results suggest that NOX4 may regulate VEGFR2-mediated IVNV through activated STAT3.
BC8_BioRED_Task1_Doc459	3249	3255	VEGFR2	Gene	25589	Altogether, our results suggest that NOX4 may regulate VEGFR2-mediated IVNV through activated STAT3.
BC8_BioRED_Task1_Doc459	3288	3293	STAT3	Gene	25125	Altogether, our results suggest that NOX4 may regulate VEGFR2-mediated IVNV through activated STAT3.
BC8_BioRED_Task1_Doc460	23	47	C-C chemokine receptor 5	Gene	1234	Lack of association of C-C chemokine receptor 5 DD32 deletion status with rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and disease severity.
BC8_BioRED_Task1_Doc460	48	61	DD32 deletion	SequenceVariant	c|DEL||32	Lack of association of C-C chemokine receptor 5 DD32 deletion status with rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and disease severity.
BC8_BioRED_Task1_Doc460	74	94	rheumatoid arthritis	Disease	D001172	Lack of association of C-C chemokine receptor 5 DD32 deletion status with rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and disease severity.
BC8_BioRED_Task1_Doc460	96	124	systemic lupus erythematosus	Disease	D008180	Lack of association of C-C chemokine receptor 5 DD32 deletion status with rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and disease severity.
BC8_BioRED_Task1_Doc460	126	141	lupus nephritis	Disease	D008181	Lack of association of C-C chemokine receptor 5 DD32 deletion status with rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and disease severity.
BC8_BioRED_Task1_Doc460	176	200	C-C chemokine receptor 5	Gene	1234	OBJECTIVE: C-C chemokine receptor 5 (CCR5) plays an important role in inflammation.
BC8_BioRED_Task1_Doc460	202	206	CCR5	Gene	1234	OBJECTIVE: C-C chemokine receptor 5 (CCR5) plays an important role in inflammation.
BC8_BioRED_Task1_Doc460	235	247	inflammation	Disease	D007249	OBJECTIVE: C-C chemokine receptor 5 (CCR5) plays an important role in inflammation.
BC8_BioRED_Task1_Doc460	251	279	32 base-pair (DD32) deletion	SequenceVariant	c|DEL||32	A 32 base-pair (DD32) deletion in the CCR5 gene leads to a nonfunctional receptor.
BC8_BioRED_Task1_Doc460	287	291	CCR5	Gene	1234	A 32 base-pair (DD32) deletion in the CCR5 gene leads to a nonfunctional receptor.
BC8_BioRED_Task1_Doc460	438	457	autoimmune diseases	Disease	D001327	This deletion has been reported to have a protective effect on the development and progression of several autoimmune diseases.
BC8_BioRED_Task1_Doc460	487	500	DD32 deletion	SequenceVariant	c|DEL||32	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	562	570	patients	OrganismTaxon	9606	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	576	596	rheumatoid arthritis	Disease	D001172	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	598	600	RA	Disease	D001172	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	603	631	systemic lupus erythematosus	Disease	D008180	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	633	636	SLE	Disease	D008180	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	643	658	lupus nephritis	Disease	D008181	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	660	662	LN	Disease	D008181	We investigated whether the DD32 deletion is associated with disease susceptibility in a population of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and lupus nephritis (LN); and whether it is associated with disease severity.
BC8_BioRED_Task1_Doc460	747	749	RA	Disease	D001172	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	750	758	patients	OrganismTaxon	9606	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	763	766	SLE	Disease	D008180	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	767	775	patients	OrganismTaxon	9606	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	781	783	LN	Disease	D008181	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	784	792	patients	OrganismTaxon	9606	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	842	846	CCR5	Gene	1234	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	847	860	DD32 deletion	SequenceVariant	c|DEL||32	METHODS: DNA samples from 405 RA patients, 97 SLE patients, 113 LN patients, and 431 healthy controls were genotyped for the CCR5 DD32 deletion.
BC8_BioRED_Task1_Doc460	918	926	patients	OrganismTaxon	9606	Differences in genotype frequencies were tested between patients and controls.
BC8_BioRED_Task1_Doc460	1110	1118	patients	OrganismTaxon	9606	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1163	1167	CCR5	Gene	1234	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1168	1172	DD32	SequenceVariant	c|DEL||32	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1174	1178	DD32	SequenceVariant	c|DEL||32	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1179	1183	DD32	SequenceVariant	c|DEL||32	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1185	1187	RA	Disease	D001172	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1218	1221	SLE	Disease	D008180	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1238	1240	LN	Disease	D008181	The genotype frequencies of patients did not differ significantly from controls (CCR5/DD32, DD32/DD32: RA 18.3% and 1.2%, respectively; SLE 17.5% and 2.1%; LN 13.3% and 1.8%; controls 20.0% and 2.8%).
BC8_BioRED_Task1_Doc460	1320	1333	DD32 deletion	SequenceVariant	c|DEL||32	However, there was a trend for lower DD32 deletion allele frequency in LN patients compared to controls (p = 0.08).
BC8_BioRED_Task1_Doc460	1354	1356	LN	Disease	D008181	However, there was a trend for lower DD32 deletion allele frequency in LN patients compared to controls (p = 0.08).
BC8_BioRED_Task1_Doc460	1357	1365	patients	OrganismTaxon	9606	However, there was a trend for lower DD32 deletion allele frequency in LN patients compared to controls (p = 0.08).
BC8_BioRED_Task1_Doc460	1448	1452	CCR5	Gene	1234	There was no significant association between the CCR5 status and disease severity in RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1484	1486	RA	Disease	D001172	There was no significant association between the CCR5 status and disease severity in RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1488	1491	SLE	Disease	D008180	There was no significant association between the CCR5 status and disease severity in RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1496	1498	LN	Disease	D008181	There was no significant association between the CCR5 status and disease severity in RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1541	1543	LN	Disease	D008181	CONCLUSION: Although an association with LN cannot be excluded, the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1568	1572	CCR5	Gene	1234	CONCLUSION: Although an association with LN cannot be excluded, the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1573	1586	DD32 deletion	SequenceVariant	c|DEL||32	CONCLUSION: Although an association with LN cannot be excluded, the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1645	1647	RA	Disease	D001172	CONCLUSION: Although an association with LN cannot be excluded, the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1649	1652	SLE	Disease	D008180	CONCLUSION: Although an association with LN cannot be excluded, the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1657	1659	LN	Disease	D008181	CONCLUSION: Although an association with LN cannot be excluded, the CCR5 DD32 deletion does not seem to be a disease susceptibility genotype for RA, SLE, or LN.
BC8_BioRED_Task1_Doc460	1690	1703	DD32 deletion	SequenceVariant	c|DEL||32	No significant effect of the DD32 deletion on disease severity was demonstrated.
BC8_BioRED_Task1_Doc461	0	5	Rab6c	Gene	84084	Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
BC8_BioRED_Task1_Doc461	27	30	rab	Gene	5870,84084	Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
BC8_BioRED_Task1_Doc461	78	87	MCF7/AdrR	CellLine	 CVCL_1452	Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells.
BC8_BioRED_Task1_Doc461	101	105	Rab6	Gene	5870	A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique.
BC8_BioRED_Task1_Doc461	120	125	Rab6c	Gene	84084	A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique.
BC8_BioRED_Task1_Doc461	207	212	human	OrganismTaxon	9606	A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique.
BC8_BioRED_Task1_Doc461	239	252	breast cancer	Disease	D001943	A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique.
BC8_BioRED_Task1_Doc461	264	273	MCF7/AdrR	CellLine	 CVCL_1452	A new Rab6 homolog cDNA, Rab6c, was discovered by a hypermethylated DNA fragment probe that was isolated from a human multidrug resistant (MDR) breast cancer cell line, MCF7/AdrR, by the methylation sensitive-representational difference analysis (MS-RDA) technique.
BC8_BioRED_Task1_Doc461	361	366	Rab6c	Gene	84084	Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines.
BC8_BioRED_Task1_Doc461	402	411	MCF7/AdrR	CellLine	 CVCL_1452	Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines.
BC8_BioRED_Task1_Doc461	416	426	MES-SA/Dx5	CellLine	CVCL_2598	Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines.
BC8_BioRED_Task1_Doc461	430	435	human	OrganismTaxon	9606	Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines.
BC8_BioRED_Task1_Doc461	440	455	uterine sarcoma	Disease	D014594	Rab6c was found to be under-expressed in MCF7/AdrR and MES-SA/Dx5 (a human MDR uterine sarcoma cell line) compared with their non-MDR parental cell lines.
BC8_BioRED_Task1_Doc461	516	525	MCF7/AdrR	CellLine	 CVCL_1452	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	557	562	Rab6c	Gene	84084	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	627	638	doxorubicin	Chemical	D004317	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	640	643	DOX	Chemical	D004317	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	646	651	taxol	Chemical	D017239	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	653	664	vinblastine	Chemical	D014747	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	670	681	vincristine	Chemical	D014750	MCF7/AdrR cells expressing the exogenous Rab6c exhibited less resistance to several anti-cancer drugs, such as doxorubicin (DOX), taxol, vinblastine, and vincristine, than the control cells containing the empty vector.
BC8_BioRED_Task1_Doc461	821	824	DOX	Chemical	D004317	Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c.
BC8_BioRED_Task1_Doc461	892	897	Rab6c	Gene	84084	Flow cytometry experiments confirmed that the transfectants' diminished resistance to DOX was caused by increased drug accumulation induced by the exogenous Rab6c.
BC8_BioRED_Task1_Doc461	927	932	Rab6c	Gene	84084	These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.
BC8_BioRED_Task1_Doc461	967	976	MCF7/AdrR	CellLine	 CVCL_1452	These results indicate that Rab6c is involved in drug resistance in MCF7/AdrR cells.
BC8_BioRED_Task1_Doc462	23	42	atrial fibrillation	Disease	D001281	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
BC8_BioRED_Task1_Doc462	46	54	warfarin	Chemical	D014859	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
BC8_BioRED_Task1_Doc462	74	84	hemorrhage	Disease	D006470	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
BC8_BioRED_Task1_Doc462	89	95	stroke	Disease	D020521	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
BC8_BioRED_Task1_Doc462	113	120	patient	OrganismTaxon	9606	People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
BC8_BioRED_Task1_Doc462	189	199	hemorrhage	Disease	D006470	OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
BC8_BioRED_Task1_Doc462	204	210	stroke	Disease	D020521	OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
BC8_BioRED_Task1_Doc462	244	263	atrial fibrillation	Disease	D001281	OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
BC8_BioRED_Task1_Doc462	281	289	warfarin	Chemical	D014859	OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
BC8_BioRED_Task1_Doc462	500	508	patients	OrganismTaxon	9606	PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.
BC8_BioRED_Task1_Doc462	612	631	atrial fibrillation	Disease	D001281	PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.
BC8_BioRED_Task1_Doc462	635	643	warfarin	Chemical	D014859	PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.
BC8_BioRED_Task1_Doc462	701	709	bleeding	Disease	D006470	MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
BC8_BioRED_Task1_Doc462	720	727	strokes	Disease	D020521	MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
BC8_BioRED_Task1_Doc462	733	741	warfarin	Chemical	D014859	MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
BC8_BioRED_Task1_Doc462	764	772	patients	OrganismTaxon	9606	MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
BC8_BioRED_Task1_Doc462	860	868	patients	OrganismTaxon	9606	RESULTS: Two hundred twenty-eight patients (42% men) with a mean age of 81.1 (range 76-94) were included in the analysis.
BC8_BioRED_Task1_Doc462	874	877	men	OrganismTaxon	9606	RESULTS: Two hundred twenty-eight patients (42% men) with a mean age of 81.1 (range 76-94) were included in the analysis.
BC8_BioRED_Task1_Doc462	967	975	warfarin	Chemical	D014859	Total follow-up on warfarin was 530 years (mean 28 months).
BC8_BioRED_Task1_Doc462	1028	1039	hemorrhages	Disease	D006470	There were 53 major hemorrhages, for an annual rate of 10.0%, including 24 (45.3%) life-threatening and five (9.4%) fatal bleeds.
BC8_BioRED_Task1_Doc462	1130	1136	bleeds	Disease	D006470	There were 53 major hemorrhages, for an annual rate of 10.0%, including 24 (45.3%) life-threatening and five (9.4%) fatal bleeds.
BC8_BioRED_Task1_Doc462	1149	1155	stroke	Disease	D020521	The annual stroke rate after initiation of warfarin was 2.6%.
BC8_BioRED_Task1_Doc462	1181	1189	warfarin	Chemical	D014859	The annual stroke rate after initiation of warfarin was 2.6%.
BC8_BioRED_Task1_Doc462	1230	1240	hemorrhage	Disease	D006470	CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
BC8_BioRED_Task1_Doc462	1345	1351	stroke	Disease	D020521	CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
BC8_BioRED_Task1_Doc462	1360	1368	warfarin	Chemical	D014859	CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
BC8_BioRED_Task1_Doc462	1406	1414	warfarin	Chemical	D014859	CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.
BC8_BioRED_Task1_Doc463	20	41	serotonin transporter	Gene	6532	Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
BC8_BioRED_Task1_Doc463	72	79	ecstasy	Chemical	D018817	Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
BC8_BioRED_Task1_Doc463	81	85	MDMA	Chemical	D018817	Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
BC8_BioRED_Task1_Doc463	103	136	3,4-methylenedioxymethamphetamine	Chemical	D018817	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	138	142	MDMA	Chemical	D018817	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	146	153	ecstasy	Chemical	D018817	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	186	195	serotonin	Chemical	D012701	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	197	201	5-HT	Chemical	D012701	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	235	241	humans	OrganismTaxon	9606	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	295	299	MDMA	Chemical	D018817	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	308	312	5-HT	Chemical	D012701	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	313	331	neurotoxic lesions	Disease	D020258	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	354	358	5-HT	Chemical	D012701	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
BC8_BioRED_Task1_Doc463	408	412	5-HT	Chemical	D012701	Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
BC8_BioRED_Task1_Doc463	475	479	5-HT	Chemical	D012701	Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
BC8_BioRED_Task1_Doc463	585	622	5-HT transporter promoter gene region	Gene	6532	Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
BC8_BioRED_Task1_Doc463	624	632	5-HTTLPR	Gene	6532	Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
BC8_BioRED_Task1_Doc463	663	667	MDMA	Chemical	D018817	Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
BC8_BioRED_Task1_Doc463	776	780	MDMA	Chemical	D018817	The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.
BC8_BioRED_Task1_Doc463	860	864	MDMA	Chemical	D018817	The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.
BC8_BioRED_Task1_Doc463	892	900	5-HTTLPR	Gene	6532	The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.
BC8_BioRED_Task1_Doc463	1014	1018	MDMA	Chemical	D018817	Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.
BC8_BioRED_Task1_Doc463	1058	1062	MDMA	Chemical	D018817	Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.
BC8_BioRED_Task1_Doc463	1100	1104	MDMA	Chemical	D018817	Fifteen moderate MDMA users (<55 lifetime tablets), 22 heavy MDMA+ users (>55 lifetime tablets), 16 ex-MDMA+ users (last tablet > 1 year ago) and 13 controls were compared on a battery of neuropsychological tests.
BC8_BioRED_Task1_Doc463	1269	1277	5-HTTLPR	Gene	6532	DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.A significant group effect was observed only on memory function tasks (p = 0.04) but not on reaction times (p = 0.61) or attention/executive functioning (p = 0.59).
BC8_BioRED_Task1_Doc463	1505	1509	MDMA	Chemical	D018817	Heavy and ex-MDMA+ users performed significantly poorer on memory tasks than controls.
BC8_BioRED_Task1_Doc463	1607	1624	memory impairment	Disease	D008569	In contrast, no evidence of memory impairment was observed in moderate MDMA users.
BC8_BioRED_Task1_Doc463	1650	1654	MDMA	Chemical	D018817	In contrast, no evidence of memory impairment was observed in moderate MDMA users.
BC8_BioRED_Task1_Doc463	1687	1695	5-HTTLPR	Gene	6532	No significant effect of 5-HTTLPR or gender was observed.
BC8_BioRED_Task1_Doc463	1737	1741	MDMA	Chemical	D018817	While the use of MDMA in quantities that may be considered "moderate" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.
BC8_BioRED_Task1_Doc463	1813	1840	impaired memory functioning	Disease	D008569	While the use of MDMA in quantities that may be considered "moderate" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.
BC8_BioRED_Task1_Doc463	1855	1859	MDMA	Chemical	D018817	While the use of MDMA in quantities that may be considered "moderate" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.
BC8_BioRED_Task1_Doc463	1889	1907	memory impairments	Disease	D008569	While the use of MDMA in quantities that may be considered "moderate" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.
BC8_BioRED_Task1_Doc463	1922	1930	5-HTTLPR	Gene	6532	No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.
BC8_BioRED_Task1_Doc463	1963	1967	MDMA	Chemical	D018817	No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.
BC8_BioRED_Task1_Doc464	10	13	Ras	Gene	3265	Activated Ras alters lens and corneal development through induction of distinct downstream targets.
BC8_BioRED_Task1_Doc464	122	125	Ras	Gene	3265	BACKGROUND: Mammalian Ras genes regulate diverse cellular processes including proliferation and differentiation and are frequently mutated in human cancers.
BC8_BioRED_Task1_Doc464	242	247	human	OrganismTaxon	9606	BACKGROUND: Mammalian Ras genes regulate diverse cellular processes including proliferation and differentiation and are frequently mutated in human cancers.
BC8_BioRED_Task1_Doc464	248	255	cancers	Disease	D009369	BACKGROUND: Mammalian Ras genes regulate diverse cellular processes including proliferation and differentiation and are frequently mutated in human cancers.
BC8_BioRED_Task1_Doc464	257	262	Tumor	Disease	D009369	Tumor development in response to Ras activation varies between different tissues and the molecular basis for these variations are poorly understood.
BC8_BioRED_Task1_Doc464	290	293	Ras	Gene	3265	Tumor development in response to Ras activation varies between different tissues and the molecular basis for these variations are poorly understood.
BC8_BioRED_Task1_Doc464	410	416	murine	OrganismTaxon	10090	The murine lens and cornea have a common embryonic origin and arise from adjacent regions of the surface ectoderm.
BC8_BioRED_Task1_Doc464	539	563	fibroblast growth factor	Gene	64654	Activation of the fibroblast growth factor (FGF) signaling pathway induces the corneal epithelial cells to proliferate and the lens epithelial cells to exit the cell cycle.
BC8_BioRED_Task1_Doc464	565	568	FGF	Gene	64654	Activation of the fibroblast growth factor (FGF) signaling pathway induces the corneal epithelial cells to proliferate and the lens epithelial cells to exit the cell cycle.
BC8_BioRED_Task1_Doc464	841	845	mice	OrganismTaxon	10090	We have generated transgenic mice that express a constitutively active version of human H-Ras in their lenses and corneas.
BC8_BioRED_Task1_Doc464	894	899	human	OrganismTaxon	9606	We have generated transgenic mice that express a constitutively active version of human H-Ras in their lenses and corneas.
BC8_BioRED_Task1_Doc464	900	905	H-Ras	Gene	3265	We have generated transgenic mice that express a constitutively active version of human H-Ras in their lenses and corneas.
BC8_BioRED_Task1_Doc464	944	947	Ras	Gene	3265	RESULTS: Ras transgenic lenses and corneal epithelial cells showed increased proliferation with concomitant increases in cyclin D1 and D2 expression.
BC8_BioRED_Task1_Doc464	1056	1072	cyclin D1 and D2	Gene	12443,12444	RESULTS: Ras transgenic lenses and corneal epithelial cells showed increased proliferation with concomitant increases in cyclin D1 and D2 expression.
BC8_BioRED_Task1_Doc464	1205	1208	cdk	Gene	12575	Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas.
BC8_BioRED_Task1_Doc464	1220	1227	p27Kip1	Gene	12576	Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas.
BC8_BioRED_Task1_Doc464	1232	1239	p57Kip2	Gene	12577	Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas.
BC8_BioRED_Task1_Doc464	1264	1267	Ras	Gene	3265	Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas.
BC8_BioRED_Task1_Doc464	1318	1322	Erk1	Gene	26417	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1327	1331	Erk2	Gene	26413	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1391	1397	Spry 1	Gene	24063	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1402	1408	Spry 2	Gene	24064	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1433	1436	Ras	Gene	3265	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1437	1440	Raf	Gene	109880	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1441	1444	Erk	Gene	26413,26417	Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells.
BC8_BioRED_Task1_Doc464	1593	1596	Ras	Gene	3265	Both lens and corneal differentiation programs were sensitive to Ras activation.
BC8_BioRED_Task1_Doc464	1609	1612	Ras	Gene	3265	Ras transgenic embryos showed a distinctive alteration in the architecture of the lens pit.
BC8_BioRED_Task1_Doc464	1701	1704	Ras	Gene	3265	Ras activation, though sufficient for upregulation of Prox1, a transcription factor critical for cell cycle exit and initiation of fiber differentiation, is not sufficient for induction of terminal fiber differentiation.
BC8_BioRED_Task1_Doc464	1755	1760	Prox1	Gene	19130	Ras activation, though sufficient for upregulation of Prox1, a transcription factor critical for cell cycle exit and initiation of fiber differentiation, is not sufficient for induction of terminal fiber differentiation.
BC8_BioRED_Task1_Doc464	1936	1946	Keratin 12	Gene	268482	Expression of Keratin 12, a marker of corneal epithelial differentiation, was reduced in the Ras transgenic corneas.
BC8_BioRED_Task1_Doc464	2015	2018	Ras	Gene	3265	Expression of Keratin 12, a marker of corneal epithelial differentiation, was reduced in the Ras transgenic corneas.
BC8_BioRED_Task1_Doc464	2093	2096	Ras	Gene	3265	CONCLUSIONS: Collectively, these results suggest that Ras activation a) induces distinct sets of downstream targets in the lens and cornea resulting in distinct cellular responses and b) is sufficient for initiation but not completion of lens fiber differentiation.
BC8_BioRED_Task1_Doc465	0	4	NEK2	Gene	4751	NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.
BC8_BioRED_Task1_Doc465	42	66	hepatocellular carcinoma	Disease	D006528	NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.
BC8_BioRED_Task1_Doc465	68	115	Never in mitosis gene A (NIMA)-related kinase 2	Gene	4751	Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) is a microtubule-associated protein that regulates spindle assembly in human cells and is overexpressed in various malignancies.
BC8_BioRED_Task1_Doc465	117	121	NEK2	Gene	4751	Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) is a microtubule-associated protein that regulates spindle assembly in human cells and is overexpressed in various malignancies.
BC8_BioRED_Task1_Doc465	128	158	microtubule-associated protein	Gene	4130	Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) is a microtubule-associated protein that regulates spindle assembly in human cells and is overexpressed in various malignancies.
BC8_BioRED_Task1_Doc465	194	199	human	OrganismTaxon	9606	Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) is a microtubule-associated protein that regulates spindle assembly in human cells and is overexpressed in various malignancies.
BC8_BioRED_Task1_Doc465	238	250	malignancies	Disease	D009369	Never in mitosis gene A (NIMA)-related kinase 2 (NEK2) is a microtubule-associated protein that regulates spindle assembly in human cells and is overexpressed in various malignancies.
BC8_BioRED_Task1_Doc465	273	277	NEK2	Gene	4751	However, the role of NEK2 in hepatocellular carcinoma (HCC) remains undetermined.
BC8_BioRED_Task1_Doc465	281	305	hepatocellular carcinoma	Disease	D006528	However, the role of NEK2 in hepatocellular carcinoma (HCC) remains undetermined.
BC8_BioRED_Task1_Doc465	307	310	HCC	Disease	D006528	However, the role of NEK2 in hepatocellular carcinoma (HCC) remains undetermined.
BC8_BioRED_Task1_Doc465	362	365	HCC	Disease	D006528	We performed RNA-seq of the HCC cell line SMMC-7721 and the normal liver cell line HL-7702 using the Ion Proton System.
BC8_BioRED_Task1_Doc465	376	385	SMMC-7721	CellLine	CVCL_0534	We performed RNA-seq of the HCC cell line SMMC-7721 and the normal liver cell line HL-7702 using the Ion Proton System.
BC8_BioRED_Task1_Doc465	417	424	HL-7702	CellLine	CVCL_6926	We performed RNA-seq of the HCC cell line SMMC-7721 and the normal liver cell line HL-7702 using the Ion Proton System.
BC8_BioRED_Task1_Doc465	454	458	NEK2	Gene	4751	NEK2 expression was detected using quantitative reverse transcription polymerase chain reaction in two cell lines and 5 matched HCC and adjacent non-tumorous liver tissues.
BC8_BioRED_Task1_Doc465	582	585	HCC	Disease	D006528	NEK2 expression was detected using quantitative reverse transcription polymerase chain reaction in two cell lines and 5 matched HCC and adjacent non-tumorous liver tissues.
BC8_BioRED_Task1_Doc465	664	668	NEK2	Gene	4751	The correlation between survival and NEK2 expression was analyzed in 359 patients with HCC using RNASeqV2 data available from The Cancer Genome Atlas (TCGA) website (https://tcga-data.nci.nih.gov/tcga/).
BC8_BioRED_Task1_Doc465	700	708	patients	OrganismTaxon	9606	The correlation between survival and NEK2 expression was analyzed in 359 patients with HCC using RNASeqV2 data available from The Cancer Genome Atlas (TCGA) website (https://tcga-data.nci.nih.gov/tcga/).
BC8_BioRED_Task1_Doc465	714	717	HCC	Disease	D006528	The correlation between survival and NEK2 expression was analyzed in 359 patients with HCC using RNASeqV2 data available from The Cancer Genome Atlas (TCGA) website (https://tcga-data.nci.nih.gov/tcga/).
BC8_BioRED_Task1_Doc465	757	763	Cancer	Disease	D009369	The correlation between survival and NEK2 expression was analyzed in 359 patients with HCC using RNASeqV2 data available from The Cancer Genome Atlas (TCGA) website (https://tcga-data.nci.nih.gov/tcga/).
BC8_BioRED_Task1_Doc465	849	853	NEK2	Gene	4751	The expression of NEK2, phospho-AKT and MMP-2 was evaluated by immunohistochemistry in 63 cases of HCC and matched adjacent non-tumorous liver tissues.
BC8_BioRED_Task1_Doc465	863	866	AKT	Gene	207	The expression of NEK2, phospho-AKT and MMP-2 was evaluated by immunohistochemistry in 63 cases of HCC and matched adjacent non-tumorous liver tissues.
BC8_BioRED_Task1_Doc465	871	876	MMP-2	Gene	4130	The expression of NEK2, phospho-AKT and MMP-2 was evaluated by immunohistochemistry in 63 cases of HCC and matched adjacent non-tumorous liver tissues.
BC8_BioRED_Task1_Doc465	930	933	HCC	Disease	D006528	The expression of NEK2, phospho-AKT and MMP-2 was evaluated by immunohistochemistry in 63 cases of HCC and matched adjacent non-tumorous liver tissues.
BC8_BioRED_Task1_Doc465	1103	1107	NEK2	Gene	4751	Relationships between protein expression and clinicopathological parameters were assessed, and the correlations between NEK2 with phospho-AKT and MMP-2 expressions were evaluated.
BC8_BioRED_Task1_Doc465	1121	1124	AKT	Gene	207	Relationships between protein expression and clinicopathological parameters were assessed, and the correlations between NEK2 with phospho-AKT and MMP-2 expressions were evaluated.
BC8_BioRED_Task1_Doc465	1129	1134	MMP-2	Gene	4130	Relationships between protein expression and clinicopathological parameters were assessed, and the correlations between NEK2 with phospho-AKT and MMP-2 expressions were evaluated.
BC8_BioRED_Task1_Doc465	1323	1326	HCC	Disease	D006528	A total of 610 differentially expressed genes (DEGs) were revealed in the transcriptome comparison, 297 of which were upregulated and 313 were downregulated in HCC.
BC8_BioRED_Task1_Doc465	1328	1332	NEK2	Gene	4751	NEK2, as the most obviously different DEG in cells and tissues from the RNA-seq data, was listed as an HCC candidate biomarker for further verification.
BC8_BioRED_Task1_Doc465	1431	1434	HCC	Disease	D006528	NEK2, as the most obviously different DEG in cells and tissues from the RNA-seq data, was listed as an HCC candidate biomarker for further verification.
BC8_BioRED_Task1_Doc465	1481	1485	NEK2	Gene	4751	NEK2 was overexpressed in HCC cells and tissues (P=0.002, P=0.013) and HCC patients with a high expression of NEK2 had a poor prognosis (P=0.0145).
BC8_BioRED_Task1_Doc465	1507	1510	HCC	Disease	D006528	NEK2 was overexpressed in HCC cells and tissues (P=0.002, P=0.013) and HCC patients with a high expression of NEK2 had a poor prognosis (P=0.0145).
BC8_BioRED_Task1_Doc465	1552	1555	HCC	Disease	D006528	NEK2 was overexpressed in HCC cells and tissues (P=0.002, P=0.013) and HCC patients with a high expression of NEK2 had a poor prognosis (P=0.0145).
BC8_BioRED_Task1_Doc465	1556	1564	patients	OrganismTaxon	9606	NEK2 was overexpressed in HCC cells and tissues (P=0.002, P=0.013) and HCC patients with a high expression of NEK2 had a poor prognosis (P=0.0145).
BC8_BioRED_Task1_Doc465	1591	1595	NEK2	Gene	4751	NEK2 was overexpressed in HCC cells and tissues (P=0.002, P=0.013) and HCC patients with a high expression of NEK2 had a poor prognosis (P=0.0145).
BC8_BioRED_Task1_Doc465	1684	1688	NEK2	Gene	4751	Clinical analysis indicated that the overexpression of NEK2 in HCC was significantly correlated with diolame complete (P<0.001), tumor nodule number (P=0.012) and recurrence (P=0.004).
BC8_BioRED_Task1_Doc465	1692	1695	HCC	Disease	D006528	Clinical analysis indicated that the overexpression of NEK2 in HCC was significantly correlated with diolame complete (P<0.001), tumor nodule number (P=0.012) and recurrence (P=0.004).
BC8_BioRED_Task1_Doc465	1758	1763	tumor	Disease	D009369	Clinical analysis indicated that the overexpression of NEK2 in HCC was significantly correlated with diolame complete (P<0.001), tumor nodule number (P=0.012) and recurrence (P=0.004).
BC8_BioRED_Task1_Doc465	1814	1818	NEK2	Gene	4751	NEK2 expression was positively correlated with the expression of phospho-AKT (r=0.883, P<0.01) and MMP-2 (r=0.781, P<0.01).
BC8_BioRED_Task1_Doc465	1887	1890	AKT	Gene	207	NEK2 expression was positively correlated with the expression of phospho-AKT (r=0.883, P<0.01) and MMP-2 (r=0.781, P<0.01).
BC8_BioRED_Task1_Doc465	1913	1918	MMP-2	Gene	4130	NEK2 expression was positively correlated with the expression of phospho-AKT (r=0.883, P<0.01) and MMP-2 (r=0.781, P<0.01).
BC8_BioRED_Task1_Doc465	1956	1960	NEK2	Gene	4751	Overexpression of NEK2 was associated with clinicopathological characteristics and poor patient outcomes, suggesting that NEK2 serves as a prognostic biomarker for HCC.
BC8_BioRED_Task1_Doc465	2026	2033	patient	OrganismTaxon	9606	Overexpression of NEK2 was associated with clinicopathological characteristics and poor patient outcomes, suggesting that NEK2 serves as a prognostic biomarker for HCC.
BC8_BioRED_Task1_Doc465	2060	2064	NEK2	Gene	4751	Overexpression of NEK2 was associated with clinicopathological characteristics and poor patient outcomes, suggesting that NEK2 serves as a prognostic biomarker for HCC.
BC8_BioRED_Task1_Doc465	2102	2105	HCC	Disease	D006528	Overexpression of NEK2 was associated with clinicopathological characteristics and poor patient outcomes, suggesting that NEK2 serves as a prognostic biomarker for HCC.
BC8_BioRED_Task1_Doc465	2121	2125	NEK2	Gene	4751	Alteration of NEK2 protein levels may contribute to invasion and metastasis of HCC, which may occur through activation of AKT signaling and promotion of MMP-2 expression.
BC8_BioRED_Task1_Doc465	2172	2189	metastasis of HCC	Disease	D006528,D009362	Alteration of NEK2 protein levels may contribute to invasion and metastasis of HCC, which may occur through activation of AKT signaling and promotion of MMP-2 expression.
BC8_BioRED_Task1_Doc465	2229	2232	AKT	Gene	207	Alteration of NEK2 protein levels may contribute to invasion and metastasis of HCC, which may occur through activation of AKT signaling and promotion of MMP-2 expression.
BC8_BioRED_Task1_Doc465	2260	2265	MMP-2	Gene	4130	Alteration of NEK2 protein levels may contribute to invasion and metastasis of HCC, which may occur through activation of AKT signaling and promotion of MMP-2 expression.
BC8_BioRED_Task1_Doc466	0	4	POLG	Gene	5428	POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion.
BC8_BioRED_Task1_Doc466	31	47	Alpers' syndrome	Disease	D002549	POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion.
BC8_BioRED_Task1_Doc466	52	79	mitochondrial DNA depletion	Disease	D028361	POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion.
BC8_BioRED_Task1_Doc466	81	97	Alpers' syndrome	Disease	D002549	Alpers' syndrome is a fatal neurogenetic disorder first described more than 70 years ago.
BC8_BioRED_Task1_Doc466	109	130	neurogenetic disorder	Disease	D009422	Alpers' syndrome is a fatal neurogenetic disorder first described more than 70 years ago.
BC8_BioRED_Task1_Doc466	215	242	mitochondrial DNA depletion	Disease	D028361	It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.
BC8_BioRED_Task1_Doc466	297	317	DNA polymerase gamma	Gene	5428	It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.
BC8_BioRED_Task1_Doc466	319	323	POLG	Gene	5428	It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.
BC8_BioRED_Task1_Doc466	356	364	seizures	Disease	D012640	It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.
BC8_BioRED_Task1_Doc466	366	383	neurodegeneration	Disease	D019636	It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.
BC8_BioRED_Task1_Doc466	389	402	liver disease	Disease	D008107	It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.
BC8_BioRED_Task1_Doc466	434	450	Alpers' syndrome	Disease	D002549	In two unrelated pedigrees of Alpers' syndrome, each affected child was found to carry a homozygous mutation in exon 17 of the POLG locus that led to a Glu873Stop mutation just upstream of the polymerase domain of the protein.
BC8_BioRED_Task1_Doc466	531	535	POLG	Gene	5428	In two unrelated pedigrees of Alpers' syndrome, each affected child was found to carry a homozygous mutation in exon 17 of the POLG locus that led to a Glu873Stop mutation just upstream of the polymerase domain of the protein.
BC8_BioRED_Task1_Doc466	556	566	Glu873Stop	SequenceVariant	rs121918047	In two unrelated pedigrees of Alpers' syndrome, each affected child was found to carry a homozygous mutation in exon 17 of the POLG locus that led to a Glu873Stop mutation just upstream of the polymerase domain of the protein.
BC8_BioRED_Task1_Doc466	689	695	G1681A	SequenceVariant	rs113994095	In addition, each affected child was heterozygous for the G1681A mutation in exon 7 that led to an Ala467Thr substitution in POLG, within the linker region of the protein.
BC8_BioRED_Task1_Doc466	730	739	Ala467Thr	SequenceVariant	rs113994095	In addition, each affected child was heterozygous for the G1681A mutation in exon 7 that led to an Ala467Thr substitution in POLG, within the linker region of the protein.
BC8_BioRED_Task1_Doc466	756	760	POLG	Gene	5428	In addition, each affected child was heterozygous for the G1681A mutation in exon 7 that led to an Ala467Thr substitution in POLG, within the linker region of the protein.
BC8_BioRED_Task1_Doc467	46	63	pancreatic cancer	Disease	D010190	Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
BC8_BioRED_Task1_Doc467	120	124	Kras	Gene	3845	Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
BC8_BioRED_Task1_Doc467	124	128	G12D	SequenceVariant	p|SUB|G|12|D	Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
BC8_BioRED_Task1_Doc467	129	133	Pdx1	Gene	18609	Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
BC8_BioRED_Task1_Doc467	138	143	mouse	OrganismTaxon	10090	Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model.
BC8_BioRED_Task1_Doc467	235	242	cancers	Disease	D009369	Differential expression of microRNAs (miRNAs) has been demonstrated in various cancers, including pancreatic cancer (PC).
BC8_BioRED_Task1_Doc467	254	271	pancreatic cancer	Disease	D010190	Differential expression of microRNAs (miRNAs) has been demonstrated in various cancers, including pancreatic cancer (PC).
BC8_BioRED_Task1_Doc467	273	275	PC	Disease	D010190	Differential expression of microRNAs (miRNAs) has been demonstrated in various cancers, including pancreatic cancer (PC).
BC8_BioRED_Task1_Doc467	333	335	PC	Disease	D010190	Due to the lack of tissue samples from early-stages of PC, the stage-specific alteration of miRNAs during PC initiation and progression is largely unknown.
BC8_BioRED_Task1_Doc467	384	386	PC	Disease	D010190	Due to the lack of tissue samples from early-stages of PC, the stage-specific alteration of miRNAs during PC initiation and progression is largely unknown.
BC8_BioRED_Task1_Doc467	539	541	PC	Disease	D010190	In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model.
BC8_BioRED_Task1_Doc467	564	568	Kras	Gene	3845	In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model.
BC8_BioRED_Task1_Doc467	568	572	G12D	SequenceVariant	p|SUB|G|12|D	In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model.
BC8_BioRED_Task1_Doc467	573	577	Pdx1	Gene	18609	In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model.
BC8_BioRED_Task1_Doc467	587	592	mouse	OrganismTaxon	10090	In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model.
BC8_BioRED_Task1_Doc467	682	689	miR-150	Gene	387168	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	691	698	miR-494	Gene	723878	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	700	707	miR-138	Gene	387156,723956	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	709	717	miR-148a	Gene	387166	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	719	727	miR-216a	Gene	387212	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	733	740	miR-217	Gene	387213	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	761	769	miR-146b	Gene	751550	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	771	778	miR-205	Gene	387201	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	780	786	miR-31	Gene	723895	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	788	795	miR-192	Gene	387187	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	801	807	miR-21	Gene	387140	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	814	818	mice	OrganismTaxon	10090	At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls.
BC8_BioRED_Task1_Doc467	903	908	Dicer	Gene	192119	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	910	920	Exportin-5	Gene	72322	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	922	927	TRKRA	Gene	18211	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	933	939	TARBP2	Gene	21357	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	966	971	DGCR8	Gene	94223	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	976	980	Ago2	Gene	239528	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	1004	1008	mice	OrganismTaxon	10090	Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice.
BC8_BioRED_Task1_Doc467	1102	1106	mice	OrganismTaxon	10090	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1134	1141	miR-216	Gene	387212	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1143	1150	miR-217	Gene	387213	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1152	1159	miR-100	Gene	723892	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1161	1168	miR-345	Gene	723946	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1170	1177	miR-141	Gene	387159	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1179	1189	miR-483-3p	Gene	723874	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1191	1198	miR-26b	Gene	387219	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1200	1207	miR-150	Gene	387168	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1209	1216	miR-195	Gene	387190	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1218	1224	Let-7b	Gene	387245	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1229	1235	Let-96	Gene	-	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1256	1262	miR-21	Gene	387140	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1264	1271	miR-205	Gene	387201	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1273	1281	miR-146b	Gene	751550	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1283	1290	miR-34c	Gene	723932	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1292	1300	miR-1273	Gene	100422821	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1302	1309	miR-223	Gene	723814	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1314	1321	miR-195	Gene	387190	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1342	1346	mice	OrganismTaxon	10090	In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice.
BC8_BioRED_Task1_Doc467	1403	1407	mice	OrganismTaxon	10090	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1455	1460	human	OrganismTaxon	9606	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1461	1463	PC	Disease	D010190	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1517	1523	Let-7b	Gene	406884	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1527	1536	CD18/HPAF	CellLine	CVCL_0313	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1541	1547	Capan1	CellLine	CVCL_0237	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1588	1592	KRAS	Gene	3845	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1597	1602	MSST1	Gene	-	Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression.
BC8_BioRED_Task1_Doc467	1700	1702	PC	Disease	D010190	Overall, the present study aids an understanding of miRNA expression patterns during PC pathogenesis and helps to facilitate the identification of promising and novel early diagnostic/prognostic markers and therapeutic targets.
BC8_BioRED_Task1_Doc468	24	36	atorvastatin	Chemical	C065179	Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
BC8_BioRED_Task1_Doc468	40	53	dexamethasone	Chemical	D003907	Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
BC8_BioRED_Task1_Doc468	62	74	hypertension	Disease	D006973	Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
BC8_BioRED_Task1_Doc468	82	85	rat	OrganismTaxon	10116	Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
BC8_BioRED_Task1_Doc468	90	103	Dexamethasone	Chemical	D003907	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	105	108	Dex	Chemical	D003907	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	118	130	hypertension	Disease	D006973	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	191	203	nitric oxide	Chemical	D009569	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	205	207	NO	Chemical	D009569	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	234	244	superoxide	Chemical	D013481	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	246	249	O2-	Chemical	D013481	Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
BC8_BioRED_Task1_Doc468	263	275	Atorvastatin	Chemical	C065179	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
BC8_BioRED_Task1_Doc468	277	280	Ato	Chemical	C065179	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
BC8_BioRED_Task1_Doc468	405	407	NO	Chemical	D009569	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
BC8_BioRED_Task1_Doc468	420	423	O2-	Chemical	D013481	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
BC8_BioRED_Task1_Doc468	455	467	hypertension	Disease	D006973	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
BC8_BioRED_Task1_Doc468	539	542	Ato	Chemical	C065179	In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.
BC8_BioRED_Task1_Doc468	557	580	endothelial NO synthase	Gene	24598	In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.
BC8_BioRED_Task1_Doc468	582	586	eNOS	Gene	24598	In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.
BC8_BioRED_Task1_Doc468	623	626	O2-	Chemical	D013481	In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.
BC8_BioRED_Task1_Doc468	650	654	rats	OrganismTaxon	10116	In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.
BC8_BioRED_Task1_Doc468	700	704	rats	OrganismTaxon	10116	Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.
BC8_BioRED_Task1_Doc468	732	735	Ato	Chemical	C065179	Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.
BC8_BioRED_Task1_Doc468	799	812	Dexamethasone	Chemical	D003907	Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.
BC8_BioRED_Task1_Doc468	880	883	Ato	Chemical	C065179	Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.
BC8_BioRED_Task1_Doc468	908	912	rats	OrganismTaxon	10116	Dexamethasone (10 microg/kg per day, s.c.) or saline was started after 4 days in Ato-treated and non-treated rats and continued for 11-13 days.
BC8_BioRED_Task1_Doc468	1069	1082	acetylcholine	Chemical	D000109	Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.
BC8_BioRED_Task1_Doc468	1110	1123	phenylephrine	Chemical	D010656	Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.
BC8_BioRED_Task1_Doc468	1178	1182	eNOS	Gene	24598	Vascular eNOS mRNA was assessed by semi-quantitative reverse transcription-polymerase chain reaction.
BC8_BioRED_Task1_Doc468	1277	1281	rats	OrganismTaxon	10116	In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).
BC8_BioRED_Task1_Doc468	1295	1298	Dex	Chemical	D003907	In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).
BC8_BioRED_Task1_Doc468	1412	1415	Ato	Chemical	C065179	In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).
BC8_BioRED_Task1_Doc468	1418	1421	Dex	Chemical	D003907	In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).
BC8_BioRED_Task1_Doc468	1586	1589	Dex	Chemical	D003907	In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).
BC8_BioRED_Task1_Doc468	1645	1649	eNOS	Gene	24598	Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).
BC8_BioRED_Task1_Doc468	1686	1689	Dex	Chemical	D003907	Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).
BC8_BioRED_Task1_Doc468	1692	1695	Ato	Chemical	C065179	Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).
BC8_BioRED_Task1_Doc468	1714	1717	Dex	Chemical	D003907	Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).
BC8_BioRED_Task1_Doc468	1777	1787	superoxide	Chemical	D013481	Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).
BC8_BioRED_Task1_Doc468	1816	1819	Dex	Chemical	D003907	Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).
BC8_BioRED_Task1_Doc468	1822	1825	Ato	Chemical	C065179	Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).
BC8_BioRED_Task1_Doc468	1869	1872	Dex	Chemical	D003907	Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).
BC8_BioRED_Task1_Doc468	1911	1914	Ato	Chemical	C065179	Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.
BC8_BioRED_Task1_Doc468	1954	1964	superoxide	Chemical	D013481	Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.
BC8_BioRED_Task1_Doc468	1995	1998	Dex	Chemical	D003907	Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.
BC8_BioRED_Task1_Doc468	2010	2014	rats	OrganismTaxon	10116	Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.
BC8_BioRED_Task1_Doc469	5	12	glucose	Chemical	D005947	High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	24	29	human	OrganismTaxon	9606	High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	84	104	diabetic nephropathy	Disease	D003928	High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	135	155	diabetic nephropathy	Disease	D003928	Podocytes play a key role in diabetic nephropathy pathogenesis, but alteration of their metabolism remains unknown in human kidney.
BC8_BioRED_Task1_Doc469	224	229	human	OrganismTaxon	9606	Podocytes play a key role in diabetic nephropathy pathogenesis, but alteration of their metabolism remains unknown in human kidney.
BC8_BioRED_Task1_Doc469	279	284	human	OrganismTaxon	9606	By using a conditionally differentiating human podocyte cell line, we addressed the functional and molecular changes in podocyte energetics during in vitro development or under high glucose conditions.
BC8_BioRED_Task1_Doc469	420	427	glucose	Chemical	D005947	By using a conditionally differentiating human podocyte cell line, we addressed the functional and molecular changes in podocyte energetics during in vitro development or under high glucose conditions.
BC8_BioRED_Task1_Doc469	448	455	glucose	Chemical	D005947	In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content.
BC8_BioRED_Task1_Doc469	576	635	peroxisome proliferator-activated receptor-g coactivator 1a	Gene	10891	In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content.
BC8_BioRED_Task1_Doc469	637	643	PGC-1a	Gene	10891	In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content.
BC8_BioRED_Task1_Doc469	819	826	glucose	Chemical	D005947	Conversely, when podocytes were cultured in high glucose (20 mM), stepwise oxidative phosphorylation biogenesis was aborted, and a glycolytic switch occurred, with consecutive lactic acidosis.
BC8_BioRED_Task1_Doc469	946	961	lactic acidosis	Disease	D000140	Conversely, when podocytes were cultured in high glucose (20 mM), stepwise oxidative phosphorylation biogenesis was aborted, and a glycolytic switch occurred, with consecutive lactic acidosis.
BC8_BioRED_Task1_Doc469	981	1059	master regulators of oxidative metabolism transcription factor A mitochondrial	Gene	10891	Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks.
BC8_BioRED_Task1_Doc469	1061	1067	PGC-1a	Gene	10891	Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks.
BC8_BioRED_Task1_Doc469	1069	1073	AMPK	Gene	5562	Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks.
BC8_BioRED_Task1_Doc469	1079	1111	serine-threonine liver kinase B1	Gene	6794	Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks.
BC8_BioRED_Task1_Doc469	1132	1139	glucose	Chemical	D005947	Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks.
BC8_BioRED_Task1_Doc469	1227	1262	myocyte-specific enhancer factor 2C	Gene	4208	Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions.
BC8_BioRED_Task1_Doc469	1264	1269	MEF2C	Gene	4208	Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions.
BC8_BioRED_Task1_Doc469	1275	1292	myogenic factor 5	Gene	4617	Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions.
BC8_BioRED_Task1_Doc469	1294	1298	MYF5	Gene	4617	Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions.
BC8_BioRED_Task1_Doc469	1333	1340	glucose	Chemical	D005947	Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions.
BC8_BioRED_Task1_Doc469	1520	1527	glucose	Chemical	D005947	Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions.
BC8_BioRED_Task1_Doc469	1577	1582	MEF2C	Gene	4208	Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1584	1588	MYF5	Gene	4617	Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1594	1600	PGC-1a	Gene	10891	Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1661	1669	patients	OrganismTaxon	9606	Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1675	1695	diabetic nephropathy	Disease	D003928	Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1724	1729	human	OrganismTaxon	9606	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1755	1760	MEF2C	Gene	4208	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1761	1765	MYF5	Gene	4617	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	1859	1866	glucose	Chemical	D005947	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	2044	2051	glucose	Chemical	D005947	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	2063	2068	human	OrganismTaxon	9606	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc469	2123	2143	diabetic nephropathy	Disease	D003928	These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.
BC8_BioRED_Task1_Doc470	0	12	Matriptase-2	Gene	164656	Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
BC8_BioRED_Task1_Doc470	26	30	iron	Chemical	D007501	Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
BC8_BioRED_Task1_Doc470	42	64	iron deficiency anemia	Disease	D018798	Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
BC8_BioRED_Task1_Doc470	65	73	patients	OrganismTaxon	9606	Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
BC8_BioRED_Task1_Doc470	167	179	matriptase-2	Gene	164656	Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels.
BC8_BioRED_Task1_Doc470	204	210	humans	OrganismTaxon	9606	Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels.
BC8_BioRED_Task1_Doc470	234	272	iron-refractory iron deficiency anemia	Disease	C562385	Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels.
BC8_BioRED_Task1_Doc470	274	279	IRIDA	Disease	C562385	Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels.
BC8_BioRED_Task1_Doc470	297	305	hepcidin	Gene	57817	Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels.
BC8_BioRED_Task1_Doc470	375	387	matriptase-2	Gene	164656	Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype.
BC8_BioRED_Task1_Doc470	389	396	TMPRSS6	Gene	164656	Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype.
BC8_BioRED_Task1_Doc470	443	448	IRIDA	Disease	C562385	Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype.
BC8_BioRED_Task1_Doc470	498	504	P686fs	SequenceVariant	p|FS|P|686||	The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine.
BC8_BioRED_Task1_Doc470	520	558	insertion of the four nucleotides CCCC	SequenceVariant	c|INS||CCCC	The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine.
BC8_BioRED_Task1_Doc470	571	587	2172_2173insCCCC	SequenceVariant	c|INS|2172_2173|CCCC	The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine.
BC8_BioRED_Task1_Doc470	715	723	c.467C>A	SequenceVariant	c|SUB|C|467|A	The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2.
BC8_BioRED_Task1_Doc470	728	736	c.468C>T	SequenceVariant	c|SUB|C|468|T	The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2.
BC8_BioRED_Task1_Doc470	781	786	A118D	SequenceVariant	p|SUB|A|118|D	The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2.
BC8_BioRED_Task1_Doc470	841	853	matriptase-2	Gene	164656	The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2.
BC8_BioRED_Task1_Doc470	891	903	matriptase-2	Gene	164656	Functional analysis of both variant matriptase-2 proteases has revealed that they lead to ineffective suppression of hepcidin transcription.
BC8_BioRED_Task1_Doc470	972	980	hepcidin	Gene	57817	Functional analysis of both variant matriptase-2 proteases has revealed that they lead to ineffective suppression of hepcidin transcription.
BC8_BioRED_Task1_Doc470	1025	1030	A118D	SequenceVariant	p|SUB|A|118|D	We also demonstrate that the A118D SEA domain mutation causes an intra-molecular structural imbalance that impairs matriptase-2 activation.
BC8_BioRED_Task1_Doc470	1111	1123	matriptase-2	Gene	164656	We also demonstrate that the A118D SEA domain mutation causes an intra-molecular structural imbalance that impairs matriptase-2 activation.
BC8_BioRED_Task1_Doc470	1186	1193	TMPRSS6	Gene	164656	Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.
BC8_BioRED_Task1_Doc470	1220	1225	IRIDA	Disease	C562385	Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.
BC8_BioRED_Task1_Doc470	1382	1394	matriptase-2	Gene	164656	Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.
BC8_BioRED_Task1_Doc470	1402	1417	iron deficiency	Disease	D018798	Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.
BC8_BioRED_Task1_Doc471	0	9	Vitamin E	Chemical	D014810	Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
BC8_BioRED_Task1_Doc471	18	40	cardiovascular disease	Disease	D002318	Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
BC8_BioRED_Task1_Doc471	61	78	diabetes mellitus	Disease	D003920	Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
BC8_BioRED_Task1_Doc471	87	98	haptoglobin	Gene	3240	Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
BC8_BioRED_Task1_Doc471	141	158	diabetes mellitus	Disease	D003920	AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease.
BC8_BioRED_Task1_Doc471	160	162	DM	Disease	D003920	AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease.
BC8_BioRED_Task1_Doc471	172	183	Haptoglobin	Gene	3240	AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease.
BC8_BioRED_Task1_Doc471	185	187	Hp	Gene	3240	AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease.
BC8_BioRED_Task1_Doc471	227	249	cardiovascular disease	Disease	D002318	AIMS: Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease.
BC8_BioRED_Task1_Doc471	286	288	Hp	Gene	3240	As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals.
BC8_BioRED_Task1_Doc471	368	379	antioxidant	Chemical	D000975	As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals.
BC8_BioRED_Task1_Doc471	380	389	vitamin E	Chemical	D014810	As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals.
BC8_BioRED_Task1_Doc471	449	451	Hp	Gene	3240	As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals.
BC8_BioRED_Task1_Doc471	456	458	DM	Disease	D003920	As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular protection to Hp 2-2 DM individuals.
BC8_BioRED_Task1_Doc471	511	513	Hp	Gene	3240	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	526	528	DM	Disease	D003920	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	602	611	vitamin E	Chemical	D014810	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	615	617	Hp	Gene	3240	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	682	688	stroke	Disease	D020521	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	690	711	myocardial infarction	Disease	D009203	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	716	736	cardiovascular death	Disease	D002318	MATERIALS & METHODS: We determined the Hp genotype on DM participants from two trials (HOPE and ICARE) and assessed the effect of vitamin E by Hp genotype on their common prespecified outcome, the composite of stroke, myocardial infarction and cardiovascular death.
BC8_BioRED_Task1_Doc471	1100	1102	Hp	Gene	3240	RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 DM individuals with vitamin E (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006).
BC8_BioRED_Task1_Doc471	1107	1109	DM	Disease	D003920	RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 DM individuals with vitamin E (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006).
BC8_BioRED_Task1_Doc471	1127	1136	vitamin E	Chemical	D014810	RESULTS: Meta-analysis of the two trials demonstrated a significant overall reduction in the composite end point in Hp 2-2 DM individuals with vitamin E (odds ratio: 0.58; 95% CI: 0.40-0.86; p = 0.006).
BC8_BioRED_Task1_Doc471	1249	1251	Hp	Gene	3240	There was a statistically significant interaction between the Hp genotype and vitamin E on the composite end point.
BC8_BioRED_Task1_Doc471	1265	1274	vitamin E	Chemical	D014810	There was a statistically significant interaction between the Hp genotype and vitamin E on the composite end point.
BC8_BioRED_Task1_Doc471	1320	1322	Hp	Gene	3240	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1336	1338	DM	Disease	D003920	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1379	1381	Hp	Gene	3240	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1391	1400	vitamin E	Chemical	D014810	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1415	1433	myocardial infarct	Disease	D009203	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1435	1441	stroke	Disease	D020521	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1445	1465	cardiovascular death	Disease	D002318	In these trials, Hp typing of 69 DM individuals and treating those with the Hp 2-2 with vitamin E prevented one myocardial infarct, stroke or cardiovascular death.
BC8_BioRED_Task1_Doc471	1494	1503	vitamin E	Chemical	D014810	Lifelong administration of vitamin E to Hp 2-2 DM individuals in the Kaiser population would increase their life expectancy by 3 years.
BC8_BioRED_Task1_Doc471	1507	1509	Hp	Gene	3240	Lifelong administration of vitamin E to Hp 2-2 DM individuals in the Kaiser population would increase their life expectancy by 3 years.
BC8_BioRED_Task1_Doc471	1514	1516	DM	Disease	D003920	Lifelong administration of vitamin E to Hp 2-2 DM individuals in the Kaiser population would increase their life expectancy by 3 years.
BC8_BioRED_Task1_Doc471	1655	1657	DM	Disease	D003920	CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
BC8_BioRED_Task1_Doc471	1678	1680	Hp	Gene	3240	CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
BC8_BioRED_Task1_Doc471	1714	1716	Hp	Gene	3240	CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
BC8_BioRED_Task1_Doc471	1726	1735	vitamin E	Chemical	D014810	CONCLUSION: A pharmacogenomic strategy of screening DM individuals for the Hp genotype and treating those with Hp 2-2 with vitamin E appears to be highly clinically effective.
BC8_BioRED_Task1_Doc472	0	7	Syncope	Disease	D013575	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
BC8_BioRED_Task1_Doc472	18	30	hyperkalemia	Disease	D006947	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
BC8_BioRED_Task1_Doc472	73	112	angiotensin-converting enzyme inhibitor	Chemical	D000806	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
BC8_BioRED_Task1_Doc472	117	131	spironolactone	Chemical	D013148	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
BC8_BioRED_Task1_Doc472	147	152	woman	OrganismTaxon	9606	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia.
BC8_BioRED_Task1_Doc472	213	234	myocardial infarction	Disease	D009203	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia.
BC8_BioRED_Task1_Doc472	278	299	loss of consciousness	Disease	D014474	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia.
BC8_BioRED_Task1_Doc472	314	325	bradycardia	Disease	D001919	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia.
BC8_BioRED_Task1_Doc472	336	348	hyperkalemia	Disease	D006947	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia.
BC8_BioRED_Task1_Doc472	377	386	potassium	Chemical	D011188	The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level.
BC8_BioRED_Task1_Doc472	464	473	potassium	Chemical	D011188	The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level.
BC8_BioRED_Task1_Doc472	494	506	hyperkalemia	Disease	D006947	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
BC8_BioRED_Task1_Doc472	545	559	spiranolactone	Chemical	D013148	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
BC8_BioRED_Task1_Doc472	564	575	aldosterone	Chemical	D000450	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
BC8_BioRED_Task1_Doc472	627	635	ramipril	Chemical	D017257	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
BC8_BioRED_Task1_Doc472	640	643	ACE	Gene	1636	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
BC8_BioRED_Task1_Doc472	804	816	hyperkalemia	Disease	D006947	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
BC8_BioRED_Task1_Doc472	840	848	patients	OrganismTaxon	9606	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
BC8_BioRED_Task1_Doc472	855	858	ACE	Gene	1636	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
BC8_BioRED_Task1_Doc472	859	862	ARB	Chemical	D057911	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
BC8_BioRED_Task1_Doc472	883	892	potassium	Chemical	D011188	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
BC8_BioRED_Task1_Doc472	926	943	renal disturbance	Disease	D007674	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.
BC8_BioRED_Task1_Doc473	46	67	surfactant protein-A2	Gene	729238	Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease.
BC8_BioRED_Task1_Doc473	96	117	meningococcal disease	Disease	D008589	Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease.
BC8_BioRED_Task1_Doc473	131	152	Meningococcal disease	Disease	D008589	BACKGROUND: Meningococcal disease occurs after colonization of the nasopharynx with Neisseria meningitidis.
BC8_BioRED_Task1_Doc473	203	225	Neisseria meningitidis	Disease	D006069	BACKGROUND: Meningococcal disease occurs after colonization of the nasopharynx with Neisseria meningitidis.
BC8_BioRED_Task1_Doc473	227	252	Surfactant protein (SP)-A	Gene	653509,729238	Surfactant protein (SP)-A and SP-D are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial sugars.
BC8_BioRED_Task1_Doc473	257	261	SP-D	Gene	6441	Surfactant protein (SP)-A and SP-D are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial sugars.
BC8_BioRED_Task1_Doc473	335	347	inflammatory	Disease	D007249	Surfactant protein (SP)-A and SP-D are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial sugars.
BC8_BioRED_Task1_Doc473	399	405	sugars	Chemical	D000073893	Surfactant protein (SP)-A and SP-D are pattern-recognition molecules of the respiratory tract that activate inflammatory and phagocytic defences after binding to microbial sugars.
BC8_BioRED_Task1_Doc473	544	549	SP-A1	Gene	653509	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	551	556	SP-A2	Gene	729238	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	562	566	SP-D	Gene	6441	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	619	627	patients	OrganismTaxon	9606	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	658	679	meningococcal disease	Disease	D008589	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	694	702	patients	OrganismTaxon	9606	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	707	711	died	Disease	D003643	METHODS: Allele frequencies of SP-A1, SP-A2, and SP-D were determined by polymerase chain reaction in 303 patients with microbiologically proven meningococcal disease, including 18 patients who died, and 222 healthy control subjects.
BC8_BioRED_Task1_Doc473	786	791	SP-A2	Gene	729238	RESULTS: Homozygosity of allele 1A1 of SP-A2 increased the risk of meningococcal disease (odds ratio [OR], 7.4; 95% confidence interval [CI], 1.3-42.4); carriage of 1A5 reduced the risk (OR, 0.3; 95% CI, 0.1-0.97).
BC8_BioRED_Task1_Doc473	814	835	meningococcal disease	Disease	D008589	RESULTS: Homozygosity of allele 1A1 of SP-A2 increased the risk of meningococcal disease (odds ratio [OR], 7.4; 95% confidence interval [CI], 1.3-42.4); carriage of 1A5 reduced the risk (OR, 0.3; 95% CI, 0.1-0.97).
BC8_BioRED_Task1_Doc473	1025	1029	SP-A	Gene	653509,729238	An analysis of the multiple single-nucleotide polymorphisms in SP-A demonstrated that homozygosity for alleles encoding lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 in the carbohydrate recognition domain was associated with an increased risk of meningococcal disease (OR, 6.7; 95% CI, 1.4-31.5).
BC8_BioRED_Task1_Doc473	1082	1146	lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223	SequenceVariant	c|SUB|Q|223|K	An analysis of the multiple single-nucleotide polymorphisms in SP-A demonstrated that homozygosity for alleles encoding lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 in the carbohydrate recognition domain was associated with an increased risk of meningococcal disease (OR, 6.7; 95% CI, 1.4-31.5).
BC8_BioRED_Task1_Doc473	1154	1166	carbohydrate	Chemical	D002241	An analysis of the multiple single-nucleotide polymorphisms in SP-A demonstrated that homozygosity for alleles encoding lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 in the carbohydrate recognition domain was associated with an increased risk of meningococcal disease (OR, 6.7; 95% CI, 1.4-31.5).
BC8_BioRED_Task1_Doc473	1227	1248	meningococcal disease	Disease	D008589	An analysis of the multiple single-nucleotide polymorphisms in SP-A demonstrated that homozygosity for alleles encoding lysine (in 1A1) rather than glutamine (in 1A5) at amino acid 223 in the carbohydrate recognition domain was associated with an increased risk of meningococcal disease (OR, 6.7; 95% CI, 1.4-31.5).
BC8_BioRED_Task1_Doc473	1307	1328	lysine at residue 223	SequenceVariant	c|Allele|K|223	Carriage of alleles encoding lysine at residue 223 was found in 61% of patients who died, compared with 35% of those who survived (OR adjusted for age, 2.9; 95% CI, 1.1-7.7).
BC8_BioRED_Task1_Doc473	1349	1357	patients	OrganismTaxon	9606	Carriage of alleles encoding lysine at residue 223 was found in 61% of patients who died, compared with 35% of those who survived (OR adjusted for age, 2.9; 95% CI, 1.1-7.7).
BC8_BioRED_Task1_Doc473	1362	1366	died	Disease	D003643	Carriage of alleles encoding lysine at residue 223 was found in 61% of patients who died, compared with 35% of those who survived (OR adjusted for age, 2.9; 95% CI, 1.1-7.7).
BC8_BioRED_Task1_Doc473	1474	1479	SP-A1	Gene	653509	Genetic variation of SP-A1 and SP-D was not associated with meningococcal disease.
BC8_BioRED_Task1_Doc473	1484	1488	SP-D	Gene	6441	Genetic variation of SP-A1 and SP-D was not associated with meningococcal disease.
BC8_BioRED_Task1_Doc473	1513	1534	meningococcal disease	Disease	D008589	Genetic variation of SP-A1 and SP-D was not associated with meningococcal disease.
BC8_BioRED_Task1_Doc473	1600	1636	glutamine with lysine at residue 223	SequenceVariant	c|SUB|Q|223|K	CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of death.
BC8_BioRED_Task1_Doc473	1644	1656	carbohydrate	Chemical	D002241	CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of death.
BC8_BioRED_Task1_Doc473	1679	1684	SP-A2	Gene	729238	CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of death.
BC8_BioRED_Task1_Doc473	1713	1734	meningococcal disease	Disease	D008589	CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of death.
BC8_BioRED_Task1_Doc473	1759	1764	death	Disease	D003643	CONCLUSIONS: Gene polymorphism resulting in the substitution of glutamine with lysine at residue 223 in the carbohydrate recognition domain of SP-A2 increases susceptibility to meningococcal disease, as well as the risk of death.
BC8_BioRED_Task1_Doc474	0	39	Primary malignant lymphoma of the brain	Disease	D016543	Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.
BC8_BioRED_Task1_Doc474	84	87	p14	Gene	11102	Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.
BC8_BioRED_Task1_Doc474	88	93	tumor	Disease	D009369	Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.
BC8_BioRED_Task1_Doc474	115	155	primary central nervous system lymphomas	Disease	D016543	Ten primary central nervous system lymphomas (PCNSL, brain lymphomas) were examined for p14 gene exon 1beta deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot-based methylation assay.
BC8_BioRED_Task1_Doc474	157	162	PCNSL	Disease	D016543	Ten primary central nervous system lymphomas (PCNSL, brain lymphomas) were examined for p14 gene exon 1beta deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot-based methylation assay.
BC8_BioRED_Task1_Doc474	164	179	brain lymphomas	Disease	D016543	Ten primary central nervous system lymphomas (PCNSL, brain lymphomas) were examined for p14 gene exon 1beta deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot-based methylation assay.
BC8_BioRED_Task1_Doc474	199	202	p14	Gene	11102	Ten primary central nervous system lymphomas (PCNSL, brain lymphomas) were examined for p14 gene exon 1beta deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot-based methylation assay.
BC8_BioRED_Task1_Doc474	723	726	p14	Gene	11102	Thus, the same deletion patterns covered the entire p14 gene for all cases except for one case, which suggested the hemizygous deletion of exons 1beta and 2 and homozygous deletion of exon 3.
BC8_BioRED_Task1_Doc474	924	930	tumors	Disease	D009369	In addition, although exon 1beta mutation is rare in various tumors, we detected a missense mutation (L50R) in one case with a hemizygous deletion.
BC8_BioRED_Task1_Doc474	965	969	L50R	SequenceVariant	p|SUB|L|50|R	In addition, although exon 1beta mutation is rare in various tumors, we detected a missense mutation (L50R) in one case with a hemizygous deletion.
BC8_BioRED_Task1_Doc474	1050	1053	p14	Gene	11102	Methylation of the 5'CpG island of the p14 gene was not suggested for any case without homozygous deletion.
BC8_BioRED_Task1_Doc474	1147	1150	p14	Gene	11102	Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
BC8_BioRED_Task1_Doc474	1263	1280	systemic lymphoma	Disease	D008223	Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
BC8_BioRED_Task1_Doc474	1290	1293	p14	Gene	11102	Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
BC8_BioRED_Task1_Doc474	1374	1388	carcinogenesis	Disease	D063646	Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
BC8_BioRED_Task1_Doc474	1397	1402	PCNSL	Disease	D016543	Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
BC8_BioRED_Task1_Doc474	1407	1424	systemic lymphoma	Disease	D008223	Our observation of frequent p14 gene abnormalities (90%) and inactivation (40-60%) was in striking contrast to the same pathological subtype of systemic lymphoma in which p14 gene abnormalities and inactivation were infrequent, suggesting a difference in carcinogenesis between PCNSL and systemic lymphoma.
BC8_BioRED_Task1_Doc475	16	21	human	OrganismTaxon	9606	Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
BC8_BioRED_Task1_Doc475	111	126	QT prolongation	Disease	D008133	Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
BC8_BioRED_Task1_Doc475	162	167	human	OrganismTaxon	9606	Field potential duration (FPD) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), which can express QT interval in an electrocardiogram, is reported to be a useful tool to predict K(+) channel and Ca(2+) channel blocker effects on QT interval.
BC8_BioRED_Task1_Doc475	331	370	K(+) channel and Ca(2+) channel blocker	Chemical	D002121,D026902	Field potential duration (FPD) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), which can express QT interval in an electrocardiogram, is reported to be a useful tool to predict K(+) channel and Ca(2+) channel blocker effects on QT interval.
BC8_BioRED_Task1_Doc475	509	524	QT prolongation	Disease	D008133	However, there is no report showing that this technique can be used to predict multichannel blocker potential for QT prolongation.
BC8_BioRED_Task1_Doc475	623	638	QT prolongation	Disease	D008133	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect QT prolongation induced by multichannel blockers.
BC8_BioRED_Task1_Doc475	907	930	Ca(2+) channel blockers	Chemical	D002121	IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc.
BC8_BioRED_Task1_Doc475	1005	1015	Amiodarone	Chemical	D000638	Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner.
BC8_BioRED_Task1_Doc475	1017	1027	Paroxetine	Chemical	D017374	Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner.
BC8_BioRED_Task1_Doc475	1029	1040	Terfenadine	Chemical	D016593	Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner.
BC8_BioRED_Task1_Doc475	1045	1055	Citalopram	Chemical	D015283	Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner.
BC8_BioRED_Task1_Doc475	1135	1146	Terfenadine	Chemical	D016593	Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).
BC8_BioRED_Task1_Doc475	1151	1161	Citalopram	Chemical	D015283	Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).
BC8_BioRED_Task1_Doc475	1191	1209	Torsade de Pointes	Disease	D016171	Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).
BC8_BioRED_Task1_Doc475	1211	1214	TdP	Disease	D016171	Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).
BC8_BioRED_Task1_Doc475	1447	1450	TdP	Disease	D016171	This study also shows that this assay can help detect EAD for drugs with TdP potential.
BC8_BioRED_Task1_Doc476	0	4	Ca2+	Chemical	D002118	Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling.
BC8_BioRED_Task1_Doc476	61	73	astrogliosis	Disease	D005911	Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling.
BC8_BioRED_Task1_Doc476	99	105	KCa3.1	Gene	16534,3783	Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling.
BC8_BioRED_Task1_Doc476	124	127	AKT	Gene	11651,207	Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling.
BC8_BioRED_Task1_Doc476	128	132	mTOR	Gene	2475,56717	Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling.
BC8_BioRED_Task1_Doc476	160	210	intermediate-conductance Ca2+-activated K+ channel	Gene	16534,3783	BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc476	211	217	KCa3.1	Gene	16534	BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc476	272	293	reactive astrogliosis	Disease	D005911	BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc476	295	297	RA	Disease	D005911	BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc476	302	321	Alzheimer's disease	Disease	D000544	BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc476	323	325	AD	Disease	D000544	BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD).
BC8_BioRED_Task1_Doc476	337	343	KCa3.1	Gene	16534,3783	METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining.
BC8_BioRED_Task1_Doc476	403	405	AD	Disease	D000544	METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining.
BC8_BioRED_Task1_Doc476	406	414	patients	OrganismTaxon	9606	METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining.
BC8_BioRED_Task1_Doc476	419	422	APP	Gene	11820,351	METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining.
BC8_BioRED_Task1_Doc476	423	426	PS1	Gene	5663	METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining.
BC8_BioRED_Task1_Doc476	427	431	mice	OrganismTaxon	10090	METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining.
BC8_BioRED_Task1_Doc476	490	493	APP	Gene	11820,351	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	494	497	PS1	Gene	5663	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	498	502	mice	OrganismTaxon	10090	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	507	513	KCa3.1	Gene	16534	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	517	520	APP	Gene	11820,351	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	521	524	PS1	Gene	5663	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	525	529	mice	OrganismTaxon	10090	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	595	610	memory deficits	Disease	D008569	APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
BC8_BioRED_Task1_Doc476	632	643	neuron loss	Disease	D009422	Glia activation and neuron loss was measured by immunostaining.
BC8_BioRED_Task1_Doc476	676	684	Fluo-4AM	Chemical	C409648	Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro.
BC8_BioRED_Task1_Doc476	715	719	Ca2+	Chemical	D000069285	Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro.
BC8_BioRED_Task1_Doc476	729	741	beta-amyloid	Gene	351	Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro.
BC8_BioRED_Task1_Doc476	743	748	Abeta	Gene	351	Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro.
BC8_BioRED_Task1_Doc476	797	803	KCa3.1	Gene	16534,3783	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	922	927	Abeta	Gene	11820,351	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	979	981	AD	Disease	D000544	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	982	990	patients	OrganismTaxon	9606	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	995	998	APP	Gene	11820,351	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	999	1002	PS1	Gene	5663	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	1003	1005	AD	Disease	D000544	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	1006	1010	mice	OrganismTaxon	10090	RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice.
BC8_BioRED_Task1_Doc476	1016	1022	KCa3.1	Gene	16534	The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes.
BC8_BioRED_Task1_Doc476	1068	1072	Ca2+	Chemical	D000069285	The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes.
BC8_BioRED_Task1_Doc476	1118	1122	Ca2+	Chemical	D002118	The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes.
BC8_BioRED_Task1_Doc476	1131	1136	Orai1	Gene	109305	The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes.
BC8_BioRED_Task1_Doc476	1205	1211	KCa3.1	Gene	16534	Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes.
BC8_BioRED_Task1_Doc476	1243	1247	Ca2+	Chemical	D000069285	Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes.
BC8_BioRED_Task1_Doc476	1279	1295	protein kinase B	Gene	11651	Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes.
BC8_BioRED_Task1_Doc476	1297	1300	AKT	Gene	11651	Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes.
BC8_BioRED_Task1_Doc476	1377	1383	KCa3.1	Gene	16534	Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro.
BC8_BioRED_Task1_Doc476	1393	1396	AKT	Gene	11651	Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro.
BC8_BioRED_Task1_Doc476	1397	1428	mechanistic target of rapamycin	Gene	56717	Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro.
BC8_BioRED_Task1_Doc476	1546	1578	78-kDa glucose-regulated protein	Gene	14828	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1583	1632	CCAAT/enhancer-binding protein homologous protein	Gene	13198	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1657	1659	RA	Disease	D005911	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1667	1698	glial fibrillary acidic protein	Gene	14580	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1717	1720	APP	Gene	11820,351	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1721	1724	PS1	Gene	5663	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1725	1727	AD	Disease	D000544	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1728	1733	mouse	OrganismTaxon	10090	Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model.
BC8_BioRED_Task1_Doc476	1756	1762	KCa3.1	Gene	16534	Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses.
BC8_BioRED_Task1_Doc476	1766	1772	KCa3.1	Gene	16534	Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses.
BC8_BioRED_Task1_Doc476	1776	1779	APP	Gene	11820,351	Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses.
BC8_BioRED_Task1_Doc476	1780	1783	PS1	Gene	5663	Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses.
BC8_BioRED_Task1_Doc476	1784	1788	mice	OrganismTaxon	10090	Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses.
BC8_BioRED_Task1_Doc476	1856	1873	neuroinflammation	Disease	D007249	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1911	1917	KCa3.1	Gene	16534	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1921	1924	APP	Gene	11820,351	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1925	1928	PS1	Gene	5663	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1929	1933	mice	OrganismTaxon	10090	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1952	1955	APP	Gene	11820,351	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1956	1959	PS1	Gene	5663	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1960	1964	mice	OrganismTaxon	10090	Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1979	1994	memory deficits	Disease	D008569	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	1999	2012	neuronal loss	Disease	D009422	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2016	2019	APP	Gene	11820,351	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2020	2023	PS1	Gene	5663	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2024	2028	mice	OrganismTaxon	10090	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2046	2052	KCa3.1	Gene	16534	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2056	2059	APP	Gene	11820,351	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2060	2063	PS1	Gene	5663	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2064	2068	mice	OrganismTaxon	10090	In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice.
BC8_BioRED_Task1_Doc476	2119	2125	KCa3.1	Gene	16534,3783	CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.
BC8_BioRED_Task1_Doc476	2159	2163	Ca2+	Chemical	D000069285	CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.
BC8_BioRED_Task1_Doc476	2253	2268	memory deficits	Disease	D008569	CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.
BC8_BioRED_Task1_Doc476	2273	2286	neuronal loss	Disease	D009422	CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.
BC8_BioRED_Task1_Doc477	61	65	DRD4	Gene	1815	Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	71	84	schizophrenia	Disease	D012559	Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	86	96	depression	Disease	D003866	Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	102	118	heroin addiction	Disease	D006556	Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	238	258	dopamine D4 receptor	Gene	1815	This study investigated the possible association between three functional polymorphisms in the promoter region of the dopamine D4 receptor (DRD4) gene and schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	260	264	DRD4	Gene	1815	This study investigated the possible association between three functional polymorphisms in the promoter region of the dopamine D4 receptor (DRD4) gene and schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	275	288	schizophrenia	Disease	D012559	This study investigated the possible association between three functional polymorphisms in the promoter region of the dopamine D4 receptor (DRD4) gene and schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	290	300	depression	Disease	D003866	This study investigated the possible association between three functional polymorphisms in the promoter region of the dopamine D4 receptor (DRD4) gene and schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	306	322	heroin addiction	Disease	D006556	This study investigated the possible association between three functional polymorphisms in the promoter region of the dopamine D4 receptor (DRD4) gene and schizophrenia, depression, and heroin addiction.
BC8_BioRED_Task1_Doc477	399	407	patients	OrganismTaxon	9606	Genomic DNA was isolated from the venous blood leukocytes of 322 unrelated patients with schizophrenia, 156 patients with depression, 300 patients with heroin addiction, and 300 healthy unrelated individuals.
BC8_BioRED_Task1_Doc477	413	426	schizophrenia	Disease	D012559	Genomic DNA was isolated from the venous blood leukocytes of 322 unrelated patients with schizophrenia, 156 patients with depression, 300 patients with heroin addiction, and 300 healthy unrelated individuals.
BC8_BioRED_Task1_Doc477	432	440	patients	OrganismTaxon	9606	Genomic DNA was isolated from the venous blood leukocytes of 322 unrelated patients with schizophrenia, 156 patients with depression, 300 patients with heroin addiction, and 300 healthy unrelated individuals.
BC8_BioRED_Task1_Doc477	446	456	depression	Disease	D003866	Genomic DNA was isolated from the venous blood leukocytes of 322 unrelated patients with schizophrenia, 156 patients with depression, 300 patients with heroin addiction, and 300 healthy unrelated individuals.
BC8_BioRED_Task1_Doc477	462	470	patients	OrganismTaxon	9606	Genomic DNA was isolated from the venous blood leukocytes of 322 unrelated patients with schizophrenia, 156 patients with depression, 300 patients with heroin addiction, and 300 healthy unrelated individuals.
BC8_BioRED_Task1_Doc477	476	492	heroin addiction	Disease	D006556	Genomic DNA was isolated from the venous blood leukocytes of 322 unrelated patients with schizophrenia, 156 patients with depression, 300 patients with heroin addiction, and 300 healthy unrelated individuals.
BC8_BioRED_Task1_Doc477	573	577	DRD4	Gene	1815	Polymorphisms in the promoter region of DRD4 (-120 bp duplication, -616C/G, and -521C/T) were genotyped using allele-specific polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc477	579	598	-120 bp duplication	SequenceVariant	c|DUP|-120||	Polymorphisms in the promoter region of DRD4 (-120 bp duplication, -616C/G, and -521C/T) were genotyped using allele-specific polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc477	600	607	-616C/G	SequenceVariant	rs747302	Polymorphisms in the promoter region of DRD4 (-120 bp duplication, -616C/G, and -521C/T) were genotyped using allele-specific polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc477	613	620	-521C/T	SequenceVariant	rs1800955	Polymorphisms in the promoter region of DRD4 (-120 bp duplication, -616C/G, and -521C/T) were genotyped using allele-specific polymerase chain reaction analysis.
BC8_BioRED_Task1_Doc477	824	843	-120 bp duplication	SequenceVariant	c|DUP|-120||	Results of this analysis indicated that there is a strong finding of -120 bp duplication allele frequencies with schizophrenia (p=0.008) and weak finding with -1240 L/S and for paranoid schizophrenia (p=0.022).
BC8_BioRED_Task1_Doc477	868	881	schizophrenia	Disease	D012559	Results of this analysis indicated that there is a strong finding of -120 bp duplication allele frequencies with schizophrenia (p=0.008) and weak finding with -1240 L/S and for paranoid schizophrenia (p=0.022).
BC8_BioRED_Task1_Doc477	914	923	-1240 L/S	SequenceVariant	p|SUB|L|-1240|S	Results of this analysis indicated that there is a strong finding of -120 bp duplication allele frequencies with schizophrenia (p=0.008) and weak finding with -1240 L/S and for paranoid schizophrenia (p=0.022).
BC8_BioRED_Task1_Doc477	932	954	paranoid schizophrenia	Disease	D012563	Results of this analysis indicated that there is a strong finding of -120 bp duplication allele frequencies with schizophrenia (p=0.008) and weak finding with -1240 L/S and for paranoid schizophrenia (p=0.022).
BC8_BioRED_Task1_Doc477	1014	1022	-521 C/T	SequenceVariant	rs1800955	Interestingly, there is a stronger finding with -521 C/T allele frequencies with heroin dependence (p=0.0002).
BC8_BioRED_Task1_Doc477	1047	1064	heroin dependence	Disease	D006556	Interestingly, there is a stronger finding with -521 C/T allele frequencies with heroin dependence (p=0.0002).
BC8_BioRED_Task1_Doc477	1122	1141	-120-bp duplication	SequenceVariant	c|DUP|-120||	These observations strongly suggest that the -120-bp duplication polymorphism of DRD4 is associated with schizophrenia and that the -521 C/T polymorphism is associated with heroin addiction.
BC8_BioRED_Task1_Doc477	1158	1162	DRD4	Gene	1815	These observations strongly suggest that the -120-bp duplication polymorphism of DRD4 is associated with schizophrenia and that the -521 C/T polymorphism is associated with heroin addiction.
BC8_BioRED_Task1_Doc477	1182	1195	schizophrenia	Disease	D012559	These observations strongly suggest that the -120-bp duplication polymorphism of DRD4 is associated with schizophrenia and that the -521 C/T polymorphism is associated with heroin addiction.
BC8_BioRED_Task1_Doc477	1209	1217	-521 C/T	SequenceVariant	rs1800955	These observations strongly suggest that the -120-bp duplication polymorphism of DRD4 is associated with schizophrenia and that the -521 C/T polymorphism is associated with heroin addiction.
BC8_BioRED_Task1_Doc477	1250	1266	heroin addiction	Disease	D006556	These observations strongly suggest that the -120-bp duplication polymorphism of DRD4 is associated with schizophrenia and that the -521 C/T polymorphism is associated with heroin addiction.
BC8_BioRED_Task1_Doc478	25	30	COX-2	Gene	4513	Genetic variation in the COX-2 gene and the association with prostate cancer risk.
BC8_BioRED_Task1_Doc478	61	76	prostate cancer	Disease	D011471	Genetic variation in the COX-2 gene and the association with prostate cancer risk.
BC8_BioRED_Task1_Doc478	83	88	COX-2	Gene	4513	COX-2 is a key enzyme in the conversion of arachidonic acid to prostaglandins.
BC8_BioRED_Task1_Doc478	126	142	arachidonic acid	Chemical	D016718	COX-2 is a key enzyme in the conversion of arachidonic acid to prostaglandins.
BC8_BioRED_Task1_Doc478	146	160	prostaglandins	Chemical	D011453	COX-2 is a key enzyme in the conversion of arachidonic acid to prostaglandins.
BC8_BioRED_Task1_Doc478	166	180	prostaglandins	Chemical	D011453	The prostaglandins produced by COX-2 are involved in inflammation and pain response in different tissues in the body.
BC8_BioRED_Task1_Doc478	193	198	COX-2	Gene	4513	The prostaglandins produced by COX-2 are involved in inflammation and pain response in different tissues in the body.
BC8_BioRED_Task1_Doc478	215	227	inflammation	Disease	D007249	The prostaglandins produced by COX-2 are involved in inflammation and pain response in different tissues in the body.
BC8_BioRED_Task1_Doc478	232	236	pain	Disease	D010146	The prostaglandins produced by COX-2 are involved in inflammation and pain response in different tissues in the body.
BC8_BioRED_Task1_Doc478	406	411	COX-2	Gene	4513	Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that COX-2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue.
BC8_BioRED_Task1_Doc478	428	433	human	OrganismTaxon	9606	Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that COX-2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue.
BC8_BioRED_Task1_Doc478	434	448	carcinogenesis	Disease	D009369	Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that COX-2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue.
BC8_BioRED_Task1_Doc478	473	488	prostate cancer	Disease	D011471	Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that COX-2 plays a role in human carcinogenesis and is overexpressed in prostate cancer tissue.
BC8_BioRED_Task1_Doc478	542	547	COX-2	Gene	4513	We examined whether sequence variants in the COX-2 gene are associated with prostate cancer risk.
BC8_BioRED_Task1_Doc478	573	588	prostate cancer	Disease	D011471	We examined whether sequence variants in the COX-2 gene are associated with prostate cancer risk.
BC8_BioRED_Task1_Doc478	652	667	cancer prostate	Disease	D011471	We analyzed a large population-based case-control study, cancer prostate in Sweden (CAPS) consisting of 1,378 cases and 782 controls.
BC8_BioRED_Task1_Doc478	804	809	COX-2	Gene	4513	We evaluated 16 single nucleotide polymorphisms (SNPs) spanning the entire COX-2 gene in 94 subjects of the control group.
BC8_BioRED_Task1_Doc478	968	976	patients	OrganismTaxon	9606	Five SNPs had a minor allele frequency of more than 5% in our study population and these were genotyped in all case patients and control subjects and gene-specific haplotypes were constructed.
BC8_BioRED_Task1_Doc478	1163	1172	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G	A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (+3100 T/G and +8365 C/T), with an odds ratio of 0.78 (95% CI=0.64-0.96) and 0.65 (95% CI=0.45-0.94) respectively.
BC8_BioRED_Task1_Doc478	1177	1186	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T	A statistically significant difference in allele frequency between cases and controls was observed for 2 of the SNPs (+3100 T/G and +8365 C/T), with an odds ratio of 0.78 (95% CI=0.64-0.96) and 0.65 (95% CI=0.45-0.94) respectively.
BC8_BioRED_Task1_Doc478	1354	1363	+3100 T/G	SequenceVariant	c|SUB|T|+3100|G	In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (p=0.036, global simulated p-value=0.046).
BC8_BioRED_Task1_Doc478	1368	1377	+8365 C/T	SequenceVariant	c|SUB|C|+8365|T	In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (p=0.036, global simulated p-value=0.046).
BC8_BioRED_Task1_Doc478	1471	1486	prostate cancer	Disease	D011471	In the haplotype analysis, 1 haplotype carrying the variant allele from both +3100 T/G and +8365 C/T, with a population frequency of 3%, was also significantly associated with decreased risk of prostate cancer (p=0.036, global simulated p-value=0.046).
BC8_BioRED_Task1_Doc478	1570	1582	inflammation	Disease	D007249	This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX-2 gene influence the risk of prostate cancer.
BC8_BioRED_Task1_Doc478	1598	1621	prostate carcinogenesis	Disease	D011471	This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX-2 gene influence the risk of prostate cancer.
BC8_BioRED_Task1_Doc478	1661	1666	COX-2	Gene	4513	This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX-2 gene influence the risk of prostate cancer.
BC8_BioRED_Task1_Doc478	1694	1709	prostate cancer	Disease	D011471	This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the COX-2 gene influence the risk of prostate cancer.
BC8_BioRED_Task1_Doc479	11	35	scleroderma renal crisis	Disease	D007674	Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
BC8_BioRED_Task1_Doc479	47	57	tacrolimus	Chemical	D016559	Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
BC8_BioRED_Task1_Doc479	62	74	prednisolone	Chemical	D011239	Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
BC8_BioRED_Task1_Doc479	91	115	Scleroderma renal crisis	Disease	D007674	Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy.
BC8_BioRED_Task1_Doc479	117	120	SRC	Disease	D007674	Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy.
BC8_BioRED_Task1_Doc479	148	166	systemic sclerosis	Disease	D012595	Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy.
BC8_BioRED_Task1_Doc479	168	171	SSc	Disease	D012595	Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy.
BC8_BioRED_Task1_Doc479	281	295	corticosteroid	Chemical	D000305	Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC.
BC8_BioRED_Task1_Doc479	341	344	SRC	Disease	D007674	Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC.
BC8_BioRED_Task1_Doc479	386	412	thrombotic microangiopathy	Disease	D057049	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
BC8_BioRED_Task1_Doc479	429	441	cyclosporine	Chemical	D016572	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
BC8_BioRED_Task1_Doc479	445	453	patients	OrganismTaxon	9606	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
BC8_BioRED_Task1_Doc479	459	462	SSc	Disease	D012595	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
BC8_BioRED_Task1_Doc479	493	500	patient	OrganismTaxon	9606	In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
BC8_BioRED_Task1_Doc479	506	509	SRC	Disease	D007674	In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
BC8_BioRED_Task1_Doc479	521	531	tacrolimus	Chemical	D016559	In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
BC8_BioRED_Task1_Doc479	536	551	corticosteroids	Chemical	D000305	In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
BC8_BioRED_Task1_Doc479	610	620	tacrolimus	Chemical	D016559	The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.
BC8_BioRED_Task1_Doc479	628	636	patients	OrganismTaxon	9606	The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.
BC8_BioRED_Task1_Doc479	642	645	SSc	Disease	D012595	The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.
BC8_BioRED_Task1_Doc480	39	44	BRCA1	Gene	672	Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis.
BC8_BioRED_Task1_Doc480	241	248	patient	OrganismTaxon	9606	The ability to scan a large gene rapidly and accurately for all possible heterozygous mutations in large numbers of patient samples will be critical for the future of medicine.
BC8_BioRED_Task1_Doc480	520	550	breast and ovarian cancer gene	Gene	672	45-kilobases (kb) exon 11 of the hereditary breast and ovarian cancer gene BRCA1.
BC8_BioRED_Task1_Doc480	551	556	BRCA1	Gene	672	45-kilobases (kb) exon 11 of the hereditary breast and ovarian cancer gene BRCA1.
BC8_BioRED_Task1_Doc480	718	725	patient	OrganismTaxon	9606	Fourteen of fifteen patient samples with known mutations were accurately diagnosed, and no false positive mutations were identified in 20 control samples.
BC8_BioRED_Task1_Doc481	0	6	NOTCH1	Gene	4851	NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
BC8_BioRED_Task1_Doc481	11	16	SOX10	Gene	6663	NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
BC8_BioRED_Task1_Doc481	77	83	Cancer	Disease	D009369	NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
BC8_BioRED_Task1_Doc481	103	127	Adenoid Cystic Carcinoma	Disease	D003528	NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.
BC8_BioRED_Task1_Doc481	164	170	cancer	Disease	D009369	PURPOSE: Although the existence of cancer stem cells (CSC) in adenoid cystic carcinoma (ACC) has been proposed, lack of assays for their propagation and uncertainty about molecular markers prevented their characterization.
BC8_BioRED_Task1_Doc481	191	215	adenoid cystic carcinoma	Disease	D003528	PURPOSE: Although the existence of cancer stem cells (CSC) in adenoid cystic carcinoma (ACC) has been proposed, lack of assays for their propagation and uncertainty about molecular markers prevented their characterization.
BC8_BioRED_Task1_Doc481	217	220	ACC	Disease	D003528	PURPOSE: Although the existence of cancer stem cells (CSC) in adenoid cystic carcinoma (ACC) has been proposed, lack of assays for their propagation and uncertainty about molecular markers prevented their characterization.
BC8_BioRED_Task1_Doc481	390	393	ACC	Disease	D003528	Our objective was to isolate CSC from ACC and provide insight into signaling pathways that support their propagation.
BC8_BioRED_Task1_Doc481	511	514	ACC	Disease	D003528	EXPERIMENTAL DESIGN: To isolate CSC from ACC and characterize them, we used ROCK inhibitor-supplemented cell culture, immunomagnetic cell sorting, andin vitro/in vivoassays for CSC viability and tumorigenicity.
BC8_BioRED_Task1_Doc481	546	550	ROCK	Gene	6093	EXPERIMENTAL DESIGN: To isolate CSC from ACC and characterize them, we used ROCK inhibitor-supplemented cell culture, immunomagnetic cell sorting, andin vitro/in vivoassays for CSC viability and tumorigenicity.
BC8_BioRED_Task1_Doc481	707	710	ACC	Disease	D003528	RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.
BC8_BioRED_Task1_Doc481	711	716	CD133	Gene	8842	RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.
BC8_BioRED_Task1_Doc481	745	751	NOTCH1	Gene	4851	RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.
BC8_BioRED_Task1_Doc481	756	761	SOX10	Gene	6663	RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.
BC8_BioRED_Task1_Doc481	795	801	tumors	Disease	D009369	RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.
BC8_BioRED_Task1_Doc481	810	814	mice	OrganismTaxon	10090	RESULTS: We identified in ACC CD133-positive CSC that expressed NOTCH1 and SOX10, formed spheroids, and initiated tumors in nude mice.
BC8_BioRED_Task1_Doc481	816	821	CD133	Gene	8842	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	824	827	ACC	Disease	D003528	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	853	859	NOTCH1	Gene	4851	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	861	866	N1ICD	Gene	4851	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	882	887	CD133	Gene	8842	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	911	915	JAG1	Gene	182	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	958	963	NR2F1	Gene	7025	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	965	970	NR2F2	Gene	7026	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	976	983	p27Kip1	Gene	1027	CD133(+)ACC cells produced activated NOTCH1 (N1ICD) and generated CD133(-)cells that expressed JAG1 as well as neural differentiation factors NR2F1, NR2F2, and p27Kip1.
BC8_BioRED_Task1_Doc481	999	1005	NOTCH1	Gene	4851	Knockdowns of NOTCH1, SOX10, and their common effector FABP7 had negative effects on each other, inhibited spheroidogenesis, and induced cell death pointing at their essential roles in CSC maintenance.
BC8_BioRED_Task1_Doc481	1007	1012	SOX10	Gene	6663	Knockdowns of NOTCH1, SOX10, and their common effector FABP7 had negative effects on each other, inhibited spheroidogenesis, and induced cell death pointing at their essential roles in CSC maintenance.
BC8_BioRED_Task1_Doc481	1040	1045	FABP7	Gene	2173	Knockdowns of NOTCH1, SOX10, and their common effector FABP7 had negative effects on each other, inhibited spheroidogenesis, and induced cell death pointing at their essential roles in CSC maintenance.
BC8_BioRED_Task1_Doc481	1209	1214	FABP7	Gene	2173	Downstream effects of FABP7 knockdown included suppression of a broad spectrum of genes involved in proliferation, ribosome biogenesis, and metabolism.
BC8_BioRED_Task1_Doc481	1366	1372	NOTCH1	Gene	4851	Among proliferation-linked NOTCH1/FABP7 targets, we identified SKP2 and its substrate p27Kip1.
BC8_BioRED_Task1_Doc481	1373	1378	FABP7	Gene	2173	Among proliferation-linked NOTCH1/FABP7 targets, we identified SKP2 and its substrate p27Kip1.
BC8_BioRED_Task1_Doc481	1402	1406	SKP2	Gene	6502	Among proliferation-linked NOTCH1/FABP7 targets, we identified SKP2 and its substrate p27Kip1.
BC8_BioRED_Task1_Doc481	1425	1432	p27Kip1	Gene	1027	Among proliferation-linked NOTCH1/FABP7 targets, we identified SKP2 and its substrate p27Kip1.
BC8_BioRED_Task1_Doc481	1436	1447	g-secretase	Gene	55851	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1459	1463	DAPT	Chemical	C419410	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1486	1491	CD133	Gene	8842	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1512	1517	N1ICD	Gene	4851	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1522	1526	SKP2	Gene	6502	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1536	1543	p27Kip1	Gene	1027	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1555	1558	ACC	Disease	D003528	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1589	1594	CD133	Gene	8842	A g-secretase inhibitor, DAPT, selectively depleted CD133(+)cells, suppressed N1ICD and SKP2, induced p27Kip1, inhibited ACC growthin vivo, and sensitized CD133(+)cells to radiation.
BC8_BioRED_Task1_Doc481	1673	1676	ACC	Disease	D003528	CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and FABP7.
BC8_BioRED_Task1_Doc481	1736	1741	CD133	Gene	8842	CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and FABP7.
BC8_BioRED_Task1_Doc481	1799	1804	SOX10	Gene	6663	CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and FABP7.
BC8_BioRED_Task1_Doc481	1806	1812	NOTCH1	Gene	4851	CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and FABP7.
BC8_BioRED_Task1_Doc481	1818	1823	FABP7	Gene	2173	CONCLUSIONS: These results establish in the majority of ACC the presence of a previously uncharacterized population of CD133(+)cells with neural stem properties, which are driven by SOX10, NOTCH1, and FABP7.
BC8_BioRED_Task1_Doc481	1855	1860	Notch	Gene	4851	Sensitivity of these cells to Notch inhibition and their dependence on SKP2 offer new opportunities for targeted ACC therapies.
BC8_BioRED_Task1_Doc481	1896	1900	SKP2	Gene	6502	Sensitivity of these cells to Notch inhibition and their dependence on SKP2 offer new opportunities for targeted ACC therapies.
BC8_BioRED_Task1_Doc481	1938	1941	ACC	Disease	D003528	Sensitivity of these cells to Notch inhibition and their dependence on SKP2 offer new opportunities for targeted ACC therapies.
BC8_BioRED_Task1_Doc482	12	24	nitric oxide	Chemical	D009569	The role of nitric oxide in convulsions induced by lindane in rats.
BC8_BioRED_Task1_Doc482	28	39	convulsions	Disease	D012640	The role of nitric oxide in convulsions induced by lindane in rats.
BC8_BioRED_Task1_Doc482	51	58	lindane	Chemical	D001556	The role of nitric oxide in convulsions induced by lindane in rats.
BC8_BioRED_Task1_Doc482	62	66	rats	OrganismTaxon	10116	The role of nitric oxide in convulsions induced by lindane in rats.
BC8_BioRED_Task1_Doc482	68	75	Lindane	Chemical	D001556	Lindane is an organochloride pesticide and scabicide.
BC8_BioRED_Task1_Doc482	82	96	organochloride	Chemical	D006843	Lindane is an organochloride pesticide and scabicide.
BC8_BioRED_Task1_Doc482	97	106	pesticide	Chemical	D010575	Lindane is an organochloride pesticide and scabicide.
BC8_BioRED_Task1_Doc482	111	120	scabicide	Chemical	D056810	Lindane is an organochloride pesticide and scabicide.
BC8_BioRED_Task1_Doc482	132	143	convulsions	Disease	D012640	It evokes convulsions mainly trough the blockage of GABA(A) receptors.
BC8_BioRED_Task1_Doc482	174	191	GABA(A) receptors	Gene	29705	It evokes convulsions mainly trough the blockage of GABA(A) receptors.
BC8_BioRED_Task1_Doc482	193	205	Nitric oxide	Chemical	D009569	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	207	209	NO	Chemical	D009569	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	306	316	L-arginine	Chemical	D001120	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	331	343	NO syntheses	Gene	24598	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	345	348	NOS	Gene	24598	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	355	361	L-NAME	Chemical	D019331	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	363	366	NOS	Gene	24598	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	400	408	epilepsy	Disease	D004827	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
BC8_BioRED_Task1_Doc482	478	480	NO	Chemical	D009569	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
BC8_BioRED_Task1_Doc482	526	533	lindane	Chemical	D001556	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
BC8_BioRED_Task1_Doc482	542	550	epilepsy	Disease	D004827	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
BC8_BioRED_Task1_Doc482	573	577	rats	OrganismTaxon	10116	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.
BC8_BioRED_Task1_Doc482	601	611	L-arginine	Chemical	D001120	The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.)
BC8_BioRED_Task1_Doc482	693	703	convulsion	Disease	D012640	in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	763	773	convulsion	Disease	D012640	in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	792	799	lindane	Chemical	D001556	in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	857	863	L-NAME	Chemical	D019331	On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.)
BC8_BioRED_Task1_Doc482	905	915	convulsion	Disease	D012640	decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	969	979	convulsion	Disease	D012640	decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	1007	1017	convulsive	Disease	D012640	decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	1026	1033	lindane	Chemical	D001556	decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
BC8_BioRED_Task1_Doc482	1130	1134	rats	OrganismTaxon	10116	EEG analyses showed increase of number and duration of ictal periods in EEG of rats receiving l-arginine prior to lindane and decrease of this number in rats pretreated with L-NAME.
BC8_BioRED_Task1_Doc482	1145	1155	l-arginine	Chemical	D001120	EEG analyses showed increase of number and duration of ictal periods in EEG of rats receiving l-arginine prior to lindane and decrease of this number in rats pretreated with L-NAME.
BC8_BioRED_Task1_Doc482	1165	1172	lindane	Chemical	D001556	EEG analyses showed increase of number and duration of ictal periods in EEG of rats receiving l-arginine prior to lindane and decrease of this number in rats pretreated with L-NAME.
BC8_BioRED_Task1_Doc482	1204	1208	rats	OrganismTaxon	10116	EEG analyses showed increase of number and duration of ictal periods in EEG of rats receiving l-arginine prior to lindane and decrease of this number in rats pretreated with L-NAME.
BC8_BioRED_Task1_Doc482	1225	1231	L-NAME	Chemical	D019331	EEG analyses showed increase of number and duration of ictal periods in EEG of rats receiving l-arginine prior to lindane and decrease of this number in rats pretreated with L-NAME.
BC8_BioRED_Task1_Doc482	1275	1277	NO	Chemical	D009569	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
BC8_BioRED_Task1_Doc482	1305	1315	convulsant	Disease	D012640	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
BC8_BioRED_Task1_Doc482	1319	1322	rat	OrganismTaxon	10116	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
BC8_BioRED_Task1_Doc482	1332	1339	lindane	Chemical	D001556	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
BC8_BioRED_Task1_Doc482	1340	1348	seizures	Disease	D012640	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.
BC8_BioRED_Task1_Doc483	25	35	olanzapine	Chemical	C076029	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
BC8_BioRED_Task1_Doc483	43	54	risperidone	Chemical	D018967	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
BC8_BioRED_Task1_Doc483	90	103	schizophrenia	Disease	D012559	Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
BC8_BioRED_Task1_Doc483	186	196	olanzapine	Chemical	C076029	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
BC8_BioRED_Task1_Doc483	204	215	risperidone	Chemical	D018967	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
BC8_BioRED_Task1_Doc483	219	227	patients	OrganismTaxon	9606	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
BC8_BioRED_Task1_Doc483	247	260	schizophrenia	Disease	D012559	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
BC8_BioRED_Task1_Doc483	379	392	schizophrenia	Disease	D012559	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
BC8_BioRED_Task1_Doc483	400	425	schizophreniform disorder	Disease	D011618	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
BC8_BioRED_Task1_Doc483	436	460	schizoaffective disorder	Disease	D011618	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
BC8_BioRED_Task1_Doc483	507	517	olanzapine	Chemical	C076029	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
BC8_BioRED_Task1_Doc483	537	548	risperidone	Chemical	D018967	METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
BC8_BioRED_Task1_Doc483	624	634	olanzapine	Chemical	C076029	RESULTS: Response rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%).
BC8_BioRED_Task1_Doc483	667	678	risperidone	Chemical	D018967	RESULTS: Response rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (54.3%, 95% CI=39.9%-68.7%).
BC8_BioRED_Task1_Doc483	766	776	olanzapine	Chemical	C076029	Among those responding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequent ratings not meeting response criteria.
BC8_BioRED_Task1_Doc483	823	834	risperidone	Chemical	D018967	Among those responding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%-65.0%) than in the risperidone group (18.9%, 95% CI=0%-39.2%) had subsequent ratings not meeting response criteria.
BC8_BioRED_Task1_Doc483	962	974	parkinsonism	Disease	D010302	Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications.
BC8_BioRED_Task1_Doc483	979	988	akathisia	Disease	D017109	Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications.
BC8_BioRED_Task1_Doc483	1025	1047	Extrapyramidal symptom	Disease	D001480	Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
BC8_BioRED_Task1_Doc483	1095	1106	risperidone	Chemical	D018967	Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
BC8_BioRED_Task1_Doc483	1137	1147	olanzapine	Chemical	C076029	Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
BC8_BioRED_Task1_Doc483	1168	1179	weight gain	Disease	D015430	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
BC8_BioRED_Task1_Doc483	1194	1204	olanzapine	Chemical	C076029	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
BC8_BioRED_Task1_Doc483	1215	1226	risperidone	Chemical	D018967	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
BC8_BioRED_Task1_Doc483	1327	1337	olanzapine	Chemical	C076029	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
BC8_BioRED_Task1_Doc483	1373	1384	risperidone	Chemical	D018967	Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
BC8_BioRED_Task1_Doc483	1494	1504	olanzapine	Chemical	C076029	Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8-25.7) versus 28.2 (95% CI=26.7-29.7) with olanzapine and 23.9 (95% CI=22.5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone.
BC8_BioRED_Task1_Doc483	1569	1580	risperidone	Chemical	D018967	Body mass index at baseline and at 4 months was 24.3 (95% CI=22.8-25.7) versus 28.2 (95% CI=26.7-29.7) with olanzapine and 23.9 (95% CI=22.5-25.3) versus 26.7 (95% CI=25.2-28.2) with risperidone.
BC8_BioRED_Task1_Doc483	1618	1629	risperidone	Chemical	D018967	CONCLUSIONS: Clinical outcomes with risperidone were equal to those with olanzapine, and response may be more stable.
BC8_BioRED_Task1_Doc483	1655	1665	olanzapine	Chemical	C076029	CONCLUSIONS: Clinical outcomes with risperidone were equal to those with olanzapine, and response may be more stable.
BC8_BioRED_Task1_Doc483	1700	1710	Olanzapine	Chemical	C076029	Olanzapine may have an advantage for motor side effects.
BC8_BioRED_Task1_Doc483	1799	1810	weight gain	Disease	D015430	Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
BC8_BioRED_Task1_Doc483	1816	1827	weight gain	Disease	D015430	Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
BC8_BioRED_Task1_Doc483	1845	1855	olanzapine	Chemical	C076029	Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.
BC8_BioRED_Task1_Doc484	0	15	Succinylcholine	Chemical	D013390	Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.
BC8_BioRED_Task1_Doc484	24	48	masseter muscle rigidity	Disease	D014313	Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.
BC8_BioRED_Task1_Doc484	106	130	Masseter muscle rigidity	Disease	D014313	Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.
BC8_BioRED_Task1_Doc484	218	240	malignant hyperthermia	Disease	D008305	Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.
BC8_BioRED_Task1_Doc484	358	382	masseter muscle rigidity	Disease	D014313	The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.
BC8_BioRED_Task1_Doc484	419	443	masseter muscle rigidity	Disease	D014313	Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.
BC8_BioRED_Task1_Doc484	445	457	jaw of steel	Disease	D014313	Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.
BC8_BioRED_Task1_Doc484	465	480	succinylcholine	Chemical	D013390	Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.
BC8_BioRED_Task1_Doc484	482	485	Sch	Chemical	D013390	Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.
BC8_BioRED_Task1_Doc484	642	650	propofol	Chemical	D015742	Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.
BC8_BioRED_Task1_Doc484	716	738	malignant hyperthermia	Disease	D008305	Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.
BC8_BioRED_Task1_Doc485	48	69	ataxia-telangiectasia	Disease	D001260	Mutations associated with variant phenotypes in ataxia-telangiectasia.
BC8_BioRED_Task1_Doc485	107	128	ataxia-telangiectasia	Disease	D001260	We have identified 14 families with ataxia-telangiectasia (A-T) in which mutation of the ATM gene is associated with a less severe clinical and cellular phenotype (approximately 10% -15% of A-T families identified in the United Kingdom).
BC8_BioRED_Task1_Doc485	130	133	A-T	Disease	D001260	We have identified 14 families with ataxia-telangiectasia (A-T) in which mutation of the ATM gene is associated with a less severe clinical and cellular phenotype (approximately 10% -15% of A-T families identified in the United Kingdom).
BC8_BioRED_Task1_Doc485	160	163	ATM	Gene	472	We have identified 14 families with ataxia-telangiectasia (A-T) in which mutation of the ATM gene is associated with a less severe clinical and cellular phenotype (approximately 10% -15% of A-T families identified in the United Kingdom).
BC8_BioRED_Task1_Doc485	261	264	A-T	Disease	D001260	We have identified 14 families with ataxia-telangiectasia (A-T) in which mutation of the ATM gene is associated with a less severe clinical and cellular phenotype (approximately 10% -15% of A-T families identified in the United Kingdom).
BC8_BioRED_Task1_Doc485	361	377	137-bp insertion	SequenceVariant	c|INS||137	In 10 of these families, all the homozygotes have a 137-bp insertion in their cDNA caused by a point mutation in a sequence resembling a splice-donor site.
BC8_BioRED_Task1_Doc485	476	479	A-T	Disease	D001260	The second A-T allele has a different mutation in each patient.
BC8_BioRED_Task1_Doc485	520	527	patient	OrganismTaxon	9606	The second A-T allele has a different mutation in each patient.
BC8_BioRED_Task1_Doc485	577	585	patients	OrganismTaxon	9606	We show that the less severe phenotype in these patients is caused by some degree of normal splicing, which occurs as an alternative product from the insertion-containing allele.
BC8_BioRED_Task1_Doc485	787	795	patients	OrganismTaxon	9606	The level of the 137-bp PCR product containing the insertion was lowest in two patients who showed a later onset of cerebellar ataxia.
BC8_BioRED_Task1_Doc485	824	841	cerebellar ataxia	Disease	D002524	The level of the 137-bp PCR product containing the insertion was lowest in two patients who showed a later onset of cerebellar ataxia.
BC8_BioRED_Task1_Doc485	1004	1007	A-T	Disease	D001260	Mutations detected in two of four of these are missense mutations, normally rare in A-T patients.
BC8_BioRED_Task1_Doc485	1008	1016	patients	OrganismTaxon	9606	Mutations detected in two of four of these are missense mutations, normally rare in A-T patients.
BC8_BioRED_Task1_Doc485	1095	1098	A-T	Disease	D001260	The demonstration of mutations giving rise to a slightly milder phenotype in A-T raises the interesting question of what range of phenotypes might occur in individuals in whom both mutations are milder.
BC8_BioRED_Task1_Doc485	1298	1301	ATM	Gene	472	One possibility might be that individuals who are compound heterozygotes for ATM mutations are more common than we realize..
BC8_BioRED_Task1_Doc486	21	46	prostate specific antigen	Gene	354	Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
BC8_BioRED_Task1_Doc486	74	91	androgen receptor	Gene	367	Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
BC8_BioRED_Task1_Doc486	117	132	prostate cancer	Disease	D011471	Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
BC8_BioRED_Task1_Doc486	198	223	prostate specific antigen	Gene	354	BACKGROUND: Recent data has suggested that polymorphisms in the prostate specific antigen (PSA) may increase prostate cancer (PC) risk.
BC8_BioRED_Task1_Doc486	225	228	PSA	Gene	354	BACKGROUND: Recent data has suggested that polymorphisms in the prostate specific antigen (PSA) may increase prostate cancer (PC) risk.
BC8_BioRED_Task1_Doc486	243	258	prostate cancer	Disease	D011471	BACKGROUND: Recent data has suggested that polymorphisms in the prostate specific antigen (PSA) may increase prostate cancer (PC) risk.
BC8_BioRED_Task1_Doc486	260	262	PC	Disease	D011471	BACKGROUND: Recent data has suggested that polymorphisms in the prostate specific antigen (PSA) may increase prostate cancer (PC) risk.
BC8_BioRED_Task1_Doc486	274	277	PSA	Gene	354	The PSA gene contains a G/A substitution in the androgen response element (ARE) 1 region.
BC8_BioRED_Task1_Doc486	294	297	G/A	SequenceVariant	c|SUB|G||A	The PSA gene contains a G/A substitution in the androgen response element (ARE) 1 region.
BC8_BioRED_Task1_Doc486	318	326	androgen	Chemical	D000728	The PSA gene contains a G/A substitution in the androgen response element (ARE) 1 region.
BC8_BioRED_Task1_Doc486	364	381	androgen receptor	Gene	367	The androgen receptor (AR) gene has polymorphic regions containing variable length glutamine and glycine repeats and these are believed to be associated with PC risk.
BC8_BioRED_Task1_Doc486	383	385	AR	Gene	367	The androgen receptor (AR) gene has polymorphic regions containing variable length glutamine and glycine repeats and these are believed to be associated with PC risk.
BC8_BioRED_Task1_Doc486	518	520	PC	Disease	D011471	The androgen receptor (AR) gene has polymorphic regions containing variable length glutamine and glycine repeats and these are believed to be associated with PC risk.
BC8_BioRED_Task1_Doc486	541	543	PC	Disease	D011471	The effect on PC risks from PSA polymorphisms alone and synergistically with the AR gene was examined in this report.
BC8_BioRED_Task1_Doc486	555	558	PSA	Gene	354	The effect on PC risks from PSA polymorphisms alone and synergistically with the AR gene was examined in this report.
BC8_BioRED_Task1_Doc486	608	610	AR	Gene	367	The effect on PC risks from PSA polymorphisms alone and synergistically with the AR gene was examined in this report.
BC8_BioRED_Task1_Doc486	666	668	PC	Disease	D011471	METHODS: One hundred PC patients and an age matched cohort of 79 benign prostate hyperplasia and 67 population controls were entered in this study.
BC8_BioRED_Task1_Doc486	669	677	patients	OrganismTaxon	9606	METHODS: One hundred PC patients and an age matched cohort of 79 benign prostate hyperplasia and 67 population controls were entered in this study.
BC8_BioRED_Task1_Doc486	710	737	benign prostate hyperplasia	Disease	D011470	METHODS: One hundred PC patients and an age matched cohort of 79 benign prostate hyperplasia and 67 population controls were entered in this study.
BC8_BioRED_Task1_Doc486	826	829	PSA	Gene	354	DNA was extracted from blood and PSA/ARE promoter region amplified by PCR.
BC8_BioRED_Task1_Doc486	895	900	Nhe 1	Gene	6548	PCR products were cut with Nhe 1 restriction enzyme to distinguish G/A alleles.
BC8_BioRED_Task1_Doc486	935	938	G/A	SequenceVariant	c|SUB|G||A	PCR products were cut with Nhe 1 restriction enzyme to distinguish G/A alleles.
BC8_BioRED_Task1_Doc486	948	950	AR	Gene	367	AR/CAG and GGC repeat length was detected by automated fluorescence from PCR products.
BC8_BioRED_Task1_Doc486	951	969	CAG and GGC repeat	SequenceVariant	c|DUP||CAG_GGC|	AR/CAG and GGC repeat length was detected by automated fluorescence from PCR products.
BC8_BioRED_Task1_Doc486	1076	1079	PSA	Gene	354	RESULTS: We found a significantly higher PSA/GG distribution in PC (30%) than either benign prostatic hyperplasia (BPH) (18%) or population controls (16%) (P = 0.025).
BC8_BioRED_Task1_Doc486	1099	1101	PC	Disease	D011471	RESULTS: We found a significantly higher PSA/GG distribution in PC (30%) than either benign prostatic hyperplasia (BPH) (18%) or population controls (16%) (P = 0.025).
BC8_BioRED_Task1_Doc486	1120	1148	benign prostatic hyperplasia	Disease	D011470	RESULTS: We found a significantly higher PSA/GG distribution in PC (30%) than either benign prostatic hyperplasia (BPH) (18%) or population controls (16%) (P = 0.025).
BC8_BioRED_Task1_Doc486	1150	1153	BPH	Disease	D011470	RESULTS: We found a significantly higher PSA/GG distribution in PC (30%) than either benign prostatic hyperplasia (BPH) (18%) or population controls (16%) (P = 0.025).
BC8_BioRED_Task1_Doc486	1276	1279	men	OrganismTaxon	9606	Furthermore the GG distribution within cases was even greater in younger men (< 65 years; 42%; P = 0.012).
BC8_BioRED_Task1_Doc486	1329	1332	PSA	Gene	354	Additionally, when PSA genotype was cross classified with CAG repeat, significantly more cases than both BPH and population controls were observed to have a short (< 22) CAG/GG genotype (P = 0.006).
BC8_BioRED_Task1_Doc486	1368	1378	CAG repeat	SequenceVariant	c|DUP||CAG|	Additionally, when PSA genotype was cross classified with CAG repeat, significantly more cases than both BPH and population controls were observed to have a short (< 22) CAG/GG genotype (P = 0.006).
BC8_BioRED_Task1_Doc486	1415	1418	BPH	Disease	D011470	Additionally, when PSA genotype was cross classified with CAG repeat, significantly more cases than both BPH and population controls were observed to have a short (< 22) CAG/GG genotype (P = 0.006).
BC8_BioRED_Task1_Doc486	1552	1555	PSA	Gene	354	CONCLUSIONS: Our results indicate that the PSA/ARE GG genotype confers an increased risk of PC especially among younger men.
BC8_BioRED_Task1_Doc486	1601	1603	PC	Disease	D011471	CONCLUSIONS: Our results indicate that the PSA/ARE GG genotype confers an increased risk of PC especially among younger men.
BC8_BioRED_Task1_Doc486	1629	1632	men	OrganismTaxon	9606	CONCLUSIONS: Our results indicate that the PSA/ARE GG genotype confers an increased risk of PC especially among younger men.
BC8_BioRED_Task1_Doc486	1685	1701	glutamine repeat	SequenceVariant	c|DUP||G|	Moreover, we confirm previous results that a short glutamine repeat in conjunction with GG genotype significantly increases the risk of malignant disease.
BC8_BioRED_Task1_Doc486	1770	1787	malignant disease	Disease	D009369	Moreover, we confirm previous results that a short glutamine repeat in conjunction with GG genotype significantly increases the risk of malignant disease.
BC8_BioRED_Task1_Doc487	11	37	inferior colliculus lesion	Disease	D001927	Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.
BC8_BioRED_Task1_Doc487	41	54	metronidazole	Chemical	D008795	Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.
BC8_BioRED_Task1_Doc487	63	77	encephalopathy	Disease	D001927	Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.
BC8_BioRED_Task1_Doc487	219	246	inferior colliculus lesions	Disease	D001927	OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.
BC8_BioRED_Task1_Doc487	250	263	metronidazole	Chemical	D008795	OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.
BC8_BioRED_Task1_Doc487	272	286	encephalopathy	Disease	D001927	OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.
BC8_BioRED_Task1_Doc487	457	465	patients	OrganismTaxon	9606	MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).
BC8_BioRED_Task1_Doc487	469	472	men	OrganismTaxon	9606	MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).
BC8_BioRED_Task1_Doc487	479	484	women	OrganismTaxon	9606	MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).
BC8_BioRED_Task1_Doc487	511	524	metronidazole	Chemical	D008795	MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).
BC8_BioRED_Task1_Doc487	533	547	encephalopathy	Disease	D001927	MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole-induced encephalopathy (age range; 43-78 years).
BC8_BioRED_Task1_Doc487	595	608	metronidazole	Chemical	D008795	They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.
BC8_BioRED_Task1_Doc487	678	687	infection	Disease	D007239	They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.
BC8_BioRED_Task1_Doc487	941	949	patients	OrganismTaxon	9606	Follow-up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration.
BC8_BioRED_Task1_Doc487	999	1012	metronidazole	Chemical	D008795	Follow-up MRIs were performed on 5 patients from third to 14th days after discontinuation of metronidazole administration.
BC8_BioRED_Task1_Doc487	1603	1610	patient	OrganismTaxon	9606	High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.
BC8_BioRED_Task1_Doc487	1826	1834	patients	OrganismTaxon	9606	All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.
BC8_BioRED_Task1_Doc487	1845	1852	patient	OrganismTaxon	9606	All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.
BC8_BioRED_Task1_Doc487	1869	1884	callosal lesion	Disease	D001927	All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.
BC8_BioRED_Task1_Doc487	1920	1947	inferior colliculus lesions	Disease	D001927	CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.
BC8_BioRED_Task1_Doc487	1994	2007	metronidazole	Chemical	D008795	CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.
BC8_BioRED_Task1_Doc487	2016	2030	encephalopathy	Disease	D001927	CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.
BC8_BioRED_Task1_Doc488	5	27	glycine encephalopathy	Disease	D020158	Mild glycine encephalopathy (NKH) in a large kindred due to a silent exonic GLDC splice mutation.
BC8_BioRED_Task1_Doc488	29	32	NKH	Disease	D020158	Mild glycine encephalopathy (NKH) in a large kindred due to a silent exonic GLDC splice mutation.
BC8_BioRED_Task1_Doc488	76	80	GLDC	Gene	2731	Mild glycine encephalopathy (NKH) in a large kindred due to a silent exonic GLDC splice mutation.
BC8_BioRED_Task1_Doc488	133	155	glycine encephalopathy	Disease	D020158	BACKGROUND: Classic neonatal-onset glycine encephalopathy (GE) is devastating and life threatening.
BC8_BioRED_Task1_Doc488	157	159	GE	Disease	D020158	BACKGROUND: Classic neonatal-onset glycine encephalopathy (GE) is devastating and life threatening.
BC8_BioRED_Task1_Doc488	389	391	GE	Disease	D020158	OBJECTIVE: To determine the clinical and biochemical phenotype and molecular basis of mild GE in nine children from a consanguineous Israeli Bedouin kindred.
BC8_BioRED_Task1_Doc488	494	498	GLDC	Gene	2731	METHODS: Genomic DNA was screened for GLDC, AMT, and GCSH gene mutations.
BC8_BioRED_Task1_Doc488	500	503	AMT	Gene	275	METHODS: Genomic DNA was screened for GLDC, AMT, and GCSH gene mutations.
BC8_BioRED_Task1_Doc488	509	513	GCSH	Gene	2653	METHODS: Genomic DNA was screened for GLDC, AMT, and GCSH gene mutations.
BC8_BioRED_Task1_Doc488	530	534	GLDC	Gene	2731	GLDC expression in lymphoblasts was studied by Northern blot and reverse transcriptase PCR analysis.
BC8_BioRED_Task1_Doc488	667	676	hypotonia	Disease	D009123	RESULTS: Clinical features included hypotonia, abnormal movements, convulsions, and moderate mental retardation with relative sparing of gross motor function, activities of daily living skills, and receptive language.
BC8_BioRED_Task1_Doc488	678	696	abnormal movements	Disease	D009069	RESULTS: Clinical features included hypotonia, abnormal movements, convulsions, and moderate mental retardation with relative sparing of gross motor function, activities of daily living skills, and receptive language.
BC8_BioRED_Task1_Doc488	698	709	convulsions	Disease	D012640	RESULTS: Clinical features included hypotonia, abnormal movements, convulsions, and moderate mental retardation with relative sparing of gross motor function, activities of daily living skills, and receptive language.
BC8_BioRED_Task1_Doc488	724	742	mental retardation	Disease	D008607	RESULTS: Clinical features included hypotonia, abnormal movements, convulsions, and moderate mental retardation with relative sparing of gross motor function, activities of daily living skills, and receptive language.
BC8_BioRED_Task1_Doc488	849	859	Aggression	Disease	D001523	Aggression and irritability were prominent.
BC8_BioRED_Task1_Doc488	864	876	irritability	Disease	D001523	Aggression and irritability were prominent.
BC8_BioRED_Task1_Doc488	965	973	patients	OrganismTaxon	9606	All nine patients were homozygous and their parents heterozygous for a novel, translationally silent GLDC exon 22 transversion c.2607C>A.
BC8_BioRED_Task1_Doc488	1057	1061	GLDC	Gene	2731	All nine patients were homozygous and their parents heterozygous for a novel, translationally silent GLDC exon 22 transversion c.2607C>A.
BC8_BioRED_Task1_Doc488	1083	1092	c.2607C>A	SequenceVariant	rs386833565	All nine patients were homozygous and their parents heterozygous for a novel, translationally silent GLDC exon 22 transversion c.2607C>A.
BC8_BioRED_Task1_Doc488	1106	1110	GLDC	Gene	2731	Lymphoblast GLDC mRNA levels were considerably reduced.
BC8_BioRED_Task1_Doc488	1305	1314	c.2607C>A	SequenceVariant	rs386833565	Homozygosity for c.2607C>A was also identified in an unrelated but haplotypically identical patient with an unusually favorable outcome despite severe neonatal-onset GE.
BC8_BioRED_Task1_Doc488	1380	1387	patient	OrganismTaxon	9606	Homozygosity for c.2607C>A was also identified in an unrelated but haplotypically identical patient with an unusually favorable outcome despite severe neonatal-onset GE.
BC8_BioRED_Task1_Doc488	1454	1456	GE	Disease	D020158	Homozygosity for c.2607C>A was also identified in an unrelated but haplotypically identical patient with an unusually favorable outcome despite severe neonatal-onset GE.
BC8_BioRED_Task1_Doc488	1626	1630	GLDC	Gene	2731	CONCLUSIONS: The mutation in this kindred led to missplicing and reduced GLDC (glycine decarboxylase) expression.
BC8_BioRED_Task1_Doc488	1632	1653	glycine decarboxylase	Gene	2731	CONCLUSIONS: The mutation in this kindred led to missplicing and reduced GLDC (glycine decarboxylase) expression.
BC8_BioRED_Task1_Doc488	1699	1703	GLDC	Gene	2731	The 4 to 6% of normally spliced GLDC mRNA in the patients may account for their relatively favorable clinical outcome compared with patients with classic glycine encephalopathy.
BC8_BioRED_Task1_Doc488	1716	1724	patients	OrganismTaxon	9606	The 4 to 6% of normally spliced GLDC mRNA in the patients may account for their relatively favorable clinical outcome compared with patients with classic glycine encephalopathy.
BC8_BioRED_Task1_Doc488	1799	1807	patients	OrganismTaxon	9606	The 4 to 6% of normally spliced GLDC mRNA in the patients may account for their relatively favorable clinical outcome compared with patients with classic glycine encephalopathy.
BC8_BioRED_Task1_Doc488	1821	1843	glycine encephalopathy	Disease	D020158	The 4 to 6% of normally spliced GLDC mRNA in the patients may account for their relatively favorable clinical outcome compared with patients with classic glycine encephalopathy.
BC8_BioRED_Task1_Doc489	18	34	apolipoprotein E	Gene	348	Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc489	46	66	arginine 150 proline	SequenceVariant	p|SUB|R|150|P	Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc489	99	125	lipoprotein glomerulopathy	Disease	C567089	Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
BC8_BioRED_Task1_Doc489	144	170	Lipoprotein glomerulopathy	Disease	C567089	BACKGROUND/AIMS: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE).
BC8_BioRED_Task1_Doc489	172	175	LPG	Disease	C567089	BACKGROUND/AIMS: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE).
BC8_BioRED_Task1_Doc489	212	220	thrombus	Disease	D013927	BACKGROUND/AIMS: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE).
BC8_BioRED_Task1_Doc489	249	279	dilated glomerular capillaries	Disease	D007674	BACKGROUND/AIMS: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE).
BC8_BioRED_Task1_Doc489	310	326	apolipoprotein E	Gene	348	BACKGROUND/AIMS: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE).
BC8_BioRED_Task1_Doc489	328	332	apoE	Gene	348	BACKGROUND/AIMS: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE).
BC8_BioRED_Task1_Doc489	389	393	apoE	Gene	348	Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG, but LPG may not be caused by apoE gene mutations in Chinese patients.
BC8_BioRED_Task1_Doc489	432	435	LPG	Disease	C567089	Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG, but LPG may not be caused by apoE gene mutations in Chinese patients.
BC8_BioRED_Task1_Doc489	441	444	LPG	Disease	C567089	Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG, but LPG may not be caused by apoE gene mutations in Chinese patients.
BC8_BioRED_Task1_Doc489	466	470	apoE	Gene	348	Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG, but LPG may not be caused by apoE gene mutations in Chinese patients.
BC8_BioRED_Task1_Doc489	497	505	patients	OrganismTaxon	9606	Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG, but LPG may not be caused by apoE gene mutations in Chinese patients.
BC8_BioRED_Task1_Doc489	567	571	apoE	Gene	348	This study investigated the association of a new variant of apoE with LPG in a Chinese family.
BC8_BioRED_Task1_Doc489	577	580	LPG	Disease	C567089	This study investigated the association of a new variant of apoE with LPG in a Chinese family.
BC8_BioRED_Task1_Doc489	615	619	apoE	Gene	348	METHODS: The apoE gene in a family with 4 LPG patients was sequenced.
BC8_BioRED_Task1_Doc489	644	647	LPG	Disease	C567089	METHODS: The apoE gene in a family with 4 LPG patients was sequenced.
BC8_BioRED_Task1_Doc489	648	656	patients	OrganismTaxon	9606	METHODS: The apoE gene in a family with 4 LPG patients was sequenced.
BC8_BioRED_Task1_Doc489	730	734	apoE	Gene	348	The polymerase chain reaction product of coding region of apoE exon 4 was cloned into pMD 18-T vector and then sequenced.
BC8_BioRED_Task1_Doc489	843	847	apoE	Gene	348	RESULTS: A novel point mutation in exon 4 of the apoE gene was identified in all 4 LPG patients and 1 asymptomatic family member.
BC8_BioRED_Task1_Doc489	877	880	LPG	Disease	C567089	RESULTS: A novel point mutation in exon 4 of the apoE gene was identified in all 4 LPG patients and 1 asymptomatic family member.
BC8_BioRED_Task1_Doc489	881	889	patients	OrganismTaxon	9606	RESULTS: A novel point mutation in exon 4 of the apoE gene was identified in all 4 LPG patients and 1 asymptomatic family member.
BC8_BioRED_Task1_Doc489	965	1007	G to C point mutation in exon 4 (base 308)	SequenceVariant	c|SUB|G|308|C	Sequence analysis confirmed a nucleotide G to C point mutation in exon 4 (base 308) of the apoE gene in all patients and the asymptomatic family member.
BC8_BioRED_Task1_Doc489	1015	1019	apoE	Gene	348	Sequence analysis confirmed a nucleotide G to C point mutation in exon 4 (base 308) of the apoE gene in all patients and the asymptomatic family member.
BC8_BioRED_Task1_Doc489	1032	1040	patients	OrganismTaxon	9606	Sequence analysis confirmed a nucleotide G to C point mutation in exon 4 (base 308) of the apoE gene in all patients and the asymptomatic family member.
BC8_BioRED_Task1_Doc489	1139	1191	proline residue for arginine residue at position 150	SequenceVariant	p|SUB|R|150|P	This missense mutation denotes amino acid substitution of the proline residue for arginine residue at position 150 of apoE.
BC8_BioRED_Task1_Doc489	1195	1199	apoE	Gene	348	This missense mutation denotes amino acid substitution of the proline residue for arginine residue at position 150 of apoE.
BC8_BioRED_Task1_Doc489	1207	1215	patients	OrganismTaxon	9606	Those patients were all heterozygotes with apoE Guangzhou.
BC8_BioRED_Task1_Doc489	1244	1248	apoE	Gene	348	Those patients were all heterozygotes with apoE Guangzhou.
BC8_BioRED_Task1_Doc489	1309	1313	apoE	Gene	348	One of 2 grandsons was a heterozygous carrier of apoE Guangzhou, although he did not have proteinuria.
BC8_BioRED_Task1_Doc489	1350	1361	proteinuria	Disease	D011507	One of 2 grandsons was a heterozygous carrier of apoE Guangzhou, although he did not have proteinuria.
BC8_BioRED_Task1_Doc489	1414	1418	apoE	Gene	348	CONCLUSION: The results of this study suggest that apoE (arginine 150 proline) is a novel apoE variant that etiologically related to LPG.
BC8_BioRED_Task1_Doc489	1420	1440	arginine 150 proline	SequenceVariant	p|SUB|R|150|P	CONCLUSION: The results of this study suggest that apoE (arginine 150 proline) is a novel apoE variant that etiologically related to LPG.
BC8_BioRED_Task1_Doc489	1453	1457	apoE	Gene	348	CONCLUSION: The results of this study suggest that apoE (arginine 150 proline) is a novel apoE variant that etiologically related to LPG.
BC8_BioRED_Task1_Doc489	1496	1499	LPG	Disease	C567089	CONCLUSION: The results of this study suggest that apoE (arginine 150 proline) is a novel apoE variant that etiologically related to LPG.
BC8_BioRED_Task1_Doc489	1515	1519	apoE	Gene	348	This variant (apoE Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to lipids.
BC8_BioRED_Task1_Doc489	1589	1593	apoE	Gene	348	This variant (apoE Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to lipids.
BC8_BioRED_Task1_Doc489	1633	1639	lipids	Chemical	D008055	This variant (apoE Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to lipids.
BC8_BioRED_Task1_Doc490	0	39	Congenital disorder of glycosylation Ic	Disease	C535741	Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation.
BC8_BioRED_Task1_Doc490	73	79	hALG-6	Gene	29929	Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation.
BC8_BioRED_Task1_Doc490	117	156	congenital disorder of glycosylation-Ic	Disease	C535741	We describe a new cause of congenital disorder of glycosylation-Ic (CDG-Ic) in a young girl with a rather mild CDG phenotype.
BC8_BioRED_Task1_Doc490	158	164	CDG-Ic	Disease	C535741	We describe a new cause of congenital disorder of glycosylation-Ic (CDG-Ic) in a young girl with a rather mild CDG phenotype.
BC8_BioRED_Task1_Doc490	201	204	CDG	Disease	D018981	We describe a new cause of congenital disorder of glycosylation-Ic (CDG-Ic) in a young girl with a rather mild CDG phenotype.
BC8_BioRED_Task1_Doc490	238	267	lipid-linked oligosaccharides	Chemical	C023023	Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A).
BC8_BioRED_Task1_Doc490	282	289	glucose	Chemical	D005947	Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A).
BC8_BioRED_Task1_Doc490	322	326	ALG6	Gene	29929	Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A).
BC8_BioRED_Task1_Doc490	404	410	338G>A	SequenceVariant	rs768372697	Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A).
BC8_BioRED_Task1_Doc490	457	464	patient	OrganismTaxon	9606	However, haplotype analysis showed that the patient does not carry any paternal DNA markers extending 33kb in the telomeric direction from the ALG6 region, and microsatellite analysis extended the abnormal region to at least 2.5Mb.
BC8_BioRED_Task1_Doc490	556	560	ALG6	Gene	29929	However, haplotype analysis showed that the patient does not carry any paternal DNA markers extending 33kb in the telomeric direction from the ALG6 region, and microsatellite analysis extended the abnormal region to at least 2.5Mb.
BC8_BioRED_Task1_Doc490	694	712	deletion (10-12Mb)	SequenceVariant	c|DEL||10-12MB	We used high-resolution karyotyping to confirm a deletion (10-12Mb) [del(1)(p31.2p32.3)] and found no structural abnormalities in the father, suggesting a de novo event.
BC8_BioRED_Task1_Doc490	714	732	del(1)(p31.2p32.3)	SequenceVariant	c|DEL|p31.2_p32.3|	We used high-resolution karyotyping to confirm a deletion (10-12Mb) [del(1)(p31.2p32.3)] and found no structural abnormalities in the father, suggesting a de novo event.
BC8_BioRED_Task1_Doc490	849	852	CDG	Disease	D018981	Our findings extend the causes of CDG to larger DNA deletions and identify the first Japanese CDG-Ic mutation.
BC8_BioRED_Task1_Doc490	909	915	CDG-Ic	Disease	C535741	Our findings extend the causes of CDG to larger DNA deletions and identify the first Japanese CDG-Ic mutation.
BC8_BioRED_Task1_Doc491	40	45	MLYCD	Gene	23417	Novel compound heterozygous mutation of MLYCD in a Chinese patient with malonic aciduria.
BC8_BioRED_Task1_Doc491	59	66	patient	OrganismTaxon	9606	Novel compound heterozygous mutation of MLYCD in a Chinese patient with malonic aciduria.
BC8_BioRED_Task1_Doc491	72	88	malonic aciduria	Disease	C535702	Novel compound heterozygous mutation of MLYCD in a Chinese patient with malonic aciduria.
BC8_BioRED_Task1_Doc491	161	177	malonic aciduria	Disease	C535702	A 3-year-old Chinese boy presented with prominent clinical features of malonic aciduria, including developmental delay, short stature, brain abnormalities and massive excretion of malonic acid and methylmalonic acid.
BC8_BioRED_Task1_Doc491	189	208	developmental delay	Disease	D002658	A 3-year-old Chinese boy presented with prominent clinical features of malonic aciduria, including developmental delay, short stature, brain abnormalities and massive excretion of malonic acid and methylmalonic acid.
BC8_BioRED_Task1_Doc491	210	223	short stature	Disease	D006130	A 3-year-old Chinese boy presented with prominent clinical features of malonic aciduria, including developmental delay, short stature, brain abnormalities and massive excretion of malonic acid and methylmalonic acid.
BC8_BioRED_Task1_Doc491	225	244	brain abnormalities	Disease	D001927	A 3-year-old Chinese boy presented with prominent clinical features of malonic aciduria, including developmental delay, short stature, brain abnormalities and massive excretion of malonic acid and methylmalonic acid.
BC8_BioRED_Task1_Doc491	270	282	malonic acid	Chemical	C030290	A 3-year-old Chinese boy presented with prominent clinical features of malonic aciduria, including developmental delay, short stature, brain abnormalities and massive excretion of malonic acid and methylmalonic acid.
BC8_BioRED_Task1_Doc491	287	305	methylmalonic acid	Chemical	D008764	A 3-year-old Chinese boy presented with prominent clinical features of malonic aciduria, including developmental delay, short stature, brain abnormalities and massive excretion of malonic acid and methylmalonic acid.
BC8_BioRED_Task1_Doc491	421	426	MLYCD	Gene	23417	Molecular characterization by DNA sequencing analysis and multiplex ligation-dependent probe amplification of the MLYCD gene revealed a heterozygous mutation (c.920T>G, p.Leu307Arg) in the patient and his father and a heterozygous deletion comprising exon 1 in the patient and his mother.
BC8_BioRED_Task1_Doc491	466	474	c.920T>G	SequenceVariant	c|SUB|T|920|G	Molecular characterization by DNA sequencing analysis and multiplex ligation-dependent probe amplification of the MLYCD gene revealed a heterozygous mutation (c.920T>G, p.Leu307Arg) in the patient and his father and a heterozygous deletion comprising exon 1 in the patient and his mother.
BC8_BioRED_Task1_Doc491	476	487	p.Leu307Arg	SequenceVariant	p|SUB|L|307|R	Molecular characterization by DNA sequencing analysis and multiplex ligation-dependent probe amplification of the MLYCD gene revealed a heterozygous mutation (c.920T>G, p.Leu307Arg) in the patient and his father and a heterozygous deletion comprising exon 1 in the patient and his mother.
BC8_BioRED_Task1_Doc491	496	503	patient	OrganismTaxon	9606	Molecular characterization by DNA sequencing analysis and multiplex ligation-dependent probe amplification of the MLYCD gene revealed a heterozygous mutation (c.920T>G, p.Leu307Arg) in the patient and his father and a heterozygous deletion comprising exon 1 in the patient and his mother.
BC8_BioRED_Task1_Doc491	572	579	patient	OrganismTaxon	9606	Molecular characterization by DNA sequencing analysis and multiplex ligation-dependent probe amplification of the MLYCD gene revealed a heterozygous mutation (c.920T>G, p.Leu307Arg) in the patient and his father and a heterozygous deletion comprising exon 1 in the patient and his mother.
BC8_BioRED_Task1_Doc491	619	627	c.920T>G	SequenceVariant	c|SUB|T|920|G	The missense mutation (c.920T>G) was not found in 100 healthy controls and has not been reported previously.
BC8_BioRED_Task1_Doc491	797	802	MLYCD	Gene	23417	Our findings expand the number of reported cases and add a novel entry to the repertoire of MLYCD mutations.
BC8_BioRED_Task1_Doc492	21	27	SLC2A2	Gene	6514	Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	29	34	GLUT2	Gene	6514	Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	81	107	impaired glucose tolerance	Disease	D018149	Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	111	126	type 2 diabetes	Disease	D003924	Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	140	148	Diabetes	Disease	D003920	Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	167	193	Impaired insulin secretion	Disease	D003920	Impaired insulin secretion is a fundamental defect in type 2 diabetes.
BC8_BioRED_Task1_Doc492	221	236	type 2 diabetes	Disease	D003924	Impaired insulin secretion is a fundamental defect in type 2 diabetes.
BC8_BioRED_Task1_Doc492	350	357	insulin	Gene	3630	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	369	375	SLC2A2	Gene	6514	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	386	391	GLUT2	Gene	6514	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	394	397	GCK	Gene	2645	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	399	403	TCF1	Gene	6927	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	414	424	HNF-1alpha	Gene	6927	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	427	432	HNF4A	Gene	3172	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	434	437	GIP	Gene	2695	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	443	448	GLP1R	Gene	2740	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	490	516	impaired glucose tolerance	Disease	D018149	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	518	521	IGT	Disease	D018149	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	526	541	type 2 diabetes	Disease	D003924	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	573	581	Diabetes	Disease	D003920	The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in the genes regulating insulin secretion (SLC2A2 [encoding GLUT2], GCK, TCF1 [encoding HNF-1alpha], HNF4A, GIP, and GLP1R) are associated with the conversion from impaired glucose tolerance (IGT) to type 2 diabetes in participants of the Finnish Diabetes Prevention Study.
BC8_BioRED_Task1_Doc492	622	628	SLC2A2	Gene	6514	With the exception of SLC2A2, other genes were not associated with the risk of type 2 diabetes.
BC8_BioRED_Task1_Doc492	679	694	type 2 diabetes	Disease	D003924	With the exception of SLC2A2, other genes were not associated with the risk of type 2 diabetes.
BC8_BioRED_Task1_Doc492	713	719	SLC2A2	Gene	6514	All four SNPs of SLC2A2 predicted the conversion to diabetes, and rs5393 (AA genotype) increased the risk of type 2 diabetes in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).
BC8_BioRED_Task1_Doc492	748	756	diabetes	Disease	D003920	All four SNPs of SLC2A2 predicted the conversion to diabetes, and rs5393 (AA genotype) increased the risk of type 2 diabetes in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).
BC8_BioRED_Task1_Doc492	762	768	rs5393	SequenceVariant	rs5393	All four SNPs of SLC2A2 predicted the conversion to diabetes, and rs5393 (AA genotype) increased the risk of type 2 diabetes in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).
BC8_BioRED_Task1_Doc492	805	820	type 2 diabetes	Disease	D003924	All four SNPs of SLC2A2 predicted the conversion to diabetes, and rs5393 (AA genotype) increased the risk of type 2 diabetes in the entire study population by threefold (odds ratio 3.04, 95% CI 1.34-6.88, P = 0.008).
BC8_BioRED_Task1_Doc492	926	941	type 2 diabetes	Disease	D003924	The risk for type 2 diabetes in the AA genotype carriers was increased in the control group (5.56 [1.78-17.39], P = 0.003) but not in the intervention group.
BC8_BioRED_Task1_Doc492	1100	1106	SLC2A2	Gene	6514	We conclude that the SNPs of SLC2A2 predict the conversion to diabetes in obese subjects with IGT.
BC8_BioRED_Task1_Doc492	1133	1141	diabetes	Disease	D003920	We conclude that the SNPs of SLC2A2 predict the conversion to diabetes in obese subjects with IGT.
BC8_BioRED_Task1_Doc492	1145	1150	obese	Disease	D009765	We conclude that the SNPs of SLC2A2 predict the conversion to diabetes in obese subjects with IGT.
BC8_BioRED_Task1_Doc492	1165	1168	IGT	Disease	D018149	We conclude that the SNPs of SLC2A2 predict the conversion to diabetes in obese subjects with IGT.
BC8_BioRED_Task1_Doc493	39	43	TMC1	Gene	117531	Identities, frequencies and origins of TMC1 mutations causing DFNB7/B11 deafness in Pakistan.
BC8_BioRED_Task1_Doc493	62	80	DFNB7/B11 deafness	Disease	C563417	Identities, frequencies and origins of TMC1 mutations causing DFNB7/B11 deafness in Pakistan.
BC8_BioRED_Task1_Doc493	94	116	Non-syndromic deafness	Disease	D003638	Non-syndromic deafness is genetically heterogeneous.
BC8_BioRED_Task1_Doc493	188	221	transmembrane channel-like gene 1	Gene	117531	We previously reported that mutations of transmembrane channel-like gene 1 (TMC1) cause non-syndromic recessive deafness at the DFNB7/B11 locus on chromosome 9q13-q21 in nine Pakistani families.
BC8_BioRED_Task1_Doc493	223	227	TMC1	Gene	117531	We previously reported that mutations of transmembrane channel-like gene 1 (TMC1) cause non-syndromic recessive deafness at the DFNB7/B11 locus on chromosome 9q13-q21 in nine Pakistani families.
BC8_BioRED_Task1_Doc493	235	267	non-syndromic recessive deafness	Disease	C564609	We previously reported that mutations of transmembrane channel-like gene 1 (TMC1) cause non-syndromic recessive deafness at the DFNB7/B11 locus on chromosome 9q13-q21 in nine Pakistani families.
BC8_BioRED_Task1_Doc493	275	284	DFNB7/B11	Gene	117531	We previously reported that mutations of transmembrane channel-like gene 1 (TMC1) cause non-syndromic recessive deafness at the DFNB7/B11 locus on chromosome 9q13-q21 in nine Pakistani families.
BC8_BioRED_Task1_Doc493	422	426	TMC1	Gene	117531	The goal of this study was to define the identities, origins and frequencies of TMC1 mutations in an expanded cohort of 557 large Pakistani families segregating recessive deafness.
BC8_BioRED_Task1_Doc493	503	521	recessive deafness	Disease	C564609	The goal of this study was to define the identities, origins and frequencies of TMC1 mutations in an expanded cohort of 557 large Pakistani families segregating recessive deafness.
BC8_BioRED_Task1_Doc493	615	650	autosomal recessive (DFNB) deafness	Disease	C564609	We screened affected family members for homozygosity at short-tandem repeats flanking known autosomal recessive (DFNB) deafness loci, followed by TMC1 sequence analysis in families segregating deafness linked to DFNB7/B11.
BC8_BioRED_Task1_Doc493	669	673	TMC1	Gene	117531	We screened affected family members for homozygosity at short-tandem repeats flanking known autosomal recessive (DFNB) deafness loci, followed by TMC1 sequence analysis in families segregating deafness linked to DFNB7/B11.
BC8_BioRED_Task1_Doc493	716	724	deafness	Disease	D003638	We screened affected family members for homozygosity at short-tandem repeats flanking known autosomal recessive (DFNB) deafness loci, followed by TMC1 sequence analysis in families segregating deafness linked to DFNB7/B11.
BC8_BioRED_Task1_Doc493	735	744	DFNB7/B11	Gene	117531	We screened affected family members for homozygosity at short-tandem repeats flanking known autosomal recessive (DFNB) deafness loci, followed by TMC1 sequence analysis in families segregating deafness linked to DFNB7/B11.
BC8_BioRED_Task1_Doc493	788	806	DFNB7/B11 deafness	Disease	C563417	We identified 10 new families segregating DFNB7/B11 deafness and TMC1 mutations, including three novel alleles.
BC8_BioRED_Task1_Doc493	811	815	TMC1	Gene	117531	We identified 10 new families segregating DFNB7/B11 deafness and TMC1 mutations, including three novel alleles.
BC8_BioRED_Task1_Doc493	879	883	TMC1	Gene	117531	Overall, 9 different TMC1 mutations account for deafness in 19 (3.4%) of the 557 Pakistani families.
BC8_BioRED_Task1_Doc493	906	914	deafness	Disease	D003638	Overall, 9 different TMC1 mutations account for deafness in 19 (3.4%) of the 557 Pakistani families.
BC8_BioRED_Task1_Doc493	978	984	p.R34X	SequenceVariant	rs121908073	A single mutation, p.R34X, causes deafness in 10 (1.8%) of the families.
BC8_BioRED_Task1_Doc493	993	1001	deafness	Disease	D003638	A single mutation, p.R34X, causes deafness in 10 (1.8%) of the families.
BC8_BioRED_Task1_Doc493	1053	1059	p.R34X	SequenceVariant	rs121908073	Genotype analysis of p.R34X-linked markers indicates that it arose from a common founder.
BC8_BioRED_Task1_Doc493	1139	1145	p.R34X	SequenceVariant	rs121908073	We also detected p.R34X among normal control samples of African-American and northern European origins, raising the possibility that p.R34X and other mutations of TMC1 are prevalent contributors to the genetic load of deafness across a variety of populations and continents.
BC8_BioRED_Task1_Doc493	1255	1261	p.R34X	SequenceVariant	rs121908073	We also detected p.R34X among normal control samples of African-American and northern European origins, raising the possibility that p.R34X and other mutations of TMC1 are prevalent contributors to the genetic load of deafness across a variety of populations and continents.
BC8_BioRED_Task1_Doc493	1285	1289	TMC1	Gene	117531	We also detected p.R34X among normal control samples of African-American and northern European origins, raising the possibility that p.R34X and other mutations of TMC1 are prevalent contributors to the genetic load of deafness across a variety of populations and continents.
BC8_BioRED_Task1_Doc493	1340	1348	deafness	Disease	D003638	We also detected p.R34X among normal control samples of African-American and northern European origins, raising the possibility that p.R34X and other mutations of TMC1 are prevalent contributors to the genetic load of deafness across a variety of populations and continents.
BC8_BioRED_Task1_Doc494	35	55	phosphodiesterase 4D	Gene	5144	Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
BC8_BioRED_Task1_Doc494	57	62	PDE4D	Gene	5144	Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
BC8_BioRED_Task1_Doc494	67	90	carotid atherosclerosis	Disease	D002340	Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.
BC8_BioRED_Task1_Doc494	108	128	phosphodiesterase 4D	Gene	5144	BACKGROUND: The phosphodiesterase 4D (PDE4D) gene was reported as a susceptibility gene to stroke.
BC8_BioRED_Task1_Doc494	130	135	PDE4D	Gene	5144	BACKGROUND: The phosphodiesterase 4D (PDE4D) gene was reported as a susceptibility gene to stroke.
BC8_BioRED_Task1_Doc494	183	189	stroke	Disease	D020521	BACKGROUND: The phosphodiesterase 4D (PDE4D) gene was reported as a susceptibility gene to stroke.
BC8_BioRED_Task1_Doc494	260	271	atherogenic	Disease	D050197	The genetic effect might be attributed to its role in modulating the atherogenic process in the carotid arteries.
BC8_BioRED_Task1_Doc494	460	475	atherosclerosis	Disease	D050197	Using carotid intima-media thickness (IMT) and plaque index as phenotypes, the present study sought to determine the influence of this gene on subclinical atherosclerosis.
BC8_BioRED_Task1_Doc494	532	538	stroke	Disease	D020521	METHODS: Carotid ultrasonography was performed on 1013 stroke-free subjects who participated in the health screening programs (age 52.6 +/- 12.2; 47.6% men).
BC8_BioRED_Task1_Doc494	629	632	men	OrganismTaxon	9606	METHODS: Carotid ultrasonography was performed on 1013 stroke-free subjects who participated in the health screening programs (age 52.6 +/- 12.2; 47.6% men).
BC8_BioRED_Task1_Doc494	983	986	men	OrganismTaxon	9606	Because the plaque prevalence and IMT values displayed a notable difference between men and women, we carried out sex-specific analyses in addition to analyzing the overall data.
BC8_BioRED_Task1_Doc494	991	996	women	OrganismTaxon	9606	Because the plaque prevalence and IMT values displayed a notable difference between men and women, we carried out sex-specific analyses in addition to analyzing the overall data.
BC8_BioRED_Task1_Doc494	1078	1086	Rs702553	SequenceVariant	rs702553	Rs702553 at the PDE4D gene was selected because it conferred a risk for young stroke in our previous report.
BC8_BioRED_Task1_Doc494	1094	1099	PDE4D	Gene	5144	Rs702553 at the PDE4D gene was selected because it conferred a risk for young stroke in our previous report.
BC8_BioRED_Task1_Doc494	1156	1162	stroke	Disease	D020521	Rs702553 at the PDE4D gene was selected because it conferred a risk for young stroke in our previous report.
BC8_BioRED_Task1_Doc494	1202	1208	stroke	Disease	D020521	Previous young stroke data (190 cases and 211 controls) with an additional 532 control subjects without ultrasonic data were shown as a cross-validation for the genetic effect.
BC8_BioRED_Task1_Doc494	1421	1429	rs702553	SequenceVariant	rs702553	RESULTS: In the overall analyses, the rare homozygote of rs702553 led to an OR of 3.1 (p = 0.034) for a plaque index > or = 4.
BC8_BioRED_Task1_Doc494	1568	1571	men	OrganismTaxon	9606	When subjects were stratified by sex, the genetic effect was only evident in men but not in women.
BC8_BioRED_Task1_Doc494	1583	1588	women	OrganismTaxon	9606	When subjects were stratified by sex, the genetic effect was only evident in men but not in women.
BC8_BioRED_Task1_Doc494	1770	1773	men	OrganismTaxon	9606	For dichotomized IMT data in men, the TT genotype had an OR of 2.1 (p = 0.032) for a thicker IMT at the common carotid artery compared with the (AA + AT) genotypes.
BC8_BioRED_Task1_Doc494	1909	1914	women	OrganismTaxon	9606	In women, neither IMT nor plaque index was associated with rs702553.
BC8_BioRED_Task1_Doc494	1965	1973	rs702553	SequenceVariant	rs702553	In women, neither IMT nor plaque index was associated with rs702553.
BC8_BioRED_Task1_Doc494	1990	1998	rs702553	SequenceVariant	rs702553	Similarly, SNP rs702553 was only significant in young stroke men (OR = 1.8, p = 0.025) but not in women (p = 0.27).
BC8_BioRED_Task1_Doc494	2029	2035	stroke	Disease	D020521	Similarly, SNP rs702553 was only significant in young stroke men (OR = 1.8, p = 0.025) but not in women (p = 0.27).
BC8_BioRED_Task1_Doc494	2036	2039	men	OrganismTaxon	9606	Similarly, SNP rs702553 was only significant in young stroke men (OR = 1.8, p = 0.025) but not in women (p = 0.27).
BC8_BioRED_Task1_Doc494	2073	2078	women	OrganismTaxon	9606	Similarly, SNP rs702553 was only significant in young stroke men (OR = 1.8, p = 0.025) but not in women (p = 0.27).
BC8_BioRED_Task1_Doc494	2164	2169	PDE4D	Gene	5144	CONCLUSIONS: The present study demonstrates a sex-differential effect of PDE4D on IMT, plaque index and stroke, which highlights its influence on various aspects of atherogenesis.
BC8_BioRED_Task1_Doc494	2195	2201	stroke	Disease	D020521	CONCLUSIONS: The present study demonstrates a sex-differential effect of PDE4D on IMT, plaque index and stroke, which highlights its influence on various aspects of atherogenesis.
BC8_BioRED_Task1_Doc494	2256	2269	atherogenesis	Disease	D050197	CONCLUSIONS: The present study demonstrates a sex-differential effect of PDE4D on IMT, plaque index and stroke, which highlights its influence on various aspects of atherogenesis.
BC8_BioRED_Task1_Doc495	0	9	Psoriasin	Gene	6278	Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression.
BC8_BioRED_Task1_Doc495	57	74	pancreatic cancer	Disease	D010190	Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression.
BC8_BioRED_Task1_Doc495	120	129	Psoriasin	Gene	6278	Psoriasin (S100A7) is an 11-kDa small calcium binding protein initially isolated from psoriatic skin lesions.
BC8_BioRED_Task1_Doc495	131	137	S100A7	Gene	6278	Psoriasin (S100A7) is an 11-kDa small calcium binding protein initially isolated from psoriatic skin lesions.
BC8_BioRED_Task1_Doc495	158	181	calcium binding protein	Gene	6278	Psoriasin (S100A7) is an 11-kDa small calcium binding protein initially isolated from psoriatic skin lesions.
BC8_BioRED_Task1_Doc495	206	228	psoriatic skin lesions	Disease	D011565	Psoriasin (S100A7) is an 11-kDa small calcium binding protein initially isolated from psoriatic skin lesions.
BC8_BioRED_Task1_Doc495	248	252	S100	Gene	6278	It belongs to the S100 family of proteins which play an important role in a range of cell functions including proliferation, differentiation, migration and apoptosis.
BC8_BioRED_Task1_Doc495	406	415	Psoriasin	Gene	6278	Aberrant Psoriasin expression has been implicated in a range of cancers and is often associated with poor prognosis.
BC8_BioRED_Task1_Doc495	461	468	cancers	Disease	D009369	Aberrant Psoriasin expression has been implicated in a range of cancers and is often associated with poor prognosis.
BC8_BioRED_Task1_Doc495	546	555	Psoriasin	Gene	6278	This study examined the role of Psoriasin on pancreatic cancer cell functions and the implication in progression of the disease.
BC8_BioRED_Task1_Doc495	559	576	pancreatic cancer	Disease	D010190	This study examined the role of Psoriasin on pancreatic cancer cell functions and the implication in progression of the disease.
BC8_BioRED_Task1_Doc495	657	666	Psoriasin	Gene	6278	Expression of Psoriasin was determined in a cohort of pancreatic tissues comprised of 126 pancreatic tumours and 114 adjacent non-tumour pancreatic tissues.
BC8_BioRED_Task1_Doc495	733	751	pancreatic tumours	Disease	D010190	Expression of Psoriasin was determined in a cohort of pancreatic tissues comprised of 126 pancreatic tumours and 114 adjacent non-tumour pancreatic tissues.
BC8_BioRED_Task1_Doc495	832	841	Psoriasin	Gene	6278	Knockdown and overexpression of Psoriasin in pancreatic cancer cells was performed using specifically constructed plasmids, which either had anti-Psoriasin ribozyme transgene or the full length human Psoriasin coding sequence.
BC8_BioRED_Task1_Doc495	845	862	pancreatic cancer	Disease	D010190	Knockdown and overexpression of Psoriasin in pancreatic cancer cells was performed using specifically constructed plasmids, which either had anti-Psoriasin ribozyme transgene or the full length human Psoriasin coding sequence.
BC8_BioRED_Task1_Doc495	946	955	Psoriasin	Gene	6278	Knockdown and overexpression of Psoriasin in pancreatic cancer cells was performed using specifically constructed plasmids, which either had anti-Psoriasin ribozyme transgene or the full length human Psoriasin coding sequence.
BC8_BioRED_Task1_Doc495	994	999	human	OrganismTaxon	9606	Knockdown and overexpression of Psoriasin in pancreatic cancer cells was performed using specifically constructed plasmids, which either had anti-Psoriasin ribozyme transgene or the full length human Psoriasin coding sequence.
BC8_BioRED_Task1_Doc495	1000	1009	Psoriasin	Gene	6278	Knockdown and overexpression of Psoriasin in pancreatic cancer cells was performed using specifically constructed plasmids, which either had anti-Psoriasin ribozyme transgene or the full length human Psoriasin coding sequence.
BC8_BioRED_Task1_Doc495	1027	1036	Psoriasin	Gene	6278	Psoriasin knockdown and overexpression was verified using conventional RT-PCR and qPCR.
BC8_BioRED_Task1_Doc495	1142	1151	Psoriasin	Gene	6278	The effect of manipulating Psoriasin expression on pancreatic cancer cell functions was assessed using several in vitro cell function assays.
BC8_BioRED_Task1_Doc495	1166	1183	pancreatic cancer	Disease	D010190	The effect of manipulating Psoriasin expression on pancreatic cancer cell functions was assessed using several in vitro cell function assays.
BC8_BioRED_Task1_Doc495	1272	1290	pancreatic cancers	Disease	D010190	Local invasive pancreatic cancers extended beyond the pancreas expressed higher levels of Psoriasin transcripts compared with the cancers confined to the pancreas.
BC8_BioRED_Task1_Doc495	1347	1356	Psoriasin	Gene	6278	Local invasive pancreatic cancers extended beyond the pancreas expressed higher levels of Psoriasin transcripts compared with the cancers confined to the pancreas.
BC8_BioRED_Task1_Doc495	1387	1394	cancers	Disease	D009369	Local invasive pancreatic cancers extended beyond the pancreas expressed higher levels of Psoriasin transcripts compared with the cancers confined to the pancreas.
BC8_BioRED_Task1_Doc495	1421	1436	Primary tumours	Disease	D009369	Primary tumours with distant metastases exhibited a reduced expression of Psoriasin.
BC8_BioRED_Task1_Doc495	1450	1460	metastases	Disease	D009362	Primary tumours with distant metastases exhibited a reduced expression of Psoriasin.
BC8_BioRED_Task1_Doc495	1495	1504	Psoriasin	Gene	6278	Primary tumours with distant metastases exhibited a reduced expression of Psoriasin.
BC8_BioRED_Task1_Doc495	1506	1515	Psoriasin	Gene	6278	Psoriasin overexpression cell lines exhibited significantly increased growth and migration compared to control cells.
BC8_BioRED_Task1_Doc495	1637	1646	Psoriasin	Gene	6278	In addition, Psoriasin overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.
BC8_BioRED_Task1_Doc495	1684	1701	pancreatic cancer	Disease	D010190	In addition, Psoriasin overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.
BC8_BioRED_Task1_Doc495	1758	1784	matrix metalloproteinase-2	Gene	4313	In addition, Psoriasin overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.
BC8_BioRED_Task1_Doc495	1786	1791	MMP-2	Gene	4313	In addition, Psoriasin overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.
BC8_BioRED_Task1_Doc495	1797	1802	MMP-9	Gene	4318	In addition, Psoriasin overexpression resulted in increased pancreatic cancer cell invasion which was associated with upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9.
BC8_BioRED_Task1_Doc495	1822	1831	Psoriasin	Gene	6278	Overexpression of Psoriasin also promoted aggregation and survival of pancreatic cancer cells when they lost anchorage.
BC8_BioRED_Task1_Doc495	1874	1891	pancreatic cancer	Disease	D010190	Overexpression of Psoriasin also promoted aggregation and survival of pancreatic cancer cells when they lost anchorage.
BC8_BioRED_Task1_Doc495	1961	1970	Psoriasin	Gene	6278	Taken together, higher expression of Psoriasin was associated with local invasion in pancreatic cancers.
BC8_BioRED_Task1_Doc495	2009	2027	pancreatic cancers	Disease	D010190	Taken together, higher expression of Psoriasin was associated with local invasion in pancreatic cancers.
BC8_BioRED_Task1_Doc495	2029	2038	Psoriasin	Gene	6278	Psoriasin expression is associated with pancreatic cancer cell growth, migration, cell-matrix adhesion, and invasion via regulation of MMPs.
BC8_BioRED_Task1_Doc495	2069	2086	pancreatic cancer	Disease	D010190	Psoriasin expression is associated with pancreatic cancer cell growth, migration, cell-matrix adhesion, and invasion via regulation of MMPs.
BC8_BioRED_Task1_Doc495	2164	2168	MMPs	Gene	4313,4318	Psoriasin expression is associated with pancreatic cancer cell growth, migration, cell-matrix adhesion, and invasion via regulation of MMPs.
BC8_BioRED_Task1_Doc495	2208	2217	Psoriasin	Gene	6278	As such, the proposed implications of Psoriasin in invasion, disease progression and as a potential therapeutic target warrant further investigation.
BC8_BioRED_Task1_Doc496	10	19	green tea	Chemical	D010936	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	24	33	vitamin E	Chemical	D014810	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	49	62	isoproterenol	Chemical	D007545	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	71	92	myocardial infarction	Disease	D009203	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	96	100	rats	OrganismTaxon	10116	Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	169	178	green tea	Chemical	D010936	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	183	192	vitamin E	Chemical	D014810	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	245	250	lipid	Chemical	D008055	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	276	288	antioxidants	Chemical	D000975	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	319	332	isoproterenol	Chemical	D007545	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	334	337	ISO	Chemical	D007545	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	347	368	myocardial infarction	Disease	D009203	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	372	376	rats	OrganismTaxon	10116	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	396	400	rats	OrganismTaxon	10116	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	415	418	ISO	Chemical	D007545	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	550	555	lipid	Chemical	D008055	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	573	584	Ca+2 ATPase	Chemical	D000252	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	668	680	antioxidants	Chemical	D000975	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	682	696	Na+/ K+ ATPase	Chemical	D000254	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	701	712	Mg+2 ATPase	Chemical	D017301	Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.
BC8_BioRED_Task1_Doc496	739	748	green tea	Chemical	D010936	Administration of green tea (100 mg/kg/day, p.o.)
BC8_BioRED_Task1_Doc496	775	784	vitamin E	Chemical	D014810	and vitamin E (100 mg/kg/day, p.o.)
BC8_BioRED_Task1_Doc496	860	863	ISO	Chemical	D007545	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	968	973	lipid	Chemical	D008055	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	988	999	Ca+2 ATPase	Chemical	D000252	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1058	1070	antioxidants	Chemical	D000975	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1072	1085	Na+/K+ ATPase	Chemical	D000254	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1090	1101	Mg+2 ATPase	Chemical	D017301	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1121	1124	ISO	Chemical	D007545	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1143	1152	green tea	Chemical	D010936	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1156	1165	vitamin E	Chemical	D014810	together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.
BC8_BioRED_Task1_Doc496	1249	1258	green tea	Chemical	D010936	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	1263	1272	vitamin E	Chemical	D014810	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	1280	1283	ISO	Chemical	D007545	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	1292	1313	myocardial infarction	Disease	D009203	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc496	1317	1321	rats	OrganismTaxon	10116	These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.
BC8_BioRED_Task1_Doc497	27	35	morphine	Chemical	D009020	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	48	70	sodium channel blocker	Chemical	D026941	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	72	79	CNSB002	Chemical	C401121	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	84	87	rat	OrganismTaxon	10116	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	98	110	inflammatory	Disease	D007249	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	115	131	neuropathic pain	Disease	D009437	Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	197	204	CNSB002	Chemical	C401121	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	208	230	sodium channel blocker	Chemical	D026941	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	296	304	morphine	Chemical	D009020	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	308	311	rat	OrganismTaxon	10116	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	322	334	inflammatory	Disease	D007249	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	339	355	neuropathic pain	Disease	D009437	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
BC8_BioRED_Task1_Doc497	411	419	morphine	Chemical	D009020	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	424	431	CNSB002	Chemical	C401121	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	582	585	rat	OrganismTaxon	10116	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	586	590	pain	Disease	D010146	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	599	610	carrageenan	Chemical	D002351	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	623	635	inflammation	Disease	D007249	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	640	654	streptozotocin	Chemical	D013311	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	656	659	STZ	Chemical	D013311	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	669	688	diabetic neuropathy	Disease	D003929	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.
BC8_BioRED_Task1_Doc497	735	743	morphine	Chemical	D009020	RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination.
BC8_BioRED_Task1_Doc497	756	763	CNSB002	Chemical	C401121	RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination.
BC8_BioRED_Task1_Doc497	786	793	CNSB002	Chemical	C401121	RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination.
BC8_BioRED_Task1_Doc497	799	807	morphine	Chemical	D009020	RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination.
BC8_BioRED_Task1_Doc497	880	892	hyperalgesia	Disease	D006930	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	940	951	carrageenan	Chemical	D002351	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	998	1001	STZ	Chemical	D013311	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1010	1020	neuropathy	Disease	D009422	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1031	1038	CNSB002	Chemical	C401121	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1043	1051	morphine	Chemical	D009020	The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1168	1176	morphine	Chemical	D009020	The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1208	1215	CNSB002	Chemical	C401121	The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1290	1301	carrageenan	Chemical	D002351	The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1331	1341	neuropathy	Disease	D009422	The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
BC8_BioRED_Task1_Doc497	1394	1402	morphine	Chemical	D009020	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
BC8_BioRED_Task1_Doc497	1455	1462	CNSB002	Chemical	C401121	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
BC8_BioRED_Task1_Doc497	1514	1526	hyperalgesia	Disease	D006930	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
BC8_BioRED_Task1_Doc497	1534	1546	inflammatory	Disease	D007249	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
BC8_BioRED_Task1_Doc497	1551	1562	neuropathic	Disease	D009422	The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
BC8_BioRED_Task1_Doc497	1763	1771	morphine	Chemical	D009020	CONCLUSIONS: The maximum antihyperalgesic effect achievable with nonsedating doses of morphine may be increased significantly when the drug is used in combination with CNSB002.
BC8_BioRED_Task1_Doc497	1845	1852	CNSB002	Chemical	C401121	CONCLUSIONS: The maximum antihyperalgesic effect achievable with nonsedating doses of morphine may be increased significantly when the drug is used in combination with CNSB002.
BC8_BioRED_Task1_Doc498	15	30	methamphetamine	Chemical	D008694	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
BC8_BioRED_Task1_Doc498	53	65	dopaminergic	Chemical	D004298	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
BC8_BioRED_Task1_Doc498	66	79	neurotoxicity	Disease	D020258	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
BC8_BioRED_Task1_Doc498	83	87	mice	OrganismTaxon	10090	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
BC8_BioRED_Task1_Doc498	91	109	lipopolysaccharide	Chemical	D008070	Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
BC8_BioRED_Task1_Doc498	185	200	methamphetamine	Chemical	D008694	Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.
BC8_BioRED_Task1_Doc498	209	237	dopaminergic terminal damage	Disease	D009422	Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.
BC8_BioRED_Task1_Doc498	279	297	lipopolysaccharide	Chemical	D008070	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	305	317	inflammatory	Disease	D007249	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	322	334	inflammatory	Disease	D007249	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	371	386	methamphetamine	Chemical	D008694	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	409	417	dopamine	Chemical	D004298	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	418	431	neurotoxicity	Disease	D020258	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	433	451	Lipopolysaccharide	Chemical	D008070	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.
BC8_BioRED_Task1_Doc498	510	525	methamphetamine	Chemical	D008694	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.
BC8_BioRED_Task1_Doc498	535	547	hyperthermia	Disease	D005334	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.
BC8_BioRED_Task1_Doc498	580	598	lipopolysaccharide	Chemical	D008070	Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.
BC8_BioRED_Task1_Doc498	619	634	methamphetamine	Chemical	D008694	Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.
BC8_BioRED_Task1_Doc498	652	660	dopamine	Chemical	D004298	Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.
BC8_BioRED_Task1_Doc498	665	695	3,4-dihydroxyphenylacetic acid	Chemical	D015102	Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.
BC8_BioRED_Task1_Doc498	772	790	lipopolysaccharide	Chemical	D008070	As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.
BC8_BioRED_Task1_Doc498	847	862	methamphetamine	Chemical	D008694	As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.
BC8_BioRED_Task1_Doc498	879	894	methamphetamine	Chemical	D008694	As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.
BC8_BioRED_Task1_Doc498	912	920	dopamine	Chemical	D004298	As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.
BC8_BioRED_Task1_Doc498	925	955	3,4-dihydroxyphenylacetic acid	Chemical	D015102	As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.
BC8_BioRED_Task1_Doc498	1006	1024	lipopolysaccharide	Chemical	D008070	Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.
BC8_BioRED_Task1_Doc498	1065	1080	methamphetamine	Chemical	D008694	Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.
BC8_BioRED_Task1_Doc498	1099	1107	dopamine	Chemical	D004298	Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.
BC8_BioRED_Task1_Doc498	1112	1142	3,4-dihydroxyphenylacetic acid	Chemical	D015102	Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.
BC8_BioRED_Task1_Doc498	1212	1230	lipopolysaccharide	Chemical	D008070	Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.
BC8_BioRED_Task1_Doc498	1306	1321	methamphetamine	Chemical	D008694	Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.
BC8_BioRED_Task1_Doc498	1372	1390	lipopolysaccharide	Chemical	D008070	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	1445	1460	methamphetamine	Chemical	D008694	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	1483	1491	dopamine	Chemical	D004298	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc498	1492	1505	neurotoxicity	Disease	D020258	We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.
BC8_BioRED_Task1_Doc499	14	26	hypertension	Disease	D006973	Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.
BC8_BioRED_Task1_Doc499	38	50	nitric oxide	Chemical	D009569	Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.
BC8_BioRED_Task1_Doc499	52	54	NO	Chemical	D009569	Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.
BC8_BioRED_Task1_Doc499	127	139	nitric oxide	Chemical	D009569	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
BC8_BioRED_Task1_Doc499	141	143	NO	Chemical	D009569	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
BC8_BioRED_Task1_Doc499	148	160	hypertension	Disease	D006973	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
BC8_BioRED_Task1_Doc499	178	198	arterial dysfunction	Disease	D018754	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
BC8_BioRED_Task1_Doc499	213	225	hypertension	Disease	D006973	Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.
BC8_BioRED_Task1_Doc499	252	254	NO	Chemical	D009569	Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.
BC8_BioRED_Task1_Doc499	365	377	endothelin-1	Gene	24323	These include augmented endothelin-1 (ET-1) release, increased sympathetic nervous system activity, and elevated tissue oxidative stress.
BC8_BioRED_Task1_Doc499	379	383	ET-1	Gene	24323	These include augmented endothelin-1 (ET-1) release, increased sympathetic nervous system activity, and elevated tissue oxidative stress.
BC8_BioRED_Task1_Doc499	564	587	Nomega-nitro-L-arginine	Chemical	D019335	We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in Nomega-nitro-L-arginine (LNNA) hypertension through these mechanisms.
BC8_BioRED_Task1_Doc499	589	593	LNNA	Chemical	D019335	We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in Nomega-nitro-L-arginine (LNNA) hypertension through these mechanisms.
BC8_BioRED_Task1_Doc499	595	607	hypertension	Disease	D006973	We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in Nomega-nitro-L-arginine (LNNA) hypertension through these mechanisms.
BC8_BioRED_Task1_Doc499	634	638	Rats	OrganismTaxon	10116	Rats were treated with the NO synthase inhibitor LNNA (0.5 g/L in drinking water) for 2 weeks.
BC8_BioRED_Task1_Doc499	661	672	NO synthase	Gene	24598	Rats were treated with the NO synthase inhibitor LNNA (0.5 g/L in drinking water) for 2 weeks.
BC8_BioRED_Task1_Doc499	683	687	LNNA	Chemical	D019335	Rats were treated with the NO synthase inhibitor LNNA (0.5 g/L in drinking water) for 2 weeks.
BC8_BioRED_Task1_Doc499	765	769	rats	OrganismTaxon	10116	Mean arterial pressure of conscious rats was 119 +/- 2 mm Hg in control and 194 +/- 5 mm Hg in LNNA rats (P<0.05).
BC8_BioRED_Task1_Doc499	824	828	LNNA	Chemical	D019335	Mean arterial pressure of conscious rats was 119 +/- 2 mm Hg in control and 194 +/- 5 mm Hg in LNNA rats (P<0.05).
BC8_BioRED_Task1_Doc499	829	833	rats	OrganismTaxon	10116	Mean arterial pressure of conscious rats was 119 +/- 2 mm Hg in control and 194 +/- 5 mm Hg in LNNA rats (P<0.05).
BC8_BioRED_Task1_Doc499	953	967	norepinephrine	Chemical	D009638	Maximal contraction to norepinephrine was modestly reduced in arteries from LNNA compared with control rats whereas the maximum contraction to ET-1 was significantly reduced (54% control).
BC8_BioRED_Task1_Doc499	1006	1010	LNNA	Chemical	D019335	Maximal contraction to norepinephrine was modestly reduced in arteries from LNNA compared with control rats whereas the maximum contraction to ET-1 was significantly reduced (54% control).
BC8_BioRED_Task1_Doc499	1033	1037	rats	OrganismTaxon	10116	Maximal contraction to norepinephrine was modestly reduced in arteries from LNNA compared with control rats whereas the maximum contraction to ET-1 was significantly reduced (54% control).
BC8_BioRED_Task1_Doc499	1073	1077	ET-1	Gene	24323	Maximal contraction to norepinephrine was modestly reduced in arteries from LNNA compared with control rats whereas the maximum contraction to ET-1 was significantly reduced (54% control).
BC8_BioRED_Task1_Doc499	1155	1169	norepinephrine	Chemical	D009638	Maximum contraction of vena cava to norepinephrine (37% control) also was reduced but no change in response to ET-1 was observed.
BC8_BioRED_Task1_Doc499	1230	1234	ET-1	Gene	24323	Maximum contraction of vena cava to norepinephrine (37% control) also was reduced but no change in response to ET-1 was observed.
BC8_BioRED_Task1_Doc499	1342	1346	LNNA	Chemical	D019335	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA.
BC8_BioRED_Task1_Doc499	1347	1359	hypertension	Disease	D006973	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA.
BC8_BioRED_Task1_Doc499	1382	1386	LNNA	Chemical	D019335	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA.
BC8_BioRED_Task1_Doc499	1392	1402	superoxide	Chemical	D013481	The superoxide scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).
BC8_BioRED_Task1_Doc499	1413	1419	tempol	Chemical	C001803	The superoxide scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).
BC8_BioRED_Task1_Doc499	1503	1507	rats	OrganismTaxon	10116	The superoxide scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).
BC8_BioRED_Task1_Doc499	1548	1552	LNNA	Chemical	D019335	The superoxide scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).
BC8_BioRED_Task1_Doc499	1553	1557	rats	OrganismTaxon	10116	The superoxide scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg).
BC8_BioRED_Task1_Doc499	1641	1654	hexamethonium	Chemical	D018738	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
BC8_BioRED_Task1_Doc499	1694	1698	LNNA	Chemical	D019335	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
BC8_BioRED_Task1_Doc499	1699	1711	hypertensive	Disease	D006973	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
BC8_BioRED_Task1_Doc499	1712	1716	rats	OrganismTaxon	10116	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
BC8_BioRED_Task1_Doc499	1756	1760	rats	OrganismTaxon	10116	Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
BC8_BioRED_Task1_Doc499	1838	1842	LNNA	Chemical	D019335	Carotid arteries, vena cava, and sympathetic ganglia from LNNA rats had higher basal levels of superoxide compared with those from control rats.
BC8_BioRED_Task1_Doc499	1843	1847	rats	OrganismTaxon	10116	Carotid arteries, vena cava, and sympathetic ganglia from LNNA rats had higher basal levels of superoxide compared with those from control rats.
BC8_BioRED_Task1_Doc499	1875	1885	superoxide	Chemical	D013481	Carotid arteries, vena cava, and sympathetic ganglia from LNNA rats had higher basal levels of superoxide compared with those from control rats.
BC8_BioRED_Task1_Doc499	1919	1923	rats	OrganismTaxon	10116	Carotid arteries, vena cava, and sympathetic ganglia from LNNA rats had higher basal levels of superoxide compared with those from control rats.
BC8_BioRED_Task1_Doc499	1955	1957	NO	Chemical	D009569	These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of hypertension.
BC8_BioRED_Task1_Doc499	2129	2141	hypertension	Disease	D006973	These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of hypertension.
